words,sentence_id,labels
Central,0,O
action,0,O
of,0,O
narcotic,0,O
analgesics,0,O
.,0,O
Part,1,O
IV,1,O
.,1,O
Noradrenergic,2,O
influences,2,O
on,2,O
the,2,O
activity,2,O
of,2,O
analgesics,2,O
in,2,O
rats,2,O
.,2,O
The,3,O
effect,3,O
of,3,O
clonidine,3,B-Chemical
",",3,O
naphazoline,3,B-Chemical
and,3,O
xylometazoline,3,B-Chemical
on,3,O
analgesia,3,O
induced,3,O
by,3,O
morphine,3,B-Chemical
",",3,O
codeine,3,B-Chemical
",",3,O
fentanyl,3,B-Chemical
and,3,O
pentazocine,3,B-Chemical
",",3,O
and,3,O
on,3,O
cataleptic,3,B-Disease
effect,3,O
of,3,O
morphine,3,B-Chemical
",",3,O
codine,3,B-Chemical
and,3,O
fentanyl,3,B-Chemical
was,3,O
studied,3,O
in,3,O
rats,3,O
.,3,O
The,4,O
biochemical,4,O
assays,4,O
on,4,O
the,4,O
influence,4,O
of,4,O
four,4,O
analgesics,4,O
on,4,O
the,4,O
brain,4,O
concentration,4,O
and,4,O
turnover,4,O
of,4,O
noradrenaline,4,B-Chemical
(,4,O
NA,4,B-Chemical
),4,O
were,4,O
also,4,O
performed,4,O
.,4,O
It,5,O
was,5,O
found,5,O
that,5,O
three,5,O
drugs,5,O
stimulating,5,O
central,5,O
NA,5,B-Chemical
receptors,5,O
failed,5,O
to,5,O
affect,5,O
the,5,O
analgesic,5,O
ED50,5,O
of,5,O
all,5,O
antinociceptive,5,O
agents,5,O
and,5,O
they,5,O
enhanced,5,O
catalepsy,5,B-Disease
induced,5,O
by,5,O
morphine,5,B-Chemical
and,5,O
fentanyl,5,B-Chemical
.,5,O
Codeine,6,B-Chemical
catalepsy,6,B-Disease
was,6,O
increased,6,O
by,6,O
clonidine,6,B-Chemical
and,6,O
decreased,6,O
by,6,O
naphazoline,6,B-Chemical
and,6,O
xylometazoline,6,B-Chemical
.,6,O
The,7,O
brain,7,O
concentration,7,O
of,7,O
NA,7,B-Chemical
was,7,O
not,7,O
changed,7,O
by,7,O
morphine,7,B-Chemical
and,7,O
fentanyl,7,B-Chemical
",",7,O
but,7,O
one,7,O
of,7,O
the,7,O
doses,7,O
of,7,O
codeine,7,B-Chemical
(,7,O
45,7,O
mg/kg,7,O
),7,O
slightly,7,O
enhanced,7,O
it,7,O
.,7,O
Pentazocine,8,B-Chemical
dose-dependently,8,O
decreased,8,O
the,8,O
brain,8,O
level,8,O
of,8,O
NA,8,B-Chemical
.,8,O
The,9,O
rate,9,O
of,9,O
NA,9,B-Chemical
turnover,9,O
was,9,O
not,9,O
altered,9,O
by,9,O
analgesics,9,O
except,9,O
for,9,O
the,9,O
higher,9,O
dose,9,O
of,9,O
fentanyl,9,B-Chemical
(,9,O
0.2,9,O
mg/kg,9,O
),9,O
following,9,O
which,9,O
the,9,O
disappearance,9,O
of,9,O
NA,9,B-Chemical
from,9,O
the,9,O
brain,9,O
was,9,O
diminished,9,O
.,9,O
The,10,O
results,10,O
are,10,O
discussed,10,O
in,10,O
the,10,O
light,10,O
of,10,O
various,10,O
and,10,O
non-uniform,10,O
data,10,O
from,10,O
the,10,O
literature,10,O
.,10,O
It,11,O
is,11,O
suggested,11,O
that,11,O
in,11,O
rats,11,O
the,11,O
brain,11,O
NA,11,B-Chemical
plays,11,O
a,11,O
less,11,O
important,11,O
function,11,O
than,11,O
the,11,O
other,11,O
monoamines,11,B-Chemical
in,11,O
the,11,O
behavioural,11,O
activity,11,O
of,11,O
potent,11,O
analgesics,11,O
.,11,O
On,12,O
the,12,O
antiarrhythmic,12,O
activity,12,O
of,12,O
one,12,O
N-substituted,12,O
piperazine,12,B-Chemical
derivative,12,O
of,12,O
trans-2-amino-3-hydroxy-1,12,B-Chemical
",",12,I-Chemical
2,12,I-Chemical
",",12,I-Chemical
3,12,I-Chemical
",",12,I-Chemical
4-tetrahydroanaphthalene,12,I-Chemical
.,12,O
The,13,O
antiarrhythmic,13,O
activity,13,O
of,13,O
the,13,O
compound,13,O
N-,13,B-Chemical
(,13,I-Chemical
"trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl",13,I-Chemical
),13,I-Chemical
-N-,13,I-Chemical
(,13,I-Chemical
3-oxo-3-phenyl-2-methylpropyl,13,I-Chemical
),13,I-Chemical
-piperazine,13,I-Chemical
hydrochloride,13,I-Chemical
",",13,O
referred,13,O
to,13,O
as,13,O
P11,13,B-Chemical
",",13,O
is,13,O
studied,13,O
on,13,O
anaesthesized,13,O
cats,13,O
and,13,O
Wistar,13,O
albino,13,O
rats,13,O
",",13,O
as,13,O
well,13,O
as,13,O
on,13,O
non-anaesthesized,13,O
rabbits,13,O
.,13,O
Four,14,O
types,14,O
of,14,O
experimental,14,O
arrhythmia,14,B-Disease
are,14,O
used,14,O
--,14,O
with,14,O
BaCl2,14,B-Chemical
",",14,O
with,14,O
chloroform-adrenaline,14,B-Chemical
",",14,O
with,14,O
strophantine,14,B-Chemical
G,14,I-Chemical
and,14,O
with,14,O
aconitine,14,B-Chemical
.,14,O
The,15,O
compound,15,O
P11,15,B-Chemical
is,15,O
introduced,15,O
in,15,O
doses,15,O
of,15,O
0.25,15,O
and,15,O
0.50,15,O
mg/kg,15,O
intravenously,15,O
and,15,O
10,15,O
mg/kg,15,O
orally,15,O
.,15,O
The,16,O
compound,16,O
manifests,16,O
antiarrhythmic,16,O
activity,16,O
in,16,O
all,16,O
models,16,O
of,16,O
experimental,16,O
arrhythmia,16,B-Disease
used,16,O
",",16,O
causing,16,O
greatest,16,O
inhibition,16,O
on,16,O
the,16,O
arrhythmia,16,B-Disease
induced,16,O
by,16,O
chloroform-adrenaline,16,B-Chemical
(,16,O
in,16,O
90,16,O
per,16,O
cent,16,O
),16,O
and,16,O
with,16,O
BaCl2,16,B-Chemical
(,16,O
in,16,O
84,16,O
per,16,O
cent,16,O
),16,O
.,16,O
The,17,O
results,17,O
obtained,17,O
are,17,O
associated,17,O
with,17,O
the,17,O
beta-adrenoblocking,17,O
and,17,O
with,17,O
the,17,O
membrane-stabilizing,17,O
action,17,O
of,17,O
the,17,O
compound,17,O
.,17,O
Modification,18,O
by,18,O
propranolol,18,B-Chemical
of,18,O
cardiovascular,18,O
effects,18,O
of,18,O
induced,18,O
hypoglycaemia,18,B-Disease
.,18,O
The,19,O
cardiovascular,19,O
effects,19,O
of,19,O
hypoglycaemia,19,B-Disease
",",19,O
with,19,O
and,19,O
without,19,O
beta-blockade,19,O
",",19,O
were,19,O
compared,19,O
in,19,O
fourteen,19,O
healthy,19,O
men,19,O
.,19,O
Eight,20,O
received,20,O
insulin,20,O
alone,20,O
",",20,O
and,20,O
eight,20,O
",",20,O
including,20,O
two,20,O
of,20,O
the,20,O
original,20,O
insulin-only,20,O
group,20,O
",",20,O
were,20,O
given,20,O
propranolol,20,B-Chemical
and,20,O
insulin,20,O
.,20,O
In,21,O
the,21,O
insulin-group,21,O
the,21,O
period,21,O
of,21,O
hypoglycaemia,21,B-Disease
was,21,O
associated,21,O
with,21,O
an,21,O
increase,21,O
in,21,O
heart-rate,21,O
and,21,O
a,21,O
fall,21,O
in,21,O
diastolic,21,O
blood-pressure,21,O
.,21,O
In,22,O
the,22,O
propranolol-insulin,22,B-Chemical
group,22,O
there,22,O
was,22,O
a,22,O
significant,22,O
fall,22,O
in,22,O
heart-rate,22,O
in,22,O
most,22,O
subjects,22,O
and,22,O
an,22,O
increase,22,O
in,22,O
diastolic,22,O
pressure,22,O
.,22,O
Typical,23,O
S-T/T,23,O
changes,23,O
occurred,23,O
in,23,O
the,23,O
insulin-group,23,O
but,23,O
in,23,O
none,23,O
of,23,O
the,23,O
propranolol-insulin,23,B-Chemical
group,23,O
.,23,O
Hypertension,24,B-Disease
in,24,O
diabetics,24,B-Disease
prone,24,O
to,24,O
hypoglycaemia,24,B-Disease
attacks,24,O
should,24,O
not,24,O
be,24,O
treated,24,O
with,24,O
beta-blockers,24,O
because,24,O
these,24,O
drugs,24,O
may,24,O
cause,24,O
a,24,O
sharp,24,O
rise,24,O
in,24,O
blood-pressure,24,O
in,24,O
such,24,O
patients,24,O
.,24,O
Prevention,25,O
and,25,O
treatment,25,O
of,25,O
endometrial,25,B-Disease
disease,25,I-Disease
in,25,O
climacteric,25,O
women,25,O
receiving,25,O
oestrogen,25,B-Chemical
therapy,25,O
.,25,O
The,26,O
treatment,26,O
regimens,26,O
are,26,O
described,26,O
in,26,O
74,26,O
patients,26,O
with,26,O
endometrial,26,B-Disease
disease,26,I-Disease
among,26,O
850,26,O
climacteric,26,O
women,26,O
receiving,26,O
oestrogen,26,B-Chemical
therapy,26,O
.,26,O
Cystic,27,O
hyperplasia,27,B-Disease
was,27,O
associated,27,O
with,27,O
unopposed,27,O
oestrogen,27,B-Chemical
therapy,27,O
without,27,O
progestagen,27,B-Chemical
.,27,O
Two,28,O
courses,28,O
of,28,O
21,28,O
days,28,O
of,28,O
5,28,O
mg,28,O
norethisterone,28,B-Chemical
daily,28,O
caused,28,O
reversion,28,O
to,28,O
normal,28,O
in,28,O
all,28,O
57,28,O
cases,28,O
of,28,O
cystic,28,O
hyperplasia,28,B-Disease
and,28,O
6,28,O
of,28,O
the,28,O
8,28,O
cases,28,O
of,28,O
atypical,28,O
hyperplasia,28,B-Disease
.,28,O
4,29,O
cases,29,O
of,29,O
endometrial,29,B-Disease
carcinoma,29,I-Disease
referred,29,O
from,29,O
elsewhere,29,O
demonstrated,29,O
the,29,O
problems,29,O
of,29,O
inappropriate,29,O
and,29,O
unsupervised,29,O
unopposed,29,O
oestrogen,29,B-Chemical
therapy,29,O
and,29,O
the,29,O
difficulty,29,O
in,29,O
distinguishing,29,O
severe,29,O
hyperplasia,29,B-Disease
from,29,O
malignancy,29,B-Disease
.,29,O
Cyclical,30,O
low-dose,30,O
oestrogen,30,B-Chemical
therapy,30,O
with,30,O
7,30,O
--,30,O
13,30,O
days,30,O
of,30,O
progestagen,30,B-Chemical
does,30,O
not,30,O
seem,30,O
to,30,O
increase,30,O
the,30,O
risk,30,O
of,30,O
endometrial,30,B-Disease
hyperplasia,30,I-Disease
or,30,O
carcinoma,30,B-Disease
.,30,O
Pure,31,B-Disease
red,31,I-Disease
cell,31,I-Disease
aplasia,31,I-Disease
",",31,O
toxic,31,B-Disease
dermatitis,31,I-Disease
and,31,O
lymphadenopathy,31,B-Disease
in,31,O
a,31,O
patient,31,O
taking,31,O
diphenylhydantoin,31,B-Chemical
.,31,O
A,32,O
patient,32,O
taking,32,O
diphenylhydantoin,32,B-Chemical
for,32,O
3,32,O
weeks,32,O
developed,32,O
a,32,O
generalized,32,O
skin,32,B-Disease
rash,32,I-Disease
",",32,O
lymphadenopathy,32,B-Disease
and,32,O
pure,32,B-Disease
red,32,I-Disease
cell,32,I-Disease
aplasia,32,I-Disease
.,32,O
After,33,O
withdrawal,33,O
of,33,O
the,33,O
pharmacon,33,O
all,33,O
symptoms,33,O
disappeared,33,O
spontaneously,33,O
.,33,O
Skin,34,B-Disease
rash,34,I-Disease
is,34,O
a,34,O
well-known,34,O
complication,34,O
of,34,O
diphenylhydantoin,34,B-Chemical
treatment,34,O
as,34,O
is,34,O
benign,34,O
and,34,O
malignant,34,O
lymphadenopathy,34,B-Disease
.,34,O
Pure,35,B-Disease
red,35,I-Disease
cell,35,I-Disease
aplasia,35,I-Disease
associated,35,O
with,35,O
diphenylhydantoin,35,B-Chemical
medication,35,O
has,35,O
been,35,O
reported,35,O
in,35,O
3,35,O
patients,35,O
.,35,O
The,36,O
exact,36,O
mechanism,36,O
by,36,O
which,36,O
diphenylhydantoin,36,B-Chemical
exerts,36,O
its,36,O
toxic,36,O
effects,36,O
is,36,O
not,36,O
known,36,O
.,36,O
In,37,O
this,37,O
patient,37,O
the,37,O
time,37,O
relation,37,O
between,37,O
the,37,O
ingestion,37,O
of,37,O
diphenylhydantoin,37,B-Chemical
and,37,O
the,37,O
occurrence,37,O
of,37,O
the,37,O
skin,37,B-Disease
rash,37,I-Disease
",",37,O
lymphadenopathy,37,B-Disease
and,37,O
pure,37,B-Disease
red,37,I-Disease
cell,37,I-Disease
aplasia,37,I-Disease
is,37,O
very,37,O
suggestive,37,O
of,37,O
a,37,O
direct,37,O
connection,37,O
.,37,O
Continuous,38,O
infusion,38,O
tobramycin,38,B-Chemical
combined,38,O
with,38,O
carbenicillin,38,B-Chemical
for,38,O
infections,38,B-Disease
in,38,O
cancer,38,B-Disease
patients,38,O
.,38,O
The,39,O
cure,39,O
rate,39,O
of,39,O
infections,39,B-Disease
in,39,O
cancer,39,B-Disease
patients,39,O
is,39,O
adversely,39,O
affected,39,O
by,39,O
neutropenia,39,B-Disease
(,39,O
less,39,O
than,39,O
"1,000/mm3",39,O
),39,O
.,39,O
In,40,O
particular,40,O
",",40,O
patients,40,O
with,40,O
severe,40,O
neutropenia,40,B-Disease
(,40,O
less,40,O
than,40,O
100/mm3,40,O
),40,O
have,40,O
shown,40,O
a,40,O
poor,40,O
response,40,O
to,40,O
antibiotics,40,O
.,40,O
To,41,O
overcome,41,O
the,41,O
adverse,41,O
effects,41,O
of,41,O
neutropenia,41,B-Disease
",",41,O
tobramycin,41,B-Chemical
was,41,O
given,41,O
by,41,O
continuous,41,O
infusion,41,O
and,41,O
combined,41,O
with,41,O
intermittent,41,O
carbenicillin,41,B-Chemical
.,41,O
Tobramycin,42,B-Chemical
was,42,O
given,42,O
to,42,O
a,42,O
total,42,O
daily,42,O
dose,42,O
of,42,O
300,42,O
mg/m2,42,O
and,42,O
carbenicillin,42,B-Chemical
was,42,O
given,42,O
at,42,O
a,42,O
dose,42,O
of,42,O
5,42,O
gm,42,O
every,42,O
four,42,O
hours,42,O
.,42,O
There,43,O
were,43,O
125,43,O
infectious,43,O
episodes,43,O
in,43,O
116,43,O
cancer,43,B-Disease
patients,43,O
receiving,43,O
myelosuppressive,43,O
chemotherapy,43,O
.,43,O
The,44,O
overall,44,O
cure,44,O
rate,44,O
was,44,O
70,44,O
%,44,O
.,44,O
Pneumonia,45,B-Disease
was,45,O
the,45,O
most,45,O
common,45,O
infection,45,B-Disease
and,45,O
61,45,O
%,45,O
of,45,O
59,45,O
episodes,45,O
were,45,O
cured,45,O
.,45,O
Gram-negative,46,O
bacilli,46,O
were,46,O
the,46,O
most,46,O
common,46,O
causative,46,O
organisms,46,O
and,46,O
69,46,O
%,46,O
of,46,O
these,46,O
infections,46,B-Disease
were,46,O
cured,46,O
.,46,O
The,47,O
most,47,O
common,47,O
pathogen,47,O
was,47,O
Klebsiella,47,O
pneumoniae,47,B-Disease
and,47,O
this,47,O
",",47,O
together,47,O
with,47,O
Escherichia,47,O
coli,47,O
and,47,O
Pseudomonas,47,O
aeruginosa,47,O
",",47,O
accounted,47,O
for,47,O
74,47,O
%,47,O
of,47,O
all,47,O
gram-negative,47,B-Disease
bacillary,47,I-Disease
infections,47,I-Disease
.,47,O
Response,48,O
was,48,O
not,48,O
influenced,48,O
by,48,O
the,48,O
initial,48,O
neutrophil,48,O
count,48,O
",",48,O
with,48,O
a,48,O
62,48,O
%,48,O
cure,48,O
rate,48,O
for,48,O
39,48,O
episodes,48,O
associated,48,O
with,48,O
severe,48,O
neutropenia,48,B-Disease
.,48,O
However,49,O
",",49,O
failure,49,O
of,49,O
the,49,O
neutrophil,49,O
count,49,O
to,49,O
increase,49,O
during,49,O
therapy,49,O
adversely,49,O
affected,49,O
response,49,O
.,49,O
Azotemia,50,B-Disease
was,50,O
the,50,O
major,50,O
side,50,O
effect,50,O
recognized,50,O
",",50,O
and,50,O
it,50,O
occurred,50,O
in,50,O
11,50,O
%,50,O
of,50,O
episodes,50,O
.,50,O
Major,51,O
azotemia,51,B-Disease
(,51,O
serum,51,O
creatinine,51,B-Chemical
greater,51,O
than,51,O
2.5,51,O
mg/dl,51,O
or,51,O
BUN,51,O
greater,51,O
than,51,O
50,51,O
mg/dl,51,O
),51,O
occurred,51,O
in,51,O
only,51,O
2,51,O
%,51,O
.,51,O
Azotemia,52,B-Disease
was,52,O
not,52,O
related,52,O
to,52,O
duration,52,O
of,52,O
therapy,52,O
or,52,O
serum,52,O
tobramycin,52,B-Chemical
concentration,52,O
.,52,O
This,53,O
antibiotic,53,O
regimen,53,O
showed,53,O
both,53,O
therapeutic,53,O
efficacy,53,O
and,53,O
acceptable,53,O
renal,53,B-Disease
toxicity,53,I-Disease
for,53,O
these,53,O
patients,53,O
.,53,O
Indomethacin,54,B-Chemical
induced,54,O
hypotension,54,B-Disease
in,54,O
sodium,54,B-Chemical
and,54,O
volume,54,O
depleted,54,O
rats,54,O
.,54,O
After,55,O
a,55,O
single,55,O
oral,55,O
dose,55,O
of,55,O
4,55,O
mg/kg,55,O
indomethacin,55,B-Chemical
(,55,O
IDM,55,B-Chemical
),55,O
to,55,O
sodium,55,B-Chemical
and,55,O
volume,55,O
depleted,55,O
rats,55,O
plasma,55,O
renin,55,O
activity,55,O
(,55,O
PRA,55,O
),55,O
and,55,O
systolic,55,O
blood,55,O
pressure,55,O
fell,55,O
significantly,55,O
within,55,O
four,55,O
hours,55,O
.,55,O
In,56,O
sodium,56,B-Chemical
repleted,56,O
animals,56,O
indomethacin,56,B-Chemical
did,56,O
not,56,O
change,56,O
systolic,56,O
blood,56,O
pressure,56,O
(,56,O
BP,56,O
),56,O
although,56,O
plasma,56,O
renin,56,O
activity,56,O
was,56,O
decreased,56,O
.,56,O
Thus,57,O
",",57,O
indomethacin,57,B-Chemical
by,57,O
inhibition,57,O
of,57,O
prostaglandin,57,B-Chemical
synthesis,57,O
may,57,O
diminish,57,O
the,57,O
blood,57,O
pressure,57,O
maintaining,57,O
effect,57,O
of,57,O
the,57,O
stimulated,57,O
renin-angiotensin,57,O
system,57,O
in,57,O
sodium,57,B-Chemical
and,57,O
volume,57,O
depletion,57,O
.,57,O
Recurrent,58,O
subarachnoid,58,B-Disease
hemorrhage,58,I-Disease
associated,58,O
with,58,O
aminocaproic,58,B-Chemical
acid,58,I-Chemical
therapy,58,O
and,58,O
acute,58,B-Disease
renal,58,I-Disease
artery,58,I-Disease
thrombosis,58,I-Disease
.,58,O
Case,59,O
report,59,O
.,59,O
Epsilon,60,B-Chemical
aminocaproic,60,I-Chemical
acid,60,I-Chemical
(,60,O
EACA,60,B-Chemical
),60,O
has,60,O
been,60,O
used,60,O
to,60,O
prevent,60,O
rebleeding,60,O
in,60,O
patients,60,O
with,60,O
subarachnoid,60,B-Disease
hemorrhage,60,I-Disease
(,60,O
SAH,60,B-Disease
),60,O
.,60,O
Although,61,O
this,61,O
agent,61,O
does,61,O
decrease,61,O
the,61,O
frequency,61,O
of,61,O
rebleeding,61,O
",",61,O
several,61,O
reports,61,O
have,61,O
described,61,O
thrombotic,61,B-Disease
complications,61,O
of,61,O
EACA,61,B-Chemical
therapy,61,O
.,61,O
These,62,O
complications,62,O
have,62,O
included,62,O
clinical,62,O
deterioration,62,O
and,62,O
intracranial,62,B-Disease
vascular,62,I-Disease
thrombosis,62,I-Disease
in,62,O
patients,62,O
with,62,O
SAH,62,B-Disease
",",62,O
arteriolar,62,O
and,62,O
capillary,62,O
fibrin,62,O
thrombi,62,B-Disease
in,62,O
patients,62,O
with,62,O
fibrinolytic,62,O
syndromes,62,O
treated,62,O
with,62,O
EACA,62,B-Chemical
",",62,O
or,62,O
other,62,O
thromboembolic,62,B-Disease
phenomena,62,I-Disease
.,62,O
Since,63,O
intravascular,63,O
fibrin,63,O
thrombi,63,B-Disease
are,63,O
often,63,O
observed,63,O
in,63,O
patients,63,O
with,63,O
fibrinolytic,63,O
disorders,63,O
",",63,O
EACA,63,B-Chemical
should,63,O
not,63,O
be,63,O
implicated,63,O
in,63,O
the,63,O
pathogenesis,63,O
of,63,O
fibrin,63,O
thrombi,63,B-Disease
in,63,O
patients,63,O
with,63,O
disseminated,63,B-Disease
intravascular,63,I-Disease
coagulation,63,I-Disease
or,63,O
other,63,O
``,63,O
consumption,63,B-Disease
coagulopathies,63,I-Disease
.,63,O
'',63,O
This,64,O
report,64,O
describes,64,O
subtotal,64,O
infarction,64,B-Disease
of,64,O
the,64,O
kidney,64,O
due,64,O
to,64,O
thrombosis,64,B-Disease
of,64,I-Disease
a,64,I-Disease
normal,64,I-Disease
renal,64,I-Disease
artery,64,I-Disease
.,64,O
This,65,O
occlusion,65,O
occurred,65,O
after,65,O
EACA,65,B-Chemical
therapy,65,O
in,65,O
a,65,O
patient,65,O
with,65,O
SAH,65,B-Disease
and,65,O
histopathological,65,O
documentation,65,O
of,65,O
recurrent,65,O
SAH,65,B-Disease
.,65,O
The,66,O
corresponding,66,O
clinical,66,O
event,66,O
was,66,O
characterized,66,O
by,66,O
marked,66,O
hypertension,66,B-Disease
and,66,O
abrupt,66,O
neurological,66,O
deterioration,66,O
.,66,O
Long-term,67,O
propranolol,67,B-Chemical
therapy,67,O
in,67,O
pregnancy,67,O
:,67,O
maternal,67,O
and,67,O
fetal,67,O
outcome,67,O
.,67,O
Propranolol,68,B-Chemical
",",68,O
a,68,O
beta-adrenergic,68,O
blocking,68,O
agent,68,O
",",68,O
has,68,O
found,68,O
an,68,O
important,68,O
position,68,O
in,68,O
the,68,O
practice,68,O
of,68,O
medicine,68,O
.,68,O
Its,69,O
use,69,O
in,69,O
pregnancy,69,O
",",69,O
however,69,O
",",69,O
is,69,O
an,69,O
open,69,O
question,69,O
as,69,O
a,69,O
number,69,O
of,69,O
detrimental,69,O
side,69,O
effects,69,O
have,69,O
been,69,O
reported,69,O
in,69,O
the,69,O
fetus,69,O
and,69,O
neonate,69,O
.,69,O
Ten,70,O
patients,70,O
and,70,O
12,70,O
pregnancies,70,O
are,70,O
reported,70,O
where,70,O
chronic,70,O
propranolol,70,B-Chemical
has,70,O
been,70,O
administered,70,O
.,70,O
Five,71,O
patients,71,O
with,71,O
serial,71,O
pregnancies,71,O
with,71,O
and,71,O
without,71,O
propranolol,71,B-Chemical
therapy,71,O
are,71,O
also,71,O
examined,71,O
.,71,O
Maternal,72,O
",",72,O
fetal,72,O
",",72,O
and,72,O
neonatal,72,O
complications,72,O
are,72,O
examined,72,O
.,72,O
An,73,O
attempt,73,O
is,73,O
made,73,O
to,73,O
differentiate,73,O
drug-related,73,O
complications,73,O
from,73,O
maternal,73,O
disease,73,O
--,73,O
related,73,O
complications,73,O
.,73,O
We,74,O
conclude,74,O
that,74,O
previously,74,O
reported,74,O
hypoglycemia,74,B-Disease
",",74,O
hyperbilirubinemia,74,B-Disease
",",74,O
polycythemia,74,B-Disease
",",74,O
neonatal,74,B-Disease
apnea,74,I-Disease
",",74,O
and,74,O
bradycardia,74,B-Disease
are,74,O
not,74,O
invariable,74,O
and,74,O
can,74,O
not,74,O
be,74,O
statistically,74,O
correlated,74,O
with,74,O
chronic,74,O
propranolol,74,B-Chemical
therapy,74,O
.,74,O
Growth,75,B-Disease
retardation,75,I-Disease
",",75,O
however,75,O
",",75,O
appears,75,O
to,75,O
be,75,O
significant,75,O
in,75,O
both,75,O
of,75,O
our,75,O
series,75,O
.,75,O
Use,76,O
of,76,O
propranolol,76,B-Chemical
in,76,O
the,76,O
treatment,76,O
of,76,O
idiopathic,76,B-Disease
orthostatic,76,I-Disease
hypotension,76,I-Disease
.,76,O
Five,77,O
patients,77,O
with,77,O
idiopathic,77,B-Disease
orthostatic,77,I-Disease
hypotension,77,I-Disease
who,77,O
had,77,O
physiologic,77,O
and,77,O
biochemical,77,O
evidence,77,O
of,77,O
severe,77,O
autonomic,77,O
dysfunction,77,O
were,77,O
included,77,O
in,77,O
the,77,O
study,77,O
.,77,O
They,78,O
all,78,O
exhibited,78,O
markedly,78,O
reduced,78,O
plasma,78,O
catecholamines,78,B-Chemical
and,78,O
plasma,78,O
renin,78,O
activity,78,O
in,78,O
both,78,O
recumbent,78,O
and,78,O
upright,78,O
positions,78,O
and,78,O
had,78,O
marked,78,O
hypersensitivity,78,B-Disease
to,78,O
the,78,O
pressor,78,O
effects,78,O
of,78,O
infused,78,O
norepinephrine,78,B-Chemical
.,78,O
Treatment,79,O
with,79,O
propanolol,79,B-Chemical
administered,79,O
intravenously,79,O
(,79,O
1-5,79,O
mg,79,O
),79,O
produced,79,O
increases,79,O
in,79,O
supine,79,O
and,79,O
upright,79,O
blood,79,O
pressure,79,O
in,79,O
4,79,O
of,79,O
the,79,O
5,79,O
individuals,79,O
with,79,O
rises,79,O
ranging,79,O
from,79,O
11/6,79,O
to,79,O
22/11,79,O
mmHg,79,O
.,79,O
Chronic,80,O
oral,80,O
administration,80,O
of,80,O
propranolol,80,B-Chemical
(,80,O
40-160,80,O
mg/day,80,O
),80,O
also,80,O
elevated,80,O
the,80,O
blood,80,O
pressures,80,O
of,80,O
these,80,O
individuals,80,O
with,80,O
increases,80,O
in,80,O
the,80,O
order,80,O
of,80,O
20-35/15-25,80,O
mmg,80,O
being,80,O
observed,80,O
.,80,O
In,81,O
1,81,O
patient,81,O
",",81,O
marked,81,O
hypertension,81,B-Disease
was,81,O
induced,81,O
by,81,O
propranolol,81,B-Chemical
and,81,O
the,81,O
drug,81,O
had,81,O
to,81,O
be,81,O
withdrawn,81,O
.,81,O
It,82,O
otherwise,82,O
was,82,O
well,82,O
tolerated,82,O
and,82,O
no,82,O
important,82,O
side,82,O
effects,82,O
were,82,O
observed,82,O
.,82,O
Treatment,83,O
has,83,O
been,83,O
continued,83,O
in,83,O
3,83,O
individuals,83,O
for,83,O
6-13,83,O
months,83,O
with,83,O
persistence,83,O
of,83,O
the,83,O
pressor,83,O
effect,83,O
",",83,O
although,83,O
there,83,O
appears,83,O
to,83,O
have,83,O
been,83,O
some,83,O
decrease,83,O
in,83,O
the,83,O
degree,83,O
of,83,O
response,83,O
with,83,O
time,83,O
.,83,O
Hemodynamic,84,O
measurements,84,O
in,84,O
1,84,O
of,84,O
the,84,O
patients,84,O
demonstrated,84,O
an,84,O
increase,84,O
in,84,O
total,84,O
peripheral,84,O
resistance,84,O
and,84,O
essentially,84,O
no,84,O
change,84,O
in,84,O
cardiac,84,O
output,84,O
following,84,O
propranolol,84,B-Chemical
therapy,84,O
.,84,O
The,85,O
studies,85,O
suggest,85,O
that,85,O
propranolol,85,B-Chemical
is,85,O
a,85,O
useful,85,O
drug,85,O
in,85,O
selected,85,O
patients,85,O
with,85,O
severe,85,O
idiopathic,85,B-Disease
orthostatic,85,I-Disease
hypotension,85,I-Disease
.,85,O
Total,86,O
intravenous,86,O
anesthesia,86,O
with,86,O
etomidate,86,B-Chemical
.,86,O
III,87,O
.,87,O
Some,88,O
observations,88,O
in,88,O
adults,88,O
.,88,O
An,89,O
investigation,89,O
was,89,O
undertaken,89,O
to,89,O
determine,89,O
the,89,O
dosage,89,O
of,89,O
etomidate,89,B-Chemical
required,89,O
to,89,O
maintain,89,O
sleep,89,O
in,89,O
adults,89,O
undergoing,89,O
surgery,89,O
under,89,O
regional,89,O
local,89,O
anesthesia,89,O
.,89,O
Premedication,90,O
of,90,O
diazepam,90,B-Chemical
10,90,O
mg,90,O
and,90,O
atropine,90,B-Chemical
0.5,90,O
mg,90,O
was,90,O
given,90,O
",",90,O
and,90,O
sleep,90,O
was,90,O
induced,90,O
and,90,O
maintained,90,O
by,90,O
intermittent,90,O
intravenous,90,O
injections,90,O
of,90,O
etomidate,90,B-Chemical
0.1/mg/kg,90,O
",",90,O
given,90,O
whenever,90,O
the,90,O
patient,90,O
would,90,O
open,90,O
his,90,O
eyes,90,O
on,90,O
request,90,O
.,90,O
A,91,O
mean,91,O
overall,91,O
dose,91,O
of,91,O
etomidate,91,B-Chemical
17.4,91,O
microgram/kg/min,91,O
.,91,O
was,92,O
required,92,O
to,92,O
maintain,92,O
sleep,92,O
",",92,O
but,92,O
great,92,O
individual,92,O
variation,92,O
occurred,92,O
",",92,O
with,92,O
older,92,O
patients,92,O
requiring,92,O
less,92,O
drug,92,O
.,92,O
The,93,O
investigation,93,O
was,93,O
discontinued,93,O
after,93,O
18,93,O
patients,93,O
because,93,O
of,93,O
the,93,O
frequency,93,O
and,93,O
intensity,93,O
of,93,O
side-effects,93,O
",",93,O
particularly,93,O
pain,93,B-Disease
and,93,O
myoclonia,93,B-Disease
",",93,O
which,93,O
caused,93,O
the,93,O
technique,93,O
to,93,O
be,93,O
abandoned,93,O
in,93,O
two,93,O
cases,93,O
.,93,O
It,94,O
is,94,O
considered,94,O
unlikely,94,O
that,94,O
etomidate,94,B-Chemical
will,94,O
prove,94,O
to,94,O
be,94,O
the,94,O
hypnotic,94,O
of,94,O
choice,94,O
for,94,O
a,94,O
totally,94,O
intravenous,94,O
anesthetic,94,O
technique,94,O
in,94,O
adults,94,O
because,94,O
of,94,O
the,94,O
high,94,O
incidence,94,O
of,94,O
myoclonia,94,B-Disease
after,94,O
prolonged,94,O
administration,94,O
.,94,O
In,95,O
several,95,O
patients,95,O
uncontrollable,95,O
muscle,95,O
movements,95,O
persisted,95,O
for,95,O
many,95,O
minutes,95,O
after,95,O
complete,95,O
recovery,95,O
of,95,O
consciousness,95,O
.,95,O
A,96,O
method,96,O
for,96,O
the,96,O
measurement,96,O
of,96,O
tremor,96,B-Disease
",",96,O
and,96,O
a,96,O
comparison,96,O
of,96,O
the,96,O
effects,96,O
of,96,O
tocolytic,96,O
beta-mimetics,96,O
.,96,O
A,97,O
method,97,O
permitting,97,O
measurement,97,O
of,97,O
finger,97,O
tremor,97,B-Disease
as,97,O
a,97,O
displacement-time,97,O
curve,97,O
is,97,O
described,97,O
",",97,O
using,97,O
a,97,O
test,97,O
system,97,O
with,97,O
simple,97,O
amplitude,97,O
calibration,97,O
.,97,O
The,98,O
coordinates,98,O
of,98,O
the,98,O
inversion,98,O
points,98,O
of,98,O
the,98,O
displacement-time,98,O
curves,98,O
were,98,O
transferred,98,O
through,98,O
graphical,98,O
input,98,O
equipment,98,O
to,98,O
punched,98,O
tape,98,O
.,98,O
By,99,O
means,99,O
of,99,O
a,99,O
computer,99,O
program,99,O
",",99,O
periods,99,O
and,99,O
amplitudes,99,O
of,99,O
tremor,99,B-Disease
oscillations,99,O
were,99,O
calculated,99,O
and,99,O
classified,99,O
.,99,O
The,100,O
event,100,O
frequency,100,O
for,100,O
each,100,O
class,100,O
of,100,O
periods,100,O
and,100,O
amplitudes,100,O
was,100,O
determined,100,O
.,100,O
The,101,O
actions,101,O
of,101,O
fenoterol-hydrobromide,101,B-Chemical
",",101,O
ritodrin-HCl,101,B-Chemical
and,101,O
placebo,101,O
given,101,O
to,101,O
10,101,O
healthy,101,O
subjects,101,O
by,101,O
intravenous,101,O
infusion,101,O
in,101,O
a,101,O
double-blind,101,O
crossover,101,O
study,101,O
were,101,O
tested,101,O
by,101,O
this,101,O
method,101,O
.,101,O
At,102,O
therapeutic,102,O
doses,102,O
both,102,O
substances,102,O
raised,102,O
the,102,O
mean,102,O
tremor,102,B-Disease
amplitude,102,O
to,102,O
about,102,O
three,102,O
times,102,O
the,102,O
control,102,O
level,102,O
.,102,O
At,103,O
the,103,O
same,103,O
time,103,O
",",103,O
the,103,O
mean,103,O
period,103,O
within,103,O
each,103,O
class,103,O
of,103,O
amplitudes,103,O
shortened,103,O
by,103,O
10,103,O
--,103,O
20,103,O
ms,103,O
",",103,O
whereas,103,O
the,103,O
mean,103,O
periods,103,O
calculated,103,O
from,103,O
all,103,O
oscillations,103,O
together,103,O
did,103,O
not,103,O
change,103,O
significantly,103,O
.,103,O
After,104,O
the,104,O
end,104,O
of,104,O
fenoterol-hydrobromide,104,B-Chemical
infusion,104,O
",",104,O
tremor,104,B-Disease
amplitudes,104,O
decreased,104,O
significantly,104,O
faster,104,O
than,104,O
those,104,O
following,104,O
ritodrin-HCl,104,B-Chemical
infusion,104,O
.,104,O
Bilateral,105,O
retinal,105,B-Disease
artery,105,I-Disease
and,105,I-Disease
choriocapillaris,105,I-Disease
occlusion,105,I-Disease
following,105,O
the,105,O
injection,105,O
of,105,O
long-acting,105,O
corticosteroid,105,B-Chemical
suspensions,105,O
in,105,O
combination,105,O
with,105,O
other,105,O
drugs,105,O
:,105,O
I,105,O
.,105,O
Clinical,106,O
studies,106,O
.,106,O
Two,107,O
well-documented,107,O
cases,107,O
of,107,O
bilateral,107,O
retinal,107,B-Disease
artery,107,I-Disease
and,107,I-Disease
choriocapillaris,107,I-Disease
occlusions,107,I-Disease
with,107,O
blindness,107,B-Disease
following,107,O
head,107,O
and,107,O
neck,107,O
soft-tissue,107,O
injection,107,O
with,107,O
methylprednisolone,107,B-Chemical
acetate,107,I-Chemical
in,107,O
combination,107,O
with,107,O
lidocaine,107,B-Chemical
",",107,O
epinephrine,107,B-Chemical
",",107,O
or,107,O
penicillin,107,B-Chemical
are,107,O
reported,107,O
.,107,O
One,108,O
case,108,O
had,108,O
only,108,O
a,108,O
unilateral,108,O
injection,108,O
.,108,O
The,109,O
acute,109,O
observations,109,O
included,109,O
hazy,109,O
sensorium,109,O
",",109,O
superior,109,O
gaze,109,O
palsy,109,B-Disease
",",109,O
pupillary,109,B-Disease
abnormalities,109,I-Disease
",",109,O
and,109,O
conjunctival,109,O
hemorrhages,109,B-Disease
with,109,O
edema,109,B-Disease
.,109,O
Follow-up,110,O
changes,110,O
showed,110,O
marked,110,O
visual,110,B-Disease
loss,110,I-Disease
",",110,O
constricted,110,O
visual,110,O
fields,110,O
",",110,O
optic,110,O
nerve,110,O
pallor,110,O
",",110,O
vascular,110,O
attenuation,110,O
",",110,O
and,110,O
chorioretinal,110,B-Disease
atrophy,110,I-Disease
.,110,O
The,111,O
literature,111,O
is,111,O
reviewed,111,O
",",111,O
and,111,O
possible,111,O
causes,111,O
are,111,O
discussed,111,O
.,111,O
Experimental,112,O
progressive,112,O
muscular,112,B-Disease
dystrophy,112,I-Disease
and,112,O
its,112,O
treatment,112,O
with,112,O
high,112,O
doses,112,O
anabolizing,112,O
agents,112,O
.,112,O
We,113,O
are,113,O
still,113,O
a,113,O
long,113,O
way,113,O
from,113,O
discovering,113,O
an,113,O
unequivocal,113,O
pathogenetic,113,O
interpretation,113,O
of,113,O
progressive,113,O
muscular,113,B-Disease
dystrophy,113,I-Disease
in,113,O
man,113,O
.,113,O
Noteworthy,114,O
efforts,114,O
have,114,O
been,114,O
made,114,O
in,114,O
the,114,O
experimental,114,O
field,114,O
;,114,O
a,114,O
recessive,114,O
autosomic,114,O
form,114,O
found,114,O
in,114,O
the,114,O
mouse,114,O
seems,114,O
to,114,O
bear,114,O
the,114,O
closest,114,O
resemblance,114,O
to,114,O
the,114,O
human,114,O
form,114,O
from,114,O
the,114,O
genetic,114,O
point,114,O
of,114,O
view,114,O
.,114,O
Myopathy,115,B-Disease
due,115,O
to,115,O
lack,115,O
of,115,O
vitamin,115,B-Chemical
E,115,I-Chemical
and,115,O
myopathy,115,B-Disease
induced,115,O
by,115,O
certain,115,O
viruses,115,O
have,115,O
much,115,O
in,115,O
common,115,O
anatomically,115,O
and,115,O
pathologically,115,O
with,115,O
the,115,O
human,115,O
form,115,O
.,115,O
The,116,O
authors,116,O
induced,116,O
myodystrophy,116,B-Disease
in,116,O
the,116,O
rat,116,O
by,116,O
giving,116,O
it,116,O
a,116,O
diet,116,O
lacking,116,O
in,116,O
vitamin,116,B-Chemical
E.,116,O
The,116,O
pharmacological,116,O
characteristics,116,O
of,116,O
vitamin,116,B-Chemical
E,116,I-Chemical
and,116,O
the,116,O
degenerative,116,O
changes,116,O
brought,116,O
about,116,O
by,116,O
its,116,O
deficiency,116,O
",",116,O
especially,116,O
in,116,O
the,116,O
muscles,116,O
",",116,O
are,116,O
illustrated,116,O
.,116,O
It,117,O
is,117,O
thus,117,O
confirmed,117,O
that,117,O
the,117,O
histological,117,O
characteristics,117,O
of,117,O
myopathic,117,B-Disease
rat,117,O
muscle,117,O
induced,117,O
experimentally,117,O
are,117,O
extraordinarily,117,O
similar,117,O
to,117,O
those,117,O
of,117,O
human,117,O
myopathy,117,B-Disease
as,117,O
confirmed,117,O
during,117,O
biopsies,117,O
performed,117,O
at,117,O
the,117,O
Orthopaedic,117,O
Traumatological,117,O
Centre,117,O
",",117,O
Florence,117,O
.,117,O
The,118,O
encouraging,118,O
results,118,O
obtained,118,O
in,118,O
various,118,O
authoratative,118,O
departments,118,O
in,118,O
myopathic,118,B-Disease
patients,118,O
by,118,O
using,118,O
anabolizing,118,O
steroids,118,B-Chemical
have,118,O
encouraged,118,O
the,118,O
authors,118,O
to,118,O
investigate,118,O
the,118,O
beneficial,118,O
effects,118,O
of,118,O
one,118,O
anabolizing,118,O
agent,118,O
(,118,O
Dianabol,118,B-Chemical
",",118,O
CIBA,118,B-Chemical
),118,O
at,118,O
high,118,O
doses,118,O
in,118,O
rats,118,O
rendered,118,O
myopathic,118,B-Disease
by,118,O
a,118,O
diet,118,O
deficient,118,O
in,118,O
vitamin,118,B-Chemical
E.,118,O
In,118,O
this,118,O
way,118,O
they,118,O
obtained,118,O
appreciable,118,O
changes,118,O
in,118,O
body,118,O
weight,118,O
(,118,O
increased,118,O
from,118,O
50,118,O
to,118,O
70,118,O
g,118,O
after,118,O
forty,118,O
days,118,O
at,118,O
a,118,O
dose,118,O
of,118,O
5,118,O
mg,118,O
per,118,O
day,118,O
of,118,O
anabolizing,118,O
agent,118,O
),118,O
",",118,O
but,118,O
most,118,O
of,118,O
all,118,O
they,118,O
found,118,O
histological,118,O
changes,118,O
due,118,O
to,118,O
``,118,O
regenerative,118,O
'',118,O
changes,118,O
in,118,O
the,118,O
muscle,118,O
tissue,118,O
",",118,O
which,118,O
however,118,O
maintained,118,O
its,118,O
myopathic,118,B-Disease
characteristics,118,O
in,118,O
the,118,O
control,118,O
animals,118,O
that,118,O
were,118,O
not,118,O
treated,118,O
with,118,O
the,118,O
anabolizing,118,O
agent,118,O
.,118,O
The,119,O
authors,119,O
conclude,119,O
by,119,O
affirming,119,O
the,119,O
undoubted,119,O
efficacy,119,O
of,119,O
the,119,O
anabolizing,119,O
steroids,119,B-Chemical
in,119,O
experimental,119,O
myopathic,119,B-Disease
disease,119,I-Disease
",",119,O
but,119,O
they,119,O
have,119,O
reservations,119,O
as,119,O
to,119,O
the,119,O
transfer,119,O
of,119,O
the,119,O
results,119,O
into,119,O
the,119,O
human,119,O
field,119,O
",",119,O
where,119,O
high,119,O
dosage,119,O
can,119,O
not,119,O
be,119,O
carried,119,O
out,119,O
continuously,119,O
because,119,O
of,119,O
the,119,O
effects,119,O
of,119,O
the,119,O
drug,119,O
on,119,O
virility,119,O
;,119,O
because,119,O
the,119,O
tissue,119,O
injury,119,O
too,119,O
often,119,O
occurs,119,O
at,119,O
an,119,O
irreversible,119,O
stage,119,O
vis-a-vis,119,O
the,119,O
``,119,O
regeneration,119,O
'',119,O
of,119,O
the,119,O
muscle,119,O
tissue,119,O
;,119,O
and,119,O
finally,119,O
because,119,O
the,119,O
dystrophic,119,O
injurious,119,O
agent,119,O
is,119,O
certainly,119,O
not,119,O
the,119,O
lack,119,O
of,119,O
vitamin,119,B-Chemical
E,119,I-Chemical
but,119,O
something,119,O
as,119,O
yet,119,O
unknown,119,O
.,119,O
Cephalothin-induced,120,B-Chemical
immune,120,O
hemolytic,120,B-Disease
anemia,120,I-Disease
.,120,O
A,121,O
patient,121,O
with,121,O
renal,121,B-Disease
disease,121,I-Disease
developed,121,O
Coombs-positive,121,O
hemolytic,121,B-Disease
anemia,121,I-Disease
while,121,O
receiving,121,O
cephalothin,121,B-Chemical
therapy,121,O
.,121,O
An,122,O
anti-cephalothin,122,O
IgG,122,O
antibody,122,O
was,122,O
detected,122,O
in,122,O
the,122,O
patient,122,O
's,122,O
serum,122,O
and,122,O
in,122,O
the,122,O
eluates,122,O
from,122,O
her,122,O
erythrocytes,122,O
.,122,O
In,123,O
addition,123,O
",",123,O
nonimmunologic,123,O
binding,123,O
of,123,O
normal,123,O
and,123,O
patient,123,O
's,123,O
serum,123,O
proteins,123,O
to,123,O
her,123,O
own,123,O
and,123,O
cephalothin-coated,123,B-Chemical
normal,123,O
red,123,O
cells,123,O
was,123,O
demonstrated,123,O
.,123,O
Skin,124,O
tests,124,O
and,124,O
in,124,O
vitro,124,O
lymphocyte,124,O
stimulation,124,O
revealed,124,O
that,124,O
the,124,O
patient,124,O
was,124,O
sensitized,124,O
to,124,O
cephalothin,124,B-Chemical
and,124,O
also,124,O
to,124,O
ampicillin,124,B-Chemical
.,124,O
Careful,125,O
investigation,125,O
of,125,O
drug-induced,125,O
hemolytic,125,B-Disease
anemias,125,I-Disease
reveals,125,O
the,125,O
complexity,125,O
of,125,O
the,125,O
immune,125,O
mechanisms,125,O
involved,125,O
.,125,O
Kaliuretic,126,O
effect,126,O
of,126,O
L-dopa,126,B-Chemical
treatment,126,O
in,126,O
parkinsonian,126,B-Disease
patients,126,O
.,126,O
Hypokalemia,127,B-Disease
",",127,O
sometimes,127,O
severe,127,O
",",127,O
was,127,O
observed,127,O
in,127,O
some,127,O
L-dopa-treated,127,B-Chemical
parkinsonian,127,B-Disease
patients,127,O
.,127,O
The,128,O
influence,128,O
of,128,O
L-dopa,128,B-Chemical
on,128,O
the,128,O
renal,128,O
excretion,128,O
of,128,O
potassium,128,B-Chemical
was,128,O
studied,128,O
in,128,O
3,128,O
patients,128,O
with,128,O
hypokalemia,128,B-Disease
and,128,O
in,128,O
5,128,O
normokalemic,128,O
patients,128,O
by,128,O
determination,128,O
of,128,O
renal,128,O
plasma,128,O
flow,128,O
",",128,O
glomerular,128,O
filtration,128,O
rate,128,O
",",128,O
plasma,128,O
concentration,128,O
of,128,O
potassium,128,B-Chemical
and,128,O
sodium,128,B-Chemical
as,128,O
well,128,O
as,128,O
urinary,128,O
excretion,128,O
of,128,O
potassium,128,B-Chemical
",",128,O
sodium,128,B-Chemical
and,128,O
aldosterone,128,B-Chemical
.,128,O
L-Dopa,129,B-Chemical
intake,129,O
was,129,O
found,129,O
to,129,O
cause,129,O
an,129,O
increased,129,O
excretion,129,O
of,129,O
potassium,129,B-Chemical
",",129,O
and,129,O
sometimes,129,O
also,129,O
of,129,O
sodium,129,B-Chemical
",",129,O
in,129,O
the,129,O
hypokalemic,129,O
but,129,O
not,129,O
in,129,O
the,129,O
normokalemic,129,O
patients,129,O
.,129,O
This,130,O
effect,130,O
on,130,O
the,130,O
renal,130,O
function,130,O
could,130,O
be,130,O
prohibited,130,O
by,130,O
the,130,O
administration,130,O
of,130,O
a,130,O
peripheral,130,O
dopa,130,O
decarbodylase,130,O
inhibitor,130,O
.,130,O
It,131,O
is,131,O
not,131,O
known,131,O
why,131,O
this,131,O
effect,131,O
occurred,131,O
in,131,O
some,131,O
individuals,131,O
but,131,O
not,131,O
in,131,O
others,131,O
",",131,O
but,131,O
our,131,O
results,131,O
indicate,131,O
a,131,O
correlation,131,O
between,131,O
aldosterone,131,B-Chemical
production,131,O
and,131,O
this,131,O
renal,131,O
effect,131,O
of,131,O
L-dopa,131,B-Chemical
.,131,O
Phenytoin,132,B-Chemical
encephalopathy,132,B-Disease
as,132,O
probable,132,O
idiosyncratic,132,O
reaction,132,O
:,132,O
case,132,O
report,132,O
.,132,O
A,133,O
case,133,O
of,133,O
phenytoin,133,B-Chemical
(,133,O
DPH,133,B-Chemical
),133,O
encephalopathy,133,B-Disease
with,133,O
increasing,133,O
seizures,133,B-Disease
and,133,O
EEG,133,O
and,133,O
mental,133,O
changes,133,O
is,133,O
described,133,O
.,133,O
Despite,134,O
adequate,134,O
oral,134,O
dosage,134,O
of,134,O
DPH,134,B-Chemical
(,134,O
5,134,O
mg/kg/daily,134,O
),134,O
the,134,O
plasma,134,O
level,134,O
was,134,O
very,134,O
low,134,O
(,134,O
2.8,134,O
microgramg/ml,134,O
),134,O
.,134,O
The,135,O
encephalopathy,135,B-Disease
was,135,O
probably,135,O
an,135,O
idiosyncratic,135,O
and,135,O
not,135,O
toxic,135,O
or,135,O
allergic,135,O
reaction,135,O
.,135,O
In,136,O
fact,136,O
the,136,O
concentration,136,O
of,136,O
free,136,O
DPH,136,B-Chemical
was,136,O
normal,136,O
",",136,O
the,136,O
patient,136,O
presented,136,O
a,136,O
retarded,136,O
morbilliform,136,O
rash,136,B-Disease
during,136,O
DPH,136,B-Chemical
treatment,136,O
",",136,O
the,136,O
protidogram,136,O
was,136,O
normal,136,O
",",136,O
and,136,O
an,136,O
intradermic,136,O
DPH,136,B-Chemical
injection,136,O
had,136,O
no,136,O
local,136,O
effect,136,O
.,136,O
The,137,O
authors,137,O
conclude,137,O
that,137,O
in,137,O
a,137,O
patient,137,O
starting,137,O
DPH,137,B-Chemical
treatment,137,O
an,137,O
unexpected,137,O
increase,137,O
in,137,O
seizures,137,B-Disease
",",137,O
with,137,O
EEG,137,O
and,137,O
mental,137,O
changes,137,O
occurring,137,O
simultaneously,137,O
",",137,O
should,137,O
alert,137,O
the,137,O
physician,137,O
to,137,O
the,137,O
possible,137,O
need,137,O
for,137,O
eliminating,137,O
DPH,137,B-Chemical
from,137,O
the,137,O
therapeutic,137,O
regimen,137,O
",",137,O
even,137,O
if,137,O
plasma,137,O
concentrations,137,O
are,137,O
low,137,O
.,137,O
Effects,138,O
of,138,O
exercise,138,O
on,138,O
the,138,O
severity,138,O
of,138,O
isoproterenol-induced,138,B-Chemical
myocardial,138,B-Disease
infarction,138,I-Disease
.,138,O
The,139,O
effect,139,O
of,139,O
exercise,139,O
on,139,O
the,139,O
severity,139,O
of,139,O
isoproterenol-induced,139,B-Chemical
myocardial,139,B-Disease
infarction,139,I-Disease
was,139,O
studied,139,O
in,139,O
male,139,O
rats,139,O
.,139,O
Ninety-three,140,O
rats,140,O
were,140,O
randomly,140,O
divided,140,O
into,140,O
three,140,O
groups,140,O
.,140,O
The,141,O
exercise-isoproterenol,141,O
(,141,O
E-1,141,O
),141,O
and,141,O
exercise,141,O
control,141,O
(,141,O
EC,141,O
),141,O
groups,141,O
exercised,141,O
daily,141,O
for,141,O
thirty,141,O
days,141,O
on,141,O
a,141,O
treadmill,141,O
at,141,O
1,141,O
mph,141,O
",",141,O
2,141,O
%,141,O
grade,141,O
while,141,O
animals,141,O
of,141,O
the,141,O
sedentary-isoproterenol,141,O
(,141,O
S-I,141,O
),141,O
group,141,O
remained,141,O
sedentary,141,O
.,141,O
Eight,142,O
animals,142,O
were,142,O
assigned,142,O
to,142,O
the,142,O
sedentary,142,O
control,142,O
(,142,O
SC,142,O
),142,O
group,142,O
which,142,O
remained,142,O
sedentary,142,O
throughout,142,O
the,142,O
experimental,142,O
period,142,O
.,142,O
Forty-eight,143,O
hours,143,O
after,143,O
the,143,O
final,143,O
exercise,143,O
period,143,O
",",143,O
S-I,143,O
and,143,O
E-I,143,O
animals,143,O
received,143,O
a,143,O
single,143,O
subcutaneous,143,O
injection,143,O
of,143,O
isoproterenol,143,B-Chemical
(,143,O
250,143,O
mg/kg,143,O
body,143,O
weight,143,O
),143,O
.,143,O
Animals,144,O
of,144,O
the,144,O
S-I,144,O
group,144,O
exhibited,144,O
significantly,144,O
(,144,O
Pp,144,O
less,144,O
than,144,O
0.05,144,O
),144,O
greater,144,O
mortality,144,O
from,144,O
the,144,O
effects,144,O
of,144,O
isoproterenol,144,B-Chemical
than,144,O
animals,144,O
of,144,O
the,144,O
E-I,144,O
group,144,O
.,144,O
Serum,145,O
CPK,145,O
activity,145,O
for,145,O
E-I,145,O
animals,145,O
was,145,O
significantly,145,O
(,145,O
p,145,O
less,145,O
than,145,O
0.05,145,O
),145,O
greater,145,O
than,145,O
for,145,O
animals,145,O
in,145,O
the,145,O
S-I,145,O
and,145,O
EC,145,O
groups,145,O
twenty,145,O
hours,145,O
following,145,O
isoproterenol,145,B-Chemical
injection,145,O
.,145,O
No,146,O
statistically,146,O
significant,146,O
differences,146,O
were,146,O
observed,146,O
between,146,O
the,146,O
two,146,O
isoproterenol,146,B-Chemical
treated,146,O
groups,146,O
for,146,O
severity,146,O
of,146,O
the,146,O
induced,146,O
lesions,146,O
",",146,O
changes,146,O
in,146,O
heart,146,O
weight,146,O
",",146,O
or,146,O
heart,146,O
weight,146,O
to,146,O
body,146,O
weight,146,O
ratios,146,O
.,146,O
The,147,O
results,147,O
indicated,147,O
that,147,O
exercise,147,O
reduced,147,O
the,147,O
mortality,147,O
associated,147,O
with,147,O
the,147,O
effects,147,O
of,147,O
large,147,O
dosages,147,O
of,147,O
isoproterenol,147,B-Chemical
but,147,O
had,147,O
little,147,O
on,147,O
the,147,O
severity,147,O
of,147,O
the,147,O
infarction,147,B-Disease
.,147,O
Fetal,148,O
risks,148,O
due,148,O
to,148,O
warfarin,148,B-Chemical
therapy,148,O
during,148,O
pregnancy,148,O
.,148,O
Two,149,O
mothers,149,O
with,149,O
heart,149,O
valve,149,O
prosthesis,149,O
were,149,O
treated,149,O
with,149,O
warfarin,149,B-Chemical
during,149,O
pregnancy,149,O
.,149,O
In,150,O
the,150,O
first,150,O
case,150,O
a,150,O
caesarean,150,O
section,150,O
was,150,O
done,150,O
one,150,O
week,150,O
after,150,O
replacement,150,O
of,150,O
warfarin,150,B-Chemical
with,150,O
heparin,150,B-Chemical
.,150,O
The,151,O
baby,151,O
died,151,O
of,151,O
cerebral,151,O
and,151,O
pulmonary,151,O
hemorrhage,151,O
.,151,O
The,152,O
second,152,O
mother,152,O
had,152,O
a,152,O
male,152,O
infant,152,O
by,152,O
caesarean,152,O
section,152,O
.,152,O
The,153,O
baby,153,O
showed,153,O
warfarin-induced,153,B-Chemical
embryopathy,153,B-Disease
with,153,O
nasal,153,B-Disease
hypoplasia,153,I-Disease
and,153,O
stippled,153,B-Disease
epiphyses,153,I-Disease
(,153,O
chondrodysplasia,153,B-Disease
punctata,153,I-Disease
),153,O
.,153,O
Nasal,154,B-Disease
hypoplasia,154,I-Disease
with,154,O
or,154,O
without,154,O
stippled,154,B-Disease
epiphyses,154,I-Disease
has,154,O
now,154,O
been,154,O
reported,154,O
in,154,O
11,154,O
infants,154,O
born,154,O
to,154,O
mothers,154,O
treated,154,O
with,154,O
warfarin,154,B-Chemical
during,154,O
the,154,O
first,154,O
trimester,154,O
",",154,O
and,154,O
a,154,O
causal,154,O
association,154,O
is,154,O
probable,154,O
.,154,O
In,155,O
view,155,O
of,155,O
the,155,O
risks,155,O
to,155,O
both,155,O
mother,155,O
and,155,O
fetus,155,O
in,155,O
women,155,O
with,155,O
prosthetic,155,O
cardiac,155,O
valves,155,O
it,155,O
is,155,O
recommended,155,O
that,155,O
therapeutic,155,O
abortion,155,O
be,155,O
advised,155,O
as,155,O
the,155,O
first,155,O
alternative,155,O
.,155,O
Effect,156,O
of,156,O
D-Glucarates,156,B-Chemical
on,156,O
basic,156,O
antibiotic-induced,156,O
renal,156,B-Disease
damage,156,I-Disease
in,156,O
rats,156,O
.,156,O
Dehydrated,157,B-Disease
rats,157,O
regularly,157,O
develop,157,O
acute,157,B-Disease
renal,157,I-Disease
failure,157,I-Disease
following,157,O
single,157,O
injection,157,O
of,157,O
aminoglycoside,157,B-Chemical
antibiotics,157,O
combined,157,O
with,157,O
dextran,157,O
or,157,O
of,157,O
antibiotics,157,O
only,157,O
.,157,O
Oral,158,O
administration,158,O
of,158,O
"2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone",158,B-Chemical
protected,158,O
rats,158,O
against,158,O
renal,158,B-Disease
failure,158,I-Disease
induced,158,O
by,158,O
kanamycin-dextran,158,B-Chemical
.,158,O
The,159,O
protective,159,O
effect,159,O
was,159,O
prevalent,159,O
among,159,O
D-glucarates,159,B-Chemical
",",159,O
and,159,O
also,159,O
to,159,O
other,159,O
saccharic,159,B-Chemical
acid,159,I-Chemical
",",159,O
hexauronic,159,B-Chemical
acids,159,I-Chemical
and,159,O
hexaaldonic,159,B-Chemical
acids,159,I-Chemical
",",159,O
although,159,O
to,159,O
a,159,O
lesser,159,O
degree,159,O
",",159,O
but,159,O
not,159,O
to,159,O
a,159,O
hexaaldose,159,O
",",159,O
sugar,159,B-Chemical
alcohols,159,I-Chemical
",",159,O
substances,159,O
inthe,159,O
TCA,159,B-Chemical
cycle,159,O
and,159,O
other,159,O
acidic,159,O
compounds,159,O
.,159,O
D-Glucarates,160,B-Chemical
were,160,O
effective,160,O
against,160,O
renal,160,B-Disease
damage,160,I-Disease
induced,160,O
by,160,O
peptide,160,O
antibiotics,160,O
as,160,O
well,160,O
as,160,O
various,160,O
aminoglycoside,160,B-Chemical
antibitocis,160,O
.,160,O
Dose-responses,161,O
were,161,O
observed,161,O
in,161,O
the,161,O
protective,161,O
effect,161,O
of,161,O
D-Glucarates,161,B-Chemical
.,161,O
With,162,O
a,162,O
D-glucarate,162,B-Chemical
of,162,O
a,162,O
fixed,162,O
size,162,O
of,162,O
dose,162,O
",",162,O
approximately,162,O
the,162,O
same,162,O
degree,162,O
of,162,O
protection,162,O
was,162,O
obtained,162,O
against,162,O
renal,162,B-Disease
damages,162,I-Disease
induced,162,O
by,162,O
different,162,O
basic,162,O
antibiotics,162,O
despite,162,O
large,162,O
disparities,162,O
in,162,O
administration,162,O
doses,162,O
of,162,O
different,162,O
antibiotics,162,O
.,162,O
D-Glucarates,163,B-Chemical
had,163,O
the,163,O
ability,163,O
to,163,O
prevent,163,O
renal,163,B-Disease
damage,163,I-Disease
but,163,O
not,163,O
to,163,O
cure,163,O
it,163,O
.,163,O
Rats,164,O
excreted,164,O
acidic,164,O
urine,164,O
when,164,O
they,164,O
were,164,O
spared,164,O
from,164,O
renal,164,B-Disease
lesions,164,I-Disease
by,164,O
monosaccharides,164,B-Chemical
.,164,O
The,165,O
reduction,165,O
effect,165,O
of,165,O
D-glucarates,165,B-Chemical
against,165,O
nephrotoxicity,165,B-Disease
of,165,O
basic,165,O
antibiotics,165,O
was,165,O
discussed,165,O
.,165,O
Paraplegia,166,B-Disease
following,166,O
intrathecal,166,O
methotrexate,166,B-Chemical
:,166,O
report,166,O
of,166,O
a,166,O
case,166,O
and,166,O
review,166,O
of,166,O
the,166,O
literature,166,O
.,166,O
A,167,O
patient,167,O
who,167,O
developed,167,O
paraplegia,167,B-Disease
following,167,O
the,167,O
intrathecal,167,O
instillation,167,O
of,167,O
methotrexate,167,B-Chemical
is,167,O
discribed,167,O
.,167,O
The,168,O
ten,168,O
previously,168,O
reported,168,O
cases,168,O
of,168,O
this,168,O
unusual,168,O
complication,168,O
are,168,O
reviewed,168,O
.,168,O
The,169,O
following,169,O
factors,169,O
appear,169,O
to,169,O
predispose,169,O
to,169,O
the,169,O
development,169,O
of,169,O
this,169,O
complication,169,O
:,169,O
abnormal,169,O
cerebrospinal,169,O
dynamics,169,O
related,169,O
to,169,O
the,169,O
presence,169,O
of,169,O
central,169,B-Disease
nervous,169,I-Disease
system,169,I-Disease
leukemia,169,I-Disease
",",169,O
and,169,O
epidural,169,O
cerebrospinal,169,O
leakage,169,O
;,169,O
elevated,169,O
cerebrospinal,169,O
fluid,169,O
methothexate,169,B-Chemical
concentration,169,O
related,169,O
to,169,O
abnormal,169,O
cerebrospinal,169,O
fluid,169,O
dynamics,169,O
and,169,O
to,169,O
inappropriately,169,O
high,169,O
methotrexate,169,B-Chemical
doses,169,O
based,169,O
on,169,O
body,169,O
surface,169,O
area,169,O
calculations,169,O
in,169,O
older,169,O
children,169,O
and,169,O
adults,169,O
;,169,O
the,169,O
presence,169,O
of,169,O
neurotoxic,169,B-Disease
preservatives,169,O
in,169,O
commercially,169,O
available,169,O
methotrexate,169,B-Chemical
preparations,169,O
and,169,O
diluents,169,O
;,169,O
and,169,O
the,169,O
use,169,O
of,169,O
methotrexate,169,B-Chemical
diluents,169,O
of,169,O
unphysiologic,169,O
pH,169,O
",",169,O
ionic,169,O
content,169,O
and,169,O
osmolarity,169,O
.,169,O
The,170,O
role,170,O
of,170,O
methotrexate,170,B-Chemical
contaminants,170,O
",",170,O
local,170,O
folate,170,B-Disease
deficiency,170,I-Disease
",",170,O
and,170,O
cranial,170,O
irradiation,170,O
in,170,O
the,170,O
pathogenesis,170,O
of,170,O
intrathecal,170,O
methotrexate,170,B-Chemical
toxicity,170,B-Disease
is,170,O
unclear,170,O
.,170,O
The,171,O
incidence,171,O
of,171,O
neurotoxicity,171,B-Disease
may,171,O
be,171,O
reduced,171,O
by,171,O
employing,171,O
lower,171,O
doses,171,O
of,171,O
methotrexate,171,B-Chemical
in,171,O
the,171,O
presence,171,O
of,171,O
central,171,B-Disease
nervous,171,I-Disease
system,171,I-Disease
leukemia,171,I-Disease
",",171,O
in,171,O
older,171,O
children,171,O
and,171,O
adults,171,O
",",171,O
and,171,O
in,171,O
the,171,O
presence,171,O
of,171,O
epidural,171,O
leakage,171,O
.,171,O
Only,172,O
preservative-free,172,O
methotrexate,172,B-Chemical
in,172,O
Elliott,172,O
's,172,O
B,172,O
Solution,172,O
at,172,O
a,172,O
concentration,172,O
of,172,O
not,172,O
more,172,O
than,172,O
1,172,O
mg/ml,172,O
should,172,O
be,172,O
used,172,O
for,172,O
intrathecal,172,O
administration,172,O
.,172,O
Periodic,173,O
monitoring,173,O
of,173,O
cerebruspinal,173,O
fluid,173,O
methotrexate,173,B-Chemical
levels,173,O
may,173,O
be,173,O
predictive,173,O
of,173,O
the,173,O
development,173,O
of,173,O
serious,173,O
neurotoxicity,173,B-Disease
.,173,O
Centrally,174,O
mediated,174,O
cardiovascular,174,O
effects,174,O
of,174,O
intracisternal,174,O
application,174,O
of,174,O
carbachol,174,B-Chemical
in,174,O
anesthetized,174,O
rats,174,O
.,174,O
The,175,O
pressor,175,O
response,175,O
to,175,O
the,175,O
intracisternal,175,O
(,175,O
i.c,175,O
.,175,O
),175,O
injection,176,O
of,176,O
carbachol,176,B-Chemical
(,176,O
1,176,O
mug,176,O
),176,O
in,176,O
anesthetized,176,O
rats,176,O
was,176,O
analyzed,176,O
.,176,O
This,177,O
response,177,O
was,177,O
significantly,177,O
reduced,177,O
by,177,O
the,177,O
intravenous,177,O
(,177,O
i.v,177,O
.,177,O
),177,O
injection,178,O
of,178,O
guanethidine,178,B-Chemical
(,178,O
5,178,O
mg,178,O
),178,O
",",178,O
hexamethonium,178,B-Chemical
(,178,O
10,178,O
mg,178,O
),178,O
or,178,O
phentolamine,178,B-Chemical
(,178,O
5,178,O
mg,178,O
),178,O
",",178,O
and,178,O
conversely,178,O
",",178,O
potentiated,178,O
by,178,O
i.v,178,O
.,178,O
desmethylimipramine,179,B-Chemical
(,179,O
0.3,179,O
mg,179,O
),179,O
",",179,O
while,179,O
propranolol,179,B-Chemical
(,179,O
0.5,179,O
mg,179,O
),179,O
i.v,179,O
.,179,O
selectively,180,O
inhibited,180,O
the,180,O
enlargement,180,B-Disease
of,180,I-Disease
pulse,180,I-Disease
pressure,180,I-Disease
and,180,O
the,180,O
tachycardia,180,B-Disease
following,180,O
i.c,180,O
.,180,O
carbachol,181,B-Chemical
(,181,O
1,181,O
mug,181,O
),181,O
.,181,O
On,182,O
the,182,O
other,182,O
hand,182,O
",",182,O
the,182,O
pressor,182,O
response,182,O
to,182,O
i.c,182,O
.,182,O
carbachol,183,B-Chemical
(,183,O
1,183,O
mug,183,O
),183,O
was,183,O
almost,183,O
completely,183,O
blocked,183,O
by,183,O
i.c,183,O
.,183,O
atropine,184,B-Chemical
(,184,O
3,184,O
mug,184,O
),184,O
or,184,O
hexamethonium,184,B-Chemical
(,184,O
500,184,O
mug,184,O
),184,O
",",184,O
and,184,O
significantly,184,O
reduced,184,O
by,184,O
i.c,184,O
.,184,O
chlorpromazine,185,B-Chemical
(,185,O
50,185,O
mug,185,O
),185,O
but,185,O
significantly,185,O
potentiated,185,O
by,185,O
i.c,185,O
.,185,O
desmethylimipramine,186,B-Chemical
(,186,O
30,186,O
mug,186,O
),186,O
.,186,O
The,187,O
pressor,187,O
response,187,O
to,187,O
i.c,187,O
.,187,O
carbachol,188,B-Chemical
(,188,O
1,188,O
mug,188,O
),188,O
remained,188,O
unchanged,188,O
after,188,O
sectioning,188,O
of,188,O
the,188,O
bilateral,188,O
cervical,188,O
vagal,188,O
nerves,188,O
but,188,O
disappeared,188,O
after,188,O
sectioning,188,O
of,188,O
the,188,O
spinal,188,O
cord,188,O
(,188,O
C7-C8,188,O
),188,O
.,188,O
From,189,O
the,189,O
above,189,O
result,189,O
it,189,O
is,189,O
suggested,189,O
that,189,O
the,189,O
pressor,189,O
response,189,O
to,189,O
i.c,189,O
.,189,O
carbachol,190,B-Chemical
ortral,190,O
and,190,O
peripheral,190,O
adrenergic,190,O
mechanisms,190,O
",",190,O
and,190,O
that,190,O
the,190,O
sympathetic,190,O
trunk,190,O
is,190,O
the,190,O
main,190,O
pathway,190,O
.,190,O
Hyperglycemic,191,B-Disease
effect,191,O
of,191,O
amino,191,B-Chemical
compounds,191,O
structurally,191,O
related,191,O
to,191,O
caproate,191,B-Chemical
in,191,O
rats,191,O
.,191,O
The,192,O
chronic,192,O
feeding,192,O
of,192,O
small,192,O
amounts,192,O
(,192,O
0.3-3,192,O
%,192,O
of,192,O
diet,192,O
weight,192,O
),192,O
of,192,O
certain,192,O
amino,192,B-Chemical
derivatives,192,O
of,192,O
caproate,192,B-Chemical
resulted,192,O
in,192,O
hyperglycemia,192,B-Disease
",",192,O
an,192,O
elevated,192,O
glucose,192,B-Chemical
tolerance,192,O
curve,192,O
and,192,O
",",192,O
occasionally,192,O
",",192,O
glucosuria,192,B-Disease
.,192,O
Effective,193,O
compounds,193,O
included,193,O
norleucine,193,B-Chemical
",",193,O
norvaline,193,B-Chemical
",",193,O
glutamate,193,B-Chemical
",",193,O
epsilon-aminocaproate,193,B-Chemical
",",193,O
methionine,193,B-Chemical
",",193,O
and,193,O
leucine,193,B-Chemical
.,193,O
Fatty,194,B-Disease
liver,194,I-Disease
induced,194,O
by,194,O
tetracycline,194,B-Chemical
in,194,O
the,194,O
rat,194,O
.,194,O
Dose-response,195,O
relationships,195,O
and,195,O
effect,195,O
of,195,O
sex,195,O
.,195,O
Dose-response,196,O
relationships,196,O
",",196,O
biochemical,196,O
mechanisms,196,O
",",196,O
and,196,O
sex,196,O
differences,196,O
in,196,O
the,196,O
experimental,196,O
fatty,196,B-Disease
liver,196,I-Disease
induced,196,O
by,196,O
tetracycline,196,B-Chemical
were,196,O
studied,196,O
in,196,O
the,196,O
intact,196,O
rat,196,O
and,196,O
with,196,O
the,196,O
isolated,196,O
perfused,196,O
rat,196,O
liver,196,O
in,196,O
vitro,196,O
.,196,O
In,197,O
the,197,O
intact,197,O
male,197,O
and,197,O
female,197,O
rat,197,O
",",197,O
no,197,O
direct,197,O
relationship,197,O
was,197,O
observed,197,O
between,197,O
dose,197,O
of,197,O
tetracycline,197,B-Chemical
and,197,O
hepatic,197,O
accumulation,197,O
of,197,O
triglyceride,197,B-Chemical
.,197,O
With,198,O
provision,198,O
of,198,O
adequate,198,O
oleic,198,B-Chemical
acid,198,I-Chemical
as,198,O
a,198,O
substrate,198,O
for,198,O
the,198,O
isolated,198,O
perfused,198,O
liver,198,O
",",198,O
a,198,O
direct,198,O
relationship,198,O
was,198,O
observed,198,O
between,198,O
dose,198,O
of,198,O
tetracycline,198,B-Chemical
and,198,O
both,198,O
accumulation,198,O
of,198,O
triglyceride,198,B-Chemical
in,198,O
the,198,O
liver,198,O
and,198,O
depression,198,B-Disease
of,198,O
output,198,O
of,198,O
triglyceride,198,B-Chemical
by,198,O
livers,198,O
from,198,O
male,198,O
and,198,O
female,198,O
rats,198,O
.,198,O
Marked,199,O
differences,199,O
were,199,O
observed,199,O
between,199,O
female,199,O
and,199,O
male,199,O
rats,199,O
with,199,O
regard,199,O
to,199,O
base,199,O
line,199,O
(,199,O
control,199,O
),199,O
hepatic,199,O
concentration,199,O
of,199,O
triglyceride,199,B-Chemical
and,199,O
output,199,O
of,199,O
triglyceride,199,B-Chemical
.,199,O
Accumulation,200,O
of,200,O
hepatic,200,O
triglyceride,200,B-Chemical
",",200,O
as,200,O
a,200,O
per,200,O
cent,200,O
of,200,O
control,200,O
values,200,O
",",200,O
in,200,O
response,200,O
to,200,O
graded,200,O
doses,200,O
of,200,O
tetracycline,200,B-Chemical
",",200,O
did,200,O
not,200,O
differ,200,O
significantly,200,O
between,200,O
male,200,O
",",200,O
female,200,O
and,200,O
pregnant,200,O
rat,200,O
livers,200,O
.,200,O
However,201,O
",",201,O
livers,201,O
from,201,O
female,201,O
",",201,O
and,201,O
especially,201,O
pregnant,201,O
female,201,O
rats,201,O
",",201,O
were,201,O
strikingly,201,O
resistant,201,O
to,201,O
the,201,O
effects,201,O
of,201,O
tetracycline,201,B-Chemical
on,201,O
depression,201,B-Disease
of,201,O
output,201,O
of,201,O
triglyceride,201,B-Chemical
under,201,O
these,201,O
experimental,201,O
conditions,201,O
.,201,O
These,202,O
differences,202,O
between,202,O
the,202,O
sexes,202,O
could,202,O
not,202,O
be,202,O
related,202,O
to,202,O
altered,202,O
disposition,202,O
of,202,O
tetracycline,202,B-Chemical
or,202,O
altered,202,O
uptake,202,O
of,202,O
oleic,202,B-Chemical
acid,202,I-Chemical
.,202,O
Depressed,203,O
hepatic,203,O
secretion,203,O
of,203,O
triglyceride,203,B-Chemical
accounted,203,O
only,203,O
for,203,O
30,203,O
to,203,O
50,203,O
%,203,O
of,203,O
accumulated,203,O
hepatic,203,O
triglyceride,203,B-Chemical
",",203,O
indicating,203,O
that,203,O
additional,203,O
mechanisms,203,O
must,203,O
be,203,O
involved,203,O
in,203,O
the,203,O
production,203,O
of,203,O
the,203,O
triglyceride-rich,203,B-Chemical
fatty,203,B-Disease
liver,203,I-Disease
in,203,O
response,203,O
to,203,O
tetracycline,203,B-Chemical
.,203,O
Fatal,204,O
myeloencephalopathy,204,B-Disease
due,204,O
to,204,O
intrathecal,204,O
vincristine,204,B-Chemical
administration,204,O
.,204,O
Vincristine,205,B-Chemical
was,205,O
accidentally,205,O
given,205,O
intrathecally,205,O
to,205,O
a,205,O
child,205,O
with,205,O
leukaemia,205,B-Disease
",",205,O
producing,205,O
sensory,205,B-Disease
and,205,I-Disease
motor,205,I-Disease
dysfunction,205,I-Disease
followed,205,O
by,205,O
encephalopathy,205,B-Disease
and,205,O
death,205,O
.,205,O
Separate,206,O
times,206,O
for,206,O
administering,206,O
vincristine,206,B-Chemical
and,206,O
intrathecal,206,O
therapy,206,O
is,206,O
recommended,206,O
.,206,O
Progesterone,207,B-Chemical
potentiation,207,O
of,207,O
bupivacaine,207,B-Chemical
arrhythmogenicity,207,O
in,207,O
pentobarbital-anesthetized,207,B-Chemical
rats,207,O
and,207,O
beating,207,O
rat,207,O
heart,207,O
cell,207,O
cultures,207,O
.,207,O
The,208,O
effects,208,O
of,208,O
progesterone,208,B-Chemical
treatment,208,O
on,208,O
bupivacaine,208,B-Chemical
arrhythmogenicity,208,O
in,208,O
beating,208,O
rat,208,O
heart,208,O
myocyte,208,O
cultures,208,O
and,208,O
on,208,O
anesthetized,208,O
rats,208,O
were,208,O
determined,208,O
.,208,O
After,209,O
determining,209,O
the,209,O
bupivacaine,209,B-Chemical
AD50,209,O
(,209,O
the,209,O
concentration,209,O
of,209,O
bupivacaine,209,B-Chemical
that,209,O
caused,209,O
50,209,O
%,209,O
of,209,O
all,209,O
beating,209,O
rat,209,O
heart,209,O
myocyte,209,O
cultures,209,O
to,209,O
become,209,O
arrhythmic,209,B-Disease
),209,O
",",209,O
we,209,O
determined,209,O
the,209,O
effect,209,O
of,209,O
1-hour,209,O
progesterone,209,B-Chemical
HCl,209,B-Chemical
exposure,209,O
on,209,O
myocyte,209,O
contractile,209,O
rhythm,209,O
.,209,O
Each,210,O
concentration,210,O
of,210,O
progesterone,210,B-Chemical
(,210,O
6.25,210,O
",",210,O
12.5,210,O
",",210,O
25,210,O
",",210,O
and,210,O
50,210,O
micrograms/ml,210,O
),210,O
caused,210,O
a,210,O
significant,210,O
and,210,O
concentration-dependent,210,O
reduction,210,O
in,210,O
the,210,O
AD50,210,O
for,210,O
bupivacaine,210,B-Chemical
.,210,O
Estradiol,211,B-Chemical
treatment,211,O
also,211,O
increased,211,O
the,211,O
arrhythmogenicity,211,O
of,211,O
bupivacaine,211,B-Chemical
in,211,O
myocyte,211,O
cultures,211,O
",",211,O
but,211,O
was,211,O
only,211,O
one,211,O
fourth,211,O
as,211,O
potent,211,O
as,211,O
progesterone,211,B-Chemical
.,211,O
Neither,212,O
progesterone,212,B-Chemical
nor,212,O
estradiol,212,B-Chemical
effects,212,O
on,212,O
bupivacaine,212,B-Chemical
arrhythmogenicity,212,O
were,212,O
potentiated,212,O
by,212,O
epinephrine,212,B-Chemical
.,212,O
Chronic,213,O
progesterone,213,B-Chemical
pretreatment,213,O
(,213,O
5,213,O
mg/kg/day,213,O
for,213,O
21,213,O
days,213,O
),213,O
caused,213,O
a,213,O
significant,213,O
increase,213,O
in,213,O
bupivacaine,213,B-Chemical
arrhythmogenicity,213,O
in,213,O
intact,213,O
pentobarbital-anesthetized,213,B-Chemical
rats,213,O
.,213,O
There,214,O
was,214,O
a,214,O
significant,214,O
decrease,214,O
in,214,O
the,214,O
time,214,O
to,214,O
onset,214,O
of,214,O
arrhythmia,214,B-Disease
as,214,O
compared,214,O
with,214,O
control,214,O
nonprogesterone-treated,214,O
rats,214,O
(,214,O
6.2,214,O
+/-,214,O
1.3,214,O
vs.,214,O
30.8,214,O
+/-,214,O
2.5,214,O
min,214,O
",",214,O
mean,214,O
+/-,214,O
SE,214,O
),214,O
.,214,O
The,215,O
results,215,O
of,215,O
this,215,O
study,215,O
indicate,215,O
that,215,O
progesterone,215,B-Chemical
can,215,O
potentiate,215,O
bupivacaine,215,B-Chemical
arrhythmogenicity,215,O
both,215,O
in,215,O
vivo,215,O
and,215,O
in,215,O
vitro,215,O
.,215,O
Potentiation,216,O
of,216,O
bupivacaine,216,B-Chemical
arrhythmia,216,B-Disease
in,216,O
myocyte,216,O
cultures,216,O
suggests,216,O
that,216,O
this,216,O
effect,216,O
is,216,O
at,216,O
least,216,O
partly,216,O
mediated,216,O
at,216,O
the,216,O
myocyte,216,O
level,216,O
.,216,O
Acute,217,B-Disease
renal,217,I-Disease
failure,217,I-Disease
occurring,217,O
during,217,O
intravenous,217,O
desferrioxamine,217,B-Chemical
therapy,217,O
:,217,O
recovery,217,O
after,217,O
haemodialysis,217,O
.,217,O
A,218,O
patient,218,O
with,218,O
transfusion-dependent,218,O
thalassemia,218,B-Disease
was,218,O
undergoing,218,O
home,218,O
intravenous,218,O
desferrioxamine,218,B-Chemical
(,218,O
DFX,218,B-Chemical
),218,O
treatment,218,O
by,218,O
means,218,O
of,218,O
a,218,O
totally,218,O
implanted,218,O
system,218,O
because,218,O
of,218,O
his,218,O
poor,218,O
compliance,218,O
with,218,O
the,218,O
nightly,218,O
subcutaneous,218,O
therapy,218,O
.,218,O
Due,219,O
to,219,O
an,219,O
accidental,219,O
malfunctioning,219,O
of,219,O
the,219,O
infusion,219,O
pump,219,O
",",219,O
the,219,O
patient,219,O
was,219,O
inadvertently,219,O
administered,219,O
a,219,O
toxic,219,O
dosage,219,O
of,219,O
the,219,O
drug,219,O
which,219,O
caused,219,O
renal,219,B-Disease
insufficiency,219,I-Disease
.,219,O
Given,220,O
the,220,O
progressive,220,O
deterioration,220,O
of,220,O
the,220,O
symptoms,220,O
and,220,O
of,220,O
the,220,O
laboratory,220,O
values,220,O
",",220,O
despite,220,O
adequate,220,O
medical,220,O
treatment,220,O
",",220,O
a,220,O
decision,220,O
was,220,O
made,220,O
to,220,O
introduce,220,O
haemodialytical,220,O
therapy,220,O
in,220,O
order,220,O
to,220,O
remove,220,O
the,220,O
drug,220,O
and,220,O
therapy,220,O
reduce,220,O
the,220,O
nephrotoxicity,220,B-Disease
.,220,O
From,221,O
the,221,O
results,221,O
obtained,221,O
",",221,O
haemodialysis,221,O
can,221,O
therefore,221,O
be,221,O
suggested,221,O
as,221,O
a,221,O
useful,221,O
therapy,221,O
in,221,O
rare,221,O
cases,221,O
of,221,O
progressive,221,O
acute,221,B-Disease
renal,221,I-Disease
failure,221,I-Disease
caused,221,O
by,221,O
desferrioxamine,221,B-Chemical
.,221,O
Neuroleptic-associated,222,B-Chemical
hyperprolactinemia,222,B-Disease
.,222,O
Can,223,O
it,223,O
be,223,O
treated,223,O
with,223,O
bromocriptine,223,B-Chemical
?,223,O
Six,224,O
stable,224,O
psychiatric,224,O
outpatients,224,O
with,224,O
hyperprolactinemia,224,B-Disease
and,224,O
amenorrhea/oligomenorrhea,224,B-Disease
associated,224,O
with,224,O
their,224,O
neuroleptic,224,B-Chemical
medications,224,I-Chemical
were,224,O
treated,224,O
with,224,O
bromocriptine,224,B-Chemical
.,224,O
Daily,225,O
dosages,225,O
of,225,O
5-10,225,O
mg,225,O
corrected,225,O
the,225,O
hyperprolactinemia,225,B-Disease
and,225,O
restored,225,O
menstruation,225,O
in,225,O
four,225,O
of,225,O
the,225,O
six,225,O
patients,225,O
.,225,O
One,226,O
woman,226,O
",",226,O
however,226,O
",",226,O
developed,226,O
worsened,226,O
psychiatric,226,B-Disease
symptoms,226,I-Disease
while,226,O
taking,226,O
bromocriptine,226,B-Chemical
",",226,O
and,226,O
it,226,O
was,226,O
discontinued,226,O
.,226,O
Thus,227,O
",",227,O
three,227,O
of,227,O
six,227,O
patients,227,O
had,227,O
their,227,O
menstrual,227,O
irregularity,227,O
successfully,227,O
corrected,227,O
with,227,O
bromocriptine,227,B-Chemical
.,227,O
This,228,O
suggests,228,O
that,228,O
bromocriptine,228,B-Chemical
should,228,O
be,228,O
further,228,O
evaluated,228,O
as,228,O
potential,228,O
therapy,228,O
for,228,O
neuroleptic-associated,228,B-Chemical
hyperprolactinemia,228,B-Disease
and,228,O
amenorrhea/galactorrhea,228,B-Disease
.,228,O
Ethacrynic,229,B-Chemical
acid-induced,229,O
convulsions,229,B-Disease
and,229,O
brain,229,O
neurotransmitters,229,O
in,229,O
mice,229,O
.,229,O
Intracerebroventricular,230,O
injection,230,O
of,230,O
ethacrynic,230,B-Chemical
acid,230,I-Chemical
(,230,O
50,230,O
%,230,O
convulsive,230,B-Disease
dose,230,O
;,230,O
50,230,O
micrograms/mouse,230,O
),230,O
accelerated,230,O
the,230,O
synthesis/turnover,230,O
of,230,O
5-hydroxytryptamine,230,B-Chemical
(,230,O
5-HT,230,B-Chemical
),230,O
but,230,O
suppressed,230,O
the,230,O
synthesis,230,O
of,230,O
gamma-aminobutyric,230,B-Chemical
acid,230,I-Chemical
and,230,O
acetylcholine,230,B-Chemical
in,230,O
mouse,230,O
brain,230,O
.,230,O
These,231,O
effects,231,O
were,231,O
completely,231,O
antagonized,231,O
by,231,O
pretreatment,231,O
with,231,O
a,231,O
glutamate/N-methyl-D-aspartate,231,B-Chemical
antagonist,231,O
",",231,O
aminophosphonovaleric,231,B-Chemical
acid,231,I-Chemical
.,231,O
In,232,O
ethacrynic,232,B-Chemical
acid-induced,232,O
convulsions,232,B-Disease
",",232,O
these,232,O
neurotransmitter,232,O
systems,232,O
may,232,O
be,232,O
differentially,232,O
modulated,232,O
",",232,O
probably,232,O
through,232,O
activation,232,O
of,232,O
glutaminergic,232,O
neurons,232,O
in,232,O
the,232,O
brain,232,O
.,232,O
Pharmacology,233,O
of,233,O
gamma-aminobutyric,233,B-Chemical
acidA,233,O
receptor,233,O
complex,233,O
after,233,O
the,233,O
in,233,O
vivo,233,O
administration,233,O
of,233,O
the,233,O
anxioselective,233,O
and,233,O
anticonvulsant,233,O
beta-carboline,233,B-Chemical
derivative,233,O
abecarnil,233,B-Chemical
.,233,O
In,234,O
rodents,234,O
",",234,O
the,234,O
effect,234,O
of,234,O
the,234,O
beta-carboline,234,B-Chemical
derivative,234,O
isopropyl-6-,234,B-Chemical
benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate,234,I-Chemical
(,234,O
abecarrnil,234,B-Chemical
),234,O
",",234,O
a,234,O
new,234,O
ligand,234,O
for,234,O
benzodiazepine,234,B-Chemical
receptors,234,O
possessing,234,O
anxiolytic,234,O
and,234,O
anticonvulsant,234,O
properties,234,O
",",234,O
was,234,O
evaluated,234,O
on,234,O
the,234,O
function,234,O
of,234,O
central,234,O
gamma-aminobutyric,234,B-Chemical
acid,234,I-Chemical
(,234,O
GABA,234,B-Chemical
),234,O
A,234,O
receptor,234,O
complex,234,O
",",234,O
both,234,O
in,234,O
vitro,234,O
and,234,O
in,234,O
vivo,234,O
.,234,O
Added,235,O
in,235,O
vitro,235,O
to,235,O
rat,235,O
cortical,235,O
membrane,235,O
preparation,235,O
",",235,O
abecarnil,235,B-Chemical
increased,235,O
[,235,O
3H,235,O
],235,O
GABA,235,B-Chemical
binding,235,O
",",235,O
enhanced,235,O
muscimol-stimulated,235,B-Chemical
36Cl-,235,O
uptake,235,O
and,235,O
reduced,235,O
the,235,O
binding,235,O
of,235,O
t-,235,B-Chemical
[,235,I-Chemical
35S,235,I-Chemical
],235,I-Chemical
butylbicyclophosphorothionate,235,I-Chemical
(,235,O
[,235,B-Chemical
35S,235,I-Chemical
],235,I-Chemical
TBPS,235,I-Chemical
),235,O
.,235,O
These,236,O
effects,236,O
were,236,O
similar,236,O
to,236,O
those,236,O
induced,236,O
by,236,O
diazepam,236,B-Chemical
",",236,O
whereas,236,O
the,236,O
partial,236,O
agonist,236,O
Ro,236,B-Chemical
16-6028,236,I-Chemical
(,236,O
tert-butyl-,236,B-Chemical
(,236,I-Chemical
S,236,I-Chemical
),236,I-Chemical
"-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-",236,I-Chemical
imidazo,236,I-Chemical
[,236,I-Chemical
"1,5-a",236,I-Chemical
],236,I-Chemical
-pyrrolo-,236,I-Chemical
[,236,I-Chemical
"2,1-c",236,I-Chemical
],236,I-Chemical
[,236,I-Chemical
"1,4",236,I-Chemical
],236,I-Chemical
benzodiazepine-1-carboxylate,236,I-Chemical
),236,O
showed,236,O
very,236,O
weak,236,O
efficacy,236,O
in,236,O
these,236,O
biochemical,236,O
tests,236,O
.,236,O
After,237,O
i.p,237,O
.,237,O
injection,238,O
to,238,O
rats,238,O
",",238,O
abecarnil,238,B-Chemical
and,238,O
diazepam,238,B-Chemical
decreased,238,O
in,238,O
a,238,O
time-dependent,238,O
and,238,O
dose-related,238,O
(,238,O
0.25-20,238,O
mg/kg,238,O
i.p,238,O
.,238,O
),238,O
manner,239,O
[,239,B-Chemical
35S,239,I-Chemical
],239,I-Chemical
TBPS,239,I-Chemical
binding,239,O
measured,239,O
ex,239,O
vivo,239,O
in,239,O
the,239,O
cerebral,239,O
cortex,239,O
.,239,O
Moreover,240,O
",",240,O
both,240,O
drugs,240,O
at,240,O
the,240,O
dose,240,O
of,240,O
0.5,240,O
mg/kg,240,O
antagonized,240,O
completely,240,O
the,240,O
convulsant,240,O
activity,240,O
and,240,O
the,240,O
increase,240,O
of,240,O
[,240,B-Chemical
35S,240,I-Chemical
],240,I-Chemical
TBPS,240,I-Chemical
binding,240,O
induced,240,O
by,240,O
isoniazide,240,B-Chemical
(,240,O
350,240,O
mg/kg,240,O
s.c.,240,O
),240,O
as,240,O
well,240,O
as,240,O
the,240,O
increase,240,O
of,240,O
[,240,B-Chemical
35S,240,I-Chemical
],240,I-Chemical
TBPS,240,I-Chemical
binding,240,O
induced,240,O
by,240,O
foot-shock,240,O
stress,240,O
.,240,O
To,241,O
better,241,O
correlate,241,O
the,241,O
biochemical,241,O
and,241,O
the,241,O
pharmacological,241,O
effects,241,O
",",241,O
we,241,O
studied,241,O
the,241,O
action,241,O
of,241,O
abecarnil,241,B-Chemical
on,241,O
[,241,B-Chemical
35S,241,I-Chemical
],241,I-Chemical
TBPS,241,I-Chemical
binding,241,O
",",241,O
exploratory,241,O
motility,241,O
and,241,O
on,241,O
isoniazid-induced,241,B-Chemical
biochemical,241,O
and,241,O
pharmacological,241,O
effects,241,O
in,241,O
mice,241,O
.,241,O
In,242,O
these,242,O
animals,242,O
",",242,O
abecarnil,242,B-Chemical
produced,242,O
a,242,O
paralleled,242,O
dose-dependent,242,O
(,242,O
0.05-1,242,O
mg/kg,242,O
i.p,242,O
.,242,O
),242,O
reduction,243,O
of,243,O
both,243,O
motor,243,O
behavior,243,O
and,243,O
cortical,243,O
[,243,O
35S,243,O
],243,O
TBPS,243,O
binding,243,O
.,243,O
Moreover,244,O
",",244,O
0.05,244,O
mg/kg,244,O
of,244,O
this,244,O
beta-carboline,244,B-Chemical
reduced,244,O
markedly,244,O
the,244,O
increase,244,O
of,244,O
[,244,B-Chemical
35S,244,I-Chemical
],244,I-Chemical
TBPS,244,I-Chemical
binding,244,O
and,244,O
the,244,O
convulsions,244,B-Disease
induced,244,O
by,244,O
isoniazid,244,B-Chemical
(,244,O
200,244,O
mg/kg,244,O
s.c.,244,O
),244,O
.,244,O
(,245,O
ABSTRACT,245,O
TRUNCATED,245,O
AT,245,O
250,245,O
WORDS,245,O
),245,O
Recurrent,246,O
myocardial,246,B-Disease
infarction,246,I-Disease
in,246,O
a,246,O
postpartum,246,O
patient,246,O
receiving,246,O
bromocriptine,246,B-Chemical
.,246,O
Myocardial,247,B-Disease
infarction,247,I-Disease
in,247,O
puerperium,247,O
is,247,O
infrequently,247,O
reported,247,O
.,247,O
Spasm,248,B-Disease
",",248,O
coronary,248,O
dissection,248,O
",",248,O
or,248,O
atheromatous,248,O
etiology,248,O
has,248,O
been,248,O
described,248,O
.,248,O
Bromocriptine,249,B-Chemical
has,249,O
been,249,O
implicated,249,O
in,249,O
several,249,O
previous,249,O
case,249,O
reports,249,O
of,249,O
myocardial,249,B-Disease
infarction,249,I-Disease
in,249,O
the,249,O
puerperium,249,O
.,249,O
Our,250,O
case,250,O
(,250,O
including,250,O
an,250,O
inadvertent,250,O
rechallenge,250,O
),250,O
suggests,250,O
such,250,O
a,250,O
relationship,250,O
.,250,O
Although,251,O
generally,251,O
regarded,251,O
as,251,O
``,251,O
safe,251,O
",",251,O
'',251,O
possible,251,O
serious,251,O
cardiac,251,O
effects,251,O
of,251,O
bromocriptine,251,B-Chemical
should,251,O
be,251,O
acknowledged,251,O
.,251,O
Asterixis,252,B-Disease
induced,252,O
by,252,O
carbamazepine,252,B-Chemical
therapy,252,O
.,252,O
There,253,O
are,253,O
very,253,O
few,253,O
reports,253,O
about,253,O
asterixis,253,B-Disease
as,253,O
a,253,O
side,253,O
effect,253,O
of,253,O
treatment,253,O
with,253,O
psychopharmacologic,253,O
agents,253,O
.,253,O
In,254,O
this,254,O
report,254,O
we,254,O
present,254,O
four,254,O
patients,254,O
treated,254,O
with,254,O
a,254,O
combination,254,O
of,254,O
different,254,O
psychotropic,254,O
drugs,254,O
",",254,O
in,254,O
whom,254,O
asterixis,254,B-Disease
was,254,O
triggered,254,O
either,254,O
by,254,O
adding,254,O
carbamazepine,254,B-Chemical
(,254,O
CBZ,254,B-Chemical
),254,O
to,254,O
a,254,O
treatment,254,O
regimen,254,O
",",254,O
or,254,O
by,254,O
increasing,254,O
its,254,O
dosage,254,O
.,254,O
Neither,255,O
dosage,255,O
nor,255,O
serum,255,O
levels,255,O
of,255,O
CBZ,255,B-Chemical
were,255,O
in,255,O
a,255,O
higher,255,O
range,255,O
.,255,O
We,256,O
consider,256,O
asterixis,256,B-Disease
to,256,O
be,256,O
an,256,O
easily,256,O
overlooked,256,O
sign,256,O
of,256,O
neurotoxicity,256,B-Disease
",",256,O
which,256,O
may,256,O
occur,256,O
even,256,O
at,256,O
low,256,O
or,256,O
moderate,256,O
dosage,256,O
levels,256,O
",",256,O
if,256,O
certain,256,O
drugs,256,O
as,256,O
lithium,256,B-Chemical
or,256,O
clozapine,256,B-Chemical
are,256,O
used,256,O
in,256,O
combination,256,O
with,256,O
CBZ,256,B-Chemical
.,256,O
Pharmacodynamics,257,O
of,257,O
the,257,O
hypotensive,257,B-Disease
effect,257,O
of,257,O
levodopa,257,B-Chemical
in,257,O
parkinsonian,257,B-Disease
patients,257,O
.,257,O
Blood,258,O
pressure,258,O
effects,258,O
of,258,O
i.v,258,O
.,258,O
levodopa,259,B-Chemical
were,259,O
examined,259,O
in,259,O
parkinsonian,259,B-Disease
patients,259,O
with,259,O
stable,259,O
and,259,O
fluctuating,259,O
responses,259,O
to,259,O
levodopa,259,B-Chemical
.,259,O
The,260,O
magnitude,260,O
of,260,O
the,260,O
hypotensive,260,B-Disease
effect,260,O
of,260,O
levodopa,260,B-Chemical
was,260,O
concentration,260,O
dependent,260,O
and,260,O
was,260,O
fit,260,O
to,260,O
an,260,O
Emax,260,O
model,260,O
in,260,O
fluctuating,260,O
responders,260,O
.,260,O
Stable,261,O
responders,261,O
demonstrated,261,O
a,261,O
small,261,O
hypotensive,261,B-Disease
response,261,O
.,261,O
Baseline,262,O
blood,262,O
pressures,262,O
were,262,O
higher,262,O
in,262,O
fluctuating,262,O
patients,262,O
;,262,O
a,262,O
higher,262,O
baseline,262,O
blood,262,O
pressure,262,O
correlated,262,O
with,262,O
greater,262,O
hypotensive,262,B-Disease
effects,262,O
.,262,O
Antiparkinsonian,263,O
effects,263,O
of,263,O
levodopa,263,B-Chemical
temporally,263,O
correlated,263,O
with,263,O
blood,263,O
pressure,263,O
changes,263,O
.,263,O
Phenylalanine,264,B-Chemical
",",264,O
a,264,O
large,264,O
neutral,264,O
amino,264,B-Chemical
acid,264,I-Chemical
(,264,O
LNAA,264,O
),264,O
competing,264,O
with,264,O
levodopa,264,B-Chemical
for,264,O
transport,264,O
across,264,O
the,264,O
blood-brain,264,O
barrier,264,O
",",264,O
reduced,264,O
the,264,O
hypotensive,264,B-Disease
and,264,O
antiparkinsonian,264,O
effects,264,O
of,264,O
levodopa,264,B-Chemical
.,264,O
We,265,O
conclude,265,O
that,265,O
levodopa,265,B-Chemical
has,265,O
a,265,O
central,265,O
hypotensive,265,B-Disease
action,265,O
that,265,O
parallels,265,O
the,265,O
motor,265,O
effects,265,O
in,265,O
fluctuating,265,O
patients,265,O
.,265,O
The,266,O
hypotensive,266,B-Disease
effect,266,O
appears,266,O
to,266,O
be,266,O
related,266,O
to,266,O
the,266,O
higher,266,O
baseline,266,O
blood,266,O
pressure,266,O
we,266,O
observed,266,O
in,266,O
fluctuating,266,O
patients,266,O
relative,266,O
to,266,O
stable,266,O
patients,266,O
.,266,O
Syndrome,267,B-Disease
of,267,I-Disease
inappropriate,267,I-Disease
secretion,267,I-Disease
of,267,I-Disease
antidiuretic,267,I-Disease
hormone,267,I-Disease
after,267,O
infusional,267,O
vincristine,267,B-Chemical
.,267,O
A,268,O
77-year-old,268,O
woman,268,O
with,268,O
refractory,268,O
multiple,268,B-Disease
myeloma,268,I-Disease
was,268,O
treated,268,O
with,268,O
a,268,O
4-day,268,O
continuous,268,O
intravenous,268,O
infusion,268,O
of,268,O
vincristine,268,B-Chemical
and,268,O
doxorubicin,268,B-Chemical
and,268,O
4,268,O
days,268,O
of,268,O
oral,268,O
dexamethasone,268,B-Chemical
.,268,O
Nine,269,O
days,269,O
after,269,O
her,269,O
second,269,O
cycle,269,O
she,269,O
presented,269,O
with,269,O
lethargy,269,B-Disease
and,269,O
weakness,269,B-Disease
associated,269,O
with,269,O
hyponatremia,269,B-Disease
.,269,O
Evaluation,270,O
revealed,270,O
the,270,O
syndrome,270,B-Disease
of,270,I-Disease
inappropriate,270,I-Disease
secretion,270,I-Disease
of,270,I-Disease
antidiuretic,270,I-Disease
hormone,270,I-Disease
",",270,O
which,270,O
was,270,O
attributed,270,O
to,270,O
the,270,O
vincristine,270,B-Chemical
infusion,270,O
.,270,O
After,271,O
normal,271,O
serum,271,O
sodium,271,B-Chemical
levels,271,O
returned,271,O
",",271,O
further,271,O
doxorubicin,271,B-Chemical
and,271,O
dexamethasone,271,B-Chemical
chemotherapy,271,O
without,271,O
vincristine,271,B-Chemical
did,271,O
not,271,O
produce,271,O
this,271,O
complication,271,O
.,271,O
Heart,272,B-Disease
failure,272,I-Disease
:,272,O
to,272,O
digitalise,272,O
or,272,O
not,272,O
?,272,O
The,273,O
view,273,O
against,273,O
.,273,O
Despite,274,O
extensive,274,O
clinical,274,O
experience,274,O
the,274,O
role,274,O
of,274,O
digoxin,274,B-Chemical
is,274,O
still,274,O
not,274,O
well,274,O
defined,274,O
.,274,O
In,275,O
patients,275,O
with,275,O
atrial,275,B-Disease
fibrillation,275,I-Disease
digoxin,275,B-Chemical
is,275,O
beneficial,275,O
for,275,O
ventricular,275,O
rate,275,O
control,275,O
.,275,O
For,276,O
patients,276,O
in,276,O
sinus,276,O
rhythm,276,O
and,276,O
heart,276,B-Disease
failure,276,I-Disease
the,276,O
situation,276,O
is,276,O
less,276,O
clear,276,O
.,276,O
Digoxin,277,B-Chemical
has,277,O
a,277,O
narrow,277,O
therapeutic,277,O
:,277,O
toxic,277,O
ratio,277,O
and,277,O
concentrations,277,O
are,277,O
affected,277,O
by,277,O
a,277,O
number,277,O
of,277,O
drugs,277,O
.,277,O
Also,278,O
",",278,O
digoxin,278,B-Chemical
has,278,O
undesirable,278,O
effects,278,O
such,278,O
as,278,O
increasing,278,O
peripheral,278,O
resistance,278,O
and,278,O
myocardial,278,O
demands,278,O
",",278,O
and,278,O
causing,278,O
arrhythmias,278,B-Disease
.,278,O
There,279,O
is,279,O
a,279,O
paucity,279,O
of,279,O
data,279,O
from,279,O
well-designed,279,O
trials,279,O
.,279,O
The,280,O
trials,280,O
that,280,O
are,280,O
available,280,O
are,280,O
generally,280,O
small,280,O
with,280,O
limitations,280,O
in,280,O
design,280,O
and,280,O
these,280,O
show,280,O
variation,280,O
in,280,O
patient,280,O
benefit,280,O
.,280,O
More,281,O
convincing,281,O
evidence,281,O
is,281,O
required,281,O
showing,281,O
that,281,O
digoxin,281,B-Chemical
improves,281,O
symptoms,281,O
or,281,O
exercise,281,O
capacity,281,O
.,281,O
Furthermore,282,O
",",282,O
no,282,O
trial,282,O
has,282,O
had,282,O
sufficient,282,O
power,282,O
to,282,O
evaluate,282,O
mortality,282,O
.,282,O
Pooled,283,O
analysis,283,O
of,283,O
the,283,O
effects,283,O
of,283,O
other,283,O
inotropic,283,O
drugs,283,O
shows,283,O
an,283,O
excess,283,O
mortality,283,O
and,283,O
there,283,O
is,283,O
a,283,O
possibility,283,O
that,283,O
digoxin,283,B-Chemical
may,283,O
increase,283,O
mortality,283,O
after,283,O
myocardial,283,B-Disease
infarction,283,I-Disease
(,283,O
MI,283,B-Disease
),283,O
.,283,O
Angiotensin-converting,284,B-Chemical
enzyme,284,O
(,284,O
ACE,284,O
),284,O
inhibitors,284,O
should,284,O
be,284,O
used,284,O
first,284,O
as,284,O
they,284,O
are,284,O
safer,284,O
",",284,O
do,284,O
not,284,O
require,284,O
blood,284,O
level,284,O
monitoring,284,O
",",284,O
modify,284,O
progression,284,O
of,284,O
disease,284,O
",",284,O
relieve,284,O
symptoms,284,O
",",284,O
improve,284,O
exercise,284,O
tolerance,284,O
and,284,O
reduce,284,O
mortality,284,O
.,284,O
Caution,285,O
should,285,O
be,285,O
exercised,285,O
in,285,O
using,285,O
digoxin,285,B-Chemical
until,285,O
large,285,O
mortality,285,O
trials,285,O
are,285,O
completed,285,O
showing,285,O
either,285,O
benefit,285,O
or,285,O
harm,285,O
.,285,O
Until,286,O
then,286,O
digoxin,286,B-Chemical
should,286,O
be,286,O
considered,286,O
a,286,O
third-line,286,O
therapy,286,O
.,286,O
Isradipine,287,B-Chemical
treatment,287,O
for,287,O
hypertension,287,B-Disease
in,287,O
general,287,O
practice,287,O
in,287,O
Hong,287,O
Kong,287,O
.,287,O
A,288,O
6-week,288,O
open,288,O
study,288,O
of,288,O
the,288,O
introduction,288,O
of,288,O
isradipine,288,B-Chemical
treatment,288,O
was,288,O
conducted,288,O
in,288,O
general,288,O
practice,288,O
in,288,O
Hong,288,O
Kong,288,O
.,288,O
303,289,O
Chinese,289,O
patients,289,O
with,289,O
mild,289,O
to,289,O
moderate,289,O
hypertension,289,B-Disease
entered,289,O
the,289,O
study,289,O
.,289,O
Side,290,O
effects,290,O
were,290,O
reported,290,O
in,290,O
21,290,O
%,290,O
of,290,O
patients,290,O
and,290,O
caused,290,O
withdrawal,290,O
from,290,O
the,290,O
study,290,O
in,290,O
3,290,O
patients,290,O
.,290,O
The,291,O
main,291,O
side-effects,291,O
were,291,O
headache,291,B-Disease
",",291,O
dizziness,291,B-Disease
",",291,O
palpitation,291,B-Disease
and,291,O
flushing,291,B-Disease
and,291,O
these,291,O
were,291,O
not,291,O
more,291,O
frequent,291,O
than,291,O
reported,291,O
in,291,O
other,291,O
studies,291,O
with,291,O
isradipine,291,B-Chemical
or,291,O
with,291,O
placebo,291,O
.,291,O
Supine,292,O
blood,292,O
pressure,292,O
was,292,O
reduced,292,O
(,292,O
P,292,O
less,292,O
than,292,O
0.01,292,O
),292,O
from,292,O
170,292,O
+/-,292,O
20/102,292,O
+/-,292,O
6,292,O
mmHg,292,O
to,292,O
153,292,O
+/-,292,O
19/92,292,O
+/-,292,O
8,292,O
",",292,O
147,292,O
+/-,292,O
18/88,292,O
+/-,292,O
7,292,O
and,292,O
144,292,O
+/-,292,O
14/87,292,O
+/-,292,O
6,292,O
mmHg,292,O
at,292,O
2,292,O
",",292,O
4,292,O
and,292,O
6,292,O
weeks,292,O
respectively,292,O
in,292,O
evaluable,292,O
patients,292,O
.,292,O
Similar,293,O
reductions,293,O
occurred,293,O
in,293,O
standing,293,O
blood,293,O
pressure,293,O
and,293,O
there,293,O
was,293,O
no,293,O
evidence,293,O
of,293,O
postural,293,B-Disease
hypotension,293,I-Disease
.,293,O
Normalization,294,O
and,294,O
responder,294,O
rates,294,O
at,294,O
6,294,O
weeks,294,O
were,294,O
86,294,O
%,294,O
and,294,O
69,294,O
%,294,O
respectively,294,O
.,294,O
Dosage,295,O
was,295,O
increased,295,O
from,295,O
2.5,295,O
mg,295,O
b.d,295,O
.,295,O
to,296,O
5,296,O
mg,296,O
b.d,296,O
.,296,O
at,297,O
4,297,O
weeks,297,O
in,297,O
patients,297,O
with,297,O
diastolic,297,O
blood,297,O
pressure,297,O
greater,297,O
than,297,O
90,297,O
mmHg,297,O
and,297,O
their,297,O
further,297,O
response,297,O
was,297,O
greater,297,O
than,297,O
those,297,O
remaining,297,O
on,297,O
2.5,297,O
mg,297,O
b.d,297,O
.,297,O
Intravascular,298,O
hemolysis,298,B-Disease
and,298,O
acute,298,B-Disease
renal,298,I-Disease
failure,298,I-Disease
following,298,O
intermittent,298,O
rifampin,298,B-Chemical
therapy,298,O
.,298,O
Renal,299,B-Disease
failure,299,I-Disease
is,299,O
a,299,O
rare,299,O
complication,299,O
associated,299,O
with,299,O
the,299,O
use,299,O
of,299,O
rifampin,299,B-Chemical
.,299,O
Intravascular,300,O
hemolysis,300,B-Disease
leading,300,O
to,300,O
acute,300,B-Disease
renal,300,I-Disease
failure,300,I-Disease
following,300,O
rifampin,300,B-Chemical
therapy,300,O
is,300,O
extremely,300,O
rare,300,O
.,300,O
Two,301,O
patients,301,O
with,301,O
leprosy,301,B-Disease
who,301,O
developed,301,O
hemolysis,301,B-Disease
and,301,O
acute,301,B-Disease
renal,301,I-Disease
failure,301,I-Disease
following,301,O
rifampin,301,B-Chemical
are,301,O
reported,301,O
.,301,O
Zidovudine-induced,302,B-Chemical
hepatitis,302,B-Disease
.,302,O
A,303,O
case,303,O
of,303,O
acute,303,O
hepatitis,303,B-Disease
induced,303,O
by,303,O
zidovudine,303,B-Chemical
in,303,O
a,303,O
38-year-old,303,O
patient,303,O
with,303,O
AIDS,303,B-Disease
is,303,O
presented,303,O
.,303,O
The,304,O
mechanism,304,O
whereby,304,O
the,304,O
hepatitis,304,B-Disease
was,304,O
induced,304,O
is,304,O
not,304,O
known,304,O
.,304,O
However,305,O
",",305,O
the,305,O
patient,305,O
tolerated,305,O
well,305,O
an,305,O
alternative,305,O
reverse,305,O
transcriptase,305,O
inhibitor,305,O
",",305,O
2,305,B-Chemical
',305,I-Chemical
3,305,I-Chemical
',305,I-Chemical
dideoxyinosine,305,I-Chemical
.,305,O
Physicians,306,O
caring,306,O
for,306,O
patients,306,O
with,306,O
AIDS,306,B-Disease
should,306,O
be,306,O
aware,306,O
of,306,O
this,306,O
hitherto,306,O
rarely,306,O
reported,306,O
complication,306,O
.,306,O
Thoracic,307,B-Disease
hematomyelia,307,I-Disease
secondary,307,O
to,307,O
coumadin,307,B-Chemical
anticoagulant,307,O
therapy,307,O
:,307,O
a,307,O
case,307,O
report,307,O
.,307,O
A,308,O
case,308,O
of,308,O
thoracic,308,B-Disease
hematomyelia,308,I-Disease
secondary,308,O
to,308,O
anticoagulant,308,O
therapy,308,O
is,308,O
presented,308,O
.,308,O
Clinical,309,O
features,309,O
",",309,O
similar,309,O
to,309,O
2,309,O
other,309,O
previously,309,O
reported,309,O
cases,309,O
",",309,O
are,309,O
discussed,309,O
.,309,O
A,310,O
high,310,O
index,310,O
of,310,O
suspicion,310,O
may,310,O
lead,310,O
to,310,O
a,310,O
quick,310,O
diagnostic,310,O
procedure,310,O
and,310,O
successful,310,O
decompressive,310,O
surgery,310,O
.,310,O
Mania,311,B-Disease
associated,311,O
with,311,O
fluoxetine,311,B-Chemical
treatment,311,O
in,311,O
adolescents,311,O
.,311,O
Fluoxetine,312,B-Chemical
",",312,O
a,312,O
selective,312,O
serotonin,312,B-Chemical
reuptake,312,O
inhibitor,312,O
",",312,O
is,312,O
gaining,312,O
increased,312,O
acceptance,312,O
in,312,O
the,312,O
treatment,312,O
of,312,O
adolescent,312,O
depression,312,B-Disease
.,312,O
Generally,313,O
safe,313,O
and,313,O
well,313,O
tolerated,313,O
by,313,O
adults,313,O
",",313,O
fluoxetine,313,B-Chemical
has,313,O
been,313,O
reported,313,O
to,313,O
induce,313,O
mania,313,B-Disease
.,313,O
The,314,O
cases,314,O
of,314,O
five,314,O
depressed,314,B-Disease
adolescents,314,O
",",314,O
14-16,314,O
years,314,O
of,314,O
age,314,O
",",314,O
who,314,O
developed,314,O
mania,314,B-Disease
during,314,O
pharmacotherapy,314,O
with,314,O
fluoxetine,314,B-Chemical
",",314,O
are,314,O
reported,314,O
here,314,O
.,314,O
Apparent,315,O
risk,315,O
factors,315,O
for,315,O
the,315,O
development,315,O
of,315,O
mania,315,B-Disease
or,315,O
hypomania,315,B-Disease
during,315,O
fluoxetine,315,B-Chemical
pharmacotherapy,315,O
in,315,O
this,315,O
population,315,O
were,315,O
the,315,O
combination,315,O
of,315,O
attention-deficit,315,B-Disease
hyperactivity,315,I-Disease
disorder,315,I-Disease
and,315,O
affective,315,O
instability,315,O
;,315,O
major,315,O
depression,315,B-Disease
with,315,O
psychotic,315,B-Disease
features,315,O
;,315,O
a,315,O
family,315,O
history,315,O
of,315,O
affective,315,B-Disease
disorder,315,I-Disease
",",315,O
especially,315,O
bipolar,315,B-Disease
disorder,315,I-Disease
;,315,O
and,315,O
a,315,O
diagnosis,315,O
of,315,O
bipolar,315,B-Disease
disorder,315,I-Disease
.,315,O
Further,316,O
study,316,O
is,316,O
needed,316,O
to,316,O
determine,316,O
the,316,O
optimal,316,O
dosage,316,O
and,316,O
to,316,O
identify,316,O
risk,316,O
factors,316,O
that,316,O
increase,316,O
individual,316,O
vulnerability,316,O
to,316,O
fluoxetine,316,B-Chemical
induced,316,O
mania,316,B-Disease
in,316,O
adolescents,316,O
.,316,O
Gemfibrozil-lovastatin,317,B-Chemical
therapy,317,O
for,317,O
primary,317,O
hyperlipoproteinemias,317,B-Disease
.,317,O
The,318,O
specific,318,O
aim,318,O
of,318,O
this,318,O
retrospective,318,O
",",318,O
observational,318,O
study,318,O
was,318,O
to,318,O
assess,318,O
safety,318,O
and,318,O
efficacy,318,O
of,318,O
long-term,318,O
(,318,O
21,318,O
months/patient,318,O
),318,O
",",318,O
open-label,318,O
",",318,O
gemfibrozil-lovastatin,318,B-Chemical
treatment,318,O
in,318,O
80,318,O
patients,318,O
with,318,O
primary,318,O
mixed,318,O
hyperlipidemia,318,B-Disease
(,318,O
68,318,O
%,318,O
of,318,O
whom,318,O
had,318,O
atherosclerotic,318,B-Disease
vascular,318,I-Disease
disease,318,I-Disease
),318,O
.,318,O
Because,319,O
ideal,319,O
lipid,319,O
targets,319,O
were,319,O
not,319,O
reached,319,O
(,319,O
low-density,319,O
lipoprotein,319,O
(,319,O
LDL,319,O
),319,O
cholesterol,319,B-Chemical
less,319,O
than,319,O
130,319,O
mg/dl,319,O
",",319,O
high-density,319,O
lipoprotein,319,O
(,319,O
HDL,319,O
),319,O
cholesterol,319,B-Chemical
greater,319,O
than,319,O
35,319,O
mg/dl,319,O
",",319,O
or,319,O
total,319,O
cholesterol/HDL,319,B-Chemical
cholesterol,319,B-Chemical
less,319,O
than,319,O
4.5,319,O
mg/dl,319,O
),319,O
with,319,O
diet,319,O
plus,319,O
a,319,O
single,319,O
drug,319,O
",",319,O
gemfibrozil,319,B-Chemical
(,319,O
1.2,319,O
g/day,319,O
),319,O
-lovastatin,319,O
(,319,O
primarily,319,O
20,319,O
or,319,O
40,319,O
mg,319,O
),319,O
treatment,319,O
was,319,O
given,319,O
.,319,O
Follow-up,320,O
visits,320,O
were,320,O
scheduled,320,O
with,320,O
2-drug,320,O
therapy,320,O
every,320,O
6,320,O
to,320,O
8,320,O
weeks,320,O
",",320,O
an,320,O
average,320,O
of,320,O
10.3,320,O
visits,320,O
per,320,O
patient,320,O
",",320,O
with,320,O
741,320,O
batteries,320,O
of,320,O
6,320,O
liver,320,O
function,320,O
tests,320,O
and,320,O
714,320,O
creatine,320,B-Chemical
phosphokinase,320,O
levels,320,O
measured,320,O
.,320,O
Only,321,O
1,321,O
of,321,O
the,321,O
"4,446",321,O
liver,321,O
function,321,O
tests,321,O
(,321,O
0.02,321,O
%,321,O
),321,O
",",321,O
a,321,O
gamma,321,O
glutamyl,321,O
transferase,321,O
",",321,O
was,321,O
greater,321,O
than,321,O
or,321,O
equal,321,O
to,321,O
3,321,O
times,321,O
the,321,O
upper,321,O
normal,321,O
limit,321,O
.,321,O
Of,322,O
the,322,O
714,322,O
creatine,322,B-Chemical
phosphokinase,322,O
levels,322,O
",",322,O
9,322,O
%,322,O
were,322,O
high,322,O
;,322,O
only,322,O
1,322,O
(,322,O
0.1,322,O
%,322,O
),322,O
was,322,O
greater,322,O
than,322,O
or,322,O
equal,322,O
to,322,O
3,322,O
times,322,O
the,322,O
upper,322,O
normal,322,O
limit,322,O
.,322,O
With,323,O
2-drug,323,O
therapy,323,O
",",323,O
mean,323,O
total,323,O
cholesterol,323,B-Chemical
decreased,323,O
22,323,O
%,323,O
from,323,O
255,323,O
to,323,O
200,323,O
mg/dl,323,O
",",323,O
triglyceride,323,B-Chemical
levels,323,O
decreased,323,O
35,323,O
%,323,O
from,323,O
236,323,O
to,323,O
154,323,O
mg/dl,323,O
",",323,O
LDL,323,O
cholesterol,323,B-Chemical
decreased,323,O
26,323,O
%,323,O
from,323,O
176,323,O
to,323,O
131,323,O
mg/dl,323,O
",",323,O
and,323,O
the,323,O
total,323,O
cholesterol/HDL,323,B-Chemical
cholesterol,323,B-Chemical
ratio,323,O
decreased,323,O
24,323,O
%,323,O
from,323,O
7.1,323,O
to,323,O
5.4,323,O
",",323,O
all,323,O
p,323,O
less,323,O
than,323,O
or,323,O
equal,323,O
to,323,O
0.0001,323,O
.,323,O
Myositis,324,B-Disease
",",324,O
attributable,324,O
to,324,O
the,324,O
drug,324,O
combination,324,O
and,324,O
symptomatic,324,O
enough,324,O
to,324,O
discontinue,324,O
it,324,O
",",324,O
occurred,324,O
in,324,O
3,324,O
%,324,O
of,324,O
patients,324,O
",",324,O
and,324,O
in,324,O
1,324,O
%,324,O
with,324,O
concurrent,324,O
high,324,O
creatine,324,B-Chemical
phosphokinase,324,O
(,324,O
769,324,O
U/liter,324,O
),324,O
;,324,O
no,324,O
patients,324,O
had,324,O
rhabdomyolysis,324,B-Disease
or,324,O
myoglobinuria,324,B-Disease
.,324,O
(,325,O
ABSTRACT,325,O
TRUNCATED,325,O
AT,325,O
250,325,O
WORDS,325,O
),325,O
Hepatocellular,326,B-Disease
carcinoma,326,I-Disease
in,326,O
Fanconi,326,B-Disease
's,326,I-Disease
anemia,326,I-Disease
treated,326,O
with,326,O
androgen,326,B-Chemical
and,326,O
corticosteroid,326,B-Chemical
.,326,O
The,327,O
case,327,O
of,327,O
an,327,O
11-year-old,327,O
boy,327,O
is,327,O
reported,327,O
who,327,O
was,327,O
known,327,O
to,327,O
have,327,O
Fanconi,327,B-Disease
's,327,I-Disease
anemia,327,I-Disease
for,327,O
3,327,O
years,327,O
and,327,O
was,327,O
treated,327,O
with,327,O
androgens,327,B-Chemical
",",327,O
corticosteroids,327,B-Chemical
and,327,O
transfusions,327,O
.,327,O
Two,328,O
weeks,328,O
before,328,O
his,328,O
death,328,O
he,328,O
was,328,O
readmitted,328,O
because,328,O
of,328,O
aplastic,328,O
crisis,328,O
with,328,O
septicemia,328,B-Disease
and,328,O
marked,328,O
abnormalities,328,O
in,328,O
liver,328,O
function,328,O
and,328,O
died,328,O
of,328,O
hemorrhagic,328,B-Disease
bronchopneumonia,328,I-Disease
.,328,O
At,329,O
autopsy,329,O
peliosis,329,B-Disease
and,329,O
multiple,329,O
hepatic,329,B-Disease
tumors,329,I-Disease
were,329,O
found,329,O
which,329,O
histologically,329,O
proved,329,O
to,329,O
be,329,O
well-differentiated,329,O
hepatocellular,329,B-Disease
carcinoma,329,I-Disease
.,329,O
This,330,O
case,330,O
contributes,330,O
to,330,O
the,330,O
previous,330,O
observations,330,O
that,330,O
non-metastasizing,330,O
hepatic,330,B-Disease
neoplasms,330,I-Disease
and,330,O
peliosis,330,B-Disease
can,330,O
develop,330,O
in,330,O
patients,330,O
with,330,O
androgen-,330,B-Chemical
and,330,O
corticosteroid-treated,330,B-Chemical
Fanconi,330,B-Disease
's,330,I-Disease
anemia,330,I-Disease
.,330,O
Chronic,331,O
lesion,331,O
of,331,O
rostral,331,O
ventrolateral,331,O
medulla,331,O
in,331,O
spontaneously,331,O
hypertensive,331,B-Disease
rats,331,O
.,331,O
We,332,O
studied,332,O
the,332,O
effects,332,O
of,332,O
chronic,332,O
selective,332,O
neuronal,332,O
lesion,332,O
of,332,O
rostral,332,O
ventrolateral,332,O
medulla,332,O
on,332,O
mean,332,O
arterial,332,O
pressure,332,O
",",332,O
heart,332,O
rate,332,O
",",332,O
and,332,O
neurogenic,332,O
tone,332,O
in,332,O
conscious,332,O
",",332,O
unrestrained,332,O
spontaneously,332,O
hypertensive,332,B-Disease
rats,332,O
.,332,O
The,333,O
lesions,333,O
were,333,O
placed,333,O
via,333,O
bilateral,333,O
microinjections,333,O
of,333,O
30,333,O
nmol/200,333,O
nl,333,O
N-methyl-D-aspartic,333,B-Chemical
acid,333,I-Chemical
.,333,O
The,334,O
restimulation,334,O
of,334,O
this,334,O
area,334,O
with,334,O
N-methyl-D-aspartic,334,B-Chemical
acid,334,I-Chemical
15,334,O
days,334,O
postlesion,334,O
failed,334,O
to,334,O
produce,334,O
a,334,O
pressor,334,O
response,334,O
.,334,O
One,335,O
day,335,O
postlesion,335,O
",",335,O
the,335,O
resting,335,O
mean,335,O
arterial,335,O
pressure,335,O
was,335,O
significantly,335,O
decreased,335,O
in,335,O
lesioned,335,O
rats,335,O
when,335,O
compared,335,O
with,335,O
sham,335,O
rats,335,O
(,335,O
100,335,O
+/-,335,O
7,335,O
versus,335,O
173,335,O
+/-,335,O
4,335,O
mm,335,O
Hg,335,O
",",335,O
p,335,O
less,335,O
than,335,O
0.05,335,O
),335,O
.,335,O
Fifteen,336,O
days,336,O
later,336,O
",",336,O
the,336,O
lesioned,336,O
group,336,O
still,336,O
showed,336,O
values,336,O
significantly,336,O
lower,336,O
than,336,O
the,336,O
sham,336,O
group,336,O
(,336,O
150,336,O
+/-,336,O
6,336,O
versus,336,O
167,336,O
+/-,336,O
5,336,O
mm,336,O
Hg,336,O
",",336,O
p,336,O
less,336,O
than,336,O
0.05,336,O
),336,O
.,336,O
No,337,O
significant,337,O
heart,337,O
rate,337,O
differences,337,O
were,337,O
observed,337,O
between,337,O
the,337,O
sham,337,O
and,337,O
lesioned,337,O
groups,337,O
.,337,O
The,338,O
ganglionic,338,O
blocker,338,O
trimethaphan,338,B-Chemical
(,338,O
5,338,O
mg/kg,338,O
i.v,338,O
.,338,O
),338,O
caused,339,O
similar,339,O
reductions,339,O
in,339,O
mean,339,O
arterial,339,O
pressure,339,O
in,339,O
both,339,O
lesioned,339,O
and,339,O
sham,339,O
groups,339,O
.,339,O
The,340,O
trimethaphan-induced,340,B-Chemical
hypotension,340,B-Disease
was,340,O
accompanied,340,O
by,340,O
a,340,O
significant,340,O
bradycardia,340,B-Disease
in,340,O
lesioned,340,O
rats,340,O
(,340,O
-32,340,O
+/-,340,O
13,340,O
beats,340,O
per,340,O
minute,340,O
),340,O
but,340,O
a,340,O
tachycardia,340,B-Disease
in,340,O
sham,340,O
rats,340,O
(,340,O
+33,340,O
+/-,340,O
12,340,O
beats,340,O
per,340,O
minute,340,O
),340,O
1,340,O
day,340,O
postlesion,340,O
.,340,O
Therefore,341,O
",",341,O
rostral,341,O
ventrolateral,341,O
medulla,341,O
neurons,341,O
appear,341,O
to,341,O
play,341,O
a,341,O
significant,341,O
role,341,O
in,341,O
maintaining,341,O
hypertension,341,B-Disease
in,341,O
conscious,341,O
spontaneously,341,O
hypertensive,341,B-Disease
rats,341,O
.,341,O
Spinal,342,O
or,342,O
suprabulbar,342,O
structures,342,O
could,342,O
be,342,O
responsible,342,O
for,342,O
the,342,O
gradual,342,O
recovery,342,O
of,342,O
the,342,O
hypertension,342,B-Disease
in,342,O
the,342,O
lesioned,342,O
rats,342,O
.,342,O
Damage,343,B-Disease
of,343,I-Disease
substantia,343,I-Disease
nigra,343,I-Disease
pars,343,I-Disease
reticulata,343,I-Disease
during,343,O
pilocarpine-induced,343,B-Chemical
status,343,B-Disease
epilepticus,343,I-Disease
in,343,O
the,343,O
rat,343,O
:,343,O
immunohistochemical,343,O
study,343,O
of,343,O
neurons,343,O
",",343,O
astrocytes,343,O
and,343,O
serum-protein,343,O
extravasation,343,O
.,343,O
The,344,O
substantia,344,O
nigra,344,O
has,344,O
a,344,O
gating,344,O
function,344,O
controlling,344,O
the,344,O
spread,344,O
of,344,O
epileptic,344,B-Disease
seizure,344,I-Disease
activity,344,O
.,344,O
Additionally,345,O
",",345,O
in,345,O
models,345,O
of,345,O
prolonged,345,B-Disease
status,345,I-Disease
epilepticus,345,I-Disease
the,345,O
pars,345,O
reticulata,345,O
of,345,O
substantia,345,O
nigra,345,O
(,345,O
SNR,345,O
),345,O
suffers,345,O
from,345,O
a,345,O
massive,345,O
lesion,345,O
which,345,O
may,345,O
arise,345,O
from,345,O
a,345,O
massive,345,O
metabolic,345,B-Disease
derangement,345,I-Disease
and,345,O
hyperexcitation,345,O
developing,345,O
in,345,O
the,345,O
activated,345,O
SNR,345,O
.,345,O
In,346,O
this,346,O
study,346,O
",",346,O
status,346,B-Disease
epilepticus,346,I-Disease
was,346,O
induced,346,O
by,346,O
systemic,346,O
injection,346,O
of,346,O
pilocarpine,346,B-Chemical
in,346,O
rats,346,O
.,346,O
The,347,O
neuropathology,347,O
of,347,O
SNR,347,O
was,347,O
investigated,347,O
using,347,O
immunohistochemical,347,O
techniques,347,O
with,347,O
the,347,O
major,347,O
emphasis,347,O
on,347,O
the,347,O
time-course,347,O
of,347,O
changes,347,O
in,347,O
neurons,347,O
and,347,O
astrocytes,347,O
.,347,O
Animals,348,O
surviving,348,O
20,348,O
",",348,O
30,348,O
",",348,O
40,348,O
",",348,O
60,348,O
min,348,O
",",348,O
2,348,O
",",348,O
3,348,O
",",348,O
6,348,O
hours,348,O
",",348,O
1,348,O
",",348,O
2,348,O
",",348,O
and,348,O
3,348,O
days,348,O
after,348,O
induction,348,O
of,348,O
status,348,B-Disease
epilepticus,348,I-Disease
were,348,O
perfusion-fixed,348,O
",",348,O
and,348,O
brains,348,O
processed,348,O
for,348,O
immunohistochemical,348,O
staining,348,O
of,348,O
SNR,348,O
.,348,O
Nissl-staining,349,O
and,349,O
antibodies,349,O
against,349,O
the,349,O
neuron-specific,349,O
calcium-binding,349,B-Chemical
protein,349,O
",",349,O
parvalbumin,349,O
",",349,O
served,349,O
to,349,O
detect,349,O
neuronal,349,B-Disease
damage,349,I-Disease
in,349,O
SNR,349,O
.,349,O
Antibodies,350,O
against,350,O
the,350,O
astroglia-specific,350,O
cytoskeletal,350,O
protein,350,O
",",350,O
glial,350,O
fibrillary,350,O
acidic,350,O
protein,350,O
(,350,O
GFAP,350,O
),350,O
",",350,O
and,350,O
against,350,O
the,350,O
glial,350,O
calcium-binding,350,B-Chemical
protein,350,O
",",350,O
S-100,350,O
protein,350,O
",",350,O
were,350,O
used,350,O
to,350,O
assess,350,O
the,350,O
status,350,O
of,350,O
astrocytes,350,O
.,350,O
Immunohistochemical,351,O
staining,351,O
for,351,O
serum-albumin,351,O
and,351,O
immunoglobulins,351,O
in,351,O
brain,351,O
tissue,351,O
was,351,O
taken,351,O
as,351,O
indicator,351,O
of,351,O
blood-brain,351,O
barrier,351,O
disturbances,351,O
and,351,O
vasogenic,351,B-Disease
edema,351,I-Disease
formation,351,O
.,351,O
Immunohistochemical,352,O
staining,352,O
indicated,352,O
loss,352,O
of,352,O
GFAP-staining,352,O
already,352,O
at,352,O
30,352,O
min,352,O
after,352,O
induction,352,O
of,352,O
seizures,352,B-Disease
in,352,O
an,352,O
oval,352,O
focus,352,O
situated,352,O
in,352,O
the,352,O
center,352,O
of,352,O
SNR,352,O
while,352,O
sparing,352,O
medial,352,O
and,352,O
lateral,352,O
aspects,352,O
.,352,O
At,353,O
1,353,O
h,353,O
there,353,O
was,353,O
additional,353,O
vacuolation,353,O
in,353,O
S-100,353,O
protein,353,O
staining,353,O
.,353,O
By,354,O
2,354,O
hours,354,O
",",354,O
parvalbumin-staining,354,O
changed,354,O
in,354,O
the,354,O
central,354,O
SNR,354,O
indicating,354,O
neuronal,354,B-Disease
damage,354,I-Disease
",",354,O
and,354,O
Nissl-staining,354,O
visualized,354,O
some,354,O
neuronal,354,O
distortion,354,O
.,354,O
Staining,355,O
for,355,O
serum-proteins,355,O
occurred,355,O
in,355,O
a,355,O
patchy,355,O
manner,355,O
throughout,355,O
the,355,O
forebrain,355,O
during,355,O
the,355,O
first,355,O
hours,355,O
.,355,O
By,356,O
6,356,O
h,356,O
",",356,O
vasogenic,356,B-Disease
edema,356,I-Disease
covered,356,O
the,356,O
lesioned,356,B-Disease
SNR,356,I-Disease
.,356,O
By,357,O
24,357,O
h,357,O
",",357,O
glial,357,O
and,357,O
neuronal,357,O
markers,357,O
indicated,357,O
a,357,O
massive,357,O
lesion,357,O
in,357,O
the,357,O
center,357,O
of,357,O
SNR,357,O
.,357,O
By,358,O
48-72,358,O
h,358,O
",",358,O
astrocytes,358,O
surrounding,358,O
the,358,O
lesion,358,O
increased,358,O
in,358,O
size,358,O
",",358,O
and,358,O
polymorphic,358,O
phagocytotic,358,O
cells,358,O
invaded,358,O
the,358,O
damaged,358,O
area,358,O
.,358,O
In,359,O
a,359,O
further,359,O
group,359,O
of,359,O
animals,359,O
surviving,359,O
1,359,O
to,359,O
5,359,O
days,359,O
",",359,O
conventional,359,O
paraffin-sections,359,O
confirmed,359,O
the,359,O
neuronal,359,O
and,359,O
glial,359,O
damage,359,B-Disease
of,359,I-Disease
SNR,359,I-Disease
.,359,O
Additional,360,O
pathology,360,O
of,360,O
similar,360,O
quality,360,O
was,360,O
found,360,O
in,360,O
the,360,O
globus,360,O
pallidus,360,O
.,360,O
Since,361,O
astrocytes,361,O
were,361,O
always,361,O
damaged,361,O
in,361,O
parallel,361,O
with,361,O
neurons,361,O
in,361,O
SNR,361,O
it,361,O
is,361,O
proposed,361,O
that,361,O
the,361,O
anatomical,361,O
and,361,O
functional,361,O
interrelationship,361,O
between,361,O
neurons,361,O
and,361,O
astrocytes,361,O
is,361,O
particularly,361,O
tight,361,O
in,361,O
SNR,361,O
.,361,O
Both,362,O
cell,362,O
elements,362,O
may,362,O
suffer,362,O
in,362,O
common,362,O
from,362,O
metabolic,362,O
disturbance,362,O
and,362,O
neurotransmitter,362,B-Disease
dysfunction,362,I-Disease
as,362,O
occur,362,O
during,362,O
massive,362,O
status,362,B-Disease
epilepticus,362,I-Disease
.,362,O
Reduced,363,O
cardiotoxicity,363,B-Disease
of,363,O
doxorubicin,363,B-Chemical
given,363,O
in,363,O
the,363,O
form,363,O
of,363,O
N-,363,B-Chemical
(,363,I-Chemical
2-hydroxypropyl,363,I-Chemical
),363,I-Chemical
methacrylamide,363,I-Chemical
conjugates,363,O
:,363,O
and,363,O
experimental,363,O
study,363,O
in,363,O
the,363,O
rat,363,O
.,363,O
A,364,O
rat,364,O
model,364,O
was,364,O
used,364,O
to,364,O
evaluate,364,O
the,364,O
general,364,O
acute,364,O
toxicity,364,B-Disease
and,364,O
the,364,O
late,364,O
cardiotoxicity,364,B-Disease
of,364,O
4,364,O
mg/kg,364,O
doxorubicin,364,B-Chemical
(,364,O
DOX,364,B-Chemical
),364,O
given,364,O
either,364,O
as,364,O
free,364,O
drug,364,O
or,364,O
in,364,O
the,364,O
form,364,O
of,364,O
three,364,O
N-,364,B-Chemical
(,364,I-Chemical
2-hydroxypropyl,364,I-Chemical
),364,I-Chemical
methacrylamide,364,I-Chemical
(,364,O
HPMA,364,B-Chemical
),364,O
copolymer,364,O
conjugates,364,O
.,364,O
In,365,O
these,365,O
HPMA,365,B-Chemical
copolymers,365,O
",",365,O
DOX,365,B-Chemical
was,365,O
covalently,365,O
bound,365,O
via,365,O
peptide,365,O
linkages,365,O
that,365,O
were,365,O
either,365,O
non-biodegradable,365,O
(,365,O
Gly-Gly,365,O
),365,O
or,365,O
degradable,365,O
by,365,O
lysosomal,365,O
proteinases,365,O
(,365,O
Gly-Phe-Leu-Gly,365,B-Chemical
),365,O
.,365,O
In,366,O
addition,366,O
",",366,O
one,366,O
biodegradable,366,O
conjugate,366,O
containing,366,O
galactosamine,366,B-Chemical
was,366,O
used,366,O
;,366,O
this,366,O
residue,366,O
was,366,O
targeted,366,O
to,366,O
the,366,O
liver,366,O
.,366,O
Over,367,O
the,367,O
first,367,O
3,367,O
weeks,367,O
after,367,O
the,367,O
i.v,367,O
.,367,O
administration,368,O
of,368,O
free,368,O
and,368,O
polymer-bound,368,O
DOX,368,B-Chemical
",",368,O
all,368,O
animals,368,O
showed,368,O
a,368,O
transient,368,O
reduction,368,O
in,368,O
body,368,O
weight,368,O
.,368,O
However,369,O
",",369,O
the,369,O
maximal,369,O
reduction,369,O
in,369,O
body,369,O
weight,369,O
seen,369,O
in,369,O
animals,369,O
that,369,O
received,369,O
polymer-bound,369,O
DOX,369,B-Chemical
(,369,O
4,369,O
mg/kg,369,O
),369,O
was,369,O
significantly,369,O
lower,369,O
than,369,O
that,369,O
observed,369,O
in,369,O
those,369,O
that,369,O
received,369,O
free,369,O
DOX,369,B-Chemical
(,369,O
4,369,O
mg/kg,369,O
),369,O
or,369,O
a,369,O
mixture,369,O
of,369,O
the,369,O
unmodified,369,O
parent,369,O
HPMA,369,B-Chemical
copolymer,369,O
and,369,O
free,369,O
DOX,369,B-Chemical
(,369,O
4,369,O
mg/kg,369,O
;,369,O
P,369,O
less,369,O
than,369,O
0.01,369,O
),369,O
.,369,O
Throughout,370,O
the,370,O
study,370,O
(,370,O
20,370,O
weeks,370,O
),370,O
",",370,O
deaths,370,O
related,370,O
to,370,O
cardiotoxicity,370,B-Disease
were,370,O
observed,370,O
only,370,O
in,370,O
animals,370,O
that,370,O
received,370,O
either,370,O
free,370,O
DOX,370,B-Chemical
or,370,O
the,370,O
mixture,370,O
of,370,O
HPMA,370,B-Chemical
copolymer,370,O
and,370,O
free,370,O
DOX,370,B-Chemical
;,370,O
in,370,O
these,370,O
cases,370,O
",",370,O
histological,370,O
investigations,370,O
revealed,370,O
marked,370,O
changes,370,O
in,370,O
the,370,O
heart,370,O
that,370,O
were,370,O
consistent,370,O
with,370,O
DOX-induced,370,B-Chemical
cardiotoxicity,370,B-Disease
.,370,O
Sequential,371,O
measurements,371,O
of,371,O
cardiac,371,O
output,371,O
in,371,O
surviving,371,O
animals,371,O
that,371,O
received,371,O
either,371,O
free,371,O
DOX,371,B-Chemical
or,371,O
the,371,O
mixture,371,O
of,371,O
HPMA,371,B-Chemical
copolymer,371,O
and,371,O
free,371,O
DOX,371,B-Chemical
showed,371,O
a,371,O
reduction,371,O
of,371,O
approximately,371,O
30,371,O
%,371,O
in,371,O
function,371,O
beginning,371,O
at,371,O
the,371,O
4th,371,O
week,371,O
after,371,O
drug,371,O
administration,371,O
.,371,O
The,372,O
heart,372,O
rate,372,O
in,372,O
these,372,O
animals,372,O
was,372,O
approximately,372,O
12,372,O
%,372,O
lower,372,O
than,372,O
that,372,O
measured,372,O
in,372,O
age-matched,372,O
control,372,O
rats,372,O
(,372,O
P,372,O
less,372,O
than,372,O
0.05,372,O
),372,O
.,372,O
Animals,373,O
that,373,O
were,373,O
given,373,O
the,373,O
HPMA,373,B-Chemical
copolymer,373,O
conjugates,373,O
containing,373,O
DOX,373,B-Chemical
exhibited,373,O
no,373,O
significant,373,O
change,373,O
in,373,O
cardiac,373,O
output,373,O
throughout,373,O
the,373,O
study,373,O
(,373,O
P,373,O
less,373,O
than,373,O
0.05,373,O
),373,O
.,373,O
In,374,O
addition,374,O
",",374,O
no,374,O
significant,374,O
histological,374,O
change,374,O
was,374,O
observed,374,O
in,374,O
the,374,O
heart,374,O
of,374,O
animals,374,O
that,374,O
received,374,O
DOX,374,B-Chemical
in,374,O
the,374,O
form,374,O
of,374,O
HPMA,374,B-Chemical
copolymer,374,O
conjugates,374,O
and,374,O
were,374,O
killed,374,O
at,374,O
the,374,O
end,374,O
of,374,O
the,374,O
study,374,O
.,374,O
However,375,O
",",375,O
these,375,O
animals,375,O
had,375,O
shown,375,O
a,375,O
significant,375,O
increase,375,O
in,375,O
heart,375,O
rate,375,O
beginning,375,O
at,375,O
8,375,O
weeks,375,O
after,375,O
drug,375,O
administration,375,O
(,375,O
P,375,O
less,375,O
than,375,O
0.01,375,O
),375,O
.,375,O
(,376,O
ABSTRACT,376,O
TRUNCATED,376,O
AT,376,O
400,376,O
WORDS,376,O
),376,O
Topical,377,O
0.025,377,O
%,377,O
capsaicin,377,B-Chemical
in,377,O
chronic,377,O
post-herpetic,377,B-Disease
neuralgia,377,I-Disease
:,377,O
efficacy,377,O
",",377,O
predictors,377,O
of,377,O
response,377,O
and,377,O
long-term,377,O
course,377,O
.,377,O
In,378,O
order,378,O
to,378,O
evaluate,378,O
the,378,O
efficacy,378,O
",",378,O
time-course,378,O
of,378,O
action,378,O
and,378,O
predictors,378,O
of,378,O
response,378,O
to,378,O
topical,378,O
capsaicin,378,B-Chemical
",",378,O
39,378,O
patients,378,O
with,378,O
chronic,378,O
post-herpetic,378,B-Disease
neuralgia,378,I-Disease
(,378,O
PHN,378,B-Disease
),378,O
",",378,O
median,378,O
duration,378,O
24,378,O
months,378,O
",",378,O
were,378,O
treated,378,O
with,378,O
0.025,378,O
%,378,O
capsaicin,378,B-Chemical
cream,378,O
for,378,O
8,378,O
weeks,378,O
.,378,O
During,379,O
therapy,379,O
the,379,O
patients,379,O
rated,379,O
their,379,O
pain,379,B-Disease
on,379,O
a,379,O
visual,379,O
analogue,379,O
scale,379,O
(,379,O
VAS,379,O
),379,O
and,379,O
a,379,O
verbal,379,O
outcome,379,O
scale,379,O
.,379,O
A,380,O
follow-up,380,O
investigation,380,O
was,380,O
performed,380,O
10-12,380,O
months,380,O
after,380,O
study,380,O
onset,380,O
on,380,O
the,380,O
patients,380,O
who,380,O
had,380,O
improved,380,O
.,380,O
Nineteen,381,O
patients,381,O
(,381,O
48.7,381,O
%,381,O
),381,O
substantially,381,O
improved,381,O
after,381,O
the,381,O
8-week,381,O
trial,381,O
;,381,O
5,381,O
(,381,O
12.8,381,O
%,381,O
),381,O
discontinued,381,O
therapy,381,O
due,381,O
to,381,O
side-effects,381,O
such,381,O
as,381,O
intolerable,381,O
capsaicin-induced,381,B-Chemical
burning,381,O
sensations,381,O
(,381,O
4,381,O
),381,O
or,381,O
mastitis,381,B-Disease
(,381,O
1,381,O
),381,O
;,381,O
15,381,O
(,381,O
38.5,381,O
%,381,O
),381,O
reported,381,O
no,381,O
benefit,381,O
.,381,O
The,382,O
decrease,382,O
in,382,O
VAS,382,O
ratings,382,O
was,382,O
significant,382,O
after,382,O
2,382,O
weeks,382,O
of,382,O
continuous,382,O
application,382,O
.,382,O
Of,383,O
the,383,O
responders,383,O
72.2,383,O
%,383,O
were,383,O
still,383,O
improved,383,O
at,383,O
the,383,O
follow-up,383,O
;,383,O
only,383,O
one-third,383,O
of,383,O
them,383,O
had,383,O
continued,383,O
application,383,O
irregularly,383,O
.,383,O
Treatment,384,O
effect,384,O
was,384,O
not,384,O
dependent,384,O
on,384,O
patient,384,O
's,384,O
age,384,O
",",384,O
duration,384,O
or,384,O
localization,384,O
of,384,O
PHN,384,B-Disease
(,384,O
trigeminal,384,O
involvement,384,O
was,384,O
excluded,384,O
),384,O
",",384,O
sensory,384,B-Disease
disturbance,384,I-Disease
or,384,O
pain,384,B-Disease
character,384,O
.,384,O
Treatment,385,O
response,385,O
was,385,O
not,385,O
correlated,385,O
with,385,O
the,385,O
incidence,385,O
",",385,O
time-course,385,O
or,385,O
severity,385,O
of,385,O
capsaicin-induced,385,B-Chemical
burning,385,O
.,385,O
If,386,O
confirmed,386,O
in,386,O
controlled,386,O
trials,386,O
",",386,O
the,386,O
long-term,386,O
results,386,O
of,386,O
this,386,O
open,386,O
",",386,O
non-randomized,386,O
study,386,O
might,386,O
indicate,386,O
that,386,O
the,386,O
analgesic,386,O
effect,386,O
of,386,O
capsaicin,386,B-Chemical
in,386,O
PHN,386,B-Disease
is,386,O
mediated,386,O
by,386,O
both,386,O
interference,386,O
with,386,O
neuropeptide,386,O
metabolism,386,O
and,386,O
morphological,386,O
changes,386,O
(,386,O
perhaps,386,O
degeneration,386,O
),386,O
of,386,O
nociceptive,386,O
afferents,386,O
.,386,O
Serotonin,387,B-Chemical
reuptake,387,O
inhibitors,387,O
",",387,O
paranoia,387,B-Disease
",",387,O
and,387,O
the,387,O
ventral,387,O
basal,387,O
ganglia,387,O
.,387,O
Antidepressants,388,O
have,388,O
previously,388,O
been,388,O
associated,388,O
with,388,O
paranoid,388,B-Disease
reactions,388,O
in,388,O
psychiatric,388,O
patients,388,O
.,388,O
Five,389,O
cases,389,O
of,389,O
paranoid,389,B-Disease
exacerbation,389,O
with,389,O
the,389,O
serotonin,389,B-Chemical
reuptake,389,O
inhibitors,389,O
fluoxetine,389,B-Chemical
and,389,O
amitriptyline,389,B-Chemical
are,389,O
reported,389,O
here,389,O
.,389,O
Elements,390,O
common,390,O
to,390,O
these,390,O
cases,390,O
included,390,O
a,390,O
history,390,O
of,390,O
paranoid,390,B-Disease
symptomatology,390,O
and,390,O
the,390,O
concomitant,390,O
occurrence,390,O
of,390,O
depressive,390,O
and,390,O
psychotic,390,O
symptoms,390,O
.,390,O
Complicated,391,O
depressive,391,B-Disease
disorders,391,I-Disease
(,391,O
including,391,O
atypicality,391,O
of,391,O
course,391,O
and,391,O
symptomatology,391,O
",",391,O
chronicity,391,O
",",391,O
psychosis,391,B-Disease
",",391,O
bipolarity,391,O
",",391,O
and,391,O
secondary,391,O
onset,391,O
in,391,O
the,391,O
course,391,O
of,391,O
a,391,O
primary,391,O
psychosis,391,B-Disease
),391,O
may,391,O
present,391,O
particular,391,O
vulnerability,391,O
to,391,O
paranoid,391,B-Disease
exacerbations,391,O
associated,391,O
with,391,O
serotonin,391,B-Chemical
reuptake,391,O
inhibitors,391,O
.,391,O
Although,392,O
the,392,O
pharmacology,392,O
and,392,O
neurobiology,392,O
of,392,O
paranoia,392,B-Disease
remain,392,O
cryptic,392,O
",",392,O
several,392,O
mechanisms,392,O
",",392,O
including,392,O
5HT3,392,O
receptor-mediated,392,O
dopamine,392,B-Chemical
release,392,O
",",392,O
beta-noradrenergic,392,O
receptor,392,O
downregulation,392,O
",",392,O
or,392,O
GABAB,392,O
receptor,392,O
upregulation,392,O
acting,392,O
in,392,O
the,392,O
vicinity,392,O
of,392,O
the,392,O
ventral,392,O
basal,392,O
ganglia,392,O
(,392,O
possibly,392,O
in,392,O
lateral,392,O
orbitofrontal,392,O
or,392,O
anterior,392,O
cingulate,392,O
circuits,392,O
),392,O
",",392,O
might,392,O
apply,392,O
to,392,O
this,392,O
phenomenon,392,O
.,392,O
These,393,O
cases,393,O
call,393,O
attention,393,O
to,393,O
possible,393,O
paranoid,393,B-Disease
exacerbations,393,O
with,393,O
serotonin,393,B-Chemical
reuptake,393,O
blockers,393,O
in,393,O
select,393,O
patients,393,O
and,393,O
raise,393,O
neurobiological,393,O
considerations,393,O
regarding,393,O
paranoia,393,B-Disease
.,393,O
Five,394,O
cases,394,O
of,394,O
encephalitis,394,B-Disease
during,394,O
treatment,394,O
of,394,O
loiasis,394,B-Disease
with,394,O
diethylcarbamazine,394,B-Chemical
.,394,O
Five,395,O
cases,395,O
of,395,O
encephalitis,395,B-Disease
following,395,O
treatment,395,O
with,395,O
diethylcarbamazine,395,B-Chemical
(,395,O
DEC,395,B-Chemical
),395,O
were,395,O
observed,395,O
in,395,O
Congolese,395,O
patients,395,O
with,395,O
Loa,395,O
loa,395,O
filariasis,395,B-Disease
.,395,O
Two,396,O
cases,396,O
had,396,O
a,396,O
fatal,396,O
outcome,396,O
and,396,O
one,396,O
resulted,396,O
in,396,O
severe,396,O
sequelae,396,O
.,396,O
The,397,O
notable,397,O
fact,397,O
was,397,O
that,397,O
this,397,O
complication,397,O
occurred,397,O
in,397,O
three,397,O
patients,397,O
hospitalized,397,O
before,397,O
treatment,397,O
began,397,O
",",397,O
with,397,O
whom,397,O
particularly,397,O
strict,397,O
therapeutic,397,O
precautions,397,O
were,397,O
taken,397,O
",",397,O
i.e.,397,O
",",397,O
initial,397,O
dose,397,O
less,397,O
than,397,O
10,397,O
mg,397,O
of,397,O
DEC,397,B-Chemical
",",397,O
very,397,O
gradual,397,O
dose,397,O
increases,397,O
",",397,O
and,397,O
associated,397,O
anti-allergic,397,O
treatment,397,O
.,397,O
This,398,O
type,398,O
of,398,O
drug-induced,398,O
complication,398,O
may,398,O
not,398,O
be,398,O
that,398,O
uncommon,398,O
in,398,O
highly,398,O
endemic,398,O
regions,398,O
.,398,O
It,399,O
occurs,399,O
primarily,399,O
",",399,O
but,399,O
not,399,O
exclusively,399,O
",",399,O
in,399,O
subjects,399,O
presenting,399,O
with,399,O
a,399,O
high,399,O
microfilarial,399,O
load,399,O
.,399,O
The,400,O
relationship,400,O
between,400,O
the,400,O
occurrence,400,O
of,400,O
encephalitis,400,B-Disease
and,400,O
the,400,O
decrease,400,O
in,400,O
microfilaremia,400,B-Disease
is,400,O
evident,400,O
.,400,O
The,401,O
pathophysiological,401,O
mechanisms,401,O
are,401,O
discussed,401,O
in,401,O
the,401,O
light,401,O
of,401,O
these,401,O
observations,401,O
and,401,O
the,401,O
few,401,O
other,401,O
comments,401,O
on,401,O
this,401,O
subject,401,O
published,401,O
in,401,O
the,401,O
literature,401,O
.,401,O
Delirium,402,B-Disease
in,402,O
an,402,O
elderly,402,O
woman,402,O
possibly,402,O
associated,402,O
with,402,O
administration,402,O
of,402,O
misoprostol,402,B-Chemical
.,402,O
Misoprostol,403,B-Chemical
has,403,O
been,403,O
associated,403,O
with,403,O
adverse,403,O
reactions,403,O
",",403,O
including,403,O
gastrointestinal,403,O
symptoms,403,O
",",403,O
gynecologic,403,O
problems,403,O
",",403,O
and,403,O
headache,403,B-Disease
.,403,O
Changes,404,O
in,404,O
mental,404,O
status,404,O
",",404,O
however,404,O
",",404,O
have,404,O
not,404,O
been,404,O
reported,404,O
.,404,O
We,405,O
present,405,O
a,405,O
case,405,O
in,405,O
which,405,O
an,405,O
89-year-old,405,O
woman,405,O
in,405,O
a,405,O
long-term,405,O
care,405,O
facility,405,O
became,405,O
confused,405,O
after,405,O
the,405,O
initiation,405,O
of,405,O
misoprostol,405,B-Chemical
therapy,405,O
.,405,O
The,406,O
patient,406,O
's,406,O
change,406,O
in,406,O
mental,406,O
status,406,O
was,406,O
first,406,O
reported,406,O
nine,406,O
days,406,O
after,406,O
the,406,O
initiation,406,O
of,406,O
therapy,406,O
.,406,O
Her,407,O
delirium,407,B-Disease
significantly,407,O
improved,407,O
after,407,O
misoprostol,407,B-Chemical
was,407,O
discontinued,407,O
and,407,O
her,407,O
mental,407,O
status,407,O
returned,407,O
to,407,O
normal,407,O
within,407,O
a,407,O
week,407,O
.,407,O
Because,408,O
no,408,O
other,408,O
factors,408,O
related,408,O
to,408,O
this,408,O
patient,408,O
changed,408,O
significantly,408,O
",",408,O
the,408,O
delirium,408,B-Disease
experienced,408,O
by,408,O
this,408,O
patient,408,O
possibly,408,O
resulted,408,O
from,408,O
misoprostol,408,B-Chemical
therapy,408,O
.,408,O
Hepatocellular,409,O
oxidant,409,O
stress,409,O
following,409,O
intestinal,409,O
ischemia-reperfusion,409,B-Disease
injury,409,I-Disease
.,409,O
Reperfusion,410,O
of,410,O
ischemic,410,B-Disease
intestine,410,O
results,410,O
in,410,O
acute,410,O
liver,410,B-Disease
dysfunction,410,I-Disease
characterized,410,O
by,410,O
hepatocellular,410,O
enzyme,410,O
release,410,O
into,410,O
plasma,410,O
",",410,O
reduction,410,O
in,410,O
bile,410,O
flow,410,O
rate,410,O
",",410,O
and,410,O
neutrophil,410,O
sequestration,410,O
within,410,O
the,410,O
liver,410,O
.,410,O
The,411,O
pathophysiology,411,O
underlying,411,O
this,411,O
acute,411,O
hepatic,411,B-Disease
injury,411,I-Disease
is,411,O
unknown,411,O
.,411,O
This,412,O
study,412,O
was,412,O
undertaken,412,O
to,412,O
determine,412,O
whether,412,O
oxidants,412,O
are,412,O
associated,412,O
with,412,O
the,412,O
hepatic,412,B-Disease
injury,412,I-Disease
and,412,O
to,412,O
determine,412,O
the,412,O
relative,412,O
value,412,O
of,412,O
several,412,O
indirect,412,O
methods,412,O
of,412,O
assessing,412,O
oxidant,412,O
exposure,412,O
in,412,O
vivo,412,O
.,412,O
Rats,413,O
were,413,O
subjected,413,O
to,413,O
a,413,O
standardized,413,O
intestinal,413,O
ischemia-reperfusion,413,B-Disease
injury,413,I-Disease
.,413,O
Hepatic,414,O
tissue,414,O
was,414,O
assayed,414,O
for,414,O
lipid,414,O
peroxidation,414,O
products,414,O
and,414,O
oxidized,414,O
and,414,O
reduced,414,O
glutathione,414,O
.,414,O
There,415,O
was,415,O
no,415,O
change,415,O
in,415,O
hepatic,415,O
tissue,415,O
total,415,O
glutathione,415,B-Chemical
following,415,O
intestinal,415,O
ischemia-reperfusion,415,B-Disease
injury,415,I-Disease
.,415,O
Oxidized,416,B-Chemical
glutathione,416,I-Chemical
(,416,O
GSSG,416,B-Chemical
),416,O
increased,416,O
significantly,416,O
following,416,O
30,416,O
and,416,O
60,416,O
min,416,O
of,416,O
reperfusion,416,O
.,416,O
There,417,O
was,417,O
no,417,O
increase,417,O
in,417,O
any,417,O
of,417,O
the,417,O
products,417,O
of,417,O
lipid,417,O
peroxidation,417,O
associated,417,O
with,417,O
this,417,O
injury,417,O
.,417,O
An,418,O
increase,418,O
in,418,O
GSSG,418,B-Chemical
within,418,O
hepatic,418,O
tissue,418,O
during,418,O
intestinal,418,O
reperfusion,418,O
suggests,418,O
exposure,418,O
of,418,O
hepatocytes,418,O
to,418,O
an,418,O
oxidant,418,O
stress,418,O
.,418,O
The,419,O
lack,419,O
of,419,O
a,419,O
significant,419,O
increase,419,O
in,419,O
products,419,O
of,419,O
lipid,419,O
peroxidation,419,O
suggests,419,O
that,419,O
the,419,O
oxidant,419,O
stress,419,O
is,419,O
of,419,O
insufficient,419,O
magnitude,419,O
to,419,O
result,419,O
in,419,O
irreversible,419,O
injury,419,O
to,419,O
hepatocyte,419,O
cell,419,O
membranes,419,O
.,419,O
These,420,O
data,420,O
also,420,O
suggest,420,O
that,420,O
the,420,O
measurement,420,O
of,420,O
tissue,420,O
GSSG,420,B-Chemical
may,420,O
be,420,O
a,420,O
more,420,O
sensitive,420,O
indicator,420,O
of,420,O
oxidant,420,O
stress,420,O
than,420,O
measurement,420,O
of,420,O
products,420,O
of,420,O
lipid,420,O
peroxidation,420,O
.,420,O
Diphenhydramine,421,B-Chemical
prevents,421,O
the,421,O
haemodynamic,421,O
changes,421,O
of,421,O
cimetidine,421,B-Chemical
in,421,O
ICU,421,O
patients,421,O
.,421,O
Cimetidine,422,B-Chemical
",",422,O
a,422,O
histamine,422,B-Chemical
2,422,O
(,422,O
H2,422,O
),422,O
antagonist,422,O
",",422,O
produces,422,O
a,422,O
decrease,422,O
in,422,O
arterial,422,O
pressure,422,O
due,422,O
to,422,O
vasodilatation,422,O
",",422,O
especially,422,O
in,422,O
critically,422,O
ill,422,O
patients,422,O
.,422,O
This,423,O
may,423,O
be,423,O
because,423,O
cimetidine,423,B-Chemical
acts,423,O
as,423,O
a,423,O
histamine,423,B-Chemical
agonist,423,O
.,423,O
We,424,O
",",424,O
therefore,424,O
",",424,O
investigated,424,O
the,424,O
effects,424,O
of,424,O
the,424,O
histamine,424,B-Chemical
1,424,O
(,424,O
H1,424,O
),424,O
receptor,424,O
antagonist,424,O
",",424,O
diphenhydramine,424,B-Chemical
",",424,O
on,424,O
the,424,O
haemodynamic,424,O
changes,424,O
observed,424,O
after,424,O
cimetidine,424,B-Chemical
in,424,O
ICU,424,O
patients,424,O
.,424,O
Each,425,O
patient,425,O
was,425,O
studied,425,O
on,425,O
two,425,O
separate,425,O
days,425,O
.,425,O
In,426,O
a,426,O
random,426,O
fashion,426,O
",",426,O
they,426,O
received,426,O
cimetidine,426,B-Chemical
200,426,O
mg,426,O
iv,426,O
on,426,O
one,426,O
day,426,O
",",426,O
and,426,O
on,426,O
the,426,O
other,426,O
",",426,O
a,426,O
pretreatment,426,O
of,426,O
diphenhydramine,426,B-Chemical
40,426,O
mg,426,O
iv,426,O
with,426,O
cimetidine,426,B-Chemical
200,426,O
mg,426,O
iv,426,O
.,426,O
In,427,O
the,427,O
non-pretreatment,427,O
group,427,O
",",427,O
mean,427,O
arterial,427,O
pressure,427,O
(,427,O
MAP,427,O
),427,O
decreased,427,O
from,427,O
107.4,427,O
+/-,427,O
8.4,427,O
mmHg,427,O
to,427,O
86.7,427,O
+/-,427,O
11.4,427,O
mmHg,427,O
(,427,O
P,427,O
less,427,O
than,427,O
0.01,427,O
),427,O
two,427,O
minutes,427,O
after,427,O
cimetidine,427,B-Chemical
.,427,O
Also,428,O
",",428,O
systemic,428,O
vascular,428,O
resistance,428,O
(,428,O
SVR,428,O
),428,O
decreased,428,O
during,428,O
the,428,O
eight-minute,428,O
observation,428,O
period,428,O
(,428,O
P,428,O
less,428,O
than,428,O
0.01,428,O
),428,O
.,428,O
In,429,O
contrast,429,O
",",429,O
in,429,O
the,429,O
pretreatment,429,O
group,429,O
",",429,O
little,429,O
haemodynamic,429,O
change,429,O
was,429,O
seen,429,O
.,429,O
We,430,O
conclude,430,O
that,430,O
an,430,O
H1,430,O
antagonist,430,O
may,430,O
be,430,O
useful,430,O
in,430,O
preventing,430,O
hypotension,430,B-Disease
caused,430,O
by,430,O
iv,430,O
cimetidine,430,B-Chemical
",",430,O
since,430,O
the,430,O
vasodilating,430,O
activity,430,O
of,430,O
cimetidine,430,B-Chemical
is,430,O
mediated,430,O
",",430,O
in,430,O
part,430,O
",",430,O
through,430,O
the,430,O
H1,430,O
receptor,430,O
.,430,O
Acute,431,B-Disease
renal,431,I-Disease
failure,431,I-Disease
due,431,O
to,431,O
rifampicin,431,B-Chemical
.,431,O
A,432,O
23-year-old,432,O
male,432,O
patient,432,O
with,432,O
bacteriologically,432,O
proven,432,O
pulmonary,432,B-Disease
tuberculosis,432,I-Disease
was,432,O
treated,432,O
with,432,O
the,432,O
various,432,O
regimens,432,O
of,432,O
antituberculosis,432,O
drugs,432,O
for,432,O
nearly,432,O
15,432,O
months,432,O
.,432,O
Rifampicin,433,B-Chemical
was,433,O
administered,433,O
thrice,433,O
as,433,O
one,433,O
of,433,O
the,433,O
3-4,433,O
drug,433,O
regimen,433,O
and,433,O
each,433,O
time,433,O
he,433,O
developed,433,O
untoward,433,O
side,433,O
effects,433,O
like,433,O
nausea,433,B-Disease
",",433,O
vomiting,433,B-Disease
and,433,O
fever,433,B-Disease
with,433,O
chills,433,O
and,433,O
rigors,433,O
.,433,O
The,434,O
last,434,O
such,434,O
episode,434,O
was,434,O
of,434,O
acute,434,O
renal,434,O
failure,434,O
at,434,O
which,434,O
stage,434,O
the,434,O
patient,434,O
was,434,O
seen,434,O
by,434,O
the,434,O
authors,434,O
of,434,O
this,434,O
report,434,O
.,434,O
The,435,O
patient,435,O
",",435,O
however,435,O
",",435,O
made,435,O
a,435,O
full,435,O
recovery,435,O
.,435,O
Severe,436,O
polyneuropathy,436,B-Disease
and,436,O
motor,436,O
loss,436,O
after,436,O
intrathecal,436,O
thiotepa,436,B-Chemical
combination,436,O
chemotherapy,436,O
:,436,O
description,436,O
of,436,O
two,436,O
cases,436,O
.,436,O
Two,437,O
cases,437,O
of,437,O
severe,437,O
delayed,437,O
neurologic,437,B-Disease
toxicity,437,I-Disease
related,437,O
to,437,O
the,437,O
administration,437,O
of,437,O
intrathecal,437,O
(,437,O
IT,437,O
),437,O
combination,437,O
chemotherapy,437,O
including,437,O
thiotepa,437,B-Chemical
(,437,O
TSPA,437,B-Chemical
),437,O
are,437,O
presented,437,O
.,437,O
Both,438,O
cases,438,O
developed,438,O
axonal,438,B-Disease
neuropathy,438,I-Disease
with,438,O
motor,438,O
predominance,438,O
in,438,O
the,438,O
lower,438,O
extremities,438,O
1,438,O
and,438,O
6,438,O
months,438,O
after,438,O
IT,438,O
chemotherapy,438,O
was,438,O
administered,438,O
.,438,O
Neurologic,439,B-Disease
toxicities,439,I-Disease
have,439,O
been,439,O
described,439,O
with,439,O
IT-methotrexate,439,O
",",439,O
IT-cytosine,439,O
arabinoside,439,I-Chemical
and,439,O
IT-TSPA,439,O
.,439,O
To,440,O
our,440,O
knowledge,440,O
",",440,O
however,440,O
",",440,O
axonal,440,B-Disease
neuropathy,440,I-Disease
following,440,O
administration,440,O
of,440,O
these,440,O
three,440,O
agents,440,O
has,440,O
not,440,O
been,440,O
previously,440,O
described,440,O
.,440,O
In,441,O
spite,441,O
of,441,O
the,441,O
fact,441,O
that,441,O
TSPA,441,B-Chemical
is,441,O
a,441,O
useful,441,O
IT,441,O
agent,441,O
",",441,O
its,441,O
combination,441,O
with,441,O
MTX,441,B-Chemical
",",441,O
ara-C,441,B-Chemical
and,441,O
radiotherapy,441,O
could,441,O
cause,441,O
severe,441,O
neurotoxicity,441,B-Disease
.,441,O
This,442,O
unexpected,442,O
complication,442,O
indicates,442,O
the,442,O
need,442,O
for,442,O
further,442,O
toxicology,442,O
research,442,O
on,442,O
IT-TSPA,442,O
.,442,O
Effects,443,O
of,443,O
cromakalim,443,B-Chemical
and,443,O
pinacidil,443,B-Chemical
on,443,O
large,443,O
epicardial,443,O
and,443,O
small,443,O
coronary,443,O
arteries,443,O
in,443,O
conscious,443,O
dogs,443,O
.,443,O
The,444,O
effects,444,O
of,444,O
i.v,444,O
.,444,O
bolus,445,O
administration,445,O
of,445,O
cromakalim,445,B-Chemical
(,445,O
1-10,445,O
micrograms/kg,445,O
),445,O
and,445,O
pinacidil,445,B-Chemical
(,445,O
3-100,445,O
micrograms/kg,445,O
),445,O
on,445,O
large,445,O
(,445,O
circumflex,445,O
artery,445,O
),445,O
and,445,O
small,445,O
coronary,445,O
arteries,445,O
and,445,O
on,445,O
systemic,445,O
hemodynamics,445,O
were,445,O
investigated,445,O
in,445,O
chronically,445,O
instrumented,445,O
conscious,445,O
dogs,445,O
and,445,O
compared,445,O
to,445,O
those,445,O
of,445,O
nitroglycerin,445,B-Chemical
(,445,O
0.03-10,445,O
micrograms/kg,445,O
),445,O
.,445,O
Nitroglycerin,446,B-Chemical
",",446,O
up,446,O
to,446,O
0.3,446,O
micrograms/kg,446,O
",",446,O
selectively,446,O
increased,446,O
circumflex,446,O
artery,446,O
diameter,446,O
(,446,O
CxAD,446,O
),446,O
without,446,O
simultaneously,446,O
affecting,446,O
any,446,O
other,446,O
cardiac,446,O
or,446,O
systemic,446,O
hemodynamic,446,O
parameter,446,O
.,446,O
In,447,O
contrast,447,O
",",447,O
cromakalim,447,B-Chemical
and,447,O
pinacidil,447,B-Chemical
at,447,O
all,447,O
doses,447,O
and,447,O
nitroglycerin,447,B-Chemical
at,447,O
doses,447,O
higher,447,O
than,447,O
0.3,447,O
micrograms/kg,447,O
simultaneously,447,O
and,447,O
dose-dependently,447,O
increased,447,O
CxAD,447,O
",",447,O
coronary,447,O
blood,447,O
flow,447,O
and,447,O
heart,447,O
rate,447,O
and,447,O
decreased,447,O
coronary,447,O
vascular,447,O
resistance,447,O
and,447,O
aortic,447,O
pressure,447,O
.,447,O
Cromakalim,448,B-Chemical
was,448,O
approximately,448,O
8-,448,O
to,448,O
9.5-fold,448,O
more,448,O
potent,448,O
than,448,O
pinacidil,448,B-Chemical
in,448,O
increasing,448,O
CxAD,448,O
.,448,O
Vasodilation,449,O
of,449,O
large,449,O
and,449,O
small,449,O
coronary,449,O
vessels,449,O
and,449,O
hypotension,449,B-Disease
induced,449,O
by,449,O
cromakalim,449,B-Chemical
and,449,O
pinacidil,449,B-Chemical
were,449,O
not,449,O
affected,449,O
by,449,O
prior,449,O
combined,449,O
beta,449,O
adrenergic,449,O
and,449,O
muscarinic,449,O
receptors,449,O
blockade,449,O
but,449,O
drug-induced,449,O
tachycardia,449,B-Disease
was,449,O
abolished,449,O
.,449,O
When,450,O
circumflex,450,O
artery,450,O
blood,450,O
flow,450,O
was,450,O
maintained,450,O
constant,450,O
",",450,O
the,450,O
increases,450,O
in,450,O
CxAD,450,O
induced,450,O
by,450,O
cromakalim,450,B-Chemical
(,450,O
10,450,O
micrograms/kg,450,O
),450,O
",",450,O
pinacidil,450,B-Chemical
(,450,O
30,450,O
micrograms/kg,450,O
),450,O
and,450,O
nitroglycerin,450,B-Chemical
(,450,O
10,450,O
micrograms/kg,450,O
),450,O
were,450,O
reduced,450,O
by,450,O
68,450,O
+/-,450,O
7,450,O
",",450,O
54,450,O
+/-,450,O
9,450,O
and,450,O
1,450,O
+/-,450,O
1,450,O
%,450,O
",",450,O
respectively,450,O
.,450,O
Thus,451,O
",",451,O
whereas,451,O
nitroglycerin,451,B-Chemical
preferentially,451,O
and,451,O
flow-independently,451,O
dilates,451,O
large,451,O
coronary,451,O
arteries,451,O
",",451,O
cromakalim,451,B-Chemical
and,451,O
pinacidil,451,B-Chemical
dilate,451,O
both,451,O
large,451,O
and,451,O
small,451,O
coronary,451,O
arteries,451,O
and,451,O
this,451,O
effect,451,O
is,451,O
not,451,O
dependent,451,O
upon,451,O
the,451,O
simultaneous,451,O
beta,451,O
adrenoceptors-mediated,451,O
rise,451,O
in,451,O
myocardial,451,O
metabolic,451,O
demand,451,O
.,451,O
Finally,452,O
",",452,O
two,452,O
mechanisms,452,O
at,452,O
least,452,O
",",452,O
direct,452,O
vasodilation,452,O
and,452,O
flow,452,O
dependency,452,O
",",452,O
are,452,O
involved,452,O
in,452,O
the,452,O
cromakalim-,452,B-Chemical
and,452,O
pinacidil-induced,452,B-Chemical
increase,452,O
in,452,O
CxAD,452,O
.,452,O
Mefenamic,453,B-Chemical
acid-induced,453,O
neutropenia,453,B-Disease
and,453,O
renal,453,B-Disease
failure,453,I-Disease
in,453,O
elderly,453,O
females,453,O
with,453,O
hypothyroidism,453,B-Disease
.,453,O
We,454,O
report,454,O
mefenamic,454,B-Chemical
acid-induced,454,O
non-oliguric,454,O
renal,454,B-Disease
failure,454,I-Disease
and,454,O
severe,454,O
neutropenia,454,B-Disease
occurring,454,O
simultaneously,454,O
in,454,O
two,454,O
elderly,454,O
females,454,O
.,454,O
The,455,O
neutropenia,455,B-Disease
was,455,O
due,455,O
to,455,O
maturation,455,O
arrest,455,O
of,455,O
the,455,O
myeloid,455,O
series,455,O
in,455,O
one,455,O
patient,455,O
.,455,O
Both,456,O
patients,456,O
were,456,O
also,456,O
hypothyroid,456,B-Disease
",",456,O
but,456,O
it,456,O
is,456,O
not,456,O
clear,456,O
whether,456,O
this,456,O
was,456,O
a,456,O
predisposing,456,O
factor,456,O
to,456,O
the,456,O
development,456,O
of,456,O
these,456,O
adverse,456,O
reactions,456,O
.,456,O
However,457,O
",",457,O
it,457,O
would,457,O
seem,457,O
prudent,457,O
not,457,O
to,457,O
use,457,O
mefenamic,457,B-Chemical
acid,457,I-Chemical
in,457,O
hypothyroid,457,B-Disease
patients,457,O
until,457,O
the,457,O
hypothyroidism,457,B-Disease
has,457,O
been,457,O
corrected,457,O
.,457,O
Etiology,458,O
of,458,O
hypercalcemia,458,B-Disease
in,458,O
hemodialysis,458,O
patients,458,O
on,458,O
calcium,458,B-Chemical
carbonate,458,I-Chemical
therapy,458,O
.,458,O
Fourteen,459,O
of,459,O
39,459,O
dialysis,459,O
patients,459,O
(,459,O
36,459,O
%,459,O
),459,O
became,459,O
hypercalcemic,459,B-Disease
after,459,O
switching,459,O
to,459,O
calcium,459,B-Chemical
carbonate,459,I-Chemical
as,459,O
their,459,O
principal,459,O
phosphate,459,B-Chemical
binder,459,O
.,459,O
In,460,O
order,460,O
to,460,O
identify,460,O
risk,460,O
factors,460,O
associated,460,O
with,460,O
the,460,O
development,460,O
of,460,O
hypercalcemia,460,B-Disease
",",460,O
indirect,460,O
parameters,460,O
of,460,O
intestinal,460,O
calcium,460,B-Chemical
reabsorption,460,O
and,460,O
bone,460,O
turnover,460,O
rate,460,O
in,460,O
these,460,O
14,460,O
patients,460,O
were,460,O
compared,460,O
with,460,O
results,460,O
in,460,O
14,460,O
eucalcemic,460,O
patients,460,O
matched,460,O
for,460,O
age,460,O
",",460,O
sex,460,O
",",460,O
length,460,O
of,460,O
time,460,O
on,460,O
dialysis,460,O
",",460,O
and,460,O
etiology,460,O
of,460,O
renal,460,B-Disease
disease,460,I-Disease
.,460,O
In,461,O
addition,461,O
to,461,O
experiencing,461,O
hypercalcemic,461,B-Disease
episodes,461,O
with,461,O
peak,461,O
calcium,461,B-Chemical
values,461,O
of,461,O
2.7,461,O
to,461,O
3.8,461,O
mmol/L,461,O
(,461,O
10.7,461,O
to,461,O
15.0,461,O
mg/dL,461,O
),461,O
",",461,O
patients,461,O
in,461,O
the,461,O
hypercalcemic,461,B-Disease
group,461,O
exhibited,461,O
a,461,O
significant,461,O
increase,461,O
in,461,O
the,461,O
mean,461,O
calcium,461,B-Chemical
concentration,461,O
obtained,461,O
during,461,O
6,461,O
months,461,O
before,461,O
the,461,O
switch,461,O
",",461,O
compared,461,O
with,461,O
the,461,O
mean,461,O
value,461,O
obtained,461,O
during,461,O
the,461,O
7,461,O
months,461,O
of,461,O
observation,461,O
after,461,O
the,461,O
switch,461,O
(,461,O
2.4,461,O
+/-,461,O
0.03,461,O
to,461,O
2.5,461,O
+/-,461,O
0.03,461,O
mmol/L,461,O
[,461,O
9.7,461,O
+/-,461,O
0.2,461,O
to,461,O
10.2,461,O
+/-,461,O
0.1,461,O
mg/dL,461,O
],461,O
",",461,O
P,461,O
=,461,O
0.006,461,O
),461,O
.,461,O
In,462,O
contrast,462,O
",",462,O
eucalcemic,462,O
patients,462,O
exhibited,462,O
no,462,O
change,462,O
in,462,O
mean,462,O
calcium,462,B-Chemical
values,462,O
over,462,O
the,462,O
same,462,O
time,462,O
period,462,O
(,462,O
2.3,462,O
+/-,462,O
0.05,462,O
to,462,O
2.3,462,O
+/-,462,O
0.05,462,O
mmol/L,462,O
[,462,O
9.2,462,O
+/-,462,O
0.2,462,O
to,462,O
9.2,462,O
+/-,462,O
0.2,462,O
mg/dL,462,O
],462,O
),462,O
.,462,O
CaCO3,463,B-Chemical
dosage,463,O
",",463,O
calculated,463,O
dietary,463,O
calcium,463,B-Chemical
intake,463,O
",",463,O
and,463,O
circulating,463,O
levels,463,O
of,463,O
vitamin,463,B-Chemical
D,463,I-Chemical
metabolites,463,O
were,463,O
similar,463,O
in,463,O
both,463,O
groups,463,O
.,463,O
Physical,464,O
activity,464,O
index,464,O
and,464,O
predialysis,464,O
serum,464,O
bicarbonate,464,B-Chemical
levels,464,O
also,464,O
were,464,O
similar,464,O
in,464,O
both,464,O
groups,464,O
.,464,O
However,465,O
",",465,O
there,465,O
was,465,O
a,465,O
significant,465,O
difference,465,O
in,465,O
parameters,465,O
reflecting,465,O
bone,465,O
turnover,465,O
rates,465,O
between,465,O
groups,465,O
.,465,O
(,466,O
ABSTRACT,466,O
TRUNCATED,466,O
AT,466,O
250,466,O
WORDS,466,O
),466,O
Methyldopa-induced,467,B-Chemical
hemolytic,467,B-Disease
anemia,467,I-Disease
in,467,O
a,467,O
15,467,O
year,467,O
old,467,O
presenting,467,O
as,467,O
near-syncope,467,O
.,467,O
Methyldopa,468,B-Chemical
is,468,O
an,468,O
antihypertensive,468,O
medication,468,O
which,468,O
is,468,O
available,468,O
generically,468,O
and,468,O
under,468,O
the,468,O
trade,468,O
name,468,O
Aldomet,468,B-Chemical
that,468,O
is,468,O
widely,468,O
prescribed,468,O
in,468,O
the,468,O
adult,468,O
population,468,O
and,468,O
infrequently,468,O
used,468,O
in,468,O
children,468,O
.,468,O
Methyldopa,469,B-Chemical
causes,469,O
an,469,O
autoimmune,469,B-Disease
hemolytic,469,I-Disease
anemia,469,I-Disease
in,469,O
a,469,O
small,469,O
percentage,469,O
of,469,O
patients,469,O
who,469,O
take,469,O
the,469,O
drug,469,O
.,469,O
We,470,O
report,470,O
a,470,O
case,470,O
of,470,O
methyldopa-induced,470,B-Chemical
hemolytic,470,B-Disease
anemia,470,I-Disease
in,470,O
a,470,O
15-year-old,470,O
boy,470,O
who,470,O
presented,470,O
to,470,O
the,470,O
emergency,470,B-Disease
department,470,I-Disease
with,470,O
near-syncope,470,O
.,470,O
The,471,O
boy,471,O
had,471,O
been,471,O
treated,471,O
with,471,O
intravenous,471,O
methyldopa,471,B-Chemical
during,471,O
a,471,O
trauma,471,B-Disease
admission,471,O
seven,471,O
weeks,471,O
prior,471,O
to,471,O
presentation,471,O
.,471,O
Evaluation,472,O
revealed,472,O
a,472,O
hemoglobin,472,O
of,472,O
three,472,O
grams,472,O
",",472,O
3+,472,O
Coombs,472,O
',472,O
test,472,O
with,472,O
polyspecific,472,O
anti-human,472,O
globulin,472,O
and,472,O
monospecific,472,O
IgG,472,O
reagents,472,O
",",472,O
and,472,O
a,472,O
warm,472,O
reacting,472,O
autoantibody,472,O
.,472,O
Transfusion,473,O
and,473,O
corticosteroid,473,B-Chemical
therapy,473,O
resulted,473,O
in,473,O
a,473,O
complete,473,O
recovery,473,O
of,473,O
the,473,O
patient,473,O
.,473,O
Emergency,474,O
physicians,474,O
treating,474,O
children,474,O
must,474,O
be,474,O
aware,474,O
of,474,O
this,474,O
syndrome,474,O
in,474,O
order,474,O
to,474,O
diagnose,474,O
and,474,O
treat,474,O
it,474,O
correctly,474,O
.,474,O
A,475,O
brief,475,O
review,475,O
of,475,O
autoimmune,475,O
and,475,O
drug-induced,475,O
hemolytic,475,B-Disease
anemias,475,I-Disease
is,475,O
provided,475,O
.,475,O
The,476,O
long-term,476,O
safety,476,O
of,476,O
danazol,476,B-Chemical
in,476,O
women,476,O
with,476,O
hereditary,476,B-Disease
angioedema,476,I-Disease
.,476,O
Although,477,O
the,477,O
short-term,477,O
safety,477,O
(,477,O
less,477,O
than,477,O
or,477,O
equal,477,O
to,477,O
6,477,O
months,477,O
),477,O
of,477,O
danazol,477,B-Chemical
has,477,O
been,477,O
established,477,O
in,477,O
a,477,O
variety,477,O
of,477,O
settings,477,O
",",477,O
no,477,O
information,477,O
exists,477,O
as,477,O
to,477,O
its,477,O
long-term,477,O
safety,477,O
.,477,O
We,478,O
therefore,478,O
investigated,478,O
the,478,O
long-term,478,O
safety,478,O
of,478,O
danazol,478,B-Chemical
by,478,O
performing,478,O
a,478,O
retrospective,478,O
chart,478,O
review,478,O
of,478,O
60,478,O
female,478,O
patients,478,O
with,478,O
hereditary,478,B-Disease
angioedema,478,I-Disease
treated,478,O
with,478,O
danazol,478,B-Chemical
for,478,O
a,478,O
continuous,478,O
period,478,O
of,478,O
6,478,O
months,478,O
or,478,O
longer,478,O
.,478,O
The,479,O
mean,479,O
age,479,O
of,479,O
the,479,O
patients,479,O
was,479,O
35.2,479,O
years,479,O
and,479,O
the,479,O
mean,479,O
duration,479,O
of,479,O
therapy,479,O
was,479,O
59.7,479,O
months,479,O
.,479,O
Virtually,480,O
all,480,O
patients,480,O
experienced,480,O
one,480,O
or,480,O
more,480,O
adverse,480,O
reactions,480,O
.,480,O
Menstrual,481,B-Disease
abnormalities,481,I-Disease
(,481,O
79,481,O
%,481,O
),481,O
",",481,O
weight,481,B-Disease
gain,481,I-Disease
(,481,O
60,481,O
%,481,O
),481,O
",",481,O
muscle,481,B-Disease
cramps/myalgias,481,O
(,481,O
40,481,O
%,481,O
),481,O
",",481,O
and,481,O
transaminase,481,O
elevations,481,O
(,481,O
40,481,O
%,481,O
),481,O
were,481,O
the,481,O
most,481,O
common,481,O
adverse,481,O
reactions,481,O
.,481,O
The,482,O
drug,482,O
was,482,O
discontinued,482,O
due,482,O
to,482,O
adverse,482,O
reactions,482,O
in,482,O
8,482,O
patients,482,O
.,482,O
No,483,O
patient,483,O
has,483,O
died,483,O
or,483,O
suffered,483,O
any,483,O
apparent,483,O
long-term,483,O
sequelae,483,O
that,483,O
were,483,O
directly,483,O
attributable,483,O
to,483,O
the,483,O
drug,483,O
.,483,O
We,484,O
conclude,484,O
that,484,O
",",484,O
despite,484,O
a,484,O
relatively,484,O
high,484,O
incidence,484,O
of,484,O
adverse,484,O
reactions,484,O
",",484,O
danazol,484,B-Chemical
has,484,O
proven,484,O
to,484,O
be,484,O
remarkably,484,O
safe,484,O
over,484,O
the,484,O
long-term,484,O
in,484,O
this,484,O
group,484,O
of,484,O
patients,484,O
.,484,O
Patient,485,O
tolerance,485,O
study,485,O
of,485,O
topical,485,O
chlorhexidine,485,B-Chemical
diphosphanilate,485,I-Chemical
:,485,O
a,485,O
new,485,O
topical,485,O
agent,485,O
for,485,O
burns,485,B-Disease
.,485,O
Effective,486,O
topical,486,O
antimicrobial,486,O
agents,486,O
decrease,486,O
infection,486,B-Disease
and,486,O
mortality,486,O
in,486,O
burn,486,B-Disease
patients,486,O
.,486,O
Chlorhexidine,487,B-Chemical
phosphanilate,487,I-Chemical
(,487,O
CHP,487,B-Chemical
),487,O
",",487,O
a,487,O
new,487,O
broad-spectrum,487,O
antimicrobial,487,O
agent,487,O
",",487,O
has,487,O
been,487,O
evaluated,487,O
as,487,O
a,487,O
topical,487,O
burn,487,B-Disease
wound,487,O
dressing,487,O
in,487,O
cream,487,O
form,487,O
",",487,O
but,487,O
preliminary,487,O
clinical,487,O
trials,487,O
reported,487,O
that,487,O
it,487,O
was,487,O
painful,487,O
upon,487,O
application,487,O
.,487,O
This,488,O
study,488,O
compared,488,O
various,488,O
concentrations,488,O
of,488,O
CHP,488,B-Chemical
to,488,O
determine,488,O
if,488,O
a,488,O
tolerable,488,O
concentration,488,O
could,488,O
be,488,O
identified,488,O
with,488,O
retention,488,O
of,488,O
antimicrobial,488,O
efficacy,488,O
.,488,O
Twenty-nine,489,O
burn,489,B-Disease
patients,489,O
",",489,O
each,489,O
with,489,O
two,489,O
similar,489,O
burns,489,B-Disease
which,489,O
could,489,O
be,489,O
separately,489,O
treated,489,O
",",489,O
were,489,O
given,489,O
pairs,489,O
of,489,O
treatments,489,O
at,489,O
successive,489,O
12-h,489,O
intervals,489,O
over,489,O
a,489,O
3-day,489,O
period,489,O
.,489,O
One,490,O
burn,490,B-Disease
site,490,O
was,490,O
treated,490,O
with,490,O
each,490,O
of,490,O
four,490,O
different,490,O
CHP,490,B-Chemical
concentrations,490,O
",",490,O
from,490,O
0.25,490,O
per,490,O
cent,490,O
to,490,O
2,490,O
per,490,O
cent,490,O
",",490,O
their,490,O
vehicle,490,O
",",490,O
and,490,O
1,490,O
per,490,O
cent,490,O
silver,490,B-Chemical
sulphadiazine,490,I-Chemical
(,490,O
AgSD,490,B-Chemical
),490,O
cream,490,O
",",490,O
an,490,O
antimicrobial,490,O
agent,490,O
frequently,490,O
used,490,O
for,490,O
topical,490,O
treatment,490,O
of,490,O
burn,490,B-Disease
wounds,490,O
.,490,O
The,491,O
other,491,O
site,491,O
was,491,O
always,491,O
treated,491,O
with,491,O
AgSD,491,B-Chemical
cream,491,O
.,491,O
There,492,O
was,492,O
a,492,O
direct,492,O
relationship,492,O
between,492,O
CHP,492,B-Chemical
concentration,492,O
and,492,O
patients,492,O
',492,O
ratings,492,O
of,492,O
pain,492,B-Disease
on,492,O
an,492,O
analogue,492,O
scale,492,O
.,492,O
The,493,O
0.25,493,O
per,493,O
cent,493,O
CHP,493,B-Chemical
cream,493,O
was,493,O
closest,493,O
to,493,O
AgSD,493,B-Chemical
in,493,O
pain,493,B-Disease
tolerance,493,O
;,493,O
however,493,O
",",493,O
none,493,O
of,493,O
the,493,O
treatments,493,O
differed,493,O
statistically,493,O
from,493,O
AgSD,493,B-Chemical
or,493,O
from,493,O
each,493,O
other,493,O
.,493,O
In,494,O
addition,494,O
",",494,O
ease,494,O
of,494,O
application,494,O
of,494,O
CHP,494,B-Chemical
creams,494,O
was,494,O
less,494,O
satisfactory,494,O
than,494,O
that,494,O
of,494,O
AgSD,494,B-Chemical
.,494,O
It,495,O
was,495,O
concluded,495,O
that,495,O
formulations,495,O
at,495,O
or,495,O
below,495,O
0.5,495,O
per,495,O
cent,495,O
CHP,495,B-Chemical
may,495,O
prove,495,O
acceptable,495,O
for,495,O
wound,495,O
care,495,O
",",495,O
but,495,O
the,495,O
vehicle,495,O
system,495,O
needs,495,O
pharmaceutical,495,O
improvement,495,O
to,495,O
render,495,O
it,495,O
more,495,O
tolerable,495,O
and,495,O
easier,495,O
to,495,O
use,495,O
.,495,O
Dose-dependent,496,O
neurotoxicity,496,B-Disease
of,496,O
high-dose,496,O
busulfan,496,B-Chemical
in,496,O
children,496,O
:,496,O
a,496,O
clinical,496,O
and,496,O
pharmacological,496,O
study,496,O
.,496,O
Busulfan,497,B-Chemical
is,497,O
known,497,O
to,497,O
be,497,O
neurotoxic,497,B-Disease
in,497,O
animals,497,O
and,497,O
humans,497,O
",",497,O
but,497,O
its,497,O
acute,497,O
neurotoxicity,497,B-Disease
remains,497,O
poorly,497,O
characterized,497,O
in,497,O
children,497,O
.,497,O
We,498,O
report,498,O
here,498,O
a,498,O
retrospective,498,O
study,498,O
of,498,O
123,498,O
children,498,O
(,498,O
median,498,O
age,498,O
",",498,O
6.5,498,O
years,498,O
),498,O
receiving,498,O
high-dose,498,O
busulfan,498,B-Chemical
in,498,O
combined,498,O
chemotherapy,498,O
before,498,O
bone,498,O
marrow,498,O
transplantation,498,O
for,498,O
malignant,498,O
solid,498,O
tumors,498,B-Disease
",",498,O
brain,498,B-Disease
tumors,498,I-Disease
excluded,498,O
.,498,O
Busulfan,499,B-Chemical
was,499,O
given,499,O
p.o.,499,O
",",499,O
every,499,O
6,499,O
hours,499,O
for,499,O
16,499,O
doses,499,O
over,499,O
4,499,O
days,499,O
.,499,O
Two,500,O
total,500,O
doses,500,O
were,500,O
consecutively,500,O
used,500,O
:,500,O
16,500,O
mg/kg,500,O
",",500,O
then,500,O
600,500,O
mg/m2,500,O
.,500,O
The,501,O
dose,501,O
calculation,501,O
on,501,O
the,501,O
basis,501,O
of,501,O
body,501,O
surface,501,O
area,501,O
results,501,O
in,501,O
higher,501,O
doses,501,O
in,501,O
young,501,O
children,501,O
than,501,O
in,501,O
older,501,O
patients,501,O
(,501,O
16,501,O
to,501,O
28,501,O
mg/kg,501,O
),501,O
.,501,O
Ninety-six,502,O
patients,502,O
were,502,O
not,502,O
given,502,O
anticonvulsive,502,O
prophylaxis,502,O
;,502,O
7,502,O
(,502,O
7.5,502,O
%,502,O
),502,O
developed,502,O
seizures,502,B-Disease
during,502,O
the,502,O
4,502,O
days,502,O
of,502,O
the,502,O
busulfan,502,B-Chemical
course,502,O
or,502,O
within,502,O
24,502,O
h,502,O
after,502,O
the,502,O
last,502,O
dosing,502,O
.,502,O
When,503,O
the,503,O
total,503,O
busulfan,503,B-Chemical
dose,503,O
was,503,O
taken,503,O
into,503,O
account,503,O
",",503,O
there,503,O
was,503,O
a,503,O
significant,503,O
difference,503,O
in,503,O
terms,503,O
of,503,O
neurotoxicity,503,B-Disease
incidence,503,O
among,503,O
patients,503,O
under,503,O
16,503,O
mg/kg,503,O
(,503,O
1,503,O
of,503,O
57,503,O
",",503,O
1.7,503,O
%,503,O
),503,O
and,503,O
patients,503,O
under,503,O
600,503,O
mg/m2,503,O
(,503,O
6,503,O
of,503,O
39,503,O
",",503,O
15.4,503,O
%,503,O
),503,O
(,503,O
P,503,O
less,503,O
than,503,O
0.02,503,O
),503,O
.,503,O
Twenty-seven,504,O
patients,504,O
were,504,O
given,504,O
a,504,O
600-mg/m2,504,O
busulfan,504,B-Chemical
total,504,O
dose,504,O
with,504,O
continuous,504,O
i.v,504,O
.,504,O
infusion,505,O
of,505,O
clonazepam,505,B-Chemical
;,505,O
none,505,O
had,505,O
any,505,O
neurological,505,B-Disease
symptoms,505,I-Disease
.,505,O
Busulfan,506,B-Chemical
levels,506,O
were,506,O
measured,506,O
by,506,O
a,506,O
gas,506,O
chromatographic-mass,506,O
spectrometry,506,O
assay,506,O
in,506,O
the,506,O
plasma,506,O
and,506,O
cerebrospinal,506,O
fluid,506,O
of,506,O
9,506,O
children,506,O
without,506,O
central,506,B-Disease
nervous,506,I-Disease
system,506,I-Disease
disease,506,I-Disease
under,506,O
600,506,O
mg/m2,506,O
busulfan,506,B-Chemical
with,506,O
clonazepam,506,B-Chemical
:,506,O
busulfan,506,B-Chemical
cerebrospinal,506,O
fluid,506,O
:,506,O
plasma,506,O
ratio,506,O
was,506,O
1.39,506,O
.,506,O
This,507,O
was,507,O
significantly,507,O
different,507,O
(,507,O
P,507,O
less,507,O
than,507,O
0.02,507,O
),507,O
from,507,O
the,507,O
cerebrospinal,507,O
fluid,507,O
:,507,O
plasma,507,O
ratio,507,O
previously,507,O
defined,507,O
in,507,O
children,507,O
receiving,507,O
a,507,O
16-mg/kg,507,O
total,507,O
dose,507,O
of,507,O
busulfan,507,B-Chemical
.,507,O
This,508,O
study,508,O
shows,508,O
that,508,O
busulfan,508,B-Chemical
neurotoxicity,508,B-Disease
is,508,O
dose-dependent,508,O
in,508,O
children,508,O
and,508,O
efficiently,508,O
prevented,508,O
by,508,O
clonazepam,508,B-Chemical
.,508,O
A,509,O
busulfan,509,B-Chemical
dose,509,O
calculated,509,O
on,509,O
the,509,O
basis,509,O
of,509,O
body,509,O
surface,509,O
area,509,O
",",509,O
resulting,509,O
in,509,O
higher,509,O
doses,509,O
in,509,O
young,509,O
children,509,O
",",509,O
was,509,O
followed,509,O
by,509,O
increased,509,O
neurotoxicity,509,B-Disease
",",509,O
close,509,O
to,509,O
neurotoxicity,509,B-Disease
incidence,509,O
observed,509,O
in,509,O
adults,509,O
.,509,O
Since,510,O
plasma,510,O
pharmacokinetic,510,O
studies,510,O
showed,510,O
a,510,O
faster,510,O
busulfan,510,B-Chemical
clearance,510,O
in,510,O
children,510,O
than,510,O
in,510,O
adults,510,O
",",510,O
this,510,O
new,510,O
dose,510,O
may,510,O
approximate,510,O
more,510,O
closely,510,O
the,510,O
adult,510,O
systemic,510,O
exposure,510,O
obtained,510,O
after,510,O
the,510,O
usual,510,O
16-mg/kg,510,O
total,510,O
dose,510,O
",",510,O
with,510,O
potential,510,O
inferences,510,O
in,510,O
terms,510,O
of,510,O
anticancer,510,O
or,510,O
myeloablative,510,O
effects,510,O
.,510,O
The,511,O
busulfan,511,B-Chemical
dose,511,O
in,511,O
children,511,O
and,511,O
infants,511,O
undergoing,511,O
bone,511,O
marrow,511,O
transplantation,511,O
should,511,O
be,511,O
reconsidered,511,O
on,511,O
the,511,O
basis,511,O
of,511,O
pharmacokinetic,511,O
studies,511,O
.,511,O
Histamine,512,B-Chemical
antagonists,512,O
and,512,O
d-tubocurarine-induced,512,B-Chemical
hypotension,512,B-Disease
in,512,O
cardiac,512,O
surgical,512,O
patients,512,O
.,512,O
Hemodynamic,513,O
effects,513,O
and,513,O
histamine,513,B-Chemical
release,513,O
by,513,O
bolus,513,O
injection,513,O
of,513,O
0.35,513,O
mg/kg,513,O
of,513,O
d-tubocurarine,513,B-Chemical
were,513,O
studied,513,O
in,513,O
24,513,O
patients,513,O
.,513,O
H1-,514,O
and,514,O
H2-histamine,514,O
antagonists,514,O
or,514,O
placebo,514,O
were,514,O
given,514,O
before,514,O
dosing,514,O
with,514,O
d-tubocurarine,514,B-Chemical
in,514,O
a,514,O
randomized,514,O
double-blind,514,O
fashion,514,O
to,514,O
four,514,O
groups,514,O
:,514,O
group,514,O
1,514,O
--,514,O
placebo,514,O
;,514,O
group,514,O
2,514,O
--,514,O
cimetidine,514,B-Chemical
",",514,O
4,514,O
mg/kg,514,O
",",514,O
plus,514,O
placebo,514,O
;,514,O
group,514,O
3,514,O
--,514,O
chlorpheniramine,514,B-Chemical
",",514,O
0.1,514,O
mg/kg,514,O
",",514,O
plus,514,O
placebo,514,O
;,514,O
and,514,O
group,514,O
4,514,O
--,514,O
cimetidine,514,B-Chemical
plus,514,O
chlorpheniramine,514,B-Chemical
.,514,O
Histamine,515,B-Chemical
release,515,O
occurred,515,O
in,515,O
most,515,O
patients,515,O
",",515,O
the,515,O
highest,515,O
level,515,O
2,515,O
minutes,515,O
after,515,O
d-tubocurarine,515,B-Chemical
dosing,515,O
.,515,O
Group,516,O
1,516,O
had,516,O
a,516,O
moderate,516,O
negative,516,O
correlation,516,O
between,516,O
plasma,516,O
histamine,516,B-Chemical
change,516,O
and,516,O
systemic,516,O
vascular,516,O
resistance,516,O
(,516,O
r,516,O
=,516,O
0.58,516,O
;,516,O
P,516,O
less,516,O
than,516,O
0.05,516,O
),516,O
not,516,O
present,516,O
in,516,O
group,516,O
4,516,O
.,516,O
Prior,517,O
dosing,517,O
with,517,O
antagonists,517,O
partially,517,O
prevented,517,O
the,517,O
fall,517,O
in,517,O
systemic,517,O
vascular,517,O
resistance,517,O
.,517,O
These,518,O
data,518,O
demonstrate,518,O
that,518,O
the,518,O
hemodynamic,518,O
changes,518,O
associated,518,O
with,518,O
d-tubocurarine,518,B-Chemical
dosing,518,O
are,518,O
only,518,O
partially,518,O
explained,518,O
by,518,O
histamine,518,B-Chemical
release,518,O
.,518,O
Thus,519,O
prior,519,O
dosing,519,O
with,519,O
H1-,519,O
and,519,O
H2-antagonists,519,O
provides,519,O
only,519,O
partial,519,O
protection,519,O
.,519,O
Convulsant,520,O
effect,520,O
of,520,O
lindane,520,B-Chemical
and,520,O
regional,520,O
brain,520,O
concentration,520,O
of,520,O
GABA,520,B-Chemical
and,520,O
dopamine,520,B-Chemical
.,520,O
Lindane,521,B-Chemical
(,521,O
gamma-hexachlorocyclohexane,521,B-Chemical
),521,O
is,521,O
an,521,O
organochlorine,521,O
insecticide,521,O
with,521,O
known,521,O
neurotoxic,521,B-Disease
effects,521,O
.,521,O
Its,522,O
mechanism,522,O
of,522,O
action,522,O
is,522,O
not,522,O
well,522,O
understood,522,O
although,522,O
it,522,O
has,522,O
been,522,O
proposed,522,O
that,522,O
lindane,522,B-Chemical
acts,522,O
as,522,O
a,522,O
non-competitive,522,O
antagonist,522,O
at,522,O
the,522,O
gamma-aminobutyric,522,B-Chemical
acid,522,I-Chemical
(,522,O
GABA,522,B-Chemical
),522,O
-A,522,O
receptor,522,O
.,522,O
We,523,O
studied,523,O
the,523,O
effect,523,O
of,523,O
lindane,523,B-Chemical
(,523,O
150,523,O
mg/kg,523,O
),523,O
on,523,O
the,523,O
GABAergic,523,O
and,523,O
dopaminergic,523,O
systems,523,O
by,523,O
measuring,523,O
the,523,O
concentration,523,O
of,523,O
GABA,523,B-Chemical
",",523,O
dopamine,523,B-Chemical
and,523,O
its,523,O
metabolites,523,O
in,523,O
7,523,O
brain,523,O
areas,523,O
at,523,O
the,523,O
onset,523,O
of,523,O
seizures,523,B-Disease
.,523,O
All,524,O
animals,524,O
suffered,524,O
tonic,524,O
convulsions,524,B-Disease
at,524,O
18.3,524,O
+/-,524,O
1.4,524,O
min,524,O
after,524,O
lindane,524,B-Chemical
administration,524,O
.,524,O
The,525,O
concentration,525,O
of,525,O
GABA,525,B-Chemical
was,525,O
only,525,O
slightly,525,O
but,525,O
significantly,525,O
decreased,525,O
in,525,O
the,525,O
colliculi,525,O
without,525,O
modifications,525,O
in,525,O
the,525,O
other,525,O
areas,525,O
.,525,O
The,526,O
concentration,526,O
of,526,O
dopamine,526,B-Chemical
was,526,O
increased,526,O
in,526,O
the,526,O
mesencephalon,526,O
and,526,O
that,526,O
of,526,O
its,526,O
metabolite,526,O
DOPAC,526,B-Chemical
was,526,O
also,526,O
increased,526,O
in,526,O
the,526,O
mesencephalon,526,O
and,526,O
the,526,O
striatum,526,O
.,526,O
Unusual,527,O
complications,527,O
of,527,O
antithyroid,527,O
drug,527,O
therapy,527,O
:,527,O
four,527,O
case,527,O
reports,527,O
and,527,O
review,527,O
of,527,O
literature,527,O
.,527,O
Two,528,O
cases,528,O
of,528,O
propylthiouracil-associated,528,B-Chemical
acute,528,O
hepatitis,528,B-Disease
",",528,O
one,528,O
case,528,O
of,528,O
fatal,528,O
methimazole-associated,528,B-Chemical
hepatocellular,528,B-Disease
necrosis,528,I-Disease
and,528,O
one,528,O
case,528,O
of,528,O
propylthiouracil-associated,528,B-Chemical
lupus-like,528,B-Disease
syndrome,528,I-Disease
are,528,O
described,528,O
.,528,O
The,529,O
literature,529,O
related,529,O
to,529,O
antithyroid,529,O
drug,529,O
side,529,O
effects,529,O
and,529,O
the,529,O
mechanisms,529,O
for,529,O
their,529,O
occurrence,529,O
are,529,O
reviewed,529,O
and,529,O
the,529,O
efficacy,529,O
and,529,O
complications,529,O
of,529,O
thyroidectomy,529,O
and,529,O
radioiodine,529,O
compared,529,O
to,529,O
those,529,O
of,529,O
antithyroid,529,O
drugs,529,O
.,529,O
It,530,O
is,530,O
concluded,530,O
that,530,O
in,530,O
most,530,O
circumstances,530,O
131I,530,O
is,530,O
the,530,O
therapy,530,O
of,530,O
choice,530,O
for,530,O
hyperthyroidism,530,B-Disease
.,530,O
Anticonvulsant,531,O
actions,531,O
of,531,O
MK-801,531,B-Chemical
on,531,O
the,531,O
lithium-pilocarpine,531,B-Chemical
model,531,O
of,531,O
status,531,B-Disease
epilepticus,531,I-Disease
in,531,O
rats,531,O
.,531,O
MK-801,532,B-Chemical
",",532,O
a,532,O
noncompetitive,532,O
N-methyl-D-aspartate,532,B-Chemical
(,532,O
NMDA,532,B-Chemical
),532,O
receptor,532,O
antagonist,532,O
",",532,O
was,532,O
tested,532,O
for,532,O
anticonvulsant,532,O
effects,532,O
in,532,O
rats,532,O
using,532,O
two,532,O
seizure,532,B-Disease
models,532,O
",",532,O
coadministration,532,O
of,532,O
lithium,532,B-Chemical
and,532,O
pilocarpine,532,B-Chemical
and,532,O
administration,532,O
of,532,O
a,532,O
high,532,O
dose,532,O
of,532,O
pilocarpine,532,B-Chemical
alone,532,O
.,532,O
Three,533,O
major,533,O
results,533,O
are,533,O
reported,533,O
.,533,O
First,534,O
",",534,O
pretreatment,534,O
with,534,O
MK-801,534,B-Chemical
produced,534,O
an,534,O
effective,534,O
and,534,O
dose-dependent,534,O
anticonvulsant,534,O
action,534,O
with,534,O
the,534,O
lithium-pilocarpine,534,B-Chemical
model,534,O
but,534,O
not,534,O
with,534,O
rats,534,O
treated,534,O
with,534,O
pilocarpine,534,B-Chemical
alone,534,O
",",534,O
suggesting,534,O
that,534,O
different,534,O
biochemical,534,O
mechanisms,534,O
control,534,O
seizures,534,B-Disease
in,534,O
these,534,O
two,534,O
models,534,O
.,534,O
Second,535,O
",",535,O
the,535,O
anticonvulsant,535,O
effect,535,O
of,535,O
MK-801,535,B-Chemical
in,535,O
the,535,O
lithium-pilocarpine,535,B-Chemical
model,535,O
only,535,O
occurred,535,O
after,535,O
initial,535,O
periods,535,O
of,535,O
seizure,535,B-Disease
activity,535,O
.,535,O
This,536,O
observation,536,O
is,536,O
suggested,536,O
to,536,O
be,536,O
an,536,O
in,536,O
vivo,536,O
demonstration,536,O
of,536,O
the,536,O
conclusion,536,O
derived,536,O
from,536,O
in,536,O
vitro,536,O
experiments,536,O
that,536,O
MK-801,536,B-Chemical
binding,536,O
requires,536,O
agonist-induced,536,O
opening,536,O
of,536,O
the,536,O
channel,536,O
sites,536,O
of,536,O
the,536,O
NMDA,536,B-Chemical
receptor,536,O
.,536,O
Third,537,O
",",537,O
although,537,O
it,537,O
is,537,O
relatively,537,O
easy,537,O
to,537,O
block,537,O
seizures,537,B-Disease
induced,537,O
by,537,O
lithium,537,B-Chemical
and,537,O
pilocarpine,537,B-Chemical
by,537,O
administration,537,O
of,537,O
anticonvulsants,537,O
prior,537,O
to,537,O
pilocarpine,537,B-Chemical
",",537,O
it,537,O
is,537,O
more,537,O
difficult,537,O
to,537,O
terminate,537,O
ongoing,537,O
status,537,B-Disease
epilepticus,537,I-Disease
and,537,O
block,537,O
the,537,O
lethality,537,O
of,537,O
the,537,O
seizures,537,B-Disease
.,537,O
Administration,538,O
of,538,O
MK-801,538,B-Chemical
30,538,O
or,538,O
60,538,O
min,538,O
after,538,O
pilocarpine,538,B-Chemical
",",538,O
i.e.,538,O
",",538,O
during,538,O
status,538,B-Disease
epilepticus,538,I-Disease
",",538,O
gradually,538,O
reduced,538,O
electrical,538,O
and,538,O
behavioral,538,O
seizure,538,B-Disease
activity,538,O
and,538,O
greatly,538,O
enhanced,538,O
the,538,O
survival,538,O
rate,538,O
.,538,O
These,539,O
results,539,O
suggest,539,O
that,539,O
activation,539,O
of,539,O
NMDA,539,B-Chemical
receptors,539,O
plays,539,O
an,539,O
important,539,O
role,539,O
in,539,O
status,539,B-Disease
epilepticus,539,I-Disease
and,539,O
brain,539,B-Disease
damage,539,I-Disease
in,539,O
the,539,O
lithium-pilocarpine,539,B-Chemical
model,539,O
.,539,O
This,540,O
was,540,O
further,540,O
supported,540,O
by,540,O
results,540,O
showing,540,O
that,540,O
nonconvulsive,540,O
doses,540,O
of,540,O
NMDA,540,B-Chemical
and,540,O
pilocarpine,540,B-Chemical
were,540,O
synergistic,540,O
",",540,O
resulting,540,O
in,540,O
status,540,B-Disease
epilepticus,540,I-Disease
and,540,O
subsequent,540,O
mortality,540,O
.,540,O
Nifedipine,541,B-Chemical
induced,541,O
bradycardia,541,B-Disease
in,541,O
a,541,O
patient,541,O
with,541,O
autonomic,541,B-Disease
neuropathy,541,I-Disease
.,541,O
An,542,O
80,542,O
year,542,O
old,542,O
diabetic,542,B-Disease
male,542,O
with,542,O
evidence,542,O
of,542,O
peripheral,542,O
and,542,O
autonomic,542,O
neuropathy,542,O
was,542,O
admitted,542,O
with,542,O
chest,542,B-Disease
pain,542,I-Disease
.,542,O
He,543,O
was,543,O
found,543,O
to,543,O
have,543,O
atrial,543,B-Disease
flutter,543,I-Disease
at,543,O
a,543,O
ventricular,543,O
rate,543,O
of,543,O
70/min,543,O
which,543,O
slowed,543,O
down,543,O
to,543,O
30-40/min,543,O
when,543,O
nifedipine,543,B-Chemical
(,543,O
60,543,O
mg,543,O
),543,O
in,543,O
3,543,O
divided,543,O
doses,543,O
",",543,O
during,543,O
which,543,O
he,543,O
was,543,O
paced,543,O
at,543,O
a,543,O
rate,543,O
of,543,O
70/min,543,O
.,543,O
This,544,O
is,544,O
inconsistent,544,O
with,544,O
the,544,O
well-established,544,O
finding,544,O
that,544,O
nifedipine,544,B-Chemical
induces,544,O
tachycardia,544,B-Disease
in,544,O
normally,544,O
innervated,544,O
hearts,544,O
.,544,O
However,545,O
",",545,O
in,545,O
hearts,545,O
deprived,545,O
of,545,O
compensatory,545,O
sympathetic,545,O
drive,545,O
",",545,O
it,545,O
may,545,O
lead,545,O
to,545,O
bradycardia,545,B-Disease
.,545,O
The,546,O
effect,546,O
of,546,O
haloperidol,546,B-Chemical
in,546,O
cocaine,546,B-Chemical
and,546,O
amphetamine,546,B-Chemical
intoxication,546,O
.,546,O
The,547,O
effectiveness,547,O
of,547,O
haloperidol,547,B-Chemical
pretreatment,547,O
in,547,O
preventing,547,O
the,547,O
toxic,547,O
effects,547,O
of,547,O
high,547,O
doses,547,O
of,547,O
amphetamine,547,B-Chemical
and,547,O
cocaine,547,B-Chemical
was,547,O
studied,547,O
in,547,O
rats,547,O
.,547,O
In,548,O
this,548,O
model,548,O
",",548,O
toxic,548,O
effects,548,O
were,548,O
induced,548,O
by,548,O
intraperitoneal,548,O
(,548,O
i.p,548,O
.,548,O
),548,O
injection,549,O
of,549,O
amphetamine,549,B-Chemical
75,549,O
mg/kg,549,O
(,549,O
100,549,O
%,549,O
death,549,O
rate,549,O
),549,O
or,549,O
cocaine,549,B-Chemical
70,549,O
mg/kg,549,O
(,549,O
82,549,O
%,549,O
death,549,O
rate,549,O
),549,O
.,549,O
Haloperidol,550,B-Chemical
failed,550,O
to,550,O
prevent,550,O
amphetamine-induced,550,B-Chemical
seizures,550,B-Disease
",",550,O
but,550,O
did,550,O
lower,550,O
the,550,O
mortality,550,O
rate,550,O
at,550,O
most,550,O
doses,550,O
tested,550,O
.,550,O
Haloperidol,551,B-Chemical
decreased,551,O
the,551,O
incidence,551,O
of,551,O
cocaine-induced,551,B-Chemical
seizures,551,B-Disease
at,551,O
the,551,O
two,551,O
highest,551,O
doses,551,O
",",551,O
but,551,O
the,551,O
lowering,551,O
of,551,O
the,551,O
mortality,551,O
rate,551,O
did,551,O
not,551,O
reach,551,O
statistical,551,O
significance,551,O
at,551,O
any,551,O
dose,551,O
.,551,O
These,552,O
data,552,O
suggest,552,O
a,552,O
protective,552,O
role,552,O
for,552,O
the,552,O
central,552,O
dopamine,552,B-Chemical
blocker,552,O
haloperidol,552,B-Chemical
against,552,O
death,552,O
from,552,O
high-dose,552,O
amphetamine,552,B-Chemical
exposure,552,O
without,552,O
reducing,552,O
the,552,O
incidence,552,O
of,552,O
seizures,552,B-Disease
.,552,O
In,553,O
contrast,553,O
",",553,O
haloperidol,553,B-Chemical
demonstrated,553,O
an,553,O
ability,553,O
to,553,O
reduce,553,O
cocaine-induced,553,B-Chemical
seizures,553,B-Disease
without,553,O
significantly,553,O
reducing,553,O
mortality,553,O
.,553,O
Autoradiographic,554,O
evidence,554,O
of,554,O
estrogen,554,B-Chemical
binding,554,O
sites,554,O
in,554,O
nuclei,554,O
of,554,O
diethylstilbesterol,554,B-Chemical
induced,554,O
hamster,554,O
renal,554,B-Disease
carcinomas,554,I-Disease
.,554,O
Estrogen,555,B-Chemical
binding,555,O
sites,555,O
were,555,O
demonstrated,555,O
by,555,O
autoradiography,555,O
in,555,O
one,555,O
transplantable,555,O
and,555,O
five,555,O
primary,555,O
diethylstilbesterol,555,B-Chemical
induced,555,O
renal,555,B-Disease
carcinomas,555,I-Disease
in,555,O
three,555,O
hamsters,555,O
.,555,O
Radiolabelling,556,O
",",556,O
following,556,O
the,556,O
in,556,O
vivo,556,O
injection,556,O
of,556,O
3H-17,556,O
beta,556,O
estradiol,556,B-Chemical
",",556,O
was,556,O
increased,556,O
only,556,O
over,556,O
the,556,O
nuclei,556,O
of,556,O
tumor,556,B-Disease
cells,556,O
;,556,O
stereologic,556,O
analysis,556,O
revealed,556,O
a,556,O
4.5-,556,O
to,556,O
6.7-times,556,O
higher,556,O
concentration,556,O
of,556,O
reduced,556,O
silver,556,B-Chemical
grains,556,O
over,556,O
nuclei,556,O
than,556,O
cytoplasm,556,O
of,556,O
these,556,O
cells,556,O
.,556,O
Despite,557,O
rapid,557,O
tubular,557,O
excretion,557,O
of,557,O
estradiol,557,B-Chemical
which,557,O
peaked,557,O
in,557,O
less,557,O
than,557,O
1,557,O
h,557,O
",",557,O
the,557,O
normal,557,O
cells,557,O
did,557,O
not,557,O
appear,557,O
to,557,O
bind,557,O
the,557,O
ligand,557,O
.,557,O
This,558,O
is,558,O
the,558,O
first,558,O
published,558,O
report,558,O
documenting,558,O
the,558,O
preferential,558,O
in,558,O
vivo,558,O
binding,558,O
of,558,O
estrogen,558,B-Chemical
to,558,O
nuclei,558,O
of,558,O
cells,558,O
in,558,O
estrogen,558,B-Chemical
induced,558,O
hamster,558,O
renal,558,B-Disease
carcinomas,558,I-Disease
.,558,O
Bradycardia,559,B-Disease
due,559,O
to,559,O
biperiden,559,B-Chemical
.,559,O
In,560,O
a,560,O
38-year-old,560,O
male,560,O
patient,560,O
suffering,560,O
from,560,O
a,560,O
severe,560,O
postzosteric,560,B-Disease
trigeminal,560,B-Disease
neuralgia,560,I-Disease
",",560,O
intravenous,560,O
application,560,O
of,560,O
10,560,O
mg,560,O
biperiden,560,B-Chemical
lactate,560,I-Chemical
led,560,O
to,560,O
a,560,O
long-lasting,560,O
paradoxical,560,O
reaction,560,O
characterized,560,O
by,560,O
considerable,560,O
bradycardia,560,B-Disease
",",560,O
dysarthria,560,B-Disease
",",560,O
and,560,O
dysphagia,560,B-Disease
.,560,O
The,561,O
heart,561,O
rate,561,O
was,561,O
back,561,O
to,561,O
normal,561,O
within,561,O
12,561,O
hours,561,O
upon,561,O
administration,561,O
of,561,O
orciprenaline,561,B-Chemical
under,561,O
cardiac,561,O
monitoring,561,O
in,561,O
an,561,O
intensive,561,O
care,561,O
unit,561,O
.,561,O
Bradycardia,562,B-Disease
induced,562,O
by,562,O
biperiden,562,B-Chemical
is,562,O
attributed,562,O
to,562,O
the,562,O
speed,562,O
of,562,O
injection,562,O
and,562,O
to,562,O
a,562,O
dose-related,562,O
dual,562,O
effect,562,O
of,562,O
atropine-like,562,B-Chemical
drugs,562,O
on,562,O
muscarine,562,B-Chemical
receptors,562,O
.,562,O
Deliberate,563,O
hypotension,563,B-Disease
induced,563,O
by,563,O
labetalol,563,B-Chemical
with,563,O
halothane,563,B-Chemical
",",563,O
enflurane,563,B-Chemical
or,563,O
isoflurane,563,B-Chemical
for,563,O
middle-ear,563,O
surgery,563,O
.,563,O
The,564,O
feasibility,564,O
of,564,O
using,564,O
labetalol,564,B-Chemical
",",564,O
an,564,O
alpha-,564,O
and,564,O
beta-adrenergic,564,O
blocking,564,O
agent,564,O
",",564,O
as,564,O
a,564,O
hypotensive,564,B-Disease
agent,564,O
in,564,O
combination,564,O
with,564,O
inhalation,564,O
anaesthetics,564,O
(,564,O
halothane,564,B-Chemical
",",564,O
enflurane,564,B-Chemical
or,564,O
isoflurane,564,B-Chemical
),564,O
was,564,O
studied,564,O
in,564,O
23,564,O
adult,564,O
patients,564,O
undergoing,564,O
middle-ear,564,O
surgery,564,O
.,564,O
The,565,O
mean,565,O
arterial,565,O
pressure,565,O
was,565,O
decreased,565,O
from,565,O
86,565,O
+/-,565,O
5,565,O
(,565,O
s.e,565,O
.,565,O
mean,566,O
),566,O
mmHg,566,O
to,566,O
52,566,O
+/-,566,O
1,566,O
mmHg,566,O
(,566,O
11.5,566,O
+/-,566,O
0.7,566,O
to,566,O
6.9,566,O
+/-,566,O
0.1,566,O
kPa,566,O
),566,O
for,566,O
98,566,O
+/-,566,O
10,566,O
min,566,O
in,566,O
the,566,O
halothane,566,B-Chemical
(,566,O
H,566,B-Chemical
),566,O
group,566,O
",",566,O
from,566,O
79,566,O
+/-,566,O
5,566,O
to,566,O
53,566,O
+/-,566,O
1,566,O
mmHg,566,O
(,566,O
10.5,566,O
+/-,566,O
0.7,566,O
to,566,O
7.1,566,O
+/-,566,O
0.1,566,O
kPa,566,O
),566,O
for,566,O
129,566,O
+/-,566,O
11,566,O
min,566,O
in,566,O
the,566,O
enflurane,566,B-Chemical
(,566,O
E,566,B-Chemical
),566,O
group,566,O
",",566,O
and,566,O
from,566,O
80,566,O
+/-,566,O
4,566,O
to,566,O
49,566,O
+/-,566,O
1,566,O
mmHg,566,O
(,566,O
10.7,566,O
+/-,566,O
0.5,566,O
to,566,O
6.5,566,O
+/-,566,O
0.1,566,O
kPa,566,O
),566,O
for,566,O
135,566,O
+/-,566,O
15,566,O
min,566,O
in,566,O
the,566,O
isoflurane,566,B-Chemical
(,566,O
I,566,B-Chemical
),566,O
group,566,O
.,566,O
The,567,O
mean,567,O
H,567,B-Chemical
concentration,567,O
during,567,O
hypotension,567,B-Disease
in,567,O
the,567,O
inspiratory,567,O
gas,567,O
was,567,O
0.7,567,O
+/-,567,O
0.1,567,O
vol,567,O
%,567,O
",",567,O
the,567,O
mean,567,O
E,567,B-Chemical
concentration,567,O
1.6,567,O
+/-,567,O
0.2,567,O
vol,567,O
%,567,O
",",567,O
and,567,O
the,567,O
mean,567,O
I,567,B-Chemical
concentration,567,O
1.0,567,O
+/-,567,O
0.1,567,O
vol,567,O
%,567,O
.,567,O
In,568,O
addition,568,O
",",568,O
the,568,O
patients,568,O
received,568,O
fentanyl,568,B-Chemical
and,568,O
d-tubocurarine,568,B-Chemical
.,568,O
The,569,O
initial,569,O
dose,569,O
of,569,O
labetalol,569,B-Chemical
for,569,O
lowering,569,O
blood,569,O
pressure,569,O
was,569,O
similar,569,O
",",569,O
0.52-0.59,569,O
mg/kg,569,O
",",569,O
in,569,O
all,569,O
the,569,O
groups,569,O
.,569,O
During,570,O
hypotension,570,B-Disease
",",570,O
the,570,O
heart,570,O
rate,570,O
was,570,O
stable,570,O
without,570,O
tachy-,570,B-Disease
or,570,I-Disease
bradycardia,570,I-Disease
.,570,O
The,571,O
operating,571,O
conditions,571,O
regarding,571,O
bleeding,571,B-Disease
were,571,O
estimated,571,O
in,571,O
a,571,O
double-blind,571,O
manner,571,O
",",571,O
and,571,O
did,571,O
not,571,O
differ,571,O
significantly,571,O
between,571,O
the,571,O
groups,571,O
.,571,O
During,572,O
hypotension,572,B-Disease
",",572,O
the,572,O
serum,572,O
creatinine,572,B-Chemical
concentration,572,O
rose,572,O
significantly,572,O
in,572,O
all,572,O
groups,572,O
from,572,O
the,572,O
values,572,O
before,572,O
hypotension,572,B-Disease
and,572,O
returned,572,O
postoperatively,572,O
to,572,O
the,572,O
initial,572,O
level,572,O
in,572,O
the,572,O
other,572,O
groups,572,O
",",572,O
except,572,O
the,572,O
isoflurane,572,B-Chemical
group,572,O
.,572,O
After,573,O
hypotension,573,B-Disease
there,573,O
was,573,O
no,573,O
rebound,573,O
phenomenon,573,O
in,573,O
either,573,O
blood,573,O
pressure,573,O
or,573,O
heart,573,O
rate,573,O
.,573,O
These,574,O
results,574,O
indicate,574,O
that,574,O
labetalol,574,B-Chemical
induces,574,O
easily,574,O
adjustable,574,O
hypotension,574,B-Disease
without,574,O
compensatory,574,O
tachycardia,574,B-Disease
and,574,O
rebound,574,O
hypertension,574,B-Disease
.,574,O
Convulsion,575,B-Disease
following,575,O
intravenous,575,O
fluorescein,575,B-Chemical
angiography,575,O
.,575,O
Tonic-clonic,576,B-Disease
seizures,576,I-Disease
followed,576,O
intravenous,576,O
fluorescein,576,B-Chemical
injection,576,O
for,576,O
fundus,576,O
angiography,576,O
in,576,O
a,576,O
47-year-old,576,O
male,576,O
.,576,O
Despite,577,O
precautions,577,O
this,577,O
adverse,577,O
reaction,577,O
recurred,577,O
on,577,O
re-exposure,577,O
to,577,O
intravenous,577,O
fluorescein,577,B-Chemical
.,577,O
Pharmacology,578,O
of,578,O
ACC-9653,578,B-Chemical
(,578,O
phenytoin,578,B-Chemical
prodrug,578,O
),578,O
.,578,O
ACC-9653,579,B-Chemical
",",579,O
the,579,O
disodium,579,B-Chemical
phosphate,579,I-Chemical
ester,579,I-Chemical
of,579,O
"3-hydroxymethyl-5,5-diphenylhydantoin",579,B-Chemical
",",579,O
is,579,O
a,579,O
prodrug,579,O
of,579,O
phenytoin,579,B-Chemical
with,579,O
advantageous,579,O
physicochemical,579,O
properties,579,O
.,579,O
ACC-9653,580,B-Chemical
is,580,O
rapidly,580,O
converted,580,O
enzymatically,580,O
to,580,O
phenytoin,580,B-Chemical
in,580,O
vivo,580,O
.,580,O
ACC-9653,581,B-Chemical
and,581,O
phenytoin,581,B-Chemical
sodium,581,I-Chemical
have,581,O
equivalent,581,O
anticonvulsant,581,O
activity,581,O
against,581,O
seizures,581,B-Disease
induced,581,O
by,581,O
maximal,581,O
electroshock,581,O
(,581,O
MES,581,O
),581,O
in,581,O
mice,581,O
following,581,O
i.p.,581,O
",",581,O
oral,581,O
",",581,O
or,581,O
i.v,581,O
.,581,O
administration,582,O
.,582,O
The,583,O
ED50,583,O
doses,583,O
were,583,O
16,583,O
mg/kg,583,O
for,583,O
i.v,583,O
.,583,O
ACC-9653,584,B-Chemical
and,584,O
8,584,O
mg/kg,584,O
for,584,O
i.v,584,O
.,584,O
phenytoin,585,B-Chemical
sodium,585,I-Chemical
.,585,O
ACC-9653,586,B-Chemical
and,586,O
phenytoin,586,B-Chemical
sodium,586,I-Chemical
have,586,O
similar,586,O
antiarrhythmic,586,O
activity,586,O
against,586,O
ouabain-induced,586,B-Chemical
ventricular,586,B-Disease
tachycardia,586,I-Disease
in,586,O
anesthetized,586,O
dogs,586,O
.,586,O
The,587,O
total,587,O
doses,587,O
of,587,O
ACC-9653,587,B-Chemical
or,587,O
phenytoin,587,B-Chemical
sodium,587,I-Chemical
necessary,587,O
to,587,O
convert,587,O
the,587,O
arrhythmia,587,B-Disease
to,587,O
a,587,O
normal,587,O
sinus,587,O
rhythm,587,O
were,587,O
24,587,O
+/-,587,O
6,587,O
and,587,O
14,587,O
+/-,587,O
3,587,O
mg/kg,587,O
",",587,O
respectively,587,O
.,587,O
Only,588,O
phenytoin,588,B-Chemical
sodium,588,I-Chemical
displayed,588,O
in,588,O
vitro,588,O
antiarrhythmic,588,O
activity,588,O
against,588,O
strophanthidin-induced,588,B-Chemical
arrhythmias,588,B-Disease
in,588,O
guinea,588,O
pig,588,O
right,588,O
atria,588,O
.,588,O
In,589,O
anesthetized,589,O
dogs,589,O
",",589,O
a,589,O
high,589,O
dose,589,O
of,589,O
ACC-9653,589,B-Chemical
(,589,O
31,589,O
mg/kg,589,O
),589,O
was,589,O
infused,589,O
over,589,O
15,589,O
",",589,O
20,589,O
",",589,O
and,589,O
30,589,O
min,589,O
and,589,O
the,589,O
responses,589,O
were,589,O
compared,589,O
to,589,O
an,589,O
equimolar,589,O
dose,589,O
of,589,O
phenytoin,589,B-Chemical
sodium,589,I-Chemical
(,589,O
21,589,O
mg/kg,589,O
),589,O
.,589,O
The,590,O
ACC-9653,590,B-Chemical
and,590,O
phenytoin,590,B-Chemical
sodium,590,I-Chemical
treatments,590,O
produced,590,O
similar,590,O
marked,590,O
reductions,590,O
in,590,O
diastolic,590,O
blood,590,O
pressure,590,O
and,590,O
contractile,590,O
force,590,O
(,590,O
LVdP/dt,590,O
),590,O
.,590,O
The,591,O
maximum,591,O
effects,591,O
of,591,O
each,591,O
treatment,591,O
occurred,591,O
at,591,O
the,591,O
time,591,O
of,591,O
maximum,591,O
phenytoin,591,B-Chemical
sodium,591,I-Chemical
levels,591,O
.,591,O
Acute,592,O
toxicity,592,B-Disease
studies,592,O
of,592,O
ACC-9653,592,B-Chemical
and,592,O
phenytoin,592,B-Chemical
sodium,592,I-Chemical
were,592,O
carried,592,O
out,592,O
in,592,O
mice,592,O
",",592,O
rats,592,O
",",592,O
rabbits,592,O
",",592,O
and,592,O
dogs,592,O
by,592,O
i.v.,592,O
",",592,O
i.m.,592,O
",",592,O
and,592,O
i.p,592,O
.,592,O
routes,593,O
of,593,O
administration,593,O
.,593,O
The,594,O
systemic,594,O
toxic,594,O
signs,594,O
of,594,O
both,594,O
agents,594,O
were,594,O
similar,594,O
and,594,O
occurred,594,O
at,594,O
approximately,594,O
equivalent,594,O
doses,594,O
.,594,O
Importantly,595,O
",",595,O
the,595,O
local,595,O
irritation,595,O
of,595,O
ACC-9653,595,B-Chemical
was,595,O
markedly,595,O
less,595,O
than,595,O
phenytoin,595,B-Chemical
sodium,595,I-Chemical
following,595,O
i.m,595,O
.,595,O
administration,596,O
.,596,O
(,597,O
ABSTRACT,597,O
TRUNCATED,597,O
AT,597,O
250,597,O
WORDS,597,O
),597,O
Tachyphylaxis,598,O
to,598,O
systemic,598,O
but,598,O
not,598,O
to,598,O
airway,598,O
responses,598,O
during,598,O
prolonged,598,O
therapy,598,O
with,598,O
high,598,O
dose,598,O
inhaled,598,O
salbutamol,598,B-Chemical
in,598,O
asthmatics,598,B-Disease
.,598,O
High,599,O
doses,599,O
of,599,O
inhaled,599,O
salbutamol,599,B-Chemical
produce,599,O
substantial,599,O
improvements,599,O
in,599,O
airway,599,O
response,599,O
in,599,O
patients,599,O
with,599,O
asthma,599,B-Disease
",",599,O
and,599,O
are,599,O
associated,599,O
with,599,O
dose-dependent,599,O
systemic,599,O
beta-adrenoceptor,599,O
responses,599,O
.,599,O
The,600,O
purpose,600,O
of,600,O
the,600,O
present,600,O
study,600,O
was,600,O
to,600,O
investigate,600,O
whether,600,O
tachyphylaxis,600,O
occurs,600,O
during,600,O
prolonged,600,O
treatment,600,O
with,600,O
high,600,O
dose,600,O
inhaled,600,O
salbutamol,600,B-Chemical
.,600,O
Twelve,601,O
asthmatic,601,B-Disease
patients,601,O
(,601,O
FEV1,601,O
",",601,O
81,601,O
+/-,601,O
4,601,O
%,601,O
predicted,601,O
),601,O
",",601,O
requiring,601,O
only,601,O
occasional,601,O
inhaled,601,O
beta-agonists,601,O
as,601,O
their,601,O
sole,601,O
therapy,601,O
",",601,O
were,601,O
given,601,O
a,601,O
14-day,601,O
treatment,601,O
with,601,O
high,601,O
dose,601,O
inhaled,601,O
salbutamol,601,B-Chemical
(,601,O
HDS,601,O
),601,O
",",601,O
"4,000",601,O
micrograms,601,O
daily,601,O
",",601,O
low,601,O
dose,601,O
inhaled,601,O
salbutamol,601,B-Chemical
(,601,O
LDS,601,O
),601,O
",",601,O
800,601,O
micrograms,601,O
daily,601,O
",",601,O
or,601,O
placebo,601,O
(,601,O
PI,601,O
),601,O
by,601,O
metered-dose,601,O
inhaler,601,O
in,601,O
a,601,O
double-blind,601,O
",",601,O
randomized,601,O
crossover,601,O
design,601,O
.,601,O
During,602,O
the,602,O
14-day,602,O
run-in,602,O
and,602,O
during,602,O
washout,602,O
periods,602,O
",",602,O
inhaled,602,O
beta-agonists,602,O
were,602,O
withheld,602,O
and,602,O
ipratropium,602,B-Chemical
bromide,602,I-Chemical
was,602,O
substituted,602,O
for,602,O
rescue,602,O
purposes,602,O
.,602,O
At,603,O
the,603,O
end,603,O
of,603,O
each,603,O
14-day,603,O
treatment,603,O
",",603,O
a,603,O
dose-response,603,O
curve,603,O
(,603,O
DRC,603,O
),603,O
was,603,O
performed,603,O
",",603,O
and,603,O
airway,603,O
(,603,O
FEV1,603,O
",",603,O
FEF25-75,603,O
),603,O
chronotropic,603,O
(,603,O
HR,603,O
),603,O
",",603,O
tremor,603,B-Disease
",",603,O
and,603,O
metabolic,603,O
(,603,O
K,603,B-Chemical
",",603,O
Glu,603,B-Chemical
),603,O
responses,603,O
were,603,O
measured,603,O
at,603,O
each,603,O
step,603,O
(,603,O
from,603,O
100,603,O
to,603,O
"4,000",603,O
micrograms,603,O
),603,O
.,603,O
Treatment,604,O
had,604,O
no,604,O
significant,604,O
effect,604,O
on,604,O
baseline,604,O
values,604,O
.,604,O
There,605,O
were,605,O
dose-dependent,605,O
increases,605,O
in,605,O
FEV1,605,O
and,605,O
FEF25-75,605,O
(,605,O
p,605,O
less,605,O
than,605,O
0.001,605,O
),605,O
",",605,O
and,605,O
pretreatment,605,O
with,605,O
HDS,605,O
did,605,O
not,605,O
displace,605,O
the,605,O
DRC,605,O
to,605,O
the,605,O
right,605,O
.,605,O
DRC,606,O
for,606,O
HR,606,O
(,606,O
p,606,O
less,606,O
than,606,O
0.001,606,O
),606,O
",",606,O
K,606,B-Chemical
(,606,O
p,606,O
less,606,O
than,606,O
0.001,606,O
),606,O
",",606,O
and,606,O
Glu,606,B-Chemical
(,606,O
p,606,O
less,606,O
than,606,O
0.005,606,O
),606,O
were,606,O
attenuated,606,O
after,606,O
treatment,606,O
with,606,O
HDS,606,O
compared,606,O
with,606,O
PI,606,O
.,606,O
There,607,O
were,607,O
also,607,O
differences,607,O
between,607,O
HDS,607,O
and,607,O
LDS,607,O
for,607,O
HR,607,O
(,607,O
p,607,O
less,607,O
than,607,O
0.001,607,O
),607,O
and,607,O
Glu,607,B-Chemical
(,607,O
p,607,O
less,607,O
than,607,O
0.05,607,O
),607,O
responses,607,O
.,607,O
Frequency,608,O
and,608,O
severity,608,O
of,608,O
subjective,608,O
adverse,608,O
effects,608,O
were,608,O
also,608,O
reduced,608,O
after,608,O
HDS,608,O
:,608,O
tremor,608,B-Disease
(,608,O
p,608,O
less,608,O
than,608,O
0.001,608,O
),608,O
",",608,O
palpitations,608,B-Disease
(,608,O
p,608,O
less,608,O
than,608,O
0.001,608,O
),608,O
.,608,O
(,609,O
ABSTRACT,609,O
TRUNCATED,609,O
AT,609,O
250,609,O
WORDS,609,O
),609,O
Phenytoin,610,B-Chemical
induced,610,O
fatal,610,O
hepatic,610,B-Disease
injury,610,I-Disease
.,610,O
A,611,O
61,611,O
year,611,O
old,611,O
female,611,O
developed,611,O
fatal,611,O
hepatic,611,B-Disease
failure,611,I-Disease
after,611,O
phenytoin,611,B-Chemical
administration,611,O
.,611,O
A,612,O
typical,612,O
multisystem,612,O
clinical,612,O
pattern,612,O
precedes,612,O
the,612,O
manifestations,612,O
of,612,O
hepatic,612,B-Disease
injury,612,I-Disease
.,612,O
The,613,O
hematologic,613,O
",",613,O
biochemical,613,O
and,613,O
pathologic,613,O
features,613,O
indicate,613,O
a,613,O
mixed,613,O
hepatocellular,613,B-Disease
damage,613,I-Disease
due,613,O
to,613,O
drug,613,B-Disease
hypersensitivity,613,I-Disease
.,613,O
In,614,O
a,614,O
patient,614,O
receiving,614,O
phenytoin,614,B-Chemical
who,614,O
presents,614,O
a,614,O
viral-like,614,O
illness,614,O
",",614,O
early,614,O
recognition,614,O
and,614,O
discontinuation,614,O
of,614,O
the,614,O
drug,614,O
are,614,O
mandatory,614,O
.,614,O
Treatment,615,O
of,615,O
lethal,615,O
pertussis,615,B-Chemical
vaccine,615,I-Chemical
reaction,615,O
with,615,O
histamine,615,B-Chemical
H1,615,O
antagonists,615,O
.,615,O
We,616,O
studied,616,O
mortality,616,O
after,616,O
pertussis,616,B-Disease
immunization,616,O
in,616,O
the,616,O
mouse,616,O
.,616,O
Without,617,O
treatment,617,O
",",617,O
73,617,O
of,617,O
92,617,O
animals,617,O
(,617,O
80,617,O
%,617,O
),617,O
died,617,O
after,617,O
injection,617,O
of,617,O
bovine,617,O
serum,617,O
albumin,617,O
(,617,O
BSA,617,O
),617,O
on,617,O
day,617,O
+7,617,O
of,617,O
pertussis,617,B-Disease
immunization,617,O
.,617,O
After,618,O
pretreatment,618,O
with,618,O
3,618,O
mg,618,O
of,618,O
cyproheptadine,618,B-Chemical
",",618,O
2,618,O
mg,618,O
mianserin,618,B-Chemical
",",618,O
or,618,O
2,618,O
mg,618,O
chlorpheniramine,618,B-Chemical
",",618,O
only,618,O
5,618,O
of,618,O
105,618,O
animals,618,O
(,618,O
5,618,O
%,618,O
),618,O
died,618,O
after,618,O
receiving,618,O
BSA,618,O
on,618,O
day,618,O
+7,618,O
(,618,O
p,618,O
less,618,O
than,618,O
0.001,618,O
),618,O
.,618,O
Blockade,619,O
of,619,O
histamine,619,B-Chemical
H1,619,O
receptors,619,O
may,619,O
reduce,619,O
mortality,619,O
in,619,O
pertussis,619,B-Disease
immunization-induced,619,O
encephalopathy,619,B-Disease
in,619,O
mice,619,O
.,619,O
Support,620,O
for,620,O
adrenaline-hypertension,620,B-Chemical
hypothesis,620,O
:,620,O
18,620,O
hour,620,O
pressor,620,O
effect,620,O
after,620,O
6,620,O
hours,620,O
adrenaline,620,B-Chemical
infusion,620,O
.,620,O
In,621,O
a,621,O
double,621,O
blind,621,O
",",621,O
crossover,621,O
study,621,O
6,621,O
h,621,O
infusions,621,O
of,621,O
adrenaline,621,B-Chemical
(,621,O
15,621,O
ng/kg/min,621,O
;,621,O
1,621,O
ng,621,O
=,621,O
5.458,621,O
pmol,621,O
),621,O
",",621,O
noradrenaline,621,B-Chemical
(,621,O
30,621,O
ng/kg/min,621,O
;,621,O
1,621,O
ng,621,O
=,621,O
5.911,621,O
pmol,621,O
),621,O
",",621,O
and,621,O
a,621,O
5,621,O
%,621,O
dextrose,621,B-Chemical
solution,621,O
(,621,O
5.4,621,O
ml/h,621,O
),621,O
",",621,O
were,621,O
given,621,O
to,621,O
ten,621,O
healthy,621,O
volunteers,621,O
in,621,O
random,621,O
order,621,O
2,621,O
weeks,621,O
apart,621,O
.,621,O
By,622,O
means,622,O
of,622,O
intra-arterial,622,O
ambulatory,622,O
monitoring,622,O
the,622,O
haemodynamic,622,O
effects,622,O
were,622,O
followed,622,O
for,622,O
18,622,O
h,622,O
after,622,O
the,622,O
infusions,622,O
were,622,O
stopped,622,O
.,622,O
Adrenaline,623,B-Chemical
",",623,O
but,623,O
not,623,O
noradrenaline,623,B-Chemical
",",623,O
caused,623,O
a,623,O
delayed,623,O
and,623,O
protracted,623,O
pressor,623,O
effect,623,O
.,623,O
Over,624,O
the,624,O
total,624,O
postinfusion,624,O
period,624,O
systolic,624,O
and,624,O
diastolic,624,O
arterial,624,O
pressure,624,O
were,624,O
6,624,O
(,624,O
SEM,624,O
2,624,O
),624,O
%,624,O
and,624,O
7,624,O
(,624,O
2,624,O
),624,O
%,624,O
",",624,O
respectively,624,O
",",624,O
higher,624,O
than,624,O
after,624,O
dextrose,624,B-Chemical
infusion,624,O
(,624,O
ANOVA,624,O
",",624,O
p,624,O
less,624,O
than,624,O
0.001,624,O
),624,O
.,624,O
Thus,625,O
",",625,O
``,625,O
stress,625,O
'',625,O
levels,625,O
of,625,O
adrenaline,625,B-Chemical
(,625,O
230,625,O
pg/ml,625,O
),625,O
for,625,O
6,625,O
h,625,O
cause,625,O
a,625,O
delayed,625,O
and,625,O
protracted,625,O
pressor,625,O
effect,625,O
.,625,O
These,626,O
findings,626,O
are,626,O
strong,626,O
support,626,O
for,626,O
the,626,O
adrenaline-hypertension,626,B-Chemical
hypothesis,626,O
in,626,O
man,626,O
.,626,O
Effect,627,O
of,627,O
alkylxanthines,627,B-Chemical
on,627,O
gentamicin-induced,627,B-Chemical
acute,627,B-Disease
renal,627,I-Disease
failure,627,I-Disease
in,627,O
the,627,O
rat,627,O
.,627,O
Adenosine,628,B-Chemical
antagonists,628,O
have,628,O
been,628,O
previously,628,O
shown,628,O
to,628,O
be,628,O
of,628,O
benefit,628,O
in,628,O
some,628,O
ischaemic,628,B-Disease
and,628,O
nephrotoxic,628,B-Disease
models,628,O
of,628,O
acute,628,B-Disease
renal,628,I-Disease
failure,628,I-Disease
(,628,O
ARF,628,B-Disease
),628,O
.,628,O
In,629,O
the,629,O
present,629,O
study,629,O
",",629,O
the,629,O
effects,629,O
of,629,O
three,629,O
alkylxanthines,629,B-Chemical
with,629,O
different,629,O
potencies,629,O
as,629,O
adenosine,629,B-Chemical
antagonists,629,O
8-phenyltheophylline,629,B-Chemical
",",629,O
theophylline,629,B-Chemical
and,629,O
enprofylline,629,B-Chemical
",",629,O
were,629,O
examined,629,O
in,629,O
rats,629,O
developing,629,O
acute,629,B-Disease
renal,629,I-Disease
failure,629,I-Disease
after,629,O
4,629,O
daily,629,O
injections,629,O
of,629,O
gentamicin,629,B-Chemical
(,629,O
200,629,O
mg,629,O
kg-1,629,O
),629,O
.,629,O
Renal,630,O
function,630,O
was,630,O
assessed,630,O
by,630,O
biochemical,630,O
(,630,O
plasma,630,O
urea,630,B-Chemical
and,630,O
creatinine,630,B-Chemical
),630,O
",",630,O
functional,630,O
(,630,O
urine,630,O
analysis,630,O
and,630,O
[,630,O
3H,630,O
],630,O
inulin,630,O
and,630,O
[,630,O
14C,630,O
],630,O
p-aminohippuric,630,B-Chemical
acid,630,I-Chemical
clearances,630,O
),630,O
and,630,O
morphological,630,O
(,630,O
degree,630,O
of,630,O
necrosis,630,B-Disease
),630,O
indices,630,O
.,630,O
The,631,O
various,631,O
drug,631,O
treatments,631,O
produced,631,O
improvements,631,O
in,631,O
some,631,O
",",631,O
but,631,O
not,631,O
all,631,O
",",631,O
measurements,631,O
of,631,O
renal,631,O
function,631,O
.,631,O
However,632,O
",",632,O
any,632,O
improvement,632,O
produced,632,O
by,632,O
drug,632,O
treatment,632,O
was,632,O
largely,632,O
a,632,O
result,632,O
of,632,O
a,632,O
beneficial,632,O
effect,632,O
exerted,632,O
by,632,O
its,632,O
vehicle,632,O
(,632,O
polyethylene,632,B-Chemical
glycol,632,I-Chemical
and,632,O
NaOH,632,B-Chemical
),632,O
.,632,O
The,633,O
lack,633,O
of,633,O
any,633,O
consistent,633,O
protective,633,O
effect,633,O
noted,633,O
with,633,O
the,633,O
alkylxanthines,633,B-Chemical
tested,633,O
in,633,O
the,633,O
present,633,O
study,633,O
indicates,633,O
that,633,O
adenosine,633,B-Chemical
plays,633,O
little,633,O
",",633,O
if,633,O
any,633,O
",",633,O
pathophysiological,633,O
role,633,O
in,633,O
gentamicin-induced,633,B-Chemical
ARF,633,B-Disease
.,633,O
Adverse,634,O
ocular,634,O
reactions,634,O
possibly,634,O
associated,634,O
with,634,O
isotretinoin,634,B-Chemical
.,634,O
A,635,O
total,635,O
of,635,O
261,635,O
adverse,635,O
ocular,635,O
reactions,635,O
occurred,635,O
in,635,O
237,635,O
patients,635,O
who,635,O
received,635,O
isotretinoin,635,B-Chemical
",",635,O
a,635,O
commonly,635,O
used,635,O
drug,635,O
in,635,O
the,635,O
treatment,635,O
of,635,O
severe,635,O
cystic,635,O
acne,635,B-Disease
.,635,O
Blepharoconjunctivitis,636,B-Disease
",",636,O
subjective,636,O
complaints,636,O
of,636,O
dry,636,B-Disease
eyes,636,I-Disease
",",636,O
blurred,636,B-Disease
vision,636,I-Disease
",",636,O
contact,636,O
lens,636,O
intolerance,636,O
",",636,O
and,636,O
photodermatitis,636,B-Disease
are,636,O
reversible,636,O
side,636,O
effects,636,O
.,636,O
More,637,O
serious,637,O
ocular,637,O
adverse,637,O
reactions,637,O
include,637,O
papilledema,637,B-Disease
",",637,O
pseudotumor,637,B-Disease
cerebri,637,I-Disease
",",637,O
and,637,O
white,637,O
or,637,O
gray,637,O
subepithelial,637,O
corneal,637,B-Disease
opacities,637,I-Disease
;,637,O
all,637,O
of,637,O
these,637,O
are,637,O
reversible,637,O
if,637,O
the,637,O
drug,637,O
is,637,O
discontinued,637,O
.,637,O
Reported,638,O
cases,638,O
of,638,O
decreased,638,O
dark,638,O
adaptation,638,O
are,638,O
under,638,O
investigation,638,O
.,638,O
Isotretinoin,639,B-Chemical
is,639,O
contraindicated,639,O
in,639,O
pregnancy,639,O
because,639,O
of,639,O
the,639,O
many,639,O
reported,639,O
congenital,639,B-Disease
abnormalities,639,I-Disease
after,639,O
maternal,639,O
use,639,O
(,639,O
including,639,O
microphthalmos,639,B-Disease
",",639,O
orbital,639,O
hypertelorism,639,B-Disease
",",639,O
and,639,O
optic,639,B-Disease
nerve,639,I-Disease
hypoplasia,639,I-Disease
),639,O
.,639,O
Procaterol,640,B-Chemical
and,640,O
terbutaline,640,B-Chemical
in,640,O
bronchial,640,B-Disease
asthma,640,I-Disease
.,640,O
A,641,O
double-blind,641,O
",",641,O
placebo-controlled,641,O
",",641,O
cross-over,641,O
study,641,O
.,641,O
Procaterol,642,B-Chemical
",",642,O
a,642,O
new,642,O
beta-2,642,O
adrenoceptor,642,O
stimulant,642,O
",",642,O
was,642,O
studied,642,O
in,642,O
a,642,O
double-blind,642,O
",",642,O
placebo-controlled,642,O
",",642,O
cross-over,642,O
trial,642,O
in,642,O
patients,642,O
with,642,O
bronchial,642,B-Disease
asthma,642,I-Disease
.,642,O
Oral,643,O
procaterol,643,B-Chemical
50,643,O
micrograms,643,O
b.d.,643,O
",",643,O
procaterol,643,B-Chemical
100,643,O
micrograms,643,O
b.d.,643,O
",",643,O
and,643,O
terbutaline,643,B-Chemical
5,643,O
mg,643,O
t.i.d.,643,O
",",643,O
were,643,O
compared,643,O
when,643,O
given,643,O
randomly,643,O
in,643,O
1-week,643,O
treatment,643,O
periods,643,O
.,643,O
The,644,O
best,644,O
clinical,644,O
effect,644,O
was,644,O
found,644,O
with,644,O
terbutaline,644,B-Chemical
.,644,O
Both,645,O
anti-asthmatic,645,O
and,645,O
tremorgenic,645,B-Disease
effects,645,O
of,645,O
procaterol,645,B-Chemical
were,645,O
dose-related,645,O
.,645,O
Procaterol,646,B-Chemical
appeared,646,O
effective,646,O
in,646,O
the,646,O
doses,646,O
tested,646,O
",",646,O
and,646,O
a,646,O
twice,646,O
daily,646,O
regimen,646,O
would,646,O
appear,646,O
to,646,O
be,646,O
suitable,646,O
with,646,O
this,646,O
drug,646,O
.,646,O
Subacute,647,O
effects,647,O
of,647,O
propranolol,647,B-Chemical
and,647,O
B,647,O
24/76,647,O
on,647,O
isoproterenol-induced,647,B-Chemical
rat,647,O
heart,647,B-Disease
hypertrophy,647,I-Disease
in,647,O
correlation,647,O
with,647,O
blood,647,O
pressure,647,O
.,647,O
We,648,O
compared,648,O
the,648,O
potential,648,O
beta-receptor,648,O
blocker,648,O
",",648,O
B,648,O
24/76,648,O
i.e,648,O
.,648,O
1-,649,O
(,649,O
"2,4-dichlorophenoxy",649,O
),649,O
-3,649,O
[,649,O
"2-3,4-dimethoxyphenyl",649,O
),649,O
ethanolamino,649,O
],649,O
-prop,649,O
an-2-ol,649,O
",",649,O
which,649,O
is,649,O
characterized,649,O
by,649,O
beta,649,O
1-adrenoceptor,649,O
blocking,649,O
and,649,O
beta,649,O
2-adrenoceptor,649,O
stimulating,649,O
properties,649,O
with,649,O
propranolol,649,B-Chemical
.,649,O
The,650,O
studies,650,O
were,650,O
performed,650,O
using,650,O
an,650,O
experimental,650,O
model,650,O
of,650,O
isoproterenol-induced,650,B-Chemical
heart,650,B-Disease
hypertrophy,650,I-Disease
in,650,O
rats,650,O
.,650,O
A,651,O
correlation,651,O
of,651,O
the,651,O
blood,651,O
pressure,651,O
was,651,O
neither,651,O
found,651,O
in,651,O
the,651,O
development,651,O
nor,651,O
in,651,O
the,651,O
attempt,651,O
to,651,O
suppress,651,O
the,651,O
development,651,O
of,651,O
heart,651,B-Disease
hypertrophy,651,I-Disease
with,651,O
the,651,O
two,651,O
beta-receptor,651,O
blockers,651,O
.,651,O
Both,652,O
beta-blockers,652,O
influenced,652,O
the,652,O
development,652,O
of,652,O
hypertrophy,652,B-Disease
to,652,O
a,652,O
different,652,O
",",652,O
but,652,O
not,652,O
reproducible,652,O
extent,652,O
.,652,O
It,653,O
was,653,O
possible,653,O
to,653,O
suppress,653,O
the,653,O
increased,653,O
ornithine,653,B-Chemical
decarboxylase,653,O
activity,653,O
with,653,O
both,653,O
beta-blockers,653,O
in,653,O
hypertrophied,653,B-Disease
hearts,653,I-Disease
",",653,O
but,653,O
there,653,O
was,653,O
no,653,O
effect,653,O
on,653,O
the,653,O
heart,653,O
mass,653,O
.,653,O
Neither,654,O
propranolol,654,B-Chemical
nor,654,O
B,654,O
24/76,654,O
could,654,O
stop,654,O
the,654,O
changes,654,O
in,654,O
the,654,O
characteristic,654,O
myosin,654,O
isoenzyme,654,O
pattern,654,O
of,654,O
the,654,O
hypertrophied,654,B-Disease
rat,654,O
heart,654,O
.,654,O
Thus,655,O
",",655,O
the,655,O
investigations,655,O
did,655,O
not,655,O
provide,655,O
any,655,O
evidence,655,O
that,655,O
the,655,O
beta-receptor,655,O
blockers,655,O
propranolol,655,B-Chemical
and,655,O
B,655,O
24/76,655,O
have,655,O
the,655,O
potency,655,O
to,655,O
prevent,655,O
isoproterenol,655,B-Chemical
from,655,O
producing,655,O
heart,655,B-Disease
hypertrophy,655,I-Disease
.,655,O
Increased,656,O
anxiogenic,656,O
effects,656,O
of,656,O
caffeine,656,B-Chemical
in,656,O
panic,656,B-Disease
disorders,656,I-Disease
.,656,O
The,657,O
effects,657,O
of,657,O
oral,657,O
administration,657,O
of,657,O
caffeine,657,B-Chemical
(,657,O
10,657,O
mg/kg,657,O
),657,O
on,657,O
behavioral,657,O
ratings,657,O
",",657,O
somatic,657,O
symptoms,657,O
",",657,O
blood,657,O
pressure,657,O
and,657,O
plasma,657,O
levels,657,O
of,657,O
3-methoxy-4-hydroxyphenethyleneglycol,657,B-Chemical
(,657,O
MHPG,657,B-Chemical
),657,O
and,657,O
cortisol,657,B-Chemical
were,657,O
determined,657,O
in,657,O
17,657,O
healthy,657,O
subjects,657,O
and,657,O
21,657,O
patients,657,O
meeting,657,O
DSM-III,657,O
criteria,657,O
for,657,O
agoraphobia,657,B-Disease
with,657,O
panic,657,B-Disease
attacks,657,I-Disease
or,657,O
panic,657,B-Disease
disorder,657,I-Disease
.,657,O
Caffeine,658,B-Chemical
produced,658,O
significantly,658,O
greater,658,O
increases,658,O
in,658,O
subject-rated,658,O
anxiety,658,B-Disease
",",658,O
nervousness,658,O
",",658,O
fear,658,O
",",658,O
nausea,658,B-Disease
",",658,O
palpitations,658,B-Disease
",",658,O
restlessness,658,B-Disease
",",658,O
and,658,O
tremors,658,B-Disease
in,658,O
the,658,O
patients,658,O
compared,658,O
with,658,O
healthy,658,O
subjects,658,O
.,658,O
In,659,O
the,659,O
patients,659,O
",",659,O
but,659,O
not,659,O
the,659,O
healthy,659,O
subjects,659,O
",",659,O
these,659,O
symptoms,659,O
were,659,O
significantly,659,O
correlated,659,O
with,659,O
plasma,659,O
caffeine,659,B-Chemical
levels,659,O
.,659,O
Seventy-one,660,O
percent,660,O
of,660,O
the,660,O
patients,660,O
reported,660,O
that,660,O
the,660,O
behavioral,660,O
effects,660,O
of,660,O
caffeine,660,B-Chemical
were,660,O
similar,660,O
to,660,O
those,660,O
experienced,660,O
during,660,O
panic,660,B-Disease
attacks,660,I-Disease
.,660,O
Caffeine,661,B-Chemical
did,661,O
not,661,O
alter,661,O
plasma,661,O
MHPG,661,B-Chemical
levels,661,O
in,661,O
either,661,O
the,661,O
healthy,661,O
subjects,661,O
or,661,O
patients,661,O
.,661,O
Caffeine,662,B-Chemical
increased,662,O
plasma,662,O
cortisol,662,B-Chemical
levels,662,O
equally,662,O
in,662,O
the,662,O
patient,662,O
and,662,O
healthy,662,O
groups,662,O
.,662,O
Because,663,O
caffeine,663,B-Chemical
is,663,O
an,663,O
adenosine,663,B-Chemical
receptor,663,O
antagonist,663,O
",",663,O
these,663,O
results,663,O
suggest,663,O
that,663,O
some,663,O
panic,663,B-Disease
disorder,663,I-Disease
patients,663,O
may,663,O
have,663,O
abnormalities,663,B-Disease
in,663,I-Disease
neuronal,663,I-Disease
systems,663,I-Disease
involving,663,O
adenosine,663,B-Chemical
.,663,O
Patients,664,O
with,664,O
anxiety,664,B-Disease
disorders,664,I-Disease
may,664,O
benefit,664,O
by,664,O
avoiding,664,O
caffeine-containing,664,B-Chemical
foods,664,O
and,664,O
beverages,664,O
.,664,O
Comparison,665,O
of,665,O
the,665,O
effect,665,O
of,665,O
oxitropium,665,B-Chemical
bromide,665,I-Chemical
and,665,O
of,665,O
slow-release,665,O
theophylline,665,B-Chemical
on,665,O
nocturnal,665,O
asthma,665,B-Disease
.,665,O
The,666,O
effects,666,O
of,666,O
a,666,O
new,666,O
inhaled,666,O
antimuscarinic,666,O
drug,666,O
",",666,O
oxitropium,666,B-Chemical
bromide,666,I-Chemical
",",666,O
and,666,O
of,666,O
a,666,O
slow-release,666,O
theophylline,666,B-Chemical
preparation,666,O
upon,666,O
nocturnal,666,O
asthma,666,B-Disease
were,666,O
compared,666,O
in,666,O
a,666,O
placebo-controlled,666,O
double-blind,666,O
study,666,O
.,666,O
Two,667,O
samples,667,O
were,667,O
studied,667,O
:,667,O
12,667,O
patients,667,O
received,667,O
oxitropium,667,B-Chemical
at,667,O
600,667,O
micrograms,667,O
(,667,O
6,667,O
subjects,667,O
),667,O
or,667,O
at,667,O
400,667,O
micrograms,667,O
t.i.d,667,O
.,667,O
(,668,O
6,668,O
subjects,668,O
),668,O
whereas,668,O
11,668,O
received,668,O
theophylline,668,B-Chemical
at,668,O
300,668,O
mg,668,O
b.i.d,668,O
.,668,O
Morning,669,O
dipping,669,O
",",669,O
assessed,669,O
by,669,O
the,669,O
fall,669,O
in,669,O
peak,669,O
flow,669,O
overnight,669,O
",",669,O
was,669,O
significantly,669,O
reduced,669,O
in,669,O
the,669,O
periods,669,O
when,669,O
either,669,O
active,669,O
drug,669,O
was,669,O
taken,669,O
",",669,O
whereas,669,O
no,669,O
difference,669,O
was,669,O
noticed,669,O
during,669,O
the,669,O
placebo,669,O
administration,669,O
.,669,O
No,670,O
significant,670,O
difference,670,O
was,670,O
noticed,670,O
between,670,O
results,670,O
obtained,670,O
with,670,O
either,670,O
active,670,O
drug,670,O
",",670,O
as,670,O
well,670,O
as,670,O
with,670,O
either,670,O
dosage,670,O
of,670,O
oxitropium,670,B-Chemical
.,670,O
No,671,O
subject,671,O
reported,671,O
side,671,O
effects,671,O
of,671,O
oxitropium,671,B-Chemical
",",671,O
as,671,O
compared,671,O
to,671,O
three,671,O
subjects,671,O
reporting,671,O
nausea,671,B-Disease
",",671,O
vomiting,671,B-Disease
and,671,O
tremors,671,B-Disease
after,671,O
theophylline,671,B-Chemical
.,671,O
Oxitropium,672,B-Chemical
proves,672,O
to,672,O
be,672,O
a,672,O
valuable,672,O
alternative,672,O
to,672,O
theophylline,672,B-Chemical
in,672,O
nocturnal,672,O
asthma,672,B-Disease
",",672,O
since,672,O
it,672,O
is,672,O
equally,672,O
potent,672,O
",",672,O
safer,672,O
and,672,O
does,672,O
not,672,O
require,672,O
the,672,O
titration,672,O
of,672,O
dosage,672,O
.,672,O
Penicillin,673,B-Chemical
anaphylaxis,673,B-Disease
.,673,O
A,674,O
case,674,O
of,674,O
oral,674,O
penicillin,674,B-Chemical
anaphylaxis,674,B-Disease
is,674,O
described,674,O
",",674,O
and,674,O
the,674,O
terminology,674,O
",",674,O
occurrence,674,O
",",674,O
clinical,674,O
manifestations,674,O
",",674,O
pathogenesis,674,O
",",674,O
prevention,674,O
",",674,O
and,674,O
treatment,674,O
of,674,O
anaphylaxis,674,B-Disease
are,674,O
reviewed,674,O
.,674,O
Emergency,675,O
physicians,675,O
should,675,O
be,675,O
aware,675,O
of,675,O
oral,675,O
penicillin,675,B-Chemical
anaphylaxis,675,B-Disease
in,675,O
order,675,O
to,675,O
prevent,675,O
its,675,O
occurrence,675,O
by,675,O
prescribing,675,O
the,675,O
antibiotic,675,O
judiciously,675,O
and,675,O
knowledgeably,675,O
and,675,O
to,675,O
offer,675,O
optimal,675,O
medical,675,O
therapy,675,O
once,675,O
this,675,O
life-threatening,675,O
reaction,675,O
has,675,O
begun,675,O
.,675,O
Reversible,676,O
valproic,676,B-Chemical
acid-induced,676,O
dementia,676,B-Disease
:,676,O
a,676,O
case,676,O
report,676,O
.,676,O
Reversible,677,O
valproic,677,B-Chemical
acid-induced,677,O
dementia,677,B-Disease
was,677,O
documented,677,O
in,677,O
a,677,O
21-year-old,677,O
man,677,O
with,677,O
epilepsy,677,B-Disease
who,677,O
had,677,O
a,677,O
3-year,677,O
history,677,O
of,677,O
insidious,677,O
progressive,677,O
decline,677,O
in,677,O
global,677,O
cognitive,677,O
abilities,677,O
documented,677,O
by,677,O
serial,677,O
neuropsychological,677,O
studies,677,O
.,677,O
Repeat,678,O
neuropsychological,678,O
testing,678,O
7,678,O
weeks,678,O
after,678,O
discontinuation,678,O
of,678,O
the,678,O
drug,678,O
revealed,678,O
dramatic,678,O
improvement,678,O
in,678,O
IQ,678,O
",",678,O
memory,678,O
",",678,O
naming,678,O
",",678,O
and,678,O
other,678,O
tasks,678,O
commensurate,678,O
with,678,O
clinical,678,O
recovery,678,O
in,678,O
his,678,O
intellectual,678,O
capacity,678,O
.,678,O
Possible,679,O
pathophysiological,679,O
mechanisms,679,O
which,679,O
may,679,O
have,679,O
been,679,O
operative,679,O
in,679,O
this,679,O
case,679,O
include,679,O
:,679,O
a,679,O
direct,679,O
central,679,O
nervous,679,O
system,679,O
(,679,O
CNS,679,O
),679,O
toxic,679,O
effect,679,O
of,679,O
valproic,679,B-Chemical
acid,679,I-Chemical
;,679,O
a,679,O
paradoxical,679,O
epileptogenic,679,O
effect,679,O
secondary,679,O
to,679,O
the,679,O
drug,679,O
;,679,O
and,679,O
an,679,O
indirect,679,O
CNS,679,O
toxic,679,O
effect,679,O
mediated,679,O
through,679,O
valproic,679,B-Chemical
acid-induced,679,O
hyperammonemia,679,B-Disease
.,679,O
Reversal,680,O
of,680,O
scopolamine-induced,680,B-Chemical
amnesia,680,B-Disease
of,680,O
passive,680,O
avoidance,680,O
by,680,O
pre-,680,O
and,680,O
post-training,680,O
naloxone,680,B-Chemical
.,680,O
In,681,O
a,681,O
series,681,O
of,681,O
five,681,O
experiments,681,O
",",681,O
the,681,O
modulating,681,O
role,681,O
of,681,O
naloxone,681,B-Chemical
on,681,O
a,681,O
scopolamine-induced,681,B-Chemical
retention,681,B-Disease
deficit,681,I-Disease
in,681,O
a,681,O
passive,681,O
avoidance,681,O
paradigm,681,O
was,681,O
investigated,681,O
in,681,O
mice,681,O
.,681,O
Scopolamine,682,B-Chemical
",",682,O
but,682,O
not,682,O
methyl,682,B-Chemical
scopolamine,682,I-Chemical
(,682,O
1,682,O
and,682,O
3,682,O
mg/kg,682,O
),682,O
",",682,O
induced,682,O
an,682,O
amnesia,682,B-Disease
as,682,O
measured,682,O
by,682,O
latency,682,O
and,682,O
duration,682,O
parameters,682,O
.,682,O
Naloxone,683,B-Chemical
(,683,O
0.3,683,O
",",683,O
1,683,O
",",683,O
3,683,O
",",683,O
and,683,O
10,683,O
mg/kg,683,O
),683,O
injected,683,O
prior,683,O
to,683,O
training,683,O
attenuated,683,O
the,683,O
retention,683,B-Disease
deficit,683,I-Disease
with,683,O
a,683,O
peak,683,O
of,683,O
activity,683,O
at,683,O
3,683,O
mg/kg,683,O
.,683,O
The,684,O
effect,684,O
of,684,O
naloxone,684,B-Chemical
could,684,O
be,684,O
antagonized,684,O
with,684,O
morphine,684,B-Chemical
(,684,O
1,684,O
",",684,O
3,684,O
",",684,O
and,684,O
10,684,O
mg/kg,684,O
),684,O
",",684,O
demonstrating,684,O
the,684,O
opioid,684,O
specificity,684,O
of,684,O
the,684,O
naloxone,684,B-Chemical
effect,684,O
.,684,O
Post-training,685,O
administration,685,O
of,685,O
naloxone,685,B-Chemical
(,685,O
3,685,O
mg/kg,685,O
),685,O
as,685,O
a,685,O
single,685,O
or,685,O
as,685,O
a,685,O
split,685,O
dose,685,O
also,685,O
attenuated,685,O
the,685,O
scopolamine-induced,685,B-Chemical
amnesia,685,B-Disease
.,685,O
Control,686,O
experiments,686,O
indicated,686,O
that,686,O
neither,686,O
an,686,O
increase,686,O
in,686,O
pain,686,B-Disease
sensitivity,686,O
(,686,O
pre-training,686,O
naloxone,686,B-Chemical
),686,O
nor,686,O
an,686,O
induced,686,O
aversive,686,O
state,686,O
(,686,O
post-training,686,O
naloxone,686,B-Chemical
),686,O
appear,686,O
to,686,O
be,686,O
responsible,686,O
for,686,O
the,686,O
influence,686,O
of,686,O
naloxone,686,B-Chemical
on,686,O
the,686,O
scopolamine-induced,686,B-Chemical
retention,686,B-Disease
deficit,686,I-Disease
.,686,O
These,687,O
results,687,O
extend,687,O
previous,687,O
findings,687,O
implicating,687,O
a,687,O
cholinergic-opioid,687,O
interaction,687,O
in,687,O
memory,687,O
processes,687,O
.,687,O
A,688,O
possible,688,O
mechanism,688,O
for,688,O
this,688,O
interaction,688,O
involving,688,O
the,688,O
septo-hippocampal,688,O
cholinergic,688,O
pathway,688,O
is,688,O
discussed,688,O
.,688,O
Electron,689,O
microscopic,689,O
investigations,689,O
of,689,O
the,689,O
cyclophosphamide-induced,689,B-Chemical
lesions,689,B-Disease
of,689,I-Disease
the,689,I-Disease
urinary,689,I-Disease
bladder,689,I-Disease
of,689,O
the,689,O
rat,689,O
and,689,O
their,689,O
prevention,689,O
by,689,O
mesna,689,B-Chemical
.,689,O
Fully,690,O
developed,690,O
cyclophosphamide-induced,690,B-Chemical
cystitis,690,B-Disease
is,690,O
characterized,690,O
by,690,O
nearly,690,O
complete,690,O
detachment,690,O
of,690,O
the,690,O
urothelium,690,O
",",690,O
severe,690,O
submucosal,690,O
edema,690,B-Disease
owing,690,O
to,690,O
damage,690,O
to,690,O
the,690,O
microvascular,690,O
bed,690,O
and,690,O
focal,690,O
muscle,690,O
necroses,690,B-Disease
.,690,O
The,691,O
initial,691,O
response,691,O
to,691,O
the,691,O
primary,691,O
attack,691,O
by,691,O
the,691,O
cyclophosphamide,691,B-Chemical
metabolites,691,O
seems,691,O
to,691,O
be,691,O
fragmentation,691,O
of,691,O
the,691,O
luminal,691,B-Chemical
membrane,691,O
.,691,O
This,692,O
damages,692,O
the,692,O
cellular,692,O
barrier,692,O
against,692,O
the,692,O
hypertonic,692,O
urine,692,O
.,692,O
Subsequent,693,O
breaks,693,O
in,693,O
the,693,O
lateral,693,O
cell,693,O
membranes,693,O
of,693,O
the,693,O
superficial,693,O
cells,693,O
and,693,O
in,693,O
all,693,O
the,693,O
plasma,693,O
membranes,693,O
of,693,O
the,693,O
intermediate,693,O
and,693,O
basal,693,O
cells,693,O
",",693,O
intercellular,693,O
and,693,O
intracellular,693,O
edema,693,B-Disease
and,693,O
disintegration,693,O
of,693,O
the,693,O
desmosomes,693,O
and,693,O
hemidesmosomes,693,O
lead,693,O
to,693,O
progressive,693,O
degeneration,693,O
and,693,O
detachment,693,O
of,693,O
the,693,O
epithelial,693,O
cells,693,O
with,693,O
exposure,693,O
and,693,O
splitting,693,O
of,693,O
the,693,O
basal,693,O
membrane,693,O
.,693,O
The,694,O
morphological,694,O
changes,694,O
of,694,O
the,694,O
endothelial,694,O
cells,694,O
",",694,O
which,694,O
become,694,O
more,694,O
pronounced,694,O
in,694,O
the,694,O
later,694,O
stages,694,O
of,694,O
the,694,O
experiment,694,O
",",694,O
the,694,O
involvement,694,O
of,694,O
blood,694,O
vessels,694,O
regardless,694,O
of,694,O
their,694,O
diameter,694,O
and,694,O
the,694,O
location-dependent,694,O
extent,694,O
of,694,O
the,694,O
damage,694,O
indicate,694,O
a,694,O
direct,694,O
type,694,O
of,694,O
damage,694,O
which,694,O
is,694,O
preceded,694,O
by,694,O
a,694,O
mediator-induced,694,O
increase,694,O
in,694,O
permeability,694,O
",",694,O
the,694,O
morphological,694,O
correlate,694,O
of,694,O
which,694,O
is,694,O
the,694,O
formation,694,O
of,694,O
gaps,694,O
in,694,O
the,694,O
interendothelial,694,O
cell,694,O
connections,694,O
on,694,O
the,694,O
venules,694,O
.,694,O
These,695,O
changes,695,O
can,695,O
be,695,O
effectively,695,O
prevented,695,O
by,695,O
mesna,695,B-Chemical
.,695,O
The,696,O
only,696,O
sign,696,O
of,696,O
a,696,O
possible,696,O
involvement,696,O
is,696,O
the,696,O
increase,696,O
in,696,O
the,696,O
number,696,O
of,696,O
specific,696,O
granules,696,O
with,696,O
a,696,O
presumed,696,O
lysosomal,696,O
function,696,O
in,696,O
the,696,O
superficial,696,O
cells,696,O
.,696,O
Increase,697,O
in,697,O
intragastric,697,O
pressure,697,O
during,697,O
suxamethonium-induced,697,B-Chemical
muscle,697,B-Disease
fasciculations,697,I-Disease
in,697,O
children,697,O
:,697,O
inhibition,697,O
by,697,O
alfentanil,697,B-Chemical
.,697,O
Changes,698,O
in,698,O
intragastric,698,O
pressure,698,O
after,698,O
the,698,O
administration,698,O
of,698,O
suxamethonium,698,B-Chemical
1.5,698,O
mg,698,O
kg-1,698,O
i.v,698,O
.,698,O
were,699,O
studied,699,O
in,699,O
32,699,O
children,699,O
(,699,O
mean,699,O
age,699,O
6.9,699,O
yr,699,O
),699,O
pretreated,699,O
with,699,O
either,699,O
physiological,699,O
saline,699,O
or,699,O
alfentanil,699,B-Chemical
50,699,O
micrograms,699,O
kg-1,699,O
.,699,O
Anaesthesia,700,O
was,700,O
induced,700,O
with,700,O
thiopentone,700,B-Chemical
5,700,O
mg,700,O
kg-1,700,O
.,700,O
The,701,O
incidence,701,O
and,701,O
intensity,701,O
of,701,O
muscle,701,B-Disease
fasciculations,701,I-Disease
caused,701,O
by,701,O
suxamethonium,701,B-Chemical
were,701,O
significantly,701,O
greater,701,O
in,701,O
the,701,O
control,701,O
than,701,O
in,701,O
the,701,O
alfentanil,701,B-Chemical
group,701,O
.,701,O
The,702,O
intragastric,702,O
pressure,702,O
during,702,O
muscle,702,B-Disease
fasciculations,702,I-Disease
was,702,O
significantly,702,O
higher,702,O
in,702,O
the,702,O
control,702,O
group,702,O
(,702,O
16,702,O
+/-,702,O
0.7,702,O
(,702,O
SEM,702,O
),702,O
cm,702,O
H2O,702,B-Chemical
),702,O
than,702,O
in,702,O
the,702,O
alfentanil,702,B-Chemical
group,702,O
(,702,O
7.7,702,O
+/-,702,O
1.5,702,O
(,702,O
SEM,702,O
),702,O
cm,702,O
H2O,702,B-Chemical
),702,O
.,702,O
The,703,O
increase,703,O
in,703,O
intragastric,703,O
pressure,703,O
was,703,O
directly,703,O
related,703,O
to,703,O
the,703,O
intensity,703,O
of,703,O
muscle,703,B-Disease
fasciculations,703,I-Disease
(,703,O
regression,703,O
line,703,O
:,703,O
y,703,O
=,703,O
0.5,703,O
+,703,O
4.78x,703,O
with,703,O
r,703,O
of,703,O
0.78,703,O
),703,O
.,703,O
It,704,O
is,704,O
concluded,704,O
that,704,O
intragastric,704,O
pressure,704,O
increases,704,O
significantly,704,O
during,704,O
muscle,704,B-Disease
fasciculations,704,I-Disease
caused,704,O
by,704,O
suxamethonium,704,B-Chemical
in,704,O
healthy,704,O
children,704,O
.,704,O
Alfentanil,705,B-Chemical
50,705,O
micrograms,705,O
kg-1,705,O
effectively,705,O
inhibits,705,O
the,705,O
incidence,705,O
and,705,O
intensity,705,O
of,705,O
suxamethonium-induced,705,B-Chemical
muscle,705,B-Disease
fasciculations,705,I-Disease
;,705,O
moreover,705,O
",",705,O
intragastric,705,O
pressure,705,O
remains,705,O
at,705,O
its,705,O
control,705,O
value,705,O
.,705,O
Acute,706,O
insulin,706,O
treatment,706,O
normalizes,706,O
the,706,O
resistance,706,O
to,706,O
the,706,O
cardiotoxic,706,B-Disease
effect,706,O
of,706,O
isoproterenol,706,B-Chemical
in,706,O
streptozotocin,706,B-Chemical
diabetic,706,B-Disease
rats,706,O
.,706,O
A,707,O
morphometric,707,O
study,707,O
of,707,O
isoproterenol,707,B-Chemical
induced,707,O
myocardial,707,O
fibrosis,707,B-Disease
.,707,O
The,708,O
acute,708,O
effect,708,O
of,708,O
insulin,708,O
treatment,708,O
on,708,O
the,708,O
earlier,708,O
reported,708,O
protective,708,O
effect,708,O
of,708,O
streptozotocin,708,B-Chemical
diabetes,708,B-Disease
against,708,O
the,708,O
cardiotoxic,708,B-Disease
effect,708,O
of,708,O
high,708,O
doses,708,O
of,708,O
isoproterenol,708,B-Chemical
(,708,O
ISO,708,B-Chemical
),708,O
was,708,O
investigated,708,O
in,708,O
rats,708,O
.,708,O
Thirty,709,O
to,709,O
135,709,O
min,709,O
after,709,O
the,709,O
injection,709,O
of,709,O
crystalline,709,O
insulin,709,O
",",709,O
ISO,709,B-Chemical
was,709,O
given,709,O
subcutaneously,709,O
and,709,O
when,709,O
ISO,709,B-Chemical
induced,709,O
fibrosis,709,B-Disease
in,709,O
the,709,O
myocardium,709,O
was,709,O
morphometrically,709,O
analyzed,709,O
7,709,O
days,709,O
later,709,O
",",709,O
a,709,O
highly,709,O
significant,709,O
correlation,709,O
(,709,O
r,709,O
=,709,O
0.83,709,O
",",709,O
2,709,O
p,709,O
=,709,O
0.006,709,O
),709,O
to,709,O
the,709,O
slope,709,O
of,709,O
the,709,O
fall,709,O
in,709,O
blood,709,O
glucose,709,B-Chemical
after,709,O
insulin,709,O
treatment,709,O
appeared,709,O
.,709,O
The,710,O
myocardial,710,O
content,710,O
of,710,O
catecholamines,710,B-Chemical
was,710,O
estimated,710,O
in,710,O
these,710,O
8,710,O
day,710,O
diabetic,710,B-Disease
rats,710,O
.,710,O
The,711,O
norepinephrine,711,B-Chemical
content,711,O
was,711,O
significantly,711,O
increased,711,O
while,711,O
epinephrine,711,B-Chemical
remained,711,O
unchanged,711,O
.,711,O
An,712,O
enhanced,712,O
sympathetic,712,O
nervous,712,O
system,712,O
activity,712,O
with,712,O
a,712,O
consequent,712,O
down,712,O
regulation,712,O
of,712,O
the,712,O
myocardial,712,O
beta-adrenergic,712,O
receptors,712,O
could,712,O
",",712,O
therefore,712,O
",",712,O
explain,712,O
this,712,O
catecholamine,712,B-Chemical
resistance,712,O
.,712,O
The,713,O
rapid,713,O
reversion,713,O
after,713,O
insulin,713,O
treatment,713,O
excludes,713,O
the,713,O
possibility,713,O
that,713,O
streptozotocin,713,B-Chemical
in,713,O
itself,713,O
causes,713,O
the,713,O
ISO,713,B-Chemical
resistance,713,O
and,713,O
points,713,O
towards,713,O
a,713,O
direct,713,O
insulin,713,O
effect,713,O
on,713,O
myocardial,713,O
catecholamine,713,B-Chemical
sensitivity,713,O
in,713,O
diabetic,713,B-Disease
rats,713,O
.,713,O
The,714,O
phenomenon,714,O
described,714,O
might,714,O
elucidate,714,O
pathogenetic,714,O
mechanisms,714,O
behind,714,O
toxic,714,O
myocardial,714,O
cell,714,O
degeneration,714,O
and,714,O
may,714,O
possibly,714,O
have,714,O
relevance,714,O
for,714,O
acute,714,O
cardiovascular,714,O
complications,714,O
in,714,O
diabetic,714,B-Disease
patients,714,O
.,714,O
Differential,715,O
effects,715,O
of,715,O
non-steroidal,715,O
anti-inflammatory,715,O
drugs,715,O
on,715,O
seizures,715,B-Disease
produced,715,O
by,715,O
pilocarpine,715,B-Chemical
in,715,O
rats,715,O
.,715,O
The,716,O
muscarinic,716,O
cholinergic,716,O
agonist,716,O
pilocarpine,716,B-Chemical
induces,716,O
in,716,O
rats,716,O
seizures,716,B-Disease
and,716,O
status,716,B-Disease
epilepticus,716,I-Disease
followed,716,O
by,716,O
widespread,716,O
damage,716,O
to,716,O
the,716,O
forebrain,716,O
.,716,O
The,717,O
present,717,O
study,717,O
was,717,O
designed,717,O
to,717,O
investigate,717,O
the,717,O
effect,717,O
of,717,O
5,717,O
non-steroidal,717,O
anti-inflammatory,717,O
drugs,717,O
",",717,O
sodium,717,B-Chemical
salicylate,717,I-Chemical
",",717,O
phenylbutazone,717,B-Chemical
",",717,O
indomethacin,717,B-Chemical
",",717,O
ibuprofen,717,B-Chemical
and,717,O
mefenamic,717,B-Chemical
acid,717,I-Chemical
",",717,O
on,717,O
seizures,717,B-Disease
produced,717,O
by,717,O
pilocarpine,717,B-Chemical
.,717,O
Pretreatment,718,O
of,718,O
rats,718,O
with,718,O
sodium,718,B-Chemical
salicylate,718,I-Chemical
",",718,O
ED50,718,O
103,718,O
mg/kg,718,O
(,718,O
60-174,718,O
),718,O
",",718,O
and,718,O
phenylbutazone,718,B-Chemical
",",718,O
59,718,O
mg/kg,718,O
(,718,O
50-70,718,O
),718,O
converted,718,O
the,718,O
non-convulsant,718,O
dose,718,O
of,718,O
pilocarpine,718,B-Chemical
",",718,O
200,718,O
mg/kg,718,O
",",718,O
to,718,O
a,718,O
convulsant,718,O
one,718,O
.,718,O
Indomethacin,719,B-Chemical
",",719,O
1-10,719,O
mg/kg,719,O
",",719,O
and,719,O
ibuprofen,719,B-Chemical
",",719,O
10-100,719,O
mg/kg,719,O
",",719,O
failed,719,O
to,719,O
modulate,719,O
seizures,719,B-Disease
produced,719,O
by,719,O
pilocarpine,719,B-Chemical
.,719,O
Mefenamic,720,B-Chemical
acid,720,I-Chemical
",",720,O
26,720,O
(,720,O
22-30,720,O
),720,O
mg/kg,720,O
",",720,O
prevented,720,O
seizures,720,B-Disease
and,720,O
protected,720,O
rats,720,O
from,720,O
seizure-related,720,B-Disease
brain,720,B-Disease
damage,720,I-Disease
induced,720,O
by,720,O
pilocarpine,720,B-Chemical
",",720,O
380,720,O
mg/kg,720,O
.,720,O
These,721,O
results,721,O
indicate,721,O
that,721,O
non-steroidal,721,O
anti-inflammatory,721,O
drugs,721,O
differentially,721,O
modulate,721,O
the,721,O
threshold,721,O
for,721,O
pilocarpine-induced,721,B-Chemical
seizures,721,B-Disease
.,721,O
Acute,722,B-Disease
neurologic,722,I-Disease
dysfunction,722,I-Disease
after,722,O
high-dose,722,O
etoposide,722,B-Chemical
therapy,722,O
for,722,O
malignant,722,B-Disease
glioma,722,I-Disease
.,722,O
Etoposide,723,B-Chemical
(,723,O
VP-16-213,723,B-Chemical
),723,O
has,723,O
been,723,O
used,723,O
in,723,O
the,723,O
treatment,723,O
of,723,O
many,723,O
solid,723,O
tumors,723,B-Disease
and,723,O
hematologic,723,B-Disease
malignancies,723,I-Disease
.,723,O
When,724,O
used,724,O
in,724,O
high,724,O
doses,724,O
and,724,O
in,724,O
conjunction,724,O
with,724,O
autologous,724,O
bone,724,O
marrow,724,O
transplantation,724,O
",",724,O
this,724,O
agent,724,O
has,724,O
activity,724,O
against,724,O
several,724,O
treatment-resistant,724,O
cancers,724,B-Disease
including,724,O
malignant,724,B-Disease
glioma,724,I-Disease
.,724,O
In,725,O
six,725,O
of,725,O
eight,725,O
patients,725,O
(,725,O
75,725,O
%,725,O
),725,O
who,725,O
we,725,O
treated,725,O
for,725,O
recurrent,725,O
or,725,O
resistant,725,O
glioma,725,B-Disease
",",725,O
sudden,725,O
severe,725,O
neurologic,725,B-Disease
deterioration,725,I-Disease
occurred,725,O
.,725,O
This,726,O
developed,726,O
a,726,O
median,726,O
of,726,O
9,726,O
days,726,O
after,726,O
initiation,726,O
of,726,O
high-dose,726,O
etoposide,726,B-Chemical
therapy,726,O
.,726,O
Significant,727,O
clinical,727,O
manifestations,727,O
have,727,O
included,727,O
confusion,727,B-Disease
",",727,O
papilledema,727,B-Disease
",",727,O
somnolence,727,B-Disease
",",727,O
exacerbation,727,O
of,727,O
motor,727,B-Disease
deficits,727,I-Disease
",",727,O
and,727,O
sharp,727,O
increase,727,O
in,727,O
seizure,727,B-Disease
activity,727,O
.,727,O
These,728,O
abnormalities,728,O
resolved,728,O
rapidly,728,O
after,728,O
initiation,728,O
of,728,O
high-dose,728,O
intravenous,728,O
dexamethasone,728,B-Chemical
therapy,728,O
.,728,O
In,729,O
all,729,O
patients,729,O
",",729,O
computerized,729,O
tomographic,729,O
(,729,O
CT,729,O
),729,O
brain,729,O
scans,729,O
demonstrated,729,O
stability,729,O
in,729,O
tumor,729,B-Disease
size,729,O
and,729,O
peritumor,729,O
edema,729,B-Disease
when,729,O
compared,729,O
with,729,O
pretransplant,729,O
scans,729,O
.,729,O
This,730,O
complication,730,O
appears,730,O
to,730,O
represent,730,O
a,730,O
significant,730,O
new,730,O
toxicity,730,B-Disease
of,730,O
high-dose,730,O
etoposide,730,B-Chemical
therapy,730,O
for,730,O
malignant,730,B-Disease
glioma,730,I-Disease
.,730,O
Progressive,731,O
bile,731,B-Disease
duct,731,I-Disease
injury,731,I-Disease
after,731,O
thiabendazole,731,B-Chemical
administration,731,O
.,731,O
A,732,O
27-yr-old,732,O
man,732,O
developed,732,O
jaundice,732,B-Disease
2,732,O
wk,732,O
after,732,O
exposure,732,O
to,732,O
thiabendazole,732,B-Chemical
.,732,O
Cholestasis,733,B-Disease
persisted,733,O
for,733,O
3,733,O
yr,733,O
",",733,O
at,733,O
which,733,O
time,733,O
a,733,O
liver,733,O
transplant,733,O
was,733,O
performed,733,O
.,733,O
Two,734,O
liver,734,O
biopsy,734,O
specimens,734,O
and,734,O
the,734,O
hepatectomy,734,O
specimen,734,O
were,734,O
remarkable,734,O
for,734,O
almost,734,O
complete,734,O
disappearance,734,O
of,734,O
interlobular,734,O
bile,734,O
ducts,734,O
.,734,O
Prominent,735,O
fibrosis,735,B-Disease
and,735,O
hepatocellular,735,O
regeneration,735,O
were,735,O
also,735,O
present,735,O
;,735,O
however,735,O
",",735,O
the,735,O
lobular,735,O
architecture,735,O
was,735,O
preserved,735,O
.,735,O
This,736,O
case,736,O
represents,736,O
an,736,O
example,736,O
of,736,O
``,736,O
idiosyncratic,736,O
'',736,O
drug-induced,736,B-Disease
liver,736,I-Disease
damage,736,I-Disease
in,736,O
which,736,O
the,736,O
primary,736,O
target,736,O
of,736,O
injury,736,O
is,736,O
the,736,O
bile,736,O
duct,736,O
.,736,O
An,737,O
autoimmune,737,O
pathogenesis,737,O
of,737,O
the,737,O
bile,737,B-Disease
duct,737,I-Disease
destruction,737,I-Disease
is,737,O
suggested,737,O
.,737,O
Differential,738,O
effects,738,O
of,738,O
"1,4-dihydropyridine",738,B-Chemical
calcium,738,B-Chemical
channel,738,I-Chemical
blockers,738,I-Chemical
:,738,O
therapeutic,738,O
implications,738,O
.,738,O
Increasing,739,O
recognition,739,O
of,739,O
the,739,O
importance,739,O
of,739,O
calcium,739,B-Chemical
in,739,O
the,739,O
pathogenesis,739,O
of,739,O
cardiovascular,739,B-Disease
disease,739,I-Disease
has,739,O
stimulated,739,O
research,739,O
into,739,O
the,739,O
use,739,O
of,739,O
calcium,739,B-Chemical
channel,739,I-Chemical
blocking,739,I-Chemical
agents,739,I-Chemical
for,739,O
treatment,739,O
of,739,O
a,739,O
variety,739,O
of,739,O
cardiovascular,739,B-Disease
diseases,739,I-Disease
.,739,O
The,740,O
favorable,740,O
efficacy,740,O
and,740,O
tolerability,740,O
profiles,740,O
of,740,O
these,740,O
agents,740,O
make,740,O
them,740,O
attractive,740,O
therapeutic,740,O
modalities,740,O
.,740,O
Clinical,741,O
applications,741,O
of,741,O
calcium,741,B-Chemical
channel,741,I-Chemical
blockers,741,I-Chemical
parallel,741,O
their,741,O
tissue,741,O
selectivity,741,O
.,741,O
In,742,O
contrast,742,O
to,742,O
verapamil,742,B-Chemical
and,742,O
diltiazem,742,B-Chemical
",",742,O
which,742,O
are,742,O
roughly,742,O
equipotent,742,O
in,742,O
their,742,O
actions,742,O
on,742,O
the,742,O
heart,742,O
and,742,O
vascular,742,O
smooth,742,O
muscle,742,O
",",742,O
the,742,O
dihydropyridine,742,B-Chemical
calcium,742,B-Chemical
channel,742,I-Chemical
blockers,742,I-Chemical
are,742,O
a,742,O
group,742,O
of,742,O
potent,742,O
peripheral,742,O
vasodilator,742,O
agents,742,O
that,742,O
exert,742,O
minimal,742,O
electrophysiologic,742,O
effects,742,O
on,742,O
cardiac,742,O
nodal,742,O
or,742,O
conduction,742,O
tissue,742,O
.,742,O
As,743,O
the,743,O
first,743,O
dihydropyridine,743,B-Chemical
available,743,O
for,743,O
use,743,O
in,743,O
the,743,O
United,743,O
States,743,O
",",743,O
nifedipine,743,B-Chemical
controls,743,O
angina,743,B-Disease
and,743,O
hypertension,743,B-Disease
with,743,O
minimal,743,O
depression,743,O
of,743,O
cardiac,743,O
function,743,O
.,743,O
Additional,744,O
members,744,O
of,744,O
this,744,O
group,744,O
of,744,O
calcium,744,B-Chemical
channel,744,I-Chemical
blockers,744,I-Chemical
have,744,O
been,744,O
studied,744,O
for,744,O
a,744,O
variety,744,O
of,744,O
indications,744,O
for,744,O
which,744,O
they,744,O
may,744,O
offer,744,O
advantages,744,O
over,744,O
current,744,O
therapy,744,O
.,744,O
Once,745,O
or,745,O
twice,745,O
daily,745,O
dosage,745,O
possible,745,O
with,745,O
nitrendipine,745,B-Chemical
and,745,O
nisoldipine,745,B-Chemical
offers,745,O
a,745,O
convenient,745,O
administration,745,O
schedule,745,O
",",745,O
which,745,O
encourages,745,O
patient,745,O
compliance,745,O
in,745,O
long-term,745,O
therapy,745,O
of,745,O
hypertension,745,B-Disease
.,745,O
The,746,O
coronary,746,O
vasodilating,746,O
properties,746,O
of,746,O
nisoldipine,746,B-Chemical
have,746,O
led,746,O
to,746,O
the,746,O
investigation,746,O
of,746,O
this,746,O
agent,746,O
for,746,O
use,746,O
in,746,O
angina,746,B-Disease
.,746,O
Selectivity,747,O
for,747,O
the,747,O
cerebrovascular,747,O
bed,747,O
makes,747,O
nimodipine,747,B-Chemical
potentially,747,O
useful,747,O
in,747,O
the,747,O
treatment,747,O
of,747,O
subarachnoid,747,B-Disease
hemorrhage,747,I-Disease
",",747,O
migraine,747,B-Disease
headache,747,I-Disease
",",747,O
dementia,747,B-Disease
",",747,O
and,747,O
stroke,747,B-Disease
.,747,O
In,748,O
general,748,O
",",748,O
the,748,O
dihydropyridine,748,B-Chemical
calcium,748,B-Chemical
channel,748,I-Chemical
blockers,748,I-Chemical
are,748,O
usually,748,O
well,748,O
tolerated,748,O
",",748,O
with,748,O
headache,748,B-Disease
",",748,O
facial,748,O
flushing,748,B-Disease
",",748,O
palpitations,748,B-Disease
",",748,O
edema,748,B-Disease
",",748,O
nausea,748,B-Disease
",",748,O
anorexia,748,B-Disease
",",748,O
and,748,O
dizziness,748,B-Disease
being,748,O
the,748,O
more,748,O
common,748,O
adverse,748,O
effects,748,O
.,748,O
The,749,O
enhancement,749,O
of,749,O
aminonucleoside,749,B-Chemical
nephrosis,749,B-Disease
by,749,O
the,749,O
co-administration,749,O
of,749,O
protamine,749,O
.,749,O
An,750,O
experimental,750,O
model,750,O
of,750,O
focal,750,B-Disease
segmental,750,I-Disease
glomerular,750,I-Disease
sclerosis,750,I-Disease
(,750,O
FSGS,750,B-Disease
),750,O
was,750,O
developed,750,O
in,750,O
rats,750,O
by,750,O
the,750,O
combined,750,O
administration,750,O
of,750,O
puromycin-aminonucleoside,750,B-Chemical
(,750,O
AMNS,750,B-Chemical
),750,O
and,750,O
protamine,750,B-Chemical
sulfate,750,I-Chemical
(,750,O
PS,750,B-Chemical
),750,O
.,750,O
Male,751,O
Sprague-Dawley,751,O
rats,751,O
",",751,O
uninephrectomized,751,O
three,751,O
weeks,751,O
before,751,O
",",751,O
received,751,O
daily,751,O
injections,751,O
of,751,O
subcutaneous,751,O
AMNS,751,B-Chemical
(,751,O
1,751,O
mg/100,751,O
g,751,O
body,751,O
wt,751,O
),751,O
and,751,O
intravenous,751,O
PS,751,B-Chemical
(,751,O
2,751,O
separated,751,O
doses,751,O
of,751,O
2.5,751,O
mg/100,751,O
g,751,O
body,751,O
wt,751,O
),751,O
for,751,O
four,751,O
days,751,O
.,751,O
The,752,O
series,752,O
of,752,O
injections,752,O
were,752,O
repeated,752,O
another,752,O
three,752,O
times,752,O
at,752,O
10,752,O
day,752,O
intervals,752,O
.,752,O
The,753,O
animals,753,O
were,753,O
sacrificed,753,O
on,753,O
days,753,O
24,753,O
",",753,O
52,753,O
",",753,O
and,753,O
80,753,O
.,753,O
They,754,O
developed,754,O
nephrotic,754,B-Disease
syndrome,754,I-Disease
and,754,O
finally,754,O
renal,754,B-Disease
failure,754,I-Disease
.,754,O
The,755,O
time-course,755,O
curve,755,O
of,755,O
creatinine,755,B-Chemical
clearance,755,O
dropped,755,O
and,755,O
showed,755,O
significant,755,O
difference,755,O
(,755,O
P,755,O
less,755,O
than,755,O
0.01,755,O
),755,O
from,755,O
that,755,O
of,755,O
each,755,O
control,755,O
group,755,O
",",755,O
such,755,O
as,755,O
",",755,O
AMNS,755,B-Chemical
alone,755,O
",",755,O
PS,755,B-Chemical
alone,755,O
or,755,O
saline,755,O
injected,755,O
.,755,O
Their,756,O
glomeruli,756,O
showed,756,O
changes,756,O
of,756,O
progressive,756,O
FSGS,756,B-Disease
.,756,O
The,757,O
ultrastructural,757,O
studies,757,O
in,757,O
the,757,O
initial,757,O
stage,757,O
revealed,757,O
significant,757,O
lack,757,O
of,757,O
particles,757,O
of,757,O
perfused,757,O
ruthenium,757,B-Chemical
red,757,O
on,757,O
the,757,O
lamina,757,O
rara,757,O
externa,757,O
and,757,O
marked,757,O
changes,757,O
in,757,O
epithelial,757,O
cell,757,O
cytoplasm,757,O
.,757,O
Therefore,758,O
",",758,O
it,758,O
is,758,O
suggested,758,O
that,758,O
the,758,O
administration,758,O
of,758,O
PS,758,B-Chemical
enhances,758,O
the,758,O
toxicity,758,B-Disease
of,758,O
AMNS,758,B-Chemical
on,758,O
the,758,O
glomerulus,758,O
and,758,O
readily,758,O
produces,758,O
progressive,758,O
FSGS,758,B-Disease
in,758,O
rats,758,O
resulting,758,O
in,758,O
the,758,O
end-stage,758,B-Disease
renal,758,I-Disease
disease,758,I-Disease
.,758,O
Theophylline,759,B-Chemical
neurotoxicity,759,B-Disease
in,759,O
pregnant,759,O
rats,759,O
.,759,O
The,760,O
purpose,760,O
of,760,O
this,760,O
investigation,760,O
was,760,O
to,760,O
determine,760,O
whether,760,O
the,760,O
neurotoxicity,760,B-Disease
of,760,O
theophylline,760,B-Chemical
is,760,O
altered,760,O
in,760,O
advanced,760,O
pregnancy,760,O
.,760,O
Sprague-Dawley,761,O
rats,761,O
that,761,O
were,761,O
20,761,O
days,761,O
pregnant,761,O
and,761,O
nonpregnant,761,O
rats,761,O
of,761,O
the,761,O
same,761,O
age,761,O
and,761,O
strain,761,O
received,761,O
infusions,761,O
of,761,O
aminophylline,761,B-Chemical
until,761,O
onset,761,O
of,761,O
maximal,761,O
seizures,761,B-Disease
which,761,O
occurred,761,O
after,761,O
28,761,O
and,761,O
30,761,O
minutes,761,O
respectively,761,O
.,761,O
Theophylline,762,B-Chemical
concentrations,762,O
at,762,O
this,762,O
endpoint,762,O
in,762,O
serum,762,O
(,762,O
total,762,O
),762,O
and,762,O
CSF,762,O
were,762,O
similar,762,O
but,762,O
serum,762,O
(,762,O
free,762,O
),762,O
and,762,O
brain,762,O
concentrations,762,O
were,762,O
slightly,762,O
different,762,O
in,762,O
pregnant,762,O
rats,762,O
.,762,O
Theophylline,763,B-Chemical
serum,763,O
protein,763,O
binding,763,O
determined,763,O
by,763,O
equilibrium,763,O
dialysis,763,O
was,763,O
lower,763,O
in,763,O
pregnant,763,O
rats,763,O
.,763,O
Fetal,764,O
serum,764,O
concentrations,764,O
at,764,O
onset,764,O
of,764,O
seizures,764,B-Disease
in,764,O
the,764,O
mother,764,O
were,764,O
similar,764,O
to,764,O
maternal,764,O
brain,764,O
and,764,O
CSF,764,O
concentrations,764,O
and,764,O
correlated,764,O
significantly,764,O
with,764,O
the,764,O
former,764,O
.,764,O
It,765,O
is,765,O
concluded,765,O
that,765,O
advanced,765,O
pregnancy,765,O
has,765,O
a,765,O
negligible,765,O
effect,765,O
on,765,O
the,765,O
neurotoxic,765,B-Disease
response,765,O
to,765,O
theophylline,765,B-Chemical
in,765,O
rats,765,O
.,765,O
Hyperkalemia,766,B-Disease
induced,766,O
by,766,O
indomethacin,766,B-Chemical
and,766,O
naproxen,766,B-Chemical
and,766,O
reversed,766,O
by,766,O
fludrocortisone,766,B-Chemical
.,766,O
We,767,O
have,767,O
described,767,O
a,767,O
patient,767,O
with,767,O
severe,767,O
rheumatoid,767,B-Disease
arthritis,767,I-Disease
and,767,O
a,767,O
history,767,O
of,767,O
mefenamic,767,B-Chemical
acid,767,I-Chemical
nephropathy,767,B-Disease
in,767,O
whom,767,O
hyperkalemia,767,B-Disease
and,767,O
inappropriate,767,O
hypoaldosteronism,767,B-Disease
were,767,O
caused,767,O
by,767,O
both,767,O
indomethacin,767,B-Chemical
and,767,O
naproxen,767,B-Chemical
",",767,O
without,767,O
major,767,O
decline,767,O
in,767,O
renal,767,O
function,767,O
.,767,O
It,768,O
is,768,O
likely,768,O
that,768,O
preexisting,768,O
renal,768,B-Disease
disease,768,I-Disease
predisposed,768,O
this,768,O
patient,768,O
to,768,O
type,768,B-Disease
IV,768,I-Disease
renal,768,I-Disease
tubular,768,I-Disease
acidosis,768,I-Disease
with,768,O
prostaglandin,768,B-Chemical
synthetase,768,O
inhibitors,768,O
.,768,O
Because,769,O
he,769,O
was,769,O
unable,769,O
to,769,O
discontinue,769,O
nonsteroidal,769,O
anti-inflammatory,769,O
drug,769,O
therapy,769,O
",",769,O
fludrocortisone,769,B-Chemical
was,769,O
added,769,O
",",769,O
correcting,769,O
the,769,O
hyperkalemia,769,B-Disease
and,769,O
allowing,769,O
indomethacin,769,B-Chemical
therapy,769,O
to,769,O
be,769,O
continued,769,O
safely,769,O
.,769,O
Hypotension,770,B-Disease
as,770,O
a,770,O
manifestation,770,O
of,770,O
cardiotoxicity,770,B-Disease
in,770,O
three,770,O
patients,770,O
receiving,770,O
cisplatin,770,B-Chemical
and,770,O
5-fluorouracil,770,B-Chemical
.,770,O
Cardiac,771,O
symptoms,771,O
",",771,O
including,771,O
hypotension,771,B-Disease
",",771,O
developed,771,O
in,771,O
three,771,O
patients,771,O
with,771,O
advanced,771,O
colorectal,771,B-Disease
carcinoma,771,I-Disease
while,771,O
being,771,O
treated,771,O
with,771,O
cisplatin,771,B-Chemical
(,771,O
CDDP,771,B-Chemical
),771,O
and,771,O
5-fluorouracil,771,B-Chemical
(,771,O
5-FU,771,B-Chemical
),771,O
.,771,O
In,772,O
two,772,O
patients,772,O
",",772,O
hypotension,772,B-Disease
was,772,O
associated,772,O
with,772,O
severe,772,O
left,772,B-Disease
ventricular,772,I-Disease
dysfunction,772,I-Disease
.,772,O
All,773,O
three,773,O
patients,773,O
required,773,O
therapy,773,O
discontinuation,773,O
.,773,O
Cardiac,774,O
enzymes,774,O
remained,774,O
normal,774,O
despite,774,O
transient,774,O
electrocardiographic,774,O
(,774,O
EKG,774,O
),774,O
changes,774,O
.,774,O
The,775,O
presentation,775,O
and,775,O
cardiac,775,O
evaluation,775,O
(,775,O
hemodynamic,775,O
",",775,O
echocardiographic,775,O
",",775,O
and,775,O
scintigraphic,775,O
),775,O
of,775,O
these,775,O
patients,775,O
suggest,775,O
new,775,O
manifestations,775,O
of,775,O
5-FU,775,B-Chemical
cardiotoxicity,775,B-Disease
that,775,O
may,775,O
be,775,O
influenced,775,O
by,775,O
CDDP,775,B-Chemical
.,775,O
The,776,O
possible,776,O
pathophysiologic,776,O
mechanisms,776,O
are,776,O
discussed,776,O
.,776,O
Fatal,777,O
aplastic,777,B-Disease
anemia,777,I-Disease
in,777,O
a,777,O
patient,777,O
treated,777,O
with,777,O
carbamazepine,777,B-Chemical
.,777,O
A,778,O
case,778,O
of,778,O
fatal,778,O
aplastic,778,B-Disease
anemia,778,I-Disease
due,778,O
to,778,O
carbamazepine,778,B-Chemical
treatment,778,O
in,778,O
an,778,O
epileptic,778,B-Disease
woman,778,O
is,778,O
reported,778,O
.,778,O
Despite,779,O
concerns,779,O
of,779,O
fatal,779,O
bone,779,B-Disease
marrow,779,I-Disease
toxicity,779,I-Disease
due,779,O
to,779,O
carbamazepine,779,B-Chemical
",",779,O
this,779,O
is,779,O
only,779,O
the,779,O
fourth,779,O
documented,779,O
and,779,O
published,779,O
report,779,O
.,779,O
Carbamazepine,780,B-Chemical
is,780,O
a,780,O
safe,780,O
drug,780,O
",",780,O
but,780,O
physicians,780,O
and,780,O
patients,780,O
should,780,O
be,780,O
aware,780,O
of,780,O
the,780,O
exceedingly,780,O
rare,780,O
but,780,O
potentially,780,O
fatal,780,O
side,780,O
effects,780,O
",",780,O
better,780,O
prevented,780,O
by,780,O
clinical,780,O
than,780,O
by,780,O
laboratory,780,O
monitoring,780,O
.,780,O
Participation,781,O
of,781,O
a,781,O
bulbospinal,781,O
serotonergic,781,O
pathway,781,O
in,781,O
the,781,O
rat,781,O
brain,781,O
in,781,O
clonidine-induced,781,B-Chemical
hypotension,781,B-Disease
and,781,O
bradycardia,781,B-Disease
.,781,O
The,782,O
effects,782,O
of,782,O
microinjection,782,O
of,782,O
clonidine,782,B-Chemical
(,782,O
1-10,782,O
micrograms,782,O
in,782,O
1,782,O
microliter,782,O
),782,O
into,782,O
a,782,O
region,782,O
adjacent,782,O
to,782,O
the,782,O
ventrolateral,782,O
surface,782,O
of,782,O
the,782,O
medulla,782,O
oblongata,782,O
on,782,O
cardiovascular,782,O
function,782,O
were,782,O
assessed,782,O
in,782,O
urethane-anesthetized,782,B-Chemical
rats,782,O
.,782,O
Intramedullary,783,O
administration,783,O
of,783,O
clonidine,783,B-Chemical
",",783,O
but,783,O
not,783,O
saline,783,O
vehicle,783,O
",",783,O
caused,783,O
a,783,O
dose-dependent,783,O
decrease,783,O
in,783,O
both,783,O
the,783,O
mean,783,O
arterial,783,O
pressure,783,O
and,783,O
the,783,O
heart,783,O
rate,783,O
.,783,O
The,784,O
clonidine-induced,784,B-Chemical
hypotension,784,B-Disease
was,784,O
antagonized,784,O
by,784,O
prior,784,O
spinal,784,O
transection,784,O
",",784,O
but,784,O
not,784,O
bilateral,784,O
vagotomy,784,O
.,784,O
On,785,O
the,785,O
other,785,O
hand,785,O
",",785,O
the,785,O
clonidine-induced,785,B-Chemical
bradycardia,785,B-Disease
was,785,O
antagonized,785,O
by,785,O
prior,785,O
bilateral,785,O
vagotomy,785,O
",",785,O
but,785,O
not,785,O
spinal,785,O
transection,785,O
.,785,O
Furthermore,786,O
",",786,O
selective,786,O
destruction,786,O
of,786,O
the,786,O
spinal,786,O
5-HT,786,B-Chemical
nerves,786,O
",",786,O
produced,786,O
by,786,O
bilateral,786,O
spinal,786,O
injection,786,O
of,786,O
"5,7-dihydroxytryptamine",786,B-Chemical
",",786,O
reduced,786,O
the,786,O
magnitude,786,O
of,786,O
the,786,O
vasodepressor,786,O
or,786,O
the,786,O
bradycardiac,786,B-Disease
responses,786,O
to,786,O
clonidine,786,B-Chemical
microinjected,786,O
into,786,O
the,786,O
area,786,O
near,786,O
the,786,O
ventrolateral,786,O
surface,786,O
of,786,O
the,786,O
medulla,786,O
oblongata,786,O
in,786,O
rats,786,O
.,786,O
The,787,O
data,787,O
indicate,787,O
that,787,O
a,787,O
bulbospinal,787,O
serotonergic,787,O
pathway,787,O
is,787,O
involved,787,O
in,787,O
development,787,O
of,787,O
clonidine-induced,787,B-Chemical
hypotension,787,B-Disease
and,787,O
bradycardia,787,B-Disease
.,787,O
The,788,O
induced,788,O
hypotension,788,B-Disease
is,788,O
brought,788,O
about,788,O
by,788,O
a,788,O
decrease,788,O
in,788,O
sympathetic,788,O
efferent,788,O
activity,788,O
",",788,O
whereas,788,O
the,788,O
induced,788,O
bradycardia,788,B-Disease
was,788,O
due,788,O
to,788,O
an,788,O
increase,788,O
in,788,O
vagal,788,O
efferent,788,O
activity,788,O
.,788,O
Hypertension,789,B-Disease
in,789,O
neuroblastoma,789,B-Disease
induced,789,O
by,789,O
imipramine,789,B-Chemical
.,789,O
Hypertension,790,B-Disease
is,790,O
a,790,O
well-known,790,O
finding,790,O
in,790,O
some,790,O
patients,790,O
with,790,O
neuroblastoma,790,B-Disease
.,790,O
However,791,O
",",791,O
it,791,O
has,791,O
not,791,O
previously,791,O
been,791,O
described,791,O
in,791,O
association,791,O
with,791,O
the,791,O
use,791,O
of,791,O
Imipramine,791,B-Chemical
.,791,O
We,792,O
report,792,O
the,792,O
occurrence,792,O
of,792,O
severe,792,O
hypertension,792,B-Disease
(,792,O
blood,792,O
pressure,792,O
190/160,792,O
),792,O
in,792,O
a,792,O
4-year-old,792,O
girl,792,O
with,792,O
neuroblastoma,792,B-Disease
who,792,O
was,792,O
given,792,O
Imipramine,792,B-Chemical
to,792,O
control,792,O
a,792,O
behavior,792,B-Disease
disorder,792,I-Disease
.,792,O
It,793,O
was,793,O
determined,793,O
later,793,O
that,793,O
this,793,O
patient,793,O
's,793,O
tumor,793,B-Disease
was,793,O
recurring,793,O
at,793,O
the,793,O
time,793,O
of,793,O
her,793,O
hypertensive,793,B-Disease
episode,793,O
.,793,O
Since,794,O
she,794,O
had,794,O
no,794,O
blood,794,O
pressure,794,O
elevation,794,O
at,794,O
initial,794,O
diagnosis,794,O
and,794,O
none,794,O
following,794,O
discontinuation,794,O
of,794,O
the,794,O
Imipramine,794,B-Chemical
(,794,O
when,794,O
she,794,O
was,794,O
in,794,O
florid,794,O
relapse,794,O
),794,O
",",794,O
we,794,O
believe,794,O
that,794,O
this,794,O
drug,794,O
rather,794,O
than,794,O
her,794,O
underlying,794,O
disease,794,O
alone,794,O
caused,794,O
her,794,O
hypertension,794,B-Disease
.,794,O
The,795,O
mechanism,795,O
for,795,O
this,795,O
reaction,795,O
is,795,O
believed,795,O
to,795,O
be,795,O
increased,795,O
levels,795,O
of,795,O
vasoactive,795,O
catecholamines,795,B-Chemical
due,795,O
to,795,O
interference,795,O
of,795,O
their,795,O
physiologic,795,O
inactivation,795,O
by,795,O
Imipramine,795,B-Chemical
.,795,O
From,796,O
this,796,O
experience,796,O
",",796,O
we,796,O
urge,796,O
extreme,796,O
caution,796,O
in,796,O
the,796,O
use,796,O
of,796,O
tricyclic,796,O
antidepressants,796,O
in,796,O
children,796,O
with,796,O
active,796,O
neuroblastoma,796,B-Disease
.,796,O
Rechallenge,797,O
of,797,O
patients,797,O
who,797,O
developed,797,O
oral,797,B-Disease
candidiasis,797,I-Disease
or,797,O
hoarseness,797,B-Disease
with,797,O
beclomethasone,797,B-Chemical
dipropionate,797,I-Chemical
.,797,O
Of,798,O
158,798,O
asthmatic,798,B-Disease
patients,798,O
who,798,O
were,798,O
placed,798,O
on,798,O
inhaled,798,O
beclomethasone,798,B-Chemical
",",798,O
15,798,O
(,798,O
9.5,798,O
%,798,O
),798,O
developed,798,O
either,798,O
hoarseness,798,B-Disease
(,798,O
8,798,O
),798,O
",",798,O
oral,798,O
thrush,798,B-Disease
(,798,O
6,798,O
),798,O
",",798,O
or,798,O
both,798,O
(,798,O
1,798,O
),798,O
.,798,O
When,799,O
their,799,O
adverse,799,O
reactions,799,O
subsided,799,O
",",799,O
seven,799,O
of,799,O
these,799,O
15,799,O
patients,799,O
were,799,O
rechallenged,799,O
with,799,O
inhaled,799,O
beclomethasone,799,B-Chemical
.,799,O
These,800,O
included,800,O
five,800,O
cases,800,O
who,800,O
developed,800,O
hoarseness,800,B-Disease
and,800,O
three,800,O
who,800,O
developed,800,O
Candidiasis,800,B-Disease
.,800,O
One,801,O
patient,801,O
had,801,O
both,801,O
.,801,O
Oral,802,O
thrush,802,B-Disease
did,802,O
not,802,O
recur,802,O
",",802,O
but,802,O
60,802,O
%,802,O
(,802,O
3/5,802,O
),802,O
of,802,O
patients,802,O
with,802,O
hoarseness,802,B-Disease
had,802,O
recurrence,802,O
.,802,O
We,803,O
conclude,803,O
that,803,O
patients,803,O
may,803,O
be,803,O
restarted,803,O
on,803,O
inhaled,803,O
beclomethasone,803,B-Chemical
when,803,O
clinically,803,O
indicated,803,O
;,803,O
however,803,O
",",803,O
because,803,O
of,803,O
the,803,O
high,803,O
recurrence,803,O
rate,803,O
",",803,O
patients,803,O
who,803,O
develop,803,O
hoarseness,803,B-Disease
should,803,O
not,803,O
be,803,O
re-challenged,803,O
.,803,O
Concomitant,804,O
use,804,O
of,804,O
oral,804,O
prednisone,804,B-Chemical
and,804,O
topical,804,O
beclomethasone,804,B-Chemical
may,804,O
increase,804,O
the,804,O
risk,804,O
of,804,O
developing,804,O
hoarseness,804,B-Disease
or,804,O
candidiasis,804,B-Disease
.,804,O
Cyclophosphamide,805,B-Chemical
cardiotoxicity,805,B-Disease
:,805,O
an,805,O
analysis,805,O
of,805,O
dosing,805,O
as,805,O
a,805,O
risk,805,O
factor,805,O
.,805,O
Patients,806,O
who,806,O
undergo,806,O
bone,806,O
marrow,806,O
transplantation,806,O
are,806,O
generally,806,O
immunosuppressed,806,O
with,806,O
a,806,O
dose,806,O
of,806,O
cyclophosphamide,806,B-Chemical
(,806,O
CYA,806,B-Chemical
),806,O
which,806,O
is,806,O
usually,806,O
calculated,806,O
based,806,O
on,806,O
the,806,O
patient,806,O
's,806,O
weight,806,O
.,806,O
At,807,O
these,807,O
high,807,O
doses,807,O
of,807,O
CYA,807,B-Chemical
",",807,O
serious,807,O
cardiotoxicity,807,B-Disease
may,807,O
occur,807,O
",",807,O
but,807,O
definitive,807,O
risk,807,O
factors,807,O
for,807,O
the,807,O
development,807,O
of,807,O
such,807,O
cardiotoxicity,807,B-Disease
have,807,O
not,807,O
been,807,O
described,807,O
.,807,O
Since,808,O
chemotherapeutic,808,O
agent,808,O
toxicity,808,B-Disease
generally,808,O
correlates,808,O
with,808,O
dose,808,O
per,808,O
body,808,O
surface,808,O
area,808,O
",",808,O
we,808,O
retrospectively,808,O
calculated,808,O
the,808,O
dose,808,O
of,808,O
CYA,808,B-Chemical
in,808,O
patients,808,O
transplanted,808,O
at,808,O
our,808,O
institution,808,O
to,808,O
determine,808,O
whether,808,O
the,808,O
incidence,808,O
of,808,O
CYA,808,B-Chemical
cardiotoxicity,808,B-Disease
correlated,808,O
with,808,O
the,808,O
dose,808,O
per,808,O
body,808,O
surface,808,O
area,808,O
.,808,O
Eighty,809,O
patients,809,O
who,809,O
were,809,O
to,809,O
receive,809,O
CYA,809,B-Chemical
50,809,O
mg/kg/d,809,O
for,809,O
four,809,O
days,809,O
as,809,O
preparation,809,O
for,809,O
marrow,809,O
grafting,809,O
underwent,809,O
a,809,O
total,809,O
of,809,O
84,809,O
transplants,809,O
for,809,O
aplastic,809,B-Disease
anemia,809,I-Disease
",",809,O
Wiskott-Aldrich,809,B-Disease
syndrome,809,I-Disease
",",809,O
or,809,O
severe,809,B-Disease
combined,809,I-Disease
immunodeficiency,809,I-Disease
syndrome,809,I-Disease
.,809,O
Fourteen,810,O
of,810,O
84,810,O
(,810,O
17,810,O
%,810,O
),810,O
patients,810,O
had,810,O
symptoms,810,O
and,810,O
signs,810,O
consistent,810,O
with,810,O
CYA,810,B-Chemical
cardiotoxicity,810,B-Disease
within,810,O
ten,810,O
days,810,O
of,810,O
receiving,810,O
1,810,O
to,810,O
4,810,O
doses,810,O
of,810,O
CYA,810,B-Chemical
.,810,O
Six,811,O
of,811,O
the,811,O
14,811,O
patients,811,O
died,811,O
with,811,O
congestive,811,B-Disease
heart,811,I-Disease
failure,811,I-Disease
.,811,O
The,812,O
dose,812,O
of,812,O
CYA,812,B-Chemical
per,812,O
body,812,O
surface,812,O
area,812,O
was,812,O
calculated,812,O
for,812,O
all,812,O
patients,812,O
and,812,O
the,812,O
patients,812,O
were,812,O
divided,812,O
into,812,O
two,812,O
groups,812,O
based,812,O
on,812,O
daily,812,O
CYA,812,B-Chemical
dose,812,O
:,812,O
Group,812,O
1,812,O
",",812,O
CYA,812,B-Chemical
less,812,O
than,812,O
or,812,O
equal,812,O
to,812,O
1.55,812,O
g/m2/d,812,O
;,812,O
Group,812,O
2,812,O
",",812,O
CYA,812,B-Chemical
greater,812,O
than,812,O
1.55,812,O
g/m2/d,812,O
.,812,O
Cardiotoxicity,813,B-Disease
that,813,O
was,813,O
thought,813,O
to,813,O
be,813,O
related,813,O
to,813,O
CYA,813,B-Chemical
occurred,813,O
in,813,O
1/32,813,O
(,813,O
3,813,O
%,813,O
),813,O
of,813,O
patients,813,O
in,813,O
Group,813,O
1,813,O
and,813,O
in,813,O
13/52,813,O
(,813,O
25,813,O
%,813,O
),813,O
patients,813,O
in,813,O
Group,813,O
2,813,O
(,813,O
P,813,O
less,813,O
than,813,O
0.025,813,O
),813,O
.,813,O
Congestive,814,B-Disease
heart,814,I-Disease
failure,814,I-Disease
caused,814,O
or,814,O
contributed,814,O
to,814,O
death,814,O
in,814,O
0/32,814,O
patients,814,O
in,814,O
Group,814,O
1,814,O
v,814,O
6/52,814,O
(,814,O
12,814,O
%,814,O
),814,O
of,814,O
patients,814,O
in,814,O
Group,814,O
2,814,O
(,814,O
P,814,O
less,814,O
than,814,O
0.25,814,O
),814,O
.,814,O
There,815,O
was,815,O
no,815,O
difference,815,O
in,815,O
the,815,O
rate,815,O
of,815,O
engraftment,815,O
of,815,O
evaluable,815,O
patients,815,O
in,815,O
the,815,O
two,815,O
groups,815,O
(,815,O
P,815,O
greater,815,O
than,815,O
0.5,815,O
),815,O
.,815,O
We,816,O
conclude,816,O
that,816,O
the,816,O
CYA,816,B-Chemical
cardiotoxicity,816,B-Disease
correlates,816,O
with,816,O
CYA,816,B-Chemical
dosage,816,O
as,816,O
calculated,816,O
by,816,O
body,816,O
surface,816,O
area,816,O
",",816,O
and,816,O
that,816,O
patients,816,O
with,816,O
aplastic,816,B-Disease
anemia,816,I-Disease
and,816,O
immunodeficiencies,816,B-Disease
can,816,O
be,816,O
effectively,816,O
prepared,816,O
for,816,O
bone,816,O
marrow,816,O
grafting,816,O
at,816,O
a,816,O
CYA,816,B-Chemical
dose,816,O
of,816,O
1.55,816,O
g/m2/d,816,O
for,816,O
four,816,O
days,816,O
with,816,O
a,816,O
lower,816,O
incidence,816,O
of,816,O
cardiotoxicity,816,B-Disease
than,816,O
patients,816,O
whose,816,O
CYA,816,B-Chemical
dosage,816,O
is,816,O
calculated,816,O
based,816,O
on,816,O
weight,816,O
.,816,O
This,817,O
study,817,O
reaffirms,817,O
the,817,O
principle,817,O
that,817,O
drug,817,O
toxicity,817,B-Disease
correlates,817,O
with,817,O
dose,817,O
per,817,O
body,817,O
surface,817,O
area,817,O
.,817,O
Studies,818,O
of,818,O
risk,818,O
factors,818,O
for,818,O
aminoglycoside,818,B-Chemical
nephrotoxicity,818,B-Disease
.,818,O
The,819,O
epidemiology,819,O
of,819,O
aminoglycoside-induced,819,B-Chemical
nephrotoxicity,819,B-Disease
is,819,O
not,819,O
fully,819,O
understood,819,O
.,819,O
Experimental,820,O
studies,820,O
in,820,O
healthy,820,O
human,820,O
volunteers,820,O
indicate,820,O
aminoglycosides,820,B-Chemical
cause,820,O
proximal,820,O
tubular,820,O
damage,820,O
in,820,O
most,820,O
patients,820,O
",",820,O
but,820,O
rarely,820,O
",",820,O
if,820,O
ever,820,O
",",820,O
cause,820,O
glomerular,820,B-Disease
or,820,I-Disease
tubular,820,I-Disease
dysfunction,820,I-Disease
.,820,O
Clinical,821,O
trials,821,O
of,821,O
aminoglycosides,821,B-Chemical
in,821,O
seriously,821,O
ill,821,O
patients,821,O
indicate,821,O
that,821,O
the,821,O
relative,821,O
risk,821,O
for,821,O
developing,821,O
acute,821,B-Disease
renal,821,I-Disease
failure,821,I-Disease
during,821,O
therapy,821,O
ranges,821,O
from,821,O
8,821,O
to,821,O
10,821,O
and,821,O
that,821,O
the,821,O
attributable,821,O
risk,821,O
is,821,O
70,821,O
%,821,O
to,821,O
80,821,O
%,821,O
.,821,O
Further,822,O
analysis,822,O
of,822,O
these,822,O
data,822,O
suggests,822,O
that,822,O
the,822,O
duration,822,O
of,822,O
therapy,822,O
",",822,O
plasma,822,O
aminoglycoside,822,B-Chemical
levels,822,O
",",822,O
liver,822,B-Disease
disease,822,I-Disease
",",822,O
advanced,822,O
age,822,O
",",822,O
high,822,O
initial,822,O
estimated,822,O
creatinine,822,B-Chemical
clearance,822,O
and,822,O
",",822,O
possibly,822,O
",",822,O
female,822,O
gender,822,O
all,822,O
increase,822,O
the,822,O
risk,822,O
for,822,O
nephrotoxicity,822,B-Disease
.,822,O
Other,823,O
causes,823,O
of,823,O
acute,823,B-Disease
renal,823,I-Disease
failure,823,I-Disease
",",823,O
such,823,O
as,823,O
shock,823,B-Disease
",",823,O
appear,823,O
to,823,O
have,823,O
an,823,O
additive,823,O
effect,823,O
.,823,O
Predictive,824,O
models,824,O
have,824,O
been,824,O
developed,824,O
from,824,O
these,824,O
analyses,824,O
that,824,O
should,824,O
be,824,O
useful,824,O
for,824,O
identifying,824,O
patients,824,O
at,824,O
high,824,O
risk,824,O
.,824,O
These,825,O
models,825,O
may,825,O
also,825,O
be,825,O
useful,825,O
in,825,O
developing,825,O
insights,825,O
into,825,O
the,825,O
pathophysiology,825,O
of,825,O
aminoglycoside-induced,825,B-Chemical
nephrotoxicity,825,B-Disease
.,825,O
Flurothyl,826,B-Chemical
seizure,826,B-Disease
thresholds,826,O
in,826,O
mice,826,O
treated,826,O
neonatally,826,O
with,826,O
a,826,O
single,826,O
injection,826,O
of,826,O
monosodium,826,B-Chemical
glutamate,826,I-Chemical
(,826,O
MSG,826,B-Chemical
),826,O
:,826,O
evaluation,826,O
of,826,O
experimental,826,O
parameters,826,O
in,826,O
flurothyl,826,B-Chemical
seizure,826,B-Disease
testing,826,O
.,826,O
Monosodium,827,B-Chemical
glutamate,827,I-Chemical
(,827,O
MSG,827,B-Chemical
),827,O
administration,827,O
to,827,O
neonatal,827,O
rodents,827,O
produces,827,O
convulsions,827,B-Disease
and,827,O
results,827,O
in,827,O
numerous,827,O
biochemical,827,O
and,827,O
behavioral,827,O
deficits,827,O
.,827,O
These,828,O
studies,828,O
were,828,O
undertaken,828,O
to,828,O
determine,828,O
if,828,O
neonatal,828,O
administration,828,O
of,828,O
MSG,828,B-Chemical
produced,828,O
permanent,828,O
alterations,828,O
in,828,O
seizure,828,B-Disease
susceptibility,828,O
",",828,O
since,828,O
previous,828,O
investigations,828,O
were,828,O
inconclusive,828,O
.,828,O
A,829,O
flurothyl,829,B-Chemical
ether,829,B-Chemical
seizure,829,B-Disease
screening,829,O
technique,829,O
was,829,O
used,829,O
to,829,O
evaluate,829,O
seizure,829,B-Disease
susceptibility,829,O
in,829,O
adult,829,O
mice,829,O
that,829,O
received,829,O
neonatal,829,O
injections,829,O
of,829,O
MSG,829,B-Chemical
(,829,O
4,829,O
mg/g,829,O
and,829,O
1,829,O
mg/g,829,O
),829,O
.,829,O
MSG,830,B-Chemical
treatment,830,O
resulted,830,O
in,830,O
significant,830,O
reductions,830,O
in,830,O
whole,830,O
brain,830,O
weight,830,O
but,830,O
did,830,O
not,830,O
alter,830,O
seizure,830,B-Disease
threshold,830,O
.,830,O
A,831,O
naloxone,831,B-Chemical
(,831,O
5,831,O
mg/kg,831,O
),831,O
challenge,831,O
was,831,O
also,831,O
ineffective,831,O
in,831,O
altering,831,O
the,831,O
seizure,831,B-Disease
thresholds,831,O
of,831,O
either,831,O
control,831,O
of,831,O
MSG-treated,831,B-Chemical
mice,831,O
.,831,O
Flurothyl,832,B-Chemical
ether,832,B-Chemical
produced,832,O
hypothermia,832,B-Disease
which,832,O
was,832,O
correlated,832,O
with,832,O
the,832,O
duration,832,O
of,832,O
flurothyl,832,B-Chemical
exposure,832,O
;,832,O
however,832,O
",",832,O
the,832,O
relationship,832,O
of,832,O
hypothermia,832,B-Disease
to,832,O
seizure,832,B-Disease
induction,832,O
was,832,O
unclear,832,O
.,832,O
Flurothyl,833,B-Chemical
seizure,833,B-Disease
testing,833,O
proved,833,O
to,833,O
be,833,O
a,833,O
rapid,833,O
and,833,O
reliable,833,O
technique,833,O
with,833,O
which,833,O
to,833,O
evaluate,833,O
seizure,833,B-Disease
susceptibility,833,O
.,833,O
Susceptibility,834,O
to,834,O
seizures,834,B-Disease
produced,834,O
by,834,O
pilocarpine,834,B-Chemical
in,834,O
rats,834,O
after,834,O
microinjection,834,O
of,834,O
isoniazid,834,B-Chemical
or,834,O
gamma-vinyl-GABA,834,B-Chemical
into,834,O
the,834,O
substantia,834,O
nigra,834,O
.,834,O
Pilocarpine,835,B-Chemical
",",835,O
given,835,O
intraperitoneally,835,O
to,835,O
rats,835,O
",",835,O
reproduces,835,O
the,835,O
neuropathological,835,O
sequelae,835,O
of,835,O
temporal,835,B-Disease
lobe,835,I-Disease
epilepsy,835,I-Disease
and,835,O
provides,835,O
a,835,O
relevant,835,O
animal,835,O
model,835,O
for,835,O
studying,835,O
mechanisms,835,O
of,835,O
buildup,835,O
of,835,O
convulsive,835,B-Disease
activity,835,O
and,835,O
pathways,835,O
operative,835,O
in,835,O
the,835,O
generalization,835,O
and,835,O
propagation,835,O
of,835,O
seizures,835,B-Disease
within,835,O
the,835,O
forebrain,835,O
.,835,O
In,836,O
the,836,O
present,836,O
study,836,O
",",836,O
the,836,O
effects,836,O
of,836,O
manipulating,836,O
the,836,O
activity,836,O
of,836,O
the,836,O
gamma-aminobutyric,836,B-Chemical
acid,836,I-Chemical
(,836,O
GABA,836,B-Chemical
),836,O
-mediated,836,O
synaptic,836,O
inhibition,836,O
within,836,O
the,836,O
substantia,836,O
nigra,836,O
on,836,O
seizures,836,B-Disease
produced,836,O
by,836,O
pilocarpine,836,B-Chemical
in,836,O
rats,836,O
",",836,O
were,836,O
investigated,836,O
.,836,O
In,837,O
animals,837,O
pretreated,837,O
with,837,O
microinjections,837,O
of,837,O
isoniazid,837,B-Chemical
",",837,O
150,837,O
micrograms,837,O
",",837,O
an,837,O
inhibitor,837,O
of,837,O
activity,837,O
of,837,O
the,837,O
GABA-synthesizing,837,B-Chemical
enzyme,837,O
",",837,O
L-glutamic,837,B-Chemical
acid,837,I-Chemical
decarboxylase,837,O
",",837,O
into,837,O
the,837,O
substantia,837,O
nigra,837,O
pars,837,O
reticulata,837,O
(,837,O
SNR,837,O
),837,O
",",837,O
bilaterally,837,O
",",837,O
non-convulsant,837,O
doses,837,O
of,837,O
pilocarpine,837,B-Chemical
",",837,O
100,837,O
and,837,O
200,837,O
mg/kg,837,O
",",837,O
resulted,837,O
in,837,O
severe,837,O
motor,837,O
limbic,837,O
seizures,837,B-Disease
and,837,O
status,837,B-Disease
epilepticus,837,I-Disease
.,837,O
Electroencephalographic,838,O
and,838,O
behavioral,838,O
monitoring,838,O
revealed,838,O
a,838,O
profound,838,O
reduction,838,O
of,838,O
the,838,O
threshold,838,O
for,838,O
pilocarpine-induced,838,B-Chemical
convulsions,838,B-Disease
.,838,O
Morphological,839,O
analysis,839,O
of,839,O
frontal,839,O
forebrain,839,O
sections,839,O
with,839,O
light,839,O
microscopy,839,O
revealed,839,O
seizure-related,839,B-Disease
damage,839,O
to,839,O
the,839,O
hippocampal,839,O
formation,839,O
",",839,O
thalamus,839,O
",",839,O
amygdala,839,O
",",839,O
olfactory,839,O
cortex,839,O
",",839,O
substantia,839,O
nigra,839,O
and,839,O
neocortex,839,O
",",839,O
which,839,O
is,839,O
typically,839,O
observed,839,O
with,839,O
pilocarpine,839,B-Chemical
in,839,O
doses,839,O
exceeding,839,O
350,839,O
mg/kg,839,O
.,839,O
Bilateral,840,O
intrastriatal,840,O
injections,840,O
of,840,O
isoniazid,840,B-Chemical
did,840,O
not,840,O
augment,840,O
seizures,840,B-Disease
produced,840,O
by,840,O
pilocarpine,840,B-Chemical
",",840,O
200,840,O
mg/kg,840,O
.,840,O
Application,841,O
of,841,O
an,841,O
irreversible,841,O
inhibitor,841,O
of,841,O
GABA,841,B-Chemical
transaminase,841,O
",",841,O
gamma-vinyl-GABA,841,B-Chemical
(,841,O
D,841,B-Chemical
",",841,I-Chemical
L-4-amino-hex-5-enoic,841,I-Chemical
acid,841,I-Chemical
),841,O
",",841,O
5,841,O
micrograms,841,O
",",841,O
into,841,O
the,841,O
SNR,841,O
",",841,O
bilaterally,841,O
",",841,O
suppressed,841,O
the,841,O
appearance,841,O
of,841,O
electrographic,841,O
and,841,O
behavioral,841,O
seizures,841,B-Disease
produced,841,O
by,841,O
pilocarpine,841,B-Chemical
",",841,O
380,841,O
mg/kg,841,O
.,841,O
This,842,O
treatment,842,O
was,842,O
also,842,O
sufficient,842,O
to,842,O
protect,842,O
animals,842,O
from,842,O
the,842,O
occurrence,842,O
of,842,O
brain,842,B-Disease
damage,842,I-Disease
.,842,O
Microinjections,843,O
of,843,O
gamma-vinyl-GABA,843,B-Chemical
",",843,O
5,843,O
micrograms,843,O
",",843,O
into,843,O
the,843,O
dorsal,843,O
striatum,843,O
",",843,O
bilaterally,843,O
",",843,O
failed,843,O
to,843,O
prevent,843,O
the,843,O
development,843,O
of,843,O
convulsions,843,B-Disease
produced,843,O
by,843,O
pilocarpine,843,B-Chemical
",",843,O
380,843,O
mg/kg,843,O
.,843,O
The,844,O
results,844,O
demonstrate,844,O
that,844,O
the,844,O
threshold,844,O
for,844,O
pilocarpine-induced,844,B-Chemical
seizures,844,B-Disease
in,844,O
rats,844,O
is,844,O
subjected,844,O
to,844,O
the,844,O
regulation,844,O
of,844,O
the,844,O
GABA-mediated,844,B-Chemical
synaptic,844,O
inhibition,844,O
within,844,O
the,844,O
substantia,844,O
nigra,844,O
.,844,O
Human,845,O
and,845,O
canine,845,O
ventricular,845,O
vasoactive,845,O
intestinal,845,O
polypeptide,845,O
:,845,O
decrease,845,O
with,845,O
heart,845,B-Disease
failure,845,I-Disease
.,845,O
Vasoactive,846,O
intestinal,846,O
polypeptide,846,O
(,846,O
VIP,846,O
),846,O
is,846,O
a,846,O
systemic,846,O
and,846,O
coronary,846,O
vasodilator,846,O
that,846,O
may,846,O
have,846,O
positive,846,O
inotropic,846,O
properties,846,O
.,846,O
Myocardial,847,O
levels,847,O
of,847,O
VIP,847,O
were,847,O
assayed,847,O
before,847,O
and,847,O
after,847,O
the,847,O
development,847,O
of,847,O
heart,847,B-Disease
failure,847,I-Disease
in,847,O
two,847,O
canine,847,O
models,847,O
.,847,O
In,848,O
the,848,O
first,848,O
",",848,O
cobalt,848,B-Chemical
cardiomyopathy,848,B-Disease
was,848,O
induced,848,O
in,848,O
eight,848,O
dogs,848,O
;,848,O
VIP,848,O
(,848,O
by,848,O
radioimmunoassay,848,O
),848,O
decreased,848,O
from,848,O
35,848,O
+/-,848,O
11,848,O
pg/mg,848,O
protein,848,O
(,848,O
mean,848,O
+/-,848,O
SD,848,O
),848,O
to,848,O
5,848,O
+/-,848,O
4,848,O
pg/mg,848,O
protein,848,O
(,848,O
P,848,O
less,848,O
than,848,O
0.05,848,O
),848,O
.,848,O
In,849,O
six,849,O
dogs,849,O
with,849,O
doxorubicin-induced,849,B-Chemical
heart,849,B-Disease
failure,849,I-Disease
",",849,O
VIP,849,O
decreased,849,O
from,849,O
31,849,O
+/-,849,O
7,849,O
to,849,O
11,849,O
+/-,849,O
4,849,O
pg/mg,849,O
protein,849,O
(,849,O
P,849,O
less,849,O
than,849,O
0.05,849,O
),849,O
.,849,O
In,850,O
addition,850,O
",",850,O
VIP,850,O
content,850,O
of,850,O
left,850,O
ventricular,850,O
muscle,850,O
of,850,O
resected,850,O
failing,850,O
hearts,850,O
in,850,O
10,850,O
patients,850,O
receiving,850,O
a,850,O
heart,850,O
transplant,850,O
was,850,O
compared,850,O
with,850,O
the,850,O
papillary,850,O
muscles,850,O
in,850,O
14,850,O
patients,850,O
(,850,O
five,850,O
with,850,O
rheumatic,850,B-Disease
disease,850,I-Disease
",",850,O
nine,850,O
with,850,O
myxomatous,850,B-Disease
degeneration,850,I-Disease
),850,O
receiving,850,O
mitral,850,O
valve,850,O
prostheses,850,O
.,850,O
The,851,O
lowest,851,O
myocardial,851,O
VIP,851,O
concentration,851,O
was,851,O
found,851,O
in,851,O
the,851,O
hearts,851,O
of,851,O
patients,851,O
with,851,O
coronary,851,B-Disease
disease,851,I-Disease
(,851,O
one,851,O
patient,851,O
receiving,851,O
a,851,O
transplant,851,O
and,851,O
three,851,O
receiving,851,O
mitral,851,O
prostheses,851,O
),851,O
(,851,O
6.3,851,O
+/-,851,O
1.9,851,O
pg/mg,851,O
protein,851,O
),851,O
.,851,O
The,852,O
other,852,O
patients,852,O
undergoing,852,O
transplantation,852,O
had,852,O
an,852,O
average,852,O
ejection,852,O
fraction,852,O
of,852,O
17,852,O
%,852,O
+/-,852,O
6,852,O
%,852,O
and,852,O
a,852,O
VIP,852,O
level,852,O
of,852,O
8.8,852,O
+/-,852,O
3.9,852,O
pg/mg,852,O
protein,852,O
.,852,O
The,853,O
hearts,853,O
without,853,O
coronary,853,B-Disease
artery,853,I-Disease
disease,853,I-Disease
(,853,O
average,853,O
ejection,853,O
fraction,853,O
of,853,O
this,853,O
group,853,O
62,853,O
%,853,O
+/-,853,O
10,853,O
%,853,O
),853,O
had,853,O
a,853,O
VIP,853,O
concentration,853,O
of,853,O
14.1,853,O
+/-,853,O
7.9,853,O
pg/mg,853,O
protein,853,O
",",853,O
and,853,O
this,853,O
was,853,O
greater,853,O
than,853,O
in,853,O
hearts,853,O
of,853,O
the,853,O
patients,853,O
with,853,O
coronary,853,B-Disease
disease,853,I-Disease
and,853,O
the,853,O
hearts,853,O
of,853,O
patients,853,O
receiving,853,O
a,853,O
transplant,853,O
(,853,O
P,853,O
less,853,O
than,853,O
0.05,853,O
),853,O
.,853,O
Myocardial,854,O
catecholamines,854,B-Chemical
were,854,O
also,854,O
determined,854,O
in,854,O
14,854,O
subjects,854,O
;,854,O
a,854,O
weak,854,O
correlation,854,O
(,854,O
r,854,O
=,854,O
0.57,854,O
",",854,O
P,854,O
less,854,O
than,854,O
0.05,854,O
),854,O
between,854,O
the,854,O
tissue,854,O
concentrations,854,O
of,854,O
VIP,854,O
and,854,O
norepinephrine,854,B-Chemical
was,854,O
noted,854,O
.,854,O
(,855,O
ABSTRACT,855,O
TRUNCATED,855,O
AT,855,O
250,855,O
WORDS,855,O
),855,O
Non-invasive,856,O
detection,856,O
of,856,O
coronary,856,B-Disease
artery,856,I-Disease
disease,856,I-Disease
by,856,O
body,856,O
surface,856,O
electrocardiographic,856,O
mapping,856,O
after,856,O
dipyridamole,856,B-Chemical
infusion,856,O
.,856,O
Electrocardiographic,857,O
changes,857,O
after,857,O
dipyridamole,857,B-Chemical
infusion,857,O
(,857,O
0.568,857,O
mg/kg/4,857,O
min,857,O
),857,O
were,857,O
studied,857,O
in,857,O
41,857,O
patients,857,O
with,857,O
coronary,857,B-Disease
artery,857,I-Disease
disease,857,I-Disease
and,857,O
compared,857,O
with,857,O
those,857,O
after,857,O
submaximal,857,O
treadmill,857,O
exercise,857,O
by,857,O
use,857,O
of,857,O
the,857,O
body,857,O
surface,857,O
mapping,857,O
technique,857,O
.,857,O
Patients,858,O
were,858,O
divided,858,O
into,858,O
three,858,O
groups,858,O
;,858,O
19,858,O
patients,858,O
without,858,O
myocardial,858,B-Disease
infarction,858,I-Disease
(,858,O
non-MI,858,O
group,858,O
),858,O
",",858,O
14,858,O
with,858,O
anterior,858,B-Disease
infarction,858,I-Disease
(,858,O
ANT-MI,858,B-Disease
),858,O
and,858,O
eight,858,O
with,858,O
inferior,858,B-Disease
infarction,858,I-Disease
(,858,O
INF-MI,858,B-Disease
),858,O
.,858,O
Eighty-seven,859,O
unipolar,859,O
electrocardiograms,859,O
(,859,O
ECGs,859,O
),859,O
distributed,859,O
over,859,O
the,859,O
entire,859,O
thoracic,859,O
surface,859,O
were,859,O
simultaneously,859,O
recorded,859,O
.,859,O
After,860,O
dipyridamole,860,B-Chemical
",",860,O
ischemic,860,B-Disease
ST-segment,860,O
depression,860,B-Disease
(,860,O
0.05,860,O
mV,860,O
or,860,O
more,860,O
),860,O
was,860,O
observed,860,O
in,860,O
84,860,O
%,860,O
of,860,O
the,860,O
non-MI,860,O
group,860,O
",",860,O
29,860,O
%,860,O
of,860,O
the,860,O
ANT-MI,860,B-Disease
group,860,O
",",860,O
63,860,O
%,860,O
of,860,O
the,860,O
INF-MI,860,B-Disease
group,860,O
and,860,O
61,860,O
%,860,O
of,860,O
the,860,O
total,860,O
population,860,O
.,860,O
Exercise-induced,861,O
ST,861,O
depression,861,B-Disease
was,861,O
observed,861,O
in,861,O
84,861,O
%,861,O
of,861,O
the,861,O
non-MI,861,O
group,861,O
",",861,O
43,861,O
%,861,O
of,861,O
the,861,O
ANT-MI,861,B-Disease
group,861,O
",",861,O
38,861,O
%,861,O
of,861,O
the,861,O
INF-MI,861,B-Disease
group,861,O
and,861,O
61,861,O
%,861,O
of,861,O
the,861,O
total,861,O
.,861,O
For,862,O
individual,862,O
patients,862,O
",",862,O
there,862,O
were,862,O
no,862,O
obvious,862,O
differences,862,O
between,862,O
the,862,O
body,862,O
surface,862,O
distribution,862,O
of,862,O
ST,862,O
depression,862,B-Disease
in,862,O
both,862,O
tests,862,O
.,862,O
The,863,O
increase,863,O
in,863,O
pressure,863,O
rate,863,O
product,863,O
after,863,O
dipyridamole,863,B-Chemical
was,863,O
significantly,863,O
less,863,O
than,863,O
that,863,O
during,863,O
the,863,O
treadmill,863,O
exercise,863,O
.,863,O
The,864,O
data,864,O
suggest,864,O
that,864,O
the,864,O
dipyridamole-induced,864,B-Chemical
myocardial,864,B-Disease
ischemia,864,I-Disease
is,864,O
caused,864,O
by,864,O
the,864,O
inhomogenous,864,O
distribution,864,O
of,864,O
myocardial,864,O
blood,864,O
flow,864,O
.,864,O
We,865,O
conclude,865,O
that,865,O
the,865,O
dipyridamole,865,B-Chemical
ECG,865,O
test,865,O
is,865,O
as,865,O
useful,865,O
as,865,O
the,865,O
exercise,865,O
ECG,865,O
test,865,O
for,865,O
the,865,O
assessment,865,O
of,865,O
coronary,865,B-Disease
artery,865,I-Disease
disease,865,I-Disease
.,865,O
Bradycardia,866,B-Disease
after,866,O
high-dose,866,O
intravenous,866,O
methylprednisolone,866,B-Chemical
therapy,866,O
.,866,O
In,867,O
5,867,O
consecutive,867,O
patients,867,O
with,867,O
rheumatoid,867,B-Disease
arthritis,867,I-Disease
who,867,O
received,867,O
intravenous,867,O
high-dose,867,O
methylprednisolone,867,B-Chemical
(,867,O
MP,867,B-Chemical
),867,O
therapy,867,O
(,867,O
1,867,O
g,867,O
daily,867,O
for,867,O
2,867,O
or,867,O
3,867,O
consecutive,867,O
days,867,O
),867,O
",",867,O
a,867,O
decline,867,O
in,867,O
pulse,867,O
rate,867,O
was,867,O
observed,867,O
",",867,O
most,867,O
pronounced,867,O
on,867,O
day,867,O
4,867,O
.,867,O
In,868,O
one,868,O
of,868,O
the,868,O
5,868,O
patients,868,O
the,868,O
bradycardia,868,B-Disease
was,868,O
associated,868,O
with,868,O
complaints,868,O
of,868,O
substernal,868,O
pressure,868,O
.,868,O
Reversal,869,O
to,869,O
normal,869,O
heart,869,O
rate,869,O
was,869,O
found,869,O
on,869,O
day,869,O
7,869,O
.,869,O
Electrocardiographic,870,O
registrations,870,O
showed,870,O
sinus,870,B-Disease
bradycardia,870,I-Disease
in,870,O
all,870,O
cases,870,O
.,870,O
No,871,O
significant,871,O
changes,871,O
in,871,O
plasma,871,O
concentrations,871,O
of,871,O
electrolytes,871,O
were,871,O
found,871,O
.,871,O
Careful,872,O
observation,872,O
of,872,O
patients,872,O
receiving,872,O
high-dose,872,O
MP,872,B-Chemical
is,872,O
recommended,872,O
.,872,O
High-dose,873,O
MP,873,B-Chemical
may,873,O
be,873,O
contraindicated,873,O
in,873,O
patients,873,O
with,873,O
known,873,O
heart,873,B-Disease
disease,873,I-Disease
.,873,O
Two,874,O
cases,874,O
of,874,O
downbeat,874,B-Disease
nystagmus,874,I-Disease
and,874,O
oscillopsia,874,B-Disease
associated,874,O
with,874,O
carbamazepine,874,B-Chemical
.,874,O
Downbeat,875,B-Disease
nystagmus,875,I-Disease
is,875,O
often,875,O
associated,875,O
with,875,O
structural,875,O
lesions,875,O
at,875,O
the,875,O
craniocervical,875,O
junction,875,O
",",875,O
but,875,O
has,875,O
occasionally,875,O
been,875,O
reported,875,O
as,875,O
a,875,O
manifestation,875,O
of,875,O
metabolic,875,O
imbalance,875,O
or,875,O
drug,875,O
intoxication,875,O
.,875,O
We,876,O
recorded,876,O
the,876,O
eye,876,O
movements,876,O
of,876,O
two,876,O
patients,876,O
with,876,O
reversible,876,O
downbeat,876,B-Disease
nystagmus,876,I-Disease
related,876,O
to,876,O
carbamazepine,876,B-Chemical
therapy,876,O
.,876,O
The,877,O
nystagmus,877,B-Disease
of,877,O
both,877,O
patients,877,O
resolved,877,O
after,877,O
reduction,877,O
of,877,O
the,877,O
serum,877,O
carbamazepine,877,B-Chemical
levels,877,O
.,877,O
Neuroradiologic,878,O
investigations,878,O
including,878,O
magnetic,878,O
resonance,878,O
imaging,878,O
scans,878,O
in,878,O
both,878,O
patients,878,O
showed,878,O
no,878,O
evidence,878,O
of,878,O
intracranial,878,O
abnormality,878,O
.,878,O
In,879,O
patients,879,O
with,879,O
downbeat,879,B-Disease
nystagmus,879,I-Disease
who,879,O
are,879,O
taking,879,O
anticonvulsant,879,O
medications,879,O
",",879,O
consideration,879,O
should,879,O
be,879,O
given,879,O
to,879,O
reduction,879,O
in,879,O
dose,879,O
before,879,O
further,879,O
investigation,879,O
is,879,O
undertaken,879,O
.,879,O
Improvement,880,O
by,880,O
denopamine,880,B-Chemical
(,880,O
TA-064,880,B-Chemical
),880,O
of,880,O
pentobarbital-induced,880,B-Chemical
cardiac,880,B-Disease
failure,880,I-Disease
in,880,O
the,880,O
dog,880,O
heart-lung,880,O
preparation,880,O
.,880,O
The,881,O
efficacy,881,O
of,881,O
denopamine,881,B-Chemical
",",881,O
an,881,O
orally,881,O
active,881,O
beta,881,O
1-adrenoceptor,881,O
agonist,881,O
",",881,O
in,881,O
improving,881,O
cardiac,881,B-Disease
failure,881,I-Disease
was,881,O
assessed,881,O
in,881,O
dog,881,O
heart-lung,881,O
preparations,881,O
.,881,O
Cardiac,882,O
functions,882,O
depressed,882,O
by,882,O
pentobarbital,882,B-Chemical
(,882,O
118,882,O
+/-,882,O
28,882,O
mg,882,O
;,882,O
mean,882,O
value,882,O
+/-,882,O
SD,882,O
),882,O
such,882,O
that,882,O
cardiac,882,O
output,882,O
and,882,O
maximum,882,O
rate,882,O
of,882,O
rise,882,O
of,882,O
left,882,O
ventricular,882,O
pressure,882,O
(,882,O
LV,882,O
dP/dt,882,O
max,882,O
),882,O
had,882,O
been,882,O
reduced,882,O
by,882,O
about,882,O
35,882,O
%,882,O
and,882,O
26,882,O
%,882,O
of,882,O
the,882,O
respective,882,O
controls,882,O
were,882,O
improved,882,O
by,882,O
denopamine,882,B-Chemical
(,882,O
10-300,882,O
micrograms,882,O
),882,O
in,882,O
a,882,O
dose-dependent,882,O
manner,882,O
.,882,O
With,883,O
100,883,O
micrograms,883,O
denopamine,883,B-Chemical
",",883,O
almost,883,O
complete,883,O
restoration,883,O
of,883,O
cardiac,883,O
performance,883,O
was,883,O
attained,883,O
",",883,O
associated,883,O
with,883,O
a,883,O
slight,883,O
increase,883,O
in,883,O
heart,883,O
rate,883,O
.,883,O
No,884,O
arrhythmias,884,B-Disease
were,884,O
induced,884,O
by,884,O
these,884,O
doses,884,O
of,884,O
denopamine,884,B-Chemical
.,884,O
The,885,O
results,885,O
warrant,885,O
clinical,885,O
trials,885,O
of,885,O
denopamine,885,B-Chemical
in,885,O
the,885,O
treatment,885,O
of,885,O
cardiac,885,B-Disease
failure,885,I-Disease
.,885,O
Clonazepam,886,B-Chemical
monotherapy,886,O
for,886,O
epilepsy,886,B-Disease
in,886,O
childhood,886,O
.,886,O
Sixty,887,O
patients,887,O
(,887,O
age-range,887,O
one,887,O
month,887,O
to,887,O
14,887,O
years,887,O
),887,O
with,887,O
other,887,O
types,887,O
of,887,O
epilepsy,887,B-Disease
than,887,O
infantile,887,B-Disease
spasms,887,I-Disease
were,887,O
treated,887,O
with,887,O
clonazepam,887,B-Chemical
.,887,O
Disappearance,888,O
of,888,O
seizures,888,B-Disease
and,888,O
normalization,888,O
of,888,O
abnormal,888,O
EEG,888,O
with,888,O
disappearance,888,O
of,888,O
seizures,888,B-Disease
were,888,O
recognized,888,O
in,888,O
77,888,O
%,888,O
and,888,O
50,888,O
%,888,O
",",888,O
respectively,888,O
.,888,O
Seizures,889,B-Disease
disappeared,889,O
in,889,O
71,889,O
%,889,O
of,889,O
the,889,O
patients,889,O
with,889,O
generalized,889,O
seizures,889,B-Disease
and,889,O
89,889,O
%,889,O
of,889,O
partial,889,O
seizures,889,B-Disease
.,889,O
Improvement,890,O
of,890,O
abnormal,890,O
EEG,890,O
was,890,O
noticed,890,O
in,890,O
76,890,O
%,890,O
of,890,O
diffuse,890,O
paroxysms,890,O
and,890,O
in,890,O
67,890,O
%,890,O
of,890,O
focal,890,O
paroxysms,890,O
.,890,O
In,891,O
excellent,891,O
cases,891,O
",",891,O
mean,891,O
effective,891,O
dosages,891,O
were,891,O
0.086,891,O
+/-,891,O
0.021,891,O
mg/kg/day,891,O
in,891,O
infants,891,O
and,891,O
0.057,891,O
+/-,891,O
0.022,891,O
mg/kg/day,891,O
in,891,O
schoolchildren,891,O
",",891,O
this,891,O
difference,891,O
was,891,O
statistically,891,O
significant,891,O
(,891,O
p,891,O
less,891,O
than,891,O
0.005,891,O
),891,O
.,891,O
The,892,O
incidence,892,O
of,892,O
side,892,O
effects,892,O
such,892,O
as,892,O
drowsiness,892,B-Disease
and,892,O
ataxia,892,B-Disease
was,892,O
only,892,O
5,892,O
%,892,O
.,892,O
Postmarketing,893,O
study,893,O
of,893,O
timolol-hydrochlorothiazide,893,B-Chemical
antihypertensive,893,O
therapy,893,O
.,893,O
A,894,O
postmarketing,894,O
surveillance,894,O
study,894,O
was,894,O
conducted,894,O
to,894,O
determine,894,O
the,894,O
safety,894,O
and,894,O
efficacy,894,O
of,894,O
a,894,O
fixed-ratio,894,O
combination,894,O
containing,894,O
10,894,O
mg,894,O
of,894,O
timolol,894,B-Chemical
maleate,894,I-Chemical
and,894,O
25,894,O
mg,894,O
of,894,O
hydrochlorothiazide,894,B-Chemical
",",894,O
administered,894,O
twice,894,O
daily,894,O
for,894,O
one,894,O
month,894,O
to,894,O
hypertensive,894,B-Disease
patients,894,O
.,894,O
Data,895,O
on,895,O
"9,037",895,O
patients,895,O
were,895,O
collected,895,O
by,895,O
"1,455",895,O
participating,895,O
physicians,895,O
.,895,O
Mean,896,O
systolic,896,O
blood,896,O
pressure,896,O
decreased,896,O
25,896,O
mmHg,896,O
and,896,O
mean,896,O
diastolic,896,O
blood,896,O
pressure,896,O
declined,896,O
15,896,O
mmHg,896,O
after,896,O
one,896,O
month,896,O
of,896,O
timolol-hydrochlorothiazide,896,B-Chemical
therapy,896,O
(,896,O
P,896,O
less,896,O
than,896,O
0.01,896,O
",",896,O
both,896,O
comparisons,896,O
),896,O
.,896,O
Age,897,O
",",897,O
race,897,O
",",897,O
and,897,O
sex,897,O
appeared,897,O
to,897,O
have,897,O
no,897,O
influence,897,O
on,897,O
the,897,O
decrease,897,O
in,897,O
blood,897,O
pressure,897,O
.,897,O
The,898,O
antihypertensive,898,O
effect,898,O
of,898,O
the,898,O
drug,898,O
was,898,O
greater,898,O
in,898,O
patients,898,O
with,898,O
more,898,O
severe,898,O
hypertension,898,B-Disease
.,898,O
Overall,899,O
",",899,O
"1,453",899,O
patients,899,O
experienced,899,O
a,899,O
total,899,O
of,899,O
"2,658",899,O
adverse,899,O
events,899,O
",",899,O
the,899,O
most,899,O
common,899,O
being,899,O
fatigue,899,B-Disease
",",899,O
dizziness,899,B-Disease
",",899,O
and,899,O
weakness,899,B-Disease
.,899,O
Treatment,900,O
in,900,O
590,900,O
patients,900,O
was,900,O
discontinued,900,O
because,900,O
of,900,O
adverse,900,O
events,900,O
.,900,O
Salicylate,901,B-Chemical
nephropathy,901,B-Disease
in,901,O
the,901,O
Gunn,901,O
rat,901,O
:,901,O
potential,901,O
role,901,O
of,901,O
prostaglandins,901,B-Chemical
.,901,O
We,902,O
examined,902,O
the,902,O
potential,902,O
role,902,O
of,902,O
prostaglandins,902,B-Chemical
in,902,O
the,902,O
development,902,O
of,902,O
analgesic,902,O
nephropathy,902,B-Disease
in,902,O
the,902,O
Gunn,902,O
strain,902,O
of,902,O
rat,902,O
.,902,O
The,903,O
homozygous,903,O
Gunn,903,O
rats,903,O
have,903,O
unconjugated,903,O
hyperbilirubinemia,903,B-Disease
due,903,O
to,903,O
the,903,O
absence,903,O
of,903,O
glucuronyl,903,B-Chemical
transferase,903,O
",",903,O
leading,903,O
to,903,O
marked,903,O
bilirubin,903,B-Chemical
deposition,903,O
in,903,O
renal,903,O
medulla,903,O
and,903,O
papilla,903,O
.,903,O
These,904,O
rats,904,O
are,904,O
also,904,O
highly,904,O
susceptible,904,O
to,904,O
develop,904,O
papillary,904,B-Disease
necrosis,904,I-Disease
with,904,O
analgesic,904,O
administration,904,O
.,904,O
We,905,O
used,905,O
homozygous,905,O
(,905,O
jj,905,O
),905,O
and,905,O
phenotypically,905,O
normal,905,O
heterozygous,905,O
(,905,O
jJ,905,O
),905,O
animals,905,O
.,905,O
Four,906,O
groups,906,O
of,906,O
rats,906,O
(,906,O
n,906,O
=,906,O
7,906,O
),906,O
were,906,O
studied,906,O
:,906,O
jj,906,O
and,906,O
jJ,906,O
rats,906,O
treated,906,O
either,906,O
with,906,O
aspirin,906,B-Chemical
300,906,O
mg/kg,906,O
every,906,O
other,906,O
day,906,O
or,906,O
sham-treated,906,O
.,906,O
After,907,O
one,907,O
week,907,O
",",907,O
slices,907,O
of,907,O
cortex,907,O
",",907,O
outer,907,O
and,907,O
inner,907,O
medulla,907,O
from,907,O
one,907,O
kidney,907,O
were,907,O
incubated,907,O
in,907,O
buffer,907,O
and,907,O
prostaglandin,907,B-Chemical
synthesis,907,O
was,907,O
determined,907,O
by,907,O
radioimmunoassay,907,O
.,907,O
The,908,O
other,908,O
kidney,908,O
was,908,O
examined,908,O
histologically,908,O
.,908,O
A,909,O
marked,909,O
corticomedullary,909,O
gradient,909,O
of,909,O
prostaglandin,909,B-Chemical
synthesis,909,O
was,909,O
observed,909,O
in,909,O
all,909,O
groups,909,O
.,909,O
PGE2,910,B-Chemical
synthesis,910,O
was,910,O
significantly,910,O
higher,910,O
in,910,O
outer,910,O
medulla,910,O
",",910,O
but,910,O
not,910,O
cortex,910,O
or,910,O
inner,910,O
medulla,910,O
",",910,O
of,910,O
jj,910,O
(,910,O
38,910,O
+/-,910,O
6,910,O
ng/mg,910,O
prot,910,O
),910,O
than,910,O
jJ,910,O
rats,910,O
(,910,O
15,910,O
+/-,910,O
3,910,O
),910,O
(,910,O
p,910,O
less,910,O
than,910,O
0.01,910,O
),910,O
.,910,O
Aspirin,911,B-Chemical
treatment,911,O
reduced,911,O
PGE2,911,B-Chemical
synthesis,911,O
in,911,O
all,911,O
regions,911,O
",",911,O
but,911,O
outer,911,O
medullary,911,O
PGE2,911,B-Chemical
remained,911,O
higher,911,O
in,911,O
jj,911,O
(,911,O
18,911,O
+/-,911,O
3,911,O
),911,O
than,911,O
jJ,911,O
rats,911,O
(,911,O
9,911,O
+/-,911,O
2,911,O
),911,O
(,911,O
p,911,O
less,911,O
than,911,O
0.05,911,O
),911,O
.,911,O
PGF2,912,B-Chemical
alpha,912,I-Chemical
was,912,O
also,912,O
significantly,912,O
higher,912,O
in,912,O
the,912,O
outer,912,O
medulla,912,O
of,912,O
jj,912,O
rats,912,O
with,912,O
and,912,O
without,912,O
aspirin,912,B-Chemical
administration,912,O
(,912,O
p,912,O
less,912,O
than,912,O
0.05,912,O
),912,O
.,912,O
The,913,O
changes,913,O
in,913,O
renal,913,O
prostaglandin,913,B-Chemical
synthesis,913,O
were,913,O
accompanied,913,O
by,913,O
evidence,913,O
of,913,O
renal,913,B-Disease
damage,913,I-Disease
in,913,O
aspirin-treated,913,B-Chemical
jj,913,O
but,913,O
not,913,O
jJ,913,O
rats,913,O
as,913,O
evidenced,913,O
by,913,O
:,913,O
increased,913,O
incidence,913,O
and,913,O
severity,913,O
of,913,O
hematuria,913,B-Disease
(,913,O
p,913,O
less,913,O
than,913,O
0.01,913,O
),913,O
;,913,O
increased,913,O
serum,913,O
creatinine,913,B-Chemical
(,913,O
p,913,O
less,913,O
than,913,O
0.05,913,O
),913,O
;,913,O
and,913,O
increase,913,O
in,913,O
outer,913,O
medullary,913,O
histopathologic,913,O
lesions,913,O
(,913,O
p,913,O
less,913,O
than,913,O
0.005,913,O
compared,913,O
to,913,O
either,913,O
sham-treated,913,O
jj,913,O
or,913,O
aspirin-treated,913,B-Chemical
jJ,913,O
),913,O
.,913,O
These,914,O
results,914,O
suggest,914,O
that,914,O
enhanced,914,O
prostaglandin,914,B-Chemical
synthesis,914,O
contributes,914,O
to,914,O
maintenance,914,O
of,914,O
renal,914,O
function,914,O
and,914,O
morphological,914,O
integrity,914,O
",",914,O
and,914,O
that,914,O
inhibition,914,O
of,914,O
prostaglandin,914,B-Chemical
synthesis,914,O
may,914,O
lead,914,O
to,914,O
pathological,914,B-Disease
renal,914,I-Disease
medullary,914,I-Disease
lesions,914,I-Disease
and,914,O
deterioration,914,B-Disease
of,914,I-Disease
renal,914,I-Disease
function,914,I-Disease
.,914,O
Prophylactic,915,O
lidocaine,915,B-Chemical
in,915,O
the,915,O
early,915,O
phase,915,O
of,915,O
suspected,915,O
myocardial,915,B-Disease
infarction,915,I-Disease
.,915,O
Four,916,O
hundred,916,O
two,916,O
patients,916,O
with,916,O
suspected,916,O
myocardial,916,B-Disease
infarction,916,I-Disease
seen,916,O
within,916,O
6,916,O
hours,916,O
of,916,O
the,916,O
onset,916,O
of,916,O
symptoms,916,O
entered,916,O
a,916,O
double-blind,916,O
randomized,916,O
trial,916,O
of,916,O
lidocaine,916,B-Chemical
vs,916,O
placebo,916,O
.,916,O
During,917,O
the,917,O
1,917,O
hour,917,O
after,917,O
administration,917,O
of,917,O
the,917,O
drug,917,O
the,917,O
incidence,917,O
of,917,O
ventricular,917,B-Disease
fibrillation,917,I-Disease
or,917,O
sustained,917,O
ventricular,917,B-Disease
tachycardia,917,I-Disease
among,917,O
the,917,O
204,917,O
patients,917,O
with,917,O
acute,917,O
myocardial,917,B-Disease
infarction,917,I-Disease
was,917,O
low,917,O
",",917,O
1.5,917,O
%,917,O
.,917,O
Lidocaine,918,B-Chemical
",",918,O
given,918,O
in,918,O
a,918,O
300,918,O
mg,918,O
dose,918,O
intramuscularly,918,O
followed,918,O
by,918,O
100,918,O
mg,918,O
intravenously,918,O
",",918,O
did,918,O
not,918,O
prevent,918,O
sustained,918,O
ventricular,918,B-Disease
tachycardia,918,I-Disease
",",918,O
although,918,O
there,918,O
was,918,O
a,918,O
significant,918,O
reduction,918,O
in,918,O
the,918,O
number,918,O
of,918,O
patients,918,O
with,918,O
warning,918,O
arrhythmias,918,B-Disease
between,918,O
15,918,O
and,918,O
45,918,O
minutes,918,O
after,918,O
the,918,O
administration,918,O
of,918,O
lidocaine,918,B-Chemical
(,918,O
p,918,O
less,918,O
than,918,O
0.05,918,O
),918,O
.,918,O
The,919,O
average,919,O
plasma,919,O
lidocaine,919,B-Chemical
level,919,O
10,919,O
minutes,919,O
after,919,O
administration,919,O
for,919,O
patients,919,O
without,919,O
a,919,O
myocardial,919,B-Disease
infarction,919,I-Disease
was,919,O
significantly,919,O
higher,919,O
than,919,O
that,919,O
for,919,O
patients,919,O
with,919,O
an,919,O
acute,919,O
infarction,919,B-Disease
.,919,O
The,920,O
mean,920,O
plasma,920,O
lidocaine,920,B-Chemical
level,920,O
of,920,O
patients,920,O
on,920,O
beta-blocking,920,O
agents,920,O
was,920,O
no,920,O
different,920,O
from,920,O
that,920,O
in,920,O
patients,920,O
not,920,O
on,920,O
beta,920,O
blocking,920,O
agents,920,O
.,920,O
During,921,O
the,921,O
1-hour,921,O
study,921,O
period,921,O
",",921,O
the,921,O
incidence,921,O
of,921,O
central,921,O
nervous,921,O
system,921,O
side,921,O
effects,921,O
was,921,O
significantly,921,O
greater,921,O
in,921,O
the,921,O
lidocaine,921,B-Chemical
group,921,O
",",921,O
hypotension,921,B-Disease
occurred,921,O
in,921,O
11,921,O
patients,921,O
",",921,O
nine,921,O
of,921,O
whom,921,O
had,921,O
received,921,O
lidocaine,921,B-Chemical
",",921,O
and,921,O
four,921,O
patients,921,O
died,921,O
from,921,O
asystole,921,B-Disease
",",921,O
three,921,O
of,921,O
whom,921,O
had,921,O
had,921,O
lidocaine,921,B-Chemical
.,921,O
We,922,O
can,922,O
not,922,O
advocate,922,O
the,922,O
administration,922,O
of,922,O
lidocaine,922,B-Chemical
prophylactically,922,O
in,922,O
the,922,O
early,922,O
hours,922,O
of,922,O
suspected,922,O
myocardial,922,B-Disease
infarction,922,I-Disease
.,922,O
Evidence,923,O
for,923,O
a,923,O
cholinergic,923,O
role,923,O
in,923,O
haloperidol-induced,923,B-Chemical
catalepsy,923,B-Disease
.,923,O
Experiments,924,O
in,924,O
mice,924,O
tested,924,O
previous,924,O
evidence,924,O
that,924,O
activation,924,O
of,924,O
cholinergic,924,O
systems,924,O
promotes,924,O
catalepsy,924,B-Disease
and,924,O
that,924,O
cholinergic,924,O
mechanisms,924,O
need,924,O
to,924,O
be,924,O
intact,924,O
for,924,O
full,924,O
expression,924,O
of,924,O
neuroleptic-induced,924,B-Chemical
catalepsy,924,B-Disease
.,924,O
Large,925,O
doses,925,O
of,925,O
the,925,O
cholinomimetic,925,O
",",925,O
pilocarpine,925,B-Chemical
",",925,O
could,925,O
induce,925,O
catalepsy,925,B-Disease
when,925,O
peripheral,925,O
cholinergic,925,O
receptors,925,O
were,925,O
blocked,925,O
.,925,O
Low,926,O
doses,926,O
of,926,O
pilocarpine,926,B-Chemical
caused,926,O
a,926,O
pronounced,926,O
enhancement,926,O
of,926,O
the,926,O
catalepsy,926,B-Disease
that,926,O
was,926,O
induced,926,O
by,926,O
the,926,O
dopaminergic,926,O
blocker,926,O
",",926,O
haloperidol,926,B-Chemical
.,926,O
A,927,O
muscarinic,927,O
receptor,927,O
blocker,927,O
",",927,O
atropine,927,B-Chemical
",",927,O
disrupted,927,O
haloperidol-induced,927,B-Chemical
catalepsy,927,B-Disease
.,927,O
Intracranial,928,O
injection,928,O
of,928,O
an,928,O
acetylcholine-synthesis,928,B-Chemical
inhibitor,928,O
",",928,O
hemicholinium,928,B-Chemical
",",928,O
prevented,928,O
the,928,O
catalepsy,928,B-Disease
that,928,O
is,928,O
usually,928,O
induced,928,O
by,928,O
haloperidol,928,B-Chemical
.,928,O
These,929,O
findings,929,O
suggest,929,O
the,929,O
hypothesis,929,O
that,929,O
the,929,O
catalepsy,929,B-Disease
that,929,O
is,929,O
produced,929,O
by,929,O
neuroleptics,929,B-Chemical
such,929,O
as,929,O
haloperidol,929,B-Chemical
is,929,O
actually,929,O
mediated,929,O
by,929,O
intrinsic,929,O
central,929,O
cholinergic,929,O
systems,929,O
.,929,O
Alternatively,930,O
",",930,O
activation,930,O
of,930,O
central,930,O
cholinergic,930,O
systems,930,O
could,930,O
promote,930,O
catalepsy,930,B-Disease
by,930,O
suppression,930,O
of,930,O
dopaminergic,930,O
systems,930,O
.,930,O
Cardiovascular,931,B-Disease
dysfunction,931,I-Disease
and,931,O
hypersensitivity,931,B-Disease
to,931,O
sodium,931,B-Chemical
pentobarbital,931,I-Chemical
induced,931,O
by,931,O
chronic,931,O
barium,931,B-Chemical
chloride,931,I-Chemical
ingestion,931,O
.,931,O
Barium-supplemented,932,B-Chemical
Long-Evans,932,O
hooded,932,O
rats,932,O
were,932,O
characterized,932,O
by,932,O
a,932,O
persistent,932,O
hypertension,932,B-Disease
that,932,O
was,932,O
evident,932,O
after,932,O
1,932,O
month,932,O
of,932,O
barium,932,B-Chemical
(,932,O
100,932,O
micrograms/ml,932,O
mineral,932,O
fortified,932,O
water,932,O
),932,O
treatment,932,O
.,932,O
Analysis,933,O
of,933,O
in,933,O
vivo,933,O
myocardial,933,O
excitability,933,O
",",933,O
contractility,933,O
",",933,O
and,933,O
metabolic,933,O
characteristics,933,O
at,933,O
16,933,O
months,933,O
revealed,933,O
other,933,O
significant,933,O
barium-induced,933,B-Chemical
disturbances,933,B-Disease
within,933,I-Disease
the,933,I-Disease
cardiovascular,933,I-Disease
system,933,I-Disease
.,933,O
The,934,O
most,934,O
distinctive,934,O
aspect,934,O
of,934,O
the,934,O
barium,934,B-Chemical
effect,934,O
was,934,O
a,934,O
demonstrated,934,O
hypersensitivity,934,B-Disease
of,934,O
the,934,O
cardiovascular,934,O
system,934,O
to,934,O
sodium,934,B-Chemical
pentobarbital,934,I-Chemical
.,934,O
Under,935,O
barbiturate,935,B-Chemical
anesthesia,935,O
",",935,O
virtually,935,O
all,935,O
of,935,O
the,935,O
myocardial,935,O
contractile,935,O
indices,935,O
were,935,O
depressed,935,O
significantly,935,O
in,935,O
barium-exposed,935,B-Chemical
rats,935,O
relative,935,O
to,935,O
the,935,O
corresponding,935,O
control-fed,935,O
rats,935,O
.,935,O
The,936,O
lack,936,O
of,936,O
a,936,O
similar,936,O
response,936,O
to,936,O
ketamine,936,B-Chemical
and,936,O
xylazine,936,B-Chemical
anesthesia,936,O
revealed,936,O
that,936,O
the,936,O
cardiovascular,936,O
actions,936,O
of,936,O
sodium,936,B-Chemical
pentobarbital,936,I-Chemical
in,936,O
barium-treated,936,B-Chemical
rats,936,O
were,936,O
linked,936,O
specifically,936,O
to,936,O
this,936,O
anesthetic,936,O
",",936,O
and,936,O
were,936,O
not,936,O
representative,936,O
of,936,O
a,936,O
generalized,936,O
anesthetic,936,O
response,936,O
.,936,O
Other,937,O
myocardial,937,O
pathophysiologic,937,O
and,937,O
metabolic,937,O
changes,937,O
induced,937,O
by,937,O
barium,937,B-Chemical
were,937,O
manifest,937,O
",",937,O
irrespective,937,O
of,937,O
the,937,O
anesthetic,937,O
employed,937,O
.,937,O
The,938,O
contractile,938,O
element,938,O
shortening,938,O
velocity,938,O
of,938,O
the,938,O
cardiac,938,O
muscle,938,O
fibers,938,O
was,938,O
significantly,938,O
slower,938,O
in,938,O
both,938,O
groups,938,O
of,938,O
barium-treated,938,B-Chemical
rats,938,O
relative,938,O
to,938,O
the,938,O
control,938,O
groups,938,O
",",938,O
irrespective,938,O
of,938,O
the,938,O
anesthetic,938,O
regimen,938,O
.,938,O
Similarly,939,O
",",939,O
significant,939,O
disturbances,939,O
in,939,O
myocardial,939,O
energy,939,O
metabolism,939,O
were,939,O
detected,939,O
in,939,O
the,939,O
barium-exposed,939,B-Chemical
rats,939,O
which,939,O
were,939,O
consistent,939,O
with,939,O
the,939,O
reduced,939,O
contractile,939,O
element,939,O
shortening,939,O
velocity,939,O
.,939,O
In,940,O
addition,940,O
",",940,O
the,940,O
excitability,940,O
of,940,O
the,940,O
cardiac,940,O
conduction,940,O
system,940,O
was,940,O
depressed,940,O
preferentially,940,O
in,940,O
the,940,O
atrioventricular,940,O
nodal,940,O
region,940,O
of,940,O
hearts,940,O
from,940,O
barium-exposed,940,B-Chemical
rats,940,O
.,940,O
Overall,941,O
",",941,O
the,941,O
altered,941,O
cardiac,941,O
contractility,941,O
and,941,O
excitability,941,O
characteristics,941,O
",",941,O
the,941,O
myocardial,941,O
metabolic,941,B-Disease
disturbances,941,I-Disease
",",941,O
and,941,O
the,941,O
hypersensitivity,941,B-Disease
of,941,O
the,941,O
cardiovascular,941,O
system,941,O
to,941,O
sodium,941,B-Chemical
pentobarbital,941,I-Chemical
suggest,941,O
the,941,O
existence,941,O
of,941,O
a,941,O
heretofore,941,O
undescribed,941,O
cardiomyopathic,941,B-Disease
disorder,941,I-Disease
induced,941,O
by,941,O
chronic,941,O
barium,941,B-Chemical
exposure,941,O
.,941,O
These,942,O
experimental,942,O
findings,942,O
represent,942,O
the,942,O
first,942,O
indication,942,O
that,942,O
life-long,942,O
barium,942,B-Chemical
ingestion,942,O
may,942,O
have,942,O
significant,942,O
adverse,942,O
effects,942,O
on,942,O
the,942,O
mammalian,942,O
cardiovascular,942,O
system,942,O
.,942,O
Propranolol,943,B-Chemical
antagonism,943,O
of,943,O
phenylpropanolamine-induced,943,B-Chemical
hypertension,943,B-Disease
.,943,O
Phenylpropanolamine,944,B-Chemical
(,944,O
PPA,944,B-Chemical
),944,O
overdose,944,B-Disease
can,944,O
cause,944,O
severe,944,O
hypertension,944,B-Disease
",",944,O
intracerebral,944,B-Disease
hemorrhage,944,I-Disease
",",944,O
and,944,O
death,944,O
.,944,O
We,945,O
studied,945,O
the,945,O
efficacy,945,O
and,945,O
safety,945,O
of,945,O
propranolol,945,B-Chemical
in,945,O
the,945,O
treatment,945,O
of,945,O
PPA-induced,945,B-Chemical
hypertension,945,B-Disease
.,945,O
Subjects,946,O
received,946,O
propranolol,946,B-Chemical
either,946,O
by,946,O
mouth,946,O
for,946,O
48,946,O
hours,946,O
before,946,O
PPA,946,B-Chemical
or,946,O
as,946,O
a,946,O
rapid,946,O
intravenous,946,O
infusion,946,O
after,946,O
PPA,946,B-Chemical
.,946,O
PPA,947,B-Chemical
",",947,O
75,947,O
mg,947,O
alone,947,O
",",947,O
increased,947,O
blood,947,O
pressure,947,O
(,947,O
31,947,O
+/-,947,O
14,947,O
mm,947,O
Hg,947,O
systolic,947,O
",",947,O
20,947,O
+/-,947,O
5,947,O
mm,947,O
Hg,947,O
diastolic,947,O
),947,O
",",947,O
and,947,O
propranolol,947,B-Chemical
pretreatment,947,O
antagonized,947,O
this,947,O
increase,947,O
(,947,O
12,947,O
+/-,947,O
10,947,O
mm,947,O
Hg,947,O
systolic,947,O
",",947,O
10,947,O
+/-,947,O
7,947,O
mm,947,O
Hg,947,O
diastolic,947,O
),947,O
.,947,O
Intravenous,948,O
propranolol,948,B-Chemical
after,948,O
PPA,948,B-Chemical
also,948,O
decreased,948,O
blood,948,O
pressure,948,O
.,948,O
Left,949,O
ventricular,949,O
function,949,O
(,949,O
assessed,949,O
by,949,O
echocardiography,949,O
),949,O
showed,949,O
that,949,O
PPA,949,B-Chemical
increased,949,O
the,949,O
stroke,949,B-Disease
volume,949,O
30,949,O
%,949,O
(,949,O
from,949,O
62.5,949,O
+/-,949,O
20.9,949,O
to,949,O
80.8,949,O
+/-,949,O
22.4,949,O
ml,949,O
),949,O
",",949,O
the,949,O
ejection,949,O
fraction,949,O
9,949,O
%,949,O
(,949,O
from,949,O
64,949,O
%,949,O
+/-,949,O
10,949,O
%,949,O
to,949,O
70,949,O
%,949,O
+/-,949,O
7,949,O
%,949,O
),949,O
",",949,O
and,949,O
cardiac,949,O
output,949,O
14,949,O
%,949,O
(,949,O
from,949,O
3.6,949,O
+/-,949,O
0.6,949,O
to,949,O
4.1,949,O
+/-,949,O
1.0,949,O
L/min,949,O
),949,O
.,949,O
Intravenous,950,O
propranolol,950,B-Chemical
reversed,950,O
these,950,O
effects,950,O
.,950,O
Systemic,951,O
vascular,951,O
resistance,951,O
was,951,O
increased,951,O
by,951,O
PPA,951,B-Chemical
28,951,O
%,951,O
(,951,O
from,951,O
1710,951,O
+/-,951,O
200,951,O
to,951,O
2190,951,O
+/-,951,O
700,951,O
dyne,951,O
X,951,O
sec/cm5,951,O
),951,O
and,951,O
was,951,O
further,951,O
increased,951,O
by,951,O
propranolol,951,B-Chemical
22,951,O
%,951,O
(,951,O
to,951,O
2660,951,O
+/-,951,O
1200,951,O
dyne,951,O
X,951,O
sec/cm5,951,O
),951,O
.,951,O
We,952,O
conclude,952,O
that,952,O
PPA,952,B-Chemical
increases,952,O
blood,952,O
pressure,952,O
by,952,O
increasing,952,O
systemic,952,O
vascular,952,O
resistance,952,O
and,952,O
cardiac,952,O
output,952,O
",",952,O
and,952,O
that,952,O
propranolol,952,B-Chemical
antagonizes,952,O
this,952,O
increase,952,O
by,952,O
reversing,952,O
the,952,O
effect,952,O
of,952,O
PPA,952,B-Chemical
on,952,O
cardiac,952,O
output,952,O
.,952,O
That,953,O
propranolol,953,B-Chemical
antagonizes,953,O
the,953,O
pressor,953,O
effect,953,O
of,953,O
PPA,953,B-Chemical
is,953,O
in,953,O
contrast,953,O
to,953,O
the,953,O
interaction,953,O
in,953,O
which,953,O
propranolol,953,B-Chemical
enhances,953,O
the,953,O
pressor,953,O
effect,953,O
of,953,O
norepinephrine,953,B-Chemical
.,953,O
This,954,O
is,954,O
probably,954,O
because,954,O
PPA,954,B-Chemical
has,954,O
less,954,O
beta,954,O
2,954,O
activity,954,O
than,954,O
does,954,O
norepinephrine,954,B-Chemical
.,954,O
Mesangial,955,O
function,955,O
and,955,O
glomerular,955,B-Disease
sclerosis,955,I-Disease
in,955,O
rats,955,O
with,955,O
aminonucleoside,955,B-Chemical
nephrosis,955,B-Disease
.,955,O
The,956,O
possible,956,O
relationship,956,O
between,956,O
mesangial,956,B-Disease
dysfunction,956,I-Disease
and,956,O
development,956,O
of,956,O
glomerular,956,B-Disease
sclerosis,956,I-Disease
was,956,O
studied,956,O
in,956,O
the,956,O
puromycin,956,B-Chemical
aminonucleoside,956,I-Chemical
(,956,O
PAN,956,B-Chemical
),956,O
model,956,O
.,956,O
Five,957,O
male,957,O
Wistar,957,O
rats,957,O
received,957,O
repeated,957,O
subcutaneous,957,O
PAN,957,B-Chemical
injections,957,O
;,957,O
five,957,O
controls,957,O
received,957,O
saline,957,O
only,957,O
.,957,O
After,958,O
4,958,O
weeks,958,O
the,958,O
PAN,958,B-Chemical
rats,958,O
were,958,O
severely,958,O
proteinuric,958,B-Disease
(,958,O
190,958,O
+/-,958,O
80,958,O
mg/24,958,O
hr,958,O
),958,O
",",958,O
and,958,O
all,958,O
rats,958,O
were,958,O
given,958,O
colloidal,958,O
carbon,958,B-Chemical
(,958,O
CC,958,O
),958,O
intravenously,958,O
.,958,O
At,959,O
5,959,O
months,959,O
glomerular,959,B-Disease
sclerosis,959,I-Disease
was,959,O
found,959,O
in,959,O
7.6,959,O
+/-,959,O
3.4,959,O
%,959,O
of,959,O
the,959,O
glomeruli,959,O
of,959,O
PAN,959,B-Chemical
rats,959,O
;,959,O
glomeruli,959,O
of,959,O
the,959,O
controls,959,O
were,959,O
normal,959,O
.,959,O
Glomeruli,960,O
of,960,O
PAN,960,B-Chemical
rats,960,O
contained,960,O
significantly,960,O
more,960,O
CC,960,O
than,960,O
glomeruli,960,O
of,960,O
controls,960,O
.,960,O
Glomeruli,961,O
with,961,O
sclerosis,961,B-Disease
contained,961,O
significantly,961,O
more,961,O
CC,961,O
than,961,O
non-sclerotic,961,O
glomeruli,961,O
in,961,O
the,961,O
same,961,O
kidneys,961,O
.,961,O
CC,962,O
was,962,O
preferentially,962,O
localized,962,O
within,962,O
the,962,O
sclerotic,962,O
areas,962,O
of,962,O
the,962,O
affected,962,O
glomeruli,962,O
.,962,O
Since,963,O
mesangial,963,O
CC,963,O
clearance,963,O
from,963,O
the,963,O
mesangium,963,O
did,963,O
not,963,O
change,963,O
during,963,O
chronic,963,O
PAN,963,B-Chemical
treatment,963,O
",",963,O
we,963,O
conclude,963,O
that,963,O
this,963,O
preferential,963,O
CC,963,O
localization,963,O
within,963,O
the,963,O
lesions,963,O
is,963,O
caused,963,O
by,963,O
an,963,O
increased,963,O
CC,963,O
uptake,963,O
shortly,963,O
after,963,O
injection,963,O
in,963,O
apparent,963,O
vulnerable,963,O
areas,963,O
where,963,O
sclerosis,963,B-Disease
will,963,O
develop,963,O
subsequently,963,O
.,963,O
Cluster,964,O
analysis,964,O
showed,964,O
a,964,O
random,964,O
distribution,964,O
of,964,O
lesions,964,O
in,964,O
the,964,O
PAN,964,B-Chemical
glomeruli,964,O
in,964,O
concordance,964,O
with,964,O
the,964,O
random,964,O
localization,964,O
of,964,O
mesangial,964,O
areas,964,O
with,964,O
dysfunction,964,O
in,964,O
this,964,O
model,964,O
.,964,O
Similar,965,O
to,965,O
the,965,O
remnant,965,O
kidney,965,O
model,965,O
in,965,O
PAN,965,B-Chemical
nephrosis,965,B-Disease
the,965,O
development,965,O
of,965,O
glomerular,965,B-Disease
sclerosis,965,I-Disease
may,965,O
be,965,O
related,965,O
to,965,O
``,965,O
mesangial,965,O
overloading,965,O
.,965,O
'',965,O
Relationship,966,O
between,966,O
nicotine-induced,966,B-Chemical
seizures,966,B-Disease
and,966,O
hippocampal,966,O
nicotinic,966,O
receptors,966,O
.,966,O
A,967,O
controversy,967,O
has,967,O
existed,967,O
for,967,O
several,967,O
years,967,O
concerning,967,O
the,967,O
physiological,967,O
relevance,967,O
of,967,O
the,967,O
nicotinic,967,O
receptor,967,O
measured,967,O
by,967,O
alpha-bungarotoxin,967,O
binding,967,O
.,967,O
Using,968,O
mice,968,O
derived,968,O
from,968,O
a,968,O
classical,968,O
F2,968,O
and,968,O
backcross,968,O
genetic,968,O
design,968,O
",",968,O
a,968,O
relationship,968,O
between,968,O
nicotine-induced,968,B-Chemical
seizures,968,B-Disease
and,968,O
alpha-bungarotoxin,968,O
nicotinic,968,O
receptor,968,O
concentration,968,O
was,968,O
found,968,O
.,968,O
Mice,969,O
sensitive,969,O
to,969,O
the,969,O
convulsant,969,O
effects,969,O
of,969,O
nicotine,969,B-Chemical
had,969,O
greater,969,O
alpha-bungarotoxin,969,O
binding,969,O
in,969,O
the,969,O
hippocampus,969,O
than,969,O
seizure,969,B-Disease
insensitive,969,O
mice,969,O
.,969,O
The,970,O
binding,970,O
sites,970,O
from,970,O
seizure,970,B-Disease
sensitive,970,O
and,970,O
resistant,970,O
mice,970,O
were,970,O
equally,970,O
affected,970,O
by,970,O
treatment,970,O
with,970,O
dithiothreitol,970,B-Chemical
",",970,O
trypsin,970,O
or,970,O
heat,970,O
.,970,O
Thus,971,O
it,971,O
appears,971,O
that,971,O
the,971,O
difference,971,O
between,971,O
seizure,971,B-Disease
sensitive,971,O
and,971,O
insensitive,971,O
animals,971,O
may,971,O
be,971,O
due,971,O
to,971,O
a,971,O
difference,971,O
in,971,O
hippocampal,971,O
nicotinic,971,O
receptor,971,O
concentration,971,O
as,971,O
measured,971,O
with,971,O
alpha-bungarotoxin,971,O
binding,971,O
.,971,O
The,972,O
role,972,O
of,972,O
p-aminophenol,972,B-Chemical
in,972,O
acetaminophen-induced,972,B-Chemical
nephrotoxicity,972,B-Disease
:,972,O
effect,972,O
of,972,O
bis,972,B-Chemical
(,972,I-Chemical
p-nitrophenyl,972,I-Chemical
),972,I-Chemical
phosphate,972,I-Chemical
on,972,O
acetaminophen,972,B-Chemical
and,972,O
p-aminophenol,972,B-Chemical
nephrotoxicity,972,B-Disease
and,972,O
metabolism,972,O
in,972,O
Fischer,972,O
344,972,O
rats,972,O
.,972,O
Acetaminophen,973,B-Chemical
(,973,O
APAP,973,B-Chemical
),973,O
produces,973,O
proximal,973,O
tubular,973,B-Disease
necrosis,973,I-Disease
in,973,O
Fischer,973,O
344,973,O
(,973,O
F344,973,O
),973,O
rats,973,O
.,973,O
Recently,974,O
",",974,O
p-aminophenol,974,B-Chemical
(,974,O
PAP,974,B-Chemical
),974,O
",",974,O
a,974,O
known,974,O
potent,974,O
nephrotoxicant,974,O
",",974,O
was,974,O
identified,974,O
as,974,O
a,974,O
metabolite,974,O
of,974,O
APAP,974,B-Chemical
in,974,O
F344,974,O
rats,974,O
.,974,O
The,975,O
purpose,975,O
of,975,O
this,975,O
study,975,O
was,975,O
to,975,O
determine,975,O
if,975,O
PAP,975,B-Chemical
formation,975,O
is,975,O
a,975,O
requisite,975,O
step,975,O
in,975,O
APAP-induced,975,B-Chemical
nephrotoxicity,975,B-Disease
.,975,O
Therefore,976,O
",",976,O
the,976,O
effect,976,O
of,976,O
bis,976,B-Chemical
(,976,I-Chemical
p-nitrophenyl,976,I-Chemical
),976,I-Chemical
phosphate,976,I-Chemical
(,976,O
BNPP,976,B-Chemical
),976,O
",",976,O
an,976,O
acylamidase,976,O
inhibitor,976,O
",",976,O
on,976,O
APAP,976,B-Chemical
and,976,O
PAP,976,B-Chemical
nephrotoxicity,976,B-Disease
and,976,O
metabolism,976,O
was,976,O
determined,976,O
.,976,O
BNPP,977,B-Chemical
(,977,O
1,977,O
to,977,O
8,977,O
mM,977,O
),977,O
reduced,977,O
APAP,977,B-Chemical
deacetylation,977,O
and,977,O
covalent,977,O
binding,977,O
in,977,O
F344,977,O
renal,977,O
cortical,977,O
homogenates,977,O
in,977,O
a,977,O
concentration-dependent,977,O
manner,977,O
.,977,O
Pretreatment,978,O
of,978,O
animals,978,O
with,978,O
BNPP,978,B-Chemical
prior,978,O
to,978,O
APAP,978,B-Chemical
or,978,O
PAP,978,B-Chemical
administration,978,O
resulted,978,O
in,978,O
marked,978,O
reduction,978,O
of,978,O
APAP,978,B-Chemical
(,978,O
900,978,O
mg/kg,978,O
),978,O
nephrotoxicity,978,B-Disease
but,978,O
not,978,O
PAP,978,B-Chemical
nephrotoxicity,978,B-Disease
.,978,O
This,979,O
result,979,O
was,979,O
not,979,O
due,979,O
to,979,O
altered,979,O
disposition,979,O
of,979,O
either,979,O
APAP,979,B-Chemical
or,979,O
acetylated,979,O
metabolites,979,O
in,979,O
plasma,979,O
or,979,O
renal,979,O
cortical,979,O
and,979,O
hepatic,979,O
tissue,979,O
.,979,O
Rather,980,O
",",980,O
BNPP,980,B-Chemical
pretreatment,980,O
reduced,980,O
the,980,O
fraction,980,O
of,980,O
APAP,980,B-Chemical
excreted,980,O
as,980,O
PAP,980,B-Chemical
by,980,O
64,980,O
and,980,O
75,980,O
%,980,O
after,980,O
APAP,980,B-Chemical
doses,980,O
of,980,O
750,980,O
and,980,O
900,980,O
mg/kg,980,O
.,980,O
BNPP,981,B-Chemical
did,981,O
not,981,O
alter,981,O
the,981,O
excretion,981,O
of,981,O
APAP,981,B-Chemical
or,981,O
any,981,O
of,981,O
its,981,O
non-deacetylated,981,O
metabolites,981,O
nor,981,O
did,981,O
BNPP,981,B-Chemical
alter,981,O
excretion,981,O
of,981,O
PAP,981,B-Chemical
or,981,O
its,981,O
metabolites,981,O
after,981,O
PAP,981,B-Chemical
doses,981,O
of,981,O
150,981,O
and,981,O
300,981,O
mg/kg,981,O
.,981,O
Therefore,982,O
",",982,O
the,982,O
BNPP-induced,982,B-Chemical
reduction,982,O
in,982,O
APAP-induced,982,B-Chemical
nephrotoxicity,982,B-Disease
appears,982,O
to,982,O
be,982,O
due,982,O
to,982,O
inhibition,982,O
of,982,O
APAP,982,B-Chemical
deacetylation,982,O
.,982,O
It,983,O
is,983,O
concluded,983,O
that,983,O
PAP,983,B-Chemical
formation,983,O
",",983,O
in,983,O
vivo,983,O
",",983,O
accounts,983,O
",",983,O
at,983,O
least,983,O
in,983,O
part,983,O
",",983,O
for,983,O
APAP-induced,983,B-Chemical
renal,983,B-Disease
tubular,983,I-Disease
necrosis,983,I-Disease
.,983,O
Morphine-induced,984,B-Chemical
seizures,984,B-Disease
in,984,O
newborn,984,O
infants,984,O
.,984,O
Two,985,O
neonates,985,O
suffered,985,O
from,985,O
generalized,985,O
seizures,985,B-Disease
during,985,O
the,985,O
course,985,O
of,985,O
intravenous,985,O
morphine,985,B-Chemical
sulfate,985,I-Chemical
for,985,O
post-operative,985,O
analgesia,985,O
.,985,O
They,986,O
received,986,O
morphine,986,B-Chemical
in,986,O
doses,986,O
of,986,O
32,986,O
micrograms/kg/hr,986,O
and,986,O
40,986,O
micrograms/kg/hr,986,O
larger,986,O
than,986,O
a,986,O
group,986,O
of,986,O
10,986,O
neonates,986,O
who,986,O
received,986,O
6-24,986,O
micrograms/kg/hr,986,O
and,986,O
had,986,O
no,986,O
seizures,986,B-Disease
.,986,O
Plasma,987,O
concentrations,987,O
of,987,O
morphine,987,B-Chemical
in,987,O
these,987,O
neonates,987,O
was,987,O
excessive,987,O
(,987,O
60,987,O
and,987,O
90,987,O
mg/ml,987,O
),987,O
.,987,O
Other,988,O
known,988,O
reasons,988,O
for,988,O
seizures,988,B-Disease
were,988,O
ruled,988,O
out,988,O
and,988,O
the,988,O
convulsions,988,B-Disease
stopped,988,O
a,988,O
few,988,O
hours,988,O
after,988,O
cessation,988,O
of,988,O
morphine,988,B-Chemical
and,988,O
did,988,O
not,988,O
reoccur,988,O
in,988,O
the,988,O
subsequent,988,O
8,988,O
months,988,O
.,988,O
It,989,O
is,989,O
suggested,989,O
that,989,O
post-operative,989,O
intravenous,989,O
morphine,989,B-Chemical
should,989,O
not,989,O
exceed,989,O
20,989,O
micrograms/kg/ml,989,O
in,989,O
neonates,989,O
.,989,O
Effect,990,O
of,990,O
vincristine,990,B-Chemical
sulfate,990,I-Chemical
on,990,O
Pseudomonas,990,B-Disease
infections,990,I-Disease
in,990,O
monkeys,990,O
.,990,O
In,991,O
rhesus,991,O
monkeys,991,O
",",991,O
intravenous,991,O
challenge,991,O
with,991,O
0.6,991,O
x,991,O
10,991,O
(,991,O
10,991,O
),991,O
to,991,O
2.2,991,O
x,991,O
10,991,O
(,991,O
10,991,O
),991,O
Pseudomonas,991,O
aeruginosa,991,O
organisms,991,O
caused,991,O
acute,991,O
illness,991,O
of,991,O
4,991,O
to,991,O
5,991,O
days,991,O
',991,O
duration,991,O
with,991,O
spontaneous,991,O
recovery,991,O
in,991,O
13,991,O
of,991,O
15,991,O
monkeys,991,O
;,991,O
blood,991,O
cultures,991,O
became,991,O
negative,991,O
3,991,O
to,991,O
17,991,O
days,991,O
after,991,O
challenge,991,O
.,991,O
Leukocytosis,992,B-Disease
was,992,O
observed,992,O
in,992,O
all,992,O
monkeys,992,O
.,992,O
Intravenous,993,O
or,993,O
intratracheal,993,O
inoculation,993,O
of,993,O
2.0,993,O
to,993,O
2.5,993,O
mg,993,O
of,993,O
vincristine,993,B-Chemical
sulfate,993,I-Chemical
was,993,O
followed,993,O
by,993,O
leukopenia,993,B-Disease
in,993,O
4,993,O
to,993,O
5,993,O
days,993,O
.,993,O
Intravenous,994,O
inoculation,994,O
of,994,O
4.2,994,O
x,994,O
10,994,O
(,994,O
10,994,O
),994,O
to,994,O
7.8,994,O
x,994,O
10,994,O
(,994,O
10,994,O
),994,O
pyocin,994,O
type,994,O
6,994,O
Pseudomonas,994,O
organisms,994,O
in,994,O
monkeys,994,O
given,994,O
vincristine,994,B-Chemical
sulfate,994,I-Chemical
4,994,O
days,994,O
previously,994,O
resulted,994,O
in,994,O
fatal,994,O
infection,994,B-Disease
in,994,O
11,994,O
of,994,O
14,994,O
monkeys,994,O
",",994,O
whereas,994,O
none,994,O
of,994,O
four,994,O
receiving,994,O
Pseudomonas,994,O
alone,994,O
died,994,O
.,994,O
These,995,O
studies,995,O
suggest,995,O
that,995,O
an,995,O
antimetabolite-induced,995,O
leukopenia,995,B-Disease
predisposes,995,O
to,995,O
severe,995,O
Pseudomonas,995,O
sepsis,995,B-Disease
and,995,O
that,995,O
such,995,O
monkeys,995,O
may,995,O
serve,995,O
as,995,O
a,995,O
biological,995,O
model,995,O
for,995,O
study,995,O
of,995,O
comparative,995,O
efficacy,995,O
of,995,O
antimicrobial,995,O
agents,995,O
.,995,O
Central,996,O
excitatory,996,O
actions,996,O
of,996,O
flurazepam,996,B-Chemical
.,996,O
Toxic,997,O
actions,997,O
of,997,O
flurazepam,997,B-Chemical
(,997,O
FZP,997,B-Chemical
),997,O
were,997,O
studied,997,O
in,997,O
cats,997,O
",",997,O
mice,997,O
and,997,O
rats,997,O
.,997,O
High,998,O
doses,998,O
caused,998,O
an,998,O
apparent,998,O
central,998,O
excitation,998,O
",",998,O
most,998,O
clearly,998,O
seen,998,O
as,998,O
clonic,998,O
convulsions,998,B-Disease
",",998,O
superimposed,998,O
on,998,O
general,998,O
depression,998,B-Disease
.,998,O
Following,999,O
a,999,O
lethal,999,O
dose,999,O
",",999,O
death,999,O
was,999,O
always,999,O
associated,999,O
with,999,O
convulsions,999,B-Disease
.,999,O
Comparing,1000,O
the,1000,O
relative,1000,O
sensitivity,1000,O
to,1000,O
central,1000,O
depression,1000,B-Disease
and,1000,O
excitation,1000,O
revealed,1000,O
that,1000,O
rats,1000,O
were,1000,O
least,1000,O
likely,1000,O
to,1000,O
have,1000,O
convulsions,1000,B-Disease
at,1000,O
doses,1000,O
that,1000,O
did,1000,O
not,1000,O
first,1000,O
cause,1000,O
loss,1000,B-Disease
of,1000,I-Disease
consciousness,1000,I-Disease
",",1000,O
while,1000,O
cats,1000,O
most,1000,O
clearly,1000,O
showed,1000,O
marked,1000,O
central,1000,O
excitatory,1000,O
actions,1000,O
.,1000,O
Signs,1001,O
of,1001,O
FZP,1001,B-Chemical
toxocity,1001,B-Disease
in,1001,O
cats,1001,O
included,1001,O
excessive,1001,O
salivation,1001,B-Disease
",",1001,O
extreme,1001,O
apprehensive,1001,O
behavior,1001,O
",",1001,O
retching,1001,O
",",1001,O
muscle,1001,B-Disease
tremors,1001,I-Disease
and,1001,O
convulsions,1001,B-Disease
.,1001,O
An,1002,O
interaction,1002,O
between,1002,O
FZP,1002,B-Chemical
and,1002,O
pentylenetetrazol,1002,B-Chemical
(,1002,O
PTZ,1002,B-Chemical
),1002,O
was,1002,O
shown,1002,O
by,1002,O
pretreating,1002,O
mice,1002,O
with,1002,O
FZP,1002,B-Chemical
before,1002,O
PTZ,1002,B-Chemical
challenge,1002,O
.,1002,O
As,1003,O
a,1003,O
function,1003,O
of,1003,O
dose,1003,O
",",1003,O
FZP,1003,B-Chemical
first,1003,O
protected,1003,O
against,1003,O
convulsions,1003,B-Disease
and,1003,O
death,1003,O
.,1003,O
At,1004,O
higher,1004,O
doses,1004,O
",",1004,O
however,1004,O
",",1004,O
convulsions,1004,B-Disease
again,1004,O
emerged,1004,O
.,1004,O
These,1005,O
doses,1005,O
of,1005,O
FZP,1005,B-Chemical
were,1005,O
lower,1005,O
than,1005,O
those,1005,O
that,1005,O
would,1005,O
alone,1005,O
cause,1005,O
convulsions,1005,B-Disease
.,1005,O
These,1006,O
results,1006,O
may,1006,O
be,1006,O
relevant,1006,O
to,1006,O
the,1006,O
use,1006,O
of,1006,O
FZP,1006,B-Chemical
in,1006,O
clinical,1006,O
situations,1006,O
in,1006,O
which,1006,O
there,1006,O
is,1006,O
increased,1006,O
neural,1006,O
excitability,1006,O
",",1006,O
such,1006,O
as,1006,O
epilepsy,1006,B-Disease
or,1006,O
sedative-hypnotic,1006,O
drug,1006,O
withdrawal,1006,O
.,1006,O
Evidence,1007,O
for,1007,O
cardiac,1007,O
beta,1007,O
2-adrenoceptors,1007,O
in,1007,O
man,1007,O
.,1007,O
We,1008,O
compared,1008,O
the,1008,O
effects,1008,O
of,1008,O
single,1008,O
doses,1008,O
of,1008,O
50,1008,O
mg,1008,O
atenolol,1008,B-Chemical
(,1008,O
cardioselective,1008,O
),1008,O
",",1008,O
40,1008,O
mg,1008,O
propranolol,1008,B-Chemical
(,1008,O
nonselective,1008,O
),1008,O
",",1008,O
and,1008,O
placebo,1008,O
on,1008,O
both,1008,O
exercise-,1008,O
and,1008,O
isoproterenol-induced,1008,B-Chemical
tachycardia,1008,B-Disease
in,1008,O
two,1008,O
experiments,1008,O
involving,1008,O
nine,1008,O
normal,1008,O
subjects,1008,O
.,1008,O
Maximal,1009,O
exercise,1009,O
heart,1009,O
rate,1009,O
was,1009,O
reduced,1009,O
from,1009,O
187,1009,O
+/-,1009,O
4,1009,O
(,1009,O
SEM,1009,O
),1009,O
after,1009,O
placebo,1009,O
to,1009,O
146,1009,O
+/-,1009,O
7,1009,O
bpm,1009,O
after,1009,O
atenolol,1009,B-Chemical
and,1009,O
138,1009,O
+/-,1009,O
6,1009,O
bpm,1009,O
after,1009,O
propranolol,1009,B-Chemical
",",1009,O
but,1009,O
there,1009,O
were,1009,O
no,1009,O
differences,1009,O
between,1009,O
the,1009,O
drugs,1009,O
.,1009,O
The,1010,O
effects,1010,O
on,1010,O
isoproterenol,1010,B-Chemical
tachycardia,1010,B-Disease
were,1010,O
determined,1010,O
before,1010,O
and,1010,O
after,1010,O
atropine,1010,B-Chemical
(,1010,O
0.04,1010,O
mg/kg,1010,O
IV,1010,O
),1010,O
.,1010,O
Isoproterenol,1011,B-Chemical
sensitivity,1011,O
was,1011,O
determined,1011,O
as,1011,O
the,1011,O
intravenous,1011,O
dose,1011,O
that,1011,O
increased,1011,O
heart,1011,O
rate,1011,O
by,1011,O
25,1011,O
bpm,1011,O
(,1011,O
CD25,1011,O
),1011,O
and,1011,O
this,1011,O
was,1011,O
increased,1011,O
from,1011,O
1.8,1011,O
+/-,1011,O
0.3,1011,O
micrograms,1011,O
after,1011,O
placebo,1011,O
to,1011,O
38.9,1011,O
+/-,1011,O
8.3,1011,O
micrograms,1011,O
after,1011,O
propranolol,1011,B-Chemical
and,1011,O
8.3,1011,O
+/-,1011,O
1.7,1011,O
micrograms,1011,O
after,1011,O
atenolol,1011,B-Chemical
.,1011,O
The,1012,O
difference,1012,O
in,1012,O
the,1012,O
effects,1012,O
of,1012,O
the,1012,O
two,1012,O
was,1012,O
significant,1012,O
.,1012,O
After,1013,O
atropine,1013,B-Chemical
the,1013,O
CD25,1013,O
was,1013,O
unchanged,1013,O
after,1013,O
placebo,1013,O
(,1013,O
2.3,1013,O
+/-,1013,O
0.3,1013,O
micrograms,1013,O
),1013,O
and,1013,O
atenolol,1013,B-Chemical
(,1013,O
7.7,1013,O
+/-,1013,O
1.3,1013,O
micrograms,1013,O
),1013,O
;,1013,O
it,1013,O
was,1013,O
reduced,1013,O
after,1013,O
propranolol,1013,B-Chemical
(,1013,O
24.8,1013,O
+/-,1013,O
5.0,1013,O
micrograms,1013,O
),1013,O
",",1013,O
but,1013,O
remained,1013,O
different,1013,O
from,1013,O
atenolol,1013,B-Chemical
.,1013,O
This,1014,O
change,1014,O
with,1014,O
propranolol,1014,B-Chemical
sensitivity,1014,O
was,1014,O
calculated,1014,O
as,1014,O
the,1014,O
apparent,1014,O
Ka,1014,O
",",1014,O
this,1014,O
was,1014,O
unchanged,1014,O
by,1014,O
atropine,1014,B-Chemical
(,1014,O
11.7,1014,O
+/-,1014,O
2.1,1014,O
and,1014,O
10.1,1014,O
+/-,1014,O
2.5,1014,O
ml/ng,1014,O
),1014,O
.,1014,O
These,1015,O
data,1015,O
are,1015,O
consistent,1015,O
with,1015,O
the,1015,O
hypothesis,1015,O
that,1015,O
exercise-induced,1015,O
tachycardia,1015,B-Disease
results,1015,O
largely,1015,O
from,1015,O
beta,1015,O
1-receptor,1015,O
activation,1015,O
that,1015,O
is,1015,O
blocked,1015,O
by,1015,O
both,1015,O
cardioselective,1015,O
and,1015,O
nonselective,1015,O
drugs,1015,O
",",1015,O
whereas,1015,O
isoproterenol,1015,B-Chemical
activates,1015,O
both,1015,O
beta,1015,O
1-,1015,O
and,1015,O
beta,1015,O
2-receptors,1015,O
so,1015,O
that,1015,O
after,1015,O
cardioselective,1015,O
blockade,1015,O
there,1015,O
remains,1015,O
a,1015,O
beta,1015,O
2-component,1015,O
that,1015,O
can,1015,O
be,1015,O
blocked,1015,O
with,1015,O
a,1015,O
nonselective,1015,O
drug,1015,O
.,1015,O
While,1016,O
there,1016,O
appear,1016,O
to,1016,O
be,1016,O
beta,1016,O
2-receptors,1016,O
in,1016,O
the,1016,O
human,1016,O
heart,1016,O
",",1016,O
their,1016,O
physiologic,1016,O
or,1016,O
pathologic,1016,O
roles,1016,O
remain,1016,O
to,1016,O
be,1016,O
defined,1016,O
.,1016,O
Hormones,1017,O
and,1017,O
risk,1017,O
of,1017,O
breast,1017,B-Disease
cancer,1017,I-Disease
.,1017,O
This,1018,O
paper,1018,O
reports,1018,O
the,1018,O
results,1018,O
of,1018,O
a,1018,O
study,1018,O
of,1018,O
50,1018,O
menopausal,1018,O
women,1018,O
receiving,1018,O
hormonal,1018,O
replacement,1018,O
therapy,1018,O
.,1018,O
The,1019,O
majority,1019,O
(,1019,O
29,1019,O
),1019,O
had,1019,O
surgical,1019,O
menopause,1019,O
;,1019,O
their,1019,O
mean,1019,O
age,1019,O
was,1019,O
45.7,1019,O
years,1019,O
.,1019,O
It,1020,O
was,1020,O
hypothesized,1020,O
that,1020,O
progestins,1020,B-Chemical
could,1020,O
equilibrate,1020,O
the,1020,O
effects,1020,O
of,1020,O
the,1020,O
estrogenic,1020,O
stimulation,1020,O
on,1020,O
the,1020,O
mammary,1020,O
and,1020,O
endometrial,1020,O
target,1020,O
tissues,1020,O
of,1020,O
women,1020,O
on,1020,O
hormonal,1020,O
replacement,1020,O
therapy,1020,O
.,1020,O
The,1021,O
treatment,1021,O
schedule,1021,O
consisted,1021,O
of,1021,O
conjugated,1021,B-Chemical
estrogens,1021,I-Chemical
(,1021,O
Premarin,1021,B-Chemical
),1021,O
1.25,1021,O
mg/day,1021,O
for,1021,O
21,1021,O
days,1021,O
and,1021,O
Medroxyprogesterone,1021,B-Chemical
acetate,1021,I-Chemical
10,1021,O
mg/day,1021,O
for,1021,O
10,1021,O
days,1021,O
in,1021,O
each,1021,O
month,1021,O
.,1021,O
The,1022,O
mean,1022,O
treatment,1022,O
period,1022,O
was,1022,O
18,1022,O
months,1022,O
.,1022,O
During,1023,O
the,1023,O
follow-up,1023,O
period,1023,O
",",1023,O
attention,1023,O
was,1023,O
paid,1023,O
to,1023,O
breast,1023,O
modifications,1023,O
as,1023,O
evidenced,1023,O
by,1023,O
symptomatology,1023,O
",",1023,O
physical,1023,O
examination,1023,O
",",1023,O
and,1023,O
plate,1023,O
thermography,1023,O
.,1023,O
Mastodynia,1024,B-Disease
was,1024,O
reported,1024,O
by,1024,O
21,1024,O
patients,1024,O
",",1024,O
and,1024,O
physical,1024,O
examination,1024,O
revealed,1024,O
a,1024,O
light,1024,O
increase,1024,O
in,1024,O
breast,1024,O
firmness,1024,O
in,1024,O
12,1024,O
women,1024,O
and,1024,O
a,1024,O
moderate,1024,O
increase,1024,O
in,1024,O
breast,1024,O
nodularity,1024,O
in,1024,O
2,1024,O
women,1024,O
.,1024,O
Themography,1025,O
confirmed,1025,O
the,1025,O
existence,1025,O
of,1025,O
an,1025,O
excessive,1025,O
breast,1025,O
stimulation,1025,O
in,1025,O
1,1025,O
women,1025,O
who,1025,O
complained,1025,O
of,1025,O
moderate,1025,O
mastodynia,1025,B-Disease
and,1025,O
in,1025,O
5,1025,O
of,1025,O
the,1025,O
7,1025,O
women,1025,O
who,1025,O
complained,1025,O
of,1025,O
severe,1025,O
mastodynia,1025,B-Disease
.,1025,O
Normalization,1026,O
was,1026,O
obtained,1026,O
by,1026,O
halving,1026,O
the,1026,O
estrogen,1026,B-Chemical
dose,1026,O
.,1026,O
These,1027,O
results,1027,O
suggest,1027,O
that,1027,O
hormonal,1027,O
replacement,1027,O
therapy,1027,O
can,1027,O
be,1027,O
safely,1027,O
prescribed,1027,O
if,1027,O
the,1027,O
following,1027,O
criteria,1027,O
are,1027,O
satisfied,1027,O
:,1027,O
1,1027,O
),1027,O
preliminary,1027,O
evaluation,1027,O
of,1027,O
patients,1027,O
from,1027,O
a,1027,O
clinical,1027,O
",",1027,O
metabolic,1027,O
",",1027,O
cytologic,1027,O
",",1027,O
and,1027,O
mammographic,1027,O
perspective,1027,O
;,1027,O
2,1027,O
),1027,O
cyclic,1027,O
treatment,1027,O
schedule,1027,O
",",1027,O
with,1027,O
a,1027,O
progestative,1027,O
phase,1027,O
of,1027,O
10,1027,O
days,1027,O
;,1027,O
and,1027,O
3,1027,O
),1027,O
periodic,1027,O
complete,1027,O
follow-up,1027,O
",",1027,O
with,1027,O
accurate,1027,O
thermographic,1027,O
evaluation,1027,O
of,1027,O
the,1027,O
breast,1027,O
target,1027,O
tissues,1027,O
.,1027,O
Early,1028,O
infections,1028,B-Disease
in,1028,O
kidney,1028,O
",",1028,O
heart,1028,O
",",1028,O
and,1028,O
liver,1028,O
transplant,1028,O
recipients,1028,O
on,1028,O
cyclosporine,1028,B-Chemical
.,1028,O
Eighty-one,1029,O
renal,1029,O
",",1029,O
seventeen,1029,O
heart,1029,O
",",1029,O
and,1029,O
twenty-four,1029,O
liver,1029,O
transplant,1029,O
patients,1029,O
were,1029,O
followed,1029,O
for,1029,O
infection,1029,B-Disease
.,1029,O
Seventeen,1030,O
renal,1030,O
patients,1030,O
received,1030,O
azathioprine,1030,B-Chemical
(,1030,O
Aza,1030,B-Chemical
),1030,O
and,1030,O
prednisone,1030,B-Chemical
as,1030,O
part,1030,O
of,1030,O
a,1030,O
randomized,1030,O
trial,1030,O
of,1030,O
immunosuppression,1030,O
with,1030,O
21,1030,O
cyclosporine-and-prednisone-treated,1030,B-Chemical
renal,1030,O
transplant,1030,O
patients,1030,O
.,1030,O
All,1031,O
others,1031,O
received,1031,O
cyclosporine,1031,B-Chemical
and,1031,O
prednisone,1031,B-Chemical
.,1031,O
The,1032,O
randomized,1032,O
Aza,1032,B-Chemical
patients,1032,O
had,1032,O
more,1032,O
overall,1032,O
infections,1032,B-Disease
(,1032,O
P,1032,O
less,1032,O
than,1032,O
0.05,1032,O
),1032,O
and,1032,O
more,1032,O
nonviral,1032,O
infections,1032,B-Disease
(,1032,O
P,1032,O
less,1032,O
than,1032,O
0.02,1032,O
),1032,O
than,1032,O
the,1032,O
randomized,1032,O
cyclosporine,1032,B-Chemical
patients,1032,O
.,1032,O
Heart,1033,O
and,1033,O
liver,1033,O
patients,1033,O
had,1033,O
more,1033,O
infections,1033,B-Disease
than,1033,O
cyclosporine,1033,B-Chemical
renal,1033,O
patients,1033,O
but,1033,O
fewer,1033,O
infections,1033,B-Disease
than,1033,O
the,1033,O
Aza,1033,B-Chemical
renal,1033,O
patients,1033,O
.,1033,O
There,1034,O
were,1034,O
no,1034,O
infectious,1034,O
deaths,1034,O
in,1034,O
renal,1034,O
transplant,1034,O
patients,1034,O
on,1034,O
cyclosporine,1034,B-Chemical
or,1034,O
Aza,1034,B-Chemical
",",1034,O
but,1034,O
infection,1034,B-Disease
played,1034,O
a,1034,O
major,1034,O
role,1034,O
in,1034,O
3,1034,O
out,1034,O
of,1034,O
6,1034,O
cardiac,1034,O
transplant,1034,O
deaths,1034,O
and,1034,O
in,1034,O
8,1034,O
out,1034,O
of,1034,O
9,1034,O
liver,1034,O
transplant,1034,O
deaths,1034,O
.,1034,O
Renal,1035,O
patients,1035,O
on,1035,O
cyclosporine,1035,B-Chemical
had,1035,O
the,1035,O
fewest,1035,O
bacteremias,1035,B-Disease
.,1035,O
Analysis,1036,O
of,1036,O
site,1036,O
of,1036,O
infection,1036,B-Disease
showed,1036,O
a,1036,O
preponderance,1036,O
of,1036,O
abdominal,1036,B-Disease
infections,1036,I-Disease
in,1036,O
liver,1036,O
patients,1036,O
",",1036,O
intrathoracic,1036,O
infections,1036,B-Disease
in,1036,O
heart,1036,O
patients,1036,O
",",1036,O
and,1036,O
urinary,1036,B-Disease
tract,1036,I-Disease
infections,1036,I-Disease
in,1036,O
renal,1036,O
patients,1036,O
.,1036,O
Pulmonary,1037,O
infections,1037,B-Disease
were,1037,O
less,1037,O
common,1037,O
in,1037,O
cyclosporine-treated,1037,B-Chemical
renal,1037,O
patients,1037,O
than,1037,O
in,1037,O
Aza-treated,1037,B-Chemical
patients,1037,O
(,1037,O
P,1037,O
less,1037,O
than,1037,O
0.05,1037,O
),1037,O
.,1037,O
Aza,1038,B-Chemical
patients,1038,O
had,1038,O
significantly,1038,O
more,1038,O
staphylococcal,1038,B-Disease
infections,1038,I-Disease
than,1038,O
all,1038,O
other,1038,O
transplant,1038,O
groups,1038,O
(,1038,O
P,1038,O
less,1038,O
than,1038,O
0.005,1038,O
),1038,O
",",1038,O
and,1038,O
systemic,1038,O
fungal,1038,B-Disease
infections,1038,I-Disease
occurred,1038,O
only,1038,O
in,1038,O
the,1038,O
liver,1038,O
transplant,1038,O
group,1038,O
.,1038,O
Cytomegalovirus,1039,O
(,1039,O
CMV,1039,O
),1039,O
shedding,1039,O
or,1039,O
serological,1039,O
rises,1039,O
in,1039,O
antibody,1039,O
titer,1039,O
",",1039,O
or,1039,O
both,1039,O
occurred,1039,O
in,1039,O
78,1039,O
%,1039,O
of,1039,O
cyclosporine,1039,B-Chemical
patients,1039,O
and,1039,O
76,1039,O
%,1039,O
of,1039,O
Aza,1039,B-Chemical
patients,1039,O
.,1039,O
Of,1040,O
the,1040,O
cyclosporine,1040,B-Chemical
patients,1040,O
",",1040,O
15,1040,O
%,1040,O
had,1040,O
symptoms,1040,O
related,1040,O
to,1040,O
CMV,1040,B-Disease
infection,1040,I-Disease
.,1040,O
Serological,1041,O
evidence,1041,O
for,1041,O
Epstein,1041,B-Disease
Barr,1041,I-Disease
Virus,1041,I-Disease
infection,1041,I-Disease
was,1041,O
found,1041,O
in,1041,O
20,1041,O
%,1041,O
of,1041,O
65,1041,O
cyclosporine,1041,B-Chemical
patients,1041,O
studied,1041,O
.,1041,O
Three,1042,O
had,1042,O
associated,1042,O
symptoms,1042,O
",",1042,O
and,1042,O
one,1042,O
developed,1042,O
a,1042,O
lymphoma,1042,B-Disease
.,1042,O
Structure-activity,1043,O
and,1043,O
dose-effect,1043,O
relationships,1043,O
of,1043,O
the,1043,O
antagonism,1043,O
of,1043,O
picrotoxin-induced,1043,B-Chemical
seizures,1043,B-Disease
by,1043,O
cholecystokinin,1043,B-Chemical
",",1043,O
fragments,1043,O
and,1043,O
analogues,1043,O
of,1043,O
cholecystokinin,1043,B-Chemical
in,1043,O
mice,1043,O
.,1043,O
Intraperitoneal,1044,O
administration,1044,O
of,1044,O
cholecystokinin,1044,B-Chemical
octapeptide,1044,I-Chemical
sulphate,1044,O
ester,1044,O
(,1044,O
CCK-8-SE,1044,B-Chemical
),1044,O
and,1044,O
nonsulphated,1044,O
cholecystokinin,1044,B-Chemical
octapeptide,1044,I-Chemical
(,1044,O
CCK-8-NS,1044,B-Chemical
),1044,O
enhanced,1044,O
the,1044,O
latency,1044,O
of,1044,O
seizures,1044,B-Disease
induced,1044,O
by,1044,O
picrotoxin,1044,B-Chemical
in,1044,O
mice,1044,O
.,1044,O
Experiments,1045,O
with,1045,O
N-,1045,O
and,1045,O
C-terminal,1045,O
fragments,1045,O
revealed,1045,O
that,1045,O
the,1045,O
C-terminal,1045,O
tetrapeptide,1045,O
(,1045,O
CCK-5-8,1045,O
),1045,O
was,1045,O
the,1045,O
active,1045,O
centre,1045,O
of,1045,O
the,1045,O
CCK,1045,O
octapeptide,1045,O
molecule,1045,O
.,1045,O
The,1046,O
analogues,1046,O
CCK-8-SE,1046,B-Chemical
and,1046,O
CCK-8-NS,1046,B-Chemical
(,1046,O
dose,1046,O
range,1046,O
0.2-6.4,1046,O
mumol/kg,1046,O
),1046,O
and,1046,O
caerulein,1046,B-Chemical
dose,1046,O
range,1046,O
0.1-0.8,1046,O
mumol/kg,1046,O
),1046,O
showed,1046,O
bell-shaped,1046,O
dose-effect,1046,O
curves,1046,O
",",1046,O
with,1046,O
the,1046,O
greatest,1046,O
maximum,1046,O
inhibition,1046,O
for,1046,O
CCK-8-NS,1046,B-Chemical
.,1046,O
The,1047,O
peptide,1047,O
CCK-5-8,1047,O
had,1047,O
weak,1047,O
anticonvulsant,1047,O
activity,1047,O
in,1047,O
comparison,1047,O
to,1047,O
the,1047,O
octapeptides,1047,O
",",1047,O
3.2,1047,O
mumol/kg,1047,O
and,1047,O
larger,1047,O
doses,1047,O
of,1047,O
the,1047,O
reference,1047,O
drug,1047,O
",",1047,O
diazepam,1047,B-Chemical
",",1047,O
totally,1047,O
prevented,1047,O
picrotoxin-induced,1047,B-Chemical
seizures,1047,B-Disease
and,1047,O
mortality,1047,O
.,1047,O
The,1048,O
maximum,1048,O
effect,1048,O
of,1048,O
the,1048,O
peptides,1048,O
tested,1048,O
was,1048,O
less,1048,O
than,1048,O
that,1048,O
of,1048,O
diazepam,1048,B-Chemical
.,1048,O
Experiments,1049,O
with,1049,O
analogues,1049,O
and,1049,O
derivatives,1049,O
of,1049,O
CCK-5-8,1049,O
demonstrated,1049,O
that,1049,O
the,1049,O
effectiveness,1049,O
of,1049,O
the,1049,O
beta-alanyl,1049,O
derivatives,1049,O
of,1049,O
CCK-5-8,1049,O
were,1049,O
enhanced,1049,O
and,1049,O
that,1049,O
they,1049,O
were,1049,O
equipotent,1049,O
with,1049,O
CCK-8-SE,1049,B-Chemical
.,1049,O
Of,1050,O
the,1050,O
CCK-2-8,1050,O
analogues,1050,O
",",1050,O
Ser,1050,O
(,1050,O
SO3H,1050,O
),1050,O
7-Ac-CCK-2-8-SE,1050,O
and,1050,O
Thr,1050,O
(,1050,O
SO3H,1050,O
),1050,O
7-Ac-CCK-2-8-SE,1050,O
and,1050,O
Hyp,1050,O
(,1050,O
SO3H,1050,O
),1050,O
-Ac-CCK-2-8-SE,1050,O
were,1050,O
slightly,1050,O
more,1050,O
active,1050,O
than,1050,O
CCK-8-SE,1050,B-Chemical
.,1050,O
Vasopressin,1051,B-Chemical
as,1051,O
a,1051,O
possible,1051,O
contributor,1051,O
to,1051,O
hypertension,1051,B-Disease
.,1051,O
The,1052,O
role,1052,O
of,1052,O
vasopressin,1052,B-Chemical
as,1052,O
a,1052,O
pressor,1052,O
agent,1052,O
to,1052,O
the,1052,O
hypertensive,1052,B-Disease
process,1052,O
was,1052,O
examined,1052,O
.,1052,O
Vasopressin,1053,B-Chemical
plays,1053,O
a,1053,O
major,1053,O
role,1053,O
in,1053,O
the,1053,O
pathogenesis,1053,O
of,1053,O
DOCA-salt,1053,B-Chemical
hypertension,1053,B-Disease
",",1053,O
since,1053,O
the,1053,O
elevation,1053,O
of,1053,O
blood,1053,O
pressure,1053,O
was,1053,O
not,1053,O
substantial,1053,O
in,1053,O
the,1053,O
rats,1053,O
with,1053,O
lithium-treated,1053,B-Chemical
diabetes,1053,B-Disease
insipidus,1053,I-Disease
after,1053,O
DOCA-salt,1053,B-Chemical
treatment,1053,O
.,1053,O
Administration,1054,O
of,1054,O
DDAVP,1054,B-Chemical
which,1054,O
has,1054,O
antidiuretic,1054,O
action,1054,O
but,1054,O
minimal,1054,O
vasopressor,1054,O
effect,1054,O
failed,1054,O
to,1054,O
increase,1054,O
blood,1054,O
pressure,1054,O
to,1054,O
the,1054,O
levels,1054,O
observed,1054,O
after,1054,O
administration,1054,O
of,1054,O
AVP,1054,O
.,1054,O
Furthermore,1055,O
",",1055,O
the,1055,O
pressor,1055,O
action,1055,O
of,1055,O
vasopressin,1055,B-Chemical
appears,1055,O
to,1055,O
be,1055,O
important,1055,O
in,1055,O
the,1055,O
development,1055,O
of,1055,O
this,1055,O
model,1055,O
of,1055,O
hypertension,1055,B-Disease
",",1055,O
since,1055,O
the,1055,O
enhanced,1055,O
pressor,1055,O
responsiveness,1055,O
to,1055,O
the,1055,O
hormone,1055,O
was,1055,O
observed,1055,O
in,1055,O
the,1055,O
initial,1055,O
stage,1055,O
of,1055,O
hypertension,1055,B-Disease
.,1055,O
Increased,1056,O
secretion,1056,O
of,1056,O
vasopressin,1056,B-Chemical
from,1056,O
neurohypophysis,1056,O
also,1056,O
promotes,1056,O
the,1056,O
function,1056,O
of,1056,O
the,1056,O
hormone,1056,O
as,1056,O
a,1056,O
pathogenetic,1056,O
factor,1056,O
in,1056,O
hypertension,1056,B-Disease
.,1056,O
An,1057,O
unproportional,1057,O
release,1057,O
of,1057,O
vasopressin,1057,B-Chemical
compared,1057,O
to,1057,O
plasma,1057,O
osmolality,1057,O
may,1057,O
be,1057,O
induced,1057,O
by,1057,O
the,1057,O
absence,1057,O
of,1057,O
an,1057,O
adjusting,1057,O
control,1057,O
of,1057,O
angiotensin,1057,B-Chemical
II,1057,O
forming,1057,O
and,1057,O
receptor,1057,O
binding,1057,O
capacity,1057,O
for,1057,O
sodium,1057,B-Chemical
balance,1057,O
in,1057,O
the,1057,O
brain,1057,O
.,1057,O
However,1058,O
",",1058,O
the,1058,O
role,1058,O
of,1058,O
vasopressin,1058,B-Chemical
remains,1058,O
to,1058,O
be,1058,O
determined,1058,O
in,1058,O
human,1058,O
essential,1058,O
hypertension,1058,B-Disease
.,1058,O
Toxic,1059,B-Disease
hepatitis,1059,I-Disease
induced,1059,O
by,1059,O
disulfiram,1059,B-Chemical
in,1059,O
a,1059,O
non-alcoholic,1059,O
.,1059,O
A,1060,O
reversible,1060,O
toxic,1060,B-Disease
liver,1060,I-Disease
damage,1060,I-Disease
was,1060,O
observed,1060,O
in,1060,O
a,1060,O
non-alcoholic,1060,O
woman,1060,O
treated,1060,O
with,1060,O
disulfiram,1060,B-Chemical
.,1060,O
The,1061,O
causative,1061,O
relationship,1061,O
was,1061,O
proven,1061,O
by,1061,O
challenge,1061,O
.,1061,O
Atrial,1062,B-Disease
thrombosis,1062,I-Disease
involving,1062,O
the,1062,O
heart,1062,O
of,1062,O
F-344,1062,O
rats,1062,O
ingesting,1062,O
quinacrine,1062,B-Chemical
hydrochloride,1062,I-Chemical
.,1062,O
Quinacrine,1063,B-Chemical
hydrochloride,1063,I-Chemical
is,1063,O
toxic,1063,O
for,1063,O
the,1063,O
heart,1063,O
of,1063,O
F-344,1063,O
rats,1063,O
.,1063,O
Rats,1064,O
treated,1064,O
with,1064,O
500,1064,O
ppm,1064,O
quinacrine,1064,B-Chemical
hydrochloride,1064,I-Chemical
in,1064,O
the,1064,O
diet,1064,O
all,1064,O
developed,1064,O
a,1064,O
high,1064,O
incidence,1064,O
of,1064,O
left,1064,O
atrial,1064,B-Disease
thrombosis,1064,I-Disease
.,1064,O
The,1065,O
lesion,1065,O
was,1065,O
associated,1065,O
with,1065,O
cardiac,1065,B-Disease
hypertrophy,1065,I-Disease
and,1065,O
dilatation,1065,O
and,1065,O
focal,1065,O
myocardial,1065,B-Disease
degeneration,1065,I-Disease
.,1065,O
Rats,1066,O
died,1066,O
from,1066,O
cardiac,1066,B-Disease
hypertrophy,1066,I-Disease
with,1066,O
severe,1066,O
acute,1066,O
and,1066,O
chronic,1066,O
congestion,1066,O
of,1066,O
the,1066,O
lungs,1066,O
",",1066,O
liver,1066,O
",",1066,O
and,1066,O
other,1066,O
organs,1066,O
.,1066,O
Seventy,1067,O
percent,1067,O
of,1067,O
rats,1067,O
given,1067,O
250,1067,O
ppm,1067,O
quinacrine,1067,B-Chemical
hydrochloride,1067,I-Chemical
and,1067,O
"1,000",1067,O
ppm,1067,O
sodium,1067,B-Chemical
nitrite,1067,I-Chemical
simultaneously,1067,O
in,1067,O
the,1067,O
diet,1067,O
had,1067,O
thrombosis,1067,B-Disease
of,1067,O
the,1067,O
atria,1067,O
of,1067,O
the,1067,O
heart,1067,O
",",1067,O
while,1067,O
untreated,1067,O
control,1067,O
rats,1067,O
in,1067,O
this,1067,O
laboratory,1067,O
did,1067,O
not,1067,O
have,1067,O
atrial,1067,B-Disease
thrombosis,1067,I-Disease
.,1067,O
Sodium,1068,B-Chemical
nitrite,1068,I-Chemical
in,1068,O
combination,1068,O
with,1068,O
quinacrine,1068,B-Chemical
hydrochloride,1068,I-Chemical
appeared,1068,O
to,1068,O
have,1068,O
no,1068,O
additional,1068,O
effect,1068,O
.,1068,O
Alternating,1069,B-Disease
sinus,1069,I-Disease
rhythm,1069,I-Disease
and,1069,O
intermittent,1069,O
sinoatrial,1069,B-Disease
block,1069,I-Disease
induced,1069,O
by,1069,O
propranolol,1069,B-Chemical
.,1069,O
Alternating,1070,B-Disease
sinus,1070,I-Disease
rhythm,1070,I-Disease
and,1070,O
intermittent,1070,O
sinoatrial,1070,B-Disease
(,1070,I-Disease
S-A,1070,I-Disease
),1070,I-Disease
block,1070,I-Disease
was,1070,O
observed,1070,O
in,1070,O
a,1070,O
57-year-old,1070,O
woman,1070,O
",",1070,O
under,1070,O
treatment,1070,O
for,1070,O
angina,1070,B-Disease
with,1070,O
80,1070,O
mg,1070,O
propranolol,1070,B-Chemical
daily,1070,O
.,1070,O
The,1071,O
electrocardiogram,1071,O
showed,1071,O
alternation,1071,O
of,1071,O
long,1071,O
and,1071,O
short,1071,O
P-P,1071,O
intervals,1071,O
and,1071,O
occasional,1071,O
pauses,1071,O
.,1071,O
These,1072,O
pauses,1072,O
were,1072,O
always,1072,O
preceded,1072,O
by,1072,O
the,1072,O
short,1072,O
P-P,1072,O
intervals,1072,O
and,1072,O
were,1072,O
usually,1072,O
followed,1072,O
by,1072,O
one,1072,O
or,1072,O
two,1072,O
P-P,1072,O
intervals,1072,O
of,1072,O
0.92-0.95,1072,O
s,1072,O
representing,1072,O
the,1072,O
basic,1072,O
sinus,1072,O
cycle,1072,O
.,1072,O
Following,1073,O
these,1073,O
basic,1073,O
sinus,1073,O
cycles,1073,O
",",1073,O
alternating,1073,B-Disease
rhythm,1073,I-Disease
started,1073,O
with,1073,O
the,1073,O
longer,1073,O
P-P,1073,O
interval,1073,O
.,1073,O
The,1074,O
long,1074,O
P-P,1074,O
intervals,1074,O
ranged,1074,O
between,1074,O
1.04-1.12,1074,O
s,1074,O
and,1074,O
the,1074,O
short,1074,O
P-P,1074,O
intervals,1074,O
between,1074,O
0.80-0.84,1074,O
s,1074,O
",",1074,O
respectively,1074,O
.,1074,O
The,1075,O
duration,1075,O
of,1075,O
the,1075,O
pauses,1075,O
were,1075,O
equal,1075,O
or,1075,O
almost,1075,O
equal,1075,O
to,1075,O
one,1075,O
short,1075,O
plus,1075,O
one,1075,O
long,1075,O
P-P,1075,O
interval,1075,O
or,1075,O
to,1075,O
twice,1075,O
the,1075,O
basic,1075,O
sinus,1075,O
cycle,1075,O
.,1075,O
In,1076,O
one,1076,O
recording,1076,O
a,1076,O
short,1076,O
period,1076,O
of,1076,O
regular,1076,O
sinus,1076,O
rhythm,1076,O
with,1076,O
intermittent,1076,O
2/1,1076,O
S-A,1076,B-Disease
block,1076,I-Disease
was,1076,O
observed,1076,O
.,1076,O
This,1077,O
short,1077,O
period,1077,O
of,1077,O
sinus,1077,O
rhythm,1077,O
was,1077,O
interrupted,1077,O
by,1077,O
sudden,1077,O
prolongation,1077,O
of,1077,O
the,1077,O
P-P,1077,O
interval,1077,O
starting,1077,O
the,1077,O
alternative,1077,O
rhythm,1077,O
.,1077,O
There,1078,O
were,1078,O
small,1078,O
changes,1078,O
in,1078,O
the,1078,O
shape,1078,O
of,1078,O
the,1078,O
P,1078,O
waves,1078,O
and,1078,O
P-R,1078,O
intervals,1078,O
.,1078,O
S-A,1079,O
conduction,1079,O
through,1079,O
two,1079,O
pathways,1079,O
",",1079,O
the,1079,O
first,1079,O
with,1079,O
2/1,1079,O
block,1079,O
the,1079,O
second,1079,O
having,1079,O
0.12-0.14,1079,O
s,1079,O
longer,1079,O
conduction,1079,O
time,1079,O
and,1079,O
with,1079,O
occasional,1079,O
2/1,1079,O
block,1079,O
was,1079,O
proposed,1079,O
for,1079,O
the,1079,O
explanation,1079,O
of,1079,O
the,1079,O
alternating,1079,O
P-P,1079,O
interval,1079,O
and,1079,O
other,1079,O
electrocardiographic,1079,O
features,1079,O
seen,1079,O
.,1079,O
Atropine,1080,B-Chemical
1,1080,O
mg,1080,O
given,1080,O
intravenously,1080,O
resulted,1080,O
in,1080,O
shortening,1080,O
of,1080,O
all,1080,O
P-P,1080,O
intervals,1080,O
without,1080,O
changing,1080,O
the,1080,O
rhythm,1080,O
.,1080,O
The,1081,O
abnormal,1081,O
rhythm,1081,O
disappeared,1081,O
with,1081,O
the,1081,O
withdrawal,1081,O
of,1081,O
propranolol,1081,B-Chemical
and,1081,O
when,1081,O
the,1081,O
drug,1081,O
was,1081,O
restarted,1081,O
a,1081,O
2/1,1081,O
S-A,1081,B-Disease
block,1081,I-Disease
was,1081,O
seen,1081,O
.,1081,O
This,1082,O
was,1082,O
accepted,1082,O
as,1082,O
evidence,1082,O
for,1082,O
propranolol,1082,B-Chemical
being,1082,O
the,1082,O
cause,1082,O
of,1082,O
this,1082,O
conduction,1082,B-Disease
disorder,1082,I-Disease
.,1082,O
Antitumor,1083,O
effect,1083,O
",",1083,O
cardiotoxicity,1083,B-Disease
",",1083,O
and,1083,O
nephrotoxicity,1083,B-Disease
of,1083,O
doxorubicin,1083,B-Chemical
in,1083,O
the,1083,O
IgM,1083,O
solid,1083,O
immunocytoma-bearing,1083,B-Disease
LOU/M/WSL,1083,O
rat,1083,O
.,1083,O
Antitumor,1084,O
activity,1084,O
",",1084,O
cardiotoxicity,1084,B-Disease
",",1084,O
and,1084,O
nephrotoxicity,1084,B-Disease
induced,1084,O
by,1084,O
doxorubicin,1084,B-Chemical
were,1084,O
studied,1084,O
in,1084,O
LOU/M/WSL,1084,O
inbred,1084,O
rats,1084,O
each,1084,O
bearing,1084,O
a,1084,O
transplantable,1084,O
solid,1084,O
IgM,1084,O
immunocytoma,1084,B-Disease
.,1084,O
Animals,1085,O
with,1085,O
a,1085,O
tumor,1085,B-Disease
(,1085,O
diameter,1085,O
",",1085,O
15.8,1085,O
+/-,1085,O
3.3,1085,O
mm,1085,O
),1085,O
were,1085,O
treated,1085,O
with,1085,O
iv,1085,O
injections,1085,O
of,1085,O
doxorubicin,1085,B-Chemical
on,1085,O
5,1085,O
consecutive,1085,O
days,1085,O
",",1085,O
followed,1085,O
by,1085,O
1,1085,O
weekly,1085,O
injection,1085,O
for,1085,O
7,1085,O
weeks,1085,O
(,1085,O
dose,1085,O
range,1085,O
",",1085,O
0.015-4.0,1085,O
mg/kg,1085,O
body,1085,O
wt,1085,O
),1085,O
.,1085,O
Tumor,1086,B-Disease
regression,1086,O
was,1086,O
observed,1086,O
with,1086,O
0.5,1086,O
mg,1086,O
doxorubicin/kg,1086,B-Chemical
.,1086,O
Complete,1087,O
disappearance,1087,O
of,1087,O
the,1087,O
tumor,1087,B-Disease
was,1087,O
induced,1087,O
with,1087,O
1.0,1087,O
mg,1087,O
doxorubicin/kg,1087,B-Chemical
.,1087,O
Histologic,1088,O
evidence,1088,O
of,1088,O
cardiotoxicity,1088,B-Disease
scored,1088,O
as,1088,O
grade,1088,O
III,1088,O
was,1088,O
only,1088,O
observed,1088,O
at,1088,O
a,1088,O
dose,1088,O
of,1088,O
1.0,1088,O
mg,1088,O
doxorubicin/kg,1088,B-Chemical
.,1088,O
Light,1089,O
microscopic,1089,O
evidence,1089,O
of,1089,O
renal,1089,B-Disease
damage,1089,I-Disease
was,1089,O
seen,1089,O
above,1089,O
a,1089,O
dose,1089,O
of,1089,O
0.5,1089,O
mg,1089,O
doxorubicin/kg,1089,B-Chemical
",",1089,O
which,1089,O
resulted,1089,O
in,1089,O
albuminuria,1089,B-Disease
and,1089,O
very,1089,O
low,1089,O
serum,1089,O
albumin,1089,O
levels,1089,O
.,1089,O
In,1090,O
the,1090,O
group,1090,O
that,1090,O
received,1090,O
1.0,1090,O
mg,1090,O
doxorubicin/kg,1090,B-Chemical
",",1090,O
the,1090,O
serum,1090,O
albumin,1090,O
level,1090,O
decreased,1090,O
from,1090,O
33.6,1090,O
+/-,1090,O
4.1,1090,O
to,1090,O
1.5,1090,O
+/-,1090,O
0.5,1090,O
g/liter,1090,O
.,1090,O
Ascites,1091,B-Disease
and,1091,O
hydrothorax,1091,B-Disease
were,1091,O
observed,1091,O
simultaneously,1091,O
.,1091,O
The,1092,O
same,1092,O
experiments,1092,O
were,1092,O
performed,1092,O
with,1092,O
non-tumor-bearing,1092,O
rats,1092,O
",",1092,O
in,1092,O
which,1092,O
no,1092,O
major,1092,O
differences,1092,O
were,1092,O
observed,1092,O
.,1092,O
In,1093,O
conclusion,1093,O
",",1093,O
antitumor,1093,O
activity,1093,O
",",1093,O
cardiotoxicity,1093,B-Disease
",",1093,O
and,1093,O
nephrotoxicity,1093,B-Disease
were,1093,O
studied,1093,O
simultaneously,1093,O
in,1093,O
the,1093,O
same,1093,O
LOU/M/WSL,1093,O
rat,1093,O
.,1093,O
Albuminuria,1094,B-Disease
due,1094,O
to,1094,O
renal,1094,B-Disease
damage,1094,I-Disease
led,1094,O
to,1094,O
extremely,1094,O
low,1094,O
serum,1094,O
albumin,1094,O
levels,1094,O
",",1094,O
so,1094,O
ascites,1094,B-Disease
and,1094,O
hydrothorax,1094,B-Disease
were,1094,O
not,1094,O
necessarily,1094,O
a,1094,O
consequence,1094,O
of,1094,O
the,1094,O
observed,1094,O
cardiomyopathy,1094,B-Disease
.,1094,O
Intraoperative,1095,O
bradycardia,1095,B-Disease
and,1095,O
hypotension,1095,B-Disease
associated,1095,O
with,1095,O
timolol,1095,B-Chemical
and,1095,O
pilocarpine,1095,B-Chemical
eye,1095,O
drops,1095,O
.,1095,O
A,1096,O
69-yr-old,1096,O
man,1096,O
",",1096,O
who,1096,O
was,1096,O
concurrently,1096,O
being,1096,O
treated,1096,O
with,1096,O
pilocarpine,1096,B-Chemical
nitrate,1096,I-Chemical
and,1096,O
timolol,1096,B-Chemical
maleate,1096,I-Chemical
eye,1096,O
drops,1096,O
",",1096,O
developed,1096,O
a,1096,O
bradycardia,1096,B-Disease
and,1096,O
became,1096,O
hypotensive,1096,B-Disease
during,1096,O
halothane,1096,B-Chemical
anaesthesia,1096,O
.,1096,O
Both,1097,O
timolol,1097,B-Chemical
and,1097,O
pilocarpine,1097,B-Chemical
were,1097,O
subsequently,1097,O
identified,1097,O
in,1097,O
a,1097,O
24-h,1097,O
collection,1097,O
of,1097,O
urine,1097,O
.,1097,O
Timolol,1098,B-Chemical
(,1098,O
but,1098,O
not,1098,O
pilocarpine,1098,B-Chemical
),1098,O
was,1098,O
detected,1098,O
in,1098,O
a,1098,O
sample,1098,O
of,1098,O
plasma,1098,O
removed,1098,O
during,1098,O
surgery,1098,O
;,1098,O
the,1098,O
plasma,1098,O
concentration,1098,O
of,1098,O
timolol,1098,B-Chemical
(,1098,O
2.6,1098,O
ng,1098,O
ml-1,1098,O
),1098,O
was,1098,O
consistent,1098,O
with,1098,O
partial,1098,O
beta-adrenoceptor,1098,O
blockade,1098,O
.,1098,O
It,1099,O
is,1099,O
postulated,1099,O
that,1099,O
this,1099,O
action,1099,O
may,1099,O
have,1099,O
been,1099,O
enhanced,1099,O
during,1099,O
halothane,1099,B-Chemical
anaesthesia,1099,O
with,1099,O
resultant,1099,O
bradycardia,1099,B-Disease
and,1099,O
hypotension,1099,B-Disease
.,1099,O
Pilocarpine,1100,B-Chemical
may,1100,O
have,1100,O
had,1100,O
a,1100,O
contributory,1100,O
effect,1100,O
.,1100,O
Succinylcholine,1101,B-Chemical
apnoea,1101,B-Disease
:,1101,O
attempted,1101,O
reversal,1101,O
with,1101,O
anticholinesterases,1101,O
.,1101,O
Anticholinesterases,1102,O
were,1102,O
administered,1102,O
in,1102,O
an,1102,O
attempt,1102,O
to,1102,O
antagonize,1102,O
prolonged,1102,O
neuromuscular,1102,B-Disease
blockade,1102,I-Disease
following,1102,O
the,1102,O
administration,1102,O
of,1102,O
succinylcholine,1102,B-Chemical
in,1102,O
a,1102,O
patient,1102,O
later,1102,O
found,1102,O
to,1102,O
be,1102,O
homozygous,1102,O
for,1102,O
atypical,1102,O
plasma,1102,O
cholinesterase,1102,O
.,1102,O
Edrophonium,1103,B-Chemical
10,1103,O
mg,1103,O
",",1103,O
given,1103,O
74,1103,O
min,1103,O
after,1103,O
succinylcholine,1103,B-Chemical
",",1103,O
when,1103,O
train-of-four,1103,O
stimulation,1103,O
was,1103,O
characteristic,1103,O
of,1103,O
phase,1103,O
II,1103,O
block,1103,O
",",1103,O
produced,1103,O
partial,1103,O
antagonism,1103,O
which,1103,O
was,1103,O
not,1103,O
sustained,1103,O
.,1103,O
Repeated,1104,O
doses,1104,O
of,1104,O
edrophonium,1104,B-Chemical
to,1104,O
70,1104,O
mg,1104,O
and,1104,O
neostigmine,1104,B-Chemical
to,1104,O
2.5,1104,O
mg,1104,O
did,1104,O
not,1104,O
antagonize,1104,O
or,1104,O
augment,1104,O
the,1104,O
block,1104,O
.,1104,O
Spontaneous,1105,O
respiration,1105,O
recommenced,1105,O
200,1105,O
min,1105,O
after,1105,O
succinylcholine,1105,B-Chemical
administration,1105,O
.,1105,O
It,1106,O
is,1106,O
concluded,1106,O
that,1106,O
anticholinesterases,1106,O
are,1106,O
only,1106,O
partially,1106,O
effective,1106,O
in,1106,O
restoring,1106,O
neuromuscular,1106,O
function,1106,O
in,1106,O
succinylcholine,1106,B-Chemical
apnoea,1106,B-Disease
despite,1106,O
muscle,1106,O
twitch,1106,O
activity,1106,O
typical,1106,O
of,1106,O
phase,1106,O
II,1106,O
block,1106,O
.,1106,O
Effect,1107,O
of,1107,O
doxorubicin,1107,B-Chemical
on,1107,O
[,1107,B-Chemical
omega-I-131,1107,I-Chemical
],1107,I-Chemical
heptadecanoic,1107,I-Chemical
acid,1107,I-Chemical
myocardial,1107,O
scintigraphy,1107,O
and,1107,O
echocardiography,1107,O
in,1107,O
dogs,1107,O
.,1107,O
The,1108,O
effects,1108,O
of,1108,O
serial,1108,O
treatment,1108,O
with,1108,O
doxorubicin,1108,B-Chemical
on,1108,O
dynamic,1108,O
myocardial,1108,O
scintigraphy,1108,O
with,1108,O
[,1108,B-Chemical
omega-I-131,1108,I-Chemical
],1108,I-Chemical
heptadecanoic,1108,I-Chemical
acid,1108,I-Chemical
(,1108,O
I-131,1108,B-Chemical
HA,1108,I-Chemical
),1108,O
",",1108,O
and,1108,O
on,1108,O
global,1108,O
left-ventricular,1108,O
function,1108,O
determined,1108,O
echocardiographically,1108,O
",",1108,O
were,1108,O
studied,1108,O
in,1108,O
a,1108,O
group,1108,O
of,1108,O
nine,1108,O
mongrel,1108,O
dogs,1108,O
.,1108,O
Total,1109,O
extractable,1109,O
myocardial,1109,O
lipid,1109,O
was,1109,O
compared,1109,O
postmortem,1109,O
between,1109,O
a,1109,O
group,1109,O
of,1109,O
control,1109,O
dogs,1109,O
and,1109,O
doxorubicin-treated,1109,B-Chemical
dogs,1109,O
.,1109,O
A,1110,O
significant,1110,O
and,1110,O
then,1110,O
progressive,1110,O
fall,1110,O
in,1110,O
global,1110,O
LV,1110,O
function,1110,O
was,1110,O
observed,1110,O
at,1110,O
a,1110,O
cumulative,1110,O
doxorubicin,1110,B-Chemical
dose,1110,O
of,1110,O
4,1110,O
mg/kg,1110,O
.,1110,O
A,1111,O
significant,1111,O
increase,1111,O
in,1111,O
the,1111,O
myocardial,1111,O
t1/2,1111,O
of,1111,O
the,1111,O
I-131,1111,B-Chemical
HA,1111,I-Chemical
was,1111,O
observed,1111,O
only,1111,O
at,1111,O
a,1111,O
higher,1111,O
cumulative,1111,O
dose,1111,O
",",1111,O
10,1111,O
mg/kg,1111,O
.,1111,O
No,1112,O
significant,1112,O
alteration,1112,O
in,1112,O
total,1112,O
extractable,1112,O
myocardial,1112,O
lipids,1112,O
was,1112,O
observed,1112,O
between,1112,O
control,1112,O
dogs,1112,O
and,1112,O
those,1112,O
treated,1112,O
with,1112,O
doxorubicin,1112,B-Chemical
.,1112,O
Our,1113,O
findings,1113,O
suggest,1113,O
that,1113,O
the,1113,O
changes,1113,O
leading,1113,O
to,1113,O
an,1113,O
alteration,1113,O
of,1113,O
myocardial,1113,O
dynamic,1113,O
imaging,1113,O
with,1113,O
I-131,1113,B-Chemical
HA,1113,I-Chemical
are,1113,O
not,1113,O
the,1113,O
initiating,1113,O
factor,1113,O
in,1113,O
doxorubicin,1113,B-Chemical
cardiotoxicity,1113,B-Disease
.,1113,O
Hemodynamics,1114,O
and,1114,O
myocardial,1114,O
metabolism,1114,O
under,1114,O
deliberate,1114,O
hypotension,1114,B-Disease
.,1114,O
An,1115,O
experimental,1115,O
study,1115,O
in,1115,O
dogs,1115,O
.,1115,O
Coronary,1116,O
blood,1116,O
flow,1116,O
",",1116,O
cardiac,1116,O
work,1116,O
and,1116,O
metabolism,1116,O
were,1116,O
studied,1116,O
in,1116,O
dogs,1116,O
under,1116,O
sodium,1116,B-Chemical
nitroprusside,1116,I-Chemical
(,1116,O
SNP,1116,B-Chemical
),1116,O
and,1116,O
trimetaphan,1116,B-Chemical
(,1116,O
TMP,1116,B-Chemical
),1116,O
deliberate,1116,O
hypotension,1116,B-Disease
(,1116,O
20,1116,O
%,1116,O
and,1116,O
40,1116,O
%,1116,O
mean,1116,O
pressure,1116,O
decrease,1116,O
from,1116,O
baseline,1116,O
),1116,O
.,1116,O
Regarding,1117,O
the,1117,O
effects,1117,O
of,1117,O
drug-induced,1117,O
hypotension,1117,B-Disease
on,1117,O
coronary,1117,O
blood,1117,O
flow,1117,O
",",1117,O
aortic,1117,O
and,1117,O
coronary,1117,O
sinus,1117,O
metabolic,1117,O
data,1117,O
(,1117,O
pH,1117,O
",",1117,O
pO2,1117,O
",",1117,O
pCO2,1117,O
),1117,O
we,1117,O
could,1117,O
confirm,1117,O
that,1117,O
nitroprusside,1117,B-Chemical
hypotension,1117,B-Disease
could,1117,O
be,1117,O
safely,1117,O
used,1117,O
to,1117,O
30,1117,O
%,1117,O
mean,1117,O
blood,1117,O
pressure,1117,O
decrease,1117,O
from,1117,O
control,1117,O
",",1117,O
trimetaphan,1117,B-Chemical
hypotension,1117,B-Disease
to,1117,O
20,1117,O
%,1117,O
mean,1117,O
blood,1117,O
pressure,1117,O
decrease,1117,O
.,1117,O
Cardiac,1118,O
work,1118,O
was,1118,O
significantly,1118,O
reduced,1118,O
during,1118,O
SNP,1118,B-Chemical
hypotension,1118,B-Disease
.,1118,O
Myocardial,1119,O
O2,1119,B-Chemical
consumption,1119,O
and,1119,O
O2,1119,B-Chemical
availability,1119,O
were,1119,O
directly,1119,O
dependent,1119,O
on,1119,O
the,1119,O
coronary,1119,O
perfusion,1119,O
.,1119,O
Careful,1120,O
invasive,1120,O
monitoring,1120,O
of,1120,O
the,1120,O
blood,1120,O
pressure,1120,O
",",1120,O
blood,1120,O
gases,1120,O
and,1120,O
of,1120,O
the,1120,O
ECG,1120,O
ST-T,1120,O
segment,1120,O
is,1120,O
mandatory,1120,O
.,1120,O
Evidence,1121,O
for,1121,O
a,1121,O
selective,1121,O
brain,1121,O
noradrenergic,1121,O
involvement,1121,O
in,1121,O
the,1121,O
locomotor,1121,O
stimulant,1121,O
effects,1121,O
of,1121,O
amphetamine,1121,B-Chemical
in,1121,O
the,1121,O
rat,1121,O
.,1121,O
Male,1122,O
rats,1122,O
received,1122,O
the,1122,O
noradrenaline,1122,B-Chemical
neurotoxin,1122,O
DSP4,1122,B-Chemical
(,1122,O
50,1122,O
mg/kg,1122,O
),1122,O
7,1122,O
days,1122,O
prior,1122,O
to,1122,O
injection,1122,O
of,1122,O
D-amphetamine,1122,B-Chemical
(,1122,O
10,1122,O
or,1122,O
40,1122,O
mumol/kg,1122,O
i.p,1122,O
.,1122,O
),1122,O
.,1122,O
The,1123,O
hyperactivity,1123,B-Disease
induced,1123,O
by,1123,O
D-amphetamine,1123,B-Chemical
(,1123,O
10,1123,O
mumol/kg,1123,O
),1123,O
was,1123,O
significantly,1123,O
reduced,1123,O
by,1123,O
DSP4,1123,B-Chemical
pretreatment,1123,O
.,1123,O
However,1124,O
",",1124,O
the,1124,O
increased,1124,O
rearings,1124,O
and,1124,O
the,1124,O
amphetamine-induced,1124,B-Chemical
stereotypies,1124,B-Disease
were,1124,O
not,1124,O
blocked,1124,O
by,1124,O
pretreatment,1124,O
with,1124,O
DSP4,1124,B-Chemical
.,1124,O
The,1125,O
reduction,1125,O
of,1125,O
amphetamine,1125,B-Chemical
hyperactivity,1125,B-Disease
induced,1125,O
by,1125,O
DSP4,1125,B-Chemical
was,1125,O
blocked,1125,O
by,1125,O
pretreatment,1125,O
with,1125,O
the,1125,O
noradrenaline-uptake,1125,B-Chemical
blocking,1125,O
agent,1125,O
",",1125,O
desipramine,1125,B-Chemical
",",1125,O
which,1125,O
prevents,1125,O
the,1125,O
neurotoxic,1125,B-Disease
action,1125,O
of,1125,O
DSP4,1125,B-Chemical
.,1125,O
The,1126,O
present,1126,O
results,1126,O
suggest,1126,O
a,1126,O
selective,1126,O
involvement,1126,O
of,1126,O
central,1126,O
noradrenergic,1126,O
neurones,1126,O
in,1126,O
the,1126,O
locomotor,1126,O
stimulant,1126,O
effect,1126,O
of,1126,O
amphetamine,1126,B-Chemical
in,1126,O
the,1126,O
rat,1126,O
.,1126,O
Accelerated,1127,B-Disease
junctional,1127,I-Disease
rhythms,1127,I-Disease
during,1127,O
oral,1127,O
verapamil,1127,B-Chemical
therapy,1127,O
.,1127,O
This,1128,O
study,1128,O
examined,1128,O
the,1128,O
frequency,1128,O
of,1128,O
atrioventricular,1128,O
(,1128,O
AV,1128,O
),1128,O
dissociation,1128,O
and,1128,O
accelerated,1128,B-Disease
junctional,1128,I-Disease
rhythms,1128,I-Disease
in,1128,O
59,1128,O
patients,1128,O
receiving,1128,O
oral,1128,O
verapamil,1128,B-Chemical
.,1128,O
Accelerated,1129,B-Disease
junctional,1129,I-Disease
rhythms,1129,I-Disease
and,1129,O
AV,1129,O
dissociation,1129,O
were,1129,O
frequent,1129,O
in,1129,O
patients,1129,O
with,1129,O
supraventricular,1129,B-Disease
tachyarrhythmias,1129,I-Disease
",",1129,O
particularly,1129,O
AV,1129,O
nodal,1129,O
reentry,1129,O
.,1129,O
Verapamil,1130,B-Chemical
administration,1130,O
to,1130,O
these,1130,O
patients,1130,O
led,1130,O
to,1130,O
an,1130,O
asymptomatic,1130,O
increase,1130,O
in,1130,O
activity,1130,O
of,1130,O
these,1130,O
junctional,1130,O
pacemakers,1130,O
.,1130,O
In,1131,O
patients,1131,O
with,1131,O
various,1131,O
chest,1131,B-Disease
pain,1131,I-Disease
syndromes,1131,O
",",1131,O
verapamil,1131,B-Chemical
neither,1131,O
increased,1131,O
the,1131,O
frequency,1131,O
of,1131,O
junctional,1131,O
rhythms,1131,O
nor,1131,O
suppressed,1131,O
their,1131,O
role,1131,O
as,1131,O
escape,1131,O
rhythms,1131,O
under,1131,O
physiologically,1131,O
appropriate,1131,O
circumstances,1131,O
.,1131,O
Interstrain,1132,O
variation,1132,O
in,1132,O
acute,1132,O
toxic,1132,O
response,1132,O
to,1132,O
caffeine,1132,B-Chemical
among,1132,O
inbred,1132,O
mice,1132,O
.,1132,O
Acute,1133,O
toxic,1133,O
dosage-dependent,1133,O
behavioral,1133,O
effects,1133,O
of,1133,O
caffeine,1133,B-Chemical
were,1133,O
compared,1133,O
in,1133,O
adult,1133,O
males,1133,O
from,1133,O
seven,1133,O
inbred,1133,O
mouse,1133,O
strains,1133,O
(,1133,O
A/J,1133,O
",",1133,O
BALB/cJ,1133,O
",",1133,O
CBA/J,1133,O
",",1133,O
C3H/HeJ,1133,O
",",1133,O
C57BL/6J,1133,O
",",1133,O
DBA/2J,1133,O
",",1133,O
SWR/J,1133,O
),1133,O
.,1133,O
C57BL/6J,1134,O
",",1134,O
chosen,1134,O
as,1134,O
a,1134,O
``,1134,O
prototypic,1134,O
'',1134,O
mouse,1134,O
strain,1134,O
",",1134,O
was,1134,O
used,1134,O
to,1134,O
determine,1134,O
behavioral,1134,O
responses,1134,O
to,1134,O
a,1134,O
broad,1134,O
range,1134,O
(,1134,O
5-500,1134,O
mg/kg,1134,O
),1134,O
of,1134,O
caffeine,1134,B-Chemical
doses,1134,O
.,1134,O
Five,1135,O
phenotypic,1135,O
characteristics,1135,O
--,1135,O
locomotor,1135,O
activity,1135,O
",",1135,O
righting,1135,O
ability,1135,O
",",1135,O
clonic,1135,B-Disease
seizure,1135,I-Disease
induction,1135,O
",",1135,O
stress-induced,1135,O
lethality,1135,O
",",1135,O
death,1135,O
without,1135,O
external,1135,O
stress,1135,O
--,1135,O
were,1135,O
scored,1135,O
at,1135,O
various,1135,O
caffeine,1135,B-Chemical
doses,1135,O
in,1135,O
drug-naive,1135,O
animals,1135,O
under,1135,O
empirically,1135,O
optimized,1135,O
",",1135,O
rigidly,1135,O
constant,1135,O
experimental,1135,O
conditions,1135,O
.,1135,O
Mice,1136,O
(,1136,O
n,1136,O
=,1136,O
12,1136,O
for,1136,O
each,1136,O
point,1136,O
),1136,O
received,1136,O
single,1136,O
IP,1136,O
injections,1136,O
of,1136,O
a,1136,O
fixed,1136,O
volume/g,1136,O
body,1136,O
weight,1136,O
of,1136,O
physiological,1136,O
saline,1136,O
carrier,1136,O
with,1136,O
or,1136,O
without,1136,O
caffeine,1136,B-Chemical
in,1136,O
doses,1136,O
ranging,1136,O
from,1136,O
125-500,1136,O
mg/kg,1136,O
.,1136,O
Loss,1137,O
of,1137,O
righting,1137,O
ability,1137,O
was,1137,O
scored,1137,O
at,1137,O
1,1137,O
",",1137,O
3,1137,O
",",1137,O
5,1137,O
min,1137,O
post,1137,O
dosing,1137,O
and,1137,O
at,1137,O
5,1137,O
min,1137,O
intervals,1137,O
thereafter,1137,O
for,1137,O
20,1137,O
min,1137,O
.,1137,O
In,1138,O
the,1138,O
same,1138,O
animals,1138,O
the,1138,O
occurrence,1138,O
of,1138,O
clonic,1138,B-Disease
seizures,1138,I-Disease
was,1138,O
scored,1138,O
as,1138,O
to,1138,O
time,1138,O
of,1138,O
onset,1138,O
and,1138,O
severity,1138,O
for,1138,O
20,1138,O
min,1138,O
after,1138,O
drug,1138,O
administration,1138,O
.,1138,O
When,1139,O
these,1139,O
proceeded,1139,O
to,1139,O
tonic,1139,B-Disease
seizures,1139,I-Disease
",",1139,O
death,1139,O
occurred,1139,O
in,1139,O
less,1139,O
than,1139,O
20,1139,O
min,1139,O
.,1139,O
Animals,1140,O
surviving,1140,O
for,1140,O
20,1140,O
min,1140,O
were,1140,O
immediately,1140,O
stressed,1140,O
by,1140,O
a,1140,O
swim,1140,O
test,1140,O
in,1140,O
25,1140,O
degrees,1140,O
C,1140,O
water,1140,O
",",1140,O
and,1140,O
death-producing,1140,O
tonic,1140,B-Disease
seizures,1140,I-Disease
were,1140,O
scored,1140,O
for,1140,O
2,1140,O
min,1140,O
.,1140,O
In,1141,O
other,1141,O
animals,1141,O
locomotor,1141,O
activity,1141,O
was,1141,O
measured,1141,O
15,1141,O
or,1141,O
60,1141,O
min,1141,O
after,1141,O
caffeine,1141,B-Chemical
administration,1141,O
.,1141,O
By,1142,O
any,1142,O
single,1142,O
behavioral,1142,O
criterion,1142,O
or,1142,O
a,1142,O
combination,1142,O
of,1142,O
these,1142,O
criteria,1142,O
",",1142,O
marked,1142,O
differences,1142,O
in,1142,O
response,1142,O
to,1142,O
toxic,1142,O
caffeine,1142,B-Chemical
doses,1142,O
were,1142,O
observed,1142,O
between,1142,O
strains,1142,O
.,1142,O
These,1143,O
results,1143,O
indicate,1143,O
that,1143,O
behavioral,1143,O
toxicity,1143,B-Disease
testing,1143,O
of,1143,O
alkylxanthines,1143,B-Chemical
in,1143,O
a,1143,O
single,1143,O
mouse,1143,O
strain,1143,O
may,1143,O
be,1143,O
misleading,1143,O
and,1143,O
suggest,1143,O
that,1143,O
toxic,1143,O
responses,1143,O
of,1143,O
the,1143,O
central,1143,O
nervous,1143,O
system,1143,O
to,1143,O
this,1143,O
class,1143,O
of,1143,O
compounds,1143,O
are,1143,O
genetically,1143,O
influenced,1143,O
in,1143,O
mammals,1143,O
.,1143,O
Treatment,1144,O
of,1144,O
ovarian,1144,B-Disease
cancer,1144,I-Disease
with,1144,O
a,1144,O
combination,1144,O
of,1144,O
cis-platinum,1144,B-Chemical
",",1144,O
adriamycin,1144,B-Chemical
",",1144,O
cyclophosphamide,1144,B-Chemical
and,1144,O
hexamethylmelamine,1144,B-Chemical
.,1144,O
During,1145,O
the,1145,O
last,1145,O
2,1145,O
1/2,1145,O
years,1145,O
",",1145,O
38,1145,O
patients,1145,O
with,1145,O
ovarian,1145,B-Disease
cancer,1145,I-Disease
were,1145,O
treated,1145,O
with,1145,O
a,1145,O
combination,1145,O
of,1145,O
cisplatinum,1145,B-Chemical
(,1145,O
CPDD,1145,B-Chemical
),1145,O
",",1145,O
50,1145,O
mg/m2,1145,O
",",1145,O
adriamycin,1145,B-Chemical
",",1145,O
30,1145,O
mg/m2,1145,O
",",1145,O
cyclophosphamide,1145,B-Chemical
",",1145,O
300,1145,O
mg/m2,1145,O
",",1145,O
on,1145,O
day,1145,O
1,1145,O
;,1145,O
and,1145,O
hexamethylmelamine,1145,B-Chemical
(,1145,O
HMM,1145,B-Chemical
),1145,O
",",1145,O
6,1145,O
mg/kg,1145,O
daily,1145,O
",",1145,O
for,1145,O
14,1145,O
days,1145,O
.,1145,O
Each,1146,O
course,1146,O
was,1146,O
repeated,1146,O
monthly,1146,O
.,1146,O
2,1147,O
patients,1147,O
had,1147,O
stage,1147,O
II,1147,O
",",1147,O
14,1147,O
stage,1147,O
III,1147,O
and,1147,O
22,1147,O
stage,1147,O
IV,1147,O
disease,1147,O
.,1147,O
14,1148,O
of,1148,O
the,1148,O
38,1148,O
patients,1148,O
were,1148,O
previously,1148,O
treated,1148,O
with,1148,O
chemotherapy,1148,O
",",1148,O
1,1148,O
with,1148,O
radiation,1148,O
",",1148,O
6,1148,O
with,1148,O
both,1148,O
chemotherapy,1148,O
and,1148,O
radiation,1148,O
",",1148,O
and,1148,O
17,1148,O
did,1148,O
not,1148,O
have,1148,O
any,1148,O
treatment,1148,O
before,1148,O
CPDD,1148,B-Chemical
combination,1148,O
.,1148,O
31,1149,O
of,1149,O
the,1149,O
38,1149,O
cases,1149,O
(,1149,O
81.5,1149,O
%,1149,O
),1149,O
demonstrated,1149,O
objective,1149,O
responses,1149,O
lasting,1149,O
for,1149,O
2,1149,O
months,1149,O
or,1149,O
more,1149,O
.,1149,O
These,1150,O
responses,1150,O
were,1150,O
partial,1150,O
in,1150,O
19,1150,O
and,1150,O
complete,1150,O
in,1150,O
12,1150,O
cases,1150,O
.,1150,O
Hematologic,1151,B-Disease
toxicity,1151,I-Disease
was,1151,O
moderate,1151,O
and,1151,O
with,1151,O
reversible,1151,O
anemia,1151,B-Disease
developing,1151,O
in,1151,O
71,1151,O
%,1151,O
of,1151,O
patients,1151,O
.,1151,O
Gastrointestinal,1152,O
side,1152,O
effects,1152,O
from,1152,O
CPDD,1152,B-Chemical
were,1152,O
universal,1152,O
.,1152,O
HMM,1153,B-Chemical
gastrointestinal,1153,B-Disease
toxicity,1153,I-Disease
necessitated,1153,O
discontinuation,1153,O
of,1153,O
the,1153,O
drug,1153,O
in,1153,O
5,1153,O
patients,1153,O
.,1153,O
Severe,1154,O
nephrotoxicity,1154,B-Disease
was,1154,O
observed,1154,O
in,1154,O
2,1154,O
patients,1154,O
but,1154,O
was,1154,O
reversible,1154,O
.,1154,O
There,1155,O
were,1155,O
no,1155,O
drug-related,1155,O
deaths,1155,O
.,1155,O
Nontraumatic,1156,O
dissecting,1156,B-Disease
aneurysm,1156,I-Disease
of,1156,O
the,1156,O
basilar,1156,O
artery,1156,O
.,1156,O
A,1157,O
case,1157,O
of,1157,O
nontraumatic,1157,O
dissecting,1157,B-Disease
aneurysm,1157,I-Disease
of,1157,O
the,1157,O
basilar,1157,O
artery,1157,O
in,1157,O
association,1157,O
with,1157,O
hypertension,1157,B-Disease
",",1157,O
smoke,1157,O
",",1157,O
and,1157,O
oral,1157,B-Chemical
contraceptives,1157,I-Chemical
is,1157,O
reported,1157,O
in,1157,O
a,1157,O
young,1157,O
female,1157,O
patient,1157,O
with,1157,O
a,1157,O
locked-in,1157,B-Disease
syndrome,1157,I-Disease
.,1157,O
Propylthiouracil-induced,1158,B-Chemical
hepatic,1158,B-Disease
damage,1158,I-Disease
.,1158,O
Two,1159,O
cases,1159,O
of,1159,O
propylthiouracil-induced,1159,B-Chemical
liver,1159,B-Disease
damage,1159,I-Disease
have,1159,O
been,1159,O
observed,1159,O
.,1159,O
The,1160,O
first,1160,O
case,1160,O
is,1160,O
of,1160,O
an,1160,O
acute,1160,O
type,1160,O
of,1160,O
damage,1160,O
",",1160,O
proven,1160,O
by,1160,O
rechallenge,1160,O
;,1160,O
the,1160,O
second,1160,O
presents,1160,O
a,1160,O
clinical,1160,O
and,1160,O
histologic,1160,O
picture,1160,O
resembling,1160,O
chronic,1160,B-Disease
active,1160,I-Disease
hepatitis,1160,I-Disease
",",1160,O
with,1160,O
spontaneous,1160,O
remission,1160,O
.,1160,O
Studies,1161,O
on,1161,O
the,1161,O
bradycardia,1161,B-Disease
induced,1161,O
by,1161,O
bepridil,1161,B-Chemical
.,1161,O
Bepridil,1162,B-Chemical
",",1162,O
a,1162,O
novel,1162,O
active,1162,O
compound,1162,O
for,1162,O
prophylactic,1162,O
treatment,1162,O
of,1162,O
anginal,1162,B-Disease
attacks,1162,I-Disease
",",1162,O
induced,1162,O
persistent,1162,O
bradycardia,1162,B-Disease
and,1162,O
a,1162,O
non-specific,1162,O
anti-tachycardial,1162,O
effect,1162,O
",",1162,O
the,1162,O
mechanisms,1162,O
of,1162,O
which,1162,O
were,1162,O
investigated,1162,O
in,1162,O
vitro,1162,O
and,1162,O
in,1162,O
vivo,1162,O
.,1162,O
In,1163,O
vitro,1163,O
perfusion,1163,O
of,1163,O
bepridil,1163,B-Chemical
in,1163,O
the,1163,O
life-support,1163,O
medium,1163,O
for,1163,O
isolated,1163,O
sino-atrial,1163,O
tissue,1163,O
from,1163,O
rabbit,1163,O
heart,1163,O
",",1163,O
caused,1163,O
a,1163,O
reduction,1163,O
in,1163,O
action,1163,O
potential,1163,O
(,1163,O
AP,1163,O
),1163,O
spike,1163,O
frequency,1163,O
(,1163,O
recorded,1163,O
by,1163,O
KCl,1163,B-Chemical
microelectrodes,1163,O
),1163,O
starting,1163,O
at,1163,O
doses,1163,O
of,1163,O
5,1163,O
X,1163,O
10,1163,O
(,1163,O
-6,1163,O
),1163,O
M.,1163,O
This,1163,O
effect,1163,O
was,1163,O
dose-dependent,1163,O
up,1163,O
to,1163,O
concentrations,1163,O
of,1163,O
5,1163,O
X,1163,O
10,1163,O
(,1163,O
-5,1163,O
),1163,O
M,1163,O
",",1163,O
whereupon,1163,O
blockade,1163,O
of,1163,O
sinus,1163,O
activity,1163,O
set,1163,O
in,1163,O
.,1163,O
Bepridil,1164,B-Chemical
at,1164,O
a,1164,O
dose,1164,O
of,1164,O
5,1164,O
X,1164,O
10,1164,O
(,1164,O
-6,1164,O
),1164,O
M,1164,O
",",1164,O
induced,1164,O
a,1164,O
concomitant,1164,O
reduction,1164,O
in,1164,O
AP,1164,O
amplitude,1164,O
(,1164,O
falling,1164,O
from,1164,O
71,1164,O
+/-,1164,O
8,1164,O
mV,1164,O
to,1164,O
47,1164,O
+/-,1164,O
6,1164,O
mV,1164,O
),1164,O
",",1164,O
maximum,1164,O
systolic,1164,O
depolarization,1164,O
velocity,1164,O
(,1164,O
phase,1164,O
0,1164,O
),1164,O
which,1164,O
fell,1164,O
from,1164,O
1.85,1164,O
+/-,1164,O
0.35,1164,O
V/s,1164,O
to,1164,O
0.84,1164,O
+/-,1164,O
0.28,1164,O
V/s,1164,O
",",1164,O
together,1164,O
with,1164,O
maximum,1164,O
diastolic,1164,O
depolarization,1164,O
velocity,1164,O
(,1164,O
phase,1164,O
4,1164,O
),1164,O
which,1164,O
fell,1164,O
from,1164,O
38,1164,O
+/-,1164,O
3,1164,O
mV/s,1164,O
to,1164,O
24,1164,O
+/-,1164,O
5,1164,O
mV/s,1164,O
.,1164,O
In,1165,O
vivo,1165,O
injection,1165,O
of,1165,O
bepridil,1165,B-Chemical
at,1165,O
a,1165,O
dose,1165,O
of,1165,O
5,1165,O
mg/kg,1165,O
(,1165,O
i.v,1165,O
.,1165,O
),1165,O
into,1166,O
6,1166,O
anaesthetized,1166,O
dogs,1166,O
which,1166,O
had,1166,O
undergone,1166,O
ablation,1166,O
of,1166,O
all,1166,O
the,1166,O
extrinsic,1166,O
cardiac,1166,O
afferent,1166,O
nerve,1166,O
supply,1166,O
",",1166,O
together,1166,O
with,1166,O
a,1166,O
bilateral,1166,O
medullo-adrenalectomy,1166,O
",",1166,O
caused,1166,O
a,1166,O
marked,1166,O
reduction,1166,O
in,1166,O
heart,1166,O
rate,1166,O
which,1166,O
fell,1166,O
from,1166,O
98.7,1166,O
+/-,1166,O
4.2,1166,O
beats/min,1166,O
to,1166,O
76,1166,O
+/-,1166,O
5.3,1166,O
beats/min,1166,O
sustained,1166,O
for,1166,O
more,1166,O
than,1166,O
45,1166,O
min,1166,O
.,1166,O
It,1167,O
is,1167,O
concluded,1167,O
that,1167,O
bepridil,1167,B-Chemical
reduces,1167,O
heart,1167,O
rate,1167,O
by,1167,O
acting,1167,O
directly,1167,O
on,1167,O
the,1167,O
sinus,1167,O
node,1167,O
.,1167,O
This,1168,O
effect,1168,O
",",1168,O
which,1168,O
results,1168,O
in,1168,O
a,1168,O
flattening,1168,O
of,1168,O
the,1168,O
phase,1168,O
0,1168,O
and,1168,O
phase,1168,O
4,1168,O
slope,1168,O
",",1168,O
together,1168,O
with,1168,O
a,1168,O
longer,1168,O
AP,1168,O
duration,1168,O
",",1168,O
may,1168,O
be,1168,O
due,1168,O
to,1168,O
an,1168,O
increase,1168,O
in,1168,O
the,1168,O
time,1168,O
constants,1168,O
of,1168,O
slow,1168,O
inward,1168,O
ionic,1168,O
currents,1168,O
(,1168,O
already,1168,O
demonstrated,1168,O
elsewhere,1168,O
),1168,O
",",1168,O
but,1168,O
also,1168,O
to,1168,O
an,1168,O
increased,1168,O
time,1168,O
constant,1168,O
for,1168,O
deactivation,1168,O
of,1168,O
the,1168,O
outward,1168,O
potassium,1168,B-Chemical
current,1168,O
(,1168,O
Ip,1168,O
),1168,O
.,1168,O
Hepatitis,1169,B-Disease
and,1169,O
renal,1169,B-Disease
tubular,1169,I-Disease
acidosis,1169,I-Disease
after,1169,O
anesthesia,1169,O
with,1169,O
methoxyflurane,1169,B-Chemical
.,1169,O
A,1170,O
69-year-old,1170,O
man,1170,O
operated,1170,O
for,1170,O
acute,1170,B-Disease
cholecystitis,1170,I-Disease
under,1170,O
methoxyflurane,1170,B-Chemical
anesthesia,1170,O
developed,1170,O
postoperatively,1170,O
a,1170,O
hepatic,1170,B-Disease
insufficiency,1170,I-Disease
syndrome,1170,I-Disease
and,1170,O
renal,1170,B-Disease
tubular,1170,I-Disease
acidosis,1170,I-Disease
.,1170,O
Massive,1171,O
bleeding,1171,B-Disease
appeared,1171,O
during,1171,O
surgery,1171,O
which,1171,O
lasted,1171,O
for,1171,O
six,1171,O
hours,1171,O
.,1171,O
Postoperative,1172,O
evolution,1172,O
under,1172,O
supportive,1172,O
therapy,1172,O
was,1172,O
favourable,1172,O
.,1172,O
Complete,1173,O
recovery,1173,O
was,1173,O
confirmed,1173,O
by,1173,O
repeated,1173,O
controls,1173,O
performed,1173,O
over,1173,O
a,1173,O
period,1173,O
of,1173,O
one,1173,O
year,1173,O
after,1173,O
surgery,1173,O
.,1173,O
Pituitary,1174,O
response,1174,O
to,1174,O
luteinizing,1174,O
hormone-releasing,1174,O
hormone,1174,O
during,1174,O
haloperidol-induced,1174,B-Chemical
hyperprolactinemia,1174,B-Disease
.,1174,O
The,1175,O
effects,1175,O
of,1175,O
a,1175,O
6-hour,1175,O
infusion,1175,O
with,1175,O
haloperidol,1175,B-Chemical
on,1175,O
serum,1175,O
prolactin,1175,O
and,1175,O
luteinizing,1175,O
hormone,1175,O
(,1175,O
LH,1175,O
),1175,O
levels,1175,O
was,1175,O
studied,1175,O
in,1175,O
a,1175,O
group,1175,O
of,1175,O
male,1175,O
subjects,1175,O
.,1175,O
Five,1176,O
hours,1176,O
after,1176,O
starting,1176,O
the,1176,O
infusions,1176,O
",",1176,O
a,1176,O
study,1176,O
of,1176,O
the,1176,O
pituitary,1176,O
responses,1176,O
to,1176,O
LH-releasing,1176,O
hormone,1176,O
(,1176,O
LH-RH,1176,O
),1176,O
was,1176,O
carried,1176,O
out,1176,O
.,1176,O
Control,1177,O
patients,1177,O
received,1177,O
infusions,1177,O
of,1177,O
0.9,1177,O
%,1177,O
NaCl,1177,B-Chemical
solution,1177,O
.,1177,O
During,1178,O
the,1178,O
course,1178,O
of,1178,O
haloperidol,1178,B-Chemical
infusions,1178,O
",",1178,O
significant,1178,O
hyperprolactinemia,1178,B-Disease
was,1178,O
found,1178,O
",",1178,O
together,1178,O
with,1178,O
an,1178,O
abolished,1178,O
pituitary,1178,O
response,1178,O
to,1178,O
LH-RH,1178,O
",",1178,O
as,1178,O
compared,1178,O
with,1178,O
responses,1178,O
of,1178,O
control,1178,O
subjects,1178,O
.,1178,O
Antirifampicin,1179,O
antibodies,1179,O
in,1179,O
acute,1179,O
rifampicin-associated,1179,B-Chemical
renal,1179,B-Disease
failure,1179,I-Disease
.,1179,O
5,1180,O
patients,1180,O
with,1180,O
acute,1180,B-Disease
renal,1180,I-Disease
failure,1180,I-Disease
(,1180,O
3,1180,O
with,1180,O
thrombopenia,1180,B-Disease
and,1180,O
hemolysis,1180,B-Disease
),1180,O
induced,1180,O
by,1180,O
the,1180,O
reintroduction,1180,O
of,1180,O
rifampicin,1180,B-Chemical
are,1180,O
described,1180,O
.,1180,O
No,1181,O
correlation,1181,O
was,1181,O
found,1181,O
between,1181,O
the,1181,O
severity,1181,O
of,1181,O
clinical,1181,O
manifestations,1181,O
and,1181,O
the,1181,O
total,1181,O
dose,1181,O
taken,1181,O
by,1181,O
the,1181,O
patients,1181,O
.,1181,O
In,1182,O
all,1182,O
but,1182,O
1,1182,O
patient,1182,O
",",1182,O
antirifampicin,1182,O
antibodies,1182,O
were,1182,O
detected,1182,O
.,1182,O
Antibodies,1183,O
suggested,1183,O
to,1183,O
be,1183,O
of,1183,O
the,1183,O
IgM,1183,O
class,1183,O
were,1183,O
detected,1183,O
in,1183,O
all,1183,O
3,1183,O
patients,1183,O
with,1183,O
hematological,1183,B-Disease
disorders,1183,I-Disease
.,1183,O
The,1184,O
pattern,1184,O
of,1184,O
non-specific,1184,O
acute,1184,B-Disease
tubular,1184,I-Disease
necrosis,1184,I-Disease
found,1184,O
in,1184,O
the,1184,O
2,1184,O
biopsied,1184,O
patients,1184,O
",",1184,O
indistinguishable,1184,O
from,1184,O
that,1184,O
of,1184,O
ischemic,1184,O
origin,1184,O
",",1184,O
raised,1184,O
the,1184,O
possibility,1184,O
of,1184,O
a,1184,O
vascular-mediated,1184,O
damage,1184,O
.,1184,O
In,1185,O
3,1185,O
patients,1185,O
",",1185,O
the,1185,O
possibility,1185,O
of,1185,O
a,1185,O
triggering,1185,O
immunoallergic,1185,O
mechanism,1185,O
is,1185,O
discussed,1185,O
.,1185,O
Cardiovascular,1186,O
effects,1186,O
of,1186,O
hypotension,1186,B-Disease
induced,1186,O
by,1186,O
adenosine,1186,B-Chemical
triphosphate,1186,I-Chemical
and,1186,O
sodium,1186,B-Chemical
nitroprusside,1186,I-Chemical
on,1186,O
dogs,1186,O
with,1186,O
denervated,1186,O
hearts,1186,O
.,1186,O
Adenosine,1187,B-Chemical
triphosphate,1187,I-Chemical
(,1187,O
ATP,1187,B-Chemical
),1187,O
and,1187,O
sodium,1187,B-Chemical
nitroprusside,1187,I-Chemical
(,1187,O
SNP,1187,B-Chemical
),1187,O
are,1187,O
administered,1187,O
to,1187,O
patients,1187,O
to,1187,O
induce,1187,O
and,1187,O
control,1187,O
hypotension,1187,B-Disease
during,1187,O
anesthesia,1187,O
.,1187,O
SNP,1188,B-Chemical
is,1188,O
authorized,1188,O
for,1188,O
clinical,1188,O
use,1188,O
in,1188,O
USA,1188,O
and,1188,O
UK,1188,O
",",1188,O
and,1188,O
ATP,1188,B-Chemical
is,1188,O
clinically,1188,O
used,1188,O
in,1188,O
other,1188,O
countries,1188,O
such,1188,O
as,1188,O
Japan,1188,O
.,1188,O
We,1189,O
investigated,1189,O
how,1189,O
these,1189,O
two,1189,O
drugs,1189,O
act,1189,O
on,1189,O
the,1189,O
cardiovascular,1189,O
systems,1189,O
of,1189,O
20,1189,O
dogs,1189,O
whose,1189,O
hearts,1189,O
had,1189,O
been,1189,O
denervated,1189,O
by,1189,O
a,1189,O
procedure,1189,O
we,1189,O
had,1189,O
devised,1189,O
.,1189,O
ATP,1190,B-Chemical
(,1190,O
10,1190,O
dogs,1190,O
),1190,O
or,1190,O
SNP,1190,B-Chemical
(,1190,O
10,1190,O
dogs,1190,O
),1190,O
was,1190,O
administered,1190,O
to,1190,O
reduce,1190,O
mean,1190,O
arterial,1190,O
pressure,1190,O
by,1190,O
30,1190,O
%,1190,O
to,1190,O
70,1190,O
%,1190,O
of,1190,O
control,1190,O
.,1190,O
Before,1191,O
",",1191,O
during,1191,O
and,1191,O
after,1191,O
induced,1191,O
hypotension,1191,B-Disease
",",1191,O
we,1191,O
measured,1191,O
major,1191,O
cardiovascular,1191,O
parameters,1191,O
.,1191,O
Hypotension,1192,B-Disease
induced,1192,O
by,1192,O
ATP,1192,B-Chemical
was,1192,O
accompanied,1192,O
by,1192,O
significant,1192,O
decreases,1192,O
in,1192,O
mean,1192,O
pulmonary,1192,O
arterial,1192,O
pressure,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.001,1192,O
),1192,O
",",1192,O
central,1192,O
venous,1192,O
pressure,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.001,1192,O
),1192,O
",",1192,O
left,1192,O
ventricular,1192,O
end-diastolic,1192,O
pressure,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.001,1192,O
),1192,O
",",1192,O
total,1192,O
peripheral,1192,O
resistance,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.001,1192,O
),1192,O
",",1192,O
rate,1192,O
pressure,1192,O
product,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.001,1192,O
),1192,O
",",1192,O
total,1192,O
body,1192,O
oxygen,1192,B-Chemical
consumption,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.05,1192,O
),1192,O
",",1192,O
and,1192,O
heart,1192,O
rate,1192,O
(,1192,O
p,1192,O
less,1192,O
than,1192,O
0.001,1192,O
),1192,O
;,1192,O
all,1192,O
these,1192,O
variables,1192,O
returned,1192,O
normal,1192,O
within,1192,O
30,1192,O
min,1192,O
after,1192,O
ATP,1192,B-Chemical
was,1192,O
stopped,1192,O
.,1192,O
Cardiac,1193,O
output,1193,O
did,1193,O
not,1193,O
change,1193,O
.,1193,O
During,1194,O
hypotension,1194,B-Disease
produced,1194,O
by,1194,O
SNP,1194,B-Chemical
similar,1194,O
decreases,1194,O
were,1194,O
observed,1194,O
in,1194,O
mean,1194,O
pulmonary,1194,O
arterial,1194,O
pressure,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.01,1194,O
),1194,O
",",1194,O
central,1194,O
venous,1194,O
pressure,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.001,1194,O
),1194,O
",",1194,O
left,1194,O
ventricular,1194,O
end-diastolic,1194,O
pressure,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.01,1194,O
),1194,O
",",1194,O
total,1194,O
peripheral,1194,O
resistance,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.001,1194,O
),1194,O
",",1194,O
rate,1194,O
pressure,1194,O
product,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.001,1194,O
),1194,O
",",1194,O
and,1194,O
oxygen,1194,B-Chemical
content,1194,O
difference,1194,O
between,1194,O
arterial,1194,O
and,1194,O
mixed,1194,O
venous,1194,O
blood,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.05,1194,O
),1194,O
",",1194,O
while,1194,O
heart,1194,O
rate,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.001,1194,O
),1194,O
and,1194,O
cardiac,1194,O
output,1194,O
(,1194,O
p,1194,O
less,1194,O
than,1194,O
0.05,1194,O
),1194,O
were,1194,O
increased,1194,O
.,1194,O
Recoveries,1195,O
of,1195,O
heart,1195,O
rate,1195,O
and,1195,O
left,1195,O
ventricular,1195,O
end-diastolic,1195,O
pressure,1195,O
were,1195,O
not,1195,O
shown,1195,O
within,1195,O
60,1195,O
min,1195,O
after,1195,O
SNP,1195,B-Chemical
had,1195,O
been,1195,O
stopped,1195,O
.,1195,O
Both,1196,O
ATP,1196,B-Chemical
and,1196,O
SNP,1196,B-Chemical
should,1196,O
act,1196,O
on,1196,O
the,1196,O
pacemaker,1196,O
tissue,1196,O
of,1196,O
the,1196,O
heart,1196,O
.,1196,O
Comparative,1197,O
study,1197,O
:,1197,O
Endografine,1197,B-Chemical
(,1197,O
diatrizoate,1197,B-Chemical
),1197,O
",",1197,O
Vasurix,1197,B-Chemical
polyvidone,1197,I-Chemical
(,1197,O
acetrizoate,1197,B-Chemical
),1197,O
",",1197,O
Dimer-X,1197,B-Chemical
(,1197,O
iocarmate,1197,B-Chemical
),1197,O
and,1197,O
Hexabrix,1197,B-Chemical
(,1197,O
ioxaglate,1197,B-Chemical
),1197,O
in,1197,O
hysterosalpingography,1197,O
.,1197,O
Side,1198,O
effects,1198,O
of,1198,O
hysterosalpingography,1198,O
with,1198,O
Dimer-X,1198,B-Chemical
",",1198,O
Hexabrix,1198,B-Chemical
",",1198,O
Vasurix,1198,B-Chemical
polyvidone,1198,I-Chemical
and,1198,O
Endografine,1198,B-Chemical
in,1198,O
142,1198,O
consecutive,1198,O
patients,1198,O
",",1198,O
receiving,1198,O
one,1198,O
of,1198,O
the,1198,O
four,1198,O
tested,1198,O
media,1198,O
were,1198,O
evaluated,1198,O
from,1198,O
replies,1198,O
to,1198,O
postal,1198,O
questionnaires,1198,O
.,1198,O
The,1199,O
Dimer-X,1199,B-Chemical
group,1199,O
had,1199,O
a,1199,O
higher,1199,O
incidence,1199,O
of,1199,O
nausea,1199,B-Disease
and,1199,O
dizziness,1199,B-Disease
.,1199,O
The,1200,O
Endografine,1200,B-Chemical
group,1200,O
had,1200,O
a,1200,O
higher,1200,O
incidence,1200,O
of,1200,O
abdominal,1200,B-Disease
pain,1200,I-Disease
.,1200,O
These,1201,O
differences,1201,O
occur,1201,O
especially,1201,O
in,1201,O
the,1201,O
age,1201,O
groups,1201,O
under,1201,O
30,1201,O
years,1201,O
.,1201,O
Hexabrix,1202,B-Chemical
and,1202,O
Vasurix,1202,B-Chemical
polyvidone,1202,I-Chemical
are,1202,O
considered,1202,O
the,1202,O
best,1202,O
contrast,1202,B-Chemical
media,1202,I-Chemical
for,1202,O
hysterosalpingography,1202,O
and,1202,O
perhaps,1202,O
because,1202,O
of,1202,O
its,1202,O
low,1202,O
toxicity,1202,B-Disease
Hexabrix,1202,B-Chemical
should,1202,O
be,1202,O
preferred,1202,O
.,1202,O
Post-suxamethonium,1203,O
pains,1203,B-Disease
in,1203,O
Nigerian,1203,O
surgical,1203,O
patients,1203,O
.,1203,O
Contrary,1204,O
to,1204,O
an,1204,O
earlier,1204,O
report,1204,O
by,1204,O
Coxon,1204,O
",",1204,O
scoline,1204,B-Chemical
pain,1204,B-Disease
occurs,1204,O
in,1204,O
African,1204,O
negroes,1204,O
.,1204,O
Its,1205,O
incidence,1205,O
was,1205,O
determined,1205,O
in,1205,O
a,1205,O
prospective,1205,O
study,1205,O
involving,1205,O
a,1205,O
total,1205,O
of,1205,O
100,1205,O
Nigerian,1205,O
patients,1205,O
(,1205,O
50,1205,O
out-patients,1205,O
and,1205,O
50,1205,O
in-patients,1205,O
),1205,O
.,1205,O
About,1206,O
62,1206,O
%,1206,O
of,1206,O
the,1206,O
out-patients,1206,O
developed,1206,O
scoline,1206,B-Chemical
pain,1206,B-Disease
as,1206,O
compared,1206,O
with,1206,O
about,1206,O
26,1206,O
%,1206,O
among,1206,O
the,1206,O
in-patients,1206,O
.,1206,O
The,1207,O
abolition,1207,O
of,1207,O
muscle,1207,O
fasciculations,1207,B-Disease
(,1207,O
by,1207,O
0.075mg/kg,1207,O
dose,1207,O
of,1207,O
Fazadinium,1207,B-Chemical
),1207,O
did,1207,O
not,1207,O
influence,1207,O
the,1207,O
occurrence,1207,O
of,1207,O
scoline,1207,B-Chemical
pain,1207,B-Disease
.,1207,O
Neither,1208,O
the,1208,O
type,1208,O
of,1208,O
induction,1208,O
agent,1208,O
(,1208,O
Althesin,1208,B-Chemical
or,1208,O
Thiopentone,1208,B-Chemical
),1208,O
nor,1208,O
the,1208,O
salt,1208,O
preparation,1208,O
of,1208,O
suxamethonium,1208,B-Chemical
used,1208,O
(,1208,O
chloride,1208,B-Chemical
or,1208,O
bromide,1208,B-Chemical
),1208,O
",",1208,O
affected,1208,O
the,1208,O
incidence,1208,O
of,1208,O
scoline,1208,B-Chemical
pain,1208,B-Disease
.,1208,O
Invasive,1209,O
carcinoma,1209,B-Disease
of,1209,I-Disease
the,1209,I-Disease
renal,1209,I-Disease
pelvis,1209,I-Disease
following,1209,O
cyclophosphamide,1209,B-Chemical
therapy,1209,O
for,1209,O
nonmalignant,1209,O
disease,1209,O
.,1209,O
A,1210,O
47-year-old,1210,O
woman,1210,O
with,1210,O
right,1210,O
hydroureteronephrosis,1210,B-Disease
due,1210,O
to,1210,O
ureterovesical,1210,O
junction,1210,O
obstruction,1210,O
had,1210,O
gross,1210,O
hematuria,1210,B-Disease
after,1210,O
being,1210,O
treated,1210,O
for,1210,O
five,1210,O
years,1210,O
wtih,1210,O
cyclophosphamide,1210,B-Chemical
for,1210,O
cerebral,1210,B-Disease
vasculitis,1210,I-Disease
.,1210,O
A,1211,O
right,1211,O
nephroureterectomy,1211,O
was,1211,O
required,1211,O
for,1211,O
control,1211,O
of,1211,O
bleeding,1211,B-Disease
.,1211,O
The,1212,O
pathology,1212,O
specimen,1212,O
contained,1212,O
clinically,1212,O
occult,1212,O
invasive,1212,O
carcinoma,1212,B-Disease
of,1212,I-Disease
the,1212,I-Disease
renal,1212,I-Disease
pelvis,1212,I-Disease
.,1212,O
Although,1213,O
the,1213,O
ability,1213,O
of,1213,O
cyclophosphamide,1213,B-Chemical
to,1213,O
cause,1213,O
hemorrhagic,1213,O
cystitis,1213,O
and,1213,O
urine,1213,O
cytologic,1213,O
abnormalities,1213,O
indistinguishable,1213,O
from,1213,O
high,1213,O
grade,1213,O
carcinoma,1213,B-Disease
is,1213,O
well,1213,O
known,1213,O
",",1213,O
it,1213,O
is,1213,O
less,1213,O
widely,1213,O
appreciated,1213,O
that,1213,O
it,1213,O
is,1213,O
also,1213,O
associated,1213,O
with,1213,O
carcinoma,1213,B-Disease
of,1213,I-Disease
the,1213,I-Disease
urinary,1213,I-Disease
tract,1213,I-Disease
.,1213,O
Twenty,1214,O
carcinomas,1214,B-Disease
of,1214,I-Disease
the,1214,I-Disease
urinary,1214,I-Disease
bladder,1214,I-Disease
and,1214,O
one,1214,O
carcinoma,1214,B-Disease
of,1214,I-Disease
the,1214,I-Disease
prostate,1214,I-Disease
have,1214,O
been,1214,O
reported,1214,O
in,1214,O
association,1214,O
with,1214,O
its,1214,O
use,1214,O
.,1214,O
The,1215,O
present,1215,O
case,1215,O
is,1215,O
the,1215,O
first,1215,O
carcinoma,1215,B-Disease
of,1215,I-Disease
the,1215,I-Disease
renal,1215,I-Disease
pelvis,1215,I-Disease
reported,1215,O
in,1215,O
association,1215,O
with,1215,O
cyclophosphamide,1215,B-Chemical
treatment,1215,O
.,1215,O
It,1216,O
is,1216,O
the,1216,O
third,1216,O
urinary,1216,B-Disease
tract,1216,I-Disease
cancer,1216,I-Disease
reported,1216,O
in,1216,O
association,1216,O
with,1216,O
cyclophosphamide,1216,B-Chemical
treatment,1216,O
for,1216,O
nonmalignant,1216,O
disease,1216,O
.,1216,O
The,1217,O
association,1217,O
of,1217,O
the,1217,O
tumor,1217,B-Disease
with,1217,O
preexisting,1217,O
hydroureteronephrosis,1217,B-Disease
suggests,1217,O
that,1217,O
stasis,1217,O
prolonged,1217,O
and,1217,O
intensified,1217,O
exposure,1217,O
of,1217,O
upper,1217,O
urinary,1217,O
tract,1217,O
epithelium,1217,O
to,1217,O
cyclophosphamide,1217,B-Chemical
.,1217,O
Patients,1218,O
who,1218,O
are,1218,O
candidates,1218,O
for,1218,O
long-term,1218,O
cyclophosphamide,1218,B-Chemical
treatment,1218,O
should,1218,O
be,1218,O
routinely,1218,O
evaluated,1218,O
for,1218,O
obstructive,1218,B-Disease
uropathy,1218,I-Disease
.,1218,O
Medial,1219,O
changes,1219,O
in,1219,O
arterial,1219,O
spasm,1219,B-Disease
induced,1219,O
by,1219,O
L-norepinephrine,1219,B-Chemical
.,1219,O
In,1220,O
normal,1220,O
rats,1220,O
",",1220,O
the,1220,O
media,1220,O
of,1220,O
small,1220,O
arteries,1220,O
(,1220,O
0.4,1220,O
--,1220,O
0.2,1220,O
mm,1220,O
in,1220,O
diameter,1220,O
),1220,O
previously,1220,O
was,1220,O
shown,1220,O
to,1220,O
contain,1220,O
intracellular,1220,O
vacuoles,1220,O
",",1220,O
identified,1220,O
ultrastructurally,1220,O
as,1220,O
herniations,1220,O
of,1220,O
one,1220,O
smooth,1220,O
muscle,1220,O
cell,1220,O
into,1220,O
another,1220,O
.,1220,O
The,1221,O
hypothesis,1221,O
that,1221,O
intense,1221,O
vasoconstriction,1221,O
would,1221,O
increase,1221,O
the,1221,O
number,1221,O
of,1221,O
such,1221,O
vacuoles,1221,O
has,1221,O
been,1221,O
tested,1221,O
.,1221,O
In,1222,O
the,1222,O
media,1222,O
of,1222,O
the,1222,O
saphenous,1222,O
artery,1222,O
and,1222,O
its,1222,O
distal,1222,O
branch,1222,O
",",1222,O
vasoconstriction,1222,O
induced,1222,O
by,1222,O
L-norepinephrine,1222,B-Chemical
produced,1222,O
many,1222,O
cell-to-cell,1222,O
hernias,1222,B-Disease
within,1222,O
15,1222,O
minutes,1222,O
.,1222,O
At,1223,O
1,1223,O
day,1223,O
their,1223,O
number,1223,O
was,1223,O
reduced,1223,O
to,1223,O
about,1223,O
1/10,1223,O
of,1223,O
the,1223,O
original,1223,O
number,1223,O
.,1223,O
By,1224,O
7,1224,O
days,1224,O
the,1224,O
vessel,1224,O
was,1224,O
almost,1224,O
restored,1224,O
to,1224,O
normal,1224,O
.,1224,O
Triple,1225,O
stimulation,1225,O
over,1225,O
1,1225,O
day,1225,O
induced,1225,O
more,1225,O
severe,1225,O
changes,1225,O
in,1225,O
the,1225,O
media,1225,O
.,1225,O
These,1226,O
findings,1226,O
suggest,1226,O
that,1226,O
smooth,1226,O
muscle,1226,O
cells,1226,O
are,1226,O
susceptible,1226,O
to,1226,O
damage,1226,O
in,1226,O
the,1226,O
course,1226,O
of,1226,O
their,1226,O
specific,1226,O
function,1226,O
.,1226,O
The,1227,O
experimental,1227,O
data,1227,O
are,1227,O
discussed,1227,O
in,1227,O
relation,1227,O
to,1227,O
medial,1227,O
changes,1227,O
observed,1227,O
in,1227,O
other,1227,O
instances,1227,O
of,1227,O
arterial,1227,O
spasm,1227,B-Disease
.,1227,O
Endothelial,1228,O
changes,1228,O
that,1228,O
developed,1228,O
in,1228,O
the,1228,O
same,1228,O
experimental,1228,O
model,1228,O
were,1228,O
described,1228,O
in,1228,O
a,1228,O
previous,1228,O
paper,1228,O
.,1228,O
Abnormalities,1229,O
of,1229,O
the,1229,O
pupil,1229,O
and,1229,O
visual-evoked,1229,O
potential,1229,O
in,1229,O
quinine,1229,B-Chemical
amblyopia,1229,B-Disease
.,1229,O
Total,1230,O
blindness,1230,B-Disease
with,1230,O
a,1230,O
transient,1230,O
tonic,1230,B-Disease
pupillary,1230,I-Disease
response,1230,O
",",1230,O
denervation,1230,O
supersensitivity,1230,O
",",1230,O
and,1230,O
abnormal,1230,O
visual-evoked,1230,O
potentials,1230,O
developed,1230,O
in,1230,O
a,1230,O
54-year-old,1230,O
man,1230,O
after,1230,O
the,1230,O
use,1230,O
of,1230,O
quinine,1230,B-Chemical
sulfate,1230,I-Chemical
for,1230,O
leg,1230,B-Disease
cramps,1230,I-Disease
.,1230,O
He,1231,O
later,1231,O
recovered,1231,O
normal,1231,O
visual,1231,O
acuity,1231,O
.,1231,O
A,1232,O
transient,1232,O
tonic,1232,B-Disease
pupillary,1232,I-Disease
response,1232,O
",",1232,O
denervation,1232,O
supersensitivity,1232,O
",",1232,O
and,1232,O
abnormal,1232,O
visual-evoked,1232,O
potentials,1232,O
in,1232,O
quinine,1232,B-Chemical
toxicity,1232,B-Disease
",",1232,O
to,1232,O
our,1232,O
knowledge,1232,O
",",1232,O
have,1232,O
not,1232,O
been,1232,O
previously,1232,O
reported,1232,O
.,1232,O
Suxamethonium-induced,1233,B-Chemical
jaw,1233,B-Disease
stiffness,1233,I-Disease
and,1233,O
myalgia,1233,B-Disease
associated,1233,O
with,1233,O
atypical,1233,O
cholinesterase,1233,O
:,1233,O
case,1233,O
report,1233,O
.,1233,O
An,1234,O
11-year-old,1234,O
boy,1234,O
was,1234,O
given,1234,O
halothane,1234,B-Chemical
",",1234,O
nitrous,1234,B-Chemical
oxide,1234,I-Chemical
and,1234,O
oxygen,1234,B-Chemical
",",1234,O
pancuronium,1234,B-Chemical
0.4,1234,O
mg,1234,O
and,1234,O
suxamethonium,1234,B-Chemical
100,1234,O
mg,1234,O
for,1234,O
induction,1234,O
of,1234,O
anaesthesia,1234,O
.,1234,O
In,1235,O
response,1235,O
to,1235,O
this,1235,O
a,1235,O
marked,1235,O
jaw,1235,B-Disease
stiffness,1235,I-Disease
occurred,1235,O
which,1235,O
lasted,1235,O
for,1235,O
two,1235,O
minutes,1235,O
and,1235,O
the,1235,O
anaesthesia,1235,O
were,1235,O
terminated,1235,O
.,1235,O
Four,1236,O
hours,1236,O
of,1236,O
apnoea,1236,B-Disease
ensued,1236,O
and,1236,O
he,1236,O
suffered,1236,O
generalized,1236,O
severe,1236,O
myalgia,1236,B-Disease
lasting,1236,O
for,1236,O
one,1236,O
week,1236,O
.,1236,O
He,1237,O
was,1237,O
found,1237,O
to,1237,O
have,1237,O
atypical,1237,O
plasma,1237,O
cholinesterase,1237,O
with,1237,O
a,1237,O
dibucaine,1237,B-Chemical
number,1237,O
of,1237,O
12,1237,O
",",1237,O
indicating,1237,O
homozygocity,1237,O
.,1237,O
This,1238,O
was,1238,O
verified,1238,O
by,1238,O
study,1238,O
of,1238,O
the,1238,O
family,1238,O
.,1238,O
The,1239,O
case,1239,O
shows,1239,O
that,1239,O
prolonged,1239,B-Disease
jaw,1239,I-Disease
rigidity,1239,I-Disease
and,1239,O
myalgia,1239,B-Disease
may,1239,O
occur,1239,O
after,1239,O
suxamethonium,1239,B-Chemical
in,1239,O
patients,1239,O
with,1239,O
atypical,1239,O
cholinesterase,1239,O
despite,1239,O
pretreatment,1239,O
with,1239,O
pancuronium,1239,B-Chemical
.,1239,O
Indomethacin-induced,1240,B-Chemical
hyperkalemia,1240,B-Disease
in,1240,O
three,1240,O
patients,1240,O
with,1240,O
gouty,1240,B-Disease
arthritis,1240,I-Disease
.,1240,O
We,1241,O
describe,1241,O
three,1241,O
patients,1241,O
in,1241,O
whom,1241,O
severe,1241,O
",",1241,O
life-threatening,1241,O
hyperkalemia,1241,B-Disease
and,1241,O
renal,1241,B-Disease
insufficiency,1241,I-Disease
developed,1241,O
after,1241,O
treatment,1241,O
of,1241,O
acute,1241,O
gouty,1241,B-Disease
arthritis,1241,I-Disease
with,1241,O
indomethacin,1241,B-Chemical
.,1241,O
This,1242,O
complication,1242,O
may,1242,O
result,1242,O
from,1242,O
an,1242,O
inhibition,1242,O
of,1242,O
prostaglandin,1242,B-Chemical
synthesis,1242,O
and,1242,O
consequent,1242,O
hyporeninemic,1242,B-Disease
hypoaidosteronism,1242,I-Disease
.,1242,O
Careful,1243,O
attention,1243,O
to,1243,O
renal,1243,O
function,1243,O
and,1243,O
potassium,1243,B-Chemical
balance,1243,O
in,1243,O
patients,1243,O
receiving,1243,O
indomethacin,1243,B-Chemical
or,1243,O
other,1243,O
nonsteroidal,1243,O
anti-inflammatory,1243,O
agents,1243,O
",",1243,O
particularly,1243,O
in,1243,O
those,1243,O
patients,1243,O
with,1243,O
diabetes,1243,B-Disease
mellitus,1243,I-Disease
or,1243,O
preexisting,1243,O
renal,1243,B-Disease
disease,1243,I-Disease
",",1243,O
will,1243,O
help,1243,O
prevent,1243,O
this,1243,O
potentially,1243,O
serious,1243,O
complication,1243,O
.,1243,O
Etomidate,1244,B-Chemical
:,1244,O
a,1244,O
foreshortened,1244,O
clinical,1244,O
trial,1244,O
.,1244,O
A,1245,O
clinical,1245,O
evaluation,1245,O
of,1245,O
etomidate,1245,B-Chemical
for,1245,O
outpatient,1245,O
cystoscopy,1245,O
was,1245,O
embarked,1245,O
upon,1245,O
.,1245,O
Unpremedicated,1246,O
patients,1246,O
were,1246,O
given,1246,O
fentanyl,1246,B-Chemical
1,1246,O
microgram/kg,1246,O
followed,1246,O
by,1246,O
etomidate,1246,B-Chemical
0.3,1246,O
mg/kg,1246,O
.,1246,O
Anaesthesia,1247,O
was,1247,O
maintained,1247,O
with,1247,O
intermittent,1247,O
etomidate,1247,B-Chemical
in,1247,O
2-4,1247,O
mg,1247,O
doses,1247,O
.,1247,O
Patients,1248,O
were,1248,O
interviewed,1248,O
personally,1248,O
later,1248,O
the,1248,O
same,1248,O
day,1248,O
",",1248,O
and,1248,O
by,1248,O
questionnaire,1248,O
three,1248,O
to,1248,O
four,1248,O
weeks,1248,O
later,1248,O
.,1248,O
The,1249,O
trial,1249,O
was,1249,O
discontinued,1249,O
after,1249,O
20,1249,O
cases,1249,O
because,1249,O
of,1249,O
an,1249,O
unacceptable,1249,O
incidence,1249,O
of,1249,O
side,1249,O
effects,1249,O
.,1249,O
Venous,1250,O
pain,1250,B-Disease
occurred,1250,O
in,1250,O
68,1250,O
%,1250,O
of,1250,O
patients,1250,O
and,1250,O
50,1250,O
%,1250,O
had,1250,O
redness,1250,O
",",1250,O
pain,1250,B-Disease
or,1250,O
swelling,1250,B-Disease
related,1250,O
to,1250,O
the,1250,O
injection,1250,O
site,1250,O
",",1250,O
in,1250,O
some,1250,O
cases,1250,O
lasting,1250,O
up,1250,O
to,1250,O
three,1250,O
weeks,1250,O
after,1250,O
anaesthesia,1250,O
.,1250,O
Skeletal,1251,O
movements,1251,O
occurred,1251,O
in,1251,O
50,1251,O
%,1251,O
of,1251,O
patients,1251,O
;,1251,O
30,1251,O
%,1251,O
experienced,1251,O
respiratory,1251,B-Disease
upset,1251,I-Disease
",",1251,O
one,1251,O
sufficiently,1251,O
severe,1251,O
to,1251,O
necessitate,1251,O
abandoning,1251,O
the,1251,O
technique,1251,O
.,1251,O
Nausea,1252,B-Disease
and,1252,O
vomiting,1252,B-Disease
occurred,1252,O
in,1252,O
40,1252,O
%,1252,O
and,1252,O
25,1252,O
%,1252,O
had,1252,O
disturbing,1252,O
emergence,1252,O
psychoses,1252,B-Disease
.,1252,O
Levodopa-induced,1253,B-Chemical
dyskinesias,1253,B-Disease
are,1253,O
improved,1253,O
by,1253,O
fluoxetine,1253,B-Chemical
.,1253,O
We,1254,O
evaluated,1254,O
the,1254,O
severity,1254,O
of,1254,O
motor,1254,B-Disease
disability,1254,I-Disease
and,1254,O
dyskinesias,1254,B-Disease
in,1254,O
seven,1254,O
levodopa-responsive,1254,B-Chemical
patients,1254,O
with,1254,O
Parkinson,1254,B-Disease
's,1254,I-Disease
disease,1254,I-Disease
after,1254,O
an,1254,O
acute,1254,O
challenge,1254,O
with,1254,O
the,1254,O
mixed,1254,O
dopamine,1254,B-Chemical
agonist,1254,O
",",1254,O
apomorphine,1254,B-Chemical
",",1254,O
before,1254,O
and,1254,O
after,1254,O
the,1254,O
administration,1254,O
of,1254,O
fluoxetine,1254,B-Chemical
(,1254,O
20,1254,O
mg,1254,O
twice,1254,O
per,1254,O
day,1254,O
),1254,O
for,1254,O
11,1254,O
+/-,1254,O
1,1254,O
days,1254,O
.,1254,O
After,1255,O
fluoxetine,1255,B-Chemical
treatment,1255,O
",",1255,O
there,1255,O
was,1255,O
a,1255,O
significant,1255,O
47,1255,O
%,1255,O
improvement,1255,O
(,1255,O
p,1255,O
<,1255,O
0.05,1255,O
),1255,O
of,1255,O
apomorphine-induced,1255,B-Chemical
dyskinesias,1255,B-Disease
without,1255,O
modification,1255,O
of,1255,O
parkinsonian,1255,B-Disease
motor,1255,B-Disease
disability,1255,I-Disease
.,1255,O
The,1256,O
dyskinesias,1256,B-Disease
were,1256,O
reduced,1256,O
predominantly,1256,O
in,1256,O
the,1256,O
lower,1256,O
limbs,1256,O
during,1256,O
the,1256,O
onset,1256,O
and,1256,O
disappearance,1256,O
of,1256,O
dystonic,1256,O
dyskinesias,1256,O
(,1256,O
onset-,1256,O
and,1256,O
end-of-dose,1256,O
dyskinesias,1256,B-Disease
),1256,O
and,1256,O
in,1256,O
the,1256,O
upper,1256,O
limbs,1256,O
during,1256,O
choreic,1256,O
mid-dose,1256,O
dyskinesias,1256,O
.,1256,O
The,1257,O
results,1257,O
suggest,1257,O
that,1257,O
increased,1257,O
brain,1257,O
serotoninergic,1257,O
transmission,1257,O
with,1257,O
fluoxetine,1257,B-Chemical
may,1257,O
reduce,1257,O
levodopa-,1257,B-Chemical
or,1257,O
dopamine,1257,B-Chemical
agonist-induced,1257,O
dyskinesias,1257,B-Disease
without,1257,O
aggravating,1257,O
parkinsonian,1257,B-Disease
motor,1257,B-Disease
disability,1257,I-Disease
.,1257,O
A,1258,O
large,1258,O
population-based,1258,O
follow-up,1258,O
study,1258,O
of,1258,O
trimethoprim-sulfamethoxazole,1258,B-Chemical
",",1258,O
trimethoprim,1258,B-Chemical
",",1258,O
and,1258,O
cephalexin,1258,B-Chemical
for,1258,O
uncommon,1258,O
serious,1258,O
drug,1258,B-Disease
toxicity,1258,I-Disease
.,1258,O
We,1259,O
conducted,1259,O
a,1259,O
population-based,1259,O
45-day,1259,O
follow-up,1259,O
study,1259,O
of,1259,O
"232,390",1259,O
people,1259,O
who,1259,O
were,1259,O
prescribed,1259,O
trimethoprim-sulfamethoxazole,1259,B-Chemical
(,1259,O
TMP-SMZ,1259,B-Chemical
),1259,O
",",1259,O
"266,951",1259,O
prescribed,1259,O
trimethoprim,1259,B-Chemical
alone,1259,O
",",1259,O
and,1259,O
"196,397",1259,O
prescribed,1259,O
cephalexin,1259,B-Chemical
",",1259,O
to,1259,O
estimate,1259,O
the,1259,O
risk,1259,O
of,1259,O
serious,1259,O
liver,1259,O
",",1259,O
blood,1259,O
",",1259,O
skin,1259,O
",",1259,O
and,1259,O
renal,1259,O
disorders,1259,O
resulting,1259,O
in,1259,O
referral,1259,O
or,1259,O
hospitalization,1259,O
associated,1259,O
with,1259,O
these,1259,O
drugs,1259,O
.,1259,O
The,1260,O
results,1260,O
were,1260,O
based,1260,O
on,1260,O
information,1260,O
recorded,1260,O
on,1260,O
office,1260,O
computers,1260,O
by,1260,O
selected,1260,O
general,1260,O
practitioners,1260,O
in,1260,O
the,1260,O
United,1260,O
Kingdom,1260,O
",",1260,O
together,1260,O
with,1260,O
a,1260,O
review,1260,O
of,1260,O
clinical,1260,O
records,1260,O
.,1260,O
The,1261,O
risk,1261,O
of,1261,O
clinically,1261,O
important,1261,O
idiopathic,1261,O
liver,1261,B-Disease
disease,1261,I-Disease
was,1261,O
similar,1261,O
for,1261,O
persons,1261,O
prescribed,1261,O
TMP-SMZ,1261,B-Chemical
(,1261,O
"5.2/100,000",1261,O
),1261,O
and,1261,O
those,1261,O
prescribed,1261,O
trimethoprim,1261,B-Chemical
alone,1261,O
(,1261,O
"3.8/100,000",1261,O
),1261,O
.,1261,O
The,1262,O
risk,1262,O
for,1262,O
those,1262,O
prescribed,1262,O
cephalexin,1262,B-Chemical
was,1262,O
somewhat,1262,O
lower,1262,O
(,1262,O
"2.0/100,000",1262,O
),1262,O
.,1262,O
Only,1263,O
five,1263,O
patients,1263,O
experienced,1263,O
blood,1263,O
disorders,1263,O
",",1263,O
one,1263,O
of,1263,O
whom,1263,O
was,1263,O
exposed,1263,O
to,1263,O
TMP-SMZ,1263,B-Chemical
;,1263,O
of,1263,O
seven,1263,O
with,1263,O
erythema,1263,B-Disease
multiforme,1263,I-Disease
and,1263,O
Stevens-Johnson,1263,B-Disease
syndrome,1263,I-Disease
",",1263,O
four,1263,O
were,1263,O
exposed,1263,O
to,1263,O
TMP-SMZ,1263,B-Chemical
.,1263,O
The,1264,O
one,1264,O
case,1264,O
of,1264,O
toxic,1264,B-Disease
epidermal,1264,I-Disease
necrolysis,1264,I-Disease
occurred,1264,O
in,1264,O
a,1264,O
patient,1264,O
who,1264,O
took,1264,O
cephalexin,1264,B-Chemical
.,1264,O
Finally,1265,O
",",1265,O
only,1265,O
five,1265,O
cases,1265,O
of,1265,O
acute,1265,O
parenchymal,1265,O
renal,1265,B-Disease
disease,1265,I-Disease
occurred,1265,O
",",1265,O
none,1265,O
likely,1265,O
to,1265,O
be,1265,O
caused,1265,O
by,1265,O
a,1265,O
study,1265,O
drug,1265,O
.,1265,O
We,1266,O
conclude,1266,O
that,1266,O
the,1266,O
risk,1266,O
of,1266,O
the,1266,O
serious,1266,O
diseases,1266,O
studied,1266,O
is,1266,O
small,1266,O
for,1266,O
the,1266,O
three,1266,O
agents,1266,O
",",1266,O
and,1266,O
compares,1266,O
reasonably,1266,O
with,1266,O
the,1266,O
risk,1266,O
for,1266,O
many,1266,O
other,1266,O
antibiotics,1266,O
.,1266,O
Clinical,1267,O
safety,1267,O
of,1267,O
lidocaine,1267,B-Chemical
in,1267,O
patients,1267,O
with,1267,O
cocaine-associated,1267,B-Chemical
myocardial,1267,B-Disease
infarction,1267,I-Disease
.,1267,O
STUDY,1268,O
OBJECTIVE,1268,O
:,1268,O
To,1268,O
evaluate,1268,O
the,1268,O
safety,1268,O
of,1268,O
lidocaine,1268,B-Chemical
in,1268,O
the,1268,O
setting,1268,O
of,1268,O
cocaine-induced,1268,B-Chemical
myocardial,1268,B-Disease
infarction,1268,I-Disease
(,1268,O
MI,1268,B-Disease
),1268,O
.,1268,O
DESIGN,1269,O
:,1269,O
A,1269,O
retrospective,1269,O
",",1269,O
multicenter,1269,O
study,1269,O
.,1269,O
SETTING,1270,O
:,1270,O
Twenty-nine,1270,O
university,1270,O
",",1270,O
university-affiliated,1270,O
",",1270,O
or,1270,O
community,1270,O
hospitals,1270,O
during,1270,O
a,1270,O
6-year,1270,O
period,1270,O
(,1270,O
total,1270,O
of,1270,O
117,1270,O
cumulative,1270,O
hospital-years,1270,O
),1270,O
.,1270,O
PARTICIPANTS,1271,O
:,1271,O
Patients,1271,O
with,1271,O
cocaine-associated,1271,B-Chemical
MI,1271,B-Disease
who,1271,O
received,1271,O
lidocaine,1271,B-Chemical
in,1271,O
the,1271,O
emergency,1271,O
department,1271,O
.,1271,O
RESULTS,1272,O
:,1272,O
Of,1272,O
29,1272,O
patients,1272,O
who,1272,O
received,1272,O
lidocaine,1272,B-Chemical
in,1272,O
the,1272,O
setting,1272,O
of,1272,O
cocaine-associated,1272,B-Chemical
MI,1272,B-Disease
",",1272,O
no,1272,O
patient,1272,O
died,1272,O
;,1272,O
exhibited,1272,O
bradydysrhythmias,1272,B-Disease
",",1272,O
ventricular,1272,B-Disease
tachycardia,1272,I-Disease
",",1272,O
or,1272,O
ventricular,1272,B-Disease
fibrillation,1272,I-Disease
;,1272,O
or,1272,O
experienced,1272,O
seizures,1272,B-Disease
after,1272,O
administration,1272,O
of,1272,O
lidocaine,1272,B-Chemical
(,1272,O
95,1272,O
%,1272,O
confidence,1272,O
interval,1272,O
",",1272,O
0,1272,O
%,1272,O
to,1272,O
11,1272,O
%,1272,O
),1272,O
.,1272,O
CONCLUSION,1273,O
:,1273,O
Despite,1273,O
theoretical,1273,O
concerns,1273,O
that,1273,O
lidocaine,1273,B-Chemical
may,1273,O
enhance,1273,O
cocaine,1273,B-Chemical
toxicity,1273,B-Disease
",",1273,O
the,1273,O
use,1273,O
of,1273,O
lidocaine,1273,B-Chemical
in,1273,O
patients,1273,O
with,1273,O
cocaine-associated,1273,B-Chemical
MI,1273,B-Disease
was,1273,O
not,1273,O
associated,1273,O
with,1273,O
significant,1273,O
cardiovascular,1273,O
or,1273,O
central,1273,O
nervous,1273,O
system,1273,O
toxicity,1273,O
.,1273,O
Paclitaxel,1274,B-Chemical
3-hour,1274,O
infusion,1274,O
given,1274,O
alone,1274,O
and,1274,O
combined,1274,O
with,1274,O
carboplatin,1274,B-Chemical
:,1274,O
preliminary,1274,O
results,1274,O
of,1274,O
dose-escalation,1274,O
trials,1274,O
.,1274,O
Paclitaxel,1275,B-Chemical
(,1275,O
Taxol,1275,B-Chemical
;,1275,O
Bristol-Myers,1275,O
Squibb,1275,O
Company,1275,O
",",1275,O
Princeton,1275,O
",",1275,O
NJ,1275,O
),1275,O
by,1275,O
3-hour,1275,O
infusion,1275,O
was,1275,O
combined,1275,O
with,1275,O
carboplatin,1275,B-Chemical
in,1275,O
a,1275,O
phase,1275,O
I/II,1275,O
study,1275,O
directed,1275,O
to,1275,O
patients,1275,O
with,1275,O
non-small,1275,B-Disease
cell,1275,I-Disease
lung,1275,I-Disease
cancer,1275,I-Disease
.,1275,O
Carboplatin,1276,B-Chemical
was,1276,O
given,1276,O
at,1276,O
a,1276,O
fixed,1276,O
target,1276,O
area,1276,O
under,1276,O
the,1276,O
concentration-time,1276,O
curve,1276,O
of,1276,O
6.0,1276,O
by,1276,O
the,1276,O
Calvert,1276,O
formula,1276,O
",",1276,O
whereas,1276,O
paclitaxel,1276,B-Chemical
was,1276,O
escalated,1276,O
in,1276,O
patient,1276,O
cohorts,1276,O
from,1276,O
150,1276,O
mg/m2,1276,O
(,1276,O
dose,1276,O
level,1276,O
I,1276,O
),1276,O
to,1276,O
175,1276,O
",",1276,O
200,1276,O
",",1276,O
225,1276,O
",",1276,O
and,1276,O
250,1276,O
mg/m2,1276,O
.,1276,O
The,1277,O
225,1277,O
mg/m2,1277,O
level,1277,O
was,1277,O
expanded,1277,O
for,1277,O
the,1277,O
phase,1277,O
II,1277,O
study,1277,O
since,1277,O
the,1277,O
highest,1277,O
level,1277,O
achieved,1277,O
(,1277,O
250,1277,O
mg/m2,1277,O
),1277,O
required,1277,O
modification,1277,O
because,1277,O
of,1277,O
nonhematologic,1277,O
toxicities,1277,B-Disease
(,1277,O
arthralgia,1277,B-Disease
and,1277,O
sensory,1277,B-Disease
neuropathy,1277,I-Disease
),1277,O
.,1277,O
Therapeutic,1278,O
effects,1278,O
were,1278,O
noted,1278,O
at,1278,O
all,1278,O
dose,1278,O
levels,1278,O
",",1278,O
with,1278,O
objective,1278,O
responses,1278,O
in,1278,O
17,1278,O
(,1278,O
two,1278,O
complete,1278,O
and,1278,O
15,1278,O
partial,1278,O
regressions,1278,O
),1278,O
of,1278,O
41,1278,O
previously,1278,O
untreated,1278,O
patients,1278,O
.,1278,O
Toxicities,1279,B-Disease
were,1279,O
compared,1279,O
with,1279,O
a,1279,O
cohort,1279,O
of,1279,O
patients,1279,O
in,1279,O
a,1279,O
phase,1279,O
I,1279,O
trial,1279,O
of,1279,O
paclitaxel,1279,B-Chemical
alone,1279,O
at,1279,O
identical,1279,O
dose,1279,O
levels,1279,O
.,1279,O
Carboplatin,1280,B-Chemical
did,1280,O
not,1280,O
appear,1280,O
to,1280,O
add,1280,O
to,1280,O
the,1280,O
hematologic,1280,B-Disease
toxicities,1280,I-Disease
observed,1280,O
",",1280,O
and,1280,O
the,1280,O
paclitaxel/carboplatin,1280,B-Chemical
combination,1280,O
could,1280,O
be,1280,O
dosed,1280,O
every,1280,O
3,1280,O
weeks,1280,O
.,1280,O
The,1281,O
dose-dependent,1281,O
effect,1281,O
of,1281,O
misoprostol,1281,B-Chemical
on,1281,O
indomethacin-induced,1281,B-Chemical
renal,1281,B-Disease
dysfunction,1281,I-Disease
in,1281,O
well,1281,O
compensated,1281,O
cirrhosis,1281,B-Disease
.,1281,O
Misoprostol,1282,B-Chemical
(,1282,O
200,1282,O
micrograms,1282,O
),1282,O
has,1282,O
been,1282,O
shown,1282,O
to,1282,O
acutely,1282,O
counteract,1282,O
the,1282,O
indomethacin-induced,1282,B-Chemical
renal,1282,B-Disease
dysfunction,1282,I-Disease
in,1282,O
well,1282,O
compensated,1282,O
cirrhotic,1282,B-Disease
patients,1282,O
.,1282,O
The,1283,O
aim,1283,O
of,1283,O
this,1283,O
study,1283,O
was,1283,O
to,1283,O
determine,1283,O
if,1283,O
the,1283,O
prophylactic,1283,O
value,1283,O
of,1283,O
misoprostol,1283,B-Chemical
was,1283,O
dose-dependent,1283,O
.,1283,O
Parameters,1284,O
of,1284,O
renal,1284,O
hemodynamics,1284,O
and,1284,O
tubular,1284,O
sodium,1284,B-Chemical
and,1284,O
water,1284,O
handling,1284,O
were,1284,O
assessed,1284,O
by,1284,O
clearance,1284,O
techniques,1284,O
in,1284,O
26,1284,O
well,1284,O
compensated,1284,O
cirrhotic,1284,B-Disease
patients,1284,O
before,1284,O
and,1284,O
after,1284,O
an,1284,O
oral,1284,O
combination,1284,O
of,1284,O
50,1284,O
mg,1284,O
of,1284,O
indomethacin,1284,B-Chemical
and,1284,O
various,1284,O
doses,1284,O
of,1284,O
misoprostol,1284,B-Chemical
.,1284,O
The,1285,O
200-micrograms,1285,O
dose,1285,O
was,1285,O
able,1285,O
to,1285,O
totally,1285,O
abolish,1285,O
the,1285,O
deleterious,1285,O
renal,1285,O
effects,1285,O
of,1285,O
indomethacin,1285,B-Chemical
",",1285,O
whereas,1285,O
the,1285,O
800-micrograms,1285,O
dose,1285,O
resulted,1285,O
in,1285,O
significant,1285,O
worsening,1285,O
of,1285,O
renal,1285,O
hemodynamics,1285,O
and,1285,O
sodium,1285,B-Chemical
retention,1285,O
.,1285,O
These,1286,O
changes,1286,O
were,1286,O
maximal,1286,O
in,1286,O
the,1286,O
hour,1286,O
immediately,1286,O
after,1286,O
medications,1286,O
and,1286,O
slowly,1286,O
returned,1286,O
toward,1286,O
base-line,1286,O
levels,1286,O
thereafter,1286,O
.,1286,O
These,1287,O
results,1287,O
suggest,1287,O
that,1287,O
the,1287,O
renal,1287,O
protective,1287,O
effects,1287,O
of,1287,O
misoprostol,1287,B-Chemical
is,1287,O
dose-dependent,1287,O
.,1287,O
However,1288,O
",",1288,O
until,1288,O
this,1288,O
apparent,1288,O
ability,1288,O
of,1288,O
200,1288,O
micrograms,1288,O
of,1288,O
misoprostol,1288,B-Chemical
to,1288,O
prevent,1288,O
the,1288,O
adverse,1288,O
effects,1288,O
of,1288,O
indomethacin,1288,B-Chemical
on,1288,O
renal,1288,O
function,1288,O
is,1288,O
confirmed,1288,O
with,1288,O
chronic,1288,O
frequent,1288,O
dosing,1288,O
",",1288,O
it,1288,O
would,1288,O
be,1288,O
prudent,1288,O
to,1288,O
avoid,1288,O
nonsteroidal,1288,O
anti-inflammatory,1288,O
therapy,1288,O
in,1288,O
patients,1288,O
with,1288,O
cirrhosis,1288,B-Disease
.,1288,O
Increased,1289,O
frequency,1289,O
and,1289,O
severity,1289,O
of,1289,O
angio-oedema,1289,B-Disease
related,1289,O
to,1289,O
long-term,1289,O
therapy,1289,O
with,1289,O
angiotensin-converting,1289,B-Chemical
enzyme,1289,I-Chemical
inhibitor,1289,I-Chemical
in,1289,O
two,1289,O
patients,1289,O
.,1289,O
Adverse,1290,O
reactions,1290,O
to,1290,O
drugs,1290,O
are,1290,O
well,1290,O
recognized,1290,O
as,1290,O
a,1290,O
cause,1290,O
of,1290,O
acute,1290,O
or,1290,O
chronic,1290,O
urticaria,1290,B-Disease
",",1290,O
and,1290,O
angio-oedema,1290,B-Disease
.,1290,O
Angiotensin-converting,1291,B-Chemical
enzyme,1291,I-Chemical
(,1291,I-Chemical
ACE,1291,I-Chemical
),1291,I-Chemical
inhibitors,1291,I-Chemical
",",1291,O
used,1291,O
to,1291,O
treat,1291,O
hypertension,1291,B-Disease
and,1291,O
congestive,1291,B-Disease
heart,1291,I-Disease
failure,1291,I-Disease
",",1291,O
were,1291,O
introduced,1291,O
in,1291,O
Europe,1291,O
in,1291,O
the,1291,O
middle,1291,O
of,1291,O
the,1291,O
eighties,1291,O
",",1291,O
and,1291,O
the,1291,O
use,1291,O
of,1291,O
these,1291,O
drugs,1291,O
has,1291,O
increased,1291,O
progressively,1291,O
.,1291,O
Soon,1292,O
after,1292,O
the,1292,O
introduction,1292,O
of,1292,O
ACE,1292,B-Chemical
inhibitors,1292,I-Chemical
",",1292,O
acute,1292,O
bouts,1292,O
of,1292,O
angio-oedema,1292,B-Disease
were,1292,O
reported,1292,O
in,1292,O
association,1292,O
with,1292,O
the,1292,O
use,1292,O
of,1292,O
these,1292,O
drugs,1292,O
.,1292,O
We,1293,O
wish,1293,O
to,1293,O
draw,1293,O
attention,1293,O
to,1293,O
the,1293,O
possibility,1293,O
of,1293,O
adverse,1293,O
reactions,1293,O
to,1293,O
ACE,1293,B-Chemical
inhibitors,1293,I-Chemical
after,1293,O
long-term,1293,O
use,1293,O
and,1293,O
in,1293,O
patients,1293,O
with,1293,O
pre-existing,1293,O
angio-oedema,1293,B-Disease
.,1293,O
Myoclonus,1294,B-Disease
associated,1294,O
with,1294,O
lorazepam,1294,B-Chemical
therapy,1294,O
in,1294,O
very-low-birth-weight,1294,O
infants,1294,O
.,1294,O
Lorazepam,1295,B-Chemical
is,1295,O
being,1295,O
used,1295,O
with,1295,O
increasing,1295,O
frequency,1295,O
as,1295,O
a,1295,O
sedative,1295,O
in,1295,O
the,1295,O
newborn,1295,O
and,1295,O
the,1295,O
young,1295,O
infant,1295,O
.,1295,O
Concern,1296,O
has,1296,O
been,1296,O
raised,1296,O
with,1296,O
regard,1296,O
to,1296,O
the,1296,O
safety,1296,O
of,1296,O
lorazepam,1296,B-Chemical
in,1296,O
this,1296,O
age,1296,O
group,1296,O
",",1296,O
especially,1296,O
in,1296,O
very-low-birth-weight,1296,O
(,1296,O
VLBW,1296,O
;,1296,O
<,1296,O
"1,500",1296,O
g,1296,O
),1296,O
infants,1296,O
.,1296,O
Three,1297,O
young,1297,O
infants,1297,O
",",1297,O
all,1297,O
of,1297,O
birth,1297,O
weight,1297,O
<,1297,O
"1,500",1297,O
g,1297,O
",",1297,O
experienced,1297,O
myoclonus,1297,B-Disease
following,1297,O
the,1297,O
intravenous,1297,O
administration,1297,O
of,1297,O
lorazepam,1297,B-Chemical
.,1297,O
The,1298,O
potential,1298,O
neurotoxic,1298,B-Disease
effects,1298,O
of,1298,O
the,1298,O
drug,1298,O
(,1298,O
and,1298,O
its,1298,O
vehicle,1298,O
),1298,O
in,1298,O
this,1298,O
population,1298,O
are,1298,O
discussed,1298,O
.,1298,O
Injectable,1299,O
lorazepam,1299,B-Chemical
should,1299,O
be,1299,O
used,1299,O
with,1299,O
caution,1299,O
in,1299,O
VLBW,1299,O
infants,1299,O
.,1299,O
Transvenous,1300,O
right,1300,O
ventricular,1300,O
pacing,1300,O
during,1300,O
cardiopulmonary,1300,O
resuscitation,1300,O
of,1300,O
pediatric,1300,O
patients,1300,O
with,1300,O
acute,1300,O
cardiomyopathy,1300,B-Disease
.,1300,O
We,1301,O
describe,1301,O
the,1301,O
cardiopulmonary,1301,O
resuscitation,1301,O
efforts,1301,O
on,1301,O
five,1301,O
patients,1301,O
who,1301,O
presented,1301,O
in,1301,O
acute,1301,O
circulatory,1301,B-Disease
failure,1301,I-Disease
from,1301,O
myocardial,1301,B-Disease
dysfunction,1301,I-Disease
.,1301,O
Three,1302,O
patients,1302,O
had,1302,O
acute,1302,O
viral,1302,O
myocarditis,1302,B-Disease
",",1302,O
one,1302,O
had,1302,O
a,1302,O
carbamazepine-induced,1302,B-Chemical
acute,1302,O
eosinophilic,1302,O
myocarditis,1302,O
",",1302,O
and,1302,O
one,1302,O
had,1302,O
cardiac,1302,O
hemosiderosis,1302,O
resulting,1302,O
in,1302,O
acute,1302,O
cardiogenic,1302,B-Disease
shock,1302,I-Disease
.,1302,O
All,1303,O
patients,1303,O
were,1303,O
continuously,1303,O
monitored,1303,O
with,1303,O
central,1303,O
venous,1303,O
and,1303,O
arterial,1303,O
catheters,1303,O
in,1303,O
addition,1303,O
to,1303,O
routine,1303,O
noninvasive,1303,O
monitoring,1303,O
.,1303,O
An,1304,O
introducer,1304,O
sheath,1304,O
",",1304,O
a,1304,O
pacemaker,1304,O
",",1304,O
and,1304,O
sterile,1304,O
pacing,1304,O
wires,1304,O
were,1304,O
made,1304,O
readily,1304,O
available,1304,O
for,1304,O
the,1304,O
patients,1304,O
",",1304,O
should,1304,O
the,1304,O
need,1304,O
arise,1304,O
to,1304,O
terminate,1304,O
resistant,1304,O
cardiac,1304,O
dysrhythmias,1304,B-Disease
.,1304,O
All,1305,O
patients,1305,O
developed,1305,O
cardiocirculatory,1305,O
arrest,1305,O
associated,1305,O
with,1305,O
extreme,1305,O
hypotension,1305,B-Disease
and,1305,O
dysrhythmias,1305,B-Disease
within,1305,O
the,1305,O
first,1305,O
48,1305,O
hours,1305,O
of,1305,O
their,1305,O
admission,1305,O
to,1305,O
the,1305,O
pediatric,1305,O
intensive,1305,O
care,1305,O
unit,1305,O
(,1305,O
PICU,1305,O
),1305,O
.,1305,O
Right,1306,O
ventricular,1306,O
pacemaker,1306,O
wires,1306,O
were,1306,O
inserted,1306,O
in,1306,O
all,1306,O
of,1306,O
them,1306,O
during,1306,O
cardiopulmonary,1306,O
resuscitation,1306,O
(,1306,O
CPR,1306,O
),1306,O
.,1306,O
In,1307,O
four,1307,O
patients,1307,O
",",1307,O
cardiac,1307,O
pacing,1307,O
was,1307,O
used,1307,O
",",1307,O
resulting,1307,O
in,1307,O
a,1307,O
temporary,1307,O
captured,1307,O
rhythm,1307,O
and,1307,O
restoration,1307,O
of,1307,O
their,1307,O
cardiac,1307,O
output,1307,O
.,1307,O
These,1308,O
patients,1308,O
had,1308,O
a,1308,O
second,1308,O
event,1308,O
of,1308,O
cardiac,1308,B-Disease
arrest,1308,I-Disease
",",1308,O
resulting,1308,O
in,1308,O
death,1308,O
",",1308,O
within,1308,O
10,1308,O
to,1308,O
60,1308,O
minutes,1308,O
.,1308,O
In,1309,O
one,1309,O
patient,1309,O
",",1309,O
cardiac,1309,O
pacing,1309,O
was,1309,O
not,1309,O
used,1309,O
",",1309,O
because,1309,O
he,1309,O
converted,1309,O
to,1309,O
normal,1309,O
sinus,1309,O
rhythm,1309,O
by,1309,O
electrical,1309,O
defibrillation,1309,O
within,1309,O
three,1309,O
minutes,1309,O
of,1309,O
initiating,1309,O
CPR,1309,O
.,1309,O
We,1310,O
conclude,1310,O
that,1310,O
cardiac,1310,O
pacing,1310,O
during,1310,O
resuscitative,1310,O
efforts,1310,O
in,1310,O
pediatric,1310,O
patients,1310,O
suffering,1310,O
from,1310,O
acute,1310,O
myocardial,1310,B-Disease
dysfunction,1310,I-Disease
may,1310,O
not,1310,O
have,1310,O
long-term,1310,O
value,1310,O
in,1310,O
and,1310,O
of,1310,O
itself,1310,O
;,1310,O
however,1310,O
",",1310,O
if,1310,O
temporary,1310,O
hemodynamic,1310,O
stability,1310,O
is,1310,O
achieved,1310,O
by,1310,O
this,1310,O
procedure,1310,O
",",1310,O
it,1310,O
may,1310,O
provide,1310,O
additional,1310,O
time,1310,O
needed,1310,O
to,1310,O
institute,1310,O
other,1310,O
therapeutic,1310,O
modalities,1310,O
.,1310,O
Efficacy,1311,O
and,1311,O
safety,1311,O
of,1311,O
granisetron,1311,B-Chemical
",",1311,O
a,1311,O
selective,1311,O
5-hydroxytryptamine-3,1311,B-Chemical
receptor,1311,O
antagonist,1311,O
",",1311,O
in,1311,O
the,1311,O
prevention,1311,O
of,1311,O
nausea,1311,B-Disease
and,1311,O
vomiting,1311,B-Disease
induced,1311,O
by,1311,O
high-dose,1311,O
cisplatin,1311,B-Chemical
.,1311,O
PURPOSE,1312,O
:,1312,O
To,1312,O
assess,1312,O
the,1312,O
antiemetic,1312,O
effects,1312,O
and,1312,O
safety,1312,O
profile,1312,O
of,1312,O
four,1312,O
different,1312,O
doses,1312,O
of,1312,O
granisetron,1312,B-Chemical
(,1312,O
Kytril,1312,B-Chemical
;,1312,O
SmithKline,1312,O
Beecham,1312,O
Pharmaceuticals,1312,O
",",1312,O
Philadelphia,1312,O
",",1312,O
PA,1312,O
),1312,O
when,1312,O
administered,1312,O
as,1312,O
a,1312,O
single,1312,O
intravenous,1312,O
(,1312,O
IV,1312,O
),1312,O
dose,1312,O
for,1312,O
prophylaxis,1312,O
of,1312,O
cisplatin-induced,1312,B-Chemical
nausea,1312,B-Disease
and,1312,O
vomiting,1312,B-Disease
.,1312,O
PATIENTS,1313,O
AND,1313,O
METHODS,1313,O
:,1313,O
One,1313,O
hundred,1313,O
eighty-four,1313,O
chemotherapy-naive,1313,O
patients,1313,O
receiving,1313,O
high-dose,1313,O
cisplatin,1313,B-Chemical
(,1313,O
81,1313,O
to,1313,O
120,1313,O
mg/m2,1313,O
),1313,O
were,1313,O
randomized,1313,O
to,1313,O
receive,1313,O
one,1313,O
of,1313,O
four,1313,O
granisetron,1313,B-Chemical
doses,1313,O
(,1313,O
5,1313,O
",",1313,O
10,1313,O
",",1313,O
20,1313,O
",",1313,O
or,1313,O
40,1313,O
micrograms/kg,1313,O
),1313,O
administered,1313,O
before,1313,O
chemotherapy,1313,O
.,1313,O
Patients,1314,O
were,1314,O
observed,1314,O
on,1314,O
an,1314,O
inpatient,1314,O
basis,1314,O
for,1314,O
18,1314,O
to,1314,O
24,1314,O
hours,1314,O
",",1314,O
and,1314,O
vital,1314,O
signs,1314,O
",",1314,O
nausea,1314,B-Disease
",",1314,O
vomiting,1314,B-Disease
",",1314,O
retching,1314,O
",",1314,O
and,1314,O
appetite,1314,O
were,1314,O
assessed,1314,O
.,1314,O
Safety,1315,O
analyses,1315,O
included,1315,O
incidence,1315,O
of,1315,O
adverse,1315,O
experiences,1315,O
and,1315,O
laboratory,1315,O
parameter,1315,O
changes,1315,O
.,1315,O
RESULTS,1316,O
:,1316,O
After,1316,O
granisetron,1316,B-Chemical
doses,1316,O
of,1316,O
5,1316,O
",",1316,O
10,1316,O
",",1316,O
20,1316,O
",",1316,O
and,1316,O
40,1316,O
micrograms/kg,1316,O
",",1316,O
a,1316,O
major,1316,O
response,1316,O
(,1316,O
<,1316,O
or,1316,O
=,1316,O
two,1316,O
vomiting,1316,B-Disease
or,1316,O
retching,1316,O
episodes,1316,O
",",1316,O
and,1316,O
no,1316,O
antiemetic,1316,O
rescue,1316,O
),1316,O
was,1316,O
recorded,1316,O
in,1316,O
23,1316,O
%,1316,O
",",1316,O
57,1316,O
%,1316,O
",",1316,O
58,1316,O
%,1316,O
",",1316,O
and,1316,O
60,1316,O
%,1316,O
of,1316,O
patients,1316,O
",",1316,O
respectively,1316,O
",",1316,O
and,1316,O
a,1316,O
complete,1316,O
response,1316,O
(,1316,O
no,1316,O
vomiting,1316,B-Disease
or,1316,O
retching,1316,O
",",1316,O
and,1316,O
no,1316,O
antiemetic,1316,O
rescue,1316,O
),1316,O
in,1316,O
18,1316,O
%,1316,O
",",1316,O
41,1316,O
%,1316,O
",",1316,O
40,1316,O
%,1316,O
",",1316,O
and,1316,O
47,1316,O
%,1316,O
of,1316,O
patients,1316,O
",",1316,O
respectively,1316,O
.,1316,O
There,1317,O
was,1317,O
a,1317,O
statistically,1317,O
longer,1317,O
time,1317,O
to,1317,O
first,1317,O
episode,1317,O
of,1317,O
nausea,1317,B-Disease
(,1317,O
P,1317,O
=,1317,O
.0015,1317,O
),1317,O
and,1317,O
vomiting,1317,B-Disease
(,1317,O
P,1317,O
=,1317,O
.0001,1317,O
),1317,O
",",1317,O
and,1317,O
fewer,1317,O
patients,1317,O
were,1317,O
administered,1317,O
additional,1317,O
antiemetic,1317,O
medication,1317,O
in,1317,O
the,1317,O
10-micrograms/kg,1317,O
dosing,1317,O
groups,1317,O
than,1317,O
in,1317,O
the,1317,O
5-micrograms/kg,1317,O
dosing,1317,O
group,1317,O
.,1317,O
As,1318,O
granisetron,1318,B-Chemical
dose,1318,O
increased,1318,O
",",1318,O
appetite,1318,O
return,1318,O
increased,1318,O
(,1318,O
P,1318,O
=,1318,O
.040,1318,O
),1318,O
.,1318,O
Headache,1319,B-Disease
was,1319,O
the,1319,O
most,1319,O
frequently,1319,O
reported,1319,O
adverse,1319,O
event,1319,O
(,1319,O
20,1319,O
%,1319,O
),1319,O
.,1319,O
CONCLUSION,1320,O
:,1320,O
A,1320,O
single,1320,O
10-,1320,O
",",1320,O
20-,1320,O
",",1320,O
or,1320,O
40-micrograms/kg,1320,O
dose,1320,O
of,1320,O
granisetron,1320,B-Chemical
was,1320,O
effective,1320,O
in,1320,O
controlling,1320,O
vomiting,1320,B-Disease
in,1320,O
57,1320,O
%,1320,O
to,1320,O
60,1320,O
%,1320,O
of,1320,O
patients,1320,O
who,1320,O
received,1320,O
cisplatin,1320,B-Chemical
at,1320,O
doses,1320,O
greater,1320,O
than,1320,O
81,1320,O
mg/m2,1320,O
and,1320,O
totally,1320,O
prevented,1320,O
vomiting,1320,B-Disease
in,1320,O
40,1320,O
%,1320,O
to,1320,O
47,1320,O
%,1320,O
of,1320,O
patients,1320,O
.,1320,O
There,1321,O
were,1321,O
no,1321,O
statistically,1321,O
significant,1321,O
differences,1321,O
in,1321,O
efficacy,1321,O
between,1321,O
the,1321,O
10-micrograms/kg,1321,O
dose,1321,O
and,1321,O
the,1321,O
20-,1321,O
and,1321,O
40-micrograms/kg,1321,O
doses,1321,O
.,1321,O
Granisetron,1322,B-Chemical
was,1322,O
well,1322,O
tolerated,1322,O
at,1322,O
all,1322,O
doses,1322,O
.,1322,O
Adverse,1323,O
interaction,1323,O
between,1323,O
clonidine,1323,B-Chemical
and,1323,O
verapamil,1323,B-Chemical
.,1323,O
OBJECTIVE,1324,O
:,1324,O
To,1324,O
report,1324,O
two,1324,O
cases,1324,O
of,1324,O
a,1324,O
possible,1324,O
adverse,1324,O
interaction,1324,O
between,1324,O
clonidine,1324,B-Chemical
and,1324,O
verapamil,1324,B-Chemical
resulting,1324,O
in,1324,O
atrioventricular,1324,B-Disease
(,1324,I-Disease
AV,1324,I-Disease
),1324,I-Disease
block,1324,I-Disease
in,1324,O
both,1324,O
patients,1324,O
and,1324,O
severe,1324,O
hypotension,1324,B-Disease
in,1324,O
one,1324,O
patient,1324,O
.,1324,O
CASE,1325,O
SUMMARIES,1325,O
:,1325,O
A,1325,O
54-year-old,1325,O
woman,1325,O
with,1325,O
hyperaldosteronism,1325,B-Disease
was,1325,O
treated,1325,O
with,1325,O
verapamil,1325,B-Chemical
480,1325,O
mg/d,1325,O
and,1325,O
spironolactone,1325,B-Chemical
100,1325,O
mg/d,1325,O
.,1325,O
After,1326,O
the,1326,O
addition,1326,O
of,1326,O
a,1326,O
minimal,1326,O
dose,1326,O
of,1326,O
clonidine,1326,B-Chemical
(,1326,O
0.15,1326,O
mg,1326,O
bid,1326,O
),1326,O
",",1326,O
she,1326,O
developed,1326,O
complete,1326,O
AV,1326,B-Disease
block,1326,I-Disease
and,1326,O
severe,1326,O
hypotension,1326,B-Disease
",",1326,O
which,1326,O
resolved,1326,O
upon,1326,O
cessation,1326,O
of,1326,O
all,1326,O
medications,1326,O
.,1326,O
A,1327,O
65-year-old,1327,O
woman,1327,O
was,1327,O
treated,1327,O
with,1327,O
extended-release,1327,O
verapamil,1327,B-Chemical
240,1327,O
mg/d,1327,O
.,1327,O
After,1328,O
the,1328,O
addition,1328,O
of,1328,O
clonidine,1328,B-Chemical
0.15,1328,O
mg,1328,O
bid,1328,O
she,1328,O
developed,1328,O
complete,1328,O
AV,1328,B-Disease
block,1328,I-Disease
",",1328,O
which,1328,O
resolved,1328,O
after,1328,O
all,1328,O
therapy,1328,O
was,1328,O
stopped,1328,O
.,1328,O
DISCUSSION,1329,O
:,1329,O
An,1329,O
adverse,1329,O
interaction,1329,O
between,1329,O
clonidine,1329,B-Chemical
and,1329,O
verapamil,1329,B-Chemical
has,1329,O
not,1329,O
been,1329,O
reported,1329,O
previously,1329,O
.,1329,O
We,1330,O
describe,1330,O
two,1330,O
such,1330,O
cases,1330,O
and,1330,O
discuss,1330,O
the,1330,O
various,1330,O
mechanisms,1330,O
that,1330,O
might,1330,O
cause,1330,O
such,1330,O
an,1330,O
interaction,1330,O
.,1330,O
Clinicians,1331,O
should,1331,O
be,1331,O
acquainted,1331,O
with,1331,O
this,1331,O
possibly,1331,O
fatal,1331,O
interaction,1331,O
between,1331,O
two,1331,O
commonly,1331,O
used,1331,O
antihypertensive,1331,O
drugs,1331,O
.,1331,O
CONCLUSIONS,1332,O
:,1332,O
Caution,1332,O
is,1332,O
recommended,1332,O
in,1332,O
combining,1332,O
clonidine,1332,B-Chemical
and,1332,O
verapamil,1332,B-Chemical
therapy,1332,O
",",1332,O
even,1332,O
in,1332,O
patients,1332,O
who,1332,O
do,1332,O
not,1332,O
have,1332,O
sinus,1332,O
or,1332,O
AV,1332,O
node,1332,O
dysfunction,1332,O
.,1332,O
The,1333,O
two,1333,O
drugs,1333,O
may,1333,O
act,1333,O
synergistically,1333,O
on,1333,O
both,1333,O
the,1333,O
AV,1333,O
node,1333,O
and,1333,O
the,1333,O
peripheral,1333,O
circulation,1333,O
.,1333,O
Pharmacological,1334,O
studies,1334,O
on,1334,O
a,1334,O
new,1334,O
dihydrothienopyridine,1334,B-Chemical
calcium,1334,I-Chemical
antagonist,1334,O
",",1334,O
S-312-d.,1334,B-Chemical
5th,1334,O
communication,1334,O
:,1334,O
anticonvulsant,1334,O
effects,1334,O
in,1334,O
mice,1334,O
.,1334,O
S-312,1335,B-Chemical
",",1335,O
S-312-d,1335,B-Chemical
",",1335,O
but,1335,O
not,1335,O
S-312-l,1335,B-Chemical
",",1335,O
L-type,1335,O
calcium,1335,B-Chemical
channel,1335,O
antagonists,1335,O
",",1335,O
showed,1335,O
anticonvulsant,1335,O
effects,1335,O
on,1335,O
the,1335,O
audiogenic,1335,B-Disease
tonic,1335,I-Disease
convulsions,1335,I-Disease
in,1335,O
DBA/2,1335,O
mice,1335,O
;,1335,O
and,1335,O
their,1335,O
ED50,1335,O
values,1335,O
were,1335,O
18.4,1335,O
(,1335,O
12.8-27.1,1335,O
),1335,O
mg/kg,1335,O
",",1335,O
p.o,1335,O
.,1335,O
and,1336,O
15.0,1336,O
(,1336,O
10.2-23.7,1336,O
),1336,O
mg/kg,1336,O
",",1336,O
p.o.,1336,O
",",1336,O
respectively,1336,O
",",1336,O
while,1336,O
that,1336,O
of,1336,O
flunarizine,1336,B-Chemical
was,1336,O
34.0,1336,O
(,1336,O
26.0-44.8,1336,O
),1336,O
mg/kg,1336,O
",",1336,O
p.o,1336,O
.,1336,O
Although,1337,O
moderate,1337,O
anticonvulsant,1337,O
effects,1337,O
of,1337,O
S-312-d,1337,B-Chemical
in,1337,O
higher,1337,O
doses,1337,O
were,1337,O
observed,1337,O
against,1337,O
the,1337,O
clonic,1337,O
convulsions,1337,B-Disease
induced,1337,O
by,1337,O
pentylenetetrazole,1337,B-Chemical
(,1337,O
85,1337,O
mg/kg,1337,O
",",1337,O
s.c.,1337,O
),1337,O
or,1337,O
bemegride,1337,B-Chemical
(,1337,O
40,1337,O
mg/kg,1337,O
",",1337,O
s.c.,1337,O
),1337,O
",",1337,O
no,1337,O
effects,1337,O
were,1337,O
observed,1337,O
in,1337,O
convulsions,1337,B-Disease
induced,1337,O
by,1337,O
N-methyl-D-aspartate,1337,B-Chemical
",",1337,O
picrotoxin,1337,B-Chemical
",",1337,O
or,1337,O
electroshock,1337,O
in,1337,O
Slc,1337,O
:,1337,O
ddY,1337,O
mice,1337,O
.,1337,O
S-312-d,1338,B-Chemical
may,1338,O
be,1338,O
useful,1338,O
in,1338,O
the,1338,O
therapy,1338,O
of,1338,O
certain,1338,O
types,1338,O
of,1338,O
human,1338,O
epilepsy,1338,B-Disease
.,1338,O
Transmural,1339,O
myocardial,1339,B-Disease
infarction,1339,I-Disease
with,1339,O
sumatriptan,1339,B-Chemical
.,1339,O
For,1340,O
sumatriptan,1340,B-Chemical
",",1340,O
tightness,1340,O
in,1340,O
the,1340,O
chest,1340,O
caused,1340,O
by,1340,O
an,1340,O
unknown,1340,O
mechanism,1340,O
has,1340,O
been,1340,O
reported,1340,O
in,1340,O
3-5,1340,O
%,1340,O
of,1340,O
users,1340,O
.,1340,O
We,1341,O
describe,1341,O
a,1341,O
47-year-old,1341,O
woman,1341,O
with,1341,O
an,1341,O
acute,1341,O
myocardial,1341,B-Disease
infarction,1341,I-Disease
after,1341,O
administration,1341,O
of,1341,O
sumatriptan,1341,B-Chemical
6,1341,O
mg,1341,O
subcutaneously,1341,O
for,1341,O
cluster,1341,B-Disease
headache,1341,I-Disease
.,1341,O
The,1342,O
patient,1342,O
had,1342,O
no,1342,O
history,1342,O
of,1342,O
underlying,1342,O
ischaemic,1342,B-Disease
heart,1342,I-Disease
disease,1342,I-Disease
or,1342,O
Prinzmetal,1342,B-Disease
's,1342,I-Disease
angina,1342,I-Disease
.,1342,O
She,1343,O
recovered,1343,O
without,1343,O
complications,1343,O
.,1343,O
Flumazenil,1344,B-Chemical
induces,1344,O
seizures,1344,B-Disease
and,1344,O
death,1344,O
in,1344,O
mixed,1344,O
cocaine-diazepam,1344,B-Chemical
intoxications,1344,O
.,1344,O
STUDY,1345,O
HYPOTHESIS,1345,O
:,1345,O
Administration,1345,O
of,1345,O
the,1345,O
benzodiazepine,1345,B-Chemical
antagonist,1345,O
flumazenil,1345,B-Chemical
may,1345,O
unmask,1345,O
seizures,1345,B-Disease
in,1345,O
mixed,1345,O
cocaine-benzodiazepine,1345,B-Chemical
intoxication,1345,O
.,1345,O
DESIGN,1346,O
:,1346,O
Male,1346,O
Sprague-Dawley,1346,O
rats,1346,O
received,1346,O
100,1346,O
mg/kg,1346,O
cocaine,1346,B-Chemical
IP,1346,O
alone,1346,O
",",1346,O
5,1346,O
mg/kg,1346,O
diazepam,1346,B-Chemical
alone,1346,O
",",1346,O
or,1346,O
a,1346,O
combination,1346,O
of,1346,O
diazepam,1346,B-Chemical
and,1346,O
cocaine,1346,B-Chemical
.,1346,O
Three,1347,O
minutes,1347,O
later,1347,O
",",1347,O
groups,1347,O
were,1347,O
challenged,1347,O
with,1347,O
vehicle,1347,O
or,1347,O
flumazenil,1347,B-Chemical
5,1347,O
or,1347,O
10,1347,O
mg/kg,1347,O
IP,1347,O
.,1347,O
Animal,1348,O
behavior,1348,O
",",1348,O
seizures,1348,B-Disease
(,1348,O
time,1348,O
to,1348,O
and,1348,O
incidence,1348,O
),1348,O
",",1348,O
death,1348,O
(,1348,O
time,1348,O
to,1348,O
and,1348,O
incidence,1348,O
),1348,O
",",1348,O
and,1348,O
cortical,1348,O
EEG,1348,O
tracings,1348,O
were,1348,O
recorded,1348,O
.,1348,O
INTERVENTIONS,1349,O
:,1349,O
Administration,1349,O
of,1349,O
flumazenil,1349,B-Chemical
to,1349,O
animals,1349,O
after,1349,O
they,1349,O
had,1349,O
received,1349,O
a,1349,O
combination,1349,O
dose,1349,O
of,1349,O
cocaine,1349,B-Chemical
and,1349,O
diazepam,1349,B-Chemical
.,1349,O
RESULTS,1350,O
:,1350,O
In,1350,O
group,1350,O
1,1350,O
",",1350,O
animals,1350,O
received,1350,O
cocaine,1350,B-Chemical
followed,1350,O
by,1350,O
vehicle,1350,O
.,1350,O
This,1351,O
resulted,1351,O
in,1351,O
100,1351,O
%,1351,O
developing,1351,O
seizures,1351,B-Disease
and,1351,O
death,1351,O
.,1351,O
Group,1352,O
2,1352,O
received,1352,O
diazepam,1352,B-Chemical
alone,1352,O
followed,1352,O
by,1352,O
vehicle,1352,O
.,1352,O
Animals,1353,O
became,1353,O
somnolent,1353,O
and,1353,O
none,1353,O
died,1353,O
.,1353,O
Group,1354,O
3,1354,O
received,1354,O
diazepam,1354,B-Chemical
followed,1354,O
by,1354,O
5,1354,O
mg/kg,1354,O
flumazenil,1354,B-Chemical
.,1354,O
Animals,1355,O
became,1355,O
somnolent,1355,O
after,1355,O
diazepam,1355,B-Chemical
and,1355,O
then,1355,O
active,1355,O
after,1355,O
flumazenil,1355,B-Chemical
administration,1355,O
.,1355,O
In,1356,O
group,1356,O
4,1356,O
",",1356,O
a,1356,O
combination,1356,O
of,1356,O
cocaine,1356,B-Chemical
and,1356,O
diazepam,1356,B-Chemical
was,1356,O
administered,1356,O
simultaneously,1356,O
.,1356,O
This,1357,O
resulted,1357,O
in,1357,O
no,1357,O
overt,1357,O
or,1357,O
EEG-detectable,1357,O
seizures,1357,B-Disease
and,1357,O
a,1357,O
50,1357,O
%,1357,O
incidence,1357,O
of,1357,O
death,1357,O
.,1357,O
Group,1358,O
5,1358,O
received,1358,O
a,1358,O
similar,1358,O
combination,1358,O
of,1358,O
cocaine,1358,B-Chemical
and,1358,O
diazepam,1358,B-Chemical
",",1358,O
followed,1358,O
later,1358,O
by,1358,O
5,1358,O
mg/kg,1358,O
flumazenil,1358,B-Chemical
.,1358,O
This,1359,O
resulted,1359,O
in,1359,O
an,1359,O
increased,1359,O
incidence,1359,O
of,1359,O
seizures,1359,B-Disease
",",1359,O
90,1359,O
%,1359,O
(,1359,O
P,1359,O
<,1359,O
.01,1359,O
),1359,O
",",1359,O
and,1359,O
death,1359,O
",",1359,O
100,1359,O
%,1359,O
(,1359,O
P,1359,O
<,1359,O
or,1359,O
=,1359,O
.01,1359,O
),1359,O
",",1359,O
compared,1359,O
with,1359,O
group,1359,O
4,1359,O
.,1359,O
Group,1360,O
6,1360,O
received,1360,O
cocaine,1360,B-Chemical
and,1360,O
diazepam,1360,B-Chemical
followed,1360,O
by,1360,O
10,1360,O
mg/kg,1360,O
flumazenil,1360,B-Chemical
.,1360,O
This,1361,O
also,1361,O
resulted,1361,O
in,1361,O
an,1361,O
increased,1361,O
incidence,1361,O
of,1361,O
seizures,1361,B-Disease
",",1361,O
90,1361,O
%,1361,O
(,1361,O
P,1361,O
<,1361,O
or,1361,O
=,1361,O
.01,1361,O
),1361,O
",",1361,O
and,1361,O
death,1361,O
",",1361,O
90,1361,O
%,1361,O
(,1361,O
P,1361,O
<,1361,O
or,1361,O
=,1361,O
.05,1361,O
),1361,O
",",1361,O
compared,1361,O
with,1361,O
group,1361,O
4,1361,O
.,1361,O
CONCLUSION,1362,O
:,1362,O
Flumazenil,1362,B-Chemical
can,1362,O
unmask,1362,O
seizures,1362,B-Disease
and,1362,O
increase,1362,O
the,1362,O
incidence,1362,O
of,1362,O
death,1362,O
in,1362,O
a,1362,O
model,1362,O
of,1362,O
combined,1362,O
cocaine-diazepam,1362,B-Chemical
intoxications,1362,O
.,1362,O
Mechanisms,1363,O
for,1363,O
protective,1363,O
effects,1363,O
of,1363,O
free,1363,O
radical,1363,O
scavengers,1363,O
on,1363,O
gentamicin-mediated,1363,B-Chemical
nephropathy,1363,B-Disease
in,1363,O
rats,1363,O
.,1363,O
Studies,1364,O
were,1364,O
performed,1364,O
to,1364,O
examine,1364,O
the,1364,O
mechanisms,1364,O
for,1364,O
the,1364,O
protective,1364,O
effects,1364,O
of,1364,O
free,1364,O
radical,1364,O
scavengers,1364,O
on,1364,O
gentamicin,1364,B-Chemical
(,1364,O
GM,1364,B-Chemical
),1364,O
-mediated,1364,O
nephropathy,1364,B-Disease
.,1364,O
Administration,1365,O
of,1365,O
GM,1365,B-Chemical
at,1365,O
40,1365,O
mg/kg,1365,O
sc,1365,O
for,1365,O
13,1365,O
days,1365,O
to,1365,O
rats,1365,O
induced,1365,O
a,1365,O
significant,1365,O
reduction,1365,O
in,1365,O
renal,1365,O
blood,1365,O
flow,1365,O
(,1365,O
RBF,1365,O
),1365,O
and,1365,O
inulin,1365,O
clearance,1365,O
(,1365,O
CIn,1365,O
),1365,O
as,1365,O
well,1365,O
as,1365,O
marked,1365,O
tubular,1365,B-Disease
damage,1365,I-Disease
.,1365,O
A,1366,O
significant,1366,O
reduction,1366,O
in,1366,O
urinary,1366,O
guanosine,1366,B-Chemical
"3',5'-cyclic",1366,I-Chemical
monophosphate,1366,I-Chemical
(,1366,O
cGMP,1366,B-Chemical
),1366,O
excretion,1366,O
and,1366,O
a,1366,O
significant,1366,O
increase,1366,O
in,1366,O
renal,1366,O
cortical,1366,O
renin,1366,O
and,1366,O
endothelin-1,1366,O
contents,1366,O
were,1366,O
also,1366,O
observed,1366,O
in,1366,O
GM-mediated,1366,B-Chemical
nephropathy,1366,B-Disease
.,1366,O
Superoxide,1367,B-Chemical
dismutase,1367,O
(,1367,O
SOD,1367,O
),1367,O
or,1367,O
dimethylthiourea,1367,B-Chemical
(,1367,O
DMTU,1367,B-Chemical
),1367,O
significantly,1367,O
lessened,1367,O
the,1367,O
GM-induced,1367,B-Chemical
decrement,1367,O
in,1367,O
CIn,1367,O
.,1367,O
The,1368,O
SOD-induced,1368,O
increase,1368,O
in,1368,O
glomerular,1368,O
filtration,1368,O
rate,1368,O
was,1368,O
associated,1368,O
with,1368,O
a,1368,O
marked,1368,O
improvement,1368,O
in,1368,O
RBF,1368,O
",",1368,O
an,1368,O
increase,1368,O
in,1368,O
urinary,1368,O
cGMP,1368,B-Chemical
excretion,1368,O
",",1368,O
and,1368,O
a,1368,O
decrease,1368,O
in,1368,O
renal,1368,O
renin,1368,O
and,1368,O
endothelin-1,1368,O
content,1368,O
.,1368,O
SOD,1369,O
did,1369,O
not,1369,O
attenuate,1369,O
the,1369,O
tubular,1369,B-Disease
damage,1369,I-Disease
.,1369,O
In,1370,O
contrast,1370,O
",",1370,O
DMTU,1370,B-Chemical
significantly,1370,O
reduced,1370,O
the,1370,O
tubular,1370,B-Disease
damage,1370,I-Disease
and,1370,O
lipid,1370,O
peroxidation,1370,O
",",1370,O
but,1370,O
it,1370,O
did,1370,O
not,1370,O
affect,1370,O
renal,1370,O
hemodynamics,1370,O
and,1370,O
vasoactive,1370,O
substances,1370,O
.,1370,O
Neither,1371,O
SOD,1371,O
nor,1371,O
DMTU,1371,B-Chemical
affected,1371,O
the,1371,O
renal,1371,O
cortical,1371,O
GM,1371,B-Chemical
content,1371,O
in,1371,O
GM-treated,1371,B-Chemical
rats,1371,O
.,1371,O
These,1372,O
results,1372,O
suggest,1372,O
that,1372,O
1,1372,O
),1372,O
both,1372,O
SOD,1372,O
and,1372,O
DMTU,1372,B-Chemical
have,1372,O
protective,1372,O
effects,1372,O
on,1372,O
GM-mediated,1372,B-Chemical
nephropathy,1372,B-Disease
",",1372,O
2,1372,O
),1372,O
the,1372,O
mechanisms,1372,O
for,1372,O
the,1372,O
protective,1372,O
effects,1372,O
differ,1372,O
for,1372,O
SOD,1372,O
and,1372,O
DMTU,1372,B-Chemical
",",1372,O
and,1372,O
3,1372,O
),1372,O
superoxide,1372,B-Chemical
anions,1372,O
play,1372,O
a,1372,O
critical,1372,O
role,1372,O
in,1372,O
GM-induced,1372,B-Chemical
renal,1372,O
vasoconstriction,1372,O
.,1372,O
Assessment,1373,O
of,1373,O
cardiomyocyte,1373,O
DNA,1373,O
synthesis,1373,O
during,1373,O
hypertrophy,1373,B-Disease
in,1373,O
adult,1373,O
mice,1373,O
.,1373,O
The,1374,O
ability,1374,O
of,1374,O
cardiomyocytes,1374,O
to,1374,O
synthesize,1374,O
DNA,1374,O
in,1374,O
response,1374,O
to,1374,O
experimentally,1374,O
induced,1374,O
cardiac,1374,B-Disease
hypertrophy,1374,I-Disease
was,1374,O
assessed,1374,O
in,1374,O
adult,1374,O
mice,1374,O
.,1374,O
Isoproterenol,1375,B-Chemical
delivered,1375,O
by,1375,O
osmotic,1375,O
minipump,1375,O
implantation,1375,O
in,1375,O
adult,1375,O
C3Heb/FeJ,1375,O
mice,1375,O
resulted,1375,O
in,1375,O
a,1375,O
46,1375,O
%,1375,O
increase,1375,O
in,1375,O
heart,1375,O
weight,1375,O
and,1375,O
a,1375,O
19.3,1375,O
%,1375,O
increase,1375,O
in,1375,O
cardiomyocyte,1375,O
area,1375,O
.,1375,O
No,1376,O
DNA,1376,O
synthesis,1376,O
",",1376,O
as,1376,O
assessed,1376,O
by,1376,O
autoradiographic,1376,O
analysis,1376,O
of,1376,O
isolated,1376,O
cardiomyocytes,1376,O
",",1376,O
was,1376,O
observed,1376,O
in,1376,O
control,1376,O
or,1376,O
hypertrophic,1376,B-Disease
hearts,1376,I-Disease
.,1376,O
A,1377,O
survey,1377,O
of,1377,O
15,1377,O
independent,1377,O
inbred,1377,O
strains,1377,O
of,1377,O
mice,1377,O
revealed,1377,O
that,1377,O
ventricular,1377,O
cardiomyocyte,1377,O
nuclear,1377,O
number,1377,O
ranged,1377,O
from,1377,O
3,1377,O
to,1377,O
13,1377,O
%,1377,O
mononucleate,1377,O
",",1377,O
suggesting,1377,O
that,1377,O
cardiomyocyte,1377,O
terminal,1377,O
differentiation,1377,O
is,1377,O
influenced,1377,O
directly,1377,O
or,1377,O
indirectly,1377,O
by,1377,O
genetic,1377,O
background,1377,O
.,1377,O
To,1378,O
determine,1378,O
whether,1378,O
the,1378,O
capacity,1378,O
for,1378,O
reactive,1378,O
DNA,1378,O
synthesis,1378,O
was,1378,O
also,1378,O
subject,1378,O
to,1378,O
genetic,1378,O
regulation,1378,O
",",1378,O
cardiac,1378,B-Disease
hypertrophy,1378,I-Disease
was,1378,O
induced,1378,O
in,1378,O
the,1378,O
strains,1378,O
of,1378,O
mice,1378,O
comprising,1378,O
the,1378,O
extremes,1378,O
of,1378,O
the,1378,O
nuclear,1378,O
number,1378,O
survey,1378,O
.,1378,O
These,1379,O
data,1379,O
indicate,1379,O
that,1379,O
adult,1379,O
mouse,1379,O
atrial,1379,O
and,1379,O
ventricular,1379,O
cardiomyocytes,1379,O
do,1379,O
not,1379,O
synthesize,1379,O
DNA,1379,O
in,1379,O
response,1379,O
to,1379,O
isoproterenol-induced,1379,B-Chemical
cardiac,1379,B-Disease
hypertrophy,1379,I-Disease
.,1379,O
Central,1380,O
cardiovascular,1380,O
effects,1380,O
of,1380,O
AVP,1380,B-Chemical
and,1380,O
ANP,1380,O
in,1380,O
normotensive,1380,O
and,1380,O
spontaneously,1380,O
hypertensive,1380,B-Disease
rats,1380,O
.,1380,O
The,1381,O
purpose,1381,O
of,1381,O
the,1381,O
present,1381,O
study,1381,O
was,1381,O
to,1381,O
compare,1381,O
influence,1381,O
of,1381,O
central,1381,O
arginine,1381,B-Chemical
vasopressin,1381,I-Chemical
(,1381,O
AVP,1381,B-Chemical
),1381,O
and,1381,O
of,1381,O
atrial,1381,O
natriuretic,1381,O
peptide,1381,O
(,1381,O
ANP,1381,O
),1381,O
on,1381,O
control,1381,O
of,1381,O
arterial,1381,O
blood,1381,O
pressure,1381,O
(,1381,O
MAP,1381,O
),1381,O
and,1381,O
heart,1381,O
rate,1381,O
(,1381,O
HR,1381,O
),1381,O
in,1381,O
normotensive,1381,O
(,1381,O
WKY,1381,O
),1381,O
and,1381,O
spontaneously,1381,O
hypertensive,1381,B-Disease
(,1381,O
SHR,1381,O
),1381,O
rats,1381,O
.,1381,O
Three,1382,O
series,1382,O
of,1382,O
experiments,1382,O
were,1382,O
performed,1382,O
on,1382,O
30,1382,O
WKY,1382,O
and,1382,O
30,1382,O
SHR,1382,O
",",1382,O
chronically,1382,O
instrumented,1382,O
with,1382,O
guide,1382,O
tubes,1382,O
in,1382,O
the,1382,O
lateral,1382,O
ventricle,1382,O
(,1382,O
LV,1382,O
),1382,O
and,1382,O
arterial,1382,O
and,1382,O
venous,1382,O
catheters,1382,O
.,1382,O
MAP,1383,O
and,1383,O
HR,1383,O
were,1383,O
monitored,1383,O
before,1383,O
and,1383,O
after,1383,O
i.v,1383,O
.,1383,O
injections,1384,O
of,1384,O
either,1384,O
vehicle,1384,O
or,1384,O
1,1384,O
",",1384,O
10,1384,O
and,1384,O
50,1384,O
ng,1384,O
of,1384,O
AVP,1384,B-Chemical
and,1384,O
25,1384,O
",",1384,O
125,1384,O
and,1384,O
500,1384,O
ng,1384,O
of,1384,O
ANP,1384,O
.,1384,O
Sensitivity,1385,O
of,1385,O
cardiac,1385,O
component,1385,O
of,1385,O
baroreflex,1385,O
(,1385,O
CCB,1385,O
),1385,O
",",1385,O
expressed,1385,O
as,1385,O
a,1385,O
slope,1385,O
of,1385,O
the,1385,O
regression,1385,O
line,1385,O
was,1385,O
determined,1385,O
from,1385,O
relationships,1385,O
between,1385,O
systolic,1385,O
arterial,1385,O
pressure,1385,O
(,1385,O
SAP,1385,O
),1385,O
and,1385,O
HR,1385,O
period,1385,O
(,1385,O
HRp,1385,O
),1385,O
during,1385,O
phenylephrine,1385,B-Chemical
(,1385,O
Phe,1385,B-Chemical
),1385,O
-induced,1385,O
hypertension,1385,B-Disease
and,1385,O
sodium,1385,B-Chemical
nitroprusside,1385,I-Chemical
(,1385,O
SN,1385,B-Chemical
),1385,O
-induced,1385,O
hypotension,1385,B-Disease
.,1385,O
CCB,1386,O
was,1386,O
measured,1386,O
before,1386,O
and,1386,O
after,1386,O
administration,1386,O
of,1386,O
either,1386,O
vehicle,1386,O
",",1386,O
AVP,1386,B-Chemical
",",1386,O
ANP,1386,O
",",1386,O
or,1386,O
both,1386,O
peptides,1386,O
together,1386,O
.,1386,O
Increases,1387,O
of,1387,O
MAP,1387,O
occurred,1387,O
after,1387,O
LV,1387,O
administration,1387,O
of,1387,O
1,1387,O
",",1387,O
10,1387,O
and,1387,O
50,1387,O
ng,1387,O
of,1387,O
AVP,1387,B-Chemical
in,1387,O
WKY,1387,O
and,1387,O
of,1387,O
10,1387,O
and,1387,O
50,1387,O
ng,1387,O
in,1387,O
SHR,1387,O
.,1387,O
ANP,1388,O
did,1388,O
not,1388,O
cause,1388,O
significant,1388,O
changes,1388,O
in,1388,O
MAP,1388,O
in,1388,O
both,1388,O
strains,1388,O
as,1388,O
compared,1388,O
to,1388,O
vehicle,1388,O
",",1388,O
but,1388,O
it,1388,O
abolished,1388,O
AVP-induced,1388,B-Chemical
MAP,1388,O
increase,1388,O
in,1388,O
WKY,1388,O
and,1388,O
SHR,1388,O
.,1388,O
CCB,1389,O
was,1389,O
reduced,1389,O
in,1389,O
WKY,1389,O
and,1389,O
SHR,1389,O
after,1389,O
LV,1389,O
administration,1389,O
of,1389,O
AVP,1389,B-Chemical
during,1389,O
SN-induced,1389,B-Chemical
hypotension,1389,B-Disease
.,1389,O
In,1390,O
SHR,1390,O
but,1390,O
not,1390,O
in,1390,O
WKY,1390,O
administration,1390,O
of,1390,O
ANP,1390,O
",",1390,O
AVP,1390,B-Chemical
and,1390,O
ANP,1390,O
+,1390,O
AVP,1390,B-Chemical
decreased,1390,O
CCB,1390,O
during,1390,O
Phe-induced,1390,B-Chemical
MAP,1390,O
elevation,1390,O
.,1390,O
The,1391,O
results,1391,O
indicate,1391,O
that,1391,O
centrally,1391,O
applied,1391,O
AVP,1391,B-Chemical
and,1391,O
ANP,1391,O
exert,1391,O
differential,1391,O
effects,1391,O
on,1391,O
blood,1391,O
pressure,1391,O
and,1391,O
baroreflex,1391,O
control,1391,O
of,1391,O
heart,1391,O
rate,1391,O
in,1391,O
WKY,1391,O
and,1391,O
SHR,1391,O
and,1391,O
suggest,1391,O
interaction,1391,O
of,1391,O
these,1391,O
two,1391,O
peptides,1391,O
in,1391,O
blood,1391,O
pressure,1391,O
regulation,1391,O
at,1391,O
the,1391,O
level,1391,O
of,1391,O
central,1391,O
nervous,1391,O
system,1391,O
.,1391,O
Cutaneous,1392,O
exposure,1392,O
to,1392,O
warfarin-like,1392,B-Chemical
anticoagulant,1392,O
causing,1392,O
an,1392,O
intracerebral,1392,B-Disease
hemorrhage,1392,I-Disease
:,1392,O
a,1392,O
case,1392,O
report,1392,O
.,1392,O
A,1393,O
case,1393,O
of,1393,O
intercerebral,1393,O
hematoma,1393,B-Disease
due,1393,O
to,1393,O
warfarin-induced,1393,B-Chemical
coagulopathy,1393,B-Disease
is,1393,O
presented,1393,O
.,1393,O
The,1394,O
39-year-old,1394,O
woman,1394,O
had,1394,O
spread,1394,O
a,1394,O
warfarin-type,1394,B-Chemical
rat,1394,O
poison,1394,O
around,1394,O
her,1394,O
house,1394,O
weekly,1394,O
using,1394,O
her,1394,O
bare,1394,O
hands,1394,O
",",1394,O
with,1394,O
no,1394,O
washing,1394,O
post,1394,O
application,1394,O
.,1394,O
Percutaneous,1395,O
absorption,1395,O
of,1395,O
warfarin,1395,B-Chemical
causing,1395,O
coagulopathy,1395,B-Disease
",",1395,O
reported,1395,O
three,1395,O
times,1395,O
in,1395,O
the,1395,O
past,1395,O
",",1395,O
is,1395,O
a,1395,O
significant,1395,O
risk,1395,O
if,1395,O
protective,1395,O
measures,1395,O
",",1395,O
such,1395,O
as,1395,O
gloves,1395,O
",",1395,O
are,1395,O
not,1395,O
used,1395,O
.,1395,O
An,1396,O
adverse,1396,O
drug,1396,O
interaction,1396,O
with,1396,O
piroxicam,1396,B-Chemical
",",1396,O
which,1396,O
she,1396,O
took,1396,O
occasionally,1396,O
",",1396,O
may,1396,O
have,1396,O
exacerbated,1396,O
the,1396,O
coagulopathy,1396,B-Disease
.,1396,O
Pediatric,1397,O
heart,1397,O
transplantation,1397,O
without,1397,O
chronic,1397,O
maintenance,1397,O
steroids,1397,B-Chemical
.,1397,O
From,1398,O
1986,1398,O
to,1398,O
February,1398,O
1993,1398,O
",",1398,O
40,1398,O
children,1398,O
aged,1398,O
2,1398,O
months,1398,O
to,1398,O
18,1398,O
years,1398,O
(,1398,O
average,1398,O
age,1398,O
10.4,1398,O
+/-,1398,O
5.8,1398,O
years,1398,O
),1398,O
underwent,1398,O
heart,1398,O
transplantation,1398,O
.,1398,O
Indications,1399,O
for,1399,O
transplantation,1399,O
were,1399,O
idiopathic,1399,B-Disease
cardiomyopathy,1399,I-Disease
(,1399,O
52,1399,O
%,1399,O
),1399,O
",",1399,O
congenital,1399,B-Disease
heart,1399,I-Disease
disease,1399,I-Disease
(,1399,O
35,1399,O
%,1399,O
),1399,O
with,1399,O
and,1399,O
without,1399,O
prior,1399,O
repair,1399,O
(,1399,O
71,1399,O
%,1399,O
and,1399,O
29,1399,O
%,1399,O
",",1399,O
respectively,1399,O
),1399,O
",",1399,O
hypertrophic,1399,B-Disease
cardiomyopathy,1399,I-Disease
(,1399,O
5,1399,O
%,1399,O
),1399,O
",",1399,O
valvular,1399,B-Disease
heart,1399,I-Disease
disease,1399,I-Disease
(,1399,O
3,1399,O
%,1399,O
),1399,O
",",1399,O
and,1399,O
doxorubicin,1399,B-Chemical
cardiomyopathy,1399,B-Disease
(,1399,O
5,1399,O
%,1399,O
),1399,O
.,1399,O
Patients,1400,O
were,1400,O
managed,1400,O
with,1400,O
cyclosporine,1400,B-Chemical
and,1400,O
azathioprine,1400,B-Chemical
.,1400,O
No,1401,O
prophylaxis,1401,O
with,1401,O
antilymphocyte,1401,O
globulin,1401,O
was,1401,O
used,1401,O
.,1401,O
Steroids,1402,B-Chemical
were,1402,O
given,1402,O
to,1402,O
39,1402,O
%,1402,O
of,1402,O
patients,1402,O
for,1402,O
refractory,1402,O
rejection,1402,O
",",1402,O
but,1402,O
weaning,1402,O
was,1402,O
always,1402,O
attempted,1402,O
and,1402,O
generally,1402,O
successful,1402,O
(,1402,O
64,1402,O
%,1402,O
),1402,O
.,1402,O
Five,1403,O
patients,1403,O
(,1403,O
14,1403,O
%,1403,O
),1403,O
received,1403,O
maintenance,1403,O
steroids,1403,B-Chemical
.,1403,O
Four,1404,O
patients,1404,O
died,1404,O
in,1404,O
the,1404,O
perioperative,1404,O
period,1404,O
and,1404,O
one,1404,O
died,1404,O
4,1404,O
months,1404,O
later,1404,O
.,1404,O
There,1405,O
have,1405,O
been,1405,O
no,1405,O
deaths,1405,O
related,1405,O
to,1405,O
rejection,1405,O
or,1405,O
infection,1405,B-Disease
.,1405,O
Average,1406,O
follow-up,1406,O
was,1406,O
36,1406,O
+/-,1406,O
19,1406,O
months,1406,O
(,1406,O
range,1406,O
1,1406,O
to,1406,O
65,1406,O
months,1406,O
),1406,O
.,1406,O
Cumulative,1407,O
survival,1407,O
is,1407,O
88,1407,O
%,1407,O
at,1407,O
5,1407,O
years,1407,O
.,1407,O
In,1408,O
patients,1408,O
less,1408,O
than,1408,O
7,1408,O
years,1408,O
of,1408,O
age,1408,O
",",1408,O
rejection,1408,O
was,1408,O
monitored,1408,O
noninvasively,1408,O
.,1408,O
In,1409,O
the,1409,O
first,1409,O
postoperative,1409,O
month,1409,O
",",1409,O
89,1409,O
%,1409,O
of,1409,O
patients,1409,O
were,1409,O
treated,1409,O
for,1409,O
rejection,1409,O
.,1409,O
Freedom,1410,O
from,1410,O
serious,1410,O
infections,1410,B-Disease
was,1410,O
83,1410,O
%,1410,O
at,1410,O
1,1410,O
month,1410,O
and,1410,O
65,1410,O
%,1410,O
at,1410,O
1,1410,O
year,1410,O
.,1410,O
Cytomegalovirus,1411,B-Disease
infections,1411,I-Disease
were,1411,O
treated,1411,O
successfully,1411,O
with,1411,O
ganciclovir,1411,B-Chemical
in,1411,O
11,1411,O
patients,1411,O
.,1411,O
No,1412,O
impairment,1412,O
of,1412,O
growth,1412,O
was,1412,O
observed,1412,O
in,1412,O
children,1412,O
who,1412,O
underwent,1412,O
transplantation,1412,O
compared,1412,O
with,1412,O
a,1412,O
control,1412,O
population,1412,O
.,1412,O
Twenty-one,1413,O
patients,1413,O
(,1413,O
60,1413,O
%,1413,O
),1413,O
have,1413,O
undergone,1413,O
annual,1413,O
catheterizations,1413,O
and,1413,O
no,1413,O
sign,1413,O
of,1413,O
graft,1413,O
atherosclerosis,1413,B-Disease
has,1413,O
been,1413,O
observed,1413,O
.,1413,O
Seizures,1414,B-Disease
occurred,1414,O
in,1414,O
five,1414,O
patients,1414,O
(,1414,O
14,1414,O
%,1414,O
),1414,O
and,1414,O
hypertension,1414,B-Disease
was,1414,O
treated,1414,O
in,1414,O
10,1414,O
patients,1414,O
(,1414,O
28,1414,O
%,1414,O
),1414,O
.,1414,O
No,1415,O
patient,1415,O
was,1415,O
disabled,1415,O
and,1415,O
no,1415,O
lymphoproliferative,1415,B-Disease
disorder,1415,I-Disease
was,1415,O
observed,1415,O
.,1415,O
(,1416,O
ABSTRACT,1416,O
TRUNCATED,1416,O
AT,1416,O
250,1416,O
WORDS,1416,O
),1416,O
Delirium,1417,B-Disease
during,1417,O
fluoxetine,1417,B-Chemical
treatment,1417,O
.,1417,O
A,1418,O
case,1418,O
report,1418,O
.,1418,O
The,1419,O
correlation,1419,O
between,1419,O
high,1419,O
serum,1419,O
tricyclic,1419,O
antidepressant,1419,O
concentrations,1419,O
and,1419,O
central,1419,O
nervous,1419,O
system,1419,O
side,1419,O
effects,1419,O
has,1419,O
been,1419,O
well,1419,O
established,1419,O
.,1419,O
Only,1420,O
a,1420,O
few,1420,O
reports,1420,O
exist,1420,O
",",1420,O
however,1420,O
",",1420,O
on,1420,O
the,1420,O
relationship,1420,O
between,1420,O
the,1420,O
serum,1420,O
concentrations,1420,O
of,1420,O
selective,1420,O
serotonin,1420,B-Chemical
reuptake,1420,O
inhibitors,1420,O
(,1420,O
SSRIs,1420,O
),1420,O
and,1420,O
their,1420,O
toxic,1420,O
effects,1420,O
.,1420,O
In,1421,O
some,1421,O
cases,1421,O
",",1421,O
a,1421,O
high,1421,O
serum,1421,O
concentration,1421,O
of,1421,O
citalopram,1421,B-Chemical
(,1421,O
>,1421,O
600,1421,O
nmol/L,1421,O
),1421,O
in,1421,O
elderly,1421,O
patients,1421,O
has,1421,O
been,1421,O
associated,1421,O
with,1421,O
increased,1421,O
somnolence,1421,B-Disease
and,1421,O
movement,1421,B-Disease
difficulties,1421,I-Disease
.,1421,O
Widespread,1422,O
cognitive,1422,B-Disease
disorders,1422,I-Disease
",",1422,O
such,1422,O
as,1422,O
delirium,1422,B-Disease
",",1422,O
have,1422,O
not,1422,O
been,1422,O
previously,1422,O
linked,1422,O
with,1422,O
high,1422,O
blood,1422,O
levels,1422,O
of,1422,O
SSRIs,1422,O
.,1422,O
In,1423,O
this,1423,O
report,1423,O
",",1423,O
we,1423,O
describe,1423,O
a,1423,O
patient,1423,O
with,1423,O
acute,1423,O
hyperkinetic,1423,B-Disease
delirium,1423,B-Disease
connected,1423,O
with,1423,O
a,1423,O
high,1423,O
serum,1423,O
total,1423,O
fluoxetine,1423,B-Chemical
(,1423,O
fluoxetine,1423,B-Chemical
plus,1423,O
desmethylfluoxetine,1423,B-Chemical
),1423,O
concentration,1423,O
.,1423,O
Pulmonary,1424,B-Disease
edema,1424,I-Disease
and,1424,O
shock,1424,B-Disease
after,1424,O
high-dose,1424,O
aracytine-C,1424,B-Chemical
for,1424,O
lymphoma,1424,B-Disease
;,1424,O
possible,1424,O
role,1424,O
of,1424,O
TNF-alpha,1424,O
and,1424,O
PAF,1424,O
.,1424,O
Four,1425,O
out,1425,O
of,1425,O
23,1425,O
consecutive,1425,O
patients,1425,O
treated,1425,O
with,1425,O
high-dose,1425,O
Ara-C,1425,B-Chemical
for,1425,O
lymphomas,1425,B-Disease
in,1425,O
our,1425,O
institution,1425,O
developed,1425,O
a,1425,O
strikingly,1425,O
similar,1425,O
syndrome,1425,O
during,1425,O
the,1425,O
perfusion,1425,O
.,1425,O
It,1426,O
was,1426,O
characterized,1426,O
by,1426,O
the,1426,O
onset,1426,O
of,1426,O
fever,1426,B-Disease
",",1426,O
diarrhea,1426,B-Disease
",",1426,O
shock,1426,B-Disease
",",1426,O
pulmonary,1426,B-Disease
edema,1426,I-Disease
",",1426,O
acute,1426,B-Disease
renal,1426,I-Disease
failure,1426,I-Disease
",",1426,O
metabolic,1426,B-Disease
acidosis,1426,I-Disease
",",1426,O
weight,1426,B-Disease
gain,1426,I-Disease
and,1426,O
leukocytosis,1426,B-Disease
.,1426,O
Thorough,1427,O
bacteriological,1427,O
screening,1427,O
failed,1427,O
to,1427,O
provide,1427,O
evidence,1427,O
of,1427,O
infection,1427,B-Disease
.,1427,O
Sequential,1428,O
biological,1428,O
assays,1428,O
of,1428,O
IL-1,1428,O
",",1428,O
IL-2,1428,O
",",1428,O
TNF,1428,O
and,1428,O
PAF,1428,O
were,1428,O
performed,1428,O
during,1428,O
Ara-C,1428,B-Chemical
infusion,1428,O
to,1428,O
ten,1428,O
patients,1428,O
",",1428,O
including,1428,O
the,1428,O
four,1428,O
who,1428,O
developed,1428,O
the,1428,O
syndrome,1428,O
.,1428,O
TNF,1429,O
and,1429,O
PAF,1429,O
activity,1429,O
was,1429,O
found,1429,O
in,1429,O
the,1429,O
serum,1429,O
of,1429,O
respectively,1429,O
two,1429,O
and,1429,O
four,1429,O
of,1429,O
the,1429,O
cases,1429,O
",",1429,O
but,1429,O
not,1429,O
in,1429,O
the,1429,O
six,1429,O
controls,1429,O
.,1429,O
As,1430,O
TNF,1430,O
and,1430,O
PAF,1430,O
are,1430,O
thought,1430,O
to,1430,O
be,1430,O
involved,1430,O
in,1430,O
the,1430,O
development,1430,O
of,1430,O
septic,1430,O
shock,1430,B-Disease
and,1430,O
adult,1430,B-Disease
respiratory,1430,I-Disease
distress,1430,I-Disease
syndrome,1430,I-Disease
",",1430,O
we,1430,O
hypothesize,1430,O
that,1430,O
high-dose,1430,O
Ara-C,1430,B-Chemical
may,1430,O
be,1430,O
associated,1430,O
with,1430,O
cytokine,1430,O
release,1430,O
.,1430,O
Protective,1431,O
effect,1431,O
of,1431,O
clentiazem,1431,B-Chemical
against,1431,O
epinephrine-induced,1431,B-Chemical
cardiac,1431,B-Disease
injury,1431,I-Disease
in,1431,O
rats,1431,O
.,1431,O
We,1432,O
investigated,1432,O
the,1432,O
effects,1432,O
of,1432,O
clentiazem,1432,B-Chemical
",",1432,O
a,1432,O
"1,5-benzothiazepine",1432,B-Chemical
calcium,1432,B-Chemical
antagonist,1432,O
",",1432,O
on,1432,O
epinephrine-induced,1432,B-Chemical
cardiomyopathy,1432,B-Disease
in,1432,O
rats,1432,O
.,1432,O
With,1433,O
2-week,1433,O
chronic,1433,O
epinephrine,1433,B-Chemical
infusion,1433,O
",",1433,O
16,1433,O
of,1433,O
30,1433,O
rats,1433,O
died,1433,O
within,1433,O
4,1433,O
days,1433,O
",",1433,O
and,1433,O
severe,1433,O
ischemic,1433,B-Disease
lesions,1433,I-Disease
and,1433,O
fibrosis,1433,B-Disease
of,1433,O
the,1433,O
left,1433,O
ventricles,1433,O
were,1433,O
observed,1433,O
.,1433,O
In,1434,O
epinephrine-treated,1434,B-Chemical
rats,1434,O
",",1434,O
left,1434,O
atrial,1434,O
and,1434,O
left,1434,O
ventricular,1434,O
papillary,1434,O
muscle,1434,O
contractile,1434,O
responses,1434,O
to,1434,O
isoproterenol,1434,B-Chemical
were,1434,O
reduced,1434,O
",",1434,O
but,1434,O
responses,1434,O
to,1434,O
calcium,1434,B-Chemical
were,1434,O
normal,1434,O
or,1434,O
enhanced,1434,O
compared,1434,O
to,1434,O
controls,1434,O
.,1434,O
Left,1435,O
ventricular,1435,O
alpha,1435,O
and,1435,O
beta,1435,O
adrenoceptor,1435,O
densities,1435,O
were,1435,O
also,1435,O
reduced,1435,O
compared,1435,O
to,1435,O
controls,1435,O
.,1435,O
Treatment,1436,O
with,1436,O
clentiazem,1436,B-Chemical
prevented,1436,O
epinephrine-induced,1436,B-Chemical
death,1436,O
(,1436,O
P,1436,O
<,1436,O
.05,1436,O
),1436,O
",",1436,O
and,1436,O
attenuated,1436,O
the,1436,O
ventricular,1436,O
ischemic,1436,B-Disease
lesions,1436,I-Disease
and,1436,O
fibrosis,1436,B-Disease
",",1436,O
in,1436,O
a,1436,O
dose-dependent,1436,O
manner,1436,O
.,1436,O
Left,1437,O
atrial,1437,O
and,1437,O
left,1437,O
ventricular,1437,O
papillary,1437,O
muscle,1437,O
contractile,1437,O
responses,1437,O
to,1437,O
isoproterenol,1437,B-Chemical
were,1437,O
reduced,1437,O
compared,1437,O
to,1437,O
controls,1437,O
in,1437,O
groups,1437,O
treated,1437,O
with,1437,O
clentiazem,1437,B-Chemical
alone,1437,O
",",1437,O
but,1437,O
combined,1437,O
with,1437,O
epinephrine,1437,B-Chemical
",",1437,O
clentiazem,1437,B-Chemical
restored,1437,O
left,1437,O
atrial,1437,O
responses,1437,O
and,1437,O
enhanced,1437,O
left,1437,O
ventricular,1437,O
papillary,1437,O
responses,1437,O
to,1437,O
isoproterenol,1437,B-Chemical
.,1437,O
On,1438,O
the,1438,O
other,1438,O
hand,1438,O
clentiazem,1438,B-Chemical
did,1438,O
not,1438,O
prevent,1438,O
epinephrine-induced,1438,B-Chemical
down-regulation,1438,O
of,1438,O
alpha,1438,O
and,1438,O
beta,1438,O
adrenoceptors,1438,O
.,1438,O
Interestingly,1439,O
",",1439,O
clentiazem,1439,B-Chemical
",",1439,O
infused,1439,O
alone,1439,O
",",1439,O
resulted,1439,O
in,1439,O
decreased,1439,O
adrenergic,1439,O
receptor,1439,O
densities,1439,O
in,1439,O
the,1439,O
left,1439,O
ventricle,1439,O
.,1439,O
Clentiazem,1440,B-Chemical
also,1440,O
did,1440,O
not,1440,O
prevent,1440,O
the,1440,O
enhanced,1440,O
responses,1440,O
to,1440,O
calcium,1440,B-Chemical
seen,1440,O
in,1440,O
the,1440,O
epinephrine-treated,1440,B-Chemical
animals,1440,O
",",1440,O
although,1440,O
the,1440,O
high,1440,O
dose,1440,O
of,1440,O
clentiazem,1440,B-Chemical
partially,1440,O
attenuated,1440,O
the,1440,O
maximal,1440,O
response,1440,O
to,1440,O
calcium,1440,B-Chemical
compared,1440,O
to,1440,O
epinephrine-treated,1440,B-Chemical
animals,1440,O
.,1440,O
In,1441,O
conclusion,1441,O
",",1441,O
clentiazem,1441,B-Chemical
attenuated,1441,O
epinephrine-induced,1441,B-Chemical
cardiac,1441,B-Disease
injury,1441,I-Disease
",",1441,O
possibly,1441,O
through,1441,O
its,1441,O
effect,1441,O
on,1441,O
the,1441,O
adrenergic,1441,O
pathway,1441,O
.,1441,O
Cocaine,1442,B-Chemical
induced,1442,O
myocardial,1442,B-Disease
ischemia,1442,I-Disease
.,1442,O
We,1443,O
report,1443,O
a,1443,O
case,1443,O
of,1443,O
myocardial,1443,B-Disease
ischemia,1443,I-Disease
induced,1443,O
by,1443,O
cocaine,1443,B-Chemical
.,1443,O
The,1444,O
ischemia,1444,B-Disease
probably,1444,O
induced,1444,O
by,1444,O
coronary,1444,B-Disease
artery,1444,I-Disease
spasm,1444,I-Disease
was,1444,O
reversed,1444,O
by,1444,O
nitroglycerin,1444,B-Chemical
and,1444,O
calcium,1444,B-Chemical
blocking,1444,O
agents,1444,O
.,1444,O
Doxorubicin-induced,1445,B-Chemical
cardiotoxicity,1445,B-Disease
monitored,1445,O
by,1445,O
ECG,1445,O
in,1445,O
freely,1445,O
moving,1445,O
mice,1445,O
.,1445,O
A,1446,O
new,1446,O
model,1446,O
to,1446,O
test,1446,O
potential,1446,O
protectors,1446,O
.,1446,O
In,1447,O
laboratory,1447,O
animals,1447,O
",",1447,O
histology,1447,O
is,1447,O
most,1447,O
commonly,1447,O
used,1447,O
to,1447,O
study,1447,O
doxorubicin-induced,1447,B-Chemical
cardiotoxicity,1447,B-Disease
.,1447,O
However,1448,O
",",1448,O
for,1448,O
monitoring,1448,O
during,1448,O
treatment,1448,O
",",1448,O
large,1448,O
numbers,1448,O
of,1448,O
animals,1448,O
are,1448,O
needed,1448,O
.,1448,O
Recently,1449,O
we,1449,O
developed,1449,O
a,1449,O
new,1449,O
method,1449,O
to,1449,O
measure,1449,O
ECG,1449,O
values,1449,O
in,1449,O
freely,1449,O
moving,1449,O
mice,1449,O
by,1449,O
telemetry,1449,O
.,1449,O
With,1450,O
this,1450,O
model,1450,O
we,1450,O
investigated,1450,O
the,1450,O
effect,1450,O
of,1450,O
chronic,1450,O
doxorubicin,1450,B-Chemical
administration,1450,O
on,1450,O
the,1450,O
ECG,1450,O
of,1450,O
freely,1450,O
moving,1450,O
BALB/c,1450,O
mice,1450,O
and,1450,O
the,1450,O
efficacy,1450,O
of,1450,O
ICRF-187,1450,B-Chemical
as,1450,O
a,1450,O
protective,1450,O
agent,1450,O
.,1450,O
The,1451,O
ST,1451,O
interval,1451,O
significantly,1451,O
widened,1451,O
from,1451,O
15.0,1451,O
+/-,1451,O
1.5,1451,O
to,1451,O
56.8,1451,O
+/-,1451,O
11.8,1451,O
ms,1451,O
in,1451,O
week,1451,O
10,1451,O
(,1451,O
7,1451,O
weekly,1451,O
doses,1451,O
of,1451,O
4,1451,O
mg/kg,1451,O
doxorubicin,1451,B-Chemical
given,1451,O
i.v,1451,O
.,1451,O
plus,1452,O
3,1452,O
weeks,1452,O
of,1452,O
observation,1452,O
),1452,O
.,1452,O
The,1453,O
ECG,1453,O
of,1453,O
the,1453,O
control,1453,O
animals,1453,O
did,1453,O
not,1453,O
change,1453,O
during,1453,O
the,1453,O
entire,1453,O
study,1453,O
.,1453,O
After,1454,O
sacrifice,1454,O
the,1454,O
hearts,1454,O
of,1454,O
doxorubicin-treated,1454,B-Chemical
animals,1454,O
were,1454,O
enlarged,1454,O
and,1454,O
the,1454,O
atria,1454,O
were,1454,O
hypertrophic,1454,B-Disease
.,1454,O
As,1455,O
this,1455,O
schedule,1455,O
exerted,1455,O
more,1455,O
toxicity,1455,B-Disease
than,1455,O
needed,1455,O
to,1455,O
investigate,1455,O
protective,1455,O
agents,1455,O
",",1455,O
the,1455,O
protection,1455,O
of,1455,O
ICRF-187,1455,B-Chemical
was,1455,O
determined,1455,O
using,1455,O
a,1455,O
dose,1455,O
schedule,1455,O
with,1455,O
lower,1455,O
general,1455,O
toxicity,1455,B-Disease
(,1455,O
6,1455,O
weekly,1455,O
doses,1455,O
of,1455,O
4,1455,O
mg/kg,1455,O
doxorubicin,1455,B-Chemical
given,1455,O
i.v,1455,O
.,1455,O
plus,1456,O
2,1456,O
weeks,1456,O
of,1456,O
observation,1456,O
),1456,O
.,1456,O
On,1457,O
this,1457,O
schedule,1457,O
",",1457,O
the,1457,O
animals,1457,O
',1457,O
hearts,1457,O
appeared,1457,O
normal,1457,O
after,1457,O
sacrifice,1457,O
and,1457,O
ICRF-187,1457,B-Chemical
(,1457,O
50,1457,O
mg/kg,1457,O
given,1457,O
i.p,1457,O
.,1457,O
1,1458,O
h,1458,O
before,1458,O
doxorubicin,1458,B-Chemical
),1458,O
provided,1458,O
almost,1458,O
full,1458,O
protection,1458,O
.,1458,O
These,1459,O
data,1459,O
were,1459,O
confirmed,1459,O
by,1459,O
histology,1459,O
.,1459,O
The,1460,O
results,1460,O
indicate,1460,O
that,1460,O
this,1460,O
new,1460,O
model,1460,O
is,1460,O
very,1460,O
sensitive,1460,O
and,1460,O
enables,1460,O
monitoring,1460,O
of,1460,O
the,1460,O
development,1460,O
of,1460,O
cardiotoxicity,1460,B-Disease
with,1460,O
time,1460,O
.,1460,O
These,1461,O
findings,1461,O
result,1461,O
in,1461,O
a,1461,O
model,1461,O
that,1461,O
allows,1461,O
the,1461,O
testing,1461,O
of,1461,O
protectors,1461,O
against,1461,O
doxorubicin-induced,1461,B-Chemical
cardiotoxicity,1461,B-Disease
as,1461,O
demonstrated,1461,O
by,1461,O
the,1461,O
protection,1461,O
provided,1461,O
by,1461,O
ICRF-187,1461,B-Chemical
.,1461,O
Epinephrine,1462,B-Chemical
dysrhythmogenicity,1462,O
is,1462,O
not,1462,O
enhanced,1462,O
by,1462,O
subtoxic,1462,O
bupivacaine,1462,B-Chemical
in,1462,O
dogs,1462,O
.,1462,O
Since,1463,O
bupivacaine,1463,B-Chemical
and,1463,O
epinephrine,1463,B-Chemical
may,1463,O
both,1463,O
precipitate,1463,O
dysrhythmias,1463,B-Disease
",",1463,O
circulating,1463,O
bupivacaine,1463,B-Chemical
during,1463,O
regional,1463,O
anesthesia,1463,O
could,1463,O
potentiate,1463,O
dysrhythmogenic,1463,O
effects,1463,O
of,1463,O
epinephrine,1463,B-Chemical
.,1463,O
We,1464,O
therefore,1464,O
examined,1464,O
whether,1464,O
bupivacaine,1464,B-Chemical
alters,1464,O
the,1464,O
dysrhythmogenicity,1464,O
of,1464,O
subsequent,1464,O
administration,1464,O
of,1464,O
epinephrine,1464,B-Chemical
in,1464,O
conscious,1464,O
",",1464,O
healthy,1464,O
dogs,1464,O
and,1464,O
in,1464,O
anesthetized,1464,O
dogs,1464,O
with,1464,O
myocardial,1464,B-Disease
infarction,1464,I-Disease
.,1464,O
Forty-one,1465,O
conscious,1465,O
dogs,1465,O
received,1465,O
10,1465,O
micrograms.kg-1.min-1,1465,O
epinephrine,1465,B-Chemical
.,1465,O
Seventeen,1466,O
animals,1466,O
responded,1466,O
with,1466,O
ventricular,1466,B-Disease
tachycardia,1466,I-Disease
(,1466,O
VT,1466,B-Disease
),1466,O
within,1466,O
3,1466,O
min,1466,O
.,1466,O
After,1467,O
3,1467,O
h,1467,O
",",1467,O
these,1467,O
responders,1467,O
randomly,1467,O
received,1467,O
1,1467,O
or,1467,O
2,1467,O
mg/kg,1467,O
bupivacaine,1467,B-Chemical
or,1467,O
saline,1467,O
over,1467,O
5,1467,O
min,1467,O
",",1467,O
followed,1467,O
by,1467,O
10,1467,O
micrograms.kg-1.min-1,1467,O
epinephrine,1467,B-Chemical
.,1467,O
In,1468,O
the,1468,O
bupivacaine,1468,B-Chemical
groups,1468,O
",",1468,O
epinephrine,1468,B-Chemical
caused,1468,O
fewer,1468,O
prodysrhythmic,1468,O
effects,1468,O
than,1468,O
without,1468,O
bupivacaine,1468,B-Chemical
.,1468,O
VT,1469,B-Disease
appeared,1469,O
in,1469,O
fewer,1469,O
dogs,1469,O
and,1469,O
at,1469,O
a,1469,O
later,1469,O
time,1469,O
",",1469,O
and,1469,O
there,1469,O
were,1469,O
more,1469,O
sinoatrial,1469,O
beats,1469,O
and,1469,O
less,1469,O
ectopies,1469,O
.,1469,O
Epinephrine,1470,B-Chemical
shortened,1470,O
QT,1470,O
less,1470,O
after,1470,O
bupivacaine,1470,B-Chemical
than,1470,O
in,1470,O
control,1470,O
animals,1470,O
.,1470,O
One,1471,O
day,1471,O
after,1471,O
experimental,1471,O
myocardial,1471,B-Disease
infarction,1471,I-Disease
",",1471,O
six,1471,O
additional,1471,O
halothane-anesthetized,1471,B-Chemical
dogs,1471,O
received,1471,O
4,1471,O
micrograms.kg-1.min-1,1471,O
epinephrine,1471,B-Chemical
until,1471,O
VT,1471,B-Disease
appeared,1471,O
.,1471,O
After,1472,O
45,1472,O
min,1472,O
",",1472,O
1,1472,O
mg/kg,1472,O
bupivacaine,1472,B-Chemical
was,1472,O
injected,1472,O
over,1472,O
5,1472,O
min,1472,O
",",1472,O
again,1472,O
followed,1472,O
by,1472,O
4,1472,O
micrograms.kg-1.min-1,1472,O
epinephrine,1472,B-Chemical
.,1472,O
In,1473,O
these,1473,O
dogs,1473,O
",",1473,O
the,1473,O
prodysrhythmic,1473,O
response,1473,O
to,1473,O
epinephrine,1473,B-Chemical
was,1473,O
also,1473,O
mitigated,1473,O
by,1473,O
preceding,1473,O
bupivacaine,1473,B-Chemical
.,1473,O
Bupivacaine,1474,B-Chemical
antagonizes,1474,O
epinephrine,1474,B-Chemical
dysrhythmogenicity,1474,O
in,1474,O
conscious,1474,O
dogs,1474,O
susceptible,1474,O
to,1474,O
VT,1474,B-Disease
and,1474,O
in,1474,O
anesthetized,1474,O
dogs,1474,O
with,1474,O
spontaneous,1474,O
postinfarct,1474,O
dysrhythmias,1474,B-Disease
.,1474,O
There,1475,O
is,1475,O
no,1475,O
evidence,1475,O
that,1475,O
systemic,1475,O
subtoxic,1475,O
bupivacaine,1475,B-Chemical
administration,1475,O
enhances,1475,O
the,1475,O
dysrhythmogenicity,1475,O
of,1475,O
subsequent,1475,O
epinephrine,1475,B-Chemical
.,1475,O
Milk-alkali,1476,B-Disease
syndrome,1476,I-Disease
induced,1476,O
by,1476,O
"1,25",1476,B-Chemical
(,1476,I-Chemical
OH,1476,I-Chemical
),1476,I-Chemical
2D,1476,I-Chemical
in,1476,O
a,1476,O
patient,1476,O
with,1476,O
hypoparathyroidism,1476,B-Disease
.,1476,O
Milk-alkali,1477,B-Disease
syndrome,1477,I-Disease
was,1477,O
first,1477,O
described,1477,O
70,1477,O
years,1477,O
ago,1477,O
in,1477,O
the,1477,O
context,1477,O
of,1477,O
the,1477,O
treatment,1477,O
of,1477,O
peptic,1477,B-Disease
ulcer,1477,I-Disease
disease,1477,I-Disease
with,1477,O
large,1477,O
amounts,1477,O
of,1477,O
calcium,1477,B-Chemical
and,1477,O
alkali,1477,B-Chemical
.,1477,O
Although,1478,O
with,1478,O
current,1478,O
ulcer,1478,B-Disease
therapy,1478,O
(,1478,O
H-2,1478,O
blockers,1478,O
",",1478,O
omeprazole,1478,B-Chemical
",",1478,O
and,1478,O
sucralfate,1478,B-Chemical
),1478,O
",",1478,O
the,1478,O
frequency,1478,O
of,1478,O
milk-alkali,1478,B-Disease
syndrome,1478,I-Disease
has,1478,O
decreased,1478,O
significantly,1478,O
",",1478,O
the,1478,O
classic,1478,O
triad,1478,O
of,1478,O
hypercalcemia,1478,B-Disease
",",1478,O
alkalosis,1478,B-Disease
",",1478,O
and,1478,O
renal,1478,B-Disease
impairment,1478,I-Disease
remains,1478,O
the,1478,O
hallmark,1478,O
of,1478,O
the,1478,O
syndrome,1478,O
.,1478,O
Milk-alkali,1479,B-Disease
syndrome,1479,I-Disease
can,1479,O
present,1479,O
serious,1479,O
and,1479,O
occasionally,1479,O
life-threatening,1479,O
illness,1479,O
unless,1479,O
diagnosed,1479,O
and,1479,O
treated,1479,O
appropriately,1479,O
.,1479,O
This,1480,O
article,1480,O
presents,1480,O
a,1480,O
patient,1480,O
with,1480,O
hypoparathyroidism,1480,B-Disease
who,1480,O
was,1480,O
treated,1480,O
with,1480,O
calcium,1480,B-Chemical
carbonate,1480,I-Chemical
and,1480,O
calcitriol,1480,B-Chemical
resulting,1480,O
in,1480,O
two,1480,O
admissions,1480,O
to,1480,O
the,1480,O
hospital,1480,O
for,1480,O
milk-alkali,1480,B-Disease
syndrome,1480,I-Disease
.,1480,O
The,1481,O
patient,1481,O
was,1481,O
successfully,1481,O
treated,1481,O
with,1481,O
intravenous,1481,O
pamidronate,1481,B-Chemical
on,1481,O
his,1481,O
first,1481,O
admission,1481,O
and,1481,O
with,1481,O
hydrocortisone,1481,B-Chemical
on,1481,O
the,1481,O
second,1481,O
.,1481,O
This,1482,O
illustrates,1482,O
intravenous,1482,O
pamidronate,1482,B-Chemical
as,1482,O
a,1482,O
valuable,1482,O
therapeutic,1482,O
tool,1482,O
when,1482,O
milk-alkali,1482,B-Disease
syndrome,1482,I-Disease
presents,1482,O
as,1482,O
hypercalcemic,1482,B-Disease
emergency,1482,I-Disease
.,1482,O
Famotidine-associated,1483,B-Chemical
delirium,1483,B-Disease
.,1483,O
A,1484,O
series,1484,O
of,1484,O
six,1484,O
cases,1484,O
.,1484,O
Famotidine,1485,B-Chemical
is,1485,O
a,1485,O
histamine,1485,O
H2-receptor,1485,O
antagonist,1485,O
used,1485,O
in,1485,O
inpatient,1485,O
settings,1485,O
for,1485,O
prevention,1485,O
of,1485,O
stress,1485,O
ulcers,1485,B-Disease
and,1485,O
is,1485,O
showing,1485,O
increasing,1485,O
popularity,1485,O
because,1485,O
of,1485,O
its,1485,O
low,1485,O
cost,1485,O
.,1485,O
Although,1486,O
all,1486,O
of,1486,O
the,1486,O
currently,1486,O
available,1486,O
H2-receptor,1486,O
antagonists,1486,O
have,1486,O
shown,1486,O
the,1486,O
propensity,1486,O
to,1486,O
cause,1486,O
delirium,1486,B-Disease
",",1486,O
only,1486,O
two,1486,O
previously,1486,O
reported,1486,O
cases,1486,O
have,1486,O
been,1486,O
associated,1486,O
with,1486,O
famotidine,1486,B-Chemical
.,1486,O
The,1487,O
authors,1487,O
report,1487,O
on,1487,O
six,1487,O
cases,1487,O
of,1487,O
famotidine-associated,1487,B-Chemical
delirium,1487,B-Disease
in,1487,O
hospitalized,1487,O
patients,1487,O
who,1487,O
cleared,1487,O
completely,1487,O
upon,1487,O
removal,1487,O
of,1487,O
famotidine,1487,B-Chemical
.,1487,O
The,1488,O
pharmacokinetics,1488,O
of,1488,O
famotidine,1488,B-Chemical
are,1488,O
reviewed,1488,O
",",1488,O
with,1488,O
no,1488,O
change,1488,O
in,1488,O
its,1488,O
metabolism,1488,O
in,1488,O
the,1488,O
elderly,1488,O
population,1488,O
seen,1488,O
.,1488,O
The,1489,O
implications,1489,O
of,1489,O
using,1489,O
famotidine,1489,B-Chemical
in,1489,O
elderly,1489,O
persons,1489,O
are,1489,O
discussed,1489,O
.,1489,O
Encephalopathy,1490,B-Disease
during,1490,O
amitriptyline,1490,B-Chemical
therapy,1490,O
:,1490,O
are,1490,O
neuroleptic,1490,B-Disease
malignant,1490,I-Disease
syndrome,1490,I-Disease
and,1490,O
serotonin,1490,B-Disease
syndrome,1490,I-Disease
spectrum,1490,O
disorders,1490,O
?,1490,O
This,1491,O
report,1491,O
describes,1491,O
a,1491,O
case,1491,O
of,1491,O
encephalopathy,1491,B-Disease
developed,1491,O
in,1491,O
the,1491,O
course,1491,O
of,1491,O
amitriptyline,1491,B-Chemical
therapy,1491,O
",",1491,O
during,1491,O
a,1491,O
remission,1491,O
of,1491,O
unipolar,1491,B-Disease
depression,1491,I-Disease
.,1491,O
This,1492,O
patient,1492,O
could,1492,O
have,1492,O
been,1492,O
diagnosed,1492,O
as,1492,O
having,1492,O
either,1492,O
neuroleptic,1492,B-Disease
malignant,1492,I-Disease
syndrome,1492,I-Disease
(,1492,O
NMS,1492,B-Disease
),1492,O
or,1492,O
serotonin,1492,B-Disease
syndrome,1492,I-Disease
(,1492,O
SS,1492,B-Disease
),1492,O
.,1492,O
The,1493,O
major,1493,O
determinant,1493,O
of,1493,O
the,1493,O
symptoms,1493,O
may,1493,O
have,1493,O
been,1493,O
dopamine/serotonin,1493,B-Chemical
imbalance,1493,O
in,1493,O
the,1493,O
central,1493,O
nervous,1493,O
system,1493,O
.,1493,O
The,1494,O
NMS-like,1494,B-Disease
encephalopathy,1494,B-Disease
that,1494,O
develops,1494,O
in,1494,O
association,1494,O
with,1494,O
the,1494,O
use,1494,O
of,1494,O
antidepressants,1494,O
indicates,1494,O
that,1494,O
NMS,1494,B-Disease
and,1494,O
SS,1494,B-Disease
are,1494,O
spectrum,1494,O
disorders,1494,O
induced,1494,O
by,1494,O
drugs,1494,O
with,1494,O
both,1494,O
antidopaminergic,1494,O
and,1494,O
serotonergic,1494,O
effects,1494,O
.,1494,O
Genetic,1495,O
separation,1495,O
of,1495,O
tumor,1495,B-Disease
growth,1495,O
and,1495,O
hemorrhagic,1495,B-Disease
phenotypes,1495,O
in,1495,O
an,1495,O
estrogen-induced,1495,B-Chemical
tumor,1495,B-Disease
.,1495,O
Chronic,1496,O
administration,1496,O
of,1496,O
estrogen,1496,B-Chemical
to,1496,O
the,1496,O
Fischer,1496,O
344,1496,O
(,1496,O
F344,1496,O
),1496,O
rat,1496,O
induces,1496,O
growth,1496,O
of,1496,O
large,1496,O
",",1496,O
hemorrhagic,1496,B-Disease
pituitary,1496,B-Disease
tumors,1496,I-Disease
.,1496,O
Ten,1497,O
weeks,1497,O
of,1497,O
diethylstilbestrol,1497,B-Chemical
(,1497,O
DES,1497,B-Chemical
),1497,O
treatment,1497,O
caused,1497,O
female,1497,O
F344,1497,O
rat,1497,O
pituitaries,1497,O
to,1497,O
grow,1497,O
to,1497,O
an,1497,O
average,1497,O
of,1497,O
109.2,1497,O
+/-,1497,O
6.3,1497,O
mg,1497,O
(,1497,O
mean,1497,O
+/-,1497,O
SE,1497,O
),1497,O
versus,1497,O
11.3,1497,O
+/-,1497,O
1.4,1497,O
mg,1497,O
for,1497,O
untreated,1497,O
rats,1497,O
",",1497,O
and,1497,O
to,1497,O
become,1497,O
highly,1497,O
hemorrhagic,1497,B-Disease
.,1497,O
The,1498,O
same,1498,O
DES,1498,B-Chemical
treatment,1498,O
produced,1498,O
no,1498,O
significant,1498,O
growth,1498,O
(,1498,O
8.9,1498,O
+/-,1498,O
0.5,1498,O
mg,1498,O
for,1498,O
treated,1498,O
females,1498,O
versus,1498,O
8.7,1498,O
+/-,1498,O
1.1,1498,O
for,1498,O
untreated,1498,O
females,1498,O
),1498,O
or,1498,O
morphological,1498,O
changes,1498,O
in,1498,O
Brown,1498,O
Norway,1498,O
(,1498,O
BN,1498,O
),1498,O
rat,1498,O
pituitaries,1498,O
.,1498,O
An,1499,O
F1,1499,O
hybrid,1499,O
of,1499,O
F344,1499,O
and,1499,O
BN,1499,O
exhibited,1499,O
significant,1499,O
pituitary,1499,O
growth,1499,O
after,1499,O
10,1499,O
weeks,1499,O
of,1499,O
DES,1499,B-Chemical
treatment,1499,O
with,1499,O
an,1499,O
average,1499,O
mass,1499,O
of,1499,O
26.3,1499,O
+/-,1499,O
0.7,1499,O
mg,1499,O
compared,1499,O
with,1499,O
8.6,1499,O
+/-,1499,O
0.9,1499,O
mg,1499,O
for,1499,O
untreated,1499,O
rats,1499,O
.,1499,O
Surprisingly,1500,O
",",1500,O
the,1500,O
F1,1500,O
hybrid,1500,O
tumors,1500,B-Disease
were,1500,O
not,1500,O
hemorrhagic,1500,B-Disease
and,1500,O
had,1500,O
hemoglobin,1500,O
content,1500,O
and,1500,O
outward,1500,O
appearance,1500,O
identical,1500,O
to,1500,O
that,1500,O
of,1500,O
BN,1500,O
.,1500,O
Expression,1501,O
of,1501,O
both,1501,O
growth,1501,O
and,1501,O
morphological,1501,O
changes,1501,O
is,1501,O
due,1501,O
to,1501,O
multiple,1501,O
genes,1501,O
.,1501,O
However,1502,O
",",1502,O
while,1502,O
DES-induced,1502,B-Chemical
pituitary,1502,O
growth,1502,O
exhibited,1502,O
quantitative,1502,O
",",1502,O
additive,1502,O
inheritance,1502,O
",",1502,O
the,1502,O
hemorrhagic,1502,B-Disease
phenotype,1502,O
exhibited,1502,O
recessive,1502,O
",",1502,O
epistatic,1502,O
inheritance,1502,O
.,1502,O
Only,1503,O
5,1503,O
of,1503,O
the,1503,O
160,1503,O
F2,1503,O
pituitaries,1503,O
exhibited,1503,O
the,1503,O
hemorrhagic,1503,B-Disease
phenotype,1503,O
;,1503,O
36,1503,O
of,1503,O
the,1503,O
160,1503,O
F2,1503,O
pituitaries,1503,O
were,1503,O
in,1503,O
the,1503,O
F344,1503,O
range,1503,O
of,1503,O
mass,1503,O
",",1503,O
but,1503,O
31,1503,O
of,1503,O
these,1503,O
were,1503,O
not,1503,O
hemorrhagic,1503,B-Disease
",",1503,O
indicating,1503,O
that,1503,O
the,1503,O
hemorrhagic,1503,B-Disease
phenotype,1503,O
is,1503,O
not,1503,O
merely,1503,O
a,1503,O
consequence,1503,O
of,1503,O
extensive,1503,O
growth,1503,O
.,1503,O
The,1504,O
hemorrhagic,1504,B-Disease
F2,1504,O
pituitaries,1504,O
were,1504,O
all,1504,O
among,1504,O
the,1504,O
most,1504,O
massive,1504,O
",",1504,O
indicating,1504,O
that,1504,O
some,1504,O
of,1504,O
the,1504,O
genes,1504,O
regulate,1504,O
both,1504,O
phenotypes,1504,O
.,1504,O
Increased,1505,O
expression,1505,O
of,1505,O
neuronal,1505,O
nitric,1505,B-Chemical
oxide,1505,I-Chemical
synthase,1505,O
in,1505,O
bladder,1505,O
afferent,1505,O
pathways,1505,O
following,1505,O
chronic,1505,O
bladder,1505,B-Disease
irritation,1505,I-Disease
.,1505,O
Immunocytochemical,1506,O
techniques,1506,O
were,1506,O
used,1506,O
to,1506,O
examine,1506,O
alterations,1506,O
in,1506,O
the,1506,O
expression,1506,O
of,1506,O
neuronal,1506,O
nitric,1506,B-Chemical
oxide,1506,I-Chemical
synthase,1506,O
(,1506,O
NOS,1506,O
),1506,O
in,1506,O
bladder,1506,O
pathways,1506,O
following,1506,O
acute,1506,O
and,1506,O
chronic,1506,O
irritation,1506,B-Disease
of,1506,I-Disease
the,1506,I-Disease
urinary,1506,I-Disease
tract,1506,I-Disease
of,1506,O
the,1506,O
rat,1506,O
.,1506,O
Chemical,1507,O
cystitis,1507,B-Disease
was,1507,O
induced,1507,O
by,1507,O
cyclophosphamide,1507,B-Chemical
(,1507,O
CYP,1507,B-Chemical
),1507,O
which,1507,O
is,1507,O
metabolized,1507,O
to,1507,O
acrolein,1507,B-Chemical
",",1507,O
an,1507,O
irritant,1507,O
eliminated,1507,O
in,1507,O
the,1507,O
urine,1507,O
.,1507,O
Injection,1508,O
of,1508,O
CYP,1508,B-Chemical
(,1508,O
n,1508,O
=,1508,O
10,1508,O
",",1508,O
75,1508,O
mg/kg,1508,O
",",1508,O
i.p,1508,O
.,1508,O
),1508,O
2,1509,O
hours,1509,O
prior,1509,O
to,1509,O
perfusion,1509,O
(,1509,O
acute,1509,O
treatment,1509,O
),1509,O
of,1509,O
the,1509,O
animals,1509,O
increased,1509,O
Fos-immunoreactivity,1509,O
(,1509,O
IR,1509,O
),1509,O
in,1509,O
neurons,1509,O
in,1509,O
the,1509,O
dorsal,1509,O
commissure,1509,O
",",1509,O
dorsal,1509,O
horn,1509,O
",",1509,O
and,1509,O
autonomic,1509,O
regions,1509,O
of,1509,O
spinal,1509,O
segments,1509,O
(,1509,O
L1-L2,1509,O
and,1509,O
L6-S1,1509,O
),1509,O
which,1509,O
receive,1509,O
afferent,1509,O
inputs,1509,O
from,1509,O
the,1509,O
bladder,1509,O
",",1509,O
urethra,1509,O
",",1509,O
and,1509,O
ureter,1509,O
.,1509,O
Fos-IR,1510,O
in,1510,O
the,1510,O
spinal,1510,O
cord,1510,O
was,1510,O
not,1510,O
changed,1510,O
in,1510,O
rats,1510,O
receiving,1510,O
chronic,1510,O
CYP,1510,B-Chemical
treatment,1510,O
(,1510,O
n,1510,O
=,1510,O
15,1510,O
",",1510,O
75,1510,O
mg/kg,1510,O
",",1510,O
i.p.,1510,O
",",1510,O
every,1510,O
3rd,1510,O
day,1510,O
for,1510,O
2,1510,O
weeks,1510,O
),1510,O
.,1510,O
In,1511,O
control,1511,O
animals,1511,O
and,1511,O
in,1511,O
animals,1511,O
treated,1511,O
acutely,1511,O
with,1511,O
CYP,1511,B-Chemical
",",1511,O
only,1511,O
small,1511,O
numbers,1511,O
of,1511,O
NOS-IR,1511,O
cells,1511,O
(,1511,O
0.5-0.7,1511,O
cell,1511,O
profiles/sections,1511,O
),1511,O
were,1511,O
detected,1511,O
in,1511,O
the,1511,O
L6-S1,1511,O
dorsal,1511,O
root,1511,O
ganglia,1511,O
(,1511,O
DRG,1511,O
),1511,O
.,1511,O
Chronic,1512,O
CYP,1512,B-Chemical
administration,1512,O
significantly,1512,O
(,1512,O
P,1512,O
<,1512,O
or,1512,O
=,1512,O
.002,1512,O
),1512,O
increased,1512,O
bladder,1512,O
weight,1512,O
by,1512,O
60,1512,O
%,1512,O
and,1512,O
increased,1512,O
(,1512,O
7-,1512,O
to,1512,O
11-fold,1512,O
),1512,O
the,1512,O
numbers,1512,O
of,1512,O
NOS-immunoreactive,1512,O
(,1512,O
IR,1512,O
),1512,O
afferent,1512,O
neurons,1512,O
in,1512,O
the,1512,O
L6-S1,1512,O
DRG,1512,O
.,1512,O
A,1513,O
small,1513,O
increase,1513,O
(,1513,O
1.5-fold,1513,O
),1513,O
also,1513,O
occurred,1513,O
in,1513,O
the,1513,O
L1,1513,O
DRG,1513,O
",",1513,O
but,1513,O
no,1513,O
change,1513,O
was,1513,O
detected,1513,O
in,1513,O
the,1513,O
L2,1513,O
and,1513,O
L5,1513,O
DRG,1513,O
.,1513,O
Bladder,1514,O
afferent,1514,O
cells,1514,O
in,1514,O
the,1514,O
L6-S1,1514,O
DRG,1514,O
labeled,1514,O
by,1514,O
Fluorogold,1514,O
(,1514,O
40,1514,O
microliters,1514,O
),1514,O
injected,1514,O
into,1514,O
the,1514,O
bladder,1514,O
wall,1514,O
did,1514,O
not,1514,O
exhibit,1514,O
NOS-IR,1514,O
in,1514,O
control,1514,O
animals,1514,O
;,1514,O
however,1514,O
",",1514,O
following,1514,O
chronic,1514,O
CYP,1514,B-Chemical
administration,1514,O
",",1514,O
a,1514,O
significant,1514,O
percentage,1514,O
of,1514,O
bladder,1514,O
afferent,1514,O
neurons,1514,O
were,1514,O
NOS-IR,1514,O
:,1514,O
L6,1514,O
(,1514,O
19.8,1514,O
+/-,1514,O
4.6,1514,O
%,1514,O
),1514,O
and,1514,O
S1,1514,O
(,1514,O
25.3,1514,O
+/-,1514,O
2.9,1514,O
%,1514,O
),1514,O
.,1514,O
These,1515,O
results,1515,O
indicate,1515,O
that,1515,O
neuronal,1515,O
gene,1515,O
expression,1515,O
in,1515,O
visceral,1515,O
sensory,1515,O
pathways,1515,O
can,1515,O
be,1515,O
upregulated,1515,O
by,1515,O
chemical,1515,O
irritation,1515,O
of,1515,O
afferent,1515,O
receptors,1515,O
in,1515,O
the,1515,O
urinary,1515,O
tract,1515,O
and/or,1515,O
that,1515,O
pathological,1515,O
changes,1515,O
in,1515,O
the,1515,O
urinary,1515,O
tract,1515,O
can,1515,O
initiate,1515,O
chemical,1515,O
signals,1515,O
that,1515,O
alter,1515,O
the,1515,O
chemical,1515,O
properties,1515,O
of,1515,O
visceral,1515,O
afferent,1515,O
neurons,1515,O
.,1515,O
Effects,1516,O
of,1516,O
a,1516,O
new,1516,O
calcium,1516,B-Chemical
antagonist,1516,O
",",1516,O
CD-832,1516,B-Chemical
",",1516,O
on,1516,O
isoproterenol-induced,1516,B-Chemical
myocardial,1516,B-Disease
ischemia,1516,I-Disease
in,1516,O
dogs,1516,O
with,1516,O
partial,1516,O
coronary,1516,B-Disease
stenosis,1516,I-Disease
.,1516,O
Effects,1517,O
of,1517,O
CD-832,1517,B-Chemical
on,1517,O
isoproterenol,1517,B-Chemical
(,1517,O
ISO,1517,B-Chemical
),1517,O
-induced,1517,O
myocardial,1517,B-Disease
ischemia,1517,I-Disease
were,1517,O
studied,1517,O
in,1517,O
dogs,1517,O
with,1517,O
partial,1517,O
coronary,1517,B-Disease
stenosis,1517,I-Disease
of,1517,O
the,1517,O
left,1517,O
circumflex,1517,O
coronary,1517,O
artery,1517,O
and,1517,O
findings,1517,O
were,1517,O
compared,1517,O
with,1517,O
those,1517,O
for,1517,O
nifedipine,1517,B-Chemical
or,1517,O
diltiazem,1517,B-Chemical
.,1517,O
In,1518,O
the,1518,O
presence,1518,O
of,1518,O
coronary,1518,B-Disease
artery,1518,I-Disease
stenosis,1518,I-Disease
",",1518,O
3-min,1518,O
periods,1518,O
of,1518,O
intracoronary,1518,O
ISO,1518,B-Chemical
infusion,1518,O
(,1518,O
10,1518,O
ng/kg/min,1518,O
),1518,O
increased,1518,O
heart,1518,O
rate,1518,O
and,1518,O
maximal,1518,O
rate,1518,O
of,1518,O
left,1518,O
ventricular,1518,O
pressure,1518,O
rise,1518,O
",",1518,O
which,1518,O
resulted,1518,O
in,1518,O
a,1518,O
decrease,1518,O
in,1518,O
percentage,1518,O
segmental,1518,O
shortening,1518,O
and,1518,O
ST-segment,1518,O
elevation,1518,O
of,1518,O
the,1518,O
epicardial,1518,O
electrocardiogram,1518,O
.,1518,O
After,1519,O
the,1519,O
control,1519,O
ISO,1519,B-Chemical
infusion,1519,O
with,1519,O
stenosis,1519,B-Disease
was,1519,O
performed,1519,O
",",1519,O
equihypotensive,1519,O
doses,1519,O
of,1519,O
CD-832,1519,B-Chemical
(,1519,O
3,1519,O
and,1519,O
10,1519,O
micrograms/kg/min,1519,O
",",1519,O
n,1519,O
=,1519,O
7,1519,O
),1519,O
",",1519,O
nifedipine,1519,B-Chemical
(,1519,O
1,1519,O
and,1519,O
3,1519,O
micrograms/kg/min,1519,O
",",1519,O
n,1519,O
=,1519,O
9,1519,O
),1519,O
or,1519,O
diltiazem,1519,B-Chemical
(,1519,O
10,1519,O
and,1519,O
30,1519,O
micrograms/kg/min,1519,O
",",1519,O
n,1519,O
=,1519,O
7,1519,O
),1519,O
were,1519,O
infused,1519,O
5,1519,O
min,1519,O
before,1519,O
and,1519,O
during,1519,O
the,1519,O
second,1519,O
and,1519,O
third,1519,O
ISO,1519,B-Chemical
infusion,1519,O
.,1519,O
Both,1520,O
CD-832,1520,B-Chemical
and,1520,O
diltiazem,1520,B-Chemical
",",1520,O
but,1520,O
not,1520,O
nifedipine,1520,B-Chemical
",",1520,O
significantly,1520,O
reduced,1520,O
the,1520,O
increase,1520,O
in,1520,O
heart,1520,O
rate,1520,O
induced,1520,O
by,1520,O
ISO,1520,B-Chemical
infusion,1520,O
.,1520,O
In,1521,O
contrast,1521,O
to,1521,O
nifedipine,1521,B-Chemical
",",1521,O
CD-832,1521,B-Chemical
(,1521,O
10,1521,O
micrograms/kg/min,1521,O
),1521,O
prevented,1521,O
the,1521,O
decrease,1521,O
in,1521,O
percentage,1521,O
segmental,1521,O
shortening,1521,O
from,1521,O
32,1521,O
+/-,1521,O
12,1521,O
%,1521,O
to,1521,O
115,1521,O
+/-,1521,O
26,1521,O
%,1521,O
of,1521,O
the,1521,O
control,1521,O
value,1521,O
(,1521,O
P,1521,O
<,1521,O
.01,1521,O
),1521,O
and,1521,O
ST-segment,1521,O
elevation,1521,O
from,1521,O
5.6,1521,O
+/-,1521,O
1.0,1521,O
mV,1521,O
to,1521,O
1.6,1521,O
+/-,1521,O
1.3,1521,O
mV,1521,O
(,1521,O
P,1521,O
<,1521,O
.01,1521,O
),1521,O
at,1521,O
3,1521,O
min,1521,O
after,1521,O
ISO,1521,B-Chemical
infusion,1521,O
with,1521,O
stenosis,1521,B-Disease
.,1521,O
Diltiazem,1522,B-Chemical
(,1522,O
30,1522,O
micrograms/kg/min,1522,O
),1522,O
also,1522,O
prevented,1522,O
the,1522,O
decrease,1522,O
in,1522,O
percentage,1522,O
segmental,1522,O
shortening,1522,O
from,1522,O
34,1522,O
+/-,1522,O
14,1522,O
%,1522,O
to,1522,O
63,1522,O
+/-,1522,O
18,1522,O
%,1522,O
of,1522,O
the,1522,O
control,1522,O
value,1522,O
(,1522,O
P,1522,O
<,1522,O
.05,1522,O
),1522,O
and,1522,O
ST-segment,1522,O
elevation,1522,O
from,1522,O
4.7,1522,O
+/-,1522,O
0.7,1522,O
mV,1522,O
to,1522,O
2.1,1522,O
+/-,1522,O
0.7,1522,O
mV,1522,O
(,1522,O
P,1522,O
<,1522,O
.01,1522,O
),1522,O
at,1522,O
3,1522,O
min,1522,O
after,1522,O
ISO,1522,B-Chemical
infusion,1522,O
with,1522,O
stenosis,1522,B-Disease
.,1522,O
These,1523,O
data,1523,O
show,1523,O
that,1523,O
CD-832,1523,B-Chemical
improves,1523,O
myocardial,1523,B-Disease
ischemia,1523,I-Disease
during,1523,O
ISO,1523,B-Chemical
infusion,1523,O
with,1523,O
stenosis,1523,B-Disease
and,1523,O
suggest,1523,O
that,1523,O
the,1523,O
negative,1523,O
chronotropic,1523,O
property,1523,O
of,1523,O
CD-832,1523,B-Chemical
plays,1523,O
a,1523,O
major,1523,O
role,1523,O
in,1523,O
the,1523,O
beneficial,1523,O
effects,1523,O
of,1523,O
CD-832,1523,B-Chemical
.,1523,O
The,1524,O
effect,1524,O
of,1524,O
recombinant,1524,O
human,1524,O
insulin-like,1524,O
growth,1524,O
factor-I,1524,O
on,1524,O
chronic,1524,O
puromycin,1524,B-Chemical
aminonucleoside,1524,I-Chemical
nephropathy,1524,B-Disease
in,1524,O
rats,1524,O
.,1524,O
We,1525,O
recently,1525,O
demonstrated,1525,O
that,1525,O
recombinant,1525,O
hGH,1525,O
exacerbates,1525,O
renal,1525,O
functional,1525,O
and,1525,O
structural,1525,O
injury,1525,O
in,1525,O
chronic,1525,O
puromycin,1525,B-Chemical
aminonucleoside,1525,I-Chemical
(,1525,O
PAN,1525,B-Chemical
),1525,O
nephropathy,1525,B-Disease
",",1525,O
an,1525,O
experimental,1525,O
model,1525,O
of,1525,O
glomerular,1525,B-Disease
disease,1525,I-Disease
.,1525,O
Therefore,1526,O
",",1526,O
we,1526,O
examined,1526,O
whether,1526,O
recombinant,1526,O
human,1526,O
(,1526,O
rh,1526,O
),1526,O
IGF-I,1526,O
is,1526,O
a,1526,O
safer,1526,O
alternative,1526,O
for,1526,O
the,1526,O
treatment,1526,O
of,1526,O
growth,1526,B-Disease
failure,1526,I-Disease
in,1526,O
rats,1526,O
with,1526,O
chronic,1526,O
PAN,1526,B-Chemical
nephropathy,1526,B-Disease
.,1526,O
The,1527,O
glomerulopathy,1527,B-Disease
was,1527,O
induced,1527,O
by,1527,O
seven,1527,O
serial,1527,O
injections,1527,O
of,1527,O
PAN,1527,B-Chemical
over,1527,O
12,1527,O
wk,1527,O
.,1527,O
Experimental,1528,O
animals,1528,O
(,1528,O
n,1528,O
=,1528,O
6,1528,O
),1528,O
received,1528,O
rhIGF-I,1528,O
",",1528,O
400,1528,O
micrograms/d,1528,O
",",1528,O
whereas,1528,O
control,1528,O
rats,1528,O
(,1528,O
n,1528,O
=,1528,O
6,1528,O
),1528,O
received,1528,O
the,1528,O
vehicle,1528,O
.,1528,O
rhIGF-I,1529,O
improved,1529,O
weight,1529,O
gain,1529,O
by,1529,O
14,1529,O
%,1529,O
(,1529,O
p,1529,O
<,1529,O
0.05,1529,O
),1529,O
",",1529,O
without,1529,O
altering,1529,O
hematocrit,1529,O
or,1529,O
blood,1529,O
pressure,1529,O
in,1529,O
rats,1529,O
with,1529,O
renal,1529,B-Disease
disease,1529,I-Disease
.,1529,O
Urinary,1530,O
protein,1530,O
excretion,1530,O
was,1530,O
unaltered,1530,O
by,1530,O
rhIGF-I,1530,O
treatment,1530,O
in,1530,O
rats,1530,O
with,1530,O
chronic,1530,O
PAN,1530,B-Chemical
nephropathy,1530,B-Disease
.,1530,O
After,1531,O
12,1531,O
wk,1531,O
",",1531,O
the,1531,O
inulin,1531,O
clearance,1531,O
was,1531,O
higher,1531,O
in,1531,O
rhIGF-I-treated,1531,O
rats,1531,O
",",1531,O
0.48,1531,O
+/-,1531,O
0.08,1531,O
versus,1531,O
0.24,1531,O
+/-,1531,O
0.06,1531,O
mL/min/100,1531,O
g,1531,O
of,1531,O
body,1531,O
weight,1531,O
in,1531,O
untreated,1531,O
PAN,1531,B-Chemical
nephropathy,1531,B-Disease
animals,1531,O
",",1531,O
p,1531,O
<,1531,O
0.05,1531,O
.,1531,O
The,1532,O
improvement,1532,O
in,1532,O
GFR,1532,O
was,1532,O
not,1532,O
associated,1532,O
with,1532,O
enhanced,1532,O
glomerular,1532,B-Disease
hypertrophy,1532,I-Disease
or,1532,O
increased,1532,O
segmental,1532,O
glomerulosclerosis,1532,B-Disease
",",1532,O
tubulointerstitial,1532,B-Disease
injury,1532,I-Disease
",",1532,O
or,1532,O
renal,1532,O
cortical,1532,O
malondialdehyde,1532,B-Chemical
content,1532,O
.,1532,O
In,1533,O
rats,1533,O
with,1533,O
PAN,1533,B-Chemical
nephropathy,1533,B-Disease
",",1533,O
administration,1533,O
of,1533,O
rhIGF-I,1533,O
increased,1533,O
IGF-I,1533,O
and,1533,O
GH,1533,O
receptor,1533,O
gene,1533,O
expression,1533,O
",",1533,O
without,1533,O
altering,1533,O
the,1533,O
steady,1533,O
state,1533,O
level,1533,O
of,1533,O
IGF-I,1533,O
receptor,1533,O
mRNA,1533,O
.,1533,O
In,1534,O
normal,1534,O
rats,1534,O
with,1534,O
intact,1534,O
kidneys,1534,O
",",1534,O
rhIGF-I,1534,O
administration,1534,O
(,1534,O
n,1534,O
=,1534,O
4,1534,O
),1534,O
did,1534,O
not,1534,O
alter,1534,O
weight,1534,O
gain,1534,O
",",1534,O
blood,1534,O
pressure,1534,O
",",1534,O
proteinuria,1534,B-Disease
",",1534,O
GFR,1534,O
",",1534,O
glomerular,1534,O
planar,1534,O
area,1534,O
",",1534,O
renal,1534,O
cortical,1534,O
malondialdehyde,1534,B-Chemical
content,1534,O
",",1534,O
or,1534,O
glomerular,1534,O
or,1534,O
tubulointerstitial,1534,B-Disease
damage,1534,I-Disease
",",1534,O
compared,1534,O
with,1534,O
untreated,1534,O
animals,1534,O
(,1534,O
n,1534,O
=,1534,O
4,1534,O
),1534,O
.,1534,O
rhIGF-I,1535,O
treatment,1535,O
reduced,1535,O
the,1535,O
steady,1535,O
state,1535,O
renal,1535,O
IGF-I,1535,O
mRNA,1535,O
level,1535,O
but,1535,O
did,1535,O
not,1535,O
modify,1535,O
gene,1535,O
expression,1535,O
of,1535,O
the,1535,O
IGF-I,1535,O
or,1535,O
GH,1535,O
receptors,1535,O
.,1535,O
We,1536,O
conclude,1536,O
that,1536,O
:,1536,O
1,1536,O
),1536,O
administration,1536,O
of,1536,O
rhIGF-I,1536,O
improves,1536,O
growth,1536,O
and,1536,O
GFR,1536,O
in,1536,O
rats,1536,O
with,1536,O
chronic,1536,O
PAN,1536,B-Chemical
nephropathy,1536,B-Disease
and,1536,O
2,1536,O
),1536,O
unlike,1536,O
rhGH,1536,O
",",1536,O
long-term,1536,O
use,1536,O
of,1536,O
rhIGF-I,1536,O
does,1536,O
not,1536,O
worsen,1536,O
renal,1536,O
functional,1536,O
and,1536,O
structural,1536,O
injury,1536,O
in,1536,O
this,1536,O
disease,1536,O
model,1536,O
.,1536,O
Nefiracetam,1537,B-Chemical
(,1537,O
DM-9384,1537,B-Chemical
),1537,O
reverses,1537,O
apomorphine-induced,1537,B-Chemical
amnesia,1537,B-Disease
of,1537,O
a,1537,O
passive,1537,O
avoidance,1537,O
response,1537,O
:,1537,O
delayed,1537,O
emergence,1537,O
of,1537,O
the,1537,O
memory,1537,O
retention,1537,O
effects,1537,O
.,1537,O
Nefiracetam,1538,B-Chemical
is,1538,O
a,1538,O
novel,1538,O
pyrrolidone,1538,B-Chemical
derivative,1538,O
which,1538,O
attenuates,1538,O
scopolamine-induced,1538,B-Chemical
learning,1538,B-Disease
and,1538,I-Disease
post-training,1538,I-Disease
consolidation,1538,I-Disease
deficits,1538,I-Disease
.,1538,O
Given,1539,O
that,1539,O
apomorphine,1539,B-Chemical
inhibits,1539,O
passive,1539,O
avoidance,1539,O
retention,1539,O
when,1539,O
given,1539,O
during,1539,O
training,1539,O
or,1539,O
in,1539,O
a,1539,O
defined,1539,O
10-12h,1539,O
post-training,1539,O
period,1539,O
",",1539,O
we,1539,O
evaluated,1539,O
the,1539,O
ability,1539,O
of,1539,O
nefiracetam,1539,B-Chemical
to,1539,O
attenuate,1539,O
amnesia,1539,B-Disease
induced,1539,O
by,1539,O
dopaminergic,1539,O
agonism,1539,O
.,1539,O
A,1540,O
step-down,1540,O
passive,1540,O
avoidance,1540,O
paradigm,1540,O
was,1540,O
employed,1540,O
and,1540,O
nefiracetam,1540,B-Chemical
(,1540,O
3,1540,O
mg/kg,1540,O
),1540,O
and,1540,O
apomorphine,1540,B-Chemical
(,1540,O
0.5,1540,O
mg/kg,1540,O
),1540,O
were,1540,O
given,1540,O
alone,1540,O
or,1540,O
in,1540,O
combination,1540,O
during,1540,O
training,1540,O
and,1540,O
at,1540,O
the,1540,O
10-12h,1540,O
post-training,1540,O
period,1540,O
of,1540,O
consolidation,1540,O
.,1540,O
Co-administration,1541,O
of,1541,O
nefiracetam,1541,B-Chemical
and,1541,O
apomorphine,1541,B-Chemical
during,1541,O
training,1541,O
or,1541,O
10h,1541,O
thereafter,1541,O
produced,1541,O
no,1541,O
significant,1541,O
anti-amnesic,1541,O
effect,1541,O
.,1541,O
However,1542,O
",",1542,O
administration,1542,O
of,1542,O
nefiracetam,1542,B-Chemical
during,1542,O
training,1542,O
completely,1542,O
reversed,1542,O
the,1542,O
amnesia,1542,B-Disease
induced,1542,O
by,1542,O
apomorphine,1542,B-Chemical
at,1542,O
the,1542,O
10h,1542,O
post-training,1542,O
time,1542,O
and,1542,O
the,1542,O
converse,1542,O
was,1542,O
also,1542,O
true,1542,O
.,1542,O
These,1543,O
effects,1543,O
were,1543,O
not,1543,O
mediated,1543,O
by,1543,O
a,1543,O
dopaminergic,1543,O
mechanism,1543,O
as,1543,O
nefiracetam,1543,B-Chemical
",",1543,O
at,1543,O
millimolar,1543,O
concentrations,1543,O
",",1543,O
failed,1543,O
to,1543,O
displace,1543,O
either,1543,O
[,1543,O
3H,1543,O
],1543,O
SCH,1543,B-Chemical
23390,1543,I-Chemical
or,1543,O
[,1543,O
3H,1543,O
],1543,O
spiperone,1543,B-Chemical
binding,1543,O
from,1543,O
D1,1543,O
or,1543,O
D2,1543,O
dopamine,1543,B-Chemical
receptor,1543,O
subtypes,1543,O
",",1543,O
respectively,1543,O
.,1543,O
It,1544,O
is,1544,O
suggested,1544,O
that,1544,O
nefiracetam,1544,B-Chemical
augments,1544,O
molecular,1544,O
processes,1544,O
in,1544,O
the,1544,O
early,1544,O
stages,1544,O
of,1544,O
events,1544,O
which,1544,O
ultimately,1544,O
lead,1544,O
to,1544,O
consolidation,1544,O
of,1544,O
memory,1544,O
.,1544,O
Human,1545,O
corticotropin-releasing,1545,B-Chemical
hormone,1545,O
and,1545,O
thyrotropin-releasing,1545,B-Chemical
hormone,1545,O
modulate,1545,O
the,1545,O
hypercapnic,1545,B-Disease
ventilatory,1545,O
response,1545,O
in,1545,O
humans,1545,O
.,1545,O
Human,1546,O
corticotropin-releasing,1546,B-Chemical
hormone,1546,O
(,1546,O
hCRH,1546,O
),1546,O
and,1546,O
thyrotropin-releasing,1546,B-Chemical
hormone,1546,O
(,1546,O
TRH,1546,O
),1546,O
are,1546,O
known,1546,O
to,1546,O
stimulate,1546,O
ventilation,1546,O
after,1546,O
i.v,1546,O
.,1546,O
administration,1547,O
in,1547,O
humans,1547,O
.,1547,O
In,1548,O
a,1548,O
placebo-controlled,1548,O
",",1548,O
single-blind,1548,O
study,1548,O
we,1548,O
aimed,1548,O
to,1548,O
clarify,1548,O
if,1548,O
both,1548,O
peptides,1548,O
act,1548,O
by,1548,O
altering,1548,O
central,1548,O
chemosensitivity,1548,O
.,1548,O
Two,1549,O
subsequent,1549,O
CO2-rebreathing,1549,B-Chemical
tests,1549,O
were,1549,O
performed,1549,O
in,1549,O
healthy,1549,O
young,1549,O
volunteers,1549,O
.,1549,O
During,1550,O
the,1550,O
first,1550,O
test,1550,O
0.9,1550,O
%,1550,O
NaCl,1550,B-Chemical
was,1550,O
given,1550,O
i.v,1550,O
.,1550,O
;,1551,O
during,1551,O
the,1551,O
second,1551,O
test,1551,O
200,1551,O
micrograms,1551,O
of,1551,O
hCRH,1551,O
(,1551,O
n,1551,O
=,1551,O
12,1551,O
),1551,O
or,1551,O
400,1551,O
micrograms,1551,O
of,1551,O
TRH,1551,O
(,1551,O
n,1551,O
=,1551,O
6,1551,O
),1551,O
was,1551,O
administered,1551,O
i.v,1551,O
.,1551,O
Nine,1552,O
subjects,1552,O
received,1552,O
0.9,1552,O
%,1552,O
NaCl,1552,O
i.v,1552,O
.,1552,O
during,1553,O
both,1553,O
rebreathing,1553,O
manoeuvres,1553,O
.,1553,O
The,1554,O
CO2-response,1554,O
curves,1554,O
for,1554,O
the,1554,O
two,1554,O
tests,1554,O
were,1554,O
compared,1554,O
within,1554,O
the,1554,O
same,1554,O
subject,1554,O
.,1554,O
In,1555,O
the,1555,O
hCRH,1555,O
group,1555,O
a,1555,O
marked,1555,O
parallel,1555,O
shift,1555,O
of,1555,O
the,1555,O
CO2-response,1555,O
curve,1555,O
to,1555,O
the,1555,O
left,1555,O
was,1555,O
observed,1555,O
after,1555,O
hCRH,1555,O
(,1555,O
P,1555,O
<,1555,O
0.01,1555,O
),1555,O
.,1555,O
The,1556,O
same,1556,O
effect,1556,O
occurred,1556,O
following,1556,O
TRH,1556,O
but,1556,O
was,1556,O
less,1556,O
striking,1556,O
(,1556,O
P,1556,O
=,1556,O
0.05,1556,O
),1556,O
.,1556,O
hCRH,1557,O
and,1557,O
TRH,1557,O
caused,1557,O
a,1557,O
reduction,1557,O
in,1557,O
the,1557,O
CO2,1557,O
threshold,1557,O
.,1557,O
The,1558,O
CO2-response,1558,O
curves,1558,O
in,1558,O
the,1558,O
control,1558,O
group,1558,O
were,1558,O
nearly,1558,O
identical,1558,O
.,1558,O
The,1559,O
results,1559,O
indicate,1559,O
an,1559,O
additive,1559,O
effect,1559,O
of,1559,O
both,1559,O
releasing,1559,O
hormones,1559,O
on,1559,O
the,1559,O
hypercapnic,1559,O
ventilatory,1559,O
response,1559,O
in,1559,O
humans,1559,O
",",1559,O
presumably,1559,O
independent,1559,O
of,1559,O
central,1559,O
chemosensitivity,1559,O
.,1559,O
Lamivudine,1560,B-Chemical
is,1560,O
effective,1560,O
in,1560,O
suppressing,1560,O
hepatitis,1560,B-Disease
B,1560,I-Disease
virus,1560,O
DNA,1560,O
in,1560,O
Chinese,1560,O
hepatitis,1560,B-Chemical
B,1560,I-Chemical
surface,1560,I-Chemical
antigen,1560,I-Chemical
carriers,1560,O
:,1560,O
a,1560,O
placebo-controlled,1560,O
trial,1560,O
.,1560,O
Lamivudine,1561,B-Chemical
is,1561,O
a,1561,O
novel,1561,O
"2',3'-dideoxy",1561,B-Chemical
cytosine,1561,I-Chemical
analogue,1561,O
that,1561,O
has,1561,O
potent,1561,O
inhibitory,1561,O
effects,1561,O
on,1561,O
hepatitis,1561,B-Disease
B,1561,I-Disease
virus,1561,O
replication,1561,O
in,1561,O
vitro,1561,O
and,1561,O
in,1561,O
vivo,1561,O
.,1561,O
We,1562,O
performed,1562,O
a,1562,O
single-blind,1562,O
",",1562,O
placebo-controlled,1562,O
study,1562,O
to,1562,O
assess,1562,O
its,1562,O
effectiveness,1562,O
and,1562,O
safety,1562,O
in,1562,O
Chinese,1562,O
hepatitis,1562,B-Chemical
B,1562,I-Chemical
surface,1562,I-Chemical
antigen,1562,I-Chemical
(,1562,O
HBsAg,1562,B-Chemical
),1562,O
carriers,1562,O
.,1562,O
Forty-two,1563,O
Chinese,1563,O
HBsAg,1563,B-Chemical
carriers,1563,O
were,1563,O
randomized,1563,O
to,1563,O
receive,1563,O
placebo,1563,O
(,1563,O
6,1563,O
patients,1563,O
),1563,O
or,1563,O
lamivudine,1563,B-Chemical
orally,1563,O
in,1563,O
dosages,1563,O
of,1563,O
25,1563,O
mg,1563,O
",",1563,O
100,1563,O
mg,1563,O
",",1563,O
or,1563,O
300,1563,O
mg,1563,O
daily,1563,O
(,1563,O
12,1563,O
patients,1563,O
for,1563,O
each,1563,O
dosage,1563,O
),1563,O
.,1563,O
The,1564,O
drug,1564,O
was,1564,O
given,1564,O
for,1564,O
4,1564,O
weeks,1564,O
.,1564,O
The,1565,O
patients,1565,O
were,1565,O
closely,1565,O
monitored,1565,O
clinically,1565,O
",",1565,O
biochemically,1565,O
",",1565,O
and,1565,O
serologically,1565,O
up,1565,O
to,1565,O
4,1565,O
weeks,1565,O
after,1565,O
drug,1565,O
treatment,1565,O
.,1565,O
All,1566,O
36,1566,O
patients,1566,O
receiving,1566,O
lamivudine,1566,B-Chemical
had,1566,O
a,1566,O
decrease,1566,O
in,1566,O
hepatitis,1566,B-Disease
B,1566,I-Disease
virus,1566,O
(,1566,O
HBV,1566,O
),1566,O
DNA,1566,O
values,1566,O
of,1566,O
>,1566,O
90,1566,O
%,1566,O
(,1566,O
P,1566,O
<,1566,O
.001,1566,O
compared,1566,O
with,1566,O
placebo,1566,O
),1566,O
.,1566,O
Although,1567,O
25,1567,O
mg,1567,O
of,1567,O
lamivudine,1567,B-Chemical
was,1567,O
slightly,1567,O
less,1567,O
effective,1567,O
than,1567,O
100,1567,O
mg,1567,O
(,1567,O
P,1567,O
=,1567,O
.011,1567,O
),1567,O
and,1567,O
300,1567,O
mg,1567,O
(,1567,O
P,1567,O
=,1567,O
.005,1567,O
),1567,O
",",1567,O
it,1567,O
still,1567,O
induced,1567,O
94,1567,O
%,1567,O
suppression,1567,O
of,1567,O
HBV,1567,O
DNA,1567,O
after,1567,O
the,1567,O
fourth,1567,O
week,1567,O
of,1567,O
therapy,1567,O
.,1567,O
HBV,1568,O
DNA,1568,O
values,1568,O
returned,1568,O
to,1568,O
pretreatment,1568,O
levels,1568,O
within,1568,O
4,1568,O
weeks,1568,O
of,1568,O
cessation,1568,O
of,1568,O
therapy,1568,O
.,1568,O
There,1569,O
was,1569,O
no,1569,O
change,1569,O
in,1569,O
the,1569,O
hepatitis,1569,B-Disease
B,1569,I-Disease
e,1569,O
antigen,1569,O
status,1569,O
or,1569,O
in,1569,O
aminotransferase,1569,O
levels,1569,O
.,1569,O
No,1570,O
serious,1570,O
adverse,1570,O
events,1570,O
were,1570,O
observed,1570,O
.,1570,O
In,1571,O
conclusion,1571,O
",",1571,O
a,1571,O
4-week,1571,O
course,1571,O
of,1571,O
lamivudine,1571,B-Chemical
was,1571,O
safe,1571,O
and,1571,O
effective,1571,O
in,1571,O
suppression,1571,O
of,1571,O
HBV,1571,O
DNA,1571,O
in,1571,O
Chinese,1571,O
HBsAg,1571,B-Chemical
carriers,1571,O
.,1571,O
The,1572,O
suppression,1572,O
was,1572,O
>,1572,O
90,1572,O
%,1572,O
but,1572,O
reversible,1572,O
.,1572,O
Studies,1573,O
with,1573,O
long-term,1573,O
lamivudine,1573,B-Chemical
administration,1573,O
should,1573,O
be,1573,O
performed,1573,O
to,1573,O
determine,1573,O
if,1573,O
prolonged,1573,O
suppression,1573,O
of,1573,O
HBV,1573,O
DNA,1573,O
can,1573,O
be,1573,O
achieved,1573,O
.,1573,O
Population-based,1574,O
study,1574,O
of,1574,O
risk,1574,O
of,1574,O
venous,1574,B-Disease
thromboembolism,1574,I-Disease
associated,1574,O
with,1574,O
various,1574,O
oral,1574,B-Chemical
contraceptives,1574,I-Chemical
.,1574,O
BACKGROUND,1575,O
:,1575,O
Four,1575,O
studies,1575,O
published,1575,O
since,1575,O
December,1575,O
",",1575,O
1995,1575,O
",",1575,O
reported,1575,O
that,1575,O
the,1575,O
incidence,1575,O
of,1575,O
venous,1575,B-Disease
thromboembolism,1575,I-Disease
(,1575,O
VTE,1575,B-Disease
),1575,O
was,1575,O
higher,1575,O
in,1575,O
women,1575,O
who,1575,O
used,1575,O
oral,1575,B-Chemical
contraceptives,1575,I-Chemical
(,1575,O
OCs,1575,B-Chemical
),1575,O
containing,1575,O
the,1575,O
third-generation,1575,O
progestagens,1575,B-Chemical
gestodene,1575,B-Chemical
or,1575,O
desogestrel,1575,B-Chemical
than,1575,O
in,1575,O
users,1575,O
of,1575,O
OCs,1575,B-Chemical
containing,1575,O
second-generation,1575,O
progestagens,1575,B-Chemical
.,1575,O
However,1576,O
",",1576,O
confounding,1576,O
and,1576,O
bias,1576,O
in,1576,O
the,1576,O
design,1576,O
of,1576,O
these,1576,O
studies,1576,O
may,1576,O
have,1576,O
affected,1576,O
the,1576,O
findings,1576,O
.,1576,O
The,1577,O
aim,1577,O
of,1577,O
our,1577,O
study,1577,O
was,1577,O
to,1577,O
re-examine,1577,O
the,1577,O
association,1577,O
between,1577,O
risk,1577,O
of,1577,O
VTE,1577,B-Disease
and,1577,O
OC,1577,B-Chemical
use,1577,O
with,1577,O
a,1577,O
different,1577,O
study,1577,O
design,1577,O
and,1577,O
analysis,1577,O
to,1577,O
avoid,1577,O
some,1577,O
of,1577,O
the,1577,O
bias,1577,O
and,1577,O
confounding,1577,O
of,1577,O
the,1577,O
earlier,1577,O
studies,1577,O
.,1577,O
METHODS,1578,O
:,1578,O
We,1578,O
used,1578,O
computer,1578,O
records,1578,O
of,1578,O
patients,1578,O
from,1578,O
143,1578,O
general,1578,O
practices,1578,O
in,1578,O
the,1578,O
UK,1578,O
.,1578,O
The,1579,O
study,1579,O
was,1579,O
based,1579,O
on,1579,O
the,1579,O
medical,1579,O
records,1579,O
of,1579,O
about,1579,O
"540,000",1579,O
women,1579,O
born,1579,O
between,1579,O
1941,1579,O
and,1579,O
1981,1579,O
.,1579,O
All,1580,O
women,1580,O
who,1580,O
had,1580,O
a,1580,O
recorded,1580,O
diagnosis,1580,O
of,1580,O
deep-vein,1580,B-Disease
thrombosis,1580,I-Disease
",",1580,O
venous,1580,B-Disease
thrombosis,1580,I-Disease
not,1580,O
otherwise,1580,O
specified,1580,O
",",1580,O
or,1580,O
pulmonary,1580,O
embolus,1580,O
during,1580,O
the,1580,O
study,1580,O
period,1580,O
",",1580,O
and,1580,O
who,1580,O
had,1580,O
been,1580,O
treated,1580,O
with,1580,O
an,1580,O
anticoagulant,1580,O
were,1580,O
identified,1580,O
as,1580,O
potential,1580,O
cases,1580,O
of,1580,O
VTE,1580,B-Disease
.,1580,O
We,1581,O
did,1581,O
a,1581,O
cohort,1581,O
analysis,1581,O
to,1581,O
estimate,1581,O
and,1581,O
compare,1581,O
incidence,1581,O
of,1581,O
VTE,1581,B-Disease
in,1581,O
users,1581,O
of,1581,O
the,1581,O
main,1581,O
OC,1581,B-Chemical
preparations,1581,O
",",1581,O
and,1581,O
a,1581,O
nested,1581,O
case-control,1581,O
study,1581,O
to,1581,O
calculate,1581,O
the,1581,O
odds,1581,O
ratios,1581,O
of,1581,O
VTE,1581,B-Disease
associated,1581,O
with,1581,O
use,1581,O
of,1581,O
different,1581,O
types,1581,O
of,1581,O
OC,1581,B-Chemical
",",1581,O
after,1581,O
adjustment,1581,O
for,1581,O
potential,1581,O
confounding,1581,O
factors,1581,O
.,1581,O
In,1582,O
the,1582,O
case-control,1582,O
study,1582,O
",",1582,O
we,1582,O
matched,1582,O
cases,1582,O
to,1582,O
controls,1582,O
by,1582,O
exact,1582,O
year,1582,O
of,1582,O
birth,1582,O
",",1582,O
practice,1582,O
",",1582,O
and,1582,O
current,1582,O
use,1582,O
of,1582,O
OCs,1582,B-Chemical
.,1582,O
We,1583,O
used,1583,O
a,1583,O
multiple,1583,O
logistic,1583,O
regression,1583,O
model,1583,O
that,1583,O
included,1583,O
body-mass,1583,O
index,1583,O
",",1583,O
number,1583,O
of,1583,O
cycles,1583,O
",",1583,O
change,1583,O
in,1583,O
type,1583,O
of,1583,O
OC,1583,B-Chemical
prescribed,1583,O
within,1583,O
3,1583,O
months,1583,O
of,1583,O
the,1583,O
event,1583,O
",",1583,O
previous,1583,O
pregnancy,1583,O
",",1583,O
and,1583,O
concurrent,1583,O
disease,1583,O
.,1583,O
FINDINGS,1584,O
:,1584,O
85,1584,O
women,1584,O
met,1584,O
the,1584,O
inclusion,1584,O
criteria,1584,O
for,1584,O
VTE,1584,B-Disease
",",1584,O
two,1584,O
of,1584,O
whom,1584,O
were,1584,O
users,1584,O
of,1584,O
progestagen-only,1584,B-Chemical
OCs,1584,B-Chemical
.,1584,O
Of,1585,O
the,1585,O
83,1585,O
cases,1585,O
of,1585,O
VTE,1585,B-Disease
associated,1585,O
with,1585,O
use,1585,O
of,1585,O
combined,1585,O
OCs,1585,B-Chemical
",",1585,O
43,1585,O
were,1585,O
recorded,1585,O
as,1585,O
deep-vein,1585,B-Disease
thrombosis,1585,I-Disease
",",1585,O
35,1585,O
as,1585,O
pulmonary,1585,O
thrombosis,1585,B-Disease
",",1585,O
and,1585,O
five,1585,O
as,1585,O
venous,1585,B-Disease
thrombosis,1585,I-Disease
not,1585,O
otherwise,1585,O
specified,1585,O
.,1585,O
The,1586,O
crude,1586,O
rate,1586,O
of,1586,O
VTE,1586,B-Disease
per,1586,O
"10,000",1586,O
woman-years,1586,O
was,1586,O
4.10,1586,O
in,1586,O
current,1586,O
users,1586,O
of,1586,O
any,1586,O
OC,1586,B-Chemical
",",1586,O
3.10,1586,O
in,1586,O
users,1586,O
of,1586,O
second-generation,1586,O
OCs,1586,B-Chemical
",",1586,O
and,1586,O
4.96,1586,O
in,1586,O
users,1586,O
of,1586,O
third-generation,1586,O
preparations,1586,O
.,1586,O
After,1587,O
adjustment,1587,O
for,1587,O
age,1587,O
",",1587,O
the,1587,O
rate,1587,O
ratio,1587,O
of,1587,O
VTE,1587,B-Disease
in,1587,O
users,1587,O
of,1587,O
third-generation,1587,O
relative,1587,O
to,1587,O
second-generation,1587,O
OCs,1587,B-Chemical
was,1587,O
1.68,1587,O
(,1587,O
95,1587,O
%,1587,O
CI,1587,O
1.04-2.75,1587,O
),1587,O
.,1587,O
Logistic,1588,O
regression,1588,O
showed,1588,O
no,1588,O
significant,1588,O
difference,1588,O
in,1588,O
the,1588,O
risk,1588,O
of,1588,O
VTE,1588,B-Disease
between,1588,O
users,1588,O
of,1588,O
third-generation,1588,O
and,1588,O
second-generation,1588,O
OCs,1588,B-Chemical
.,1588,O
Among,1589,O
users,1589,O
of,1589,O
third-generation,1589,O
progestagens,1589,B-Chemical
",",1589,O
the,1589,O
risk,1589,O
of,1589,O
VTE,1589,B-Disease
was,1589,O
higher,1589,O
in,1589,O
users,1589,O
of,1589,O
desogestrel,1589,B-Chemical
with,1589,O
20,1589,O
g,1589,O
ethinyloestradiol,1589,B-Chemical
than,1589,O
in,1589,O
users,1589,O
of,1589,O
gestodene,1589,B-Chemical
or,1589,O
desogestrel,1589,B-Chemical
with,1589,O
30,1589,O
g,1589,O
ethinyloestradiol,1589,B-Chemical
.,1589,O
With,1590,O
all,1590,O
second-generation,1590,O
OCs,1590,B-Chemical
as,1590,O
the,1590,O
reference,1590,O
",",1590,O
the,1590,O
odds,1590,O
ratios,1590,O
for,1590,O
VTE,1590,B-Disease
were,1590,O
3.49,1590,O
(,1590,O
1.21-10.12,1590,O
),1590,O
for,1590,O
desogestrel,1590,B-Chemical
plus,1590,O
20,1590,O
g,1590,O
ethinyloestradiol,1590,B-Chemical
and,1590,O
1.18,1590,O
(,1590,O
0.66-2.17,1590,O
),1590,O
for,1590,O
the,1590,O
other,1590,O
third-generation,1590,O
progestagens,1590,B-Chemical
.,1590,O
INTERPRETATION,1591,O
:,1591,O
The,1591,O
previously,1591,O
reported,1591,O
increase,1591,O
in,1591,O
odds,1591,O
ratio,1591,O
associated,1591,O
with,1591,O
third-generation,1591,O
OCs,1591,B-Chemical
when,1591,O
compared,1591,O
with,1591,O
second-generation,1591,O
products,1591,O
is,1591,O
likely,1591,O
to,1591,O
have,1591,O
been,1591,O
the,1591,O
result,1591,O
of,1591,O
residual,1591,O
confounding,1591,O
by,1591,O
age,1591,O
.,1591,O
The,1592,O
increased,1592,O
odds,1592,O
ratio,1592,O
associated,1592,O
with,1592,O
products,1592,O
containing,1592,O
20,1592,O
micrograms,1592,O
ethinyloestradiol,1592,B-Chemical
and,1592,O
desogestrel,1592,B-Chemical
compared,1592,O
with,1592,O
the,1592,O
30,1592,O
micrograms,1592,O
product,1592,O
is,1592,O
biologically,1592,O
implausible,1592,O
",",1592,O
and,1592,O
is,1592,O
likely,1592,O
to,1592,O
be,1592,O
the,1592,O
result,1592,O
of,1592,O
preferential,1592,O
prescribing,1592,O
and,1592,O
",",1592,O
thus,1592,O
",",1592,O
confounding,1592,O
.,1592,O
MK-801,1593,B-Chemical
augments,1593,O
pilocarpine-induced,1593,B-Chemical
electrographic,1593,O
seizure,1593,B-Disease
but,1593,O
protects,1593,O
against,1593,O
brain,1593,B-Disease
damage,1593,I-Disease
in,1593,O
rats,1593,O
.,1593,O
1,1594,O
.,1594,O
The,1595,O
authors,1595,O
examined,1595,O
the,1595,O
anticonvulsant,1595,O
effects,1595,O
of,1595,O
MK-801,1595,B-Chemical
on,1595,O
the,1595,O
pilocarpine-induced,1595,B-Chemical
seizure,1595,B-Disease
model,1595,O
.,1595,O
Intraperitoneal,1596,O
injection,1596,O
of,1596,O
pilocarpine,1596,B-Chemical
(,1596,O
400,1596,O
mg/kg,1596,O
),1596,O
induced,1596,O
tonic,1596,B-Disease
and,1596,I-Disease
clonic,1596,I-Disease
seizure,1596,I-Disease
.,1596,O
Scopolamine,1597,B-Chemical
(,1597,O
10,1597,O
mg/kg,1597,O
),1597,O
and,1597,O
pentobarbital,1597,B-Chemical
(,1597,O
5,1597,O
mg/kg,1597,O
),1597,O
prevented,1597,O
development,1597,O
of,1597,O
pilocarpine-induced,1597,B-Chemical
behavioral,1597,O
seizure,1597,B-Disease
but,1597,O
MK-801,1597,B-Chemical
(,1597,O
0.5,1597,O
mg/kg,1597,O
),1597,O
did,1597,O
not,1597,O
.,1597,O
2,1598,O
.,1598,O
An,1599,O
electrical,1599,O
seizure,1599,B-Disease
measured,1599,O
with,1599,O
hippocampal,1599,O
EEG,1599,O
appeared,1599,O
in,1599,O
the,1599,O
pilocarpine-treated,1599,B-Chemical
group,1599,O
.,1599,O
Scopolamine,1600,B-Chemical
and,1600,O
pentobarbital,1600,B-Chemical
blocked,1600,O
the,1600,O
pilocarpine-induced,1600,B-Chemical
electrographic,1600,O
seizure,1600,B-Disease
",",1600,O
MK-801,1600,B-Chemical
treatment,1600,O
augmented,1600,O
the,1600,O
electrographic,1600,O
seizure,1600,B-Disease
induced,1600,O
by,1600,O
pilocarpine,1600,B-Chemical
.,1600,O
3,1601,O
.,1601,O
Brain,1602,B-Disease
damage,1602,I-Disease
was,1602,O
assessed,1602,O
by,1602,O
examining,1602,O
the,1602,O
hippocampus,1602,O
microscopically,1602,O
.,1602,O
Pilocarpine,1603,B-Chemical
produced,1603,O
neuronal,1603,B-Disease
death,1603,I-Disease
in,1603,O
the,1603,O
hippocampus,1603,O
",",1603,O
which,1603,O
showed,1603,O
pyknotic,1603,O
changes,1603,O
.,1603,O
Pentobarbital,1604,B-Chemical
",",1604,O
scopolamine,1604,B-Chemical
and,1604,O
MK-801,1604,B-Chemical
protected,1604,O
the,1604,O
brain,1604,B-Disease
damage,1604,I-Disease
by,1604,O
pilocarpine,1604,B-Chemical
",",1604,O
though,1604,O
in,1604,O
the,1604,O
MK-801-treated,1604,B-Chemical
group,1604,O
",",1604,O
the,1604,O
pyramidal,1604,O
cells,1604,O
of,1604,O
hippocampus,1604,O
appeared,1604,O
darker,1604,O
than,1604,O
normal,1604,O
.,1604,O
In,1605,O
all,1605,O
treatments,1605,O
",",1605,O
granule,1605,O
cells,1605,O
of,1605,O
the,1605,O
dentate,1605,O
gyrus,1605,O
were,1605,O
not,1605,O
affected,1605,O
.,1605,O
4,1606,O
.,1606,O
These,1607,O
results,1607,O
indicate,1607,O
that,1607,O
status,1607,B-Disease
epilepticus,1607,I-Disease
induced,1607,O
by,1607,O
pilocarpine,1607,B-Chemical
is,1607,O
initiated,1607,O
by,1607,O
cholinergic,1607,O
overstimulation,1607,O
and,1607,O
propagated,1607,O
by,1607,O
glutamatergic,1607,O
transmission,1607,O
",",1607,O
the,1607,O
elevation,1607,O
of,1607,O
which,1607,O
may,1607,O
cause,1607,O
brain,1607,B-Disease
damage,1607,I-Disease
through,1607,O
an,1607,O
excitatory,1607,O
NMDA,1607,B-Chemical
receptor-mediated,1607,O
mechanism,1607,O
.,1607,O
Paclitaxel,1608,B-Chemical
",",1608,O
5-fluorouracil,1608,B-Chemical
",",1608,O
and,1608,O
folinic,1608,B-Chemical
acid,1608,I-Chemical
in,1608,O
metastatic,1608,O
breast,1608,B-Disease
cancer,1608,I-Disease
:,1608,O
BRE-26,1608,O
",",1608,O
a,1608,O
phase,1608,O
II,1608,O
trial,1608,O
.,1608,O
5-Fluorouracil,1609,B-Chemical
plus,1609,O
folinic,1609,B-Chemical
acid,1609,I-Chemical
and,1609,O
paclitaxel,1609,B-Chemical
(,1609,O
Taxol,1609,B-Chemical
;,1609,O
Bristol-Myers,1609,O
Squibb,1609,O
Company,1609,O
",",1609,O
Princeton,1609,O
",",1609,O
NJ,1609,O
),1609,O
are,1609,O
effective,1609,O
salvage,1609,O
therapies,1609,O
for,1609,O
metastatic,1609,O
breast,1609,B-Disease
cancer,1609,I-Disease
patients,1609,O
.,1609,O
Paclitaxel,1610,B-Chemical
and,1610,O
5-fluorouracil,1610,B-Chemical
have,1610,O
additive,1610,O
cytotoxicity,1610,B-Disease
in,1610,O
MCF-7,1610,O
cell,1610,O
lines,1610,O
.,1610,O
We,1611,O
performed,1611,O
a,1611,O
phase,1611,O
II,1611,O
trial,1611,O
of,1611,O
paclitaxel,1611,B-Chemical
175,1611,O
mg/m2,1611,O
over,1611,O
3,1611,O
hours,1611,O
on,1611,O
day,1611,O
I,1611,O
followed,1611,O
by,1611,O
folinic,1611,B-Chemical
acid,1611,I-Chemical
300,1611,O
mg,1611,O
over,1611,O
1,1611,O
hour,1611,O
before,1611,O
5-fluorouracil,1611,B-Chemical
350,1611,O
mg/m2,1611,O
on,1611,O
days,1611,O
1,1611,O
to,1611,O
3,1611,O
every,1611,O
28,1611,O
days,1611,O
(,1611,O
TFL,1611,O
),1611,O
in,1611,O
women,1611,O
with,1611,O
metastatic,1611,O
breast,1611,B-Disease
cancer,1611,I-Disease
.,1611,O
Analysis,1612,O
is,1612,O
reported,1612,O
on,1612,O
37,1612,O
patients,1612,O
with,1612,O
a,1612,O
minimum,1612,O
of,1612,O
6,1612,O
months,1612,O
follow-up,1612,O
who,1612,O
received,1612,O
a,1612,O
total,1612,O
of,1612,O
192,1612,O
cycles,1612,O
of,1612,O
TFL,1612,O
:,1612,O
nine,1612,O
cycles,1612,O
(,1612,O
5,1612,O
%,1612,O
),1612,O
were,1612,O
associated,1612,O
with,1612,O
grade,1612,O
3/4,1612,O
neutropenia,1612,B-Disease
requiring,1612,O
hospitalization,1612,O
;,1612,O
seven,1612,O
(,1612,O
4,1612,O
%,1612,O
),1612,O
cycles,1612,O
in,1612,O
two,1612,O
patients,1612,O
required,1612,O
granulocyte,1612,B-Chemical
colony-stimulating,1612,I-Chemical
factor,1612,I-Chemical
due,1612,O
to,1612,O
neutropenia,1612,B-Disease
;,1612,O
no,1612,O
patient,1612,O
required,1612,O
platelet,1612,O
transfusions,1612,O
.,1612,O
Grade,1613,O
3/4,1613,O
nonhematologic,1613,O
toxicities,1613,B-Disease
were,1613,O
uncommon,1613,O
.,1613,O
Among,1614,O
the,1614,O
34,1614,O
patients,1614,O
evaluable,1614,O
for,1614,O
response,1614,O
",",1614,O
there,1614,O
were,1614,O
three,1614,O
complete,1614,O
responses,1614,O
(,1614,O
9,1614,O
%,1614,O
),1614,O
and,1614,O
18,1614,O
partial,1614,O
responses,1614,O
(,1614,O
53,1614,O
%,1614,O
),1614,O
for,1614,O
an,1614,O
overall,1614,O
response,1614,O
rate,1614,O
of,1614,O
62,1614,O
%,1614,O
.,1614,O
Of,1615,O
the,1615,O
19,1615,O
evaluable,1615,O
patients,1615,O
with,1615,O
prior,1615,O
doxorubicin,1615,B-Chemical
exposure,1615,O
",",1615,O
11,1615,O
(,1615,O
58,1615,O
%,1615,O
),1615,O
responded,1615,O
compared,1615,O
with,1615,O
nine,1615,O
of,1615,O
15,1615,O
(,1615,O
60,1615,O
%,1615,O
),1615,O
without,1615,O
prior,1615,O
doxorubicin,1615,B-Chemical
.,1615,O
Plasma,1616,O
paclitaxel,1616,B-Chemical
concentrations,1616,O
were,1616,O
measured,1616,O
at,1616,O
the,1616,O
completion,1616,O
of,1616,O
paclitaxel,1616,B-Chemical
infusion,1616,O
and,1616,O
at,1616,O
24,1616,O
hours,1616,O
in,1616,O
19,1616,O
patients,1616,O
.,1616,O
TFL,1617,O
is,1617,O
an,1617,O
active,1617,O
",",1617,O
well-tolerated,1617,O
regimen,1617,O
in,1617,O
metastatic,1617,O
breast,1617,B-Disease
cancer,1617,I-Disease
.,1617,O
Efficacy,1618,O
and,1618,O
proarrhythmia,1618,B-Disease
with,1618,O
the,1618,O
use,1618,O
of,1618,O
d,1618,B-Chemical
",",1618,I-Chemical
l-sotalol,1618,I-Chemical
for,1618,O
sustained,1618,O
ventricular,1618,B-Disease
tachyarrhythmias,1618,I-Disease
.,1618,O
This,1619,O
study,1619,O
prospectively,1619,O
evaluated,1619,O
the,1619,O
clinical,1619,O
efficacy,1619,O
",",1619,O
the,1619,O
incidence,1619,O
of,1619,O
torsades,1619,B-Disease
de,1619,I-Disease
pointes,1619,I-Disease
",",1619,O
and,1619,O
the,1619,O
presumable,1619,O
risk,1619,O
factors,1619,O
for,1619,O
torsades,1619,B-Disease
de,1619,I-Disease
pointes,1619,I-Disease
in,1619,O
patients,1619,O
treated,1619,O
with,1619,O
d,1619,B-Chemical
",",1619,I-Chemical
l-sotalol,1619,I-Chemical
for,1619,O
sustained,1619,O
ventricular,1619,B-Disease
tachyarrhythmias,1619,I-Disease
.,1619,O
Eighty-one,1620,O
consecutive,1620,O
patients,1620,O
(,1620,O
54,1620,O
with,1620,O
coronary,1620,B-Disease
artery,1620,I-Disease
disease,1620,I-Disease
",",1620,O
and,1620,O
20,1620,O
with,1620,O
dilated,1620,B-Disease
cardiomyopathy,1620,I-Disease
),1620,O
with,1620,O
inducible,1620,O
sustained,1620,O
ventricular,1620,B-Disease
tachycardia,1620,I-Disease
or,1620,O
ventricular,1620,B-Disease
fibrillation,1620,I-Disease
received,1620,O
oral,1620,O
d,1620,B-Chemical
",",1620,I-Chemical
l-sotalol,1620,I-Chemical
to,1620,O
prevent,1620,O
induction,1620,O
of,1620,O
the,1620,O
ventricular,1620,B-Disease
tachyarrhythmia,1620,I-Disease
.,1620,O
During,1621,O
oral,1621,O
loading,1621,O
with,1621,O
d,1621,B-Chemical
",",1621,I-Chemical
l-sotalol,1621,I-Chemical
",",1621,O
continuous,1621,O
electrocardiographic,1621,O
(,1621,O
ECG,1621,O
),1621,O
monitoring,1621,O
was,1621,O
performed,1621,O
.,1621,O
Those,1622,O
patients,1622,O
in,1622,O
whom,1622,O
d,1622,B-Chemical
",",1622,I-Chemical
l-sotalol,1622,I-Chemical
prevented,1622,O
induction,1622,O
of,1622,O
ventricular,1622,B-Disease
tachycardia,1622,I-Disease
or,1622,O
ventricular,1622,B-Disease
fibrillation,1622,I-Disease
were,1622,O
discharged,1622,O
with,1622,O
the,1622,O
drug,1622,O
and,1622,O
followed,1622,O
up,1622,O
on,1622,O
an,1622,O
outpatient,1622,O
basis,1622,O
for,1622,O
21,1622,O
+/-,1622,O
18,1622,O
months,1622,O
.,1622,O
Induction,1623,O
of,1623,O
the,1623,O
ventricular,1623,B-Disease
tachyarrhythmia,1623,I-Disease
was,1623,O
prevented,1623,O
by,1623,O
oral,1623,O
d,1623,B-Chemical
",",1623,I-Chemical
l-sotalol,1623,I-Chemical
in,1623,O
35,1623,O
(,1623,O
43,1623,O
%,1623,O
),1623,O
patients,1623,O
;,1623,O
the,1623,O
ventricular,1623,B-Disease
tachyarrhythmia,1623,I-Disease
remained,1623,O
inducible,1623,O
in,1623,O
40,1623,O
(,1623,O
49,1623,O
%,1623,O
),1623,O
patients,1623,O
;,1623,O
and,1623,O
two,1623,O
(,1623,O
2.5,1623,O
%,1623,O
),1623,O
patients,1623,O
did,1623,O
not,1623,O
tolerate,1623,O
even,1623,O
40,1623,O
mg,1623,O
of,1623,O
d,1623,B-Chemical
",",1623,I-Chemical
l-sotalol,1623,I-Chemical
once,1623,O
daily,1623,O
.,1623,O
Four,1624,O
(,1624,O
5,1624,O
%,1624,O
),1624,O
patients,1624,O
had,1624,O
from,1624,O
torsades,1624,B-Disease
de,1624,I-Disease
pointes,1624,I-Disease
during,1624,O
the,1624,O
initial,1624,O
oral,1624,O
treatment,1624,O
with,1624,O
d,1624,B-Chemical
",",1624,I-Chemical
l-sotalol,1624,I-Chemical
.,1624,O
Neither,1625,O
ECG,1625,O
[,1625,O
sinus-cycle,1625,O
length,1625,O
(,1625,O
SCL,1625,O
),1625,O
",",1625,O
QT,1625,O
or,1625,O
QTc,1625,O
interval,1625,O
",",1625,O
or,1625,O
U,1625,O
wave,1625,O
],1625,O
nor,1625,O
clinical,1625,O
parameters,1625,O
identified,1625,O
patients,1625,O
at,1625,O
risk,1625,O
for,1625,O
torsades,1625,B-Disease
de,1625,I-Disease
pointes,1625,I-Disease
.,1625,O
However,1626,O
",",1626,O
the,1626,O
oral,1626,O
dose,1626,O
of,1626,O
d,1626,B-Chemical
",",1626,I-Chemical
l-sotalol,1626,I-Chemical
was,1626,O
significantly,1626,O
lower,1626,O
in,1626,O
patients,1626,O
with,1626,O
torsades,1626,B-Disease
de,1626,I-Disease
pointes,1626,I-Disease
(,1626,O
200,1626,O
+/-,1626,O
46,1626,O
vs.,1626,O
328,1626,O
+/-,1626,O
53,1626,O
mg/day,1626,O
;,1626,O
p,1626,O
=,1626,O
0.0017,1626,O
),1626,O
.,1626,O
Risk,1627,O
factors,1627,O
associated,1627,O
with,1627,O
the,1627,O
development,1627,O
of,1627,O
torsades,1627,B-Disease
de,1627,I-Disease
pointes,1627,I-Disease
were,1627,O
the,1627,O
appearance,1627,O
of,1627,O
an,1627,O
U,1627,O
wave,1627,O
(,1627,O
p,1627,O
=,1627,O
0.049,1627,O
),1627,O
",",1627,O
female,1627,O
gender,1627,O
(,1627,O
p,1627,O
=,1627,O
0.015,1627,O
),1627,O
",",1627,O
and,1627,O
significant,1627,O
dose-corrected,1627,O
changes,1627,O
of,1627,O
SCL,1627,O
",",1627,O
QT,1627,O
interval,1627,O
",",1627,O
and,1627,O
QTc,1627,O
interval,1627,O
(,1627,O
p,1627,O
<,1627,O
0.05,1627,O
),1627,O
.,1627,O
During,1628,O
follow-up,1628,O
",",1628,O
seven,1628,O
(,1628,O
20,1628,O
%,1628,O
),1628,O
patients,1628,O
had,1628,O
a,1628,O
nonfatal,1628,O
ventricular,1628,B-Disease
tachycardia,1628,I-Disease
recurrence,1628,O
",",1628,O
and,1628,O
two,1628,O
(,1628,O
6,1628,O
%,1628,O
),1628,O
patients,1628,O
died,1628,O
suddenly,1628,O
.,1628,O
One,1629,O
female,1629,O
patient,1629,O
with,1629,O
stable,1629,O
cardiac,1629,B-Disease
disease,1629,I-Disease
had,1629,O
recurrent,1629,O
torsades,1629,B-Disease
de,1629,I-Disease
pointes,1629,I-Disease
after,1629,O
2,1629,O
years,1629,O
of,1629,O
successful,1629,O
treatment,1629,O
with,1629,O
d,1629,B-Chemical
",",1629,I-Chemical
l-sotalol,1629,I-Chemical
.,1629,O
Torsades,1630,B-Disease
de,1630,I-Disease
pointes,1630,I-Disease
occurred,1630,O
early,1630,O
during,1630,O
treatment,1630,O
even,1630,O
with,1630,O
low,1630,O
doses,1630,O
of,1630,O
oral,1630,O
d,1630,B-Chemical
",",1630,I-Chemical
l-sotalol,1630,I-Chemical
.,1630,O
Pronounced,1631,O
changes,1631,O
in,1631,O
the,1631,O
surface,1631,O
ECG,1631,O
(,1631,O
cycle,1631,O
length,1631,O
",",1631,O
QT,1631,O
",",1631,O
and,1631,O
QTc,1631,O
),1631,O
in,1631,O
relation,1631,O
to,1631,O
the,1631,O
dose,1631,O
of,1631,O
oral,1631,O
d,1631,B-Chemical
",",1631,I-Chemical
l-sotalol,1631,I-Chemical
might,1631,O
identify,1631,O
a,1631,O
subgroup,1631,O
of,1631,O
patients,1631,O
with,1631,O
an,1631,O
increased,1631,O
risk,1631,O
for,1631,O
torsades,1631,B-Disease
de,1631,I-Disease
pointes,1631,I-Disease
.,1631,O
Other,1632,O
ECG,1632,O
parameters,1632,O
before,1632,O
the,1632,O
application,1632,O
of,1632,O
d,1632,B-Chemical
",",1632,I-Chemical
l-sotalol,1632,I-Chemical
did,1632,O
not,1632,O
identify,1632,O
patients,1632,O
at,1632,O
increased,1632,O
risk,1632,O
for,1632,O
torsades,1632,B-Disease
de,1632,I-Disease
pointes,1632,I-Disease
.,1632,O
Recurrence,1633,O
rates,1633,O
of,1633,O
ventricular,1633,B-Disease
tachyarrhythmias,1633,I-Disease
are,1633,O
high,1633,O
despite,1633,O
complete,1633,O
suppression,1633,O
of,1633,O
the,1633,O
arrhythmia,1633,B-Disease
during,1633,O
programmed,1633,O
stimulation,1633,O
.,1633,O
Therefore,1634,O
programmed,1634,O
electrical,1634,O
stimulation,1634,O
in,1634,O
the,1634,O
case,1634,O
of,1634,O
d,1634,B-Chemical
",",1634,I-Chemical
l-sotalol,1634,I-Chemical
seems,1634,O
to,1634,O
be,1634,O
of,1634,O
limited,1634,O
prognostic,1634,O
value,1634,O
.,1634,O
Chronic,1635,O
hyperprolactinemia,1635,B-Disease
and,1635,O
changes,1635,O
in,1635,O
dopamine,1635,B-Chemical
neurons,1635,O
.,1635,O
The,1636,O
tuberoinfundibular,1636,O
dopaminergic,1636,O
(,1636,O
TIDA,1636,O
),1636,O
system,1636,O
is,1636,O
known,1636,O
to,1636,O
inhibit,1636,O
prolactin,1636,O
(,1636,O
PRL,1636,O
),1636,O
secretion,1636,O
.,1636,O
In,1637,O
young,1637,O
animals,1637,O
this,1637,O
system,1637,O
responds,1637,O
to,1637,O
acute,1637,O
elevations,1637,O
in,1637,O
serum,1637,O
PRL,1637,O
by,1637,O
increasing,1637,O
its,1637,O
activity,1637,O
.,1637,O
However,1638,O
",",1638,O
this,1638,O
responsiveness,1638,O
is,1638,O
lost,1638,O
in,1638,O
aging,1638,O
rats,1638,O
with,1638,O
chronically,1638,O
high,1638,O
serum,1638,O
PRL,1638,O
levels,1638,O
.,1638,O
The,1639,O
purpose,1639,O
of,1639,O
this,1639,O
study,1639,O
was,1639,O
to,1639,O
induce,1639,O
hyperprolactinemia,1639,B-Disease
in,1639,O
rats,1639,O
for,1639,O
extended,1639,O
periods,1639,O
of,1639,O
time,1639,O
and,1639,O
examine,1639,O
its,1639,O
effects,1639,O
on,1639,O
dopaminergic,1639,O
systems,1639,O
in,1639,O
the,1639,O
brain,1639,O
.,1639,O
Hyperprolactinemia,1640,B-Disease
was,1640,O
induced,1640,O
by,1640,O
treatment,1640,O
with,1640,O
haloperidol,1640,B-Chemical
",",1640,O
a,1640,O
dopamine,1640,B-Chemical
receptor,1640,O
antagonist,1640,O
",",1640,O
and,1640,O
Palkovits,1640,O
',1640,O
microdissection,1640,O
technique,1640,O
in,1640,O
combination,1640,O
with,1640,O
high-performance,1640,O
liquid,1640,O
chromatography,1640,O
was,1640,O
used,1640,O
to,1640,O
measure,1640,O
neurotransmitter,1640,O
concentrations,1640,O
in,1640,O
several,1640,O
areas,1640,O
of,1640,O
the,1640,O
brain,1640,O
.,1640,O
After,1641,O
6,1641,O
months,1641,O
of,1641,O
hyperprolactinemia,1641,B-Disease
",",1641,O
dopamine,1641,B-Chemical
(,1641,O
DA,1641,B-Chemical
),1641,O
concentrations,1641,O
in,1641,O
the,1641,O
median,1641,O
eminence,1641,O
(,1641,O
ME,1641,O
),1641,O
increased,1641,O
by,1641,O
84,1641,O
%,1641,O
over,1641,O
the,1641,O
control,1641,O
group,1641,O
.,1641,O
Nine,1642,O
months,1642,O
of,1642,O
hyperprolactinemia,1642,B-Disease
produced,1642,O
a,1642,O
50,1642,O
%,1642,O
increase,1642,O
in,1642,O
DA,1642,B-Chemical
concentrations,1642,O
in,1642,O
the,1642,O
ME,1642,O
over,1642,O
the,1642,O
control,1642,O
group,1642,O
.,1642,O
However,1643,O
",",1643,O
DA,1643,B-Chemical
response,1643,O
was,1643,O
lost,1643,O
if,1643,O
a,1643,O
9-month,1643,O
long,1643,O
haloperidol-induced,1643,B-Chemical
hyperprolactinemia,1643,B-Disease
was,1643,O
followed,1643,O
by,1643,O
a,1643,O
1,1643,O
1/2,1643,O
month-long,1643,O
extremely,1643,O
high,1643,O
increase,1643,O
in,1643,O
serum,1643,O
PRL,1643,O
levels,1643,O
produced,1643,O
by,1643,O
implantation,1643,O
of,1643,O
MMQ,1643,O
cells,1643,O
under,1643,O
the,1643,O
kidney,1643,O
capsule,1643,O
.,1643,O
There,1644,O
was,1644,O
no,1644,O
change,1644,O
in,1644,O
the,1644,O
levels,1644,O
of,1644,O
DA,1644,B-Chemical
",",1644,O
norepinephrine,1644,B-Chemical
(,1644,O
NE,1644,B-Chemical
),1644,O
",",1644,O
serotonin,1644,B-Chemical
(,1644,O
5-HT,1644,B-Chemical
),1644,O
",",1644,O
or,1644,O
their,1644,O
metabolites,1644,O
in,1644,O
the,1644,O
arcuate,1644,O
nucleus,1644,O
(,1644,O
AN,1644,O
),1644,O
",",1644,O
medial,1644,O
preoptic,1644,O
area,1644,O
(,1644,O
MPA,1644,O
),1644,O
",",1644,O
caudate,1644,O
putamen,1644,O
(,1644,O
CP,1644,O
),1644,O
",",1644,O
substantia,1644,O
nigra,1644,O
(,1644,O
SN,1644,O
),1644,O
",",1644,O
and,1644,O
zona,1644,O
incerta,1644,O
(,1644,O
ZI,1644,O
),1644,O
",",1644,O
except,1644,O
for,1644,O
a,1644,O
decrease,1644,O
in,1644,O
5-hydroxyindoleacetic,1644,B-Chemical
acid,1644,I-Chemical
(,1644,O
5-HIAA,1644,B-Chemical
),1644,O
in,1644,O
the,1644,O
AN,1644,O
after,1644,O
6-months,1644,O
of,1644,O
hyperprolactinemia,1644,B-Disease
and,1644,O
an,1644,O
increase,1644,O
in,1644,O
DA,1644,B-Chemical
concentrations,1644,O
in,1644,O
the,1644,O
AN,1644,O
after,1644,O
9-months,1644,O
of,1644,O
hyperprolactinemia,1644,B-Disease
.,1644,O
These,1645,O
results,1645,O
demonstrate,1645,O
that,1645,O
hyperprolactinemia,1645,B-Disease
specifically,1645,O
affects,1645,O
TIDA,1645,O
neurons,1645,O
and,1645,O
these,1645,O
effects,1645,O
vary,1645,O
",",1645,O
depending,1645,O
on,1645,O
the,1645,O
duration,1645,O
and,1645,O
intensity,1645,O
of,1645,O
hyperprolactinemia,1645,B-Disease
.,1645,O
The,1646,O
age-related,1646,O
decrease,1646,O
in,1646,O
hypothalamic,1646,O
dopamine,1646,B-Chemical
function,1646,O
may,1646,O
be,1646,O
associated,1646,O
with,1646,O
increases,1646,O
in,1646,O
PRL,1646,O
secretion,1646,O
.,1646,O
Treatment-related,1647,O
disseminated,1647,O
necrotizing,1647,O
leukoencephalopathy,1647,B-Disease
with,1647,O
characteristic,1647,O
contrast,1647,O
enhancement,1647,O
of,1647,O
the,1647,O
white,1647,O
matter,1647,O
.,1647,O
This,1648,O
report,1648,O
describes,1648,O
unique,1648,O
contrast,1648,O
enhancement,1648,O
of,1648,O
the,1648,O
white,1648,O
matter,1648,O
on,1648,O
T1-weighted,1648,O
magnetic,1648,O
resonance,1648,O
images,1648,O
of,1648,O
two,1648,O
patients,1648,O
with,1648,O
disseminated,1648,O
necrotizing,1648,O
leukoencephalopathy,1648,B-Disease
",",1648,O
which,1648,O
developed,1648,O
from,1648,O
acute,1648,B-Disease
lymphoblastic,1648,I-Disease
leukemia,1648,I-Disease
treated,1648,O
with,1648,O
high-dose,1648,O
methotrexate,1648,B-Chemical
.,1648,O
In,1649,O
both,1649,O
patients,1649,O
",",1649,O
the,1649,O
enhancement,1649,O
was,1649,O
more,1649,O
pronounced,1649,O
near,1649,O
the,1649,O
base,1649,O
of,1649,O
the,1649,O
brain,1649,O
than,1649,O
at,1649,O
the,1649,O
vertex,1649,O
.,1649,O
Necropsy,1650,O
of,1650,O
the,1650,O
first,1650,O
case,1650,O
revealed,1650,O
loss,1650,B-Disease
of,1650,I-Disease
myelination,1650,I-Disease
and,1650,O
necrosis,1650,B-Disease
of,1650,O
the,1650,O
white,1650,O
matter,1650,O
.,1650,O
Possible,1651,O
mechanisms,1651,O
causing,1651,O
such,1651,O
a,1651,O
leukoencephalopathy,1651,B-Disease
are,1651,O
discussed,1651,O
.,1651,O
Thrombotic,1652,B-Disease
complications,1652,O
in,1652,O
acute,1652,B-Disease
promyelocytic,1652,I-Disease
leukemia,1652,I-Disease
during,1652,O
all-trans-retinoic,1652,B-Chemical
acid,1652,I-Chemical
therapy,1652,O
.,1652,O
A,1653,O
case,1653,O
of,1653,O
acute,1653,B-Disease
renal,1653,I-Disease
failure,1653,I-Disease
",",1653,O
due,1653,O
to,1653,O
occlusion,1653,B-Disease
of,1653,I-Disease
renal,1653,I-Disease
vessels,1653,I-Disease
in,1653,O
a,1653,O
patient,1653,O
with,1653,O
acute,1653,B-Disease
promyelocytic,1653,I-Disease
leukemia,1653,I-Disease
(,1653,O
APL,1653,B-Disease
),1653,O
treated,1653,O
with,1653,O
all-trans-retinoic,1653,B-Chemical
acid,1653,I-Chemical
(,1653,O
ATRA,1653,B-Chemical
),1653,O
and,1653,O
tranexamic,1653,B-Chemical
acid,1653,I-Chemical
has,1653,O
been,1653,O
described,1653,O
recently,1653,O
.,1653,O
We,1654,O
report,1654,O
a,1654,O
case,1654,O
of,1654,O
acute,1654,B-Disease
renal,1654,I-Disease
failure,1654,I-Disease
in,1654,O
an,1654,O
APL,1654,B-Disease
patient,1654,O
treated,1654,O
with,1654,O
ATRA,1654,B-Chemical
alone,1654,O
.,1654,O
This,1655,O
case,1655,O
further,1655,O
supports,1655,O
the,1655,O
concern,1655,O
about,1655,O
thromboembolic,1655,B-Disease
complications,1655,O
associated,1655,O
with,1655,O
ATRA,1655,B-Chemical
therapy,1655,O
in,1655,O
APL,1655,B-Disease
patients,1655,O
.,1655,O
The,1656,O
patients,1656,O
",",1656,O
a,1656,O
43-year-old,1656,O
man,1656,O
",",1656,O
presented,1656,O
all,1656,O
the,1656,O
signs,1656,O
and,1656,O
symptoms,1656,O
of,1656,O
APL,1656,B-Disease
and,1656,O
was,1656,O
included,1656,O
in,1656,O
a,1656,O
treatment,1656,O
protocol,1656,O
with,1656,O
ATRA,1656,B-Chemical
.,1656,O
After,1657,O
10,1657,O
days,1657,O
of,1657,O
treatment,1657,O
",",1657,O
he,1657,O
developed,1657,O
acute,1657,B-Disease
renal,1657,I-Disease
failure,1657,I-Disease
that,1657,O
was,1657,O
completely,1657,O
reversible,1657,O
after,1657,O
complete,1657,O
remission,1657,O
of,1657,O
APL,1657,B-Disease
was,1657,O
achieved,1657,O
and,1657,O
therapy,1657,O
discontinued,1657,O
.,1657,O
We,1658,O
conclude,1658,O
that,1658,O
ATRA,1658,B-Chemical
is,1658,O
a,1658,O
valid,1658,O
therapeutic,1658,O
choice,1658,O
for,1658,O
patients,1658,O
with,1658,O
APL,1658,B-Disease
",",1658,O
although,1658,O
the,1658,O
procoagulant,1658,O
tendency,1658,O
is,1658,O
not,1658,O
completely,1658,O
corrected,1658,O
.,1658,O
Thrombotic,1659,B-Disease
events,1659,O
",",1659,O
however,1659,O
",",1659,O
could,1659,O
be,1659,O
avoided,1659,O
by,1659,O
using,1659,O
low-dose,1659,O
heparin,1659,B-Chemical
.,1659,O
Pupillary,1660,O
changes,1660,O
associated,1660,O
with,1660,O
the,1660,O
development,1660,O
of,1660,O
stimulant-induced,1660,O
mania,1660,B-Disease
:,1660,O
a,1660,O
case,1660,O
report,1660,O
.,1660,O
A,1661,O
30-year-old,1661,O
cocaine-dependent,1661,B-Chemical
man,1661,O
who,1661,O
was,1661,O
a,1661,O
subject,1661,O
in,1661,O
a,1661,O
study,1661,O
evaluating,1661,O
the,1661,O
anticraving,1661,O
efficacy,1661,O
of,1661,O
the,1661,O
stimulant,1661,O
medication,1661,O
diethylpropion,1661,B-Chemical
(,1661,O
DEP,1661,B-Chemical
),1661,O
became,1661,O
manic,1661,B-Disease
during,1661,O
his,1661,O
second,1661,O
week,1661,O
on,1661,O
the,1661,O
study,1661,O
drug,1661,O
.,1661,O
Pupillometric,1662,O
changes,1662,O
while,1662,O
on,1662,O
DEP,1662,B-Chemical
",",1662,O
especially,1662,O
changes,1662,O
in,1662,O
the,1662,O
total,1662,O
power,1662,O
of,1662,O
pupillary,1662,B-Disease
oscillation,1662,I-Disease
",",1662,O
were,1662,O
dramatically,1662,O
different,1662,O
than,1662,O
those,1662,O
observed,1662,O
in,1662,O
the,1662,O
eight,1662,O
other,1662,O
study,1662,O
subjects,1662,O
who,1662,O
did,1662,O
not,1662,O
become,1662,O
manic,1662,B-Disease
.,1662,O
The,1663,O
large,1663,O
changes,1663,O
in,1663,O
total,1663,O
power,1663,O
of,1663,O
pupillary,1663,B-Disease
oscillation,1663,I-Disease
occurred,1663,O
a,1663,O
few,1663,O
days,1663,O
before,1663,O
the,1663,O
patient,1663,O
became,1663,O
fully,1663,O
manic,1663,B-Disease
.,1663,O
Such,1664,O
medication-associated,1664,O
changes,1664,O
in,1664,O
the,1664,O
total,1664,O
power,1664,O
of,1664,O
pupillary,1664,B-Disease
oscillation,1664,I-Disease
might,1664,O
be,1664,O
of,1664,O
utility,1664,O
in,1664,O
identifying,1664,O
persons,1664,O
at,1664,O
risk,1664,O
for,1664,O
manic-like,1664,B-Disease
adverse,1664,O
effects,1664,O
during,1664,O
the,1664,O
medical,1664,O
use,1664,O
of,1664,O
psychomotor,1664,O
stimulants,1664,O
or,1664,O
sympathomimetic,1664,O
agents,1664,O
.,1664,O
The,1665,O
negative,1665,O
mucosal,1665,O
potential,1665,O
:,1665,O
separating,1665,O
central,1665,O
and,1665,O
peripheral,1665,O
effects,1665,O
of,1665,O
NSAIDs,1665,O
in,1665,O
man,1665,O
.,1665,O
OBJECTIVE,1666,O
:,1666,O
We,1666,O
wanted,1666,O
to,1666,O
test,1666,O
whether,1666,O
assessment,1666,O
of,1666,O
both,1666,O
a,1666,O
central,1666,O
pain-related,1666,B-Disease
signal,1666,O
(,1666,O
chemo-somatosensory,1666,O
evoked,1666,O
potential,1666,O
",",1666,O
CSSEP,1666,O
),1666,O
and,1666,O
a,1666,O
concomitantly,1666,O
recorded,1666,O
peripheral,1666,O
signal,1666,O
(,1666,O
negative,1666,O
mucosal,1666,O
potential,1666,O
",",1666,O
NMP,1666,O
),1666,O
allows,1666,O
for,1666,O
separation,1666,O
of,1666,O
central,1666,O
and,1666,O
peripheral,1666,O
effects,1666,O
of,1666,O
NSAIDs,1666,O
.,1666,O
For,1667,O
this,1667,O
purpose,1667,O
",",1667,O
experimental,1667,O
conditions,1667,O
were,1667,O
created,1667,O
in,1667,O
which,1667,O
NSAIDs,1667,O
had,1667,O
previously,1667,O
been,1667,O
observed,1667,O
to,1667,O
produce,1667,O
effects,1667,O
on,1667,O
phasic,1667,O
and,1667,O
tonic,1667,O
pain,1667,B-Disease
by,1667,O
either,1667,O
central,1667,O
or,1667,O
peripheral,1667,O
mechanisms,1667,O
.,1667,O
METHODS,1668,O
:,1668,O
According,1668,O
to,1668,O
a,1668,O
double-blind,1668,O
",",1668,O
randomised,1668,O
",",1668,O
controlled,1668,O
",",1668,O
threefold,1668,O
cross-over,1668,O
design,1668,O
",",1668,O
18,1668,O
healthy,1668,O
subjects,1668,O
(,1668,O
11,1668,O
males,1668,O
",",1668,O
7,1668,O
females,1668,O
;,1668,O
mean,1668,O
age,1668,O
26,1668,O
years,1668,O
),1668,O
received,1668,O
either,1668,O
placebo,1668,O
",",1668,O
400,1668,O
mg,1668,O
ibuprofen,1668,B-Chemical
",",1668,O
or,1668,O
800,1668,O
mg,1668,O
ibuprofen,1668,B-Chemical
.,1668,O
Phasic,1669,O
pain,1669,B-Disease
was,1669,O
applied,1669,O
by,1669,O
means,1669,O
of,1669,O
short,1669,O
pulses,1669,O
of,1669,O
CO2,1669,B-Chemical
to,1669,O
the,1669,O
nasal,1669,O
mucosa,1669,O
(,1669,O
stimulus,1669,O
duration,1669,O
500,1669,O
ms,1669,O
",",1669,O
interval,1669,O
approximately,1669,O
60,1669,O
s,1669,O
),1669,O
",",1669,O
and,1669,O
tonic,1669,O
pain,1669,B-Disease
was,1669,O
induced,1669,O
in,1669,O
the,1669,O
nasal,1669,O
cavity,1669,O
by,1669,O
means,1669,O
of,1669,O
dry,1669,O
air,1669,O
of,1669,O
controlled,1669,O
temperature,1669,O
",",1669,O
humidity,1669,O
and,1669,O
flow,1669,O
rate,1669,O
(,1669,O
22,1669,O
degrees,1669,O
C,1669,O
",",1669,O
0,1669,O
%,1669,O
relative,1669,O
humidity,1669,O
",",1669,O
145,1669,O
ml.s-1,1669,O
),1669,O
.,1669,O
Both,1670,O
CSSEPs,1670,O
as,1670,O
central,1670,O
and,1670,O
NMPs,1670,O
as,1670,O
peripheral,1670,O
correlates,1670,O
of,1670,O
pain,1670,B-Disease
were,1670,O
obtained,1670,O
in,1670,O
response,1670,O
to,1670,O
the,1670,O
CO2,1670,B-Chemical
stimuli,1670,O
.,1670,O
Additionally,1671,O
",",1671,O
the,1671,O
subjects,1671,O
rated,1671,O
the,1671,O
intensity,1671,O
of,1671,O
both,1671,O
phasic,1671,O
and,1671,O
tonic,1671,O
pain,1671,B-Disease
by,1671,O
means,1671,O
of,1671,O
visual,1671,O
analogue,1671,O
scales,1671,O
.,1671,O
RESULTS,1672,O
:,1672,O
As,1672,O
described,1672,O
earlier,1672,O
",",1672,O
administration,1672,O
of,1672,O
ibuprofen,1672,B-Chemical
was,1672,O
followed,1672,O
by,1672,O
a,1672,O
decrease,1672,O
in,1672,O
tonic,1672,O
pain,1672,B-Disease
but-relative,1672,O
to,1672,O
placebo-an,1672,O
increase,1672,O
in,1672,O
correlates,1672,O
of,1672,O
phasic,1672,O
pain,1672,B-Disease
",",1672,O
indicating,1672,O
a,1672,O
specific,1672,O
effect,1672,O
of,1672,O
ibuprofen,1672,B-Chemical
on,1672,O
the,1672,O
interaction,1672,O
between,1672,O
the,1672,O
pain,1672,B-Disease
stimuli,1672,O
under,1672,O
these,1672,O
special,1672,O
experimental,1672,O
conditions,1672,O
.,1672,O
Based,1673,O
on,1673,O
the,1673,O
similar,1673,O
behaviour,1673,O
of,1673,O
CSSEP,1673,O
and,1673,O
NMP,1673,O
",",1673,O
it,1673,O
was,1673,O
concluded,1673,O
that,1673,O
the,1673,O
pharmacological,1673,O
process,1673,O
underlying,1673,O
this,1673,O
phenomenon,1673,O
was,1673,O
localised,1673,O
in,1673,O
the,1673,O
periphery,1673,O
.,1673,O
By,1674,O
means,1674,O
of,1674,O
the,1674,O
simultaneous,1674,O
recording,1674,O
of,1674,O
interrelated,1674,O
peripheral,1674,O
and,1674,O
central,1674,O
electrophysiologic,1674,O
correlates,1674,O
of,1674,O
nociception,1674,O
",",1674,O
it,1674,O
was,1674,O
possible,1674,O
to,1674,O
separate,1674,O
central,1674,O
and,1674,O
peripheral,1674,O
effects,1674,O
of,1674,O
an,1674,O
NSAID,1674,O
.,1674,O
The,1675,O
major,1675,O
advantage,1675,O
of,1675,O
this,1675,O
pain,1675,B-Disease
model,1675,O
is,1675,O
the,1675,O
possibility,1675,O
of,1675,O
obtaining,1675,O
peripheral,1675,O
pain-related,1675,B-Disease
activity,1675,O
directly,1675,O
using,1675,O
a,1675,O
non-invasive,1675,O
technique,1675,O
in,1675,O
humans,1675,O
.,1675,O
Acute,1676,O
severe,1676,O
depression,1676,B-Disease
following,1676,O
peri-operative,1676,O
ondansetron,1676,B-Chemical
.,1676,O
A,1677,O
41-year-old,1677,O
woman,1677,O
with,1677,O
a,1677,O
strong,1677,O
history,1677,O
of,1677,O
postoperative,1677,B-Disease
nausea,1677,I-Disease
and,1677,I-Disease
vomiting,1677,I-Disease
presented,1677,O
for,1677,O
abdominal,1677,O
hysterectomy,1677,O
3,1677,O
months,1677,O
after,1677,O
a,1677,O
previous,1677,O
anaesthetic,1677,O
where,1677,O
ondansetron,1677,B-Chemical
prophylaxis,1677,O
had,1677,O
been,1677,O
used,1677,O
.,1677,O
She,1678,O
had,1678,O
developed,1678,O
a,1678,O
severe,1678,O
acute,1678,O
major,1678,B-Disease
depression,1678,I-Disease
disorder,1678,I-Disease
almost,1678,O
immediately,1678,O
thereafter,1678,O
",",1678,O
possibly,1678,O
related,1678,O
to,1678,O
the,1678,O
use,1678,O
of,1678,O
a,1678,O
serotonin,1678,B-Chemical
antagonist,1678,O
.,1678,O
Nine,1679,O
years,1679,O
before,1679,O
she,1679,O
had,1679,O
experienced,1679,O
a,1679,O
self-limited,1679,O
puerperal,1679,O
depressive,1679,B-Disease
episode,1679,I-Disease
.,1679,O
Anaesthesia,1680,O
with,1680,O
a,1680,O
propofol,1680,B-Chemical
infusion,1680,O
and,1680,O
avoidance,1680,O
of,1680,O
serotonin,1680,B-Chemical
antagonists,1680,O
provided,1680,O
a,1680,O
nausea-free,1680,B-Disease
postoperative,1680,O
course,1680,O
without,1680,O
exacerbation,1680,O
of,1680,O
the,1680,O
depression,1680,B-Disease
disorder,1680,I-Disease
.,1680,O
Hypertensive,1681,B-Disease
response,1681,O
during,1681,O
dobutamine,1681,B-Chemical
stress,1681,O
echocardiography,1681,O
.,1681,O
Among,1682,O
"3,129",1682,O
dobutamine,1682,B-Chemical
stress,1682,O
echocardiographic,1682,O
studies,1682,O
",",1682,O
a,1682,O
hypertensive,1682,B-Disease
response,1682,O
",",1682,O
defined,1682,O
as,1682,O
systolic,1682,O
blood,1682,O
pressure,1682,O
(,1682,O
BP,1682,O
),1682,O
>,1682,O
or,1682,O
=,1682,O
220,1682,O
mm,1682,O
Hg,1682,O
and/or,1682,O
diastolic,1682,O
BP,1682,O
>,1682,O
or,1682,O
=,1682,O
110,1682,O
mm,1682,O
Hg,1682,O
",",1682,O
occurred,1682,O
in,1682,O
30,1682,O
patients,1682,O
(,1682,O
1,1682,O
%,1682,O
),1682,O
.,1682,O
Patients,1683,O
with,1683,O
this,1683,O
response,1683,O
more,1683,O
often,1683,O
had,1683,O
a,1683,O
history,1683,O
of,1683,O
hypertension,1683,B-Disease
and,1683,O
had,1683,O
higher,1683,O
resting,1683,O
systolic,1683,O
and,1683,O
diastolic,1683,O
BP,1683,O
before,1683,O
dobutamine,1683,B-Chemical
infusion,1683,O
.,1683,O
Continuously,1684,O
nebulized,1684,O
albuterol,1684,B-Chemical
in,1684,O
severe,1684,O
exacerbations,1684,O
of,1684,O
asthma,1684,B-Disease
in,1684,O
adults,1684,O
:,1684,O
a,1684,O
case-controlled,1684,O
study,1684,O
.,1684,O
A,1685,O
retrospective,1685,O
",",1685,O
case-controlled,1685,O
analysis,1685,O
comparing,1685,O
patients,1685,O
admitted,1685,O
to,1685,O
a,1685,O
medical,1685,O
intensive,1685,O
care,1685,O
unit,1685,O
with,1685,O
severe,1685,O
exacerbations,1685,O
of,1685,O
asthma,1685,B-Disease
who,1685,O
received,1685,O
continuously,1685,O
nebulized,1685,O
albuterol,1685,B-Chemical
(,1685,O
CNA,1685,O
),1685,O
versus,1685,O
intermittent,1685,O
albuterol,1685,B-Chemical
(,1685,O
INA,1685,O
),1685,O
treatments,1685,O
is,1685,O
reported,1685,O
.,1685,O
Forty,1686,O
matched,1686,O
pairs,1686,O
of,1686,O
patients,1686,O
with,1686,O
asthma,1686,B-Disease
are,1686,O
compared,1686,O
.,1686,O
CNA,1687,O
was,1687,O
administered,1687,O
for,1687,O
a,1687,O
mean,1687,O
of,1687,O
11,1687,O
+/-,1687,O
10,1687,O
hr,1687,O
.,1687,O
The,1688,O
incidence,1688,O
of,1688,O
cardiac,1688,B-Disease
dysrhythmias,1688,I-Disease
was,1688,O
similar,1688,O
between,1688,O
groups,1688,O
.,1688,O
Symptomatic,1689,O
hypokalemia,1689,B-Disease
did,1689,O
not,1689,O
occur,1689,O
.,1689,O
CNA,1690,O
patients,1690,O
had,1690,O
higher,1690,O
heart,1690,O
rates,1690,O
during,1690,O
treatment,1690,O
",",1690,O
which,1690,O
may,1690,O
reflect,1690,O
severity,1690,O
of,1690,O
illness,1690,O
.,1690,O
The,1691,O
incidence,1691,O
of,1691,O
intubation,1691,O
was,1691,O
similar,1691,O
.,1691,O
We,1692,O
conclude,1692,O
that,1692,O
CNA,1692,O
and,1692,O
INA,1692,O
demonstrated,1692,O
similar,1692,O
profiles,1692,O
with,1692,O
regard,1692,O
to,1692,O
safety,1692,O
",",1692,O
morbidity,1692,O
",",1692,O
and,1692,O
mortality,1692,O
.,1692,O
Hyperosmolar,1693,B-Disease
nonketotic,1693,I-Disease
coma,1693,I-Disease
precipitated,1693,O
by,1693,O
lithium-induced,1693,B-Chemical
nephrogenic,1693,B-Disease
diabetes,1693,I-Disease
insipidus,1693,I-Disease
.,1693,O
A,1694,O
45-year-old,1694,O
man,1694,O
",",1694,O
with,1694,O
a,1694,O
10-year,1694,O
history,1694,O
of,1694,O
manic,1694,B-Disease
depression,1694,I-Disease
treated,1694,O
with,1694,O
lithium,1694,B-Chemical
",",1694,O
was,1694,O
admitted,1694,O
with,1694,O
hyperosmolar,1694,B-Disease
",",1694,I-Disease
nonketotic,1694,I-Disease
coma,1694,I-Disease
.,1694,O
He,1695,O
gave,1695,O
a,1695,O
five-year,1695,O
history,1695,O
of,1695,O
polyuria,1695,B-Disease
and,1695,O
polydipsia,1695,B-Disease
",",1695,O
during,1695,O
which,1695,O
time,1695,O
urinalysis,1695,O
had,1695,O
been,1695,O
negative,1695,O
for,1695,O
glucose,1695,B-Chemical
.,1695,O
After,1696,O
recovery,1696,O
from,1696,O
hyperglycaemia,1696,B-Disease
",",1696,O
he,1696,O
remained,1696,O
polyuric,1696,B-Disease
despite,1696,O
normal,1696,O
blood,1696,O
glucose,1696,B-Chemical
concentrations,1696,O
;,1696,O
water,1696,O
deprivation,1696,O
testing,1696,O
indicated,1696,O
nephrogenic,1696,B-Disease
diabetes,1696,I-Disease
insipidus,1696,I-Disease
",",1696,O
likely,1696,O
to,1696,O
be,1696,O
lithium-induced,1696,B-Chemical
.,1696,O
We,1697,O
hypothesize,1697,O
that,1697,O
when,1697,O
this,1697,O
man,1697,O
developed,1697,O
type,1697,B-Disease
2,1697,I-Disease
diabetes,1697,I-Disease
",",1697,O
chronic,1697,O
polyuria,1697,B-Disease
due,1697,O
to,1697,O
nephrogenic,1697,B-Disease
diabetes,1697,I-Disease
insipidus,1697,I-Disease
was,1697,O
sufficient,1697,O
to,1697,O
precipitate,1697,O
hyperosmolar,1697,O
dehydration,1697,B-Disease
.,1697,O
Effects,1698,O
of,1698,O
the,1698,O
intracoronary,1698,O
infusion,1698,O
of,1698,O
cocaine,1698,B-Chemical
on,1698,O
left,1698,O
ventricular,1698,O
systolic,1698,O
and,1698,O
diastolic,1698,O
function,1698,O
in,1698,O
humans,1698,O
.,1698,O
BACKGROUND,1699,O
:,1699,O
In,1699,O
dogs,1699,O
",",1699,O
a,1699,O
large,1699,O
amount,1699,O
of,1699,O
intravenous,1699,O
cocaine,1699,B-Chemical
causes,1699,O
a,1699,O
profound,1699,O
deterioration,1699,B-Disease
of,1699,I-Disease
left,1699,I-Disease
ventricular,1699,I-Disease
(,1699,I-Disease
LV,1699,I-Disease
),1699,I-Disease
systolic,1699,I-Disease
function,1699,I-Disease
and,1699,O
an,1699,O
increase,1699,O
in,1699,O
LV,1699,O
end-diastolic,1699,O
pressure,1699,O
.,1699,O
This,1700,O
study,1700,O
was,1700,O
done,1700,O
to,1700,O
assess,1700,O
the,1700,O
influence,1700,O
of,1700,O
a,1700,O
high,1700,O
intracoronary,1700,O
cocaine,1700,B-Chemical
concentration,1700,O
on,1700,O
LV,1700,O
systolic,1700,O
and,1700,O
diastolic,1700,O
function,1700,O
in,1700,O
humans,1700,O
.,1700,O
METHODS,1701,O
AND,1701,O
RESULTS,1701,O
:,1701,O
In,1701,O
20,1701,O
patients,1701,O
(,1701,O
14,1701,O
men,1701,O
and,1701,O
6,1701,O
women,1701,O
aged,1701,O
39,1701,O
to,1701,O
72,1701,O
years,1701,O
),1701,O
referred,1701,O
for,1701,O
cardiac,1701,O
catheterization,1701,O
for,1701,O
the,1701,O
evaluation,1701,O
of,1701,O
chest,1701,B-Disease
pain,1701,I-Disease
",",1701,O
we,1701,O
measured,1701,O
heart,1701,O
rate,1701,O
",",1701,O
systemic,1701,O
arterial,1701,O
pressure,1701,O
",",1701,O
LV,1701,O
pressure,1701,O
and,1701,O
its,1701,O
first,1701,O
derivative,1701,O
(,1701,O
dP/dt,1701,O
),1701,O
",",1701,O
and,1701,O
LV,1701,O
volumes,1701,O
and,1701,O
ejection,1701,O
fraction,1701,O
before,1701,O
and,1701,O
during,1701,O
the,1701,O
final,1701,O
2,1701,O
to,1701,O
3,1701,O
minutes,1701,O
of,1701,O
a,1701,O
15-minute,1701,O
intracoronary,1701,O
infusion,1701,O
of,1701,O
saline,1701,O
(,1701,O
n=10,1701,O
",",1701,O
control,1701,O
subjects,1701,O
),1701,O
or,1701,O
cocaine,1701,B-Chemical
hydrochloride,1701,I-Chemical
1,1701,O
mg/min,1701,O
(,1701,O
n=10,1701,O
),1701,O
.,1701,O
No,1702,O
variable,1702,O
changed,1702,O
with,1702,O
saline,1702,O
.,1702,O
With,1703,O
cocaine,1703,B-Chemical
",",1703,O
the,1703,O
drug,1703,O
concentration,1703,O
in,1703,O
blood,1703,O
obtained,1703,O
from,1703,O
the,1703,O
coronary,1703,O
sinus,1703,O
was,1703,O
3.0+/-0.4,1703,O
(,1703,O
mean+/-SD,1703,O
),1703,O
mg/L,1703,O
",",1703,O
similar,1703,O
in,1703,O
magnitude,1703,O
to,1703,O
the,1703,O
blood,1703,O
cocaine,1703,B-Chemical
concentration,1703,O
reported,1703,O
in,1703,O
abusers,1703,O
dying,1703,O
of,1703,O
cocaine,1703,B-Chemical
intoxication,1703,O
.,1703,O
Cocaine,1704,B-Chemical
induced,1704,O
no,1704,O
significant,1704,O
change,1704,O
in,1704,O
heart,1704,O
rate,1704,O
",",1704,O
LV,1704,O
dP/dt,1704,O
(,1704,O
positive,1704,O
or,1704,O
negative,1704,O
),1704,O
",",1704,O
or,1704,O
LV,1704,O
end-diastolic,1704,O
volume,1704,O
",",1704,O
but,1704,O
it,1704,O
caused,1704,O
an,1704,O
increase,1704,O
in,1704,O
systolic,1704,O
and,1704,O
mean,1704,O
arterial,1704,O
pressures,1704,O
",",1704,O
LV,1704,O
end-diastolic,1704,O
pressure,1704,O
",",1704,O
and,1704,O
LV,1704,O
end-systolic,1704,O
volume,1704,O
",",1704,O
as,1704,O
well,1704,O
as,1704,O
a,1704,O
decrease,1704,O
in,1704,O
LV,1704,O
ejection,1704,O
fraction,1704,O
.,1704,O
CONCLUSIONS,1705,O
:,1705,O
In,1705,O
humans,1705,O
",",1705,O
the,1705,O
intracoronary,1705,O
infusion,1705,O
of,1705,O
cocaine,1705,B-Chemical
sufficient,1705,O
in,1705,O
amount,1705,O
to,1705,O
achieve,1705,O
a,1705,O
high,1705,O
drug,1705,O
concentration,1705,O
in,1705,O
coronary,1705,O
sinus,1705,O
blood,1705,O
causes,1705,O
a,1705,O
deterioration,1705,B-Disease
of,1705,I-Disease
LV,1705,I-Disease
systolic,1705,I-Disease
and,1705,I-Disease
diastolic,1705,I-Disease
performance,1705,I-Disease
.,1705,O
Ascending,1706,O
dose,1706,O
tolerance,1706,O
study,1706,O
of,1706,O
intramuscular,1706,O
carbetocin,1706,B-Chemical
administered,1706,O
after,1706,O
normal,1706,O
vaginal,1706,O
birth,1706,O
.,1706,O
OBJECTIVE,1707,O
:,1707,O
To,1707,O
determine,1707,O
the,1707,O
maximum,1707,O
tolerated,1707,O
dose,1707,O
(,1707,O
MTD,1707,O
),1707,O
of,1707,O
carbetocin,1707,B-Chemical
(,1707,O
a,1707,O
long-acting,1707,O
synthetic,1707,O
analogue,1707,O
of,1707,O
oxytocin,1707,B-Chemical
),1707,O
",",1707,O
when,1707,O
administered,1707,O
immediately,1707,O
after,1707,O
vaginal,1707,O
delivery,1707,O
at,1707,O
term,1707,O
.,1707,O
MATERIALS,1708,O
AND,1708,O
METHODS,1708,O
:,1708,O
Carbetocin,1708,B-Chemical
was,1708,O
given,1708,O
as,1708,O
an,1708,O
intramuscular,1708,O
injection,1708,O
immediately,1708,O
after,1708,O
the,1708,O
birth,1708,O
of,1708,O
the,1708,O
infant,1708,O
in,1708,O
45,1708,O
healthy,1708,O
women,1708,O
with,1708,O
normal,1708,O
singleton,1708,O
pregnancies,1708,O
who,1708,O
delivered,1708,O
vaginally,1708,O
at,1708,O
term,1708,O
.,1708,O
Dosage,1709,O
groups,1709,O
of,1709,O
15,1709,O
",",1709,O
30,1709,O
",",1709,O
50,1709,O
",",1709,O
75,1709,O
",",1709,O
100,1709,O
",",1709,O
125,1709,O
",",1709,O
150,1709,O
",",1709,O
175,1709,O
or,1709,O
200,1709,O
microg,1709,O
carbetocin,1709,B-Chemical
were,1709,O
assigned,1709,O
to,1709,O
blocks,1709,O
of,1709,O
three,1709,O
women,1709,O
according,1709,O
to,1709,O
the,1709,O
continual,1709,O
reassessment,1709,O
method,1709,O
(,1709,O
CRM,1709,O
),1709,O
.,1709,O
RESULTS,1710,O
:,1710,O
All,1710,O
dosage,1710,O
groups,1710,O
consisted,1710,O
of,1710,O
three,1710,O
women,1710,O
",",1710,O
except,1710,O
those,1710,O
with,1710,O
100,1710,O
microg,1710,O
(,1710,O
n=6,1710,O
),1710,O
and,1710,O
200,1710,O
microg,1710,O
(,1710,O
n=18,1710,O
),1710,O
.,1710,O
Recorded,1711,O
were,1711,O
dose-limiting,1711,O
adverse,1711,O
events,1711,O
:,1711,O
hyper-,1711,B-Disease
or,1711,I-Disease
hypotension,1711,I-Disease
(,1711,O
three,1711,O
),1711,O
",",1711,O
severe,1711,O
abdominal,1711,B-Disease
pain,1711,I-Disease
(,1711,O
0,1711,O
),1711,O
",",1711,O
vomiting,1711,B-Disease
(,1711,O
0,1711,O
),1711,O
and,1711,O
retained,1711,B-Disease
placenta,1711,I-Disease
(,1711,O
four,1711,O
),1711,O
.,1711,O
Serious,1712,O
adverse,1712,O
events,1712,O
occurred,1712,O
in,1712,O
seven,1712,O
women,1712,O
:,1712,O
six,1712,O
cases,1712,O
with,1712,O
blood,1712,B-Disease
loss,1712,I-Disease
>,1712,O
or,1712,O
=,1712,O
1000,1712,O
ml,1712,O
",",1712,O
four,1712,O
cases,1712,O
of,1712,O
manual,1712,O
placenta,1712,O
removal,1712,O
",",1712,O
five,1712,O
cases,1712,O
of,1712,O
additional,1712,O
oxytocics,1712,O
administration,1712,O
and,1712,O
five,1712,O
cases,1712,O
of,1712,O
blood,1712,O
transfusion,1712,O
.,1712,O
Maximum,1713,O
blood,1713,B-Disease
loss,1713,I-Disease
was,1713,O
greatest,1713,O
at,1713,O
the,1713,O
upper,1713,O
and,1713,O
lower,1713,O
dose,1713,O
levels,1713,O
",",1713,O
and,1713,O
lowest,1713,O
in,1713,O
the,1713,O
70-125,1713,O
microg,1713,O
dose,1713,O
range,1713,O
.,1713,O
Four,1714,O
out,1714,O
of,1714,O
six,1714,O
cases,1714,O
with,1714,O
blood,1714,B-Disease
loss,1714,I-Disease
>,1714,O
or,1714,O
=,1714,O
1000,1714,O
ml,1714,O
occurred,1714,O
in,1714,O
the,1714,O
200,1714,O
microg,1714,O
group,1714,O
.,1714,O
The,1715,O
majority,1715,O
of,1715,O
additional,1715,O
administration,1715,O
of,1715,O
oxytocics,1715,O
(,1715,O
4/5,1715,O
),1715,O
and,1715,O
blood,1715,O
transfusion,1715,O
(,1715,O
3/5,1715,O
),1715,O
occurred,1715,O
in,1715,O
the,1715,O
dose,1715,O
groups,1715,O
of,1715,O
200,1715,O
microg,1715,O
.,1715,O
All,1716,O
retained,1716,O
placentae,1716,O
were,1716,O
found,1716,O
in,1716,O
the,1716,O
group,1716,O
of,1716,O
200,1716,O
microg,1716,O
.,1716,O
CONCLUSION,1717,O
:,1717,O
The,1717,O
MTD,1717,O
was,1717,O
calculated,1717,O
to,1717,O
be,1717,O
at,1717,O
200,1717,O
microg,1717,O
carbetocin,1717,B-Chemical
.,1717,O
Heparin-induced,1718,B-Chemical
thrombocytopenia,1718,B-Disease
",",1718,O
paradoxical,1718,O
thromboembolism,1718,B-Disease
",",1718,O
and,1718,O
other,1718,O
side,1718,O
effects,1718,O
of,1718,O
heparin,1718,B-Chemical
therapy,1718,O
.,1718,O
Although,1719,O
several,1719,O
new,1719,O
anticoagulant,1719,O
drugs,1719,O
are,1719,O
in,1719,O
development,1719,O
",",1719,O
heparin,1719,B-Chemical
remains,1719,O
the,1719,O
drug,1719,O
of,1719,O
choice,1719,O
for,1719,O
most,1719,O
anticoagulation,1719,O
needs,1719,O
.,1719,O
The,1720,O
clinical,1720,O
effects,1720,O
of,1720,O
heparin,1720,B-Chemical
are,1720,O
meritorious,1720,O
",",1720,O
but,1720,O
side,1720,O
effects,1720,O
do,1720,O
exist,1720,O
.,1720,O
Important,1721,O
untoward,1721,O
effects,1721,O
of,1721,O
heparin,1721,B-Chemical
therapy,1721,O
including,1721,O
heparin-induced,1721,B-Chemical
thrombocytopenia,1721,B-Disease
",",1721,O
heparin-associated,1721,B-Chemical
osteoporosis,1721,B-Disease
",",1721,O
eosinophilia,1721,B-Disease
",",1721,O
skin,1721,B-Disease
reactions,1721,I-Disease
",",1721,O
allergic,1721,B-Disease
reactions,1721,I-Disease
other,1721,O
than,1721,O
thrombocytopenia,1721,B-Disease
and,1721,O
alopecia,1721,B-Disease
will,1721,O
be,1721,O
discussed,1721,O
in,1721,O
this,1721,O
article,1721,O
.,1721,O
Nonopaque,1722,O
crystal,1722,O
deposition,1722,O
causing,1722,O
ureteric,1722,B-Disease
obstruction,1722,I-Disease
in,1722,O
patients,1722,O
with,1722,O
HIV,1722,O
undergoing,1722,O
indinavir,1722,B-Chemical
therapy,1722,O
.,1722,O
OBJECTIVE,1723,O
:,1723,O
We,1723,O
describe,1723,O
the,1723,O
unique,1723,O
CT,1723,O
features,1723,O
of,1723,O
ureteric,1723,B-Disease
calculi,1723,I-Disease
in,1723,O
six,1723,O
HIV-infected,1723,B-Disease
patients,1723,O
receiving,1723,O
indinavir,1723,B-Chemical
",",1723,O
the,1723,O
most,1723,O
commonly,1723,O
used,1723,O
HIV,1723,O
protease,1723,O
inhibitor,1723,O
",",1723,O
which,1723,O
is,1723,O
associated,1723,O
with,1723,O
an,1723,O
increased,1723,O
incidence,1723,O
of,1723,O
urolithiasis,1723,B-Disease
.,1723,O
CONCLUSION,1724,O
:,1724,O
Ureteric,1724,B-Disease
obstruction,1724,I-Disease
caused,1724,O
by,1724,O
precipitated,1724,O
indinavir,1724,B-Chemical
crystals,1724,O
may,1724,O
be,1724,O
difficult,1724,O
to,1724,O
diagnose,1724,O
with,1724,O
unenhanced,1724,O
CT,1724,O
.,1724,O
The,1725,O
calculi,1725,O
are,1725,O
not,1725,O
opaque,1725,O
",",1725,O
and,1725,O
secondary,1725,O
signs,1725,O
of,1725,O
obstruction,1725,O
may,1725,O
be,1725,O
absent,1725,O
or,1725,O
minimal,1725,O
and,1725,O
should,1725,O
be,1725,O
sought,1725,O
carefully,1725,O
.,1725,O
Images,1726,O
may,1726,O
need,1726,O
to,1726,O
be,1726,O
obtained,1726,O
using,1726,O
i.v,1726,O
.,1726,O
contrast,1727,O
material,1727,O
to,1727,O
enable,1727,O
diagnosis,1727,O
of,1727,O
ureteric,1727,O
stones,1727,O
or,1727,O
obstruction,1727,O
in,1727,O
patients,1727,O
with,1727,O
HIV,1727,B-Disease
infection,1727,I-Disease
who,1727,O
receive,1727,O
indinavir,1727,B-Chemical
therapy,1727,O
.,1727,O
Ischemic,1728,B-Disease
colitis,1728,I-Disease
and,1728,O
sumatriptan,1728,B-Chemical
use,1728,O
.,1728,O
Sumatriptan,1729,B-Chemical
succinate,1729,I-Chemical
",",1729,O
a,1729,O
serotonin-1,1729,B-Chemical
(,1729,O
5-hydroxytryptamine-1,1729,B-Chemical
),1729,O
receptor,1729,O
agonist,1729,O
",",1729,O
is,1729,O
an,1729,O
antimigraine,1729,O
drug,1729,O
that,1729,O
is,1729,O
reported,1729,O
to,1729,O
act,1729,O
by,1729,O
selectively,1729,O
constricting,1729,O
intracranial,1729,O
arteries,1729,O
.,1729,O
Recently,1730,O
",",1730,O
vasopressor,1730,O
responses,1730,O
that,1730,O
are,1730,O
distinct,1730,O
from,1730,O
the,1730,O
cranial,1730,O
circulation,1730,O
have,1730,O
been,1730,O
demonstrated,1730,O
to,1730,O
occur,1730,O
in,1730,O
the,1730,O
systemic,1730,O
",",1730,O
pulmonary,1730,O
",",1730,O
and,1730,O
coronary,1730,O
circulations,1730,O
.,1730,O
Cases,1731,O
have,1731,O
been,1731,O
published,1731,O
of,1731,O
coronary,1731,B-Disease
vasospasm,1731,I-Disease
",",1731,O
myocardial,1731,B-Disease
ischemia,1731,I-Disease
",",1731,O
and,1731,O
myocardial,1731,B-Disease
infarction,1731,I-Disease
occurring,1731,O
after,1731,O
sumatriptan,1731,B-Chemical
use,1731,O
.,1731,O
We,1732,O
report,1732,O
on,1732,O
the,1732,O
development,1732,O
of,1732,O
8,1732,O
serious,1732,O
cases,1732,O
of,1732,O
ischemic,1732,B-Disease
colitis,1732,I-Disease
in,1732,O
patients,1732,O
with,1732,O
migraine,1732,B-Disease
treated,1732,O
with,1732,O
sumatriptan,1732,B-Chemical
.,1732,O
Pallidotomy,1733,O
with,1733,O
the,1733,O
gamma,1733,O
knife,1733,O
:,1733,O
a,1733,O
positive,1733,O
experience,1733,O
.,1733,O
51,1734,O
patients,1734,O
with,1734,O
medically,1734,O
refractory,1734,O
Parkinson,1734,B-Disease
's,1734,I-Disease
disease,1734,I-Disease
underwent,1734,O
stereotactic,1734,O
posteromedial,1734,O
pallidotomy,1734,O
between,1734,O
August,1734,O
1993,1734,O
and,1734,O
February,1734,O
1997,1734,O
for,1734,O
treatment,1734,O
of,1734,O
bradykinesia,1734,B-Disease
",",1734,O
rigidity,1734,B-Disease
",",1734,O
and,1734,O
L-DOPA-induced,1734,B-Chemical
dyskinesias,1734,B-Disease
.,1734,O
In,1735,O
29,1735,O
patients,1735,O
",",1735,O
the,1735,O
pallidotomies,1735,O
were,1735,O
performed,1735,O
with,1735,O
the,1735,O
Leksell,1735,O
Gamma,1735,O
Knife,1735,O
and,1735,O
in,1735,O
22,1735,O
they,1735,O
were,1735,O
performed,1735,O
with,1735,O
the,1735,O
standard,1735,O
radiofrequency,1735,O
(,1735,O
RF,1735,O
),1735,O
method,1735,O
.,1735,O
Clinical,1736,O
assessment,1736,O
as,1736,O
well,1736,O
as,1736,O
blinded,1736,O
ratings,1736,O
of,1736,O
Unified,1736,O
Parkinson,1736,B-Disease
's,1736,I-Disease
Disease,1736,I-Disease
Rating,1736,O
Scale,1736,O
(,1736,O
UPDRS,1736,O
),1736,O
scores,1736,O
were,1736,O
carried,1736,O
out,1736,O
pre-,1736,O
and,1736,O
postoperatively,1736,O
.,1736,O
Mean,1737,O
follow-up,1737,O
time,1737,O
is,1737,O
20.6,1737,O
months,1737,O
(,1737,O
range,1737,O
6-48,1737,O
),1737,O
and,1737,O
all,1737,O
except,1737,O
4,1737,O
patients,1737,O
have,1737,O
been,1737,O
followed,1737,O
more,1737,O
than,1737,O
one,1737,O
year,1737,O
.,1737,O
85,1738,O
percent,1738,O
of,1738,O
patients,1738,O
with,1738,O
dyskinesias,1738,B-Disease
were,1738,O
relieved,1738,O
of,1738,O
symptoms,1738,O
",",1738,O
regardless,1738,O
of,1738,O
whether,1738,O
the,1738,O
pallidotomies,1738,O
were,1738,O
performed,1738,O
with,1738,O
the,1738,O
Gamma,1738,O
Knife,1738,O
or,1738,O
radiofrequency,1738,O
methods,1738,O
.,1738,O
About,1739,O
2/3,1739,O
of,1739,O
the,1739,O
patients,1739,O
in,1739,O
both,1739,O
Gamma,1739,O
Knife,1739,O
and,1739,O
radiofrequency,1739,O
groups,1739,O
showed,1739,O
improvements,1739,O
in,1739,O
bradykinesia,1739,B-Disease
and,1739,O
rigidity,1739,B-Disease
",",1739,O
although,1739,O
when,1739,O
considered,1739,O
as,1739,O
a,1739,O
group,1739,O
neither,1739,O
the,1739,O
Gamma,1739,O
Knife,1739,O
nor,1739,O
the,1739,O
radiofrequency,1739,O
group,1739,O
showed,1739,O
statistically,1739,O
significant,1739,O
improvements,1739,O
in,1739,O
UPDRS,1739,O
scores,1739,O
.,1739,O
One,1740,O
patient,1740,O
in,1740,O
the,1740,O
Gamma,1740,O
Knife,1740,O
group,1740,O
(,1740,O
3.4,1740,O
%,1740,O
),1740,O
developed,1740,O
a,1740,O
homonymous,1740,B-Disease
hemianopsia,1740,I-Disease
9,1740,O
months,1740,O
following,1740,O
treatment,1740,O
and,1740,O
5,1740,O
patients,1740,O
(,1740,O
27.7,1740,O
%,1740,O
),1740,O
in,1740,O
the,1740,O
radiofrequency,1740,O
group,1740,O
became,1740,O
transiently,1740,O
confused,1740,O
postoperatively,1740,O
.,1740,O
No,1741,O
other,1741,O
complications,1741,O
were,1741,O
seen,1741,O
.,1741,O
Gamma,1742,O
Knife,1742,O
pallidotomy,1742,O
is,1742,O
as,1742,O
effective,1742,O
as,1742,O
radiofrequency,1742,O
pallidotomy,1742,O
in,1742,O
controlling,1742,O
certain,1742,O
of,1742,O
the,1742,O
symptoms,1742,O
of,1742,O
Parkinson,1742,B-Disease
's,1742,I-Disease
disease,1742,I-Disease
.,1742,O
It,1743,O
may,1743,O
be,1743,O
the,1743,O
only,1743,O
practical,1743,O
technique,1743,O
available,1743,O
in,1743,O
certain,1743,O
patients,1743,O
",",1743,O
such,1743,O
as,1743,O
those,1743,O
who,1743,O
take,1743,O
anticoagulants,1743,O
",",1743,O
have,1743,O
bleeding,1743,B-Disease
diatheses,1743,O
or,1743,O
serious,1743,O
systemic,1743,O
medical,1743,O
illnesses,1743,O
.,1743,O
It,1744,O
is,1744,O
a,1744,O
viable,1744,O
option,1744,O
for,1744,O
other,1744,O
patients,1744,O
as,1744,O
well,1744,O
.,1744,O
Neuroleptic,1745,B-Disease
malignant,1745,I-Disease
syndrome,1745,I-Disease
and,1745,O
methylphenidate,1745,B-Chemical
.,1745,O
A,1746,O
1-year-old,1746,O
female,1746,O
presented,1746,O
with,1746,O
neuroleptic,1746,B-Disease
malignant,1746,I-Disease
syndrome,1746,I-Disease
probably,1746,O
caused,1746,O
by,1746,O
methylphenidate,1746,B-Chemical
.,1746,O
She,1747,O
had,1747,O
defects,1747,O
in,1747,O
the,1747,O
supratentorial,1747,O
brain,1747,O
including,1747,O
the,1747,O
basal,1747,O
ganglia,1747,O
and,1747,O
the,1747,O
striatum,1747,O
(,1747,O
multicystic,1747,B-Disease
encephalomalacia,1747,I-Disease
),1747,O
due,1747,O
to,1747,O
severe,1747,O
perinatal,1747,O
hypoxic-ischemic,1747,B-Disease
encephalopathy,1747,I-Disease
",",1747,O
which,1747,O
was,1747,O
considered,1747,O
to,1747,O
be,1747,O
a,1747,O
possible,1747,O
predisposing,1747,O
factor,1747,O
causing,1747,O
neuroleptic,1747,B-Disease
malignant,1747,I-Disease
syndrome,1747,I-Disease
.,1747,O
A,1748,O
dopaminergic,1748,O
blockade,1748,O
mechanism,1748,O
generally,1748,O
is,1748,O
accepted,1748,O
as,1748,O
the,1748,O
pathogenesis,1748,O
of,1748,O
this,1748,O
syndrome,1748,O
.,1748,O
However,1749,O
",",1749,O
methylphenidate,1749,B-Chemical
is,1749,O
a,1749,O
dopamine,1749,B-Chemical
agonist,1749,O
via,1749,O
the,1749,O
inhibition,1749,O
of,1749,O
uptake,1749,O
of,1749,O
dopamine,1749,B-Chemical
",",1749,O
and,1749,O
therefore,1749,O
dopaminergic,1749,O
systems,1749,O
in,1749,O
the,1749,O
brainstem,1749,O
(,1749,O
mainly,1749,O
the,1749,O
midbrain,1749,O
),1749,O
and,1749,O
the,1749,O
spinal,1749,O
cord,1749,O
were,1749,O
unlikely,1749,O
to,1749,O
participate,1749,O
in,1749,O
the,1749,O
onset,1749,O
of,1749,O
this,1749,O
syndrome,1749,O
.,1749,O
A,1750,O
relative,1750,O
gamma-aminobutyric,1750,B-Chemical
acid-ergic,1750,O
deficiency,1750,O
might,1750,O
occur,1750,O
because,1750,O
diazepam,1750,B-Chemical
",",1750,O
a,1750,O
gamma-aminobutyric,1750,B-Chemical
acid-mimetic,1750,O
agent,1750,O
",",1750,O
was,1750,O
strikingly,1750,O
effective,1750,O
.,1750,O
This,1751,O
is,1751,O
the,1751,O
first,1751,O
reported,1751,O
patient,1751,O
with,1751,O
neuroleptic,1751,B-Disease
malignant,1751,I-Disease
syndrome,1751,I-Disease
probably,1751,O
caused,1751,O
by,1751,O
methylphenidate,1751,B-Chemical
.,1751,O
Differential,1752,O
effects,1752,O
of,1752,O
17alpha-ethinylestradiol,1752,B-Chemical
on,1752,O
the,1752,O
neutral,1752,O
and,1752,O
acidic,1752,O
pathways,1752,O
of,1752,O
bile,1752,B-Chemical
salt,1752,I-Chemical
synthesis,1752,O
in,1752,O
the,1752,O
rat,1752,O
.,1752,O
Effects,1753,O
of,1753,O
17alpha-ethinylestradiol,1753,B-Chemical
(,1753,O
EE,1753,B-Chemical
),1753,O
on,1753,O
the,1753,O
neutral,1753,O
and,1753,O
acidic,1753,O
biosynthetic,1753,O
pathways,1753,O
of,1753,O
bile,1753,B-Chemical
salt,1753,I-Chemical
(,1753,O
BS,1753,B-Chemical
),1753,O
synthesis,1753,O
were,1753,O
evaluated,1753,O
in,1753,O
rats,1753,O
with,1753,O
an,1753,O
intact,1753,O
enterohepatic,1753,O
circulation,1753,O
and,1753,O
in,1753,O
rats,1753,O
with,1753,O
long-term,1753,O
bile,1753,O
diversion,1753,O
to,1753,O
induce,1753,O
BS,1753,B-Chemical
synthesis,1753,O
.,1753,O
For,1754,O
this,1754,O
purpose,1754,O
",",1754,O
bile,1754,B-Chemical
salt,1754,I-Chemical
pool,1754,O
composition,1754,O
",",1754,O
synthesis,1754,O
of,1754,O
individual,1754,O
BS,1754,B-Chemical
in,1754,O
vivo,1754,O
",",1754,O
hepatic,1754,O
activities,1754,O
",",1754,O
and,1754,O
expression,1754,O
levels,1754,O
of,1754,O
cholesterol,1754,B-Chemical
7alpha-hydroxylase,1754,O
(,1754,O
CYP7A,1754,O
),1754,O
",",1754,O
and,1754,O
sterol,1754,B-Chemical
27-hydroxylase,1754,O
(,1754,O
CYP27,1754,O
),1754,O
",",1754,O
as,1754,O
well,1754,O
as,1754,O
of,1754,O
other,1754,O
enzymes,1754,O
involved,1754,O
in,1754,O
BS,1754,B-Chemical
synthesis,1754,O
",",1754,O
were,1754,O
analyzed,1754,O
in,1754,O
rats,1754,O
treated,1754,O
with,1754,O
EE,1754,B-Chemical
(,1754,O
5,1754,O
mg/kg,1754,O
",",1754,O
3,1754,O
days,1754,O
),1754,O
or,1754,O
its,1754,O
vehicle,1754,O
.,1754,O
BS,1755,B-Chemical
pool,1755,O
size,1755,O
was,1755,O
decreased,1755,O
by,1755,O
27,1755,O
%,1755,O
but,1755,O
total,1755,O
BS,1755,B-Chemical
synthesis,1755,O
was,1755,O
not,1755,O
affected,1755,O
by,1755,O
EE,1755,B-Chemical
in,1755,O
intact,1755,O
rats,1755,O
.,1755,O
Synthesis,1756,O
of,1756,O
cholate,1756,B-Chemical
was,1756,O
reduced,1756,O
by,1756,O
68,1756,O
%,1756,O
in,1756,O
EE-treated,1756,B-Chemical
rats,1756,O
",",1756,O
while,1756,O
that,1756,O
of,1756,O
chenodeoxycholate,1756,B-Chemical
was,1756,O
increased,1756,O
by,1756,O
60,1756,O
%,1756,O
.,1756,O
The,1757,O
recently,1757,O
identified,1757,O
Delta22-isomer,1757,O
of,1757,O
beta-muricholate,1757,O
contributed,1757,O
for,1757,O
5.4,1757,O
%,1757,O
and,1757,O
18.3,1757,O
%,1757,O
(,1757,O
P,1757,O
<,1757,O
0.01,1757,O
),1757,O
to,1757,O
the,1757,O
pool,1757,O
in,1757,O
control,1757,O
and,1757,O
EE-treated,1757,B-Chemical
rats,1757,O
",",1757,O
respectively,1757,O
",",1757,O
but,1757,O
could,1757,O
not,1757,O
be,1757,O
detected,1757,O
in,1757,O
bile,1757,O
after,1757,O
exhaustion,1757,O
of,1757,O
the,1757,O
pool,1757,O
.,1757,O
A,1758,O
clear,1758,O
reduction,1758,O
of,1758,O
BS,1758,B-Chemical
synthesis,1758,O
was,1758,O
found,1758,O
in,1758,O
bile-diverted,1758,O
rats,1758,O
treated,1758,O
with,1758,O
EE,1758,B-Chemical
",",1758,O
yet,1758,O
biliary,1758,O
BS,1758,B-Chemical
composition,1758,O
was,1758,O
only,1758,O
minimally,1758,O
affected,1758,O
.,1758,O
Activity,1759,O
of,1759,O
CYP7A,1759,O
was,1759,O
decreased,1759,O
by,1759,O
EE,1759,B-Chemical
in,1759,O
both,1759,O
intact,1759,O
and,1759,O
bile-diverted,1759,O
rats,1759,O
",",1759,O
whereas,1759,O
the,1759,O
activity,1759,O
of,1759,O
the,1759,O
CYP27,1759,O
was,1759,O
not,1759,O
affected,1759,O
.,1759,O
Hepatic,1760,O
mRNA,1760,O
levels,1760,O
of,1760,O
CYP7A,1760,O
were,1760,O
significantly,1760,O
reduced,1760,O
by,1760,O
EE,1760,B-Chemical
in,1760,O
bile-diverted,1760,O
rats,1760,O
only,1760,O
;,1760,O
CYP27,1760,O
mRNA,1760,O
levels,1760,O
were,1760,O
not,1760,O
affected,1760,O
by,1760,O
EE,1760,B-Chemical
.,1760,O
In,1761,O
addition,1761,O
",",1761,O
mRNA,1761,O
levels,1761,O
of,1761,O
sterol,1761,B-Chemical
12alpha-hydroxylase,1761,O
and,1761,O
lithocholate,1761,O
6beta-hydroxylase,1761,O
were,1761,O
increased,1761,O
by,1761,O
bile,1761,O
diversion,1761,O
and,1761,O
suppressed,1761,O
by,1761,O
EE,1761,B-Chemical
.,1761,O
This,1762,O
study,1762,O
shows,1762,O
that,1762,O
17alpha-ethinylestradiol,1762,B-Chemical
(,1762,O
EE,1762,B-Chemical
),1762,O
-induced,1762,O
intrahepatic,1762,B-Disease
cholestasis,1762,I-Disease
in,1762,O
rats,1762,O
is,1762,O
associated,1762,O
with,1762,O
selective,1762,O
inhibition,1762,O
of,1762,O
the,1762,O
neutral,1762,O
pathway,1762,O
of,1762,O
bile,1762,B-Chemical
salt,1762,I-Chemical
(,1762,O
BS,1762,B-Chemical
),1762,O
synthesis,1762,O
.,1762,O
Simultaneous,1763,O
impairment,1763,O
of,1763,O
other,1763,O
enzymes,1763,O
in,1763,O
the,1763,O
BS,1763,B-Chemical
biosynthetic,1763,O
pathways,1763,O
may,1763,O
contribute,1763,O
to,1763,O
overall,1763,O
effects,1763,O
of,1763,O
EE,1763,B-Chemical
on,1763,O
BS,1763,B-Chemical
synthesis,1763,O
.,1763,O
Glibenclamide-sensitive,1764,B-Chemical
hypotension,1764,B-Disease
produced,1764,O
by,1764,O
helodermin,1764,B-Chemical
assessed,1764,O
in,1764,O
the,1764,O
rat,1764,O
.,1764,O
The,1765,O
effects,1765,O
of,1765,O
helodermin,1765,B-Chemical
",",1765,O
a,1765,O
basic,1765,O
35-amino,1765,O
acid,1765,I-Chemical
peptide,1765,O
isolated,1765,O
from,1765,O
the,1765,O
venom,1765,O
of,1765,O
a,1765,O
lizard,1765,O
salivary,1765,O
gland,1765,O
",",1765,O
on,1765,O
arterial,1765,O
blood,1765,O
pressure,1765,O
and,1765,O
heart,1765,O
rate,1765,O
were,1765,O
examined,1765,O
in,1765,O
the,1765,O
rat,1765,O
",",1765,O
focusing,1765,O
on,1765,O
the,1765,O
possibility,1765,O
that,1765,O
activation,1765,O
of,1765,O
ATP,1765,B-Chemical
sensitive,1765,O
K+,1765,B-Chemical
(,1765,O
K,1765,B-Chemical
(,1765,O
ATP,1765,B-Chemical
),1765,O
),1765,O
channels,1765,O
is,1765,O
involved,1765,O
in,1765,O
the,1765,O
responses,1765,O
.,1765,O
The,1766,O
results,1766,O
were,1766,O
also,1766,O
compared,1766,O
with,1766,O
those,1766,O
of,1766,O
vasoactive,1766,O
intestinal,1766,O
polypeptide,1766,O
(,1766,O
VIP,1766,O
),1766,O
.,1766,O
Helodermin,1767,B-Chemical
produced,1767,O
hypotension,1767,B-Disease
in,1767,O
a,1767,O
dose-dependent,1767,O
manner,1767,O
with,1767,O
approximately,1767,O
similar,1767,O
potency,1767,O
and,1767,O
duration,1767,O
to,1767,O
VIP,1767,O
.,1767,O
Hypotension,1768,B-Disease
induced,1768,O
by,1768,O
both,1768,O
peptides,1768,O
was,1768,O
significantly,1768,O
attenuated,1768,O
by,1768,O
glibenclamide,1768,B-Chemical
",",1768,O
which,1768,O
abolished,1768,O
a,1768,O
levcromakalim-produced,1768,B-Chemical
decrease,1768,O
in,1768,O
arterial,1768,O
blood,1768,O
pressure,1768,O
.,1768,O
Oxyhemoglobin,1769,O
did,1769,O
not,1769,O
affect,1769,O
helodermin-induced,1769,B-Chemical
hypotension,1769,B-Disease
",",1769,O
whereas,1769,O
it,1769,O
shortened,1769,O
the,1769,O
duration,1769,O
of,1769,O
acetylcholine,1769,B-Chemical
(,1769,O
ACh,1769,B-Chemical
),1769,O
-produced,1769,O
hypotension,1769,B-Disease
.,1769,O
These,1770,O
findings,1770,O
suggest,1770,O
that,1770,O
helodermin-produced,1770,B-Chemical
hypotension,1770,B-Disease
is,1770,O
partly,1770,O
attributable,1770,O
to,1770,O
the,1770,O
activation,1770,O
of,1770,O
glibenclamide-sensitive,1770,B-Chemical
K+,1770,B-Chemical
channels,1770,O
(,1770,O
K,1770,B-Chemical
(,1770,O
ATP,1770,B-Chemical
),1770,O
channels,1770,O
),1770,O
",",1770,O
which,1770,O
presumably,1770,O
exist,1770,O
on,1770,O
arterial,1770,O
smooth,1770,O
muscle,1770,O
cells,1770,O
.,1770,O
EDRF,1771,O
(,1771,O
endothelium-derived,1771,O
relaxing,1771,O
factor,1771,O
),1771,O
/nitric,1771,O
oxide,1771,I-Chemical
does,1771,O
not,1771,O
seem,1771,O
to,1771,O
play,1771,O
an,1771,O
important,1771,O
role,1771,O
in,1771,O
the,1771,O
peptide-produced,1771,O
hypotension,1771,B-Disease
.,1771,O
Long-term,1772,O
efficacy,1772,O
and,1772,O
adverse,1772,O
event,1772,O
of,1772,O
nifedipine,1772,B-Chemical
sustained-release,1772,O
tablets,1772,O
for,1772,O
cyclosporin,1772,B-Chemical
A-induced,1772,O
hypertension,1772,B-Disease
in,1772,O
patients,1772,O
with,1772,O
psoriasis,1772,B-Disease
.,1772,O
Thirteen,1773,O
psoriatic,1773,B-Disease
patients,1773,O
with,1773,O
hypertension,1773,B-Disease
during,1773,O
the,1773,O
course,1773,O
of,1773,O
cyclosporin,1773,B-Chemical
A,1773,I-Chemical
therapy,1773,O
were,1773,O
treated,1773,O
for,1773,O
25,1773,O
months,1773,O
with,1773,O
a,1773,O
calcium,1773,B-Chemical
channel,1773,O
blocker,1773,O
",",1773,O
sustained-release,1773,O
nifedipine,1773,B-Chemical
",",1773,O
to,1773,O
study,1773,O
the,1773,O
clinical,1773,O
antihypertensive,1773,O
effects,1773,O
and,1773,O
adverse,1773,O
events,1773,O
during,1773,O
treatment,1773,O
with,1773,O
both,1773,O
drugs,1773,O
.,1773,O
Seven,1774,O
of,1774,O
the,1774,O
13,1774,O
patients,1774,O
had,1774,O
exhibited,1774,O
a,1774,O
subclinical,1774,O
hypertensive,1774,B-Disease
state,1774,O
before,1774,O
cyclosporin,1774,B-Chemical
A,1774,I-Chemical
therapy,1774,O
.,1774,O
Both,1775,O
systolic,1775,O
and,1775,O
diastolic,1775,O
blood,1775,O
pressures,1775,O
of,1775,O
these,1775,O
13,1775,O
patients,1775,O
were,1775,O
decreased,1775,O
significantly,1775,O
after,1775,O
4,1775,O
weeks,1775,O
of,1775,O
nifedipine,1775,B-Chemical
therapy,1775,O
",",1775,O
and,1775,O
blood,1775,O
pressure,1775,O
was,1775,O
maintained,1775,O
within,1775,O
the,1775,O
normal,1775,O
range,1775,O
thereafter,1775,O
for,1775,O
25,1775,O
months,1775,O
.,1775,O
The,1776,O
adverse,1776,O
events,1776,O
during,1776,O
combined,1776,O
therapy,1776,O
with,1776,O
cyclosporin,1776,B-Chemical
A,1776,I-Chemical
and,1776,O
nifedipine,1776,B-Chemical
included,1776,O
an,1776,O
increase,1776,O
in,1776,O
blood,1776,B-Chemical
urea,1776,I-Chemical
nitrogen,1776,I-Chemical
levels,1776,O
in,1776,O
9,1776,O
of,1776,O
the,1776,O
13,1776,O
patients,1776,O
and,1776,O
development,1776,O
of,1776,O
gingival,1776,B-Disease
hyperplasia,1776,I-Disease
in,1776,O
2,1776,O
of,1776,O
the,1776,O
13,1776,O
patients,1776,O
.,1776,O
Our,1777,O
findings,1777,O
indicate,1777,O
that,1777,O
sustained-release,1777,O
nifedipine,1777,B-Chemical
is,1777,O
useful,1777,O
for,1777,O
hypertensive,1777,B-Disease
psoriatic,1777,B-Disease
patients,1777,O
under,1777,O
long-term,1777,O
treatment,1777,O
with,1777,O
cyclosporin,1777,B-Chemical
A,1777,I-Chemical
",",1777,O
but,1777,O
that,1777,O
these,1777,O
patients,1777,O
should,1777,O
be,1777,O
monitored,1777,O
for,1777,O
gingival,1777,B-Disease
hyperplasia,1777,I-Disease
.,1777,O
Torsade,1778,B-Disease
de,1778,I-Disease
pointes,1778,I-Disease
ventricular,1778,B-Disease
tachycardia,1778,I-Disease
during,1778,O
low,1778,O
dose,1778,O
intermittent,1778,O
dobutamine,1778,B-Chemical
treatment,1778,O
in,1778,O
a,1778,O
patient,1778,O
with,1778,O
dilated,1778,B-Disease
cardiomyopathy,1778,I-Disease
and,1778,O
congestive,1778,B-Disease
heart,1778,I-Disease
failure,1778,I-Disease
.,1778,O
The,1779,O
authors,1779,O
describe,1779,O
the,1779,O
case,1779,O
of,1779,O
a,1779,O
56-year-old,1779,O
woman,1779,O
with,1779,O
chronic,1779,O
",",1779,O
severe,1779,O
heart,1779,B-Disease
failure,1779,I-Disease
secondary,1779,O
to,1779,O
dilated,1779,B-Disease
cardiomyopathy,1779,I-Disease
and,1779,O
absence,1779,O
of,1779,O
significant,1779,O
ventricular,1779,B-Disease
arrhythmias,1779,I-Disease
who,1779,O
developed,1779,O
QT,1779,B-Disease
prolongation,1779,I-Disease
and,1779,O
torsade,1779,B-Disease
de,1779,I-Disease
pointes,1779,I-Disease
ventricular,1779,B-Disease
tachycardia,1779,I-Disease
during,1779,O
one,1779,O
cycle,1779,O
of,1779,O
intermittent,1779,O
low,1779,O
dose,1779,O
(,1779,O
2.5,1779,O
mcg/kg,1779,O
per,1779,O
min,1779,O
),1779,O
dobutamine,1779,B-Chemical
.,1779,O
This,1780,O
report,1780,O
of,1780,O
torsade,1780,B-Disease
de,1780,I-Disease
pointes,1780,I-Disease
ventricular,1780,B-Disease
tachycardia,1780,I-Disease
during,1780,O
intermittent,1780,O
dobutamine,1780,B-Chemical
supports,1780,O
the,1780,O
hypothesis,1780,O
that,1780,O
unpredictable,1780,O
fatal,1780,O
arrhythmias,1780,B-Disease
may,1780,O
occur,1780,O
even,1780,O
with,1780,O
low,1780,O
doses,1780,O
and,1780,O
in,1780,O
patients,1780,O
with,1780,O
no,1780,O
history,1780,O
of,1780,O
significant,1780,O
rhythm,1780,O
disturbances,1780,O
.,1780,O
The,1781,O
mechanisms,1781,O
of,1781,O
proarrhythmic,1781,O
effects,1781,O
of,1781,O
Dubutamine,1781,B-Chemical
are,1781,O
discussed,1781,O
.,1781,O
Positive,1782,O
skin,1782,O
tests,1782,O
in,1782,O
late,1782,O
reactions,1782,O
to,1782,O
radiographic,1782,O
contrast,1782,B-Chemical
media,1782,I-Chemical
.,1782,O
In,1783,O
the,1783,O
last,1783,O
few,1783,O
years,1783,O
delayed,1783,O
reactions,1783,O
several,1783,O
hours,1783,O
after,1783,O
the,1783,O
injection,1783,O
of,1783,O
radiographic,1783,O
and,1783,O
contrast,1783,B-Chemical
materials,1783,I-Chemical
(,1783,O
PRC,1783,B-Chemical
),1783,O
have,1783,O
been,1783,O
described,1783,O
with,1783,O
increasing,1783,O
frequency,1783,O
.,1783,O
The,1784,O
authors,1784,O
report,1784,O
two,1784,O
observations,1784,O
on,1784,O
patients,1784,O
with,1784,O
delayed,1784,O
reactions,1784,O
in,1784,O
whom,1784,O
intradermoreactions,1784,O
(,1784,O
IDR,1784,O
),1784,O
and,1784,O
patch,1784,O
tests,1784,O
to,1784,O
a,1784,O
series,1784,O
of,1784,O
ionic,1784,O
and,1784,O
non,1784,O
ionic,1784,O
PRC,1784,B-Chemical
were,1784,O
studied,1784,O
.,1784,O
After,1785,O
angiography,1785,O
by,1785,O
the,1785,O
venous,1785,O
route,1785,O
in,1785,O
patient,1785,O
n,1785,O
degree,1785,O
1,1785,O
a,1785,O
biphasic,1785,O
reaction,1785,O
with,1785,O
an,1785,O
immediate,1785,O
reaction,1785,O
(,1785,O
dyspnea,1785,B-Disease
",",1785,O
loss,1785,B-Disease
of,1785,I-Disease
consciousness,1785,I-Disease
),1785,O
and,1785,O
delayed,1785,O
macro-papular,1785,B-Disease
rash,1785,I-Disease
appeared,1785,O
",",1785,O
whilst,1785,O
patient,1785,O
n,1785,O
degree,1785,O
2,1785,O
developed,1785,O
a,1785,O
generalised,1785,O
sensation,1785,O
of,1785,O
heat,1785,O
",",1785,O
persistent,1785,O
pain,1785,B-Disease
at,1785,O
the,1785,O
site,1785,O
of,1785,O
injection,1785,O
immediately,1785,O
and,1785,O
a,1785,O
generalised,1785,O
macro-papular,1785,O
reaction,1785,O
after,1785,O
24,1785,O
hours,1785,O
.,1785,O
The,1786,O
skin,1786,O
tests,1786,O
revealed,1786,O
positive,1786,O
delayed,1786,O
reactions,1786,O
of,1786,O
24,1786,O
hours,1786,O
and,1786,O
48,1786,O
hours,1786,O
by,1786,O
IDR,1786,O
and,1786,O
patch,1786,O
tests,1786,O
to,1786,O
only,1786,O
some,1786,O
PRC,1786,B-Chemical
with,1786,O
common,1786,O
chains,1786,O
in,1786,O
their,1786,O
structures,1786,O
.,1786,O
The,1787,O
positive,1787,O
skin,1787,O
tests,1787,O
are,1787,O
in,1787,O
favour,1787,O
of,1787,O
immunological,1787,O
reactions,1787,O
and,1787,O
may,1787,O
help,1787,O
in,1787,O
diagnosis,1787,O
of,1787,O
allergy,1787,B-Disease
in,1787,O
the,1787,O
patients,1787,O
.,1787,O
Risk,1788,O
of,1788,O
transient,1788,O
hyperammonemic,1788,O
encephalopathy,1788,O
in,1788,O
cancer,1788,B-Disease
patients,1788,O
who,1788,O
received,1788,O
continuous,1788,O
infusion,1788,O
of,1788,O
5-fluorouracil,1788,B-Chemical
with,1788,O
the,1788,O
complication,1788,O
of,1788,O
dehydration,1788,B-Disease
and,1788,O
infection,1788,B-Disease
.,1788,O
From,1789,O
1986,1789,O
to,1789,O
1998,1789,O
",",1789,O
29,1789,O
cancer,1789,B-Disease
patients,1789,O
who,1789,O
had,1789,O
32,1789,O
episodes,1789,O
of,1789,O
transient,1789,O
hyperammonemic,1789,O
encephalopathy,1789,O
related,1789,O
to,1789,O
continuous,1789,O
infusion,1789,O
of,1789,O
5-fluorouracil,1789,B-Chemical
(,1789,O
5-FU,1789,B-Chemical
),1789,O
were,1789,O
identified,1789,O
.,1789,O
None,1790,O
of,1790,O
the,1790,O
patients,1790,O
had,1790,O
decompensated,1790,O
liver,1790,B-Disease
disease,1790,I-Disease
.,1790,O
Onset,1791,O
of,1791,O
hyperammonemic,1791,O
encephalopathy,1791,O
varied,1791,O
from,1791,O
0.5,1791,O
to,1791,O
5,1791,O
days,1791,O
(,1791,O
mean,1791,O
:,1791,O
2.6,1791,O
+/-,1791,O
1.3,1791,O
days,1791,O
),1791,O
after,1791,O
the,1791,O
initiation,1791,O
of,1791,O
chemotherapy,1791,O
.,1791,O
Plasma,1792,O
ammonium,1792,B-Chemical
level,1792,O
ranged,1792,O
from,1792,O
248,1792,O
to,1792,O
2387,1792,O
microg,1792,O
%,1792,O
(,1792,O
mean,1792,O
:,1792,O
626,1792,O
+/-,1792,O
431,1792,O
microg,1792,O
%,1792,O
),1792,O
.,1792,O
Among,1793,O
the,1793,O
32,1793,O
episodes,1793,O
",",1793,O
26,1793,O
(,1793,O
81,1793,O
%,1793,O
),1793,O
had,1793,O
various,1793,O
degrees,1793,O
of,1793,O
azotemia,1793,B-Disease
",",1793,O
18,1793,O
(,1793,O
56,1793,O
%,1793,O
),1793,O
occurred,1793,O
during,1793,O
bacterial,1793,B-Disease
infections,1793,I-Disease
and,1793,O
14,1793,O
(,1793,O
44,1793,O
%,1793,O
),1793,O
without,1793,O
infection,1793,B-Disease
occurred,1793,O
during,1793,O
periods,1793,O
of,1793,O
dehydration,1793,B-Disease
.,1793,O
Higher,1794,O
plasma,1794,O
ammonium,1794,B-Chemical
levels,1794,O
and,1794,O
more,1794,O
rapid,1794,O
onset,1794,O
of,1794,O
hyperammonemia,1794,B-Disease
were,1794,O
seen,1794,O
in,1794,O
18,1794,O
patients,1794,O
with,1794,O
bacterial,1794,B-Disease
infections,1794,I-Disease
(,1794,O
p=0.003,1794,O
and,1794,O
0.0006,1794,O
",",1794,O
respectively,1794,O
),1794,O
and,1794,O
in,1794,O
nine,1794,O
patients,1794,O
receiving,1794,O
high,1794,O
daily,1794,O
doses,1794,O
(,1794,O
2600,1794,O
or,1794,O
1800,1794,O
mg/m2,1794,O
),1794,O
of,1794,O
5-FU,1794,B-Chemical
(,1794,O
p=0.0001,1794,O
and,1794,O
<,1794,O
0.0001,1794,O
",",1794,O
respectively,1794,O
),1794,O
.,1794,O
In,1795,O
25,1795,O
out,1795,O
of,1795,O
32,1795,O
episodes,1795,O
(,1795,O
78,1795,O
%,1795,O
),1795,O
",",1795,O
plasma,1795,O
ammonium,1795,B-Chemical
levels,1795,O
and,1795,O
mental,1795,O
status,1795,O
returned,1795,O
to,1795,O
normal,1795,O
within,1795,O
2,1795,O
days,1795,O
after,1795,O
adequate,1795,O
management,1795,O
.,1795,O
In,1796,O
conclusion,1796,O
",",1796,O
hyperammonemic,1796,O
encephalopathy,1796,O
can,1796,O
occur,1796,O
in,1796,O
patients,1796,O
receiving,1796,O
continuous,1796,O
infusion,1796,O
of,1796,O
5-FU,1796,B-Chemical
.,1796,O
Azotemia,1797,B-Disease
",",1797,O
body,1797,O
fluid,1797,O
insufficiency,1797,O
and,1797,O
bacterial,1797,B-Disease
infections,1797,I-Disease
were,1797,O
frequently,1797,O
found,1797,O
in,1797,O
these,1797,O
patients,1797,O
.,1797,O
It,1798,O
is,1798,O
therefore,1798,O
important,1798,O
to,1798,O
recognize,1798,O
this,1798,O
condition,1798,O
in,1798,O
patients,1798,O
receiving,1798,O
continuous,1798,O
infusion,1798,O
of,1798,O
5-FU,1798,B-Chemical
.,1798,O
The,1799,O
effects,1799,O
of,1799,O
quinine,1799,B-Chemical
and,1799,O
4-aminopyridine,1799,B-Chemical
on,1799,O
conditioned,1799,O
place,1799,O
preference,1799,O
and,1799,O
changes,1799,O
in,1799,O
motor,1799,O
activity,1799,O
induced,1799,O
by,1799,O
morphine,1799,B-Chemical
in,1799,O
rats,1799,O
.,1799,O
1,1800,O
.,1800,O
The,1801,O
effects,1801,O
of,1801,O
two,1801,O
unselective,1801,O
potassium,1801,B-Chemical
(,1801,O
K,1801,B-Chemical
(,1801,O
+,1801,O
),1801,O
-,1801,O
),1801,O
channel,1801,O
blockers,1801,O
",",1801,O
quinine,1801,B-Chemical
(,1801,O
12.5,1801,O
",",1801,O
25,1801,O
and,1801,O
50,1801,O
mg/kg,1801,O
),1801,O
and,1801,O
4-aminopyridine,1801,B-Chemical
(,1801,O
1,1801,O
and,1801,O
2,1801,O
mg/kg,1801,O
),1801,O
",",1801,O
on,1801,O
conditioned,1801,O
place,1801,O
preference,1801,O
and,1801,O
biphasic,1801,O
changes,1801,O
in,1801,O
motor,1801,O
activity,1801,O
induced,1801,O
by,1801,O
morphine,1801,B-Chemical
(,1801,O
10,1801,O
mg/kg,1801,O
),1801,O
were,1801,O
tested,1801,O
in,1801,O
Wistar,1801,O
rats,1801,O
.,1801,O
Quinine,1802,B-Chemical
is,1802,O
known,1802,O
to,1802,O
block,1802,O
voltage-,1802,O
",",1802,O
calcium-,1802,B-Chemical
and,1802,O
ATP-sensitive,1802,B-Chemical
K,1802,B-Chemical
(,1802,O
+,1802,O
),1802,O
-channels,1802,O
while,1802,O
4-aminopyridine,1802,B-Chemical
is,1802,O
known,1802,O
to,1802,O
block,1802,O
voltage-sensitive,1802,O
K,1802,B-Chemical
(,1802,O
+,1802,O
),1802,O
-channels,1802,O
.,1802,O
2,1803,O
.,1803,O
In,1804,O
the,1804,O
counterbalanced,1804,O
method,1804,O
",",1804,O
quinine,1804,B-Chemical
attenuated,1804,O
morphine-induced,1804,B-Chemical
place,1804,O
preference,1804,O
",",1804,O
whereas,1804,O
4-aminopyridine,1804,B-Chemical
was,1804,O
ineffective,1804,O
.,1804,O
In,1805,O
the,1805,O
motor,1805,O
activity,1805,O
test,1805,O
measured,1805,O
with,1805,O
an,1805,O
Animex-activity,1805,O
meter,1805,O
neither,1805,O
of,1805,O
the,1805,O
K,1805,B-Chemical
(,1805,O
+,1805,O
),1805,O
-channel,1805,O
blockers,1805,O
affected,1805,O
morphine-induced,1805,B-Chemical
hypoactivity,1805,B-Disease
",",1805,O
but,1805,O
both,1805,O
K,1805,B-Chemical
(,1805,O
+,1805,O
),1805,O
-channel,1805,O
blockers,1805,O
prevented,1805,O
morphine-induced,1805,B-Chemical
secondary,1805,O
hyperactivity,1805,B-Disease
.,1805,O
3,1806,O
.,1806,O
These,1807,O
results,1807,O
suggest,1807,O
the,1807,O
involvement,1807,O
of,1807,O
quinine-sensitive,1807,B-Chemical
but,1807,O
not,1807,O
4-aminopyridine-sensitive,1807,B-Chemical
K,1807,B-Chemical
(,1807,O
+,1807,O
),1807,O
-channels,1807,O
in,1807,O
morphine,1807,B-Chemical
reward,1807,O
.,1807,O
It,1808,O
is,1808,O
also,1808,O
suggested,1808,O
that,1808,O
the,1808,O
blockade,1808,O
of,1808,O
K,1808,B-Chemical
(,1808,O
+,1808,O
),1808,O
-channels,1808,O
sensitive,1808,O
to,1808,O
these,1808,O
blockers,1808,O
is,1808,O
not,1808,O
sufficient,1808,O
to,1808,O
prevent,1808,O
morphine-induced,1808,B-Chemical
hypoactivity,1808,B-Disease
whereas,1808,O
morphine-induced,1808,B-Chemical
hyperactivity,1808,B-Disease
seems,1808,O
to,1808,O
be,1808,O
connected,1808,O
to,1808,O
both,1808,O
quinine-,1808,B-Chemical
and,1808,O
4-aminopyridine-sensitive,1808,B-Chemical
K,1808,B-Chemical
(,1808,O
+,1808,O
),1808,O
-channels,1808,O
.,1808,O
Nociceptin/orphanin,1809,B-Chemical
FQ,1809,I-Chemical
and,1809,O
nocistatin,1809,B-Chemical
on,1809,O
learning,1809,O
and,1809,O
memory,1809,O
impairment,1809,O
induced,1809,O
by,1809,O
scopolamine,1809,B-Chemical
in,1809,O
mice,1809,O
.,1809,O
1,1810,O
.,1810,O
Nociceptin,1811,B-Chemical
",",1811,O
also,1811,O
known,1811,O
as,1811,O
orphanin,1811,B-Chemical
FQ,1811,I-Chemical
",",1811,O
is,1811,O
an,1811,O
endogenous,1811,O
ligand,1811,O
for,1811,O
the,1811,O
orphan,1811,O
opioid,1811,O
receptor-like,1811,O
receptor,1811,O
1,1811,O
(,1811,O
ORL1,1811,O
),1811,O
and,1811,O
involves,1811,O
in,1811,O
various,1811,O
functions,1811,O
in,1811,O
the,1811,O
central,1811,O
nervous,1811,O
system,1811,O
(,1811,O
CNS,1811,O
),1811,O
.,1811,O
On,1812,O
the,1812,O
other,1812,O
hand,1812,O
",",1812,O
nocistatin,1812,B-Chemical
is,1812,O
recently,1812,O
isolated,1812,O
from,1812,O
the,1812,O
same,1812,O
precursor,1812,O
as,1812,O
nociceptin,1812,B-Chemical
and,1812,O
blocks,1812,O
nociceptin-induced,1812,B-Chemical
allodynia,1812,B-Disease
and,1812,O
hyperalgesia,1812,B-Disease
.,1812,O
2,1813,O
.,1813,O
Although,1814,O
ORL1,1814,O
receptors,1814,O
which,1814,O
display,1814,O
a,1814,O
high,1814,O
degree,1814,O
of,1814,O
sequence,1814,O
homology,1814,O
with,1814,O
classical,1814,O
opioid,1814,O
receptors,1814,O
are,1814,O
abundant,1814,O
in,1814,O
the,1814,O
hippocampus,1814,O
",",1814,O
little,1814,O
is,1814,O
known,1814,O
regarding,1814,O
their,1814,O
role,1814,O
in,1814,O
learning,1814,O
and,1814,O
memory,1814,O
.,1814,O
3,1815,O
.,1815,O
The,1816,O
present,1816,O
study,1816,O
was,1816,O
designed,1816,O
to,1816,O
investigate,1816,O
whether,1816,O
nociceptin/orphanin,1816,B-Chemical
FQ,1816,I-Chemical
and,1816,O
nocistatin,1816,B-Chemical
could,1816,O
modulate,1816,O
impairment,1816,O
of,1816,O
learning,1816,O
and,1816,O
memory,1816,O
induced,1816,O
by,1816,O
scopolamine,1816,B-Chemical
",",1816,O
a,1816,O
muscarinic,1816,O
cholinergic,1816,O
receptor,1816,O
antagonist,1816,O
",",1816,O
using,1816,O
spontaneous,1816,O
alternation,1816,O
of,1816,O
Y-maze,1816,O
and,1816,O
step-down,1816,O
type,1816,O
passive,1816,O
avoidance,1816,O
tasks,1816,O
in,1816,O
mice,1816,O
.,1816,O
4,1817,O
.,1817,O
While,1818,O
nocistatin,1818,B-Chemical
(,1818,O
0.5-5.0,1818,O
nmol,1818,O
mouse-1,1818,O
",",1818,O
i.c.v,1818,O
.,1818,O
),1818,O
administered,1819,O
30,1819,O
min,1819,O
before,1819,O
spontaneous,1819,O
alternation,1819,O
performance,1819,O
or,1819,O
the,1819,O
training,1819,O
session,1819,O
of,1819,O
the,1819,O
passive,1819,O
avoidance,1819,O
task,1819,O
",",1819,O
had,1819,O
no,1819,O
effect,1819,O
on,1819,O
spontaneous,1819,O
alternation,1819,O
or,1819,O
passive,1819,O
avoidance,1819,O
behaviours,1819,O
",",1819,O
a,1819,O
lower,1819,O
per,1819,O
cent,1819,O
alternation,1819,O
and,1819,O
shorter,1819,O
median,1819,O
step-down,1819,O
latency,1819,O
in,1819,O
the,1819,O
retention,1819,O
test,1819,O
were,1819,O
obtained,1819,O
in,1819,O
nociceptin,1819,B-Chemical
(,1819,O
1.5,1819,O
and/or,1819,O
5.0,1819,O
nmol,1819,O
mouse-1,1819,O
",",1819,O
i.c.v,1819,O
.,1819,O
),1820,O
-treated,1820,O
normal,1820,O
mice,1820,O
.,1820,O
5,1821,O
.,1821,O
Administration,1822,O
of,1822,O
nocistatin,1822,O
(,1822,O
1.5,1822,O
and/or,1822,O
5.0,1822,O
nmol,1822,O
mouse-1,1822,O
",",1822,O
i.c.v,1822,O
.,1822,O
),1822,O
30,1823,O
min,1823,O
before,1823,O
spontaneous,1823,O
alternation,1823,O
performance,1823,O
or,1823,O
the,1823,O
training,1823,O
session,1823,O
of,1823,O
the,1823,O
passive,1823,O
avoidance,1823,O
task,1823,O
",",1823,O
attenuated,1823,O
the,1823,O
scopolamine-induced,1823,O
impairment,1823,O
of,1823,O
spontaneous,1823,O
alternation,1823,O
and,1823,O
passive,1823,O
avoidance,1823,O
behaviours,1823,O
.,1823,O
6,1824,O
.,1824,O
These,1825,O
results,1825,O
indicated,1825,O
that,1825,O
nocistatin,1825,O
",",1825,O
a,1825,O
new,1825,O
biologically,1825,O
active,1825,O
peptide,1825,O
",",1825,O
ameliorates,1825,O
impairments,1825,O
of,1825,O
spontaneous,1825,O
alternation,1825,O
and,1825,O
passive,1825,O
avoidance,1825,O
induced,1825,O
by,1825,O
scopolamine,1825,O
",",1825,O
and,1825,O
suggested,1825,O
that,1825,O
these,1825,O
peptides,1825,O
play,1825,O
opposite,1825,O
roles,1825,O
in,1825,O
learning,1825,O
and,1825,O
memory,1825,O
.,1825,O
Meloxicam-induced,1826,B-Chemical
liver,1826,B-Disease
toxicity,1826,I-Disease
.,1826,O
We,1827,O
report,1827,O
the,1827,O
case,1827,O
of,1827,O
a,1827,O
female,1827,O
patient,1827,O
with,1827,O
rheumatoid,1827,B-Disease
arthritis,1827,I-Disease
who,1827,O
developed,1827,O
acute,1827,O
cytolytic,1827,O
hepatitis,1827,B-Disease
due,1827,O
to,1827,O
meloxicam,1827,B-Chemical
.,1827,O
Recently,1828,O
introduced,1828,O
in,1828,O
Belgium,1828,O
",",1828,O
meloxicam,1828,B-Chemical
is,1828,O
the,1828,O
first,1828,O
nonsteroidal,1828,O
antiinflammatory,1828,O
drug,1828,O
with,1828,O
selective,1828,O
action,1828,O
on,1828,O
the,1828,O
inducible,1828,O
form,1828,O
of,1828,O
cyclooxygenase,1828,O
2,1828,O
.,1828,O
The,1829,O
acute,1829,O
cytolytic,1829,O
hepatitis,1829,B-Disease
occurred,1829,O
rapidly,1829,O
after,1829,O
meloxicam,1829,B-Chemical
administration,1829,O
and,1829,O
was,1829,O
associated,1829,O
with,1829,O
the,1829,O
development,1829,O
of,1829,O
antinuclear,1829,O
antibodies,1829,O
suggesting,1829,O
a,1829,O
hypersensitivity,1829,B-Disease
mechanism,1829,O
.,1829,O
This,1830,O
first,1830,O
case,1830,O
of,1830,O
meloxicam,1830,B-Chemical
related,1830,O
liver,1830,B-Disease
toxicity,1830,I-Disease
demonstrates,1830,O
the,1830,O
potential,1830,O
of,1830,O
this,1830,O
drug,1830,O
to,1830,O
induce,1830,O
hepatic,1830,B-Disease
damage,1830,I-Disease
.,1830,O
Induction,1831,O
of,1831,O
apoptosis,1831,O
by,1831,O
remoxipride,1831,B-Chemical
metabolites,1831,O
in,1831,O
HL60,1831,O
and,1831,O
CD34+/CD19-,1831,O
human,1831,O
bone,1831,O
marrow,1831,O
progenitor,1831,O
cells,1831,O
:,1831,O
potential,1831,O
relevance,1831,O
to,1831,O
remoxipride-induced,1831,B-Chemical
aplastic,1831,B-Disease
anemia,1831,I-Disease
.,1831,O
The,1832,O
antipsychotic,1832,O
agent,1832,O
",",1832,O
remoxipride,1832,B-Chemical
[,1832,O
(,1832,B-Chemical
S,1832,I-Chemical
),1832,I-Chemical
-,1832,I-Chemical
(,1832,I-Chemical
-,1832,I-Chemical
),1832,I-Chemical
-3-bromo-N-,1832,I-Chemical
[,1832,I-Chemical
(,1832,I-Chemical
1-ethyl-2-pyrrolidinyl,1832,I-Chemical
),1832,I-Chemical
methyl,1832,I-Chemical
],1832,I-Chemical
"-2,6-dimethoxybenz",1832,I-Chemical
amide,1832,I-Chemical
],1832,O
has,1832,O
been,1832,O
associated,1832,O
with,1832,O
acquired,1832,O
aplastic,1832,B-Disease
anemia,1832,I-Disease
.,1832,O
We,1833,O
have,1833,O
examined,1833,O
the,1833,O
ability,1833,O
of,1833,O
remoxipride,1833,B-Chemical
",",1833,O
three,1833,O
pyrrolidine,1833,B-Chemical
ring,1833,O
metabolites,1833,O
and,1833,O
five,1833,O
aromatic,1833,O
ring,1833,O
metabolites,1833,O
of,1833,O
the,1833,O
parent,1833,O
compound,1833,O
to,1833,O
induce,1833,O
apoptosis,1833,O
in,1833,O
HL60,1833,O
cells,1833,O
and,1833,O
human,1833,O
bone,1833,O
marrow,1833,O
progenitor,1833,O
(,1833,O
HBMP,1833,O
),1833,O
cells,1833,O
.,1833,O
Cells,1834,O
were,1834,O
treated,1834,O
for,1834,O
0-24,1834,O
h,1834,O
with,1834,O
each,1834,O
compound,1834,O
(,1834,O
0-200,1834,O
microM,1834,O
),1834,O
.,1834,O
Apoptosis,1835,O
was,1835,O
assessed,1835,O
by,1835,O
fluorescence,1835,O
microscopy,1835,O
in,1835,O
Hoechst,1835,B-Chemical
33342-,1835,O
and,1835,O
propidium,1835,B-Chemical
iodide,1835,I-Chemical
stained,1835,O
cell,1835,O
samples,1835,O
.,1835,O
Results,1836,O
were,1836,O
confirmed,1836,O
by,1836,O
determination,1836,O
of,1836,O
internucleosomal,1836,O
DNA,1836,O
fragmentation,1836,O
using,1836,O
gel,1836,O
electrophoresis,1836,O
for,1836,O
HL60,1836,O
cell,1836,O
samples,1836,O
and,1836,O
terminal,1836,O
deoxynucleotidyl,1836,O
transferase,1836,O
assay,1836,O
in,1836,O
HBMP,1836,O
cells,1836,O
.,1836,O
The,1837,O
catechol,1837,B-Chemical
and,1837,O
hydroquinone,1837,B-Chemical
metabolites,1837,O
",",1837,O
NCQ436,1837,B-Chemical
and,1837,O
NCQ344,1837,B-Chemical
",",1837,O
induced,1837,O
apoptosis,1837,O
in,1837,O
HL60,1837,O
and,1837,O
HBMP,1837,O
cells,1837,O
in,1837,O
a,1837,O
time-,1837,O
and,1837,O
concentration,1837,O
dependent,1837,O
manner,1837,O
",",1837,O
while,1837,O
the,1837,O
phenols,1837,B-Chemical
",",1837,O
NCR181,1837,O
",",1837,O
FLA873,1837,O
",",1837,O
and,1837,O
FLA797,1837,B-Chemical
",",1837,O
and,1837,O
the,1837,O
derivatives,1837,O
formed,1837,O
by,1837,O
oxidation,1837,O
of,1837,O
the,1837,O
pyrrolidine,1837,B-Chemical
ring,1837,O
",",1837,O
FLA838,1837,O
",",1837,O
NCM001,1837,O
",",1837,O
and,1837,O
NCL118,1837,O
",",1837,O
had,1837,O
no,1837,O
effect,1837,O
.,1837,O
No,1838,O
necrosis,1838,B-Disease
was,1838,O
observed,1838,O
in,1838,O
cells,1838,O
treated,1838,O
with,1838,O
NCQ436,1838,B-Chemical
but,1838,O
NCQ344,1838,B-Chemical
had,1838,O
a,1838,O
biphasic,1838,O
effect,1838,O
in,1838,O
both,1838,O
cell,1838,O
types,1838,O
",",1838,O
inducing,1838,O
apoptosis,1838,O
at,1838,O
lower,1838,O
concentrations,1838,O
and,1838,O
necrosis,1838,B-Disease
at,1838,O
higher,1838,O
concentrations,1838,O
.,1838,O
These,1839,O
data,1839,O
show,1839,O
that,1839,O
the,1839,O
catechol,1839,B-Chemical
and,1839,O
hydroquinone,1839,B-Chemical
metabolites,1839,O
of,1839,O
remoxipride,1839,B-Chemical
have,1839,O
direct,1839,O
toxic,1839,O
effects,1839,O
in,1839,O
HL60,1839,O
and,1839,O
HBMP,1839,O
cells,1839,O
",",1839,O
leading,1839,O
to,1839,O
apoptosis,1839,O
",",1839,O
while,1839,O
the,1839,O
phenol,1839,B-Chemical
metabolites,1839,O
were,1839,O
inactive,1839,O
.,1839,O
Similarly,1840,O
",",1840,O
benzene-derived,1840,B-Chemical
catechol,1840,B-Chemical
and,1840,O
hydroquinone,1840,B-Chemical
",",1840,O
but,1840,O
not,1840,O
phenol,1840,B-Chemical
",",1840,O
induce,1840,O
apoptosis,1840,O
in,1840,O
HBMP,1840,O
cells,1840,O
[,1840,O
Moran,1840,O
et,1840,O
al.,1840,O
",",1840,O
Mol,1840,O
.,1840,O
Pharmacol.,1841,O
",",1841,O
50,1841,O
(,1841,O
1996,1841,O
),1841,O
610-615,1841,O
],1841,O
.,1841,O
We,1842,O
propose,1842,O
that,1842,O
remoxipride,1842,B-Chemical
and,1842,O
benzene,1842,B-Chemical
may,1842,O
induce,1842,O
aplastic,1842,B-Disease
anemia,1842,I-Disease
via,1842,O
production,1842,O
of,1842,O
similar,1842,O
reactive,1842,O
metabolites,1842,O
and,1842,O
that,1842,O
the,1842,O
ability,1842,O
of,1842,O
NCQ436,1842,B-Chemical
and,1842,O
NCQ344,1842,B-Chemical
to,1842,O
induce,1842,O
apoptosis,1842,O
in,1842,O
HBMP,1842,O
cells,1842,O
may,1842,O
contribute,1842,O
to,1842,O
the,1842,O
mechanism,1842,O
underlying,1842,O
acquired,1842,O
aplastic,1842,B-Disease
anemia,1842,I-Disease
that,1842,O
has,1842,O
been,1842,O
associated,1842,O
with,1842,O
remoxipride,1842,B-Chemical
.,1842,O
Synthesis,1843,O
and,1843,O
preliminary,1843,O
pharmacological,1843,O
investigations,1843,O
of,1843,O
1-,1843,B-Chemical
(,1843,I-Chemical
"1,2-dihydro-2-acenaphthylenyl",1843,I-Chemical
),1843,I-Chemical
piperazine,1843,I-Chemical
derivatives,1843,O
as,1843,O
potential,1843,O
atypical,1843,O
antipsychotic,1843,O
agents,1843,O
in,1843,O
mice,1843,O
.,1843,O
In,1844,O
research,1844,O
towards,1844,O
the,1844,O
development,1844,O
of,1844,O
new,1844,O
atypical,1844,O
antipsychotic,1844,O
agents,1844,O
",",1844,O
one,1844,O
strategy,1844,O
is,1844,O
that,1844,O
the,1844,O
dopaminergic,1844,O
system,1844,O
can,1844,O
be,1844,O
modulated,1844,O
through,1844,O
manipulation,1844,O
of,1844,O
the,1844,O
serotonergic,1844,O
system,1844,O
.,1844,O
The,1845,O
synthesis,1845,O
and,1845,O
preliminary,1845,O
pharmacological,1845,O
evaluation,1845,O
of,1845,O
a,1845,O
series,1845,O
of,1845,O
potential,1845,O
atypical,1845,O
antipsychotic,1845,O
agents,1845,O
based,1845,O
on,1845,O
the,1845,O
structure,1845,O
of,1845,O
1-,1845,B-Chemical
(,1845,I-Chemical
"1,2-dihydro-2-acenaphthylenyl",1845,I-Chemical
),1845,I-Chemical
piperazine,1845,I-Chemical
(,1845,O
7,1845,O
),1845,O
is,1845,O
described,1845,O
.,1845,O
Compound,1846,O
7e,1846,O
",",1846,O
5-,1846,B-Chemical
{,1846,I-Chemical
2-,1846,I-Chemical
[,1846,I-Chemical
4-,1846,I-Chemical
(,1846,I-Chemical
"1,2-dihydro-2-acenaphthylenyl",1846,I-Chemical
),1846,I-Chemical
piperazinyl,1846,I-Chemical
],1846,I-Chemical
ethyl,1846,I-Chemical
},1846,I-Chemical
"-2,3-dihy",1846,I-Chemical
dro-1H-,1846,I-Chemical
indol-2-one,1846,I-Chemical
",",1846,O
from,1846,O
this,1846,O
series,1846,O
showed,1846,O
significant,1846,O
affinities,1846,O
at,1846,O
the,1846,O
5-HT1A,1846,O
and,1846,O
5-HT2A,1846,O
receptors,1846,O
and,1846,O
moderate,1846,O
affinity,1846,O
at,1846,O
the,1846,O
D2,1846,O
receptor,1846,O
.,1846,O
7e,1847,O
exhibits,1847,O
a,1847,O
high,1847,O
reversal,1847,O
of,1847,O
catalepsy,1847,B-Disease
induced,1847,O
by,1847,O
haloperidol,1847,B-Chemical
indicating,1847,O
its,1847,O
atypical,1847,O
antipsychotic,1847,O
nature,1847,O
.,1847,O
Sub-chronic,1848,O
inhibition,1848,O
of,1848,O
nitric-oxide,1848,B-Chemical
synthesis,1848,O
modifies,1848,O
haloperidol-induced,1848,B-Chemical
catalepsy,1848,B-Disease
and,1848,O
the,1848,O
number,1848,O
of,1848,O
NADPH-diaphorase,1848,B-Chemical
neurons,1848,O
in,1848,O
mice,1848,O
.,1848,O
RATIONALE,1849,O
:,1849,O
NG-nitro-L-arginine,1849,B-Chemical
(,1849,O
L-NOARG,1849,B-Chemical
),1849,O
",",1849,O
an,1849,O
inhibitor,1849,O
of,1849,O
nitric-oxide,1849,B-Chemical
synthase,1849,O
(,1849,O
NOS,1849,O
),1849,O
",",1849,O
induces,1849,O
catalepsy,1849,B-Disease
in,1849,O
mice,1849,O
.,1849,O
This,1850,O
effect,1850,O
undergoes,1850,O
rapid,1850,O
tolerance,1850,O
",",1850,O
showing,1850,O
a,1850,O
significant,1850,O
decrease,1850,O
after,1850,O
2,1850,O
days,1850,O
of,1850,O
sub-chronic,1850,O
L-NOARG,1850,B-Chemical
treatment,1850,O
.,1850,O
Nitric,1851,B-Chemical
oxide,1851,I-Chemical
(,1851,O
NO,1851,B-Chemical
),1851,O
has,1851,O
been,1851,O
shown,1851,O
to,1851,O
influence,1851,O
dopaminergic,1851,O
neurotransmission,1851,O
in,1851,O
the,1851,O
striatum,1851,O
.,1851,O
Neuroleptic,1852,O
drugs,1852,O
such,1852,O
as,1852,O
haloperidol,1852,B-Chemical
",",1852,O
which,1852,O
block,1852,O
dopamine,1852,B-Chemical
receptors,1852,O
",",1852,O
also,1852,O
cause,1852,O
catalepsy,1852,B-Disease
in,1852,O
rodents,1852,O
.,1852,O
OBJECTIVES,1853,O
:,1853,O
To,1853,O
investigate,1853,O
the,1853,O
effects,1853,O
of,1853,O
subchronic,1853,O
L-NOARG,1853,B-Chemical
treatment,1853,O
in,1853,O
haloperidol-induced,1853,B-Chemical
catalepsy,1853,B-Disease
and,1853,O
the,1853,O
number,1853,O
of,1853,O
NOS,1853,O
neurons,1853,O
in,1853,O
areas,1853,O
related,1853,O
to,1853,O
motor,1853,O
control,1853,O
.,1853,O
METHODS,1854,O
:,1854,O
Male,1854,O
albino,1854,O
Swiss,1854,O
mice,1854,O
were,1854,O
treated,1854,O
sub-chronically,1854,O
(,1854,O
twice,1854,O
a,1854,O
day,1854,O
for,1854,O
4,1854,O
days,1854,O
),1854,O
with,1854,O
L-NOARG,1854,B-Chemical
(,1854,O
40,1854,O
mg/kg,1854,O
i.p,1854,O
.,1854,O
),1854,O
or,1855,O
haloperidol,1855,B-Chemical
(,1855,O
1,1855,O
mg/kg,1855,O
i.p,1855,O
.,1855,O
),1855,O
.,1855,O
Catalepsy,1856,B-Disease
was,1856,O
evaluated,1856,O
at,1856,O
the,1856,O
beginning,1856,O
and,1856,O
the,1856,O
end,1856,O
of,1856,O
the,1856,O
treatments,1856,O
.,1856,O
Reduced,1857,O
nicotinamide,1857,B-Chemical
adenine,1857,I-Chemical
dinucleotide,1857,I-Chemical
phosphate-diaphorase,1857,O
(,1857,O
NADPH-d,1857,B-Chemical
),1857,O
histochemistry,1857,O
was,1857,O
also,1857,O
employed,1857,O
to,1857,O
visualize,1857,O
NOS,1857,O
as,1857,O
an,1857,O
index,1857,O
of,1857,O
enzyme,1857,O
expression,1857,O
in,1857,O
mice,1857,O
brain,1857,O
regions,1857,O
related,1857,O
to,1857,O
motor,1857,O
control,1857,O
.,1857,O
RESULTS,1858,O
:,1858,O
L-NOARG,1858,B-Chemical
sub-chronic,1858,O
administration,1858,O
produced,1858,O
tolerance,1858,O
of,1858,O
L-NOARG,1858,B-Chemical
and,1858,O
of,1858,O
haloperidol-induced,1858,B-Chemical
catalepsy,1858,B-Disease
.,1858,O
It,1859,O
also,1859,O
induced,1859,O
an,1859,O
increase,1859,O
in,1859,O
the,1859,O
number,1859,O
of,1859,O
NADPH-d-positive,1859,B-Chemical
cells,1859,O
in,1859,O
the,1859,O
dorsal,1859,O
part,1859,O
of,1859,O
the,1859,O
caudate,1859,O
and,1859,O
accumbens,1859,O
nuclei,1859,O
compared,1859,O
with,1859,O
haloperidol,1859,B-Chemical
and,1859,O
in,1859,O
the,1859,O
pedunculopontine,1859,O
tegmental,1859,O
nucleus,1859,O
compared,1859,O
with,1859,O
saline,1859,O
.,1859,O
In,1860,O
contrast,1860,O
",",1860,O
there,1860,O
was,1860,O
a,1860,O
decrease,1860,O
in,1860,O
NADPH-d,1860,B-Chemical
neuron,1860,O
number,1860,O
in,1860,O
the,1860,O
substantia,1860,O
nigra,1860,O
",",1860,O
pars,1860,O
compacta,1860,O
in,1860,O
both,1860,O
haloperidol-treated,1860,B-Chemical
and,1860,O
L-NOARG-treated,1860,B-Chemical
animals,1860,O
.,1860,O
CONCLUSIONS,1861,O
:,1861,O
The,1861,O
results,1861,O
give,1861,O
further,1861,O
support,1861,O
to,1861,O
the,1861,O
hypothesis,1861,O
that,1861,O
NO,1861,B-Chemical
plays,1861,O
a,1861,O
role,1861,O
in,1861,O
motor,1861,O
behavior,1861,O
control,1861,O
and,1861,O
suggest,1861,O
that,1861,O
it,1861,O
may,1861,O
take,1861,O
part,1861,O
in,1861,O
the,1861,O
synaptic,1861,O
changes,1861,O
produced,1861,O
by,1861,O
antipsychotic,1861,O
treatment,1861,O
.,1861,O
Prolonged,1862,O
left,1862,B-Disease
ventricular,1862,I-Disease
dysfunction,1862,I-Disease
occurs,1862,O
in,1862,O
patients,1862,O
with,1862,O
coronary,1862,B-Disease
artery,1862,I-Disease
disease,1862,I-Disease
after,1862,O
both,1862,O
dobutamine,1862,B-Chemical
and,1862,O
exercise,1862,O
induced,1862,O
myocardial,1862,B-Disease
ischaemia,1862,I-Disease
.,1862,O
OBJECTIVE,1863,O
:,1863,O
To,1863,O
determine,1863,O
whether,1863,O
pharmacological,1863,O
stress,1863,O
leads,1863,O
to,1863,O
prolonged,1863,O
but,1863,O
reversible,1863,O
left,1863,B-Disease
ventricular,1863,I-Disease
dysfunction,1863,I-Disease
in,1863,O
patients,1863,O
with,1863,O
coronary,1863,B-Disease
artery,1863,I-Disease
disease,1863,I-Disease
",",1863,O
similar,1863,O
to,1863,O
that,1863,O
seen,1863,O
after,1863,O
exercise,1863,O
.,1863,O
DESIGN,1864,O
:,1864,O
A,1864,O
randomised,1864,O
crossover,1864,O
study,1864,O
of,1864,O
recovery,1864,O
time,1864,O
of,1864,O
systolic,1864,O
and,1864,O
diastolic,1864,O
left,1864,O
ventricular,1864,O
function,1864,O
after,1864,O
exercise,1864,O
and,1864,O
dobutamine,1864,B-Chemical
induced,1864,O
ischaemia,1864,B-Disease
.,1864,O
SUBJECTS,1865,O
:,1865,O
10,1865,O
patients,1865,O
with,1865,O
stable,1865,B-Disease
angina,1865,I-Disease
",",1865,O
angiographically,1865,O
proven,1865,O
coronary,1865,B-Disease
artery,1865,I-Disease
disease,1865,I-Disease
",",1865,O
and,1865,O
normal,1865,O
left,1865,O
ventricular,1865,O
function,1865,O
.,1865,O
INTERVENTIONS,1866,O
:,1866,O
Treadmill,1866,O
exercise,1866,O
and,1866,O
dobutamine,1866,B-Chemical
stress,1866,O
were,1866,O
performed,1866,O
on,1866,O
different,1866,O
days,1866,O
.,1866,O
Quantitative,1867,O
assessment,1867,O
of,1867,O
systolic,1867,O
and,1867,O
diastolic,1867,O
left,1867,O
ventricular,1867,O
function,1867,O
was,1867,O
performed,1867,O
using,1867,O
transthoracic,1867,O
echocardiography,1867,O
at,1867,O
baseline,1867,O
and,1867,O
at,1867,O
regular,1867,O
intervals,1867,O
after,1867,O
each,1867,O
test,1867,O
.,1867,O
RESULTS,1868,O
:,1868,O
Both,1868,O
forms,1868,O
of,1868,O
stress,1868,O
led,1868,O
to,1868,O
prolonged,1868,O
but,1868,O
reversible,1868,O
systolic,1868,O
and,1868,O
diastolic,1868,O
dysfunction,1868,O
.,1868,O
There,1869,O
was,1869,O
no,1869,O
difference,1869,O
in,1869,O
the,1869,O
maximum,1869,O
double,1869,O
product,1869,O
(,1869,O
p,1869,O
=,1869,O
0.53,1869,O
),1869,O
or,1869,O
ST,1869,O
depression,1869,B-Disease
(,1869,O
p,1869,O
=,1869,O
0.63,1869,O
),1869,O
with,1869,O
either,1869,O
form,1869,O
of,1869,O
stress,1869,O
.,1869,O
After,1870,O
exercise,1870,O
",",1870,O
ejection,1870,O
fraction,1870,O
was,1870,O
reduced,1870,O
at,1870,O
15,1870,O
and,1870,O
30,1870,O
minutes,1870,O
compared,1870,O
with,1870,O
baseline,1870,O
(,1870,O
mean,1870,O
(,1870,O
SEM,1870,O
),1870,O
",",1870,O
-5.6,1870,O
(,1870,O
1.5,1870,O
),1870,O
%,1870,O
",",1870,O
p,1870,O
<,1870,O
0.05,1870,O
;,1870,O
and,1870,O
-6.1,1870,O
(,1870,O
2.2,1870,O
),1870,O
%,1870,O
",",1870,O
p,1870,O
<,1870,O
0,1870,O
.,1870,O
01,1871,O
),1871,O
",",1871,O
and,1871,O
at,1871,O
30,1871,O
and,1871,O
45,1871,O
minutes,1871,O
after,1871,O
dobutamine,1871,B-Chemical
(,1871,O
-10.8,1871,O
(,1871,O
1.8,1871,O
),1871,O
%,1871,O
and,1871,O
-5,1871,O
.,1871,O
5,1872,O
(,1872,O
1.8,1872,O
),1872,O
%,1872,O
",",1872,O
both,1872,O
p,1872,O
<,1872,O
0.01,1872,O
),1872,O
.,1872,O
Regional,1873,O
analysis,1873,O
showed,1873,O
a,1873,O
reduction,1873,O
in,1873,O
the,1873,O
worst,1873,O
affected,1873,O
segment,1873,O
15,1873,O
and,1873,O
30,1873,O
minutes,1873,O
after,1873,O
exercise,1873,O
(,1873,O
-27.9,1873,O
(,1873,O
7.2,1873,O
),1873,O
%,1873,O
and,1873,O
-28.6,1873,O
(,1873,O
5.7,1873,O
),1873,O
%,1873,O
",",1873,O
both,1873,O
p,1873,O
<,1873,O
0.01,1873,O
),1873,O
",",1873,O
and,1873,O
at,1873,O
30,1873,O
minutes,1873,O
after,1873,O
dobutamine,1873,B-Chemical
(,1873,O
-32,1873,O
(,1873,O
5.3,1873,O
),1873,O
%,1873,O
",",1873,O
p,1873,O
<,1873,O
0.01,1873,O
),1873,O
.,1873,O
The,1874,O
isovolumic,1874,O
relaxation,1874,O
period,1874,O
was,1874,O
prolonged,1874,O
45,1874,O
minutes,1874,O
after,1874,O
each,1874,O
form,1874,O
of,1874,O
stress,1874,O
(,1874,O
p,1874,O
<,1874,O
0.05,1874,O
),1874,O
.,1874,O
CONCLUSIONS,1875,O
:,1875,O
In,1875,O
patients,1875,O
with,1875,O
coronary,1875,B-Disease
artery,1875,I-Disease
disease,1875,I-Disease
",",1875,O
dobutamine,1875,B-Chemical
induced,1875,O
ischaemia,1875,B-Disease
results,1875,O
in,1875,O
prolonged,1875,O
reversible,1875,O
left,1875,B-Disease
ventricular,1875,I-Disease
dysfunction,1875,I-Disease
",",1875,O
presumed,1875,O
to,1875,O
be,1875,O
myocardial,1875,B-Disease
stunning,1875,I-Disease
",",1875,O
similar,1875,O
to,1875,O
that,1875,O
seen,1875,O
after,1875,O
exercise,1875,O
.,1875,O
Dobutamine,1876,B-Chemical
induced,1876,O
ischaemia,1876,B-Disease
could,1876,O
therefore,1876,O
be,1876,O
used,1876,O
to,1876,O
study,1876,O
the,1876,O
pathophysiology,1876,O
of,1876,O
this,1876,O
phenomenon,1876,O
further,1876,O
in,1876,O
patients,1876,O
with,1876,O
coronary,1876,B-Disease
artery,1876,I-Disease
disease,1876,I-Disease
.,1876,O
Anorexigens,1877,O
and,1877,O
pulmonary,1877,B-Disease
hypertension,1877,I-Disease
in,1877,O
the,1877,O
United,1877,O
States,1877,O
:,1877,O
results,1877,O
from,1877,O
the,1877,O
surveillance,1877,O
of,1877,O
North,1877,O
American,1877,O
pulmonary,1877,B-Disease
hypertension,1877,I-Disease
.,1877,O
BACKGROUND,1878,O
:,1878,O
The,1878,O
use,1878,O
of,1878,O
appetite,1878,O
suppressants,1878,O
in,1878,O
Europe,1878,O
has,1878,O
been,1878,O
associated,1878,O
with,1878,O
the,1878,O
development,1878,O
of,1878,O
primary,1878,B-Disease
pulmonary,1878,I-Disease
hypertension,1878,I-Disease
(,1878,O
PPH,1878,B-Disease
),1878,O
.,1878,O
Recently,1879,O
",",1879,O
fenfluramine,1879,B-Chemical
appetite,1879,O
suppressants,1879,O
became,1879,O
widely,1879,O
used,1879,O
in,1879,O
the,1879,O
United,1879,O
States,1879,O
but,1879,O
were,1879,O
withdrawn,1879,O
in,1879,O
September,1879,O
1997,1879,O
because,1879,O
of,1879,O
concerns,1879,O
over,1879,O
adverse,1879,O
effects,1879,O
.,1879,O
MATERIALS,1880,O
AND,1880,O
METHODS,1880,O
:,1880,O
We,1880,O
conducted,1880,O
a,1880,O
prospective,1880,O
surveillance,1880,O
study,1880,O
on,1880,O
patients,1880,O
diagnosed,1880,O
with,1880,O
pulmonary,1880,B-Disease
hypertension,1880,I-Disease
at,1880,O
12,1880,O
large,1880,O
referral,1880,O
centers,1880,O
in,1880,O
North,1880,O
America,1880,O
.,1880,O
Data,1881,O
collected,1881,O
on,1881,O
patients,1881,O
seen,1881,O
from,1881,O
September,1881,O
1,1881,O
",",1881,O
1996,1881,O
",",1881,O
to,1881,O
December,1881,O
31,1881,O
",",1881,O
1997,1881,O
",",1881,O
included,1881,O
the,1881,O
cause,1881,O
of,1881,O
the,1881,O
pulmonary,1881,B-Disease
hypertension,1881,I-Disease
and,1881,O
its,1881,O
severity,1881,O
.,1881,O
Patients,1882,O
with,1882,O
no,1882,O
identifiable,1882,O
cause,1882,O
of,1882,O
pulmonary,1882,B-Disease
hypertension,1882,I-Disease
were,1882,O
classed,1882,O
as,1882,O
PPH,1882,B-Disease
.,1882,O
A,1883,O
history,1883,O
of,1883,O
drug,1883,O
exposure,1883,O
also,1883,O
was,1883,O
taken,1883,O
with,1883,O
special,1883,O
attention,1883,O
on,1883,O
the,1883,O
use,1883,O
of,1883,O
antidepressants,1883,O
",",1883,O
anorexigens,1883,O
",",1883,O
and,1883,O
amphetamines,1883,B-Chemical
.,1883,O
RESULTS,1884,O
:,1884,O
Five,1884,O
hundred,1884,O
seventy-nine,1884,O
patients,1884,O
were,1884,O
studied,1884,O
",",1884,O
205,1884,O
with,1884,O
PPH,1884,B-Disease
and,1884,O
374,1884,O
with,1884,O
pulmonary,1884,B-Disease
hypertension,1884,I-Disease
from,1884,O
other,1884,O
causes,1884,O
(,1884,O
secondary,1884,O
pulmonary,1884,B-Disease
hypertension,1884,I-Disease
[,1884,O
SPH,1884,O
],1884,O
),1884,O
.,1884,O
The,1885,O
use,1885,O
of,1885,O
anorexigens,1885,O
was,1885,O
common,1885,O
in,1885,O
both,1885,O
groups,1885,O
.,1885,O
However,1886,O
",",1886,O
of,1886,O
the,1886,O
medications,1886,O
surveyed,1886,O
",",1886,O
only,1886,O
the,1886,O
fenfluramines,1886,B-Chemical
had,1886,O
a,1886,O
significant,1886,O
preferential,1886,O
association,1886,O
with,1886,O
PPH,1886,B-Disease
as,1886,O
compared,1886,O
with,1886,O
SPH,1886,O
(,1886,O
adjusted,1886,O
odds,1886,O
ratio,1886,O
for,1886,O
use,1886,O
>,1886,O
6,1886,O
months,1886,O
",",1886,O
7.5,1886,O
;,1886,O
95,1886,O
%,1886,O
confidence,1886,O
interval,1886,O
",",1886,O
1.7,1886,O
to,1886,O
32.4,1886,O
),1886,O
.,1886,O
The,1887,O
association,1887,O
was,1887,O
stronger,1887,O
with,1887,O
longer,1887,O
duration,1887,O
of,1887,O
use,1887,O
when,1887,O
compared,1887,O
to,1887,O
shorter,1887,O
duration,1887,O
of,1887,O
use,1887,O
and,1887,O
was,1887,O
more,1887,O
pronounced,1887,O
in,1887,O
recent,1887,O
users,1887,O
than,1887,O
in,1887,O
remote,1887,O
users,1887,O
.,1887,O
An,1888,O
unexpectedly,1888,O
high,1888,O
(,1888,O
11.4,1888,O
%,1888,O
),1888,O
number,1888,O
of,1888,O
patients,1888,O
with,1888,O
SPH,1888,O
had,1888,O
used,1888,O
anorexigens,1888,O
.,1888,O
CONCLUSION,1889,O
:,1889,O
The,1889,O
magnitude,1889,O
of,1889,O
the,1889,O
association,1889,O
with,1889,O
PPH,1889,B-Disease
",",1889,O
the,1889,O
increase,1889,O
of,1889,O
association,1889,O
with,1889,O
increasing,1889,O
duration,1889,O
of,1889,O
use,1889,O
",",1889,O
and,1889,O
the,1889,O
specificity,1889,O
for,1889,O
fenfluramines,1889,B-Chemical
are,1889,O
consistent,1889,O
with,1889,O
previous,1889,O
studies,1889,O
indicating,1889,O
that,1889,O
fenfluramines,1889,B-Chemical
are,1889,O
causally,1889,O
related,1889,O
to,1889,O
PPH,1889,B-Disease
.,1889,O
The,1890,O
high,1890,O
prevalence,1890,O
of,1890,O
anorexigen,1890,O
use,1890,O
in,1890,O
patients,1890,O
with,1890,O
SPH,1890,O
also,1890,O
raises,1890,O
the,1890,O
possibility,1890,O
that,1890,O
these,1890,O
drugs,1890,O
precipitate,1890,O
pulmonary,1890,B-Disease
hypertension,1890,I-Disease
in,1890,O
patients,1890,O
with,1890,O
underlying,1890,O
conditions,1890,O
associated,1890,O
with,1890,O
SPH,1890,O
.,1890,O
Clinical,1891,O
aspects,1891,O
of,1891,O
heparin-induced,1891,B-Chemical
thrombocytopenia,1891,B-Disease
and,1891,O
thrombosis,1891,B-Disease
and,1891,O
other,1891,O
side,1891,O
effects,1891,O
of,1891,O
heparin,1891,B-Chemical
therapy,1891,O
.,1891,O
Heparin,1892,B-Chemical
",",1892,O
first,1892,O
used,1892,O
to,1892,O
prevent,1892,O
the,1892,O
clotting,1892,O
of,1892,O
blood,1892,O
in,1892,O
vitro,1892,O
",",1892,O
has,1892,O
been,1892,O
clinically,1892,O
used,1892,O
to,1892,O
treat,1892,O
thrombosis,1892,B-Disease
for,1892,O
more,1892,O
than,1892,O
50,1892,O
years,1892,O
.,1892,O
Although,1893,O
several,1893,O
new,1893,O
anticoagulant,1893,O
drugs,1893,O
are,1893,O
in,1893,O
development,1893,O
",",1893,O
heparin,1893,B-Chemical
remains,1893,O
the,1893,O
anticoagulant,1893,O
of,1893,O
choice,1893,O
to,1893,O
treat,1893,O
acute,1893,O
thrombotic,1893,B-Disease
episodes,1893,O
.,1893,O
The,1894,O
clinical,1894,O
effects,1894,O
of,1894,O
heparin,1894,B-Chemical
are,1894,O
meritorious,1894,O
",",1894,O
but,1894,O
side,1894,O
effects,1894,O
do,1894,O
exist,1894,O
.,1894,O
Bleeding,1895,B-Disease
is,1895,O
the,1895,O
primary,1895,O
untoward,1895,O
effect,1895,O
of,1895,O
heparin,1895,B-Chemical
.,1895,O
Major,1896,O
bleeding,1896,B-Disease
is,1896,O
of,1896,O
primary,1896,O
concern,1896,O
in,1896,O
patients,1896,O
receiving,1896,O
heparin,1896,B-Chemical
therapy,1896,O
.,1896,O
However,1897,O
",",1897,O
additional,1897,O
important,1897,O
untoward,1897,O
effects,1897,O
of,1897,O
heparin,1897,B-Chemical
therapy,1897,O
include,1897,O
heparin-induced,1897,B-Chemical
thrombocytopenia,1897,B-Disease
",",1897,O
heparin-associated,1897,B-Chemical
osteoporosis,1897,B-Disease
",",1897,O
eosinophilia,1897,B-Disease
",",1897,O
skin,1897,B-Disease
reactions,1897,I-Disease
",",1897,O
allergic,1897,B-Disease
reactions,1897,I-Disease
other,1897,O
than,1897,O
thrombocytopenia,1897,B-Disease
",",1897,O
alopecia,1897,B-Disease
",",1897,O
transaminasemia,1897,O
",",1897,O
hyperkalemia,1897,B-Disease
",",1897,O
hypoaldosteronism,1897,B-Disease
",",1897,O
and,1897,O
priapism,1897,B-Disease
.,1897,O
These,1898,O
side,1898,O
effects,1898,O
are,1898,O
relatively,1898,O
rare,1898,O
in,1898,O
a,1898,O
given,1898,O
individual,1898,O
",",1898,O
but,1898,O
given,1898,O
the,1898,O
extremely,1898,O
widespread,1898,O
use,1898,O
of,1898,O
heparin,1898,B-Chemical
",",1898,O
some,1898,O
are,1898,O
quite,1898,O
common,1898,O
",",1898,O
particularly,1898,O
HITT,1898,B-Disease
and,1898,O
osteoporosis,1898,B-Disease
.,1898,O
Although,1899,O
reasonable,1899,O
incidences,1899,O
of,1899,O
many,1899,O
of,1899,O
these,1899,O
side,1899,O
effects,1899,O
can,1899,O
be,1899,O
``,1899,O
softly,1899,O
'',1899,O
deduced,1899,O
from,1899,O
current,1899,O
reports,1899,O
dealing,1899,O
with,1899,O
unfractionated,1899,O
heparin,1899,B-Chemical
",",1899,O
at,1899,O
present,1899,O
the,1899,O
incidences,1899,O
of,1899,O
these,1899,O
side,1899,O
effects,1899,O
with,1899,O
newer,1899,O
low,1899,O
molecular,1899,O
weight,1899,O
heparins,1899,B-Chemical
appear,1899,O
to,1899,O
be,1899,O
much,1899,O
less,1899,O
common,1899,O
.,1899,O
However,1900,O
",",1900,O
only,1900,O
longer,1900,O
experience,1900,O
will,1900,O
more,1900,O
clearly,1900,O
define,1900,O
the,1900,O
incidence,1900,O
of,1900,O
each,1900,O
side,1900,O
effect,1900,O
with,1900,O
low,1900,O
molecular,1900,O
weight,1900,O
preparations,1900,O
.,1900,O
A,1901,O
case,1901,O
of,1901,O
bilateral,1901,O
optic,1901,B-Disease
neuropathy,1901,I-Disease
in,1901,O
a,1901,O
patient,1901,O
on,1901,O
tacrolimus,1901,B-Chemical
(,1901,O
FK506,1901,B-Chemical
),1901,O
therapy,1901,O
after,1901,O
liver,1901,O
transplantation,1901,O
.,1901,O
PURPOSE,1902,O
:,1902,O
To,1902,O
report,1902,O
a,1902,O
case,1902,O
of,1902,O
bilateral,1902,O
optic,1902,B-Disease
neuropathy,1902,I-Disease
in,1902,O
a,1902,O
patient,1902,O
receiving,1902,O
tacrolimus,1902,B-Chemical
(,1902,O
FK,1902,B-Chemical
506,1902,I-Chemical
",",1902,O
Prograf,1902,O
;,1902,O
Fujisawa,1902,O
USA,1902,O
",",1902,O
Inc,1902,O
",",1902,O
Deerfield,1902,O
",",1902,O
Illinois,1902,O
),1902,O
for,1902,O
immunosuppression,1902,O
after,1902,O
orthotropic,1902,O
liver,1902,O
transplantation,1902,O
.,1902,O
METHOD,1903,O
:,1903,O
Case,1903,O
report,1903,O
.,1903,O
In,1904,O
a,1904,O
58-year-old,1904,O
man,1904,O
receiving,1904,O
tacrolimus,1904,B-Chemical
after,1904,O
orthotropic,1904,O
liver,1904,O
transplantation,1904,O
",",1904,O
serial,1904,O
neuro-ophthalmologic,1904,O
examinations,1904,O
and,1904,O
laboratory,1904,O
studies,1904,O
were,1904,O
performed,1904,O
.,1904,O
RESULTS,1905,O
:,1905,O
The,1905,O
patient,1905,O
had,1905,O
episodic,1905,O
deterioration,1905,O
of,1905,O
vision,1905,O
in,1905,O
both,1905,O
eyes,1905,O
",",1905,O
with,1905,O
clinical,1905,O
features,1905,O
resembling,1905,O
ischemic,1905,B-Disease
optic,1905,I-Disease
neuropathies,1905,I-Disease
.,1905,O
Deterioration,1906,B-Disease
of,1906,I-Disease
vision,1906,I-Disease
occurred,1906,O
despite,1906,O
discontinuation,1906,O
of,1906,O
the,1906,O
tacrolimus,1906,B-Chemical
.,1906,O
CONCLUSION,1907,O
:,1907,O
Tacrolimus,1907,B-Chemical
and,1907,O
other,1907,O
immunosuppressive,1907,O
agents,1907,O
may,1907,O
be,1907,O
associated,1907,O
with,1907,O
optic,1907,B-Disease
nerve,1907,I-Disease
toxicity,1907,I-Disease
.,1907,O
Hypercalcemia,1908,B-Disease
",",1908,O
arrhythmia,1908,B-Disease
",",1908,O
and,1908,O
mood,1908,O
stabilizers,1908,O
.,1908,O
Recent,1909,O
findings,1909,O
in,1909,O
a,1909,O
bipolar,1909,B-Disease
patient,1909,O
receiving,1909,O
maintenance,1909,O
lithium,1909,B-Chemical
therapy,1909,O
who,1909,O
developed,1909,O
hypercalcemia,1909,B-Disease
and,1909,O
severe,1909,O
bradyarrhythmia,1909,B-Disease
prompted,1909,O
the,1909,O
authors,1909,O
to,1909,O
conduct,1909,O
a,1909,O
retrospective,1909,O
study,1909,O
of,1909,O
bipolar,1909,B-Disease
patients,1909,O
with,1909,O
lithium-associated,1909,B-Chemical
hypercalcemia,1909,B-Disease
.,1909,O
A,1910,O
printout,1910,O
of,1910,O
all,1910,O
cases,1910,O
of,1910,O
hypercalcemia,1910,B-Disease
that,1910,O
presented,1910,O
during,1910,O
a,1910,O
1-year,1910,O
period,1910,O
was,1910,O
generated,1910,O
.,1910,O
After,1911,O
eliminating,1911,O
spurious,1911,O
hypercalcemias,1911,B-Disease
or,1911,O
those,1911,O
associated,1911,O
with,1911,O
intravenous,1911,O
fluids,1911,O
",",1911,O
the,1911,O
authors,1911,O
identified,1911,O
18,1911,O
non-lithium-treated,1911,O
patients,1911,O
with,1911,O
hypercalcemias,1911,B-Disease
related,1911,O
to,1911,O
malignancies,1911,B-Disease
and,1911,O
other,1911,O
medical,1911,O
conditions,1911,O
(,1911,O
group,1911,O
A,1911,O
),1911,O
and,1911,O
12,1911,O
patients,1911,O
with,1911,O
lithium-associated,1911,B-Chemical
hypercalcemia,1911,B-Disease
(,1911,O
group,1911,O
B,1911,O
),1911,O
.,1911,O
Patients,1912,O
in,1912,O
group,1912,O
B,1912,O
were,1912,O
not,1912,O
comparable,1912,O
to,1912,O
those,1912,O
in,1912,O
group,1912,O
A,1912,O
",",1912,O
as,1912,O
the,1912,O
latter,1912,O
were,1912,O
medically,1912,O
compromised,1912,O
and,1912,O
were,1912,O
receiving,1912,O
multiple,1912,O
pharmacotherapies,1912,O
.,1912,O
Thus,1913,O
",",1913,O
two,1913,O
control,1913,O
groups,1913,O
were,1913,O
generated,1913,O
:,1913,O
group,1913,O
C1,1913,O
",",1913,O
which,1913,O
included,1913,O
age-,1913,O
and,1913,O
sex-comparable,1913,O
lithium-treated,1913,B-Chemical
bipolar,1913,B-Disease
normocalcemic,1913,O
patients,1913,O
",",1913,O
and,1913,O
group,1913,O
C2,1913,O
",",1913,O
which,1913,O
included,1913,O
bipolar,1913,B-Disease
normocalcemic,1913,O
patients,1913,O
treated,1913,O
with,1913,O
anticonvulsant,1913,O
mood,1913,O
stabilizers,1913,O
.,1913,O
The,1914,O
electrocardiographic,1914,O
(,1914,O
ECG,1914,O
),1914,O
findings,1914,O
for,1914,O
patients,1914,O
in,1914,O
group,1914,O
B,1914,O
were,1914,O
compared,1914,O
with,1914,O
those,1914,O
of,1914,O
patients,1914,O
in,1914,O
groups,1914,O
C1,1914,O
and,1914,O
C2,1914,O
.,1914,O
It,1915,O
was,1915,O
found,1915,O
that,1915,O
these,1915,O
groups,1915,O
did,1915,O
not,1915,O
differ,1915,O
in,1915,O
their,1915,O
overall,1915,O
frequency,1915,O
of,1915,O
ECG,1915,O
abnormalities,1915,O
;,1915,O
however,1915,O
",",1915,O
there,1915,O
were,1915,O
significant,1915,O
differences,1915,O
in,1915,O
the,1915,O
frequency,1915,O
of,1915,O
conduction,1915,O
defects,1915,O
.,1915,O
Patients,1916,O
with,1916,O
hypercalcemia,1916,B-Disease
resulting,1916,O
from,1916,O
medical,1916,O
diseases,1916,O
and,1916,O
bipolar,1916,B-Disease
patients,1916,O
with,1916,O
lithium-associated,1916,B-Chemical
hypercalcemia,1916,B-Disease
had,1916,O
significantly,1916,O
higher,1916,O
frequencies,1916,O
of,1916,O
conduction,1916,O
defects,1916,O
.,1916,O
Patients,1917,O
in,1917,O
group,1917,O
A,1917,O
had,1917,O
significant,1917,O
mortality,1917,O
at,1917,O
2-year,1917,O
follow-up,1917,O
(,1917,O
28,1917,O
%,1917,O
),1917,O
",",1917,O
in,1917,O
contrast,1917,O
to,1917,O
zero,1917,O
mortality,1917,O
in,1917,O
the,1917,O
other,1917,O
three,1917,O
groups,1917,O
.,1917,O
The,1918,O
clinical,1918,O
implications,1918,O
of,1918,O
these,1918,O
findings,1918,O
are,1918,O
discussed,1918,O
.,1918,O
Attenuation,1919,O
of,1919,O
nephrotoxicity,1919,B-Disease
by,1919,O
a,1919,O
novel,1919,O
lipid,1919,O
nanosphere,1919,O
(,1919,O
NS-718,1919,O
),1919,O
incorporating,1919,O
amphotericin,1919,B-Chemical
B.,1919,O
NS-718,1919,O
",",1919,O
a,1919,O
lipid,1919,O
nanosphere,1919,O
incorporating,1919,O
amphotericin,1919,B-Chemical
B,1919,I-Chemical
",",1919,O
is,1919,O
effective,1919,O
against,1919,O
pathogenic,1919,O
fungi,1919,O
and,1919,O
has,1919,O
low,1919,O
toxicity,1919,B-Disease
.,1919,O
We,1920,O
compared,1920,O
the,1920,O
toxicity,1920,B-Disease
of,1920,O
NS-718,1920,O
with,1920,O
that,1920,O
of,1920,O
Fungizone,1920,B-Chemical
(,1920,O
amphotericin,1920,B-Chemical
B-sodium,1920,I-Chemical
deoxycholate,1920,I-Chemical
;,1920,O
D-AmB,1920,B-Chemical
),1920,O
in,1920,O
vitro,1920,O
using,1920,O
renal,1920,O
cell,1920,O
cultures,1920,O
and,1920,O
in,1920,O
vivo,1920,O
by,1920,O
biochemical,1920,O
analysis,1920,O
",",1920,O
histopathological,1920,O
study,1920,O
of,1920,O
the,1920,O
kidney,1920,O
and,1920,O
pharmacokinetic,1920,O
study,1920,O
of,1920,O
amphotericin,1920,B-Chemical
B,1920,I-Chemical
following,1920,O
intravenous,1920,O
infusion,1920,O
of,1920,O
the,1920,O
formulation,1920,O
in,1920,O
rats,1920,O
.,1920,O
Incubation,1921,O
with,1921,O
NS-718,1921,O
resulted,1921,O
in,1921,O
significantly,1921,O
less,1921,O
damage,1921,O
of,1921,O
cultured,1921,O
human,1921,O
renal,1921,O
proximal,1921,O
tubular,1921,O
epithelial,1921,O
cells,1921,O
compared,1921,O
with,1921,O
D-AmB,1921,B-Chemical
.,1921,O
Serum,1922,O
blood,1922,O
urea,1922,B-Chemical
and,1922,O
creatinine,1922,B-Chemical
concentrations,1922,O
increased,1922,O
significantly,1922,O
in,1922,O
rats,1922,O
given,1922,O
an,1922,O
iv,1922,O
infusion,1922,O
of,1922,O
D-AmB,1922,B-Chemical
3,1922,O
mg/kg,1922,O
but,1922,O
not,1922,O
in,1922,O
those,1922,O
given,1922,O
the,1922,O
same,1922,O
dose,1922,O
of,1922,O
NS-718,1922,O
.,1922,O
Histopathological,1923,O
examination,1923,O
of,1923,O
the,1923,O
kidney,1923,O
showed,1923,O
tubular,1923,B-Disease
necrosis,1923,I-Disease
in,1923,O
D-AmB-treated,1923,B-Chemical
rats,1923,O
but,1923,O
no,1923,O
change,1923,O
in,1923,O
NS-718-treated,1923,O
rats,1923,O
.,1923,O
Amphotericin,1924,B-Chemical
B,1924,I-Chemical
concentrations,1924,O
in,1924,O
the,1924,O
kidney,1924,O
in,1924,O
NS-718-treated,1924,O
rats,1924,O
were,1924,O
higher,1924,O
than,1924,O
those,1924,O
in,1924,O
D-AmB-treated,1924,B-Chemical
rats,1924,O
.,1924,O
Our,1925,O
in,1925,O
vitro,1925,O
and,1925,O
in,1925,O
vivo,1925,O
results,1925,O
suggest,1925,O
that,1925,O
incorporation,1925,O
of,1925,O
amphotericin,1925,B-Chemical
B,1925,I-Chemical
into,1925,O
lipid,1925,O
nanospheres,1925,O
of,1925,O
NS-718,1925,O
attenuates,1925,O
the,1925,O
nephrotoxicity,1925,B-Disease
of,1925,O
amphotericin,1925,B-Chemical
B,1925,I-Chemical
.,1925,O
Patterns,1926,O
of,1926,O
sulfadiazine,1926,B-Chemical
acute,1926,B-Disease
nephrotoxicity,1926,I-Disease
.,1926,O
Sulfadiazine,1927,B-Chemical
acute,1927,B-Disease
nephrotoxicity,1927,I-Disease
is,1927,O
reviving,1927,O
specially,1927,O
because,1927,O
of,1927,O
its,1927,O
use,1927,O
in,1927,O
toxoplasmosis,1927,B-Disease
in,1927,O
HIV-positive,1927,O
patients,1927,O
.,1927,O
We,1928,O
report,1928,O
4,1928,O
cases,1928,O
",",1928,O
one,1928,O
of,1928,O
them,1928,O
in,1928,O
a,1928,O
previously,1928,O
healthy,1928,O
person,1928,O
.,1928,O
Under,1929,O
treatment,1929,O
with,1929,O
sulfadiazine,1929,B-Chemical
they,1929,O
developed,1929,O
oliguria,1929,B-Disease
",",1929,O
abdominal,1929,B-Disease
pain,1929,I-Disease
",",1929,O
renal,1929,B-Disease
failure,1929,I-Disease
and,1929,O
showed,1929,O
multiple,1929,O
radiolucent,1929,O
renal,1929,B-Disease
calculi,1929,I-Disease
in,1929,O
echography,1929,O
.,1929,O
All,1930,O
patients,1930,O
recovered,1930,O
their,1930,O
previous,1930,O
normal,1930,O
renal,1930,O
function,1930,O
after,1930,O
adequate,1930,O
hydration,1930,O
and,1930,O
alcalinization,1930,O
.,1930,O
A,1931,O
nephrostomy,1931,O
tube,1931,O
had,1931,O
to,1931,O
be,1931,O
placed,1931,O
in,1931,O
one,1931,O
of,1931,O
the,1931,O
patients,1931,O
for,1931,O
ureteral,1931,B-Disease
lithiasis,1931,I-Disease
in,1931,O
a,1931,O
single,1931,O
functional,1931,O
kidney,1931,O
.,1931,O
None,1932,O
of,1932,O
them,1932,O
needed,1932,O
dialysis,1932,O
or,1932,O
a,1932,O
renal,1932,O
biopsy,1932,O
because,1932,O
of,1932,O
a,1932,O
typical,1932,O
benign,1932,O
course,1932,O
.,1932,O
Treatment,1933,O
with,1933,O
sulfadiazine,1933,B-Chemical
requires,1933,O
exquisite,1933,O
control,1933,O
of,1933,O
renal,1933,O
function,1933,O
",",1933,O
an,1933,O
increase,1933,O
in,1933,O
water,1933,O
ingestion,1933,O
and,1933,O
possibly,1933,O
the,1933,O
alcalinization,1933,O
of,1933,O
the,1933,O
urine,1933,O
.,1933,O
We,1934,O
communicate,1934,O
a,1934,O
case,1934,O
in,1934,O
a,1934,O
previously,1934,O
healthy,1934,O
person,1934,O
",",1934,O
a,1934,O
fact,1934,O
not,1934,O
found,1934,O
in,1934,O
the,1934,O
recent,1934,O
literature,1934,O
.,1934,O
Probably,1935,O
many,1935,O
more,1935,O
cases,1935,O
are,1935,O
not,1935,O
detected,1935,O
.,1935,O
We,1936,O
think,1936,O
that,1936,O
a,1936,O
prospective,1936,O
study,1936,O
would,1936,O
be,1936,O
useful,1936,O
.,1936,O
Downbeat,1937,B-Disease
nystagmus,1937,I-Disease
associated,1937,O
with,1937,O
intravenous,1937,O
patient-controlled,1937,O
administration,1937,O
of,1937,O
morphine,1937,B-Chemical
.,1937,O
IMPLICATIONS,1938,O
:,1938,O
This,1938,O
case,1938,O
documents,1938,O
a,1938,O
patient,1938,O
who,1938,O
developed,1938,O
dizziness,1938,B-Disease
with,1938,O
downbeating,1938,B-Disease
nystagmus,1938,I-Disease
while,1938,O
receiving,1938,O
a,1938,O
relatively,1938,O
large,1938,O
dose,1938,O
of,1938,O
IV,1938,O
patient-controlled,1938,O
analgesia,1938,O
morphine,1938,B-Chemical
.,1938,O
Although,1939,O
there,1939,O
have,1939,O
been,1939,O
case,1939,O
reports,1939,O
of,1939,O
epidural,1939,O
morphine,1939,B-Chemical
with,1939,O
these,1939,O
symptoms,1939,O
and,1939,O
signs,1939,O
",",1939,O
this,1939,O
has,1939,O
not,1939,O
been,1939,O
previously,1939,O
documented,1939,O
with,1939,O
IV,1939,O
or,1939,O
patient-controlled,1939,O
analgesia,1939,O
morphine,1939,B-Chemical
.,1939,O
Hemodynamic,1940,O
and,1940,O
antiadrenergic,1940,O
effects,1940,O
of,1940,O
dronedarone,1940,B-Chemical
and,1940,O
amiodarone,1940,B-Chemical
in,1940,O
animals,1940,O
with,1940,O
a,1940,O
healed,1940,O
myocardial,1940,B-Disease
infarction,1940,I-Disease
.,1940,O
The,1941,O
hemodynamic,1941,O
and,1941,O
antiadrenergic,1941,O
effects,1941,O
of,1941,O
dronedarone,1941,B-Chemical
",",1941,O
a,1941,O
noniodinated,1941,O
compound,1941,O
structurally,1941,O
related,1941,O
to,1941,O
amiodarone,1941,B-Chemical
",",1941,O
were,1941,O
compared,1941,O
with,1941,O
those,1941,O
of,1941,O
amiodarone,1941,B-Chemical
after,1941,O
prolonged,1941,O
oral,1941,O
administration,1941,O
",",1941,O
both,1941,O
at,1941,O
rest,1941,O
and,1941,O
during,1941,O
sympathetic,1941,O
stimulation,1941,O
in,1941,O
conscious,1941,O
dogs,1941,O
with,1941,O
a,1941,O
healed,1941,O
myocardial,1941,B-Disease
infarction,1941,I-Disease
.,1941,O
All,1942,O
dogs,1942,O
(,1942,O
n,1942,O
=,1942,O
6,1942,O
),1942,O
randomly,1942,O
received,1942,O
orally,1942,O
dronedarone,1942,B-Chemical
(,1942,O
10,1942,O
and,1942,O
30,1942,O
mg/kg,1942,O
),1942,O
",",1942,O
amiodarone,1942,B-Chemical
(,1942,O
10,1942,O
and,1942,O
30,1942,O
mg/kg,1942,O
),1942,O
",",1942,O
and,1942,O
placebo,1942,O
twice,1942,O
daily,1942,O
for,1942,O
7,1942,O
days,1942,O
",",1942,O
with,1942,O
a,1942,O
3-week,1942,O
washout,1942,O
between,1942,O
consecutive,1942,O
treatments,1942,O
.,1942,O
Heart,1943,O
rate,1943,O
(,1943,O
HR,1943,O
),1943,O
",",1943,O
mean,1943,O
arterial,1943,O
pressure,1943,O
(,1943,O
MBP,1943,O
),1943,O
",",1943,O
positive,1943,O
rate,1943,O
of,1943,O
increase,1943,O
of,1943,O
left,1943,O
ventricular,1943,O
pressure,1943,O
(,1943,O
+LVdP/dt,1943,O
),1943,O
",",1943,O
echocardiographically,1943,O
assessed,1943,O
left,1943,O
ventricular,1943,O
ejection,1943,O
fraction,1943,O
(,1943,O
LVEF,1943,O
),1943,O
",",1943,O
and,1943,O
fractional,1943,O
shortening,1943,O
(,1943,O
FS,1943,O
),1943,O
",",1943,O
as,1943,O
well,1943,O
as,1943,O
chronotropic,1943,O
response,1943,O
to,1943,O
isoproterenol,1943,B-Chemical
and,1943,O
exercise-induced,1943,O
sympathetic,1943,O
stimulation,1943,O
were,1943,O
evaluated,1943,O
under,1943,O
baseline,1943,O
and,1943,O
posttreatment,1943,O
conditions,1943,O
.,1943,O
Resting,1944,O
values,1944,O
of,1944,O
LVEF,1944,O
",",1944,O
FS,1944,O
",",1944,O
+LVdP/dt,1944,O
",",1944,O
and,1944,O
MBP,1944,O
remained,1944,O
unchanged,1944,O
whatever,1944,O
the,1944,O
drug,1944,O
and,1944,O
the,1944,O
dosing,1944,O
regimen,1944,O
",",1944,O
whereas,1944,O
resting,1944,O
HR,1944,O
was,1944,O
significantly,1944,O
and,1944,O
dose-dependently,1944,O
lowered,1944,O
after,1944,O
dronedarone,1944,B-Chemical
and,1944,O
to,1944,O
a,1944,O
lesser,1944,O
extent,1944,O
after,1944,O
amiodarone,1944,B-Chemical
.,1944,O
Both,1945,O
dronedarone,1945,B-Chemical
and,1945,O
amiodarone,1945,B-Chemical
significantly,1945,O
reduced,1945,O
the,1945,O
exercise-induced,1945,O
tachycardia,1945,B-Disease
and,1945,O
",",1945,O
at,1945,O
the,1945,O
highest,1945,O
dose,1945,O
",",1945,O
decreased,1945,O
the,1945,O
isoproterenol-induced,1945,B-Chemical
tachycardia,1945,B-Disease
.,1945,O
Thus,1946,O
",",1946,O
dronedarone,1946,B-Chemical
and,1946,O
amiodarone,1946,B-Chemical
displayed,1946,O
a,1946,O
similar,1946,O
level,1946,O
of,1946,O
antiadrenergic,1946,O
effect,1946,O
and,1946,O
did,1946,O
not,1946,O
impair,1946,O
the,1946,O
resting,1946,O
left,1946,O
ventricular,1946,O
function,1946,O
.,1946,O
Consequently,1947,O
",",1947,O
dronedarone,1947,B-Chemical
might,1947,O
be,1947,O
particularly,1947,O
suitable,1947,O
for,1947,O
the,1947,O
treatment,1947,O
and,1947,O
prevention,1947,O
of,1947,O
various,1947,O
clinical,1947,O
arrhythmias,1947,B-Disease
",",1947,O
without,1947,O
compromising,1947,O
the,1947,O
left,1947,O
ventricular,1947,O
function,1947,O
.,1947,O
Phase,1948,O
2,1948,O
trial,1948,O
of,1948,O
liposomal,1948,O
doxorubicin,1948,B-Chemical
(,1948,O
40,1948,O
mg/m,1948,O
(,1948,O
2,1948,O
),1948,O
),1948,O
in,1948,O
platinum/paclitaxel-refractory,1948,B-Chemical
ovarian,1948,O
and,1948,O
fallopian,1948,O
tube,1948,O
cancers,1948,O
and,1948,O
primary,1948,O
carcinoma,1948,B-Disease
of,1948,I-Disease
the,1948,I-Disease
peritoneum,1948,I-Disease
.,1948,O
BACKGROUND,1949,O
:,1949,O
Several,1949,O
studies,1949,O
have,1949,O
demonstrated,1949,O
liposomal,1949,O
doxorubicin,1949,B-Chemical
(,1949,O
Doxil,1949,B-Chemical
),1949,O
to,1949,O
be,1949,O
an,1949,O
active,1949,O
antineoplastic,1949,O
agent,1949,O
in,1949,O
platinum-resistant,1949,B-Chemical
ovarian,1949,B-Disease
cancer,1949,I-Disease
",",1949,O
with,1949,O
dose,1949,O
limiting,1949,O
toxicity,1949,B-Disease
of,1949,O
the,1949,O
standard,1949,O
dosing,1949,O
regimen,1949,O
(,1949,O
50,1949,O
mg/m,1949,O
(,1949,O
2,1949,O
),1949,O
q,1949,O
4,1949,O
weeks,1949,O
),1949,O
being,1949,O
severe,1949,O
erythrodysesthesia,1949,B-Disease
(,1949,O
``,1949,O
hand-foot,1949,B-Disease
syndrome,1949,I-Disease
'',1949,O
),1949,O
and,1949,O
stomatitis,1949,B-Disease
.,1949,O
We,1950,O
wished,1950,O
to,1950,O
develop,1950,O
a,1950,O
more,1950,O
tolerable,1950,O
liposomal,1950,O
doxorubicin,1950,B-Chemical
treatment,1950,O
regimen,1950,O
and,1950,O
document,1950,O
its,1950,O
level,1950,O
of,1950,O
activity,1950,O
in,1950,O
a,1950,O
well-defined,1950,O
patient,1950,O
population,1950,O
with,1950,O
platinum/paclitaxel-refractory,1950,B-Chemical
disease,1950,O
.,1950,O
METHODS,1951,O
AND,1951,O
MATERIALS,1951,O
:,1951,O
Patients,1951,O
with,1951,O
ovarian,1951,O
or,1951,O
fallopian,1951,O
tube,1951,O
cancers,1951,O
or,1951,O
primary,1951,O
peritoneal,1951,B-Disease
carcinoma,1951,I-Disease
with,1951,O
platinum/paclitaxel-refractory,1951,B-Chemical
disease,1951,O
(,1951,O
stable,1951,O
or,1951,O
progressive,1951,O
disease,1951,O
following,1951,O
treatment,1951,O
with,1951,O
these,1951,O
agents,1951,O
or,1951,O
previous,1951,O
objective,1951,O
response,1951,O
<,1951,O
3,1951,O
months,1951,O
in,1951,O
duration,1951,O
),1951,O
were,1951,O
treated,1951,O
with,1951,O
liposomal,1951,O
doxorubicin,1951,B-Chemical
at,1951,O
a,1951,O
dose,1951,O
of,1951,O
40,1951,O
mg/m,1951,O
(,1951,O
2,1951,O
),1951,O
q,1951,O
4,1951,O
weeks,1951,O
.,1951,O
RESULTS,1952,O
:,1952,O
A,1952,O
total,1952,O
of,1952,O
49,1952,O
patients,1952,O
(,1952,O
median,1952,O
age,1952,O
:,1952,O
60,1952,O
;,1952,O
range,1952,O
41-81,1952,O
),1952,O
entered,1952,O
this,1952,O
phase,1952,O
2,1952,O
trial,1952,O
.,1952,O
The,1953,O
median,1953,O
number,1953,O
of,1953,O
prior,1953,O
regimens,1953,O
was,1953,O
2,1953,O
(,1953,O
range,1953,O
:,1953,O
1-6,1953,O
),1953,O
.,1953,O
Six,1954,O
(,1954,O
12,1954,O
%,1954,O
),1954,O
and,1954,O
4,1954,O
(,1954,O
8,1954,O
%,1954,O
),1954,O
patients,1954,O
experienced,1954,O
grade,1954,O
2,1954,O
hand-foot,1954,B-Disease
syndrome,1954,I-Disease
and,1954,O
stomatitis,1954,B-Disease
",",1954,O
respectively,1954,O
(,1954,O
no,1954,O
episodes,1954,O
of,1954,O
grade,1954,O
3,1954,O
),1954,O
.,1954,O
One,1955,O
patient,1955,O
developed,1955,O
grade,1955,O
3,1955,O
diarrhea,1955,B-Disease
requiring,1955,O
hospitalization,1955,O
for,1955,O
hydration,1955,O
.,1955,O
Six,1956,O
(,1956,O
12,1956,O
%,1956,O
),1956,O
individuals,1956,O
required,1956,O
dose,1956,O
reductions,1956,O
.,1956,O
The,1957,O
median,1957,O
number,1957,O
of,1957,O
courses,1957,O
of,1957,O
liposomal,1957,O
doxorubicin,1957,B-Chemical
administered,1957,O
on,1957,O
this,1957,O
protocol,1957,O
was,1957,O
2,1957,O
(,1957,O
range,1957,O
:,1957,O
1-12,1957,O
),1957,O
.,1957,O
Four,1958,O
of,1958,O
44,1958,O
patients,1958,O
(,1958,O
9,1958,O
%,1958,O
),1958,O
evaluable,1958,O
for,1958,O
response,1958,O
exhibited,1958,O
objective,1958,O
and,1958,O
subjective,1958,O
evidence,1958,O
of,1958,O
an,1958,O
antineoplastic,1958,O
effect,1958,O
of,1958,O
therapy,1958,O
.,1958,O
CONCLUSION,1959,O
:,1959,O
This,1959,O
modified,1959,O
liposomal,1959,O
doxorubicin,1959,B-Chemical
regimen,1959,O
results,1959,O
in,1959,O
less,1959,O
toxicity,1959,B-Disease
(,1959,O
stomatitis,1959,B-Disease
",",1959,O
hand-foot,1959,B-Disease
syndrome,1959,I-Disease
),1959,O
than,1959,O
the,1959,O
standard,1959,O
FDA-approved,1959,O
dose,1959,O
schedule,1959,O
.,1959,O
Definite,1960,O
",",1960,O
although,1960,O
limited,1960,O
",",1960,O
antineoplastic,1960,O
activity,1960,O
is,1960,O
observed,1960,O
in,1960,O
patients,1960,O
with,1960,O
well-defined,1960,O
platinum-,1960,B-Chemical
and,1960,O
paclitaxel-refractory,1960,B-Chemical
ovarian,1960,B-Disease
cancer,1960,I-Disease
.,1960,O
Efficacy,1961,O
of,1961,O
olanzapine,1961,B-Chemical
in,1961,O
acute,1961,O
bipolar,1961,B-Disease
mania,1961,I-Disease
:,1961,O
a,1961,O
double-blind,1961,O
",",1961,O
placebo-controlled,1961,O
study,1961,O
.,1961,O
The,1962,O
Olanzipine,1962,B-Chemical
HGGW,1962,O
Study,1962,O
Group,1962,O
.,1962,O
BACKGROUND,1963,O
:,1963,O
We,1963,O
compared,1963,O
the,1963,O
efficacy,1963,O
and,1963,O
safety,1963,O
of,1963,O
olanzapine,1963,B-Chemical
vs,1963,O
placebo,1963,O
for,1963,O
the,1963,O
treatment,1963,O
of,1963,O
acute,1963,O
bipolar,1963,B-Disease
mania,1963,I-Disease
.,1963,O
METHODS,1964,O
:,1964,O
Four-week,1964,O
",",1964,O
randomized,1964,O
",",1964,O
double-blind,1964,O
",",1964,O
parallel,1964,O
study,1964,O
.,1964,O
A,1965,O
total,1965,O
of,1965,O
115,1965,O
patients,1965,O
with,1965,O
a,1965,O
DSM-IV,1965,O
diagnosis,1965,O
of,1965,O
bipolar,1965,B-Disease
disorder,1965,I-Disease
",",1965,O
manic,1965,B-Disease
or,1965,O
mixed,1965,O
",",1965,O
were,1965,O
randomized,1965,O
to,1965,O
olanzapine,1965,B-Chemical
",",1965,O
5,1965,O
to,1965,O
20,1965,O
mg/d,1965,O
(,1965,O
n,1965,O
=,1965,O
55,1965,O
),1965,O
",",1965,O
or,1965,O
placebo,1965,O
(,1965,O
n,1965,O
=,1965,O
60,1965,O
),1965,O
.,1965,O
The,1966,O
primary,1966,O
efficacy,1966,O
measure,1966,O
was,1966,O
the,1966,O
Young-Mania,1966,O
Rating,1966,O
Scale,1966,O
(,1966,O
Y-MRS,1966,O
),1966,O
total,1966,O
score,1966,O
.,1966,O
Response,1967,O
and,1967,O
euthymia,1967,O
were,1967,O
defined,1967,O
",",1967,O
a,1967,O
priori,1967,O
",",1967,O
as,1967,O
at,1967,O
least,1967,O
a,1967,O
50,1967,O
%,1967,O
improvement,1967,O
from,1967,O
baseline,1967,O
to,1967,O
end,1967,O
point,1967,O
and,1967,O
as,1967,O
a,1967,O
score,1967,O
of,1967,O
no,1967,O
less,1967,O
than,1967,O
12,1967,O
at,1967,O
end,1967,O
point,1967,O
in,1967,O
the,1967,O
Y-MRS,1967,O
total,1967,O
score,1967,O
",",1967,O
respectively,1967,O
.,1967,O
Safety,1968,O
was,1968,O
assessed,1968,O
using,1968,O
adverse,1968,O
events,1968,O
",",1968,O
Extrapyramidal,1968,B-Disease
Symptom,1968,I-Disease
(,1968,O
EPS,1968,B-Disease
),1968,O
rating,1968,O
scales,1968,O
",",1968,O
laboratory,1968,O
values,1968,O
",",1968,O
electrocardiograms,1968,O
",",1968,O
vital,1968,O
signs,1968,O
",",1968,O
and,1968,O
weight,1968,O
change,1968,O
.,1968,O
RESULTS,1969,O
:,1969,O
Olanzapine-treated,1969,B-Chemical
patients,1969,O
demonstrated,1969,O
a,1969,O
statistically,1969,O
significant,1969,O
greater,1969,O
mean,1969,O
(,1969,O
+/-,1969,O
SD,1969,O
),1969,O
improvement,1969,O
in,1969,O
Y-MRS,1969,O
total,1969,O
score,1969,O
than,1969,O
placebo-treated,1969,O
patients,1969,O
(,1969,O
-14.8,1969,O
+/-,1969,O
12.5,1969,O
and,1969,O
-8.1,1969,O
+/-,1969,O
12.7,1969,O
",",1969,O
respectively,1969,O
;,1969,O
P,1969,O
<,1969,O
.001,1969,O
),1969,O
",",1969,O
which,1969,O
was,1969,O
evident,1969,O
at,1969,O
the,1969,O
first,1969,O
postbaseline,1969,O
observation,1969,O
1,1969,O
week,1969,O
after,1969,O
randomization,1969,O
and,1969,O
was,1969,O
maintained,1969,O
throughout,1969,O
the,1969,O
study,1969,O
(,1969,O
last,1969,O
observation,1969,O
carried,1969,O
forward,1969,O
),1969,O
.,1969,O
Olanzapine-treated,1970,B-Chemical
patients,1970,O
demonstrated,1970,O
a,1970,O
higher,1970,O
rate,1970,O
of,1970,O
response,1970,O
(,1970,O
65,1970,O
%,1970,O
vs,1970,O
43,1970,O
%,1970,O
",",1970,O
respectively,1970,O
;,1970,O
P,1970,O
=.02,1970,O
),1970,O
and,1970,O
euthymia,1970,O
(,1970,O
61,1970,O
%,1970,O
vs,1970,O
36,1970,O
%,1970,O
",",1970,O
respectively,1970,O
;,1970,O
P,1970,O
=,1970,O
.,1970,O
01,1971,O
),1971,O
than,1971,O
placebo-treated,1971,O
patients,1971,O
.,1971,O
There,1972,O
were,1972,O
no,1972,O
statistically,1972,O
significant,1972,O
differences,1972,O
in,1972,O
EPSs,1972,B-Disease
between,1972,O
groups,1972,O
.,1972,O
However,1973,O
",",1973,O
olanzapine-treated,1973,B-Chemical
patients,1973,O
had,1973,O
a,1973,O
statistically,1973,O
significant,1973,O
greater,1973,O
mean,1973,O
(,1973,O
+/-,1973,O
SD,1973,O
),1973,O
weight,1973,B-Disease
gain,1973,I-Disease
than,1973,O
placebo-treated,1973,O
patients,1973,O
(,1973,O
2.1,1973,O
+/-,1973,O
2.8,1973,O
vs,1973,O
0.45,1973,O
+/-,1973,O
2.3,1973,O
kg,1973,O
",",1973,O
respectively,1973,O
),1973,O
and,1973,O
also,1973,O
experienced,1973,O
more,1973,O
treatment-emergent,1973,O
somnolence,1973,B-Disease
(,1973,O
21,1973,O
patients,1973,O
[,1973,O
38.2,1973,O
%,1973,O
],1973,O
vs,1973,O
5,1973,O
[,1973,O
8.3,1973,O
%,1973,O
],1973,O
",",1973,O
respectively,1973,O
),1973,O
.,1973,O
CONCLUSION,1974,O
:,1974,O
Olanzapine,1974,B-Chemical
demonstrated,1974,O
greater,1974,O
efficacy,1974,O
than,1974,O
placebo,1974,O
in,1974,O
the,1974,O
treatment,1974,O
of,1974,O
acute,1974,O
bipolar,1974,B-Disease
mania,1974,I-Disease
and,1974,O
was,1974,O
generally,1974,O
well,1974,O
tolerated,1974,O
.,1974,O
The,1975,O
effect,1975,O
of,1975,O
pupil,1975,B-Disease
dilation,1975,I-Disease
with,1975,O
tropicamide,1975,B-Chemical
on,1975,O
vision,1975,O
and,1975,O
driving,1975,O
simulator,1975,O
performance,1975,O
.,1975,O
PURPOSE,1976,O
:,1976,O
To,1976,O
assess,1976,O
the,1976,O
effect,1976,O
of,1976,O
pupil,1976,B-Disease
dilation,1976,I-Disease
on,1976,O
vision,1976,O
and,1976,O
driving,1976,O
ability,1976,O
.,1976,O
METHODS,1977,O
:,1977,O
A,1977,O
series,1977,O
of,1977,O
tests,1977,O
on,1977,O
various,1977,O
parameters,1977,O
of,1977,O
visual,1977,O
function,1977,O
and,1977,O
driving,1977,O
simulator,1977,O
performance,1977,O
were,1977,O
performed,1977,O
on,1977,O
12,1977,O
healthy,1977,O
drivers,1977,O
",",1977,O
before,1977,O
and,1977,O
after,1977,O
pupil,1977,B-Disease
dilation,1977,I-Disease
using,1977,O
guttae,1977,O
tropicamide,1977,B-Chemical
1,1977,O
%,1977,O
.,1977,O
A,1978,O
driving,1978,O
simulator,1978,O
(,1978,O
Transport,1978,O
Research,1978,O
Laboratory,1978,O
),1978,O
was,1978,O
used,1978,O
to,1978,O
measure,1978,O
reaction,1978,O
time,1978,O
(,1978,O
RT,1978,O
),1978,O
",",1978,O
speed,1978,O
maintenance,1978,O
and,1978,O
steering,1978,O
accuracy,1978,O
.,1978,O
Tests,1979,O
of,1979,O
basic,1979,O
visual,1979,O
function,1979,O
included,1979,O
high-,1979,O
and,1979,O
low-contrast,1979,O
visual,1979,O
acuity,1979,O
(,1979,O
HCVA,1979,O
and,1979,O
LCVA,1979,O
),1979,O
",",1979,O
Pelli-Robson,1979,O
contrast,1979,O
threshold,1979,O
(,1979,O
CT,1979,O
),1979,O
and,1979,O
Goldmann,1979,O
perimetry,1979,O
(,1979,O
FIELDS,1979,O
),1979,O
.,1979,O
Useful,1980,O
Field,1980,O
of,1980,O
View,1980,O
(,1980,O
UFOV,1980,O
--,1980,O
a,1980,O
test,1980,O
of,1980,O
visual,1980,O
attention,1980,O
),1980,O
was,1980,O
also,1980,O
undertaken,1980,O
.,1980,O
The,1981,O
mean,1981,O
differences,1981,O
in,1981,O
the,1981,O
pre-,1981,O
and,1981,O
post-dilatation,1981,O
measurements,1981,O
were,1981,O
tested,1981,O
for,1981,O
statistical,1981,O
significance,1981,O
at,1981,O
the,1981,O
95,1981,O
%,1981,O
level,1981,O
using,1981,O
one-tail,1981,O
paired,1981,O
t-tests,1981,O
.,1981,O
RESULTS,1982,O
:,1982,O
Pupillary,1982,B-Disease
dilation,1982,I-Disease
resulted,1982,O
in,1982,O
a,1982,O
statistically,1982,O
significant,1982,O
deterioration,1982,O
in,1982,O
CT,1982,O
and,1982,O
HCVA,1982,O
only,1982,O
.,1982,O
Five,1983,O
of,1983,O
12,1983,O
drivers,1983,O
also,1983,O
exhibited,1983,O
deterioration,1983,O
in,1983,O
LCVA,1983,O
",",1983,O
CT,1983,O
and,1983,O
RT,1983,O
.,1983,O
Little,1984,O
evidence,1984,O
emerged,1984,O
for,1984,O
deterioration,1984,O
in,1984,O
FIELDS,1984,O
and,1984,O
UFOV,1984,O
.,1984,O
Also,1985,O
",",1985,O
7,1985,O
of,1985,O
12,1985,O
drivers,1985,O
appeared,1985,O
to,1985,O
adjust,1985,O
their,1985,O
driving,1985,O
behaviour,1985,O
by,1985,O
reducing,1985,O
their,1985,O
speed,1985,O
on,1985,O
the,1985,O
driving,1985,O
simulator,1985,O
",",1985,O
leading,1985,O
to,1985,O
improved,1985,O
steering,1985,O
accuracy,1985,O
.,1985,O
CONCLUSIONS,1986,O
:,1986,O
Pupillary,1986,B-Disease
dilation,1986,I-Disease
may,1986,O
lead,1986,O
to,1986,O
a,1986,O
decrease,1986,O
in,1986,O
vision,1986,O
and,1986,O
daylight,1986,O
driving,1986,O
performance,1986,O
in,1986,O
young,1986,O
people,1986,O
.,1986,O
A,1987,O
larger,1987,O
study,1987,O
",",1987,O
including,1987,O
a,1987,O
broader,1987,O
spectrum,1987,O
of,1987,O
subjects,1987,O
",",1987,O
is,1987,O
warranted,1987,O
before,1987,O
guidelines,1987,O
can,1987,O
be,1987,O
recommended,1987,O
.,1987,O
A,1988,O
case,1988,O
of,1988,O
isotretinoin,1988,B-Disease
embryopathy,1988,I-Disease
with,1988,O
bilateral,1988,O
anotia,1988,B-Disease
and,1988,O
Taussig-Bing,1988,B-Disease
malformation,1988,I-Disease
.,1988,O
We,1989,O
report,1989,O
a,1989,O
newborn,1989,O
infant,1989,O
with,1989,O
multiple,1989,O
congenital,1989,O
anomalies,1989,O
(,1989,O
anotia,1989,B-Disease
and,1989,O
Taussig-Bing,1989,B-Disease
malformation,1989,I-Disease
),1989,O
due,1989,O
to,1989,O
exposure,1989,O
to,1989,O
isotretinoin,1989,B-Chemical
within,1989,O
the,1989,O
first,1989,O
trimester,1989,O
.,1989,O
In,1990,O
this,1990,O
paper,1990,O
we,1990,O
aim,1990,O
to,1990,O
draw,1990,O
to,1990,O
the,1990,O
fact,1990,O
that,1990,O
caution,1990,O
is,1990,O
needed,1990,O
when,1990,O
prescribing,1990,O
vitamin,1990,B-Chemical
A-containing,1990,O
drugs,1990,O
to,1990,O
women,1990,O
of,1990,O
childbearing,1990,O
years,1990,O
.,1990,O
Effect,1991,O
of,1991,O
methoxamine,1991,B-Chemical
on,1991,O
maximum,1991,O
urethral,1991,O
pressure,1991,O
in,1991,O
women,1991,O
with,1991,O
genuine,1991,O
stress,1991,B-Disease
incontinence,1991,I-Disease
:,1991,O
a,1991,O
placebo-controlled,1991,O
",",1991,O
double-blind,1991,O
crossover,1991,O
study,1991,O
.,1991,O
The,1992,O
aim,1992,O
of,1992,O
the,1992,O
study,1992,O
was,1992,O
to,1992,O
evaluate,1992,O
the,1992,O
potential,1992,O
role,1992,O
for,1992,O
a,1992,O
selective,1992,O
alpha1-adrenoceptor,1992,O
agonist,1992,O
in,1992,O
the,1992,O
treatment,1992,O
of,1992,O
urinary,1992,B-Disease
stress,1992,I-Disease
incontinence,1992,I-Disease
.,1992,O
A,1993,O
randomised,1993,O
",",1993,O
double-blind,1993,O
",",1993,O
placebo-controlled,1993,O
",",1993,O
crossover,1993,O
study,1993,O
design,1993,O
was,1993,O
employed,1993,O
.,1993,O
Half,1994,O
log,1994,O
incremental,1994,O
doses,1994,O
of,1994,O
intravenous,1994,O
methoxamine,1994,B-Chemical
or,1994,O
placebo,1994,O
(,1994,O
saline,1994,O
),1994,O
were,1994,O
administered,1994,O
to,1994,O
a,1994,O
group,1994,O
of,1994,O
women,1994,O
with,1994,O
genuine,1994,O
stress,1994,B-Disease
incontinence,1994,I-Disease
while,1994,O
measuring,1994,O
maximum,1994,O
urethral,1994,O
pressure,1994,O
(,1994,O
MUP,1994,O
),1994,O
",",1994,O
blood,1994,O
pressure,1994,O
",",1994,O
heart,1994,O
rate,1994,O
",",1994,O
and,1994,O
symptomatic,1994,O
side,1994,O
effects,1994,O
.,1994,O
Methoxamine,1995,B-Chemical
evoked,1995,O
non-significant,1995,O
increases,1995,O
in,1995,O
MUP,1995,O
and,1995,O
diastolic,1995,O
blood,1995,O
pressure,1995,O
but,1995,O
caused,1995,O
a,1995,B-Disease
significant,1995,I-Disease
rise,1995,I-Disease
in,1995,I-Disease
systolic,1995,I-Disease
blood,1995,I-Disease
pressure,1995,I-Disease
and,1995,O
significant,1995,O
fall,1995,O
in,1995,O
heart,1995,O
rate,1995,O
at,1995,O
maximum,1995,O
dosage,1995,O
.,1995,O
Systemic,1996,O
side,1996,O
effects,1996,O
including,1996,O
piloerection,1996,O
",",1996,O
headache,1996,B-Disease
",",1996,O
and,1996,O
cold,1996,O
extremities,1996,O
were,1996,O
experienced,1996,O
in,1996,O
all,1996,O
subjects,1996,O
.,1996,O
The,1997,O
results,1997,O
indicate,1997,O
that,1997,O
the,1997,O
clinical,1997,O
usefulness,1997,O
of,1997,O
direct,1997,O
",",1997,O
peripherally,1997,O
acting,1997,O
sub-type-selective,1997,O
alpha1-adrenoceptor,1997,O
agonists,1997,O
in,1997,O
the,1997,O
medical,1997,O
treatment,1997,O
of,1997,O
stress,1997,B-Disease
incontinence,1997,I-Disease
may,1997,O
be,1997,O
limited,1997,O
by,1997,O
associated,1997,O
piloerection,1997,O
and,1997,O
cardiovascular,1997,O
side,1997,O
effects,1997,O
.,1997,O
Toleration,1998,O
of,1998,O
high,1998,O
doses,1998,O
of,1998,O
angiotensin-converting,1998,B-Chemical
enzyme,1998,I-Chemical
inhibitors,1998,I-Chemical
in,1998,O
patients,1998,O
with,1998,O
chronic,1998,O
heart,1998,B-Disease
failure,1998,I-Disease
:,1998,O
results,1998,O
from,1998,O
the,1998,O
ATLAS,1998,O
trial,1998,O
.,1998,O
The,1999,O
Assessment,1999,O
of,1999,O
Treatment,1999,O
with,1999,O
Lisinopril,1999,B-Chemical
and,1999,O
Survival,1999,O
.,1999,O
BACKGROUND,2000,O
:,2000,O
Treatment,2000,O
with,2000,O
angiotensin-converting,2000,B-Chemical
enzyme,2000,I-Chemical
(,2000,I-Chemical
ACE,2000,I-Chemical
),2000,I-Chemical
inhibitors,2000,I-Chemical
reduces,2000,O
mortality,2000,O
and,2000,O
morbidity,2000,O
in,2000,O
patients,2000,O
with,2000,O
chronic,2000,O
heart,2000,B-Disease
failure,2000,I-Disease
(,2000,O
CHF,2000,B-Disease
),2000,O
",",2000,O
but,2000,O
most,2000,O
affected,2000,O
patients,2000,O
are,2000,O
not,2000,O
receiving,2000,O
these,2000,O
agents,2000,O
or,2000,O
are,2000,O
being,2000,O
treated,2000,O
with,2000,O
doses,2000,O
lower,2000,O
than,2000,O
those,2000,O
found,2000,O
to,2000,O
be,2000,O
efficacious,2000,O
in,2000,O
trials,2000,O
",",2000,O
primarily,2000,O
because,2000,O
of,2000,O
concerns,2000,O
about,2000,O
the,2000,O
safety,2000,O
and,2000,O
tolerability,2000,O
of,2000,O
these,2000,O
agents,2000,O
",",2000,O
especially,2000,O
at,2000,O
the,2000,O
recommended,2000,O
doses,2000,O
.,2000,O
The,2001,O
present,2001,O
study,2001,O
examines,2001,O
the,2001,O
safety,2001,O
and,2001,O
tolerability,2001,O
of,2001,O
high-,2001,O
compared,2001,O
with,2001,O
low-dose,2001,O
lisinopril,2001,B-Chemical
in,2001,O
CHF,2001,B-Disease
.,2001,O
METHODS,2002,O
:,2002,O
The,2002,O
Assessment,2002,O
of,2002,O
Lisinopril,2002,B-Chemical
and,2002,O
Survival,2002,O
study,2002,O
was,2002,O
a,2002,O
multicenter,2002,O
",",2002,O
randomized,2002,O
",",2002,O
double-blind,2002,O
trial,2002,O
in,2002,O
which,2002,O
patients,2002,O
with,2002,O
or,2002,O
without,2002,O
previous,2002,O
ACE,2002,B-Chemical
inhibitor,2002,I-Chemical
treatment,2002,O
were,2002,O
stabilized,2002,O
receiving,2002,O
medium-dose,2002,O
lisinopril,2002,B-Chemical
(,2002,O
12.5,2002,O
or,2002,O
15.0,2002,O
mg,2002,O
once,2002,O
daily,2002,O
[,2002,O
OD,2002,O
],2002,O
),2002,O
for,2002,O
2,2002,O
to,2002,O
4,2002,O
weeks,2002,O
and,2002,O
then,2002,O
randomized,2002,O
to,2002,O
high-,2002,O
(,2002,O
35.0,2002,O
or,2002,O
32.5,2002,O
mg,2002,O
OD,2002,O
),2002,O
or,2002,O
low-dose,2002,O
(,2002,O
5.0,2002,O
or,2002,O
2.5,2002,O
mg,2002,O
OD,2002,O
),2002,O
groups,2002,O
.,2002,O
Patients,2003,O
with,2003,O
New,2003,O
York,2003,O
Heart,2003,O
Association,2003,O
classes,2003,O
II,2003,O
to,2003,O
IV,2003,O
CHF,2003,B-Disease
and,2003,O
left,2003,O
ventricular,2003,O
ejection,2003,O
fractions,2003,O
of,2003,O
no,2003,O
greater,2003,O
than,2003,O
0.30,2003,O
(,2003,O
n,2003,O
=,2003,O
3164,2003,O
),2003,O
were,2003,O
randomized,2003,O
and,2003,O
followed,2003,O
up,2003,O
for,2003,O
a,2003,O
median,2003,O
of,2003,O
46,2003,O
months,2003,O
.,2003,O
We,2004,O
examined,2004,O
the,2004,O
occurrence,2004,O
of,2004,O
adverse,2004,O
events,2004,O
and,2004,O
the,2004,O
need,2004,O
for,2004,O
discontinuation,2004,O
and,2004,O
dose,2004,O
reduction,2004,O
during,2004,O
treatment,2004,O
",",2004,O
with,2004,O
a,2004,O
focus,2004,O
on,2004,O
hypotension,2004,B-Disease
and,2004,O
renal,2004,B-Disease
dysfunction,2004,I-Disease
.,2004,O
RESULTS,2005,O
:,2005,O
Of,2005,O
405,2005,O
patients,2005,O
not,2005,O
previously,2005,O
receiving,2005,O
an,2005,O
ACE,2005,B-Chemical
inhibitor,2005,I-Chemical
",",2005,O
doses,2005,O
in,2005,O
only,2005,O
4.2,2005,O
%,2005,O
could,2005,O
not,2005,O
be,2005,O
titrated,2005,O
to,2005,O
the,2005,O
medium,2005,O
doses,2005,O
required,2005,O
for,2005,O
randomization,2005,O
because,2005,O
of,2005,O
symptoms,2005,O
possibly,2005,O
related,2005,O
to,2005,O
hypotension,2005,B-Disease
(,2005,O
2.0,2005,O
%,2005,O
),2005,O
or,2005,O
because,2005,O
of,2005,O
renal,2005,B-Disease
dysfunction,2005,I-Disease
or,2005,O
hyperkalemia,2005,B-Disease
(,2005,O
2.3,2005,O
%,2005,O
),2005,O
.,2005,O
Doses,2006,O
in,2006,O
more,2006,O
than,2006,O
90,2006,O
%,2006,O
of,2006,O
randomized,2006,O
patients,2006,O
in,2006,O
the,2006,O
high-,2006,O
and,2006,O
low-dose,2006,O
groups,2006,O
were,2006,O
titrated,2006,O
to,2006,O
their,2006,O
assigned,2006,O
target,2006,O
",",2006,O
and,2006,O
the,2006,O
mean,2006,O
doses,2006,O
of,2006,O
blinded,2006,O
medication,2006,O
in,2006,O
both,2006,O
groups,2006,O
remained,2006,O
similar,2006,O
throughout,2006,O
the,2006,O
study,2006,O
.,2006,O
Withdrawals,2007,O
occurred,2007,O
in,2007,O
27.1,2007,O
%,2007,O
of,2007,O
the,2007,O
high-,2007,O
and,2007,O
30.7,2007,O
%,2007,O
of,2007,O
the,2007,O
low-dose,2007,O
groups,2007,O
.,2007,O
Subgroups,2008,O
presumed,2008,O
to,2008,O
be,2008,O
at,2008,O
higher,2008,O
risk,2008,O
for,2008,O
ACE,2008,B-Chemical
inhibitor,2008,I-Chemical
intolerance,2008,O
(,2008,O
blood,2008,O
pressure,2008,O
",",2008,O
<,2008,O
120,2008,O
mm,2008,O
Hg,2008,O
;,2008,O
creatinine,2008,B-Chemical
",",2008,O
>,2008,O
or,2008,O
=132.6,2008,O
micromol/L,2008,O
[,2008,O
>,2008,O
or,2008,O
=1.5,2008,O
mg/dL,2008,O
],2008,O
;,2008,O
age,2008,O
",",2008,O
>,2008,O
or,2008,O
=70,2008,O
years,2008,O
;,2008,O
and,2008,O
patients,2008,O
with,2008,O
diabetes,2008,B-Disease
),2008,O
generally,2008,O
tolerated,2008,O
the,2008,O
high-dose,2008,O
strategy,2008,O
.,2008,O
CONCLUSIONS,2009,O
:,2009,O
These,2009,O
findings,2009,O
demonstrate,2009,O
that,2009,O
ACE,2009,B-Chemical
inhibitor,2009,I-Chemical
therapy,2009,O
in,2009,O
most,2009,O
patients,2009,O
with,2009,O
CHF,2009,B-Disease
can,2009,O
be,2009,O
successfully,2009,O
titrated,2009,O
to,2009,O
and,2009,O
maintained,2009,O
at,2009,O
high,2009,O
doses,2009,O
",",2009,O
and,2009,O
that,2009,O
more,2009,O
aggressive,2009,O
use,2009,O
of,2009,O
these,2009,O
agents,2009,O
is,2009,O
warranted,2009,O
.,2009,O
Cocaine,2010,B-Chemical
",",2010,O
ethanol,2010,B-Chemical
",",2010,O
and,2010,O
cocaethylene,2010,B-Chemical
cardiotoxity,2010,B-Disease
in,2010,O
an,2010,O
animal,2010,O
model,2010,O
of,2010,O
cocaine,2010,O
and,2010,O
ethanol,2010,O
abuse,2010,O
.,2010,O
OBJECTIVES,2011,O
:,2011,O
Simultaneous,2011,O
abuse,2011,O
of,2011,O
cocaine,2011,O
and,2011,O
ethanol,2011,O
affects,2011,O
12,2011,O
million,2011,O
Americans,2011,O
annually,2011,O
.,2011,O
In,2012,O
combination,2012,O
",",2012,O
these,2012,O
substances,2012,O
are,2012,O
substantially,2012,O
more,2012,O
toxic,2012,O
than,2012,O
either,2012,O
drug,2012,O
alone,2012,O
.,2012,O
Their,2013,O
combined,2013,O
cardiac,2013,B-Disease
toxicity,2013,I-Disease
may,2013,O
be,2013,O
due,2013,O
to,2013,O
independent,2013,O
effects,2013,O
of,2013,O
each,2013,O
drug,2013,O
;,2013,O
however,2013,O
",",2013,O
they,2013,O
may,2013,O
also,2013,O
be,2013,O
due,2013,O
to,2013,O
cocaethylene,2013,B-Chemical
(,2013,O
CE,2013,B-Chemical
),2013,O
",",2013,O
a,2013,O
cocaine,2013,B-Chemical
metabolite,2013,O
formed,2013,O
only,2013,O
in,2013,O
the,2013,O
presence,2013,O
of,2013,O
ethanol,2013,B-Chemical
.,2013,O
The,2014,O
purpose,2014,O
of,2014,O
this,2014,O
study,2014,O
was,2014,O
to,2014,O
delineate,2014,O
the,2014,O
role,2014,O
of,2014,O
CE,2014,B-Chemical
in,2014,O
the,2014,O
combined,2014,O
cardiotoxicity,2014,B-Disease
of,2014,O
cocaine,2014,B-Chemical
and,2014,O
ethanol,2014,B-Chemical
in,2014,O
a,2014,O
model,2014,O
simulating,2014,O
their,2014,O
abuse,2014,O
.,2014,O
METHODS,2015,O
:,2015,O
Twenty-three,2015,O
dogs,2015,O
were,2015,O
randomized,2015,O
to,2015,O
receive,2015,O
either,2015,O
1,2015,O
),2015,O
three,2015,O
intravenous,2015,O
(,2015,O
IV,2015,O
),2015,O
boluses,2015,O
of,2015,O
cocaine,2015,B-Chemical
7.5,2015,O
mg/kg,2015,O
with,2015,O
ethanol,2015,B-Chemical
(,2015,O
1,2015,O
g/kg,2015,O
),2015,O
as,2015,O
an,2015,O
IV,2015,O
infusion,2015,O
(,2015,O
C+E,2015,O
",",2015,O
n,2015,O
=,2015,O
8,2015,O
),2015,O
",",2015,O
2,2015,O
),2015,O
three,2015,O
cocaine,2015,B-Chemical
boluses,2015,O
only,2015,O
(,2015,O
C,2015,O
",",2015,O
n,2015,O
=,2015,O
6,2015,O
),2015,O
",",2015,O
3,2015,O
),2015,O
ethanol,2015,B-Chemical
infusion,2015,O
only,2015,O
(,2015,O
E,2015,O
",",2015,O
n,2015,O
=,2015,O
5,2015,O
),2015,O
",",2015,O
or,2015,O
4,2015,O
),2015,O
placebo,2015,O
boluses,2015,O
and,2015,O
infusion,2015,O
(,2015,O
n,2015,O
=,2015,O
4,2015,O
),2015,O
.,2015,O
Hemodynamic,2016,O
measurements,2016,O
",",2016,O
electrocardiograms,2016,O
",",2016,O
and,2016,O
serum,2016,O
drug,2016,O
concentrations,2016,O
were,2016,O
obtained,2016,O
at,2016,O
baseline,2016,O
",",2016,O
and,2016,O
then,2016,O
at,2016,O
fixed,2016,O
time,2016,O
intervals,2016,O
after,2016,O
each,2016,O
drug,2016,O
was,2016,O
administered,2016,O
.,2016,O
RESULTS,2017,O
:,2017,O
Two,2017,O
of,2017,O
eight,2017,O
dogs,2017,O
in,2017,O
the,2017,O
C+E,2017,O
group,2017,O
experienced,2017,O
cardiovascular,2017,B-Disease
collapse,2017,I-Disease
.,2017,O
The,2018,O
most,2018,O
dramatic,2018,O
hemodynamic,2018,O
changes,2018,O
occurred,2018,O
after,2018,O
each,2018,O
cocaine,2018,B-Chemical
bolus,2018,O
in,2018,O
the,2018,O
C+E,2018,O
and,2018,O
C,2018,O
only,2018,O
groups,2018,O
;,2018,O
however,2018,O
",",2018,O
persistent,2018,O
hemodynamic,2018,O
changes,2018,O
occurred,2018,O
in,2018,O
the,2018,O
C+E,2018,O
group,2018,O
.,2018,O
Peak,2019,O
CE,2019,B-Chemical
levels,2019,O
were,2019,O
associated,2019,O
with,2019,O
a,2019,O
45,2019,O
%,2019,O
(,2019,O
SD,2019,O
+/-,2019,O
22,2019,O
%,2019,O
",",2019,O
95,2019,O
%,2019,O
CI,2019,O
=,2019,O
22,2019,O
%,2019,O
to,2019,O
69,2019,O
%,2019,O
),2019,O
decrease,2019,B-Disease
in,2019,I-Disease
cardiac,2019,I-Disease
output,2019,I-Disease
(,2019,O
p,2019,O
<,2019,O
0.05,2019,O
),2019,O
",",2019,O
a,2019,O
56,2019,O
%,2019,O
(,2019,O
SD,2019,O
+/-,2019,O
23,2019,O
%,2019,O
",",2019,O
95,2019,O
%,2019,O
CI,2019,O
=,2019,O
32,2019,O
%,2019,O
to,2019,O
80,2019,O
%,2019,O
),2019,O
decrease,2019,O
in,2019,O
dP/dt,2019,O
(,2019,O
max,2019,O
),2019,O
(,2019,O
p,2019,O
<,2019,O
.006,2019,O
),2019,O
",",2019,O
and,2019,O
a,2019,O
23,2019,O
%,2019,O
(,2019,O
SD,2019,O
+/-,2019,O
15,2019,O
%,2019,O
",",2019,O
95,2019,O
%,2019,O
CI,2019,O
=,2019,O
7,2019,O
%,2019,O
to,2019,O
49,2019,O
%,2019,O
),2019,O
decrease,2019,O
in,2019,O
SVO,2019,O
(,2019,O
2,2019,O
),2019,O
(,2019,O
p,2019,O
<,2019,O
0.025,2019,O
),2019,O
.,2019,O
Ventricular,2020,B-Disease
arrhythmias,2020,I-Disease
were,2020,O
primarily,2020,O
observed,2020,O
in,2020,O
the,2020,O
C+E,2020,O
group,2020,O
",",2020,O
in,2020,O
which,2020,O
four,2020,O
of,2020,O
eight,2020,O
dogs,2020,O
experienced,2020,O
ventricular,2020,B-Disease
tachycardia,2020,I-Disease
.,2020,O
CONCLUSIONS,2021,O
:,2021,O
Cocaine,2021,B-Chemical
and,2021,O
ethanol,2021,B-Chemical
in,2021,O
combination,2021,O
were,2021,O
more,2021,O
toxic,2021,O
than,2021,O
either,2021,O
substance,2021,O
alone,2021,O
.,2021,O
Co-administration,2022,O
resulted,2022,O
in,2022,O
prolonged,2022,O
cardiac,2022,B-Disease
toxicity,2022,I-Disease
and,2022,O
was,2022,O
dysrhythmogenic,2022,O
.,2022,O
Peak,2023,O
serum,2023,O
cocaethylene,2023,B-Chemical
concentrations,2023,O
were,2023,O
associated,2023,O
with,2023,O
prolonged,2023,O
myocardial,2023,B-Disease
depression,2023,I-Disease
.,2023,O
Worsening,2024,O
of,2024,O
Parkinsonism,2024,B-Disease
after,2024,O
the,2024,O
use,2024,O
of,2024,O
veralipride,2024,B-Chemical
for,2024,O
treatment,2024,O
of,2024,O
menopause,2024,O
:,2024,O
case,2024,O
report,2024,O
.,2024,O
We,2025,O
describe,2025,O
a,2025,O
female,2025,O
patient,2025,O
with,2025,O
stable,2025,O
Parkinson,2025,B-Disease
's,2025,I-Disease
disease,2025,I-Disease
who,2025,O
has,2025,O
shown,2025,O
a,2025,O
marked,2025,O
worsening,2025,O
of,2025,O
her,2025,O
motor,2025,O
functions,2025,O
following,2025,O
therapy,2025,O
of,2025,O
menopause,2025,O
related,2025,O
symptoms,2025,O
with,2025,O
veralipride,2025,B-Chemical
",",2025,O
as,2025,O
well,2025,O
as,2025,O
the,2025,O
improvement,2025,O
of,2025,O
her,2025,O
symptoms,2025,O
back,2025,O
to,2025,O
baseline,2025,O
after,2025,O
discontinuation,2025,O
of,2025,O
the,2025,O
drug,2025,O
.,2025,O
We,2026,O
emphasize,2026,O
the,2026,O
anti-dopaminergic,2026,O
effect,2026,O
of,2026,O
veralipride,2026,B-Chemical
.,2026,O
Viracept,2027,B-Chemical
and,2027,O
irregular,2027,B-Disease
heartbeat,2027,I-Disease
warning,2027,O
.,2027,O
A,2028,O
group,2028,O
of,2028,O
doctors,2028,O
in,2028,O
Boston,2028,O
warn,2028,O
that,2028,O
the,2028,O
protease,2028,O
inhibitor,2028,O
Viracept,2028,B-Chemical
may,2028,O
cause,2028,O
an,2028,O
irregular,2028,B-Disease
heart,2028,I-Disease
beat,2028,I-Disease
",",2028,O
known,2028,O
as,2028,O
bradycardia,2028,B-Disease
",",2028,O
in,2028,O
people,2028,O
with,2028,O
HIV,2028,O
.,2028,O
Bradycardia,2029,B-Disease
occurred,2029,O
in,2029,O
a,2029,O
45-year-old,2029,O
male,2029,O
patient,2029,O
who,2029,O
was,2029,O
Viracept,2029,B-Chemical
in,2029,O
combination,2029,O
with,2029,O
other,2029,O
anti-HIV,2029,O
drugs,2029,O
.,2029,O
The,2030,O
symptoms,2030,O
ceased,2030,O
after,2030,O
switching,2030,O
to,2030,O
another,2030,O
drug,2030,O
combination,2030,O
.,2030,O
Frequency,2031,O
of,2031,O
appearance,2031,O
of,2031,O
myeloperoxidase-antineutrophil,2031,O
cytoplasmic,2031,O
antibody,2031,O
(,2031,O
MPO-ANCA,2031,O
),2031,O
in,2031,O
Graves,2031,B-Disease
',2031,I-Disease
disease,2031,I-Disease
patients,2031,O
treated,2031,O
with,2031,O
propylthiouracil,2031,B-Chemical
and,2031,O
the,2031,O
relationship,2031,O
between,2031,O
MPO-ANCA,2031,O
and,2031,O
clinical,2031,O
manifestations,2031,O
.,2031,O
OBJECTIVE,2032,O
:,2032,O
Myeloperoxidase,2032,O
antineutrophil,2032,O
cytoplasmic,2032,O
antibody,2032,O
(,2032,O
MPO-ANCA,2032,O
),2032,O
-positive,2032,O
vasculitis,2032,B-Disease
has,2032,O
been,2032,O
reported,2032,O
in,2032,O
patients,2032,O
with,2032,O
Graves,2032,B-Disease
',2032,I-Disease
disease,2032,I-Disease
who,2032,O
were,2032,O
treated,2032,O
with,2032,O
propylthiouracil,2032,B-Chemical
(,2032,O
PTU,2032,B-Chemical
),2032,O
.,2032,O
The,2033,O
appearance,2033,O
of,2033,O
MPO-ANCA,2033,O
in,2033,O
these,2033,O
cases,2033,O
was,2033,O
suspected,2033,O
of,2033,O
being,2033,O
related,2033,O
to,2033,O
PTU,2033,B-Chemical
because,2033,O
the,2033,O
titres,2033,O
of,2033,O
MPO-ANCA,2033,O
decreased,2033,O
when,2033,O
PTU,2033,B-Chemical
was,2033,O
stopped,2033,O
.,2033,O
Nevertheless,2034,O
",",2034,O
there,2034,O
have,2034,O
been,2034,O
no,2034,O
studies,2034,O
on,2034,O
the,2034,O
temporal,2034,O
relationship,2034,O
between,2034,O
the,2034,O
appearance,2034,O
of,2034,O
MPO-ANCA,2034,O
and,2034,O
vasculitis,2034,B-Disease
during,2034,O
PTU,2034,B-Chemical
therapy,2034,O
",",2034,O
or,2034,O
on,2034,O
the,2034,O
incidence,2034,O
of,2034,O
MPO-ANCA,2034,O
in,2034,O
untreated,2034,O
Graves,2034,B-Disease
',2034,I-Disease
disease,2034,I-Disease
patients,2034,O
.,2034,O
Therefore,2035,O
",",2035,O
we,2035,O
sought,2035,O
to,2035,O
address,2035,O
these,2035,O
parameters,2035,O
in,2035,O
patients,2035,O
with,2035,O
Graves,2035,B-Disease
',2035,I-Disease
disease,2035,I-Disease
.,2035,O
PATIENTS,2036,O
:,2036,O
We,2036,O
investigated,2036,O
102,2036,O
untreated,2036,O
patients,2036,O
with,2036,O
hyperthyroidism,2036,B-Disease
due,2036,O
to,2036,O
Graves,2036,B-Disease
',2036,I-Disease
disease,2036,I-Disease
for,2036,O
the,2036,O
presence,2036,O
of,2036,O
MPO-ANCA,2036,O
",",2036,O
and,2036,O
for,2036,O
the,2036,O
development,2036,O
vasculitis,2036,B-Disease
after,2036,O
starting,2036,O
PTU,2036,B-Chemical
therapy,2036,O
.,2036,O
Twenty-nine,2037,O
of,2037,O
them,2037,O
were,2037,O
later,2037,O
excluded,2037,O
because,2037,O
of,2037,O
adverse,2037,O
effects,2037,O
of,2037,O
PTU,2037,B-Chemical
or,2037,O
because,2037,O
the,2037,O
observation,2037,O
period,2037,O
was,2037,O
less,2037,O
than,2037,O
3,2037,O
months,2037,O
.,2037,O
The,2038,O
remaining,2038,O
73,2038,O
patients,2038,O
(,2038,O
55,2038,O
women,2038,O
and,2038,O
18,2038,O
men,2038,O
),2038,O
",",2038,O
all,2038,O
of,2038,O
whom,2038,O
were,2038,O
examined,2038,O
for,2038,O
more,2038,O
than,2038,O
3,2038,O
months,2038,O
",",2038,O
were,2038,O
adopted,2038,O
as,2038,O
the,2038,O
subjects,2038,O
of,2038,O
the,2038,O
investigation,2038,O
.,2038,O
The,2039,O
median,2039,O
observation,2039,O
period,2039,O
was,2039,O
23.6,2039,O
months,2039,O
(,2039,O
range,2039,O
:,2039,O
3-37,2039,O
months,2039,O
),2039,O
.,2039,O
MEASUREMENTS,2040,O
:,2040,O
MPO-ANCA,2040,O
was,2040,O
measured,2040,O
at,2040,O
intervals,2040,O
of,2040,O
2-6,2040,O
months,2040,O
.,2040,O
RESULTS,2041,O
:,2041,O
Before,2041,O
treatment,2041,O
",",2041,O
the,2041,O
MPO-ANCA,2041,O
titres,2041,O
of,2041,O
all,2041,O
102,2041,O
untreated,2041,O
Graves,2041,B-Disease
',2041,I-Disease
disease,2041,I-Disease
patients,2041,O
were,2041,O
within,2041,O
the,2041,O
reference,2041,O
range,2041,O
(,2041,O
below,2041,O
10,2041,O
U/ml,2041,O
),2041,O
.,2041,O
Three,2042,O
(,2042,O
4.1,2042,O
%,2042,O
),2042,O
of,2042,O
the,2042,O
73,2042,O
patients,2042,O
were,2042,O
positive,2042,O
for,2042,O
MPO-ANCA,2042,O
at,2042,O
13,2042,O
",",2042,O
16,2042,O
and,2042,O
17,2042,O
months,2042,O
",",2042,O
respectively,2042,O
",",2042,O
after,2042,O
the,2042,O
start,2042,O
of,2042,O
PTU,2042,B-Chemical
therapy,2042,O
.,2042,O
In,2043,O
two,2043,O
of,2043,O
them,2043,O
",",2043,O
the,2043,O
MPO-ANCA,2043,O
titres,2043,O
transiently,2043,O
increased,2043,O
to,2043,O
12.8,2043,O
and,2043,O
15.0,2043,O
U/ml,2043,O
",",2043,O
respectively,2043,O
",",2043,O
despite,2043,O
continued,2043,O
PTU,2043,B-Chemical
therapy,2043,O
",",2043,O
but,2043,O
no,2043,O
vasculitic,2043,B-Disease
disorders,2043,I-Disease
developed,2043,O
.,2043,O
In,2044,O
the,2044,O
third,2044,O
patient,2044,O
",",2044,O
the,2044,O
MPO-ANCA,2044,O
titre,2044,O
increased,2044,O
to,2044,O
204,2044,O
U/ml,2044,O
and,2044,O
she,2044,O
developed,2044,O
a,2044,O
higher,2044,O
fever,2044,B-Disease
",",2044,O
oral,2044,B-Disease
ulcers,2044,I-Disease
and,2044,O
polyarthralgia,2044,B-Disease
",",2044,O
but,2044,O
the,2044,O
symptoms,2044,O
resolved,2044,O
2,2044,O
weeks,2044,O
after,2044,O
stopping,2044,O
PTU,2044,B-Chemical
therapy,2044,O
",",2044,O
and,2044,O
the,2044,O
MPO-ANCA,2044,O
titre,2044,O
decreased,2044,O
to,2044,O
20.7,2044,O
U/ml,2044,O
by,2044,O
4,2044,O
months,2044,O
after,2044,O
discontinuing,2044,O
PTU,2044,B-Chemical
.,2044,O
CONCLUSIONS,2045,O
:,2045,O
PTU,2045,B-Chemical
therapy,2045,O
may,2045,O
be,2045,O
related,2045,O
to,2045,O
the,2045,O
appearance,2045,O
of,2045,O
MPO-ANCA,2045,O
",",2045,O
but,2045,O
MPO-ANCA,2045,O
does,2045,O
not,2045,O
appear,2045,O
to,2045,O
be,2045,O
closely,2045,O
related,2045,O
to,2045,O
vasculitis,2045,B-Disease
.,2045,O
Prevalence,2046,O
of,2046,O
heart,2046,B-Disease
disease,2046,I-Disease
in,2046,O
asymptomatic,2046,O
chronic,2046,O
cocaine,2046,B-Chemical
users,2046,O
.,2046,O
To,2047,O
determine,2047,O
the,2047,O
prevalence,2047,O
of,2047,O
heart,2047,B-Disease
disease,2047,I-Disease
in,2047,O
outpatient,2047,O
young,2047,O
asymptomatic,2047,O
chronic,2047,O
cocaine,2047,B-Chemical
users,2047,O
",",2047,O
35,2047,O
cocaine,2047,B-Chemical
users,2047,O
and,2047,O
32,2047,O
age-matched,2047,O
controls,2047,O
underwent,2047,O
resting,2047,O
and,2047,O
exercise,2047,O
electrocardiography,2047,O
(,2047,O
ECG,2047,O
),2047,O
and,2047,O
Doppler,2047,O
echocardiography,2047,O
.,2047,O
Findings,2048,O
consistent,2048,O
with,2048,O
coronary,2048,B-Disease
artery,2048,I-Disease
disease,2048,I-Disease
were,2048,O
detected,2048,O
in,2048,O
12,2048,O
(,2048,O
34,2048,O
%,2048,O
),2048,O
patients,2048,O
and,2048,O
3,2048,O
(,2048,O
9,2048,O
%,2048,O
),2048,O
controls,2048,O
(,2048,O
p,2048,O
=,2048,O
0.01,2048,O
),2048,O
.,2048,O
Decreased,2049,O
left,2049,O
ventricular,2049,O
systolic,2049,O
function,2049,O
was,2049,O
demonstrated,2049,O
in,2049,O
5,2049,O
(,2049,O
14,2049,O
%,2049,O
),2049,O
patients,2049,O
",",2049,O
but,2049,O
in,2049,O
none,2049,O
of,2049,O
the,2049,O
controls,2049,O
(,2049,O
p,2049,O
=,2049,O
0.055,2049,O
),2049,O
.,2049,O
Finally,2050,O
",",2050,O
resting,2050,O
and,2050,O
peak,2050,O
exercise,2050,O
abnormal,2050,B-Disease
left,2050,I-Disease
ventricular,2050,I-Disease
filling,2050,I-Disease
was,2050,O
detected,2050,O
in,2050,O
38,2050,O
and,2050,O
35,2050,O
%,2050,O
of,2050,O
patients,2050,O
as,2050,O
compared,2050,O
to,2050,O
19,2050,O
and,2050,O
9,2050,O
%,2050,O
of,2050,O
controls,2050,O
",",2050,O
respectively,2050,O
(,2050,O
p,2050,O
=,2050,O
0.11,2050,O
and,2050,O
0.02,2050,O
",",2050,O
respectively,2050,O
),2050,O
.,2050,O
We,2051,O
conclude,2051,O
that,2051,O
coronary,2051,O
artery,2051,O
or,2051,O
myocardial,2051,O
disease,2051,O
is,2051,O
common,2051,O
(,2051,O
38,2051,O
%,2051,O
),2051,O
in,2051,O
young,2051,O
asymptomatic,2051,O
chronic,2051,O
cocaine,2051,B-Chemical
users,2051,O
.,2051,O
Therefore,2052,O
",",2052,O
screening,2052,O
ECG,2052,O
and,2052,O
echocardiography,2052,O
may,2052,O
be,2052,O
warranted,2052,O
in,2052,O
these,2052,O
patients,2052,O
.,2052,O
Cardioprotective,2053,O
effects,2053,O
of,2053,O
Picrorrhiza,2053,O
kurroa,2053,O
against,2053,O
isoproterenol-induced,2053,B-Chemical
myocardial,2053,O
stress,2053,O
in,2053,O
rats,2053,O
.,2053,O
The,2054,O
cardioprotective,2054,O
effect,2054,O
of,2054,O
the,2054,O
ethanol,2054,B-Chemical
extract,2054,O
of,2054,O
Picrorrhiza,2054,O
kurroa,2054,O
rhizomes,2054,O
and,2054,O
roots,2054,O
(,2054,O
PK,2054,O
),2054,O
on,2054,O
isoproterenol-induced,2054,B-Chemical
myocardial,2054,B-Disease
infarction,2054,I-Disease
in,2054,O
rats,2054,O
with,2054,O
respect,2054,O
to,2054,O
lipid,2054,O
metabolism,2054,O
in,2054,O
serum,2054,O
and,2054,O
heart,2054,O
tissue,2054,O
has,2054,O
been,2054,O
investigated,2054,O
.,2054,O
Oral,2055,O
pre-treatment,2055,O
with,2055,O
PK,2055,O
(,2055,O
80,2055,O
mg,2055,O
kg,2055,O
(,2055,O
-1,2055,O
),2055,O
day,2055,O
(,2055,O
-1,2055,O
),2055,O
for,2055,O
15,2055,O
days,2055,O
),2055,O
significantly,2055,O
prevented,2055,O
the,2055,O
isoproterenol-induced,2055,B-Chemical
myocardial,2055,B-Disease
infarction,2055,I-Disease
and,2055,O
maintained,2055,O
the,2055,O
rats,2055,O
at,2055,O
near,2055,O
normal,2055,O
status,2055,O
.,2055,O
Phase,2056,O
2,2056,O
early,2056,O
afterdepolarization,2056,O
as,2056,O
a,2056,O
trigger,2056,O
of,2056,O
polymorphic,2056,O
ventricular,2056,B-Disease
tachycardia,2056,I-Disease
in,2056,O
acquired,2056,O
long-QT,2056,B-Disease
syndrome,2056,I-Disease
:,2056,O
direct,2056,O
evidence,2056,O
from,2056,O
intracellular,2056,O
recordings,2056,O
in,2056,O
the,2056,O
intact,2056,O
left,2056,O
ventricular,2056,O
wall,2056,O
.,2056,O
BACKGROUND,2057,O
:,2057,O
This,2057,O
study,2057,O
examined,2057,O
the,2057,O
role,2057,O
of,2057,O
phase,2057,O
2,2057,O
early,2057,O
afterdepolarization,2057,O
(,2057,O
EAD,2057,O
),2057,O
in,2057,O
producing,2057,O
a,2057,O
trigger,2057,O
to,2057,O
initiate,2057,O
torsade,2057,B-Disease
de,2057,I-Disease
pointes,2057,I-Disease
(,2057,O
TdP,2057,B-Disease
),2057,O
with,2057,O
QT,2057,B-Disease
prolongation,2057,I-Disease
induced,2057,O
by,2057,O
dl-sotalol,2057,O
and,2057,O
azimilide,2057,B-Chemical
.,2057,O
The,2058,O
contribution,2058,O
of,2058,O
transmural,2058,O
dispersion,2058,O
of,2058,O
repolarization,2058,O
(,2058,O
TDR,2058,O
),2058,O
to,2058,O
transmural,2058,O
propagation,2058,O
of,2058,O
EAD,2058,O
and,2058,O
the,2058,O
maintenance,2058,O
of,2058,O
TdP,2058,B-Disease
was,2058,O
also,2058,O
evaluated,2058,O
.,2058,O
METHODS,2059,O
AND,2059,O
RESULTS,2059,O
:,2059,O
Transmembrane,2059,O
action,2059,O
potentials,2059,O
from,2059,O
epicardium,2059,O
",",2059,O
midmyocardium,2059,O
",",2059,O
and,2059,O
endocardium,2059,O
were,2059,O
recorded,2059,O
simultaneously,2059,O
",",2059,O
together,2059,O
with,2059,O
a,2059,O
transmural,2059,O
ECG,2059,O
",",2059,O
in,2059,O
arterially,2059,O
perfused,2059,O
canine,2059,O
and,2059,O
rabbit,2059,O
left,2059,O
ventricular,2059,O
preparations,2059,O
.,2059,O
dl-Sotalol,2060,O
preferentially,2060,O
prolonged,2060,O
action,2060,O
potential,2060,O
duration,2060,O
(,2060,O
APD,2060,O
),2060,O
in,2060,O
M,2060,O
cells,2060,O
dose-dependently,2060,O
(,2060,O
1,2060,O
to,2060,O
100,2060,O
micromol/L,2060,O
),2060,O
",",2060,O
leading,2060,O
to,2060,O
QT,2060,B-Disease
prolongation,2060,I-Disease
and,2060,O
an,2060,O
increase,2060,O
in,2060,O
TDR,2060,O
.,2060,O
Azimilide,2061,B-Chemical
",",2061,O
however,2061,O
",",2061,O
significantly,2061,O
prolonged,2061,O
APD,2061,O
and,2061,O
QT,2061,O
interval,2061,O
at,2061,O
concentrations,2061,O
from,2061,O
0.1,2061,O
to,2061,O
10,2061,O
micromol/L,2061,O
but,2061,O
shortened,2061,O
them,2061,O
at,2061,O
30,2061,O
micromol/L,2061,O
.,2061,O
Unlike,2062,O
dl-sotalol,2062,O
",",2062,O
azimilide,2062,B-Chemical
(,2062,O
>,2062,O
3,2062,O
micromol/L,2062,O
),2062,O
increased,2062,O
epicardial,2062,O
APD,2062,O
markedly,2062,O
",",2062,O
causing,2062,O
a,2062,O
diminished,2062,O
TDR,2062,O
.,2062,O
Although,2063,O
both,2063,O
dl-sotalol,2063,O
and,2063,O
azimilide,2063,B-Chemical
rarely,2063,O
induced,2063,O
EADs,2063,O
in,2063,O
canine,2063,O
left,2063,O
ventricles,2063,O
",",2063,O
they,2063,O
produced,2063,O
frequent,2063,O
EADs,2063,O
in,2063,O
rabbits,2063,O
",",2063,O
in,2063,O
which,2063,O
more,2063,O
pronounced,2063,O
QT,2063,B-Disease
prolongation,2063,I-Disease
was,2063,O
seen,2063,O
.,2063,O
An,2064,O
increase,2064,O
in,2064,O
TDR,2064,O
by,2064,O
dl-sotalol,2064,O
facilitated,2064,O
transmural,2064,O
propagation,2064,O
of,2064,O
EADs,2064,O
that,2064,O
initiated,2064,O
multiple,2064,O
episodes,2064,O
of,2064,O
spontaneous,2064,O
TdP,2064,B-Disease
in,2064,O
3,2064,O
of,2064,O
6,2064,O
rabbit,2064,O
left,2064,O
ventricles,2064,O
.,2064,O
Of,2065,O
note,2065,O
",",2065,O
although,2065,O
azimilide,2065,B-Chemical
(,2065,O
3,2065,O
to,2065,O
10,2065,O
micromol/L,2065,O
),2065,O
increased,2065,O
APD,2065,O
more,2065,O
than,2065,O
dl-sotalol,2065,O
",",2065,O
its,2065,O
EADs,2065,O
often,2065,O
failed,2065,O
to,2065,O
propagate,2065,O
transmurally,2065,O
",",2065,O
probably,2065,O
because,2065,O
of,2065,O
a,2065,O
diminished,2065,O
TDR,2065,O
.,2065,O
CONCLUSIONS,2066,O
:,2066,O
This,2066,O
study,2066,O
provides,2066,O
the,2066,O
first,2066,O
direct,2066,O
evidence,2066,O
from,2066,O
intracellular,2066,O
action,2066,O
potential,2066,O
recordings,2066,O
that,2066,O
phase,2066,O
2,2066,O
EAD,2066,O
can,2066,O
be,2066,O
generated,2066,O
from,2066,O
intact,2066,O
ventricular,2066,O
wall,2066,O
and,2066,O
produce,2066,O
a,2066,O
trigger,2066,O
to,2066,O
initiate,2066,O
the,2066,O
onset,2066,O
of,2066,O
TdP,2066,B-Disease
under,2066,O
QT,2066,B-Disease
prolongation,2066,I-Disease
.,2066,O
A,2067,O
pilot,2067,O
study,2067,O
to,2067,O
assess,2067,O
the,2067,O
safety,2067,O
of,2067,O
dobutamine,2067,B-Chemical
stress,2067,O
echocardiography,2067,O
in,2067,O
the,2067,O
emergency,2067,O
department,2067,O
evaluation,2067,O
of,2067,O
cocaine-associated,2067,B-Chemical
chest,2067,B-Disease
pain,2067,I-Disease
.,2067,O
STUDY,2068,O
OBJECTIVE,2068,O
:,2068,O
Chest,2068,B-Disease
pain,2068,I-Disease
in,2068,O
the,2068,O
setting,2068,O
of,2068,O
cocaine,2068,B-Chemical
use,2068,O
poses,2068,O
a,2068,O
diagnostic,2068,O
dilemma,2068,O
.,2068,O
Dobutamine,2069,B-Chemical
stress,2069,O
echocardiography,2069,O
(,2069,O
DSE,2069,O
),2069,O
is,2069,O
a,2069,O
widely,2069,O
available,2069,O
and,2069,O
sensitive,2069,O
test,2069,O
for,2069,O
evaluating,2069,O
cardiac,2069,O
ischemia,2069,B-Disease
.,2069,O
Because,2070,O
of,2070,O
the,2070,O
theoretical,2070,O
concern,2070,O
regarding,2070,O
administration,2070,O
of,2070,O
dobutamine,2070,B-Chemical
in,2070,O
the,2070,O
setting,2070,O
of,2070,O
cocaine,2070,B-Chemical
use,2070,O
",",2070,O
we,2070,O
conducted,2070,O
a,2070,O
pilot,2070,O
study,2070,O
to,2070,O
assess,2070,O
the,2070,O
safety,2070,O
of,2070,O
DSE,2070,O
in,2070,O
emergency,2070,O
department,2070,O
patients,2070,O
with,2070,O
cocaine-associated,2070,B-Chemical
chest,2070,B-Disease
pain,2070,I-Disease
.,2070,O
METHODS,2071,O
:,2071,O
A,2071,O
prospective,2071,O
case,2071,O
series,2071,O
was,2071,O
conducted,2071,O
in,2071,O
the,2071,O
intensive,2071,O
diagnostic,2071,O
and,2071,O
treatment,2071,O
unit,2071,O
in,2071,O
the,2071,O
ED,2071,O
of,2071,O
an,2071,O
urban,2071,O
tertiary-care,2071,O
teaching,2071,O
hospital,2071,O
.,2071,O
Patients,2072,O
were,2072,O
eligible,2072,O
for,2072,O
DSE,2072,O
if,2072,O
they,2072,O
had,2072,O
used,2072,O
cocaine,2072,B-Chemical
within,2072,O
24,2072,O
hours,2072,O
preceding,2072,O
the,2072,O
onset,2072,O
of,2072,O
chest,2072,B-Disease
pain,2072,I-Disease
and,2072,O
had,2072,O
a,2072,O
normal,2072,O
ECG,2072,O
and,2072,O
tropinin,2072,O
I,2072,O
level,2072,O
.,2072,O
Patients,2073,O
exhibiting,2073,O
signs,2073,O
of,2073,O
continuing,2073,O
cocaine,2073,B-Chemical
toxicity,2073,B-Disease
were,2073,O
excluded,2073,O
from,2073,O
the,2073,O
study,2073,O
.,2073,O
All,2074,O
patients,2074,O
were,2074,O
admitted,2074,O
to,2074,O
the,2074,O
hospital,2074,O
for,2074,O
serial,2074,O
testing,2074,O
after,2074,O
the,2074,O
DSE,2074,O
testing,2074,O
in,2074,O
the,2074,O
intensive,2074,O
diagnostic,2074,O
and,2074,O
treatment,2074,O
unit,2074,O
.,2074,O
RESULTS,2075,O
:,2075,O
Twenty-four,2075,O
patients,2075,O
were,2075,O
enrolled,2075,O
.,2075,O
Two,2076,O
patients,2076,O
had,2076,O
inadequate,2076,O
resting,2076,O
images,2076,O
",",2076,O
one,2076,O
DSE,2076,O
was,2076,O
terminated,2076,O
because,2076,O
of,2076,O
inferior,2076,O
hypokinesis,2076,B-Disease
",",2076,O
another,2076,O
DSE,2076,O
was,2076,O
terminated,2076,O
because,2076,O
of,2076,O
a,2076,O
rate-related,2076,O
atrial,2076,O
conduction,2076,O
deficit,2076,O
",",2076,O
and,2076,O
1,2076,O
patient,2076,O
did,2076,O
not,2076,O
reach,2076,O
the,2076,O
target,2076,O
heart,2076,O
rate,2076,O
.,2076,O
Thus,2077,O
",",2077,O
19,2077,O
patients,2077,O
completed,2077,O
a,2077,O
DSE,2077,O
and,2077,O
reached,2077,O
their,2077,O
target,2077,O
heart,2077,O
rates,2077,O
.,2077,O
None,2078,O
of,2078,O
the,2078,O
patients,2078,O
experienced,2078,O
signs,2078,O
of,2078,O
exaggerated,2078,O
adrenergic,2078,O
response,2078,O
",",2078,O
which,2078,O
was,2078,O
defined,2078,O
as,2078,O
a,2078,O
systolic,2078,O
blood,2078,O
pressure,2078,O
of,2078,O
greater,2078,O
than,2078,O
200,2078,O
mm,2078,O
Hg,2078,O
or,2078,O
the,2078,O
occurrence,2078,O
of,2078,O
tachydysrhythmias,2078,B-Disease
(,2078,O
excluding,2078,O
sinus,2078,B-Disease
tachycardia,2078,I-Disease
),2078,O
.,2078,O
Further,2079,O
suggesting,2079,O
lack,2079,O
of,2079,O
exaggerated,2079,O
adrenergic,2079,O
response,2079,O
",",2079,O
13,2079,O
(,2079,O
65,2079,O
%,2079,O
),2079,O
of,2079,O
20,2079,O
patients,2079,O
required,2079,O
supplemental,2079,O
atropine,2079,B-Chemical
to,2079,O
reach,2079,O
their,2079,O
target,2079,O
heart,2079,O
rates,2079,O
.,2079,O
CONCLUSION,2080,O
:,2080,O
No,2080,O
exaggerated,2080,O
adrenergic,2080,O
response,2080,O
was,2080,O
detected,2080,O
when,2080,O
dobutamine,2080,B-Chemical
was,2080,O
administered,2080,O
to,2080,O
patients,2080,O
with,2080,O
cocaine-related,2080,B-Chemical
chest,2080,B-Disease
pain,2080,I-Disease
.,2080,O
Prenatal,2081,O
cocaine,2081,B-Chemical
exposure,2081,O
and,2081,O
cranial,2081,O
sonographic,2081,O
findings,2081,O
in,2081,O
preterm,2081,B-Disease
infants,2081,I-Disease
.,2081,O
PURPOSE,2082,O
:,2082,O
Prenatal,2082,O
cocaine,2082,B-Chemical
exposure,2082,O
has,2082,O
been,2082,O
linked,2082,O
with,2082,O
subependymal,2082,O
hemorrhage,2082,B-Disease
and,2082,O
the,2082,O
formation,2082,O
of,2082,O
cysts,2082,B-Disease
that,2082,O
are,2082,O
detectable,2082,O
on,2082,O
cranial,2082,O
sonography,2082,O
in,2082,O
neonates,2082,O
born,2082,O
at,2082,O
term,2082,O
.,2082,O
We,2083,O
sought,2083,O
to,2083,O
determine,2083,O
if,2083,O
prenatal,2083,O
cocaine,2083,B-Chemical
exposure,2083,O
increases,2083,O
the,2083,O
incidence,2083,O
of,2083,O
subependymal,2083,O
cysts,2083,O
in,2083,O
preterm,2083,B-Disease
infants,2083,I-Disease
.,2083,O
METHODS,2084,O
:,2084,O
We,2084,O
retrospectively,2084,O
reviewed,2084,O
the,2084,O
medical,2084,O
records,2084,O
and,2084,O
cranial,2084,O
sonograms,2084,O
obtained,2084,O
during,2084,O
a,2084,O
1-year,2084,O
period,2084,O
on,2084,O
122,2084,O
premature,2084,B-Disease
(,2084,I-Disease
<,2084,I-Disease
36,2084,I-Disease
weeks,2084,I-Disease
of,2084,I-Disease
gestation,2084,I-Disease
),2084,I-Disease
infants,2084,I-Disease
.,2084,O
Infants,2085,O
were,2085,O
categorized,2085,O
into,2085,O
1,2085,O
of,2085,O
2,2085,O
groups,2085,O
:,2085,O
those,2085,O
exposed,2085,O
to,2085,O
cocaine,2085,B-Chemical
and,2085,O
those,2085,O
not,2085,O
exposed,2085,O
to,2085,O
cocaine,2085,B-Chemical
.,2085,O
Infants,2086,O
were,2086,O
assigned,2086,O
to,2086,O
the,2086,O
cocaine-exposed,2086,B-Chemical
group,2086,O
if,2086,O
there,2086,O
was,2086,O
a,2086,O
maternal,2086,O
history,2086,O
of,2086,O
cocaine,2086,B-Disease
abuse,2086,I-Disease
during,2086,O
pregnancy,2086,O
or,2086,O
if,2086,O
maternal,2086,O
or,2086,O
neonatal,2086,O
urine,2086,O
toxicology,2086,O
results,2086,O
were,2086,O
positive,2086,O
at,2086,O
the,2086,O
time,2086,O
of,2086,O
delivery,2086,O
.,2086,O
RESULTS,2087,O
:,2087,O
Five,2087,O
of,2087,O
the,2087,O
122,2087,O
infants,2087,O
were,2087,O
excluded,2087,O
from,2087,O
the,2087,O
study,2087,O
because,2087,O
of,2087,O
insufficient,2087,O
medical,2087,O
and,2087,O
drug,2087,O
histories,2087,O
.,2087,O
The,2088,O
incidence,2088,O
of,2088,O
subependymal,2088,O
cysts,2088,O
in,2088,O
the,2088,O
117,2088,O
remaining,2088,O
infants,2088,O
was,2088,O
14,2088,O
%,2088,O
(,2088,O
16,2088,O
of,2088,O
117,2088,O
),2088,O
.,2088,O
The,2089,O
incidence,2089,O
of,2089,O
subependymal,2089,O
cysts,2089,O
in,2089,O
infants,2089,O
exposed,2089,O
to,2089,O
cocaine,2089,B-Chemical
prenatally,2089,O
was,2089,O
44,2089,O
%,2089,O
(,2089,O
8,2089,O
of,2089,O
18,2089,O
),2089,O
compared,2089,O
with,2089,O
8,2089,O
%,2089,O
(,2089,O
8,2089,O
of,2089,O
99,2089,O
),2089,O
in,2089,O
the,2089,O
unexposed,2089,O
group,2089,O
(,2089,O
p,2089,O
<,2089,O
0.01,2089,O
),2089,O
.,2089,O
CONCLUSIONS,2090,O
:,2090,O
We,2090,O
found,2090,O
an,2090,O
increased,2090,O
incidence,2090,O
of,2090,O
subependymal,2090,O
cyst,2090,O
formation,2090,O
in,2090,O
preterm,2090,B-Disease
infants,2090,I-Disease
who,2090,O
were,2090,O
exposed,2090,O
to,2090,O
cocaine,2090,B-Chemical
prenatally,2090,O
.,2090,O
This,2091,O
result,2091,O
is,2091,O
consistent,2091,O
with,2091,O
results,2091,O
of,2091,O
similar,2091,O
studies,2091,O
in,2091,O
term,2091,O
infants,2091,O
.,2091,O
Thalidomide,2092,B-Chemical
neuropathy,2092,B-Disease
in,2092,O
patients,2092,O
treated,2092,O
for,2092,O
metastatic,2092,O
prostate,2092,B-Disease
cancer,2092,I-Disease
.,2092,O
We,2093,O
prospectively,2093,O
evaluated,2093,O
thalidomide-induced,2093,B-Chemical
neuropathy,2093,B-Disease
using,2093,O
electrodiagnostic,2093,O
studies,2093,O
.,2093,O
Sixty-seven,2094,O
men,2094,O
with,2094,O
metastatic,2094,O
androgen-independent,2094,B-Chemical
prostate,2094,B-Disease
cancer,2094,I-Disease
in,2094,O
an,2094,O
open-label,2094,O
trial,2094,O
of,2094,O
oral,2094,O
thalidomide,2094,B-Chemical
underwent,2094,O
neurologic,2094,O
examinations,2094,O
and,2094,O
nerve,2094,O
conduction,2094,O
studies,2094,O
(,2094,O
NCS,2094,O
),2094,O
prior,2094,O
to,2094,O
and,2094,O
at,2094,O
3-month,2094,O
intervals,2094,O
during,2094,O
treatment,2094,O
.,2094,O
NCS,2095,O
included,2095,O
recording,2095,O
of,2095,O
sensory,2095,O
nerve,2095,O
action,2095,O
potentials,2095,O
(,2095,O
SNAPs,2095,O
),2095,O
from,2095,O
median,2095,O
",",2095,O
radial,2095,O
",",2095,O
ulnar,2095,O
",",2095,O
and,2095,O
sural,2095,O
nerves,2095,O
.,2095,O
SNAP,2096,O
amplitudes,2096,O
for,2096,O
each,2096,O
nerve,2096,O
were,2096,O
expressed,2096,O
as,2096,O
the,2096,O
percentage,2096,O
of,2096,O
its,2096,O
baseline,2096,O
",",2096,O
and,2096,O
the,2096,O
mean,2096,O
of,2096,O
the,2096,O
four,2096,O
was,2096,O
termed,2096,O
the,2096,O
SNAP,2096,O
index,2096,O
.,2096,O
A,2097,O
40,2097,O
%,2097,O
decline,2097,O
in,2097,O
the,2097,O
SNAP,2097,O
index,2097,O
was,2097,O
considered,2097,O
clinically,2097,O
significant,2097,O
.,2097,O
Thalidomide,2098,B-Chemical
was,2098,O
discontinued,2098,O
in,2098,O
55,2098,O
patients,2098,O
for,2098,O
lack,2098,O
of,2098,O
therapeutic,2098,O
response,2098,O
.,2098,O
Of,2099,O
67,2099,O
patients,2099,O
initially,2099,O
enrolled,2099,O
",",2099,O
24,2099,O
remained,2099,O
on,2099,O
thalidomide,2099,B-Chemical
for,2099,O
3,2099,O
months,2099,O
",",2099,O
8,2099,O
remained,2099,O
at,2099,O
6,2099,O
months,2099,O
",",2099,O
and,2099,O
3,2099,O
remained,2099,O
at,2099,O
9,2099,O
months,2099,O
.,2099,O
Six,2100,O
patients,2100,O
developed,2100,O
neuropathy,2100,B-Disease
.,2100,O
Clinical,2101,O
symptoms,2101,O
and,2101,O
a,2101,O
decline,2101,O
in,2101,O
the,2101,O
SNAP,2101,O
index,2101,O
occurred,2101,O
concurrently,2101,O
.,2101,O
Older,2102,O
age,2102,O
and,2102,O
cumulative,2102,O
dose,2102,O
were,2102,O
possible,2102,O
contributing,2102,O
factors,2102,O
.,2102,O
Neuropathy,2103,B-Disease
may,2103,O
thus,2103,O
be,2103,O
a,2103,O
common,2103,O
complication,2103,O
of,2103,O
thalidomide,2103,B-Chemical
in,2103,O
older,2103,O
patients,2103,O
.,2103,O
The,2104,O
SNAP,2104,O
index,2104,O
can,2104,O
be,2104,O
used,2104,O
to,2104,O
monitor,2104,O
peripheral,2104,B-Disease
neuropathy,2104,I-Disease
",",2104,O
but,2104,O
not,2104,O
for,2104,O
early,2104,O
detection,2104,O
.,2104,O
Overexpression,2105,O
of,2105,O
copper/zinc-superoxide,2105,B-Chemical
dismutase,2105,O
protects,2105,O
from,2105,O
kanamycin-induced,2105,B-Chemical
hearing,2105,B-Disease
loss,2105,I-Disease
.,2105,O
The,2106,O
participation,2106,O
of,2106,O
reactive,2106,O
oxygen,2106,B-Chemical
species,2106,O
in,2106,O
aminoglycoside-induced,2106,B-Chemical
ototoxicity,2106,B-Disease
has,2106,O
been,2106,O
deduced,2106,O
from,2106,O
observations,2106,O
that,2106,O
aminoglycoside-iron,2106,B-Chemical
complexes,2106,O
catalyze,2106,O
the,2106,O
formation,2106,O
of,2106,O
superoxide,2106,B-Chemical
radicals,2106,O
in,2106,O
vitro,2106,O
and,2106,O
that,2106,O
antioxidants,2106,O
attenuate,2106,O
ototoxicity,2106,B-Disease
in,2106,O
vivo,2106,O
.,2106,O
We,2107,O
therefore,2107,O
hypothesized,2107,O
that,2107,O
overexpression,2107,O
of,2107,O
Cu/Zn-superoxide,2107,B-Chemical
dismutase,2107,O
(,2107,O
h-SOD1,2107,O
),2107,O
should,2107,O
protect,2107,O
transgenic,2107,O
mice,2107,O
from,2107,O
ototoxicity,2107,B-Disease
.,2107,O
Immunocytochemistry,2108,O
confirmed,2108,O
expression,2108,O
of,2108,O
h-SOD1,2108,O
in,2108,O
inner,2108,O
ear,2108,O
tissues,2108,O
of,2108,O
transgenic,2108,O
C57BL/6-TgN,2108,O
[,2108,O
SOD1,2108,O
],2108,O
3Cje,2108,O
mice,2108,O
.,2108,O
Transgenic,2109,O
and,2109,O
nontransgenic,2109,O
littermates,2109,O
received,2109,O
kanamycin,2109,B-Chemical
(,2109,O
400,2109,O
mg/kg,2109,O
body,2109,O
weight/day,2109,O
),2109,O
for,2109,O
10,2109,O
days,2109,O
beginning,2109,O
on,2109,O
day,2109,O
10,2109,O
after,2109,O
birth,2109,O
.,2109,O
Auditory,2110,O
thresholds,2110,O
were,2110,O
tested,2110,O
by,2110,O
evoked,2110,O
auditory,2110,O
brain,2110,O
stem,2110,O
responses,2110,O
at,2110,O
1,2110,O
month,2110,O
after,2110,O
birth,2110,O
.,2110,O
In,2111,O
nontransgenic,2111,O
animals,2111,O
",",2111,O
the,2111,O
threshold,2111,O
in,2111,O
the,2111,O
kanamycin-treated,2111,B-Chemical
group,2111,O
was,2111,O
45-50,2111,O
dB,2111,O
higher,2111,O
than,2111,O
in,2111,O
saline-injected,2111,O
controls,2111,O
.,2111,O
In,2112,O
the,2112,O
transgenic,2112,O
group,2112,O
",",2112,O
kanamycin,2112,B-Chemical
increased,2112,O
the,2112,O
threshold,2112,O
by,2112,O
only,2112,O
15,2112,O
dB,2112,O
over,2112,O
the,2112,O
respective,2112,O
controls,2112,O
.,2112,O
The,2113,O
effects,2113,O
were,2113,O
similar,2113,O
at,2113,O
12,2113,O
and,2113,O
24,2113,O
kHz,2113,O
.,2113,O
The,2114,O
protection,2114,O
by,2114,O
overexpression,2114,O
of,2114,O
superoxide,2114,B-Chemical
dismutase,2114,O
supports,2114,O
the,2114,O
hypothesis,2114,O
that,2114,O
oxidant,2114,O
stress,2114,O
plays,2114,O
a,2114,O
significant,2114,O
role,2114,O
in,2114,O
aminoglycoside-induced,2114,B-Chemical
ototoxicity,2114,B-Disease
.,2114,O
The,2115,O
results,2115,O
also,2115,O
suggest,2115,O
transgenic,2115,O
animals,2115,O
as,2115,O
suitable,2115,O
models,2115,O
to,2115,O
investigate,2115,O
the,2115,O
underlying,2115,O
mechanisms,2115,O
and,2115,O
possible,2115,O
strategies,2115,O
for,2115,O
prevention,2115,O
.,2115,O
Prednisone,2116,B-Chemical
induces,2116,O
anxiety,2116,B-Disease
and,2116,O
glial,2116,O
cerebral,2116,O
changes,2116,O
in,2116,O
rats,2116,O
.,2116,O
OBJECTIVE,2117,O
:,2117,O
To,2117,O
assess,2117,O
whether,2117,O
prednisone,2117,B-Chemical
(,2117,O
PDN,2117,B-Chemical
),2117,O
produces,2117,O
anxiety,2117,B-Disease
and/or,2117,O
cerebral,2117,O
glial,2117,O
changes,2117,O
in,2117,O
rats,2117,O
.,2117,O
METHODS,2118,O
:,2118,O
Male,2118,O
Wistar,2118,O
rats,2118,O
were,2118,O
studied,2118,O
and,2118,O
3,2118,O
groups,2118,O
were,2118,O
formed,2118,O
(,2118,O
8,2118,O
rats,2118,O
per,2118,O
group,2118,O
),2118,O
.,2118,O
The,2119,O
moderate-dose,2119,O
group,2119,O
received,2119,O
5,2119,O
mg/kg/day,2119,O
PDN,2119,B-Chemical
released,2119,O
from,2119,O
a,2119,O
subcutaneous,2119,O
implant,2119,O
.,2119,O
In,2120,O
the,2120,O
high-dose,2120,O
group,2120,O
",",2120,O
implants,2120,O
containing,2120,O
PDN,2120,B-Chemical
equivalent,2120,O
to,2120,O
60,2120,O
mg/kg/day,2120,O
were,2120,O
applied,2120,O
.,2120,O
In,2121,O
the,2121,O
control,2121,O
group,2121,O
implants,2121,O
contained,2121,O
no,2121,O
PDN,2121,B-Chemical
.,2121,O
Anxiety,2122,B-Disease
was,2122,O
assessed,2122,O
using,2122,O
an,2122,O
open,2122,O
field,2122,O
and,2122,O
elevated,2122,O
plus-maze,2122,O
devices,2122,O
.,2122,O
The,2123,O
number,2123,O
of,2123,O
cells,2123,O
and,2123,O
cytoplasmic,2123,O
transformation,2123,O
of,2123,O
astrocytes,2123,O
and,2123,O
microglia,2123,O
cells,2123,O
were,2123,O
assessed,2123,O
by,2123,O
immunohistochemical,2123,O
analyses,2123,O
.,2123,O
RESULTS,2124,O
:,2124,O
Anxiety,2124,B-Disease
was,2124,O
documented,2124,O
in,2124,O
both,2124,O
groups,2124,O
of,2124,O
PDN,2124,B-Chemical
treated,2124,O
rats,2124,O
compared,2124,O
with,2124,O
controls,2124,O
.,2124,O
The,2125,O
magnitude,2125,O
of,2125,O
transformation,2125,O
of,2125,O
the,2125,O
microglia,2125,O
assessed,2125,O
by,2125,O
the,2125,O
number,2125,O
of,2125,O
intersections,2125,O
was,2125,O
significantly,2125,O
higher,2125,O
in,2125,O
the,2125,O
PDN,2125,B-Chemical
groups,2125,O
than,2125,O
in,2125,O
controls,2125,O
in,2125,O
the,2125,O
prefrontal,2125,O
cortex,2125,O
(,2125,O
moderate-dose,2125,O
",",2125,O
24.1,2125,O
;,2125,O
high-dose,2125,O
",",2125,O
23.6,2125,O
;,2125,O
controls,2125,O
18.7,2125,O
;,2125,O
p,2125,O
<,2125,O
0.01,2125,O
),2125,O
and,2125,O
striatum,2125,O
(,2125,O
moderate-dose,2125,O
25.6,2125,O
;,2125,O
high-dose,2125,O
26.3,2125,O
;,2125,O
controls,2125,O
18.9,2125,O
;,2125,O
p,2125,O
<,2125,O
0.01,2125,O
),2125,O
",",2125,O
but,2125,O
not,2125,O
in,2125,O
hippocampus,2125,O
.,2125,O
The,2126,O
number,2126,O
of,2126,O
stained,2126,O
microglia,2126,O
cells,2126,O
was,2126,O
significantly,2126,O
higher,2126,O
in,2126,O
the,2126,O
PDN,2126,B-Chemical
treated,2126,O
groups,2126,O
in,2126,O
the,2126,O
prefrontal,2126,O
cortex,2126,O
than,2126,O
in,2126,O
controls,2126,O
(,2126,O
moderate-dose,2126,O
",",2126,O
29.1,2126,O
;,2126,O
high-dose,2126,O
",",2126,O
28.4,2126,O
;,2126,O
control,2126,O
",",2126,O
17.7,2126,O
cells,2126,O
per,2126,O
field,2126,O
;,2126,O
p,2126,O
<,2126,O
0.01,2126,O
),2126,O
.,2126,O
Stained,2127,O
microglia,2127,O
cells,2127,O
were,2127,O
significantly,2127,O
more,2127,O
numerous,2127,O
striatum,2127,O
and,2127,O
hippocampus,2127,O
in,2127,O
the,2127,O
high-dose,2127,O
group,2127,O
compared,2127,O
to,2127,O
controls,2127,O
.,2127,O
CONCLUSION,2128,O
:,2128,O
Subacute,2128,O
exposure,2128,O
to,2128,O
PDN,2128,B-Chemical
induced,2128,O
anxiety,2128,B-Disease
and,2128,O
reactivity,2128,O
of,2128,O
microglia,2128,O
.,2128,O
The,2129,O
relevance,2129,O
of,2129,O
these,2129,O
features,2129,O
for,2129,O
patients,2129,O
using,2129,O
PDN,2129,B-Chemical
remains,2129,O
to,2129,O
be,2129,O
elucidated,2129,O
.,2129,O
Phase,2130,O
II,2130,O
study,2130,O
of,2130,O
carboplatin,2130,B-Chemical
and,2130,O
liposomal,2130,O
doxorubicin,2130,B-Chemical
in,2130,O
patients,2130,O
with,2130,O
recurrent,2130,O
squamous,2130,O
cell,2130,O
carcinoma,2130,O
of,2130,O
the,2130,O
cervix,2130,O
.,2130,O
BACKGROUND,2131,O
:,2131,O
The,2131,O
activity,2131,O
of,2131,O
the,2131,O
combination,2131,O
of,2131,O
carboplatin,2131,B-Chemical
and,2131,O
liposomal,2131,O
doxorubicin,2131,B-Chemical
was,2131,O
tested,2131,O
in,2131,O
a,2131,O
Phase,2131,O
II,2131,O
study,2131,O
of,2131,O
patients,2131,O
with,2131,O
recurrent,2131,O
cervical,2131,B-Disease
carcinoma,2131,I-Disease
.,2131,O
METHODS,2132,O
:,2132,O
The,2132,O
combination,2132,O
of,2132,O
carboplatin,2132,B-Chemical
(,2132,O
area,2132,O
under,2132,O
the,2132,O
concentration,2132,O
curve,2132,O
[,2132,O
AUC,2132,O
],2132,O
",",2132,O
5,2132,O
),2132,O
and,2132,O
liposomal,2132,O
doxorubicin,2132,B-Chemical
(,2132,O
Doxil,2132,B-Chemical
;,2132,O
starting,2132,O
dose,2132,O
",",2132,O
40,2132,O
mg/m,2132,O
(,2132,O
2,2132,O
),2132,O
),2132,O
was,2132,O
administered,2132,O
intravenously,2132,O
every,2132,O
28,2132,O
days,2132,O
to,2132,O
37,2132,O
patients,2132,O
with,2132,O
recurrent,2132,O
squamous,2132,O
cell,2132,O
cervical,2132,O
carcinoma,2132,O
to,2132,O
determine,2132,O
antitumor,2132,O
activity,2132,O
and,2132,O
toxicity,2132,B-Disease
profile,2132,O
.,2132,O
RESULTS,2133,O
:,2133,O
Twenty-nine,2133,O
patients,2133,O
were,2133,O
assessable,2133,O
for,2133,O
response,2133,O
",",2133,O
and,2133,O
35,2133,O
patients,2133,O
were,2133,O
assessable,2133,O
for,2133,O
toxicity,2133,B-Disease
.,2133,O
The,2134,O
overall,2134,O
response,2134,O
rate,2134,O
was,2134,O
38,2134,O
%,2134,O
",",2134,O
the,2134,O
median,2134,O
time,2134,O
to,2134,O
response,2134,O
was,2134,O
10,2134,O
weeks,2134,O
",",2134,O
the,2134,O
median,2134,O
duration,2134,O
of,2134,O
response,2134,O
was,2134,O
26,2134,O
weeks,2134,O
",",2134,O
and,2134,O
the,2134,O
median,2134,O
survival,2134,O
was,2134,O
37,2134,O
weeks,2134,O
.,2134,O
The,2135,O
main,2135,O
toxic,2135,O
effect,2135,O
was,2135,O
myelosuppression,2135,B-Disease
",",2135,O
with,2135,O
Grade,2135,O
3,2135,O
and,2135,O
4,2135,O
neutropenia,2135,B-Disease
in,2135,O
16,2135,O
patients,2135,O
",",2135,O
anemia,2135,B-Disease
in,2135,O
12,2135,O
patients,2135,O
",",2135,O
thrombocytopenia,2135,B-Disease
in,2135,O
11,2135,O
patients,2135,O
",",2135,O
and,2135,O
neutropenic,2135,O
fever,2135,O
in,2135,O
3,2135,O
patients,2135,O
.,2135,O
Four,2136,O
patients,2136,O
had,2136,O
five,2136,O
infusion-related,2136,O
reactions,2136,O
during,2136,O
the,2136,O
infusion,2136,O
of,2136,O
liposomal,2136,O
doxorubicin,2136,B-Chemical
",",2136,O
leading,2136,O
to,2136,O
treatment,2136,O
discontinuation,2136,O
in,2136,O
three,2136,O
patients,2136,O
.,2136,O
Grade,2137,O
>,2137,O
or,2137,O
=,2137,O
2,2137,O
nonhematologic,2137,O
toxicity,2137,B-Disease
included,2137,O
nausea,2137,B-Disease
in,2137,O
17,2137,O
patients,2137,O
",",2137,O
emesis,2137,B-Disease
in,2137,O
14,2137,O
patients,2137,O
",",2137,O
fatigue,2137,B-Disease
in,2137,O
9,2137,O
patients,2137,O
",",2137,O
mucositis,2137,B-Disease
and/or,2137,O
stomatitis,2137,B-Disease
in,2137,O
8,2137,O
patients,2137,O
",",2137,O
constipation,2137,B-Disease
in,2137,O
6,2137,O
patients,2137,O
",",2137,O
weight,2137,B-Disease
loss,2137,I-Disease
in,2137,O
5,2137,O
patients,2137,O
",",2137,O
hand-foot,2137,B-Disease
syndrome,2137,I-Disease
in,2137,O
2,2137,O
patients,2137,O
",",2137,O
and,2137,O
skin,2137,B-Disease
reactions,2137,I-Disease
in,2137,O
3,2137,O
patients,2137,O
.,2137,O
CONCLUSIONS,2138,O
:,2138,O
The,2138,O
combination,2138,O
of,2138,O
carboplatin,2138,B-Chemical
and,2138,O
liposomal,2138,O
doxorubicin,2138,B-Chemical
has,2138,O
modest,2138,O
activity,2138,O
in,2138,O
patients,2138,O
with,2138,O
recurrent,2138,O
cervical,2138,B-Disease
carcinoma,2138,I-Disease
.,2138,O
Antimicrobial-induced,2139,O
mania,2139,B-Disease
(,2139,O
antibiomania,2139,B-Disease
),2139,O
:,2139,O
a,2139,O
review,2139,O
of,2139,O
spontaneous,2139,O
reports,2139,O
.,2139,O
The,2140,O
authors,2140,O
reviewed,2140,O
reported,2140,O
cases,2140,O
of,2140,O
antibiotic-induced,2140,O
manic,2140,B-Disease
episodes,2140,O
by,2140,O
means,2140,O
of,2140,O
a,2140,O
MEDLINE,2140,O
and,2140,O
PsychLit,2140,O
search,2140,O
for,2140,O
reports,2140,O
of,2140,O
antibiotic-induced,2140,O
mania,2140,B-Disease
.,2140,O
Unpublished,2141,O
reports,2141,O
were,2141,O
requested,2141,O
from,2141,O
the,2141,O
World,2141,O
Health,2141,O
Organization,2141,O
(,2141,O
WHO,2141,O
),2141,O
and,2141,O
the,2141,O
Food,2141,O
and,2141,O
Drug,2141,O
Administration,2141,O
(,2141,O
FDA,2141,O
),2141,O
.,2141,O
Twenty-one,2142,O
reports,2142,O
of,2142,O
antimicrobial-induced,2142,O
mania,2142,B-Disease
were,2142,O
found,2142,O
in,2142,O
the,2142,O
literature,2142,O
.,2142,O
There,2143,O
were,2143,O
6,2143,O
cases,2143,O
implicating,2143,O
clarithromycin,2143,B-Chemical
",",2143,O
13,2143,O
implicating,2143,O
isoniazid,2143,B-Chemical
",",2143,O
and,2143,O
1,2143,O
case,2143,O
each,2143,O
implicating,2143,O
erythromycin,2143,B-Chemical
and,2143,O
amoxicillin,2143,B-Chemical
.,2143,O
The,2144,O
WHO,2144,O
reported,2144,O
82,2144,O
cases,2144,O
.,2144,O
Of,2145,O
these,2145,O
",",2145,O
clarithromycin,2145,B-Chemical
was,2145,O
implicated,2145,O
in,2145,O
23,2145,O
(,2145,O
27.6,2145,O
%,2145,O
),2145,O
cases,2145,O
",",2145,O
ciprofloxacin,2145,B-Chemical
in,2145,O
12,2145,O
(,2145,O
14.4,2145,O
%,2145,O
),2145,O
cases,2145,O
",",2145,O
and,2145,O
ofloxacin,2145,B-Chemical
in,2145,O
10,2145,O
(,2145,O
12,2145,O
%,2145,O
),2145,O
cases,2145,O
.,2145,O
Cotrimoxazole,2146,B-Chemical
",",2146,O
metronidazole,2146,B-Chemical
",",2146,O
and,2146,O
erythromycin,2146,B-Chemical
were,2146,O
involved,2146,O
in,2146,O
15,2146,O
reported,2146,O
manic,2146,B-Disease
episodes,2146,O
.,2146,O
Cases,2147,O
reported,2147,O
by,2147,O
the,2147,O
FDA,2147,O
showed,2147,O
clarithromycin,2147,B-Chemical
and,2147,O
ciprofloxacin,2147,B-Chemical
to,2147,O
be,2147,O
the,2147,O
most,2147,O
frequently,2147,O
associated,2147,O
with,2147,O
the,2147,O
development,2147,O
of,2147,O
mania,2147,B-Disease
.,2147,O
Statistical,2148,O
analysis,2148,O
of,2148,O
the,2148,O
data,2148,O
would,2148,O
not,2148,O
have,2148,O
demonstrated,2148,O
a,2148,O
significant,2148,O
statistical,2148,O
correlative,2148,O
risk,2148,O
and,2148,O
was,2148,O
therefore,2148,O
not,2148,O
undertaken,2148,O
.,2148,O
Patients,2149,O
have,2149,O
an,2149,O
increased,2149,O
risk,2149,O
of,2149,O
developing,2149,O
mania,2149,B-Disease
while,2149,O
being,2149,O
treated,2149,O
with,2149,O
antimicrobials,2149,O
.,2149,O
Although,2150,O
this,2150,O
is,2150,O
not,2150,O
a,2150,O
statistically,2150,O
significant,2150,O
risk,2150,O
",",2150,O
physicians,2150,O
must,2150,O
be,2150,O
aware,2150,O
of,2150,O
the,2150,O
effect,2150,O
and,2150,O
reversibility,2150,O
.,2150,O
Further,2151,O
research,2151,O
clearly,2151,O
is,2151,O
required,2151,O
to,2151,O
determine,2151,O
the,2151,O
incidence,2151,O
of,2151,O
antimicrobial-induced,2151,O
mania,2151,B-Disease
",",2151,O
the,2151,O
relative,2151,O
risk,2151,O
factors,2151,O
of,2151,O
developing,2151,O
an,2151,O
antimicrobial-induced,2151,O
manic,2151,B-Disease
episode,2151,O
among,2151,O
various,2151,O
demographic,2151,O
populations,2151,O
",",2151,O
and,2151,O
the,2151,O
incidence,2151,O
of,2151,O
patients,2151,O
who,2151,O
continue,2151,O
to,2151,O
have,2151,O
persistent,2151,O
affective,2151,O
disorders,2151,O
once,2151,O
the,2151,O
initial,2151,O
episode,2151,O
",",2151,O
which,2151,O
occurs,2151,O
while,2151,O
the,2151,O
patient,2151,O
is,2151,O
taking,2151,O
antibiotics,2151,O
",",2151,O
subsides,2151,O
.,2151,O
The,2152,O
authors,2152,O
elected,2152,O
to,2152,O
name,2152,O
this,2152,O
syndrome,2152,O
``,2152,O
antibiomania,2152,B-Disease
.,2152,O
'',2152,O
Levodopa-induced,2153,B-Chemical
ocular,2153,B-Disease
dyskinesias,2153,I-Disease
in,2153,O
Parkinson,2153,B-Disease
's,2153,I-Disease
disease,2153,I-Disease
.,2153,O
Levodopa-induced,2154,B-Chemical
ocular,2154,B-Disease
dyskinesias,2154,I-Disease
are,2154,O
very,2154,O
uncommon,2154,O
.,2154,O
Usually,2155,O
they,2155,O
occur,2155,O
simultaneously,2155,O
with,2155,O
limb,2155,O
peak-dose,2155,O
choreatic,2155,B-Disease
dyskinesias,2155,I-Disease
.,2155,O
We,2156,O
report,2156,O
on,2156,O
a,2156,O
patient,2156,O
with,2156,O
leftward,2156,O
and,2156,O
upward,2156,O
deviations,2156,O
of,2156,O
gaze,2156,O
during,2156,O
the,2156,O
peak,2156,O
effect,2156,O
of,2156,O
levodopa,2156,B-Chemical
",",2156,O
and,2156,O
hypothesize,2156,O
that,2156,O
a,2156,O
severe,2156,O
dopaminergic,2156,O
denervation,2156,O
in,2156,O
the,2156,O
caudate,2156,O
nucleus,2156,O
is,2156,O
needed,2156,O
for,2156,O
the,2156,O
appearance,2156,O
of,2156,O
these,2156,O
levodopa-induce,2156,B-Chemical
ocular,2156,B-Disease
dyskinesias,2156,I-Disease
.,2156,O
A,2157,O
comparison,2157,O
of,2157,O
glyceryl,2157,B-Chemical
trinitrate,2157,I-Chemical
with,2157,O
diclofenac,2157,B-Chemical
for,2157,O
the,2157,O
treatment,2157,O
of,2157,O
primary,2157,O
dysmenorrhea,2157,B-Disease
:,2157,O
an,2157,O
open,2157,O
",",2157,O
randomized,2157,O
",",2157,O
cross-over,2157,O
trial,2157,O
.,2157,O
Primary,2158,O
dysmenorrhea,2158,B-Disease
is,2158,O
a,2158,O
syndrome,2158,O
characterized,2158,O
by,2158,O
painful,2158,O
uterine,2158,O
contractility,2158,O
caused,2158,O
by,2158,O
a,2158,O
hypersecretion,2158,O
of,2158,O
endometrial,2158,O
prostaglandins,2158,B-Chemical
;,2158,O
non-steroidal,2158,O
anti-inflammatory,2158,O
drugs,2158,O
are,2158,O
the,2158,O
first,2158,O
choice,2158,O
for,2158,O
its,2158,O
treatment,2158,O
.,2158,O
However,2159,O
",",2159,O
in,2159,O
vivo,2159,O
and,2159,O
in,2159,O
vitro,2159,O
studies,2159,O
have,2159,O
demonstrated,2159,O
that,2159,O
myometrial,2159,O
cells,2159,O
are,2159,O
also,2159,O
targets,2159,O
of,2159,O
the,2159,O
relaxant,2159,O
effects,2159,O
of,2159,O
nitric,2159,B-Chemical
oxide,2159,I-Chemical
(,2159,O
NO,2159,B-Chemical
),2159,O
.,2159,O
The,2160,O
aim,2160,O
of,2160,O
the,2160,O
present,2160,O
study,2160,O
was,2160,O
to,2160,O
determine,2160,O
the,2160,O
efficacy,2160,O
of,2160,O
glyceryl,2160,B-Chemical
trinitrate,2160,I-Chemical
(,2160,O
GTN,2160,B-Chemical
),2160,O
",",2160,O
an,2160,O
NO,2160,B-Chemical
donor,2160,O
",",2160,O
in,2160,O
the,2160,O
resolution,2160,O
of,2160,O
primary,2160,O
dysmenorrhea,2160,B-Disease
in,2160,O
comparison,2160,O
with,2160,O
diclofenac,2160,B-Chemical
(,2160,O
DCF,2160,B-Chemical
),2160,O
.,2160,O
A,2161,O
total,2161,O
of,2161,O
24,2161,O
patients,2161,O
with,2161,O
the,2161,O
diagnosis,2161,O
of,2161,O
severe,2161,O
primary,2161,O
dysmenorrhea,2161,B-Disease
were,2161,O
studied,2161,O
during,2161,O
two,2161,O
consecutive,2161,O
menstrual,2161,O
cycles,2161,O
.,2161,O
In,2162,O
an,2162,O
open,2162,O
",",2162,O
cross-over,2162,O
",",2162,O
controlled,2162,O
design,2162,O
",",2162,O
patients,2162,O
were,2162,O
randomized,2162,O
to,2162,O
receive,2162,O
either,2162,O
DCF,2162,B-Chemical
per,2162,O
os,2162,O
or,2162,O
GTN,2162,B-Chemical
patches,2162,O
the,2162,O
first,2162,O
days,2162,O
of,2162,O
menses,2162,O
",",2162,O
when,2162,O
menstrual,2162,O
cramps,2162,O
became,2162,O
unendurable,2162,O
.,2162,O
In,2163,O
the,2163,O
subsequent,2163,O
cycle,2163,O
the,2163,O
other,2163,O
treatment,2163,O
was,2163,O
used,2163,O
.,2163,O
Patients,2164,O
received,2164,O
up,2164,O
to,2164,O
3,2164,O
doses/day,2164,O
of,2164,O
50,2164,O
mg,2164,O
DCF,2164,B-Chemical
or,2164,O
2.5,2164,O
mg/24,2164,O
h,2164,O
transdermal,2164,O
GTN,2164,B-Chemical
for,2164,O
the,2164,O
first,2164,O
3,2164,O
days,2164,O
of,2164,O
the,2164,O
cycle,2164,O
",",2164,O
according,2164,O
to,2164,O
their,2164,O
needs,2164,O
.,2164,O
The,2165,O
participants,2165,O
recorded,2165,O
menstrual,2165,O
symptoms,2165,O
and,2165,O
possible,2165,O
side-effects,2165,O
at,2165,O
different,2165,O
times,2165,O
(,2165,O
0,2165,O
",",2165,O
30,2165,O
",",2165,O
60,2165,O
",",2165,O
120,2165,O
minutes,2165,O
),2165,O
after,2165,O
the,2165,O
first,2165,O
dose,2165,O
of,2165,O
medication,2165,O
on,2165,O
the,2165,O
first,2165,O
day,2165,O
of,2165,O
the,2165,O
cycle,2165,O
",",2165,O
with,2165,O
both,2165,O
drugs,2165,O
.,2165,O
The,2166,O
difference,2166,O
in,2166,O
pain,2166,B-Disease
intensity,2166,O
score,2166,O
(,2166,O
DPI,2166,O
),2166,O
was,2166,O
the,2166,O
main,2166,O
outcome,2166,O
variable,2166,O
.,2166,O
Both,2167,O
treatments,2167,O
significantly,2167,O
reduced,2167,O
DPI,2167,O
by,2167,O
the,2167,O
30th,2167,O
minute,2167,O
(,2167,O
GTN,2167,B-Chemical
",",2167,O
-12.8,2167,O
+/-,2167,O
17.9,2167,O
;,2167,O
DCF,2167,B-Chemical
",",2167,O
-18.9,2167,O
+/-,2167,O
16.6,2167,O
),2167,O
.,2167,O
However,2168,O
",",2168,O
DCF,2168,B-Chemical
continued,2168,O
to,2168,O
be,2168,O
effective,2168,O
in,2168,O
reducing,2168,O
pelvic,2168,B-Disease
pain,2168,I-Disease
for,2168,O
two,2168,O
hours,2168,O
",",2168,O
whereas,2168,O
GTN,2168,B-Chemical
scores,2168,O
remained,2168,O
more,2168,O
or,2168,O
less,2168,O
stable,2168,O
after,2168,O
30,2168,O
min,2168,O
and,2168,O
significantly,2168,O
higher,2168,O
than,2168,O
those,2168,O
for,2168,O
DFC,2168,O
(,2168,O
after,2168,O
one,2168,O
hour,2168,O
:,2168,O
GTN,2168,B-Chemical
",",2168,O
-12.8,2168,O
+/-,2168,O
17.9,2168,O
;,2168,O
DFC,2168,O
",",2168,O
-18.9,2168,O
+/-,2168,O
16.6,2168,O
and,2168,O
after,2168,O
two,2168,O
hours,2168,O
:,2168,O
GTN,2168,B-Chemical
",",2168,O
-23.7,2168,O
+/-,2168,O
20.5,2168,O
;,2168,O
DFC,2168,O
",",2168,O
-59.7,2168,O
+/-,2168,O
17.9,2168,O
",",2168,O
p,2168,O
=,2168,O
0.0001,2168,O
),2168,O
.,2168,O
Low,2169,B-Disease
back,2169,I-Disease
pain,2169,I-Disease
was,2169,O
also,2169,O
relieved,2169,O
by,2169,O
both,2169,O
drugs,2169,O
.,2169,O
Headache,2170,B-Disease
was,2170,O
significantly,2170,O
increased,2170,O
by,2170,O
GTN,2170,B-Chemical
but,2170,O
not,2170,O
by,2170,O
DCF,2170,B-Chemical
.,2170,O
Eight,2171,O
patients,2171,O
stopped,2171,O
using,2171,O
GTN,2171,B-Chemical
because,2171,O
headache,2171,B-Disease
--,2171,O
attributed,2171,O
to,2171,O
its,2171,O
use,2171,O
--,2171,O
became,2171,O
intolerable,2171,O
.,2171,O
These,2172,O
findings,2172,O
indicate,2172,O
that,2172,O
GTN,2172,B-Chemical
has,2172,O
a,2172,O
reduced,2172,O
efficacy,2172,O
and,2172,O
tolerability,2172,O
by,2172,O
comparison,2172,O
with,2172,O
DCF,2172,B-Chemical
in,2172,O
the,2172,O
treatment,2172,O
of,2172,O
primary,2172,O
dysmenorrhea,2172,B-Disease
.,2172,O
Temocapril,2173,B-Chemical
",",2173,O
a,2173,O
long-acting,2173,O
non-SH,2173,O
group,2173,O
angiotensin,2173,B-Chemical
converting,2173,O
enzyme,2173,O
inhibitor,2173,O
",",2173,O
modulates,2173,O
glomerular,2173,B-Disease
injury,2173,I-Disease
in,2173,O
chronic,2173,O
puromycin,2173,B-Chemical
aminonucleoside,2173,I-Chemical
nephrosis,2173,B-Disease
.,2173,O
The,2174,O
purpose,2174,O
of,2174,O
the,2174,O
present,2174,O
study,2174,O
was,2174,O
to,2174,O
determine,2174,O
whether,2174,O
chronic,2174,O
administration,2174,O
of,2174,O
temocapril,2174,B-Chemical
",",2174,O
a,2174,O
long-acting,2174,O
non-SH,2174,O
group,2174,O
angiotensin,2174,B-Chemical
converting,2174,O
enzyme,2174,O
(,2174,O
ACE,2174,O
),2174,O
inhibitor,2174,O
",",2174,O
reduced,2174,O
proteinuria,2174,B-Disease
",",2174,O
inhibited,2174,O
glomerular,2174,O
hypertrophy,2174,B-Disease
and,2174,O
prevented,2174,O
glomerulosclerosis,2174,B-Disease
in,2174,O
chronic,2174,O
puromycin,2174,B-Chemical
aminonucleoside,2174,I-Chemical
(,2174,O
PAN,2174,B-Chemical
),2174,O
-,2174,O
induced,2174,O
nephrotic,2174,B-Disease
rats,2174,O
.,2174,O
Nephrosis,2175,B-Disease
was,2175,O
induced,2175,O
by,2175,O
injection,2175,O
of,2175,O
PAN,2175,B-Chemical
(,2175,O
15mg/100g,2175,O
body,2175,O
weight,2175,O
),2175,O
in,2175,O
male,2175,O
Sprague-Dawley,2175,O
(,2175,O
SD,2175,O
),2175,O
rats,2175,O
.,2175,O
Four,2176,O
groups,2176,O
were,2176,O
used,2176,O
",",2176,O
i,2176,O
),2176,O
the,2176,O
PAN,2176,B-Chemical
group,2176,O
(,2176,O
14,2176,O
),2176,O
",",2176,O
ii,2176,O
),2176,O
PAN/temocapril,2176,B-Chemical
(,2176,O
13,2176,O
),2176,O
",",2176,O
iii,2176,O
),2176,O
temocapril,2176,B-Chemical
(,2176,O
14,2176,O
),2176,O
and,2176,O
iv,2176,O
),2176,O
untreated,2176,O
controls,2176,O
(,2176,O
15,2176,O
),2176,O
.,2176,O
Temocapril,2177,B-Chemical
(,2177,O
8,2177,O
mg/kg/day,2177,O
),2177,O
was,2177,O
administered,2177,O
to,2177,O
the,2177,O
rats,2177,O
which,2177,O
were,2177,O
killed,2177,O
at,2177,O
weeks,2177,O
4,2177,O
",",2177,O
14,2177,O
or,2177,O
20,2177,O
.,2177,O
At,2178,O
each,2178,O
time,2178,O
point,2178,O
",",2178,O
systolic,2178,O
blood,2178,O
pressure,2178,O
(,2178,O
BP,2178,O
),2178,O
",",2178,O
urinary,2178,O
protein,2178,O
excretion,2178,O
and,2178,O
renal,2178,O
histopathological,2178,O
findings,2178,O
were,2178,O
evaluated,2178,O
",",2178,O
and,2178,O
morphometric,2178,O
image,2178,O
analysis,2178,O
was,2178,O
done,2178,O
.,2178,O
Systolic,2179,O
BP,2179,O
in,2179,O
the,2179,O
PAN,2179,B-Chemical
group,2179,O
was,2179,O
significantly,2179,O
high,2179,O
at,2179,O
4,2179,O
",",2179,O
14,2179,O
and,2179,O
20,2179,O
weeks,2179,O
",",2179,O
but,2179,O
was,2179,O
normal,2179,O
in,2179,O
the,2179,O
PAN/temocapril,2179,B-Chemical
group,2179,O
.,2179,O
Urinary,2180,O
protein,2180,O
excretion,2180,O
in,2180,O
the,2180,O
PAN,2180,B-Chemical
group,2180,O
increased,2180,O
significantly,2180,O
",",2180,O
peaking,2180,O
at,2180,O
8,2180,O
days,2180,O
",",2180,O
then,2180,O
decreased,2180,O
at,2180,O
4,2180,O
weeks,2180,O
",",2180,O
but,2180,O
rose,2180,O
again,2180,O
significantly,2180,O
at,2180,O
14,2180,O
and,2180,O
20,2180,O
weeks,2180,O
.,2180,O
Temocapril,2181,B-Chemical
did,2181,O
not,2181,O
attenuate,2181,O
proteinuria,2181,B-Disease
at,2181,O
8,2181,O
days,2181,O
",",2181,O
but,2181,O
it,2181,O
did,2181,O
markedly,2181,O
lower,2181,O
it,2181,O
from,2181,O
weeks,2181,O
4,2181,O
to,2181,O
20,2181,O
.,2181,O
The,2182,O
glomerulosclerosis,2182,B-Disease
index,2182,O
(,2182,O
GSI,2182,O
),2182,O
was,2182,O
6.21,2182,O
%,2182,O
at,2182,O
4,2182,O
weeks,2182,O
and,2182,O
respectively,2182,O
25.35,2182,O
%,2182,O
and,2182,O
30.49,2182,O
%,2182,O
at,2182,O
14,2182,O
and,2182,O
20,2182,O
weeks,2182,O
in,2182,O
the,2182,O
PAN,2182,B-Chemical
group,2182,O
.,2182,O
There,2183,O
was,2183,O
a,2183,O
significant,2183,O
correlation,2183,O
between,2183,O
urinary,2183,O
protein,2183,O
excretion,2183,O
and,2183,O
GSI,2183,O
(,2183,O
r,2183,O
=,2183,O
0.808,2183,O
",",2183,O
p,2183,O
<,2183,O
0.0001,2183,O
),2183,O
.,2183,O
The,2184,O
ratio,2184,O
of,2184,O
glomerular,2184,O
tuft,2184,O
area,2184,O
to,2184,O
the,2184,O
area,2184,O
of,2184,O
Bowman,2184,O
's,2184,O
capsules,2184,O
(,2184,O
GT/BC,2184,O
),2184,O
in,2184,O
the,2184,O
PAN,2184,B-Chemical
group,2184,O
was,2184,O
significantly,2184,O
increased,2184,O
",",2184,O
but,2184,O
it,2184,O
was,2184,O
significantly,2184,O
lower,2184,O
in,2184,O
the,2184,O
PAN/temocapril,2184,B-Chemical
group,2184,O
.,2184,O
It,2185,O
appears,2185,O
that,2185,O
temocapril,2185,B-Chemical
was,2185,O
effective,2185,O
in,2185,O
retarding,2185,O
renal,2185,O
progression,2185,O
and,2185,O
protected,2185,O
renal,2185,O
function,2185,O
in,2185,O
PAN,2185,B-Chemical
neprotic,2185,B-Disease
rats,2185,O
.,2185,O
Pulmonary,2186,B-Disease
hypertension,2186,I-Disease
after,2186,O
ibuprofen,2186,B-Chemical
prophylaxis,2186,O
in,2186,O
very,2186,O
preterm,2186,O
infants,2186,O
.,2186,O
We,2187,O
report,2187,O
three,2187,O
cases,2187,O
of,2187,O
severe,2187,O
hypoxaemia,2187,B-Disease
after,2187,O
ibuprofen,2187,B-Chemical
administration,2187,O
during,2187,O
a,2187,O
randomised,2187,O
controlled,2187,O
trial,2187,O
of,2187,O
prophylactic,2187,O
treatment,2187,O
of,2187,O
patent,2187,B-Disease
ductus,2187,I-Disease
arteriosus,2187,I-Disease
with,2187,O
ibuprofen,2187,B-Chemical
in,2187,O
premature,2187,O
infants,2187,O
born,2187,O
at,2187,O
less,2187,O
than,2187,O
28,2187,O
weeks,2187,O
of,2187,O
gestation,2187,O
.,2187,O
Echocardiography,2188,O
showed,2188,O
severely,2188,O
decreased,2188,O
pulmonary,2188,O
blood,2188,O
flow,2188,O
.,2188,O
Hypoxaemia,2189,B-Disease
resolved,2189,O
quickly,2189,O
on,2189,O
inhaled,2189,O
nitric,2189,B-Chemical
oxide,2189,I-Chemical
therapy,2189,O
.,2189,O
We,2190,O
suggest,2190,O
that,2190,O
investigators,2190,O
involved,2190,O
in,2190,O
similar,2190,O
trials,2190,O
pay,2190,O
close,2190,O
attention,2190,O
to,2190,O
pulmonary,2190,O
pressure,2190,O
if,2190,O
hypoxaemia,2190,B-Disease
occurs,2190,O
after,2190,O
prophylactic,2190,O
administration,2190,O
of,2190,O
ibuprofen,2190,B-Chemical
.,2190,O
Hyponatremia,2191,B-Disease
and,2191,O
syndrome,2191,B-Disease
of,2191,I-Disease
inappropriate,2191,I-Disease
anti-diuretic,2191,I-Disease
hormone,2191,I-Disease
reported,2191,O
with,2191,O
the,2191,O
use,2191,O
of,2191,O
Vincristine,2191,B-Chemical
:,2191,O
an,2191,O
over-representation,2191,O
of,2191,O
Asians,2191,O
?,2191,O
PURPOSE,2192,O
:,2192,O
This,2192,O
retrospective,2192,O
study,2192,O
used,2192,O
a,2192,O
pharmaceutical,2192,O
company,2192,O
's,2192,O
global,2192,O
safety,2192,O
database,2192,O
to,2192,O
determine,2192,O
the,2192,O
reporting,2192,O
rate,2192,O
of,2192,O
hyponatremia,2192,B-Disease
and/or,2192,O
syndrome,2192,B-Disease
of,2192,I-Disease
inappropriate,2192,I-Disease
secretion,2192,I-Disease
of,2192,I-Disease
anti-diuretic,2192,I-Disease
hormone,2192,I-Disease
(,2192,O
SIADH,2192,B-Disease
),2192,O
among,2192,O
vincristine-treated,2192,B-Chemical
patients,2192,O
and,2192,O
to,2192,O
explore,2192,O
the,2192,O
possibility,2192,O
of,2192,O
at-risk,2192,O
population,2192,O
subgroups,2192,O
.,2192,O
METHOD,2193,O
:,2193,O
We,2193,O
searched,2193,O
the,2193,O
Eli,2193,O
Lilly,2193,O
and,2193,O
Company,2193,O
's,2193,O
computerized,2193,O
adverse,2193,O
event,2193,O
database,2193,O
for,2193,O
all,2193,O
reported,2193,O
cases,2193,O
of,2193,O
hyponatremia,2193,B-Disease
and/or,2193,O
SIADH,2193,B-Disease
as,2193,O
of,2193,O
1,2193,O
November,2193,O
1999,2193,O
that,2193,O
had,2193,O
been,2193,O
reported,2193,O
during,2193,O
the,2193,O
use,2193,O
of,2193,O
vincristine,2193,B-Chemical
.,2193,O
RESULTS,2194,O
:,2194,O
A,2194,O
total,2194,O
of,2194,O
76,2194,O
cases,2194,O
of,2194,O
hyponatremia,2194,B-Disease
and/or,2194,O
SIADH,2194,B-Disease
associated,2194,O
with,2194,O
vincristine,2194,B-Chemical
use,2194,O
were,2194,O
identified,2194,O
.,2194,O
The,2195,O
overall,2195,O
reporting,2195,O
rate,2195,O
was,2195,O
estimated,2195,O
to,2195,O
be,2195,O
"1.3/100,000",2195,O
treated,2195,O
patients,2195,O
.,2195,O
The,2196,O
average,2196,O
age,2196,O
of,2196,O
patients,2196,O
was,2196,O
35.6,2196,O
+/-,2196,O
28.3,2196,O
years,2196,O
",",2196,O
and,2196,O
62,2196,O
%,2196,O
were,2196,O
males,2196,O
.,2196,O
Approximately,2197,O
75,2197,O
%,2197,O
of,2197,O
the,2197,O
patients,2197,O
were,2197,O
receiving,2197,O
treatment,2197,O
for,2197,O
leukemia,2197,B-Disease
or,2197,O
lymphoma,2197,B-Disease
.,2197,O
Among,2198,O
the,2198,O
39,2198,O
reports,2198,O
that,2198,O
included,2198,O
information,2198,O
on,2198,O
race,2198,O
",",2198,O
the,2198,O
racial,2198,O
distribution,2198,O
was,2198,O
:,2198,O
1,2198,O
Black,2198,O
",",2198,O
3,2198,O
Caucasian,2198,O
",",2198,O
and,2198,O
35,2198,O
Asian,2198,O
.,2198,O
CONCLUSION,2199,O
:,2199,O
Our,2199,O
data,2199,O
suggest,2199,O
that,2199,O
Asian,2199,O
patients,2199,O
may,2199,O
be,2199,O
at,2199,O
increased,2199,O
risk,2199,O
of,2199,O
hyponatremia,2199,B-Disease
and/or,2199,O
SIADH,2199,B-Disease
associated,2199,O
with,2199,O
vincristine,2199,B-Chemical
use,2199,O
.,2199,O
Although,2200,O
the,2200,O
overall,2200,O
reported,2200,O
rate,2200,O
of,2200,O
SIADH,2200,B-Disease
associated,2200,O
with,2200,O
vincristine,2200,B-Chemical
is,2200,O
very,2200,O
low,2200,O
",",2200,O
physicians,2200,O
caring,2200,O
for,2200,O
Asian,2200,O
oncology,2200,O
patients,2200,O
should,2200,O
be,2200,O
aware,2200,O
of,2200,O
this,2200,O
potential,2200,O
serious,2200,O
but,2200,O
reversible,2200,O
adverse,2200,O
event,2200,O
.,2200,O
Delayed,2201,O
toxicity,2201,B-Disease
of,2201,O
cyclophosphamide,2201,B-Chemical
on,2201,O
the,2201,O
bladder,2201,O
of,2201,O
DBA/2,2201,O
and,2201,O
C57BL/6,2201,O
female,2201,O
mouse,2201,O
.,2201,O
The,2202,O
present,2202,O
study,2202,O
describes,2202,O
the,2202,O
delayed,2202,O
development,2202,O
of,2202,O
a,2202,O
severe,2202,O
bladder,2202,O
pathology,2202,O
in,2202,O
a,2202,O
susceptible,2202,O
strain,2202,O
of,2202,O
mice,2202,O
(,2202,O
DBA/2,2202,O
),2202,O
but,2202,O
not,2202,O
in,2202,O
a,2202,O
resistant,2202,O
strain,2202,O
(,2202,O
C57BL/6,2202,O
),2202,O
when,2202,O
both,2202,O
were,2202,O
treated,2202,O
with,2202,O
a,2202,O
single,2202,O
300,2202,O
mg/kg,2202,O
dose,2202,O
of,2202,O
cyclophosphamide,2202,B-Chemical
(,2202,O
CY,2202,B-Chemical
),2202,O
.,2202,O
Inbred,2203,O
DBA/2,2203,O
and,2203,O
C57BL/6,2203,O
female,2203,O
mice,2203,O
were,2203,O
injected,2203,O
with,2203,O
CY,2203,B-Chemical
",",2203,O
and,2203,O
the,2203,O
effect,2203,O
of,2203,O
the,2203,O
drug,2203,O
on,2203,O
the,2203,O
bladder,2203,O
was,2203,O
assessed,2203,O
during,2203,O
100,2203,O
days,2203,O
by,2203,O
light,2203,O
microscopy,2203,O
using,2203,O
different,2203,O
staining,2203,O
procedures,2203,O
",",2203,O
and,2203,O
after,2203,O
30,2203,O
days,2203,O
by,2203,O
conventional,2203,O
electron,2203,O
microscopy,2203,O
.,2203,O
Early,2204,O
CY,2204,B-Chemical
toxicity,2204,B-Disease
caused,2204,O
a,2204,O
typical,2204,O
haemorrhagic,2204,B-Disease
cystitis,2204,B-Disease
in,2204,O
both,2204,O
strains,2204,O
that,2204,O
was,2204,O
completely,2204,O
repaired,2204,O
in,2204,O
about,2204,O
7-10,2204,O
days,2204,O
.,2204,O
After,2205,O
30,2205,O
days,2205,O
of,2205,O
CY,2205,B-Chemical
injection,2205,O
ulcerous,2205,O
and,2205,O
non-ulcerous,2205,O
forms,2205,O
of,2205,O
chronic,2205,O
cystitis,2205,B-Disease
appeared,2205,O
in,2205,O
86,2205,O
%,2205,O
of,2205,O
DBA/2,2205,O
mice,2205,O
but,2205,O
only,2205,O
in,2205,O
4,2205,O
%,2205,O
of,2205,O
C57BL/6,2205,O
mice,2205,O
.,2205,O
Delayed,2206,O
cystitis,2206,B-Disease
was,2206,O
characterized,2206,O
by,2206,O
infiltration,2206,O
and,2206,O
transepithelial,2206,O
passage,2206,O
into,2206,O
the,2206,O
lumen,2206,O
of,2206,O
inflammatory,2206,O
cells,2206,O
and,2206,O
by,2206,O
frequent,2206,O
exfoliation,2206,O
of,2206,O
the,2206,O
urothelium,2206,O
.,2206,O
Mast,2207,O
cells,2207,O
appeared,2207,O
in,2207,O
the,2207,O
connective,2207,O
and,2207,O
muscular,2207,O
layers,2207,O
of,2207,O
the,2207,O
bladder,2207,O
at,2207,O
a,2207,O
much,2207,O
higher,2207,O
number,2207,O
in,2207,O
DBA/2,2207,O
mice,2207,O
than,2207,O
in,2207,O
C57BL/6,2207,O
mice,2207,O
or,2207,O
untreated,2207,O
controls,2207,O
.,2207,O
Electron,2208,O
microscopy,2208,O
disclosed,2208,O
the,2208,O
absence,2208,O
of,2208,O
the,2208,O
typical,2208,O
discoidal,2208,O
vesicles,2208,O
normally,2208,O
present,2208,O
in,2208,O
the,2208,O
cytoplasm,2208,O
of,2208,O
surface,2208,O
cells,2208,O
.,2208,O
Instead,2209,O
",",2209,O
numerous,2209,O
abnormal,2209,O
vesicles,2209,O
containing,2209,O
one,2209,O
or,2209,O
several,2209,O
dark,2209,O
granules,2209,O
were,2209,O
observed,2209,O
in,2209,O
the,2209,O
cytoplasm,2209,O
of,2209,O
cells,2209,O
from,2209,O
all,2209,O
the,2209,O
epithelial,2209,O
layers,2209,O
.,2209,O
Delayed,2210,O
cystitis,2210,B-Disease
still,2210,O
persisted,2210,O
in,2210,O
DBA/2,2210,O
mice,2210,O
100,2210,O
days,2210,O
after,2210,O
treatment,2210,O
.,2210,O
These,2211,O
results,2211,O
indicate,2211,O
that,2211,O
delayed,2211,O
toxicity,2211,B-Disease
of,2211,O
CY,2211,B-Chemical
in,2211,O
female,2211,O
DBA/2,2211,O
mice,2211,O
causes,2211,O
a,2211,O
bladder,2211,O
pathology,2211,O
that,2211,O
is,2211,O
not,2211,O
observed,2211,O
in,2211,O
C57BL/6,2211,O
mice,2211,O
.,2211,O
This,2212,O
pathology,2212,O
resembles,2212,O
interstitial,2212,B-Disease
cystitis,2212,I-Disease
in,2212,O
humans,2212,O
and,2212,O
could,2212,O
perhaps,2212,O
be,2212,O
used,2212,O
as,2212,O
an,2212,O
animal,2212,O
model,2212,O
for,2212,O
studies,2212,O
on,2212,O
the,2212,O
disease,2212,O
.,2212,O
High-dose,2213,O
5-fluorouracil,2213,B-Chemical
/,2213,O
folinic,2213,B-Chemical
acid,2213,I-Chemical
in,2213,O
combination,2213,O
with,2213,O
three-weekly,2213,O
mitomycin,2213,B-Chemical
C,2213,I-Chemical
in,2213,O
the,2213,O
treatment,2213,O
of,2213,O
advanced,2213,O
gastric,2213,B-Disease
cancer,2213,I-Disease
.,2213,O
A,2214,O
phase,2214,O
II,2214,O
study,2214,O
.,2214,O
BACKGROUND,2215,O
:,2215,O
The,2215,O
24-hour,2215,O
continuous,2215,O
infusion,2215,O
of,2215,O
5-fluorouracil,2215,B-Chemical
(,2215,O
5-FU,2215,B-Chemical
),2215,O
and,2215,O
folinic,2215,B-Chemical
acid,2215,I-Chemical
(,2215,O
FA,2215,B-Chemical
),2215,O
as,2215,O
part,2215,O
of,2215,O
several,2215,O
new,2215,O
multidrug,2215,O
chemotherapy,2215,O
regimens,2215,O
in,2215,O
advanced,2215,O
gastric,2215,B-Disease
cancer,2215,I-Disease
(,2215,O
AGC,2215,B-Disease
),2215,O
has,2215,O
shown,2215,O
to,2215,O
be,2215,O
effective,2215,O
",",2215,O
with,2215,O
low,2215,O
toxicity,2215,B-Disease
.,2215,O
In,2216,O
a,2216,O
previous,2216,O
phase,2216,O
II,2216,O
study,2216,O
with,2216,O
3-weekly,2216,O
bolus,2216,O
5-FU,2216,B-Chemical
",",2216,O
FA,2216,B-Chemical
and,2216,O
mitomycin,2216,B-Chemical
C,2216,I-Chemical
(,2216,O
MMC,2216,B-Chemical
),2216,O
we,2216,O
found,2216,O
a,2216,O
low,2216,O
toxicity,2216,B-Disease
rate,2216,O
and,2216,O
response,2216,O
rates,2216,O
comparable,2216,O
to,2216,O
those,2216,O
of,2216,O
regimens,2216,O
such,2216,O
as,2216,O
ELF,2216,O
",",2216,O
FAM,2216,O
or,2216,O
FAMTX,2216,O
",",2216,O
and,2216,O
a,2216,O
promising,2216,O
median,2216,O
overall,2216,O
survival,2216,O
.,2216,O
In,2217,O
order,2217,O
to,2217,O
improve,2217,O
this,2217,O
MMC-dependent,2217,B-Chemical
schedule,2217,O
we,2217,O
initiated,2217,O
a,2217,O
phase,2217,O
II,2217,O
study,2217,O
with,2217,O
high-dose,2217,O
5-FU/FA,2217,B-Chemical
and,2217,O
3-weekly,2217,O
bolus,2217,O
MMC,2217,B-Chemical
.,2217,O
PATIENTS,2218,O
AND,2218,O
METHODS,2218,O
:,2218,O
From,2218,O
February,2218,O
",",2218,O
1998,2218,O
to,2218,O
September,2218,O
",",2218,O
2000,2218,O
we,2218,O
recruited,2218,O
33,2218,O
patients,2218,O
with,2218,O
AGC,2218,B-Disease
to,2218,O
receive,2218,O
weekly,2218,O
24-hour,2218,O
5-FU,2218,B-Chemical
"2,600",2218,O
mg/m,2218,O
(,2218,O
2,2218,O
),2218,O
preceded,2218,O
by,2218,O
2-hour,2218,O
FA,2218,B-Chemical
500,2218,O
mg/m,2218,O
(,2218,O
2,2218,O
),2218,O
for,2218,O
6,2218,O
weeks,2218,O
",",2218,O
followed,2218,O
by,2218,O
a,2218,O
2-week,2218,O
rest,2218,O
period,2218,O
.,2218,O
Bolus,2219,O
MMC,2219,B-Chemical
10,2219,O
mg/m,2219,O
(,2219,O
2,2219,O
),2219,O
was,2219,O
added,2219,O
in,2219,O
3-weekly,2219,O
intervals,2219,O
.,2219,O
Treatment,2220,O
given,2220,O
on,2220,O
an,2220,O
outpatient,2220,O
basis,2220,O
",",2220,O
using,2220,O
portable,2220,O
pump,2220,O
systems,2220,O
",",2220,O
was,2220,O
repeated,2220,O
on,2220,O
day,2220,O
57,2220,O
.,2220,O
Patients,2221,O
',2221,O
characteristics,2221,O
were,2221,O
:,2221,O
male/female,2221,O
ratio,2221,O
20/13,2221,O
;,2221,O
median,2221,O
age,2221,O
57,2221,O
(,2221,O
27-75,2221,O
),2221,O
years,2221,O
;,2221,O
median,2221,O
WHO,2221,O
status,2221,O
1,2221,O
(,2221,O
0-2,2221,O
),2221,O
.,2221,O
18,2222,O
patients,2222,O
had,2222,O
a,2222,O
primary,2222,O
AGC,2222,B-Disease
",",2222,O
and,2222,O
15,2222,O
showed,2222,O
a,2222,O
relapsed,2222,O
AGC,2222,B-Disease
.,2222,O
Median,2223,O
follow-up,2223,O
was,2223,O
11.8,2223,O
months,2223,O
(,2223,O
range,2223,O
of,2223,O
those,2223,O
surviving,2223,O
:,2223,O
2.7-11.8,2223,O
months,2223,O
),2223,O
.,2223,O
RESULTS,2224,O
:,2224,O
32,2224,O
patients,2224,O
were,2224,O
evaluable,2224,O
for,2224,O
response,2224,O
-,2224,O
complete,2224,O
remission,2224,O
9.1,2224,O
%,2224,O
(,2224,O
n,2224,O
=,2224,O
3,2224,O
),2224,O
",",2224,O
partial,2224,O
remission,2224,O
45.5,2224,O
%,2224,O
(,2224,O
n,2224,O
=,2224,O
15,2224,O
),2224,O
",",2224,O
no,2224,O
change,2224,O
27.3,2224,O
%,2224,O
(,2224,O
n,2224,O
=,2224,O
9,2224,O
),2224,O
",",2224,O
progressive,2224,O
disease,2224,O
15.1,2224,O
%,2224,O
(,2224,O
n,2224,O
=,2224,O
5,2224,O
),2224,O
.,2224,O
Median,2225,O
overall,2225,O
survival,2225,O
time,2225,O
was,2225,O
10.2,2225,O
months,2225,O
[,2225,O
95,2225,O
%,2225,O
confidence,2225,O
interval,2225,O
(,2225,O
CI,2225,O
),2225,O
:,2225,O
8.7-11.6,2225,O
],2225,O
",",2225,O
and,2225,O
median,2225,O
progression-free,2225,O
survival,2225,O
time,2225,O
was,2225,O
7.6,2225,O
months,2225,O
(,2225,O
95,2225,O
%,2225,O
CI,2225,O
:,2225,O
4.4-10.9,2225,O
),2225,O
.,2225,O
The,2226,O
worst,2226,O
toxicities,2226,B-Disease
(,2226,O
%,2226,O
),2226,O
observed,2226,O
were,2226,O
(,2226,O
CTC-NCI,2226,O
1/2/3,2226,O
),2226,O
:,2226,O
leukopenia,2226,B-Disease
45.5/18.2/6.1,2226,O
",",2226,O
thrombocytopenia,2226,B-Disease
33.3/9.1/6.1,2226,O
",",2226,O
vomitus,2226,B-Disease
24.2/9.1/0,2226,O
",",2226,O
diarrhea,2226,B-Disease
36.4/6.1/3.0,2226,O
",",2226,O
stomatitis,2226,B-Disease
18.2/9.1/0,2226,O
",",2226,O
hand-foot,2226,B-Disease
syndrome,2226,I-Disease
12.1/0/0,2226,O
.,2226,O
Two,2227,O
patients,2227,O
developed,2227,O
hemolytic-uremic,2227,B-Disease
syndrome,2227,I-Disease
(,2227,O
HUS,2227,B-Disease
),2227,O
.,2227,O
CONCLUSIONS,2228,O
:,2228,O
High-dose,2228,O
5-FU/FA/MMC,2228,B-Chemical
is,2228,O
an,2228,O
effective,2228,O
and,2228,O
well-tolerated,2228,O
outpatient,2228,O
regimen,2228,O
for,2228,O
AGC,2228,B-Disease
(,2228,O
objective,2228,O
response,2228,O
rate,2228,O
54.6,2228,O
%,2228,O
),2228,O
.,2228,O
It,2229,O
may,2229,O
serve,2229,O
as,2229,O
an,2229,O
alternative,2229,O
to,2229,O
cisplatin-containing,2229,B-Chemical
regimens,2229,O
;,2229,O
however,2229,O
",",2229,O
it,2229,O
has,2229,O
to,2229,O
be,2229,O
considered,2229,O
that,2229,O
possibly,2229,O
HUS,2229,B-Disease
may,2229,O
occur,2229,O
.,2229,O
Persistent,2230,O
sterile,2230,O
leukocyturia,2230,B-Disease
is,2230,O
associated,2230,O
with,2230,O
impaired,2230,B-Disease
renal,2230,I-Disease
function,2230,I-Disease
in,2230,O
human,2230,B-Disease
immunodeficiency,2230,I-Disease
virus,2230,I-Disease
type,2230,I-Disease
1-infected,2230,I-Disease
children,2230,O
treated,2230,O
with,2230,O
indinavir,2230,B-Chemical
.,2230,O
BACKGROUND,2231,O
:,2231,O
Prolonged,2231,O
administration,2231,O
of,2231,O
indinavir,2231,B-Chemical
is,2231,O
associated,2231,O
with,2231,O
the,2231,O
occurrence,2231,O
of,2231,O
a,2231,O
variety,2231,O
of,2231,O
renal,2231,O
complications,2231,O
in,2231,O
adults,2231,O
.,2231,O
These,2232,O
well-documented,2232,O
side,2232,O
effects,2232,O
have,2232,O
restricted,2232,O
the,2232,O
use,2232,O
of,2232,O
this,2232,O
potent,2232,O
protease,2232,O
inhibitor,2232,O
in,2232,O
children,2232,O
.,2232,O
DESIGN,2233,O
:,2233,O
A,2233,O
prospective,2233,O
study,2233,O
to,2233,O
monitor,2233,O
indinavir-related,2233,B-Chemical
nephrotoxicity,2233,B-Disease
in,2233,O
a,2233,O
cohort,2233,O
of,2233,O
30,2233,O
human,2233,B-Disease
immunodeficiency,2233,I-Disease
virus,2233,I-Disease
type,2233,I-Disease
1-infected,2233,I-Disease
children,2233,O
treated,2233,O
with,2233,O
indinavir,2233,B-Chemical
.,2233,O
METHODS,2234,O
:,2234,O
Urinary,2234,O
pH,2234,O
",",2234,O
albumin,2234,O
",",2234,O
creatinine,2234,B-Chemical
",",2234,O
the,2234,O
presence,2234,O
of,2234,O
erythrocytes,2234,O
",",2234,O
leukocytes,2234,O
",",2234,O
bacteria,2234,O
and,2234,O
crystals,2234,O
",",2234,O
and,2234,O
culture,2234,O
were,2234,O
analyzed,2234,O
every,2234,O
3,2234,O
months,2234,O
for,2234,O
96,2234,O
weeks,2234,O
.,2234,O
Serum,2235,O
creatinine,2235,B-Chemical
levels,2235,O
were,2235,O
routinely,2235,O
determined,2235,O
at,2235,O
the,2235,O
same,2235,O
time,2235,O
points,2235,O
.,2235,O
Steady-state,2236,O
pharmacokinetics,2236,O
of,2236,O
indinavir,2236,B-Chemical
were,2236,O
done,2236,O
at,2236,O
week,2236,O
4,2236,O
after,2236,O
the,2236,O
initiation,2236,O
of,2236,O
indinavir,2236,B-Chemical
.,2236,O
RESULTS,2237,O
:,2237,O
The,2237,O
cumulative,2237,O
incidence,2237,O
of,2237,O
persistent,2237,O
sterile,2237,O
leukocyturia,2237,B-Disease
(,2237,O
>,2237,O
or,2237,O
=75,2237,O
cells/,2237,O
micro,2237,O
L,2237,O
in,2237,O
at,2237,O
least,2237,O
2,2237,O
consecutive,2237,O
visits,2237,O
),2237,O
after,2237,O
96,2237,O
weeks,2237,O
was,2237,O
53,2237,O
%,2237,O
.,2237,O
Persistent,2238,O
sterile,2238,O
leukocyturia,2238,B-Disease
was,2238,O
frequently,2238,O
associated,2238,O
with,2238,O
a,2238,O
mild,2238,O
increase,2238,O
in,2238,O
the,2238,O
urine,2238,O
albumin/creatinine,2238,O
ratio,2238,O
and,2238,O
by,2238,O
microscopic,2238,O
hematuria,2238,B-Disease
.,2238,O
The,2239,O
cumulative,2239,O
incidence,2239,O
of,2239,O
serum,2239,O
creatinine,2239,B-Chemical
levels,2239,O
>,2239,O
50,2239,O
%,2239,O
above,2239,O
normal,2239,O
was,2239,O
33,2239,O
%,2239,O
after,2239,O
96,2239,O
weeks,2239,O
.,2239,O
Children,2240,O
with,2240,O
persistent,2240,O
sterile,2240,O
leukocyturia,2240,B-Disease
more,2240,O
frequently,2240,O
had,2240,O
serum,2240,O
creatinine,2240,B-Chemical
levels,2240,O
of,2240,O
50,2240,O
%,2240,O
above,2240,O
normal,2240,O
than,2240,O
those,2240,O
children,2240,O
without,2240,O
persistent,2240,O
sterile,2240,O
leukocyturia,2240,B-Disease
.,2240,O
In,2241,O
children,2241,O
younger,2241,O
than,2241,O
5.6,2241,O
years,2241,O
",",2241,O
persistent,2241,O
sterile,2241,O
leukocyturia,2241,B-Disease
was,2241,O
significantly,2241,O
more,2241,O
frequent,2241,O
than,2241,O
in,2241,O
older,2241,O
children,2241,O
.,2241,O
A,2242,O
higher,2242,O
cumulative,2242,O
incidence,2242,O
of,2242,O
persistent,2242,O
leukocyturia,2242,B-Disease
was,2242,O
found,2242,O
in,2242,O
children,2242,O
with,2242,O
an,2242,O
area,2242,O
under,2242,O
the,2242,O
curve,2242,O
>,2242,O
19,2242,O
mg/L,2242,O
x,2242,O
h,2242,O
or,2242,O
a,2242,O
peak,2242,O
serum,2242,O
level,2242,O
of,2242,O
indinavir,2242,B-Chemical
>,2242,O
12,2242,O
mg/L,2242,O
.,2242,O
In,2243,O
4,2243,O
children,2243,O
",",2243,O
indinavir,2243,B-Chemical
was,2243,O
discontinued,2243,O
because,2243,O
of,2243,O
nephrotoxicity,2243,B-Disease
.,2243,O
Subsequently,2244,O
",",2244,O
the,2244,O
serum,2244,O
creatinine,2244,B-Chemical
levels,2244,O
decreased,2244,O
",",2244,O
the,2244,O
urine,2244,O
albumin/creatinine,2244,O
ratios,2244,O
returned,2244,O
to,2244,O
zero,2244,O
",",2244,O
and,2244,O
the,2244,O
leukocyturia,2244,B-Disease
disappeared,2244,O
within,2244,O
3,2244,O
months,2244,O
.,2244,O
CONCLUSIONS,2245,O
:,2245,O
Children,2245,O
treated,2245,O
with,2245,O
indinavir,2245,B-Chemical
have,2245,O
a,2245,O
high,2245,O
cumulative,2245,O
incidence,2245,O
of,2245,O
persistent,2245,O
sterile,2245,O
leukocyturia,2245,B-Disease
.,2245,O
Children,2246,O
with,2246,O
persistent,2246,O
sterile,2246,O
leukocyturia,2246,B-Disease
more,2246,O
frequently,2246,O
had,2246,O
an,2246,O
increase,2246,O
in,2246,O
serum,2246,O
creatinine,2246,B-Chemical
levels,2246,O
of,2246,O
>,2246,O
50,2246,O
%,2246,O
above,2246,O
normal,2246,O
.,2246,O
Younger,2247,O
children,2247,O
have,2247,O
an,2247,O
additional,2247,O
risk,2247,O
for,2247,O
renal,2247,O
complications,2247,O
.,2247,O
The,2248,O
impairment,2248,B-Disease
of,2248,I-Disease
the,2248,I-Disease
renal,2248,I-Disease
function,2248,I-Disease
in,2248,O
these,2248,O
children,2248,O
occurred,2248,O
in,2248,O
the,2248,O
absence,2248,O
of,2248,O
clinical,2248,O
symptoms,2248,O
of,2248,O
nephrolithiasis,2248,B-Disease
.,2248,O
Indinavir-associated,2249,B-Chemical
nephrotoxicity,2249,B-Disease
must,2249,O
be,2249,O
monitored,2249,O
closely,2249,O
",",2249,O
especially,2249,O
in,2249,O
children,2249,O
with,2249,O
risk,2249,O
factors,2249,O
such,2249,O
as,2249,O
persistent,2249,O
sterile,2249,O
leukocyturia,2249,B-Disease
",",2249,O
age,2249,O
<,2249,O
5.6,2249,O
years,2249,O
",",2249,O
an,2249,O
area,2249,O
under,2249,O
the,2249,O
curve,2249,O
of,2249,O
indinavir,2249,B-Chemical
>,2249,O
19,2249,O
mg/L,2249,O
x,2249,O
h,2249,O
",",2249,O
and,2249,O
a,2249,O
C,2249,O
(,2249,O
max,2249,O
),2249,O
>,2249,O
12,2249,O
mg/L,2249,O
.,2249,O
Utility,2250,O
of,2250,O
troponin,2250,O
I,2250,O
in,2250,O
patients,2250,O
with,2250,O
cocaine-associated,2250,B-Chemical
chest,2250,B-Disease
pain,2250,I-Disease
.,2250,O
Baseline,2251,O
electrocardiogram,2251,O
abnormalities,2251,O
and,2251,O
market,2251,O
elevations,2251,O
not,2251,O
associated,2251,O
with,2251,O
myocardial,2251,B-Disease
necrosis,2251,I-Disease
make,2251,O
accurate,2251,O
diagnosis,2251,O
of,2251,O
myocardial,2251,B-Disease
infarction,2251,I-Disease
(,2251,O
MI,2251,B-Disease
),2251,O
difficult,2251,O
in,2251,O
patients,2251,O
with,2251,O
cocaine-associated,2251,B-Chemical
chest,2251,B-Disease
pain,2251,I-Disease
.,2251,O
Troponin,2252,O
sampling,2252,O
may,2252,O
offer,2252,O
greater,2252,O
diagnostic,2252,O
utility,2252,O
in,2252,O
these,2252,O
patients,2252,O
.,2252,O
OBJECTIVE,2253,O
:,2253,O
To,2253,O
assess,2253,O
outcomes,2253,O
based,2253,O
on,2253,O
troponin,2253,O
positivity,2253,O
in,2253,O
patients,2253,O
with,2253,O
cocaine,2253,B-Chemical
chest,2253,B-Disease
pain,2253,I-Disease
admitted,2253,O
for,2253,O
exclusion,2253,O
of,2253,O
MI,2253,B-Disease
.,2253,O
METHODS,2254,O
:,2254,O
Outcomes,2254,O
were,2254,O
examined,2254,O
in,2254,O
patients,2254,O
admitted,2254,O
for,2254,O
possible,2254,O
MI,2254,B-Disease
after,2254,O
cocaine,2254,B-Chemical
use,2254,O
.,2254,O
All,2255,O
patients,2255,O
underwent,2255,O
a,2255,O
rapid,2255,O
rule-in,2255,O
protocol,2255,O
that,2255,O
included,2255,O
serial,2255,O
sampling,2255,O
of,2255,O
creatine,2255,B-Chemical
kinase,2255,O
(,2255,O
CK,2255,O
),2255,O
",",2255,O
CK-MB,2255,O
",",2255,O
and,2255,O
cardiac,2255,O
troponin,2255,O
I,2255,O
(,2255,O
cTnI,2255,O
),2255,O
over,2255,O
eight,2255,O
hours,2255,O
.,2255,O
Outcomes,2256,O
included,2256,O
CK-MB,2256,O
MI,2256,B-Disease
(,2256,O
CK-MB,2256,O
>,2256,O
or=,2256,O
8,2256,O
ng/mL,2256,O
with,2256,O
a,2256,O
relative,2256,O
index,2256,O
[,2256,O
(,2256,O
CK-MB,2256,O
x,2256,O
100,2256,O
),2256,O
/total,2256,O
CK,2256,O
],2256,O
>,2256,O
or=,2256,O
4,2256,O
",",2256,O
cardiac,2256,B-Disease
death,2256,I-Disease
",",2256,O
and,2256,O
significant,2256,O
coronary,2256,B-Disease
disease,2256,I-Disease
(,2256,O
>,2256,O
or=50,2256,O
%,2256,O
),2256,O
.,2256,O
RESULTS,2257,O
:,2257,O
Of,2257,O
the,2257,O
246,2257,O
admitted,2257,O
patients,2257,O
",",2257,O
34,2257,O
(,2257,O
14,2257,O
%,2257,O
),2257,O
met,2257,O
CK-MB,2257,O
criteria,2257,O
for,2257,O
MI,2257,B-Disease
and,2257,O
38,2257,O
(,2257,O
16,2257,O
%,2257,O
),2257,O
had,2257,O
cTnI,2257,O
elevations,2257,O
.,2257,O
Angiography,2258,O
was,2258,O
performed,2258,O
in,2258,O
29,2258,O
of,2258,O
38,2258,O
patients,2258,O
who,2258,O
were,2258,O
cTnI-positive,2258,O
",",2258,O
with,2258,O
significant,2258,O
disease,2258,O
present,2258,O
in,2258,O
25,2258,O
(,2258,O
86,2258,O
%,2258,O
),2258,O
.,2258,O
Three,2259,O
of,2259,O
the,2259,O
four,2259,O
patients,2259,O
without,2259,O
significant,2259,O
disease,2259,O
who,2259,O
had,2259,O
cTnI,2259,O
elevations,2259,O
met,2259,O
CK-MB,2259,O
criteria,2259,O
for,2259,O
MI,2259,B-Disease
",",2259,O
and,2259,O
the,2259,O
other,2259,O
had,2259,O
a,2259,O
peak,2259,O
CK-MB,2259,O
level,2259,O
of,2259,O
13,2259,O
ng/mL,2259,O
.,2259,O
Sensitivities,2260,O
",",2260,O
specificities,2260,O
",",2260,O
and,2260,O
positive,2260,O
and,2260,O
negative,2260,O
likelihood,2260,O
ratios,2260,O
for,2260,O
predicting,2260,O
cardiac,2260,B-Disease
death,2260,I-Disease
or,2260,O
significant,2260,O
disease,2260,O
were,2260,O
high,2260,O
for,2260,O
both,2260,O
CK-MB,2260,O
MI,2260,B-Disease
and,2260,O
cTnI,2260,O
and,2260,O
were,2260,O
not,2260,O
significantly,2260,O
different,2260,O
.,2260,O
CONCLUSIONS,2261,O
:,2261,O
Most,2261,O
patients,2261,O
with,2261,O
cTnI,2261,O
elevations,2261,O
meet,2261,O
CK-MB,2261,O
criteria,2261,O
for,2261,O
MI,2261,B-Disease
",",2261,O
as,2261,O
well,2261,O
as,2261,O
have,2261,O
a,2261,O
high,2261,O
incidence,2261,O
of,2261,O
underlying,2261,O
significant,2261,O
disease,2261,O
.,2261,O
Troponin,2262,O
appears,2262,O
to,2262,O
have,2262,O
an,2262,O
equivalent,2262,O
diagnostic,2262,O
accuracy,2262,O
compared,2262,O
with,2262,O
CK-MB,2262,O
for,2262,O
diagnosing,2262,O
necrosis,2262,B-Disease
in,2262,O
patients,2262,O
with,2262,O
cocaine-associated,2262,B-Chemical
chest,2262,B-Disease
pain,2262,I-Disease
and,2262,O
suspected,2262,O
MI,2262,B-Disease
.,2262,O
Acute,2263,O
interstitial,2263,B-Disease
nephritis,2263,I-Disease
due,2263,O
to,2263,O
nicergoline,2263,B-Chemical
(,2263,O
Sermion,2263,B-Chemical
),2263,O
.,2263,O
We,2264,O
report,2264,O
a,2264,O
case,2264,O
of,2264,O
acute,2264,O
interstitial,2264,B-Disease
nephritis,2264,I-Disease
(,2264,O
AIN,2264,B-Disease
),2264,O
due,2264,O
to,2264,O
nicergoline,2264,B-Chemical
(,2264,O
Sermion,2264,B-Chemical
),2264,O
.,2264,O
A,2265,O
50-year-old,2265,O
patient,2265,O
admitted,2265,O
to,2265,O
our,2265,O
hospital,2265,O
for,2265,O
fever,2265,B-Disease
and,2265,O
acute,2265,B-Disease
renal,2265,I-Disease
failure,2265,I-Disease
.,2265,O
Before,2266,O
admission,2266,O
",",2266,O
he,2266,O
had,2266,O
been,2266,O
taking,2266,O
nicergoline,2266,B-Chemical
and,2266,O
bendazac,2266,B-Chemical
lysine,2266,I-Chemical
due,2266,O
to,2266,O
retinal,2266,B-Disease
vein,2266,I-Disease
occlusion,2266,I-Disease
at,2266,O
ophthalmologic,2266,O
department,2266,O
.,2266,O
Thereafter,2267,O
",",2267,O
he,2267,O
experienced,2267,O
intermittent,2267,O
fever,2267,B-Disease
and,2267,O
skin,2267,B-Disease
rash,2267,I-Disease
.,2267,O
On,2268,O
admission,2268,O
",",2268,O
clinical,2268,O
symptoms,2268,O
(,2268,O
i.e,2268,O
.,2268,O
arthralgia,2269,B-Disease
and,2269,O
fever,2269,B-Disease
),2269,O
and,2269,O
laboratory,2269,O
findings,2269,O
(,2269,O
i.e,2269,O
.,2269,O
eosinophilia,2270,B-Disease
and,2270,O
renal,2270,B-Disease
failure,2270,I-Disease
),2270,O
suggested,2270,O
AIN,2270,B-Disease
",",2270,O
and,2270,O
which,2270,O
was,2270,O
confirmed,2270,O
by,2270,O
pathologic,2270,O
findings,2270,O
on,2270,O
renal,2270,O
biopsy,2270,O
.,2270,O
A,2271,O
lymphocyte,2271,O
transformation,2271,O
test,2271,O
demonstrated,2271,O
a,2271,O
positive,2271,O
result,2271,O
against,2271,O
nicergoline,2271,B-Chemical
.,2271,O
Treatment,2272,O
was,2272,O
consisted,2272,O
of,2272,O
withdrawal,2272,O
of,2272,O
nicergoline,2272,B-Chemical
and,2272,O
intravenous,2272,O
methylprednisolone,2272,B-Chemical
",",2272,O
and,2272,O
his,2272,O
renal,2272,O
function,2272,O
was,2272,O
completely,2272,O
recovered,2272,O
.,2272,O
To,2273,O
our,2273,O
knowledge,2273,O
",",2273,O
this,2273,O
is,2273,O
the,2273,O
first,2273,O
report,2273,O
of,2273,O
nicergoline-associated,2273,B-Chemical
AIN,2273,B-Disease
.,2273,O
Neuroleptic,2274,B-Disease
malignant,2274,I-Disease
syndrome,2274,I-Disease
complicated,2274,O
by,2274,O
massive,2274,O
intestinal,2274,O
bleeding,2274,B-Disease
in,2274,O
a,2274,O
patient,2274,O
with,2274,O
chronic,2274,B-Disease
renal,2274,I-Disease
failure,2274,I-Disease
.,2274,O
A,2275,O
patient,2275,O
with,2275,O
chronic,2275,B-Disease
renal,2275,I-Disease
failure,2275,I-Disease
(,2275,O
CRF,2275,B-Disease
),2275,O
developed,2275,O
neuroleptic,2275,B-Disease
malignant,2275,I-Disease
syndrome,2275,I-Disease
(,2275,O
NMS,2275,B-Disease
),2275,O
after,2275,O
administration,2275,O
of,2275,O
risperidone,2275,B-Chemical
and,2275,O
levomepromazine,2275,B-Chemical
.,2275,O
In,2276,O
addition,2276,O
to,2276,O
the,2276,O
typical,2276,O
symptoms,2276,O
of,2276,O
NMS,2276,B-Disease
",",2276,O
massive,2276,O
intestinal,2276,O
bleeding,2276,B-Disease
was,2276,O
observed,2276,O
during,2276,O
the,2276,O
episode,2276,O
.,2276,O
This,2277,O
report,2277,O
suggests,2277,O
that,2277,O
NMS,2277,B-Disease
in,2277,O
a,2277,O
patient,2277,O
with,2277,O
CRF,2277,B-Disease
may,2277,O
be,2277,O
complicated,2277,O
by,2277,O
intestinal,2277,O
bleeding,2277,B-Disease
and,2277,O
needs,2277,O
special,2277,O
caution,2277,O
for,2277,O
this,2277,O
complication,2277,O
.,2277,O
Blood,2278,O
brain,2278,O
barrier,2278,O
in,2278,O
right-,2278,O
and,2278,O
left-pawed,2278,O
female,2278,O
rats,2278,O
assessed,2278,O
by,2278,O
a,2278,O
new,2278,O
staining,2278,O
method,2278,O
.,2278,O
The,2279,O
asymmetrical,2279,O
breakdown,2279,O
of,2279,O
the,2279,O
blood-brain,2279,O
barrier,2279,O
(,2279,O
BBB,2279,O
),2279,O
was,2279,O
studied,2279,O
in,2279,O
female,2279,O
rats,2279,O
.,2279,O
Paw,2280,O
preference,2280,O
was,2280,O
assessed,2280,O
by,2280,O
a,2280,O
food,2280,O
reaching,2280,O
test,2280,O
.,2280,O
Adrenaline-induced,2281,B-Chemical
hypertension,2281,B-Disease
was,2281,O
used,2281,O
to,2281,O
destroy,2281,O
the,2281,O
BBB,2281,O
",",2281,O
which,2281,O
was,2281,O
evaluated,2281,O
using,2281,O
triphenyltetrazolium,2281,B-Chemical
(,2281,O
TTC,2281,B-Chemical
),2281,O
staining,2281,O
of,2281,O
the,2281,O
brain,2281,O
slices,2281,O
just,2281,O
after,2281,O
giving,2281,O
adrenaline,2281,B-Chemical
for,2281,O
30,2281,O
s.,2281,O
In,2281,O
normal,2281,O
rats,2281,O
",",2281,O
the,2281,O
whole,2281,O
brain,2281,O
sections,2281,O
exhibited,2281,O
complete,2281,O
staining,2281,O
with,2281,O
TTC,2281,B-Chemical
.,2281,O
After,2282,O
adrenaline,2282,B-Chemical
infusion,2282,O
for,2282,O
30,2282,O
s,2282,O
",",2282,O
there,2282,O
were,2282,O
large,2282,O
unstained,2282,O
areas,2282,O
in,2282,O
the,2282,O
left,2282,O
brain,2282,O
in,2282,O
right-pawed,2282,O
animals,2282,O
",",2282,O
and,2282,O
vice,2282,O
versa,2282,O
in,2282,O
left-pawed,2282,O
animals,2282,O
.,2282,O
Similar,2283,O
results,2283,O
were,2283,O
obtained,2283,O
in,2283,O
seizure-induced,2283,B-Disease
breakdown,2283,O
of,2283,O
BBB,2283,O
.,2283,O
These,2284,O
results,2284,O
were,2284,O
explained,2284,O
by,2284,O
an,2284,O
asymmetric,2284,O
cerebral,2284,O
blood,2284,O
flow,2284,O
depending,2284,O
upon,2284,O
the,2284,O
paw,2284,O
preference,2284,O
in,2284,O
rats,2284,O
.,2284,O
It,2285,O
was,2285,O
suggested,2285,O
that,2285,O
this,2285,O
new,2285,O
method,2285,O
and,2285,O
the,2285,O
results,2285,O
are,2285,O
consistent,2285,O
with,2285,O
contralateral,2285,O
motor,2285,O
control,2285,O
that,2285,O
may,2285,O
be,2285,O
important,2285,O
in,2285,O
determining,2285,O
the,2285,O
dominant,2285,O
cerebral,2285,O
hemisphere,2285,O
in,2285,O
animals,2285,O
.,2285,O
Carvedilol,2286,B-Chemical
protects,2286,O
against,2286,O
doxorubicin-induced,2286,B-Chemical
mitochondrial,2286,O
cardiomyopathy,2286,B-Disease
.,2286,O
Several,2287,O
cytopathic,2287,O
mechanisms,2287,O
have,2287,O
been,2287,O
suggested,2287,O
to,2287,O
mediate,2287,O
the,2287,O
dose-limiting,2287,O
cumulative,2287,O
and,2287,O
irreversible,2287,O
cardiomyopathy,2287,B-Disease
caused,2287,O
by,2287,O
doxorubicin,2287,B-Chemical
.,2287,O
Recent,2288,O
evidence,2288,O
indicates,2288,O
that,2288,O
oxidative,2288,O
stress,2288,O
and,2288,O
mitochondrial,2288,B-Disease
dysfunction,2288,I-Disease
are,2288,O
key,2288,O
factors,2288,O
in,2288,O
the,2288,O
pathogenic,2288,O
process,2288,O
.,2288,O
The,2289,O
objective,2289,O
of,2289,O
this,2289,O
investigation,2289,O
was,2289,O
to,2289,O
test,2289,O
the,2289,O
hypothesis,2289,O
that,2289,O
carvedilol,2289,B-Chemical
",",2289,O
a,2289,O
nonselective,2289,O
beta-adrenergic,2289,O
receptor,2289,O
antagonist,2289,O
with,2289,O
potent,2289,O
antioxidant,2289,O
properties,2289,O
",",2289,O
protects,2289,O
against,2289,O
the,2289,O
cardiac,2289,O
and,2289,O
hepatic,2289,O
mitochondrial,2289,O
bioenergetic,2289,O
dysfunction,2289,O
associated,2289,O
with,2289,O
subchronic,2289,O
doxorubicin,2289,B-Chemical
toxicity,2289,B-Disease
.,2289,O
Heart,2290,O
and,2290,O
liver,2290,O
mitochondria,2290,O
were,2290,O
isolated,2290,O
from,2290,O
rats,2290,O
treated,2290,O
for,2290,O
7,2290,O
weeks,2290,O
with,2290,O
doxorubicin,2290,B-Chemical
(,2290,O
2,2290,O
mg/kg,2290,O
sc/week,2290,O
),2290,O
",",2290,O
carvedilol,2290,B-Chemical
(,2290,O
1,2290,O
mg/kg,2290,O
ip/week,2290,O
),2290,O
",",2290,O
or,2290,O
the,2290,O
combination,2290,O
of,2290,O
the,2290,O
two,2290,O
drugs,2290,O
.,2290,O
Heart,2291,O
mitochondria,2291,O
isolated,2291,O
from,2291,O
doxorubicin-treated,2291,B-Chemical
rats,2291,O
exhibited,2291,O
depressed,2291,O
rates,2291,O
for,2291,O
state,2291,O
3,2291,O
respiration,2291,O
(,2291,O
336,2291,O
+/-,2291,O
26,2291,O
versus,2291,O
425,2291,O
+/-,2291,O
53,2291,O
natom,2291,O
O/min/mg,2291,O
protein,2291,O
),2291,O
and,2291,O
a,2291,O
lower,2291,O
respiratory,2291,O
control,2291,O
ratio,2291,O
(,2291,O
RCR,2291,O
),2291,O
(,2291,O
4.3,2291,O
+/-,2291,O
0.6,2291,O
versus,2291,O
5.8,2291,O
+/-,2291,O
0.4,2291,O
),2291,O
compared,2291,O
with,2291,O
cardiac,2291,O
mitochondria,2291,O
isolated,2291,O
from,2291,O
saline-treated,2291,O
rats,2291,O
.,2291,O
Mitochondrial,2292,O
calcium-loading,2292,B-Chemical
capacity,2292,O
and,2292,O
the,2292,O
activity,2292,O
of,2292,O
NADH-dehydrogenase,2292,O
were,2292,O
also,2292,O
suppressed,2292,O
in,2292,O
cardiac,2292,O
mitochondria,2292,O
from,2292,O
doxorubicin-treated,2292,B-Chemical
rats,2292,O
.,2292,O
Doxorubicin,2293,B-Chemical
treatment,2293,O
also,2293,O
caused,2293,O
a,2293,O
decrease,2293,O
in,2293,O
RCR,2293,O
for,2293,O
liver,2293,O
mitochondria,2293,O
(,2293,O
3.9,2293,O
+/-,2293,O
0.9,2293,O
versus,2293,O
5.6,2293,O
+/-,2293,O
0.7,2293,O
for,2293,O
control,2293,O
rats,2293,O
),2293,O
and,2293,O
inhibition,2293,O
of,2293,O
hepatic,2293,O
cytochrome,2293,O
oxidase,2293,O
activity,2293,O
.,2293,O
Coadministration,2294,O
of,2294,O
carvedilol,2294,B-Chemical
decreased,2294,O
the,2294,O
extent,2294,O
of,2294,O
cellular,2294,O
vacuolization,2294,O
in,2294,O
cardiac,2294,O
myocytes,2294,O
and,2294,O
prevented,2294,O
the,2294,O
inhibitory,2294,O
effect,2294,O
of,2294,O
doxorubicin,2294,B-Chemical
on,2294,O
mitochondrial,2294,O
respiration,2294,O
in,2294,O
both,2294,O
heart,2294,O
and,2294,O
liver,2294,O
.,2294,O
Carvedilol,2295,B-Chemical
also,2295,O
prevented,2295,O
the,2295,O
decrease,2295,O
in,2295,O
mitochondrial,2295,O
Ca,2295,B-Chemical
(,2295,O
2+,2295,O
),2295,O
loading,2295,O
capacity,2295,O
and,2295,O
the,2295,O
inhibition,2295,O
of,2295,O
the,2295,O
respiratory,2295,O
complexes,2295,O
of,2295,O
heart,2295,O
mitochondria,2295,O
caused,2295,O
by,2295,O
doxorubicin,2295,B-Chemical
.,2295,O
Carvedilol,2296,B-Chemical
by,2296,O
itself,2296,O
did,2296,O
not,2296,O
affect,2296,O
any,2296,O
of,2296,O
the,2296,O
parameters,2296,O
measured,2296,O
for,2296,O
heart,2296,O
or,2296,O
liver,2296,O
mitochondria,2296,O
.,2296,O
It,2297,O
is,2297,O
concluded,2297,O
that,2297,O
this,2297,O
protection,2297,O
by,2297,O
carvedilol,2297,B-Chemical
against,2297,O
both,2297,O
the,2297,O
structural,2297,O
and,2297,O
functional,2297,O
cardiac,2297,O
tissue,2297,O
damage,2297,O
may,2297,O
afford,2297,O
significant,2297,O
clinical,2297,O
advantage,2297,O
in,2297,O
minimizing,2297,O
the,2297,O
dose-limiting,2297,O
mitochondrial,2297,B-Disease
dysfunction,2297,I-Disease
and,2297,O
cardiomyopathy,2297,B-Disease
that,2297,O
accompanies,2297,O
long-term,2297,O
doxorubicin,2297,B-Chemical
therapy,2297,O
in,2297,O
cancer,2297,B-Disease
patients,2297,O
.,2297,O
Cocaine-induced,2298,B-Chemical
hyperactivity,2298,B-Disease
is,2298,O
more,2298,O
influenced,2298,O
by,2298,O
adenosine,2298,B-Chemical
receptor,2298,O
agonists,2298,O
than,2298,O
amphetamine-induced,2298,B-Chemical
hyperactivity,2298,B-Disease
.,2298,O
The,2299,O
influence,2299,O
of,2299,O
adenosine,2299,B-Chemical
receptor,2299,O
agonists,2299,O
and,2299,O
antagonists,2299,O
on,2299,O
cocaine-and,2299,B-Chemical
amphetamine-induced,2299,B-Chemical
hyperactivity,2299,B-Disease
was,2299,O
examined,2299,O
in,2299,O
mice,2299,O
.,2299,O
All,2300,O
adenosine,2300,B-Chemical
receptor,2300,O
agonists,2300,O
significantly,2300,O
decreased,2300,B-Disease
the,2300,I-Disease
locomotor,2300,I-Disease
activity,2300,I-Disease
in,2300,O
mice,2300,O
",",2300,O
and,2300,O
the,2300,O
effects,2300,O
were,2300,O
dose-dependent,2300,O
.,2300,O
It,2301,O
seems,2301,O
that,2301,O
adenosine,2301,B-Chemical
A1,2301,O
and,2301,O
A2,2301,O
receptors,2301,O
might,2301,O
be,2301,O
involved,2301,O
in,2301,O
this,2301,O
reaction,2301,O
.,2301,O
Moreover,2302,O
",",2302,O
all,2302,O
adenosine,2302,B-Chemical
receptor,2302,O
agonists,2302,O
:,2302,O
2-p-,2302,B-Chemical
(,2302,I-Chemical
2-carboxyethyl,2302,I-Chemical
),2302,I-Chemical
phenethylamino-5'-N-ethylcarboxamidoadenosine,2302,I-Chemical
(,2302,O
CGS,2302,B-Chemical
21680,2302,I-Chemical
),2302,O
",",2302,O
A2A,2302,O
receptor,2302,O
agonist,2302,O
",",2302,O
N6-cyclopentyladenosine,2302,B-Chemical
(,2302,O
CPA,2302,B-Chemical
),2302,O
",",2302,O
A1,2302,O
receptor,2302,O
agonist,2302,O
",",2302,O
and,2302,O
5'-N-ethylcarboxamidoadenosine,2302,B-Chemical
(,2302,O
NECA,2302,B-Chemical
),2302,O
",",2302,O
A2/A1,2302,O
receptor,2302,O
agonist,2302,O
significantly,2302,O
and,2302,O
dose-dependently,2302,O
decreased,2302,O
cocaine-induced,2302,B-Chemical
locomotor,2302,O
activity,2302,O
.,2302,O
CPA,2303,B-Chemical
reduced,2303,O
cocaine,2303,B-Chemical
action,2303,O
at,2303,O
the,2303,O
doses,2303,O
which,2303,O
",",2303,O
given,2303,O
alone,2303,O
",",2303,O
did,2303,O
not,2303,O
influence,2303,O
motility,2303,O
",",2303,O
while,2303,O
CGS,2303,B-Chemical
21680,2303,I-Chemical
and,2303,O
NECA,2303,B-Chemical
decreased,2303,O
the,2303,O
action,2303,O
of,2303,O
cocaine,2303,B-Chemical
at,2303,O
the,2303,O
doses,2303,O
which,2303,O
",",2303,O
given,2303,O
alone,2303,O
",",2303,O
decreased,2303,O
locomotor,2303,O
activity,2303,O
in,2303,O
animals,2303,O
.,2303,O
These,2304,O
results,2304,O
suggest,2304,O
the,2304,O
involvement,2304,O
of,2304,O
both,2304,O
adenosine,2304,B-Chemical
receptors,2304,O
in,2304,O
the,2304,O
action,2304,O
of,2304,O
cocaine,2304,B-Chemical
although,2304,O
agonists,2304,O
of,2304,O
A1,2304,O
receptors,2304,O
seem,2304,O
to,2304,O
have,2304,O
stronger,2304,O
influence,2304,O
on,2304,O
it,2304,O
.,2304,O
The,2305,O
selective,2305,O
blockade,2305,O
of,2305,O
A2,2305,O
adenosine,2305,B-Chemical
receptor,2305,O
by,2305,O
DMPX,2305,B-Chemical
(,2305,O
"3,7-dimethyl-1-propargylxanthine",2305,B-Chemical
),2305,O
significantly,2305,O
enhanced,2305,O
cocaine-induced,2305,B-Chemical
locomotor,2305,O
activity,2305,O
of,2305,O
animals,2305,O
.,2305,O
Caffeine,2306,B-Chemical
had,2306,O
similar,2306,O
action,2306,O
but,2306,O
the,2306,O
effect,2306,O
was,2306,O
not,2306,O
significant,2306,O
.,2306,O
CPT,2307,B-Chemical
(,2307,O
8-cyclopentyltheophylline,2307,B-Chemical
),2307,O
--,2307,O
A1,2307,O
receptor,2307,O
antagonist,2307,O
",",2307,O
did,2307,O
not,2307,O
show,2307,O
any,2307,O
influence,2307,O
in,2307,O
this,2307,O
test,2307,O
.,2307,O
Similarly,2308,O
",",2308,O
all,2308,O
adenosine,2308,B-Chemical
receptor,2308,O
agonists,2308,O
decreased,2308,O
amphetamine-induced,2308,B-Chemical
hyperactivity,2308,B-Disease
",",2308,O
but,2308,O
at,2308,O
the,2308,O
higher,2308,O
doses,2308,O
than,2308,O
those,2308,O
which,2308,O
were,2308,O
active,2308,O
in,2308,O
cocaine-induced,2308,B-Chemical
hyperactivity,2308,B-Disease
.,2308,O
The,2309,O
selective,2309,O
blockade,2309,O
of,2309,O
A2,2309,O
adenosine,2309,B-Chemical
receptors,2309,O
(,2309,O
DMPX,2309,B-Chemical
),2309,O
and,2309,O
non-selective,2309,O
blockade,2309,O
of,2309,O
adenosine,2309,B-Chemical
receptors,2309,O
(,2309,O
caffeine,2309,B-Chemical
),2309,O
significantly,2309,O
increased,2309,O
the,2309,O
action,2309,O
of,2309,O
amphetamine,2309,B-Chemical
in,2309,O
the,2309,O
locomotor,2309,O
activity,2309,O
test,2309,O
.,2309,O
Our,2310,O
results,2310,O
have,2310,O
shown,2310,O
that,2310,O
all,2310,O
adenosine,2310,B-Chemical
receptor,2310,O
agonists,2310,O
(,2310,O
A1,2310,O
and,2310,O
A2,2310,O
),2310,O
reduce,2310,O
cocaine-,2310,B-Chemical
and,2310,O
amphetamine-induced,2310,B-Chemical
locomotor,2310,O
activity,2310,O
and,2310,O
indicate,2310,O
that,2310,O
cocaine-induced,2310,B-Chemical
hyperactivity,2310,B-Disease
is,2310,O
more,2310,O
influenced,2310,O
by,2310,O
adenosine,2310,B-Chemical
receptor,2310,O
agonists,2310,O
(,2310,O
particularly,2310,O
A1,2310,O
receptors,2310,O
),2310,O
than,2310,O
amphetamine-induced,2310,B-Chemical
hyperactivity,2310,B-Disease
.,2310,O
Amiodarone,2311,B-Chemical
and,2311,O
the,2311,O
risk,2311,O
of,2311,O
bradyarrhythmia,2311,B-Disease
requiring,2311,O
permanent,2311,O
pacemaker,2311,O
in,2311,O
elderly,2311,O
patients,2311,O
with,2311,O
atrial,2311,B-Disease
fibrillation,2311,I-Disease
and,2311,O
prior,2311,O
myocardial,2311,B-Disease
infarction,2311,I-Disease
.,2311,O
OBJECTIVES,2312,O
:,2312,O
The,2312,O
aim,2312,O
of,2312,O
this,2312,O
study,2312,O
was,2312,O
to,2312,O
determine,2312,O
whether,2312,O
the,2312,O
use,2312,O
of,2312,O
amiodarone,2312,B-Chemical
in,2312,O
patients,2312,O
with,2312,O
atrial,2312,B-Disease
fibrillation,2312,I-Disease
(,2312,O
AF,2312,B-Disease
),2312,O
increases,2312,O
the,2312,O
risk,2312,O
of,2312,O
bradyarrhythmia,2312,B-Disease
requiring,2312,O
a,2312,O
permanent,2312,O
pacemaker,2312,O
.,2312,O
BACKGROUND,2313,O
:,2313,O
Reports,2313,O
of,2313,O
severe,2313,O
bradyarrhythmia,2313,B-Disease
during,2313,O
amiodarone,2313,B-Chemical
therapy,2313,O
are,2313,O
infrequent,2313,O
and,2313,O
limited,2313,O
to,2313,O
studies,2313,O
assessing,2313,O
the,2313,O
therapy,2313,O
's,2313,O
use,2313,O
in,2313,O
the,2313,O
management,2313,O
of,2313,O
patients,2313,O
with,2313,O
ventricular,2313,B-Disease
arrhythmias,2313,I-Disease
.,2313,O
METHODS,2314,O
:,2314,O
A,2314,O
study,2314,O
cohort,2314,O
of,2314,O
"8,770",2314,O
patients,2314,O
age,2314,O
>,2314,O
or,2314,O
=65,2314,O
years,2314,O
with,2314,O
a,2314,O
new,2314,O
diagnosis,2314,O
of,2314,O
AF,2314,B-Disease
was,2314,O
identified,2314,O
from,2314,O
a,2314,O
provincewide,2314,O
database,2314,O
of,2314,O
Quebec,2314,O
residents,2314,O
with,2314,O
a,2314,O
myocardial,2314,B-Disease
infarction,2314,I-Disease
(,2314,O
MI,2314,B-Disease
),2314,O
between,2314,O
1991,2314,O
and,2314,O
1999,2314,O
.,2314,O
Using,2315,O
a,2315,O
nested,2315,O
case-control,2315,O
design,2315,O
",",2315,O
477,2315,O
cases,2315,O
of,2315,O
bradyarrhythmia,2315,B-Disease
requiring,2315,O
a,2315,O
permanent,2315,O
pacemaker,2315,O
were,2315,O
matched,2315,O
(,2315,O
1:4,2315,O
),2315,O
to,2315,O
"1,908",2315,O
controls,2315,O
.,2315,O
Multivariable,2316,O
logistic,2316,O
regression,2316,O
was,2316,O
used,2316,O
to,2316,O
estimate,2316,O
the,2316,O
odds,2316,O
ratio,2316,O
(,2316,O
OR,2316,O
),2316,O
of,2316,O
pacemaker,2316,O
insertion,2316,O
associated,2316,O
with,2316,O
amiodarone,2316,B-Chemical
use,2316,O
",",2316,O
controlling,2316,O
for,2316,O
baseline,2316,O
risk,2316,O
factors,2316,O
and,2316,O
exposure,2316,O
to,2316,O
sotalol,2316,B-Chemical
",",2316,O
Class,2316,O
I,2316,O
antiarrhythmic,2316,O
agents,2316,O
",",2316,O
beta-blockers,2316,O
",",2316,O
calcium,2316,B-Chemical
channel,2316,O
blockers,2316,O
",",2316,O
and,2316,O
digoxin,2316,B-Chemical
.,2316,O
RESULTS,2317,O
:,2317,O
amiodarone,2317,B-Chemical
use,2317,O
was,2317,O
associated,2317,O
with,2317,O
an,2317,O
increased,2317,O
risk,2317,O
of,2317,O
pacemaker,2317,O
insertion,2317,O
(,2317,O
OR,2317,O
:,2317,O
2.14,2317,O
",",2317,O
95,2317,O
%,2317,O
confidence,2317,O
interval,2317,O
[,2317,O
CI,2317,O
],2317,O
:,2317,O
1.30,2317,O
to,2317,O
3.54,2317,O
),2317,O
.,2317,O
This,2318,O
effect,2318,O
was,2318,O
modified,2318,O
by,2318,O
gender,2318,O
",",2318,O
with,2318,O
a,2318,O
greater,2318,O
risk,2318,O
in,2318,O
women,2318,O
versus,2318,O
men,2318,O
(,2318,O
OR,2318,O
:,2318,O
3.86,2318,O
",",2318,O
95,2318,O
%,2318,O
CI,2318,O
:,2318,O
1.70,2318,O
to,2318,O
8.75,2318,O
vs.,2318,O
OR,2318,O
:,2318,O
1.52,2318,O
",",2318,O
95,2318,O
%,2318,O
CI,2318,O
:,2318,O
0.80,2318,O
to,2318,O
2.89,2318,O
),2318,O
.,2318,O
Digoxin,2319,B-Chemical
was,2319,O
the,2319,O
only,2319,O
other,2319,O
medication,2319,O
associated,2319,O
with,2319,O
an,2319,O
increased,2319,O
risk,2319,O
of,2319,O
pacemaker,2319,O
insertion,2319,O
(,2319,O
OR,2319,O
:,2319,O
1.78,2319,O
",",2319,O
95,2319,O
%,2319,O
CI,2319,O
:,2319,O
1.37,2319,O
to,2319,O
2.31,2319,O
),2319,O
.,2319,O
CONCLUSIONS,2320,O
:,2320,O
This,2320,O
study,2320,O
suggests,2320,O
that,2320,O
the,2320,O
use,2320,O
of,2320,O
amiodarone,2320,B-Chemical
in,2320,O
elderly,2320,O
patients,2320,O
with,2320,O
AF,2320,B-Disease
and,2320,O
a,2320,O
previous,2320,O
MI,2320,B-Disease
increases,2320,O
the,2320,O
risk,2320,O
of,2320,O
bradyarrhythmia,2320,B-Disease
requiring,2320,O
a,2320,O
permanent,2320,O
pacemaker,2320,O
.,2320,O
The,2321,O
finding,2321,O
of,2321,O
an,2321,O
augmented,2321,O
risk,2321,O
of,2321,O
pacemaker,2321,O
insertion,2321,O
in,2321,O
elderly,2321,O
women,2321,O
receiving,2321,O
amiodarone,2321,B-Chemical
requires,2321,O
further,2321,O
investigation,2321,O
.,2321,O
Indomethacin-induced,2322,B-Chemical
morphologic,2322,O
changes,2322,O
in,2322,O
the,2322,O
rat,2322,O
urinary,2322,O
bladder,2322,O
epithelium,2322,O
.,2322,O
OBJECTIVES,2323,O
:,2323,O
To,2323,O
evaluate,2323,O
the,2323,O
morphologic,2323,O
changes,2323,O
in,2323,O
rat,2323,O
urothelium,2323,O
induced,2323,O
by,2323,O
indomethacin,2323,B-Chemical
.,2323,O
Nonsteroidal,2324,O
anti-inflammatory,2324,O
drug-induced,2324,O
cystitis,2324,B-Disease
is,2324,O
a,2324,O
poorly,2324,O
recognized,2324,O
and,2324,O
under-reported,2324,O
condition,2324,O
.,2324,O
In,2325,O
addition,2325,O
to,2325,O
tiaprofenic,2325,B-Chemical
acid,2325,I-Chemical
",",2325,O
indomethacin,2325,B-Chemical
has,2325,O
been,2325,O
reported,2325,O
to,2325,O
be,2325,O
associated,2325,O
with,2325,O
this,2325,O
condition,2325,O
.,2325,O
METHODS,2326,O
:,2326,O
Three,2326,O
groups,2326,O
were,2326,O
established,2326,O
:,2326,O
a,2326,O
control,2326,O
group,2326,O
(,2326,O
n,2326,O
=,2326,O
10,2326,O
),2326,O
",",2326,O
a,2326,O
high-dose,2326,O
group,2326,O
(,2326,O
n,2326,O
=,2326,O
10,2326,O
),2326,O
",",2326,O
treated,2326,O
with,2326,O
one,2326,O
intraperitoneal,2326,O
injection,2326,O
of,2326,O
indomethacin,2326,B-Chemical
20,2326,O
mg/kg,2326,O
",",2326,O
and,2326,O
a,2326,O
therapeutic,2326,O
dose,2326,O
group,2326,O
(,2326,O
n,2326,O
=,2326,O
10,2326,O
),2326,O
in,2326,O
which,2326,O
oral,2326,O
indomethacin,2326,B-Chemical
was,2326,O
administered,2326,O
3.25,2326,O
mg/kg,2326,O
body,2326,O
weight,2326,O
daily,2326,O
for,2326,O
3,2326,O
weeks,2326,O
.,2326,O
The,2327,O
animals,2327,O
were,2327,O
then,2327,O
killed,2327,O
and,2327,O
the,2327,O
bladders,2327,O
removed,2327,O
for,2327,O
light,2327,O
and,2327,O
electron,2327,O
microscopic,2327,O
studies,2327,O
.,2327,O
RESULTS,2328,O
:,2328,O
The,2328,O
light,2328,O
microscopic,2328,O
findings,2328,O
showed,2328,O
some,2328,O
focal,2328,O
epithelial,2328,O
degeneration,2328,O
that,2328,O
was,2328,O
more,2328,O
prominent,2328,O
in,2328,O
the,2328,O
high-dose,2328,O
group,2328,O
.,2328,O
When,2329,O
compared,2329,O
with,2329,O
the,2329,O
control,2329,O
group,2329,O
",",2329,O
both,2329,O
indomethacin,2329,B-Chemical
groups,2329,O
revealed,2329,O
statistically,2329,O
increased,2329,O
numbers,2329,O
of,2329,O
mast,2329,O
cells,2329,O
in,2329,O
the,2329,O
mucosa,2329,O
(,2329,O
P,2329,O
<,2329,O
0.0001,2329,O
),2329,O
and,2329,O
penetration,2329,O
of,2329,O
lanthanum,2329,B-Chemical
nitrate,2329,I-Chemical
through,2329,O
intercellular,2329,O
areas,2329,O
of,2329,O
the,2329,O
epithelium,2329,O
.,2329,O
Furthermore,2330,O
",",2330,O
the,2330,O
difference,2330,O
in,2330,O
mast,2330,O
cell,2330,O
counts,2330,O
between,2330,O
the,2330,O
high,2330,O
and,2330,O
therapeutic,2330,O
dose,2330,O
groups,2330,O
was,2330,O
also,2330,O
statistically,2330,O
significant,2330,O
(,2330,O
P,2330,O
<,2330,O
0.0001,2330,O
),2330,O
.,2330,O
CONCLUSIONS,2331,O
:,2331,O
Indomethacin,2331,B-Chemical
resulted,2331,O
in,2331,O
histopathologic,2331,O
findings,2331,O
typical,2331,O
of,2331,O
interstitial,2331,B-Disease
cystitis,2331,I-Disease
",",2331,O
such,2331,O
as,2331,O
leaky,2331,O
bladder,2331,O
epithelium,2331,O
and,2331,O
mucosal,2331,O
mastocytosis,2331,B-Disease
.,2331,O
The,2332,O
true,2332,O
incidence,2332,O
of,2332,O
nonsteroidal,2332,O
anti-inflammatory,2332,O
drug-induced,2332,O
cystitis,2332,B-Disease
in,2332,O
humans,2332,O
must,2332,O
be,2332,O
clarified,2332,O
by,2332,O
prospective,2332,O
clinical,2332,O
trials,2332,O
.,2332,O
An,2333,O
open-label,2333,O
phase,2333,O
II,2333,O
study,2333,O
of,2333,O
low-dose,2333,O
thalidomide,2333,B-Chemical
in,2333,O
androgen-independent,2333,B-Chemical
prostate,2333,B-Disease
cancer,2333,I-Disease
.,2333,O
The,2334,O
antiangiogenic,2334,O
effects,2334,O
of,2334,O
thalidomide,2334,B-Chemical
have,2334,O
been,2334,O
assessed,2334,O
in,2334,O
clinical,2334,O
trials,2334,O
in,2334,O
patients,2334,O
with,2334,O
various,2334,O
solid,2334,O
and,2334,O
haematological,2334,B-Disease
malignancies,2334,I-Disease
.,2334,O
Thalidomide,2335,B-Chemical
blocks,2335,O
the,2335,O
activity,2335,O
of,2335,O
angiogenic,2335,O
agents,2335,O
including,2335,O
bFGF,2335,O
",",2335,O
VEGF,2335,O
and,2335,O
IL-6,2335,O
.,2335,O
We,2336,O
undertook,2336,O
an,2336,O
open-label,2336,O
study,2336,O
using,2336,O
thalidomide,2336,B-Chemical
100,2336,O
mg,2336,O
once,2336,O
daily,2336,O
for,2336,O
up,2336,O
to,2336,O
6,2336,O
months,2336,O
in,2336,O
20,2336,O
men,2336,O
with,2336,O
androgen-independent,2336,B-Chemical
prostate,2336,B-Disease
cancer,2336,I-Disease
.,2336,O
The,2337,O
mean,2337,O
time,2337,O
of,2337,O
study,2337,O
was,2337,O
109,2337,O
days,2337,O
(,2337,O
median,2337,O
107,2337,O
",",2337,O
range,2337,O
4-184,2337,O
days,2337,O
),2337,O
.,2337,O
Patients,2338,O
underwent,2338,O
regular,2338,O
measurement,2338,O
of,2338,O
prostate-specific,2338,O
antigen,2338,O
(,2338,O
PSA,2338,O
),2338,O
",",2338,O
urea,2338,B-Chemical
and,2338,O
electrolytes,2338,O
",",2338,O
serum,2338,O
bFGF,2338,O
and,2338,O
VEGF,2338,O
.,2338,O
Three,2339,O
men,2339,O
(,2339,O
15,2339,O
%,2339,O
),2339,O
showed,2339,O
a,2339,O
decline,2339,O
in,2339,O
serum,2339,O
PSA,2339,O
of,2339,O
at,2339,O
least,2339,O
50,2339,O
%,2339,O
",",2339,O
sustained,2339,O
throughout,2339,O
treatment,2339,O
.,2339,O
Of,2340,O
16,2340,O
men,2340,O
treated,2340,O
for,2340,O
at,2340,O
least,2340,O
2,2340,O
months,2340,O
",",2340,O
six,2340,O
(,2340,O
37.5,2340,O
%,2340,O
),2340,O
showed,2340,O
a,2340,O
fall,2340,O
in,2340,O
absolute,2340,O
PSA,2340,O
by,2340,O
a,2340,O
median,2340,O
of,2340,O
48,2340,O
%,2340,O
.,2340,O
Increasing,2341,O
levels,2341,O
of,2341,O
serum,2341,O
bFGF,2341,O
and,2341,O
VEGF,2341,O
were,2341,O
associated,2341,O
with,2341,O
progressive,2341,O
disease,2341,O
;,2341,O
five,2341,O
of,2341,O
six,2341,O
men,2341,O
who,2341,O
demonstrated,2341,O
a,2341,O
fall,2341,O
in,2341,O
PSA,2341,O
also,2341,O
showed,2341,O
a,2341,O
decline,2341,O
in,2341,O
bFGF,2341,O
and,2341,O
VEGF,2341,O
levels,2341,O
",",2341,O
and,2341,O
three,2341,O
of,2341,O
four,2341,O
men,2341,O
with,2341,O
a,2341,O
rising,2341,O
PSA,2341,O
showed,2341,O
an,2341,O
increase,2341,O
in,2341,O
both,2341,O
growth,2341,O
factors,2341,O
.,2341,O
Adverse,2342,O
effects,2342,O
included,2342,O
constipation,2342,B-Disease
",",2342,O
morning,2342,O
drowsiness,2342,B-Disease
",",2342,O
dizziness,2342,B-Disease
and,2342,O
rash,2342,B-Disease
",",2342,O
and,2342,O
resulted,2342,O
in,2342,O
withdrawal,2342,O
from,2342,O
the,2342,O
study,2342,O
by,2342,O
three,2342,O
men,2342,O
.,2342,O
Evidence,2343,O
of,2343,O
peripheral,2343,B-Disease
sensory,2343,I-Disease
neuropathy,2343,I-Disease
was,2343,O
found,2343,O
in,2343,O
nine,2343,O
of,2343,O
13,2343,O
men,2343,O
before,2343,O
treatment,2343,O
.,2343,O
In,2344,O
the,2344,O
seven,2344,O
men,2344,O
who,2344,O
completed,2344,O
six,2344,O
months,2344,O
on,2344,O
thalidomide,2344,B-Chemical
",",2344,O
subclinical,2344,O
evidence,2344,O
of,2344,O
peripheral,2344,B-Disease
neuropathy,2344,I-Disease
was,2344,O
found,2344,O
in,2344,O
four,2344,O
before,2344,O
treatment,2344,O
",",2344,O
but,2344,O
in,2344,O
all,2344,O
seven,2344,O
at,2344,O
repeat,2344,O
testing,2344,O
.,2344,O
The,2345,O
findings,2345,O
indicate,2345,O
that,2345,O
thalidomide,2345,B-Chemical
may,2345,O
be,2345,O
an,2345,O
option,2345,O
for,2345,O
patients,2345,O
who,2345,O
have,2345,O
failed,2345,O
other,2345,O
forms,2345,O
of,2345,O
therapy,2345,O
",",2345,O
provided,2345,O
close,2345,O
follow-up,2345,O
is,2345,O
maintained,2345,O
for,2345,O
development,2345,O
of,2345,O
peripheral,2345,B-Disease
neuropathy,2345,I-Disease
.,2345,O
Central,2346,B-Disease
nervous,2346,I-Disease
system,2346,I-Disease
toxicity,2346,I-Disease
following,2346,O
the,2346,O
administration,2346,O
of,2346,O
levobupivacaine,2346,B-Chemical
for,2346,O
lumbar,2346,O
plexus,2346,O
block,2346,O
:,2346,O
A,2346,O
report,2346,O
of,2346,O
two,2346,O
cases,2346,O
.,2346,O
BACKGROUND,2347,O
AND,2347,O
OBJECTIVES,2347,O
:,2347,O
Central,2347,O
nervous,2347,O
system,2347,O
and,2347,O
cardiac,2347,O
toxicity,2347,O
following,2347,O
the,2347,O
administration,2347,O
of,2347,O
local,2347,O
anesthetics,2347,O
is,2347,O
a,2347,O
recognized,2347,O
complication,2347,O
of,2347,O
regional,2347,O
anesthesia,2347,O
.,2347,O
Levobupivacaine,2348,B-Chemical
",",2348,O
the,2348,O
pure,2348,O
S,2348,O
(,2348,O
-,2348,O
),2348,O
enantiomer,2348,O
of,2348,O
bupivacaine,2348,B-Chemical
",",2348,O
was,2348,O
developed,2348,O
to,2348,O
improve,2348,O
the,2348,O
cardiac,2348,O
safety,2348,O
profile,2348,O
of,2348,O
bupivacaine,2348,B-Chemical
.,2348,O
We,2349,O
describe,2349,O
2,2349,O
cases,2349,O
of,2349,O
grand,2349,B-Disease
mal,2349,I-Disease
seizures,2349,I-Disease
following,2349,O
accidental,2349,O
intravascular,2349,O
injection,2349,O
of,2349,O
levobupivacaine,2349,B-Chemical
.,2349,O
CASE,2350,O
REPORT,2350,O
:,2350,O
Two,2350,O
patients,2350,O
presenting,2350,O
for,2350,O
elective,2350,O
orthopedic,2350,O
surgery,2350,O
of,2350,O
the,2350,O
lower,2350,O
limb,2350,O
underwent,2350,O
blockade,2350,O
of,2350,O
the,2350,O
lumbar,2350,O
plexus,2350,O
via,2350,O
the,2350,O
posterior,2350,O
approach,2350,O
.,2350,O
Immediately,2351,O
after,2351,O
the,2351,O
administration,2351,O
of,2351,O
levobupivacaine,2351,B-Chemical
0.5,2351,O
%,2351,O
with,2351,O
epinephrine,2351,B-Chemical
2.5,2351,O
microgram/mL,2351,O
",",2351,O
the,2351,O
patients,2351,O
developed,2351,O
grand,2351,B-Disease
mal,2351,I-Disease
seizures,2351,I-Disease
",",2351,O
despite,2351,O
negative,2351,O
aspiration,2351,O
for,2351,O
blood,2351,O
and,2351,O
no,2351,O
clinical,2351,O
signs,2351,O
of,2351,O
intravenous,2351,O
epinephrine,2351,B-Chemical
administration,2351,O
.,2351,O
The,2352,O
seizures,2352,B-Disease
were,2352,O
successfully,2352,O
treated,2352,O
with,2352,O
sodium,2352,B-Chemical
thiopental,2352,I-Chemical
in,2352,O
addition,2352,O
to,2352,O
succinylcholine,2352,B-Chemical
in,2352,O
1,2352,O
patient,2352,O
.,2352,O
Neither,2353,O
patient,2353,O
developed,2353,O
signs,2353,O
of,2353,O
cardiovascular,2353,B-Disease
toxicity,2353,I-Disease
.,2353,O
Both,2354,O
patients,2354,O
were,2354,O
treated,2354,O
preoperatively,2354,O
with,2354,O
beta-adrenergic,2354,O
antagonist,2354,O
medications,2354,O
",",2354,O
which,2354,O
may,2354,O
have,2354,O
masked,2354,O
the,2354,O
cardiovascular,2354,O
signs,2354,O
of,2354,O
the,2354,O
unintentional,2354,O
intravascular,2354,O
administration,2354,O
of,2354,O
levobupivacaine,2354,B-Chemical
with,2354,O
epinephrine,2354,B-Chemical
.,2354,O
CONCLUSIONS,2355,O
:,2355,O
Although,2355,O
levobupivacaine,2355,B-Chemical
may,2355,O
have,2355,O
a,2355,O
safer,2355,O
cardiac,2355,B-Disease
toxicity,2355,I-Disease
profile,2355,O
than,2355,O
racemic,2355,O
bupivacaine,2355,B-Chemical
",",2355,O
if,2355,O
adequate,2355,O
amounts,2355,O
of,2355,O
levobupivacaine,2355,B-Chemical
reach,2355,O
the,2355,O
circulation,2355,O
",",2355,O
it,2355,O
will,2355,O
result,2355,O
in,2355,O
convulsions,2355,B-Disease
.,2355,O
Plasma,2356,O
concentrations,2356,O
sufficient,2356,O
to,2356,O
result,2356,O
in,2356,O
central,2356,B-Disease
nervous,2356,I-Disease
system,2356,I-Disease
toxicity,2356,I-Disease
did,2356,O
not,2356,O
produce,2356,O
manifestations,2356,O
of,2356,O
cardiac,2356,B-Disease
toxicity,2356,I-Disease
in,2356,O
these,2356,O
2,2356,O
patients,2356,O
.,2356,O
Amiodarone-induced,2357,B-Chemical
torsade,2357,B-Disease
de,2357,I-Disease
pointes,2357,I-Disease
during,2357,O
bladder,2357,O
irrigation,2357,O
:,2357,O
an,2357,O
unusual,2357,O
presentation,2357,O
--,2357,O
a,2357,O
case,2357,O
report,2357,O
.,2357,O
The,2358,O
authors,2358,O
present,2358,O
a,2358,O
case,2358,O
of,2358,O
early,2358,O
(,2358,O
within,2358,O
4,2358,O
days,2358,O
),2358,O
development,2358,O
of,2358,O
torsade,2358,B-Disease
de,2358,I-Disease
pointes,2358,I-Disease
(,2358,O
TdP,2358,B-Disease
),2358,O
associated,2358,O
with,2358,O
oral,2358,O
amiodarone,2358,B-Chemical
therapy,2358,O
.,2358,O
Consistent,2359,O
with,2359,O
other,2359,O
reports,2359,O
this,2359,O
case,2359,O
of,2359,O
TdP,2359,B-Disease
occurred,2359,O
in,2359,O
the,2359,O
context,2359,O
of,2359,O
multiple,2359,O
exacerbating,2359,O
factors,2359,O
including,2359,O
hypokalemia,2359,B-Disease
and,2359,O
digoxin,2359,B-Chemical
excess,2359,O
.,2359,O
Transient,2360,O
prolongation,2360,O
of,2360,O
the,2360,O
QT,2360,O
during,2360,O
bladder,2360,O
irrigation,2360,O
prompted,2360,O
the,2360,O
episode,2360,O
of,2360,O
TdP,2360,B-Disease
.,2360,O
It,2361,O
is,2361,O
well,2361,O
known,2361,O
that,2361,O
bradycardia,2361,B-Disease
exacerbates,2361,O
acquired,2361,O
TdP,2361,B-Disease
.,2361,O
The,2362,O
authors,2362,O
speculate,2362,O
that,2362,O
the,2362,O
increased,2362,O
vagal,2362,O
tone,2362,O
during,2362,O
bladder,2362,O
irrigation,2362,O
",",2362,O
a,2362,O
vagal,2362,O
maneuver,2362,O
",",2362,O
in,2362,O
the,2362,O
context,2362,O
of,2362,O
amiodarone,2362,B-Chemical
therapy,2362,O
resulted,2362,O
in,2362,O
amiodarone-induced,2362,B-Chemical
proarrhythmia,2362,B-Disease
.,2362,O
In,2363,O
the,2363,O
absence,2363,O
of,2363,O
amiodarone,2363,B-Chemical
therapy,2363,O
",",2363,O
a,2363,O
second,2363,O
bladder,2363,O
irrigation,2363,O
did,2363,O
not,2363,O
induce,2363,O
TdP,2363,B-Disease
despite,2363,O
hypokalemia,2363,B-Disease
and,2363,O
hypomagnesemia,2363,B-Disease
.,2363,O
Anaesthetic,2364,O
complications,2364,O
associated,2364,O
with,2364,O
myotonia,2364,B-Disease
congenita,2364,I-Disease
:,2364,O
case,2364,O
study,2364,O
and,2364,O
comparison,2364,O
with,2364,O
other,2364,O
myotonic,2364,B-Disease
disorders,2364,I-Disease
.,2364,O
Myotonia,2365,B-Disease
congenita,2365,I-Disease
(,2365,O
MC,2365,B-Disease
),2365,O
is,2365,O
caused,2365,O
by,2365,O
a,2365,O
defect,2365,O
in,2365,O
the,2365,O
skeletal,2365,O
muscle,2365,O
chloride,2365,B-Chemical
channel,2365,O
function,2365,O
",",2365,O
which,2365,O
may,2365,O
cause,2365,O
sustained,2365,B-Disease
membrane,2365,I-Disease
depolarisation,2365,I-Disease
.,2365,O
We,2366,O
describe,2366,O
a,2366,O
previously,2366,O
healthy,2366,O
32-year-old,2366,O
woman,2366,O
who,2366,O
developed,2366,O
a,2366,O
life-threatening,2366,O
muscle,2366,B-Disease
spasm,2366,I-Disease
and,2366,O
secondary,2366,O
ventilation,2366,O
difficulties,2366,O
following,2366,O
a,2366,O
preoperative,2366,O
injection,2366,O
of,2366,O
suxamethonium,2366,B-Chemical
.,2366,O
The,2367,O
muscle,2367,B-Disease
spasms,2367,I-Disease
disappeared,2367,O
spontaneously,2367,O
and,2367,O
the,2367,O
surgery,2367,O
proceeded,2367,O
without,2367,O
further,2367,O
problems,2367,O
.,2367,O
When,2368,O
subsequently,2368,O
questioned,2368,O
",",2368,O
she,2368,O
reported,2368,O
minor,2368,O
symptoms,2368,O
suggesting,2368,O
a,2368,O
myotonic,2368,B-Disease
condition,2368,I-Disease
.,2368,O
Myotonia,2369,B-Disease
was,2369,O
found,2369,O
on,2369,O
clinical,2369,O
examination,2369,O
and,2369,O
EMG,2369,O
.,2369,O
The,2370,O
diagnosis,2370,O
MC,2370,B-Disease
was,2370,O
confirmed,2370,O
genetically,2370,O
.,2370,O
Neither,2371,O
the,2371,O
patient,2371,O
nor,2371,O
the,2371,O
anaesthetist,2371,O
were,2371,O
aware,2371,O
of,2371,O
the,2371,O
diagnosis,2371,O
before,2371,O
this,2371,O
potentially,2371,O
lethal,2371,O
complication,2371,O
occurred,2371,O
.,2371,O
We,2372,O
give,2372,O
a,2372,O
brief,2372,O
overview,2372,O
of,2372,O
ion,2372,B-Disease
channel,2372,I-Disease
disorders,2372,I-Disease
including,2372,O
malignant,2372,B-Disease
hyperthermia,2372,I-Disease
and,2372,O
their,2372,O
anaesthetic,2372,O
considerations,2372,O
.,2372,O
Respiratory,2373,O
pattern,2373,O
in,2373,O
a,2373,O
rat,2373,O
model,2373,O
of,2373,O
epilepsy,2373,B-Disease
.,2373,O
PURPOSE,2374,O
:,2374,O
Apnea,2374,B-Disease
is,2374,O
known,2374,O
to,2374,O
occur,2374,O
during,2374,O
seizures,2374,B-Disease
",",2374,O
but,2374,O
systematic,2374,O
studies,2374,O
of,2374,O
ictal,2374,O
respiratory,2374,O
changes,2374,O
in,2374,O
adults,2374,O
are,2374,O
few,2374,O
.,2374,O
Data,2375,O
regarding,2375,O
respiratory,2375,O
pattern,2375,O
defects,2375,O
during,2375,O
interictal,2375,O
periods,2375,O
also,2375,O
are,2375,O
scarce,2375,O
.,2375,O
Here,2376,O
we,2376,O
sought,2376,O
to,2376,O
generate,2376,O
information,2376,O
with,2376,O
regard,2376,O
to,2376,O
the,2376,O
interictal,2376,O
period,2376,O
in,2376,O
animals,2376,O
with,2376,O
pilocarpine-induced,2376,B-Chemical
epilepsy,2376,B-Disease
.,2376,O
METHODS,2377,O
:,2377,O
Twelve,2377,O
rats,2377,O
(,2377,O
six,2377,O
chronically,2377,O
epileptic,2377,B-Disease
animals,2377,O
and,2377,O
six,2377,O
controls,2377,O
),2377,O
were,2377,O
anesthetized,2377,O
",",2377,O
given,2377,O
tracheotomies,2377,O
",",2377,O
and,2377,O
subjected,2377,O
to,2377,O
hyperventilation,2377,B-Disease
or,2377,O
hypoventilation,2377,O
conditions,2377,O
.,2377,O
Breathing,2378,O
movements,2378,O
caused,2378,O
changes,2378,O
in,2378,O
thoracic,2378,O
volume,2378,O
and,2378,O
forced,2378,O
air,2378,O
to,2378,O
flow,2378,O
tidally,2378,O
through,2378,O
a,2378,O
pneumotachograph,2378,O
.,2378,O
This,2379,O
flow,2379,O
was,2379,O
measured,2379,O
by,2379,O
using,2379,O
a,2379,O
differential,2379,O
pressure,2379,O
transducer,2379,O
",",2379,O
passed,2379,O
through,2379,O
a,2379,O
polygraph,2379,O
",",2379,O
and,2379,O
from,2379,O
this,2379,O
to,2379,O
a,2379,O
computer,2379,O
with,2379,O
custom,2379,O
software,2379,O
that,2379,O
derived,2379,O
ventilation,2379,O
(,2379,O
VE,2379,O
),2379,O
",",2379,O
tidal,2379,O
volume,2379,O
(,2379,O
VT,2379,O
),2379,O
",",2379,O
inspiratory,2379,O
time,2379,O
(,2379,O
TI,2379,O
),2379,O
",",2379,O
expiratory,2379,O
time,2379,O
(,2379,O
TE,2379,O
),2379,O
",",2379,O
breathing,2379,O
frequency,2379,O
(,2379,O
f,2379,O
),2379,O
",",2379,O
and,2379,O
mean,2379,O
inspiratory,2379,O
flow,2379,O
(,2379,O
VT/TI,2379,O
),2379,O
on,2379,O
a,2379,O
breath-by-breath,2379,O
basis,2379,O
.,2379,O
RESULTS,2380,O
:,2380,O
The,2380,O
hyperventilation,2380,B-Disease
maneuver,2380,O
caused,2380,O
a,2380,O
decrease,2380,O
in,2380,O
spontaneous,2380,O
ventilation,2380,O
in,2380,O
pilocarpine-treated,2380,B-Chemical
and,2380,O
control,2380,O
rats,2380,O
.,2380,O
Although,2381,O
VE,2381,O
had,2381,O
a,2381,O
similar,2381,O
decrease,2381,O
in,2381,O
both,2381,O
groups,2381,O
",",2381,O
in,2381,O
the,2381,O
epileptic,2381,B-Disease
group,2381,O
",",2381,O
the,2381,O
decrease,2381,O
in,2381,O
VE,2381,O
was,2381,O
due,2381,O
to,2381,O
a,2381,O
significant,2381,O
(,2381,O
p,2381,O
<,2381,O
0.05,2381,O
),2381,O
increase,2381,O
in,2381,O
TE,2381,O
peak,2381,O
in,2381,O
relation,2381,O
to,2381,O
that,2381,O
of,2381,O
the,2381,O
control,2381,O
animals,2381,O
.,2381,O
The,2382,O
hypoventilation,2382,O
maneuver,2382,O
led,2382,O
to,2382,O
an,2382,O
increase,2382,O
in,2382,O
the,2382,O
arterial,2382,O
Paco2,2382,O
",",2382,O
followed,2382,O
by,2382,O
an,2382,O
increase,2382,O
in,2382,O
VE,2382,O
.,2382,O
In,2383,O
the,2383,O
epileptic,2383,B-Disease
group,2383,O
",",2383,O
the,2383,O
increase,2383,O
in,2383,O
VE,2383,O
was,2383,O
mediated,2383,O
by,2383,O
a,2383,O
significant,2383,O
(,2383,O
p,2383,O
<,2383,O
0.05,2383,O
),2383,O
decrease,2383,O
in,2383,O
TE,2383,O
peak,2383,O
compared,2383,O
with,2383,O
the,2383,O
control,2383,O
group,2383,O
.,2383,O
Systemic,2384,O
application,2384,O
of,2384,O
KCN,2384,O
",",2384,O
to,2384,O
evaluate,2384,O
the,2384,O
effects,2384,O
of,2384,O
peripheral,2384,O
chemoreception,2384,O
activation,2384,O
on,2384,O
ventilation,2384,O
",",2384,O
led,2384,O
to,2384,O
a,2384,O
similar,2384,O
increase,2384,O
in,2384,O
VE,2384,O
for,2384,O
both,2384,O
groups,2384,O
.,2384,O
CONCLUSIONS,2385,O
:,2385,O
The,2385,O
data,2385,O
indicate,2385,O
that,2385,O
pilocarpine-treated,2385,B-Chemical
animals,2385,O
have,2385,O
an,2385,O
altered,2385,O
ability,2385,O
to,2385,O
react,2385,O
to,2385,O
(,2385,O
or,2385,O
compensate,2385,O
for,2385,O
),2385,O
blood,2385,O
gas,2385,O
changes,2385,O
with,2385,O
changes,2385,O
in,2385,O
ventilation,2385,O
and,2385,O
suggest,2385,O
that,2385,O
it,2385,O
is,2385,O
centrally,2385,O
determined,2385,O
.,2385,O
We,2386,O
speculate,2386,O
on,2386,O
the,2386,O
possible,2386,O
relation,2386,O
of,2386,O
the,2386,O
current,2386,O
findings,2386,O
on,2386,O
treating,2386,O
different,2386,O
epilepsy-associated,2386,B-Disease
conditions,2386,O
.,2386,O
Increased,2387,O
serum,2387,O
soluble,2387,O
Fas,2387,O
in,2387,O
patients,2387,O
with,2387,O
acute,2387,B-Disease
liver,2387,I-Disease
failure,2387,I-Disease
due,2387,O
to,2387,O
paracetamol,2387,B-Chemical
overdose,2387,B-Disease
.,2387,O
BACKGROUND/AIMS,2388,O
:,2388,O
Experimental,2388,O
studies,2388,O
have,2388,O
suggested,2388,O
that,2388,O
apoptosis,2388,O
via,2388,O
the,2388,O
Fas/Fas,2388,O
Ligand,2388,O
signaling,2388,O
system,2388,O
may,2388,O
play,2388,O
an,2388,O
important,2388,O
role,2388,O
in,2388,O
the,2388,O
development,2388,O
of,2388,O
acute,2388,B-Disease
liver,2388,I-Disease
failure,2388,I-Disease
.,2388,O
The,2389,O
aim,2389,O
of,2389,O
the,2389,O
study,2389,O
was,2389,O
to,2389,O
investigate,2389,O
the,2389,O
soluble,2389,O
form,2389,O
of,2389,O
Fas,2389,O
in,2389,O
patients,2389,O
with,2389,O
acute,2389,B-Disease
liver,2389,I-Disease
failure,2389,I-Disease
.,2389,O
METHODOLOGY,2390,O
:,2390,O
Serum,2390,O
levels,2390,O
of,2390,O
sFas,2390,O
(,2390,O
soluble,2390,O
Fas,2390,O
),2390,O
were,2390,O
measured,2390,O
by,2390,O
ELISA,2390,O
in,2390,O
24,2390,O
patients,2390,O
with,2390,O
acute,2390,B-Disease
liver,2390,I-Disease
failure,2390,I-Disease
and,2390,O
10,2390,O
normal,2390,O
control,2390,O
subjects,2390,O
.,2390,O
Serum,2391,O
levels,2391,O
of,2391,O
tumor,2391,B-Disease
necrosis,2391,B-Disease
factor-alpha,2391,O
and,2391,O
interferon-gamma,2391,O
were,2391,O
also,2391,O
determined,2391,O
by,2391,O
ELISA,2391,O
.,2391,O
RESULTS,2392,O
:,2392,O
Serum,2392,O
sFas,2392,O
was,2392,O
significantly,2392,O
increased,2392,O
in,2392,O
patients,2392,O
with,2392,O
acute,2392,B-Disease
liver,2392,I-Disease
failure,2392,I-Disease
(,2392,O
median,2392,O
",",2392,O
26.8,2392,O
U/mL,2392,O
;,2392,O
range,2392,O
",",2392,O
6.9-52.7,2392,O
U/mL,2392,O
),2392,O
compared,2392,O
to,2392,O
the,2392,O
normal,2392,O
controls,2392,O
(,2392,O
median,2392,O
",",2392,O
8.6,2392,O
U/mL,2392,O
;,2392,O
range,2392,O
",",2392,O
6.5-12.0,2392,O
U/mL,2392,O
",",2392,O
P,2392,O
<,2392,O
0.0001,2392,O
),2392,O
.,2392,O
Levels,2393,O
were,2393,O
significantly,2393,O
greater,2393,O
in,2393,O
patients,2393,O
with,2393,O
acute,2393,B-Disease
liver,2393,I-Disease
failure,2393,I-Disease
due,2393,O
to,2393,O
paracetamol,2393,B-Chemical
overdose,2393,B-Disease
(,2393,O
median,2393,O
",",2393,O
28.7,2393,O
U/mL,2393,O
;,2393,O
range,2393,O
",",2393,O
12.8-52.7,2393,O
U/mL,2393,O
",",2393,O
n,2393,O
=,2393,O
17,2393,O
),2393,O
than,2393,O
those,2393,O
due,2393,O
to,2393,O
non-A,2393,O
to,2393,O
E,2393,O
hepatitis,2393,B-Disease
(,2393,O
median,2393,O
",",2393,O
12.5,2393,O
U/mL,2393,O
;,2393,O
range,2393,O
",",2393,O
6.9-46.0,2393,O
U/mL,2393,O
",",2393,O
n,2393,O
=,2393,O
7,2393,O
",",2393,O
P,2393,O
<,2393,O
0.01,2393,O
),2393,O
.,2393,O
There,2394,O
was,2394,O
no,2394,O
relationship,2394,O
of,2394,O
sFas,2394,O
to,2394,O
eventual,2394,O
outcome,2394,O
in,2394,O
the,2394,O
patients,2394,O
.,2394,O
A,2395,O
significant,2395,O
correlation,2395,O
was,2395,O
observed,2395,O
between,2395,O
serum,2395,O
sFas,2395,O
levels,2395,O
and,2395,O
aspartate,2395,B-Chemical
aminotransferase,2395,O
(,2395,O
r,2395,O
=,2395,O
0.613,2395,O
",",2395,O
P,2395,O
<,2395,O
0.01,2395,O
),2395,O
.,2395,O
CONCLUSIONS,2396,O
:,2396,O
The,2396,O
increased,2396,O
concentration,2396,O
of,2396,O
sFas,2396,O
in,2396,O
serum,2396,O
of,2396,O
patients,2396,O
with,2396,O
acute,2396,B-Disease
liver,2396,I-Disease
failure,2396,I-Disease
may,2396,O
reflect,2396,O
activation,2396,O
of,2396,O
Fas-mediated,2396,O
apoptosis,2396,O
in,2396,O
the,2396,O
liver,2396,O
and,2396,O
this,2396,O
together,2396,O
with,2396,O
increased,2396,O
tumor,2396,B-Disease
necrosis,2396,B-Disease
factor-alpha,2396,O
may,2396,O
be,2396,O
an,2396,O
important,2396,O
factor,2396,O
in,2396,O
liver,2396,O
cell,2396,O
loss,2396,O
.,2396,O
Bilateral,2397,O
subthalamic,2397,O
nucleus,2397,O
stimulation,2397,O
for,2397,O
Parkinson,2397,B-Disease
's,2397,I-Disease
disease,2397,I-Disease
.,2397,O
High,2398,O
frequency,2398,O
stimulation,2398,O
of,2398,O
the,2398,O
subthalamic,2398,O
nucleus,2398,O
(,2398,O
STN,2398,O
),2398,O
is,2398,O
known,2398,O
to,2398,O
ameliorate,2398,O
the,2398,O
signs,2398,O
and,2398,O
symptoms,2398,O
of,2398,O
advanced,2398,O
Parkinson,2398,B-Disease
's,2398,I-Disease
disease,2398,I-Disease
.,2398,O
AIM,2399,O
:,2399,O
We,2399,O
studied,2399,O
the,2399,O
effect,2399,O
of,2399,O
high,2399,O
frequency,2399,O
STN,2399,O
stimulation,2399,O
in,2399,O
23,2399,O
patients,2399,O
.,2399,O
METHOD,2400,O
:,2400,O
Twenty-three,2400,O
patients,2400,O
suffering,2400,O
from,2400,O
severe,2400,O
Parkinson,2400,B-Disease
's,2400,I-Disease
disease,2400,I-Disease
(,2400,O
Stages,2400,O
III-V,2400,O
on,2400,O
Hoehn,2400,O
and,2400,O
Yahr,2400,O
scale,2400,O
),2400,O
and,2400,O
",",2400,O
particularly,2400,O
bradykinesia,2400,B-Disease
",",2400,O
rigidity,2400,B-Disease
",",2400,O
and,2400,O
levodopa-induced,2400,B-Chemical
dyskinesias,2400,B-Disease
underwent,2400,O
bilateral,2400,O
implantation,2400,O
of,2400,O
electrodes,2400,O
in,2400,O
the,2400,O
STN,2400,O
.,2400,O
Preoperative,2401,O
and,2401,O
postoperative,2401,O
assessments,2401,O
of,2401,O
these,2401,O
patients,2401,O
at,2401,O
1,2401,O
",",2401,O
3,2401,O
",",2401,O
6,2401,O
and,2401,O
12,2401,O
months,2401,O
follow-up,2401,O
",",2401,O
in,2401,O
``,2401,O
on,2401,O
'',2401,O
and,2401,O
``,2401,O
off,2401,O
'',2401,O
drug,2401,O
conditions,2401,O
",",2401,O
was,2401,O
carried,2401,O
out,2401,O
using,2401,O
Unified,2401,O
Parkinson,2401,B-Disease
's,2401,I-Disease
Disease,2401,I-Disease
Rating,2401,O
Scale,2401,O
",",2401,O
Hoehn,2401,O
and,2401,O
Yahr,2401,O
staging,2401,O
",",2401,O
England,2401,O
activities,2401,O
of,2401,O
daily,2401,O
living,2401,O
score,2401,O
and,2401,O
video,2401,O
recordings,2401,O
.,2401,O
RESULTS,2402,O
:,2402,O
After,2402,O
one,2402,O
year,2402,O
of,2402,O
electrical,2402,O
stimulation,2402,O
of,2402,O
the,2402,O
STN,2402,O
",",2402,O
the,2402,O
patients,2402,O
',2402,O
scores,2402,O
for,2402,O
activities,2402,O
of,2402,O
daily,2402,O
living,2402,O
and,2402,O
motor,2402,O
examination,2402,O
scores,2402,O
(,2402,O
Unified,2402,O
Parkinson,2402,B-Disease
's,2402,I-Disease
Disease,2402,I-Disease
Rating,2402,O
Scale,2402,O
parts,2402,O
II,2402,O
and,2402,O
III,2402,O
),2402,O
off,2402,O
medication,2402,O
improved,2402,O
by,2402,O
62,2402,O
%,2402,O
and,2402,O
61,2402,O
%,2402,O
respectively,2402,O
(,2402,O
p,2402,O
<,2402,O
0.0005,2402,O
),2402,O
.,2402,O
The,2403,O
subscores,2403,O
for,2403,O
the,2403,O
akinesia,2403,B-Disease
",",2403,O
rigidity,2403,B-Disease
",",2403,O
tremor,2403,B-Disease
and,2403,O
gait,2403,O
also,2403,O
improved,2403,O
.,2403,O
(,2404,O
p,2404,O
<,2404,O
0.0005,2404,O
),2404,O
.,2404,O
The,2405,O
average,2405,O
levodopa,2405,B-Chemical
dose,2405,O
decreased,2405,O
from,2405,O
813,2405,O
mg,2405,O
to,2405,O
359,2405,O
mg,2405,O
.,2405,O
The,2406,O
cognitive,2406,O
functions,2406,O
remained,2406,O
unchanged,2406,O
.,2406,O
Two,2407,O
patients,2407,O
developed,2407,O
device-related,2407,O
complications,2407,O
and,2407,O
two,2407,O
patients,2407,O
experienced,2407,O
abnormal,2407,O
weight,2407,O
gain,2407,O
.,2407,O
CONCLUSION,2408,O
:,2408,O
Bilateral,2408,O
subthalamic,2408,O
nucleus,2408,O
stimulation,2408,O
is,2408,O
an,2408,O
effective,2408,O
treatment,2408,O
for,2408,O
advanced,2408,O
Parkinson,2408,B-Disease
's,2408,I-Disease
disease,2408,I-Disease
.,2408,O
It,2409,O
reduces,2409,O
the,2409,O
severity,2409,O
of,2409,O
``,2409,O
off,2409,O
'',2409,O
phase,2409,O
symptoms,2409,O
",",2409,O
improves,2409,O
the,2409,O
axial,2409,O
symptoms,2409,O
and,2409,O
reduces,2409,O
levodopa,2409,B-Chemical
requirements,2409,O
.,2409,O
The,2410,O
reduction,2410,O
in,2410,O
the,2410,O
levodopa,2410,B-Chemical
dose,2410,O
is,2410,O
useful,2410,O
in,2410,O
controlling,2410,O
drug-induced,2410,B-Disease
dyskinesias,2410,I-Disease
.,2410,O
Ocular,2411,O
motility,2411,O
changes,2411,O
after,2411,O
subtenon,2411,O
carboplatin,2411,B-Chemical
chemotherapy,2411,O
for,2411,O
retinoblastoma,2411,B-Disease
.,2411,O
BACKGROUND,2412,O
:,2412,O
Focal,2412,O
subtenon,2412,O
carboplatin,2412,B-Chemical
injections,2412,O
have,2412,O
recently,2412,O
been,2412,O
used,2412,O
as,2412,O
a,2412,O
presumably,2412,O
toxicity-free,2412,B-Disease
adjunct,2412,O
to,2412,O
systemic,2412,O
chemotherapy,2412,O
for,2412,O
intraocular,2412,O
retinoblastoma,2412,B-Disease
.,2412,O
OBJECTIVE,2413,O
:,2413,O
To,2413,O
report,2413,O
our,2413,O
clinical,2413,O
experience,2413,O
with,2413,O
abnormal,2413,B-Disease
ocular,2413,I-Disease
motility,2413,I-Disease
in,2413,O
patients,2413,O
treated,2413,O
with,2413,O
subtenon,2413,O
carboplatin,2413,B-Chemical
chemotherapy,2413,O
.,2413,O
METHODS,2414,O
:,2414,O
We,2414,O
noted,2414,O
abnormal,2414,B-Disease
ocular,2414,I-Disease
motility,2414,I-Disease
in,2414,O
10,2414,O
consecutive,2414,O
patients,2414,O
with,2414,O
retinoblastoma,2414,B-Disease
who,2414,O
had,2414,O
received,2414,O
subtenon,2414,O
carboplatin,2414,B-Chemical
.,2414,O
During,2415,O
ocular,2415,O
manipulation,2415,O
under,2415,O
general,2415,O
anesthesia,2415,O
",",2415,O
we,2415,O
assessed,2415,O
their,2415,O
eyes,2415,O
by,2415,O
forced,2415,O
duction,2415,O
testing,2415,O
",",2415,O
comparing,2415,O
ocular,2415,O
motility,2415,O
after,2415,O
tumor,2415,B-Disease
control,2415,O
with,2415,O
ocular,2415,O
motility,2415,O
at,2415,O
diagnosis,2415,O
.,2415,O
Eyes,2416,O
subsequently,2416,O
enucleated,2416,O
because,2416,O
of,2416,O
treatment,2416,O
failure,2416,O
(,2416,O
n,2416,O
=,2416,O
4,2416,O
),2416,O
were,2416,O
examined,2416,O
histologically,2416,O
.,2416,O
RESULTS,2417,O
:,2417,O
Limitation,2417,O
of,2417,O
ocular,2417,O
motility,2417,O
was,2417,O
detected,2417,O
in,2417,O
all,2417,O
12,2417,O
eyes,2417,O
of,2417,O
10,2417,O
patients,2417,O
treated,2417,O
for,2417,O
intraocular,2417,O
retinoblastoma,2417,B-Disease
with,2417,O
1,2417,O
to,2417,O
6,2417,O
injections,2417,O
of,2417,O
subtenon,2417,O
carboplatin,2417,B-Chemical
as,2417,O
part,2417,O
of,2417,O
multimodality,2417,O
therapy,2417,O
.,2417,O
Histopathological,2418,O
examination,2418,O
revealed,2418,O
many,2418,O
lipophages,2418,O
in,2418,O
the,2418,O
periorbital,2418,O
fat,2418,O
surrounding,2418,O
the,2418,O
optic,2418,O
nerve,2418,O
in,2418,O
1,2418,O
eye,2418,O
",",2418,O
indicative,2418,O
of,2418,O
phagocytosis,2418,O
of,2418,O
previously,2418,O
existing,2418,O
fat,2418,O
cells,2418,O
and,2418,O
suggesting,2418,O
prior,2418,O
fat,2418,O
necrosis,2418,B-Disease
.,2418,O
The,2419,O
enucleations,2419,O
were,2419,O
technically,2419,O
difficult,2419,O
and,2419,O
hazardous,2419,O
for,2419,O
globe,2419,O
rupture,2419,B-Disease
because,2419,O
of,2419,O
extensive,2419,O
orbital,2419,O
soft,2419,O
tissue,2419,O
adhesions,2419,O
.,2419,O
CONCLUSIONS,2420,O
:,2420,O
Subtenon,2420,O
carboplatin,2420,B-Chemical
chemotherapy,2420,O
is,2420,O
associated,2420,O
with,2420,O
significant,2420,O
fibrosis,2420,B-Disease
of,2420,O
orbital,2420,O
soft,2420,O
tissues,2420,O
",",2420,O
leading,2420,O
to,2420,O
mechanical,2420,O
restriction,2420,O
of,2420,O
eye,2420,O
movements,2420,O
and,2420,O
making,2420,O
subsequent,2420,O
enucleation,2420,O
difficult,2420,O
.,2420,O
Subtenon,2421,O
carboplatin,2421,B-Chemical
is,2421,O
not,2421,O
free,2421,O
of,2421,O
toxicity,2421,B-Disease
",",2421,O
and,2421,O
its,2421,O
use,2421,O
is,2421,O
best,2421,O
restricted,2421,O
to,2421,O
specific,2421,O
indications,2421,O
.,2421,O
Ethambutol,2422,B-Chemical
and,2422,O
optic,2422,B-Disease
neuropathy,2422,I-Disease
.,2422,O
PURPOSE,2423,O
:,2423,O
To,2423,O
demonstrate,2423,O
the,2423,O
association,2423,O
between,2423,O
ethambutol,2423,B-Chemical
and,2423,O
optic,2423,B-Disease
neuropathy,2423,I-Disease
.,2423,O
METHOD,2424,O
:,2424,O
Thirteen,2424,O
patients,2424,O
who,2424,O
developed,2424,O
optic,2424,B-Disease
neuropathy,2424,I-Disease
after,2424,O
being,2424,O
treated,2424,O
with,2424,O
ethambutol,2424,B-Chemical
for,2424,O
tuberculosis,2424,O
of,2424,O
the,2424,O
lung,2424,O
or,2424,O
lymph,2424,O
node,2424,O
at,2424,O
Siriraj,2424,O
Hospital,2424,O
between,2424,O
1997,2424,O
and,2424,O
2001,2424,O
were,2424,O
retrospectively,2424,O
reviewed,2424,O
.,2424,O
The,2425,O
clinical,2425,O
characteristics,2425,O
and,2425,O
initial,2425,O
and,2425,O
final,2425,O
visual,2425,O
acuity,2425,O
were,2425,O
analyzed,2425,O
to,2425,O
determine,2425,O
visual,2425,O
outcome,2425,O
.,2425,O
RESULTS,2426,O
:,2426,O
All,2426,O
patients,2426,O
had,2426,O
optic,2426,B-Disease
neuropathy,2426,I-Disease
between,2426,O
1,2426,O
to,2426,O
6,2426,O
months,2426,O
(,2426,O
mean,2426,O
=,2426,O
2.9,2426,O
months,2426,O
),2426,O
after,2426,O
starting,2426,O
ethambutol,2426,B-Chemical
therapy,2426,O
at,2426,O
a,2426,O
dosage,2426,O
ranging,2426,O
from,2426,O
13,2426,O
to,2426,O
20,2426,O
mg/kg/day,2426,O
(,2426,O
mean,2426,O
=,2426,O
17,2426,O
mg/kg/day,2426,O
),2426,O
.,2426,O
Seven,2427,O
(,2427,O
54,2427,O
%,2427,O
),2427,O
of,2427,O
the,2427,O
13,2427,O
patients,2427,O
experienced,2427,O
visual,2427,O
recovery,2427,O
after,2427,O
stopping,2427,O
the,2427,O
drug,2427,O
.,2427,O
Of,2428,O
6,2428,O
patients,2428,O
with,2428,O
irreversible,2428,O
visual,2428,B-Disease
impairment,2428,I-Disease
",",2428,O
4,2428,O
patients,2428,O
had,2428,O
diabetes,2428,B-Disease
mellitus,2428,I-Disease
",",2428,O
glaucoma,2428,B-Disease
and,2428,O
a,2428,O
history,2428,O
of,2428,O
heavy,2428,O
smoking,2428,O
.,2428,O
CONCLUSION,2429,O
:,2429,O
Early,2429,O
recognition,2429,O
of,2429,O
optic,2429,B-Disease
neuropathy,2429,I-Disease
should,2429,O
be,2429,O
considered,2429,O
in,2429,O
patients,2429,O
with,2429,O
ethambutol,2429,B-Chemical
therapy,2429,O
.,2429,O
A,2430,O
low,2430,O
dose,2430,O
and,2430,O
prompt,2430,O
discontinuation,2430,O
of,2430,O
the,2430,O
drug,2430,O
is,2430,O
recommended,2430,O
particularly,2430,O
in,2430,O
individuals,2430,O
with,2430,O
diabetes,2430,B-Disease
mellitus,2430,I-Disease
",",2430,O
glaucoma,2430,B-Disease
or,2430,O
who,2430,O
are,2430,O
heavy,2430,O
smokers,2430,O
.,2430,O
Treatment,2431,O
of,2431,O
compensatory,2431,O
gustatory,2431,B-Disease
hyperhidrosis,2431,I-Disease
with,2431,O
topical,2431,O
glycopyrrolate,2431,B-Chemical
.,2431,O
Gustatory,2432,B-Disease
hyperhidrosis,2432,I-Disease
is,2432,O
facial,2432,O
sweating,2432,B-Disease
usually,2432,O
associated,2432,O
with,2432,O
the,2432,O
eating,2432,O
of,2432,O
hot,2432,O
spicy,2432,O
food,2432,O
or,2432,O
even,2432,O
smelling,2432,O
this,2432,O
food,2432,O
.,2432,O
Current,2433,O
options,2433,O
of,2433,O
treatment,2433,O
include,2433,O
oral,2433,O
anticholinergic,2433,O
drugs,2433,O
",",2433,O
the,2433,O
topical,2433,O
application,2433,O
of,2433,O
anticholinergics,2433,O
or,2433,O
aluminum,2433,B-Chemical
chloride,2433,I-Chemical
",",2433,O
and,2433,O
the,2433,O
injection,2433,O
of,2433,O
botulinum,2433,O
toxin,2433,O
.,2433,O
Thirteen,2434,O
patients,2434,O
have,2434,O
been,2434,O
treated,2434,O
to,2434,O
date,2434,O
with,2434,O
1.5,2434,O
%,2434,O
or,2434,O
2,2434,O
%,2434,O
topical,2434,O
glycopyrrolate,2434,B-Chemical
.,2434,O
All,2435,O
patients,2435,O
had,2435,O
gustatory,2435,B-Disease
hyperhidrosis,2435,I-Disease
",",2435,O
which,2435,O
interfered,2435,O
with,2435,O
their,2435,O
social,2435,O
activities,2435,O
",",2435,O
after,2435,O
transthroacic,2435,O
endoscopic,2435,O
sympathectomy,2435,O
",",2435,O
and,2435,O
which,2435,O
was,2435,O
associated,2435,O
with,2435,O
compensatory,2435,O
focal,2435,O
hyperhidrosis,2435,B-Disease
.,2435,O
After,2436,O
applying,2436,O
topical,2436,O
glycopyrrolate,2436,B-Chemical
",",2436,O
the,2436,O
subjective,2436,O
effect,2436,O
was,2436,O
excellent,2436,O
(,2436,O
no,2436,O
sweating,2436,B-Disease
after,2436,O
eating,2436,O
hot,2436,O
spicy,2436,O
food,2436,O
),2436,O
in,2436,O
10,2436,O
patients,2436,O
(,2436,O
77,2436,O
%,2436,O
),2436,O
",",2436,O
and,2436,O
fair,2436,O
(,2436,O
clearly,2436,O
reduced,2436,O
sweating,2436,B-Disease
),2436,O
in,2436,O
3,2436,O
patients,2436,O
(,2436,O
23,2436,O
%,2436,O
),2436,O
.,2436,O
All,2437,O
had,2437,O
reported,2437,O
incidents,2437,O
of,2437,O
being,2437,O
very,2437,O
embarrassed,2437,O
whilst,2437,O
eating,2437,O
hot,2437,O
spicy,2437,O
foods,2437,O
.,2437,O
Adverse,2438,O
effects,2438,O
included,2438,O
a,2438,O
mildly,2438,O
dry,2438,B-Disease
mouth,2438,I-Disease
and,2438,O
a,2438,O
sore,2438,B-Disease
throat,2438,I-Disease
in,2438,O
2,2438,O
patients,2438,O
(,2438,O
2,2438,O
%,2438,O
glycopyrrolate,2438,B-Chemical
),2438,O
",",2438,O
a,2438,O
light,2438,O
headache,2438,B-Disease
in,2438,O
1,2438,O
patient,2438,O
(,2438,O
1.5,2438,O
%,2438,O
glycopyrrolate,2438,B-Chemical
),2438,O
.,2438,O
The,2439,O
topical,2439,O
application,2439,O
of,2439,O
a,2439,O
glycopyrrolate,2439,B-Chemical
pad,2439,O
appeared,2439,O
to,2439,O
be,2439,O
safe,2439,O
",",2439,O
efficacious,2439,O
",",2439,O
well,2439,O
tolerated,2439,O
",",2439,O
and,2439,O
a,2439,O
convenient,2439,O
method,2439,O
of,2439,O
treatment,2439,O
for,2439,O
moderate,2439,O
to,2439,O
severe,2439,O
symptoms,2439,O
of,2439,O
gustatory,2439,B-Disease
hyperhidrosis,2439,I-Disease
in,2439,O
post,2439,O
transthoracic,2439,O
endoscopic,2439,O
sympathectomy,2439,O
or,2439,O
sympathicotomy,2439,O
patients,2439,O
",",2439,O
with,2439,O
few,2439,O
side,2439,O
effects,2439,O
.,2439,O
Pharmacological,2440,O
characteristics,2440,O
and,2440,O
side,2440,O
effects,2440,O
of,2440,O
a,2440,O
new,2440,O
galenic,2440,O
formulation,2440,O
of,2440,O
propofol,2440,B-Chemical
without,2440,O
soyabean,2440,O
oil,2440,O
.,2440,O
We,2441,O
compared,2441,O
the,2441,O
pharmacokinetics,2441,O
",",2441,O
pharmacodynamics,2441,O
and,2441,O
safety,2441,O
profile,2441,O
of,2441,O
a,2441,O
new,2441,O
galenic,2441,O
formulation,2441,O
of,2441,O
propofol,2441,B-Chemical
(,2441,O
AM149,2441,O
1,2441,O
%,2441,O
),2441,O
",",2441,O
which,2441,O
does,2441,O
not,2441,O
contain,2441,O
soyabean,2441,O
oil,2441,O
",",2441,O
with,2441,O
a,2441,O
standard,2441,O
formulation,2441,O
of,2441,O
propofol,2441,B-Chemical
(,2441,O
Disoprivan,2441,B-Chemical
1,2441,O
%,2441,O
),2441,O
.,2441,O
In,2442,O
a,2442,O
randomised,2442,O
",",2442,O
double-blind,2442,O
",",2442,O
cross-over,2442,O
study,2442,O
",",2442,O
30,2442,O
healthy,2442,O
volunteers,2442,O
received,2442,O
a,2442,O
single,2442,O
intravenous,2442,O
bolus,2442,O
injection,2442,O
of,2442,O
2.5,2442,O
mg.kg-1,2442,O
propofol,2442,B-Chemical
.,2442,O
Plasma,2443,O
propofol,2443,B-Chemical
levels,2443,O
were,2443,O
measured,2443,O
for,2443,O
48,2443,O
h,2443,O
following,2443,O
drug,2443,O
administration,2443,O
and,2443,O
evaluated,2443,O
according,2443,O
to,2443,O
a,2443,O
three-compartment,2443,O
model,2443,O
.,2443,O
The,2444,O
pharmacodynamic,2444,O
parameters,2444,O
assessed,2444,O
included,2444,O
induction,2444,O
and,2444,O
emergence,2444,O
times,2444,O
",",2444,O
respiratory,2444,O
and,2444,O
cardiovascular,2444,O
effects,2444,O
",",2444,O
and,2444,O
pain,2444,B-Disease
on,2444,O
injection,2444,O
.,2444,O
Patients,2445,O
were,2445,O
monitored,2445,O
for,2445,O
side,2445,O
effects,2445,O
over,2445,O
48,2445,O
h.,2445,O
Owing,2445,O
to,2445,O
a,2445,O
high,2445,O
incidence,2445,O
of,2445,O
thrombophlebitis,2445,B-Disease
",",2445,O
the,2445,O
study,2445,O
was,2445,O
terminated,2445,O
prematurely,2445,O
and,2445,O
only,2445,O
the,2445,O
data,2445,O
of,2445,O
the,2445,O
two,2445,O
parallel,2445,O
treatment,2445,O
groups,2445,O
(,2445,O
15,2445,O
patients,2445,O
in,2445,O
each,2445,O
group,2445,O
),2445,O
were,2445,O
analysed,2445,O
.,2445,O
Plasma,2446,O
concentrations,2446,O
did,2446,O
not,2446,O
differ,2446,O
significantly,2446,O
between,2446,O
the,2446,O
two,2446,O
formulations,2446,O
.,2446,O
Anaesthesia,2447,O
induction,2447,O
and,2447,O
emergence,2447,O
times,2447,O
",",2447,O
respiratory,2447,O
and,2447,O
cardiovascular,2447,O
variables,2447,O
showed,2447,O
no,2447,O
significant,2447,O
differences,2447,O
between,2447,O
the,2447,O
two,2447,O
treatment,2447,O
groups,2447,O
.,2447,O
Pain,2448,B-Disease
on,2448,O
injection,2448,O
(,2448,O
80,2448,O
vs.,2448,O
20,2448,O
%,2448,O
",",2448,O
p,2448,O
<,2448,O
0.01,2448,O
),2448,O
and,2448,O
thrombophlebitis,2448,B-Disease
(,2448,O
93.3,2448,O
vs.,2448,O
6.6,2448,O
%,2448,O
",",2448,O
p,2448,O
<,2448,O
0.001,2448,O
),2448,O
occurred,2448,O
more,2448,O
frequently,2448,O
with,2448,O
AM149,2448,O
than,2448,O
with,2448,O
Disoprivan,2448,B-Chemical
.,2448,O
Although,2449,O
both,2449,O
formulations,2449,O
had,2449,O
similar,2449,O
pharmacokinetic,2449,O
and,2449,O
pharmacodynamic,2449,O
profiles,2449,O
the,2449,O
new,2449,O
formulation,2449,O
is,2449,O
not,2449,O
suitable,2449,O
for,2449,O
clinical,2449,O
use,2449,O
due,2449,O
to,2449,O
the,2449,O
high,2449,O
incidence,2449,O
of,2449,O
thrombophlebitis,2449,B-Disease
produced,2449,O
.,2449,O
Vinorelbine-related,2450,B-Chemical
cardiac,2450,O
events,2450,O
:,2450,O
a,2450,O
meta-analysis,2450,O
of,2450,O
randomized,2450,O
clinical,2450,O
trials,2450,O
.,2450,O
Several,2451,O
cases,2451,O
of,2451,O
cardiac,2451,O
adverse,2451,O
reactions,2451,O
related,2451,O
to,2451,O
vinorelbine,2451,B-Chemical
(,2451,O
VNR,2451,B-Chemical
),2451,O
have,2451,O
been,2451,O
reported,2451,O
in,2451,O
the,2451,O
literature,2451,O
.,2451,O
In,2452,O
order,2452,O
to,2452,O
quantify,2452,O
the,2452,O
incidence,2452,O
of,2452,O
these,2452,O
cardiac,2452,O
events,2452,O
",",2452,O
we,2452,O
performed,2452,O
a,2452,O
meta-analysis,2452,O
of,2452,O
clinical,2452,O
trials,2452,O
comparing,2452,O
VNR,2452,B-Chemical
with,2452,O
other,2452,O
chemotherapeutic,2452,O
agents,2452,O
in,2452,O
the,2452,O
treatment,2452,O
of,2452,O
various,2452,O
malignancies,2452,B-Disease
.,2452,O
Randomized,2453,O
clinical,2453,O
trials,2453,O
comparing,2453,O
VNR,2453,B-Chemical
with,2453,O
other,2453,O
drugs,2453,O
in,2453,O
the,2453,O
treatment,2453,O
of,2453,O
cancer,2453,B-Disease
were,2453,O
searched,2453,O
in,2453,O
Medline,2453,O
",",2453,O
Embase,2453,O
",",2453,O
Evidence-based,2453,O
Medicine,2453,O
Reviews,2453,O
databases,2453,O
and,2453,O
the,2453,O
Cochrane,2453,O
library,2453,O
from,2453,O
1987,2453,O
to,2453,O
2002,2453,O
.,2453,O
Outcomes,2454,O
of,2454,O
interest,2454,O
were,2454,O
severe,2454,O
cardiac,2454,O
events,2454,O
",",2454,O
toxic,2454,O
deaths,2454,O
and,2454,O
cardiac,2454,O
event-related,2454,O
deaths,2454,O
reported,2454,O
in,2454,O
each,2454,O
publication,2454,O
.,2454,O
We,2455,O
found,2455,O
19,2455,O
trials,2455,O
",",2455,O
involving,2455,O
2441,2455,O
patients,2455,O
treated,2455,O
by,2455,O
VNR,2455,B-Chemical
and,2455,O
2050,2455,O
control,2455,O
patients,2455,O
.,2455,O
The,2456,O
incidence,2456,O
of,2456,O
cardiac,2456,O
events,2456,O
with,2456,O
VNR,2456,B-Chemical
was,2456,O
1.19,2456,O
%,2456,O
[,2456,O
95,2456,O
%,2456,O
confidence,2456,O
interval,2456,O
(,2456,O
CI,2456,O
),2456,O
(,2456,O
0.75,2456,O
;,2456,O
1.67,2456,O
),2456,O
],2456,O
.,2456,O
There,2457,O
was,2457,O
no,2457,O
difference,2457,O
in,2457,O
the,2457,O
risk,2457,O
of,2457,O
cardiac,2457,O
events,2457,O
between,2457,O
VNR,2457,B-Chemical
and,2457,O
other,2457,O
drugs,2457,O
[,2457,O
odds,2457,O
ratio,2457,O
:,2457,O
0.92,2457,O
",",2457,O
95,2457,O
%,2457,O
CI,2457,O
(,2457,O
0.54,2457,O
;,2457,O
1.55,2457,O
),2457,O
],2457,O
.,2457,O
The,2458,O
risk,2458,O
of,2458,O
VNR,2458,B-Chemical
cardiac,2458,O
events,2458,O
was,2458,O
similar,2458,O
to,2458,O
vindesine,2458,B-Chemical
(,2458,O
VDS,2458,B-Chemical
),2458,O
and,2458,O
other,2458,O
cardiotoxic,2458,B-Disease
drugs,2458,O
[,2458,O
fluorouracil,2458,B-Chemical
",",2458,O
anthracyclines,2458,B-Chemical
",",2458,O
gemcitabine,2458,B-Chemical
(,2458,O
GEM,2458,B-Chemical
),2458,O
em,2458,O
leader,2458,O
],2458,O
.,2458,O
Even,2459,O
if,2459,O
it,2459,O
did,2459,O
not,2459,O
reach,2459,O
statistical,2459,O
significance,2459,O
because,2459,O
of,2459,O
a,2459,O
few,2459,O
number,2459,O
of,2459,O
cases,2459,O
",",2459,O
the,2459,O
risk,2459,O
was,2459,O
lower,2459,O
in,2459,O
trials,2459,O
excluding,2459,O
patients,2459,O
with,2459,O
cardiac,2459,O
history,2459,O
",",2459,O
and,2459,O
seemed,2459,O
to,2459,O
be,2459,O
higher,2459,O
in,2459,O
trials,2459,O
including,2459,O
patients,2459,O
with,2459,O
pre-existing,2459,O
cardiac,2459,B-Disease
diseases,2459,I-Disease
.,2459,O
Vinorelbine-related,2460,B-Chemical
cardiac,2460,O
events,2460,O
concern,2460,O
about,2460,O
1,2460,O
%,2460,O
of,2460,O
treated,2460,O
patients,2460,O
in,2460,O
clinical,2460,O
trials,2460,O
.,2460,O
However,2461,O
",",2461,O
the,2461,O
risk,2461,O
associated,2461,O
with,2461,O
VNR,2461,B-Chemical
seems,2461,O
to,2461,O
be,2461,O
similar,2461,O
to,2461,O
that,2461,O
of,2461,O
other,2461,O
chemotherapeutic,2461,O
agents,2461,O
in,2461,O
the,2461,O
same,2461,O
indications,2461,O
.,2461,O
MRI,2462,O
findings,2462,O
of,2462,O
hypoxic,2462,O
cortical,2462,O
laminar,2462,O
necrosis,2462,B-Disease
in,2462,O
a,2462,O
child,2462,O
with,2462,O
hemolytic,2462,B-Disease
anemia,2462,I-Disease
crisis,2462,O
.,2462,O
We,2463,O
present,2463,O
magnetic,2463,O
resonance,2463,O
imaging,2463,O
findings,2463,O
of,2463,O
a,2463,O
5-year-old,2463,O
girl,2463,O
who,2463,O
had,2463,O
a,2463,O
rapidly,2463,O
installing,2463,O
hemolytic,2463,B-Disease
anemia,2463,I-Disease
crisis,2463,O
induced,2463,O
by,2463,O
trimethoprim-sulfomethoxazole,2463,B-Chemical
",",2463,O
resulting,2463,O
in,2463,O
cerebral,2463,B-Disease
anoxia,2463,I-Disease
leading,2463,O
to,2463,O
permanent,2463,O
damage,2463,O
.,2463,O
Magnetic,2464,O
Resonance,2464,O
imaging,2464,O
revealed,2464,O
cortical,2464,O
laminar,2464,O
necrosis,2464,B-Disease
in,2464,O
arterial,2464,O
border,2464,O
zones,2464,O
in,2464,O
both,2464,O
cerebral,2464,O
hemispheres,2464,O
",",2464,O
ischemic,2464,O
changes,2464,O
in,2464,O
subcortical,2464,O
white,2464,O
matter,2464,O
of,2464,O
left,2464,O
cerebral,2464,O
hemisphere,2464,O
",",2464,O
and,2464,O
in,2464,O
the,2464,O
left,2464,O
putamen,2464,O
.,2464,O
Although,2465,O
cortical,2465,O
laminar,2465,O
necrosis,2465,B-Disease
is,2465,O
a,2465,O
classic,2465,O
entity,2465,O
in,2465,O
adulthood,2465,O
related,2465,O
to,2465,O
conditions,2465,O
of,2465,O
energy,2465,O
depletions,2465,O
",",2465,O
there,2465,O
are,2465,O
few,2465,O
reports,2465,O
available,2465,O
in,2465,O
children,2465,O
.,2465,O
A,2466,O
wide,2466,O
review,2466,O
of,2466,O
the,2466,O
literature,2466,O
is,2466,O
also,2466,O
presented,2466,O
.,2466,O
The,2467,O
natural,2467,O
history,2467,O
of,2467,O
Vigabatrin,2467,B-Chemical
associated,2467,O
visual,2467,B-Disease
field,2467,I-Disease
defects,2467,I-Disease
in,2467,O
patients,2467,O
electing,2467,O
to,2467,O
continue,2467,O
their,2467,O
medication,2467,O
.,2467,O
PURPOSE,2468,O
:,2468,O
To,2468,O
determine,2468,O
the,2468,O
natural,2468,O
history,2468,O
of,2468,O
visual,2468,B-Disease
field,2468,I-Disease
defects,2468,I-Disease
in,2468,O
a,2468,O
group,2468,O
of,2468,O
patients,2468,O
known,2468,O
to,2468,O
have,2468,O
Vigabatrin-associated,2468,B-Chemical
changes,2468,O
who,2468,O
elected,2468,O
to,2468,O
continue,2468,O
the,2468,O
medication,2468,O
because,2468,O
of,2468,O
good,2468,O
seizure,2468,B-Disease
control,2468,O
.,2468,O
METHODS,2469,O
:,2469,O
All,2469,O
patients,2469,O
taking,2469,O
Vigabatrin,2469,B-Chemical
alone,2469,O
or,2469,O
in,2469,O
combination,2469,O
with,2469,O
other,2469,O
antiepileptic,2469,O
drugs,2469,O
for,2469,O
at,2469,O
least,2469,O
5,2469,O
years,2469,O
(,2469,O
range,2469,O
5-12,2469,O
years,2469,O
),2469,O
were,2469,O
entered,2469,O
into,2469,O
a,2469,O
visual,2469,O
surveillance,2469,O
programme,2469,O
.,2469,O
Patients,2470,O
were,2470,O
followed,2470,O
up,2470,O
at,2470,O
6-monthly,2470,O
intervals,2470,O
for,2470,O
not,2470,O
less,2470,O
than,2470,O
18,2470,O
months,2470,O
(,2470,O
range,2470,O
18-43,2470,O
months,2470,O
),2470,O
.,2470,O
In,2471,O
all,2471,O
",",2471,O
16,2471,O
patients,2471,O
with,2471,O
unequivocal,2471,O
defects,2471,O
continued,2471,O
the,2471,O
medication,2471,O
.,2471,O
Following,2472,O
already,2472,O
published,2472,O
methodology,2472,O
(,2472,O
Eye,2472,O
2002,2472,O
;,2472,O
16,2472,O
;,2472,O
567-571,2472,O
),2472,O
monocular,2472,O
mean,2472,O
radial,2472,O
degrees,2472,O
(,2472,O
MRDs,2472,O
),2472,O
to,2472,O
the,2472,O
I/4e,2472,O
isopter,2472,O
on,2472,O
Goldmann,2472,O
perimetry,2472,O
was,2472,O
calculated,2472,O
for,2472,O
the,2472,O
right,2472,O
eye,2472,O
at,2472,O
the,2472,O
time,2472,O
of,2472,O
discovery,2472,O
of,2472,O
a,2472,O
visual,2472,B-Disease
field,2472,I-Disease
defect,2472,I-Disease
and,2472,O
again,2472,O
after,2472,O
not,2472,O
less,2472,O
than,2472,O
18,2472,O
months,2472,O
follow-up,2472,O
.,2472,O
RESULTS,2473,O
:,2473,O
Mean,2473,O
right,2473,O
eye,2473,O
MRD,2473,O
at,2473,O
presentation,2473,O
was,2473,O
36.98,2473,O
degrees,2473,O
(,2473,O
range,2473,O
22.25-51.0,2473,O
),2473,O
",",2473,O
compared,2473,O
to,2473,O
38.40,2473,O
degrees,2473,O
(,2473,O
range,2473,O
22.5-49.75,2473,O
),2473,O
after,2473,O
follow-up,2473,O
;,2473,O
P=0.338,2473,O
unpaired,2473,O
t-test,2473,O
.,2473,O
Only,2474,O
one,2474,O
patient,2474,O
demonstrated,2474,O
a,2474,O
deterioration,2474,B-Disease
in,2474,I-Disease
visual,2474,I-Disease
field,2474,I-Disease
during,2474,O
the,2474,O
study,2474,O
period,2474,O
and,2474,O
discontinued,2474,O
treatment,2474,O
.,2474,O
CONCLUSION,2475,O
:,2475,O
Established,2475,O
visual,2475,B-Disease
field,2475,I-Disease
defects,2475,I-Disease
presumed,2475,O
to,2475,O
be,2475,O
due,2475,O
to,2475,O
Vigabatrin,2475,B-Chemical
therapy,2475,O
did,2475,O
not,2475,O
usually,2475,O
progress,2475,O
in,2475,O
spite,2475,O
of,2475,O
continuing,2475,O
use,2475,O
of,2475,O
the,2475,O
medication,2475,O
.,2475,O
These,2476,O
data,2476,O
give,2476,O
support,2476,O
to,2476,O
the,2476,O
hypothesis,2476,O
that,2476,O
the,2476,O
pathogenesis,2476,O
of,2476,O
Vigabatrin-associated,2476,B-Chemical
visual,2476,B-Disease
field,2476,I-Disease
defects,2476,I-Disease
may,2476,O
be,2476,O
an,2476,O
idiosyncratic,2476,O
adverse,2476,O
drug,2476,O
reaction,2476,O
rather,2476,O
than,2476,O
dose-dependent,2476,O
toxicity,2476,B-Disease
.,2476,O
Induction,2477,O
of,2477,O
rosaceiform,2477,O
dermatitis,2477,B-Disease
during,2477,O
treatment,2477,O
of,2477,O
facial,2477,B-Disease
inflammatory,2477,I-Disease
dermatoses,2477,I-Disease
with,2477,O
tacrolimus,2477,B-Chemical
ointment,2477,O
.,2477,O
BACKGROUND,2478,O
:,2478,O
Tacrolimus,2478,B-Chemical
ointment,2478,O
is,2478,O
increasingly,2478,O
used,2478,O
for,2478,O
anti-inflammatory,2478,O
treatment,2478,O
of,2478,O
sensitive,2478,O
areas,2478,O
such,2478,O
as,2478,O
the,2478,O
face,2478,O
",",2478,O
and,2478,O
recent,2478,O
observations,2478,O
indicate,2478,O
that,2478,O
the,2478,O
treatment,2478,O
is,2478,O
effective,2478,O
in,2478,O
steroid-aggravated,2478,B-Chemical
rosacea,2478,B-Disease
and,2478,O
perioral,2478,B-Disease
dermatitis,2478,I-Disease
.,2478,O
We,2479,O
report,2479,O
on,2479,O
rosaceiform,2479,O
dermatitis,2479,B-Disease
as,2479,O
a,2479,O
complication,2479,O
of,2479,O
treatment,2479,O
with,2479,O
tacrolimus,2479,B-Chemical
ointment,2479,O
.,2479,O
OBSERVATIONS,2480,O
:,2480,O
Six,2480,O
adult,2480,O
patients,2480,O
with,2480,O
inflammatory,2480,B-Disease
facial,2480,I-Disease
dermatoses,2480,I-Disease
were,2480,O
treated,2480,O
with,2480,O
tacrolimus,2480,B-Chemical
ointment,2480,O
because,2480,O
of,2480,O
the,2480,O
ineffectiveness,2480,O
of,2480,O
standard,2480,O
treatments,2480,O
.,2480,O
Within,2481,O
2,2481,O
to,2481,O
3,2481,O
weeks,2481,O
of,2481,O
initially,2481,O
effective,2481,O
and,2481,O
well-tolerated,2481,O
treatment,2481,O
",",2481,O
3,2481,O
patients,2481,O
with,2481,O
a,2481,O
history,2481,O
of,2481,O
rosacea,2481,B-Disease
and,2481,O
1,2481,O
with,2481,O
a,2481,O
history,2481,O
of,2481,O
acne,2481,B-Disease
experienced,2481,O
sudden,2481,O
worsening,2481,O
with,2481,O
pustular,2481,O
rosaceiform,2481,O
lesions,2481,O
.,2481,O
Biopsy,2482,O
revealed,2482,O
an,2482,O
abundance,2482,O
of,2482,O
Demodex,2482,O
mites,2482,O
in,2482,O
2,2482,O
of,2482,O
these,2482,O
patients,2482,O
.,2482,O
In,2483,O
1,2483,O
patient,2483,O
with,2483,O
eyelid,2483,O
eczema,2483,B-Disease
",",2483,O
rosaceiform,2483,O
periocular,2483,B-Disease
dermatitis,2483,I-Disease
gradually,2483,O
appeared,2483,O
after,2483,O
3,2483,O
weeks,2483,O
of,2483,O
treatment,2483,O
.,2483,O
In,2484,O
1,2484,O
patient,2484,O
with,2484,O
atopic,2484,B-Disease
dermatitis,2484,I-Disease
",",2484,O
telangiectatic,2484,O
and,2484,O
papular,2484,B-Disease
rosacea,2484,I-Disease
insidiously,2484,O
appeared,2484,O
after,2484,O
5,2484,O
months,2484,O
of,2484,O
treatment,2484,O
.,2484,O
CONCLUSIONS,2485,O
:,2485,O
Our,2485,O
observations,2485,O
suggest,2485,O
that,2485,O
the,2485,O
spectrum,2485,O
of,2485,O
rosaceiform,2485,O
dermatitis,2485,B-Disease
as,2485,O
a,2485,O
complication,2485,O
of,2485,O
treatment,2485,O
with,2485,O
tacrolimus,2485,B-Chemical
ointment,2485,O
is,2485,O
heterogeneous,2485,O
.,2485,O
A,2486,O
variety,2486,O
of,2486,O
factors,2486,O
",",2486,O
such,2486,O
as,2486,O
vasoactive,2486,O
properties,2486,O
of,2486,O
tacrolimus,2486,B-Chemical
",",2486,O
proliferation,2486,O
of,2486,O
Demodex,2486,O
due,2486,O
to,2486,O
local,2486,O
immunosuppression,2486,O
",",2486,O
and,2486,O
the,2486,O
occlusive,2486,O
properties,2486,O
of,2486,O
the,2486,O
ointment,2486,O
",",2486,O
may,2486,O
be,2486,O
involved,2486,O
in,2486,O
the,2486,O
observed,2486,O
phenomena,2486,O
.,2486,O
Future,2487,O
studies,2487,O
are,2487,O
needed,2487,O
to,2487,O
identify,2487,O
individual,2487,O
risk,2487,O
factors,2487,O
.,2487,O
Structural,2488,O
abnormalities,2488,O
in,2488,O
the,2488,O
brains,2488,O
of,2488,O
human,2488,O
subjects,2488,O
who,2488,O
use,2488,O
methamphetamine,2488,B-Chemical
.,2488,O
We,2489,O
visualize,2489,O
",",2489,O
for,2489,O
the,2489,O
first,2489,O
time,2489,O
",",2489,O
the,2489,O
profile,2489,O
of,2489,O
structural,2489,B-Disease
deficits,2489,I-Disease
in,2489,I-Disease
the,2489,I-Disease
human,2489,I-Disease
brain,2489,I-Disease
associated,2489,O
with,2489,O
chronic,2489,O
methamphetamine,2489,B-Chemical
(,2489,O
MA,2489,B-Chemical
),2489,O
abuse,2489,O
.,2489,O
Studies,2490,O
of,2490,O
human,2490,O
subjects,2490,O
who,2490,O
have,2490,O
used,2490,O
MA,2490,B-Chemical
chronically,2490,O
have,2490,O
revealed,2490,O
deficits,2490,O
in,2490,O
dopaminergic,2490,O
and,2490,O
serotonergic,2490,O
systems,2490,O
and,2490,O
cerebral,2490,O
metabolic,2490,B-Disease
abnormalities,2490,I-Disease
.,2490,O
Using,2491,O
magnetic,2491,O
resonance,2491,O
imaging,2491,O
(,2491,O
MRI,2491,O
),2491,O
and,2491,O
new,2491,O
computational,2491,O
brain-mapping,2491,O
techniques,2491,O
",",2491,O
we,2491,O
determined,2491,O
the,2491,O
pattern,2491,O
of,2491,O
structural,2491,O
brain,2491,O
alterations,2491,O
associated,2491,O
with,2491,O
chronic,2491,O
MA,2491,B-Chemical
abuse,2491,O
in,2491,O
human,2491,O
subjects,2491,O
and,2491,O
related,2491,O
these,2491,O
deficits,2491,O
to,2491,O
cognitive,2491,B-Disease
impairment,2491,I-Disease
.,2491,O
We,2492,O
used,2492,O
high-resolution,2492,O
MRI,2492,O
and,2492,O
surface-based,2492,O
computational,2492,O
image,2492,O
analyses,2492,O
to,2492,O
map,2492,O
regional,2492,O
abnormalities,2492,B-Disease
in,2492,I-Disease
the,2492,I-Disease
cortex,2492,I-Disease
",",2492,I-Disease
hippocampus,2492,I-Disease
",",2492,I-Disease
white,2492,I-Disease
matter,2492,I-Disease
",",2492,I-Disease
and,2492,I-Disease
ventricles,2492,I-Disease
in,2492,O
22,2492,O
human,2492,O
subjects,2492,O
who,2492,O
used,2492,O
MA,2492,B-Chemical
and,2492,O
21,2492,O
age-matched,2492,O
",",2492,O
healthy,2492,O
controls,2492,O
.,2492,O
Cortical,2493,O
maps,2493,O
revealed,2493,O
severe,2493,O
gray-matter,2493,O
deficits,2493,O
in,2493,O
the,2493,O
cingulate,2493,O
",",2493,O
limbic,2493,O
",",2493,O
and,2493,O
paralimbic,2493,O
cortices,2493,O
of,2493,O
MA,2493,B-Chemical
abusers,2493,O
(,2493,O
averaging,2493,O
11.3,2493,O
%,2493,O
below,2493,O
control,2493,O
;,2493,O
p,2493,O
<,2493,O
0.05,2493,O
),2493,O
.,2493,O
On,2494,O
average,2494,O
",",2494,O
MA,2494,B-Chemical
abusers,2494,O
had,2494,O
7.8,2494,O
%,2494,O
smaller,2494,O
hippocampal,2494,O
volumes,2494,O
than,2494,O
control,2494,O
subjects,2494,O
(,2494,O
p,2494,O
<,2494,O
0.01,2494,O
;,2494,O
left,2494,O
",",2494,O
p,2494,O
=,2494,O
0.01,2494,O
;,2494,O
right,2494,O
",",2494,O
p,2494,O
<,2494,O
0.05,2494,O
),2494,O
and,2494,O
significant,2494,O
white-matter,2494,O
hypertrophy,2494,B-Disease
(,2494,O
7.0,2494,O
%,2494,O
;,2494,O
p,2494,O
<,2494,O
0.01,2494,O
),2494,O
.,2494,O
Hippocampal,2495,O
deficits,2495,O
were,2495,O
mapped,2495,O
and,2495,O
correlated,2495,O
with,2495,O
memory,2495,O
performance,2495,O
on,2495,O
a,2495,O
word-recall,2495,O
test,2495,O
(,2495,O
p,2495,O
<,2495,O
0.05,2495,O
),2495,O
.,2495,O
MRI-based,2496,O
maps,2496,O
suggest,2496,O
that,2496,O
chronic,2496,O
methamphetamine,2496,B-Chemical
abuse,2496,O
causes,2496,O
a,2496,O
selective,2496,O
pattern,2496,O
of,2496,O
cerebral,2496,O
deterioration,2496,O
that,2496,O
contributes,2496,O
to,2496,O
impaired,2496,B-Disease
memory,2496,I-Disease
performance,2496,I-Disease
.,2496,O
MA,2497,B-Chemical
may,2497,O
selectively,2497,O
damage,2497,O
the,2497,O
medial,2497,O
temporal,2497,O
lobe,2497,O
and,2497,O
",",2497,O
consistent,2497,O
with,2497,O
metabolic,2497,O
studies,2497,O
",",2497,O
the,2497,O
cingulate-limbic,2497,O
cortex,2497,O
",",2497,O
inducing,2497,O
neuroadaptation,2497,O
",",2497,O
neuropil,2497,O
reduction,2497,O
",",2497,O
or,2497,O
cell,2497,O
death,2497,O
.,2497,O
Prominent,2498,O
white-matter,2498,O
hypertrophy,2498,B-Disease
may,2498,O
result,2498,O
from,2498,O
altered,2498,O
myelination,2498,O
and,2498,O
adaptive,2498,O
glial,2498,O
changes,2498,O
",",2498,O
including,2498,O
gliosis,2498,B-Disease
secondary,2498,O
to,2498,O
neuronal,2498,B-Disease
damage,2498,I-Disease
.,2498,O
These,2499,O
brain,2499,O
substrates,2499,O
may,2499,O
help,2499,O
account,2499,O
for,2499,O
the,2499,O
symptoms,2499,O
of,2499,O
MA,2499,B-Chemical
abuse,2499,O
",",2499,O
providing,2499,O
therapeutic,2499,O
targets,2499,O
for,2499,O
drug-induced,2499,O
brain,2499,B-Disease
injury,2499,I-Disease
.,2499,O
Disruption,2500,O
of,2500,O
hepatic,2500,O
lipid,2500,O
homeostasis,2500,O
in,2500,O
mice,2500,O
after,2500,O
amiodarone,2500,B-Chemical
treatment,2500,O
is,2500,O
associated,2500,O
with,2500,O
peroxisome,2500,O
proliferator-activated,2500,O
receptor-alpha,2500,O
target,2500,O
gene,2500,O
activation,2500,O
.,2500,O
Amiodarone,2501,B-Chemical
",",2501,O
an,2501,O
efficacious,2501,O
and,2501,O
widely,2501,O
used,2501,O
antiarrhythmic,2501,O
agent,2501,O
",",2501,O
has,2501,O
been,2501,O
reported,2501,O
to,2501,O
cause,2501,O
hepatotoxicity,2501,B-Disease
in,2501,O
some,2501,O
patients,2501,O
.,2501,O
To,2502,O
gain,2502,O
insight,2502,O
into,2502,O
the,2502,O
mechanism,2502,O
of,2502,O
this,2502,O
unwanted,2502,O
effect,2502,O
",",2502,O
mice,2502,O
were,2502,O
administered,2502,O
various,2502,O
doses,2502,O
of,2502,O
amiodarone,2502,B-Chemical
and,2502,O
examined,2502,O
for,2502,O
changes,2502,O
in,2502,O
hepatic,2502,O
histology,2502,O
and,2502,O
gene,2502,O
regulation,2502,O
.,2502,O
Amiodarone,2503,B-Chemical
induced,2503,O
hepatomegaly,2503,B-Disease
",",2503,O
hepatocyte,2503,O
microvesicular,2503,O
lipid,2503,O
accumulation,2503,O
",",2503,O
and,2503,O
a,2503,O
significant,2503,O
decrease,2503,O
in,2503,O
serum,2503,O
triglycerides,2503,B-Chemical
and,2503,O
glucose,2503,B-Chemical
.,2503,O
Northern,2504,O
blot,2504,O
analysis,2504,O
of,2504,O
hepatic,2504,O
RNA,2504,O
revealed,2504,O
a,2504,O
dose-dependent,2504,O
increase,2504,O
in,2504,O
the,2504,O
expression,2504,O
of,2504,O
a,2504,O
number,2504,O
of,2504,O
genes,2504,O
critical,2504,O
for,2504,O
fatty,2504,B-Chemical
acid,2504,I-Chemical
oxidation,2504,O
",",2504,O
lipoprotein,2504,O
assembly,2504,O
",",2504,O
and,2504,O
lipid,2504,O
transport,2504,O
.,2504,O
Many,2505,O
of,2505,O
these,2505,O
genes,2505,O
are,2505,O
regulated,2505,O
by,2505,O
the,2505,O
peroxisome,2505,O
proliferator-activated,2505,O
receptor-alpha,2505,O
(,2505,O
PPARalpha,2505,O
),2505,O
",",2505,O
a,2505,O
ligand-activated,2505,O
nuclear,2505,O
hormone,2505,O
receptor,2505,O
transcription,2505,O
factor,2505,O
.,2505,O
The,2506,O
absence,2506,O
of,2506,O
induction,2506,O
of,2506,O
these,2506,O
genes,2506,O
as,2506,O
well,2506,O
as,2506,O
hepatomegaly,2506,B-Disease
in,2506,O
PPARalpha,2506,O
knockout,2506,O
[,2506,O
PPARalpha-/-,2506,O
],2506,O
mice,2506,O
indicated,2506,O
that,2506,O
the,2506,O
effects,2506,O
of,2506,O
amiodarone,2506,B-Chemical
were,2506,O
dependent,2506,O
upon,2506,O
the,2506,O
presence,2506,O
of,2506,O
a,2506,O
functional,2506,O
PPARalpha,2506,O
gene,2506,O
.,2506,O
Compared,2507,O
to,2507,O
wild-type,2507,O
mice,2507,O
",",2507,O
treatment,2507,O
of,2507,O
PPARalpha-/-,2507,O
mice,2507,O
with,2507,O
amiodarone,2507,B-Chemical
resulted,2507,O
in,2507,O
an,2507,O
increased,2507,O
rate,2507,O
and,2507,O
extent,2507,O
of,2507,O
total,2507,O
body,2507,O
weight,2507,B-Disease
loss,2507,I-Disease
.,2507,O
The,2508,O
inability,2508,O
of,2508,O
amiodarone,2508,B-Chemical
to,2508,O
directly,2508,O
activate,2508,O
either,2508,O
human,2508,O
or,2508,O
mouse,2508,O
PPARalpha,2508,O
transiently,2508,O
expressed,2508,O
in,2508,O
human,2508,O
HepG2,2508,O
hepatoma,2508,B-Disease
cells,2508,O
indicates,2508,O
that,2508,O
the,2508,O
effects,2508,O
of,2508,O
amiodarone,2508,B-Chemical
on,2508,O
the,2508,O
function,2508,O
of,2508,O
this,2508,O
receptor,2508,O
were,2508,O
indirect,2508,O
.,2508,O
Based,2509,O
upon,2509,O
these,2509,O
results,2509,O
",",2509,O
we,2509,O
conclude,2509,O
that,2509,O
amiodarone,2509,B-Chemical
disrupts,2509,O
hepatic,2509,O
lipid,2509,O
homeostasis,2509,O
and,2509,O
that,2509,O
the,2509,O
increased,2509,O
expression,2509,O
of,2509,O
PPARalpha,2509,O
target,2509,O
genes,2509,O
is,2509,O
secondary,2509,O
to,2509,O
this,2509,O
toxic,2509,O
effect,2509,O
.,2509,O
These,2510,O
results,2510,O
provide,2510,O
important,2510,O
new,2510,O
mechanistic,2510,O
information,2510,O
regarding,2510,O
the,2510,O
hepatotoxic,2510,B-Disease
effects,2510,O
of,2510,O
amiodarone,2510,B-Chemical
and,2510,O
indicate,2510,O
that,2510,O
PPARalpha,2510,O
protects,2510,O
against,2510,O
amiodarone-induced,2510,B-Chemical
hepatotoxicity,2510,B-Disease
.,2510,O
Safety,2511,O
and,2511,O
compliance,2511,O
with,2511,O
once-daily,2511,O
niacin,2511,B-Chemical
extended-release/lovastatin,2511,I-Chemical
as,2511,O
initial,2511,O
therapy,2511,O
in,2511,O
the,2511,O
Impact,2511,O
of,2511,O
Medical,2511,O
Subspecialty,2511,O
on,2511,O
Patient,2511,O
Compliance,2511,O
to,2511,O
Treatment,2511,O
(,2511,O
IMPACT,2511,O
),2511,O
study,2511,O
.,2511,O
Niacin,2512,B-Chemical
extended-release/lovastatin,2512,I-Chemical
is,2512,O
a,2512,O
new,2512,O
combination,2512,O
product,2512,O
approved,2512,O
for,2512,O
treatment,2512,O
of,2512,O
primary,2512,O
hypercholesterolemia,2512,B-Disease
and,2512,O
mixed,2512,O
dyslipidemia,2512,B-Disease
.,2512,O
This,2513,O
open-labeled,2513,O
",",2513,O
multicenter,2513,O
study,2513,O
evaluated,2513,O
the,2513,O
safety,2513,O
of,2513,O
bedtime,2513,O
niacin,2513,B-Chemical
extended-release/lovastatin,2513,I-Chemical
when,2513,O
dosed,2513,O
as,2513,O
initial,2513,O
therapy,2513,O
and,2513,O
patient,2513,O
compliance,2513,O
to,2513,O
treatment,2513,O
in,2513,O
various,2513,O
clinical,2513,O
practice,2513,O
settings,2513,O
.,2513,O
A,2514,O
total,2514,O
of,2514,O
"4,499",2514,O
patients,2514,O
with,2514,O
dyslipidemia,2514,B-Disease
requiring,2514,O
drug,2514,O
intervention,2514,O
was,2514,O
enrolled,2514,O
at,2514,O
"1,081",2514,O
sites,2514,O
.,2514,O
Patients,2515,O
were,2515,O
treated,2515,O
with,2515,O
1,2515,O
tablet,2515,O
(,2515,O
500,2515,O
mg,2515,O
of,2515,O
niacin,2515,B-Chemical
extended-release/20,2515,O
mg,2515,O
of,2515,O
lovastatin,2515,B-Chemical
),2515,O
once,2515,O
nightly,2515,O
for,2515,O
4,2515,O
weeks,2515,O
and,2515,O
then,2515,O
2,2515,O
tablets,2515,O
for,2515,O
8,2515,O
weeks,2515,O
.,2515,O
Patients,2516,O
also,2516,O
received,2516,O
dietary,2516,O
counseling,2516,O
",",2516,O
educational,2516,O
materials,2516,O
",",2516,O
and,2516,O
reminders,2516,O
to,2516,O
call,2516,O
a,2516,O
toll-free,2516,O
number,2516,O
that,2516,O
provided,2516,O
further,2516,O
education,2516,O
about,2516,O
dyslipidemia,2516,B-Disease
and,2516,O
niacin,2516,B-Chemical
extended-release/lovastatin,2516,I-Chemical
.,2516,O
Primary,2517,O
end,2517,O
points,2517,O
were,2517,O
study,2517,O
compliance,2517,O
",",2517,O
increases,2517,O
in,2517,O
liver,2517,O
transaminases,2517,O
to,2517,O
>,2517,O
3,2517,O
times,2517,O
the,2517,O
upper,2517,O
limit,2517,O
of,2517,O
normal,2517,O
",",2517,O
and,2517,O
clinical,2517,O
myopathy,2517,B-Disease
.,2517,O
Final,2518,O
study,2518,O
status,2518,O
was,2518,O
available,2518,O
for,2518,O
"4,217",2518,O
patients,2518,O
(,2518,O
94,2518,O
%,2518,O
),2518,O
.,2518,O
Compliance,2519,O
to,2519,O
niacin,2519,B-Chemical
extended-release/lovastatin,2519,I-Chemical
was,2519,O
77,2519,O
%,2519,O
",",2519,O
with,2519,O
"3,245",2519,O
patients,2519,O
completing,2519,O
the,2519,O
study,2519,O
.,2519,O
Patients,2520,O
in,2520,O
the,2520,O
southeast,2520,O
and,2520,O
those,2520,O
enrolled,2520,O
by,2520,O
endocrinologists,2520,O
had,2520,O
the,2520,O
lowest,2520,O
compliance,2520,O
and,2520,O
highest,2520,O
adverse,2520,O
event,2520,O
rates,2520,O
.,2520,O
Flushing,2521,B-Disease
was,2521,O
the,2521,O
most,2521,O
common,2521,O
adverse,2521,O
event,2521,O
",",2521,O
reported,2521,O
by,2521,O
18,2521,O
%,2521,O
of,2521,O
patients,2521,O
and,2521,O
leading,2521,O
to,2521,O
discontinuation,2521,O
by,2521,O
6,2521,O
%,2521,O
.,2521,O
Incidence,2522,O
of,2522,O
increased,2522,O
aspartate,2522,B-Chemical
aminotransferase,2522,O
and/or,2522,O
alanine,2522,B-Chemical
aminotransferase,2522,O
>,2522,O
3,2522,O
times,2522,O
the,2522,O
upper,2522,O
limit,2522,O
of,2522,O
normal,2522,O
was,2522,O
<,2522,O
0.3,2522,O
%,2522,O
.,2522,O
An,2523,O
increase,2523,O
of,2523,O
creatine,2523,B-Chemical
phosphokinase,2523,O
to,2523,O
>,2523,O
5,2523,O
times,2523,O
the,2523,O
upper,2523,O
limit,2523,O
of,2523,O
normal,2523,O
occurred,2523,O
in,2523,O
0.24,2523,O
%,2523,O
of,2523,O
patients,2523,O
",",2523,O
and,2523,O
no,2523,O
cases,2523,O
of,2523,O
drug-induced,2523,O
myopathy,2523,B-Disease
were,2523,O
observed,2523,O
.,2523,O
Niacin,2524,B-Chemical
extended-release/lovastatin,2524,I-Chemical
"1,000/40",2524,O
mg,2524,O
",",2524,O
dosed,2524,O
as,2524,O
initial,2524,O
therapy,2524,O
",",2524,O
was,2524,O
associated,2524,O
with,2524,O
good,2524,O
compliance,2524,O
and,2524,O
safety,2524,O
and,2524,O
had,2524,O
very,2524,O
low,2524,O
incidences,2524,O
of,2524,O
increased,2524,O
liver,2524,O
and,2524,O
muscle,2524,O
enzymes,2524,O
.,2524,O
Protective,2525,O
effect,2525,O
of,2525,O
Terminalia,2525,B-Chemical
chebula,2525,I-Chemical
against,2525,O
experimental,2525,O
myocardial,2525,B-Disease
injury,2525,I-Disease
induced,2525,O
by,2525,O
isoproterenol,2525,B-Chemical
.,2525,O
Cardioprotective,2526,O
effect,2526,O
of,2526,O
ethanolic,2526,B-Chemical
extract,2526,I-Chemical
of,2526,I-Chemical
Terminalia,2526,I-Chemical
chebula,2526,I-Chemical
fruits,2526,I-Chemical
(,2526,O
500,2526,O
mg/kg,2526,O
body,2526,O
wt,2526,O
),2526,O
was,2526,O
examined,2526,O
in,2526,O
isoproterenol,2526,B-Chemical
(,2526,O
200,2526,O
mg/kg,2526,O
body,2526,O
wt,2526,O
),2526,O
induced,2526,O
myocardial,2526,B-Disease
damage,2526,I-Disease
in,2526,O
rats,2526,O
.,2526,O
In,2527,O
isoproterenol,2527,B-Chemical
administered,2527,O
rats,2527,O
",",2527,O
the,2527,O
level,2527,O
of,2527,O
lipid,2527,O
peroxides,2527,B-Chemical
increased,2527,O
significantly,2527,O
in,2527,O
the,2527,O
serum,2527,O
and,2527,O
heart,2527,O
.,2527,O
A,2528,O
significant,2528,O
decrease,2528,O
was,2528,O
observed,2528,O
in,2528,O
the,2528,O
activity,2528,O
of,2528,O
the,2528,O
myocardial,2528,O
marker,2528,O
enzymes,2528,O
with,2528,O
a,2528,O
concomitant,2528,O
increase,2528,O
in,2528,O
their,2528,O
activity,2528,O
in,2528,O
serum,2528,O
.,2528,O
Histopathological,2529,O
examination,2529,O
was,2529,O
carried,2529,O
out,2529,O
to,2529,O
confirm,2529,O
the,2529,O
myocardial,2529,O
necrosis,2529,B-Disease
.,2529,O
T.,2530,B-Chemical
chebula,2530,I-Chemical
extract,2530,I-Chemical
pretreatment,2530,O
was,2530,O
found,2530,O
to,2530,O
ameliorate,2530,O
the,2530,O
effect,2530,O
of,2530,O
isoproterenol,2530,B-Chemical
on,2530,O
lipid,2530,O
peroxide,2530,B-Chemical
formation,2530,O
and,2530,O
retained,2530,O
the,2530,O
activities,2530,O
of,2530,O
the,2530,O
diagnostic,2530,O
marker,2530,O
enzymes,2530,O
.,2530,O
A,2531,O
case,2531,O
of,2531,O
postoperative,2531,O
anxiety,2531,B-Disease
due,2531,O
to,2531,O
low,2531,O
dose,2531,O
droperidol,2531,B-Chemical
used,2531,O
with,2531,O
patient-controlled,2531,O
analgesia,2531,O
.,2531,O
A,2532,O
multiparous,2532,O
woman,2532,O
in,2532,O
good,2532,O
psychological,2532,O
health,2532,O
underwent,2532,O
urgent,2532,O
caesarean,2532,O
section,2532,O
in,2532,O
labour,2532,O
.,2532,O
Postoperatively,2533,O
",",2533,O
she,2533,O
was,2533,O
given,2533,O
a,2533,O
patient-controlled,2533,O
analgesia,2533,O
device,2533,O
delivering,2533,O
boluses,2533,O
of,2533,O
diamorphine,2533,B-Chemical
0.5,2533,O
mg,2533,O
and,2533,O
droperidol,2533,B-Chemical
0.025,2533,O
mg.,2533,O
Whilst,2533,O
using,2533,O
the,2533,O
device,2533,O
she,2533,O
gradually,2533,O
became,2533,O
anxious,2533,O
",",2533,O
the,2533,O
feeling,2533,O
worsening,2533,O
after,2533,O
each,2533,O
bolus,2533,O
.,2533,O
The,2534,O
diagnosis,2534,O
of,2534,O
droperidol-induced,2534,B-Chemical
psychological,2534,B-Disease
disturbance,2534,I-Disease
was,2534,O
not,2534,O
made,2534,O
straight,2534,O
away,2534,O
although,2534,O
on,2534,O
subsequent,2534,O
close,2534,O
questioning,2534,O
the,2534,O
patient,2534,O
gave,2534,O
a,2534,O
very,2534,O
clear,2534,O
history,2534,O
.,2534,O
After,2535,O
she,2535,O
had,2535,O
received,2535,O
a,2535,O
total,2535,O
of,2535,O
only,2535,O
0.9,2535,O
mg,2535,O
droperidol,2535,B-Chemical
",",2535,O
a,2535,O
syringe,2535,O
containing,2535,O
diamorphine,2535,B-Chemical
only,2535,O
was,2535,O
substituted,2535,O
and,2535,O
her,2535,O
unease,2535,O
resolved,2535,O
completely,2535,O
.,2535,O
We,2536,O
feel,2536,O
that,2536,O
",",2536,O
although,2536,O
the,2536,O
dramatic,2536,O
extrapyramidal,2536,O
side,2536,O
effects,2536,O
of,2536,O
dopaminergic,2536,O
antiemetics,2536,O
are,2536,O
well,2536,O
known,2536,O
",",2536,O
more,2536,O
subtle,2536,O
manifestations,2536,O
may,2536,O
easily,2536,O
be,2536,O
overlooked,2536,O
.,2536,O
Accurate,2537,O
patient,2537,O
history,2537,O
contributes,2537,O
to,2537,O
differentiating,2537,O
diabetes,2537,B-Disease
insipidus,2537,I-Disease
:,2537,O
a,2537,O
case,2537,O
study,2537,O
.,2537,O
This,2538,O
case,2538,O
study,2538,O
highlights,2538,O
the,2538,O
important,2538,O
contribution,2538,O
of,2538,O
nursing,2538,O
in,2538,O
obtaining,2538,O
an,2538,O
accurate,2538,O
health,2538,O
history,2538,O
.,2538,O
The,2539,O
case,2539,O
discussed,2539,O
herein,2539,O
initially,2539,O
appeared,2539,O
to,2539,O
be,2539,O
neurogenic,2539,B-Disease
diabetes,2539,I-Disease
insipidus,2539,I-Disease
(,2539,O
DI,2539,B-Disease
),2539,O
secondary,2539,O
to,2539,O
a,2539,O
traumatic,2539,B-Disease
brain,2539,I-Disease
injury,2539,I-Disease
.,2539,O
The,2540,O
nursing,2540,O
staff,2540,O
",",2540,O
by,2540,O
reviewing,2540,O
the,2540,O
patient,2540,O
's,2540,O
health,2540,O
history,2540,O
with,2540,O
his,2540,O
family,2540,O
",",2540,O
discovered,2540,O
a,2540,O
history,2540,O
of,2540,O
polydipsia,2540,B-Disease
and,2540,O
long-standing,2540,O
lithium,2540,B-Chemical
use,2540,O
.,2540,O
Lithium,2541,B-Chemical
is,2541,O
implicated,2541,O
in,2541,O
drug-induced,2541,O
nephrogenic,2541,B-Disease
DI,2541,I-Disease
",",2541,O
and,2541,O
because,2541,O
the,2541,O
patient,2541,O
had,2541,O
not,2541,O
received,2541,O
lithium,2541,B-Chemical
since,2541,O
being,2541,O
admitted,2541,O
to,2541,O
the,2541,O
hospital,2541,O
",",2541,O
his,2541,O
treatment,2541,O
changed,2541,O
to,2541,O
focus,2541,O
on,2541,O
nephrogenic,2541,B-Disease
DI,2541,I-Disease
.,2541,O
By,2542,O
combining,2542,O
information,2542,O
from,2542,O
the,2542,O
patient,2542,O
history,2542,O
",",2542,O
the,2542,O
physical,2542,O
examination,2542,O
",",2542,O
and,2542,O
radiologic,2542,O
and,2542,O
laboratory,2542,O
studies,2542,O
",",2542,O
the,2542,O
critical,2542,O
care,2542,O
team,2542,O
demonstrated,2542,O
that,2542,O
the,2542,O
patient,2542,O
had,2542,O
been,2542,O
self-treating,2542,O
his,2542,O
lithium-induced,2542,B-Chemical
nephrogenic,2542,B-Disease
DI,2542,I-Disease
and,2542,O
developed,2542,O
neurogenic,2542,B-Disease
DI,2542,I-Disease
secondary,2542,O
to,2542,O
brain,2542,B-Disease
trauma,2542,I-Disease
.,2542,O
Thus,2543,O
successful,2543,O
treatment,2543,O
required,2543,O
that,2543,O
nephrogenic,2543,O
and,2543,O
neurogenic,2543,B-Disease
DI,2543,I-Disease
be,2543,O
treated,2543,O
concomitantly,2543,O
.,2543,O
Factors,2544,O
contributing,2544,O
to,2544,O
ribavirin-induced,2544,B-Chemical
anemia,2544,B-Disease
.,2544,O
BACKGROUND,2545,O
AND,2545,O
AIM,2545,O
:,2545,O
Interferon,2545,B-Chemical
and,2545,O
ribavirin,2545,B-Chemical
combination,2545,O
therapy,2545,O
for,2545,O
chronic,2545,B-Disease
hepatitis,2545,I-Disease
C,2545,I-Disease
produces,2545,O
hemolytic,2545,B-Disease
anemia,2545,I-Disease
.,2545,O
This,2546,O
study,2546,O
was,2546,O
conducted,2546,O
to,2546,O
identify,2546,O
the,2546,O
factors,2546,O
contributing,2546,O
to,2546,O
ribavirin-induced,2546,B-Chemical
anemia,2546,B-Disease
.,2546,O
METHODS,2547,O
:,2547,O
Eighty-eight,2547,O
patients,2547,O
with,2547,O
chronic,2547,B-Disease
hepatitis,2547,I-Disease
C,2547,I-Disease
who,2547,O
received,2547,O
interferon-alpha-2b,2547,B-Chemical
at,2547,O
a,2547,O
dose,2547,O
of,2547,O
6,2547,O
MU,2547,O
administered,2547,O
intramuscularly,2547,O
for,2547,O
24,2547,O
weeks,2547,O
in,2547,O
combination,2547,O
with,2547,O
ribavirin,2547,B-Chemical
administered,2547,O
orally,2547,O
at,2547,O
a,2547,O
dose,2547,O
of,2547,O
600,2547,O
mg,2547,O
or,2547,O
800,2547,O
mg,2547,O
participated,2547,O
in,2547,O
the,2547,O
study,2547,O
.,2547,O
A,2548,O
hemoglobin,2548,O
concentration,2548,O
of,2548,O
<,2548,O
10,2548,O
g/dL,2548,O
was,2548,O
defined,2548,O
as,2548,O
ribavirin-induced,2548,B-Chemical
anemia,2548,B-Disease
.,2548,O
RESULTS,2549,O
:,2549,O
Ribavirin-induced,2549,B-Chemical
anemia,2549,B-Disease
occurred,2549,O
in,2549,O
18,2549,O
(,2549,O
20.5,2549,O
%,2549,O
),2549,O
patients,2549,O
during,2549,O
treatment,2549,O
.,2549,O
A,2550,O
2,2550,O
g/dL,2550,O
decrease,2550,O
in,2550,O
hemoglobin,2550,O
concentrations,2550,O
in,2550,O
patients,2550,O
with,2550,O
anemia,2550,B-Disease
was,2550,O
observed,2550,O
at,2550,O
week,2550,O
2,2550,O
after,2550,O
the,2550,O
start,2550,O
of,2550,O
treatment,2550,O
.,2550,O
The,2551,O
hemoglobin,2551,O
concentration,2551,O
in,2551,O
patients,2551,O
with,2551,O
>,2551,O
or,2551,O
=2,2551,O
g/dL,2551,O
decrease,2551,O
at,2551,O
week,2551,O
2,2551,O
was,2551,O
observed,2551,O
to,2551,O
be,2551,O
significantly,2551,O
lower,2551,O
even,2551,O
after,2551,O
week,2551,O
2,2551,O
than,2551,O
in,2551,O
patients,2551,O
with,2551,O
<,2551,O
2,2551,O
g/dL,2551,O
decrease,2551,O
(,2551,O
P,2551,O
<,2551,O
0.01,2551,O
),2551,O
.,2551,O
A,2552,O
significant,2552,O
relationship,2552,O
was,2552,O
observed,2552,O
between,2552,O
the,2552,O
rate,2552,O
of,2552,O
reduction,2552,O
of,2552,O
hemoglobin,2552,O
concentrations,2552,O
at,2552,O
week,2552,O
2,2552,O
and,2552,O
the,2552,O
severity,2552,O
of,2552,O
anemia,2552,B-Disease
(,2552,O
P,2552,O
<,2552,O
0.01,2552,O
),2552,O
.,2552,O
Such,2553,O
factors,2553,O
as,2553,O
sex,2553,O
(,2553,O
female,2553,O
),2553,O
",",2553,O
age,2553,O
(,2553,O
>,2553,O
or,2553,O
=60,2553,O
years,2553,O
old,2553,O
),2553,O
",",2553,O
and,2553,O
the,2553,O
ribavirin,2553,B-Chemical
dose,2553,O
by,2553,O
body,2553,O
weight,2553,O
(,2553,O
12,2553,O
mg/kg,2553,O
or,2553,O
more,2553,O
),2553,O
were,2553,O
significant,2553,O
by,2553,O
univariate,2553,O
analysis,2553,O
.,2553,O
CONCLUSIONS,2554,O
:,2554,O
Careful,2554,O
administration,2554,O
is,2554,O
necessary,2554,O
in,2554,O
patients,2554,O
>,2554,O
or,2554,O
=60,2554,O
years,2554,O
old,2554,O
",",2554,O
in,2554,O
female,2554,O
patients,2554,O
",",2554,O
and,2554,O
in,2554,O
patients,2554,O
receiving,2554,O
a,2554,O
ribavirin,2554,B-Chemical
dose,2554,O
of,2554,O
12,2554,O
mg/kg,2554,O
or,2554,O
more,2554,O
.,2554,O
Patients,2555,O
who,2555,O
experience,2555,O
a,2555,O
fall,2555,O
in,2555,O
hemoglobin,2555,O
concentrations,2555,O
of,2555,O
2,2555,O
g/dL,2555,O
or,2555,O
more,2555,O
at,2555,O
week,2555,O
2,2555,O
after,2555,O
the,2555,O
start,2555,O
of,2555,O
treatment,2555,O
should,2555,O
be,2555,O
monitored,2555,O
with,2555,O
particular,2555,O
care,2555,O
.,2555,O
Oxidative,2556,O
damage,2556,O
precedes,2556,O
nitrative,2556,O
damage,2556,O
in,2556,O
adriamycin-induced,2556,B-Chemical
cardiac,2556,O
mitochondrial,2556,B-Disease
injury,2556,I-Disease
.,2556,O
The,2557,O
purpose,2557,O
of,2557,O
the,2557,O
present,2557,O
study,2557,O
was,2557,O
to,2557,O
determine,2557,O
if,2557,O
elevated,2557,O
reactive,2557,O
oxygen,2557,B-Chemical
(,2557,O
ROS,2557,O
),2557,O
/nitrogen,2557,O
species,2557,O
(,2557,O
RNS,2557,O
),2557,O
reported,2557,O
to,2557,O
be,2557,O
present,2557,O
in,2557,O
adriamycin,2557,B-Chemical
(,2557,O
ADR,2557,B-Chemical
),2557,O
-induced,2557,O
cardiotoxicity,2557,B-Disease
actually,2557,O
resulted,2557,O
in,2557,O
cardiomyocyte,2557,O
oxidative/nitrative,2557,O
damage,2557,O
",",2557,O
and,2557,O
to,2557,O
quantitatively,2557,O
determine,2557,O
the,2557,O
time,2557,O
course,2557,O
and,2557,O
subcellular,2557,O
localization,2557,O
of,2557,O
these,2557,O
postulated,2557,O
damage,2557,O
products,2557,O
using,2557,O
an,2557,O
in,2557,O
vivo,2557,O
approach,2557,O
.,2557,O
B6C3,2558,O
mice,2558,O
were,2558,O
treated,2558,O
with,2558,O
a,2558,O
single,2558,O
dose,2558,O
of,2558,O
20,2558,O
mg/kg,2558,O
ADR,2558,B-Chemical
.,2558,O
Ultrastructural,2559,O
damage,2559,O
and,2559,O
levels,2559,O
of,2559,O
4-hydroxy-2-nonenal,2559,B-Chemical
(,2559,O
4HNE,2559,B-Chemical
),2559,O
-protein,2559,O
adducts,2559,O
and,2559,O
3-nitrotyrosine,2559,B-Chemical
(,2559,O
3NT,2559,B-Chemical
),2559,O
were,2559,O
analyzed,2559,O
.,2559,O
Quantitative,2560,O
ultrastructural,2560,O
damage,2560,O
using,2560,O
computerized,2560,O
image,2560,O
techniques,2560,O
showed,2560,O
cardiomyocyte,2560,O
injury,2560,O
as,2560,O
early,2560,O
as,2560,O
3,2560,O
hours,2560,O
",",2560,O
with,2560,O
mitochondria,2560,O
being,2560,O
the,2560,O
most,2560,O
extensively,2560,O
and,2560,O
progressively,2560,O
injured,2560,O
subcellular,2560,O
organelle,2560,O
.,2560,O
Analysis,2561,O
of,2561,O
4HNE,2561,B-Chemical
protein,2561,O
adducts,2561,O
by,2561,O
immunogold,2561,O
electron,2561,O
microscopy,2561,O
showed,2561,O
appearance,2561,O
of,2561,O
4HNE,2561,B-Chemical
protein,2561,O
adducts,2561,O
in,2561,O
mitochondria,2561,O
as,2561,O
early,2561,O
as,2561,O
3,2561,O
hours,2561,O
",",2561,O
with,2561,O
a,2561,O
peak,2561,O
at,2561,O
6,2561,O
hours,2561,O
and,2561,O
subsequent,2561,O
decline,2561,O
at,2561,O
24,2561,O
hours,2561,O
.,2561,O
3NT,2562,B-Chemical
levels,2562,O
were,2562,O
significantly,2562,O
increased,2562,O
in,2562,O
all,2562,O
subcellular,2562,O
compartments,2562,O
at,2562,O
6,2562,O
hours,2562,O
and,2562,O
subsequently,2562,O
declined,2562,O
at,2562,O
24,2562,O
hours,2562,O
.,2562,O
Our,2563,O
data,2563,O
showed,2563,O
ADR,2563,B-Chemical
induced,2563,O
4HNE-protein,2563,B-Chemical
adducts,2563,O
in,2563,O
mitochondria,2563,O
at,2563,O
the,2563,O
same,2563,O
time,2563,O
point,2563,O
as,2563,O
when,2563,O
mitochondrial,2563,B-Disease
injury,2563,I-Disease
initially,2563,O
appeared,2563,O
.,2563,O
These,2564,O
results,2564,O
document,2564,O
for,2564,O
the,2564,O
first,2564,O
time,2564,O
in,2564,O
vivo,2564,O
that,2564,O
mitochondrial,2564,B-Disease
oxidative,2564,I-Disease
damage,2564,I-Disease
precedes,2564,O
nitrative,2564,O
damage,2564,O
.,2564,O
The,2565,O
progressive,2565,O
nature,2565,O
of,2565,O
mitochondrial,2565,B-Disease
injury,2565,I-Disease
suggests,2565,O
that,2565,O
mitochondria,2565,O
",",2565,O
not,2565,O
other,2565,O
subcellular,2565,O
organelles,2565,O
",",2565,O
are,2565,O
the,2565,O
major,2565,O
site,2565,O
of,2565,O
intracellular,2565,O
injury,2565,O
.,2565,O
Sotalol-induced,2566,B-Chemical
coronary,2566,B-Disease
spasm,2566,I-Disease
in,2566,O
a,2566,O
patient,2566,O
with,2566,O
dilated,2566,B-Disease
cardiomyopathy,2566,I-Disease
associated,2566,O
with,2566,O
sustained,2566,O
ventricular,2566,B-Disease
tachycardia,2566,I-Disease
.,2566,O
A,2567,O
54-year-old,2567,O
man,2567,O
with,2567,O
severe,2567,O
left,2567,O
ventricular,2567,B-Disease
dysfunction,2567,I-Disease
due,2567,O
to,2567,O
dilated,2567,B-Disease
cardiomyopathy,2567,I-Disease
was,2567,O
referred,2567,O
to,2567,O
our,2567,O
hospital,2567,O
for,2567,O
symptomatic,2567,O
incessant,2567,O
sustained,2567,O
ventricular,2567,B-Disease
tachycardia,2567,I-Disease
(,2567,O
VT,2567,B-Disease
),2567,O
.,2567,O
After,2568,O
the,2568,O
administration,2568,O
of,2568,O
nifekalant,2568,B-Chemical
hydrochloride,2568,I-Chemical
",",2568,O
sustained,2568,O
VT,2568,B-Disease
was,2568,O
terminated,2568,O
.,2568,O
An,2569,O
alternate,2569,O
class,2569,O
III,2569,O
agent,2569,O
",",2569,O
sotalol,2569,B-Chemical
",",2569,O
was,2569,O
also,2569,O
effective,2569,O
for,2569,O
the,2569,O
prevention,2569,O
of,2569,O
VT,2569,B-Disease
.,2569,O
However,2570,O
",",2570,O
one,2570,O
month,2570,O
after,2570,O
switching,2570,O
over,2570,O
nifekalant,2570,B-Chemical
to,2570,O
sotalol,2570,B-Chemical
",",2570,O
a,2570,O
short,2570,O
duration,2570,O
of,2570,O
ST,2570,O
elevation,2570,O
was,2570,O
documented,2570,O
in,2570,O
ECG,2570,O
monitoring,2570,O
at,2570,O
almost,2570,O
the,2570,O
same,2570,O
time,2570,O
for,2570,O
three,2570,O
consecutive,2570,O
days,2570,O
.,2570,O
ST,2571,O
elevation,2571,O
with,2571,O
chest,2571,O
discomfort,2571,O
disappeared,2571,O
since,2571,O
he,2571,O
began,2571,O
taking,2571,O
long-acting,2571,O
diltiazem,2571,B-Chemical
.,2571,O
Coronary,2572,B-Disease
vasospasm,2572,I-Disease
may,2572,O
be,2572,O
induced,2572,O
by,2572,O
the,2572,O
non-selective,2572,O
beta-blocking,2572,O
properties,2572,O
of,2572,O
sotalol,2572,B-Chemical
.,2572,O
Effects,2573,O
of,2573,O
the,2573,O
antidepressant,2573,O
trazodone,2573,B-Chemical
",",2573,O
a,2573,O
5-HT,2573,B-Chemical
2A/2C,2573,O
receptor,2573,O
antagonist,2573,O
",",2573,O
on,2573,O
dopamine-dependent,2573,B-Chemical
behaviors,2573,O
in,2573,O
rats,2573,O
.,2573,O
RATIONALE,2574,O
:,2574,O
5-Hydroxytryptamine,2574,B-Chemical
",",2574,O
via,2574,O
stimulation,2574,O
of,2574,O
5-HT,2574,B-Chemical
2C,2574,O
receptors,2574,O
",",2574,O
exerts,2574,O
a,2574,O
tonic,2574,O
inhibitory,2574,O
influence,2574,O
on,2574,O
dopaminergic,2574,O
neurotransmission,2574,O
",",2574,O
whereas,2574,O
activation,2574,O
of,2574,O
5-HT,2574,B-Chemical
2A,2574,O
receptors,2574,O
enhances,2574,O
stimulated,2574,O
DAergic,2574,O
neurotransmission,2574,O
.,2574,O
The,2575,O
antidepressant,2575,O
trazodone,2575,B-Chemical
is,2575,O
a,2575,O
5-HT,2575,B-Chemical
2A/2C,2575,O
receptor,2575,O
antagonist,2575,O
.,2575,O
OBJECTIVES,2576,O
:,2576,O
To,2576,O
evaluate,2576,O
the,2576,O
effect,2576,O
of,2576,O
trazodone,2576,B-Chemical
treatment,2576,O
on,2576,O
behaviors,2576,O
dependent,2576,O
on,2576,O
the,2576,O
functional,2576,O
status,2576,O
of,2576,O
the,2576,O
nigrostriatal,2576,O
DAergic,2576,O
system,2576,O
.,2576,O
METHODS,2577,O
:,2577,O
The,2577,O
effect,2577,O
of,2577,O
pretreatment,2577,O
with,2577,O
trazodone,2577,B-Chemical
on,2577,O
dexamphetamine-,2577,B-Chemical
and,2577,O
apomorphine-induced,2577,B-Chemical
oral,2577,B-Disease
stereotypies,2577,I-Disease
",",2577,O
on,2577,O
catalepsy,2577,B-Disease
induced,2577,O
by,2577,O
haloperidol,2577,B-Chemical
and,2577,O
apomorphine,2577,B-Chemical
(,2577,O
0.05,2577,O
mg/kg,2577,O
",",2577,O
i.p,2577,O
.,2577,O
),2578,O
",",2578,O
on,2578,O
ergometrine-induced,2578,O
wet,2578,O
dog,2578,O
shake,2578,O
(,2578,O
WDS,2578,O
),2578,O
behavior,2578,O
and,2578,O
fluoxetine-induced,2578,O
penile,2578,O
erections,2578,O
was,2578,O
studied,2578,O
in,2578,O
rats,2578,O
.,2578,O
We,2579,O
also,2579,O
investigated,2579,O
whether,2579,O
trazodone,2579,O
induces,2579,O
catalepsy,2579,O
in,2579,O
rats,2579,O
.,2579,O
RESULTS,2580,O
:,2580,O
Trazodone,2580,O
at,2580,O
2.5-20,2580,O
mg/kg,2580,O
i.p,2580,O
.,2580,O
did,2581,O
not,2581,O
induce,2581,O
catalepsy,2581,O
",",2581,O
and,2581,O
did,2581,O
not,2581,O
antagonize,2581,O
apomorphine,2581,O
(,2581,O
1.5,2581,O
and,2581,O
3,2581,O
mg/kg,2581,O
),2581,O
stereotypy,2581,O
and,2581,O
apomorphine,2581,O
(,2581,O
0.05,2581,O
mg/kg,2581,O
),2581,O
-induced,2581,O
catalepsy,2581,O
.,2581,O
However,2582,O
",",2582,O
pretreatment,2582,O
with,2582,O
5,2582,O
",",2582,O
10,2582,O
and,2582,O
20,2582,O
mg/kg,2582,O
i.p,2582,O
.,2582,O
trazodone,2583,O
enhanced,2583,O
dexamphetamine,2583,O
stereotypy,2583,O
",",2583,O
and,2583,O
antagonized,2583,O
haloperidol,2583,O
catalepsy,2583,O
",",2583,O
ergometrine-induced,2583,O
WDS,2583,O
behavior,2583,O
and,2583,O
fluoxetine-induced,2583,O
penile,2583,O
erections,2583,O
.,2583,O
Trazodone,2584,O
at,2584,O
30,2584,O
",",2584,O
40,2584,O
and,2584,O
50,2584,O
mg/kg,2584,O
i.p,2584,O
.,2584,O
induced,2585,O
catalepsy,2585,O
and,2585,O
antagonized,2585,O
apomorphine,2585,O
and,2585,O
dexamphetamine,2585,O
stereotypies,2585,O
.,2585,O
CONCLUSIONS,2586,O
:,2586,O
Our,2586,O
results,2586,O
indicate,2586,O
that,2586,O
trazodone,2586,O
at,2586,O
2.5-20,2586,O
mg/kg,2586,O
does,2586,O
not,2586,O
block,2586,O
pre-,2586,O
and,2586,O
postsynaptic,2586,O
striatal,2586,O
D2,2586,O
DA,2586,O
receptors,2586,O
",",2586,O
while,2586,O
at,2586,O
30,2586,O
",",2586,O
40,2586,O
and,2586,O
50,2586,O
mg/kg,2586,O
it,2586,O
blocks,2586,O
postsynaptic,2586,O
striatal,2586,O
D2,2586,O
DA,2586,O
receptors,2586,O
.,2586,O
Furthermore,2587,O
",",2587,O
at,2587,O
5,2587,O
",",2587,O
10,2587,O
and,2587,O
20,2587,O
mg/kg,2587,O
",",2587,O
trazodone,2587,O
blocks,2587,O
5-HT,2587,O
2A,2587,O
and,2587,O
5-HT,2587,O
2C,2587,O
receptors,2587,O
.,2587,O
We,2588,O
suggest,2588,O
that,2588,O
trazodone,2588,O
(,2588,O
5,2588,O
",",2588,O
10,2588,O
and,2588,O
20,2588,O
mg/kg,2588,O
),2588,O
",",2588,O
by,2588,O
blocking,2588,O
the,2588,O
5-HT,2588,O
2C,2588,O
receptors,2588,O
",",2588,O
releases,2588,O
the,2588,O
nigrostriatal,2588,O
DAergic,2588,O
neurons,2588,O
from,2588,O
tonic,2588,O
inhibition,2588,O
caused,2588,O
by,2588,O
5-HT,2588,O
",",2588,O
and,2588,O
thereby,2588,O
potentiates,2588,O
dexamphetamine,2588,O
stereotypy,2588,O
and,2588,O
antagonizes,2588,O
haloperidol,2588,O
catalepsy,2588,O
.,2588,O
Swallowing,2589,B-Disease
abnormalities,2589,I-Disease
and,2589,O
dyskinesia,2589,B-Disease
in,2589,O
Parkinson,2589,B-Disease
's,2589,I-Disease
disease,2589,I-Disease
.,2589,O
Gastrointestinal,2590,B-Disease
abnormalities,2590,I-Disease
in,2590,O
Parkinson,2590,B-Disease
's,2590,I-Disease
disease,2590,I-Disease
(,2590,O
PD,2590,B-Disease
),2590,O
have,2590,O
been,2590,O
known,2590,O
for,2590,O
almost,2590,O
two,2590,O
centuries,2590,O
",",2590,O
but,2590,O
many,2590,O
aspects,2590,O
concerning,2590,O
their,2590,O
pathophysiology,2590,O
have,2590,O
not,2590,O
been,2590,O
completely,2590,O
clarified,2590,O
.,2590,O
The,2591,O
aim,2591,O
of,2591,O
this,2591,O
study,2591,O
was,2591,O
to,2591,O
characterize,2591,O
the,2591,O
oropharyngeal,2591,O
dynamics,2591,O
in,2591,O
PD,2591,B-Disease
patients,2591,O
with,2591,O
and,2591,O
without,2591,O
levodopa-induced,2591,B-Chemical
dyskinesia,2591,B-Disease
.,2591,O
Fifteen,2592,O
dyskinetic,2592,B-Disease
",",2592,O
12,2592,O
nondyskinetic,2592,O
patients,2592,O
",",2592,O
and,2592,O
a,2592,O
control,2592,O
group,2592,O
were,2592,O
included,2592,O
.,2592,O
Patients,2593,O
were,2593,O
asked,2593,O
about,2593,O
dysphagia,2593,B-Disease
and,2593,O
evaluated,2593,O
with,2593,O
the,2593,O
Unified,2593,O
Parkinson,2593,B-Disease
's,2593,I-Disease
Disease,2593,I-Disease
Rating,2593,O
Scale,2593,O
Parts,2593,O
II,2593,O
and,2593,O
III,2593,O
and,2593,O
the,2593,O
Hoehn,2593,O
and,2593,O
Yahr,2593,O
scale,2593,O
.,2593,O
Deglutition,2594,O
was,2594,O
assessed,2594,O
using,2594,O
modified,2594,O
barium,2594,B-Chemical
swallow,2594,O
with,2594,O
videofluoroscopy,2594,O
.,2594,O
Nondyskinetic,2595,O
patients,2595,O
",",2595,O
but,2595,O
not,2595,O
the,2595,O
dyskinetic,2595,B-Disease
ones,2595,O
",",2595,O
showed,2595,O
less,2595,O
oropharyngeal,2595,O
swallowing,2595,O
efficiency,2595,O
(,2595,O
OPSE,2595,O
),2595,O
for,2595,O
liquid,2595,O
food,2595,O
than,2595,O
controls,2595,O
(,2595,O
Dunnett,2595,O
",",2595,O
P,2595,O
=,2595,O
0.02,2595,O
),2595,O
.,2595,O
Dyskinetic,2596,B-Disease
patients,2596,O
tended,2596,O
to,2596,O
have,2596,O
a,2596,O
greater,2596,O
OPSE,2596,O
than,2596,O
nondyskinetic,2596,O
(,2596,O
Dunnett,2596,O
",",2596,O
P,2596,O
=,2596,O
0.06,2596,O
),2596,O
.,2596,O
Patients,2597,O
who,2597,O
were,2597,O
using,2597,O
a,2597,O
higher,2597,O
dose,2597,O
of,2597,O
levodopa,2597,B-Chemical
had,2597,O
a,2597,O
greater,2597,O
OPSE,2597,O
and,2597,O
a,2597,O
trend,2597,O
toward,2597,O
a,2597,O
smaller,2597,O
oral,2597,O
transit,2597,O
time,2597,O
(,2597,O
Pearson,2597,O
's,2597,O
correlation,2597,O
",",2597,O
P,2597,O
=,2597,O
0.01,2597,O
and,2597,O
0.08,2597,O
",",2597,O
respectively,2597,O
),2597,O
.,2597,O
Neither,2598,O
the,2598,O
report,2598,O
of,2598,O
dysphagia,2598,B-Disease
nor,2598,O
any,2598,O
of,2598,O
the,2598,O
PD,2598,B-Disease
severity,2598,O
parameters,2598,O
correlated,2598,O
to,2598,O
the,2598,O
videofluoroscopic,2598,O
variables,2598,O
.,2598,O
In,2599,O
the,2599,O
current,2599,O
study,2599,O
",",2599,O
dyskinetic,2599,B-Disease
patients,2599,O
performed,2599,O
better,2599,O
in,2599,O
swallowing,2599,O
function,2599,O
",",2599,O
which,2599,O
could,2599,O
be,2599,O
explained,2599,O
on,2599,O
the,2599,O
basis,2599,O
of,2599,O
a,2599,O
greater,2599,O
levodopa,2599,B-Chemical
dose,2599,O
.,2599,O
Our,2600,O
results,2600,O
suggest,2600,O
a,2600,O
role,2600,O
for,2600,O
levodopa,2600,B-Chemical
in,2600,O
the,2600,O
oral,2600,O
phase,2600,O
of,2600,O
deglutition,2600,O
and,2600,O
confirm,2600,O
that,2600,O
dysphagia,2600,B-Disease
is,2600,O
not,2600,O
a,2600,O
good,2600,O
predictor,2600,O
of,2600,O
deglutition,2600,O
alterations,2600,O
in,2600,O
PD,2600,B-Disease
.,2600,O
Inhibition,2601,O
of,2601,O
nuclear,2601,O
factor-kappaB,2601,O
activation,2601,O
attenuates,2601,O
tubulointerstitial,2601,B-Disease
nephritis,2601,I-Disease
induced,2601,O
by,2601,O
gentamicin,2601,B-Chemical
.,2601,O
BACKGROUND,2602,O
:,2602,O
Animals,2602,O
treated,2602,O
with,2602,O
gentamicin,2602,B-Chemical
can,2602,O
show,2602,O
residual,2602,O
areas,2602,O
of,2602,O
interstitial,2602,O
fibrosis,2602,B-Disease
in,2602,O
the,2602,O
renal,2602,O
cortex,2602,O
.,2602,O
This,2603,O
study,2603,O
investigated,2603,O
the,2603,O
expression,2603,O
of,2603,O
nuclear,2603,O
factor-kappaB,2603,O
(,2603,O
NF-kappaB,2603,O
),2603,O
",",2603,O
mitogen-activated,2603,O
protein,2603,O
(,2603,O
MAP,2603,O
),2603,O
kinases,2603,O
and,2603,O
macrophages,2603,O
in,2603,O
the,2603,O
renal,2603,O
cortex,2603,O
and,2603,O
structural,2603,O
and,2603,O
functional,2603,O
renal,2603,O
changes,2603,O
of,2603,O
rats,2603,O
treated,2603,O
with,2603,O
gentamicin,2603,B-Chemical
or,2603,O
gentamicin,2603,B-Chemical
+,2603,O
pyrrolidine,2603,B-Chemical
dithiocarbamate,2603,I-Chemical
(,2603,O
PDTC,2603,B-Chemical
),2603,O
",",2603,O
an,2603,O
NF-kappaB,2603,O
inhibitor,2603,O
.,2603,O
METHODS,2604,O
:,2604,O
38,2604,O
female,2604,O
Wistar,2604,O
rats,2604,O
were,2604,O
injected,2604,O
with,2604,O
gentamicin,2604,B-Chemical
",",2604,O
40,2604,O
mg/kg,2604,O
",",2604,O
twice,2604,O
a,2604,O
day,2604,O
for,2604,O
9,2604,O
days,2604,O
",",2604,O
38,2604,O
with,2604,O
gentamicin,2604,B-Chemical
+,2604,O
PDTC,2604,B-Chemical
",",2604,O
and,2604,O
28,2604,O
with,2604,O
0.15,2604,O
M,2604,O
NaCl,2604,B-Chemical
solution,2604,O
.,2604,O
The,2605,O
animals,2605,O
were,2605,O
killed,2605,O
5,2605,O
and,2605,O
30,2605,O
days,2605,O
after,2605,O
these,2605,O
injections,2605,O
and,2605,O
the,2605,O
kidneys,2605,O
were,2605,O
removed,2605,O
for,2605,O
histological,2605,O
and,2605,O
immunohistochemical,2605,O
studies,2605,O
.,2605,O
The,2606,O
results,2606,O
of,2606,O
the,2606,O
immunohistochemical,2606,O
studies,2606,O
were,2606,O
scored,2606,O
according,2606,O
to,2606,O
the,2606,O
extent,2606,O
of,2606,O
staining,2606,O
.,2606,O
The,2607,O
fractional,2607,O
interstitial,2607,O
area,2607,O
was,2607,O
determined,2607,O
by,2607,O
morphometry,2607,O
.,2607,O
RESULTS,2608,O
:,2608,O
Gentamicin-treated,2608,B-Chemical
rats,2608,O
presented,2608,O
a,2608,O
transitory,2608,O
increase,2608,O
in,2608,O
plasma,2608,O
creatinine,2608,B-Chemical
levels,2608,O
.,2608,O
Increased,2609,O
ED-1,2609,O
",",2609,O
MAP,2609,O
kinases,2609,O
and,2609,O
NF-kappaB,2609,O
staining,2609,O
were,2609,O
also,2609,O
observed,2609,O
in,2609,O
the,2609,O
renal,2609,O
cortex,2609,O
from,2609,O
all,2609,O
gentamicin-treated,2609,B-Chemical
rats,2609,O
compared,2609,O
to,2609,O
control,2609,O
(,2609,O
p,2609,O
<,2609,O
0.05,2609,O
),2609,O
.,2609,O
The,2610,O
animals,2610,O
killed,2610,O
on,2610,O
day,2610,O
30,2610,O
also,2610,O
presented,2610,O
fibrosis,2610,B-Disease
in,2610,O
the,2610,O
renal,2610,O
cortex,2610,O
despite,2610,O
the,2610,O
recovery,2610,O
of,2610,O
renal,2610,O
function,2610,O
.,2610,O
Treatment,2611,O
with,2611,O
PDTC,2611,B-Chemical
reduced,2611,O
the,2611,O
functional,2611,O
and,2611,O
structural,2611,O
changes,2611,O
induced,2611,O
by,2611,O
gentamicin,2611,B-Chemical
.,2611,O
CONCLUSIONS,2612,O
:,2612,O
These,2612,O
data,2612,O
show,2612,O
that,2612,O
inhibition,2612,O
of,2612,O
NF-kappaB,2612,O
activation,2612,O
attenuates,2612,O
tubulointerstitial,2612,B-Disease
nephritis,2612,I-Disease
induced,2612,O
by,2612,O
gentamicin,2612,B-Chemical
.,2612,O
Glucose,2613,B-Chemical
metabolism,2613,O
in,2613,O
patients,2613,O
with,2613,O
schizophrenia,2613,B-Disease
treated,2613,O
with,2613,O
atypical,2613,O
antipsychotic,2613,O
agents,2613,O
:,2613,O
a,2613,O
frequently,2613,O
sampled,2613,O
intravenous,2613,O
glucose,2613,B-Chemical
tolerance,2613,O
test,2613,O
and,2613,O
minimal,2613,O
model,2613,O
analysis,2613,O
.,2613,O
BACKGROUND,2614,O
:,2614,O
While,2614,O
the,2614,O
incidence,2614,O
of,2614,O
new-onset,2614,O
diabetes,2614,B-Disease
mellitus,2614,I-Disease
may,2614,O
be,2614,O
increasing,2614,O
in,2614,O
patients,2614,O
with,2614,O
schizophrenia,2614,B-Disease
treated,2614,O
with,2614,O
certain,2614,O
atypical,2614,O
antipsychotic,2614,O
agents,2614,O
",",2614,O
it,2614,O
remains,2614,O
unclear,2614,O
whether,2614,O
atypical,2614,O
agents,2614,O
are,2614,O
directly,2614,O
affecting,2614,O
glucose,2614,B-Chemical
metabolism,2614,O
or,2614,O
simply,2614,O
increasing,2614,O
known,2614,O
risk,2614,O
factors,2614,O
for,2614,O
diabetes,2614,B-Disease
.,2614,O
OBJECTIVE,2615,O
:,2615,O
To,2615,O
study,2615,O
the,2615,O
2,2615,O
drugs,2615,O
most,2615,O
clearly,2615,O
implicated,2615,O
(,2615,O
clozapine,2615,B-Chemical
and,2615,O
olanzapine,2615,B-Chemical
),2615,O
and,2615,O
risperidone,2615,B-Chemical
using,2615,O
a,2615,O
frequently,2615,O
sampled,2615,O
intravenous,2615,O
glucose,2615,B-Chemical
tolerance,2615,O
test,2615,O
.,2615,O
DESIGN,2616,O
:,2616,O
A,2616,O
cross-sectional,2616,O
design,2616,O
in,2616,O
stable,2616,O
",",2616,O
treated,2616,O
patients,2616,O
with,2616,O
schizophrenia,2616,B-Disease
evaluated,2616,O
using,2616,O
a,2616,O
frequently,2616,O
sampled,2616,O
intravenous,2616,O
glucose,2616,B-Chemical
tolerance,2616,O
test,2616,O
and,2616,O
the,2616,O
Bergman,2616,O
minimal,2616,O
model,2616,O
analysis,2616,O
.,2616,O
SETTING,2617,O
:,2617,O
Subjects,2617,O
were,2617,O
recruited,2617,O
from,2617,O
an,2617,O
urban,2617,O
community,2617,O
mental,2617,O
health,2617,O
clinic,2617,O
and,2617,O
were,2617,O
studied,2617,O
at,2617,O
a,2617,O
general,2617,O
clinical,2617,O
research,2617,O
center,2617,O
.,2617,O
Patients,2618,O
Fifty,2618,O
subjects,2618,O
signed,2618,O
informed,2618,O
consent,2618,O
and,2618,O
41,2618,O
underwent,2618,O
the,2618,O
frequently,2618,O
sampled,2618,O
intravenous,2618,O
glucose,2618,B-Chemical
tolerance,2618,O
test,2618,O
.,2618,O
Thirty-six,2619,O
nonobese,2619,O
subjects,2619,O
with,2619,O
schizophrenia,2619,B-Disease
or,2619,O
schizoaffective,2619,B-Disease
disorder,2619,I-Disease
",",2619,O
matched,2619,O
by,2619,O
body,2619,O
mass,2619,O
index,2619,O
and,2619,O
treated,2619,O
with,2619,O
either,2619,O
clozapine,2619,B-Chemical
",",2619,O
olanzapine,2619,B-Chemical
",",2619,O
or,2619,O
risperidone,2619,B-Chemical
",",2619,O
were,2619,O
included,2619,O
in,2619,O
the,2619,O
analysis,2619,O
.,2619,O
MAIN,2620,O
OUTCOME,2620,O
MEASURES,2620,O
:,2620,O
Fasting,2620,O
plasma,2620,O
glucose,2620,B-Chemical
and,2620,O
fasting,2620,O
serum,2620,O
insulin,2620,O
levels,2620,O
",",2620,O
insulin,2620,B-Disease
sensitivity,2620,I-Disease
index,2620,O
",",2620,O
homeostasis,2620,O
model,2620,O
assessment,2620,O
of,2620,O
insulin,2620,B-Disease
resistance,2620,I-Disease
",",2620,O
and,2620,O
glucose,2620,B-Chemical
effectiveness,2620,O
.,2620,O
RESULTS,2621,O
:,2621,O
The,2621,O
mean,2621,O
+/-,2621,O
SD,2621,O
duration,2621,O
of,2621,O
treatment,2621,O
with,2621,O
the,2621,O
identified,2621,O
atypical,2621,O
antipsychotic,2621,O
agent,2621,O
was,2621,O
68.3,2621,O
+/-,2621,O
28.9,2621,O
months,2621,O
(,2621,O
clozapine,2621,B-Chemical
),2621,O
",",2621,O
29.5,2621,O
+/-,2621,O
17.5,2621,O
months,2621,O
(,2621,O
olanzapine,2621,B-Chemical
),2621,O
",",2621,O
and,2621,O
40.9,2621,O
+/-,2621,O
33.7,2621,O
(,2621,O
risperidone,2621,B-Chemical
),2621,O
.,2621,O
Fasting,2622,O
serum,2622,O
insulin,2622,O
concentrations,2622,O
differed,2622,O
among,2622,O
groups,2622,O
(,2622,O
F,2622,O
(,2622,O
33,2622,O
),2622,O
=,2622,O
3.35,2622,O
;,2622,O
P,2622,O
=,2622,O
.047,2622,O
),2622,O
(,2622,O
clozapine,2622,B-Chemical
>,2622,O
olanzapine,2622,B-Chemical
>,2622,O
risperidone,2622,B-Chemical
),2622,O
with,2622,O
significant,2622,O
differences,2622,O
between,2622,O
clozapine,2622,B-Chemical
and,2622,O
risperidone,2622,B-Chemical
(,2622,O
t,2622,O
(,2622,O
33,2622,O
),2622,O
=,2622,O
2.32,2622,O
;,2622,O
P,2622,O
=,2622,O
.03,2622,O
),2622,O
and,2622,O
olanzapine,2622,B-Chemical
and,2622,O
risperidone,2622,B-Chemical
(,2622,O
t,2622,O
(,2622,O
33,2622,O
),2622,O
=,2622,O
2.15,2622,O
;,2622,O
P,2622,O
=,2622,O
.04,2622,O
),2622,O
.,2622,O
There,2623,O
was,2623,O
a,2623,O
significant,2623,O
difference,2623,O
in,2623,O
insulin,2623,B-Disease
sensitivity,2623,I-Disease
index,2623,O
among,2623,O
groups,2623,O
(,2623,O
F,2623,O
(,2623,O
33,2623,O
),2623,O
=,2623,O
10.66,2623,O
;,2623,O
P,2623,O
<,2623,O
.001,2623,O
),2623,O
(,2623,O
clozapine,2623,B-Chemical
<,2623,O
olanzapine,2623,B-Chemical
<,2623,O
risperidone,2623,B-Chemical
),2623,O
",",2623,O
with,2623,O
subjects,2623,O
who,2623,O
received,2623,O
clozapine,2623,B-Chemical
and,2623,O
olanzapine,2623,B-Chemical
exhibiting,2623,O
significant,2623,O
insulin,2623,B-Disease
resistance,2623,I-Disease
compared,2623,O
with,2623,O
subjects,2623,O
who,2623,O
were,2623,O
treated,2623,O
with,2623,O
risperidone,2623,B-Chemical
(,2623,O
clozapine,2623,B-Chemical
vs,2623,O
risperidone,2623,B-Chemical
",",2623,O
t,2623,O
(,2623,O
33,2623,O
),2623,O
=,2623,O
-4.29,2623,O
;,2623,O
P,2623,O
<,2623,O
.001,2623,O
;,2623,O
olanzapine,2623,B-Chemical
vs,2623,O
risperidone,2623,B-Chemical
",",2623,O
t,2623,O
(,2623,O
33,2623,O
),2623,O
=,2623,O
-3.62,2623,O
;,2623,O
P,2623,O
=,2623,O
.001,2623,O
[,2623,O
P,2623,O
<,2623,O
.001,2623,O
],2623,O
),2623,O
.,2623,O
The,2624,O
homeostasis,2624,O
model,2624,O
assessment,2624,O
of,2624,O
insulin,2624,B-Disease
resistance,2624,I-Disease
also,2624,O
differed,2624,O
significantly,2624,O
among,2624,O
groups,2624,O
(,2624,O
F,2624,O
(,2624,O
33,2624,O
),2624,O
=,2624,O
4.92,2624,O
;,2624,O
P,2624,O
=,2624,O
.01,2624,O
),2624,O
(,2624,O
clozapine,2624,B-Chemical
>,2624,O
olanzapine,2624,B-Chemical
>,2624,O
risperidone,2624,B-Chemical
),2624,O
(,2624,O
clozapine,2624,B-Chemical
vs,2624,O
risperidone,2624,B-Chemical
",",2624,O
t,2624,O
(,2624,O
33,2624,O
),2624,O
=,2624,O
2.94,2624,O
;,2624,O
P,2624,O
=,2624,O
.006,2624,O
;,2624,O
olanzapine,2624,B-Chemical
vs,2624,O
risperidone,2624,B-Chemical
",",2624,O
t,2624,O
(,2624,O
33,2624,O
),2624,O
=,2624,O
2.42,2624,O
;,2624,O
P,2624,O
=,2624,O
.02,2624,O
),2624,O
.,2624,O
There,2625,O
was,2625,O
a,2625,O
significant,2625,O
difference,2625,O
among,2625,O
groups,2625,O
in,2625,O
glucose,2625,B-Chemical
effectiveness,2625,O
(,2625,O
F,2625,O
(,2625,O
30,2625,O
),2625,O
=,2625,O
4.18,2625,O
;,2625,O
P,2625,O
=,2625,O
.02,2625,O
),2625,O
(,2625,O
clozapine,2625,B-Chemical
<,2625,O
olanzapine,2625,B-Chemical
<,2625,O
risperidone,2625,B-Chemical
),2625,O
with,2625,O
significant,2625,O
differences,2625,O
between,2625,O
clozapine,2625,B-Chemical
and,2625,O
risperidone,2625,B-Chemical
(,2625,O
t,2625,O
(,2625,O
30,2625,O
),2625,O
=,2625,O
-2.59,2625,O
;,2625,O
P,2625,O
=,2625,O
.02,2625,O
),2625,O
and,2625,O
olanzapine,2625,B-Chemical
and,2625,O
risperidone,2625,B-Chemical
(,2625,O
t,2625,O
(,2625,O
30,2625,O
),2625,O
=,2625,O
-2.34,2625,O
",",2625,O
P,2625,O
=,2625,O
.03,2625,O
),2625,O
.,2625,O
CONCLUSIONS,2626,O
:,2626,O
Both,2626,O
nonobese,2626,O
clozapine-,2626,B-Chemical
and,2626,O
olanzapine-treated,2626,B-Chemical
groups,2626,O
displayed,2626,O
significant,2626,O
insulin,2626,B-Disease
resistance,2626,I-Disease
and,2626,O
impairment,2626,O
of,2626,O
glucose,2626,B-Chemical
effectiveness,2626,O
compared,2626,O
with,2626,O
risperidone-treated,2626,B-Chemical
subjects,2626,O
.,2626,O
Patients,2627,O
taking,2627,O
clozapine,2627,B-Chemical
and,2627,O
olanzapine,2627,B-Chemical
must,2627,O
be,2627,O
examined,2627,O
for,2627,O
insulin,2627,B-Disease
resistance,2627,I-Disease
and,2627,O
its,2627,O
consequences,2627,O
.,2627,O
Acute,2628,B-Disease
renal,2628,I-Disease
insufficiency,2628,I-Disease
after,2628,O
high-dose,2628,O
melphalan,2628,B-Chemical
in,2628,O
patients,2628,O
with,2628,O
primary,2628,B-Disease
systemic,2628,I-Disease
amyloidosis,2628,I-Disease
during,2628,O
stem,2628,O
cell,2628,O
transplantation,2628,O
.,2628,O
BACKGROUND,2629,O
:,2629,O
Patients,2629,O
with,2629,O
primary,2629,B-Disease
systemic,2629,I-Disease
amyloidosis,2629,I-Disease
(,2629,O
AL,2629,B-Disease
),2629,O
have,2629,O
a,2629,O
poor,2629,O
prognosis,2629,O
.,2629,O
Median,2630,O
survival,2630,O
time,2630,O
from,2630,O
standard,2630,O
treatments,2630,O
is,2630,O
only,2630,O
17,2630,O
months,2630,O
.,2630,O
High-dose,2631,O
intravenous,2631,O
melphalan,2631,B-Chemical
followed,2631,O
by,2631,O
peripheral,2631,O
blood,2631,O
stem,2631,O
cell,2631,O
transplant,2631,O
(,2631,O
PBSCT,2631,O
),2631,O
appears,2631,O
to,2631,O
be,2631,O
the,2631,O
most,2631,O
promising,2631,O
therapy,2631,O
",",2631,O
but,2631,O
treatment,2631,O
mortality,2631,O
can,2631,O
be,2631,O
high,2631,O
.,2631,O
The,2632,O
authors,2632,O
have,2632,O
noted,2632,O
the,2632,O
development,2632,O
of,2632,O
acute,2632,B-Disease
renal,2632,I-Disease
insufficiency,2632,I-Disease
immediately,2632,O
after,2632,O
melphalan,2632,B-Chemical
conditioning,2632,O
.,2632,O
This,2633,O
study,2633,O
was,2633,O
undertaken,2633,O
to,2633,O
further,2633,O
examine,2633,O
its,2633,O
risk,2633,O
factors,2633,O
and,2633,O
impact,2633,O
on,2633,O
posttransplant,2633,O
mortality,2633,O
.,2633,O
METHODS,2634,O
:,2634,O
Consecutive,2634,O
AL,2634,B-Disease
patients,2634,O
who,2634,O
underwent,2634,O
PBSCT,2634,O
were,2634,O
studied,2634,O
retrospectively,2634,O
.,2634,O
Acute,2635,B-Disease
renal,2635,I-Disease
insufficiency,2635,I-Disease
(,2635,O
ARI,2635,B-Disease
),2635,O
after,2635,O
high-dose,2635,O
melphalan,2635,B-Chemical
was,2635,O
defined,2635,O
by,2635,O
a,2635,O
minimum,2635,O
increase,2635,O
of,2635,O
0.5,2635,O
mg/dL,2635,O
(,2635,O
44,2635,O
micromol/L,2635,O
),2635,O
in,2635,O
the,2635,O
serum,2635,O
creatinine,2635,B-Chemical
level,2635,O
that,2635,O
is,2635,O
greater,2635,O
than,2635,O
50,2635,O
%,2635,O
of,2635,O
baseline,2635,O
immediately,2635,O
after,2635,O
conditioning,2635,O
.,2635,O
Urine,2636,O
sediment,2636,O
score,2636,O
was,2636,O
the,2636,O
sum,2636,O
of,2636,O
the,2636,O
individual,2636,O
types,2636,O
of,2636,O
sediment,2636,O
identified,2636,O
on,2636,O
urine,2636,O
microscopy,2636,O
.,2636,O
RESULTS,2637,O
:,2637,O
Of,2637,O
the,2637,O
80,2637,O
patients,2637,O
studied,2637,O
",",2637,O
ARI,2637,B-Disease
developed,2637,O
in,2637,O
18.8,2637,O
%,2637,O
of,2637,O
the,2637,O
patients,2637,O
after,2637,O
high-dose,2637,O
melphalan,2637,B-Chemical
.,2637,O
Univariate,2638,O
analysis,2638,O
identified,2638,O
age,2638,O
",",2638,O
hypoalbuminemia,2638,B-Disease
",",2638,O
heavy,2638,O
proteinuria,2638,B-Disease
",",2638,O
diuretic,2638,O
use,2638,O
",",2638,O
and,2638,O
urine,2638,O
sediment,2638,O
score,2638,O
(,2638,O
>,2638,O
3,2638,O
),2638,O
as,2638,O
risk,2638,O
factors,2638,O
.,2638,O
Age,2639,O
and,2639,O
urine,2639,O
sediment,2639,O
score,2639,O
remained,2639,O
independently,2639,O
significant,2639,O
risk,2639,O
factors,2639,O
in,2639,O
the,2639,O
multivariate,2639,O
analysis,2639,O
.,2639,O
Patients,2640,O
who,2640,O
had,2640,O
ARI,2640,B-Disease
after,2640,O
high-dose,2640,O
melphalan,2640,B-Chemical
underwent,2640,O
dialysis,2640,O
more,2640,O
often,2640,O
(,2640,O
P,2640,O
=,2640,O
0.007,2640,O
),2640,O
",",2640,O
and,2640,O
had,2640,O
a,2640,O
worse,2640,O
1-year,2640,O
survival,2640,O
(,2640,O
P,2640,O
=,2640,O
0.03,2640,O
),2640,O
.,2640,O
CONCLUSION,2641,O
:,2641,O
The,2641,O
timing,2641,O
of,2641,O
renal,2641,B-Disease
injury,2641,I-Disease
strongly,2641,O
suggests,2641,O
melphalan,2641,B-Chemical
as,2641,O
the,2641,O
causative,2641,O
agent,2641,O
.,2641,O
Ongoing,2642,O
tubular,2642,B-Disease
injury,2642,I-Disease
may,2642,O
be,2642,O
a,2642,O
prerequisite,2642,O
for,2642,O
renal,2642,B-Disease
injury,2642,I-Disease
by,2642,O
melphalan,2642,B-Chemical
as,2642,O
evidenced,2642,O
by,2642,O
the,2642,O
active,2642,O
urinary,2642,O
sediment,2642,O
.,2642,O
Development,2643,O
of,2643,O
ARI,2643,B-Disease
adversely,2643,O
affected,2643,O
the,2643,O
outcome,2643,O
after,2643,O
PBSCT,2643,O
.,2643,O
Effective,2644,O
preventive,2644,O
measures,2644,O
may,2644,O
help,2644,O
decrease,2644,O
the,2644,O
treatment,2644,O
mortality,2644,O
of,2644,O
PBSCT,2644,O
in,2644,O
AL,2644,B-Disease
patients,2644,O
.,2644,O
Focal,2645,O
cerebral,2645,B-Disease
ischemia,2645,I-Disease
in,2645,O
rats,2645,O
:,2645,O
effect,2645,O
of,2645,O
phenylephrine-induced,2645,B-Chemical
hypertension,2645,B-Disease
during,2645,O
reperfusion,2645,O
.,2645,O
After,2646,O
180,2646,O
min,2646,O
of,2646,O
temporary,2646,O
middle,2646,B-Disease
cerebral,2646,I-Disease
artery,2646,I-Disease
occlusion,2646,I-Disease
in,2646,O
spontaneously,2646,O
hypertensive,2646,B-Disease
rats,2646,O
",",2646,O
the,2646,O
effect,2646,O
of,2646,O
phenylephrine-induced,2646,B-Chemical
hypertension,2646,B-Disease
on,2646,O
ischemic,2646,B-Disease
brain,2646,I-Disease
injury,2646,I-Disease
and,2646,O
blood-brain,2646,O
barrier,2646,O
permeability,2646,O
was,2646,O
determined,2646,O
.,2646,O
Blood,2647,O
pressure,2647,O
was,2647,O
manipulated,2647,O
by,2647,O
one,2647,O
of,2647,O
the,2647,O
following,2647,O
schedules,2647,O
during,2647,O
120,2647,O
min,2647,O
of,2647,O
reperfusion,2647,O
:,2647,O
Control,2647,O
",",2647,O
normotensive,2647,O
reperfusion,2647,O
;,2647,O
90/hypertension,2647,O
(,2647,O
90/HTN,2647,O
),2647,O
",",2647,O
blood,2647,O
pressure,2647,O
was,2647,O
increased,2647,O
by,2647,O
35,2647,O
mm,2647,O
Hg,2647,O
during,2647,O
the,2647,O
initial,2647,O
90,2647,O
min,2647,O
of,2647,O
reperfusion,2647,O
only,2647,O
;,2647,O
15/hypertension,2647,O
(,2647,O
15/HTN,2647,O
),2647,O
",",2647,O
normotensive,2647,O
reperfusion,2647,O
for,2647,O
30,2647,O
min,2647,O
followed,2647,O
by,2647,O
15,2647,O
min,2647,O
of,2647,O
hypertension,2647,B-Disease
and,2647,O
75,2647,O
min,2647,O
of,2647,O
normotension,2647,O
.,2647,O
Part,2648,O
A,2648,O
",",2648,O
for,2648,O
eight,2648,O
rats,2648,O
in,2648,O
each,2648,O
group,2648,O
brain,2648,B-Disease
injury,2648,I-Disease
was,2648,O
evaluated,2648,O
by,2648,O
staining,2648,O
tissue,2648,O
using,2648,O
"2,3,5-triphenyltetrazolium",2648,B-Chemical
chloride,2648,I-Chemical
and,2648,O
edema,2648,B-Disease
was,2648,O
evaluated,2648,O
by,2648,O
microgravimetry,2648,O
.,2648,O
Part,2649,O
B,2649,O
",",2649,O
for,2649,O
eight,2649,O
different,2649,O
rats,2649,O
in,2649,O
each,2649,O
group,2649,O
blood-brain,2649,O
barrier,2649,O
permeability,2649,O
was,2649,O
evaluated,2649,O
by,2649,O
measuring,2649,O
the,2649,O
amount,2649,O
and,2649,O
extent,2649,O
of,2649,O
extravasation,2649,O
of,2649,O
Evans,2649,O
Blue,2649,O
dye,2649,O
.,2649,O
Brain,2650,B-Disease
injury,2650,I-Disease
(,2650,O
percentage,2650,O
of,2650,O
the,2650,O
ischemic,2650,B-Disease
hemisphere,2650,I-Disease
),2650,O
was,2650,O
less,2650,O
in,2650,O
the,2650,O
15/HTN,2650,O
group,2650,O
(,2650,O
16,2650,O
+/-,2650,O
6,2650,O
",",2650,O
mean,2650,O
+/-,2650,O
SD,2650,O
),2650,O
versus,2650,O
the,2650,O
90/HTN,2650,O
group,2650,O
(,2650,O
30,2650,O
+/-,2650,O
6,2650,O
),2650,O
",",2650,O
which,2650,O
was,2650,O
in,2650,O
turn,2650,O
less,2650,O
than,2650,O
the,2650,O
control,2650,O
group,2650,O
(,2650,O
42,2650,O
+/-,2650,O
5,2650,O
),2650,O
.,2650,O
Specific,2651,O
gravity,2651,O
was,2651,O
greater,2651,O
in,2651,O
the,2651,O
15/HTN,2651,O
group,2651,O
(,2651,O
1.043,2651,O
+/-,2651,O
0.002,2651,O
),2651,O
versus,2651,O
the,2651,O
90/HTN,2651,O
(,2651,O
1.036,2651,O
+/-,2651,O
0.003,2651,O
),2651,O
and,2651,O
control,2651,O
(,2651,O
1.037,2651,O
+/-,2651,O
0.003,2651,O
),2651,O
groups,2651,O
.,2651,O
Evans,2652,B-Chemical
Blue,2652,I-Chemical
(,2652,O
mug,2652,O
g-1,2652,O
of,2652,O
brain,2652,O
tissue,2652,O
),2652,O
was,2652,O
greater,2652,O
in,2652,O
the,2652,O
90/HTN,2652,O
group,2652,O
(,2652,O
24.4,2652,O
+/-,2652,O
6.0,2652,O
),2652,O
versus,2652,O
the,2652,O
control,2652,O
group,2652,O
(,2652,O
12.3,2652,O
+/-,2652,O
4.1,2652,O
),2652,O
",",2652,O
which,2652,O
was,2652,O
in,2652,O
turn,2652,O
greater,2652,O
than,2652,O
the,2652,O
15/HTN,2652,O
group,2652,O
(,2652,O
7.3,2652,O
+/-,2652,O
3.2,2652,O
),2652,O
.,2652,O
This,2653,O
study,2653,O
supports,2653,O
a,2653,O
hypothesis,2653,O
that,2653,O
during,2653,O
reperfusion,2653,O
",",2653,O
a,2653,O
short,2653,O
interval,2653,O
of,2653,O
hypertension,2653,B-Disease
decreases,2653,O
brain,2653,B-Disease
injury,2653,I-Disease
and,2653,O
edema,2653,B-Disease
;,2653,O
and,2653,O
that,2653,O
sustained,2653,O
hypertension,2653,B-Disease
increases,2653,O
the,2653,O
risk,2653,O
of,2653,O
vasogenic,2653,B-Disease
edema,2653,I-Disease
.,2653,O
People,2654,O
aged,2654,O
over,2654,O
75,2654,O
in,2654,O
atrial,2654,B-Disease
fibrillation,2654,I-Disease
on,2654,O
warfarin,2654,B-Chemical
:,2654,O
the,2654,O
rate,2654,O
of,2654,O
major,2654,O
hemorrhage,2654,B-Disease
and,2654,O
stroke,2654,B-Disease
in,2654,O
more,2654,O
than,2654,O
500,2654,O
patient-years,2654,O
of,2654,O
follow-up,2654,O
.,2654,O
OBJECTIVES,2655,O
:,2655,O
To,2655,O
determine,2655,O
the,2655,O
incidence,2655,O
of,2655,O
major,2655,O
hemorrhage,2655,B-Disease
and,2655,O
stroke,2655,B-Disease
in,2655,O
people,2655,O
aged,2655,O
76,2655,O
and,2655,O
older,2655,O
with,2655,O
atrial,2655,B-Disease
fibrillation,2655,I-Disease
on,2655,O
adjusted-dose,2655,O
warfarin,2655,B-Chemical
who,2655,O
had,2655,O
been,2655,O
recently,2655,O
been,2655,O
admitted,2655,O
to,2655,O
hospital,2655,O
.,2655,O
DESIGN,2656,O
:,2656,O
A,2656,O
retrospective,2656,O
observational,2656,O
cohort,2656,O
study,2656,O
.,2656,O
SETTING,2657,O
:,2657,O
A,2657,O
major,2657,O
healthcare,2657,O
network,2657,O
involving,2657,O
four,2657,O
tertiary,2657,O
hospitals,2657,O
.,2657,O
PARTICIPANTS,2658,O
:,2658,O
Two,2658,O
hundred,2658,O
thirty-five,2658,O
patients,2658,O
aged,2658,O
76,2658,O
and,2658,O
older,2658,O
admitted,2658,O
to,2658,O
a,2658,O
major,2658,O
healthcare,2658,O
network,2658,O
between,2658,O
July,2658,O
1,2658,O
",",2658,O
2001,2658,O
",",2658,O
and,2658,O
June,2658,O
30,2658,O
",",2658,O
2002,2658,O
",",2658,O
with,2658,O
atrial,2658,B-Disease
fibrillation,2658,I-Disease
on,2658,O
warfarin,2658,B-Chemical
were,2658,O
enrolled,2658,O
.,2658,O
MEASUREMENTS,2659,O
:,2659,O
Information,2659,O
regarding,2659,O
major,2659,O
bleeding,2659,B-Disease
episodes,2659,O
",",2659,O
strokes,2659,B-Disease
",",2659,O
and,2659,O
warfarin,2659,B-Chemical
use,2659,O
was,2659,O
obtained,2659,O
from,2659,O
patients,2659,O
",",2659,O
relatives,2659,O
",",2659,O
primary,2659,O
physicians,2659,O
",",2659,O
and,2659,O
medical,2659,O
records,2659,O
.,2659,O
RESULTS,2660,O
:,2660,O
Two,2660,O
hundred,2660,O
twenty-eight,2660,O
patients,2660,O
(,2660,O
42,2660,O
%,2660,O
men,2660,O
),2660,O
with,2660,O
a,2660,O
mean,2660,O
age,2660,O
of,2660,O
81.1,2660,O
(,2660,O
range,2660,O
76-94,2660,O
),2660,O
were,2660,O
included,2660,O
in,2660,O
the,2660,O
analysis,2660,O
.,2660,O
Total,2661,O
follow-up,2661,O
on,2661,O
warfarin,2661,B-Chemical
was,2661,O
530,2661,O
years,2661,O
(,2661,O
mean,2661,O
28,2661,O
months,2661,O
),2661,O
.,2661,O
There,2662,O
were,2662,O
53,2662,O
major,2662,O
hemorrhages,2662,B-Disease
",",2662,O
for,2662,O
an,2662,O
annual,2662,O
rate,2662,O
of,2662,O
10.0,2662,O
%,2662,O
",",2662,O
including,2662,O
24,2662,O
(,2662,O
45.3,2662,O
%,2662,O
),2662,O
life-threatening,2662,O
and,2662,O
five,2662,O
(,2662,O
9.4,2662,O
%,2662,O
),2662,O
fatal,2662,O
bleeds,2662,O
.,2662,O
The,2663,O
annual,2663,O
stroke,2663,B-Disease
rate,2663,O
after,2663,O
initiation,2663,O
of,2663,O
warfarin,2663,B-Chemical
was,2663,O
2.6,2663,O
%,2663,O
.,2663,O
CONCLUSION,2664,O
:,2664,O
The,2664,O
rate,2664,O
of,2664,O
major,2664,O
hemorrhage,2664,B-Disease
was,2664,O
high,2664,O
in,2664,O
this,2664,O
old,2664,O
",",2664,O
frail,2664,O
group,2664,O
",",2664,O
but,2664,O
excluding,2664,O
fatalities,2664,O
",",2664,O
resulted,2664,O
in,2664,O
no,2664,O
long-term,2664,O
sequelae,2664,O
",",2664,O
and,2664,O
the,2664,O
stroke,2664,B-Disease
rate,2664,O
on,2664,O
warfarin,2664,B-Chemical
was,2664,O
low,2664,O
",",2664,O
demonstrating,2664,O
how,2664,O
effective,2664,O
warfarin,2664,B-Chemical
treatment,2664,O
is,2664,O
.,2664,O
Safety,2665,O
of,2665,O
celecoxib,2665,B-Chemical
in,2665,O
patients,2665,O
with,2665,O
adverse,2665,O
skin,2665,B-Disease
reactions,2665,I-Disease
to,2665,O
acetaminophen,2665,B-Chemical
(,2665,O
paracetamol,2665,B-Chemical
),2665,O
and,2665,O
nimesulide,2665,B-Chemical
associated,2665,O
or,2665,O
not,2665,O
with,2665,O
common,2665,O
non-steroidal,2665,O
anti-inflammatory,2665,O
drugs,2665,O
.,2665,O
BACKGROUND,2666,O
:,2666,O
Acetaminophen,2666,B-Chemical
(,2666,O
paracetamol,2666,B-Chemical
--,2666,O
P,2666,B-Chemical
),2666,O
and,2666,O
Nimesulide,2666,B-Chemical
(,2666,O
N,2666,B-Chemical
),2666,O
are,2666,O
widely,2666,O
used,2666,O
analgesic-antipyretic/anti-inflammatory,2666,O
drugs,2666,O
.,2666,O
The,2667,O
rate,2667,O
of,2667,O
adverse,2667,O
hypersensitivity,2667,B-Disease
reactions,2667,O
to,2667,O
these,2667,O
agents,2667,O
is,2667,O
generally,2667,O
low,2667,O
.,2667,O
On,2668,O
the,2668,O
contrary,2668,O
non-steroidal,2668,O
anti-inflammatory,2668,O
drugs,2668,O
(,2668,O
NSAIDs,2668,O
),2668,O
are,2668,O
commonly,2668,O
involved,2668,O
in,2668,O
such,2668,O
reactions,2668,O
.,2668,O
Celecoxib,2669,B-Chemical
(,2669,O
CE,2669,B-Chemical
),2669,O
is,2669,O
a,2669,O
novel,2669,O
drug,2669,O
",",2669,O
with,2669,O
high,2669,O
selectivity,2669,O
and,2669,O
affinity,2669,O
for,2669,O
COX-2,2669,O
enzyme,2669,O
.,2669,O
OBJECTIVE,2670,O
:,2670,O
We,2670,O
evaluated,2670,O
the,2670,O
tolerability,2670,O
of,2670,O
CE,2670,B-Chemical
in,2670,O
a,2670,O
group,2670,O
of,2670,O
patients,2670,O
with,2670,O
documented,2670,O
history,2670,O
of,2670,O
adverse,2670,O
cutaneous,2670,B-Disease
reactions,2670,I-Disease
to,2670,O
P,2670,B-Chemical
and,2670,O
N,2670,B-Chemical
associated,2670,O
or,2670,O
not,2670,O
to,2670,O
classic,2670,O
NSAIDs,2670,O
.,2670,O
METHODS,2671,O
:,2671,O
We,2671,O
studied,2671,O
9,2671,O
patients,2671,O
with,2671,O
hypersensitivity,2671,B-Disease
to,2671,O
P,2671,B-Chemical
and,2671,O
N,2671,B-Chemical
with,2671,O
or,2671,O
without,2671,O
associated,2671,O
reactions,2671,O
to,2671,O
classic,2671,O
NSAIDs,2671,O
.,2671,O
The,2672,O
diagnosis,2672,O
of,2672,O
P,2672,B-Chemical
and,2672,O
N-induced,2672,B-Chemical
skin,2672,B-Disease
reactions,2672,I-Disease
was,2672,O
based,2672,O
in,2672,O
vivo,2672,O
challenge,2672,O
.,2672,O
The,2673,O
placebo,2673,O
was,2673,O
blindly,2673,O
administered,2673,O
at,2673,O
the,2673,O
beginning,2673,O
of,2673,O
each,2673,O
challenge,2673,O
.,2673,O
After,2674,O
three,2674,O
days,2674,O
",",2674,O
a,2674,O
cumulative,2674,O
dosage,2674,O
of,2674,O
200,2674,O
mg,2674,O
of,2674,O
CE,2674,B-Chemical
in,2674,O
refracted,2674,O
doses,2674,O
were,2674,O
given,2674,O
.,2674,O
After,2675,O
2-3,2675,O
days,2675,O
",",2675,O
a,2675,O
single,2675,O
dose,2675,O
of,2675,O
200,2675,O
mg,2675,O
was,2675,O
administered,2675,O
.,2675,O
All,2676,O
patients,2676,O
were,2676,O
observed,2676,O
for,2676,O
6,2676,O
hours,2676,O
after,2676,O
each,2676,O
challenge,2676,O
",",2676,O
and,2676,O
controlled,2676,O
again,2676,O
after,2676,O
24,2676,O
hours,2676,O
to,2676,O
exclude,2676,O
delayed,2676,O
reactions,2676,O
.,2676,O
The,2677,O
challenge,2677,O
was,2677,O
considered,2677,O
positive,2677,O
if,2677,O
one,2677,O
or,2677,O
more,2677,O
of,2677,O
the,2677,O
following,2677,O
appeared,2677,O
:,2677,O
erythema,2677,B-Disease
",",2677,O
rush,2677,O
or,2677,O
urticaria-angioedema,2677,B-Disease
.,2677,O
RESULTS,2678,O
:,2678,O
No,2678,O
reaction,2678,O
was,2678,O
observed,2678,O
with,2678,O
placebo,2678,O
and,2678,O
eight,2678,O
patients,2678,O
(,2678,O
88.8,2678,O
%,2678,O
),2678,O
tolerated,2678,O
CE,2678,B-Chemical
.,2678,O
Only,2679,O
one,2679,O
patient,2679,O
developed,2679,O
a,2679,O
moderate,2679,O
angioedema,2679,B-Disease
of,2679,O
the,2679,O
lips,2679,O
.,2679,O
CONCLUSION,2680,O
:,2680,O
Only,2680,O
one,2680,O
hypersensitivity,2680,B-Disease
reaction,2680,O
to,2680,O
CE,2680,B-Chemical
was,2680,O
documented,2680,O
among,2680,O
9,2680,O
P,2680,B-Chemical
and,2680,O
N-highly,2680,B-Chemical
NSAIDs,2680,O
intolerant,2680,O
patients,2680,O
.,2680,O
Thus,2681,O
",",2681,O
we,2681,O
conclude,2681,O
that,2681,O
CE,2681,B-Chemical
is,2681,O
a,2681,O
reasonably,2681,O
safe,2681,O
alternative,2681,O
to,2681,O
be,2681,O
used,2681,O
in,2681,O
subjects,2681,O
who,2681,O
do,2681,O
not,2681,O
tolerate,2681,O
P,2681,B-Chemical
and,2681,O
N,2681,B-Chemical
.,2681,O
Case-control,2682,O
study,2682,O
of,2682,O
regular,2682,O
analgesic,2682,O
and,2682,O
nonsteroidal,2682,O
anti-inflammatory,2682,O
use,2682,O
and,2682,O
end-stage,2682,B-Disease
renal,2682,I-Disease
disease,2682,I-Disease
.,2682,O
BACKGROUND,2683,O
:,2683,O
Studies,2683,O
on,2683,O
the,2683,O
association,2683,O
between,2683,O
the,2683,O
long-term,2683,O
use,2683,O
of,2683,O
aspirin,2683,B-Chemical
and,2683,O
other,2683,O
analgesic,2683,O
and,2683,O
nonsteroidal,2683,O
anti-inflammatory,2683,O
drugs,2683,O
(,2683,O
NSAIDs,2683,O
),2683,O
and,2683,O
end-stage,2683,B-Disease
renal,2683,I-Disease
disease,2683,I-Disease
(,2683,O
ESRD,2683,B-Disease
),2683,O
have,2683,O
given,2683,O
conflicting,2683,O
results,2683,O
.,2683,O
In,2684,O
order,2684,O
to,2684,O
examine,2684,O
this,2684,O
association,2684,O
",",2684,O
a,2684,O
case-control,2684,O
study,2684,O
with,2684,O
incident,2684,O
cases,2684,O
of,2684,O
ESRD,2684,B-Disease
was,2684,O
carried,2684,O
out,2684,O
.,2684,O
METHODS,2685,O
:,2685,O
The,2685,O
cases,2685,O
were,2685,O
all,2685,O
patients,2685,O
entering,2685,O
the,2685,O
local,2685,O
dialysis,2685,O
program,2685,O
because,2685,O
of,2685,O
ESRD,2685,B-Disease
in,2685,O
the,2685,O
study,2685,O
area,2685,O
between,2685,O
June,2685,O
1,2685,O
",",2685,O
1995,2685,O
and,2685,O
November,2685,O
30,2685,O
",",2685,O
1997,2685,O
.,2685,O
They,2686,O
were,2686,O
classified,2686,O
according,2686,O
to,2686,O
the,2686,O
underlying,2686,O
disease,2686,O
",",2686,O
which,2686,O
had,2686,O
presumably,2686,O
led,2686,O
them,2686,O
to,2686,O
ESRD,2686,B-Disease
.,2686,O
Controls,2687,O
were,2687,O
patients,2687,O
admitted,2687,O
to,2687,O
the,2687,O
same,2687,O
hospitals,2687,O
from,2687,O
where,2687,O
the,2687,O
cases,2687,O
arose,2687,O
",",2687,O
also,2687,O
matched,2687,O
by,2687,O
age,2687,O
and,2687,O
sex,2687,O
.,2687,O
Odds,2688,O
ratios,2688,O
were,2688,O
calculated,2688,O
using,2688,O
a,2688,O
conditional,2688,O
logistic,2688,O
model,2688,O
",",2688,O
including,2688,O
potential,2688,O
confounding,2688,O
factors,2688,O
",",2688,O
both,2688,O
for,2688,O
the,2688,O
whole,2688,O
study,2688,O
population,2688,O
and,2688,O
for,2688,O
the,2688,O
various,2688,O
underlying,2688,O
diseases,2688,O
.,2688,O
RESULTS,2689,O
:,2689,O
Five,2689,O
hundred,2689,O
and,2689,O
eighty-three,2689,O
cases,2689,O
and,2689,O
1190,2689,O
controls,2689,O
were,2689,O
included,2689,O
in,2689,O
the,2689,O
analysis,2689,O
.,2689,O
Long-term,2690,O
use,2690,O
of,2690,O
any,2690,O
analgesic,2690,O
was,2690,O
associated,2690,O
with,2690,O
an,2690,O
overall,2690,O
odds,2690,O
ratio,2690,O
of,2690,O
1.22,2690,O
(,2690,O
95,2690,O
%,2690,O
CI,2690,O
",",2690,O
0.89-1.66,2690,O
),2690,O
.,2690,O
For,2691,O
specific,2691,O
groups,2691,O
of,2691,O
drugs,2691,O
",",2691,O
the,2691,O
risks,2691,O
were,2691,O
1.56,2691,O
(,2691,O
1.05-2.30,2691,O
),2691,O
for,2691,O
aspirin,2691,B-Chemical
",",2691,O
1.03,2691,O
(,2691,O
0.60-1.76,2691,O
),2691,O
for,2691,O
pyrazolones,2691,B-Chemical
",",2691,O
0.80,2691,O
(,2691,O
0.39-1.63,2691,O
),2691,O
for,2691,O
paracetamol,2691,B-Chemical
",",2691,O
and,2691,O
0.94,2691,O
(,2691,O
0.57-1.56,2691,O
),2691,O
for,2691,O
nonaspirin,2691,O
NSAIDs,2691,O
.,2691,O
The,2692,O
risk,2692,O
of,2692,O
ESRD,2692,B-Disease
associated,2692,O
with,2692,O
aspirin,2692,B-Chemical
was,2692,O
related,2692,O
to,2692,O
the,2692,O
cumulated,2692,O
dose,2692,O
and,2692,O
duration,2692,O
of,2692,O
use,2692,O
",",2692,O
and,2692,O
it,2692,O
was,2692,O
particularly,2692,O
high,2692,O
among,2692,O
the,2692,O
subset,2692,O
of,2692,O
patients,2692,O
with,2692,O
vascular,2692,O
nephropathy,2692,B-Disease
as,2692,O
underlying,2692,O
disease,2692,O
[,2692,O
2.35,2692,O
(,2692,O
1.17-4.72,2692,O
),2692,O
],2692,O
.,2692,O
CONCLUSION,2693,O
:,2693,O
Our,2693,O
data,2693,O
indicate,2693,O
that,2693,O
long-term,2693,O
use,2693,O
of,2693,O
nonaspirin,2693,O
analgesic,2693,O
drugs,2693,O
and,2693,O
NSAIDs,2693,O
is,2693,O
not,2693,O
associated,2693,O
with,2693,O
an,2693,O
increased,2693,O
risk,2693,O
of,2693,O
ESRD,2693,B-Disease
.,2693,O
However,2694,O
",",2694,O
the,2694,O
chronic,2694,O
use,2694,O
of,2694,O
aspirin,2694,B-Chemical
may,2694,O
increase,2694,O
the,2694,O
risk,2694,O
of,2694,O
ESRD,2694,B-Disease
.,2694,O
Two,2695,O
cases,2695,O
of,2695,O
amisulpride,2695,B-Chemical
overdose,2695,B-Disease
:,2695,O
a,2695,O
cause,2695,O
for,2695,O
prolonged,2695,B-Disease
QT,2695,I-Disease
syndrome,2695,I-Disease
.,2695,O
Two,2696,O
cases,2696,O
of,2696,O
deliberate,2696,O
self-poisoning,2696,O
with,2696,O
5,2696,O
g,2696,O
and,2696,O
3.6,2696,O
g,2696,O
of,2696,O
amisulpride,2696,B-Chemical
",",2696,O
respectively,2696,O
",",2696,O
are,2696,O
reported,2696,O
.,2696,O
In,2697,O
both,2697,O
cases,2697,O
",",2697,O
QT,2697,B-Disease
prolongation,2697,I-Disease
and,2697,O
hypocalcaemia,2697,B-Disease
were,2697,O
noted,2697,O
.,2697,O
The,2698,O
QT,2698,B-Disease
prolongation,2698,I-Disease
appeared,2698,O
to,2698,O
respond,2698,O
to,2698,O
administration,2698,O
of,2698,O
i.v,2698,O
.,2698,O
calcium,2699,B-Chemical
gluconate,2699,I-Chemical
.,2699,O
Growth-associated,2700,O
protein,2700,O
43,2700,O
expression,2700,O
in,2700,O
hippocampal,2700,O
molecular,2700,O
layer,2700,O
of,2700,O
chronic,2700,O
epileptic,2700,B-Disease
rats,2700,O
treated,2700,O
with,2700,O
cycloheximide,2700,B-Chemical
.,2700,O
PURPOSE,2701,O
:,2701,O
GAP43,2701,O
has,2701,O
been,2701,O
thought,2701,O
to,2701,O
be,2701,O
linked,2701,O
with,2701,O
mossy,2701,O
fiber,2701,O
sprouting,2701,O
(,2701,O
MFS,2701,O
),2701,O
in,2701,O
various,2701,O
experimental,2701,O
models,2701,O
of,2701,O
epilepsy,2701,B-Disease
.,2701,O
To,2702,O
investigate,2702,O
how,2702,O
GAP43,2702,O
expression,2702,O
(,2702,O
GAP43-ir,2702,O
),2702,O
correlates,2702,O
with,2702,O
MFS,2702,O
",",2702,O
we,2702,O
assessed,2702,O
the,2702,O
intensity,2702,O
(,2702,O
densitometry,2702,O
),2702,O
and,2702,O
extension,2702,O
(,2702,O
width,2702,O
),2702,O
of,2702,O
GAP43-ir,2702,O
in,2702,O
the,2702,O
inner,2702,O
molecular,2702,O
layer,2702,O
of,2702,O
the,2702,O
dentate,2702,O
gyrus,2702,O
(,2702,O
IML,2702,O
),2702,O
of,2702,O
rats,2702,O
subject,2702,O
to,2702,O
status,2702,B-Disease
epilepticus,2702,I-Disease
induced,2702,O
by,2702,O
pilocarpine,2702,B-Chemical
(,2702,O
Pilo,2702,B-Chemical
),2702,O
",",2702,O
previously,2702,O
injected,2702,O
or,2702,O
not,2702,O
with,2702,O
cycloheximide,2702,B-Chemical
(,2702,O
CHX,2702,B-Chemical
),2702,O
",",2702,O
which,2702,O
has,2702,O
been,2702,O
shown,2702,O
to,2702,O
inhibit,2702,O
MFS,2702,O
.,2702,O
METHODS,2703,O
:,2703,O
CHX,2703,B-Chemical
was,2703,O
injected,2703,O
before,2703,O
the,2703,O
Pilo,2703,B-Chemical
injection,2703,O
in,2703,O
adult,2703,O
Wistar,2703,O
rats,2703,O
.,2703,O
The,2704,O
Pilo,2704,B-Chemical
group,2704,O
was,2704,O
injected,2704,O
with,2704,O
the,2704,O
same,2704,O
drugs,2704,O
",",2704,O
except,2704,O
for,2704,O
CHX,2704,B-Chemical
.,2704,O
Animals,2705,O
were,2705,O
killed,2705,O
between,2705,O
30,2705,O
and,2705,O
60,2705,O
days,2705,O
later,2705,O
",",2705,O
and,2705,O
brain,2705,O
sections,2705,O
were,2705,O
processed,2705,O
for,2705,O
GAP43,2705,O
immunohistochemistry,2705,O
.,2705,O
RESULTS,2706,O
:,2706,O
Densitometry,2706,O
showed,2706,O
no,2706,O
significant,2706,O
difference,2706,O
regarding,2706,O
GAP43-ir,2706,O
in,2706,O
the,2706,O
IML,2706,O
between,2706,O
Pilo,2706,B-Chemical
",",2706,O
CHX+Pilo,2706,B-Chemical
",",2706,O
and,2706,O
control,2706,O
groups,2706,O
.,2706,O
However,2707,O
",",2707,O
the,2707,O
results,2707,O
of,2707,O
the,2707,O
width,2707,O
of,2707,O
the,2707,O
GAP43-ir,2707,O
band,2707,O
in,2707,O
the,2707,O
IML,2707,O
showed,2707,O
that,2707,O
CHX+Pilo,2707,B-Chemical
and,2707,O
control,2707,O
animals,2707,O
had,2707,O
a,2707,O
significantly,2707,O
larger,2707,O
band,2707,O
(,2707,O
p,2707,O
=,2707,O
0.03,2707,O
),2707,O
as,2707,O
compared,2707,O
with,2707,O
that,2707,O
in,2707,O
the,2707,O
Pilo,2707,B-Chemical
group,2707,O
.,2707,O
CONCLUSIONS,2708,O
:,2708,O
Our,2708,O
current,2708,O
finding,2708,O
that,2708,O
animals,2708,O
in,2708,O
the,2708,O
CHX+Pilo,2708,B-Chemical
group,2708,O
have,2708,O
a,2708,O
GAP43-ir,2708,O
band,2708,O
in,2708,O
the,2708,O
IML,2708,O
",",2708,O
similar,2708,O
to,2708,O
that,2708,O
of,2708,O
controls,2708,O
",",2708,O
reinforces,2708,O
prior,2708,O
data,2708,O
on,2708,O
the,2708,O
blockade,2708,O
of,2708,O
MFS,2708,O
in,2708,O
these,2708,O
animals,2708,O
.,2708,O
The,2709,O
change,2709,O
in,2709,O
GAP43-ir,2709,O
present,2709,O
in,2709,O
Pilo-treated,2709,B-Chemical
animals,2709,O
was,2709,O
a,2709,O
thinning,2709,O
of,2709,O
the,2709,O
band,2709,O
to,2709,O
a,2709,O
very,2709,O
narrow,2709,O
layer,2709,O
just,2709,O
above,2709,O
the,2709,O
granule,2709,O
cell,2709,O
layer,2709,O
that,2709,O
is,2709,O
likely,2709,O
to,2709,O
be,2709,O
associated,2709,O
with,2709,O
the,2709,O
loss,2709,O
of,2709,O
hilar,2709,O
cell,2709,O
projections,2709,O
that,2709,O
express,2709,O
GAP-43,2709,O
.,2709,O
Nicotine,2710,B-Chemical
antagonizes,2710,O
caffeine-,2710,B-Chemical
but,2710,O
not,2710,O
pentylenetetrazole-induced,2710,B-Chemical
anxiogenic,2710,O
effect,2710,O
in,2710,O
mice,2710,O
.,2710,O
RATIONALE,2711,O
:,2711,O
Nicotine,2711,B-Chemical
and,2711,O
caffeine,2711,B-Chemical
are,2711,O
widely,2711,O
consumed,2711,O
licit,2711,O
psychoactive,2711,O
drugs,2711,O
worldwide,2711,O
.,2711,O
Epidemiological,2712,O
studies,2712,O
showed,2712,O
that,2712,O
they,2712,O
were,2712,O
generally,2712,O
used,2712,O
concurrently,2712,O
.,2712,O
Although,2713,O
some,2713,O
studies,2713,O
in,2713,O
experimental,2713,O
animals,2713,O
indicate,2713,O
clear,2713,O
pharmacological,2713,O
interactions,2713,O
between,2713,O
them,2713,O
",",2713,O
no,2713,O
studies,2713,O
have,2713,O
shown,2713,O
a,2713,O
specific,2713,O
interaction,2713,O
on,2713,O
anxiety,2713,B-Disease
responses,2713,O
.,2713,O
OBJECTIVES,2714,O
:,2714,O
The,2714,O
present,2714,O
study,2714,O
investigates,2714,O
the,2714,O
effects,2714,O
of,2714,O
nicotine,2714,B-Chemical
on,2714,O
anxiety,2714,B-Disease
induced,2714,O
by,2714,O
caffeine,2714,B-Chemical
and,2714,O
another,2714,O
anxiogenic,2714,O
drug,2714,O
",",2714,O
pentylenetetrazole,2714,B-Chemical
",",2714,O
in,2714,O
mice,2714,O
.,2714,O
The,2715,O
elevated,2715,O
plus-maze,2715,O
(,2715,O
EPM,2715,O
),2715,O
test,2715,O
was,2715,O
used,2715,O
to,2715,O
evaluate,2715,O
the,2715,O
effects,2715,O
of,2715,O
drugs,2715,O
on,2715,O
anxiety,2715,B-Disease
.,2715,O
METHODS,2716,O
:,2716,O
Adult,2716,O
male,2716,O
Swiss,2716,O
Webster,2716,O
mice,2716,O
(,2716,O
25-32,2716,O
g,2716,O
),2716,O
were,2716,O
given,2716,O
nicotine,2716,B-Chemical
(,2716,O
0.05-0.25,2716,O
mg/kg,2716,O
s.c.,2716,O
),2716,O
or,2716,O
saline,2716,O
10,2716,O
min,2716,O
before,2716,O
caffeine,2716,B-Chemical
(,2716,O
70,2716,O
mg/kg,2716,O
i.p,2716,O
.,2716,O
),2716,O
or,2717,O
pentylenetetrazole,2717,B-Chemical
(,2717,O
15,2717,O
and,2717,O
30,2717,O
mg/kg,2717,O
i.p,2717,O
.,2717,O
),2717,O
injections,2718,O
.,2718,O
After,2719,O
15,2719,O
min,2719,O
",",2719,O
mice,2719,O
were,2719,O
evaluated,2719,O
for,2719,O
their,2719,O
open-,2719,O
and,2719,O
closed-arm,2719,O
time,2719,O
and,2719,O
entries,2719,O
on,2719,O
the,2719,O
EPM,2719,O
for,2719,O
a,2719,O
10-min,2719,O
session,2719,O
.,2719,O
Locomotor,2720,O
activity,2720,O
was,2720,O
recorded,2720,O
for,2720,O
individual,2720,O
groups,2720,O
by,2720,O
using,2720,O
the,2720,O
same,2720,O
treatment,2720,O
protocol,2720,O
with,2720,O
the,2720,O
EPM,2720,O
test,2720,O
.,2720,O
RESULTS,2721,O
:,2721,O
Nicotine,2721,B-Chemical
(,2721,O
0.05-0.25,2721,O
mg/kg,2721,O
),2721,O
itself,2721,O
did,2721,O
not,2721,O
produce,2721,O
any,2721,O
significant,2721,O
effect,2721,O
in,2721,O
the,2721,O
EPM,2721,O
test,2721,O
",",2721,O
whereas,2721,O
caffeine,2721,B-Chemical
(,2721,O
70,2721,O
mg/kg,2721,O
),2721,O
and,2721,O
pentylenetetrazole,2721,B-Chemical
(,2721,O
30,2721,O
mg/kg,2721,O
),2721,O
produced,2721,O
an,2721,O
anxiogenic,2721,O
effect,2721,O
",",2721,O
apparent,2721,O
with,2721,O
decreases,2721,O
in,2721,O
open-arm,2721,O
time,2721,O
and,2721,O
entry,2721,O
.,2721,O
Nicotine,2722,B-Chemical
(,2722,O
0.25,2722,O
mg/kg,2722,O
),2722,O
pretreatment,2722,O
blocked,2722,O
the,2722,O
caffeine-,2722,B-Chemical
but,2722,O
not,2722,O
pentylenetetrazole-induced,2722,B-Chemical
anxiety,2722,B-Disease
.,2722,O
Administration,2723,O
of,2723,O
each,2723,O
drug,2723,O
and,2723,O
their,2723,O
combinations,2723,O
did,2723,O
not,2723,O
produce,2723,O
any,2723,O
effect,2723,O
on,2723,O
locomotor,2723,O
activity,2723,O
.,2723,O
CONCLUSIONS,2724,O
:,2724,O
Our,2724,O
results,2724,O
suggest,2724,O
that,2724,O
the,2724,O
antagonistic,2724,O
effect,2724,O
of,2724,O
nicotine,2724,B-Chemical
on,2724,O
caffeine-induced,2724,B-Chemical
anxiety,2724,B-Disease
is,2724,O
specific,2724,O
to,2724,O
caffeine,2724,B-Chemical
",",2724,O
instead,2724,O
of,2724,O
a,2724,O
non-specific,2724,O
anxiolytic,2724,O
effect,2724,O
.,2724,O
Thus,2725,O
",",2725,O
it,2725,O
may,2725,O
extend,2725,O
the,2725,O
current,2725,O
findings,2725,O
on,2725,O
the,2725,O
interaction,2725,O
between,2725,O
nicotine,2725,B-Chemical
and,2725,O
caffeine,2725,B-Chemical
.,2725,O
Long,2726,O
term,2726,O
hormone,2726,O
therapy,2726,O
for,2726,O
perimenopausal,2726,O
and,2726,O
postmenopausal,2726,O
women,2726,O
.,2726,O
BACKGROUND,2727,O
:,2727,O
Hormone,2727,O
therapy,2727,O
(,2727,O
HT,2727,O
),2727,O
is,2727,O
widely,2727,O
used,2727,O
for,2727,O
controlling,2727,O
menopausal,2727,B-Disease
symptoms,2727,I-Disease
.,2727,O
It,2728,O
has,2728,O
also,2728,O
been,2728,O
used,2728,O
for,2728,O
the,2728,O
management,2728,O
and,2728,O
prevention,2728,O
of,2728,O
cardiovascular,2728,B-Disease
disease,2728,I-Disease
",",2728,O
osteoporosis,2728,B-Disease
and,2728,O
dementia,2728,B-Disease
in,2728,O
older,2728,O
women,2728,O
but,2728,O
the,2728,O
evidence,2728,O
supporting,2728,O
its,2728,O
use,2728,O
for,2728,O
these,2728,O
indications,2728,O
is,2728,O
largely,2728,O
observational,2728,O
.,2728,O
OBJECTIVES,2729,O
:,2729,O
To,2729,O
assess,2729,O
the,2729,O
effect,2729,O
of,2729,O
long-term,2729,O
HT,2729,O
on,2729,O
mortality,2729,O
",",2729,O
heart,2729,B-Disease
disease,2729,I-Disease
",",2729,O
venous,2729,B-Disease
thromboembolism,2729,I-Disease
",",2729,O
stroke,2729,B-Disease
",",2729,O
transient,2729,B-Disease
ischaemic,2729,I-Disease
attacks,2729,I-Disease
",",2729,O
breast,2729,B-Disease
cancer,2729,I-Disease
",",2729,O
colorectal,2729,B-Disease
cancer,2729,I-Disease
",",2729,O
ovarian,2729,B-Disease
cancer,2729,I-Disease
",",2729,O
endometrial,2729,B-Disease
cancer,2729,I-Disease
",",2729,O
gallbladder,2729,B-Disease
disease,2729,I-Disease
",",2729,O
cognitive,2729,O
function,2729,O
",",2729,O
dementia,2729,B-Disease
",",2729,O
fractures,2729,B-Disease
and,2729,O
quality,2729,O
of,2729,O
life,2729,O
.,2729,O
SEARCH,2730,O
STRATEGY,2730,O
:,2730,O
We,2730,O
searched,2730,O
the,2730,O
following,2730,O
databases,2730,O
up,2730,O
to,2730,O
November,2730,O
2004,2730,O
:,2730,O
the,2730,O
Cochrane,2730,O
Menstrual,2730,O
Disorders,2730,O
and,2730,O
Subfertility,2730,O
Group,2730,O
Trials,2730,O
Register,2730,O
",",2730,O
Cochrane,2730,O
Central,2730,O
Register,2730,O
of,2730,O
Controlled,2730,O
Trials,2730,O
(,2730,O
CENTRAL,2730,O
),2730,O
",",2730,O
MEDLINE,2730,O
",",2730,O
EMBASE,2730,O
",",2730,O
Biological,2730,O
Abstracts,2730,O
.,2730,O
Relevant,2731,O
non-indexed,2731,O
journals,2731,O
and,2731,O
conference,2731,O
abstracts,2731,O
were,2731,O
also,2731,O
searched,2731,O
.,2731,O
SELECTION,2732,O
CRITERIA,2732,O
:,2732,O
Randomised,2732,O
double-blind,2732,O
trials,2732,O
of,2732,O
HT,2732,O
(,2732,O
oestrogens,2732,B-Chemical
with,2732,O
or,2732,O
without,2732,O
progestogens,2732,B-Chemical
),2732,O
versus,2732,O
placebo,2732,O
",",2732,O
taken,2732,O
for,2732,O
at,2732,O
least,2732,O
one,2732,O
year,2732,O
by,2732,O
perimenopausal,2732,O
or,2732,O
postmenopausal,2732,O
women,2732,O
.,2732,O
DATA,2733,O
COLLECTION,2733,O
AND,2733,O
ANALYSIS,2733,O
:,2733,O
Fifteen,2733,O
RCTs,2733,O
were,2733,O
included,2733,O
.,2733,O
Trials,2734,O
were,2734,O
assessed,2734,O
for,2734,O
quality,2734,O
and,2734,O
two,2734,O
review,2734,O
authors,2734,O
extracted,2734,O
data,2734,O
independently,2734,O
.,2734,O
They,2735,O
calculated,2735,O
risk,2735,O
ratios,2735,O
for,2735,O
dichotomous,2735,O
outcomes,2735,O
and,2735,O
weighted,2735,O
mean,2735,O
differences,2735,O
for,2735,O
continuous,2735,O
outcomes,2735,O
.,2735,O
Clinical,2736,O
heterogeneity,2736,O
precluded,2736,O
meta-analysis,2736,O
for,2736,O
most,2736,O
outcomes,2736,O
.,2736,O
MAIN,2737,O
RESULTS,2737,O
:,2737,O
All,2737,O
the,2737,O
statistically,2737,O
significant,2737,O
results,2737,O
were,2737,O
derived,2737,O
from,2737,O
the,2737,O
two,2737,O
biggest,2737,O
trials,2737,O
.,2737,O
In,2738,O
relatively,2738,O
healthy,2738,O
women,2738,O
",",2738,O
combined,2738,O
continuous,2738,O
HT,2738,O
significantly,2738,O
increased,2738,O
the,2738,O
risk,2738,O
of,2738,O
venous,2738,B-Disease
thromboembolism,2738,I-Disease
or,2738,O
coronary,2738,O
event,2738,O
(,2738,O
after,2738,O
one,2738,O
year,2738,O
's,2738,O
use,2738,O
),2738,O
",",2738,O
stroke,2738,B-Disease
(,2738,O
after,2738,O
3,2738,O
years,2738,O
),2738,O
",",2738,O
breast,2738,B-Disease
cancer,2738,I-Disease
(,2738,O
after,2738,O
5,2738,O
years,2738,O
),2738,O
and,2738,O
gallbladder,2738,B-Disease
disease,2738,I-Disease
.,2738,O
Long-term,2739,O
oestrogen-only,2739,B-Chemical
HT,2739,O
also,2739,O
significantly,2739,O
increased,2739,O
the,2739,O
risk,2739,O
of,2739,O
stroke,2739,B-Disease
and,2739,O
gallbladder,2739,B-Disease
disease,2739,I-Disease
.,2739,O
Overall,2740,O
",",2740,O
the,2740,O
only,2740,O
statistically,2740,O
significant,2740,O
benefits,2740,O
of,2740,O
HT,2740,O
were,2740,O
a,2740,O
decreased,2740,O
incidence,2740,O
of,2740,O
fractures,2740,B-Disease
and,2740,O
colon,2740,B-Disease
cancer,2740,I-Disease
with,2740,O
long-term,2740,O
use,2740,O
.,2740,O
Among,2741,O
relatively,2741,O
healthy,2741,O
women,2741,O
over,2741,O
65,2741,O
years,2741,O
taking,2741,O
continuous,2741,O
combined,2741,O
HT,2741,O
",",2741,O
there,2741,O
was,2741,O
a,2741,O
statistically,2741,O
significant,2741,O
increase,2741,O
in,2741,O
the,2741,O
incidence,2741,O
of,2741,O
dementia,2741,B-Disease
.,2741,O
Among,2742,O
women,2742,O
with,2742,O
cardiovascular,2742,B-Disease
disease,2742,I-Disease
",",2742,O
long-term,2742,O
use,2742,O
of,2742,O
combined,2742,O
continuous,2742,O
HT,2742,O
significantly,2742,O
increased,2742,O
the,2742,O
risk,2742,O
of,2742,O
venous,2742,B-Disease
thromboembolism,2742,I-Disease
.,2742,O
No,2743,O
trials,2743,O
focussed,2743,O
specifically,2743,O
on,2743,O
younger,2743,O
women,2743,O
.,2743,O
However,2744,O
",",2744,O
one,2744,O
trial,2744,O
analysed,2744,O
subgroups,2744,O
of,2744,O
2839,2744,O
relatively,2744,O
healthy,2744,O
50,2744,O
to,2744,O
59,2744,O
year-old,2744,O
women,2744,O
taking,2744,O
combined,2744,O
continuous,2744,O
HT,2744,O
and,2744,O
1637,2744,O
taking,2744,O
oestrogen-only,2744,B-Chemical
HT,2744,O
",",2744,O
versus,2744,O
similar-sized,2744,O
placebo,2744,O
groups,2744,O
.,2744,O
The,2745,O
only,2745,O
significantly,2745,O
increased,2745,O
risk,2745,O
reported,2745,O
was,2745,O
for,2745,O
venous,2745,B-Disease
thromboembolism,2745,I-Disease
in,2745,O
women,2745,O
taking,2745,O
combined,2745,O
continuous,2745,O
HT,2745,O
;,2745,O
their,2745,O
absolute,2745,O
risk,2745,O
remained,2745,O
very,2745,O
low,2745,O
.,2745,O
AUTHORS,2746,O
',2746,O
CONCLUSIONS,2746,O
:,2746,O
HT,2746,O
is,2746,O
not,2746,O
indicated,2746,O
for,2746,O
the,2746,O
routine,2746,O
management,2746,O
of,2746,O
chronic,2746,B-Disease
disease,2746,I-Disease
.,2746,O
We,2747,O
need,2747,O
more,2747,O
evidence,2747,O
on,2747,O
the,2747,O
safety,2747,O
of,2747,O
HT,2747,O
for,2747,O
menopausal,2747,O
symptom,2747,O
control,2747,O
",",2747,O
though,2747,O
short-term,2747,O
use,2747,O
appears,2747,O
to,2747,O
be,2747,O
relatively,2747,O
safe,2747,O
for,2747,O
healthy,2747,O
younger,2747,O
women,2747,O
.,2747,O
Drug-induced,2748,B-Disease
liver,2748,I-Disease
injury,2748,I-Disease
:,2748,O
an,2748,O
analysis,2748,O
of,2748,O
461,2748,O
incidences,2748,O
submitted,2748,O
to,2748,O
the,2748,O
Spanish,2748,O
registry,2748,O
over,2748,O
a,2748,O
10-year,2748,O
period,2748,O
.,2748,O
BACKGROUND,2749,O
&,2749,O
AIMS,2749,O
:,2749,O
Progress,2749,O
in,2749,O
the,2749,O
understanding,2749,O
of,2749,O
susceptibility,2749,O
factors,2749,O
to,2749,O
drug-induced,2749,B-Disease
liver,2749,I-Disease
injury,2749,I-Disease
(,2749,O
DILI,2749,B-Disease
),2749,O
and,2749,O
outcome,2749,O
predictability,2749,O
are,2749,O
hampered,2749,O
by,2749,O
the,2749,O
lack,2749,O
of,2749,O
systematic,2749,O
programs,2749,O
to,2749,O
detect,2749,O
bona,2749,O
fide,2749,O
cases,2749,O
.,2749,O
METHODS,2750,O
:,2750,O
A,2750,O
cooperative,2750,O
network,2750,O
was,2750,O
created,2750,O
in,2750,O
1994,2750,O
in,2750,O
Spain,2750,O
to,2750,O
identify,2750,O
all,2750,O
suspicions,2750,O
of,2750,O
DILI,2750,B-Disease
following,2750,O
a,2750,O
prospective,2750,O
structured,2750,O
report,2750,O
form,2750,O
.,2750,O
The,2751,O
liver,2751,B-Disease
damage,2751,I-Disease
was,2751,O
characterized,2751,O
according,2751,O
to,2751,O
hepatocellular,2751,O
",",2751,O
cholestatic,2751,B-Disease
",",2751,O
and,2751,O
mixed,2751,O
laboratory,2751,O
criteria,2751,O
and,2751,O
to,2751,O
histologic,2751,O
criteria,2751,O
when,2751,O
available,2751,O
.,2751,O
Further,2752,O
evaluation,2752,O
of,2752,O
causality,2752,O
assessment,2752,O
was,2752,O
centrally,2752,O
performed,2752,O
.,2752,O
RESULTS,2753,O
:,2753,O
Since,2753,O
April,2753,O
1994,2753,O
to,2753,O
August,2753,O
2004,2753,O
",",2753,O
461,2753,O
out,2753,O
of,2753,O
570,2753,O
submitted,2753,O
cases,2753,O
",",2753,O
involving,2753,O
505,2753,O
drugs,2753,O
",",2753,O
were,2753,O
deemed,2753,O
to,2753,O
be,2753,O
related,2753,O
to,2753,O
DILI,2753,B-Disease
.,2753,O
The,2754,O
antiinfective,2754,O
group,2754,O
of,2754,O
drugs,2754,O
was,2754,O
the,2754,O
more,2754,O
frequently,2754,O
incriminated,2754,O
",",2754,O
amoxicillin-clavulanate,2754,B-Chemical
accounting,2754,O
for,2754,O
the,2754,O
12.8,2754,O
%,2754,O
of,2754,O
the,2754,O
whole,2754,O
series,2754,O
.,2754,O
The,2755,O
hepatocellular,2755,O
pattern,2755,O
of,2755,O
damage,2755,O
was,2755,O
the,2755,O
most,2755,O
common,2755,O
(,2755,O
58,2755,O
%,2755,O
),2755,O
",",2755,O
was,2755,O
inversely,2755,O
correlated,2755,O
with,2755,O
age,2755,O
(,2755,O
P,2755,O
<,2755,O
.0001,2755,O
),2755,O
",",2755,O
and,2755,O
had,2755,O
the,2755,O
worst,2755,O
outcome,2755,O
(,2755,O
Cox,2755,O
regression,2755,O
",",2755,O
P,2755,O
<,2755,O
.034,2755,O
),2755,O
.,2755,O
Indeed,2756,O
",",2756,O
the,2756,O
incidence,2756,O
of,2756,O
liver,2756,O
transplantation,2756,O
and,2756,O
death,2756,O
in,2756,O
this,2756,O
group,2756,O
was,2756,O
11.7,2756,O
%,2756,O
if,2756,O
patients,2756,O
had,2756,O
jaundice,2756,B-Disease
at,2756,O
presentation,2756,O
",",2756,O
whereas,2756,O
the,2756,O
corresponding,2756,O
figure,2756,O
was,2756,O
3.8,2756,O
%,2756,O
in,2756,O
nonjaundiced,2756,O
patients,2756,O
(,2756,O
P,2756,O
<,2756,O
.04,2756,O
),2756,O
.,2756,O
Factors,2757,O
associated,2757,O
with,2757,O
the,2757,O
development,2757,O
of,2757,O
fulminant,2757,B-Disease
hepatic,2757,I-Disease
failure,2757,I-Disease
were,2757,O
female,2757,O
sex,2757,O
(,2757,O
OR,2757,O
=,2757,O
25,2757,O
;,2757,O
95,2757,O
%,2757,O
CI,2757,O
:,2757,O
4.1-151,2757,O
;,2757,O
P,2757,O
<,2757,O
.0001,2757,O
),2757,O
",",2757,O
hepatocellular,2757,O
damage,2757,O
(,2757,O
OR,2757,O
=,2757,O
7.9,2757,O
;,2757,O
95,2757,O
%,2757,O
CI,2757,O
:,2757,O
1.6-37,2757,O
;,2757,O
P,2757,O
<,2757,O
.009,2757,O
),2757,O
",",2757,O
and,2757,O
higher,2757,O
baseline,2757,O
plasma,2757,O
bilirubin,2757,B-Chemical
value,2757,O
(,2757,O
OR,2757,O
=,2757,O
1.15,2757,O
;,2757,O
95,2757,O
%,2757,O
CI,2757,O
:,2757,O
1.09-1.22,2757,O
;,2757,O
P,2757,O
<,2757,O
.0001,2757,O
),2757,O
.,2757,O
CONCLUSIONS,2758,O
:,2758,O
Patients,2758,O
with,2758,O
drug-induced,2758,O
hepatocellular,2758,O
jaundice,2758,B-Disease
have,2758,O
11.7,2758,O
%,2758,O
chance,2758,O
of,2758,O
progressing,2758,O
to,2758,O
death,2758,O
or,2758,O
transplantation,2758,O
.,2758,O
Amoxicillin-clavulanate,2759,B-Chemical
stands,2759,O
out,2759,O
as,2759,O
the,2759,O
most,2759,O
common,2759,O
drug,2759,O
related,2759,O
to,2759,O
DILI,2759,B-Disease
.,2759,O
Morphological,2760,O
evaluation,2760,O
of,2760,O
the,2760,O
effect,2760,O
of,2760,O
d-ribose,2760,B-Chemical
on,2760,O
adriamycin-evoked,2760,B-Chemical
cardiotoxicity,2760,B-Disease
in,2760,O
rats,2760,O
.,2760,O
The,2761,O
influence,2761,O
of,2761,O
d-ribose,2761,B-Chemical
on,2761,O
adriamycin-induced,2761,B-Chemical
myocardiopathy,2761,B-Disease
in,2761,O
rats,2761,O
was,2761,O
studied,2761,O
.,2761,O
Adriamycin,2762,B-Chemical
in,2762,O
the,2762,O
cumulative,2762,O
dose,2762,O
of,2762,O
25,2762,O
mg/kg,2762,O
evoked,2762,O
fully,2762,O
developed,2762,O
cardiac,2762,B-Disease
toxicity,2762,I-Disease
.,2762,O
D-ribose,2763,B-Chemical
in,2763,O
the,2763,O
multiple,2763,O
doses,2763,O
of,2763,O
200,2763,O
mg/kg,2763,O
did,2763,O
not,2763,O
influence,2763,O
ADR,2763,B-Chemical
cardiotoxicity,2763,B-Disease
.,2763,O
In,2764,O
vivo,2764,O
evidences,2764,O
suggesting,2764,O
the,2764,O
role,2764,O
of,2764,O
oxidative,2764,O
stress,2764,O
in,2764,O
pathogenesis,2764,O
of,2764,O
vancomycin-induced,2764,B-Chemical
nephrotoxicity,2764,B-Disease
:,2764,O
protection,2764,O
by,2764,O
erdosteine,2764,B-Chemical
.,2764,O
The,2765,O
aims,2765,O
of,2765,O
this,2765,O
study,2765,O
were,2765,O
to,2765,O
examine,2765,O
vancomycin,2765,B-Chemical
(,2765,O
VCM,2765,B-Chemical
),2765,O
-induced,2765,O
oxidative,2765,O
stress,2765,O
that,2765,O
promotes,2765,O
production,2765,O
of,2765,O
reactive,2765,O
oxygen,2765,B-Chemical
species,2765,O
(,2765,O
ROS,2765,O
),2765,O
and,2765,O
to,2765,O
investigate,2765,O
the,2765,O
role,2765,O
of,2765,O
erdosteine,2765,B-Chemical
",",2765,O
an,2765,O
expectorant,2765,O
agent,2765,O
",",2765,O
which,2765,O
has,2765,O
also,2765,O
antioxidant,2765,O
properties,2765,O
",",2765,O
on,2765,O
kidney,2765,O
tissue,2765,O
against,2765,O
the,2765,O
possible,2765,O
VCM-induced,2765,B-Chemical
renal,2765,B-Disease
impairment,2765,I-Disease
in,2765,O
rats,2765,O
.,2765,O
Rats,2766,O
were,2766,O
divided,2766,O
into,2766,O
three,2766,O
groups,2766,O
:,2766,O
sham,2766,O
",",2766,O
VCM,2766,B-Chemical
and,2766,O
VCM,2766,B-Chemical
plus,2766,O
erdosteine,2766,B-Chemical
.,2766,O
VCM,2767,B-Chemical
was,2767,O
administrated,2767,O
intraperitoneally,2767,O
(,2767,O
i.p,2767,O
.,2767,O
),2767,O
with,2768,O
200mgkg,2768,O
(,2768,O
-1,2768,O
),2768,O
twice,2768,O
daily,2768,O
for,2768,O
7,2768,O
days,2768,O
.,2768,O
Erdosteine,2769,B-Chemical
was,2769,O
administered,2769,O
orally,2769,O
.,2769,O
VCM,2770,B-Chemical
administration,2770,O
to,2770,O
control,2770,O
rats,2770,O
significantly,2770,O
increased,2770,O
renal,2770,O
malondialdehyde,2770,B-Chemical
(,2770,O
MDA,2770,B-Chemical
),2770,O
and,2770,O
urinary,2770,O
N-acetyl-beta-d-glucosaminidase,2770,O
(,2770,O
NAG,2770,O
",",2770,O
a,2770,O
marker,2770,O
of,2770,O
renal,2770,B-Disease
tubular,2770,I-Disease
injury,2770,I-Disease
),2770,O
excretion,2770,O
but,2770,O
decreased,2770,O
superoxide,2770,B-Chemical
dismutase,2770,O
(,2770,O
SOD,2770,O
),2770,O
and,2770,O
catalase,2770,O
(,2770,O
CAT,2770,O
),2770,O
activities,2770,O
.,2770,O
Erdosteine,2771,B-Chemical
administration,2771,O
with,2771,O
VCM,2771,B-Chemical
injections,2771,O
caused,2771,O
significantly,2771,O
decreased,2771,O
renal,2771,O
MDA,2771,B-Chemical
and,2771,O
urinary,2771,O
NAG,2771,O
excretion,2771,O
",",2771,O
and,2771,O
increased,2771,O
SOD,2771,O
activity,2771,O
",",2771,O
but,2771,O
not,2771,O
CAT,2771,O
activity,2771,O
in,2771,O
renal,2771,O
tissue,2771,O
when,2771,O
compared,2771,O
with,2771,O
VCM,2771,B-Chemical
alone,2771,O
.,2771,O
Erdosteine,2772,B-Chemical
showed,2772,O
histopathological,2772,O
protection,2772,O
against,2772,O
VCM-induced,2772,B-Chemical
nephrotoxicity,2772,B-Disease
.,2772,O
There,2773,O
were,2773,O
a,2773,O
significant,2773,O
dilatation,2773,O
of,2773,O
tubular,2773,O
lumens,2773,O
",",2773,O
extensive,2773,O
epithelial,2773,O
cell,2773,O
vacuolization,2773,O
",",2773,O
atrophy,2773,B-Disease
",",2773,O
desquamation,2773,B-Disease
",",2773,O
and,2773,O
necrosis,2773,B-Disease
in,2773,O
VCM-treated,2773,B-Chemical
rats,2773,O
more,2773,O
than,2773,O
those,2773,O
of,2773,O
the,2773,O
control,2773,O
and,2773,O
the,2773,O
erdosteine,2773,B-Chemical
groups,2773,O
.,2773,O
Erdosteine,2774,B-Chemical
caused,2774,O
a,2774,O
marked,2774,O
reduction,2774,O
in,2774,O
the,2774,O
extent,2774,O
of,2774,O
tubular,2774,O
damage,2774,O
.,2774,O
It,2775,O
is,2775,O
concluded,2775,O
that,2775,O
oxidative,2775,O
tubular,2775,O
damage,2775,O
plays,2775,O
an,2775,O
important,2775,O
role,2775,O
in,2775,O
the,2775,O
VCM-induced,2775,B-Chemical
nephrotoxicity,2775,B-Disease
and,2775,O
the,2775,O
modulation,2775,O
of,2775,O
oxidative,2775,O
stress,2775,O
with,2775,O
erdosteine,2775,B-Chemical
reduces,2775,O
the,2775,O
VCM-induced,2775,B-Chemical
kidney,2775,B-Disease
damage,2775,I-Disease
both,2775,O
at,2775,O
the,2775,O
biochemical,2775,O
and,2775,O
histological,2775,O
levels,2775,O
.,2775,O
Does,2776,O
domperidone,2776,B-Chemical
potentiate,2776,O
mirtazapine-associated,2776,B-Chemical
restless,2776,B-Disease
legs,2776,I-Disease
syndrome,2776,I-Disease
?,2776,O
There,2777,O
is,2777,O
now,2777,O
evidence,2777,O
to,2777,O
suggest,2777,O
a,2777,O
central,2777,O
role,2777,O
for,2777,O
the,2777,O
dopaminergic,2777,O
system,2777,O
in,2777,O
restless,2777,B-Disease
legs,2777,I-Disease
syndrome,2777,I-Disease
(,2777,O
RLS,2777,B-Disease
),2777,O
.,2777,O
For,2778,O
example,2778,O
",",2778,O
the,2778,O
symptoms,2778,O
of,2778,O
RLS,2778,B-Disease
can,2778,O
be,2778,O
dramatically,2778,O
improved,2778,O
by,2778,O
levodopa,2778,B-Chemical
and,2778,O
dopamine,2778,B-Chemical
agonists,2778,O
",",2778,O
whereas,2778,O
central,2778,O
dopamine,2778,B-Chemical
D2,2778,O
receptor,2778,O
antagonists,2778,O
can,2778,O
induce,2778,O
or,2778,O
aggravate,2778,O
RLS,2778,B-Disease
symptoms,2778,O
.,2778,O
To,2779,O
our,2779,O
knowledge,2779,O
",",2779,O
there,2779,O
is,2779,O
no,2779,O
previous,2779,O
report,2779,O
regarding,2779,O
whether,2779,O
domperidone,2779,B-Chemical
",",2779,O
a,2779,O
peripheral,2779,O
dopamine,2779,B-Chemical
D2,2779,O
receptor,2779,O
antagonist,2779,O
",",2779,O
can,2779,O
also,2779,O
induce,2779,O
or,2779,O
aggravate,2779,O
symptoms,2779,O
of,2779,O
RLS,2779,B-Disease
.,2779,O
Mirtazapine,2780,B-Chemical
",",2780,O
the,2780,O
first,2780,O
noradrenergic,2780,O
and,2780,O
specific,2780,O
serotonergic,2780,O
antidepressant,2780,O
(,2780,O
NaSSA,2780,O
),2780,O
",",2780,O
has,2780,O
been,2780,O
associated,2780,O
with,2780,O
RLS,2780,B-Disease
in,2780,O
several,2780,O
recent,2780,O
publications,2780,O
.,2780,O
The,2781,O
authors,2781,O
report,2781,O
here,2781,O
a,2781,O
depressed,2781,O
patient,2781,O
comorbid,2781,O
with,2781,O
postprandial,2781,B-Disease
dyspepsia,2781,I-Disease
who,2781,O
developed,2781,O
RLS,2781,B-Disease
after,2781,O
mirtazapine,2781,B-Chemical
had,2781,O
been,2781,O
added,2781,O
to,2781,O
his,2781,O
domperidone,2781,B-Chemical
therapy,2781,O
.,2781,O
Our,2782,O
patient,2782,O
started,2782,O
to,2782,O
have,2782,O
symptoms,2782,O
of,2782,O
RLS,2782,B-Disease
only,2782,O
after,2782,O
he,2782,O
had,2782,O
been,2782,O
treated,2782,O
with,2782,O
mirtazapine,2782,B-Chemical
",",2782,O
and,2782,O
his,2782,O
RLS,2782,B-Disease
symptoms,2782,O
resolved,2782,O
completely,2782,O
upon,2782,O
discontinuation,2782,O
of,2782,O
his,2782,O
mirtazapine,2782,B-Chemical
.,2782,O
Such,2783,O
a,2783,O
temporal,2783,O
relationship,2783,O
between,2783,O
the,2783,O
use,2783,O
of,2783,O
mirtazapine,2783,B-Chemical
and,2783,O
the,2783,O
symptoms,2783,O
of,2783,O
RLS,2783,B-Disease
in,2783,O
our,2783,O
patient,2783,O
did,2783,O
not,2783,O
support,2783,O
a,2783,O
potentiating,2783,O
effect,2783,O
of,2783,O
domperione,2783,B-Chemical
on,2783,O
mirtazapine-associated,2783,B-Chemical
RLS,2783,B-Disease
.,2783,O
However,2784,O
",",2784,O
physicians,2784,O
should,2784,O
be,2784,O
aware,2784,O
of,2784,O
the,2784,O
possibility,2784,O
that,2784,O
mirtazapine,2784,B-Chemical
can,2784,O
be,2784,O
associated,2784,O
with,2784,O
RLS,2784,B-Disease
in,2784,O
some,2784,O
individuals,2784,O
",",2784,O
especially,2784,O
those,2784,O
receiving,2784,O
concomitant,2784,O
dopamine,2784,B-Chemical
D2,2784,O
receptor,2784,O
antagonists,2784,O
.,2784,O
Antiandrogenic,2785,O
therapy,2785,O
can,2785,O
cause,2785,O
coronary,2785,B-Disease
arterial,2785,I-Disease
disease,2785,I-Disease
.,2785,O
AIM,2786,O
:,2786,O
To,2786,O
study,2786,O
the,2786,O
change,2786,O
of,2786,O
lipid,2786,O
metabolism,2786,O
by,2786,O
antiandrogen,2786,O
therapy,2786,O
in,2786,O
patients,2786,O
with,2786,O
prostate,2786,B-Disease
cancer,2786,I-Disease
.,2786,O
MATERIALS,2787,O
AND,2787,O
METHODS,2787,O
:,2787,O
We,2787,O
studied,2787,O
with,2787,O
a,2787,O
2.5,2787,O
years,2787,O
follow-up,2787,O
the,2787,O
changes,2787,O
in,2787,O
plasma,2787,O
cholesterols,2787,B-Chemical
(,2787,O
C,2787,B-Chemical
),2787,O
",",2787,O
triglycerides,2787,B-Chemical
(,2787,O
TG,2787,B-Chemical
),2787,O
",",2787,O
lipoproteins,2787,O
(,2787,O
LP,2787,O
),2787,O
",",2787,O
and,2787,O
apolipoproteins,2787,O
(,2787,O
Apo,2787,O
),2787,O
B-100,2787,O
",",2787,O
A-I,2787,O
",",2787,O
and,2787,O
A-II,2787,O
pro,2787,O
fi,2787,O
les,2787,O
in,2787,O
24,2787,O
patients,2787,O
of,2787,O
mean,2787,O
age,2787,O
60,2787,O
years,2787,O
with,2787,O
low,2787,O
risk,2787,O
prostate,2787,B-Disease
cancer,2787,I-Disease
(,2787,O
stage,2787,O
:,2787,O
T1cN0M0,2787,O
",",2787,O
Gleason,2787,O
score,2787,O
:,2787,O
2-5,2787,O
),2787,O
during,2787,O
treatment,2787,O
with,2787,O
cyproterone,2787,B-Chemical
acetate,2787,I-Chemical
(,2787,O
CPA,2787,B-Chemical
),2787,O
without,2787,O
surgical,2787,O
management,2787,O
or,2787,O
radiation,2787,O
therapy,2787,O
.,2787,O
RESULTS,2788,O
:,2788,O
Significant,2788,O
decreases,2788,O
of,2788,O
HDL-C,2788,O
",",2788,O
Apo,2788,O
A-I,2788,O
and,2788,O
Apo,2788,O
A-II,2788,O
and,2788,O
an,2788,O
increase,2788,O
of,2788,O
triglyceride,2788,B-Chemical
levels,2788,O
in,2788,O
VLDL,2788,O
were,2788,O
induced,2788,O
by,2788,O
CPA,2788,B-Chemical
.,2788,O
After,2789,O
a,2789,O
period,2789,O
of,2789,O
2.5,2789,O
years,2789,O
on,2789,O
CPA,2789,B-Chemical
treatment,2789,O
",",2789,O
four,2789,O
patients,2789,O
out,2789,O
of,2789,O
twenty-four,2789,O
were,2789,O
found,2789,O
to,2789,O
be,2789,O
affected,2789,O
by,2789,O
coronary,2789,B-Disease
heart,2789,I-Disease
disease,2789,I-Disease
.,2789,O
CONCLUSIONS,2790,O
:,2790,O
Ischaemic,2790,O
coronary,2790,B-Disease
arteriosclerosis,2790,I-Disease
with,2790,O
an,2790,O
incidence,2790,O
rate,2790,O
of,2790,O
16.6,2790,O
%,2790,O
as,2790,O
caused,2790,O
by,2790,O
prolonged,2790,O
CPA,2790,B-Chemical
therapy,2790,O
is,2790,O
mediated,2790,O
through,2790,O
changes,2790,O
in,2790,O
HDL,2790,O
cholesterol,2790,B-Chemical
",",2790,O
Apo,2790,O
A-I,2790,O
and,2790,O
Apo,2790,O
A-II,2790,O
pro,2790,O
fi,2790,O
les,2790,O
",",2790,O
other,2790,O
than,2790,O
the,2790,O
well-known,2790,O
hyperglyceridemic,2790,B-Disease
effect,2790,I-Disease
caused,2790,O
by,2790,O
estrogen,2790,B-Chemical
.,2790,O
5-Fluorouracil,2791,B-Chemical
cardiotoxicity,2791,B-Disease
induced,2791,O
by,2791,O
alpha-fluoro-beta-alanine,2791,B-Chemical
.,2791,O
Cardiotoxicity,2792,B-Disease
is,2792,O
a,2792,O
rare,2792,O
complication,2792,O
occurring,2792,O
during,2792,O
5-fluorouracil,2792,B-Chemical
(,2792,O
5-FU,2792,B-Chemical
),2792,O
treatment,2792,O
for,2792,O
malignancies,2792,B-Disease
.,2792,O
We,2793,O
herein,2793,O
report,2793,O
the,2793,O
case,2793,O
of,2793,O
a,2793,O
70-year-old,2793,O
man,2793,O
with,2793,O
5-FU-induced,2793,B-Chemical
cardiotoxicity,2793,B-Disease
",",2793,O
in,2793,O
whom,2793,O
a,2793,O
high,2793,O
serum,2793,O
level,2793,O
of,2793,O
alpha-fluoro-beta-alanine,2793,B-Chemical
(,2793,O
FBAL,2793,B-Chemical
),2793,O
was,2793,O
observed,2793,O
.,2793,O
The,2794,O
patient,2794,O
",",2794,O
who,2794,O
had,2794,O
unresectable,2794,O
colon,2794,B-Disease
cancer,2794,I-Disease
metastases,2794,O
to,2794,O
the,2794,O
liver,2794,O
and,2794,O
lung,2794,O
",",2794,O
was,2794,O
referred,2794,O
to,2794,O
us,2794,O
for,2794,O
chemotherapy,2794,O
from,2794,O
an,2794,O
affiliated,2794,O
hospital,2794,O
;,2794,O
he,2794,O
had,2794,O
no,2794,O
cardiac,2794,O
history,2794,O
.,2794,O
After,2795,O
admission,2795,O
",",2795,O
the,2795,O
patient,2795,O
received,2795,O
a,2795,O
continuous,2795,O
intravenous,2795,O
infusion,2795,O
of,2795,O
5-FU,2795,B-Chemical
(,2795,O
1000,2795,O
mg/day,2795,O
),2795,O
",",2795,O
during,2795,O
which,2795,O
precordial,2795,B-Disease
pain,2795,I-Disease
with,2795,O
right,2795,B-Disease
bundle,2795,I-Disease
branch,2795,I-Disease
block,2795,I-Disease
occurred,2795,O
concomitantly,2795,O
with,2795,O
a,2795,O
high,2795,O
serum,2795,O
FBAL,2795,B-Chemical
concentration,2795,O
of,2795,O
1955,2795,O
ng/ml,2795,O
.,2795,O
Both,2796,O
the,2796,O
precordial,2796,B-Disease
pain,2796,I-Disease
and,2796,O
the,2796,O
electrocardiographic,2796,O
changes,2796,O
disappeared,2796,O
spontaneously,2796,O
after,2796,O
the,2796,O
discontinuation,2796,O
of,2796,O
5-FU,2796,B-Chemical
.,2796,O
As,2797,O
the,2797,O
precordial,2797,B-Disease
pain,2797,I-Disease
in,2797,O
this,2797,O
patient,2797,O
was,2797,O
considered,2797,O
to,2797,O
have,2797,O
been,2797,O
due,2797,O
to,2797,O
5-FU-induced,2797,B-Chemical
cardiotoxicity,2797,B-Disease
",",2797,O
the,2797,O
administration,2797,O
of,2797,O
5-FU,2797,B-Chemical
was,2797,O
abandoned,2797,O
.,2797,O
Instead,2798,O
",",2798,O
oral,2798,O
administration,2798,O
of,2798,O
S-1,2798,O
(,2798,O
a,2798,O
derivative,2798,O
of,2798,O
5-FU,2798,B-Chemical
),2798,O
",",2798,O
at,2798,O
200,2798,O
mg/day,2798,O
twice,2798,O
a,2798,O
week,2798,O
",",2798,O
was,2798,O
instituted,2798,O
",",2798,O
because,2798,O
S-1,2798,O
has,2798,O
a,2798,O
strong,2798,O
inhibitory,2798,O
effect,2798,O
on,2798,O
dihydropyrimidine,2798,B-Chemical
dehydrogenase,2798,O
",",2798,O
which,2798,O
catalyzes,2798,O
the,2798,O
degradative,2798,O
of,2798,O
5-FU,2798,B-Chemical
into,2798,O
FBAL,2798,B-Chemical
.,2798,O
The,2799,O
serum,2799,O
FBAL,2799,B-Chemical
concentration,2799,O
subsequently,2799,O
decreased,2799,O
to,2799,O
352,2799,O
ng/ml,2799,O
",",2799,O
the,2799,O
same,2799,O
as,2799,O
the,2799,O
value,2799,O
measured,2799,O
on,2799,O
the,2799,O
first,2799,O
day,2799,O
of,2799,O
S-1,2799,O
administration,2799,O
.,2799,O
Thereafter,2800,O
",",2800,O
no,2800,O
cardiac,2800,B-Disease
symptoms,2800,I-Disease
were,2800,O
observed,2800,O
.,2800,O
The,2801,O
patient,2801,O
achieved,2801,O
a,2801,O
partial,2801,O
response,2801,O
6,2801,O
months,2801,O
after,2801,O
the,2801,O
initiation,2801,O
of,2801,O
the,2801,O
S-1,2801,O
treatment,2801,O
.,2801,O
The,2802,O
experience,2802,O
of,2802,O
this,2802,O
case,2802,O
",",2802,O
together,2802,O
with,2802,O
a,2802,O
review,2802,O
of,2802,O
the,2802,O
literature,2802,O
",",2802,O
suggests,2802,O
that,2802,O
FBAL,2802,B-Chemical
is,2802,O
related,2802,O
to,2802,O
5-FU-induced,2802,B-Chemical
cardiotoxicity,2802,B-Disease
.,2802,O
S-1,2803,O
may,2803,O
be,2803,O
administered,2803,O
safely,2803,O
to,2803,O
patients,2803,O
with,2803,O
5-FU-induced,2803,B-Chemical
cardiotoxicity,2803,B-Disease
.,2803,O
The,2804,O
influence,2804,O
of,2804,O
the,2804,O
time,2804,O
interval,2804,O
between,2804,O
monoHER,2804,B-Chemical
and,2804,O
doxorubicin,2804,B-Chemical
administration,2804,O
on,2804,O
the,2804,O
protection,2804,O
against,2804,O
doxorubicin-induced,2804,B-Chemical
cardiotoxicity,2804,B-Disease
in,2804,O
mice,2804,O
.,2804,O
PURPOSE,2805,O
:,2805,O
Despite,2805,O
its,2805,O
well-known,2805,O
cardiotoxicity,2805,B-Disease
",",2805,O
the,2805,O
anthracyclin,2805,O
doxorubicin,2805,B-Chemical
(,2805,O
DOX,2805,B-Chemical
),2805,O
continues,2805,O
to,2805,O
be,2805,O
an,2805,O
effective,2805,O
and,2805,O
widely,2805,O
used,2805,O
chemotherapeutic,2805,O
agent,2805,O
.,2805,O
DOX-induced,2806,B-Chemical
cardiac,2806,B-Disease
damage,2806,I-Disease
presumably,2806,O
results,2806,O
from,2806,O
the,2806,O
formation,2806,O
of,2806,O
free,2806,O
radicals,2806,O
by,2806,O
DOX,2806,B-Chemical
.,2806,O
Reactive,2807,O
oxygen,2807,B-Chemical
species,2807,O
particularly,2807,O
affect,2807,O
the,2807,O
cardiac,2807,O
myocytes,2807,O
because,2807,O
these,2807,O
cells,2807,O
seem,2807,O
to,2807,O
have,2807,O
a,2807,O
relatively,2807,O
poor,2807,O
antioxidant,2807,O
defense,2807,O
system,2807,O
.,2807,O
The,2808,O
semisynthetic,2808,O
flavonoid,2808,B-Chemical
monohydroxyethylrutoside,2808,B-Chemical
(,2808,O
monoHER,2808,B-Chemical
),2808,O
showed,2808,O
cardioprotection,2808,O
against,2808,O
DOX-induced,2808,B-Chemical
cardiotoxicity,2808,B-Disease
through,2808,O
its,2808,O
radical,2808,O
scavenging,2808,O
and,2808,O
iron,2808,B-Chemical
chelating,2808,O
properties,2808,O
.,2808,O
Because,2809,O
of,2809,O
the,2809,O
relatively,2809,O
short,2809,O
final,2809,O
half-life,2809,O
of,2809,O
monoHER,2809,B-Chemical
(,2809,O
about,2809,O
30,2809,O
min,2809,O
),2809,O
",",2809,O
it,2809,O
is,2809,O
expected,2809,O
that,2809,O
the,2809,O
time,2809,O
interval,2809,O
between,2809,O
monoHER,2809,B-Chemical
and,2809,O
DOX,2809,B-Chemical
might,2809,O
be,2809,O
of,2809,O
influence,2809,O
on,2809,O
the,2809,O
cardioprotective,2809,O
effect,2809,O
of,2809,O
monoHER,2809,B-Chemical
.,2809,O
Therefore,2810,O
",",2810,O
the,2810,O
aim,2810,O
of,2810,O
the,2810,O
present,2810,O
study,2810,O
was,2810,O
to,2810,O
investigate,2810,O
this,2810,O
possible,2810,O
effect,2810,O
.,2810,O
METHODS,2811,O
:,2811,O
Six,2811,O
groups,2811,O
of,2811,O
6,2811,O
BALB/c,2811,O
mice,2811,O
were,2811,O
treated,2811,O
with,2811,O
saline,2811,O
",",2811,O
DOX,2811,B-Chemical
alone,2811,O
or,2811,O
DOX,2811,B-Chemical
(,2811,O
4,2811,O
mg/kg,2811,O
i.v,2811,O
.,2811,O
),2811,O
preceded,2812,O
by,2812,O
monoHER,2812,B-Chemical
(,2812,O
500,2812,O
mg/kg,2812,O
i.p,2812,O
.,2812,O
),2812,O
with,2813,O
an,2813,O
interval,2813,O
of,2813,O
10,2813,O
",",2813,O
30,2813,O
",",2813,O
60,2813,O
or,2813,O
120,2813,O
min,2813,O
.,2813,O
After,2814,O
a,2814,O
6-week,2814,O
treatment,2814,O
period,2814,O
and,2814,O
additional,2814,O
observation,2814,O
for,2814,O
2,2814,O
weeks,2814,O
",",2814,O
the,2814,O
mice,2814,O
were,2814,O
sacrificed,2814,O
.,2814,O
Their,2815,O
cardiac,2815,O
tissues,2815,O
were,2815,O
processed,2815,O
for,2815,O
light,2815,O
microscopy,2815,O
",",2815,O
after,2815,O
which,2815,O
cardiomyocyte,2815,B-Disease
damage,2815,I-Disease
was,2815,O
evaluated,2815,O
according,2815,O
to,2815,O
Billingham,2815,O
(,2815,O
in,2815,O
Cancer,2815,B-Disease
Treat,2815,O
Rep,2815,O
62,2815,O
(,2815,O
6,2815,O
),2815,O
:865-872,2815,O
",",2815,O
1978,2815,O
),2815,O
.,2815,O
Microscopic,2816,O
evaluation,2816,O
revealed,2816,O
that,2816,O
treatment,2816,O
with,2816,O
DOX,2816,B-Chemical
alone,2816,O
induced,2816,O
significant,2816,O
cardiac,2816,B-Disease
damage,2816,I-Disease
in,2816,O
comparison,2816,O
to,2816,O
the,2816,O
saline,2816,O
control,2816,O
group,2816,O
(,2816,O
P,2816,O
<,2816,O
0.001,2816,O
),2816,O
.,2816,O
RESULTS,2817,O
:,2817,O
The,2817,O
number,2817,O
of,2817,O
damaged,2817,O
cardiomyocytes,2817,O
was,2817,O
9.6-fold,2817,O
(,2817,O
95,2817,O
%,2817,O
CI,2817,O
4.4-21.0,2817,O
),2817,O
higher,2817,O
in,2817,O
mice,2817,O
treated,2817,O
with,2817,O
DOX,2817,B-Chemical
alone,2817,O
than,2817,O
that,2817,O
in,2817,O
animals,2817,O
of,2817,O
the,2817,O
control,2817,O
group,2817,O
.,2817,O
The,2818,O
ratio,2818,O
of,2818,O
aberrant,2818,O
cardiomyocytes,2818,O
in,2818,O
mice,2818,O
treated,2818,O
with,2818,O
DOX,2818,B-Chemical
preceded,2818,O
by,2818,O
monoHER,2818,B-Chemical
and,2818,O
those,2818,O
in,2818,O
mice,2818,O
treated,2818,O
with,2818,O
saline,2818,O
ranged,2818,O
from,2818,O
1.6,2818,O
to,2818,O
2.8,2818,O
(,2818,O
mean,2818,O
2.2,2818,O
",",2818,O
95,2818,O
%,2818,O
CI,2818,O
1.2-4.1,2818,O
",",2818,O
P=0.019,2818,O
),2818,O
.,2818,O
The,2819,O
mean,2819,O
protective,2819,O
effect,2819,O
by,2819,O
adding,2819,O
monoHER,2819,B-Chemical
before,2819,O
DOX,2819,B-Chemical
led,2819,O
to,2819,O
a,2819,O
significant,2819,O
4.4-fold,2819,O
reduction,2819,O
(,2819,O
P,2819,O
<,2819,O
0.001,2819,O
",",2819,O
95,2819,O
%,2819,O
CI,2819,O
2.3-8.2,2819,O
),2819,O
of,2819,O
abnormal,2819,O
cardiomyocytes,2819,O
.,2819,O
This,2820,O
protective,2820,O
effect,2820,O
did,2820,O
not,2820,O
depend,2820,O
on,2820,O
the,2820,O
time,2820,O
interval,2820,O
between,2820,O
monoHER,2820,B-Chemical
and,2820,O
DOX,2820,B-Chemical
administration,2820,O
(,2820,O
P=0.345,2820,O
),2820,O
.,2820,O
CONCLUSION,2821,O
:,2821,O
The,2821,O
results,2821,O
indicate,2821,O
that,2821,O
in,2821,O
an,2821,O
outpatient,2821,O
clinical,2821,O
setting,2821,O
monoHER,2821,B-Chemical
may,2821,O
be,2821,O
administered,2821,O
shortly,2821,O
before,2821,O
DOX,2821,B-Chemical
.,2821,O
Clinical,2822,O
evaluation,2822,O
of,2822,O
adverse,2822,O
effects,2822,O
during,2822,O
bepridil,2822,B-Chemical
administration,2822,O
for,2822,O
atrial,2822,O
fibrillation,2822,O
and,2822,O
flutter,2822,O
.,2822,O
BACKGROUND,2823,O
:,2823,O
Bepridil,2823,B-Chemical
hydrochloride,2823,I-Chemical
(,2823,O
Bpd,2823,B-Chemical
),2823,O
has,2823,O
attracted,2823,O
attention,2823,O
as,2823,O
an,2823,O
effective,2823,O
drug,2823,O
for,2823,O
atrial,2823,B-Disease
fibrillation,2823,I-Disease
(,2823,O
AF,2823,B-Disease
),2823,O
and,2823,O
atrial,2823,B-Disease
flutter,2823,I-Disease
(,2823,O
AFL,2823,B-Disease
),2823,O
.,2823,O
However,2824,O
",",2824,O
serious,2824,O
adverse,2824,O
effects,2824,O
",",2824,O
including,2824,O
torsade,2824,B-Disease
de,2824,I-Disease
pointes,2824,I-Disease
(,2824,O
Tdp,2824,B-Disease
),2824,O
",",2824,O
have,2824,O
been,2824,O
reported,2824,O
.,2824,O
METHODS,2825,O
AND,2825,O
RESULTS,2825,O
:,2825,O
Adverse,2825,O
effects,2825,O
of,2825,O
Bpd,2825,B-Chemical
requiring,2825,O
discontinuation,2825,O
of,2825,O
treatment,2825,O
were,2825,O
evaluated,2825,O
.,2825,O
Bpd,2826,B-Chemical
was,2826,O
administered,2826,O
to,2826,O
459,2826,O
patients,2826,O
(,2826,O
361,2826,O
males,2826,O
",",2826,O
63+/-12,2826,O
years,2826,O
old,2826,O
),2826,O
comprising,2826,O
378,2826,O
AF,2826,B-Disease
and,2826,O
81,2826,O
AFL,2826,B-Disease
cases,2826,O
.,2826,O
Mean,2827,O
left,2827,O
ventricular,2827,O
ejection,2827,O
fraction,2827,O
and,2827,O
atrial,2827,O
dimension,2827,O
(,2827,O
LAD,2827,O
),2827,O
were,2827,O
66+/-11,2827,O
%,2827,O
and,2827,O
40+/-6,2827,O
mm,2827,O
",",2827,O
respectively,2827,O
.,2827,O
Adverse,2828,O
effects,2828,O
were,2828,O
observed,2828,O
in,2828,O
19,2828,O
patients,2828,O
(,2828,O
4,2828,O
%,2828,O
),2828,O
during,2828,O
an,2828,O
average,2828,O
follow-up,2828,O
of,2828,O
20,2828,O
months,2828,O
.,2828,O
There,2829,O
was,2829,O
marked,2829,O
QT,2829,B-Disease
prolongation,2829,I-Disease
greater,2829,O
than,2829,O
0.55,2829,O
s,2829,O
in,2829,O
13,2829,O
patients,2829,O
",",2829,O
bradycardia,2829,B-Disease
less,2829,O
than,2829,O
40,2829,O
beats/min,2829,O
in,2829,O
6,2829,O
patients,2829,O
",",2829,O
dizziness,2829,B-Disease
and,2829,O
general,2829,O
fatigue,2829,B-Disease
in,2829,O
1,2829,O
patient,2829,O
each,2829,O
.,2829,O
In,2830,O
4,2830,O
of,2830,O
13,2830,O
patients,2830,O
with,2830,O
QT,2830,B-Disease
prolongation,2830,I-Disease
",",2830,O
Tdp,2830,B-Disease
occurred,2830,O
.,2830,O
The,2831,O
major,2831,O
triggering,2831,O
factors,2831,O
of,2831,O
Tdp,2831,B-Disease
were,2831,O
hypokalemia,2831,B-Disease
and,2831,O
sudden,2831,O
decrease,2831,O
in,2831,O
heart,2831,O
rate,2831,O
.,2831,O
There,2832,O
were,2832,O
no,2832,O
differences,2832,O
in,2832,O
the,2832,O
clinical,2832,O
backgrounds,2832,O
of,2832,O
the,2832,O
patients,2832,O
with,2832,O
and,2832,O
without,2832,O
Tdp,2832,B-Disease
other,2832,O
than,2832,O
LAD,2832,O
and,2832,O
age,2832,O
",",2832,O
which,2832,O
were,2832,O
larger,2832,O
and,2832,O
older,2832,O
in,2832,O
the,2832,O
patients,2832,O
with,2832,O
Tdp,2832,B-Disease
.,2832,O
CONCLUSION,2833,O
:,2833,O
Careful,2833,O
observation,2833,O
of,2833,O
serum,2833,O
potassium,2833,B-Chemical
concentration,2833,O
and,2833,O
the,2833,O
ECG,2833,O
should,2833,O
always,2833,O
be,2833,O
done,2833,O
during,2833,O
Bpd,2833,B-Chemical
administration,2833,O
",",2833,O
particularly,2833,O
in,2833,O
elderly,2833,O
patients,2833,O
.,2833,O
Enhanced,2834,O
isoproterenol-induced,2834,B-Chemical
cardiac,2834,B-Disease
hypertrophy,2834,I-Disease
in,2834,O
transgenic,2834,O
rats,2834,O
with,2834,O
low,2834,O
brain,2834,O
angiotensinogen,2834,O
.,2834,O
We,2835,O
have,2835,O
previously,2835,O
shown,2835,O
that,2835,O
a,2835,O
permanent,2835,O
deficiency,2835,O
in,2835,O
the,2835,O
brain,2835,O
renin-angiotensin,2835,O
system,2835,O
(,2835,O
RAS,2835,O
),2835,O
may,2835,O
increase,2835,O
the,2835,O
sensitivity,2835,O
of,2835,O
the,2835,O
baroreflex,2835,O
control,2835,O
of,2835,O
heart,2835,O
rate,2835,O
.,2835,O
In,2836,O
this,2836,O
study,2836,O
we,2836,O
aimed,2836,O
at,2836,O
studying,2836,O
the,2836,O
involvement,2836,O
of,2836,O
the,2836,O
brain,2836,O
RAS,2836,O
in,2836,O
the,2836,O
cardiac,2836,O
reactivity,2836,O
to,2836,O
the,2836,O
beta-adrenoceptor,2836,O
(,2836,O
beta-AR,2836,O
),2836,O
agonist,2836,O
isoproterenol,2836,B-Chemical
(,2836,O
Iso,2836,B-Chemical
),2836,O
.,2836,O
Transgenic,2837,O
rats,2837,O
with,2837,O
low,2837,O
brain,2837,O
angiotensinogen,2837,O
(,2837,O
TGR,2837,O
),2837,O
were,2837,O
used,2837,O
.,2837,O
In,2838,O
isolated,2838,O
hearts,2838,O
",",2838,O
Iso,2838,B-Chemical
induced,2838,O
a,2838,O
significantly,2838,O
greater,2838,O
increase,2838,O
in,2838,O
left,2838,O
ventricular,2838,O
(,2838,O
LV,2838,O
),2838,O
pressure,2838,O
and,2838,O
maximal,2838,O
contraction,2838,O
(,2838,O
+dP/dt,2838,O
(,2838,O
max,2838,O
),2838,O
),2838,O
in,2838,O
the,2838,O
TGR,2838,O
than,2838,O
in,2838,O
the,2838,O
Sprague-Dawley,2838,O
(,2838,O
SD,2838,O
),2838,O
rats,2838,O
.,2838,O
LV,2839,B-Disease
hypertrophy,2839,I-Disease
induced,2839,O
by,2839,O
Iso,2839,B-Chemical
treatment,2839,O
was,2839,O
significantly,2839,O
higher,2839,O
in,2839,O
TGR,2839,O
than,2839,O
in,2839,O
SD,2839,O
rats,2839,O
(,2839,O
in,2839,O
g,2839,O
LV,2839,O
wt/100,2839,O
g,2839,O
body,2839,O
wt,2839,O
",",2839,O
0.28,2839,O
+/-,2839,O
0.004,2839,O
vs.,2839,O
0.24,2839,O
+/-,2839,O
0.004,2839,O
",",2839,O
respectively,2839,O
),2839,O
.,2839,O
The,2840,O
greater,2840,O
LV,2840,B-Disease
hypertrophy,2840,I-Disease
in,2840,O
TGR,2840,O
rats,2840,O
was,2840,O
associated,2840,O
with,2840,O
more,2840,O
pronounced,2840,O
downregulation,2840,O
of,2840,O
beta-AR,2840,O
and,2840,O
upregulation,2840,O
of,2840,O
LV,2840,O
beta-AR,2840,O
kinase-1,2840,O
mRNA,2840,O
levels,2840,O
compared,2840,O
with,2840,O
those,2840,O
in,2840,O
SD,2840,O
rats,2840,O
.,2840,O
The,2841,O
decrease,2841,O
in,2841,O
the,2841,O
heart,2841,O
rate,2841,O
(,2841,O
HR,2841,O
),2841,O
induced,2841,O
by,2841,O
the,2841,O
beta-AR,2841,O
antagonist,2841,O
metoprolol,2841,B-Chemical
in,2841,O
conscious,2841,O
rats,2841,O
was,2841,O
significantly,2841,O
attenuated,2841,O
in,2841,O
TGR,2841,O
compared,2841,O
with,2841,O
SD,2841,O
rats,2841,O
(,2841,O
-9.9,2841,O
+/-,2841,O
1.7,2841,O
%,2841,O
vs.,2841,O
-18.1,2841,O
+/-,2841,O
1.5,2841,O
%,2841,O
),2841,O
",",2841,O
whereas,2841,O
the,2841,O
effect,2841,O
of,2841,O
parasympathetic,2841,O
blockade,2841,O
by,2841,O
atropine,2841,B-Chemical
on,2841,O
HR,2841,O
was,2841,O
similar,2841,O
in,2841,O
both,2841,O
strains,2841,O
.,2841,O
These,2842,O
results,2842,O
indicate,2842,O
that,2842,O
TGR,2842,O
are,2842,O
more,2842,O
sensitive,2842,O
to,2842,O
beta-AR,2842,O
agonist-induced,2842,O
cardiac,2842,B-Disease
inotropic,2842,I-Disease
response,2842,O
and,2842,O
hypertrophy,2842,B-Disease
",",2842,O
possibly,2842,O
due,2842,O
to,2842,O
chronically,2842,O
low,2842,O
sympathetic,2842,O
outflow,2842,O
directed,2842,O
to,2842,O
the,2842,O
heart,2842,O
.,2842,O
Drug-induced,2843,O
long,2843,B-Disease
QT,2843,I-Disease
syndrome,2843,I-Disease
in,2843,O
injection,2843,O
drug,2843,O
users,2843,O
receiving,2843,O
methadone,2843,B-Chemical
:,2843,O
high,2843,O
frequency,2843,O
in,2843,O
hospitalized,2843,O
patients,2843,O
and,2843,O
risk,2843,O
factors,2843,O
.,2843,O
BACKGROUND,2844,O
:,2844,O
Drug-induced,2844,O
long,2844,B-Disease
QT,2844,I-Disease
syndrome,2844,I-Disease
is,2844,O
a,2844,O
serious,2844,O
adverse,2844,O
drug,2844,O
reaction,2844,O
.,2844,O
Methadone,2845,B-Chemical
prolongs,2845,O
the,2845,O
QT,2845,O
interval,2845,O
in,2845,O
vitro,2845,O
in,2845,O
a,2845,O
dose-dependent,2845,O
manner,2845,O
.,2845,O
In,2846,O
the,2846,O
inpatient,2846,O
setting,2846,O
",",2846,O
the,2846,O
frequency,2846,O
of,2846,O
QT,2846,B-Disease
interval,2846,I-Disease
prolongation,2846,I-Disease
with,2846,O
methadone,2846,B-Chemical
treatment,2846,O
",",2846,O
its,2846,O
dose,2846,O
dependence,2846,O
",",2846,O
and,2846,O
the,2846,O
importance,2846,O
of,2846,O
cofactors,2846,O
such,2846,O
as,2846,O
drug-drug,2846,O
interactions,2846,O
remain,2846,O
unknown,2846,O
.,2846,O
METHODS,2847,O
:,2847,O
We,2847,O
performed,2847,O
a,2847,O
systematic,2847,O
",",2847,O
retrospective,2847,O
study,2847,O
comparing,2847,O
active,2847,O
or,2847,O
former,2847,O
intravenous,2847,O
drug,2847,O
users,2847,O
receiving,2847,O
methadone,2847,B-Chemical
and,2847,O
those,2847,O
not,2847,O
receiving,2847,O
methadone,2847,B-Chemical
among,2847,O
all,2847,O
patients,2847,O
hospitalized,2847,O
over,2847,O
a,2847,O
5-year,2847,O
period,2847,O
in,2847,O
a,2847,O
tertiary,2847,O
care,2847,O
hospital,2847,O
.,2847,O
A,2848,O
total,2848,O
of,2848,O
167,2848,O
patients,2848,O
receiving,2848,O
methadone,2848,B-Chemical
fulfilled,2848,O
the,2848,O
inclusion,2848,O
criteria,2848,O
and,2848,O
were,2848,O
compared,2848,O
with,2848,O
a,2848,O
control,2848,O
group,2848,O
of,2848,O
80,2848,O
injection,2848,O
drug,2848,O
users,2848,O
not,2848,O
receiving,2848,O
methadone,2848,B-Chemical
.,2848,O
In,2849,O
addition,2849,O
to,2849,O
methadone,2849,B-Chemical
dose,2849,O
",",2849,O
15,2849,O
demographic,2849,O
",",2849,O
biological,2849,O
",",2849,O
and,2849,O
pharmacological,2849,O
variables,2849,O
were,2849,O
considered,2849,O
as,2849,O
potential,2849,O
risk,2849,O
factors,2849,O
for,2849,O
QT,2849,B-Disease
prolongation,2849,I-Disease
.,2849,O
RESULTS,2850,O
:,2850,O
Among,2850,O
167,2850,O
methadone,2850,B-Chemical
maintenance,2850,O
patients,2850,O
",",2850,O
the,2850,O
prevalence,2850,O
of,2850,O
QTc,2850,O
prolongation,2850,O
to,2850,O
0.50,2850,O
second,2850,O
(,2850,O
(,2850,O
1/2,2850,O
),2850,O
),2850,O
or,2850,O
longer,2850,O
was,2850,O
16.2,2850,O
%,2850,O
compared,2850,O
with,2850,O
0,2850,O
%,2850,O
in,2850,O
80,2850,O
control,2850,O
subjects,2850,O
.,2850,O
Six,2851,O
patients,2851,O
(,2851,O
3.6,2851,O
%,2851,O
),2851,O
in,2851,O
the,2851,O
methadone,2851,B-Chemical
group,2851,O
presented,2851,O
torsades,2851,B-Disease
de,2851,I-Disease
pointes,2851,I-Disease
.,2851,O
QTc,2852,O
length,2852,O
was,2852,O
weakly,2852,O
but,2852,O
significantly,2852,O
associated,2852,O
with,2852,O
methadone,2852,B-Chemical
daily,2852,O
dose,2852,O
(,2852,O
Spearman,2852,O
rank,2852,O
correlation,2852,O
coefficient,2852,O
",",2852,O
0.20,2852,O
;,2852,O
P,2852,O
<,2852,O
.01,2852,O
),2852,O
.,2852,O
Multivariate,2853,O
regression,2853,O
analysis,2853,O
allowed,2853,O
attribution,2853,O
of,2853,O
31.8,2853,O
%,2853,O
of,2853,O
QTc,2853,O
variability,2853,O
to,2853,O
methadone,2853,B-Chemical
dose,2853,O
",",2853,O
cytochrome,2853,O
P-450,2853,O
3A4,2853,O
drug-drug,2853,O
interactions,2853,O
",",2853,O
hypokalemia,2853,B-Disease
",",2853,O
and,2853,O
altered,2853,O
liver,2853,O
function,2853,O
.,2853,O
CONCLUSIONS,2854,O
:,2854,O
QT,2854,B-Disease
interval,2854,I-Disease
prolongation,2854,I-Disease
in,2854,O
methadone,2854,B-Chemical
maintenance,2854,O
patients,2854,O
hospitalized,2854,O
in,2854,O
a,2854,O
tertiary,2854,O
care,2854,O
center,2854,O
is,2854,O
a,2854,O
frequent,2854,O
finding,2854,O
.,2854,O
Methadone,2855,B-Chemical
dose,2855,O
",",2855,O
presence,2855,O
of,2855,O
cytochrome,2855,O
P-450,2855,O
3A4,2855,O
inhibitors,2855,O
",",2855,O
potassium,2855,B-Chemical
level,2855,O
",",2855,O
and,2855,O
liver,2855,O
function,2855,O
contribute,2855,O
to,2855,O
QT,2855,B-Disease
prolongation,2855,I-Disease
.,2855,O
Long,2856,B-Disease
QT,2856,I-Disease
syndrome,2856,I-Disease
can,2856,O
occur,2856,O
with,2856,O
low,2856,O
doses,2856,O
of,2856,O
methadone,2856,B-Chemical
.,2856,O
Mechanisms,2857,O
of,2857,O
hypertension,2857,B-Disease
induced,2857,O
by,2857,O
nitric,2857,B-Chemical
oxide,2857,I-Chemical
(,2857,O
NO,2857,B-Chemical
),2857,O
deficiency,2857,O
:,2857,O
focus,2857,O
on,2857,O
venous,2857,O
function,2857,O
.,2857,O
Loss,2858,O
of,2858,O
endothelial,2858,O
cell-derived,2858,O
nitric,2858,B-Chemical
oxide,2858,I-Chemical
(,2858,O
NO,2858,B-Chemical
),2858,O
in,2858,O
hypertension,2858,B-Disease
is,2858,O
a,2858,O
hallmark,2858,O
of,2858,O
arterial,2858,B-Disease
dysfunction,2858,I-Disease
.,2858,O
Experimental,2859,O
hypertension,2859,B-Disease
created,2859,O
by,2859,O
the,2859,O
removal,2859,O
of,2859,O
NO,2859,B-Chemical
",",2859,O
however,2859,O
",",2859,O
involves,2859,O
mechanisms,2859,O
in,2859,O
addition,2859,O
to,2859,O
decreased,2859,O
arterial,2859,O
vasodilator,2859,O
activity,2859,O
.,2859,O
These,2860,O
include,2860,O
augmented,2860,O
endothelin-1,2860,O
(,2860,O
ET-1,2860,O
),2860,O
release,2860,O
",",2860,O
increased,2860,O
sympathetic,2860,O
nervous,2860,O
system,2860,O
activity,2860,O
",",2860,O
and,2860,O
elevated,2860,O
tissue,2860,O
oxidative,2860,O
stress,2860,O
.,2860,O
We,2861,O
hypothesized,2861,O
that,2861,O
increased,2861,O
venous,2861,O
smooth,2861,O
muscle,2861,O
(,2861,O
venomotor,2861,O
),2861,O
tone,2861,O
plays,2861,O
a,2861,O
role,2861,O
in,2861,O
Nomega-nitro-L-arginine,2861,B-Chemical
(,2861,O
LNNA,2861,B-Chemical
),2861,O
hypertension,2861,B-Disease
through,2861,O
these,2861,O
mechanisms,2861,O
.,2861,O
Rats,2862,O
were,2862,O
treated,2862,O
with,2862,O
the,2862,O
NO,2862,B-Chemical
synthase,2862,O
inhibitor,2862,O
LNNA,2862,B-Chemical
(,2862,O
0.5,2862,O
g/L,2862,O
in,2862,O
drinking,2862,O
water,2862,O
),2862,O
for,2862,O
2,2862,O
weeks,2862,O
.,2862,O
Mean,2863,O
arterial,2863,O
pressure,2863,O
of,2863,O
conscious,2863,O
rats,2863,O
was,2863,O
119,2863,O
+/-,2863,O
2,2863,O
mm,2863,O
Hg,2863,O
in,2863,O
control,2863,O
and,2863,O
194,2863,O
+/-,2863,O
5,2863,O
mm,2863,O
Hg,2863,O
in,2863,O
LNNA,2863,B-Chemical
rats,2863,O
(,2863,O
P,2863,O
<,2863,O
0.05,2863,O
),2863,O
.,2863,O
Carotid,2864,O
arteries,2864,O
and,2864,O
vena,2864,O
cava,2864,O
were,2864,O
removed,2864,O
for,2864,O
measurement,2864,O
of,2864,O
isometric,2864,O
contraction,2864,O
.,2864,O
Maximal,2865,O
contraction,2865,O
to,2865,O
norepinephrine,2865,B-Chemical
was,2865,O
modestly,2865,O
reduced,2865,O
in,2865,O
arteries,2865,O
from,2865,O
LNNA,2865,B-Chemical
compared,2865,O
with,2865,O
control,2865,O
rats,2865,O
whereas,2865,O
the,2865,O
maximum,2865,O
contraction,2865,O
to,2865,O
ET-1,2865,O
was,2865,O
significantly,2865,O
reduced,2865,O
(,2865,O
54,2865,O
%,2865,O
control,2865,O
),2865,O
.,2865,O
Maximum,2866,O
contraction,2866,O
of,2866,O
vena,2866,O
cava,2866,O
to,2866,O
norepinephrine,2866,B-Chemical
(,2866,O
37,2866,O
%,2866,O
control,2866,O
),2866,O
also,2866,O
was,2866,O
reduced,2866,O
but,2866,O
no,2866,O
change,2866,O
in,2866,O
response,2866,O
to,2866,O
ET-1,2866,O
was,2866,O
observed,2866,O
.,2866,O
Mean,2867,O
circulatory,2867,O
filling,2867,O
pressure,2867,O
",",2867,O
an,2867,O
in,2867,O
vivo,2867,O
measure,2867,O
of,2867,O
venomotor,2867,O
tone,2867,O
",",2867,O
was,2867,O
not,2867,O
elevated,2867,O
in,2867,O
LNNA,2867,B-Chemical
hypertension,2867,B-Disease
at,2867,O
1,2867,O
or,2867,O
2,2867,O
weeks,2867,O
after,2867,O
LNNA,2867,B-Chemical
.,2867,O
The,2868,O
superoxide,2868,B-Chemical
scavenger,2868,O
tempol,2868,B-Chemical
(,2868,O
30,2868,O
",",2868,O
100,2868,O
",",2868,O
and,2868,O
300,2868,O
micromol,2868,O
kg,2868,O
(,2868,O
-1,2868,O
),2868,O
",",2868,O
IV,2868,O
),2868,O
did,2868,O
not,2868,O
change,2868,O
arterial,2868,O
pressure,2868,O
in,2868,O
control,2868,O
rats,2868,O
but,2868,O
caused,2868,O
a,2868,O
dose-dependent,2868,O
decrease,2868,O
in,2868,O
LNNA,2868,B-Chemical
rats,2868,O
(,2868,O
-18,2868,O
+/-,2868,O
8,2868,O
",",2868,O
-26,2868,O
+/-,2868,O
15,2868,O
",",2868,O
and,2868,O
-54,2868,O
+/-,2868,O
11,2868,O
mm,2868,O
Hg,2868,O
),2868,O
.,2868,O
Similarly,2869,O
",",2869,O
ganglionic,2869,O
blockade,2869,O
with,2869,O
hexamethonium,2869,B-Chemical
caused,2869,O
a,2869,O
significantly,2869,O
greater,2869,O
fall,2869,O
in,2869,O
LNNA,2869,B-Chemical
hypertensive,2869,B-Disease
rats,2869,O
(,2869,O
76,2869,O
+/-,2869,O
9,2869,O
mm,2869,O
Hg,2869,O
),2869,O
compared,2869,O
with,2869,O
control,2869,O
rats,2869,O
(,2869,O
35,2869,O
+/-,2869,O
10,2869,O
mm,2869,O
Hg,2869,O
),2869,O
.,2869,O
Carotid,2870,O
arteries,2870,O
",",2870,O
vena,2870,O
cava,2870,O
",",2870,O
and,2870,O
sympathetic,2870,O
ganglia,2870,O
from,2870,O
LNNA,2870,B-Chemical
rats,2870,O
had,2870,O
higher,2870,O
basal,2870,O
levels,2870,O
of,2870,O
superoxide,2870,B-Chemical
compared,2870,O
with,2870,O
those,2870,O
from,2870,O
control,2870,O
rats,2870,O
.,2870,O
These,2871,O
data,2871,O
suggest,2871,O
that,2871,O
while,2871,O
NO,2871,B-Chemical
deficiency,2871,O
increases,2871,O
oxidative,2871,O
stress,2871,O
and,2871,O
sympathetic,2871,O
activity,2871,O
in,2871,O
both,2871,O
arterial,2871,O
and,2871,O
venous,2871,O
vessels,2871,O
",",2871,O
the,2871,O
impact,2871,O
on,2871,O
veins,2871,O
does,2871,O
not,2871,O
make,2871,O
a,2871,O
major,2871,O
contribution,2871,O
to,2871,O
this,2871,O
form,2871,O
of,2871,O
hypertension,2871,B-Disease
.,2871,O
Association,2872,O
of,2872,O
DRD2,2872,O
polymorphisms,2872,O
and,2872,O
chlorpromazine-induced,2872,B-Chemical
extrapyramidal,2872,B-Disease
syndrome,2872,I-Disease
in,2872,O
Chinese,2872,O
schizophrenic,2872,B-Disease
patients,2872,O
.,2872,O
AIM,2873,O
:,2873,O
Extrapyramidal,2873,B-Disease
syndrome,2873,I-Disease
(,2873,O
EPS,2873,B-Disease
),2873,O
is,2873,O
most,2873,O
commonly,2873,O
affected,2873,O
by,2873,O
typical,2873,O
antipsychotic,2873,O
drugs,2873,O
that,2873,O
have,2873,O
a,2873,O
high,2873,O
affinity,2873,O
with,2873,O
the,2873,O
D2,2873,O
receptor,2873,O
.,2873,O
Recently,2874,O
",",2874,O
many,2874,O
research,2874,O
groups,2874,O
have,2874,O
reported,2874,O
on,2874,O
the,2874,O
positive,2874,O
relationship,2874,O
between,2874,O
the,2874,O
genetic,2874,O
variations,2874,O
in,2874,O
the,2874,O
DRD2,2874,O
gene,2874,O
and,2874,O
the,2874,O
therapeutic,2874,O
response,2874,O
in,2874,O
schizophrenia,2874,B-Disease
patients,2874,O
as,2874,O
a,2874,O
result,2874,O
of,2874,O
the,2874,O
role,2874,O
of,2874,O
variations,2874,O
in,2874,O
the,2874,O
receptor,2874,O
in,2874,O
modulating,2874,O
receptor,2874,O
expression,2874,O
.,2874,O
In,2875,O
this,2875,O
study,2875,O
",",2875,O
we,2875,O
evaluate,2875,O
the,2875,O
role,2875,O
DRD2,2875,O
plays,2875,O
in,2875,O
chlorpromazine-induced,2875,B-Chemical
EPS,2875,B-Disease
in,2875,O
schizophrenic,2875,B-Disease
patients,2875,O
.,2875,O
METHODS,2876,O
:,2876,O
We,2876,O
identified,2876,O
seven,2876,O
SNP,2876,O
(,2876,O
single,2876,O
nucleotide,2876,O
polymorphism,2876,O
),2876,O
(,2876,O
-141Cins,2876,O
>,2876,O
del,2876,O
",",2876,O
TaqIB,2876,O
",",2876,O
TaqID,2876,O
",",2876,O
Ser311Cys,2876,O
",",2876,O
rs6275,2876,O
",",2876,O
rs6277,2876,O
and,2876,O
TaqIA,2876,O
),2876,O
in,2876,O
the,2876,O
DRD2,2876,O
gene,2876,O
in,2876,O
146,2876,O
schizophrenic,2876,B-Disease
inpatients,2876,O
(,2876,O
59,2876,O
with,2876,O
EPS,2876,B-Disease
and,2876,O
87,2876,O
without,2876,O
EPS,2876,B-Disease
according,2876,O
to,2876,O
the,2876,O
Simpson-Angus,2876,O
Scale,2876,O
),2876,O
treated,2876,O
with,2876,O
chlorpromazine,2876,B-Chemical
after,2876,O
8,2876,O
weeks,2876,O
.,2876,O
The,2877,O
alleles,2877,O
of,2877,O
all,2877,O
loci,2877,O
were,2877,O
determined,2877,O
by,2877,O
PCR,2877,O
(,2877,O
polymerase,2877,O
chain,2877,O
reaction,2877,O
),2877,O
.,2877,O
RESULTS,2878,O
:,2878,O
Polymorphisms,2878,O
TaqID,2878,O
",",2878,O
Ser311Cys,2878,O
and,2878,O
rs6277,2878,O
were,2878,O
not,2878,O
polymorphic,2878,O
in,2878,O
the,2878,O
population,2878,O
recruited,2878,O
in,2878,O
the,2878,O
present,2878,O
study,2878,O
.,2878,O
No,2879,O
statistical,2879,O
significance,2879,O
was,2879,O
found,2879,O
in,2879,O
the,2879,O
allele,2879,O
distribution,2879,O
of,2879,O
-141Cins,2879,O
>,2879,O
del,2879,O
",",2879,O
TaqIB,2879,O
",",2879,O
rs6275,2879,O
and,2879,O
TaqIA,2879,O
or,2879,O
in,2879,O
the,2879,O
estimated,2879,O
haplotypes,2879,O
(,2879,O
constituted,2879,O
by,2879,O
TaqIB,2879,O
",",2879,O
rs6275,2879,O
and,2879,O
TaqIA,2879,O
),2879,O
in,2879,O
linkage,2879,O
disequilibrium,2879,O
between,2879,O
the,2879,O
two,2879,O
groups,2879,O
.,2879,O
CONCLUSION,2880,O
:,2880,O
Our,2880,O
results,2880,O
did,2880,O
not,2880,O
lend,2880,O
strong,2880,O
support,2880,O
to,2880,O
the,2880,O
view,2880,O
that,2880,O
the,2880,O
genetic,2880,O
variation,2880,O
of,2880,O
the,2880,O
DRD2,2880,O
gene,2880,O
plays,2880,O
a,2880,O
major,2880,O
role,2880,O
in,2880,O
the,2880,O
individually,2880,O
variable,2880,O
adverse,2880,O
effect,2880,O
induced,2880,O
by,2880,O
chlorpromazine,2880,B-Chemical
",",2880,O
at,2880,O
least,2880,O
in,2880,O
Chinese,2880,O
patients,2880,O
with,2880,O
schizophrenia,2880,B-Disease
.,2880,O
Our,2881,O
results,2881,O
confirmed,2881,O
a,2881,O
previous,2881,O
study,2881,O
on,2881,O
the,2881,O
relationship,2881,O
between,2881,O
DRD2,2881,O
and,2881,O
EPS,2881,B-Disease
in,2881,O
Caucasians,2881,O
.,2881,O
Physical,2882,O
training,2882,O
decreases,2882,O
susceptibility,2882,O
to,2882,O
subsequent,2882,O
pilocarpine-induced,2882,B-Chemical
seizures,2882,B-Disease
in,2882,O
the,2882,O
rat,2882,O
.,2882,O
Regular,2883,O
motor,2883,O
activity,2883,O
has,2883,O
many,2883,O
benefits,2883,O
for,2883,O
mental,2883,O
and,2883,O
physical,2883,O
condition,2883,O
but,2883,O
its,2883,O
implications,2883,O
for,2883,O
epilepsy,2883,B-Disease
are,2883,O
still,2883,O
controversial,2883,O
.,2883,O
In,2884,O
order,2884,O
to,2884,O
elucidate,2884,O
this,2884,O
problem,2884,O
",",2884,O
we,2884,O
have,2884,O
studied,2884,O
the,2884,O
effect,2884,O
of,2884,O
long-term,2884,O
physical,2884,O
activity,2884,O
on,2884,O
susceptibility,2884,O
to,2884,O
subsequent,2884,O
seizures,2884,B-Disease
.,2884,O
Male,2885,O
Wistar,2885,O
rats,2885,O
were,2885,O
subjected,2885,O
to,2885,O
repeated,2885,O
training,2885,O
sessions,2885,O
in,2885,O
a,2885,O
treadmill,2885,O
and,2885,O
swimming,2885,O
pool,2885,O
.,2885,O
Thereafter,2886,O
",",2886,O
seizures,2886,B-Disease
were,2886,O
induced,2886,O
by,2886,O
pilocarpine,2886,B-Chemical
injections,2886,O
in,2886,O
trained,2886,O
and,2886,O
non-trained,2886,O
control,2886,O
groups,2886,O
.,2886,O
During,2887,O
the,2887,O
acute,2887,O
period,2887,O
of,2887,O
status,2887,B-Disease
epilepticus,2887,I-Disease
",",2887,O
we,2887,O
measured,2887,O
:,2887,O
(,2887,O
1,2887,O
),2887,O
the,2887,O
latency,2887,O
of,2887,O
the,2887,O
first,2887,O
motor,2887,O
sign,2887,O
",",2887,O
(,2887,O
2,2887,O
),2887,O
the,2887,O
intensity,2887,O
of,2887,O
seizures,2887,B-Disease
",",2887,O
(,2887,O
3,2887,O
),2887,O
the,2887,O
time,2887,O
when,2887,O
it,2887,O
occurred,2887,O
within,2887,O
the,2887,O
6-h,2887,O
observation,2887,O
period,2887,O
",",2887,O
and,2887,O
(,2887,O
4,2887,O
),2887,O
the,2887,O
time,2887,O
when,2887,O
the,2887,O
acute,2887,O
period,2887,O
ended,2887,O
.,2887,O
All,2888,O
these,2888,O
behavioral,2888,O
parameters,2888,O
showed,2888,O
statistically,2888,O
significant,2888,O
changes,2888,O
suggesting,2888,O
that,2888,O
regular,2888,O
physical,2888,O
exercises,2888,O
decrease,2888,O
susceptibility,2888,O
to,2888,O
subsequently,2888,O
induced,2888,O
seizures,2888,B-Disease
and,2888,O
ameliorate,2888,O
the,2888,O
course,2888,O
of,2888,O
experimentally,2888,O
induced,2888,O
status,2888,B-Disease
epilepticus,2888,I-Disease
.,2888,O
Tonic,2889,O
dopaminergic,2889,O
stimulation,2889,O
impairs,2889,B-Disease
associative,2889,I-Disease
learning,2889,I-Disease
in,2889,O
healthy,2889,O
subjects,2889,O
.,2889,O
Endogenous,2890,O
dopamine,2890,B-Chemical
plays,2890,O
a,2890,O
central,2890,O
role,2890,O
in,2890,O
salience,2890,O
coding,2890,O
during,2890,O
associative,2890,O
learning,2890,O
.,2890,O
Administration,2891,O
of,2891,O
the,2891,O
dopamine,2891,B-Chemical
precursor,2891,O
levodopa,2891,B-Chemical
enhances,2891,O
learning,2891,O
in,2891,O
healthy,2891,O
subjects,2891,O
and,2891,O
stroke,2891,B-Disease
patients,2891,O
.,2891,O
Because,2892,O
levodopa,2892,B-Chemical
increases,2892,O
both,2892,O
phasic,2892,O
and,2892,O
tonic,2892,O
dopaminergic,2892,O
neurotransmission,2892,O
",",2892,O
the,2892,O
critical,2892,O
mechanism,2892,O
mediating,2892,O
the,2892,O
enhancement,2892,O
of,2892,O
learning,2892,O
is,2892,O
unresolved,2892,O
.,2892,O
We,2893,O
here,2893,O
probed,2893,O
how,2893,O
selective,2893,O
tonic,2893,O
dopaminergic,2893,O
stimulation,2893,O
affects,2893,O
associative,2893,O
learning,2893,O
.,2893,O
Forty,2894,O
healthy,2894,O
subjects,2894,O
were,2894,O
trained,2894,O
in,2894,O
a,2894,O
novel,2894,O
vocabulary,2894,O
of,2894,O
45,2894,O
concrete,2894,O
nouns,2894,O
over,2894,O
the,2894,O
course,2894,O
of,2894,O
5,2894,O
consecutive,2894,O
training,2894,O
days,2894,O
in,2894,O
a,2894,O
prospective,2894,O
",",2894,O
randomized,2894,O
",",2894,O
double-blind,2894,O
",",2894,O
placebo-controlled,2894,O
design,2894,O
.,2894,O
Subjects,2895,O
received,2895,O
the,2895,O
tonically,2895,O
stimulating,2895,O
dopamine-receptor,2895,B-Chemical
agonist,2895,O
pergolide,2895,B-Chemical
(,2895,O
0.1,2895,O
mg,2895,O
),2895,O
vs,2895,O
placebo,2895,O
120,2895,O
min,2895,O
before,2895,O
training,2895,O
on,2895,O
each,2895,O
training,2895,O
day,2895,O
.,2895,O
The,2896,O
dopamine,2896,B-Chemical
agonist,2896,O
significantly,2896,O
impaired,2896,B-Disease
novel,2896,I-Disease
word,2896,I-Disease
learning,2896,I-Disease
compared,2896,O
to,2896,O
placebo,2896,O
.,2896,O
This,2897,O
learning,2897,O
decrement,2897,O
persisted,2897,O
up,2897,O
to,2897,O
the,2897,O
last,2897,O
follow-up,2897,O
4,2897,O
weeks,2897,O
post-training,2897,O
.,2897,O
Subjects,2898,O
treated,2898,O
with,2898,O
pergolide,2898,B-Chemical
also,2898,O
showed,2898,O
restricted,2898,O
emotional,2898,O
responses,2898,O
compared,2898,O
to,2898,O
the,2898,O
PLACEBO,2898,O
group,2898,O
.,2898,O
The,2899,O
extent,2899,O
of,2899,O
'flattened,2899,O
',2899,O
affect,2899,O
with,2899,O
pergolide,2899,B-Chemical
was,2899,O
related,2899,O
to,2899,O
the,2899,O
degree,2899,O
of,2899,O
learning,2899,O
inhibition,2899,O
.,2899,O
These,2900,O
findings,2900,O
suggest,2900,O
that,2900,O
tonic,2900,O
occupation,2900,O
of,2900,O
dopamine,2900,B-Chemical
receptors,2900,O
impairs,2900,O
learning,2900,O
by,2900,O
competition,2900,O
with,2900,O
phasic,2900,O
dopamine,2900,B-Chemical
signals,2900,O
.,2900,O
Thus,2901,O
",",2901,O
phasic,2901,O
signaling,2901,O
seems,2901,O
to,2901,O
be,2901,O
the,2901,O
critical,2901,O
mechanism,2901,O
by,2901,O
which,2901,O
dopamine,2901,B-Chemical
enhances,2901,O
associative,2901,O
learning,2901,O
in,2901,O
healthy,2901,O
subjects,2901,O
and,2901,O
stroke,2901,B-Disease
patients,2901,O
.,2901,O
Minocycline-induced,2902,B-Chemical
vasculitis,2902,B-Disease
fulfilling,2902,O
the,2902,O
criteria,2902,O
of,2902,O
polyarteritis,2902,B-Disease
nodosa,2902,I-Disease
.,2902,O
A,2903,O
47-year-old,2903,O
man,2903,O
who,2903,O
had,2903,O
been,2903,O
taking,2903,O
minocycline,2903,B-Chemical
for,2903,O
palmoplantar,2903,B-Disease
pustulosis,2903,I-Disease
developed,2903,O
fever,2903,B-Disease
",",2903,O
myalgias,2903,B-Disease
",",2903,O
polyneuropathy,2903,B-Disease
",",2903,O
and,2903,O
testicular,2903,B-Disease
pain,2903,I-Disease
",",2903,O
with,2903,O
elevated,2903,O
C-reactive,2903,O
protein,2903,O
(,2903,O
CRP,2903,O
),2903,O
.,2903,O
Neither,2904,O
myeloperoxidase-,2904,O
nor,2904,O
proteinase-3-antineutrophil,2904,O
cytoplasmic,2904,O
antibody,2904,O
was,2904,O
positive,2904,O
.,2904,O
These,2905,O
manifestations,2905,O
met,2905,O
the,2905,O
American,2905,O
College,2905,O
of,2905,O
Rheumatology,2905,O
1990,2905,O
criteria,2905,O
for,2905,O
the,2905,O
classification,2905,O
of,2905,O
polyarteritis,2905,B-Disease
nodosa,2905,I-Disease
.,2905,O
Stopping,2906,O
minocycline,2906,B-Chemical
led,2906,O
to,2906,O
amelioration,2906,O
of,2906,O
symptoms,2906,O
and,2906,O
normalization,2906,O
of,2906,O
CRP,2906,O
level,2906,O
.,2906,O
To,2907,O
our,2907,O
knowledge,2907,O
",",2907,O
this,2907,O
is,2907,O
the,2907,O
second,2907,O
case,2907,O
of,2907,O
minocycline-induced,2907,B-Chemical
vasculitis,2907,B-Disease
satisfying,2907,O
the,2907,O
criteria,2907,O
.,2907,O
Differential,2908,O
diagnosis,2908,O
for,2908,O
drug-induced,2908,O
disease,2908,O
is,2908,O
invaluable,2908,O
even,2908,O
for,2908,O
patients,2908,O
with,2908,O
classical,2908,O
polyarteritis,2908,B-Disease
nodosa,2908,I-Disease
.,2908,O
Intramuscular,2909,O
hepatitis,2909,B-Disease
B,2909,I-Disease
immune,2909,O
globulin,2909,O
combined,2909,O
with,2909,O
lamivudine,2909,B-Chemical
in,2909,O
prevention,2909,O
of,2909,O
hepatitis,2909,B-Disease
B,2909,I-Disease
recurrence,2909,O
after,2909,O
liver,2909,O
transplantation,2909,O
.,2909,O
BACKGROUND,2910,O
:,2910,O
Combined,2910,O
hepatitis,2910,B-Disease
B,2910,I-Disease
immune,2910,O
globulin,2910,O
(,2910,O
HBIg,2910,O
),2910,O
and,2910,O
lamivudine,2910,B-Chemical
in,2910,O
prophylaxis,2910,O
of,2910,O
the,2910,O
recurrence,2910,O
of,2910,O
hepatitis,2910,B-Disease
B,2910,I-Disease
after,2910,O
liver,2910,O
transplantation,2910,O
has,2910,O
significantly,2910,O
improved,2910,O
the,2910,O
survival,2910,O
of,2910,O
HBsAg,2910,B-Chemical
positive,2910,O
patients,2910,O
.,2910,O
This,2911,O
study,2911,O
was,2911,O
undertaken,2911,O
to,2911,O
evaluate,2911,O
the,2911,O
outcomes,2911,O
of,2911,O
liver,2911,O
transplantation,2911,O
for,2911,O
patients,2911,O
with,2911,O
hepatitis,2911,B-Disease
B,2911,I-Disease
virus,2911,O
(,2911,O
HBV,2911,O
),2911,O
.,2911,O
METHODS,2912,O
:,2912,O
A,2912,O
retrospective,2912,O
chart,2912,O
analysis,2912,O
and,2912,O
a,2912,O
review,2912,O
of,2912,O
the,2912,O
organ,2912,O
transplant,2912,O
database,2912,O
identified,2912,O
51,2912,O
patients,2912,O
(,2912,O
43,2912,O
men,2912,O
and,2912,O
8,2912,O
women,2912,O
),2912,O
transplanted,2912,O
for,2912,O
benign,2912,O
HBV-related,2912,O
cirrhotic,2912,B-Disease
diseases,2912,I-Disease
between,2912,O
June,2912,O
2002,2912,O
and,2912,O
December,2912,O
2004,2912,O
who,2912,O
had,2912,O
survived,2912,O
more,2912,O
than,2912,O
3,2912,O
months,2912,O
.,2912,O
HBIg,2913,O
was,2913,O
administered,2913,O
intravenously,2913,O
during,2913,O
the,2913,O
first,2913,O
week,2913,O
and,2913,O
intramuscularly,2913,O
thereafter,2913,O
.,2913,O
RESULTS,2914,O
:,2914,O
At,2914,O
a,2914,O
median,2914,O
follow-up,2914,O
of,2914,O
14.1,2914,O
months,2914,O
",",2914,O
the,2914,O
overall,2914,O
recurrence,2914,O
rate,2914,O
in,2914,O
the,2914,O
51,2914,O
patients,2914,O
was,2914,O
3.9,2914,O
%,2914,O
(,2914,O
2/51,2914,O
),2914,O
.,2914,O
The,2915,O
overall,2915,O
patient,2915,O
survival,2915,O
was,2915,O
88.3,2915,O
%,2915,O
",",2915,O
and,2915,O
82.4,2915,O
%,2915,O
after,2915,O
1,2915,O
and,2915,O
2,2915,O
years,2915,O
",",2915,O
respectively,2915,O
.,2915,O
A,2916,O
daily,2916,O
oral,2916,O
dose,2916,O
of,2916,O
100,2916,O
mg,2916,O
lamivudine,2916,B-Chemical
for,2916,O
2,2916,O
weeks,2916,O
before,2916,O
transplantation,2916,O
for,2916,O
10,2916,O
patients,2916,O
enabled,2916,O
57.1,2916,O
%,2916,O
(,2916,O
4/7,2916,O
),2916,O
and,2916,O
62.5,2916,O
%,2916,O
(,2916,O
5/8,2916,O
),2916,O
of,2916,O
HBV-DNA,2916,O
and,2916,O
HBeAg,2916,B-Chemical
positive,2916,O
patients,2916,O
respectively,2916,O
to,2916,O
convert,2916,O
to,2916,O
be,2916,O
negative,2916,O
.,2916,O
Intramuscular,2917,O
HBIg,2917,O
was,2917,O
well,2917,O
tolerated,2917,O
in,2917,O
all,2917,O
patients,2917,O
.,2917,O
CONCLUSION,2918,O
:,2918,O
Lamivudine,2918,B-Chemical
combined,2918,O
with,2918,O
intramuscular,2918,O
HBIg,2918,O
can,2918,O
effectively,2918,O
prevent,2918,O
allograft,2918,O
from,2918,O
the,2918,O
recurrence,2918,O
of,2918,O
HBV,2918,O
after,2918,O
liver,2918,O
transplantation,2918,O
.,2918,O
Anticonvulsant,2919,O
effect,2919,O
of,2919,O
eslicarbazepine,2919,B-Chemical
acetate,2919,I-Chemical
(,2919,O
BIA,2919,B-Chemical
2-093,2919,I-Chemical
),2919,O
on,2919,O
seizures,2919,B-Disease
induced,2919,O
by,2919,O
microperfusion,2919,O
of,2919,O
picrotoxin,2919,B-Chemical
in,2919,O
the,2919,O
hippocampus,2919,O
of,2919,O
freely,2919,O
moving,2919,O
rats,2919,O
.,2919,O
Eslicarbazepine,2920,B-Chemical
acetate,2920,I-Chemical
(,2920,O
BIA,2920,B-Chemical
2-093,2920,I-Chemical
",",2920,O
S-,2920,B-Chemical
(,2920,I-Chemical
-,2920,I-Chemical
),2920,I-Chemical
"-10-acetoxy-10,11-dihydro-5H-dibenzo/b",2920,I-Chemical
",",2920,I-Chemical
f/azepine-5-carboxamide,2920,I-Chemical
),2920,O
is,2920,O
a,2920,O
novel,2920,O
antiepileptic,2920,O
drug,2920,O
",",2920,O
now,2920,O
in,2920,O
Phase,2920,O
III,2920,O
clinical,2920,O
trials,2920,O
",",2920,O
designed,2920,O
with,2920,O
the,2920,O
aim,2920,O
of,2920,O
improving,2920,O
efficacy,2920,O
and,2920,O
safety,2920,O
in,2920,O
comparison,2920,O
with,2920,O
the,2920,O
structurally,2920,O
related,2920,O
drugs,2920,O
carbamazepine,2920,B-Chemical
(,2920,O
CBZ,2920,B-Chemical
),2920,O
and,2920,O
oxcarbazepine,2920,B-Chemical
(,2920,O
OXC,2920,B-Chemical
),2920,O
.,2920,O
We,2921,O
have,2921,O
studied,2921,O
the,2921,O
effects,2921,O
of,2921,O
oral,2921,O
treatment,2921,O
with,2921,O
eslicarbazepine,2921,B-Chemical
acetate,2921,I-Chemical
on,2921,O
a,2921,O
whole-animal,2921,O
model,2921,O
in,2921,O
which,2921,O
partial,2921,O
seizures,2921,B-Disease
can,2921,O
be,2921,O
elicited,2921,O
repeatedly,2921,O
on,2921,O
different,2921,O
days,2921,O
without,2921,O
changes,2921,O
in,2921,O
threshold,2921,O
or,2921,O
seizure,2921,B-Disease
patterns,2921,O
.,2921,O
In,2922,O
the,2922,O
animals,2922,O
treated,2922,O
with,2922,O
threshold,2922,O
doses,2922,O
of,2922,O
picrotoxin,2922,B-Chemical
",",2922,O
the,2922,O
average,2922,O
number,2922,O
of,2922,O
seizures,2922,B-Disease
was,2922,O
2.3+/-1.2,2922,O
",",2922,O
and,2922,O
average,2922,O
seizure,2922,B-Disease
duration,2922,O
was,2922,O
39.5+/-8.4s,2922,O
.,2922,O
Pre-treatment,2923,O
with,2923,O
a,2923,O
dose,2923,O
of,2923,O
30,2923,O
mg/kg,2923,O
2h,2923,O
before,2923,O
picrotoxin,2923,B-Chemical
microperfusion,2923,O
prevented,2923,O
seizures,2923,B-Disease
in,2923,O
the,2923,O
75,2923,O
%,2923,O
of,2923,O
the,2923,O
rats,2923,O
.,2923,O
Lower,2924,O
doses,2924,O
(,2924,O
3,2924,O
and,2924,O
10mg/kg,2924,O
),2924,O
did,2924,O
not,2924,O
suppress,2924,O
seizures,2924,B-Disease
",",2924,O
however,2924,O
",",2924,O
after,2924,O
administration,2924,O
of,2924,O
10mg/kg,2924,O
",",2924,O
significant,2924,O
reductions,2924,O
in,2924,O
seizures,2924,B-Disease
duration,2924,O
(,2924,O
24.3+/-6.8s,2924,O
),2924,O
and,2924,O
seizure,2924,B-Disease
number,2924,O
(,2924,O
1.6+/-0.34,2924,O
),2924,O
were,2924,O
found,2924,O
.,2924,O
No,2925,O
adverse,2925,O
effects,2925,O
of,2925,O
eslicarbazepine,2925,B-Chemical
acetate,2925,I-Chemical
were,2925,O
observed,2925,O
in,2925,O
the,2925,O
behavioral/EEG,2925,O
patterns,2925,O
studied,2925,O
",",2925,O
including,2925,O
sleep/wakefulness,2925,O
cycle,2925,O
",",2925,O
at,2925,O
the,2925,O
doses,2925,O
studied,2925,O
.,2925,O
Acute,2926,B-Disease
renal,2926,I-Disease
failure,2926,I-Disease
associated,2926,O
with,2926,O
prolonged,2926,O
intake,2926,O
of,2926,O
slimming,2926,O
pills,2926,O
containing,2926,O
anthraquinones,2926,B-Chemical
.,2926,O
Chinese,2927,B-Chemical
herbal,2927,I-Chemical
medicine,2927,O
preparations,2927,O
are,2927,O
widely,2927,O
available,2927,O
and,2927,O
often,2927,O
regarded,2927,O
by,2927,O
the,2927,O
public,2927,O
as,2927,O
natural,2927,O
and,2927,O
safe,2927,O
remedies,2927,O
for,2927,O
a,2927,O
variety,2927,O
of,2927,O
medical,2927,O
conditions,2927,O
.,2927,O
Nephropathy,2928,B-Disease
caused,2928,O
by,2928,O
Chinese,2928,B-Chemical
herbs,2928,I-Chemical
has,2928,O
previously,2928,O
been,2928,O
reported,2928,O
",",2928,O
usually,2928,O
involving,2928,O
the,2928,O
use,2928,O
of,2928,O
aristolochic,2928,B-Chemical
acids,2928,I-Chemical
.,2928,O
We,2929,O
report,2929,O
a,2929,O
23-year-old,2929,O
woman,2929,O
who,2929,O
developed,2929,O
acute,2929,B-Disease
renal,2929,I-Disease
failure,2929,I-Disease
following,2929,O
prolonged,2929,O
use,2929,O
of,2929,O
a,2929,O
proprietary,2929,O
Chinese,2929,B-Chemical
herbal,2929,I-Chemical
slimming,2929,O
pill,2929,O
that,2929,O
contained,2929,O
anthraquinone,2929,B-Chemical
derivatives,2929,O
",",2929,O
extracted,2929,O
from,2929,O
Rhizoma,2929,O
Rhei,2929,O
(,2929,O
rhubarb,2929,O
),2929,O
.,2929,O
The,2930,O
renal,2930,B-Disease
injury,2930,I-Disease
was,2930,O
probably,2930,O
aggravated,2930,O
by,2930,O
the,2930,O
concomitant,2930,O
intake,2930,O
of,2930,O
a,2930,O
non-steroidal,2930,O
anti-inflammatory,2930,O
drug,2930,O
",",2930,O
diclofenac,2930,B-Chemical
.,2930,O
Renal,2931,O
pathology,2931,O
was,2931,O
that,2931,O
of,2931,O
hypocellular,2931,O
interstitial,2931,O
fibrosis,2931,B-Disease
.,2931,O
Spontaneous,2932,O
renal,2932,O
recovery,2932,O
occurred,2932,O
upon,2932,O
cessation,2932,O
of,2932,O
the,2932,O
slimming,2932,O
pills,2932,O
",",2932,O
but,2932,O
mild,2932,O
interstitial,2932,O
fibrosis,2932,B-Disease
and,2932,O
tubular,2932,O
atrophy,2932,B-Disease
was,2932,O
still,2932,O
evident,2932,O
histologically,2932,O
4,2932,O
months,2932,O
later,2932,O
.,2932,O
Although,2933,O
a,2933,O
causal,2933,O
relationship,2933,O
between,2933,O
the,2933,O
use,2933,O
of,2933,O
an,2933,O
anthraquinone-containing,2933,B-Chemical
herbal,2933,O
agent,2933,O
and,2933,O
renal,2933,B-Disease
injury,2933,I-Disease
remains,2933,O
to,2933,O
be,2933,O
proven,2933,O
",",2933,O
phytotherapy-associated,2933,O
interstitial,2933,O
nephropathy,2933,B-Disease
should,2933,O
be,2933,O
considered,2933,O
in,2933,O
patients,2933,O
who,2933,O
present,2933,O
with,2933,O
unexplained,2933,O
renal,2933,B-Disease
failure,2933,I-Disease
.,2933,O
Chloroacetaldehyde,2934,B-Chemical
as,2934,O
a,2934,O
sulfhydryl,2934,B-Chemical
reagent,2934,O
:,2934,O
the,2934,O
role,2934,O
of,2934,O
critical,2934,O
thiol,2934,B-Chemical
groups,2934,O
in,2934,O
ifosfamide,2934,B-Chemical
nephropathy,2934,B-Disease
.,2934,O
Chloroacetaldehyde,2935,B-Chemical
(,2935,O
CAA,2935,B-Chemical
),2935,O
is,2935,O
a,2935,O
metabolite,2935,O
of,2935,O
the,2935,O
alkylating,2935,O
agent,2935,O
ifosfamide,2935,B-Chemical
(,2935,O
IFO,2935,B-Chemical
),2935,O
and,2935,O
putatively,2935,O
responsible,2935,O
for,2935,O
renal,2935,B-Disease
damage,2935,I-Disease
following,2935,O
anti-tumor,2935,O
therapy,2935,O
with,2935,O
IFO,2935,B-Chemical
.,2935,O
Depletion,2936,O
of,2936,O
sulfhydryl,2936,B-Chemical
(,2936,O
SH,2936,B-Chemical
),2936,O
groups,2936,O
has,2936,O
been,2936,O
reported,2936,O
from,2936,O
cell,2936,O
culture,2936,O
",",2936,O
animal,2936,O
and,2936,O
clinical,2936,O
studies,2936,O
.,2936,O
In,2937,O
this,2937,O
work,2937,O
the,2937,O
effect,2937,O
of,2937,O
CAA,2937,B-Chemical
on,2937,O
human,2937,O
proximal,2937,O
tubule,2937,O
cells,2937,O
in,2937,O
primary,2937,O
culture,2937,O
(,2937,O
hRPTEC,2937,O
),2937,O
was,2937,O
investigated,2937,O
.,2937,O
Toxicity,2938,B-Disease
of,2938,O
CAA,2938,B-Chemical
was,2938,O
determined,2938,O
by,2938,O
protein,2938,O
content,2938,O
",",2938,O
cell,2938,O
number,2938,O
",",2938,O
LDH,2938,O
release,2938,O
",",2938,O
trypan,2938,B-Chemical
blue,2938,I-Chemical
exclusion,2938,O
assay,2938,O
and,2938,O
caspase-3,2938,O
activity,2938,O
.,2938,O
Free,2939,O
thiols,2939,B-Chemical
were,2939,O
measured,2939,O
by,2939,O
the,2939,O
method,2939,O
of,2939,O
Ellman,2939,O
.,2939,O
CAA,2940,B-Chemical
reduced,2940,O
hRPTEC,2940,O
cell,2940,O
number,2940,O
and,2940,O
protein,2940,O
",",2940,O
induced,2940,O
a,2940,O
loss,2940,O
in,2940,O
free,2940,O
intracellular,2940,O
thiols,2940,B-Chemical
and,2940,O
an,2940,O
increase,2940,O
in,2940,O
necrosis,2940,B-Disease
markers,2940,O
.,2940,O
CAA,2941,B-Chemical
but,2941,O
not,2941,O
acrolein,2941,B-Chemical
inhibited,2941,O
the,2941,O
cysteine,2941,B-Chemical
proteases,2941,O
caspase-3,2941,O
",",2941,O
caspase-8,2941,O
and,2941,O
cathepsin,2941,O
B.,2941,O
Caspase,2941,O
activation,2941,O
by,2941,O
cisplatin,2941,B-Chemical
was,2941,O
inhibited,2941,O
by,2941,O
CAA,2941,B-Chemical
.,2941,O
In,2942,O
cells,2942,O
stained,2942,O
with,2942,O
fluorescent,2942,O
dyes,2942,O
targeting,2942,O
lysosomes,2942,O
",",2942,O
CAA,2942,B-Chemical
induced,2942,O
an,2942,O
increase,2942,O
in,2942,O
lysosomal,2942,O
size,2942,O
and,2942,O
lysosomal,2942,O
leakage,2942,O
.,2942,O
The,2943,O
effects,2943,O
of,2943,O
CAA,2943,B-Chemical
on,2943,O
cysteine,2943,B-Chemical
protease,2943,O
activities,2943,O
and,2943,O
thiols,2943,B-Chemical
could,2943,O
be,2943,O
reproduced,2943,O
in,2943,O
cell,2943,O
lysate,2943,O
.,2943,O
Acidification,2944,O
",",2944,O
which,2944,O
slowed,2944,O
the,2944,O
reaction,2944,O
of,2944,O
CAA,2944,B-Chemical
with,2944,O
thiol,2944,B-Chemical
donors,2944,O
",",2944,O
could,2944,O
also,2944,O
attenuate,2944,O
effects,2944,O
of,2944,O
CAA,2944,B-Chemical
on,2944,O
necrosis,2944,B-Disease
markers,2944,O
",",2944,O
thiol,2944,B-Chemical
depletion,2944,O
and,2944,O
cysteine,2944,B-Chemical
protease,2944,O
inhibition,2944,O
in,2944,O
living,2944,O
cells,2944,O
.,2944,O
Thus,2945,O
",",2945,O
CAA,2945,B-Chemical
directly,2945,O
reacts,2945,O
with,2945,O
cellular,2945,O
protein,2945,O
and,2945,O
non-protein,2945,O
thiols,2945,B-Chemical
",",2945,O
mediating,2945,O
its,2945,O
toxicity,2945,B-Disease
on,2945,O
hRPTEC,2945,O
.,2945,O
This,2946,O
effect,2946,O
can,2946,O
be,2946,O
reduced,2946,O
by,2946,O
acidification,2946,O
.,2946,O
Therefore,2947,O
",",2947,O
urinary,2947,O
acidification,2947,O
could,2947,O
be,2947,O
an,2947,O
option,2947,O
to,2947,O
prevent,2947,O
IFO,2947,B-Chemical
nephropathy,2947,B-Disease
in,2947,O
patients,2947,O
.,2947,O
Stereological,2948,O
methods,2948,O
reveal,2948,O
the,2948,O
robust,2948,O
size,2948,O
and,2948,O
stability,2948,O
of,2948,O
ectopic,2948,O
hilar,2948,O
granule,2948,O
cells,2948,O
after,2948,O
pilocarpine-induced,2948,B-Chemical
status,2948,B-Disease
epilepticus,2948,I-Disease
in,2948,O
the,2948,O
adult,2948,O
rat,2948,O
.,2948,O
Following,2949,O
status,2949,B-Disease
epilepticus,2949,I-Disease
in,2949,O
the,2949,O
rat,2949,O
",",2949,O
dentate,2949,O
granule,2949,O
cell,2949,O
neurogenesis,2949,O
increases,2949,O
greatly,2949,O
",",2949,O
and,2949,O
many,2949,O
of,2949,O
the,2949,O
new,2949,O
neurons,2949,O
appear,2949,O
to,2949,O
develop,2949,O
ectopically,2949,O
",",2949,O
in,2949,O
the,2949,O
hilar,2949,O
region,2949,O
of,2949,O
the,2949,O
hippocampal,2949,O
formation,2949,O
.,2949,O
It,2950,O
has,2950,O
been,2950,O
suggested,2950,O
that,2950,O
the,2950,O
ectopic,2950,O
hilar,2950,O
granule,2950,O
cells,2950,O
could,2950,O
contribute,2950,O
to,2950,O
the,2950,O
spontaneous,2950,O
seizures,2950,B-Disease
that,2950,O
ultimately,2950,O
develop,2950,O
after,2950,O
status,2950,B-Disease
epilepticus,2950,I-Disease
.,2950,O
However,2951,O
",",2951,O
the,2951,O
population,2951,O
has,2951,O
never,2951,O
been,2951,O
quantified,2951,O
",",2951,O
so,2951,O
it,2951,O
is,2951,O
unclear,2951,O
whether,2951,O
it,2951,O
is,2951,O
substantial,2951,O
enough,2951,O
to,2951,O
have,2951,O
a,2951,O
strong,2951,O
influence,2951,O
on,2951,O
epileptogenesis,2951,O
.,2951,O
To,2952,O
quantify,2952,O
this,2952,O
population,2952,O
",",2952,O
the,2952,O
total,2952,O
number,2952,O
of,2952,O
ectopic,2952,O
hilar,2952,O
granule,2952,O
cells,2952,O
was,2952,O
estimated,2952,O
using,2952,O
unbiased,2952,O
stereology,2952,O
at,2952,O
different,2952,O
times,2952,O
after,2952,O
pilocarpine-induced,2952,B-Chemical
status,2952,B-Disease
epilepticus,2952,I-Disease
.,2952,O
The,2953,O
number,2953,O
of,2953,O
hilar,2953,O
neurons,2953,O
immunoreactive,2953,O
for,2953,O
Prox-1,2953,O
",",2953,O
a,2953,O
granule-cell-specific,2953,O
marker,2953,O
",",2953,O
was,2953,O
estimated,2953,O
using,2953,O
the,2953,O
optical,2953,O
fractionator,2953,O
method,2953,O
.,2953,O
The,2954,O
results,2954,O
indicate,2954,O
that,2954,O
the,2954,O
size,2954,O
of,2954,O
the,2954,O
hilar,2954,O
ectopic,2954,O
granule,2954,O
cell,2954,O
population,2954,O
after,2954,O
status,2954,B-Disease
epilepticus,2954,I-Disease
is,2954,O
substantial,2954,O
",",2954,O
and,2954,O
stable,2954,O
over,2954,O
time,2954,O
.,2954,O
Interestingly,2955,O
",",2955,O
the,2955,O
size,2955,O
of,2955,O
the,2955,O
population,2955,O
appears,2955,O
to,2955,O
be,2955,O
correlated,2955,O
with,2955,O
the,2955,O
frequency,2955,O
of,2955,O
behavioral,2955,O
seizures,2955,B-Disease
",",2955,O
because,2955,O
animals,2955,O
with,2955,O
more,2955,O
ectopic,2955,O
granule,2955,O
cells,2955,O
in,2955,O
the,2955,O
hilus,2955,O
have,2955,O
more,2955,O
frequent,2955,O
behavioral,2955,O
seizures,2955,B-Disease
.,2955,O
The,2956,O
hilar,2956,O
ectopic,2956,O
granule,2956,O
cell,2956,O
population,2956,O
does,2956,O
not,2956,O
appear,2956,O
to,2956,O
vary,2956,O
systematically,2956,O
across,2956,O
the,2956,O
septotemporal,2956,O
axis,2956,O
",",2956,O
although,2956,O
it,2956,O
is,2956,O
associated,2956,O
with,2956,O
an,2956,O
increase,2956,O
in,2956,O
volume,2956,O
of,2956,O
the,2956,O
hilus,2956,O
.,2956,O
The,2957,O
results,2957,O
provide,2957,O
new,2957,O
insight,2957,O
into,2957,O
the,2957,O
potential,2957,O
role,2957,O
of,2957,O
ectopic,2957,O
hilar,2957,O
granule,2957,O
cells,2957,O
in,2957,O
the,2957,O
pilocarpine,2957,B-Chemical
model,2957,O
of,2957,O
temporal,2957,B-Disease
lobe,2957,I-Disease
epilepsy,2957,I-Disease
.,2957,O
A,2958,O
prospective,2958,O
",",2958,O
open-label,2958,O
trial,2958,O
of,2958,O
galantamine,2958,B-Chemical
in,2958,O
autistic,2958,B-Disease
disorder,2958,I-Disease
.,2958,O
OBJECTIVE,2959,O
:,2959,O
Post-mortem,2959,O
studies,2959,O
have,2959,O
reported,2959,O
abnormalities,2959,O
of,2959,O
the,2959,O
cholinergic,2959,O
system,2959,O
in,2959,O
autism,2959,B-Disease
.,2959,O
The,2960,O
purpose,2960,O
of,2960,O
this,2960,O
study,2960,O
was,2960,O
to,2960,O
assess,2960,O
the,2960,O
use,2960,O
of,2960,O
galantamine,2960,B-Chemical
",",2960,O
an,2960,O
acetylcholinesterase,2960,O
inhibitor,2960,O
and,2960,O
nicotinic,2960,O
receptor,2960,O
modulator,2960,O
",",2960,O
in,2960,O
the,2960,O
treatment,2960,O
of,2960,O
interfering,2960,O
behaviors,2960,O
in,2960,O
children,2960,O
with,2960,O
autism,2960,B-Disease
.,2960,O
METHODS,2961,O
:,2961,O
Thirteen,2961,O
medication-free,2961,O
children,2961,O
with,2961,O
autism,2961,B-Disease
(,2961,O
mean,2961,O
age,2961,O
",",2961,O
8.8,2961,O
+/-,2961,O
3.5,2961,O
years,2961,O
),2961,O
participated,2961,O
in,2961,O
a,2961,O
12-week,2961,O
",",2961,O
open-label,2961,O
trial,2961,O
of,2961,O
galantamine,2961,B-Chemical
.,2961,O
Patients,2962,O
were,2962,O
rated,2962,O
monthly,2962,O
by,2962,O
parents,2962,O
on,2962,O
the,2962,O
Aberrant,2962,O
Behavior,2962,O
Checklist,2962,O
(,2962,O
ABC,2962,O
),2962,O
and,2962,O
the,2962,O
Conners,2962,O
',2962,O
Parent,2962,O
Rating,2962,O
Scale-Revised,2962,O
",",2962,O
and,2962,O
by,2962,O
a,2962,O
physician,2962,O
using,2962,O
the,2962,O
Children,2962,O
's,2962,O
Psychiatric,2962,O
Rating,2962,O
Scale,2962,O
and,2962,O
the,2962,O
Clinical,2962,O
Global,2962,O
Impressions,2962,O
scale,2962,O
.,2962,O
RESULTS,2963,O
:,2963,O
Patients,2963,O
showed,2963,O
a,2963,O
significant,2963,O
reduction,2963,O
in,2963,O
parent-rated,2963,O
irritability,2963,B-Disease
and,2963,O
social,2963,O
withdrawal,2963,O
on,2963,O
the,2963,O
ABC,2963,O
as,2963,O
well,2963,O
as,2963,O
significant,2963,O
improvements,2963,O
in,2963,O
emotional,2963,O
lability,2963,O
and,2963,O
inattention,2963,O
on,2963,O
the,2963,O
Conners,2963,O
',2963,O
Parent,2963,O
Rating,2963,O
Scale,2963,O
--,2963,O
Revised,2963,O
.,2963,O
Similarly,2964,O
",",2964,O
clinician,2964,O
ratings,2964,O
showed,2964,O
reductions,2964,O
in,2964,O
the,2964,O
anger,2964,O
subscale,2964,O
of,2964,O
the,2964,O
Children,2964,O
's,2964,O
Psychiatric,2964,O
Rating,2964,O
Scale,2964,O
.,2964,O
Eight,2965,O
of,2965,O
13,2965,O
participants,2965,O
were,2965,O
rated,2965,O
as,2965,O
responders,2965,O
on,2965,O
the,2965,O
basis,2965,O
of,2965,O
their,2965,O
improvement,2965,O
scores,2965,O
on,2965,O
the,2965,O
Clinical,2965,O
Global,2965,O
Impressions,2965,O
scale,2965,O
.,2965,O
Overall,2966,O
",",2966,O
galantamine,2966,B-Chemical
was,2966,O
well-tolerated,2966,O
",",2966,O
with,2966,O
no,2966,O
significant,2966,O
adverse,2966,O
effects,2966,O
apart,2966,O
from,2966,O
headaches,2966,B-Disease
in,2966,O
one,2966,O
patient,2966,O
.,2966,O
CONCLUSION,2967,O
:,2967,O
In,2967,O
this,2967,O
open,2967,O
trial,2967,O
",",2967,O
galantamine,2967,B-Chemical
was,2967,O
well-tolerated,2967,O
and,2967,O
appeared,2967,O
to,2967,O
be,2967,O
beneficial,2967,O
for,2967,O
the,2967,O
treatment,2967,O
of,2967,O
interfering,2967,O
behaviors,2967,O
in,2967,O
children,2967,O
with,2967,O
autism,2967,B-Disease
",",2967,O
particularly,2967,O
aggression,2967,B-Disease
",",2967,O
behavioral,2967,B-Disease
dyscontrol,2967,I-Disease
",",2967,O
and,2967,O
inattention,2967,B-Disease
.,2967,O
Further,2968,O
controlled,2968,O
trials,2968,O
are,2968,O
warranted,2968,O
.,2968,O
Randomized,2969,O
comparison,2969,O
of,2969,O
olanzapine,2969,B-Chemical
versus,2969,O
risperidone,2969,B-Chemical
for,2969,O
the,2969,O
treatment,2969,O
of,2969,O
first-episode,2969,O
schizophrenia,2969,B-Disease
:,2969,O
4-month,2969,O
outcomes,2969,O
.,2969,O
OBJECTIVE,2970,O
:,2970,O
The,2970,O
authors,2970,O
compared,2970,O
4-month,2970,O
treatment,2970,O
outcomes,2970,O
for,2970,O
olanzapine,2970,B-Chemical
versus,2970,O
risperidone,2970,B-Chemical
in,2970,O
patients,2970,O
with,2970,O
first-episode,2970,O
schizophrenia,2970,B-Disease
spectrum,2970,O
disorders,2970,O
.,2970,O
METHOD,2971,O
:,2971,O
One,2971,O
hundred,2971,O
twelve,2971,O
subjects,2971,O
(,2971,O
70,2971,O
%,2971,O
male,2971,O
;,2971,O
mean,2971,O
age=23.3,2971,O
years,2971,O
[,2971,O
SD,2971,O
=,2971,O
5.1,2971,O
],2971,O
),2971,O
with,2971,O
first-episode,2971,O
schizophrenia,2971,B-Disease
(,2971,O
75,2971,O
%,2971,O
),2971,O
",",2971,O
schizophreniform,2971,B-Disease
disorder,2971,I-Disease
(,2971,O
17,2971,O
%,2971,O
),2971,O
",",2971,O
or,2971,O
schizoaffective,2971,B-Disease
disorder,2971,I-Disease
(,2971,O
8,2971,O
%,2971,O
),2971,O
were,2971,O
randomly,2971,O
assigned,2971,O
to,2971,O
treatment,2971,O
with,2971,O
olanzapine,2971,B-Chemical
(,2971,O
2.5-20,2971,O
mg/day,2971,O
),2971,O
or,2971,O
risperidone,2971,B-Chemical
(,2971,O
1-6,2971,O
mg/day,2971,O
),2971,O
.,2971,O
RESULTS,2972,O
:,2972,O
Response,2972,O
rates,2972,O
did,2972,O
not,2972,O
significantly,2972,O
differ,2972,O
between,2972,O
olanzapine,2972,B-Chemical
(,2972,O
43.7,2972,O
%,2972,O
",",2972,O
95,2972,O
%,2972,O
CI=28.8,2972,O
%,2972,O
-58.6,2972,O
%,2972,O
),2972,O
and,2972,O
risperidone,2972,B-Chemical
(,2972,O
54.3,2972,O
%,2972,O
",",2972,O
95,2972,O
%,2972,O
CI=39.9,2972,O
%,2972,O
-68.7,2972,O
%,2972,O
),2972,O
.,2972,O
Among,2973,O
those,2973,O
responding,2973,O
to,2973,O
treatment,2973,O
",",2973,O
more,2973,O
subjects,2973,O
in,2973,O
the,2973,O
olanzapine,2973,B-Chemical
group,2973,O
(,2973,O
40.9,2973,O
%,2973,O
",",2973,O
95,2973,O
%,2973,O
CI=16.8,2973,O
%,2973,O
-65.0,2973,O
%,2973,O
),2973,O
than,2973,O
in,2973,O
the,2973,O
risperidone,2973,B-Chemical
group,2973,O
(,2973,O
18.9,2973,O
%,2973,O
",",2973,O
95,2973,O
%,2973,O
CI=0,2973,O
%,2973,O
-39.2,2973,O
%,2973,O
),2973,O
had,2973,O
subsequent,2973,O
ratings,2973,O
not,2973,O
meeting,2973,O
response,2973,O
criteria,2973,O
.,2973,O
Negative,2974,O
symptom,2974,O
outcomes,2974,O
and,2974,O
measures,2974,O
of,2974,O
parkinsonism,2974,B-Disease
and,2974,O
akathisia,2974,B-Disease
did,2974,O
not,2974,O
differ,2974,O
between,2974,O
medications,2974,O
.,2974,O
Extrapyramidal,2975,B-Disease
symptom,2975,I-Disease
severity,2975,O
scores,2975,O
were,2975,O
1.4,2975,O
(,2975,O
95,2975,O
%,2975,O
CI=1.2-1.6,2975,O
),2975,O
with,2975,O
risperidone,2975,B-Chemical
and,2975,O
1.2,2975,O
(,2975,O
95,2975,O
%,2975,O
CI=1.0-1.4,2975,O
),2975,O
with,2975,O
olanzapine,2975,B-Chemical
.,2975,O
Significantly,2976,O
more,2976,O
weight,2976,B-Disease
gain,2976,I-Disease
occurred,2976,O
with,2976,O
olanzapine,2976,B-Chemical
than,2976,O
with,2976,O
risperidone,2976,B-Chemical
:,2976,O
the,2976,O
increase,2976,O
in,2976,O
weight,2976,O
at,2976,O
4,2976,O
months,2976,O
relative,2976,O
to,2976,O
baseline,2976,O
weight,2976,O
was,2976,O
17.3,2976,O
%,2976,O
(,2976,O
95,2976,O
%,2976,O
CI=14.2,2976,O
%,2976,O
-20.5,2976,O
%,2976,O
),2976,O
with,2976,O
olanzapine,2976,B-Chemical
and,2976,O
11.3,2976,O
%,2976,O
(,2976,O
95,2976,O
%,2976,O
CI=8.4,2976,O
%,2976,O
-14.3,2976,O
%,2976,O
),2976,O
with,2976,O
risperidone,2976,B-Chemical
.,2976,O
Body,2977,O
mass,2977,O
index,2977,O
at,2977,O
baseline,2977,O
and,2977,O
at,2977,O
4,2977,O
months,2977,O
was,2977,O
24.3,2977,O
(,2977,O
95,2977,O
%,2977,O
CI=22.8-25.7,2977,O
),2977,O
versus,2977,O
28.2,2977,O
(,2977,O
95,2977,O
%,2977,O
CI=26.7-29.7,2977,O
),2977,O
with,2977,O
olanzapine,2977,B-Chemical
and,2977,O
23.9,2977,O
(,2977,O
95,2977,O
%,2977,O
CI=22.5-25.3,2977,O
),2977,O
versus,2977,O
26.7,2977,O
(,2977,O
95,2977,O
%,2977,O
CI=25.2-28.2,2977,O
),2977,O
with,2977,O
risperidone,2977,B-Chemical
.,2977,O
CONCLUSIONS,2978,O
:,2978,O
Clinical,2978,O
outcomes,2978,O
with,2978,O
risperidone,2978,B-Chemical
were,2978,O
equal,2978,O
to,2978,O
those,2978,O
with,2978,O
olanzapine,2978,B-Chemical
",",2978,O
and,2978,O
response,2978,O
may,2978,O
be,2978,O
more,2978,O
stable,2978,O
.,2978,O
Olanzapine,2979,B-Chemical
may,2979,O
have,2979,O
an,2979,O
advantage,2979,O
for,2979,O
motor,2979,O
side,2979,O
effects,2979,O
.,2979,O
Both,2980,O
medications,2980,O
caused,2980,O
substantial,2980,O
rapid,2980,O
weight,2980,B-Disease
gain,2980,I-Disease
",",2980,O
but,2980,O
weight,2980,B-Disease
gain,2980,I-Disease
was,2980,O
greater,2980,O
with,2980,O
olanzapine,2980,B-Chemical
.,2980,O
Early,2981,O
paracentral,2981,O
visual,2981,B-Disease
field,2981,I-Disease
loss,2981,I-Disease
in,2981,O
patients,2981,O
taking,2981,O
hydroxychloroquine,2981,B-Chemical
.,2981,O
OBJECTIVE,2982,O
:,2982,O
To,2982,O
review,2982,O
the,2982,O
natural,2982,O
history,2982,O
and,2982,O
ocular,2982,O
and,2982,O
systemic,2982,O
adverse,2982,O
effects,2982,O
of,2982,O
patients,2982,O
taking,2982,O
hydroxychloroquine,2982,B-Chemical
sulfate,2982,I-Chemical
who,2982,O
attended,2982,O
an,2982,O
ophthalmic,2982,O
screening,2982,O
program,2982,O
.,2982,O
DESIGN,2983,O
:,2983,O
Retrospective,2983,O
study,2983,O
.,2983,O
RESULTS,2984,O
:,2984,O
Records,2984,O
of,2984,O
262,2984,O
patients,2984,O
who,2984,O
were,2984,O
taking,2984,O
hydroxychloroquine,2984,B-Chemical
and,2984,O
screened,2984,O
in,2984,O
the,2984,O
Department,2984,O
of,2984,O
Ophthalmology,2984,O
were,2984,O
reviewed,2984,O
.,2984,O
Of,2985,O
the,2985,O
262,2985,O
patients,2985,O
",",2985,O
14,2985,O
(,2985,O
18,2985,O
%,2985,O
),2985,O
of,2985,O
76,2985,O
who,2985,O
had,2985,O
stopped,2985,O
treatment,2985,O
at,2985,O
the,2985,O
time,2985,O
of,2985,O
the,2985,O
study,2985,O
experienced,2985,O
documented,2985,O
adverse,2985,O
effects,2985,O
.,2985,O
Systemic,2986,O
adverse,2986,O
effects,2986,O
occurred,2986,O
in,2986,O
8,2986,O
patients,2986,O
(,2986,O
10.5,2986,O
%,2986,O
),2986,O
and,2986,O
ocular,2986,O
adverse,2986,O
effects,2986,O
",",2986,O
in,2986,O
5,2986,O
(,2986,O
6.5,2986,O
%,2986,O
),2986,O
.,2986,O
Thirty-five,2987,O
patients,2987,O
(,2987,O
13.4,2987,O
%,2987,O
),2987,O
had,2987,O
visual,2987,B-Disease
field,2987,I-Disease
abnormalities,2987,I-Disease
",",2987,O
which,2987,O
were,2987,O
attributed,2987,O
to,2987,O
hydroxychloroquine,2987,B-Chemical
treatment,2987,O
in,2987,O
4,2987,O
patients,2987,O
(,2987,O
1.5,2987,O
%,2987,O
),2987,O
.,2987,O
Three,2988,O
of,2988,O
the,2988,O
4,2988,O
patients,2988,O
were,2988,O
taking,2988,O
less,2988,O
than,2988,O
6.5,2988,O
mg/kg,2988,O
per,2988,O
day,2988,O
and,2988,O
all,2988,O
patients,2988,O
had,2988,O
normal,2988,O
renal,2988,O
and,2988,O
liver,2988,O
function,2988,O
test,2988,O
results,2988,O
.,2988,O
CONCLUSIONS,2989,O
:,2989,O
The,2989,O
current,2989,O
study,2989,O
used,2989,O
a,2989,O
protocol,2989,O
of,2989,O
visual,2989,O
acuity,2989,O
and,2989,O
color,2989,O
vision,2989,O
assessment,2989,O
",",2989,O
funduscopy,2989,O
",",2989,O
and,2989,O
Humphrey,2989,O
10-2,2989,O
visual,2989,O
field,2989,O
testing,2989,O
and,2989,O
shows,2989,O
that,2989,O
visual,2989,B-Disease
field,2989,I-Disease
defects,2989,I-Disease
appeared,2989,O
before,2989,O
any,2989,O
corresponding,2989,O
changes,2989,O
in,2989,O
any,2989,O
other,2989,O
tested,2989,O
clinical,2989,O
parameters,2989,O
;,2989,O
the,2989,O
defects,2989,O
were,2989,O
reproducible,2989,O
and,2989,O
the,2989,O
test,2989,O
parameters,2989,O
were,2989,O
reliable,2989,O
.,2989,O
Patients,2990,O
taking,2990,O
hydroxychloroquine,2990,B-Chemical
can,2990,O
demonstrate,2990,O
a,2990,O
toxic,2990,O
reaction,2990,O
in,2990,O
the,2990,O
retina,2990,O
despite,2990,O
the,2990,O
absence,2990,O
of,2990,O
known,2990,O
risk,2990,O
factors,2990,O
.,2990,O
Screening,2991,O
",",2991,O
including,2991,O
Humphrey,2991,O
10-2,2991,O
visual,2991,O
field,2991,O
assessment,2991,O
",",2991,O
is,2991,O
recommended,2991,O
2,2991,O
years,2991,O
after,2991,O
the,2991,O
initial,2991,O
baseline,2991,O
and,2991,O
yearly,2991,O
thereafter,2991,O
.,2991,O
Peri-operative,2992,O
atrioventricular,2992,B-Disease
block,2992,I-Disease
as,2992,O
a,2992,O
result,2992,O
of,2992,O
chemotherapy,2992,O
with,2992,O
epirubicin,2992,B-Chemical
and,2992,O
paclitaxel,2992,B-Chemical
.,2992,O
A,2993,O
47-year-old,2993,O
woman,2993,O
presented,2993,O
for,2993,O
mastectomy,2993,O
and,2993,O
immediate,2993,O
latissimus,2993,O
dorsi,2993,O
flap,2993,O
reconstruction,2993,O
having,2993,O
been,2993,O
diagnosed,2993,O
with,2993,O
carcinoma,2993,B-Disease
of,2993,I-Disease
the,2993,I-Disease
breast,2993,I-Disease
6,2993,O
months,2993,O
previously,2993,O
.,2993,O
In,2994,O
the,2994,O
preceding,2994,O
months,2994,O
she,2994,O
had,2994,O
received,2994,O
neo-adjuvant,2994,O
chemotherapy,2994,O
with,2994,O
epirubicin,2994,B-Chemical
",",2994,O
paclitaxel,2994,B-Chemical
(,2994,O
Taxol,2994,B-Chemical
),2994,O
and,2994,O
cyclophosphamide,2994,B-Chemical
.,2994,O
This,2995,O
had,2995,O
been,2995,O
apparently,2995,O
uncomplicated,2995,O
and,2995,O
she,2995,O
had,2995,O
maintained,2995,O
a,2995,O
remarkably,2995,O
high,2995,O
level,2995,O
of,2995,O
physical,2995,O
activity,2995,O
.,2995,O
She,2996,O
was,2996,O
found,2996,O
to,2996,O
be,2996,O
bradycardic,2996,B-Disease
at,2996,O
pre-operative,2996,O
assessment,2996,O
but,2996,O
had,2996,O
no,2996,O
cardiac,2996,O
symptoms,2996,O
.,2996,O
Second,2997,O
degree,2997,O
Mobitz,2997,O
type,2997,O
II,2997,O
atrioventricular,2997,B-Disease
block,2997,I-Disease
was,2997,O
diagnosed,2997,O
on,2997,O
electrocardiogram,2997,O
",",2997,O
and,2997,O
temporary,2997,O
transvenous,2997,O
ventricular,2997,O
pacing,2997,O
instituted,2997,O
in,2997,O
the,2997,O
peri-operative,2997,O
period,2997,O
.,2997,O
We,2998,O
discuss,2998,O
how,2998,O
evidence-based,2998,O
guidelines,2998,O
would,2998,O
not,2998,O
have,2998,O
been,2998,O
helpful,2998,O
in,2998,O
this,2998,O
case,2998,O
",",2998,O
and,2998,O
how,2998,O
chemotherapy,2998,O
can,2998,O
exhibit,2998,O
substantial,2998,O
cardiotoxicity,2998,B-Disease
that,2998,O
may,2998,O
develop,2998,O
over,2998,O
many,2998,O
years,2998,O
.,2998,O
We,2999,O
suggest,2999,O
that,2999,O
patients,2999,O
who,2999,O
have,2999,O
received,2999,O
chemotherapy,2999,O
at,2999,O
any,2999,O
time,2999,O
should,2999,O
have,2999,O
a,2999,O
pre-operative,2999,O
electrocardiogram,2999,O
even,2999,O
if,2999,O
they,2999,O
are,2999,O
asymptomatic,2999,O
.,2999,O
Risks,3000,O
and,3000,O
benefits,3000,O
of,3000,O
COX-2,3000,B-Chemical
inhibitors,3000,I-Chemical
vs,3000,O
non-selective,3000,O
NSAIDs,3000,O
:,3000,O
does,3000,O
their,3000,O
cardiovascular,3000,O
risk,3000,O
exceed,3000,O
their,3000,O
gastrointestinal,3000,O
benefit,3000,O
?,3000,O
A,3001,O
retrospective,3001,O
cohort,3001,O
study,3001,O
.,3001,O
OBJECTIVES,3002,O
:,3002,O
The,3002,O
risk,3002,O
of,3002,O
acute,3002,B-Disease
myocardial,3002,I-Disease
infarction,3002,I-Disease
(,3002,O
AMI,3002,B-Disease
),3002,O
with,3002,O
COX-2,3002,B-Chemical
inhibitors,3002,I-Chemical
may,3002,O
offset,3002,O
their,3002,O
gastrointestinal,3002,O
(,3002,O
GI,3002,O
),3002,O
benefit,3002,O
compared,3002,O
with,3002,O
non-selective,3002,O
(,3002,O
NS,3002,O
),3002,O
non-steroidal,3002,B-Chemical
anti-inflammatory,3002,I-Chemical
drugs,3002,I-Chemical
(,3002,O
NSAIDs,3002,O
),3002,O
.,3002,O
We,3003,O
aimed,3003,O
to,3003,O
compare,3003,O
the,3003,O
risks,3003,O
of,3003,O
hospitalization,3003,O
for,3003,O
AMI,3003,B-Disease
and,3003,O
GI,3003,B-Disease
bleeding,3003,I-Disease
among,3003,O
elderly,3003,O
patients,3003,O
using,3003,O
COX-2,3003,B-Chemical
inhibitors,3003,I-Chemical
",",3003,O
NS-NSAIDs,3003,O
and,3003,O
acetaminophen,3003,B-Chemical
.,3003,O
METHODS,3004,O
:,3004,O
We,3004,O
conducted,3004,O
a,3004,O
retrospective,3004,O
cohort,3004,O
study,3004,O
using,3004,O
administrative,3004,O
data,3004,O
of,3004,O
patients,3004,O
>,3004,O
or,3004,O
=65,3004,O
years,3004,O
of,3004,O
age,3004,O
who,3004,O
filled,3004,O
a,3004,O
prescription,3004,O
for,3004,O
NSAID,3004,O
or,3004,O
acetaminophen,3004,B-Chemical
during,3004,O
1999-2002,3004,O
.,3004,O
Outcomes,3005,O
were,3005,O
compared,3005,O
using,3005,O
Cox,3005,O
regression,3005,O
models,3005,O
with,3005,O
time-dependent,3005,O
exposures,3005,O
.,3005,O
RESULTS,3006,O
:,3006,O
Person-years,3006,O
of,3006,O
exposure,3006,O
among,3006,O
non-users,3006,O
of,3006,O
aspirin,3006,B-Chemical
were,3006,O
:,3006,O
"75,761",3006,O
to,3006,O
acetaminophen,3006,B-Chemical
",",3006,O
"42,671",3006,O
to,3006,O
rofecoxib,3006,B-Chemical
"65,860",3006,O
to,3006,O
celecoxib,3006,B-Chemical
",",3006,O
and,3006,O
"37,495",3006,O
to,3006,O
NS-NSAIDs,3006,O
.,3006,O
Among,3007,O
users,3007,O
of,3007,O
aspirin,3007,B-Chemical
",",3007,O
they,3007,O
were,3007,O
:,3007,O
"14,671",3007,O
to,3007,O
rofecoxib,3007,B-Chemical
",",3007,O
"22,875",3007,O
to,3007,O
celecoxib,3007,B-Chemical
",",3007,O
"9,832",3007,O
to,3007,O
NS-NSAIDs,3007,O
and,3007,O
"38,048",3007,O
to,3007,O
acetaminophen,3007,B-Chemical
.,3007,O
Among,3008,O
non-users,3008,O
of,3008,O
aspirin,3008,B-Chemical
",",3008,O
the,3008,O
adjusted,3008,O
hazard,3008,O
ratios,3008,O
(,3008,O
95,3008,O
%,3008,O
confidence,3008,O
interval,3008,O
),3008,O
of,3008,O
hospitalization,3008,O
for,3008,O
AMI/GI,3008,B-Disease
vs,3008,O
the,3008,O
acetaminophen,3008,B-Chemical
(,3008,O
with,3008,O
no,3008,O
aspirin,3008,B-Chemical
),3008,O
group,3008,O
were,3008,O
:,3008,O
rofecoxib,3008,B-Chemical
1.27,3008,O
(,3008,O
1.13,3008,O
",",3008,O
1.42,3008,O
),3008,O
",",3008,O
celecoxib,3008,B-Chemical
0.93,3008,O
(,3008,O
0.83,3008,O
",",3008,O
1.03,3008,O
),3008,O
",",3008,O
naproxen,3008,B-Chemical
1.59,3008,O
(,3008,O
1.31,3008,O
",",3008,O
1.93,3008,O
),3008,O
",",3008,O
diclofenac,3008,B-Chemical
1.17,3008,O
(,3008,O
0.99,3008,O
",",3008,O
1.38,3008,O
),3008,O
and,3008,O
ibuprofen,3008,B-Chemical
1.05,3008,O
(,3008,O
0.74,3008,O
",",3008,O
1.51,3008,O
),3008,O
.,3008,O
Among,3009,O
users,3009,O
of,3009,O
aspirin,3009,B-Chemical
",",3009,O
they,3009,O
were,3009,O
:,3009,O
rofecoxib,3009,B-Chemical
1.73,3009,O
(,3009,O
1.52,3009,O
",",3009,O
1.98,3009,O
),3009,O
",",3009,O
celecoxib,3009,B-Chemical
1.34,3009,O
(,3009,O
1.19,3009,O
",",3009,O
1.52,3009,O
),3009,O
",",3009,O
ibuprofen,3009,B-Chemical
1.51,3009,O
(,3009,O
0.95,3009,O
",",3009,O
2.41,3009,O
),3009,O
",",3009,O
diclofenac,3009,B-Chemical
1.69,3009,O
(,3009,O
1.35,3009,O
",",3009,O
2.10,3009,O
),3009,O
",",3009,O
naproxen,3009,B-Chemical
1.35,3009,O
(,3009,O
0.97,3009,O
",",3009,O
1.88,3009,O
),3009,O
and,3009,O
acetaminophen,3009,B-Chemical
1.29,3009,O
(,3009,O
1.17,3009,O
",",3009,O
1.42,3009,O
),3009,O
.,3009,O
CONCLUSION,3010,O
:,3010,O
Among,3010,O
non-users,3010,O
of,3010,O
aspirin,3010,B-Chemical
",",3010,O
naproxen,3010,B-Chemical
seemed,3010,O
to,3010,O
carry,3010,O
the,3010,O
highest,3010,O
risk,3010,O
for,3010,O
AMI/GI,3010,B-Disease
bleeding,3010,I-Disease
.,3010,O
The,3011,O
AMI/GI,3011,B-Disease
toxicity,3011,B-Disease
of,3011,O
celecoxib,3011,B-Chemical
was,3011,O
similar,3011,O
to,3011,O
that,3011,O
of,3011,O
acetaminophen,3011,B-Chemical
and,3011,O
seemed,3011,O
to,3011,O
be,3011,O
better,3011,O
than,3011,O
those,3011,O
of,3011,O
rofecoxib,3011,B-Chemical
and,3011,O
NS-NSAIDs,3011,O
.,3011,O
Among,3012,O
users,3012,O
of,3012,O
aspirin,3012,B-Chemical
",",3012,O
both,3012,O
celecoxib,3012,B-Chemical
and,3012,O
naproxen,3012,B-Chemical
seemed,3012,O
to,3012,O
be,3012,O
the,3012,O
least,3012,O
toxic,3012,O
.,3012,O
Quinine-induced,3013,B-Chemical
arrhythmia,3013,B-Disease
in,3013,O
a,3013,O
patient,3013,O
with,3013,O
severe,3013,B-Disease
malaria,3013,I-Disease
.,3013,O
It,3014,O
was,3014,O
reported,3014,O
that,3014,O
there,3014,O
was,3014,O
a,3014,O
case,3014,O
of,3014,O
severe,3014,B-Disease
malaria,3014,I-Disease
patient,3014,O
with,3014,O
jaundice,3014,B-Disease
who,3014,O
presented,3014,O
with,3014,O
arrhythmia,3014,B-Disease
(,3014,O
premature,3014,B-Disease
ventricular,3014,I-Disease
contraction,3014,I-Disease
),3014,O
while,3014,O
getting,3014,O
quinine,3014,B-Chemical
infusion,3014,O
was,3014,O
reported,3014,O
.,3014,O
A,3015,O
man,3015,O
",",3015,O
25,3015,O
years,3015,O
old,3015,O
",",3015,O
was,3015,O
admitted,3015,O
to,3015,O
hospital,3015,O
with,3015,O
high,3015,O
fever,3015,B-Disease
",",3015,O
chill,3015,B-Disease
",",3015,O
vomiting,3015,B-Disease
",",3015,O
jaundice,3015,B-Disease
.,3015,O
The,3016,O
patient,3016,O
was,3016,O
fully,3016,O
conscious,3016,O
",",3016,O
blood,3016,O
pressure,3016,O
120/80,3016,O
mmHg,3016,O
",",3016,O
pulse,3016,O
rate,3016,O
100,3016,O
x/minute,3016,O
",",3016,O
regular,3016,O
.,3016,O
On,3017,O
admission,3017,O
",",3017,O
laboratory,3017,O
examination,3017,O
showed,3017,O
Plasmodium,3017,O
falciparum,3017,O
(,3017,O
++++,3017,O
),3017,O
",",3017,O
total,3017,O
bilirubin,3017,B-Chemical
8.25,3017,O
mg/dL,3017,O
",",3017,O
conjugated,3017,O
bilirubin,3017,B-Chemical
4.36,3017,O
mg/dL,3017,O
",",3017,O
unconjugated,3017,O
bilirubin,3017,B-Chemical
3.89,3017,O
mg/dL,3017,O
",",3017,O
potassium,3017,B-Chemical
3.52,3017,O
meq/L,3017,O
Patient,3017,O
was,3017,O
diagnosed,3017,O
as,3017,O
severe,3017,B-Disease
malaria,3017,I-Disease
with,3017,O
jaundice,3017,B-Disease
and,3017,O
got,3017,O
quinine,3017,B-Chemical
infusion,3017,O
in,3017,O
dextrose,3017,B-Chemical
5,3017,O
%,3017,O
500,3017,O
mg/8,3017,O
hour,3017,O
.,3017,O
On,3018,O
the,3018,O
second,3018,O
day,3018,O
the,3018,O
patient,3018,O
had,3018,O
vomitus,3018,B-Disease
",",3018,O
diarrhea,3018,B-Disease
",",3018,O
tinnitus,3018,B-Disease
",",3018,O
loss,3018,B-Disease
of,3018,I-Disease
hearing,3018,I-Disease
.,3018,O
After,3019,O
30,3019,O
hours,3019,O
of,3019,O
quinine,3019,B-Chemical
infusion,3019,O
the,3019,O
patient,3019,O
felt,3019,O
palpitation,3019,B-Disease
and,3019,O
electrocardiography,3019,O
(,3019,O
ECG,3019,O
),3019,O
recording,3019,O
showed,3019,O
premature,3019,B-Disease
ventricular,3019,I-Disease
contraction,3019,I-Disease
(,3019,O
PVC,3019,B-Disease
),3019,O
>,3019,O
5,3019,O
x/minute,3019,O
",",3019,O
trigemini,3019,O
",",3019,O
constant,3019,O
type,3019,O
--,3019,O
sinoatrial,3019,B-Disease
block,3019,I-Disease
",",3019,O
positive,3019,O
U,3019,O
wave,3019,O
.,3019,O
He,3020,O
was,3020,O
treated,3020,O
with,3020,O
lidocaine,3020,B-Chemical
50,3020,O
mg,3020,O
intravenously,3020,O
followed,3020,O
by,3020,O
infusion,3020,O
1500,3020,O
mg,3020,O
in,3020,O
dextrose,3020,B-Chemical
5,3020,O
%,3020,O
/24,3020,O
hour,3020,O
and,3020,O
potassium,3020,B-Chemical
aspartate,3020,I-Chemical
tablet,3020,O
.,3020,O
Quinine,3021,B-Chemical
infusion,3021,O
was,3021,O
discontinued,3021,O
and,3021,O
changed,3021,O
with,3021,O
sulfate,3021,O
quinine,3021,B-Chemical
tablets,3021,O
.,3021,O
Three,3022,O
hours,3022,O
later,3022,O
the,3022,O
patient,3022,O
felt,3022,O
better,3022,O
",",3022,O
the,3022,O
frequency,3022,O
of,3022,O
PVC,3022,B-Disease
reduced,3022,O
to,3022,O
4,3022,O
-,3022,O
5,3022,O
x/minute,3022,O
and,3022,O
on,3022,O
the,3022,O
third,3022,O
day,3022,O
ECG,3022,O
was,3022,O
normal,3022,O
",",3022,O
potassium,3022,B-Chemical
level,3022,O
was,3022,O
3.34,3022,O
meq/L,3022,O
.,3022,O
He,3023,O
was,3023,O
discharged,3023,O
on,3023,O
7th,3023,O
day,3023,O
in,3023,O
good,3023,O
condition,3023,O
.,3023,O
Quinine,3024,B-Chemical
",",3024,O
like,3024,O
quinidine,3024,B-Chemical
",",3024,O
is,3024,O
a,3024,O
chincona,3024,O
alkaloid,3024,O
that,3024,O
has,3024,O
anti-arrhythmic,3024,O
property,3024,O
",",3024,O
although,3024,O
it,3024,O
also,3024,O
pro-arrhythmic,3024,O
that,3024,O
can,3024,O
cause,3024,O
various,3024,O
arrhythmias,3024,B-Disease
",",3024,O
including,3024,O
severe,3024,O
arrhythmia,3024,B-Disease
such,3024,O
as,3024,O
multiple,3024,O
PVC,3024,B-Disease
.,3024,O
Administration,3025,O
of,3025,O
parenteral,3025,O
quinine,3025,B-Chemical
must,3025,O
be,3025,O
done,3025,O
carefully,3025,O
and,3025,O
with,3025,O
good,3025,O
observation,3025,O
because,3025,O
of,3025,O
its,3025,O
pro-arrhythmic,3025,O
effect,3025,O
",",3025,O
especially,3025,O
in,3025,O
older,3025,O
patients,3025,O
who,3025,O
have,3025,O
heart,3025,B-Disease
diseases,3025,I-Disease
or,3025,O
patients,3025,O
with,3025,O
electrolyte,3025,B-Disease
disorder,3025,I-Disease
(,3025,O
hypokalemia,3025,B-Disease
),3025,O
which,3025,O
frequently,3025,O
occurs,3025,O
due,3025,O
to,3025,O
vomiting,3025,B-Disease
and,3025,O
or,3025,O
diarrhea,3025,B-Disease
in,3025,O
malaria,3025,B-Disease
cases,3025,O
.,3025,O
Penicillamine-related,3026,B-Chemical
lichenoid,3026,B-Disease
dermatitis,3026,I-Disease
and,3026,O
utility,3026,O
of,3026,O
zinc,3026,B-Chemical
acetate,3026,I-Chemical
in,3026,O
a,3026,O
Wilson,3026,B-Disease
disease,3026,I-Disease
patient,3026,O
with,3026,O
hepatic,3026,O
presentation,3026,O
",",3026,O
anxiety,3026,B-Disease
and,3026,O
SPECT,3026,O
abnormalities,3026,O
.,3026,O
Wilson,3027,B-Disease
's,3027,I-Disease
disease,3027,I-Disease
is,3027,O
an,3027,O
autosomal,3027,O
recessive,3027,O
disorder,3027,O
of,3027,O
hepatic,3027,O
copper,3027,B-Chemical
metabolism,3027,O
with,3027,O
consequent,3027,O
copper,3027,B-Chemical
accumulation,3027,O
and,3027,O
toxicity,3027,B-Disease
in,3027,O
many,3027,O
tissues,3027,O
and,3027,O
consequent,3027,O
hepatic,3027,O
",",3027,O
neurologic,3027,O
and,3027,O
psychiatric,3027,O
disorders,3027,O
.,3027,O
We,3028,O
report,3028,O
a,3028,O
case,3028,O
of,3028,O
Wilson,3028,B-Disease
's,3028,I-Disease
disease,3028,I-Disease
with,3028,O
chronic,3028,B-Disease
liver,3028,I-Disease
disease,3028,I-Disease
;,3028,O
moreover,3028,O
",",3028,O
in,3028,O
our,3028,O
patient,3028,O
",",3028,O
presenting,3028,O
also,3028,O
with,3028,O
high,3028,O
levels,3028,O
of,3028,O
state,3028,O
anxiety,3028,B-Disease
without,3028,O
depression,3028,B-Disease
",",3028,O
99mTc-ECD-SPECT,3028,O
showed,3028,O
cortical,3028,O
hypoperfusion,3028,O
in,3028,O
frontal,3028,O
lobes,3028,O
",",3028,O
more,3028,O
marked,3028,O
on,3028,O
the,3028,O
left,3028,O
frontal,3028,O
lobe,3028,O
.,3028,O
During,3029,O
the,3029,O
follow-up,3029,O
of,3029,O
our,3029,O
patient,3029,O
",",3029,O
penicillamine,3029,B-Chemical
was,3029,O
interrupted,3029,O
after,3029,O
the,3029,O
appearance,3029,O
of,3029,O
a,3029,O
lichenoid,3029,B-Disease
dermatitis,3029,I-Disease
",",3029,O
and,3029,O
zinc,3029,B-Chemical
acetate,3029,I-Chemical
permitted,3029,O
to,3029,O
continue,3029,O
the,3029,O
successful,3029,O
treatment,3029,O
of,3029,O
the,3029,O
patient,3029,O
without,3029,O
side-effects,3029,O
.,3029,O
In,3030,O
our,3030,O
case,3030,O
the,3030,O
therapy,3030,O
with,3030,O
zinc,3030,B-Chemical
acetate,3030,I-Chemical
represented,3030,O
an,3030,O
effective,3030,O
treatment,3030,O
for,3030,O
a,3030,O
Wilson,3030,B-Disease
's,3030,I-Disease
disease,3030,I-Disease
patient,3030,O
in,3030,O
which,3030,O
penicillamine-related,3030,B-Chemical
side,3030,O
effects,3030,O
appeared,3030,O
.,3030,O
The,3031,O
safety,3031,O
of,3031,O
the,3031,O
zinc,3031,B-Chemical
acetate,3031,I-Chemical
allowed,3031,O
us,3031,O
to,3031,O
avoid,3031,O
other,3031,O
potentially,3031,O
toxic,3031,O
chelating,3031,O
drugs,3031,O
;,3031,O
this,3031,O
observation,3031,O
is,3031,O
in,3031,O
line,3031,O
with,3031,O
the,3031,O
growing,3031,O
evidence,3031,O
on,3031,O
the,3031,O
efficacy,3031,O
of,3031,O
the,3031,O
drug,3031,O
in,3031,O
the,3031,O
treatment,3031,O
of,3031,O
Wilson,3031,B-Disease
's,3031,I-Disease
disease,3031,I-Disease
.,3031,O
Since,3032,O
most,3032,O
of,3032,O
Wilson,3032,B-Disease
's,3032,I-Disease
disease,3032,I-Disease
penicillamine-treated,3032,B-Chemical
patients,3032,O
do,3032,O
not,3032,O
seem,3032,O
to,3032,O
develop,3032,O
this,3032,O
skin,3032,B-Disease
lesion,3032,I-Disease
",",3032,O
it,3032,O
could,3032,O
be,3032,O
conceivable,3032,O
that,3032,O
a,3032,O
specific,3032,O
genetic,3032,O
factor,3032,O
is,3032,O
involved,3032,O
in,3032,O
drug,3032,O
response,3032,O
.,3032,O
Further,3033,O
studies,3033,O
are,3033,O
needed,3033,O
for,3033,O
a,3033,O
better,3033,O
clarification,3033,O
of,3033,O
Wilson,3033,B-Disease
's,3033,I-Disease
disease,3033,I-Disease
therapy,3033,O
",",3033,O
and,3033,O
in,3033,O
particular,3033,O
to,3033,O
differentiate,3033,O
specific,3033,O
therapies,3033,O
for,3033,O
different,3033,O
Wilson,3033,B-Disease
's,3033,I-Disease
disease,3033,I-Disease
phenotypes,3033,O
.,3033,O
A,3034,O
dramatic,3034,O
drop,3034,B-Disease
in,3034,I-Disease
blood,3034,I-Disease
pressure,3034,I-Disease
following,3034,O
prehospital,3034,O
GTN,3034,B-Chemical
administration,3034,O
.,3034,O
A,3035,O
male,3035,O
in,3035,O
his,3035,O
sixties,3035,O
with,3035,O
no,3035,O
history,3035,O
of,3035,O
cardiac,3035,O
chest,3035,B-Disease
pain,3035,I-Disease
awoke,3035,O
with,3035,O
chest,3035,B-Disease
pain,3035,I-Disease
following,3035,O
an,3035,O
afternoon,3035,O
sleep,3035,O
.,3035,O
The,3036,O
patient,3036,O
did,3036,O
not,3036,O
self,3036,O
medicate,3036,O
.,3036,O
The,3037,O
patient,3037,O
's,3037,O
observations,3037,O
were,3037,O
within,3037,O
normal,3037,O
limits,3037,O
",",3037,O
he,3037,O
was,3037,O
administered,3037,O
oxygen,3037,B-Chemical
via,3037,O
a,3037,O
face,3037,O
mask,3037,O
and,3037,O
glyceryl,3037,B-Chemical
trinitrate,3037,I-Chemical
(,3037,O
GTN,3037,B-Chemical
),3037,O
.,3037,O
Several,3038,O
minutes,3038,O
after,3038,O
the,3038,O
GTN,3038,B-Chemical
the,3038,O
patient,3038,O
experienced,3038,O
a,3038,O
sudden,3038,O
drop,3038,B-Disease
in,3038,I-Disease
blood,3038,I-Disease
pressure,3038,I-Disease
and,3038,O
heart,3038,O
rate,3038,O
",",3038,O
this,3038,O
was,3038,O
rectified,3038,O
by,3038,O
atropine,3038,B-Chemical
sulphate,3038,I-Chemical
and,3038,O
a,3038,O
fluid,3038,O
challenge,3038,O
.,3038,O
There,3039,O
was,3039,O
no,3039,O
further,3039,O
deterioration,3039,O
in,3039,O
the,3039,O
patient,3039,O
's,3039,O
condition,3039,O
during,3039,O
transport,3039,O
to,3039,O
hospital,3039,O
.,3039,O
There,3040,O
are,3040,O
very,3040,O
few,3040,O
documented,3040,O
case,3040,O
like,3040,O
this,3040,O
in,3040,O
the,3040,O
prehospital,3040,O
scientific,3040,O
literature,3040,O
.,3040,O
The,3041,O
cause,3041,O
appears,3041,O
to,3041,O
be,3041,O
the,3041,O
Bezold-Jarish,3041,O
reflex,3041,O
",",3041,O
stimulation,3041,O
of,3041,O
the,3041,O
ventricular,3041,O
walls,3041,O
which,3041,O
in,3041,O
turn,3041,O
decreases,3041,O
sympathetic,3041,O
outflow,3041,O
from,3041,O
the,3041,O
vasomotor,3041,O
centre,3041,O
.,3041,O
Prehospital,3042,O
care,3042,O
providers,3042,O
who,3042,O
are,3042,O
managing,3042,O
any,3042,O
patient,3042,O
with,3042,O
a,3042,O
syncopal,3042,B-Disease
episode,3042,I-Disease
that,3042,O
fails,3042,O
to,3042,O
recover,3042,O
within,3042,O
a,3042,O
reasonable,3042,O
time,3042,O
frame,3042,O
should,3042,O
consider,3042,O
the,3042,O
Bezold-Jarisch,3042,O
reflex,3042,O
as,3042,O
the,3042,O
cause,3042,O
and,3042,O
manage,3042,O
the,3042,O
patient,3042,O
accordingly,3042,O
.,3042,O
Acute,3043,B-Disease
encephalopathy,3043,I-Disease
and,3043,O
cerebral,3043,B-Disease
vasospasm,3043,I-Disease
after,3043,O
multiagent,3043,O
chemotherapy,3043,O
including,3043,O
PEG-asparaginase,3043,B-Chemical
and,3043,O
intrathecal,3043,O
cytarabine,3043,B-Chemical
for,3043,O
the,3043,O
treatment,3043,O
of,3043,O
acute,3043,B-Disease
lymphoblastic,3043,I-Disease
leukemia,3043,I-Disease
.,3043,O
A,3044,O
7-year-old,3044,O
girl,3044,O
with,3044,O
an,3044,O
unusual,3044,O
reaction,3044,O
to,3044,O
induction,3044,O
chemotherapy,3044,O
for,3044,O
precursor,3044,O
B-cell,3044,O
acute,3044,B-Disease
lymphoblastic,3044,I-Disease
leukemia,3044,I-Disease
(,3044,O
ALL,3044,B-Disease
),3044,O
is,3044,O
described,3044,O
.,3044,O
The,3045,O
patient,3045,O
developed,3045,O
acute,3045,B-Disease
encephalopathy,3045,I-Disease
evidenced,3045,O
by,3045,O
behavioral,3045,O
changes,3045,O
",",3045,O
aphasia,3045,B-Disease
",",3045,O
incontinence,3045,B-Disease
",",3045,O
visual,3045,B-Disease
hallucinations,3045,I-Disease
",",3045,O
and,3045,O
right-sided,3045,O
weakness,3045,B-Disease
with,3045,O
diffuse,3045,O
cerebral,3045,B-Disease
vasospasm,3045,I-Disease
on,3045,O
magnetic,3045,O
resonance,3045,O
angiography,3045,O
after,3045,O
the,3045,O
administration,3045,O
of,3045,O
intrathecal,3045,O
cytarabine,3045,B-Chemical
.,3045,O
Vincristine,3046,B-Chemical
",",3046,O
dexamethasone,3046,B-Chemical
",",3046,O
and,3046,O
polyethylene,3046,B-Chemical
glycol-asparaginase,3046,I-Chemical
were,3046,O
also,3046,O
administered,3046,O
before,3046,O
the,3046,O
episode,3046,O
as,3046,O
part,3046,O
of,3046,O
induction,3046,O
therapy,3046,O
.,3046,O
Neurologic,3047,O
status,3047,O
returned,3047,O
to,3047,O
baseline,3047,O
within,3047,O
10,3047,O
days,3047,O
of,3047,O
the,3047,O
acute,3047,O
event,3047,O
",",3047,O
and,3047,O
magnetic,3047,O
resonance,3047,O
angiography,3047,O
findings,3047,O
returned,3047,O
to,3047,O
normal,3047,O
4,3047,O
months,3047,O
later,3047,O
.,3047,O
Comparison,3048,O
of,3048,O
valsartan/hydrochlorothiazide,3048,B-Chemical
combination,3048,O
therapy,3048,O
at,3048,O
doses,3048,O
up,3048,O
to,3048,O
320/25,3048,O
mg,3048,O
versus,3048,O
monotherapy,3048,O
:,3048,O
a,3048,O
double-blind,3048,O
",",3048,O
placebo-controlled,3048,O
study,3048,O
followed,3048,O
by,3048,O
long-term,3048,O
combination,3048,O
therapy,3048,O
in,3048,O
hypertensive,3048,B-Disease
adults,3048,O
.,3048,O
BACKGROUND,3049,O
:,3049,O
One,3049,O
third,3049,O
of,3049,O
patients,3049,O
treated,3049,O
for,3049,O
hypertension,3049,B-Disease
attain,3049,O
adequate,3049,O
blood,3049,O
pressure,3049,O
(,3049,O
BP,3049,O
),3049,O
control,3049,O
",",3049,O
and,3049,O
multidrug,3049,O
regimens,3049,O
are,3049,O
often,3049,O
required,3049,O
.,3049,O
Given,3050,O
the,3050,O
lifelong,3050,O
nature,3050,O
of,3050,O
hypertension,3050,B-Disease
",",3050,O
there,3050,O
is,3050,O
a,3050,O
need,3050,O
to,3050,O
evaluate,3050,O
the,3050,O
long-term,3050,O
efficacy,3050,O
and,3050,O
tolerability,3050,O
of,3050,O
higher,3050,O
doses,3050,O
of,3050,O
combination,3050,O
anti-hypertensive,3050,O
therapies,3050,O
.,3050,O
OBJECTIVE,3051,O
:,3051,O
This,3051,O
study,3051,O
investigated,3051,O
the,3051,O
efficacy,3051,O
and,3051,O
tolerability,3051,O
of,3051,O
valsartan,3051,B-Chemical
(,3051,O
VAL,3051,B-Chemical
),3051,O
or,3051,O
hydrochlorothiazide,3051,B-Chemical
(,3051,O
HCTZ,3051,B-Chemical
),3051,O
-monotherapy,3051,O
and,3051,O
higher-dose,3051,O
combinations,3051,O
in,3051,O
patients,3051,O
with,3051,O
essential,3051,B-Disease
hypertension,3051,I-Disease
.,3051,O
METHODS,3052,O
:,3052,O
The,3052,O
first,3052,O
part,3052,O
of,3052,O
this,3052,O
study,3052,O
was,3052,O
an,3052,O
8-week,3052,O
",",3052,O
multicenter,3052,O
",",3052,O
randomized,3052,O
",",3052,O
double-blind,3052,O
",",3052,O
placebo,3052,O
controlled,3052,O
",",3052,O
parallel-group,3052,O
trial,3052,O
.,3052,O
Patients,3053,O
with,3053,O
essential,3053,B-Disease
hypertension,3053,I-Disease
(,3053,O
mean,3053,O
sitting,3053,O
diastolic,3053,O
BP,3053,O
[,3053,O
MSDBP,3053,O
],3053,O
",",3053,O
>,3053,O
or,3053,O
=95,3053,O
mm,3053,O
Hg,3053,O
and,3053,O
<,3053,O
110,3053,O
mm,3053,O
Hg,3053,O
),3053,O
were,3053,O
randomized,3053,O
to,3053,O
1,3053,O
of,3053,O
8,3053,O
treatment,3053,O
groups,3053,O
:,3053,O
VAL,3053,B-Chemical
160,3053,O
or,3053,O
320,3053,O
mg,3053,O
;,3053,O
HCTZ,3053,B-Chemical
12.5,3053,O
or,3053,O
25,3053,O
mg,3053,O
;,3053,O
VAL/HCTZ,3053,B-Chemical
160/12.5,3053,O
",",3053,O
320/12.5,3053,O
",",3053,O
or,3053,O
320/25,3053,O
mg,3053,O
;,3053,O
or,3053,O
placebo,3053,O
.,3053,O
Mean,3054,O
changes,3054,O
in,3054,O
MSDBP,3054,O
and,3054,O
mean,3054,O
sitting,3054,O
systolic,3054,O
BP,3054,O
(,3054,O
MSSBP,3054,O
),3054,O
were,3054,O
analyzed,3054,O
at,3054,O
the,3054,O
8-week,3054,O
core,3054,O
study,3054,O
end,3054,O
point,3054,O
.,3054,O
VAL/HCTZ,3055,B-Chemical
320/12.5,3055,O
and,3055,O
320/25,3055,O
mg,3055,O
were,3055,O
further,3055,O
investigated,3055,O
in,3055,O
a,3055,O
54-week,3055,O
",",3055,O
open-label,3055,O
extension,3055,O
.,3055,O
Response,3056,O
was,3056,O
defined,3056,O
as,3056,O
MSDBP,3056,O
<,3056,O
90,3056,O
mm,3056,O
Hg,3056,O
or,3056,O
a,3056,O
>,3056,O
or,3056,O
=10,3056,O
mm,3056,O
Hg,3056,O
decrease,3056,O
compared,3056,O
to,3056,O
baseline,3056,O
.,3056,O
Control,3057,O
was,3057,O
defined,3057,O
as,3057,O
MSDBP,3057,O
<,3057,O
90,3057,O
mm,3057,O
Hg,3057,O
compared,3057,O
with,3057,O
baseline,3057,O
.,3057,O
Tolerability,3058,O
was,3058,O
assessed,3058,O
by,3058,O
monitoring,3058,O
adverse,3058,O
events,3058,O
at,3058,O
randomization,3058,O
and,3058,O
all,3058,O
subsequent,3058,O
study,3058,O
visits,3058,O
and,3058,O
regular,3058,O
evaluation,3058,O
of,3058,O
hematology,3058,O
and,3058,O
blood,3058,O
chemistry,3058,O
.,3058,O
RESULTS,3059,O
:,3059,O
A,3059,O
total,3059,O
of,3059,O
1346,3059,O
patients,3059,O
were,3059,O
randomized,3059,O
into,3059,O
the,3059,O
8-week,3059,O
core,3059,O
study,3059,O
(,3059,O
734,3059,O
men,3059,O
",",3059,O
612,3059,O
women,3059,O
;,3059,O
924,3059,O
white,3059,O
",",3059,O
291,3059,O
black,3059,O
",",3059,O
23,3059,O
Asian,3059,O
",",3059,O
108,3059,O
other,3059,O
;,3059,O
mean,3059,O
age,3059,O
",",3059,O
52.7,3059,O
years,3059,O
;,3059,O
mean,3059,O
weight,3059,O
",",3059,O
92.6,3059,O
kg,3059,O
),3059,O
.,3059,O
All,3060,O
active,3060,O
treatments,3060,O
were,3060,O
associated,3060,O
with,3060,O
significantly,3060,O
reduced,3060,O
MSSBP,3060,O
and,3060,O
MSDBP,3060,O
during,3060,O
the,3060,O
core,3060,O
8-week,3060,O
study,3060,O
",",3060,O
with,3060,O
each,3060,O
monotherapy,3060,O
significantly,3060,O
contributing,3060,O
to,3060,O
the,3060,O
overall,3060,O
effect,3060,O
of,3060,O
combination,3060,O
therapy,3060,O
(,3060,O
VAL,3060,B-Chemical
and,3060,O
HCTZ,3060,B-Chemical
",",3060,O
P,3060,O
<,3060,O
0.001,3060,O
),3060,O
.,3060,O
Each,3061,O
combination,3061,O
was,3061,O
associated,3061,O
with,3061,O
significantly,3061,O
greater,3061,O
reductions,3061,O
in,3061,O
MSSBP,3061,O
and,3061,O
MSDBP,3061,O
compared,3061,O
with,3061,O
the,3061,O
monotherapies,3061,O
and,3061,O
placebo,3061,O
(,3061,O
all,3061,O
",",3061,O
P,3061,O
<,3061,O
0.001,3061,O
),3061,O
.,3061,O
The,3062,O
mean,3062,O
reduction,3062,O
in,3062,O
MSSBP/MSDBP,3062,O
with,3062,O
VAL/HCTZ,3062,B-Chemical
320/25,3062,O
mg,3062,O
was,3062,O
24.7/16.6,3062,O
mm,3062,O
Hg,3062,O
",",3062,O
compared,3062,O
with,3062,O
5.9/7.0,3062,O
mm,3062,O
Hg,3062,O
with,3062,O
placebo,3062,O
.,3062,O
The,3063,O
reduction,3063,O
in,3063,O
MSSBP,3063,O
was,3063,O
significantly,3063,O
greater,3063,O
with,3063,O
VAL/HCTZ,3063,B-Chemical
320/25,3063,O
mg,3063,O
compared,3063,O
with,3063,O
VAL/HCTZ,3063,B-Chemical
160/12.5,3063,O
mg,3063,O
(,3063,O
P,3063,O
<,3063,O
0.002,3063,O
),3063,O
.,3063,O
Rates,3064,O
of,3064,O
response,3064,O
and,3064,O
BP,3064,O
control,3064,O
were,3064,O
significantly,3064,O
higher,3064,O
in,3064,O
the,3064,O
groups,3064,O
that,3064,O
received,3064,O
combination,3064,O
treatment,3064,O
compared,3064,O
with,3064,O
those,3064,O
that,3064,O
received,3064,O
monotherapy,3064,O
.,3064,O
The,3065,O
incidence,3065,O
of,3065,O
hypokalemia,3065,B-Disease
was,3065,O
lower,3065,O
with,3065,O
VAL/HCTZ,3065,B-Chemical
combinations,3065,O
(,3065,O
1.8,3065,O
%,3065,O
-6.1,3065,O
%,3065,O
),3065,O
than,3065,O
with,3065,O
HCTZ,3065,B-Chemical
monotherapies,3065,O
(,3065,O
7.1,3065,O
%,3065,O
-13.3,3065,O
%,3065,O
),3065,O
.,3065,O
The,3066,O
majority,3066,O
of,3066,O
adverse,3066,O
events,3066,O
in,3066,O
the,3066,O
core,3066,O
study,3066,O
were,3066,O
of,3066,O
mild,3066,O
to,3066,O
moderate,3066,O
severity,3066,O
.,3066,O
The,3067,O
efficacy,3067,O
and,3067,O
tolerability,3067,O
of,3067,O
VAL/HCTZ,3067,B-Chemical
combinations,3067,O
were,3067,O
maintained,3067,O
during,3067,O
the,3067,O
extension,3067,O
(,3067,O
797,3067,O
patients,3067,O
),3067,O
.,3067,O
CONCLUSIONS,3068,O
:,3068,O
In,3068,O
this,3068,O
study,3068,O
population,3068,O
",",3068,O
combination,3068,O
therapies,3068,O
with,3068,O
VAL/HCTZ,3068,B-Chemical
were,3068,O
associated,3068,O
with,3068,O
significantly,3068,O
greater,3068,O
BP,3068,O
reductions,3068,O
compared,3068,O
with,3068,O
either,3068,O
monotherapy,3068,O
",",3068,O
were,3068,O
well,3068,O
tolerated,3068,O
",",3068,O
and,3068,O
were,3068,O
associated,3068,O
with,3068,O
less,3068,O
hypokalemia,3068,B-Disease
than,3068,O
HCTZ,3068,B-Chemical
alone,3068,O
.,3068,O
Succimer,3069,B-Chemical
chelation,3069,O
improves,3069,O
learning,3069,O
",",3069,O
attention,3069,O
",",3069,O
and,3069,O
arousal,3069,O
regulation,3069,O
in,3069,O
lead-exposed,3069,B-Chemical
rats,3069,O
but,3069,O
produces,3069,O
lasting,3069,O
cognitive,3069,B-Disease
impairment,3069,I-Disease
in,3069,O
the,3069,O
absence,3069,O
of,3069,O
lead,3069,B-Chemical
exposure,3069,O
.,3069,O
BACKGROUND,3070,O
:,3070,O
There,3070,O
is,3070,O
growing,3070,O
pressure,3070,O
for,3070,O
clinicians,3070,O
to,3070,O
prescribe,3070,O
chelation,3070,O
therapy,3070,O
at,3070,O
only,3070,O
slightly,3070,O
elevated,3070,O
blood,3070,O
lead,3070,B-Chemical
levels,3070,O
.,3070,O
However,3071,O
",",3071,O
very,3071,O
few,3071,O
studies,3071,O
have,3071,O
evaluated,3071,O
whether,3071,O
chelation,3071,O
improves,3071,O
cognitive,3071,O
outcomes,3071,O
in,3071,O
Pb-exposed,3071,B-Chemical
children,3071,O
",",3071,O
or,3071,O
whether,3071,O
these,3071,O
agents,3071,O
have,3071,O
adverse,3071,O
effects,3071,O
that,3071,O
may,3071,O
affect,3071,O
brain,3071,O
development,3071,O
in,3071,O
the,3071,O
absence,3071,O
of,3071,O
Pb,3071,B-Chemical
exposure,3071,O
.,3071,O
OBJECTIVES,3072,O
:,3072,O
The,3072,O
present,3072,O
study,3072,O
was,3072,O
designed,3072,O
to,3072,O
answer,3072,O
these,3072,O
questions,3072,O
",",3072,O
using,3072,O
a,3072,O
rodent,3072,O
model,3072,O
of,3072,O
early,3072,O
childhood,3072,O
Pb,3072,B-Chemical
exposure,3072,O
and,3072,O
treatment,3072,O
with,3072,O
succimer,3072,B-Chemical
",",3072,O
a,3072,O
widely,3072,O
used,3072,O
chelating,3072,O
agent,3072,O
for,3072,O
the,3072,O
treatment,3072,O
of,3072,O
Pb,3072,B-Disease
poisoning,3072,I-Disease
.,3072,O
RESULTS,3073,O
:,3073,O
Pb,3073,B-Chemical
exposure,3073,O
produced,3073,O
lasting,3073,O
impairments,3073,O
in,3073,O
learning,3073,O
",",3073,O
attention,3073,O
",",3073,O
inhibitory,3073,O
control,3073,O
",",3073,O
and,3073,O
arousal,3073,O
regulation,3073,O
",",3073,O
paralleling,3073,O
the,3073,O
areas,3073,O
of,3073,O
dysfunction,3073,O
seen,3073,O
in,3073,O
Pb-exposed,3073,B-Chemical
children,3073,O
.,3073,O
Succimer,3074,B-Chemical
treatment,3074,O
of,3074,O
the,3074,O
Pb-exposed,3074,B-Chemical
rats,3074,O
significantly,3074,O
improved,3074,O
learning,3074,O
",",3074,O
attention,3074,O
",",3074,O
and,3074,O
arousal,3074,O
regulation,3074,O
",",3074,O
although,3074,O
the,3074,O
efficacy,3074,O
of,3074,O
the,3074,O
treatment,3074,O
varied,3074,O
as,3074,O
a,3074,O
function,3074,O
of,3074,O
the,3074,O
Pb,3074,B-Chemical
exposure,3074,O
level,3074,O
and,3074,O
the,3074,O
specific,3074,O
functional,3074,O
deficit,3074,O
.,3074,O
In,3075,O
contrast,3075,O
",",3075,O
succimer,3075,B-Chemical
treatment,3075,O
of,3075,O
rats,3075,O
not,3075,O
previously,3075,O
exposed,3075,O
to,3075,O
Pb,3075,B-Chemical
produced,3075,O
lasting,3075,O
and,3075,O
pervasive,3075,O
cognitive,3075,O
and,3075,O
affective,3075,O
dysfunction,3075,O
comparable,3075,O
in,3075,O
magnitude,3075,O
to,3075,O
that,3075,O
produced,3075,O
by,3075,O
the,3075,O
higher,3075,O
Pb,3075,B-Chemical
exposure,3075,O
regimen,3075,O
.,3075,O
CONCLUSIONS,3076,O
:,3076,O
These,3076,O
are,3076,O
the,3076,O
first,3076,O
data,3076,O
",",3076,O
to,3076,O
our,3076,O
knowledge,3076,O
",",3076,O
to,3076,O
show,3076,O
that,3076,O
treatment,3076,O
with,3076,O
any,3076,O
chelating,3076,O
agent,3076,O
can,3076,O
alleviate,3076,O
cognitive,3076,B-Disease
deficits,3076,I-Disease
due,3076,O
to,3076,O
Pb,3076,B-Chemical
exposure,3076,O
.,3076,O
These,3077,O
findings,3077,O
suggest,3077,O
that,3077,O
it,3077,O
may,3077,O
be,3077,O
possible,3077,O
to,3077,O
identify,3077,O
a,3077,O
succimer,3077,B-Chemical
treatment,3077,O
protocol,3077,O
that,3077,O
improves,3077,O
cognitive,3077,O
outcomes,3077,O
in,3077,O
Pb-exposed,3077,B-Chemical
children,3077,O
.,3077,O
However,3078,O
",",3078,O
they,3078,O
also,3078,O
suggest,3078,O
that,3078,O
succimer,3078,B-Chemical
treatment,3078,O
should,3078,O
be,3078,O
strongly,3078,O
discouraged,3078,O
for,3078,O
children,3078,O
who,3078,O
do,3078,O
not,3078,O
have,3078,O
elevated,3078,O
tissue,3078,O
levels,3078,O
of,3078,O
Pb,3078,B-Chemical
or,3078,O
other,3078,O
heavy,3078,O
metals,3078,O
.,3078,O
Caffeine,3079,B-Chemical
challenge,3079,O
test,3079,O
in,3079,O
panic,3079,B-Disease
disorder,3079,I-Disease
and,3079,O
depression,3079,B-Disease
with,3079,O
panic,3079,B-Disease
attacks,3079,I-Disease
.,3079,O
Our,3080,O
aim,3080,O
was,3080,O
to,3080,O
observe,3080,O
if,3080,O
patients,3080,O
with,3080,O
panic,3080,B-Disease
disorder,3080,I-Disease
(,3080,O
PD,3080,B-Disease
),3080,O
and,3080,O
patients,3080,O
with,3080,O
major,3080,B-Disease
depression,3080,I-Disease
with,3080,O
panic,3080,B-Disease
attacks,3080,I-Disease
(,3080,O
MDP,3080,B-Disease
),3080,O
(,3080,O
Diagnostic,3080,O
and,3080,O
Statistical,3080,O
Manual,3080,O
of,3080,O
Mental,3080,B-Disease
Disorders,3080,I-Disease
",",3080,O
Fourth,3080,O
Edition,3080,O
criteria,3080,O
),3080,O
respond,3080,O
in,3080,O
a,3080,O
similar,3080,O
way,3080,O
to,3080,O
the,3080,O
induction,3080,O
of,3080,O
panic,3080,B-Disease
attacks,3080,I-Disease
by,3080,O
an,3080,O
oral,3080,O
caffeine,3080,B-Chemical
challenge,3080,O
test,3080,O
.,3080,O
We,3081,O
randomly,3081,O
selected,3081,O
29,3081,O
patients,3081,O
with,3081,O
PD,3081,B-Disease
",",3081,O
27,3081,O
with,3081,O
MDP,3081,B-Disease
",",3081,O
25,3081,O
with,3081,O
major,3081,B-Disease
depression,3081,I-Disease
without,3081,O
panic,3081,B-Disease
attacks,3081,I-Disease
(,3081,O
MD,3081,B-Disease
),3081,O
",",3081,O
and,3081,O
28,3081,O
healthy,3081,O
volunteers,3081,O
.,3081,O
The,3082,O
patients,3082,O
had,3082,O
no,3082,O
psychotropic,3082,O
drug,3082,O
for,3082,O
at,3082,O
least,3082,O
a,3082,O
4-week,3082,O
period,3082,O
.,3082,O
In,3083,O
a,3083,O
randomized,3083,O
double-blind,3083,O
experiment,3083,O
performed,3083,O
in,3083,O
2,3083,O
occasions,3083,O
7,3083,O
days,3083,O
apart,3083,O
",",3083,O
480,3083,O
mg,3083,O
caffeine,3083,B-Chemical
and,3083,O
a,3083,O
caffeine-free,3083,B-Chemical
(,3083,O
placebo,3083,O
),3083,O
solution,3083,O
were,3083,O
administered,3083,O
in,3083,O
a,3083,O
coffee,3083,O
form,3083,O
and,3083,O
anxiety,3083,B-Disease
scales,3083,O
were,3083,O
applied,3083,O
before,3083,O
and,3083,O
after,3083,O
each,3083,O
test,3083,O
.,3083,O
A,3084,O
total,3084,O
of,3084,O
58.6,3084,O
%,3084,O
(,3084,O
n,3084,O
=,3084,O
17,3084,O
),3084,O
of,3084,O
patients,3084,O
with,3084,O
PD,3084,B-Disease
",",3084,O
44.4,3084,O
%,3084,O
(,3084,O
n,3084,O
=,3084,O
12,3084,O
),3084,O
of,3084,O
patients,3084,O
with,3084,O
MDP,3084,B-Disease
",",3084,O
12.0,3084,O
%,3084,O
(,3084,O
n,3084,O
=,3084,O
3,3084,O
),3084,O
of,3084,O
patients,3084,O
with,3084,O
MD,3084,B-Disease
",",3084,O
and,3084,O
7.1,3084,O
%,3084,O
(,3084,O
n=,3084,O
2,3084,O
),3084,O
of,3084,O
control,3084,O
subjects,3084,O
had,3084,O
a,3084,O
panic,3084,B-Disease
attack,3084,I-Disease
after,3084,O
the,3084,O
480-mg,3084,O
caffeine,3084,B-Chemical
challenge,3084,O
test,3084,O
(,3084,O
chi,3084,O
(,3084,O
2,3084,O
),3084,O
(,3084,O
3,3084,O
),3084,O
=,3084,O
16.22,3084,O
",",3084,O
P,3084,O
=,3084,O
.001,3084,O
),3084,O
.,3084,O
The,3085,O
patients,3085,O
with,3085,O
PD,3085,B-Disease
and,3085,O
MDP,3085,B-Disease
were,3085,O
more,3085,O
sensitive,3085,O
to,3085,O
caffeine,3085,B-Chemical
than,3085,O
were,3085,O
patients,3085,O
with,3085,O
MD,3085,B-Disease
and,3085,O
healthy,3085,O
volunteers,3085,O
.,3085,O
No,3086,O
panic,3086,B-Disease
attack,3086,I-Disease
was,3086,O
observed,3086,O
after,3086,O
the,3086,O
caffeine-free,3086,B-Chemical
solution,3086,O
intake,3086,O
.,3086,O
The,3087,O
patients,3087,O
with,3087,O
MD,3087,B-Disease
had,3087,O
a,3087,O
lower,3087,O
heart,3087,O
rate,3087,O
response,3087,O
to,3087,O
the,3087,O
test,3087,O
than,3087,O
all,3087,O
the,3087,O
other,3087,O
groups,3087,O
(,3087,O
2-way,3087,O
analysis,3087,O
of,3087,O
variance,3087,O
",",3087,O
group,3087,O
by,3087,O
time,3087,O
interaction,3087,O
with,3087,O
Greenhouse-Geisser,3087,O
correction,3087,O
:,3087,O
F,3087,O
(,3087,O
"3,762",3087,O
),3087,O
=,3087,O
2.85,3087,O
",",3087,O
P,3087,O
=,3087,O
.026,3087,O
),3087,O
.,3087,O
Our,3088,O
data,3088,O
suggest,3088,O
that,3088,O
there,3088,O
is,3088,O
an,3088,O
association,3088,O
between,3088,O
panic,3088,B-Disease
attacks,3088,I-Disease
",",3088,O
no,3088,O
matter,3088,O
if,3088,O
associated,3088,O
with,3088,O
PD,3088,B-Disease
or,3088,O
MDP,3088,B-Disease
",",3088,O
and,3088,O
hyperreactivity,3088,O
to,3088,O
an,3088,O
oral,3088,O
caffeine,3088,B-Chemical
challenge,3088,O
test,3088,O
.,3088,O
Mitral,3089,O
annuloplasty,3089,O
as,3089,O
a,3089,O
ventricular,3089,O
restoration,3089,O
method,3089,O
for,3089,O
the,3089,O
failing,3089,B-Disease
left,3089,I-Disease
ventricle,3089,I-Disease
:,3089,O
a,3089,O
pilot,3089,O
study,3089,O
.,3089,O
BACKGROUND,3090,O
AND,3090,O
AIM,3090,O
OF,3090,O
THE,3090,O
STUDY,3090,O
:,3090,O
Undersized,3090,O
mitral,3090,O
annuloplasty,3090,O
(,3090,O
MAP,3090,O
),3090,O
is,3090,O
effective,3090,O
in,3090,O
patients,3090,O
with,3090,O
dilated,3090,B-Disease
cardiomyopathy,3090,I-Disease
and,3090,O
functional,3090,O
mitral,3090,B-Disease
regurgitation,3090,I-Disease
(,3090,O
MR,3090,B-Disease
),3090,O
since,3090,O
",",3090,O
as,3090,O
well,3090,O
as,3090,O
addressing,3090,O
the,3090,O
MR,3090,B-Disease
",",3090,O
the,3090,O
MAP,3090,O
may,3090,O
also,3090,O
reshape,3090,O
the,3090,O
dilated,3090,O
left,3090,O
ventricular,3090,O
(,3090,O
LV,3090,O
),3090,O
base,3090,O
.,3090,O
However,3091,O
",",3091,O
the,3091,O
direct,3091,O
benefits,3091,O
of,3091,O
this,3091,O
possible,3091,O
reshaping,3091,O
on,3091,O
LV,3091,O
function,3091,O
in,3091,O
the,3091,O
absence,3091,O
of,3091,O
underlying,3091,O
MR,3091,B-Disease
remain,3091,O
incompletely,3091,O
understood,3091,O
.,3091,O
The,3092,O
study,3092,O
aim,3092,O
was,3092,O
to,3092,O
identify,3092,O
these,3092,O
benefits,3092,O
in,3092,O
a,3092,O
canine,3092,O
model,3092,O
of,3092,O
acute,3092,O
heart,3092,B-Disease
failure,3092,I-Disease
.,3092,O
METHODS,3093,O
:,3093,O
Six,3093,O
dogs,3093,O
underwent,3093,O
MAP,3093,O
with,3093,O
a,3093,O
prosthetic,3093,O
band,3093,O
on,3093,O
the,3093,O
posterior,3093,O
mitral,3093,O
annulus,3093,O
",",3093,O
using,3093,O
four,3093,O
mattress,3093,O
sutures,3093,O
.,3093,O
The,3094,O
sutures,3094,O
were,3094,O
passed,3094,O
individually,3094,O
through,3094,O
four,3094,O
tourniquets,3094,O
and,3094,O
exteriorized,3094,O
untied,3094,O
via,3094,O
the,3094,O
left,3094,O
atriotomy,3094,O
.,3094,O
Sonomicrometry,3095,O
crystals,3095,O
were,3095,O
implanted,3095,O
around,3095,O
the,3095,O
mitral,3095,O
annulus,3095,O
and,3095,O
left,3095,O
ventricle,3095,O
to,3095,O
measure,3095,O
geometry,3095,O
and,3095,O
regional,3095,O
function,3095,O
.,3095,O
Acute,3096,O
heart,3096,B-Disease
failure,3096,I-Disease
was,3096,O
induced,3096,O
by,3096,O
propranolol,3096,B-Chemical
and,3096,O
volume,3096,O
loading,3096,O
after,3096,O
weaning,3096,O
from,3096,O
cardiopulmonary,3096,O
bypass,3096,O
;,3096,O
an,3096,O
absence,3096,O
of,3096,O
MR,3096,B-Disease
was,3096,O
confirmed,3096,O
by,3096,O
echocardiography,3096,O
.,3096,O
MAP,3097,O
was,3097,O
accomplished,3097,O
by,3097,O
cinching,3097,O
the,3097,O
tourniquets,3097,O
.,3097,O
Data,3098,O
were,3098,O
acquired,3098,O
at,3098,O
baseline,3098,O
",",3098,O
after,3098,O
induction,3098,O
of,3098,O
acute,3098,O
heart,3098,B-Disease
failure,3098,I-Disease
",",3098,O
and,3098,O
after,3098,O
MAP,3098,O
.,3098,O
RESULTS,3099,O
:,3099,O
MAP,3099,O
decreased,3099,O
mitral,3099,O
annular,3099,O
dimensions,3099,O
in,3099,O
both,3099,O
commissure-commissure,3099,O
and,3099,O
septal-lateral,3099,O
directions,3099,O
.,3099,O
Concomitantly,3100,O
",",3100,O
the,3100,O
diastolic,3100,O
diameter,3100,O
of,3100,O
the,3100,O
LV,3100,O
base,3100,O
and,3100,O
LV,3100,O
sphericity,3100,O
decreased,3100,O
(,3100,O
i.e.,3100,O
",",3100,O
improved,3100,O
),3100,O
from,3100,O
37.4,3100,O
+/-,3100,O
9.3,3100,O
to,3100,O
35.9,3100,O
+/-,3100,O
10,3100,O
mm,3100,O
(,3100,O
p,3100,O
=,3100,O
0.063,3100,O
),3100,O
",",3100,O
and,3100,O
from,3100,O
67.9,3100,O
+/-,3100,O
18.6,3100,O
%,3100,O
to,3100,O
65.3,3100,O
+/-,3100,O
18.9,3100,O
%,3100,O
(,3100,O
p,3100,O
=,3100,O
0.016,3100,O
),3100,O
",",3100,O
respectively,3100,O
.,3100,O
Decreases,3101,O
were,3101,O
evident,3101,O
in,3101,O
both,3101,O
LV,3101,O
end-diastolic,3101,O
pressure,3101,O
(,3101,O
from,3101,O
17,3101,O
+/-,3101,O
7,3101,O
to,3101,O
15,3101,O
+/-,3101,O
6,3101,O
mmHg,3101,O
",",3101,O
p,3101,O
=,3101,O
0.0480,3101,O
and,3101,O
Tau,3101,O
(,3101,O
from,3101,O
48,3101,O
+/-,3101,O
8,3101,O
to,3101,O
45,3101,O
+/-,3101,O
8,3101,O
ms,3101,O
",",3101,O
p,3101,O
<,3101,O
0.01,3101,O
),3101,O
",",3101,O
while,3101,O
fractional,3101,O
shortening,3101,O
at,3101,O
the,3101,O
LV,3101,O
base,3101,O
increased,3101,O
from,3101,O
7.7,3101,O
+/-,3101,O
4.5,3101,O
%,3101,O
to,3101,O
9.4,3101,O
+/-,3101,O
4.5,3101,O
%,3101,O
(,3101,O
p,3101,O
=,3101,O
0.045,3101,O
),3101,O
.,3101,O
After,3102,O
MAP,3102,O
",",3102,O
increases,3102,O
were,3102,O
identified,3102,O
in,3102,O
both,3102,O
cardiac,3102,O
output,3102,O
(,3102,O
from,3102,O
1.54,3102,O
+/-,3102,O
0.57,3102,O
to,3102,O
1.65,3102,O
+/-,3102,O
0.57,3102,O
1/min,3102,O
),3102,O
and,3102,O
Emax,3102,O
(,3102,O
from,3102,O
1.86,3102,O
+/-,3102,O
0.9,3102,O
to,3102,O
2.41,3102,O
+/-,3102,O
1.31,3102,O
mmHg/ml,3102,O
),3102,O
.,3102,O
CONCLUSION,3103,O
:,3103,O
The,3103,O
data,3103,O
acquired,3103,O
suggest,3103,O
that,3103,O
isolated,3103,O
MAP,3103,O
may,3103,O
have,3103,O
certain,3103,O
benefits,3103,O
on,3103,O
LV,3103,O
dimension/function,3103,O
in,3103,O
acute,3103,O
heart,3103,B-Disease
failure,3103,I-Disease
",",3103,O
even,3103,O
in,3103,O
the,3103,O
absence,3103,O
of,3103,O
MR,3103,B-Disease
.,3103,O
However,3104,O
",",3104,O
further,3104,O
investigations,3104,O
are,3104,O
warranted,3104,O
in,3104,O
a,3104,O
model,3104,O
of,3104,O
chronic,3104,O
heart,3104,B-Disease
failure,3104,I-Disease
.,3104,O
Piperacillin/tazobactam-induced,3105,B-Chemical
seizure,3105,B-Disease
rapidly,3105,O
reversed,3105,O
by,3105,O
high,3105,O
flux,3105,O
hemodialysis,3105,O
in,3105,O
a,3105,O
patient,3105,O
on,3105,O
peritoneal,3105,O
dialysis,3105,O
.,3105,O
Despite,3106,O
popular,3106,O
use,3106,O
of,3106,O
piperacillin,3106,B-Chemical
",",3106,O
the,3106,O
dire,3106,O
neurotoxicity,3106,B-Disease
associated,3106,O
with,3106,O
piperacillin,3106,B-Chemical
still,3106,O
goes,3106,O
unrecognized,3106,O
",",3106,O
leading,3106,O
to,3106,O
a,3106,O
delay,3106,O
in,3106,O
appropriate,3106,O
management,3106,O
.,3106,O
We,3107,O
report,3107,O
a,3107,O
57-year-old,3107,O
woman,3107,O
with,3107,O
end-stage,3107,B-Disease
renal,3107,I-Disease
disease,3107,I-Disease
receiving,3107,O
continuous,3107,O
ambulatory,3107,O
peritoneal,3107,O
dialysis,3107,O
(,3107,O
CAPD,3107,O
),3107,O
",",3107,O
who,3107,O
developed,3107,O
slurred,3107,O
speech,3107,O
",",3107,O
tremor,3107,B-Disease
",",3107,O
bizarre,3107,O
behavior,3107,O
",",3107,O
progressive,3107,O
mental,3107,O
confusion,3107,B-Disease
",",3107,O
and,3107,O
2,3107,O
episodes,3107,O
of,3107,O
generalized,3107,O
tonic-clonic,3107,B-Disease
seizure,3107,I-Disease
(,3107,O
GTCS,3107,B-Disease
),3107,O
after,3107,O
5,3107,O
doses,3107,O
of,3107,O
piperacillin/tazobactam,3107,B-Chemical
(,3107,O
2,3107,O
g/250,3107,O
mg,3107,O
),3107,O
were,3107,O
given,3107,O
for,3107,O
bronchiectasis,3107,B-Disease
with,3107,O
secondary,3107,B-Disease
infection,3107,I-Disease
.,3107,O
The,3108,O
laboratory,3108,O
data,3108,O
revealed,3108,O
normal,3108,O
plasma,3108,O
electrolyte,3108,O
and,3108,O
ammonia,3108,B-Chemical
levels,3108,O
but,3108,O
leukocytosis,3108,B-Disease
.,3108,O
Neurologic,3109,O
examinations,3109,O
showed,3109,O
dysarthria,3109,B-Disease
and,3109,O
bilateral,3109,O
Babinski,3109,O
sign,3109,O
.,3109,O
Computed,3110,O
tomography,3110,O
of,3110,O
brain,3110,O
and,3110,O
electroencephalogram,3110,O
were,3110,O
unremarkable,3110,O
.,3110,O
Despite,3111,O
the,3111,O
use,3111,O
of,3111,O
antiepileptic,3111,O
agents,3111,O
",",3111,O
another,3111,O
GTCS,3111,B-Disease
episode,3111,O
recurred,3111,O
after,3111,O
the,3111,O
sixth,3111,O
dose,3111,O
of,3111,O
piperacillin/tazobactam,3111,B-Chemical
.,3111,O
Brain,3112,O
magnetic,3112,O
resonance,3112,O
imaging,3112,O
did,3112,O
not,3112,O
demonstrate,3112,O
acute,3112,O
infarction,3112,B-Disease
and,3112,O
organic,3112,B-Disease
brain,3112,I-Disease
lesions,3112,I-Disease
.,3112,O
Initiation,3113,O
of,3113,O
high-flux,3113,O
hemodialysis,3113,O
rapidly,3113,O
reversed,3113,O
the,3113,O
neurologic,3113,O
symptoms,3113,O
within,3113,O
4,3113,O
hours,3113,O
.,3113,O
Piperacillin-induced,3114,B-Chemical
encephalopathy,3114,B-Disease
should,3114,O
be,3114,O
considered,3114,O
in,3114,O
any,3114,O
uremic,3114,B-Disease
patients,3114,O
with,3114,O
unexplained,3114,O
neurological,3114,O
manifestations,3114,O
.,3114,O
CAPD,3115,O
is,3115,O
inefficient,3115,O
in,3115,O
removing,3115,O
piperacillin,3115,B-Chemical
",",3115,O
whereas,3115,O
hemodialysis,3115,O
can,3115,O
rapidly,3115,O
terminate,3115,O
the,3115,O
piperacillin-induced,3115,B-Chemical
encephalopathy,3115,B-Disease
.,3115,O
Frequency,3116,O
of,3116,O
transient,3116,O
ipsilateral,3116,O
vocal,3116,B-Disease
cord,3116,I-Disease
paralysis,3116,I-Disease
in,3116,O
patients,3116,O
undergoing,3116,O
carotid,3116,O
endarterectomy,3116,O
under,3116,O
local,3116,O
anesthesia,3116,O
.,3116,O
BACKGROUND,3117,O
:,3117,O
Especially,3117,O
because,3117,O
of,3117,O
improvements,3117,O
in,3117,O
clinical,3117,O
neurologic,3117,O
monitoring,3117,O
",",3117,O
carotid,3117,O
endarterectomy,3117,O
done,3117,O
under,3117,O
local,3117,O
anesthesia,3117,O
has,3117,O
become,3117,O
the,3117,O
technique,3117,O
of,3117,O
choice,3117,O
in,3117,O
several,3117,O
centers,3117,O
.,3117,O
Temporary,3118,O
ipsilateral,3118,O
vocal,3118,B-Disease
nerve,3118,I-Disease
palsies,3118,I-Disease
due,3118,O
to,3118,O
local,3118,O
anesthetics,3118,O
have,3118,O
been,3118,O
described,3118,O
",",3118,O
however,3118,O
.,3118,O
Such,3119,O
complications,3119,O
are,3119,O
most,3119,O
important,3119,O
in,3119,O
situations,3119,O
where,3119,O
there,3119,O
is,3119,O
a,3119,O
pre-existing,3119,O
contralateral,3119,O
paralysis,3119,B-Disease
.,3119,O
We,3120,O
therefore,3120,O
examined,3120,O
the,3120,O
effect,3120,O
of,3120,O
local,3120,O
anesthesia,3120,O
on,3120,O
vocal,3120,O
cord,3120,O
function,3120,O
to,3120,O
better,3120,O
understand,3120,O
its,3120,O
possible,3120,O
consequences,3120,O
.,3120,O
METHODS,3121,O
:,3121,O
This,3121,O
prospective,3121,O
study,3121,O
included,3121,O
28,3121,O
patients,3121,O
undergoing,3121,O
carotid,3121,O
endarterectomy,3121,O
under,3121,O
local,3121,O
anesthesia,3121,O
.,3121,O
Vocal,3122,O
cord,3122,O
function,3122,O
was,3122,O
evaluated,3122,O
before,3122,O
",",3122,O
during,3122,O
",",3122,O
and,3122,O
after,3122,O
surgery,3122,O
(,3122,O
postoperative,3122,O
day,3122,O
1,3122,O
),3122,O
using,3122,O
flexible,3122,O
laryngoscopy,3122,O
.,3122,O
Anesthesia,3123,O
was,3123,O
performed,3123,O
by,3123,O
injecting,3123,O
20,3123,O
to,3123,O
40,3123,O
mL,3123,O
of,3123,O
a,3123,O
mixture,3123,O
of,3123,O
long-acting,3123,O
(,3123,O
ropivacaine,3123,B-Chemical
),3123,O
and,3123,O
short-acting,3123,O
(,3123,O
prilocaine,3123,B-Chemical
),3123,O
anesthetic,3123,O
.,3123,O
RESULTS,3124,O
:,3124,O
All,3124,O
patients,3124,O
had,3124,O
normal,3124,O
vocal,3124,O
cord,3124,O
function,3124,O
preoperatively,3124,O
.,3124,O
Twelve,3125,O
patients,3125,O
(,3125,O
43,3125,O
%,3125,O
),3125,O
were,3125,O
found,3125,O
to,3125,O
have,3125,O
intraoperative,3125,O
ipsilateral,3125,O
vocal,3125,B-Disease
cord,3125,I-Disease
paralysis,3125,I-Disease
.,3125,O
It,3126,O
resolved,3126,O
in,3126,O
all,3126,O
cases,3126,O
<,3126,O
or,3126,O
=24,3126,O
hours,3126,O
.,3126,O
There,3127,O
were,3127,O
no,3127,O
significant,3127,O
differences,3127,O
in,3127,O
operating,3127,O
time,3127,O
or,3127,O
volume,3127,O
or,3127,O
frequency,3127,O
of,3127,O
anesthetic,3127,O
administration,3127,O
in,3127,O
patients,3127,O
with,3127,O
temporary,3127,O
vocal,3127,B-Disease
cord,3127,I-Disease
paralysis,3127,I-Disease
compared,3127,O
with,3127,O
those,3127,O
without,3127,O
.,3127,O
CONCLUSION,3128,O
:,3128,O
Local,3128,O
anesthesia,3128,O
led,3128,O
to,3128,O
temporary,3128,O
ipsilateral,3128,O
vocal,3128,B-Disease
cord,3128,I-Disease
paralysis,3128,I-Disease
in,3128,O
almost,3128,O
half,3128,O
of,3128,O
these,3128,O
patients,3128,O
.,3128,O
Because,3129,O
pre-existing,3129,O
paralysis,3129,B-Disease
is,3129,O
of,3129,O
a,3129,O
relevant,3129,O
frequency,3129,O
(,3129,O
up,3129,O
to,3129,O
3,3129,O
%,3129,O
),3129,O
",",3129,O
a,3129,O
preoperative,3129,O
evaluation,3129,O
of,3129,O
vocal,3129,O
cord,3129,O
function,3129,O
before,3129,O
carotid,3129,O
endarterectomy,3129,O
under,3129,O
local,3129,O
anesthesia,3129,O
is,3129,O
recommended,3129,O
to,3129,O
avoid,3129,O
intraoperative,3129,O
bilateral,3129,O
paralysis,3129,B-Disease
.,3129,O
In,3130,O
patients,3130,O
with,3130,O
preoperative,3130,O
contralateral,3130,O
vocal,3130,B-Disease
cord,3130,I-Disease
paralysis,3130,I-Disease
",",3130,O
surgery,3130,O
under,3130,O
general,3130,O
anesthesia,3130,O
should,3130,O
be,3130,O
considered,3130,O
.,3130,O
Impaired,3131,B-Disease
fear,3131,I-Disease
recognition,3131,I-Disease
in,3131,O
regular,3131,O
recreational,3131,O
cocaine,3131,B-Chemical
users,3131,O
.,3131,O
INTRODUCTION,3132,O
:,3132,O
The,3132,O
ability,3132,O
to,3132,O
read,3132,O
facial,3132,O
expressions,3132,O
is,3132,O
essential,3132,O
for,3132,O
normal,3132,O
human,3132,O
social,3132,O
interaction,3132,O
.,3132,O
The,3133,O
aim,3133,O
of,3133,O
the,3133,O
present,3133,O
study,3133,O
was,3133,O
to,3133,O
conduct,3133,O
the,3133,O
first,3133,O
investigation,3133,O
of,3133,O
facial,3133,O
expression,3133,O
recognition,3133,O
performance,3133,O
in,3133,O
recreational,3133,O
cocaine,3133,B-Chemical
users,3133,O
.,3133,O
MATERIALS,3134,O
AND,3134,O
METHODS,3134,O
:,3134,O
Three,3134,O
groups,3134,O
",",3134,O
comprised,3134,O
of,3134,O
21,3134,O
cocaine,3134,B-Chemical
naive,3134,O
participants,3134,O
(,3134,O
CN,3134,O
),3134,O
",",3134,O
30,3134,O
occasional,3134,O
cocaine,3134,B-Chemical
(,3134,O
OC,3134,O
),3134,O
",",3134,O
and,3134,O
48,3134,O
regular,3134,O
recreational,3134,O
cocaine,3134,B-Chemical
(,3134,O
RC,3134,O
),3134,O
users,3134,O
",",3134,O
were,3134,O
compared,3134,O
.,3134,O
An,3135,O
emotional,3135,O
facial,3135,O
expression,3135,O
(,3135,O
EFE,3135,O
),3135,O
task,3135,O
consisting,3135,O
of,3135,O
a,3135,O
male,3135,O
and,3135,O
female,3135,O
face,3135,O
expressing,3135,O
six,3135,O
basic,3135,O
emotions,3135,O
(,3135,O
happiness,3135,O
",",3135,O
surprise,3135,O
",",3135,O
sadness,3135,O
",",3135,O
anger,3135,O
",",3135,O
fear,3135,O
",",3135,O
and,3135,O
disgust,3135,O
),3135,O
was,3135,O
administered,3135,O
.,3135,O
Mean,3136,O
percent,3136,O
accuracy,3136,O
and,3136,O
latencies,3136,O
for,3136,O
correct,3136,O
responses,3136,O
across,3136,O
eight,3136,O
presentations,3136,O
of,3136,O
each,3136,O
basic,3136,O
emotion,3136,O
were,3136,O
derived,3136,O
.,3136,O
Participants,3137,O
were,3137,O
also,3137,O
assessed,3137,O
with,3137,O
the,3137,O
``,3137,O
Eyes,3137,O
task,3137,O
'',3137,O
to,3137,O
investigate,3137,O
their,3137,O
ability,3137,O
to,3137,O
recognize,3137,O
more,3137,O
complex,3137,O
emotional,3137,O
states,3137,O
and,3137,O
the,3137,O
Symptom,3137,O
CheckList-90-Revised,3137,O
to,3137,O
measure,3137,O
psychopathology,3137,O
.,3137,O
RESULTS,3138,O
:,3138,O
There,3138,O
were,3138,O
no,3138,O
group,3138,O
differences,3138,O
in,3138,O
psychopathology,3138,O
or,3138,O
``,3138,O
eyes,3138,O
task,3138,O
'',3138,O
performance,3138,O
",",3138,O
but,3138,O
the,3138,O
RC,3138,O
group,3138,O
",",3138,O
who,3138,O
otherwise,3138,O
had,3138,O
similar,3138,O
illicit,3138,O
substance,3138,O
use,3138,O
histories,3138,O
to,3138,O
the,3138,O
OC,3138,O
group,3138,O
",",3138,O
exhibited,3138,O
impaired,3138,B-Disease
fear,3138,I-Disease
recognition,3138,I-Disease
accuracy,3138,O
compared,3138,O
to,3138,O
the,3138,O
OC,3138,O
and,3138,O
CN,3138,O
groups,3138,O
.,3138,O
The,3139,O
RC,3139,O
group,3139,O
also,3139,O
correctly,3139,O
identified,3139,O
anger,3139,O
",",3139,O
fear,3139,O
",",3139,O
happiness,3139,O
",",3139,O
and,3139,O
surprise,3139,O
",",3139,O
more,3139,O
slowly,3139,O
than,3139,O
CN,3139,O
",",3139,O
but,3139,O
not,3139,O
OC,3139,O
participants,3139,O
.,3139,O
The,3140,O
OC,3140,O
group,3140,O
was,3140,O
slower,3140,O
than,3140,O
CN,3140,O
when,3140,O
correctly,3140,O
identifying,3140,O
disgust,3140,O
.,3140,O
The,3141,O
selective,3141,O
deficit,3141,B-Disease
in,3141,I-Disease
fear,3141,I-Disease
recognition,3141,I-Disease
accuracy,3141,O
manifested,3141,O
by,3141,O
the,3141,O
RC,3141,O
group,3141,O
can,3141,O
not,3141,O
be,3141,O
explained,3141,O
by,3141,O
the,3141,O
subacute,3141,O
effects,3141,O
of,3141,O
cocaine,3141,B-Chemical
",",3141,O
or,3141,O
ecstasy,3141,B-Chemical
",",3141,O
because,3141,O
recent,3141,O
and,3141,O
less,3141,O
recent,3141,O
users,3141,O
of,3141,O
these,3141,O
drugs,3141,O
within,3141,O
this,3141,O
group,3141,O
were,3141,O
similarly,3141,O
impaired,3141,O
.,3141,O
Possible,3142,O
parallels,3142,O
between,3142,O
RC,3142,O
users,3142,O
and,3142,O
psychopaths,3142,B-Disease
with,3142,O
respect,3142,O
to,3142,O
impaired,3142,B-Disease
fear,3142,I-Disease
recognition,3142,I-Disease
",",3142,O
amygdala,3142,B-Disease
dysfunction,3142,I-Disease
",",3142,O
and,3142,O
etiology,3142,O
are,3142,O
discussed,3142,O
.,3142,O
Neuroprotective,3143,O
effects,3143,O
of,3143,O
melatonin,3143,B-Chemical
upon,3143,O
the,3143,O
offspring,3143,O
cerebellar,3143,O
cortex,3143,O
in,3143,O
the,3143,O
rat,3143,O
model,3143,O
of,3143,O
BCNU-induced,3143,B-Chemical
cortical,3143,B-Disease
dysplasia,3143,I-Disease
.,3143,O
Cortical,3144,B-Disease
dysplasia,3144,I-Disease
is,3144,O
a,3144,O
malformation,3144,O
characterized,3144,O
by,3144,O
defects,3144,O
in,3144,O
proliferation,3144,O
",",3144,O
migration,3144,O
and,3144,O
maturation,3144,O
.,3144,O
This,3145,O
study,3145,O
was,3145,O
designed,3145,O
to,3145,O
evaluate,3145,O
the,3145,O
alterations,3145,O
in,3145,O
offspring,3145,O
rat,3145,O
cerebellum,3145,O
induced,3145,O
by,3145,O
maternal,3145,O
exposure,3145,O
to,3145,O
carmustine-,3145,B-Chemical
[,3145,O
"1,3-bis",3145,B-Chemical
(,3145,I-Chemical
2-chloroethyl,3145,I-Chemical
),3145,I-Chemical
-1-nitrosoure,3145,I-Chemical
],3145,O
(,3145,O
BCNU,3145,B-Chemical
),3145,O
and,3145,O
to,3145,O
investigate,3145,O
the,3145,O
effects,3145,O
of,3145,O
exogenous,3145,O
melatonin,3145,B-Chemical
upon,3145,O
cerebellar,3145,O
BCNU-induced,3145,B-Chemical
cortical,3145,B-Disease
dysplasia,3145,I-Disease
",",3145,O
using,3145,O
histological,3145,O
and,3145,O
biochemical,3145,O
analyses,3145,O
.,3145,O
Pregnant,3146,O
Wistar,3146,O
rats,3146,O
were,3146,O
assigned,3146,O
to,3146,O
five,3146,O
groups,3146,O
:,3146,O
intact-control,3146,O
",",3146,O
saline-control,3146,O
",",3146,O
melatonin-treated,3146,B-Chemical
",",3146,O
BCNU-exposed,3146,B-Chemical
and,3146,O
BCNU-exposed,3146,B-Chemical
plus,3146,O
melatonin,3146,B-Chemical
.,3146,O
Rats,3147,O
were,3147,O
exposed,3147,O
to,3147,O
BCNU,3147,B-Chemical
on,3147,O
embryonic,3147,O
day,3147,O
15,3147,O
and,3147,O
melatonin,3147,B-Chemical
was,3147,O
given,3147,O
until,3147,O
delivery,3147,O
.,3147,O
Immuno/histochemistry,3148,O
and,3148,O
electron,3148,O
microscopy,3148,O
were,3148,O
carried,3148,O
out,3148,O
on,3148,O
the,3148,O
offspring,3148,O
cerebellum,3148,O
",",3148,O
and,3148,O
levels,3148,O
of,3148,O
malondialdehyde,3148,B-Chemical
and,3148,O
superoxide,3148,B-Chemical
dismutase,3148,O
were,3148,O
determined,3148,O
.,3148,O
Histopathologically,3149,O
",",3149,O
typical,3149,O
findings,3149,O
were,3149,O
observed,3149,O
in,3149,O
the,3149,O
cerebella,3149,O
from,3149,O
the,3149,O
control,3149,O
groups,3149,O
",",3149,O
but,3149,O
the,3149,O
findings,3149,O
consistent,3149,O
with,3149,O
early,3149,O
embryonic,3149,O
development,3149,O
were,3149,O
noted,3149,O
in,3149,O
BCNU-exposed,3149,B-Chemical
cortical,3149,B-Disease
dysplasia,3149,I-Disease
group,3149,O
.,3149,O
There,3150,O
was,3150,O
a,3150,O
marked,3150,O
increase,3150,O
in,3150,O
the,3150,O
number,3150,O
of,3150,O
TUNEL,3150,O
positive,3150,O
cells,3150,O
and,3150,O
nestin,3150,O
positive,3150,O
cells,3150,O
in,3150,O
BCNU-exposed,3150,B-Chemical
group,3150,O
",",3150,O
but,3150,O
a,3150,O
decreased,3150,O
immunoreactivity,3150,O
to,3150,O
glial,3150,O
fibrillary,3150,O
acidic,3150,O
protein,3150,O
",",3150,O
synaptophysin,3150,O
and,3150,O
transforming,3150,O
growth,3150,O
factor,3150,O
beta1,3150,O
was,3150,O
observed,3150,O
",",3150,O
indicating,3150,O
a,3150,O
delayed,3150,O
maturation,3150,O
",",3150,O
and,3150,O
melatonin,3150,B-Chemical
significantly,3150,O
reversed,3150,O
these,3150,O
changes,3150,O
.,3150,O
Malondialdehyde,3151,B-Chemical
level,3151,O
in,3151,O
BCNU-exposed,3151,B-Chemical
group,3151,O
was,3151,O
higher,3151,O
than,3151,O
those,3151,O
in,3151,O
control,3151,O
groups,3151,O
and,3151,O
melatonin,3151,B-Chemical
decreased,3151,O
malondialdehyde,3151,B-Chemical
levels,3151,O
in,3151,O
BCNU,3151,B-Chemical
group,3151,O
(,3151,O
P,3151,O
<,3151,O
0.01,3151,O
),3151,O
",",3151,O
while,3151,O
there,3151,O
were,3151,O
no,3151,O
significant,3151,O
differences,3151,O
in,3151,O
the,3151,O
superoxide,3151,B-Chemical
dismutase,3151,O
levels,3151,O
between,3151,O
these,3151,O
groups,3151,O
.,3151,O
These,3152,O
data,3152,O
suggest,3152,O
that,3152,O
exposure,3152,O
of,3152,O
animals,3152,O
to,3152,O
BCNU,3152,B-Chemical
during,3152,O
pregnancy,3152,O
leads,3152,O
to,3152,O
delayed,3152,O
maturation,3152,O
of,3152,O
offspring,3152,O
cerebellum,3152,O
and,3152,O
melatonin,3152,B-Chemical
protects,3152,O
the,3152,O
cerebellum,3152,O
against,3152,O
the,3152,O
effects,3152,O
of,3152,O
BCNU,3152,B-Chemical
.,3152,O
Corneal,3153,B-Disease
ulcers,3153,I-Disease
associated,3153,O
with,3153,O
aerosolized,3153,O
crack,3153,B-Chemical
cocaine,3153,I-Chemical
use,3153,O
.,3153,O
PURPOSE,3154,O
:,3154,O
We,3154,O
report,3154,O
4,3154,O
cases,3154,O
of,3154,O
corneal,3154,B-Disease
ulcers,3154,I-Disease
associated,3154,O
with,3154,O
drug,3154,B-Disease
abuse,3154,I-Disease
.,3154,O
The,3155,O
pathogenesis,3155,O
of,3155,O
these,3155,O
ulcers,3155,B-Disease
and,3155,O
management,3155,O
of,3155,O
these,3155,O
patients,3155,O
are,3155,O
also,3155,O
reviewed,3155,O
.,3155,O
METHODS,3156,O
:,3156,O
Review,3156,O
of,3156,O
all,3156,O
cases,3156,O
of,3156,O
corneal,3156,B-Disease
ulcers,3156,I-Disease
associated,3156,O
with,3156,O
drug,3156,B-Disease
abuse,3156,I-Disease
seen,3156,O
at,3156,O
our,3156,O
institution,3156,O
from,3156,O
July,3156,O
2006,3156,O
to,3156,O
December,3156,O
2006,3156,O
.,3156,O
RESULTS,3157,O
:,3157,O
Four,3157,O
patients,3157,O
with,3157,O
corneal,3157,B-Disease
ulcers,3157,I-Disease
associated,3157,O
with,3157,O
crack,3157,B-Chemical
cocaine,3157,I-Chemical
use,3157,O
were,3157,O
reviewed,3157,O
.,3157,O
All,3158,O
corneal,3158,B-Disease
ulcers,3158,I-Disease
were,3158,O
cultured,3158,O
",",3158,O
and,3158,O
the,3158,O
patients,3158,O
were,3158,O
admitted,3158,O
to,3158,O
the,3158,O
hospital,3158,O
for,3158,O
intensive,3158,O
topical,3158,O
antibiotic,3158,O
treatment,3158,O
.,3158,O
Each,3159,O
patient,3159,O
received,3159,O
comprehensive,3159,O
health,3159,O
care,3159,O
",",3159,O
including,3159,O
medical,3159,O
and,3159,O
substance,3159,B-Disease
abuse,3159,I-Disease
consultations,3159,O
.,3159,O
Streptococcal,3160,O
organisms,3160,O
were,3160,O
found,3160,O
in,3160,O
3,3160,O
cases,3160,O
and,3160,O
Capnocytophaga,3160,O
and,3160,O
Brevibacterium,3160,O
casei,3160,O
in,3160,O
1,3160,O
patient,3160,O
.,3160,O
The,3161,O
infections,3161,B-Disease
responded,3161,O
to,3161,O
antibiotic,3161,O
treatment,3161,O
.,3161,O
Two,3162,O
patients,3162,O
needed,3162,O
a,3162,O
lateral,3162,O
tarsorrhaphy,3162,O
for,3162,O
persistent,3162,O
epithelial,3162,B-Disease
defects,3162,I-Disease
.,3162,O
CONCLUSIONS,3163,O
:,3163,O
Aerosolized,3163,O
crack,3163,B-Chemical
cocaine,3163,I-Chemical
use,3163,O
can,3163,O
be,3163,O
associated,3163,O
with,3163,O
the,3163,O
development,3163,O
of,3163,O
corneal,3163,B-Disease
ulcers,3163,I-Disease
.,3163,O
Drug,3164,B-Disease
abuse,3164,I-Disease
provides,3164,O
additional,3164,O
challenges,3164,O
for,3164,O
management,3164,O
.,3164,O
Not,3165,O
only,3165,O
treatment,3165,O
of,3165,O
their,3165,O
infections,3165,B-Disease
but,3165,O
also,3165,O
the,3165,O
overall,3165,O
poor,3165,O
health,3165,O
of,3165,O
the,3165,O
patients,3165,O
and,3165,O
increased,3165,O
risk,3165,O
of,3165,O
noncompliance,3165,O
need,3165,O
to,3165,O
be,3165,O
addressed,3165,O
.,3165,O
Comprehensive,3166,O
care,3166,O
may,3166,O
provide,3166,O
the,3166,O
patient,3166,O
the,3166,O
opportunity,3166,O
to,3166,O
discontinue,3166,O
their,3166,O
substance,3166,B-Disease
abuse,3166,I-Disease
",",3166,O
improve,3166,O
their,3166,O
overall,3166,O
health,3166,O
",",3166,O
and,3166,O
prevent,3166,O
future,3166,O
corneal,3166,O
complications,3166,O
.,3166,O
Myo-inositol-1-phosphate,3167,B-Chemical
(,3167,O
MIP,3167,B-Chemical
),3167,O
synthase,3167,O
inhibition,3167,O
:,3167,O
in-vivo,3167,O
study,3167,O
in,3167,O
rats,3167,O
.,3167,O
Lithium,3168,B-Chemical
and,3168,O
valproate,3168,B-Chemical
are,3168,O
the,3168,O
prototypic,3168,O
mood,3168,O
stabilizers,3168,O
and,3168,O
have,3168,O
diverse,3168,O
structures,3168,O
and,3168,O
targets,3168,O
.,3168,O
Both,3169,O
drugs,3169,O
influence,3169,O
inositol,3169,B-Chemical
metabolism,3169,O
.,3169,O
Lithium,3170,B-Chemical
inhibits,3170,O
IMPase,3170,O
and,3170,O
valproate,3170,B-Chemical
inhibits,3170,O
MIP,3170,B-Chemical
synthase,3170,O
.,3170,O
This,3171,O
study,3171,O
shows,3171,O
that,3171,O
MIP,3171,B-Chemical
synthase,3171,O
inhibition,3171,O
does,3171,O
not,3171,O
replicate,3171,O
or,3171,O
augment,3171,O
the,3171,O
effects,3171,O
of,3171,O
lithium,3171,B-Chemical
in,3171,O
the,3171,O
inositol,3171,B-Chemical
sensitive,3171,O
pilocarpine-induced,3171,B-Chemical
seizures,3171,B-Disease
model,3171,O
.,3171,O
This,3172,O
lack,3172,O
of,3172,O
effects,3172,O
may,3172,O
stem,3172,O
from,3172,O
the,3172,O
low,3172,O
contribution,3172,O
of,3172,O
de-novo,3172,O
synthesis,3172,O
to,3172,O
cellular,3172,O
inositol,3172,B-Chemical
supply,3172,O
or,3172,O
to,3172,O
the,3172,O
inhibition,3172,O
of,3172,O
the,3172,O
de-novo,3172,O
synthesis,3172,O
by,3172,O
lithium,3172,B-Chemical
itself,3172,O
.,3172,O
Non-steroidal,3173,O
anti-inflammatory,3173,O
drugs-associated,3173,O
acute,3173,O
interstitial,3173,B-Disease
nephritis,3173,I-Disease
with,3173,O
granular,3173,O
tubular,3173,O
basement,3173,O
membrane,3173,O
deposits,3173,O
.,3173,O
Acute,3174,B-Disease
tubulo-interstitial,3174,I-Disease
nephritis,3174,I-Disease
(,3174,O
ATIN,3174,B-Disease
),3174,O
is,3174,O
an,3174,O
important,3174,O
cause,3174,O
of,3174,O
acute,3174,B-Disease
renal,3174,I-Disease
failure,3174,I-Disease
resulting,3174,O
from,3174,O
a,3174,O
variety,3174,O
of,3174,O
insults,3174,O
",",3174,O
including,3174,O
immune,3174,O
complex-mediated,3174,O
tubulo-interstitial,3174,B-Disease
injury,3174,I-Disease
",",3174,O
but,3174,O
drugs,3174,O
such,3174,O
as,3174,O
non-steroidal,3174,O
anti-inflammatory,3174,O
drugs,3174,O
(,3174,O
NSAIDs,3174,O
),3174,O
are,3174,O
a,3174,O
far,3174,O
more,3174,O
frequent,3174,O
cause,3174,O
.,3174,O
Overall,3175,O
",",3175,O
as,3175,O
an,3175,O
entity,3175,O
",",3175,O
ATIN,3175,B-Disease
remains,3175,O
under-diagnosed,3175,O
",",3175,O
as,3175,O
symptoms,3175,O
resolve,3175,O
spontaneously,3175,O
if,3175,O
the,3175,O
medication,3175,O
is,3175,O
stopped,3175,O
.,3175,O
We,3176,O
report,3176,O
on,3176,O
a,3176,O
14-year-old,3176,O
boy,3176,O
who,3176,O
developed,3176,O
acute,3176,B-Disease
renal,3176,I-Disease
failure,3176,I-Disease
2,3176,O
weeks,3176,O
after,3176,O
aortic,3176,O
valve,3176,O
surgery,3176,O
.,3176,O
He,3177,O
was,3177,O
put,3177,O
on,3177,O
aspirin,3177,B-Chemical
following,3177,O
surgery,3177,O
and,3177,O
took,3177,O
ibuprofen,3177,B-Chemical
for,3177,O
fever,3177,B-Disease
for,3177,O
nearly,3177,O
a,3177,O
week,3177,O
prior,3177,O
to,3177,O
presentation,3177,O
.,3177,O
He,3178,O
then,3178,O
presented,3178,O
to,3178,O
the,3178,O
emergency,3178,O
department,3178,O
feeling,3178,O
quite,3178,O
ill,3178,O
and,3178,O
was,3178,O
found,3178,O
to,3178,O
have,3178,O
a,3178,O
blood,3178,B-Chemical
urea,3178,I-Chemical
nitrogen,3178,I-Chemical
(,3178,O
BUN,3178,B-Chemical
),3178,O
concentration,3178,O
of,3178,O
of,3178,O
147,3178,O
mg/dl,3178,O
",",3178,O
creatinine,3178,B-Chemical
of,3178,O
15.3,3178,O
mg/dl,3178,O
and,3178,O
serum,3178,O
potassium,3178,B-Chemical
of,3178,O
8.7,3178,O
mEq/l,3178,O
.,3178,O
Dialysis,3179,O
was,3179,O
immediately,3179,O
initiated,3179,O
.,3179,O
A,3180,O
kidney,3180,O
biopsy,3180,O
showed,3180,O
inflammatory,3180,O
infiltrate,3180,O
consistent,3180,O
with,3180,O
ATIN,3180,B-Disease
.,3180,O
However,3181,O
",",3181,O
in,3181,O
the,3181,O
tubular,3181,O
basement,3181,O
membrane,3181,O
(,3181,O
TBM,3181,O
),3181,O
",",3181,O
very,3181,O
intense,3181,O
granular,3181,O
deposits,3181,O
of,3181,O
polyclonal,3181,O
IgG,3181,O
and,3181,O
C3,3181,O
were,3181,O
noted,3181,O
.,3181,O
He,3182,O
needed,3182,O
dialysis,3182,O
for,3182,O
2,3182,O
weeks,3182,O
and,3182,O
was,3182,O
treated,3182,O
successfully,3182,O
with,3182,O
steroids,3182,B-Chemical
for,3182,O
6,3182,O
months,3182,O
.,3182,O
His,3183,O
renal,3183,O
recovery,3183,O
and,3183,O
disappearance,3183,O
of,3183,O
proteinuria,3183,B-Disease
took,3183,O
a,3183,O
year,3183,O
.,3183,O
In,3184,O
conclusion,3184,O
",",3184,O
this,3184,O
is,3184,O
a,3184,O
first,3184,O
report,3184,O
of,3184,O
NSAIDs-associated,3184,O
ATIN,3184,B-Disease
",",3184,O
showing,3184,O
deposits,3184,O
of,3184,O
granular,3184,O
immune,3184,O
complex,3184,O
present,3184,O
only,3184,O
in,3184,O
the,3184,O
TBM,3184,O
and,3184,O
not,3184,O
in,3184,O
the,3184,O
glomeruli,3184,O
.,3184,O
Rifampicin-associated,3185,B-Chemical
segmental,3185,O
necrotizing,3185,O
glomerulonephritis,3185,B-Disease
in,3185,O
staphylococcal,3185,O
endocarditis,3185,O
.,3185,O
Segmental,3186,O
necrotising,3186,O
glomerulonephritis,3186,B-Disease
has,3186,O
been,3186,O
reported,3186,O
as,3186,O
complication,3186,O
of,3186,O
rifampicin,3186,B-Chemical
therapy,3186,O
in,3186,O
patients,3186,O
receiving,3186,O
treatment,3186,O
for,3186,O
tuberculosis,3186,B-Disease
.,3186,O
Changing,3187,O
epidemiology,3187,O
of,3187,O
infections,3187,B-Disease
such,3187,O
as,3187,O
infective,3187,B-Disease
endocarditis,3187,I-Disease
(,3187,O
IE,3187,B-Disease
),3187,O
has,3187,O
led,3187,O
to,3187,O
an,3187,O
increase,3187,O
in,3187,O
the,3187,O
use,3187,O
of,3187,O
rifampicin,3187,B-Chemical
for,3187,O
Staphylococcal,3187,B-Disease
infections,3187,I-Disease
.,3187,O
We,3188,O
describe,3188,O
a,3188,O
case,3188,O
of,3188,O
a,3188,O
patient,3188,O
with,3188,O
Staphylococcal,3188,O
IE,3188,O
who,3188,O
developed,3188,O
acute,3188,B-Disease
renal,3188,I-Disease
failure,3188,I-Disease
secondary,3188,O
to,3188,O
a,3188,O
segmental,3188,O
necrotising,3188,O
glomerulonephritis,3188,B-Disease
while,3188,O
being,3188,O
treated,3188,O
with,3188,O
rifampicin,3188,B-Chemical
",",3188,O
and,3188,O
review,3188,O
the,3188,O
literature,3188,O
regarding,3188,O
this,3188,O
complication,3188,O
of,3188,O
rifampicin,3188,B-Chemical
therapy,3188,O
.,3188,O
Rate,3189,O
of,3189,O
YMDD,3189,O
motif,3189,O
mutants,3189,O
in,3189,O
lamivudine-untreated,3189,B-Chemical
Iranian,3189,O
patients,3189,O
with,3189,O
chronic,3189,B-Disease
hepatitis,3189,I-Disease
B,3189,I-Disease
virus,3189,I-Disease
infection,3189,I-Disease
.,3189,O
BACKGROUND,3190,O
:,3190,O
Lamivudine,3190,B-Chemical
is,3190,O
used,3190,O
for,3190,O
the,3190,O
treatment,3190,O
of,3190,O
chronic,3190,B-Disease
hepatitis,3190,I-Disease
B,3190,I-Disease
patients,3190,O
.,3190,O
Recent,3191,O
studies,3191,O
show,3191,O
that,3191,O
the,3191,O
YMDD,3191,O
motif,3191,O
mutants,3191,O
(,3191,O
resistant,3191,O
hepatitis,3191,B-Disease
B,3191,I-Disease
virus,3191,O
),3191,O
occur,3191,O
as,3191,O
natural,3191,O
genome,3191,O
variability,3191,O
in,3191,O
lamivudine-untreated,3191,B-Chemical
chronic,3191,B-Disease
hepatitis,3191,I-Disease
B,3191,I-Disease
patients,3191,O
.,3191,O
In,3192,O
this,3192,O
study,3192,O
we,3192,O
aimed,3192,O
to,3192,O
determine,3192,O
the,3192,O
rate,3192,O
of,3192,O
YMDD,3192,O
motif,3192,O
mutants,3192,O
in,3192,O
lamivudine-untreated,3192,B-Chemical
chronic,3192,B-Disease
hepatitis,3192,I-Disease
B,3192,I-Disease
patients,3192,O
in,3192,O
Iran,3192,O
.,3192,O
PATIENTS,3193,O
AND,3193,O
METHODS,3193,O
:,3193,O
A,3193,O
total,3193,O
of,3193,O
77,3193,O
chronic,3193,B-Disease
hepatitis,3193,I-Disease
B,3193,I-Disease
patients,3193,O
who,3193,O
had,3193,O
not,3193,O
been,3193,O
treated,3193,O
with,3193,O
lamivudine,3193,B-Chemical
were,3193,O
included,3193,O
in,3193,O
the,3193,O
study,3193,O
.,3193,O
Serum,3194,O
samples,3194,O
from,3194,O
patients,3194,O
were,3194,O
tested,3194,O
by,3194,O
polymerase,3194,O
chain,3194,O
reaction-restriction,3194,O
fragment,3194,O
length,3194,O
polymorphism,3194,O
(,3194,O
PCR-RFLP,3194,O
),3194,O
for,3194,O
detection,3194,O
of,3194,O
YMDD,3194,O
motif,3194,O
mutants,3194,O
.,3194,O
All,3195,O
patients,3195,O
were,3195,O
also,3195,O
tested,3195,O
for,3195,O
liver,3195,O
enzymes,3195,O
",",3195,O
anti-HCV,3195,O
",",3195,O
HBeAg,3195,B-Chemical
",",3195,O
and,3195,O
anti-HBe,3195,O
.,3195,O
RESULTS,3196,O
:,3196,O
Of,3196,O
the,3196,O
77,3196,O
patients,3196,O
enrolled,3196,O
in,3196,O
the,3196,O
study,3196,O
",",3196,O
73,3196,O
%,3196,O
were,3196,O
male,3196,O
and,3196,O
27,3196,O
%,3196,O
were,3196,O
female,3196,O
.,3196,O
Mean,3197,O
ALT,3197,O
and,3197,O
AST,3197,O
levels,3197,O
were,3197,O
124.4+/-73.4,3197,O
and,3197,O
103.1+/-81,3197,O
IU/l,3197,O
",",3197,O
respectively,3197,O
.,3197,O
HBeAg,3198,B-Chemical
was,3198,O
positive,3198,O
in,3198,O
40,3198,O
%,3198,O
and,3198,O
anti-HBe,3198,O
in,3198,O
60,3198,O
%,3198,O
of,3198,O
the,3198,O
patients,3198,O
.,3198,O
Anti-HCV,3199,O
was,3199,O
negative,3199,O
in,3199,O
all,3199,O
of,3199,O
them,3199,O
.,3199,O
YMDD,3200,O
motif,3200,O
mutants,3200,O
were,3200,O
not,3200,O
detected,3200,O
in,3200,O
any,3200,O
of,3200,O
the,3200,O
patients,3200,O
despite,3200,O
the,3200,O
liver,3200,O
enzyme,3200,O
levels,3200,O
and,3200,O
the,3200,O
presence,3200,O
of,3200,O
HBeAg,3200,B-Chemical
or,3200,O
anti-HBe,3200,O
.,3200,O
CONCLUSION,3201,O
:,3201,O
Although,3201,O
the,3201,O
natural,3201,O
occurrence,3201,O
of,3201,O
YMDD,3201,O
motif,3201,O
mutants,3201,O
in,3201,O
lamivudine-untreated,3201,B-Chemical
patients,3201,O
with,3201,O
chronic,3201,B-Disease
hepatitis,3201,I-Disease
B,3201,I-Disease
has,3201,O
been,3201,O
reported,3201,O
",",3201,O
these,3201,O
mutants,3201,O
were,3201,O
not,3201,O
detected,3201,O
in,3201,O
Iranian,3201,O
lamivudine-untreated,3201,B-Chemical
chronic,3201,B-Disease
hepatitis,3201,I-Disease
B,3201,I-Disease
patients,3201,O
.,3201,O
Branch,3202,O
retinal,3202,B-Disease
vein,3202,I-Disease
occlusion,3202,I-Disease
and,3202,O
fluoxetine,3202,B-Chemical
.,3202,O
A,3203,O
case,3203,O
of,3203,O
branch,3203,O
retinal,3203,B-Disease
vein,3203,I-Disease
occlusion,3203,I-Disease
associated,3203,O
with,3203,O
fluoxetine-induced,3203,B-Chemical
secondary,3203,O
hypertension,3203,B-Disease
is,3203,O
described,3203,O
.,3203,O
Although,3204,O
an,3204,O
infrequent,3204,O
complication,3204,O
of,3204,O
selective,3204,O
serotonin,3204,B-Chemical
reuptake,3204,O
inhibitor,3204,O
therapy,3204,O
",",3204,O
it,3204,O
is,3204,O
important,3204,O
that,3204,O
ophthalmologists,3204,O
are,3204,O
aware,3204,O
that,3204,O
these,3204,O
agents,3204,O
can,3204,O
cause,3204,O
hypertension,3204,B-Disease
because,3204,O
this,3204,O
class,3204,O
of,3204,O
drugs,3204,O
is,3204,O
widely,3204,O
prescribed,3204,O
.,3204,O
The,3205,O
differential,3205,O
effects,3205,O
of,3205,O
bupivacaine,3205,B-Chemical
and,3205,O
lidocaine,3205,B-Chemical
on,3205,O
prostaglandin,3205,B-Chemical
E2,3205,I-Chemical
release,3205,O
",",3205,O
cyclooxygenase,3205,O
gene,3205,O
expression,3205,O
and,3205,O
pain,3205,B-Disease
in,3205,O
a,3205,O
clinical,3205,O
pain,3205,B-Disease
model,3205,O
.,3205,O
BACKGROUND,3206,O
:,3206,O
In,3206,O
addition,3206,O
to,3206,O
blocking,3206,O
nociceptive,3206,O
input,3206,O
from,3206,O
surgical,3206,O
sites,3206,O
",",3206,O
long-acting,3206,O
local,3206,O
anesthetics,3206,O
might,3206,O
directly,3206,O
modulate,3206,O
inflammation,3206,B-Disease
.,3206,O
In,3207,O
the,3207,O
present,3207,O
study,3207,O
",",3207,O
we,3207,O
describe,3207,O
the,3207,O
proinflammatory,3207,O
effects,3207,O
of,3207,O
bupivacaine,3207,B-Chemical
on,3207,O
local,3207,O
prostaglandin,3207,B-Chemical
E2,3207,I-Chemical
(,3207,O
PGE2,3207,B-Chemical
),3207,O
production,3207,O
and,3207,O
cyclooxygenase,3207,O
(,3207,O
COX,3207,O
),3207,O
gene,3207,O
expression,3207,O
that,3207,O
increases,3207,O
postoperative,3207,B-Disease
pain,3207,I-Disease
in,3207,O
human,3207,O
subjects,3207,O
.,3207,O
METHODS,3208,O
:,3208,O
Subjects,3208,O
(,3208,O
n,3208,O
=,3208,O
114,3208,O
),3208,O
undergoing,3208,O
extraction,3208,O
of,3208,O
impacted,3208,O
third,3208,O
molars,3208,O
received,3208,O
either,3208,O
2,3208,O
%,3208,O
lidocaine,3208,B-Chemical
or,3208,O
0.5,3208,O
%,3208,O
bupivacaine,3208,B-Chemical
before,3208,O
surgery,3208,O
and,3208,O
either,3208,O
rofecoxib,3208,B-Chemical
50,3208,O
mg,3208,O
or,3208,O
placebo,3208,O
orally,3208,O
90,3208,O
min,3208,O
before,3208,O
surgery,3208,O
and,3208,O
for,3208,O
the,3208,O
following,3208,O
48,3208,O
h.,3208,O
Oral,3208,O
mucosal,3208,O
biopsies,3208,O
were,3208,O
taken,3208,O
before,3208,O
surgery,3208,O
and,3208,O
48,3208,O
h,3208,O
after,3208,O
surgery,3208,O
.,3208,O
After,3209,O
extraction,3209,O
",",3209,O
a,3209,O
microdialysis,3209,O
probe,3209,O
was,3209,O
placed,3209,O
at,3209,O
the,3209,O
surgical,3209,O
site,3209,O
for,3209,O
PGE2,3209,B-Chemical
and,3209,O
thromboxane,3209,B-Chemical
B2,3209,I-Chemical
(,3209,O
TXB2,3209,B-Chemical
),3209,O
measurements,3209,O
.,3209,O
RESULTS,3210,O
:,3210,O
The,3210,O
bupivacaine/rofecoxib,3210,B-Chemical
group,3210,O
reported,3210,O
significantly,3210,O
less,3210,O
pain,3210,B-Disease
",",3210,O
as,3210,O
assessed,3210,O
by,3210,O
a,3210,O
visual,3210,O
analog,3210,O
scale,3210,O
",",3210,O
compared,3210,O
with,3210,O
the,3210,O
other,3210,O
three,3210,O
treatment,3210,O
groups,3210,O
over,3210,O
the,3210,O
first,3210,O
4,3210,O
h.,3210,O
However,3210,O
",",3210,O
the,3210,O
bupivacaine/placebo,3210,B-Chemical
group,3210,O
reported,3210,O
significantly,3210,O
more,3210,O
pain,3210,B-Disease
at,3210,O
24,3210,O
h,3210,O
and,3210,O
PGE2,3210,B-Chemical
levels,3210,O
during,3210,O
the,3210,O
first,3210,O
4,3210,O
h,3210,O
were,3210,O
significantly,3210,O
higher,3210,O
than,3210,O
the,3210,O
other,3210,O
three,3210,O
treatment,3210,O
groups,3210,O
.,3210,O
Moreover,3211,O
",",3211,O
bupivacaine,3211,B-Chemical
significantly,3211,O
increased,3211,O
COX-2,3211,O
gene,3211,O
expression,3211,O
at,3211,O
48,3211,O
h,3211,O
as,3211,O
compared,3211,O
with,3211,O
the,3211,O
lidocaine/placebo,3211,B-Chemical
group,3211,O
.,3211,O
Thromboxane,3212,B-Chemical
levels,3212,O
were,3212,O
not,3212,O
significantly,3212,O
affected,3212,O
by,3212,O
any,3212,O
of,3212,O
the,3212,O
treatments,3212,O
",",3212,O
indicating,3212,O
that,3212,O
the,3212,O
effects,3212,O
seen,3212,O
were,3212,O
attributable,3212,O
to,3212,O
inhibition,3212,O
of,3212,O
COX-2,3212,O
",",3212,O
but,3212,O
not,3212,O
COX-1,3212,O
.,3212,O
CONCLUSIONS,3213,O
:,3213,O
These,3213,O
results,3213,O
suggest,3213,O
that,3213,O
bupivacaine,3213,B-Chemical
stimulates,3213,O
COX-2,3213,O
gene,3213,O
expression,3213,O
after,3213,O
tissue,3213,B-Disease
injury,3213,I-Disease
",",3213,O
which,3213,O
is,3213,O
associated,3213,O
with,3213,O
higher,3213,O
PGE2,3213,B-Chemical
production,3213,O
and,3213,O
pain,3213,B-Disease
after,3213,O
the,3213,O
local,3213,O
anesthetic,3213,O
effect,3213,O
dissipates,3213,O
.,3213,O
p75NTR,3214,O
expression,3214,O
in,3214,O
rat,3214,O
urinary,3214,O
bladder,3214,O
sensory,3214,O
neurons,3214,O
and,3214,O
spinal,3214,O
cord,3214,O
with,3214,O
cyclophosphamide-induced,3214,B-Chemical
cystitis,3214,B-Disease
.,3214,O
A,3215,O
role,3215,O
for,3215,O
nerve,3215,O
growth,3215,O
factor,3215,O
(,3215,O
NGF,3215,O
),3215,O
in,3215,O
contributing,3215,O
to,3215,O
increased,3215,O
voiding,3215,O
frequency,3215,O
and,3215,O
altered,3215,O
sensation,3215,O
from,3215,O
the,3215,O
urinary,3215,O
bladder,3215,O
has,3215,O
been,3215,O
suggested,3215,O
.,3215,O
Previous,3216,O
studies,3216,O
have,3216,O
examined,3216,O
the,3216,O
expression,3216,O
and,3216,O
regulation,3216,O
of,3216,O
tyrosine,3216,B-Chemical
kinase,3216,O
receptors,3216,O
(,3216,O
Trks,3216,O
),3216,O
in,3216,O
micturition,3216,O
reflexes,3216,O
with,3216,O
urinary,3216,B-Disease
bladder,3216,I-Disease
inflammation,3216,I-Disease
.,3216,O
The,3217,O
present,3217,O
studies,3217,O
examine,3217,O
the,3217,O
expression,3217,O
and,3217,O
regulation,3217,O
of,3217,O
another,3217,O
receptor,3217,O
known,3217,O
to,3217,O
bind,3217,O
NGF,3217,O
",",3217,O
p75,3217,O
(,3217,O
NTR,3217,O
),3217,O
",",3217,O
after,3217,O
various,3217,O
durations,3217,O
of,3217,O
bladder,3217,B-Disease
inflammation,3217,I-Disease
induced,3217,O
by,3217,O
cyclophosphamide,3217,B-Chemical
(,3217,O
CYP,3217,B-Chemical
),3217,O
.,3217,O
CYP-induced,3218,B-Chemical
cystitis,3218,B-Disease
increased,3218,O
(,3218,O
P,3218,O
<,3218,O
or,3218,O
=,3218,O
0.001,3218,O
),3218,O
p75,3218,O
(,3218,O
NTR,3218,O
),3218,O
expression,3218,O
in,3218,O
the,3218,O
superficial,3218,O
lateral,3218,O
and,3218,O
medial,3218,O
dorsal,3218,O
horn,3218,O
in,3218,O
L1-L2,3218,O
and,3218,O
L6-S1,3218,O
spinal,3218,O
segments,3218,O
.,3218,O
The,3219,O
number,3219,O
of,3219,O
p75,3219,O
(,3219,O
NTR,3219,O
),3219,O
-immunoreactive,3219,O
(,3219,O
-IR,3219,O
),3219,O
cells,3219,O
in,3219,O
the,3219,O
lumbosacral,3219,O
dorsal,3219,O
root,3219,O
ganglia,3219,O
(,3219,O
DRG,3219,O
),3219,O
also,3219,O
increased,3219,O
(,3219,O
P,3219,O
<,3219,O
or,3219,O
=,3219,O
0.05,3219,O
),3219,O
with,3219,O
CYP-induced,3219,B-Chemical
cystitis,3219,B-Disease
(,3219,O
acute,3219,O
",",3219,O
intermediate,3219,O
",",3219,O
and,3219,O
chronic,3219,O
),3219,O
.,3219,O
Quantitative,3220,O
",",3220,O
real-time,3220,O
polymerase,3220,O
chain,3220,O
reaction,3220,O
also,3220,O
demonstrated,3220,O
significant,3220,O
increases,3220,O
(,3220,O
P,3220,O
<,3220,O
or,3220,O
=,3220,O
0.01,3220,O
),3220,O
in,3220,O
p75,3220,O
(,3220,O
NTR,3220,O
),3220,O
mRNA,3220,O
in,3220,O
DRG,3220,O
with,3220,O
intermediate,3220,O
and,3220,O
chronic,3220,O
CYP-induced,3220,B-Chemical
cystitis,3220,B-Disease
.,3220,O
Retrograde,3221,O
dye-tracing,3221,O
techniques,3221,O
with,3221,O
Fastblue,3221,O
were,3221,O
used,3221,O
to,3221,O
identify,3221,O
presumptive,3221,O
bladder,3221,O
afferent,3221,O
cells,3221,O
in,3221,O
the,3221,O
lumbosacral,3221,O
DRG,3221,O
.,3221,O
In,3222,O
bladder,3222,O
afferent,3222,O
cells,3222,O
in,3222,O
DRG,3222,O
",",3222,O
p75,3222,O
(,3222,O
NTR,3222,O
),3222,O
-IR,3222,O
was,3222,O
also,3222,O
increased,3222,O
(,3222,O
P,3222,O
<,3222,O
or,3222,O
=,3222,O
0.01,3222,O
),3222,O
with,3222,O
cystitis,3222,B-Disease
.,3222,O
In,3223,O
addition,3223,O
to,3223,O
increases,3223,O
in,3223,O
p75,3223,O
(,3223,O
NTR,3223,O
),3223,O
-IR,3223,O
in,3223,O
DRG,3223,O
cell,3223,O
bodies,3223,O
",",3223,O
increases,3223,O
(,3223,O
P,3223,O
<,3223,O
or,3223,O
=,3223,O
0.001,3223,O
),3223,O
in,3223,O
pericellular,3223,O
(,3223,O
encircling,3223,O
DRG,3223,O
cells,3223,O
),3223,O
p75,3223,O
(,3223,O
NTR,3223,O
),3223,O
-IR,3223,O
in,3223,O
DRG,3223,O
also,3223,O
increased,3223,O
.,3223,O
Confocal,3224,O
analyses,3224,O
demonstrated,3224,O
that,3224,O
pericellular,3224,O
p75,3224,O
(,3224,O
NTR,3224,O
),3224,O
-IR,3224,O
was,3224,O
not,3224,O
colocalized,3224,O
with,3224,O
the,3224,O
glial,3224,O
marker,3224,O
",",3224,O
glial,3224,O
fibrillary,3224,O
acidic,3224,O
protein,3224,O
(,3224,O
GFAP,3224,O
),3224,O
.,3224,O
These,3225,O
studies,3225,O
demonstrate,3225,O
that,3225,O
p75,3225,O
(,3225,O
NTR,3225,O
),3225,O
expression,3225,O
in,3225,O
micturition,3225,O
reflexes,3225,O
is,3225,O
present,3225,O
constitutively,3225,O
and,3225,O
modified,3225,O
by,3225,O
bladder,3225,B-Disease
inflammation,3225,I-Disease
.,3225,O
The,3226,O
functional,3226,O
significance,3226,O
of,3226,O
p75,3226,O
(,3226,O
NTR,3226,O
),3226,O
expression,3226,O
in,3226,O
micturition,3226,O
reflexes,3226,O
remains,3226,O
to,3226,O
be,3226,O
determined,3226,O
.,3226,O
Azathioprine-induced,3227,B-Chemical
suicidal,3227,O
erythrocyte,3227,O
death,3227,O
.,3227,O
BACKGROUND,3228,O
:,3228,O
Azathioprine,3228,B-Chemical
is,3228,O
widely,3228,O
used,3228,O
as,3228,O
an,3228,O
immunosuppressive,3228,O
drug,3228,O
.,3228,O
The,3229,O
side,3229,O
effects,3229,O
of,3229,O
azathioprine,3229,B-Chemical
include,3229,O
anemia,3229,B-Disease
",",3229,O
which,3229,O
has,3229,O
been,3229,O
attributed,3229,O
to,3229,O
bone,3229,O
marrow,3229,O
suppression,3229,O
.,3229,O
Alternatively,3230,O
",",3230,O
anemia,3230,B-Disease
could,3230,O
result,3230,O
from,3230,O
accelerated,3230,O
suicidal,3230,O
erythrocyte,3230,O
death,3230,O
or,3230,O
eryptosis,3230,O
",",3230,O
which,3230,O
is,3230,O
characterized,3230,O
by,3230,O
exposure,3230,O
of,3230,O
phosphatidylserine,3230,B-Chemical
(,3230,O
PS,3230,B-Chemical
),3230,O
at,3230,O
the,3230,O
erythrocyte,3230,O
surface,3230,O
and,3230,O
by,3230,O
cell,3230,O
shrinkage,3230,O
.,3230,O
METHODS,3231,O
:,3231,O
The,3231,O
present,3231,O
experiments,3231,O
explored,3231,O
whether,3231,O
azathioprine,3231,B-Chemical
influences,3231,O
eryptosis,3231,O
.,3231,O
According,3232,O
to,3232,O
annexin,3232,O
V,3232,O
binding,3232,O
",",3232,O
erythrocytes,3232,O
from,3232,O
patients,3232,O
indeed,3232,O
showed,3232,O
a,3232,O
significant,3232,O
increase,3232,O
of,3232,O
PS,3232,B-Chemical
exposure,3232,O
within,3232,O
1,3232,O
week,3232,O
of,3232,O
treatment,3232,O
with,3232,O
azathioprine,3232,B-Chemical
.,3232,O
In,3233,O
a,3233,O
second,3233,O
series,3233,O
",",3233,O
cytosolic,3233,O
Ca2+,3233,B-Chemical
activity,3233,O
(,3233,O
Fluo3,3233,B-Chemical
fluorescence,3233,O
),3233,O
",",3233,O
cell,3233,O
volume,3233,O
(,3233,O
forward,3233,O
scatter,3233,O
),3233,O
",",3233,O
and,3233,O
PS-exposure,3233,B-Chemical
(,3233,O
annexin,3233,O
V,3233,O
binding,3233,O
),3233,O
were,3233,O
determined,3233,O
by,3233,O
FACS,3233,O
analysis,3233,O
in,3233,O
erythrocytes,3233,O
from,3233,O
healthy,3233,O
volunteers,3233,O
.,3233,O
RESULTS,3234,O
:,3234,O
Exposure,3234,O
to,3234,O
azathioprine,3234,B-Chemical
(,3234,O
>,3234,O
or,3234,O
=2,3234,O
microg/mL,3234,O
),3234,O
for,3234,O
48,3234,O
hours,3234,O
increased,3234,O
cytosolic,3234,O
Ca2+,3234,B-Chemical
activity,3234,O
and,3234,O
annexin,3234,O
V,3234,O
binding,3234,O
and,3234,O
decreased,3234,O
forward,3234,O
scatter,3234,O
.,3234,O
The,3235,O
effect,3235,O
of,3235,O
azathioprine,3235,B-Chemical
on,3235,O
both,3235,O
annexin,3235,O
V,3235,O
binding,3235,O
and,3235,O
forward,3235,O
scatter,3235,O
was,3235,O
significantly,3235,O
blunted,3235,O
in,3235,O
the,3235,O
nominal,3235,O
absence,3235,O
of,3235,O
extracellular,3235,O
Ca2+,3235,B-Chemical
.,3235,O
CONCLUSIONS,3236,O
:,3236,O
Azathioprine,3236,B-Chemical
triggers,3236,O
suicidal,3236,O
erythrocyte,3236,O
death,3236,O
",",3236,O
an,3236,O
effect,3236,O
presumably,3236,O
contributing,3236,O
to,3236,O
azathioprine-induced,3236,B-Chemical
anemia,3236,B-Disease
.,3236,O
Levetiracetam,3237,B-Chemical
as,3237,O
an,3237,O
adjunct,3237,O
to,3237,O
phenobarbital,3237,B-Chemical
treatment,3237,O
in,3237,O
cats,3237,O
with,3237,O
suspected,3237,O
idiopathic,3237,B-Disease
epilepsy,3237,I-Disease
.,3237,O
OBJECTIVE,3238,O
:,3238,O
To,3238,O
assess,3238,O
pharmacokinetics,3238,O
",",3238,O
efficacy,3238,O
",",3238,O
and,3238,O
tolerability,3238,O
of,3238,O
oral,3238,O
levetiracetam,3238,B-Chemical
administered,3238,O
as,3238,O
an,3238,O
adjunct,3238,O
to,3238,O
phenobarbital,3238,B-Chemical
treatment,3238,O
in,3238,O
cats,3238,O
with,3238,O
poorly,3238,O
controlled,3238,O
suspected,3238,O
idiopathic,3238,B-Disease
epilepsy,3238,I-Disease
.,3238,O
DESIGN-Open-label,3239,O
",",3239,O
noncomparative,3239,O
clinical,3239,O
trial,3239,O
.,3239,O
ANIMALS,3240,O
:,3240,O
12,3240,O
cats,3240,O
suspected,3240,O
to,3240,O
have,3240,O
idiopathic,3240,B-Disease
epilepsy,3240,I-Disease
that,3240,O
was,3240,O
poorly,3240,O
controlled,3240,O
with,3240,O
phenobarbital,3240,B-Chemical
or,3240,O
that,3240,O
had,3240,O
unacceptable,3240,O
adverse,3240,O
effects,3240,O
when,3240,O
treated,3240,O
with,3240,O
phenobarbital,3240,B-Chemical
.,3240,O
PROCEDURES,3241,O
:,3241,O
Cats,3241,O
were,3241,O
treated,3241,O
with,3241,O
levetiracetam,3241,B-Chemical
(,3241,O
20,3241,O
mg/kg,3241,O
[,3241,O
9.1,3241,O
mg/lb,3241,O
],3241,O
",",3241,O
PO,3241,O
",",3241,O
q,3241,O
8,3241,O
h,3241,O
),3241,O
.,3241,O
After,3242,O
a,3242,O
minimum,3242,O
of,3242,O
1,3242,O
week,3242,O
of,3242,O
treatment,3242,O
",",3242,O
serum,3242,O
levetiracetam,3242,B-Chemical
concentrations,3242,O
were,3242,O
measured,3242,O
before,3242,O
and,3242,O
2,3242,O
",",3242,O
4,3242,O
",",3242,O
and,3242,O
6,3242,O
hours,3242,O
after,3242,O
drug,3242,O
administration,3242,O
",",3242,O
and,3242,O
maximum,3242,O
and,3242,O
minimum,3242,O
serum,3242,O
concentrations,3242,O
and,3242,O
elimination,3242,O
half-life,3242,O
were,3242,O
calculated,3242,O
.,3242,O
Seizure,3243,B-Disease
frequencies,3243,O
before,3243,O
and,3243,O
after,3243,O
initiation,3243,O
of,3243,O
levetiracetam,3243,B-Chemical
treatment,3243,O
were,3243,O
compared,3243,O
",",3243,O
and,3243,O
adverse,3243,O
effects,3243,O
were,3243,O
recorded,3243,O
.,3243,O
RESULTS,3244,O
:,3244,O
Median,3244,O
maximum,3244,O
serum,3244,O
levetiracetam,3244,B-Chemical
concentration,3244,O
was,3244,O
25.5,3244,O
microg/mL,3244,O
",",3244,O
median,3244,O
minimum,3244,O
serum,3244,O
levetiracetam,3244,B-Chemical
concentration,3244,O
was,3244,O
8.3,3244,O
microg/mL,3244,O
",",3244,O
and,3244,O
median,3244,O
elimination,3244,O
half-life,3244,O
was,3244,O
2.9,3244,O
hours,3244,O
.,3244,O
Median,3245,O
seizure,3245,B-Disease
frequency,3245,O
prior,3245,O
to,3245,O
treatment,3245,O
with,3245,O
levetiracetam,3245,B-Chemical
(,3245,O
2.1,3245,O
seizures/mo,3245,B-Disease
),3245,O
was,3245,O
significantly,3245,O
higher,3245,O
than,3245,O
median,3245,O
seizure,3245,B-Disease
frequency,3245,O
after,3245,O
initiation,3245,O
of,3245,O
levetiracetam,3245,B-Chemical
treatment,3245,O
(,3245,O
0.42,3245,O
seizures/mo,3245,B-Disease
),3245,O
",",3245,O
and,3245,O
7,3245,O
of,3245,O
10,3245,O
cats,3245,O
were,3245,O
classified,3245,O
as,3245,O
having,3245,O
responded,3245,O
to,3245,O
levetiracetam,3245,B-Chemical
treatment,3245,O
(,3245,O
ie,3245,O
",",3245,O
reduction,3245,O
in,3245,O
seizure,3245,B-Disease
frequency,3245,O
of,3245,O
>,3245,O
or=50,3245,O
%,3245,O
),3245,O
.,3245,O
Two,3246,O
cats,3246,O
had,3246,O
transient,3246,O
lethargy,3246,B-Disease
and,3246,O
inappetence,3246,B-Disease
.,3246,O
CONCLUSIONS,3247,O
AND,3247,O
CLINICAL,3247,O
RELEVANCE,3247,O
:,3247,O
Results,3247,O
suggested,3247,O
that,3247,O
levetiracetam,3247,B-Chemical
is,3247,O
well,3247,O
tolerated,3247,O
in,3247,O
cats,3247,O
and,3247,O
may,3247,O
be,3247,O
useful,3247,O
as,3247,O
an,3247,O
adjunct,3247,O
to,3247,O
phenobarbital,3247,B-Chemical
treatment,3247,O
in,3247,O
cats,3247,O
with,3247,O
idiopathic,3247,B-Disease
epilepsy,3247,I-Disease
.,3247,O
Clinical,3248,O
comparison,3248,O
of,3248,O
cardiorespiratory,3248,O
effects,3248,O
during,3248,O
unilateral,3248,O
and,3248,O
conventional,3248,O
spinal,3248,O
anaesthesia,3248,O
.,3248,O
BACKGROUND,3249,O
:,3249,O
Spinal,3249,O
anaesthesia,3249,O
is,3249,O
widely,3249,O
employed,3249,O
in,3249,O
clinical,3249,O
practice,3249,O
but,3249,O
has,3249,O
the,3249,O
main,3249,O
drawback,3249,O
of,3249,O
post-spinal,3249,O
block,3249,O
hypotension,3249,B-Disease
.,3249,O
Efforts,3250,O
must,3250,O
therefore,3250,O
continue,3250,O
to,3250,O
be,3250,O
made,3250,O
to,3250,O
obviate,3250,O
this,3250,O
setback,3250,O
OBJECTIVE,3250,O
:,3250,O
To,3250,O
evaluate,3250,O
the,3250,O
cardiovascular,3250,O
and,3250,O
respiratory,3250,O
changes,3250,O
during,3250,O
unilateral,3250,O
and,3250,O
conventional,3250,O
spinal,3250,O
anaesthesia,3250,O
.,3250,O
METHODS,3251,O
:,3251,O
With,3251,O
ethical,3251,O
approval,3251,O
",",3251,O
we,3251,O
studied,3251,O
74,3251,O
American,3251,O
Society,3251,O
of,3251,O
Anesthesiologists,3251,O
(,3251,O
ASA,3251,O
),3251,O
",",3251,O
physical,3251,O
status,3251,O
class,3251,O
1,3251,O
and,3251,O
2,3251,O
patients,3251,O
scheduled,3251,O
for,3251,O
elective,3251,O
unilateral,3251,O
lower,3251,O
limb,3251,O
surgery,3251,O
.,3251,O
Patients,3252,O
were,3252,O
randomly,3252,O
allocated,3252,O
into,3252,O
one,3252,O
of,3252,O
two,3252,O
groups,3252,O
:,3252,O
lateral,3252,O
and,3252,O
conventional,3252,O
spinal,3252,O
anaesthesia,3252,O
groups,3252,O
.,3252,O
In,3253,O
the,3253,O
lateral,3253,O
position,3253,O
with,3253,O
operative,3253,O
side,3253,O
down,3253,O
",",3253,O
patients,3253,O
recived,3253,O
10,3253,O
mg,3253,O
(,3253,O
2mls,3253,O
),3253,O
of,3253,O
0.5,3253,O
%,3253,O
hyperbaric,3253,O
bupivacaine,3253,B-Chemical
through,3253,O
a,3253,O
25-gauge,3253,O
spinal,3253,O
needle,3253,O
.,3253,O
Patients,3254,O
in,3254,O
the,3254,O
unilateral,3254,O
group,3254,O
were,3254,O
maintained,3254,O
in,3254,O
the,3254,O
lateral,3254,O
position,3254,O
for,3254,O
15,3254,O
minutes,3254,O
following,3254,O
spinal,3254,O
injection,3254,O
while,3254,O
those,3254,O
in,3254,O
the,3254,O
conventional,3254,O
group,3254,O
were,3254,O
turned,3254,O
supine,3254,O
immediately,3254,O
after,3254,O
injection,3254,O
.,3254,O
Blood,3255,O
pressure,3255,O
",",3255,O
heart,3255,O
rate,3255,O
",",3255,O
respiratory,3255,O
rate,3255,O
and,3255,O
oxygen,3255,B-Chemical
saturation,3255,O
were,3255,O
monitored,3255,O
over,3255,O
1,3255,O
hour,3255,O
.,3255,O
RESULTS,3256,O
:,3256,O
Three,3256,O
patients,3256,O
(,3256,O
8.1,3256,O
%,3256,O
),3256,O
in,3256,O
the,3256,O
unilateral,3256,O
group,3256,O
and,3256,O
5,3256,O
(,3256,O
13.5,3256,O
%,3256,O
),3256,O
in,3256,O
the,3256,O
conventional,3256,O
group,3256,O
developed,3256,O
hypotension,3256,B-Disease
",",3256,O
P=,3256,O
0.71,3256,O
.,3256,O
Four,3257,O
(,3257,O
10.8,3257,O
%,3257,O
),3257,O
patients,3257,O
in,3257,O
the,3257,O
conventional,3257,O
group,3257,O
and,3257,O
1,3257,O
(,3257,O
2.7,3257,O
%,3257,O
),3257,O
in,3257,O
the,3257,O
unilateral,3257,O
group,3257,O
",",3257,O
P=,3257,O
0.17,3257,O
required,3257,O
epinephrine,3257,B-Chemical
infusion,3257,O
to,3257,O
treat,3257,O
hypotension,3257,B-Disease
.,3257,O
Patients,3258,O
in,3258,O
the,3258,O
conventional,3258,O
group,3258,O
had,3258,O
statistically,3258,O
significant,3258,O
greater,3258,O
fall,3258,O
in,3258,O
the,3258,O
systolic,3258,O
blood,3258,O
pressures,3258,O
at,3258,O
15,3258,O
",",3258,O
30,3258,O
and,3258,O
45,3258,O
minutes,3258,O
when,3258,O
compared,3258,O
to,3258,O
the,3258,O
baseline,3258,O
(,3258,O
P=,3258,O
0.003,3258,O
",",3258,O
0.001,3258,O
and,3258,O
0.004,3258,O
),3258,O
.,3258,O
The,3259,O
mean,3259,O
respiratory,3259,O
rate,3259,O
and,3259,O
oxygen,3259,B-Chemical
saturations,3259,O
in,3259,O
the,3259,O
two,3259,O
groups,3259,O
were,3259,O
similar,3259,O
.,3259,O
CONCLUSION,3260,O
:,3260,O
Compared,3260,O
to,3260,O
conventional,3260,O
spinal,3260,O
anaesthesia,3260,O
",",3260,O
unilateral,3260,O
spinal,3260,O
anaesthesia,3260,O
was,3260,O
associated,3260,O
with,3260,O
fewer,3260,O
cardiovascular,3260,O
perturbations,3260,O
.,3260,O
Also,3261,O
",",3261,O
the,3261,O
type,3261,O
of,3261,O
spinal,3261,O
block,3261,O
instituted,3261,O
affected,3261,O
neither,3261,O
the,3261,O
respiratory,3261,O
rate,3261,O
nor,3261,O
the,3261,O
arterial,3261,O
oxygen,3261,B-Chemical
saturation,3261,O
.,3261,O
Spectrum,3262,O
of,3262,O
adverse,3262,O
events,3262,O
after,3262,O
generic,3262,O
HAART,3262,O
in,3262,O
southern,3262,O
Indian,3262,O
HIV-infected,3262,B-Disease
patients,3262,O
.,3262,O
To,3263,O
determine,3263,O
the,3263,O
incidence,3263,O
of,3263,O
clinically,3263,O
significant,3263,O
adverse,3263,O
events,3263,O
after,3263,O
long-term,3263,O
",",3263,O
fixed-dose,3263,O
",",3263,O
generic,3263,O
highly,3263,O
active,3263,O
antiretroviral,3263,O
therapy,3263,O
(,3263,O
HAART,3263,O
),3263,O
use,3263,O
among,3263,O
HIV-infected,3263,B-Disease
individuals,3263,O
in,3263,O
South,3263,O
India,3263,O
",",3263,O
we,3263,O
examined,3263,O
the,3263,O
experiences,3263,O
of,3263,O
3154,3263,O
HIV-infected,3263,B-Disease
individuals,3263,O
who,3263,O
received,3263,O
a,3263,O
minimum,3263,O
of,3263,O
3,3263,O
months,3263,O
of,3263,O
generic,3263,O
HAART,3263,O
between,3263,O
February,3263,O
1996,3263,O
and,3263,O
December,3263,O
2006,3263,O
at,3263,O
a,3263,O
tertiary,3263,O
HIV,3263,O
care,3263,O
referral,3263,O
center,3263,O
in,3263,O
South,3263,O
India,3263,O
.,3263,O
The,3264,O
most,3264,O
common,3264,O
regimens,3264,O
were,3264,O
3TC,3264,B-Chemical
+,3264,O
d4T,3264,B-Chemical
+,3264,O
nevirapine,3264,B-Chemical
(,3264,O
NVP,3264,B-Chemical
),3264,O
(,3264,O
54.8,3264,O
%,3264,O
),3264,O
",",3264,O
zidovudine,3264,B-Chemical
(,3264,O
AZT,3264,B-Chemical
),3264,O
+,3264,O
3TC,3264,B-Chemical
+,3264,O
NVP,3264,B-Chemical
(,3264,O
14.5,3264,O
%,3264,O
),3264,O
",",3264,O
3TC,3264,B-Chemical
+,3264,O
d4T,3264,B-Chemical
+,3264,O
efavirenz,3264,B-Chemical
(,3264,O
EFV,3264,B-Chemical
),3264,O
(,3264,O
20.1,3264,O
%,3264,O
),3264,O
",",3264,O
and,3264,O
AZT,3264,B-Chemical
+,3264,O
3TC,3264,B-Chemical
+,3264,O
EFV,3264,B-Chemical
(,3264,O
5.4,3264,O
%,3264,O
),3264,O
.,3264,O
The,3265,O
most,3265,O
common,3265,O
adverse,3265,O
events,3265,O
and,3265,O
median,3265,O
CD4,3265,O
at,3265,O
time,3265,O
of,3265,O
event,3265,O
were,3265,O
rash,3265,B-Disease
(,3265,O
15.2,3265,O
%,3265,O
;,3265,O
CD4,3265,O
",",3265,O
285,3265,O
cells/microL,3265,O
),3265,O
and,3265,O
peripheral,3265,B-Disease
neuropathy,3265,I-Disease
(,3265,O
9.0,3265,O
%,3265,O
and,3265,O
348,3265,O
cells/microL,3265,O
),3265,O
.,3265,O
Clinically,3266,O
significant,3266,O
anemia,3266,B-Disease
(,3266,O
hemoglobin,3266,O
<,3266,O
7,3266,O
g/dL,3266,O
),3266,O
was,3266,O
observed,3266,O
in,3266,O
5.4,3266,O
%,3266,O
of,3266,O
patients,3266,O
(,3266,O
CD4,3266,O
",",3266,O
165,3266,O
cells/microL,3266,O
),3266,O
and,3266,O
hepatitis,3266,B-Disease
(,3266,O
clinical,3266,O
jaundice,3266,B-Disease
with,3266,O
alanine,3266,B-Chemical
aminotransferase,3266,O
>,3266,O
5,3266,O
times,3266,O
upper,3266,O
limits,3266,O
of,3266,O
normal,3266,O
),3266,O
in,3266,O
3.5,3266,O
%,3266,O
of,3266,O
patients,3266,O
(,3266,O
CD4,3266,O
",",3266,O
260,3266,O
cells/microL,3266,O
),3266,O
.,3266,O
Women,3267,O
were,3267,O
significantly,3267,O
more,3267,O
likely,3267,O
to,3267,O
experience,3267,O
lactic,3267,B-Disease
acidosis,3267,I-Disease
",",3267,O
while,3267,O
men,3267,O
were,3267,O
significantly,3267,O
more,3267,O
likely,3267,O
to,3267,O
experience,3267,O
immune,3267,B-Disease
reconstitution,3267,I-Disease
syndrome,3267,I-Disease
(,3267,O
p,3267,O
<,3267,O
0.05,3267,O
),3267,O
.,3267,O
Among,3268,O
the,3268,O
patients,3268,O
with,3268,O
1,3268,O
year,3268,O
of,3268,O
follow-up,3268,O
",",3268,O
NVP,3268,B-Chemical
therapy,3268,O
was,3268,O
significantly,3268,O
associated,3268,O
with,3268,O
developing,3268,O
rash,3268,B-Disease
and,3268,O
d4T,3268,B-Chemical
therapy,3268,O
with,3268,O
developing,3268,O
peripheral,3268,B-Disease
neuropathy,3268,I-Disease
(,3268,O
p,3268,O
<,3268,O
0.05,3268,O
),3268,O
.,3268,O
Anemia,3269,B-Disease
and,3269,O
hepatitis,3269,B-Disease
often,3269,O
occur,3269,O
within,3269,O
12,3269,O
weeks,3269,O
of,3269,O
initiating,3269,O
generic,3269,O
HAART,3269,O
.,3269,O
Frequent,3270,O
and,3270,O
early,3270,O
monitoring,3270,O
for,3270,O
these,3270,O
toxicities,3270,B-Disease
is,3270,O
warranted,3270,O
in,3270,O
developing,3270,O
countries,3270,O
where,3270,O
generic,3270,O
HAART,3270,O
is,3270,O
increasingly,3270,O
available,3270,O
.,3270,O
Thalidomide,3271,B-Chemical
and,3271,O
sensory,3271,B-Disease
neurotoxicity,3271,I-Disease
:,3271,O
a,3271,O
neurophysiological,3271,O
study,3271,O
.,3271,O
BACKGROUND,3272,O
:,3272,O
Recent,3272,O
studies,3272,O
confirmed,3272,O
a,3272,O
high,3272,O
incidence,3272,O
of,3272,O
sensory,3272,B-Disease
axonal,3272,I-Disease
neuropathy,3272,I-Disease
in,3272,O
patients,3272,O
treated,3272,O
with,3272,O
different,3272,O
doses,3272,O
of,3272,O
thalidomide,3272,B-Chemical
.,3272,O
The,3273,O
study,3273,O
's,3273,O
aims,3273,O
were,3273,O
to,3273,O
measure,3273,O
variations,3273,O
in,3273,O
sural,3273,O
nerve,3273,O
sensory,3273,O
action,3273,O
potential,3273,O
(,3273,O
SAP,3273,O
),3273,O
amplitude,3273,O
in,3273,O
patients,3273,O
with,3273,O
refractory,3273,O
cutaneous,3273,B-Disease
lupus,3273,I-Disease
erythematosus,3273,I-Disease
(,3273,O
CLE,3273,B-Disease
),3273,O
treated,3273,O
with,3273,O
thalidomide,3273,B-Chemical
and,3273,O
use,3273,O
these,3273,O
findings,3273,O
to,3273,O
identify,3273,O
the,3273,O
neurotoxic,3273,B-Disease
potential,3273,O
of,3273,O
thalidomide,3273,B-Chemical
and,3273,O
the,3273,O
recovery,3273,O
capacity,3273,O
of,3273,O
sensory,3273,O
fibres,3273,O
after,3273,O
discontinuation,3273,O
of,3273,O
treatment,3273,O
.,3273,O
PATIENTS,3274,O
AND,3274,O
METHODS,3274,O
:,3274,O
Clinical,3274,O
and,3274,O
electrophysiological,3274,O
data,3274,O
in,3274,O
12,3274,O
female,3274,O
patients,3274,O
with,3274,O
CLE,3274,B-Disease
during,3274,O
treatment,3274,O
with,3274,O
thalidomide,3274,B-Chemical
and,3274,O
up,3274,O
to,3274,O
47,3274,O
months,3274,O
after,3274,O
discontinuation,3274,O
of,3274,O
treatment,3274,O
were,3274,O
analysed,3274,O
.,3274,O
Sural,3275,O
nerve,3275,O
SAP,3275,O
amplitude,3275,O
reduction,3275,O
>,3275,O
or,3275,O
=40,3275,O
%,3275,O
was,3275,O
the,3275,O
criteria,3275,O
for,3275,O
discontinuing,3275,O
therapy,3275,O
.,3275,O
RESULTS,3276,O
:,3276,O
During,3276,O
treatment,3276,O
",",3276,O
11,3276,O
patients,3276,O
showed,3276,O
a,3276,O
reduction,3276,O
in,3276,O
sural,3276,O
nerve,3276,O
SAP,3276,O
amplitude,3276,O
compared,3276,O
to,3276,O
baseline,3276,O
values,3276,O
(,3276,O
9,3276,O
with,3276,O
a,3276,O
reduction,3276,O
>,3276,O
or,3276,O
=50,3276,O
%,3276,O
and,3276,O
2,3276,O
<,3276,O
50,3276,O
%,3276,O
),3276,O
.,3276,O
One,3277,O
patient,3277,O
showed,3277,O
no,3277,O
changes,3277,O
in,3277,O
SAP,3277,O
amplitude,3277,O
.,3277,O
Five,3278,O
patients,3278,O
complained,3278,O
of,3278,O
paresthesias,3278,B-Disease
and,3278,O
leg,3278,O
cramps,3278,B-Disease
.,3278,O
After,3279,O
thalidomide,3279,B-Chemical
treatment,3279,O
",",3279,O
sural,3279,O
SAP,3279,O
amplitude,3279,O
recovered,3279,O
in,3279,O
3,3279,O
patients,3279,O
.,3279,O
At,3280,O
detection,3280,O
of,3280,O
reduction,3280,O
in,3280,O
sural,3280,O
nerve,3280,O
SAP,3280,O
amplitude,3280,O
",",3280,O
the,3280,O
median,3280,O
thalidomide,3280,B-Chemical
cumulative,3280,O
dose,3280,O
was,3280,O
21.4,3280,O
g.,3280,O
The,3280,O
threshold,3280,O
neurotoxic,3280,B-Disease
dosage,3280,O
is,3280,O
lower,3280,O
than,3280,O
previously,3280,O
reported,3280,O
.,3280,O
CONCLUSIONS,3281,O
:,3281,O
Sural,3281,O
nerve,3281,O
SAP,3281,O
amplitude,3281,O
reduction,3281,O
is,3281,O
a,3281,O
reliable,3281,O
and,3281,O
sensitive,3281,O
marker,3281,O
of,3281,O
degeneration,3281,O
and,3281,O
recovery,3281,O
of,3281,O
sensory,3281,O
fibres,3281,O
.,3281,O
This,3282,O
electrophysiological,3282,O
parameter,3282,O
provides,3282,O
information,3282,O
about,3282,O
subclinical,3282,O
neurotoxic,3282,B-Disease
potential,3282,O
of,3282,O
thalidomide,3282,B-Chemical
but,3282,O
is,3282,O
not,3282,O
helpful,3282,O
in,3282,O
predicting,3282,O
the,3282,O
appearance,3282,O
of,3282,O
sensory,3282,O
symptoms,3282,O
.,3282,O
Amiodarone-related,3283,B-Chemical
pulmonary,3283,B-Disease
mass,3283,I-Disease
and,3283,O
unique,3283,O
membranous,3283,B-Disease
glomerulonephritis,3283,I-Disease
in,3283,O
a,3283,O
patient,3283,O
with,3283,O
valvular,3283,B-Disease
heart,3283,I-Disease
disease,3283,I-Disease
:,3283,O
Diagnostic,3283,O
pitfall,3283,O
and,3283,O
new,3283,O
findings,3283,O
.,3283,O
Amiodarone,3284,B-Chemical
is,3284,O
an,3284,O
anti-arrhythmic,3284,O
drug,3284,O
for,3284,O
life-threatening,3284,O
tachycardia,3284,B-Disease
",",3284,O
but,3284,O
various,3284,O
adverse,3284,O
effects,3284,O
have,3284,O
been,3284,O
reported,3284,O
.,3284,O
Reported,3285,O
herein,3285,O
is,3285,O
an,3285,O
autopsy,3285,O
case,3285,O
of,3285,O
valvular,3285,B-Disease
heart,3285,I-Disease
disease,3285,I-Disease
",",3285,O
in,3285,O
a,3285,O
patient,3285,O
who,3285,O
developed,3285,O
a,3285,O
lung,3285,B-Disease
mass,3285,I-Disease
(,3285,O
1.5,3285,O
cm,3285,O
in,3285,O
diameter,3285,O
),3285,O
and,3285,O
proteinuria,3285,B-Disease
(,3285,O
2.76,3285,O
g/day,3285,O
),3285,O
after,3285,O
treatment,3285,O
with,3285,O
amiodarone,3285,B-Chemical
for,3285,O
a,3285,O
long,3285,O
time,3285,O
.,3285,O
The,3286,O
lung,3286,B-Disease
mass,3286,I-Disease
was,3286,O
highly,3286,O
suspected,3286,O
to,3286,O
be,3286,O
lung,3286,B-Disease
cancer,3286,I-Disease
on,3286,O
CT,3286,O
and,3286,O
positron,3286,O
emission,3286,O
tomography,3286,O
",",3286,O
but,3286,O
histologically,3286,O
the,3286,O
lesion,3286,O
was,3286,O
composed,3286,O
of,3286,O
lymphoplasmacytic,3286,O
infiltrates,3286,O
in,3286,O
alveolar,3286,O
walls,3286,O
and,3286,O
intra-alveolar,3286,O
accumulation,3286,O
of,3286,O
foamy,3286,O
macrophages,3286,O
containing,3286,O
characteristic,3286,O
myelinoid,3286,O
bodies,3286,O
",",3286,O
indicating,3286,O
that,3286,O
it,3286,O
was,3286,O
an,3286,O
amiodarone-related,3286,B-Chemical
lesion,3286,O
.,3286,O
In,3287,O
addition,3287,O
",",3287,O
the,3287,O
lung,3287,O
tissue,3287,O
had,3287,O
unevenly,3287,O
distributed,3287,O
hemosiderin,3287,B-Disease
deposition,3287,O
",",3287,O
and,3287,O
abnormally,3287,O
tortuous,3287,O
capillaries,3287,O
were,3287,O
seen,3287,O
in,3287,O
the,3287,O
mass,3287,O
and,3287,O
in,3287,O
heavily,3287,O
hemosiderotic,3287,B-Disease
lung,3287,O
portions,3287,O
outside,3287,O
the,3287,O
mass,3287,O
.,3287,O
In,3288,O
the,3288,O
kidneys,3288,O
",",3288,O
glomeruli,3288,O
had,3288,O
membrane,3288,O
spikes,3288,O
",",3288,O
prominent,3288,O
swelling,3288,O
of,3288,O
podocytes,3288,O
and,3288,O
subepithelial,3288,O
deposits,3288,O
",",3288,O
which,3288,O
were,3288,O
sometimes,3288,O
large,3288,O
and,3288,O
hump-like,3288,O
.,3288,O
Autoimmune,3289,B-Disease
diseases,3289,I-Disease
",",3289,O
viral,3289,B-Disease
hepatitis,3289,I-Disease
",",3289,O
malignant,3289,O
neoplasms,3289,B-Disease
or,3289,O
other,3289,O
diseases,3289,O
with,3289,O
a,3289,O
known,3289,O
relationship,3289,O
to,3289,O
membranous,3289,B-Disease
glomerulonephritis,3289,I-Disease
were,3289,O
not,3289,O
found,3289,O
.,3289,O
The,3290,O
present,3290,O
case,3290,O
highlights,3290,O
the,3290,O
possibility,3290,O
that,3290,O
differential,3290,O
diagnosis,3290,O
between,3290,O
an,3290,O
amiodarone-related,3290,B-Chemical
pulmonary,3290,B-Disease
lesion,3290,I-Disease
and,3290,O
a,3290,O
neoplasm,3290,B-Disease
can,3290,O
be,3290,O
very,3290,O
difficult,3290,O
radiologically,3290,O
",",3290,O
and,3290,O
suggests,3290,O
that,3290,O
membranous,3290,B-Disease
glomerulonephritis,3290,I-Disease
might,3290,O
be,3290,O
another,3290,O
possible,3290,O
complication,3290,O
of,3290,O
amiodarone,3290,B-Chemical
treatment,3290,O
.,3290,O
Risk,3291,O
of,3291,O
coronary,3291,B-Disease
artery,3291,I-Disease
disease,3291,I-Disease
associated,3291,O
with,3291,O
initial,3291,O
sulphonylurea,3291,B-Chemical
treatment,3291,O
of,3291,O
patients,3291,O
with,3291,O
type,3291,B-Disease
2,3291,I-Disease
diabetes,3291,I-Disease
:,3291,O
a,3291,O
matched,3291,O
case-control,3291,O
study,3291,O
.,3291,O
AIMS,3292,O
:,3292,O
This,3292,O
study,3292,O
sought,3292,O
to,3292,O
assess,3292,O
the,3292,O
risk,3292,O
of,3292,O
developing,3292,O
coronary,3292,B-Disease
artery,3292,I-Disease
disease,3292,I-Disease
(,3292,O
CAD,3292,B-Disease
),3292,O
associated,3292,O
with,3292,O
initial,3292,O
treatment,3292,O
of,3292,O
type,3292,B-Disease
2,3292,I-Disease
diabetes,3292,I-Disease
with,3292,O
different,3292,O
sulphonylureas,3292,B-Chemical
.,3292,O
METHODS,3293,O
:,3293,O
In,3293,O
type,3293,B-Disease
2,3293,I-Disease
diabetic,3293,I-Disease
patients,3293,O
",",3293,O
cases,3293,O
who,3293,O
developed,3293,O
CAD,3293,B-Disease
were,3293,O
compared,3293,O
retrospectively,3293,O
with,3293,O
controls,3293,O
that,3293,O
did,3293,O
not,3293,O
.,3293,O
The,3294,O
20-year,3294,O
risk,3294,O
of,3294,O
CAD,3294,B-Disease
at,3294,O
diagnosis,3294,O
of,3294,O
diabetes,3294,B-Disease
",",3294,O
using,3294,O
the,3294,O
UKPDS,3294,O
risk,3294,O
engine,3294,O
",",3294,O
was,3294,O
used,3294,O
to,3294,O
match,3294,O
cases,3294,O
with,3294,O
controls,3294,O
.,3294,O
RESULTS,3295,O
:,3295,O
The,3295,O
76,3295,O
cases,3295,O
of,3295,O
CAD,3295,B-Disease
were,3295,O
compared,3295,O
with,3295,O
152,3295,O
controls,3295,O
.,3295,O
The,3296,O
hazard,3296,O
of,3296,O
developing,3296,O
CAD,3296,B-Disease
(,3296,O
95,3296,O
%,3296,O
CI,3296,O
),3296,O
associated,3296,O
with,3296,O
initial,3296,O
treatment,3296,O
increased,3296,O
by,3296,O
2.4-fold,3296,O
(,3296,O
1.3-4.3,3296,O
",",3296,O
P=0.004,3296,O
),3296,O
with,3296,O
glibenclamide,3296,B-Chemical
;,3296,O
2-fold,3296,O
(,3296,O
0.9-4.6,3296,O
",",3296,O
P=0.099,3296,O
),3296,O
with,3296,O
glipizide,3296,B-Chemical
;,3296,O
2.9-fold,3296,O
(,3296,O
1.6-5.1,3296,O
",",3296,O
P=0.000,3296,O
),3296,O
with,3296,O
either,3296,O
",",3296,O
and,3296,O
was,3296,O
unchanged,3296,O
with,3296,O
metformin,3296,B-Chemical
.,3296,O
The,3297,O
hazard,3297,O
decreased,3297,O
0.3-fold,3297,O
(,3297,O
0.7-1.7,3297,O
",",3297,O
P=0.385,3297,O
),3297,O
with,3297,O
glimepiride,3297,B-Chemical
",",3297,O
0.4-fold,3297,O
(,3297,O
0.7-1.3,3297,O
",",3297,O
P=0.192,3297,O
),3297,O
with,3297,O
gliclazide,3297,B-Chemical
",",3297,O
and,3297,O
0.4-fold,3297,O
(,3297,O
0.7-1.1,3297,O
",",3297,O
P=0.09,3297,O
),3297,O
with,3297,O
either,3297,O
.,3297,O
CONCLUSIONS,3298,O
:,3298,O
Initiating,3298,O
treatment,3298,O
of,3298,O
type,3298,B-Disease
2,3298,I-Disease
diabetes,3298,I-Disease
with,3298,O
glibenclamide,3298,B-Chemical
or,3298,O
glipizide,3298,B-Chemical
is,3298,O
associated,3298,O
with,3298,O
increased,3298,O
risk,3298,O
of,3298,O
CAD,3298,B-Disease
in,3298,O
comparison,3298,O
to,3298,O
gliclazide,3298,B-Chemical
or,3298,O
glimepiride,3298,B-Chemical
.,3298,O
If,3299,O
confirmed,3299,O
",",3299,O
this,3299,O
may,3299,O
be,3299,O
important,3299,O
because,3299,O
most,3299,O
Indian,3299,O
patients,3299,O
receive,3299,O
the,3299,O
cheaper,3299,O
older,3299,O
sulphonylureas,3299,B-Chemical
",",3299,O
and,3299,O
present,3299,O
guidelines,3299,O
do,3299,O
not,3299,O
distinguish,3299,O
between,3299,O
individual,3299,O
agents,3299,O
.,3299,O
Reduced,3300,O
progression,3300,O
of,3300,O
adriamycin,3300,B-Chemical
nephropathy,3300,B-Disease
in,3300,O
spontaneously,3300,O
hypertensive,3300,B-Disease
rats,3300,O
treated,3300,O
by,3300,O
losartan,3300,B-Chemical
.,3300,O
BACKGROUND,3301,O
:,3301,O
The,3301,O
aim,3301,O
of,3301,O
the,3301,O
study,3301,O
was,3301,O
to,3301,O
investigate,3301,O
the,3301,O
antihypertensive,3301,O
effects,3301,O
of,3301,O
angiotensin,3301,B-Chemical
II,3301,I-Chemical
type-1,3301,O
receptor,3301,O
blocker,3301,O
",",3301,O
losartan,3301,B-Chemical
",",3301,O
and,3301,O
its,3301,O
potential,3301,O
in,3301,O
slowing,3301,O
down,3301,O
renal,3301,B-Disease
disease,3301,I-Disease
progression,3301,O
in,3301,O
spontaneously,3301,O
hypertensive,3301,B-Disease
rats,3301,O
(,3301,O
SHR,3301,O
),3301,O
with,3301,O
adriamycin,3301,B-Chemical
(,3301,O
ADR,3301,B-Chemical
),3301,O
nephropathy,3301,B-Disease
.,3301,O
METHODS,3302,O
:,3302,O
Six-month-old,3302,O
female,3302,O
SHR,3302,O
were,3302,O
randomly,3302,O
selected,3302,O
in,3302,O
six,3302,O
groups,3302,O
.,3302,O
Two,3303,O
control,3303,O
groups,3303,O
(,3303,O
SH,3303,O
(,3303,O
6,3303,O
),3303,O
",",3303,O
SH,3303,O
(,3303,O
12,3303,O
),3303,O
),3303,O
received,3303,O
vehicle,3303,O
.,3303,O
Groups,3304,O
ADR,3304,B-Chemical
(,3304,O
6,3304,O
),3304,O
",",3304,O
ADR+LOS,3304,B-Chemical
(,3304,O
6,3304,O
),3304,O
and,3304,O
ADR,3304,B-Chemical
(,3304,O
12,3304,O
),3304,O
",",3304,O
and,3304,O
ADR+LOS,3304,B-Chemical
(,3304,O
12,3304,O
),3304,O
received,3304,O
ADR,3304,B-Chemical
(,3304,O
2,3304,O
mg/kg/b.w,3304,O
.,3304,O
i.v,3305,O
.,3305,O
),3305,O
twice,3306,O
in,3306,O
a,3306,O
3-week,3306,O
interval,3306,O
.,3306,O
Group,3307,O
ADR+LOS,3307,B-Chemical
(,3307,O
6,3307,O
),3307,O
received,3307,O
losartan,3307,B-Chemical
(,3307,O
10,3307,O
mg/kg/b.w./day,3307,O
by,3307,O
gavages,3307,O
),3307,O
for,3307,O
6,3307,O
weeks,3307,O
and,3307,O
group,3307,O
ADR+LOS,3307,B-Chemical
(,3307,O
12,3307,O
),3307,O
for,3307,O
12,3307,O
weeks,3307,O
after,3307,O
second,3307,O
injection,3307,O
of,3307,O
ADR,3307,B-Chemical
.,3307,O
Animals,3308,O
were,3308,O
killed,3308,O
after,3308,O
6,3308,O
or,3308,O
12,3308,O
weeks,3308,O
",",3308,O
respectively,3308,O
.,3308,O
Haemodynamic,3309,O
measurements,3309,O
were,3309,O
performed,3309,O
on,3309,O
anaesthetized,3309,O
animals,3309,O
",",3309,O
blood,3309,O
and,3309,O
urine,3309,O
samples,3309,O
were,3309,O
taken,3309,O
for,3309,O
biochemical,3309,O
analysis,3309,O
and,3309,O
the,3309,O
left,3309,O
kidney,3309,O
was,3309,O
processed,3309,O
for,3309,O
morphological,3309,O
studies,3309,O
.,3309,O
RESULTS,3310,O
:,3310,O
Short-term,3310,O
losartan,3310,B-Chemical
treatment,3310,O
",",3310,O
besides,3310,O
antihypertensive,3310,O
effect,3310,O
",",3310,O
improved,3310,O
glomerular,3310,O
filtration,3310,O
rate,3310,O
and,3310,O
ameliorated,3310,O
glomerulosclerosis,3310,B-Disease
resulting,3310,O
in,3310,O
decreased,3310,O
proteinuria,3310,B-Disease
.,3310,O
Prolonged,3311,O
treatment,3311,O
with,3311,O
losartan,3311,B-Chemical
showed,3311,O
further,3311,O
reduction,3311,O
of,3311,O
glomerulosclerosis,3311,B-Disease
associated,3311,O
with,3311,O
reduced,3311,O
progression,3311,O
of,3311,O
tubular,3311,O
atrophy,3311,B-Disease
and,3311,O
interstitial,3311,B-Disease
fibrosis,3311,I-Disease
",",3311,O
thus,3311,O
preventing,3311,O
heavy,3311,O
proteinuria,3311,B-Disease
and,3311,O
chronic,3311,B-Disease
renal,3311,I-Disease
failure,3311,I-Disease
.,3311,O
Losartan,3312,B-Chemical
reduced,3312,O
uraemia,3312,B-Disease
and,3312,O
increased,3312,O
urea,3312,B-Chemical
clearance,3312,O
in,3312,O
advanced,3312,O
ADR,3312,B-Chemical
nephropathy,3312,B-Disease
in,3312,O
SHR,3312,O
.,3312,O
Histological,3313,O
examination,3313,O
showed,3313,O
that,3313,O
losartan,3313,B-Chemical
could,3313,O
prevent,3313,O
tubular,3313,O
atrophy,3313,B-Disease
",",3313,O
interstitial,3313,O
infiltration,3313,O
and,3313,O
fibrosis,3313,B-Disease
in,3313,O
ADR,3313,B-Chemical
nephropathy,3313,B-Disease
.,3313,O
CONCLUSION,3314,O
:,3314,O
Losartan,3314,B-Chemical
reduces,3314,O
the,3314,O
rate,3314,O
of,3314,O
progression,3314,O
of,3314,O
ADR-induced,3314,B-Chemical
focal,3314,B-Disease
segmental,3314,I-Disease
glomerulosclerosis,3314,I-Disease
to,3314,O
end-stage,3314,B-Disease
renal,3314,I-Disease
disease,3314,I-Disease
in,3314,O
SHR,3314,O
.,3314,O
The,3315,O
risks,3315,O
of,3315,O
aprotinin,3315,O
and,3315,O
tranexamic,3315,B-Chemical
acid,3315,I-Chemical
in,3315,O
cardiac,3315,O
surgery,3315,O
:,3315,O
a,3315,O
one-year,3315,O
follow-up,3315,O
of,3315,O
1188,3315,O
consecutive,3315,O
patients,3315,O
.,3315,O
BACKGROUND,3316,O
:,3316,O
Our,3316,O
aim,3316,O
was,3316,O
to,3316,O
investigate,3316,O
postoperative,3316,O
complications,3316,O
and,3316,O
mortality,3316,O
after,3316,O
administration,3316,O
of,3316,O
aprotinin,3316,O
compared,3316,O
to,3316,O
tranexamic,3316,B-Chemical
acid,3316,I-Chemical
in,3316,O
an,3316,O
unselected,3316,O
",",3316,O
consecutive,3316,O
cohort,3316,O
.,3316,O
METHODS,3317,O
:,3317,O
Perioperative,3317,O
data,3317,O
from,3317,O
consecutive,3317,O
cardiac,3317,O
surgery,3317,O
patients,3317,O
were,3317,O
prospectively,3317,O
collected,3317,O
between,3317,O
September,3317,O
2005,3317,O
and,3317,O
June,3317,O
2006,3317,O
in,3317,O
a,3317,O
university-affiliated,3317,O
clinic,3317,O
(,3317,O
n,3317,O
=,3317,O
1188,3317,O
),3317,O
.,3317,O
During,3318,O
the,3318,O
first,3318,O
5,3318,O
mo,3318,O
",",3318,O
596,3318,O
patients,3318,O
received,3318,O
aprotinin,3318,O
(,3318,O
Group,3318,O
A,3318,O
),3318,O
;,3318,O
in,3318,O
the,3318,O
next,3318,O
5,3318,O
mo,3318,O
",",3318,O
592,3318,O
patients,3318,O
were,3318,O
treated,3318,O
with,3318,O
tranexamic,3318,B-Chemical
acid,3318,I-Chemical
(,3318,O
Group,3318,O
T,3318,O
),3318,O
.,3318,O
Except,3319,O
for,3319,O
antifibrinolytic,3319,O
therapy,3319,O
",",3319,O
the,3319,O
anesthetic,3319,O
and,3319,O
surgical,3319,O
protocols,3319,O
remained,3319,O
unchanged,3319,O
.,3319,O
RESULTS,3320,O
:,3320,O
The,3320,O
pre-,3320,O
and,3320,O
intraoperative,3320,O
variables,3320,O
were,3320,O
comparable,3320,O
between,3320,O
the,3320,O
treatment,3320,O
groups,3320,O
.,3320,O
Postoperatively,3321,O
",",3321,O
a,3321,O
significantly,3321,O
higher,3321,O
incidence,3321,O
of,3321,O
seizures,3321,B-Disease
was,3321,O
found,3321,O
in,3321,O
Group,3321,O
T,3321,O
(,3321,O
4.6,3321,O
%,3321,O
vs,3321,O
1.2,3321,O
%,3321,O
",",3321,O
P,3321,O
<,3321,O
0.001,3321,O
),3321,O
.,3321,O
This,3322,O
difference,3322,O
was,3322,O
also,3322,O
significant,3322,O
in,3322,O
the,3322,O
primary,3322,O
valve,3322,O
surgery,3322,O
and,3322,O
the,3322,O
high,3322,O
risk,3322,O
surgery,3322,O
subgroups,3322,O
(,3322,O
7.9,3322,O
%,3322,O
vs,3322,O
1.2,3322,O
%,3322,O
",",3322,O
P,3322,O
=,3322,O
0.003,3322,O
;,3322,O
7.3,3322,O
%,3322,O
vs,3322,O
2.4,3322,O
%,3322,O
",",3322,O
P,3322,O
=,3322,O
0.035,3322,O
",",3322,O
respectively,3322,O
),3322,O
.,3322,O
Persistent,3323,O
atrial,3323,O
fibrillation,3323,O
(,3323,O
7.9,3323,O
%,3323,O
vs,3323,O
2.3,3323,O
%,3323,O
",",3323,O
P,3323,O
=,3323,O
0.020,3323,O
),3323,O
and,3323,O
renal,3323,B-Disease
failure,3323,I-Disease
(,3323,O
9.7,3323,O
%,3323,O
vs,3323,O
1.7,3323,O
%,3323,O
",",3323,O
P,3323,O
=,3323,O
0.002,3323,O
),3323,O
were,3323,O
also,3323,O
more,3323,O
common,3323,O
in,3323,O
Group,3323,O
T,3323,O
",",3323,O
in,3323,O
the,3323,O
primary,3323,O
valve,3323,O
surgery,3323,O
subgroup,3323,O
.,3323,O
On,3324,O
the,3324,O
contrary,3324,O
",",3324,O
among,3324,O
primary,3324,O
coronary,3324,O
artery,3324,O
bypass,3324,O
surgery,3324,O
patients,3324,O
",",3324,O
there,3324,O
were,3324,O
more,3324,O
acute,3324,O
myocardial,3324,B-Disease
infarctions,3324,I-Disease
and,3324,O
renal,3324,B-Disease
dysfunction,3324,I-Disease
in,3324,O
Group,3324,O
A,3324,O
(,3324,O
5.8,3324,O
%,3324,O
vs,3324,O
2.0,3324,O
%,3324,O
",",3324,O
P,3324,O
=,3324,O
0.027,3324,O
;,3324,O
22.5,3324,O
%,3324,O
vs,3324,O
15.2,3324,O
%,3324,O
",",3324,O
P,3324,O
=,3324,O
0.036,3324,O
",",3324,O
respectively,3324,O
),3324,O
.,3324,O
The,3325,O
1-yr,3325,O
mortality,3325,O
was,3325,O
significantly,3325,O
higher,3325,O
after,3325,O
aprotinin,3325,O
treatment,3325,O
in,3325,O
the,3325,O
high,3325,O
risk,3325,O
surgery,3325,O
group,3325,O
(,3325,O
17.7,3325,O
%,3325,O
vs,3325,O
9.8,3325,O
%,3325,O
",",3325,O
P,3325,O
=,3325,O
0.034,3325,O
),3325,O
.,3325,O
CONCLUSION,3326,O
:,3326,O
Both,3326,O
antifibrinolytic,3326,O
drugs,3326,O
bear,3326,O
the,3326,O
risk,3326,O
of,3326,O
adverse,3326,O
outcome,3326,O
depending,3326,O
on,3326,O
the,3326,O
type,3326,O
of,3326,O
cardiac,3326,O
surgery,3326,O
.,3326,O
Administration,3327,O
of,3327,O
aprotinin,3327,O
should,3327,O
be,3327,O
avoided,3327,O
in,3327,O
coronary,3327,O
artery,3327,O
bypass,3327,O
graft,3327,O
and,3327,O
high,3327,O
risk,3327,O
patients,3327,O
",",3327,O
whereas,3327,O
administration,3327,O
of,3327,O
tranexamic,3327,B-Chemical
acid,3327,I-Chemical
is,3327,O
not,3327,O
recommended,3327,O
in,3327,O
valve,3327,O
surgery,3327,O
.,3327,O
The,3328,O
biological,3328,O
properties,3328,O
of,3328,O
the,3328,O
optical,3328,O
isomers,3328,O
of,3328,O
propranolol,3328,B-Chemical
and,3328,O
their,3328,O
effects,3328,O
on,3328,O
cardiac,3328,B-Disease
arrhythmias,3328,I-Disease
.,3328,O
1,3329,O
.,3329,O
The,3330,O
optical,3330,O
isomers,3330,O
of,3330,O
propranolol,3330,B-Chemical
have,3330,O
been,3330,O
compared,3330,O
for,3330,O
their,3330,O
beta-blocking,3330,O
and,3330,O
antiarrhythmic,3330,O
activities.2,3330,O
.,3330,O
In,3331,O
blocking,3331,O
the,3331,O
positive,3331,O
inotropic,3331,O
and,3331,O
chronotropic,3331,O
responses,3331,O
to,3331,O
isoprenaline,3331,B-Chemical
",",3331,O
(,3331,O
+,3331,O
),3331,O
-propranolol,3331,O
had,3331,O
less,3331,O
than,3331,O
one,3331,O
hundredth,3331,O
the,3331,O
potency,3331,O
of,3331,O
(,3331,O
-,3331,O
),3331,O
-propranolol,3331,O
.,3331,O
At,3332,O
dose,3332,O
levels,3332,O
of,3332,O
(,3332,O
+,3332,O
),3332,O
-propranolol,3332,O
which,3332,O
attenuated,3332,O
the,3332,O
responses,3332,O
to,3332,O
isoprenaline,3332,B-Chemical
",",3332,O
there,3332,O
was,3332,O
a,3332,O
significant,3332,O
prolongation,3332,O
of,3332,O
the,3332,O
PR,3332,O
interval,3332,O
of,3332,O
the,3332,O
electrocardiogram.3,3332,O
.,3332,O
The,3333,O
metabolic,3333,O
responses,3333,O
to,3333,O
isoprenaline,3333,B-Chemical
in,3333,O
dogs,3333,O
(,3333,O
an,3333,O
increase,3333,O
in,3333,O
circulating,3333,O
glucose,3333,B-Chemical
",",3333,O
lactate,3333,B-Chemical
and,3333,O
free,3333,O
fatty,3333,B-Chemical
acids,3333,I-Chemical
),3333,O
were,3333,O
all,3333,O
blocked,3333,O
by,3333,O
(,3333,O
-,3333,O
),3333,O
-propranolol,3333,O
.,3333,O
(,3334,O
+,3334,O
),3334,O
-Propranolol,3334,O
had,3334,O
no,3334,O
effect,3334,O
on,3334,O
fatty,3334,B-Chemical
acid,3334,I-Chemical
mobilization,3334,O
but,3334,O
significantly,3334,O
reduced,3334,O
the,3334,O
increments,3334,O
in,3334,O
both,3334,O
lactate,3334,B-Chemical
and,3334,O
glucose.4,3334,B-Chemical
.,3334,O
Both,3335,O
isomers,3335,O
of,3335,O
propranolol,3335,B-Chemical
possessed,3335,O
similar,3335,O
depressant,3335,O
potency,3335,O
on,3335,O
isolated,3335,O
atrial,3335,O
muscle,3335,O
taken,3335,O
from,3335,O
guinea-pigs.5,3335,O
.,3335,O
The,3336,O
isomers,3336,O
of,3336,O
propranolol,3336,B-Chemical
exhibited,3336,O
similar,3336,O
local,3336,O
anaesthetic,3336,O
potencies,3336,O
on,3336,O
an,3336,O
isolated,3336,O
frog,3336,O
nerve,3336,O
preparation,3336,O
at,3336,O
a,3336,O
level,3336,O
approximately,3336,O
three,3336,O
times,3336,O
that,3336,O
of,3336,O
procaine,3336,B-Chemical
.,3336,O
The,3337,O
racemic,3337,O
compound,3337,O
was,3337,O
significantly,3337,O
less,3337,O
potent,3337,O
than,3337,O
either,3337,O
isomer.6,3337,O
.,3337,O
Both,3338,O
isomers,3338,O
of,3338,O
propranolol,3338,B-Chemical
were,3338,O
capable,3338,O
of,3338,O
preventing,3338,O
adrenaline-induced,3338,B-Chemical
cardiac,3338,B-Disease
arrhythmias,3338,I-Disease
in,3338,O
cats,3338,O
anaesthetized,3338,O
with,3338,O
halothane,3338,B-Chemical
",",3338,O
but,3338,O
the,3338,O
mean,3338,O
dose,3338,O
of,3338,O
(,3338,O
-,3338,O
),3338,O
-propranolol,3338,O
was,3338,O
0.09+/-0.02,3338,O
mg/kg,3338,O
whereas,3338,O
that,3338,O
of,3338,O
(,3338,O
+,3338,O
),3338,O
-propranolol,3338,O
was,3338,O
4.2+/-1.2,3338,O
mg/kg,3338,O
.,3338,O
At,3339,O
the,3339,O
effective,3339,O
dose,3339,O
level,3339,O
of,3339,O
(,3339,O
+,3339,O
),3339,O
-propranolol,3339,O
there,3339,O
was,3339,O
a,3339,O
significant,3339,O
prolongation,3339,O
of,3339,O
the,3339,O
PR,3339,O
interval,3339,O
of,3339,O
the,3339,O
electrocardiogram,3339,O
.,3339,O
Blockade,3340,O
of,3340,O
arrhythmias,3340,B-Disease
with,3340,O
both,3340,O
isomers,3340,O
was,3340,O
surmountable,3340,O
by,3340,O
increasing,3340,O
the,3340,O
dose,3340,O
of,3340,O
adrenaline.7,3340,B-Chemical
.,3340,O
Both,3341,O
isomers,3341,O
of,3341,O
propranolol,3341,B-Chemical
were,3341,O
also,3341,O
capable,3341,O
of,3341,O
reversing,3341,O
ventricular,3341,B-Disease
tachycardia,3341,I-Disease
caused,3341,O
by,3341,O
ouabain,3341,B-Chemical
in,3341,O
anaesthetized,3341,O
cats,3341,O
and,3341,O
dogs,3341,O
.,3341,O
The,3342,O
dose,3342,O
of,3342,O
(,3342,O
-,3342,O
),3342,O
-propranolol,3342,O
was,3342,O
significantly,3342,O
smaller,3342,O
than,3342,O
that,3342,O
of,3342,O
(,3342,O
+,3342,O
),3342,O
-propranolol,3342,O
in,3342,O
both,3342,O
species,3342,O
but,3342,O
much,3342,O
higher,3342,O
than,3342,O
that,3342,O
required,3342,O
to,3342,O
produce,3342,O
evidence,3342,O
of,3342,O
beta-blockade.8,3342,O
.,3342,O
The,3343,O
implications,3343,O
of,3343,O
these,3343,O
results,3343,O
are,3343,O
discussed,3343,O
.,3343,O
Topotecan,3344,B-Chemical
in,3344,O
combination,3344,O
with,3344,O
radiotherapy,3344,O
in,3344,O
unresectable,3344,O
glioblastoma,3344,B-Disease
:,3344,O
a,3344,O
phase,3344,O
2,3344,O
study,3344,O
.,3344,O
Improving,3345,O
glioblastoma,3345,B-Disease
multiforme,3345,I-Disease
(,3345,O
GBM,3345,B-Disease
),3345,O
treatment,3345,O
with,3345,O
radio-chemotherapy,3345,O
remains,3345,O
a,3345,O
challenge,3345,O
.,3345,O
Topotecan,3346,B-Chemical
is,3346,O
an,3346,O
attractive,3346,O
option,3346,O
as,3346,O
it,3346,O
exhibits,3346,O
growth,3346,O
inhibition,3346,O
of,3346,O
human,3346,O
glioma,3346,B-Disease
as,3346,O
well,3346,O
as,3346,O
brain,3346,O
penetration,3346,O
.,3346,O
The,3347,O
present,3347,O
study,3347,O
assessed,3347,O
the,3347,O
combination,3347,O
of,3347,O
radiotherapy,3347,O
(,3347,O
60,3347,O
Gy/30,3347,O
fractions/40,3347,O
days,3347,O
),3347,O
and,3347,O
topotecan,3347,B-Chemical
(,3347,O
0.9,3347,O
mg/m,3347,O
(,3347,O
2,3347,O
),3347,O
/day,3347,O
on,3347,O
days,3347,O
1-5,3347,O
on,3347,O
weeks,3347,O
1,3347,O
",",3347,O
3,3347,O
and,3347,O
5,3347,O
),3347,O
in,3347,O
50,3347,O
adults,3347,O
with,3347,O
histologically,3347,O
proven,3347,O
and,3347,O
untreated,3347,O
GBM,3347,B-Disease
.,3347,O
The,3348,O
incidence,3348,O
of,3348,O
non-hematological,3348,O
toxicities,3348,B-Disease
was,3348,O
low,3348,O
and,3348,O
grade,3348,O
3-4,3348,O
hematological,3348,O
toxicities,3348,B-Disease
were,3348,O
reported,3348,O
in,3348,O
20,3348,O
patients,3348,O
(,3348,O
mainly,3348,O
lymphopenia,3348,B-Disease
and,3348,O
neutropenia,3348,B-Disease
),3348,O
.,3348,O
Partial,3349,O
response,3349,O
and,3349,O
stabilization,3349,O
rates,3349,O
were,3349,O
2,3349,O
%,3349,O
and,3349,O
32,3349,O
%,3349,O
",",3349,O
respectively,3349,O
",",3349,O
with,3349,O
an,3349,O
overall,3349,O
time,3349,O
to,3349,O
progression,3349,O
of,3349,O
12,3349,O
weeks,3349,O
.,3349,O
One-year,3350,O
overall,3350,O
survival,3350,O
(,3350,O
OS,3350,O
),3350,O
rate,3350,O
was,3350,O
42,3350,O
%,3350,O
",",3350,O
with,3350,O
a,3350,O
median,3350,O
OS,3350,O
of,3350,O
40,3350,O
weeks,3350,O
.,3350,O
Topotecan,3351,B-Chemical
in,3351,O
combination,3351,O
with,3351,O
radiotherapy,3351,O
was,3351,O
well,3351,O
tolerated,3351,O
.,3351,O
However,3352,O
",",3352,O
while,3352,O
response,3352,O
and,3352,O
stabilization,3352,O
concerned,3352,O
one-third,3352,O
of,3352,O
the,3352,O
patients,3352,O
",",3352,O
the,3352,O
study,3352,O
did,3352,O
not,3352,O
show,3352,O
increased,3352,O
benefits,3352,O
in,3352,O
terms,3352,O
of,3352,O
survival,3352,O
in,3352,O
patients,3352,O
with,3352,O
unresectable,3352,O
GBM,3352,B-Disease
.,3352,O
Long-term,3353,O
lithium,3353,B-Chemical
therapy,3353,O
leading,3353,O
to,3353,O
hyperparathyroidism,3353,B-Disease
:,3353,O
a,3353,O
case,3353,O
report,3353,O
.,3353,O
PURPOSE,3354,O
:,3354,O
This,3354,O
paper,3354,O
reviews,3354,O
the,3354,O
effect,3354,O
of,3354,O
chronic,3354,O
lithium,3354,B-Chemical
therapy,3354,O
on,3354,O
serum,3354,O
calcium,3354,B-Chemical
level,3354,O
and,3354,O
parathyroid,3354,O
glands,3354,O
",",3354,O
its,3354,O
pathogenesis,3354,O
",",3354,O
and,3354,O
treatment,3354,O
options,3354,O
.,3354,O
We,3355,O
examined,3355,O
the,3355,O
case,3355,O
of,3355,O
a,3355,O
lithium-treated,3355,B-Chemical
patient,3355,O
who,3355,O
had,3355,O
recurrent,3355,O
hypercalcemia,3355,B-Disease
to,3355,O
better,3355,O
understand,3355,O
the,3355,O
disease,3355,O
process,3355,O
.,3355,O
CONCLUSION,3356,O
:,3356,O
Primary,3356,B-Disease
hyperparathyroidism,3356,I-Disease
is,3356,O
a,3356,O
rare,3356,O
but,3356,O
potentially,3356,O
life-threatening,3356,O
side,3356,O
effect,3356,O
of,3356,O
long-term,3356,O
lithium,3356,B-Chemical
therapy,3356,O
.,3356,O
Careful,3357,O
patient,3357,O
selection,3357,O
and,3357,O
long-term,3357,O
follow-up,3357,O
can,3357,O
reduce,3357,O
morbidity,3357,O
.,3357,O
PRACTICAL,3358,O
IMPLICATIONS,3358,O
:,3358,O
As,3358,O
much,3358,O
as,3358,O
15,3358,O
%,3358,O
of,3358,O
lithium-treated,3358,B-Chemical
patients,3358,O
become,3358,O
hypercalcemic,3358,B-Disease
.,3358,O
By,3359,O
routinely,3359,O
monitoring,3359,O
serum,3359,O
calcium,3359,B-Chemical
levels,3359,O
",",3359,O
healthcare,3359,O
providers,3359,O
can,3359,O
improve,3359,O
the,3359,O
quality,3359,O
of,3359,O
life,3359,O
of,3359,O
this,3359,O
patient,3359,O
group,3359,O
.,3359,O
Comparison,3360,O
of,3360,O
laryngeal,3360,O
mask,3360,O
with,3360,O
endotracheal,3360,O
tube,3360,O
for,3360,O
anesthesia,3360,O
in,3360,O
endoscopic,3360,O
sinus,3360,O
surgery,3360,O
.,3360,O
BACKGROUND,3361,O
:,3361,O
The,3361,O
purpose,3361,O
of,3361,O
this,3361,O
study,3361,O
was,3361,O
to,3361,O
compare,3361,O
surgical,3361,O
conditions,3361,O
",",3361,O
including,3361,O
the,3361,O
amount,3361,O
of,3361,O
intraoperative,3361,O
bleeding,3361,B-Disease
as,3361,O
well,3361,O
as,3361,O
intraoperative,3361,O
blood,3361,O
pressure,3361,O
",",3361,O
during,3361,O
functional,3361,O
endoscopic,3361,O
sinus,3361,O
surgery,3361,O
(,3361,O
FESS,3361,O
),3361,O
using,3361,O
flexible,3361,O
reinforced,3361,O
laryngeal,3361,O
mask,3361,O
airway,3361,O
(,3361,O
FRLMA,3361,O
),3361,O
versus,3361,O
endotracheal,3361,O
tube,3361,O
(,3361,O
ETT,3361,O
),3361,O
in,3361,O
maintaining,3361,O
controlled,3361,O
hypotension,3361,B-Disease
anesthesia,3361,O
induced,3361,O
by,3361,O
propofol-remifentanil,3361,B-Chemical
total,3361,O
i.v,3361,O
.,3361,O
anesthesia,3362,O
(,3362,O
TIVA,3362,O
),3362,O
.,3362,O
METHODS,3363,O
:,3363,O
Sixty,3363,O
normotensive,3363,O
American,3363,O
Society,3363,O
of,3363,O
Anesthesiologists,3363,O
I-II,3363,O
adult,3363,O
patients,3363,O
undergoing,3363,O
FESS,3363,O
under,3363,O
controlled,3363,O
hypotension,3363,B-Disease
anesthesia,3363,O
caused,3363,O
by,3363,O
propofol-remifentanil-TIVA,3363,B-Chemical
were,3363,O
randomly,3363,O
assigned,3363,O
into,3363,O
two,3363,O
groups,3363,O
:,3363,O
group,3363,O
I,3363,O
",",3363,O
FRLMA,3363,O
;,3363,O
group,3363,O
II,3363,O
",",3363,O
ETT,3363,O
.,3363,O
Hemorrhage,3364,B-Disease
was,3364,O
measured,3364,O
and,3364,O
the,3364,O
visibility,3364,O
of,3364,O
the,3364,O
operative,3364,O
field,3364,O
was,3364,O
evaluated,3364,O
according,3364,O
to,3364,O
a,3364,O
six-point,3364,O
scale,3364,O
.,3364,O
RESULTS,3365,O
:,3365,O
Controlled,3365,O
hypotension,3365,B-Disease
was,3365,O
achieved,3365,O
within,3365,O
a,3365,O
shorter,3365,O
period,3365,O
using,3365,O
laryngeal,3365,O
mask,3365,O
using,3365,O
lower,3365,O
rates,3365,O
of,3365,O
remifentanil,3365,B-Chemical
infusion,3365,O
and,3365,O
lower,3365,O
total,3365,O
dose,3365,O
of,3365,O
remifentanil,3365,B-Chemical
.,3365,O
CONCLUSION,3366,O
:,3366,O
In,3366,O
summary,3366,O
",",3366,O
our,3366,O
results,3366,O
indicate,3366,O
that,3366,O
airway,3366,O
management,3366,O
using,3366,O
FRLMA,3366,O
during,3366,O
controlled,3366,O
hypotension,3366,B-Disease
anesthesia,3366,O
provided,3366,O
better,3366,O
surgical,3366,O
conditions,3366,O
in,3366,O
terms,3366,O
of,3366,O
quality,3366,O
of,3366,O
operative,3366,O
field,3366,O
and,3366,O
blood,3366,O
loss,3366,O
and,3366,O
allowed,3366,O
for,3366,O
convenient,3366,O
induced,3366,O
hypotension,3366,B-Disease
with,3366,O
low,3366,O
doses,3366,O
of,3366,O
remifentanil,3366,B-Chemical
during,3366,O
TIVA,3366,O
in,3366,O
patients,3366,O
undergoing,3366,O
FESS,3366,O
.,3366,O
Nonalcoholic,3367,B-Disease
fatty,3367,I-Disease
liver,3367,I-Disease
disease,3367,I-Disease
during,3367,O
valproate,3367,B-Chemical
therapy,3367,O
.,3367,O
Valproic,3368,B-Chemical
acid,3368,I-Chemical
(,3368,O
VPA,3368,B-Chemical
),3368,O
is,3368,O
effective,3368,O
for,3368,O
the,3368,O
treatment,3368,O
of,3368,O
many,3368,O
types,3368,O
of,3368,O
epilepsy,3368,B-Disease
",",3368,O
but,3368,O
its,3368,O
use,3368,O
can,3368,O
be,3368,O
associated,3368,O
with,3368,O
an,3368,O
increase,3368,O
in,3368,O
body,3368,O
weight,3368,O
.,3368,O
We,3369,O
report,3369,O
a,3369,O
case,3369,O
of,3369,O
nonalcoholic,3369,B-Disease
fatty,3369,I-Disease
liver,3369,I-Disease
disease,3369,I-Disease
(,3369,O
NAFLD,3369,B-Disease
),3369,O
arising,3369,O
in,3369,O
a,3369,O
child,3369,O
who,3369,O
developed,3369,O
obesity,3369,B-Disease
during,3369,O
VPA,3369,B-Chemical
treatment,3369,O
.,3369,O
Laboratory,3370,O
data,3370,O
revealed,3370,O
hyperinsulinemia,3370,B-Disease
with,3370,O
insulin,3370,B-Disease
resistance,3370,I-Disease
.,3370,O
After,3371,O
the,3371,O
withdrawal,3371,O
of,3371,O
VPA,3371,B-Chemical
therapy,3371,O
",",3371,O
our,3371,O
patient,3371,O
showed,3371,O
a,3371,O
significant,3371,O
weight,3371,B-Disease
loss,3371,I-Disease
",",3371,O
a,3371,O
decrease,3371,O
of,3371,O
body,3371,O
mass,3371,O
index,3371,O
",",3371,O
and,3371,O
normalization,3371,O
of,3371,O
metabolic,3371,O
and,3371,O
endocrine,3371,O
parameters,3371,O
;,3371,O
moreover,3371,O
",",3371,O
ultrasound,3371,O
measurements,3371,O
showed,3371,O
a,3371,O
complete,3371,O
normalization,3371,O
.,3371,O
The,3372,O
present,3372,O
case,3372,O
suggests,3372,O
that,3372,O
obesity,3372,B-Disease
",",3372,O
hyperinsulinemia,3372,B-Disease
",",3372,O
insulin,3372,B-Disease
resistance,3372,I-Disease
",",3372,O
and,3372,O
long-term,3372,O
treatment,3372,O
with,3372,O
VPA,3372,B-Chemical
may,3372,O
be,3372,O
all,3372,O
associated,3372,O
with,3372,O
the,3372,O
development,3372,O
of,3372,O
NAFLD,3372,B-Disease
;,3372,O
this,3372,O
side,3372,O
effect,3372,O
is,3372,O
reversible,3372,O
after,3372,O
VPA,3372,B-Chemical
withdrawal,3372,O
.,3372,O
Carbimazole,3373,B-Chemical
induced,3373,O
ANCA,3373,B-Disease
positive,3373,I-Disease
vasculitis,3373,I-Disease
.,3373,O
Anti-thyroid,3374,B-Chemical
drugs,3374,I-Chemical
",",3374,O
like,3374,O
carbimazole,3374,B-Chemical
and,3374,O
propylthiouracil,3374,B-Chemical
(,3374,O
PTU,3374,B-Chemical
),3374,O
are,3374,O
commonly,3374,O
prescribed,3374,O
for,3374,O
the,3374,O
treatment,3374,O
of,3374,O
hyperthyroidism,3374,B-Disease
.,3374,O
One,3375,O
should,3375,O
be,3375,O
aware,3375,O
of,3375,O
the,3375,O
side,3375,O
effects,3375,O
of,3375,O
antithyroid,3375,B-Chemical
medications,3375,I-Chemical
.,3375,O
Antineutrophil,3376,B-Disease
cytoplasmic,3376,I-Disease
antibody,3376,I-Disease
(,3376,I-Disease
ANCA,3376,I-Disease
),3376,I-Disease
--,3376,I-Disease
associated,3376,I-Disease
vasculitis,3376,I-Disease
is,3376,O
a,3376,O
potentially,3376,O
life-threatening,3376,O
adverse,3376,O
effect,3376,O
of,3376,O
antithyroidmedications,3376,B-Chemical
.,3376,O
We,3377,O
report,3377,O
a,3377,O
patient,3377,O
with,3377,O
Graves,3377,B-Disease
',3377,I-Disease
disease,3377,I-Disease
who,3377,O
developed,3377,O
ANCA,3377,O
positive,3377,O
carbimazole,3377,B-Chemical
induced,3377,O
vasculitis,3377,B-Disease
.,3377,O
The,3378,O
episode,3378,O
was,3378,O
characterized,3378,O
by,3378,O
a,3378,O
vasculitic,3378,B-Disease
skin,3378,B-Disease
rash,3378,I-Disease
associated,3378,O
with,3378,O
large,3378,O
joint,3378,O
arthritis,3378,B-Disease
",",3378,O
pyrexia,3378,B-Disease
and,3378,O
parotiditis,3378,B-Disease
but,3378,O
no,3378,O
renal,3378,O
or,3378,O
pulmonary,3378,O
involvement,3378,O
.,3378,O
He,3379,O
was,3379,O
referred,3379,O
to,3379,O
us,3379,O
for,3379,O
neurological,3379,O
evaluation,3379,O
because,3379,O
he,3379,O
had,3379,O
difficulty,3379,O
in,3379,O
getting,3379,O
up,3379,O
from,3379,O
squatting,3379,O
position,3379,O
and,3379,O
was,3379,O
suspected,3379,O
to,3379,O
have,3379,O
myositis,3379,B-Disease
.,3379,O
Carbimazole,3380,B-Chemical
and,3380,O
methimazole,3380,B-Chemical
have,3380,O
a,3380,O
lower,3380,O
incidence,3380,O
of,3380,O
reported,3380,O
ANCA,3380,O
positive,3380,O
side,3380,O
effects,3380,O
than,3380,O
PUT,3380,O
.,3380,O
To,3381,O
the,3381,O
best,3381,O
of,3381,O
our,3381,O
knowledge,3381,O
this,3381,O
is,3381,O
the,3381,O
first,3381,O
ANCA,3381,O
positive,3381,O
carbimazole,3381,B-Chemical
induced,3381,O
vasculitis,3381,B-Disease
case,3381,O
reported,3381,O
from,3381,O
India,3381,O
.,3381,O
Aspirin,3382,B-Chemical
for,3382,O
the,3382,O
primary,3382,O
prevention,3382,O
of,3382,O
cardiovascular,3382,O
events,3382,O
:,3382,O
an,3382,O
update,3382,O
of,3382,O
the,3382,O
evidence,3382,O
for,3382,O
the,3382,O
U.S.,3382,O
Preventive,3382,O
Services,3382,O
Task,3382,O
Force,3382,O
.,3382,O
BACKGROUND,3383,O
:,3383,O
Coronary,3383,B-Disease
heart,3383,I-Disease
disease,3383,I-Disease
and,3383,O
cerebrovascular,3383,B-Disease
disease,3383,I-Disease
are,3383,O
leading,3383,O
causes,3383,O
of,3383,O
death,3383,O
in,3383,O
the,3383,O
United,3383,O
States,3383,O
.,3383,O
In,3384,O
2002,3384,O
",",3384,O
the,3384,O
U.S.,3384,O
Preventive,3384,O
Services,3384,O
Task,3384,O
Force,3384,O
(,3384,O
USPSTF,3384,O
),3384,O
strongly,3384,O
recommended,3384,O
that,3384,O
clinicians,3384,O
discuss,3384,O
aspirin,3384,B-Chemical
with,3384,O
adults,3384,O
who,3384,O
are,3384,O
at,3384,O
increased,3384,O
risk,3384,O
for,3384,O
coronary,3384,B-Disease
heart,3384,I-Disease
disease,3384,I-Disease
.,3384,O
PURPOSE,3385,O
:,3385,O
To,3385,O
determine,3385,O
the,3385,O
benefits,3385,O
and,3385,O
harms,3385,O
of,3385,O
taking,3385,O
aspirin,3385,B-Chemical
for,3385,O
the,3385,O
primary,3385,O
prevention,3385,O
of,3385,O
myocardial,3385,B-Disease
infarctions,3385,I-Disease
",",3385,O
strokes,3385,B-Disease
",",3385,O
and,3385,O
death,3385,O
.,3385,O
DATA,3386,O
SOURCES,3386,O
:,3386,O
MEDLINE,3386,O
and,3386,O
Cochrane,3386,O
Library,3386,O
(,3386,O
search,3386,O
dates,3386,O
",",3386,O
1,3386,O
January,3386,O
2001,3386,O
to,3386,O
28,3386,O
August,3386,O
2008,3386,O
),3386,O
",",3386,O
recent,3386,O
systematic,3386,O
reviews,3386,O
",",3386,O
reference,3386,O
lists,3386,O
of,3386,O
retrieved,3386,O
articles,3386,O
",",3386,O
and,3386,O
suggestions,3386,O
from,3386,O
experts,3386,O
.,3386,O
STUDY,3387,O
SELECTION,3387,O
:,3387,O
English-language,3387,O
randomized,3387,O
",",3387,O
controlled,3387,O
trials,3387,O
(,3387,O
RCTs,3387,O
),3387,O
;,3387,O
case-control,3387,O
studies,3387,O
;,3387,O
meta-analyses,3387,O
;,3387,O
and,3387,O
systematic,3387,O
reviews,3387,O
of,3387,O
aspirin,3387,B-Chemical
versus,3387,O
control,3387,O
for,3387,O
the,3387,O
primary,3387,O
prevention,3387,O
of,3387,O
cardiovascular,3387,B-Disease
disease,3387,I-Disease
(,3387,O
CVD,3387,B-Disease
),3387,O
were,3387,O
selected,3387,O
to,3387,O
answer,3387,O
the,3387,O
following,3387,O
questions,3387,O
:,3387,O
Does,3387,O
aspirin,3387,B-Chemical
decrease,3387,O
coronary,3387,O
heart,3387,O
events,3387,O
",",3387,O
strokes,3387,B-Disease
",",3387,O
death,3387,O
from,3387,O
coronary,3387,O
heart,3387,O
events,3387,O
or,3387,O
stroke,3387,B-Disease
",",3387,O
or,3387,O
all-cause,3387,O
mortality,3387,O
in,3387,O
adults,3387,O
without,3387,O
known,3387,O
CVD,3387,B-Disease
?,3387,O
Does,3388,O
aspirin,3388,B-Chemical
increase,3388,O
gastrointestinal,3388,B-Disease
bleeding,3388,I-Disease
or,3388,O
hemorrhagic,3388,O
strokes,3388,O
?,3388,O
DATA,3389,O
EXTRACTION,3389,O
:,3389,O
All,3389,O
studies,3389,O
were,3389,O
reviewed,3389,O
",",3389,O
abstracted,3389,O
",",3389,O
and,3389,O
rated,3389,O
for,3389,O
quality,3389,O
by,3389,O
using,3389,O
predefined,3389,O
USPSTF,3389,O
criteria,3389,O
.,3389,O
DATA,3390,O
SYNTHESIS,3390,O
:,3390,O
New,3390,O
evidence,3390,O
from,3390,O
1,3390,O
good-quality,3390,O
RCT,3390,O
",",3390,O
1,3390,O
good-quality,3390,O
meta-analysis,3390,O
",",3390,O
and,3390,O
2,3390,O
fair-quality,3390,O
subanalyses,3390,O
of,3390,O
RCTs,3390,O
demonstrates,3390,O
that,3390,O
aspirin,3390,B-Chemical
use,3390,O
reduces,3390,O
the,3390,O
number,3390,O
of,3390,O
CVD,3390,B-Disease
events,3390,O
in,3390,O
patients,3390,O
without,3390,O
known,3390,O
CVD,3390,B-Disease
.,3390,O
Men,3391,O
in,3391,O
these,3391,O
studies,3391,O
experienced,3391,O
fewer,3391,O
myocardial,3391,B-Disease
infarctions,3391,I-Disease
and,3391,O
women,3391,O
experienced,3391,O
fewer,3391,O
ischemic,3391,O
strokes,3391,B-Disease
.,3391,O
Aspirin,3392,B-Chemical
does,3392,O
not,3392,O
seem,3392,O
to,3392,O
affect,3392,O
CVD,3392,B-Disease
mortality,3392,O
or,3392,O
all-cause,3392,O
mortality,3392,O
in,3392,O
either,3392,O
men,3392,O
or,3392,O
women,3392,O
.,3392,O
The,3393,O
use,3393,O
of,3393,O
aspirin,3393,B-Chemical
for,3393,O
primary,3393,O
prevention,3393,O
increases,3393,O
the,3393,O
risk,3393,O
for,3393,O
major,3393,O
bleeding,3393,B-Disease
events,3393,O
",",3393,O
primarily,3393,O
gastrointestinal,3393,B-Disease
bleeding,3393,I-Disease
events,3393,O
",",3393,O
in,3393,O
both,3393,O
men,3393,O
and,3393,O
women,3393,O
.,3393,O
Men,3394,O
have,3394,O
an,3394,O
increased,3394,O
risk,3394,O
for,3394,O
hemorrhagic,3394,O
strokes,3394,O
with,3394,O
aspirin,3394,B-Chemical
use,3394,O
.,3394,O
A,3395,O
new,3395,O
RCT,3395,O
and,3395,O
meta-analysis,3395,O
suggest,3395,O
that,3395,O
the,3395,O
risk,3395,O
for,3395,O
hemorrhagic,3395,O
strokes,3395,O
in,3395,O
women,3395,O
is,3395,O
not,3395,O
statistically,3395,O
significantly,3395,O
increased,3395,O
.,3395,O
LIMITATIONS,3396,O
:,3396,O
New,3396,O
evidence,3396,O
on,3396,O
aspirin,3396,B-Chemical
for,3396,O
the,3396,O
primary,3396,O
prevention,3396,O
of,3396,O
CVD,3396,B-Disease
is,3396,O
limited,3396,O
.,3396,O
The,3397,O
dose,3397,O
of,3397,O
aspirin,3397,B-Chemical
used,3397,O
in,3397,O
the,3397,O
RCTs,3397,O
varied,3397,O
",",3397,O
which,3397,O
prevented,3397,O
the,3397,O
estimation,3397,O
of,3397,O
the,3397,O
most,3397,O
appropriate,3397,O
dose,3397,O
for,3397,O
primary,3397,O
prevention,3397,O
.,3397,O
Several,3398,O
of,3398,O
the,3398,O
RCTs,3398,O
were,3398,O
conducted,3398,O
within,3398,O
populations,3398,O
of,3398,O
health,3398,O
professionals,3398,O
",",3398,O
which,3398,O
potentially,3398,O
limits,3398,O
generalizability,3398,O
.,3398,O
CONCLUSION,3399,O
:,3399,O
Aspirin,3399,B-Chemical
reduces,3399,O
the,3399,O
risk,3399,O
for,3399,O
myocardial,3399,B-Disease
infarction,3399,I-Disease
in,3399,O
men,3399,O
and,3399,O
strokes,3399,B-Disease
in,3399,O
women,3399,O
.,3399,O
Aspirin,3400,B-Chemical
use,3400,O
increases,3400,O
the,3400,O
risk,3400,O
for,3400,O
serious,3400,O
bleeding,3400,B-Disease
events,3400,O
.,3400,O
Reducing,3401,O
harm,3401,O
associated,3401,O
with,3401,O
anticoagulation,3401,O
:,3401,O
practical,3401,O
considerations,3401,O
of,3401,O
argatroban,3401,B-Chemical
therapy,3401,O
in,3401,O
heparin-induced,3401,B-Chemical
thrombocytopenia,3401,B-Disease
.,3401,O
Argatroban,3402,B-Chemical
is,3402,O
a,3402,O
hepatically,3402,O
metabolized,3402,O
",",3402,O
direct,3402,O
thrombin,3402,O
inhibitor,3402,O
used,3402,O
for,3402,O
prophylaxis,3402,O
or,3402,O
treatment,3402,O
of,3402,O
thrombosis,3402,B-Disease
in,3402,O
heparin-induced,3402,B-Chemical
thrombocytopenia,3402,B-Disease
(,3402,O
HIT,3402,B-Disease
),3402,O
and,3402,O
for,3402,O
patients,3402,O
with,3402,O
or,3402,O
at,3402,O
risk,3402,O
of,3402,O
HIT,3402,B-Disease
undergoing,3402,O
percutaneous,3402,O
coronary,3402,O
intervention,3402,O
(,3402,O
PCI,3402,O
),3402,O
.,3402,O
The,3403,O
objective,3403,O
of,3403,O
this,3403,O
review,3403,O
is,3403,O
to,3403,O
summarize,3403,O
practical,3403,O
considerations,3403,O
of,3403,O
argatroban,3403,B-Chemical
therapy,3403,O
in,3403,O
HIT,3403,B-Disease
.,3403,O
The,3404,O
US,3404,O
FDA-recommended,3404,O
argatroban,3404,B-Chemical
dose,3404,O
in,3404,O
HIT,3404,B-Disease
is,3404,O
2,3404,O
microg/kg/min,3404,O
(,3404,O
reduced,3404,O
in,3404,O
patients,3404,O
with,3404,O
hepatic,3404,B-Disease
impairment,3404,I-Disease
and,3404,O
in,3404,O
paediatric,3404,O
patients,3404,O
),3404,O
",",3404,O
adjusted,3404,O
to,3404,O
achieve,3404,O
activated,3404,O
partial,3404,O
thromboplastin,3404,O
times,3404,O
(,3404,O
aPTTs,3404,O
),3404,O
1.5-3,3404,O
times,3404,O
baseline,3404,O
(,3404,O
not,3404,O
>,3404,O
100,3404,O
seconds,3404,O
),3404,O
.,3404,O
Contemporary,3405,O
experiences,3405,O
indicate,3405,O
that,3405,O
reduced,3405,O
doses,3405,O
are,3405,O
also,3405,O
needed,3405,O
in,3405,O
patients,3405,O
with,3405,O
conditions,3405,O
associated,3405,O
with,3405,O
hepatic,3405,O
hypoperfusion,3405,O
",",3405,O
e.g,3405,O
.,3405,O
heart,3406,B-Disease
failure,3406,I-Disease
",",3406,O
yet,3406,O
are,3406,O
unnecessary,3406,O
for,3406,O
renal,3406,B-Disease
dysfunction,3406,I-Disease
",",3406,O
adult,3406,O
age,3406,O
",",3406,O
sex,3406,O
",",3406,O
race/ethnicity,3406,O
or,3406,O
obesity,3406,B-Disease
.,3406,O
Argatroban,3407,B-Chemical
0.5-1.2,3407,O
microg/kg/min,3407,O
typically,3407,O
supports,3407,O
therapeutic,3407,O
aPTTs,3407,O
.,3407,O
The,3408,O
FDA-recommended,3408,O
dose,3408,O
during,3408,O
PCI,3408,O
is,3408,O
25,3408,O
microg/kg/min,3408,O
(,3408,O
350,3408,O
microg/kg,3408,O
initial,3408,O
bolus,3408,O
),3408,O
",",3408,O
adjusted,3408,O
to,3408,O
achieve,3408,O
activated,3408,O
clotting,3408,O
times,3408,O
(,3408,O
ACTs,3408,O
),3408,O
of,3408,O
300-450,3408,O
sec,3408,O
.,3408,O
For,3409,O
PCI,3409,O
",",3409,O
argatroban,3409,B-Chemical
has,3409,O
not,3409,O
been,3409,O
investigated,3409,O
in,3409,O
hepatically,3409,O
impaired,3409,O
patients,3409,O
;,3409,O
dose,3409,O
adjustment,3409,O
is,3409,O
unnecessary,3409,O
for,3409,O
adult,3409,O
age,3409,O
",",3409,O
sex,3409,O
",",3409,O
race/ethnicity,3409,O
or,3409,O
obesity,3409,B-Disease
",",3409,O
and,3409,O
lesser,3409,O
doses,3409,O
may,3409,O
be,3409,O
adequate,3409,O
with,3409,O
concurrent,3409,O
glycoprotein,3409,O
IIb/IIIa,3409,O
inhibition,3409,O
.,3409,O
Argatroban,3410,B-Chemical
prolongs,3410,O
the,3410,O
International,3410,O
Normalized,3410,O
Ratio,3410,O
",",3410,O
and,3410,O
published,3410,O
approaches,3410,O
for,3410,O
monitoring,3410,O
the,3410,O
argatroban-to-warfarin,3410,B-Chemical
transition,3410,O
should,3410,O
be,3410,O
followed,3410,O
.,3410,O
Major,3411,O
bleeding,3411,B-Disease
with,3411,O
argatroban,3411,B-Chemical
is,3411,O
0-10,3411,O
%,3411,O
in,3411,O
the,3411,O
non-interventional,3411,O
setting,3411,O
and,3411,O
0-5.8,3411,O
%,3411,O
periprocedurally,3411,O
.,3411,O
Argatroban,3412,B-Chemical
has,3412,O
no,3412,O
specific,3412,O
antidote,3412,O
",",3412,O
and,3412,O
if,3412,O
excessive,3412,O
anticoagulation,3412,O
occurs,3412,O
",",3412,O
argatroban,3412,B-Chemical
infusion,3412,O
should,3412,O
be,3412,O
stopped,3412,O
or,3412,O
reduced,3412,O
.,3412,O
Improved,3413,O
familiarity,3413,O
of,3413,O
healthcare,3413,O
professionals,3413,O
with,3413,O
argatroban,3413,B-Chemical
therapy,3413,O
in,3413,O
HIT,3413,B-Disease
",",3413,O
including,3413,O
in,3413,O
special,3413,O
populations,3413,O
and,3413,O
during,3413,O
PCI,3413,O
",",3413,O
may,3413,O
facilitate,3413,O
reduction,3413,O
of,3413,O
harm,3413,O
associated,3413,O
with,3413,O
HIT,3413,B-Disease
(,3413,O
e.g,3413,O
.,3413,O
fewer,3414,O
thromboses,3414,O
),3414,O
or,3414,O
its,3414,O
treatment,3414,O
(,3414,O
e.g,3414,O
.,3414,O
fewer,3415,O
argatroban,3415,B-Chemical
medication,3415,O
errors,3415,O
),3415,O
.,3415,O
Rhabdomyolysis,3416,B-Disease
and,3416,O
brain,3416,O
ischemic,3416,B-Disease
stroke,3416,I-Disease
in,3416,O
a,3416,O
heroin-dependent,3416,B-Chemical
male,3416,O
under,3416,O
methadone,3416,B-Chemical
maintenance,3416,O
therapy,3416,O
.,3416,O
OBJECTIVE,3417,O
:,3417,O
There,3417,O
are,3417,O
several,3417,O
complications,3417,O
associated,3417,O
with,3417,O
heroin,3417,B-Disease
abuse,3417,I-Disease
",",3417,O
some,3417,O
of,3417,O
which,3417,O
are,3417,O
life-threatening,3417,O
.,3417,O
Methadone,3418,B-Chemical
may,3418,O
aggravate,3418,O
this,3418,O
problem,3418,O
.,3418,O
METHOD,3419,O
:,3419,O
A,3419,O
clinical,3419,O
case,3419,O
description,3419,O
.,3419,O
RESULTS,3420,O
:,3420,O
A,3420,O
33-year-old,3420,O
man,3420,O
presented,3420,O
with,3420,O
rhabdomyolysis,3420,B-Disease
and,3420,O
cerebral,3420,O
ischemic,3420,B-Disease
stroke,3420,I-Disease
after,3420,O
intravenous,3420,O
heroin,3420,B-Chemical
.,3420,O
He,3421,O
had,3421,O
used,3421,O
heroin,3421,B-Chemical
since,3421,O
age,3421,O
20,3421,O
",",3421,O
and,3421,O
had,3421,O
used,3421,O
150,3421,O
mg,3421,O
methadone,3421,B-Chemical
daily,3421,O
for,3421,O
6,3421,O
months,3421,O
.,3421,O
He,3422,O
was,3422,O
found,3422,O
unconsciousness,3422,B-Disease
at,3422,O
home,3422,O
and,3422,O
was,3422,O
sent,3422,O
to,3422,O
our,3422,O
hospital,3422,O
.,3422,O
In,3423,O
the,3423,O
ER,3423,O
",",3423,O
his,3423,O
opiate,3423,O
level,3423,O
was,3423,O
4497,3423,O
ng/ml,3423,O
.,3423,O
In,3424,O
the,3424,O
ICU,3424,O
",",3424,O
we,3424,O
found,3424,O
rhabdomyolysis,3424,B-Disease
",",3424,O
acute,3424,B-Disease
renal,3424,I-Disease
failure,3424,I-Disease
and,3424,O
acute,3424,O
respiratory,3424,B-Disease
failure,3424,I-Disease
.,3424,O
After,3425,O
transfer,3425,O
to,3425,O
an,3425,O
internal,3425,O
ward,3425,O
",",3425,O
we,3425,O
noted,3425,O
aphasia,3425,B-Disease
and,3425,O
weakness,3425,B-Disease
of,3425,O
his,3425,O
left,3425,O
limbs,3425,O
.,3425,O
After,3426,O
MRI,3426,O
",",3426,O
we,3426,O
found,3426,O
cerebral,3426,B-Disease
ischemic,3426,I-Disease
infarction,3426,I-Disease
.,3426,O
CONCLUSION,3427,O
:,3427,O
Those,3427,O
using,3427,O
methadone,3427,B-Chemical
and,3427,O
heroin,3427,B-Chemical
simultaneously,3427,O
may,3427,O
increase,3427,O
risk,3427,O
of,3427,O
rhabdomyolysis,3427,B-Disease
and,3427,O
ischemic,3427,B-Disease
stroke,3427,I-Disease
.,3427,O
Patients,3428,O
under,3428,O
methadone,3428,B-Chemical
maintenance,3428,O
therapy,3428,O
should,3428,O
be,3428,O
warned,3428,O
regarding,3428,O
these,3428,O
serious,3428,O
adverse,3428,O
events,3428,O
.,3428,O
Hypotheses,3429,O
of,3429,O
heroin-related,3429,B-Chemical
rhabdomyolysis,3429,B-Disease
and,3429,O
stroke,3429,B-Disease
in,3429,O
heroin,3429,B-Chemical
abusers,3429,O
are,3429,O
discussed,3429,O
.,3429,O
Increased,3430,O
vulnerability,3430,O
to,3430,O
6-hydroxydopamine,3430,B-Chemical
lesion,3430,O
and,3430,O
reduced,3430,O
development,3430,O
of,3430,O
dyskinesias,3430,B-Disease
in,3430,O
mice,3430,O
lacking,3430,O
CB1,3430,O
cannabinoid,3430,O
receptors,3430,O
.,3430,O
Motor,3431,O
impairment,3431,O
",",3431,O
dopamine,3431,B-Chemical
(,3431,O
DA,3431,B-Chemical
),3431,O
neuronal,3431,O
activity,3431,O
and,3431,O
proenkephalin,3431,B-Chemical
(,3431,O
PENK,3431,B-Chemical
),3431,O
gene,3431,O
expression,3431,O
in,3431,O
the,3431,O
caudate-putamen,3431,O
(,3431,O
CPu,3431,O
),3431,O
were,3431,O
measured,3431,O
in,3431,O
6-OHDA-lesioned,3431,B-Chemical
and,3431,O
treated,3431,O
(,3431,O
L-DOPA+benserazide,3431,B-Chemical
),3431,O
CB1,3431,O
KO,3431,O
and,3431,O
WT,3431,O
mice,3431,O
.,3431,O
A,3432,O
lesion,3432,O
induced,3432,O
by,3432,O
6-OHDA,3432,B-Chemical
produced,3432,O
more,3432,O
severe,3432,O
motor,3432,O
deterioration,3432,O
in,3432,O
CB1,3432,O
KO,3432,O
mice,3432,O
accompanied,3432,O
by,3432,O
more,3432,O
loss,3432,O
of,3432,O
DA,3432,B-Chemical
neurons,3432,O
and,3432,O
increased,3432,O
PENK,3432,B-Chemical
gene,3432,O
expression,3432,O
in,3432,O
the,3432,O
CPu,3432,O
.,3432,O
Oxidative/nitrosative,3433,O
and,3433,O
neuroinflammatory,3433,O
parameters,3433,O
were,3433,O
estimated,3433,O
in,3433,O
the,3433,O
CPu,3433,O
and,3433,O
cingulate,3433,O
cortex,3433,O
(,3433,O
Cg,3433,O
),3433,O
.,3433,O
CB1,3434,O
KO,3434,O
mice,3434,O
exhibited,3434,O
higher,3434,O
MDA,3434,B-Chemical
levels,3434,O
and,3434,O
iNOS,3434,O
protein,3434,O
expression,3434,O
in,3434,O
the,3434,O
CPu,3434,O
and,3434,O
Cg,3434,O
compared,3434,O
to,3434,O
WT,3434,O
mice,3434,O
.,3434,O
Treatment,3435,O
with,3435,O
L-DOPA+benserazide,3435,B-Chemical
(,3435,O
12,3435,O
weeks,3435,O
),3435,O
resulted,3435,O
in,3435,O
less,3435,O
severe,3435,O
dyskinesias,3435,B-Disease
in,3435,O
CB1,3435,O
KO,3435,O
than,3435,O
in,3435,O
WT,3435,O
mice,3435,O
.,3435,O
The,3436,O
results,3436,O
revealed,3436,O
that,3436,O
the,3436,O
lack,3436,O
of,3436,O
cannabinoid,3436,O
CB1,3436,O
receptors,3436,O
increased,3436,O
the,3436,O
severity,3436,O
of,3436,O
motor,3436,O
impairment,3436,O
and,3436,O
DA,3436,B-Chemical
lesion,3436,O
",",3436,O
and,3436,O
reduced,3436,O
L-DOPA-induced,3436,B-Chemical
dyskinesias,3436,B-Disease
.,3436,O
These,3437,O
results,3437,O
suggest,3437,O
that,3437,O
activation,3437,O
of,3437,O
CB1,3437,O
receptors,3437,O
offers,3437,O
neuroprotection,3437,O
against,3437,O
dopaminergic,3437,O
lesion,3437,O
and,3437,O
the,3437,O
development,3437,O
of,3437,O
L-DOPA-induced,3437,B-Chemical
dyskinesias,3437,B-Disease
.,3437,O
Animal,3438,O
model,3438,O
of,3438,O
mania,3438,B-Disease
induced,3438,O
by,3438,O
ouabain,3438,B-Chemical
:,3438,O
Evidence,3438,O
of,3438,O
oxidative,3438,O
stress,3438,O
in,3438,O
submitochondrial,3438,O
particles,3438,O
of,3438,O
the,3438,O
rat,3438,O
brain,3438,O
.,3438,O
The,3439,O
intracerebroventricular,3439,O
(,3439,O
ICV,3439,O
),3439,O
administration,3439,O
of,3439,O
ouabain,3439,B-Chemical
(,3439,O
a,3439,O
Na,3439,B-Chemical
(,3439,O
+,3439,O
),3439,O
/K,3439,O
(,3439,O
+,3439,O
),3439,O
-ATPase,3439,O
inhibitor,3439,O
),3439,O
in,3439,O
rats,3439,O
has,3439,O
been,3439,O
suggested,3439,O
to,3439,O
mimic,3439,O
some,3439,O
symptoms,3439,O
of,3439,O
human,3439,O
bipolar,3439,B-Disease
mania,3439,I-Disease
.,3439,O
Clinical,3440,O
studies,3440,O
have,3440,O
shown,3440,O
that,3440,O
bipolar,3440,B-Disease
disorder,3440,I-Disease
may,3440,O
be,3440,O
related,3440,O
to,3440,O
mitochondrial,3440,B-Disease
dysfunction,3440,I-Disease
.,3440,O
Herein,3441,O
",",3441,O
we,3441,O
investigated,3441,O
the,3441,O
behavioral,3441,O
and,3441,O
biochemical,3441,O
effects,3441,O
induced,3441,O
by,3441,O
the,3441,O
ICV,3441,O
administration,3441,O
of,3441,O
ouabain,3441,B-Chemical
in,3441,O
rats,3441,O
.,3441,O
To,3442,O
achieve,3442,O
this,3442,O
aim,3442,O
",",3442,O
the,3442,O
effects,3442,O
of,3442,O
ouabain,3442,B-Chemical
injection,3442,O
immediately,3442,O
after,3442,O
and,3442,O
7,3442,O
days,3442,O
following,3442,O
a,3442,O
single,3442,O
ICV,3442,O
administration,3442,O
(,3442,O
at,3442,O
concentrations,3442,O
of,3442,O
10,3442,O
(,3442,O
-2,3442,O
),3442,O
and,3442,O
10,3442,O
(,3442,O
-3,3442,O
),3442,O
M,3442,O
),3442,O
on,3442,O
locomotion,3442,O
was,3442,O
measured,3442,O
using,3442,O
the,3442,O
open-field,3442,O
test,3442,O
.,3442,O
Additionally,3443,O
",",3443,O
thiobarbituric,3443,B-Chemical
acid,3443,I-Chemical
reactive,3443,O
substances,3443,O
(,3443,O
TBARSs,3443,O
),3443,O
and,3443,O
superoxide,3443,B-Chemical
production,3443,O
were,3443,O
measured,3443,O
in,3443,O
submitochondrial,3443,O
particles,3443,O
of,3443,O
the,3443,O
prefrontal,3443,O
cortex,3443,O
",",3443,O
hippocampus,3443,O
",",3443,O
striatum,3443,O
and,3443,O
amygdala,3443,O
.,3443,O
Our,3444,O
findings,3444,O
demonstrated,3444,O
that,3444,O
ouabain,3444,B-Chemical
at,3444,O
10,3444,O
(,3444,O
-2,3444,O
),3444,O
and,3444,O
10,3444,O
(,3444,O
-3,3444,O
),3444,O
M,3444,O
induced,3444,O
hyperlocomotion,3444,B-Disease
in,3444,O
rats,3444,O
",",3444,O
and,3444,O
this,3444,O
response,3444,O
remained,3444,O
up,3444,O
to,3444,O
7,3444,O
days,3444,O
following,3444,O
a,3444,O
single,3444,O
ICV,3444,O
injection,3444,O
.,3444,O
In,3445,O
addition,3445,O
",",3445,O
we,3445,O
observed,3445,O
that,3445,O
the,3445,O
persistent,3445,O
increase,3445,O
in,3445,O
the,3445,O
rat,3445,O
spontaneous,3445,O
locomotion,3445,O
is,3445,O
associated,3445,O
with,3445,O
increased,3445,O
TBARS,3445,O
levels,3445,O
and,3445,O
superoxide,3445,B-Chemical
generation,3445,O
in,3445,O
submitochondrial,3445,O
particles,3445,O
in,3445,O
the,3445,O
prefrontal,3445,O
cortex,3445,O
",",3445,O
striatum,3445,O
and,3445,O
amygdala,3445,O
.,3445,O
In,3446,O
conclusion,3446,O
",",3446,O
ouabain-induced,3446,B-Chemical
mania-like,3446,B-Disease
behavior,3446,O
may,3446,O
provide,3446,O
a,3446,O
useful,3446,O
animal,3446,O
model,3446,O
to,3446,O
test,3446,O
the,3446,O
hypothesis,3446,O
of,3446,O
the,3446,O
involvement,3446,O
of,3446,O
oxidative,3446,O
stress,3446,O
in,3446,O
bipolar,3446,B-Disease
disorder,3446,I-Disease
.,3446,O
Intraoperative,3447,O
dialysis,3447,O
during,3447,O
liver,3447,O
transplantation,3447,O
with,3447,O
citrate,3447,B-Chemical
dialysate,3447,O
.,3447,O
Liver,3448,O
transplantation,3448,O
for,3448,O
acutely,3448,O
ill,3448,O
patients,3448,O
with,3448,O
fulminant,3448,B-Disease
liver,3448,I-Disease
failure,3448,I-Disease
carries,3448,O
high,3448,O
intraoperative,3448,O
and,3448,O
immediate,3448,O
postoperative,3448,O
risks,3448,O
.,3448,O
These,3449,O
are,3449,O
increased,3449,O
with,3449,O
the,3449,O
presence,3449,O
of,3449,O
concomitant,3449,O
acute,3449,B-Disease
kidney,3449,I-Disease
injury,3449,I-Disease
(,3449,O
AKI,3449,B-Disease
),3449,O
and,3449,O
intraoperative,3449,O
dialysis,3449,O
is,3449,O
sometimes,3449,O
required,3449,O
to,3449,O
allow,3449,O
the,3449,O
transplant,3449,O
to,3449,O
proceed,3449,O
.,3449,O
The,3450,O
derangements,3450,O
in,3450,O
the,3450,O
procoagulant,3450,O
and,3450,O
anticoagulant,3450,O
pathways,3450,O
during,3450,O
fulminant,3450,B-Disease
liver,3450,I-Disease
failure,3450,I-Disease
can,3450,O
lead,3450,O
to,3450,O
difficulties,3450,O
with,3450,O
anticoagulation,3450,O
during,3450,O
dialysis,3450,O
",",3450,O
especially,3450,O
when,3450,O
continued,3450,O
in,3450,O
the,3450,O
operating,3450,O
room,3450,O
.,3450,O
Systemic,3451,O
anticoagulation,3451,O
is,3451,O
unsafe,3451,O
and,3451,O
regional,3451,O
citrate,3451,B-Chemical
anticoagulation,3451,O
in,3451,O
the,3451,O
absence,3451,O
of,3451,O
a,3451,O
functional,3451,O
liver,3451,O
carries,3451,O
the,3451,O
risk,3451,O
of,3451,O
citrate,3451,B-Chemical
toxicity,3451,B-Disease
.,3451,O
Citrate,3452,B-Chemical
dialysate,3452,O
",",3452,O
a,3452,O
new,3452,O
dialysate,3452,O
with,3452,O
citric,3452,B-Chemical
acid,3452,I-Chemical
can,3452,O
be,3452,O
used,3452,O
for,3452,O
anticoagulation,3452,O
in,3452,O
patients,3452,O
who,3452,O
can,3452,O
not,3452,O
tolerate,3452,O
heparin,3452,B-Chemical
or,3452,O
regional,3452,O
citrate,3452,B-Chemical
.,3452,O
We,3453,O
report,3453,O
a,3453,O
case,3453,O
of,3453,O
a,3453,O
40-year-old,3453,O
female,3453,O
with,3453,O
acetaminophen-induced,3453,B-Chemical
fulminant,3453,B-Disease
liver,3453,I-Disease
failure,3453,I-Disease
with,3453,O
associated,3453,O
AKI,3453,B-Disease
who,3453,O
underwent,3453,O
intraoperative,3453,O
dialytic,3453,O
support,3453,O
during,3453,O
liver,3453,O
transplantation,3453,O
anticoagulated,3453,O
with,3453,O
citrate,3453,B-Chemical
dialysate,3453,O
during,3453,O
the,3453,O
entire,3453,O
procedure,3453,O
.,3453,O
The,3454,O
patient,3454,O
tolerated,3454,O
the,3454,O
procedure,3454,O
well,3454,O
without,3454,O
any,3454,O
signs,3454,O
of,3454,O
citrate,3454,B-Chemical
toxicity,3454,B-Disease
and,3454,O
maintained,3454,O
adequate,3454,O
anticoagulation,3454,O
for,3454,O
patency,3454,O
of,3454,O
the,3454,O
dialysis,3454,O
circuit,3454,O
.,3454,O
Citrate,3455,B-Chemical
dialysate,3455,O
is,3455,O
a,3455,O
safe,3455,O
alternative,3455,O
for,3455,O
intradialytic,3455,O
support,3455,O
of,3455,O
liver,3455,O
transplantation,3455,O
in,3455,O
fulminant,3455,B-Disease
liver,3455,I-Disease
failure,3455,I-Disease
.,3455,O
Delirium,3456,B-Disease
in,3456,O
a,3456,O
patient,3456,O
with,3456,O
toxic,3456,O
flecainide,3456,B-Chemical
plasma,3456,O
concentrations,3456,O
:,3456,O
the,3456,O
role,3456,O
of,3456,O
a,3456,O
pharmacokinetic,3456,O
drug,3456,O
interaction,3456,O
with,3456,O
paroxetine,3456,B-Chemical
.,3456,O
OBJECTIVE,3457,O
:,3457,O
To,3457,O
describe,3457,O
a,3457,O
case,3457,O
of,3457,O
flecainide-induced,3457,B-Chemical
delirium,3457,B-Disease
associated,3457,O
with,3457,O
a,3457,O
pharmacokinetic,3457,O
drug,3457,O
interaction,3457,O
with,3457,O
paroxetine,3457,B-Chemical
.,3457,O
CASE,3458,O
SUMMARY,3458,O
:,3458,O
A,3458,O
69-year-old,3458,O
white,3458,O
female,3458,O
presented,3458,O
to,3458,O
the,3458,O
emergency,3458,O
department,3458,O
with,3458,O
a,3458,O
history,3458,O
of,3458,O
confusion,3458,B-Disease
and,3458,O
paranoia,3458,B-Disease
over,3458,O
the,3458,O
past,3458,O
several,3458,O
days,3458,O
.,3458,O
On,3459,O
admission,3459,O
the,3459,O
patient,3459,O
was,3459,O
taking,3459,O
carvedilol,3459,B-Chemical
12,3459,O
mg,3459,O
twice,3459,O
daily,3459,O
",",3459,O
warfarin,3459,B-Chemical
2,3459,O
mg/day,3459,O
",",3459,O
folic,3459,B-Chemical
acid,3459,I-Chemical
1,3459,O
mg/day,3459,O
",",3459,O
levothyroxine,3459,B-Chemical
100,3459,O
microg/day,3459,O
",",3459,O
pantoprazole,3459,B-Chemical
40,3459,O
mg/day,3459,O
",",3459,O
paroxetine,3459,B-Chemical
40,3459,O
mg/day,3459,O
",",3459,O
and,3459,O
flecainide,3459,B-Chemical
100,3459,O
mg,3459,O
twice,3459,O
daily,3459,O
.,3459,O
Flecainide,3460,B-Chemical
had,3460,O
been,3460,O
started,3460,O
2,3460,O
weeks,3460,O
prior,3460,O
for,3460,O
atrial,3460,B-Disease
fibrillation,3460,I-Disease
.,3460,O
Laboratory,3461,O
test,3461,O
findings,3461,O
on,3461,O
admission,3461,O
were,3461,O
notable,3461,O
only,3461,O
for,3461,O
a,3461,O
flecainide,3461,B-Chemical
plasma,3461,O
concentration,3461,O
of,3461,O
1360,3461,O
microg/L,3461,O
(,3461,O
reference,3461,O
range,3461,O
200-1000,3461,O
),3461,O
.,3461,O
A,3462,O
metabolic,3462,O
drug,3462,O
interaction,3462,O
between,3462,O
flecainide,3462,B-Chemical
and,3462,O
paroxetine,3462,B-Chemical
",",3462,O
which,3462,O
the,3462,O
patient,3462,O
had,3462,O
been,3462,O
taking,3462,O
for,3462,O
more,3462,O
than,3462,O
5,3462,O
years,3462,O
",",3462,O
was,3462,O
considered,3462,O
.,3462,O
Paroxetine,3463,B-Chemical
was,3463,O
discontinued,3463,O
and,3463,O
the,3463,O
dose,3463,O
of,3463,O
flecainide,3463,B-Chemical
was,3463,O
reduced,3463,O
to,3463,O
50,3463,O
mg,3463,O
twice,3463,O
daily,3463,O
.,3463,O
Her,3464,O
delirium,3464,B-Disease
resolved,3464,O
3,3464,O
days,3464,O
later,3464,O
.,3464,O
DISCUSSION,3465,O
:,3465,O
Flecainide,3465,B-Chemical
and,3465,O
pharmacologically,3465,O
similar,3465,O
agents,3465,O
that,3465,O
interact,3465,O
with,3465,O
sodium,3465,B-Chemical
channels,3465,O
may,3465,O
cause,3465,O
delirium,3465,B-Disease
in,3465,O
susceptible,3465,O
patients,3465,O
.,3465,O
A,3466,O
MEDLINE,3466,O
search,3466,O
(,3466,O
1966-January,3466,O
2009,3466,O
),3466,O
revealed,3466,O
one,3466,O
in,3466,O
vivo,3466,O
pharmacokinetic,3466,O
study,3466,O
on,3466,O
the,3466,O
interaction,3466,O
between,3466,O
flecainide,3466,B-Chemical
",",3466,O
a,3466,O
CYP2D6,3466,O
substrate,3466,O
",",3466,O
and,3466,O
paroxetine,3466,B-Chemical
",",3466,O
a,3466,O
CYP2D6,3466,O
inhibitor,3466,O
",",3466,O
as,3466,O
well,3466,O
as,3466,O
3,3466,O
case,3466,O
reports,3466,O
of,3466,O
flecainide-induced,3466,B-Chemical
delirium,3466,B-Disease
.,3466,O
According,3467,O
to,3467,O
the,3467,O
Naranjo,3467,O
probability,3467,O
scale,3467,O
",",3467,O
flecainide,3467,B-Chemical
was,3467,O
the,3467,O
probable,3467,O
cause,3467,O
of,3467,O
the,3467,O
patient,3467,O
's,3467,O
delirium,3467,B-Disease
;,3467,O
the,3467,O
Horn,3467,O
Drug,3467,O
Interaction,3467,O
Probability,3467,O
Scale,3467,O
indicates,3467,O
a,3467,O
possible,3467,O
pharmacokinetic,3467,O
drug,3467,O
interaction,3467,O
between,3467,O
flecainide,3467,B-Chemical
and,3467,O
paroxetine,3467,B-Chemical
.,3467,O
CONCLUSIONS,3468,O
:,3468,O
Supratherapeutic,3468,O
flecainide,3468,B-Chemical
plasma,3468,O
concentrations,3468,O
may,3468,O
cause,3468,O
delirium,3468,B-Disease
.,3468,O
Because,3469,O
toxicity,3469,B-Disease
may,3469,O
occur,3469,O
when,3469,O
flecainide,3469,B-Chemical
is,3469,O
prescribed,3469,O
with,3469,O
paroxetine,3469,B-Chemical
and,3469,O
other,3469,O
potent,3469,O
CYP2D6,3469,O
inhibitors,3469,O
",",3469,O
flecainide,3469,B-Chemical
plasma,3469,O
concentrations,3469,O
should,3469,O
be,3469,O
monitored,3469,O
closely,3469,O
with,3469,O
commencement,3469,O
of,3469,O
CYP2D6,3469,O
inhibitors,3469,O
.,3469,O
Efficacy,3470,O
of,3470,O
everolimus,3470,B-Chemical
(,3470,O
RAD001,3470,B-Chemical
),3470,O
in,3470,O
patients,3470,O
with,3470,O
advanced,3470,O
NSCLC,3470,B-Disease
previously,3470,O
treated,3470,O
with,3470,O
chemotherapy,3470,O
alone,3470,O
or,3470,O
with,3470,O
chemotherapy,3470,O
and,3470,O
EGFR,3470,O
inhibitors,3470,O
.,3470,O
BACKGROUND,3471,O
:,3471,O
Treatment,3471,O
options,3471,O
are,3471,O
scarce,3471,O
in,3471,O
pretreated,3471,O
advanced,3471,O
non-small-cell,3471,B-Disease
lung,3471,I-Disease
cancer,3471,I-Disease
(,3471,O
NSCLC,3471,B-Disease
),3471,O
patients,3471,O
.,3471,O
RAD001,3472,B-Chemical
",",3472,O
an,3472,O
oral,3472,O
inhibitor,3472,O
of,3472,O
the,3472,O
mammalian,3472,O
target,3472,O
of,3472,O
rapamycin,3472,B-Chemical
(,3472,O
mTOR,3472,O
),3472,O
",",3472,O
has,3472,O
shown,3472,O
phase,3472,O
I,3472,O
efficacy,3472,O
in,3472,O
NSCLC,3472,B-Disease
.,3472,O
METHODS,3473,O
:,3473,O
Stage,3473,O
IIIb,3473,O
or,3473,O
IV,3473,O
NSCLC,3473,B-Disease
patients,3473,O
",",3473,O
with,3473,O
two,3473,O
or,3473,O
fewer,3473,O
prior,3473,O
chemotherapy,3473,O
regimens,3473,O
",",3473,O
one,3473,O
platinum,3473,B-Chemical
based,3473,O
(,3473,O
stratum,3473,O
1,3473,O
),3473,O
or,3473,O
both,3473,O
chemotherapy,3473,O
and,3473,O
epidermal,3473,O
growth,3473,O
factor,3473,O
receptor,3473,O
tyrosine,3473,B-Chemical
kinase,3473,O
inhibitors,3473,O
(,3473,O
stratum,3473,O
2,3473,O
),3473,O
",",3473,O
received,3473,O
RAD001,3473,B-Chemical
10,3473,O
mg/day,3473,O
until,3473,O
progression,3473,O
or,3473,O
unacceptable,3473,O
toxicity,3473,B-Disease
.,3473,O
Primary,3474,O
objective,3474,O
was,3474,O
overall,3474,O
response,3474,O
rate,3474,O
(,3474,O
ORR,3474,O
),3474,O
.,3474,O
Analyses,3475,O
of,3475,O
markers,3475,O
associated,3475,O
with,3475,O
the,3475,O
mTOR,3475,O
pathway,3475,O
were,3475,O
carried,3475,O
out,3475,O
on,3475,O
archival,3475,O
tumor,3475,B-Disease
from,3475,O
a,3475,O
subgroup,3475,O
using,3475,O
immunohistochemistry,3475,O
(,3475,O
IHC,3475,O
),3475,O
and,3475,O
direct,3475,O
mutation,3475,O
sequencing,3475,O
.,3475,O
RESULTS,3476,O
:,3476,O
Eighty-five,3476,O
patients,3476,O
were,3476,O
enrolled,3476,O
",",3476,O
42,3476,O
in,3476,O
stratum,3476,O
1,3476,O
and,3476,O
43,3476,O
in,3476,O
stratum,3476,O
.,3476,O
ORR,3477,O
was,3477,O
4.7,3477,O
%,3477,O
(,3477,O
7.1,3477,O
%,3477,O
stratum,3477,O
1,3477,O
;,3477,O
2.3,3477,O
%,3477,O
stratum,3477,O
2,3477,O
),3477,O
.,3477,O
Overall,3478,O
disease,3478,O
control,3478,O
rate,3478,O
was,3478,O
47.1,3478,O
%,3478,O
.,3478,O
Median,3479,O
progression-free,3479,O
survivals,3479,O
(,3479,O
PFSs,3479,O
),3479,O
were,3479,O
2.6,3479,O
(,3479,O
stratum,3479,O
1,3479,O
),3479,O
and,3479,O
2.7,3479,O
months,3479,O
(,3479,O
stratum,3479,O
2,3479,O
),3479,O
.,3479,O
Common,3480,O
>,3480,O
or,3480,O
=grade,3480,O
3,3480,O
events,3480,O
were,3480,O
fatigue,3480,B-Disease
",",3480,O
dyspnea,3480,B-Disease
",",3480,O
stomatitis,3480,B-Disease
",",3480,O
anemia,3480,B-Disease
",",3480,O
and,3480,O
thrombocytopenia,3480,B-Disease
.,3480,O
Pneumonitis,3481,B-Disease
",",3481,O
probably,3481,O
or,3481,O
possibly,3481,O
related,3481,O
",",3481,O
mainly,3481,O
grade,3481,O
1/2,3481,O
",",3481,O
occurred,3481,O
in,3481,O
25,3481,O
%,3481,O
.,3481,O
Cox,3482,O
regression,3482,O
analysis,3482,O
of,3482,O
IHC,3482,O
scores,3482,O
found,3482,O
that,3482,O
only,3482,O
phospho,3482,O
AKT,3482,O
(,3482,O
pAKT,3482,O
),3482,O
was,3482,O
a,3482,O
significant,3482,O
independent,3482,O
predictor,3482,O
of,3482,O
worse,3482,O
PFS,3482,O
.,3482,O
CONCLUSIONS,3483,O
:,3483,O
RAD001,3483,B-Chemical
10,3483,O
mg/day,3483,O
was,3483,O
well,3483,O
tolerated,3483,O
",",3483,O
showing,3483,O
modest,3483,O
clinical,3483,O
activity,3483,O
in,3483,O
pretreated,3483,O
NSCLC,3483,B-Disease
.,3483,O
Evaluation,3484,O
of,3484,O
RAD001,3484,B-Chemical
plus,3484,O
standard,3484,O
therapy,3484,O
for,3484,O
metastatic,3484,O
NSCLC,3484,B-Disease
continues,3484,O
.,3484,O
Posttransplant,3485,O
anemia,3485,B-Disease
:,3485,O
the,3485,O
role,3485,O
of,3485,O
sirolimus,3485,B-Chemical
.,3485,O
Posttransplant,3486,O
anemia,3486,B-Disease
is,3486,O
a,3486,O
common,3486,O
problem,3486,O
that,3486,O
may,3486,O
hinder,3486,O
patients,3486,O
',3486,O
quality,3486,O
of,3486,O
life,3486,O
.,3486,O
It,3487,O
occurs,3487,O
in,3487,O
12,3487,O
to,3487,O
76,3487,O
%,3487,O
of,3487,O
patients,3487,O
",",3487,O
and,3487,O
is,3487,O
most,3487,O
common,3487,O
in,3487,O
the,3487,O
immediate,3487,O
posttransplant,3487,O
period,3487,O
.,3487,O
A,3488,O
variety,3488,O
of,3488,O
factors,3488,O
have,3488,O
been,3488,O
identified,3488,O
that,3488,O
increase,3488,O
the,3488,O
risk,3488,O
of,3488,O
posttransplant,3488,O
anemia,3488,B-Disease
",",3488,O
of,3488,O
which,3488,O
the,3488,O
level,3488,O
of,3488,O
renal,3488,O
function,3488,O
is,3488,O
most,3488,O
important,3488,O
.,3488,O
Sirolimus,3489,B-Chemical
",",3489,O
a,3489,O
mammalian,3489,O
target,3489,O
of,3489,O
rapamycin,3489,B-Chemical
inhibitor,3489,O
",",3489,O
has,3489,O
been,3489,O
implicated,3489,O
as,3489,O
playing,3489,O
a,3489,O
special,3489,O
role,3489,O
in,3489,O
posttransplant,3489,O
anemia,3489,B-Disease
.,3489,O
This,3490,O
review,3490,O
considers,3490,O
anemia,3490,B-Disease
associated,3490,O
with,3490,O
sirolimus,3490,B-Chemical
",",3490,O
including,3490,O
its,3490,O
presentation,3490,O
",",3490,O
mechanisms,3490,O
",",3490,O
and,3490,O
management,3490,O
.,3490,O
Coronary,3491,O
computerized,3491,O
tomography,3491,O
angiography,3491,O
for,3491,O
rapid,3491,O
discharge,3491,O
of,3491,O
low-risk,3491,O
patients,3491,O
with,3491,O
cocaine-associated,3491,B-Chemical
chest,3491,B-Disease
pain,3491,I-Disease
.,3491,O
BACKGROUND,3492,O
:,3492,O
Most,3492,O
patients,3492,O
presenting,3492,O
to,3492,O
emergency,3492,O
departments,3492,O
(,3492,O
EDs,3492,O
),3492,O
with,3492,O
cocaine-associated,3492,B-Chemical
chest,3492,B-Disease
pain,3492,I-Disease
are,3492,O
admitted,3492,O
for,3492,O
at,3492,O
least,3492,O
12,3492,O
hours,3492,O
and,3492,O
receive,3492,O
a,3492,O
``,3492,O
rule,3492,O
out,3492,O
acute,3492,B-Disease
coronary,3492,I-Disease
syndrome,3492,I-Disease
'',3492,O
protocol,3492,O
",",3492,O
often,3492,O
with,3492,O
noninvasive,3492,O
testing,3492,O
prior,3492,O
to,3492,O
discharge,3492,O
.,3492,O
In,3493,O
patients,3493,O
without,3493,O
cocaine,3493,B-Chemical
use,3493,O
",",3493,O
coronary,3493,O
computerized,3493,O
tomography,3493,O
angiography,3493,O
(,3493,O
CTA,3493,O
),3493,O
has,3493,O
been,3493,O
shown,3493,O
to,3493,O
be,3493,O
useful,3493,O
for,3493,O
identifying,3493,O
a,3493,O
group,3493,O
of,3493,O
patients,3493,O
at,3493,O
low,3493,O
risk,3493,O
for,3493,O
cardiac,3493,O
events,3493,O
who,3493,O
can,3493,O
be,3493,O
safely,3493,O
discharged,3493,O
.,3493,O
It,3494,O
is,3494,O
unclear,3494,O
whether,3494,O
a,3494,O
coronary,3494,O
CTA,3494,O
strategy,3494,O
would,3494,O
be,3494,O
efficacious,3494,O
in,3494,O
cocaine-associated,3494,B-Chemical
chest,3494,B-Disease
pain,3494,I-Disease
",",3494,O
as,3494,O
coronary,3494,B-Disease
vasospasm,3494,I-Disease
may,3494,O
account,3494,O
for,3494,O
some,3494,O
of,3494,O
the,3494,O
ischemia,3494,B-Disease
.,3494,O
We,3495,O
studied,3495,O
whether,3495,O
a,3495,O
negative,3495,O
coronary,3495,O
CTA,3495,O
in,3495,O
patients,3495,O
with,3495,O
cocaine-associated,3495,B-Chemical
chest,3495,B-Disease
pain,3495,I-Disease
could,3495,O
identify,3495,O
a,3495,O
subset,3495,O
safe,3495,O
for,3495,O
discharge,3495,O
.,3495,O
METHODS,3496,O
:,3496,O
We,3496,O
prospectively,3496,O
evaluated,3496,O
the,3496,O
safety,3496,O
of,3496,O
coronary,3496,O
CTA,3496,O
for,3496,O
low-risk,3496,O
patients,3496,O
who,3496,O
presented,3496,O
to,3496,O
the,3496,O
ED,3496,O
with,3496,O
cocaineassociated,3496,O
chest,3496,B-Disease
pain,3496,I-Disease
(,3496,O
self-reported,3496,O
or,3496,O
positive,3496,O
urine,3496,O
test,3496,O
),3496,O
.,3496,O
Consecutive,3497,O
patients,3497,O
received,3497,O
either,3497,O
immediate,3497,O
coronary,3497,O
CTA,3497,O
in,3497,O
the,3497,O
ED,3497,O
(,3497,O
without,3497,O
serial,3497,O
markers,3497,O
),3497,O
or,3497,O
underwent,3497,O
coronary,3497,O
CTA,3497,O
after,3497,O
a,3497,O
brief,3497,O
observation,3497,O
period,3497,O
with,3497,O
serial,3497,O
cardiac,3497,O
marker,3497,O
measurements,3497,O
.,3497,O
Patients,3498,O
with,3498,O
negative,3498,O
coronary,3498,O
CTA,3498,O
(,3498,O
maximal,3498,O
stenosis,3498,B-Disease
less,3498,O
than,3498,O
50,3498,O
%,3498,O
),3498,O
were,3498,O
discharged,3498,O
.,3498,O
The,3499,O
main,3499,O
outcome,3499,O
was,3499,O
30-day,3499,O
cardiovascular,3499,O
death,3499,O
or,3499,O
myocardial,3499,B-Disease
infarction,3499,I-Disease
.,3499,O
RESULTS,3500,O
:,3500,O
A,3500,O
total,3500,O
of,3500,O
59,3500,O
patients,3500,O
with,3500,O
cocaine-associated,3500,B-Chemical
chest,3500,B-Disease
pain,3500,I-Disease
were,3500,O
evaluated,3500,O
.,3500,O
Patients,3501,O
had,3501,O
a,3501,O
mean,3501,O
age,3501,O
of,3501,O
45.6,3501,O
+/-,3501,O
6.6,3501,O
yrs,3501,O
and,3501,O
were,3501,O
86,3501,O
%,3501,O
black,3501,O
",",3501,O
66,3501,O
%,3501,O
male,3501,O
.,3501,O
Seventy-nine,3502,O
percent,3502,O
had,3502,O
a,3502,O
normal,3502,O
or,3502,O
nonspecific,3502,O
ECG,3502,O
and,3502,O
85,3502,O
%,3502,O
had,3502,O
a,3502,O
TIMI,3502,O
score,3502,O
<,3502,O
2,3502,O
.,3502,O
Twenty,3503,O
patients,3503,O
received,3503,O
coronary,3503,O
CTA,3503,O
immediately,3503,O
in,3503,O
the,3503,O
ED,3503,O
",",3503,O
18,3503,O
of,3503,O
whom,3503,O
were,3503,O
discharged,3503,O
following,3503,O
CTA,3503,O
(,3503,O
90,3503,O
%,3503,O
),3503,O
.,3503,O
Thirty-nine,3504,O
received,3504,O
coronary,3504,O
CTA,3504,O
after,3504,O
a,3504,O
brief,3504,O
observation,3504,O
period,3504,O
",",3504,O
with,3504,O
37,3504,O
discharged,3504,O
home,3504,O
following,3504,O
CTA,3504,O
(,3504,O
95,3504,O
%,3504,O
),3504,O
.,3504,O
Six,3505,O
patients,3505,O
had,3505,O
coronary,3505,B-Disease
stenosis,3505,I-Disease
>,3505,O
or=50,3505,O
%,3505,O
.,3505,O
During,3506,O
the,3506,O
30-day,3506,O
follow-up,3506,O
period,3506,O
",",3506,O
no,3506,O
patients,3506,O
died,3506,O
of,3506,O
a,3506,O
cardiovascular,3506,O
event,3506,O
(,3506,O
0,3506,O
%,3506,O
;,3506,O
95,3506,O
%,3506,O
CI,3506,O
",",3506,O
0-6.1,3506,O
%,3506,O
),3506,O
and,3506,O
no,3506,O
patient,3506,O
sustained,3506,O
a,3506,O
nonfatal,3506,O
myocardial,3506,B-Disease
infarction,3506,I-Disease
(,3506,O
0,3506,O
%,3506,O
;,3506,O
95,3506,O
%,3506,O
CI,3506,O
",",3506,O
0-6.1,3506,O
%,3506,O
),3506,O
.,3506,O
CONCLUSIONS,3507,O
:,3507,O
Although,3507,O
cocaine-associated,3507,B-Chemical
myocardial,3507,B-Disease
ischemia,3507,I-Disease
can,3507,O
result,3507,O
from,3507,O
coronary,3507,O
vasoconstriction,3507,O
",",3507,O
patients,3507,O
with,3507,O
cocaine,3507,B-Chemical
associated,3507,O
chest,3507,B-Disease
pain,3507,I-Disease
",",3507,O
a,3507,O
non-ischemic,3507,O
ECG,3507,O
",",3507,O
and,3507,O
a,3507,O
TIMI,3507,O
risk,3507,O
score,3507,O
<,3507,O
2,3507,O
may,3507,O
be,3507,O
safely,3507,O
discharged,3507,O
from,3507,O
the,3507,O
ED,3507,O
after,3507,O
a,3507,O
negative,3507,O
coronary,3507,O
CTA,3507,O
with,3507,O
a,3507,O
low,3507,O
risk,3507,O
of,3507,O
30-day,3507,O
adverse,3507,O
events,3507,O
.,3507,O
Bilateral,3508,O
haemorrhagic,3508,O
infarction,3508,O
of,3508,O
the,3508,O
globus,3508,O
pallidus,3508,O
after,3508,O
cocaine,3508,B-Chemical
and,3508,O
alcohol,3508,B-Chemical
intoxication,3508,O
.,3508,O
Cocaine,3509,B-Chemical
is,3509,O
a,3509,O
risk,3509,O
factor,3509,O
for,3509,O
both,3509,O
ischemic,3509,O
and,3509,O
haemorrhagic,3509,O
stroke,3509,O
.,3509,O
We,3510,O
present,3510,O
the,3510,O
case,3510,O
of,3510,O
a,3510,O
31-year-old,3510,O
man,3510,O
with,3510,O
bilateral,3510,O
ischemia,3510,B-Disease
of,3510,I-Disease
the,3510,I-Disease
globus,3510,I-Disease
pallidus,3510,I-Disease
after,3510,O
excessive,3510,O
alcohol,3510,B-Chemical
and,3510,O
intranasal,3510,O
cocaine,3510,B-Chemical
use,3510,O
.,3510,O
Drug-related,3511,O
globus,3511,B-Disease
pallidus,3511,I-Disease
infarctions,3511,I-Disease
are,3511,O
most,3511,O
often,3511,O
associated,3511,O
with,3511,O
heroin,3511,B-Chemical
.,3511,O
Bilateral,3512,O
basal,3512,B-Disease
ganglia,3512,I-Disease
infarcts,3512,I-Disease
after,3512,O
the,3512,O
use,3512,O
of,3512,O
cocaine,3512,B-Chemical
",",3512,O
without,3512,O
concurrent,3512,O
heroin,3512,B-Chemical
use,3512,O
",",3512,O
have,3512,O
never,3512,O
been,3512,O
reported,3512,O
.,3512,O
In,3513,O
our,3513,O
patient,3513,O
",",3513,O
transient,3513,O
cardiac,3513,B-Disease
arrhythmia,3513,I-Disease
or,3513,O
respiratory,3513,B-Disease
dysfunction,3513,I-Disease
related,3513,O
to,3513,O
cocaine,3513,B-Chemical
and/or,3513,O
ethanol,3513,B-Chemical
use,3513,O
were,3513,O
the,3513,O
most,3513,O
likely,3513,O
causes,3513,O
of,3513,O
cerebral,3513,B-Disease
hypoperfusion,3513,I-Disease
.,3513,O
Late,3514,O
fulminant,3514,O
posterior,3514,B-Disease
reversible,3514,I-Disease
encephalopathy,3514,I-Disease
syndrome,3514,I-Disease
after,3514,O
liver,3514,O
transplant,3514,O
.,3514,O
OBJECTIVES,3515,O
:,3515,O
Posterior,3515,B-Disease
leukoencephalopathy,3515,I-Disease
due,3515,O
to,3515,O
calcineurin-inhibitor-related,3515,O
neurotoxicity,3515,B-Disease
is,3515,O
a,3515,O
rare,3515,O
but,3515,O
severe,3515,O
complication,3515,O
that,3515,O
results,3515,O
from,3515,O
treatment,3515,O
with,3515,O
immunosuppressive,3515,O
agents,3515,O
(,3515,O
primarily,3515,O
those,3515,O
administered,3515,O
after,3515,O
a,3515,O
liver,3515,O
or,3515,O
kidney,3515,O
transplant,3515,O
),3515,O
.,3515,O
The,3516,O
pathophysiologic,3516,O
mechanisms,3516,O
of,3516,O
that,3516,O
disorder,3516,O
remain,3516,O
unknown,3516,O
.,3516,O
CASE,3517,O
:,3517,O
We,3517,O
report,3517,O
the,3517,O
case,3517,O
of,3517,O
a,3517,O
46-year-old,3517,O
woman,3517,O
who,3517,O
received,3517,O
a,3517,O
liver,3517,O
transplant,3517,O
in,3517,O
our,3517,O
center,3517,O
as,3517,O
treatment,3517,O
for,3517,O
alcoholic,3517,B-Disease
cirrhosis,3517,I-Disease
and,3517,O
in,3517,O
whom,3517,O
either,3517,O
a,3517,O
fulminant,3517,O
course,3517,O
of,3517,O
posterior,3517,B-Disease
leukoencephalopathy,3517,I-Disease
or,3517,O
posterior,3517,B-Disease
reversible,3517,I-Disease
encephalopathy,3517,I-Disease
syndrome,3517,I-Disease
developed,3517,O
110,3517,O
days,3517,O
after,3517,O
transplant,3517,O
.,3517,O
After,3518,O
an,3518,O
initially,3518,O
uneventful,3518,O
course,3518,O
after,3518,O
the,3518,O
transplant,3518,O
",",3518,O
the,3518,O
patient,3518,O
rapidly,3518,O
fell,3518,O
into,3518,O
deep,3518,O
coma,3518,O
.,3518,O
RESULTS,3519,O
:,3519,O
Cerebral,3519,O
MRI,3519,O
scan,3519,O
showed,3519,O
typical,3519,O
signs,3519,O
of,3519,O
enhancement,3519,O
in,3519,O
the,3519,O
pontine,3519,O
and,3519,O
posterior,3519,O
regions,3519,O
.,3519,O
Switching,3520,O
the,3520,O
immunosuppressive,3520,O
regimen,3520,O
from,3520,O
tacrolimus,3520,B-Chemical
to,3520,O
cyclosporine,3520,B-Chemical
did,3520,O
not,3520,O
improve,3520,O
the,3520,O
clinical,3520,O
situation,3520,O
.,3520,O
The,3521,O
termination,3521,O
of,3521,O
treatment,3521,O
with,3521,O
any,3521,O
calcineurin,3521,O
inhibitor,3521,O
resulted,3521,O
in,3521,O
a,3521,O
complete,3521,O
resolution,3521,O
of,3521,O
that,3521,O
complication,3521,O
.,3521,O
CONCLUSIONS,3522,O
:,3522,O
Posterior,3522,B-Disease
reversible,3522,I-Disease
encephalopathy,3522,I-Disease
syndrome,3522,I-Disease
after,3522,O
liver,3522,O
transplant,3522,O
is,3522,O
rare,3522,O
.,3522,O
We,3523,O
recommend,3523,O
a,3523,O
complete,3523,O
cessation,3523,O
of,3523,O
any,3523,O
calcineurin,3523,O
inhibitor,3523,O
rather,3523,O
than,3523,O
a,3523,O
dose,3523,O
reduction,3523,O
.,3523,O
Prolonged,3524,O
hypothermia,3524,B-Disease
as,3524,O
a,3524,O
bridge,3524,O
to,3524,O
recovery,3524,O
for,3524,O
cerebral,3524,B-Disease
edema,3524,I-Disease
and,3524,O
intracranial,3524,B-Disease
hypertension,3524,I-Disease
associated,3524,O
with,3524,O
fulminant,3524,B-Disease
hepatic,3524,I-Disease
failure,3524,I-Disease
.,3524,O
BACKGROUND,3525,O
:,3525,O
To,3525,O
review,3525,O
evidence-based,3525,O
treatment,3525,O
options,3525,O
in,3525,O
patients,3525,O
with,3525,O
cerebral,3525,B-Disease
edema,3525,I-Disease
complicating,3525,O
fulminant,3525,B-Disease
hepatic,3525,I-Disease
failure,3525,I-Disease
(,3525,O
FHF,3525,B-Disease
),3525,O
and,3525,O
discuss,3525,O
the,3525,O
potential,3525,O
applications,3525,O
of,3525,O
hypothermia,3525,B-Disease
.,3525,O
METHOD,3526,O
:,3526,O
Case-based,3526,O
observations,3526,O
from,3526,O
a,3526,O
medical,3526,O
intensive,3526,O
care,3526,O
unit,3526,O
(,3526,O
MICU,3526,O
),3526,O
in,3526,O
a,3526,O
tertiary,3526,O
care,3526,O
facility,3526,O
in,3526,O
a,3526,O
27-year-old,3526,O
female,3526,O
with,3526,O
FHF,3526,B-Disease
from,3526,O
acetaminophen,3526,B-Chemical
and,3526,O
resultant,3526,O
cerebral,3526,B-Disease
edema,3526,I-Disease
.,3526,O
RESULTS,3527,O
:,3527,O
Our,3527,O
patient,3527,O
was,3527,O
admitted,3527,O
to,3527,O
the,3527,O
MICU,3527,O
after,3527,O
being,3527,O
found,3527,O
unresponsive,3527,O
with,3527,O
presumed,3527,O
toxicity,3527,B-Disease
from,3527,O
acetaminophen,3527,B-Chemical
which,3527,O
was,3527,O
ingested,3527,O
over,3527,O
a,3527,O
2-day,3527,O
period,3527,O
.,3527,O
The,3528,O
patient,3528,O
had,3528,O
depressed,3528,O
of,3528,O
mental,3528,O
status,3528,O
lasting,3528,O
at,3528,O
least,3528,O
24,3528,O
h,3528,O
prior,3528,O
to,3528,O
admission,3528,O
.,3528,O
Initial,3529,O
evaluation,3529,O
confirmed,3529,O
FHF,3529,B-Disease
from,3529,O
acetaminophen,3529,B-Chemical
and,3529,O
cerebral,3529,B-Disease
edema,3529,I-Disease
.,3529,O
The,3530,O
patient,3530,O
was,3530,O
treated,3530,O
with,3530,O
hyperosmolar,3530,O
therapy,3530,O
",",3530,O
hyperventilation,3530,B-Disease
",",3530,O
sedation,3530,O
",",3530,O
and,3530,O
chemical,3530,O
paralysis,3530,B-Disease
.,3530,O
Her,3531,O
intracranial,3531,O
pressure,3531,O
remained,3531,O
elevated,3531,O
despite,3531,O
maximal,3531,O
medical,3531,O
therapy,3531,O
.,3531,O
We,3532,O
then,3532,O
initiated,3532,O
therapeutic,3532,O
hypothermia,3532,B-Disease
which,3532,O
was,3532,O
continued,3532,O
for,3532,O
5,3532,O
days,3532,O
.,3532,O
At,3533,O
re-warming,3533,O
",",3533,O
patient,3533,O
had,3533,O
resolution,3533,O
of,3533,O
her,3533,O
cerebral,3533,B-Disease
edema,3533,I-Disease
and,3533,O
intracranial,3533,B-Disease
hypertension,3533,I-Disease
.,3533,O
At,3534,O
discharge,3534,O
",",3534,O
she,3534,O
had,3534,O
complete,3534,O
recovery,3534,O
of,3534,O
neurological,3534,O
and,3534,O
hepatic,3534,O
functions,3534,O
.,3534,O
CONCLUSION,3535,O
:,3535,O
In,3535,O
patients,3535,O
with,3535,O
FHF,3535,B-Disease
and,3535,O
cerebral,3535,B-Disease
edema,3535,I-Disease
from,3535,O
acetaminophen,3535,B-Chemical
overdose,3535,B-Disease
",",3535,O
prolonged,3535,O
therapeutic,3535,O
hypothermia,3535,B-Disease
could,3535,O
potentially,3535,O
be,3535,O
used,3535,O
as,3535,O
a,3535,O
life,3535,O
saving,3535,O
therapy,3535,O
and,3535,O
a,3535,O
bridge,3535,O
to,3535,O
hepatic,3535,O
and,3535,O
neurological,3535,O
recovery,3535,O
.,3535,O
A,3536,O
clinical,3536,O
trial,3536,O
of,3536,O
hypothermia,3536,B-Disease
in,3536,O
patients,3536,O
with,3536,O
this,3536,O
condition,3536,O
is,3536,O
warranted,3536,O
.,3536,O
Binasal,3537,B-Disease
visual,3537,I-Disease
field,3537,I-Disease
defects,3537,I-Disease
are,3537,O
not,3537,O
specific,3537,O
to,3537,O
vigabatrin,3537,B-Chemical
.,3537,O
This,3538,O
study,3538,O
investigated,3538,O
the,3538,O
visual,3538,B-Disease
defects,3538,I-Disease
associated,3538,O
with,3538,O
the,3538,O
antiepileptic,3538,O
drug,3538,O
vigabatrin,3538,B-Chemical
(,3538,O
VGB,3538,B-Chemical
),3538,O
.,3538,O
Two,3539,O
hundred,3539,O
four,3539,O
people,3539,O
with,3539,O
epilepsy,3539,B-Disease
were,3539,O
grouped,3539,O
on,3539,O
the,3539,O
basis,3539,O
of,3539,O
antiepileptic,3539,O
drug,3539,O
therapy,3539,O
(,3539,O
current,3539,O
",",3539,O
previous,3539,O
",",3539,O
or,3539,O
no,3539,O
exposure,3539,O
to,3539,O
VGB,3539,B-Chemical
),3539,O
.,3539,O
Groups,3540,O
were,3540,O
matched,3540,O
with,3540,O
respect,3540,O
to,3540,O
age,3540,O
",",3540,O
gender,3540,O
",",3540,O
and,3540,O
seizure,3540,B-Disease
frequency,3540,O
.,3540,O
All,3541,O
patients,3541,O
underwent,3541,O
objective,3541,O
assessment,3541,O
of,3541,O
electrophysiological,3541,O
function,3541,O
(,3541,O
wide-field,3541,O
multifocal,3541,O
electroretinography,3541,O
),3541,O
and,3541,O
conventional,3541,O
visual,3541,O
field,3541,O
testing,3541,O
(,3541,O
static,3541,O
perimetry,3541,O
),3541,O
.,3541,O
Bilateral,3542,O
visual,3542,O
field,3542,O
constriction,3542,O
was,3542,O
observed,3542,O
in,3542,O
59,3542,O
%,3542,O
of,3542,O
patients,3542,O
currently,3542,O
taking,3542,O
VGB,3542,B-Chemical
",",3542,O
43,3542,O
%,3542,O
of,3542,O
patients,3542,O
who,3542,O
previously,3542,O
took,3542,O
VGB,3542,B-Chemical
",",3542,O
and,3542,O
24,3542,O
%,3542,O
of,3542,O
patients,3542,O
with,3542,O
no,3542,O
exposure,3542,O
to,3542,O
VGB,3542,B-Chemical
.,3542,O
Assessment,3543,O
of,3543,O
retinal,3543,O
function,3543,O
revealed,3543,O
abnormal,3543,O
responses,3543,O
in,3543,O
48,3543,O
%,3543,O
of,3543,O
current,3543,O
VGB,3543,B-Chemical
users,3543,O
and,3543,O
22,3543,O
%,3543,O
of,3543,O
prior,3543,O
VGB,3543,B-Chemical
users,3543,O
",",3543,O
but,3543,O
in,3543,O
none,3543,O
of,3543,O
the,3543,O
patients,3543,O
without,3543,O
previous,3543,O
exposure,3543,O
to,3543,O
VGB,3543,B-Chemical
.,3543,O
Bilateral,3544,B-Disease
visual,3544,I-Disease
field,3544,I-Disease
abnormalities,3544,I-Disease
are,3544,O
common,3544,O
in,3544,O
the,3544,O
treated,3544,O
epilepsy,3544,B-Disease
population,3544,O
",",3544,O
irrespective,3544,O
of,3544,O
drug,3544,O
history,3544,O
.,3544,O
Assessment,3545,O
by,3545,O
conventional,3545,O
static,3545,O
perimetry,3545,O
may,3545,O
neither,3545,O
be,3545,O
sufficiently,3545,O
sensitive,3545,O
nor,3545,O
specific,3545,O
to,3545,O
reliably,3545,O
identify,3545,O
retinal,3545,B-Disease
toxicity,3545,I-Disease
associated,3545,O
with,3545,O
VGB,3545,B-Chemical
.,3545,O
Smoking,3546,O
of,3546,O
crack,3546,B-Chemical
cocaine,3546,I-Chemical
as,3546,O
a,3546,O
risk,3546,O
factor,3546,O
for,3546,O
HIV,3546,B-Disease
infection,3546,I-Disease
among,3546,O
people,3546,O
who,3546,O
use,3546,O
injection,3546,O
drugs,3546,O
.,3546,O
BACKGROUND,3547,O
:,3547,O
Little,3547,O
is,3547,O
known,3547,O
about,3547,O
the,3547,O
possible,3547,O
role,3547,O
that,3547,O
smoking,3547,O
crack,3547,B-Chemical
cocaine,3547,I-Chemical
has,3547,O
on,3547,O
the,3547,O
incidence,3547,O
of,3547,O
HIV,3547,B-Disease
infection,3547,I-Disease
.,3547,O
Given,3548,O
the,3548,O
increasing,3548,O
use,3548,O
of,3548,O
crack,3548,B-Chemical
cocaine,3548,I-Chemical
",",3548,O
we,3548,O
sought,3548,O
to,3548,O
examine,3548,O
whether,3548,O
use,3548,O
of,3548,O
this,3548,O
illicit,3548,O
drug,3548,O
has,3548,O
become,3548,O
a,3548,O
risk,3548,O
factor,3548,O
for,3548,O
HIV,3548,B-Disease
infection,3548,I-Disease
.,3548,O
METHODS,3549,O
:,3549,O
We,3549,O
included,3549,O
data,3549,O
from,3549,O
people,3549,O
participating,3549,O
in,3549,O
the,3549,O
Vancouver,3549,O
Injection,3549,O
Drug,3549,O
Users,3549,O
Study,3549,O
who,3549,O
reported,3549,O
injecting,3549,O
illicit,3549,O
drugs,3549,O
at,3549,O
least,3549,O
once,3549,O
in,3549,O
the,3549,O
month,3549,O
before,3549,O
enrolment,3549,O
",",3549,O
lived,3549,O
in,3549,O
the,3549,O
greater,3549,O
Vancouver,3549,O
area,3549,O
",",3549,O
were,3549,O
HIV-negative,3549,O
at,3549,O
enrolment,3549,O
and,3549,O
completed,3549,O
at,3549,O
least,3549,O
1,3549,O
follow-up,3549,O
study,3549,O
visit,3549,O
.,3549,O
To,3550,O
determine,3550,O
whether,3550,O
the,3550,O
risk,3550,O
of,3550,O
HIV,3550,B-Disease
seroconversion,3550,I-Disease
among,3550,O
daily,3550,O
smokers,3550,O
of,3550,O
crack,3550,B-Chemical
cocaine,3550,I-Chemical
changed,3550,O
over,3550,O
time,3550,O
",",3550,O
we,3550,O
used,3550,O
Cox,3550,O
proportional,3550,O
hazards,3550,O
regression,3550,O
and,3550,O
divided,3550,O
the,3550,O
study,3550,O
into,3550,O
3,3550,O
periods,3550,O
:,3550,O
May,3550,O
1,3550,O
",",3550,O
1996-Nov.,3550,O
30,3550,O
",",3550,O
1999,3550,O
(,3550,O
period,3550,O
1,3550,O
),3550,O
",",3550,O
Dec.,3550,O
1,3550,O
",",3550,O
1999-Nov.,3550,O
30,3550,O
",",3550,O
2002,3550,O
(,3550,O
period,3550,O
2,3550,O
),3550,O
",",3550,O
and,3550,O
Dec.,3550,O
1,3550,O
",",3550,O
2002-Dec.,3550,O
30,3550,O
",",3550,O
2005,3550,O
(,3550,O
period,3550,O
3,3550,O
),3550,O
.,3550,O
RESULTS,3551,O
:,3551,O
Overall,3551,O
",",3551,O
1048,3551,O
eligible,3551,O
injection,3551,O
drug,3551,O
users,3551,O
were,3551,O
included,3551,O
in,3551,O
our,3551,O
study,3551,O
.,3551,O
Of,3552,O
these,3552,O
",",3552,O
137,3552,O
acquired,3552,O
HIV,3552,B-Disease
infection,3552,I-Disease
during,3552,O
follow-up,3552,O
.,3552,O
The,3553,O
mean,3553,O
proportion,3553,O
of,3553,O
participants,3553,O
who,3553,O
reported,3553,O
daily,3553,O
smoking,3553,O
of,3553,O
crack,3553,B-Chemical
cocaine,3553,I-Chemical
increased,3553,O
from,3553,O
11.6,3553,O
%,3553,O
in,3553,O
period,3553,O
1,3553,O
to,3553,O
39.7,3553,O
%,3553,O
in,3553,O
period,3553,O
3,3553,O
.,3553,O
After,3554,O
adjusting,3554,O
for,3554,O
potential,3554,O
confounders,3554,O
",",3554,O
we,3554,O
found,3554,O
that,3554,O
the,3554,O
risk,3554,O
of,3554,O
HIV,3554,B-Disease
seroconversion,3554,I-Disease
among,3554,O
participants,3554,O
who,3554,O
were,3554,O
daily,3554,O
smokers,3554,O
of,3554,O
crack,3554,B-Chemical
cocaine,3554,I-Chemical
increased,3554,O
over,3554,O
time,3554,O
(,3554,O
period,3554,O
1,3554,O
:,3554,O
hazard,3554,O
ratio,3554,O
[,3554,O
HR,3554,O
],3554,O
1.03,3554,O
",",3554,O
95,3554,O
%,3554,O
confidence,3554,O
interval,3554,O
[,3554,O
CI,3554,O
],3554,O
0.57-1.85,3554,O
;,3554,O
period,3554,O
2,3554,O
:,3554,O
HR,3554,O
1.68,3554,O
",",3554,O
95,3554,O
%,3554,O
CI,3554,O
1.01-2.80,3554,O
;,3554,O
and,3554,O
period,3554,O
3,3554,O
:,3554,O
HR,3554,O
2.74,3554,O
",",3554,O
95,3554,O
%,3554,O
CI,3554,O
1.06-7.11,3554,O
),3554,O
.,3554,O
INTERPRETATION,3555,O
:,3555,O
Smoking,3555,O
of,3555,O
crack,3555,B-Chemical
cocaine,3555,I-Chemical
was,3555,O
found,3555,O
to,3555,O
be,3555,O
an,3555,O
independent,3555,O
risk,3555,O
factor,3555,O
for,3555,O
HIV,3555,B-Disease
seroconversion,3555,I-Disease
among,3555,O
people,3555,O
who,3555,O
were,3555,O
injection,3555,O
drug,3555,O
users,3555,O
.,3555,O
This,3556,O
finding,3556,O
points,3556,O
to,3556,O
the,3556,O
urgent,3556,O
need,3556,O
for,3556,O
evidence-based,3556,O
public,3556,O
health,3556,O
initiatives,3556,O
targeted,3556,O
at,3556,O
people,3556,O
who,3556,O
smoke,3556,O
crack,3556,B-Chemical
cocaine,3556,I-Chemical
.,3556,O
Fluoxetine,3557,B-Chemical
improves,3557,O
the,3557,O
memory,3557,B-Disease
deficits,3557,I-Disease
caused,3557,O
by,3557,O
the,3557,O
chemotherapy,3557,O
agent,3557,O
5-fluorouracil,3557,B-Chemical
.,3557,O
Cancer,3558,B-Disease
patients,3558,O
who,3558,O
have,3558,O
been,3558,O
treated,3558,O
with,3558,O
systemic,3558,O
adjuvant,3558,O
chemotherapy,3558,O
have,3558,O
described,3558,O
experiencing,3558,O
deteriorations,3558,O
in,3558,O
cognition,3558,O
.,3558,O
A,3559,O
widely,3559,O
used,3559,O
chemotherapeutic,3559,O
agent,3559,O
",",3559,O
5-fluorouracil,3559,B-Chemical
(,3559,O
5-FU,3559,B-Chemical
),3559,O
",",3559,O
readily,3559,O
crosses,3559,O
the,3559,O
blood-brain,3559,O
barrier,3559,O
and,3559,O
so,3559,O
could,3559,O
have,3559,O
a,3559,O
direct,3559,O
effect,3559,O
on,3559,O
brain,3559,O
function,3559,O
.,3559,O
In,3560,O
particular,3560,O
this,3560,O
anti,3560,O
mitotic,3560,O
drug,3560,O
could,3560,O
reduce,3560,O
cell,3560,O
proliferation,3560,O
in,3560,O
the,3560,O
neurogenic,3560,O
regions,3560,O
of,3560,O
the,3560,O
adult,3560,O
brain,3560,O
.,3560,O
In,3561,O
contrast,3561,O
reports,3561,O
indicate,3561,O
that,3561,O
hippocampal,3561,O
dependent,3561,O
neurogenesis,3561,O
and,3561,O
cognition,3561,O
are,3561,O
enhanced,3561,O
by,3561,O
the,3561,O
SSRI,3561,B-Chemical
antidepressant,3561,O
Fluoxetine,3561,B-Chemical
.,3561,O
In,3562,O
this,3562,O
investigation,3562,O
the,3562,O
behavioural,3562,O
effects,3562,O
of,3562,O
chronic,3562,O
(,3562,O
two,3562,O
week,3562,O
),3562,O
treatment,3562,O
with,3562,O
5-FU,3562,B-Chemical
and,3562,O
(,3562,O
three,3562,O
weeks,3562,O
),3562,O
with,3562,O
Fluoxetine,3562,B-Chemical
either,3562,O
separately,3562,O
or,3562,O
in,3562,O
combination,3562,O
with,3562,O
5-FU,3562,B-Chemical
were,3562,O
tested,3562,O
on,3562,O
adult,3562,O
Lister,3562,O
hooded,3562,O
rats,3562,O
.,3562,O
Behavioural,3563,O
effects,3563,O
were,3563,O
tested,3563,O
using,3563,O
a,3563,O
context,3563,O
dependent,3563,O
conditioned,3563,O
emotional,3563,O
response,3563,O
test,3563,O
(,3563,O
CER,3563,O
),3563,O
which,3563,O
showed,3563,O
that,3563,O
animals,3563,O
treated,3563,O
with,3563,O
5-FU,3563,B-Chemical
had,3563,O
a,3563,O
significant,3563,O
reduction,3563,O
in,3563,O
freezing,3563,O
time,3563,O
compared,3563,O
to,3563,O
controls,3563,O
.,3563,O
A,3564,O
separate,3564,O
group,3564,O
of,3564,O
animals,3564,O
was,3564,O
tested,3564,O
using,3564,O
a,3564,O
hippocampal,3564,O
dependent,3564,O
spatial,3564,O
working,3564,O
memory,3564,O
test,3564,O
",",3564,O
the,3564,O
object,3564,O
location,3564,O
recognition,3564,O
test,3564,O
(,3564,O
OLR,3564,O
),3564,O
.,3564,O
Animals,3565,O
treated,3565,O
only,3565,O
with,3565,O
5-FU,3565,B-Chemical
showed,3565,O
significant,3565,O
deficits,3565,O
in,3565,O
their,3565,O
ability,3565,O
to,3565,O
carry,3565,O
out,3565,O
the,3565,O
OLR,3565,O
task,3565,O
but,3565,O
co,3565,O
administration,3565,O
of,3565,O
Fluoxetine,3565,B-Chemical
improved,3565,O
their,3565,O
performance,3565,O
.,3565,O
5-FU,3566,B-Chemical
chemotherapy,3566,O
caused,3566,O
a,3566,O
significant,3566,O
reduction,3566,O
in,3566,O
the,3566,O
number,3566,O
of,3566,O
proliferating,3566,O
cells,3566,O
in,3566,O
the,3566,O
sub,3566,O
granular,3566,O
zone,3566,O
of,3566,O
the,3566,O
dentate,3566,O
gyrus,3566,O
compared,3566,O
to,3566,O
controls,3566,O
.,3566,O
This,3567,O
reduction,3567,O
was,3567,O
eliminated,3567,O
when,3567,O
Fluoxetine,3567,B-Chemical
was,3567,O
co,3567,O
administered,3567,O
with,3567,O
5-FU,3567,B-Chemical
.,3567,O
Fluoxetine,3568,B-Chemical
on,3568,O
its,3568,O
own,3568,O
had,3568,O
no,3568,O
effect,3568,O
on,3568,O
proliferating,3568,O
cell,3568,O
number,3568,O
or,3568,O
behaviour,3568,O
.,3568,O
These,3569,O
findings,3569,O
suggest,3569,O
that,3569,O
5-FU,3569,B-Chemical
can,3569,O
negatively,3569,O
affect,3569,O
both,3569,O
cell,3569,O
proliferation,3569,O
and,3569,O
hippocampal,3569,O
dependent,3569,O
working,3569,O
memory,3569,O
and,3569,O
that,3569,O
these,3569,O
deficits,3569,O
can,3569,O
be,3569,O
reversed,3569,O
by,3569,O
the,3569,O
simultaneous,3569,O
administration,3569,O
of,3569,O
the,3569,O
antidepressant,3569,O
Fluoxetine,3569,B-Chemical
.,3569,O
Liver-specific,3570,O
ablation,3570,O
of,3570,O
integrin-linked,3570,O
kinase,3570,O
in,3570,O
mice,3570,O
results,3570,O
in,3570,O
enhanced,3570,O
and,3570,O
prolonged,3570,O
cell,3570,O
proliferation,3570,O
and,3570,O
hepatomegaly,3570,B-Disease
after,3570,O
phenobarbital,3570,B-Chemical
administration,3570,O
.,3570,O
We,3571,O
have,3571,O
recently,3571,O
demonstrated,3571,O
that,3571,O
disruption,3571,O
of,3571,O
extracellular,3571,O
matrix,3571,O
(,3571,O
ECM,3571,O
),3571,O
/integrin,3571,O
signaling,3571,O
via,3571,O
elimination,3571,O
of,3571,O
integrin-linked,3571,O
kinase,3571,O
(,3571,O
ILK,3571,O
),3571,O
in,3571,O
hepatocytes,3571,O
interferes,3571,O
with,3571,O
signals,3571,O
leading,3571,O
to,3571,O
termination,3571,O
of,3571,O
liver,3571,O
regeneration,3571,O
.,3571,O
This,3572,O
study,3572,O
investigates,3572,O
the,3572,O
role,3572,O
of,3572,O
ILK,3572,O
in,3572,O
liver,3572,O
enlargement,3572,O
induced,3572,O
by,3572,O
phenobarbital,3572,B-Chemical
(,3572,O
PB,3572,B-Chemical
),3572,O
.,3572,O
Wild-type,3573,O
(,3573,O
WT,3573,O
),3573,O
and,3573,O
ILK,3573,O
:,3573,O
liver-/-,3573,O
mice,3573,O
were,3573,O
given,3573,O
PB,3573,B-Chemical
(,3573,O
0.1,3573,O
%,3573,O
in,3573,O
drinking,3573,O
water,3573,O
),3573,O
for,3573,O
10,3573,O
days,3573,O
.,3573,O
Livers,3574,O
were,3574,O
harvested,3574,O
on,3574,O
2,3574,O
",",3574,O
5,3574,O
",",3574,O
and,3574,O
10,3574,O
days,3574,O
during,3574,O
PB,3574,B-Chemical
administration,3574,O
.,3574,O
In,3575,O
the,3575,O
hepatocyte-specific,3575,O
ILK/liver-/-,3575,O
mice,3575,O
",",3575,O
the,3575,O
liver,3575,O
:,3575,O
body,3575,O
weight,3575,O
ratio,3575,O
was,3575,O
more,3575,O
than,3575,O
double,3575,O
as,3575,O
compared,3575,O
to,3575,O
0,3575,O
h,3575,O
at,3575,O
day,3575,O
2,3575,O
(,3575,O
2.5,3575,O
times,3575,O
),3575,O
",",3575,O
while,3575,O
at,3575,O
days,3575,O
5,3575,O
and,3575,O
10,3575,O
",",3575,O
it,3575,O
was,3575,O
enlarged,3575,O
three,3575,O
times,3575,O
.,3575,O
In,3576,O
the,3576,O
WT,3576,O
mice,3576,O
",",3576,O
the,3576,O
increase,3576,O
was,3576,O
as,3576,O
expected,3576,O
from,3576,O
previous,3576,O
literature,3576,O
(,3576,O
1.8,3576,O
times,3576,O
),3576,O
and,3576,O
seems,3576,O
to,3576,O
have,3576,O
leveled,3576,O
off,3576,O
after,3576,O
day,3576,O
2,3576,O
.,3576,O
There,3577,O
were,3577,O
slightly,3577,O
increased,3577,O
proliferating,3577,O
cell,3577,O
nuclear,3577,O
antigen-positive,3577,O
cells,3577,O
in,3577,O
the,3577,O
ILK/liver-/-,3577,O
animals,3577,O
at,3577,O
day,3577,O
2,3577,O
as,3577,O
compared,3577,O
to,3577,O
WT,3577,O
after,3577,O
PB,3577,B-Chemical
administration,3577,O
.,3577,O
In,3578,O
the,3578,O
WT,3578,O
animals,3578,O
",",3578,O
the,3578,O
proliferative,3578,O
response,3578,O
had,3578,O
come,3578,O
back,3578,O
to,3578,O
normal,3578,O
by,3578,O
days,3578,O
5,3578,O
and,3578,O
10,3578,O
.,3578,O
Hepatocytes,3579,O
of,3579,O
the,3579,O
ILK/liver-/-,3579,O
mice,3579,O
continued,3579,O
to,3579,O
proliferate,3579,O
up,3579,O
until,3579,O
day,3579,O
10,3579,O
.,3579,O
ILK/liver-/-,3580,O
mice,3580,O
also,3580,O
showed,3580,O
increased,3580,O
expression,3580,O
of,3580,O
key,3580,O
genes,3580,O
involved,3580,O
in,3580,O
hepatocyte,3580,O
proliferation,3580,O
at,3580,O
different,3580,O
time,3580,O
points,3580,O
during,3580,O
PB,3580,B-Chemical
administration,3580,O
.,3580,O
In,3581,O
summary,3581,O
",",3581,O
ECM,3581,O
proteins,3581,O
communicate,3581,O
with,3581,O
the,3581,O
signaling,3581,O
machinery,3581,O
of,3581,O
dividing,3581,O
cells,3581,O
via,3581,O
ILK,3581,O
to,3581,O
regulate,3581,O
hepatocyte,3581,O
proliferation,3581,O
and,3581,O
termination,3581,O
of,3581,O
the,3581,O
proliferative,3581,O
response,3581,O
.,3581,O
Lack,3582,O
of,3582,O
ILK,3582,O
in,3582,O
the,3582,O
hepatocytes,3582,O
imparts,3582,O
prolonged,3582,O
proliferative,3582,O
response,3582,O
not,3582,O
only,3582,O
to,3582,O
stimuli,3582,O
related,3582,O
to,3582,O
liver,3582,O
regeneration,3582,O
but,3582,O
also,3582,O
to,3582,O
xenobiotic,3582,O
chemical,3582,O
mitogens,3582,O
",",3582,O
such,3582,O
as,3582,O
PB,3582,B-Chemical
.,3582,O
Decreased,3583,O
Expression,3583,O
of,3583,O
Na/K-ATPase,3583,B-Chemical
",",3583,O
NHE3,3583,O
",",3583,O
NBC1,3583,O
",",3583,O
AQP1,3583,O
and,3583,O
OAT,3583,O
in,3583,O
Gentamicin-induced,3583,B-Chemical
Nephropathy,3583,B-Disease
.,3583,O
The,3584,O
present,3584,O
study,3584,O
was,3584,O
aimed,3584,O
to,3584,O
determine,3584,O
whether,3584,O
there,3584,O
is,3584,O
an,3584,O
altered,3584,O
regulation,3584,O
of,3584,O
tubular,3584,O
transporters,3584,O
in,3584,O
gentamicin-induced,3584,B-Chemical
nephropathy,3584,B-Disease
.,3584,O
Sprague-Dawley,3585,O
male,3585,O
rats,3585,O
(,3585,O
200~250,3585,O
g,3585,O
),3585,O
were,3585,O
subcutaneously,3585,O
injected,3585,O
with,3585,O
gentamicin,3585,B-Chemical
(,3585,O
100,3585,O
mg/kg,3585,O
per,3585,O
day,3585,O
),3585,O
for,3585,O
7,3585,O
days,3585,O
",",3585,O
and,3585,O
the,3585,O
expression,3585,O
of,3585,O
tubular,3585,O
transporters,3585,O
was,3585,O
determined,3585,O
by,3585,O
immunoblotting,3585,O
and,3585,O
immunohistochemistry,3585,O
.,3585,O
The,3586,O
mRNA,3586,O
and,3586,O
protein,3586,O
expression,3586,O
of,3586,O
OAT,3586,O
was,3586,O
also,3586,O
determined,3586,O
.,3586,O
Gentamicin-treated,3587,B-Chemical
rats,3587,O
exhibited,3587,O
significantly,3587,O
decreased,3587,O
creatinine,3587,B-Chemical
clearance,3587,O
along,3587,O
with,3587,O
increased,3587,O
plasma,3587,O
creatinine,3587,B-Chemical
levels,3587,O
.,3587,O
Accordingly,3588,O
",",3588,O
the,3588,O
fractional,3588,O
excretion,3588,O
of,3588,O
sodium,3588,B-Chemical
increased,3588,O
.,3588,O
Urine,3589,O
volume,3589,O
was,3589,O
increased,3589,O
",",3589,O
while,3589,O
urine,3589,O
osmolality,3589,O
and,3589,O
free,3589,O
water,3589,O
reabsorption,3589,O
were,3589,O
decreased,3589,O
.,3589,O
Immunoblotting,3590,O
and,3590,O
immunohistochemistry,3590,O
revealed,3590,O
decreased,3590,O
expression,3590,O
of,3590,O
Na,3590,B-Chemical
(,3590,O
+,3590,O
),3590,O
/K,3590,O
(,3590,O
+,3590,O
),3590,O
-ATPase,3590,O
",",3590,O
NHE3,3590,O
",",3590,O
NBC1,3590,O
",",3590,O
and,3590,O
AQP1,3590,O
in,3590,O
the,3590,O
kidney,3590,O
of,3590,O
gentamicin-treated,3590,B-Chemical
rats,3590,O
.,3590,O
The,3591,O
expression,3591,O
of,3591,O
OAT1,3591,O
and,3591,O
OAT3,3591,O
was,3591,O
also,3591,O
decreased,3591,O
.,3591,O
Gentamicin-induced,3592,B-Chemical
nephropathy,3592,B-Disease
may,3592,O
at,3592,O
least,3592,O
in,3592,O
part,3592,O
be,3592,O
causally,3592,O
related,3592,O
with,3592,O
a,3592,O
decreased,3592,O
expression,3592,O
of,3592,O
Na,3592,B-Chemical
(,3592,O
+,3592,O
),3592,O
/K,3592,O
(,3592,O
+,3592,O
),3592,O
-ATPase,3592,O
",",3592,O
NHE3,3592,O
",",3592,O
NBC1,3592,O
",",3592,O
AQP1,3592,O
and,3592,O
OAT,3592,O
.,3592,O
Acute,3593,B-Disease
renal,3593,I-Disease
failure,3593,I-Disease
after,3593,O
high-dose,3593,O
methotrexate,3593,B-Chemical
therapy,3593,O
in,3593,O
a,3593,O
patient,3593,O
with,3593,O
ileostomy,3593,O
.,3593,O
High-dose,3594,O
methotrexate,3594,B-Chemical
(,3594,O
HD-MTX,3594,O
),3594,O
is,3594,O
an,3594,O
important,3594,O
treatment,3594,O
for,3594,O
Burkitt,3594,B-Disease
lymphoma,3594,I-Disease
",",3594,O
but,3594,O
can,3594,O
cause,3594,O
hepatic,3594,O
and,3594,O
renal,3594,O
toxicity,3594,O
when,3594,O
its,3594,O
clearance,3594,O
is,3594,O
delayed,3594,O
.,3594,O
We,3595,O
report,3595,O
a,3595,O
case,3595,O
of,3595,O
acute,3595,B-Disease
renal,3595,I-Disease
failure,3595,I-Disease
after,3595,O
HD-MTX,3595,O
therapy,3595,O
in,3595,O
a,3595,O
patient,3595,O
with,3595,O
ileostomy,3595,O
",",3595,O
The,3595,O
patient,3595,O
was,3595,O
a,3595,O
3-year-old,3595,O
boy,3595,O
who,3595,O
had,3595,O
received,3595,O
a,3595,O
living-related,3595,O
liver,3595,O
transplantation,3595,O
for,3595,O
congenital,3595,O
biliary,3595,B-Disease
atresia,3595,I-Disease
.,3595,O
At,3596,O
day,3596,O
833,3596,O
after,3596,O
the,3596,O
transplantation,3596,O
",",3596,O
he,3596,O
was,3596,O
diagnosed,3596,O
with,3596,O
PTLD,3596,B-Disease
(,3596,O
post-transplantation,3596,B-Disease
lymphoproliferative,3596,I-Disease
disorder,3596,I-Disease
",",3596,O
Burkitt-type,3596,B-Disease
malignant,3596,I-Disease
lymphoma,3596,I-Disease
),3596,O
.,3596,O
During,3597,O
induction,3597,O
therapy,3597,O
",",3597,O
he,3597,O
suffered,3597,O
ileal,3597,O
perforation,3597,O
and,3597,O
ileostomy,3597,O
was,3597,O
performed,3597,O
.,3597,O
Subsequent,3598,O
HD-MTX,3598,O
therapy,3598,O
caused,3598,O
acute,3598,B-Disease
renal,3598,I-Disease
failure,3598,I-Disease
that,3598,O
required,3598,O
continuous,3598,O
hemodialysis,3598,O
.,3598,O
We,3599,O
supposed,3599,O
that,3599,O
intravascular,3599,O
hypovolemia,3599,B-Disease
due,3599,O
to,3599,O
substantial,3599,O
drainage,3599,O
from,3599,O
the,3599,O
ileostoma,3599,O
caused,3599,O
acute,3599,B-Disease
prerenal,3599,I-Disease
failure,3599,I-Disease
.,3599,O
After,3600,O
recovery,3600,O
of,3600,O
his,3600,O
renal,3600,O
function,3600,O
",",3600,O
we,3600,O
could,3600,O
safely,3600,O
treat,3600,O
the,3600,O
patient,3600,O
with,3600,O
HD-MTX,3600,O
therapy,3600,O
by,3600,O
controlling,3600,O
drainage,3600,O
from,3600,O
ileostoma,3600,O
with,3600,O
total,3600,O
parenteral,3600,O
nutrition,3600,O
.,3600,O
Longitudinal,3601,O
association,3601,O
of,3601,O
alcohol,3601,B-Chemical
use,3601,O
with,3601,O
HIV,3601,B-Disease
disease,3601,I-Disease
progression,3601,O
and,3601,O
psychological,3601,O
health,3601,O
of,3601,O
women,3601,O
with,3601,O
HIV,3601,O
.,3601,O
We,3602,O
evaluated,3602,O
the,3602,O
association,3602,O
of,3602,O
alcohol,3602,B-Chemical
consumption,3602,O
and,3602,O
depression,3602,B-Disease
",",3602,O
and,3602,O
their,3602,O
effects,3602,O
on,3602,O
HIV,3602,B-Disease
disease,3602,I-Disease
progression,3602,O
among,3602,O
women,3602,O
with,3602,O
HIV,3602,O
.,3602,O
The,3603,O
study,3603,O
included,3603,O
871,3603,O
women,3603,O
with,3603,O
HIV,3603,O
who,3603,O
were,3603,O
recruited,3603,O
from,3603,O
1993-1995,3603,O
in,3603,O
four,3603,O
US,3603,O
cities,3603,O
.,3603,O
The,3604,O
participants,3604,O
had,3604,O
physical,3604,O
examination,3604,O
",",3604,O
medical,3604,O
record,3604,O
extraction,3604,O
",",3604,O
and,3604,O
venipuncture,3604,O
",",3604,O
CD4+T-cell,3604,O
counts,3604,O
determination,3604,O
",",3604,O
measurement,3604,O
of,3604,O
depression,3604,B-Disease
symptoms,3604,O
(,3604,O
using,3604,O
the,3604,O
self-report,3604,O
Center,3604,O
for,3604,O
Epidemiological,3604,O
Studies-Depression,3604,O
Scale,3604,O
),3604,O
",",3604,O
and,3604,O
alcohol,3604,B-Chemical
use,3604,O
assessment,3604,O
at,3604,O
enrollment,3604,O
",",3604,O
and,3604,O
semiannually,3604,O
until,3604,O
March,3604,O
2000,3604,O
.,3604,O
Multilevel,3605,O
random,3605,O
coefficient,3605,O
ordinal,3605,O
models,3605,O
as,3605,O
well,3605,O
as,3605,O
multilevel,3605,O
models,3605,O
with,3605,O
joint,3605,O
responses,3605,O
were,3605,O
used,3605,O
in,3605,O
the,3605,O
analysis,3605,O
.,3605,O
There,3606,O
was,3606,O
no,3606,O
significant,3606,O
association,3606,O
between,3606,O
level,3606,O
of,3606,O
alcohol,3606,B-Chemical
use,3606,O
and,3606,O
CD4+,3606,O
T-cell,3606,O
counts,3606,O
.,3606,O
When,3607,O
participants,3607,O
were,3607,O
stratified,3607,O
by,3607,O
antiretroviral,3607,O
therapy,3607,O
(,3607,O
ART,3607,O
),3607,O
use,3607,O
",",3607,O
the,3607,O
association,3607,O
between,3607,O
alcohol,3607,B-Chemical
and,3607,O
CD4+,3607,O
T-cell,3607,O
did,3607,O
not,3607,O
reach,3607,O
statistical,3607,O
significance,3607,O
.,3607,O
The,3608,O
association,3608,O
between,3608,O
alcohol,3608,B-Chemical
consumption,3608,O
and,3608,O
depression,3608,B-Disease
was,3608,O
significant,3608,O
(,3608,O
p,3608,O
<,3608,O
0.001,3608,O
),3608,O
.,3608,O
Depression,3609,B-Disease
had,3609,O
a,3609,O
significant,3609,O
negative,3609,O
effect,3609,O
on,3609,O
CD4+,3609,O
T-cell,3609,O
counts,3609,O
over,3609,O
time,3609,O
regardless,3609,O
of,3609,O
ART,3609,O
use,3609,O
.,3609,O
Our,3610,O
findings,3610,O
suggest,3610,O
that,3610,O
alcohol,3610,B-Chemical
consumption,3610,O
has,3610,O
a,3610,O
direct,3610,O
association,3610,O
with,3610,O
depression,3610,B-Disease
.,3610,O
Moreover,3611,O
",",3611,O
depression,3611,B-Disease
is,3611,O
associated,3611,O
with,3611,O
HIV,3611,B-Disease
disease,3611,I-Disease
progression,3611,O
.,3611,O
Our,3612,O
findings,3612,O
have,3612,O
implications,3612,O
for,3612,O
the,3612,O
provision,3612,O
of,3612,O
alcohol,3612,B-Chemical
use,3612,O
interventions,3612,O
and,3612,O
psychological,3612,O
resources,3612,O
to,3612,O
improve,3612,O
the,3612,O
health,3612,O
of,3612,O
women,3612,O
with,3612,O
HIV,3612,O
.,3612,O
Chemokine,3613,O
CCL2,3613,O
and,3613,O
its,3613,O
receptor,3613,O
CCR2,3613,O
are,3613,O
increased,3613,O
in,3613,O
the,3613,O
hippocampus,3613,O
following,3613,O
pilocarpine-induced,3613,B-Chemical
status,3613,B-Disease
epilepticus,3613,I-Disease
.,3613,O
BACKGROUND,3614,O
:,3614,O
Neuroinflammation,3614,B-Disease
occurs,3614,O
after,3614,O
seizures,3614,B-Disease
and,3614,O
is,3614,O
implicated,3614,O
in,3614,O
epileptogenesis,3614,O
.,3614,O
CCR2,3615,O
is,3615,O
a,3615,O
chemokine,3615,O
receptor,3615,O
for,3615,O
CCL2,3615,O
and,3615,O
their,3615,O
interaction,3615,O
mediates,3615,O
monocyte,3615,O
infiltration,3615,O
in,3615,O
the,3615,O
neuroinflammatory,3615,B-Disease
cascade,3615,O
triggered,3615,O
in,3615,O
different,3615,O
brain,3615,O
pathologies,3615,O
.,3615,O
In,3616,O
this,3616,O
work,3616,O
CCR2,3616,O
and,3616,O
CCL2,3616,O
expression,3616,O
were,3616,O
examined,3616,O
following,3616,O
status,3616,B-Disease
epilepticus,3616,I-Disease
(,3616,O
SE,3616,B-Disease
),3616,O
induced,3616,O
by,3616,O
pilocarpine,3616,B-Chemical
injection,3616,O
.,3616,O
METHODS,3617,O
:,3617,O
SE,3617,B-Disease
was,3617,O
induced,3617,O
by,3617,O
pilocarpine,3617,B-Chemical
injection,3617,O
.,3617,O
Control,3618,O
rats,3618,O
were,3618,O
injected,3618,O
with,3618,O
saline,3618,O
instead,3618,O
of,3618,O
pilocarpine,3618,B-Chemical
.,3618,O
Five,3619,O
days,3619,O
after,3619,O
SE,3619,B-Disease
",",3619,O
CCR2,3619,O
staining,3619,O
in,3619,O
neurons,3619,O
and,3619,O
glial,3619,O
cells,3619,O
was,3619,O
examined,3619,O
using,3619,O
imunohistochemical,3619,O
analyses,3619,O
.,3619,O
The,3620,O
number,3620,O
of,3620,O
CCR2,3620,O
positive,3620,O
cells,3620,O
was,3620,O
determined,3620,O
using,3620,O
stereology,3620,O
probes,3620,O
in,3620,O
the,3620,O
hippocampus,3620,O
.,3620,O
CCL2,3621,O
expression,3621,O
in,3621,O
the,3621,O
hippocampus,3621,O
was,3621,O
examined,3621,O
by,3621,O
molecular,3621,O
assay,3621,O
.,3621,O
RESULTS,3622,O
:,3622,O
Increased,3622,O
CCR2,3622,O
was,3622,O
observed,3622,O
in,3622,O
the,3622,O
hippocampus,3622,O
after,3622,O
SE,3622,B-Disease
.,3622,O
Seizures,3623,B-Disease
also,3623,O
resulted,3623,O
in,3623,O
alterations,3623,O
to,3623,O
the,3623,O
cell,3623,O
types,3623,O
expressing,3623,O
CCR2,3623,O
.,3623,O
Increased,3624,O
numbers,3624,O
of,3624,O
neurons,3624,O
that,3624,O
expressed,3624,O
CCR2,3624,O
was,3624,O
observed,3624,O
following,3624,O
SE,3624,B-Disease
.,3624,O
Microglial,3625,O
cells,3625,O
were,3625,O
more,3625,O
closely,3625,O
apposed,3625,O
to,3625,O
the,3625,O
CCR2-labeled,3625,O
cells,3625,O
in,3625,O
SE,3625,B-Disease
rats,3625,O
.,3625,O
In,3626,O
addition,3626,O
",",3626,O
rats,3626,O
that,3626,O
experienced,3626,O
SE,3626,B-Disease
exhibited,3626,O
CCR2-labeling,3626,O
in,3626,O
populations,3626,O
of,3626,O
hypertrophied,3626,B-Disease
astrocytes,3626,O
",",3626,O
especially,3626,O
in,3626,O
CA1,3626,O
and,3626,O
dentate,3626,O
gyrus,3626,O
.,3626,O
These,3627,O
CCR2+,3627,O
astroctytes,3627,O
were,3627,O
not,3627,O
observed,3627,O
in,3627,O
control,3627,O
rats,3627,O
.,3627,O
Examination,3628,O
of,3628,O
CCL2,3628,O
expression,3628,O
showed,3628,O
that,3628,O
it,3628,O
was,3628,O
elevated,3628,O
in,3628,O
the,3628,O
hippocampus,3628,O
following,3628,O
SE,3628,B-Disease
.,3628,O
CONCLUSION,3629,O
:,3629,O
The,3629,O
data,3629,O
show,3629,O
that,3629,O
CCR2,3629,O
and,3629,O
CCL2,3629,O
are,3629,O
up-regulated,3629,O
in,3629,O
the,3629,O
hippocampus,3629,O
after,3629,O
pilocarpine-induced,3629,B-Chemical
SE,3629,B-Disease
.,3629,O
Seizures,3630,B-Disease
also,3630,O
result,3630,O
in,3630,O
changes,3630,O
to,3630,O
CCR2,3630,O
receptor,3630,O
expression,3630,O
in,3630,O
neurons,3630,O
and,3630,O
astrocytes,3630,O
.,3630,O
These,3631,O
changes,3631,O
might,3631,O
be,3631,O
involved,3631,O
in,3631,O
detrimental,3631,O
neuroplasticity,3631,O
and,3631,O
neuroinflammatory,3631,B-Disease
changes,3631,O
that,3631,O
occur,3631,O
following,3631,O
seizures,3631,B-Disease
.,3631,O
Metallothionein,3632,B-Chemical
induction,3632,O
reduces,3632,O
caspase-3,3632,O
activity,3632,O
and,3632,O
TNFalpha,3632,O
levels,3632,O
with,3632,O
preservation,3632,O
of,3632,O
cognitive,3632,O
function,3632,O
and,3632,O
intact,3632,O
hippocampal,3632,O
neurons,3632,O
in,3632,O
carmustine-treated,3632,B-Chemical
rats,3632,O
.,3632,O
Hippocampal,3633,O
integrity,3633,O
is,3633,O
essential,3633,O
for,3633,O
cognitive,3633,O
functions,3633,O
.,3633,O
On,3634,O
the,3634,O
other,3634,O
hand,3634,O
",",3634,O
induction,3634,O
of,3634,O
metallothionein,3634,B-Chemical
(,3634,O
MT,3634,B-Chemical
),3634,O
by,3634,O
ZnSO,3634,B-Chemical
(,3634,I-Chemical
4,3634,I-Chemical
),3634,I-Chemical
and,3634,O
its,3634,O
role,3634,O
in,3634,O
neuroprotection,3634,O
has,3634,O
been,3634,O
documented,3634,O
.,3634,O
The,3635,O
present,3635,O
study,3635,O
aimed,3635,O
to,3635,O
explore,3635,O
the,3635,O
effect,3635,O
of,3635,O
MT,3635,B-Chemical
induction,3635,O
on,3635,O
carmustine,3635,B-Chemical
(,3635,O
BCNU,3635,B-Chemical
),3635,O
-induced,3635,O
hippocampal,3635,O
cognitive,3635,B-Disease
dysfunction,3635,I-Disease
in,3635,O
rats,3635,O
.,3635,O
A,3636,O
total,3636,O
of,3636,O
60,3636,O
male,3636,O
Wistar,3636,O
albino,3636,O
rats,3636,O
were,3636,O
randomly,3636,O
divided,3636,O
into,3636,O
four,3636,O
groups,3636,O
(,3636,O
15/group,3636,O
),3636,O
:,3636,O
The,3636,O
control,3636,O
group,3636,O
injected,3636,O
with,3636,O
single,3636,O
doses,3636,O
of,3636,O
normal,3636,O
saline,3636,O
(,3636,O
i.c.v,3636,O
),3636,O
followed,3636,O
24,3636,O
h,3636,O
later,3636,O
by,3636,O
BCNU,3636,B-Chemical
solvent,3636,O
(,3636,O
i.v,3636,O
),3636,O
.,3636,O
The,3637,O
second,3637,O
group,3637,O
administered,3637,O
ZnSO,3637,B-Chemical
(,3637,I-Chemical
4,3637,I-Chemical
),3637,I-Chemical
(,3637,O
0.1,3637,O
micromol/10,3637,O
microl,3637,O
normal,3637,O
saline,3637,O
",",3637,O
i.c.v,3637,O
",",3637,O
once,3637,O
),3637,O
then,3637,O
BCNU,3637,B-Chemical
solvent,3637,O
(,3637,O
i.v,3637,O
),3637,O
after,3637,O
24,3637,O
h.,3637,O
Third,3637,O
group,3637,O
received,3637,O
BCNU,3637,B-Chemical
(,3637,O
20,3637,O
mg/kg,3637,O
",",3637,O
i.v,3637,O
",",3637,O
once,3637,O
),3637,O
24,3637,O
h,3637,O
after,3637,O
injection,3637,O
with,3637,O
normal,3637,O
saline,3637,O
(,3637,O
i.c.v,3637,O
),3637,O
.,3637,O
Fourth,3638,O
group,3638,O
received,3638,O
a,3638,O
single,3638,O
dose,3638,O
of,3638,O
ZnSO,3638,B-Chemical
(,3638,I-Chemical
4,3638,I-Chemical
),3638,I-Chemical
(,3638,O
0.1,3638,O
micromol/10,3638,O
microl,3638,O
normal,3638,O
saline,3638,O
",",3638,O
i.c.v,3638,O
),3638,O
then,3638,O
BCNU,3638,B-Chemical
(,3638,O
20,3638,O
mg/kg,3638,O
",",3638,O
i.v,3638,O
",",3638,O
once,3638,O
),3638,O
after,3638,O
24,3638,O
h.,3638,O
The,3638,O
obtained,3638,O
data,3638,O
revealed,3638,O
that,3638,O
BCNU,3638,B-Chemical
administration,3638,O
resulted,3638,O
in,3638,O
deterioration,3638,O
of,3638,O
learning,3638,O
and,3638,O
short-term,3638,O
memory,3638,O
(,3638,O
STM,3638,O
),3638,O
",",3638,O
as,3638,O
measured,3638,O
by,3638,O
using,3638,O
radial,3638,O
arm,3638,O
water,3638,O
maze,3638,O
",",3638,O
accompanied,3638,O
with,3638,O
decreased,3638,O
hippocampal,3638,O
glutathione,3638,B-Chemical
reductase,3638,O
(,3638,O
GR,3638,O
),3638,O
activity,3638,O
and,3638,O
reduced,3638,O
glutathione,3638,B-Chemical
(,3638,O
GSH,3638,B-Chemical
),3638,O
content,3638,O
.,3638,O
Also,3639,O
",",3639,O
BCNU,3639,B-Chemical
administration,3639,O
increased,3639,O
serum,3639,O
tumor,3639,B-Disease
necrosis,3639,B-Disease
factor-alpha,3639,O
(,3639,O
TNFalpha,3639,O
),3639,O
",",3639,O
hippocampal,3639,O
MT,3639,B-Chemical
and,3639,O
malondialdehyde,3639,B-Chemical
(,3639,O
MDA,3639,B-Chemical
),3639,O
contents,3639,O
as,3639,O
well,3639,O
as,3639,O
caspase-3,3639,O
activity,3639,O
in,3639,O
addition,3639,O
to,3639,O
histological,3639,O
alterations,3639,O
.,3639,O
ZnSO,3640,B-Chemical
(,3640,I-Chemical
4,3640,I-Chemical
),3640,I-Chemical
pretreatment,3640,O
counteracted,3640,O
BCNU-induced,3640,B-Chemical
inhibition,3640,O
of,3640,O
GR,3640,O
and,3640,O
depletion,3640,O
of,3640,O
GSH,3640,B-Chemical
and,3640,O
resulted,3640,O
in,3640,O
significant,3640,O
reduction,3640,O
in,3640,O
the,3640,O
levels,3640,O
of,3640,O
MDA,3640,B-Chemical
and,3640,O
TNFalpha,3640,O
as,3640,O
well,3640,O
as,3640,O
the,3640,O
activity,3640,O
of,3640,O
caspase-3,3640,O
.,3640,O
The,3641,O
histological,3641,O
features,3641,O
were,3641,O
improved,3641,O
in,3641,O
hippocampus,3641,O
of,3641,O
rats,3641,O
treated,3641,O
with,3641,O
ZnSO,3641,B-Chemical
(,3641,I-Chemical
4,3641,I-Chemical
),3641,I-Chemical
+,3641,O
BCNU,3641,B-Chemical
compared,3641,O
to,3641,O
only,3641,O
BCNU-treated,3641,B-Chemical
animals,3641,O
.,3641,O
In,3642,O
conclusion,3642,O
",",3642,O
MT,3642,B-Chemical
induction,3642,O
halts,3642,O
BCNU-induced,3642,B-Chemical
hippocampal,3642,O
toxicity,3642,B-Disease
as,3642,O
it,3642,O
prevented,3642,O
GR,3642,O
inhibition,3642,O
and,3642,O
GSH,3642,B-Chemical
depletion,3642,O
and,3642,O
counteracted,3642,O
the,3642,O
increased,3642,O
levels,3642,O
of,3642,O
TNFalpha,3642,O
",",3642,O
MDA,3642,B-Chemical
and,3642,O
caspase-3,3642,O
activity,3642,O
with,3642,O
subsequent,3642,O
preservation,3642,O
of,3642,O
cognition,3642,O
.,3642,O
Fatal,3643,O
carbamazepine,3643,B-Chemical
induced,3643,O
fulminant,3643,B-Disease
eosinophilic,3643,I-Disease
(,3643,O
hypersensitivity,3643,B-Disease
),3643,O
myocarditis,3643,B-Disease
:,3643,O
emphasis,3643,O
on,3643,O
anatomical,3643,O
and,3643,O
histological,3643,O
characteristics,3643,O
",",3643,O
mechanisms,3643,O
and,3643,O
genetics,3643,O
of,3643,O
drug,3643,B-Disease
hypersensitivity,3643,I-Disease
and,3643,O
differential,3643,O
diagnosis,3643,O
.,3643,O
The,3644,O
most,3644,O
severe,3644,O
adverse,3644,O
reactions,3644,O
to,3644,O
carbamazepine,3644,B-Chemical
have,3644,O
been,3644,O
observed,3644,O
in,3644,O
the,3644,O
haemopoietic,3644,O
system,3644,O
",",3644,O
the,3644,O
liver,3644,O
and,3644,O
the,3644,O
cardiovascular,3644,O
system,3644,O
.,3644,O
A,3645,O
frequently,3645,O
fatal,3645,O
",",3645,O
although,3645,O
exceptionally,3645,O
rare,3645,O
side,3645,O
effect,3645,O
of,3645,O
carbamazepine,3645,B-Chemical
is,3645,O
necrotizing,3645,O
eosinophilic,3645,O
(,3645,O
hypersensitivity,3645,B-Disease
),3645,O
myocarditis,3645,B-Disease
.,3645,O
We,3646,O
report,3646,O
a,3646,O
case,3646,O
of,3646,O
hypersensitivity,3646,B-Disease
myocarditis,3646,B-Disease
secondary,3646,O
to,3646,O
administration,3646,O
of,3646,O
carbamazepine,3646,B-Chemical
.,3646,O
Acute,3647,O
hypersensitivity,3647,B-Disease
myocarditis,3647,B-Disease
was,3647,O
not,3647,O
suspected,3647,O
clinically,3647,O
",",3647,O
and,3647,O
the,3647,O
diagnosis,3647,O
was,3647,O
made,3647,O
post-mortem,3647,O
.,3647,O
Histology,3648,O
revealed,3648,O
diffuse,3648,O
infiltration,3648,O
of,3648,O
the,3648,O
myocardium,3648,O
by,3648,O
eosinophils,3648,O
and,3648,O
lymphocytes,3648,O
with,3648,O
myocyte,3648,O
damage,3648,O
.,3648,O
Clinically,3649,O
",",3649,O
death,3649,O
was,3649,O
due,3649,O
to,3649,O
cardiogenic,3649,B-Disease
shock,3649,I-Disease
.,3649,O
To,3650,O
best,3650,O
of,3650,O
our,3650,O
knowledge,3650,O
this,3650,O
is,3650,O
the,3650,O
second,3650,O
case,3650,O
of,3650,O
fatal,3650,O
carbamazepine,3650,B-Chemical
induced,3650,O
myocarditis,3650,B-Disease
reported,3650,O
in,3650,O
English,3650,O
literature,3650,O
.,3650,O
Neuropsychiatric,3651,O
behaviors,3651,O
in,3651,O
the,3651,O
MPTP,3651,B-Chemical
marmoset,3651,O
model,3651,O
of,3651,O
Parkinson,3651,B-Disease
's,3651,I-Disease
disease,3651,I-Disease
.,3651,O
OBJECTIVES,3652,O
:,3652,O
Neuropsychiatric,3652,O
symptoms,3652,O
are,3652,O
increasingly,3652,O
recognised,3652,O
as,3652,O
a,3652,O
significant,3652,O
problem,3652,O
in,3652,O
patients,3652,O
with,3652,O
Parkinson,3652,B-Disease
's,3652,I-Disease
disease,3652,I-Disease
(,3652,O
PD,3652,B-Disease
),3652,O
.,3652,O
These,3653,O
symptoms,3653,O
may,3653,O
be,3653,O
due,3653,O
to,3653,O
'sensitisation,3653,O
',3653,O
following,3653,O
repeated,3653,O
levodopa,3653,B-Chemical
treatment,3653,O
or,3653,O
a,3653,O
direct,3653,O
effect,3653,O
of,3653,O
dopamine,3653,B-Chemical
on,3653,O
the,3653,O
disease,3653,O
state,3653,O
.,3653,O
The,3654,O
levodopa-treated,3654,B-Chemical
MPTP-lesioned,3654,B-Chemical
marmoset,3654,O
was,3654,O
used,3654,O
as,3654,O
a,3654,O
model,3654,O
of,3654,O
neuropsychiatric,3654,B-Disease
symptoms,3654,I-Disease
in,3654,O
PD,3654,B-Disease
patients,3654,O
.,3654,O
Here,3655,O
we,3655,O
compare,3655,O
the,3655,O
time,3655,O
course,3655,O
of,3655,O
levodopa-induced,3655,B-Chemical
motor,3655,O
fluctuations,3655,O
and,3655,O
neuropsychiatric-like,3655,B-Disease
behaviors,3655,I-Disease
to,3655,O
determine,3655,O
the,3655,O
relationship,3655,O
between,3655,O
duration,3655,O
of,3655,O
treatment,3655,O
and,3655,O
onset,3655,O
of,3655,O
symptoms,3655,O
.,3655,O
METHODS,3656,O
:,3656,O
Marmosets,3656,O
were,3656,O
administered,3656,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",3656,B-Chemical
(,3656,O
2.0,3656,O
mg/kg,3656,O
s.c.,3656,O
),3656,O
for,3656,O
five,3656,O
days,3656,O
",",3656,O
resulting,3656,O
in,3656,O
stable,3656,O
parkinsonism,3656,B-Disease
.,3656,O
Levodopa,3657,B-Chemical
(,3657,O
15,3657,O
mg/kg,3657,O
and,3657,O
benserazide,3657,B-Chemical
",",3657,O
3.75,3657,O
mg/kg,3657,O
),3657,O
p.o,3657,O
.,3657,O
b.i.d,3658,O
",",3658,O
was,3658,O
administered,3658,O
for,3658,O
30,3658,O
days,3658,O
.,3658,O
Animals,3659,O
were,3659,O
evaluated,3659,O
for,3659,O
parkinsonian,3659,B-Disease
disability,3659,I-Disease
",",3659,O
dyskinesia,3659,B-Disease
and,3659,O
on-time,3659,O
(,3659,O
motor,3659,O
fluctuations,3659,O
),3659,O
and,3659,O
neuropsychiatric-like,3659,B-Disease
behaviors,3659,I-Disease
on,3659,O
Day,3659,O
0,3659,O
(,3659,O
prior,3659,O
to,3659,O
levodopa,3659,B-Chemical
),3659,O
and,3659,O
on,3659,O
Days,3659,O
1,3659,O
",",3659,O
7,3659,O
",",3659,O
13,3659,O
",",3659,O
27,3659,O
and,3659,O
30,3659,O
of,3659,O
treatment,3659,O
using,3659,O
post,3659,O
hoc,3659,O
DVD,3659,O
analysis,3659,O
by,3659,O
a,3659,O
trained,3659,O
rater,3659,O
",",3659,O
blind,3659,O
to,3659,O
the,3659,O
treatment,3659,O
day,3659,O
.,3659,O
RESULTS,3660,O
:,3660,O
The,3660,O
neuropsychiatric-like,3660,B-Disease
behavior,3660,I-Disease
rating,3660,O
scale,3660,O
demonstrated,3660,O
high,3660,O
interrater,3660,O
reliability,3660,O
between,3660,O
three,3660,O
trained,3660,O
raters,3660,O
of,3660,O
differing,3660,O
professional,3660,O
backgrounds,3660,O
.,3660,O
As,3661,O
anticipated,3661,O
",",3661,O
animals,3661,O
exhibited,3661,O
a,3661,O
progressive,3661,O
increase,3661,O
in,3661,O
levodopa-induced,3661,B-Chemical
motor,3661,O
fluctuations,3661,O
",",3661,O
dyskinesia,3661,B-Disease
and,3661,O
wearing-off,3661,O
",",3661,O
that,3661,O
correlated,3661,O
with,3661,O
the,3661,O
duration,3661,O
of,3661,O
levodopa,3661,B-Chemical
therapy,3661,O
.,3661,O
In,3662,O
contrast,3662,O
",",3662,O
levodopa-induced,3662,B-Chemical
neuropsychiatric-like,3662,B-Disease
behaviors,3662,I-Disease
were,3662,O
present,3662,O
on,3662,O
Day,3662,O
1,3662,O
of,3662,O
levodopa,3662,B-Chemical
treatment,3662,O
and,3662,O
their,3662,O
severity,3662,O
did,3662,O
not,3662,O
correlate,3662,O
with,3662,O
duration,3662,O
of,3662,O
treatment,3662,O
.,3662,O
CONCLUSIONS,3663,O
:,3663,O
The,3663,O
data,3663,O
suggest,3663,O
that,3663,O
neuropsychiatric,3663,B-Disease
disorders,3663,I-Disease
in,3663,O
PD,3663,B-Disease
are,3663,O
more,3663,O
likely,3663,O
an,3663,O
interaction,3663,O
between,3663,O
levodopa,3663,B-Chemical
and,3663,O
the,3663,O
disease,3663,O
state,3663,O
than,3663,O
a,3663,O
consequence,3663,O
of,3663,O
sensitisation,3663,O
to,3663,O
repeated,3663,O
dopaminergic,3663,O
therapy,3663,O
.,3663,O
Contrast,3664,B-Chemical
medium,3664,I-Chemical
nephrotoxicity,3664,B-Disease
after,3664,O
renal,3664,O
artery,3664,O
and,3664,O
coronary,3664,O
angioplasty,3664,O
.,3664,O
BACKGROUND,3665,O
:,3665,O
Renal,3665,B-Disease
dysfunction,3665,I-Disease
induced,3665,O
by,3665,O
iodinated,3665,O
contrast,3665,B-Chemical
medium,3665,I-Chemical
(,3665,O
CM,3665,B-Chemical
),3665,O
administration,3665,O
can,3665,O
minimize,3665,O
the,3665,O
benefit,3665,O
of,3665,O
the,3665,O
interventional,3665,O
procedure,3665,O
in,3665,O
patients,3665,O
undergoing,3665,O
renal,3665,O
angioplasty,3665,O
(,3665,O
PTRA,3665,O
),3665,O
.,3665,O
PURPOSE,3666,O
:,3666,O
To,3666,O
compare,3666,O
the,3666,O
susceptibility,3666,O
to,3666,O
nephrotoxic,3666,B-Disease
effect,3666,O
of,3666,O
CM,3666,B-Chemical
in,3666,O
patients,3666,O
undergoing,3666,O
PTRA,3666,O
with,3666,O
that,3666,O
of,3666,O
patients,3666,O
submitted,3666,O
to,3666,O
percutaneous,3666,O
coronary,3666,O
intervention,3666,O
(,3666,O
PCI,3666,O
),3666,O
.,3666,O
MATERIAL,3667,O
AND,3667,O
METHODS,3667,O
:,3667,O
A,3667,O
total,3667,O
of,3667,O
33,3667,O
patients,3667,O
successfully,3667,O
treated,3667,O
with,3667,O
PTRA,3667,O
(,3667,O
PTRA,3667,O
group,3667,O
",",3667,O
mean,3667,O
age,3667,O
70+/-12,3667,O
years,3667,O
",",3667,O
23,3667,O
female,3667,O
",",3667,O
basal,3667,O
creatinine,3667,B-Chemical
1.46+/-0.79,3667,O
",",3667,O
range,3667,O
0.7-4.9,3667,O
mg/dl,3667,O
),3667,O
were,3667,O
compared,3667,O
with,3667,O
33,3667,O
patients,3667,O
undergoing,3667,O
successful,3667,O
PCI,3667,O
(,3667,O
PCI,3667,O
group,3667,O
),3667,O
",",3667,O
matched,3667,O
for,3667,O
basal,3667,O
creatinine,3667,B-Chemical
(,3667,O
1.44+/-0.6,3667,O
",",3667,O
range,3667,O
0.7-3.4,3667,O
mg/dl,3667,O
),3667,O
",",3667,O
gender,3667,O
",",3667,O
and,3667,O
age,3667,O
.,3667,O
In,3668,O
both,3668,O
groups,3668,O
postprocedural,3668,O
(,3668,O
48,3668,O
h,3668,O
),3668,O
serum,3668,O
creatinine,3668,B-Chemical
was,3668,O
measured,3668,O
.,3668,O
RESULTS,3669,O
:,3669,O
Postprocedural,3669,O
creatinine,3669,B-Chemical
level,3669,O
decreased,3669,O
nonsignificantly,3669,O
in,3669,O
the,3669,O
PTRA,3669,O
group,3669,O
(,3669,O
1.46+/-0.8,3669,O
vs.,3669,O
1.34+/-0.5,3669,O
mg/dl,3669,O
",",3669,O
P=NS,3669,O
),3669,O
and,3669,O
increased,3669,O
significantly,3669,O
in,3669,O
the,3669,O
PCI,3669,O
group,3669,O
(,3669,O
1.44+/-0.6,3669,O
vs.,3669,O
1.57+/-0.7,3669,O
mg/dl,3669,O
",",3669,O
P,3669,O
<,3669,O
0.02,3669,O
),3669,O
.,3669,O
Changes,3670,O
in,3670,O
serum,3670,O
creatinine,3670,B-Chemical
after,3670,O
intervention,3670,O
(,3670,O
after-before,3670,O
),3670,O
were,3670,O
significantly,3670,O
different,3670,O
between,3670,O
the,3670,O
PTRA,3670,O
and,3670,O
PCI,3670,O
groups,3670,O
(,3670,O
-0.12+/-0.5,3670,O
vs.,3670,O
0.13+/-0.3,3670,O
",",3670,O
P=0.014,3670,O
),3670,O
.,3670,O
This,3671,O
difference,3671,O
was,3671,O
not,3671,O
related,3671,O
to,3671,O
either,3671,O
a,3671,O
different,3671,O
clinical,3671,O
risk,3671,O
profile,3671,O
or,3671,O
to,3671,O
the,3671,O
volume,3671,O
of,3671,O
CM,3671,B-Chemical
administered,3671,O
.,3671,O
CONCLUSION,3672,O
:,3672,O
In,3672,O
this,3672,O
preliminary,3672,O
study,3672,O
patients,3672,O
submitted,3672,O
to,3672,O
PTRA,3672,O
showed,3672,O
a,3672,O
lower,3672,O
susceptibility,3672,O
to,3672,O
renal,3672,B-Disease
damage,3672,I-Disease
induced,3672,O
by,3672,O
CM,3672,B-Chemical
administration,3672,O
than,3672,O
PCI,3672,O
patients,3672,O
.,3672,O
The,3673,O
effectiveness,3673,O
of,3673,O
PTRA,3673,O
on,3673,O
renal,3673,O
function,3673,O
seems,3673,O
to,3673,O
be,3673,O
barely,3673,O
influenced,3673,O
by,3673,O
CM,3673,B-Chemical
toxicity,3673,B-Disease
.,3673,O
Medical,3674,O
and,3674,O
psychiatric,3674,O
outcomes,3674,O
for,3674,O
patients,3674,O
transplanted,3674,O
for,3674,O
acetaminophen-induced,3674,B-Chemical
acute,3674,B-Disease
liver,3674,I-Disease
failure,3674,I-Disease
:,3674,O
a,3674,O
case-control,3674,O
study,3674,O
.,3674,O
BACKGROUND,3675,O
:,3675,O
Acetaminophen-induced,3675,B-Chemical
hepatotoxicity,3675,B-Disease
is,3675,O
the,3675,O
most,3675,O
common,3675,O
cause,3675,O
of,3675,O
acute,3675,B-Disease
liver,3675,I-Disease
failure,3675,I-Disease
(,3675,O
ALF,3675,B-Disease
),3675,O
in,3675,O
the,3675,O
UK,3675,O
.,3675,O
Patients,3676,O
often,3676,O
consume,3676,O
the,3676,O
drug,3676,O
with,3676,O
suicidal,3676,O
intent,3676,O
or,3676,O
with,3676,O
a,3676,O
background,3676,O
of,3676,O
substance,3676,O
dependence,3676,O
.,3676,O
AIMS,3677,O
AND,3677,O
METHODS,3677,O
:,3677,O
We,3677,O
compared,3677,O
the,3677,O
severity,3677,O
of,3677,O
pretransplant,3677,O
illness,3677,O
",",3677,O
psychiatric,3677,O
co-morbidity,3677,O
",",3677,O
medical,3677,O
and,3677,O
psychosocial,3677,O
outcomes,3677,O
of,3677,O
all,3677,O
patients,3677,O
who,3677,O
had,3677,O
undergone,3677,O
liver,3677,O
transplantation,3677,O
(,3677,O
LT,3677,O
),3677,O
emergently,3677,O
between,3677,O
1999-2004,3677,O
for,3677,O
acetaminophen-induced,3677,B-Chemical
ALF,3677,B-Disease
(,3677,O
n=36,3677,O
),3677,O
with,3677,O
age-,3677,O
and,3677,O
sex-matched,3677,O
patients,3677,O
undergoing,3677,O
emergent,3677,O
LT,3677,O
for,3677,O
non-acetaminophen-induced,3677,O
ALF,3677,B-Disease
(,3677,O
n=35,3677,O
),3677,O
and,3677,O
elective,3677,O
LT,3677,O
for,3677,O
chronic,3677,B-Disease
liver,3677,I-Disease
disease,3677,I-Disease
(,3677,O
CLD,3677,B-Disease
",",3677,O
n=34,3677,O
),3677,O
.,3677,O
RESULTS,3678,O
:,3678,O
Acetaminophen-induced,3678,B-Chemical
ALF,3678,B-Disease
patients,3678,O
undergoing,3678,O
LT,3678,O
had,3678,O
a,3678,O
greater,3678,O
severity,3678,O
of,3678,O
pre-LT,3678,O
illness,3678,O
reflected,3678,O
by,3678,O
higher,3678,O
Acute,3678,O
Physiology,3678,O
and,3678,O
Chronic,3678,O
Health,3678,O
Evaluation,3678,O
II,3678,O
scores,3678,O
and,3678,O
requirement,3678,O
for,3678,O
organ,3678,O
support,3678,O
compared,3678,O
with,3678,O
the,3678,O
other,3678,O
two,3678,O
groups,3678,O
.,3678,O
Twenty,3679,O
(,3679,O
56,3679,O
%,3679,O
),3679,O
acetaminophen-induced,3679,B-Chemical
ALF,3679,B-Disease
patients,3679,O
had,3679,O
a,3679,O
formal,3679,O
psychiatric,3679,O
diagnosis,3679,O
before,3679,O
LT,3679,O
(,3679,O
non-acetaminophen-induced,3679,O
ALF=0/35,3679,B-Disease
",",3679,O
CLD=2/34,3679,B-Disease
;,3679,O
P,3679,O
<,3679,O
0.01,3679,O
for,3679,O
all,3679,O
),3679,O
and,3679,O
nine,3679,O
(,3679,O
25,3679,O
%,3679,O
),3679,O
had,3679,O
a,3679,O
previous,3679,O
suicide,3679,O
attempt,3679,O
.,3679,O
During,3680,O
follow-up,3680,O
(,3680,O
median,3680,O
5,3680,O
years,3680,O
),3680,O
",",3680,O
there,3680,O
were,3680,O
no,3680,O
significant,3680,O
differences,3680,O
in,3680,O
rejection,3680,O
(,3680,O
acute,3680,O
and,3680,O
chronic,3680,O
),3680,O
",",3680,O
graft,3680,O
failure,3680,O
or,3680,O
survival,3680,O
between,3680,O
the,3680,O
groups,3680,O
(,3680,O
acetaminophen-induced,3680,B-Chemical
ALF,3680,B-Disease
1,3680,O
year,3680,O
87,3680,O
%,3680,O
",",3680,O
5,3680,O
years,3680,O
75,3680,O
%,3680,O
;,3680,O
non-acetaminophen-induced,3680,O
ALF,3680,B-Disease
88,3680,O
%,3680,O
",",3680,O
78,3680,O
%,3680,O
;,3680,O
CLD,3680,B-Disease
93,3680,O
%,3680,O
",",3680,O
82,3680,O
%,3680,O
:,3680,O
P,3680,O
>,3680,O
0.6,3680,O
log,3680,O
rank,3680,O
),3680,O
.,3680,O
Two,3681,O
acetaminophen-induced,3681,B-Chemical
ALF,3681,B-Disease
patients,3681,O
reattempted,3681,O
suicide,3681,O
post-LT,3681,O
(,3681,O
one,3681,O
died,3681,O
8,3681,O
years,3681,O
post-LT,3681,O
),3681,O
.,3681,O
CONCLUSIONS,3682,O
:,3682,O
Despite,3682,O
a,3682,O
high,3682,O
prevalence,3682,O
of,3682,O
psychiatric,3682,O
disturbance,3682,O
",",3682,O
outcomes,3682,O
for,3682,O
patients,3682,O
transplanted,3682,O
emergently,3682,O
for,3682,O
acetaminophen-induced,3682,B-Chemical
ALF,3682,B-Disease
were,3682,O
comparable,3682,O
to,3682,O
those,3682,O
transplanted,3682,O
for,3682,O
non-acetaminophen-induced,3682,O
ALF,3682,B-Disease
and,3682,O
electively,3682,O
for,3682,O
CLD,3682,B-Disease
.,3682,O
Multidisciplinary,3683,O
approaches,3683,O
with,3683,O
long-term,3683,O
psychiatric,3683,O
follow-up,3683,O
may,3683,O
contribute,3683,O
to,3683,O
low,3683,O
post-transplant,3683,O
suicide,3683,O
rates,3683,O
seen,3683,O
and,3683,O
low,3683,O
rates,3683,O
of,3683,O
graft,3683,O
loss,3683,O
because,3683,O
of,3683,O
non-compliance,3683,O
.,3683,O
Antithrombotic,3684,O
drug,3684,O
use,3684,O
",",3684,O
cerebral,3684,B-Disease
microbleeds,3684,I-Disease
",",3684,O
and,3684,O
intracerebral,3684,B-Disease
hemorrhage,3684,I-Disease
:,3684,O
a,3684,O
systematic,3684,O
review,3684,O
of,3684,O
published,3684,O
and,3684,O
unpublished,3684,O
studies,3684,O
.,3684,O
BACKGROUND,3685,O
AND,3685,O
PURPOSE,3685,O
:,3685,O
Cerebral,3685,B-Disease
microbleeds,3685,I-Disease
(,3685,O
MB,3685,B-Disease
),3685,O
are,3685,O
potential,3685,O
risk,3685,O
factors,3685,O
for,3685,O
intracerebral,3685,B-Disease
hemorrhage,3685,I-Disease
(,3685,O
ICH,3685,B-Disease
),3685,O
",",3685,O
but,3685,O
it,3685,O
is,3685,O
unclear,3685,O
if,3685,O
they,3685,O
are,3685,O
a,3685,O
contraindication,3685,O
to,3685,O
using,3685,O
antithrombotic,3685,O
drugs,3685,O
.,3685,O
Insights,3686,O
could,3686,O
be,3686,O
gained,3686,O
by,3686,O
pooling,3686,O
data,3686,O
on,3686,O
MB,3686,B-Disease
frequency,3686,O
stratified,3686,O
by,3686,O
antithrombotic,3686,O
use,3686,O
in,3686,O
cohorts,3686,O
with,3686,O
ICH,3686,B-Disease
and,3686,O
ischemic,3686,B-Disease
stroke,3686,I-Disease
(,3686,O
IS,3686,B-Disease
),3686,O
/transient,3686,O
ischemic,3686,I-Disease
attack,3686,I-Disease
(,3686,O
TIA,3686,B-Disease
),3686,O
.,3686,O
METHODS,3687,O
:,3687,O
We,3687,O
performed,3687,O
a,3687,O
systematic,3687,O
review,3687,O
of,3687,O
published,3687,O
and,3687,O
unpublished,3687,O
data,3687,O
from,3687,O
cohorts,3687,O
with,3687,O
stroke,3687,B-Disease
or,3687,O
TIA,3687,B-Disease
to,3687,O
compare,3687,O
the,3687,O
presence,3687,O
of,3687,O
MB,3687,B-Disease
in,3687,O
:,3687,O
(,3687,O
1,3687,O
),3687,O
antithrombotic,3687,O
users,3687,O
vs,3687,O
nonantithrombotic,3687,O
users,3687,O
with,3687,O
ICH,3687,B-Disease
;,3687,O
(,3687,O
2,3687,O
),3687,O
antithrombotic,3687,O
users,3687,O
vs,3687,O
nonusers,3687,O
with,3687,O
IS/TIA,3687,B-Disease
;,3687,O
and,3687,O
(,3687,O
3,3687,O
),3687,O
ICH,3687,B-Disease
vs,3687,O
ischemic,3687,B-Disease
events,3687,O
stratified,3687,O
by,3687,O
antithrombotic,3687,O
use,3687,O
.,3687,O
We,3688,O
also,3688,O
analyzed,3688,O
published,3688,O
and,3688,O
unpublished,3688,O
follow-up,3688,O
data,3688,O
to,3688,O
determine,3688,O
the,3688,O
risk,3688,O
of,3688,O
ICH,3688,B-Disease
in,3688,O
antithrombotic,3688,O
users,3688,O
with,3688,O
MB,3688,B-Disease
.,3688,O
RESULTS,3689,O
:,3689,O
In,3689,O
a,3689,O
pooled,3689,O
analysis,3689,O
of,3689,O
1460,3689,O
ICH,3689,B-Disease
and,3689,O
3817,3689,O
IS/TIA,3689,B-Disease
",",3689,O
MB,3689,B-Disease
were,3689,O
more,3689,O
frequent,3689,O
in,3689,O
ICH,3689,B-Disease
vs,3689,O
IS/TIA,3689,B-Disease
in,3689,O
all,3689,O
treatment,3689,O
groups,3689,O
",",3689,O
but,3689,O
the,3689,O
excess,3689,O
increased,3689,O
from,3689,O
2.8,3689,O
(,3689,O
odds,3689,O
ratio,3689,O
;,3689,O
range,3689,O
",",3689,O
2.3-3.5,3689,O
),3689,O
in,3689,O
nonantithrombotic,3689,O
users,3689,O
to,3689,O
5.7,3689,O
(,3689,O
range,3689,O
",",3689,O
3.4-9.7,3689,O
),3689,O
in,3689,O
antiplatelet,3689,O
users,3689,O
and,3689,O
8.0,3689,O
(,3689,O
range,3689,O
",",3689,O
3.5-17.8,3689,O
),3689,O
in,3689,O
warfarin,3689,B-Chemical
users,3689,O
(,3689,O
P,3689,O
difference=0.01,3689,O
),3689,O
.,3689,O
There,3690,O
was,3690,O
also,3690,O
an,3690,O
excess,3690,O
of,3690,O
MB,3690,B-Disease
in,3690,O
warfarin,3690,B-Chemical
users,3690,O
vs,3690,O
nonusers,3690,O
with,3690,O
ICH,3690,B-Disease
(,3690,O
OR,3690,O
",",3690,O
2.7,3690,O
;,3690,O
95,3690,O
%,3690,O
CI,3690,O
",",3690,O
1.6-4.4,3690,O
;,3690,O
P,3690,O
<,3690,O
0.001,3690,O
),3690,O
but,3690,O
none,3690,O
in,3690,O
warfarin,3690,B-Chemical
users,3690,O
with,3690,O
IS/TIA,3690,B-Disease
(,3690,O
OR,3690,O
",",3690,O
1.3,3690,O
;,3690,O
95,3690,O
%,3690,O
CI,3690,O
",",3690,O
0.9-1.7,3690,O
;,3690,O
P=0.33,3690,O
;,3690,O
P,3690,O
difference=0.01,3690,O
),3690,O
.,3690,O
There,3691,O
was,3691,O
a,3691,O
smaller,3691,O
excess,3691,O
of,3691,O
MB,3691,B-Disease
in,3691,O
antiplatelet,3691,O
users,3691,O
vs,3691,O
nonusers,3691,O
with,3691,O
ICH,3691,B-Disease
(,3691,O
OR,3691,O
",",3691,O
1.7,3691,O
;,3691,O
95,3691,O
%,3691,O
CI,3691,O
",",3691,O
1.3-2.3,3691,O
;,3691,O
P,3691,O
<,3691,O
0.001,3691,O
),3691,O
",",3691,O
but,3691,O
findings,3691,O
were,3691,O
similar,3691,O
for,3691,O
antiplatelet,3691,O
users,3691,O
with,3691,O
IS/TIA,3691,B-Disease
(,3691,O
OR,3691,O
",",3691,O
1.4,3691,O
;,3691,O
95,3691,O
%,3691,O
CI,3691,O
",",3691,O
1.2-1.7,3691,O
;,3691,O
P,3691,O
<,3691,O
0.001,3691,O
;,3691,O
P,3691,O
difference=0.25,3691,O
),3691,O
.,3691,O
In,3692,O
pooled,3692,O
follow-up,3692,O
data,3692,O
for,3692,O
768,3692,O
antithrombotic,3692,O
users,3692,O
",",3692,O
presence,3692,O
of,3692,O
MB,3692,B-Disease
at,3692,O
baseline,3692,O
was,3692,O
associated,3692,O
with,3692,O
a,3692,O
substantially,3692,O
increased,3692,O
risk,3692,O
of,3692,O
subsequent,3692,O
ICH,3692,B-Disease
(,3692,O
OR,3692,O
",",3692,O
12.1,3692,O
;,3692,O
95,3692,O
%,3692,O
CI,3692,O
",",3692,O
3.4-42.5,3692,O
;,3692,O
P,3692,O
<,3692,O
0.001,3692,O
),3692,O
.,3692,O
CONCLUSIONS,3693,O
:,3693,O
The,3693,O
excess,3693,O
of,3693,O
MB,3693,B-Disease
in,3693,O
warfarin,3693,B-Chemical
users,3693,O
with,3693,O
ICH,3693,B-Disease
compared,3693,O
to,3693,O
other,3693,O
groups,3693,O
suggests,3693,O
that,3693,O
MB,3693,B-Disease
increase,3693,O
the,3693,O
risk,3693,O
of,3693,O
warfarin-associated,3693,B-Chemical
ICH,3693,B-Disease
.,3693,O
Limited,3694,O
prospective,3694,O
data,3694,O
corroborate,3694,O
these,3694,O
findings,3694,O
",",3694,O
but,3694,O
larger,3694,O
prospective,3694,O
studies,3694,O
are,3694,O
urgently,3694,O
required,3694,O
.,3694,O
Studies,3695,O
of,3695,O
synergy,3695,O
between,3695,O
morphine,3695,B-Chemical
and,3695,O
a,3695,O
novel,3695,O
sodium,3695,B-Chemical
channel,3695,O
blocker,3695,O
",",3695,O
CNSB002,3695,B-Chemical
",",3695,O
in,3695,O
rat,3695,O
models,3695,O
of,3695,O
inflammatory,3695,O
and,3695,O
neuropathic,3695,B-Disease
pain,3695,I-Disease
.,3695,O
OBJECTIVE,3696,O
:,3696,O
This,3696,O
study,3696,O
determined,3696,O
the,3696,O
antihyperalgesic,3696,O
effect,3696,O
of,3696,O
CNSB002,3696,B-Chemical
",",3696,O
a,3696,O
sodium,3696,B-Chemical
channel,3696,O
blocker,3696,O
with,3696,O
antioxidant,3696,O
properties,3696,O
given,3696,O
alone,3696,O
and,3696,O
in,3696,O
combinations,3696,O
with,3696,O
morphine,3696,B-Chemical
in,3696,O
rat,3696,O
models,3696,O
of,3696,O
inflammatory,3696,O
and,3696,O
neuropathic,3696,B-Disease
pain,3696,I-Disease
.,3696,O
DESIGN,3697,O
:,3697,O
Dose,3697,O
response,3697,O
curves,3697,O
for,3697,O
nonsedating,3697,O
doses,3697,O
of,3697,O
morphine,3697,B-Chemical
and,3697,O
CNSB002,3697,B-Chemical
given,3697,O
intraperitoneally,3697,O
alone,3697,O
and,3697,O
together,3697,O
in,3697,O
combinations,3697,O
were,3697,O
constructed,3697,O
for,3697,O
antihyperalgesic,3697,O
effect,3697,O
using,3697,O
paw,3697,O
withdrawal,3697,O
from,3697,O
noxious,3697,O
heat,3697,O
in,3697,O
two,3697,O
rat,3697,O
pain,3697,B-Disease
models,3697,O
:,3697,O
carrageenan-induced,3697,B-Chemical
paw,3697,O
inflammation,3697,B-Disease
and,3697,O
streptozotocin,3697,B-Chemical
(,3697,O
STZ,3697,B-Chemical
),3697,O
-induced,3697,O
diabetic,3697,B-Disease
neuropathy,3697,I-Disease
.,3697,O
RESULTS,3698,O
:,3698,O
The,3698,O
maximum,3698,O
nonsedating,3698,O
doses,3698,O
were,3698,O
:,3698,O
morphine,3698,B-Chemical
",",3698,O
3.2,3698,O
mg/kg,3698,O
;,3698,O
CNSB002,3698,B-Chemical
10.0,3698,O
mg/kg,3698,O
;,3698,O
5.0,3698,O
mg/kg,3698,O
CNSB002,3698,B-Chemical
with,3698,O
morphine,3698,B-Chemical
3.2,3698,O
mg/kg,3698,O
in,3698,O
combination,3698,O
.,3698,O
The,3699,O
doses,3699,O
calculated,3699,O
to,3699,O
cause,3699,O
50,3699,O
%,3699,O
reversal,3699,O
of,3699,O
hyperalgesia,3699,B-Disease
(,3699,O
ED50,3699,O
),3699,O
were,3699,O
7.54,3699,O
(,3699,O
1.81,3699,O
),3699,O
and,3699,O
4.83,3699,O
(,3699,O
1.54,3699,O
),3699,O
in,3699,O
the,3699,O
carrageenan,3699,B-Chemical
model,3699,O
and,3699,O
44.18,3699,O
(,3699,O
1.37,3699,O
),3699,O
and,3699,O
9.14,3699,O
(,3699,O
1.24,3699,O
),3699,O
in,3699,O
the,3699,O
STZ-induced,3699,B-Chemical
neuropathy,3699,B-Disease
model,3699,O
for,3699,O
CNSB002,3699,B-Chemical
and,3699,O
morphine,3699,B-Chemical
",",3699,O
respectively,3699,O
(,3699,O
mg/kg,3699,O
;,3699,O
mean,3699,O
",",3699,O
SEM,3699,O
),3699,O
.,3699,O
These,3700,O
values,3700,O
were,3700,O
greater,3700,O
than,3700,O
the,3700,O
maximum,3700,O
nonsedating,3700,O
doses,3700,O
.,3700,O
The,3701,O
ED50,3701,O
values,3701,O
for,3701,O
morphine,3701,B-Chemical
when,3701,O
given,3701,O
in,3701,O
combination,3701,O
with,3701,O
CNSB002,3701,B-Chemical
(,3701,O
5,3701,O
mg/kg,3701,O
),3701,O
were,3701,O
less,3701,O
than,3701,O
the,3701,O
maximum,3701,O
nonsedating,3701,O
dose,3701,O
:,3701,O
0.56,3701,O
(,3701,O
1.55,3701,O
),3701,O
in,3701,O
the,3701,O
carrageenan,3701,B-Chemical
model,3701,O
and,3701,O
1.37,3701,O
(,3701,O
1.23,3701,O
),3701,O
in,3701,O
the,3701,O
neuropathy,3701,B-Disease
model,3701,O
(,3701,O
mg/kg,3701,O
;,3701,O
mean,3701,O
",",3701,O
SEM,3701,O
),3701,O
.,3701,O
The,3702,O
antinociception,3702,O
after,3702,O
morphine,3702,B-Chemical
(,3702,O
3.2,3702,O
mg/kg,3702,O
),3702,O
was,3702,O
increased,3702,O
by,3702,O
co-administration,3702,O
with,3702,O
CNSB002,3702,B-Chemical
from,3702,O
28.0,3702,O
and,3702,O
31.7,3702,O
%,3702,O
to,3702,O
114.6,3702,O
and,3702,O
56.9,3702,O
%,3702,O
reversal,3702,O
of,3702,O
hyperalgesia,3702,B-Disease
in,3702,O
the,3702,O
inflammatory,3702,O
and,3702,O
neuropathic,3702,B-Disease
models,3702,O
",",3702,O
respectively,3702,O
(,3702,O
P,3702,O
<,3702,O
0.01,3702,O
;,3702,O
one-way,3702,O
analysis,3702,O
of,3702,O
variance-significantly,3702,O
greater,3702,O
than,3702,O
either,3702,O
drug,3702,O
given,3702,O
alone,3702,O
),3702,O
.,3702,O
CONCLUSIONS,3703,O
:,3703,O
The,3703,O
maximum,3703,O
antihyperalgesic,3703,O
effect,3703,O
achievable,3703,O
with,3703,O
nonsedating,3703,O
doses,3703,O
of,3703,O
morphine,3703,B-Chemical
may,3703,O
be,3703,O
increased,3703,O
significantly,3703,O
when,3703,O
the,3703,O
drug,3703,O
is,3703,O
used,3703,O
in,3703,O
combination,3703,O
with,3703,O
CNSB002,3703,B-Chemical
.,3703,O
Heparin-induced,3704,B-Chemical
thrombocytopenia,3704,B-Disease
:,3704,O
a,3704,O
practical,3704,O
review,3704,O
.,3704,O
Heparin-induced,3705,B-Chemical
thrombocytopenia,3705,B-Disease
(,3705,O
HIT,3705,B-Disease
),3705,O
remains,3705,O
under-recognized,3705,O
despite,3705,O
its,3705,O
potentially,3705,O
devastating,3705,O
outcomes,3705,O
.,3705,O
It,3706,O
begins,3706,O
when,3706,O
heparin,3706,B-Chemical
exposure,3706,O
stimulates,3706,O
the,3706,O
formation,3706,O
of,3706,O
heparin-platelet,3706,B-Chemical
factor,3706,O
4,3706,O
antibodies,3706,O
",",3706,O
which,3706,O
in,3706,O
turn,3706,O
triggers,3706,O
the,3706,O
release,3706,O
of,3706,O
procoagulant,3706,O
platelet,3706,O
particles,3706,O
.,3706,O
Thrombosis,3707,B-Disease
and,3707,O
thrombocytopenia,3707,B-Disease
that,3707,O
follow,3707,O
comprise,3707,O
the,3707,O
2,3707,O
hallmark,3707,O
traits,3707,O
of,3707,O
HIT,3707,B-Disease
",",3707,O
with,3707,O
the,3707,O
former,3707,O
largely,3707,O
responsible,3707,O
for,3707,O
significant,3707,O
vascular,3707,O
complications,3707,O
.,3707,O
The,3708,O
prevalence,3708,O
of,3708,O
HIT,3708,B-Disease
varies,3708,O
among,3708,O
several,3708,O
subgroups,3708,O
",",3708,O
with,3708,O
greater,3708,O
incidence,3708,O
in,3708,O
surgical,3708,O
as,3708,O
compared,3708,O
with,3708,O
medical,3708,O
populations,3708,O
.,3708,O
HIT,3709,B-Disease
must,3709,O
be,3709,O
acknowledged,3709,O
for,3709,O
its,3709,O
intense,3709,O
predilection,3709,O
for,3709,O
thrombosis,3709,B-Disease
and,3709,O
suspected,3709,O
whenever,3709,O
thrombosis,3709,B-Disease
occurs,3709,O
after,3709,O
heparin,3709,B-Chemical
exposure,3709,O
.,3709,O
Early,3710,O
recognition,3710,O
that,3710,O
incorporates,3710,O
the,3710,O
clinical,3710,O
and,3710,O
serologic,3710,O
clues,3710,O
is,3710,O
paramount,3710,O
to,3710,O
timely,3710,O
institution,3710,O
of,3710,O
treatment,3710,O
",",3710,O
as,3710,O
its,3710,O
delay,3710,O
may,3710,O
result,3710,O
in,3710,O
catastrophic,3710,O
outcomes,3710,O
.,3710,O
The,3711,O
treatment,3711,O
of,3711,O
HIT,3711,B-Disease
mandates,3711,O
an,3711,O
immediate,3711,O
cessation,3711,O
of,3711,O
all,3711,O
heparin,3711,B-Chemical
exposure,3711,O
and,3711,O
the,3711,O
institution,3711,O
of,3711,O
an,3711,O
antithrombotic,3711,O
therapy,3711,O
",",3711,O
most,3711,O
commonly,3711,O
using,3711,O
a,3711,O
direct,3711,B-Chemical
thrombin,3711,I-Chemical
inhibitor,3711,I-Chemical
.,3711,O
Current,3712,O
``,3712,O
diagnostic,3712,O
'',3712,O
tests,3712,O
",",3712,O
which,3712,O
primarily,3712,O
include,3712,O
functional,3712,O
and,3712,O
antigenic,3712,O
assays,3712,O
",",3712,O
have,3712,O
more,3712,O
of,3712,O
a,3712,O
confirmatory,3712,O
than,3712,O
diagnostic,3712,O
role,3712,O
in,3712,O
the,3712,O
management,3712,O
of,3712,O
HIT,3712,B-Disease
.,3712,O
Special,3713,O
attention,3713,O
must,3713,O
be,3713,O
paid,3713,O
to,3713,O
cardiac,3713,O
patients,3713,O
who,3713,O
are,3713,O
often,3713,O
exposed,3713,O
to,3713,O
heparin,3713,B-Chemical
multiple,3713,O
times,3713,O
during,3713,O
their,3713,O
course,3713,O
of,3713,O
treatment,3713,O
.,3713,O
Direct,3714,B-Chemical
thrombin,3714,I-Chemical
inhibitors,3714,I-Chemical
are,3714,O
appropriate,3714,O
",",3714,O
evidence-based,3714,O
alternatives,3714,O
to,3714,O
heparin,3714,B-Chemical
in,3714,O
patients,3714,O
with,3714,O
a,3714,O
history,3714,O
of,3714,O
HIT,3714,B-Disease
",",3714,O
who,3714,O
need,3714,O
to,3714,O
undergo,3714,O
percutaneous,3714,O
coronary,3714,O
intervention,3714,O
.,3714,O
As,3715,O
heparin,3715,B-Chemical
remains,3715,O
one,3715,O
of,3715,O
the,3715,O
most,3715,O
frequently,3715,O
used,3715,O
medications,3715,O
today,3715,O
with,3715,O
potential,3715,O
for,3715,O
HIT,3715,B-Disease
with,3715,O
every,3715,O
heparin,3715,B-Chemical
exposure,3715,O
",",3715,O
a,3715,O
close,3715,O
vigilance,3715,O
of,3715,O
platelet,3715,O
counts,3715,O
must,3715,O
be,3715,O
practiced,3715,O
whenever,3715,O
heparin,3715,B-Chemical
is,3715,O
initiated,3715,O
.,3715,O
Abductor,3716,O
paralysis,3716,B-Disease
after,3716,O
botox,3716,B-Chemical
injection,3716,O
for,3716,O
adductor,3716,B-Disease
spasmodic,3716,I-Disease
dysphonia,3716,I-Disease
.,3716,O
OBJECTIVES/HYPOTHESIS,3717,O
:,3717,O
Botulinum,3717,O
toxin,3717,O
(,3717,O
Botox,3717,B-Chemical
),3717,O
injections,3717,O
into,3717,O
the,3717,O
thyroarytenoid,3717,O
muscles,3717,O
are,3717,O
the,3717,O
current,3717,O
standard,3717,O
of,3717,O
care,3717,O
for,3717,O
adductor,3717,B-Disease
spasmodic,3717,I-Disease
dysphonia,3717,I-Disease
(,3717,O
ADSD,3717,B-Disease
),3717,O
.,3717,O
Reported,3718,O
adverse,3718,O
effects,3718,O
include,3718,O
a,3718,O
period,3718,O
of,3718,O
breathiness,3718,O
",",3718,O
throat,3718,B-Disease
pain,3718,I-Disease
",",3718,O
and,3718,O
difficulty,3718,O
with,3718,O
swallowing,3718,O
liquids,3718,O
.,3718,O
Here,3719,O
we,3719,O
report,3719,O
multiple,3719,O
cases,3719,O
of,3719,O
bilateral,3719,O
abductor,3719,O
paralysis,3719,B-Disease
following,3719,O
Botox,3719,B-Chemical
injections,3719,O
for,3719,O
ADSD,3719,B-Disease
",",3719,O
a,3719,O
complication,3719,O
previously,3719,O
unreported,3719,O
.,3719,O
STUDY,3720,O
DESIGN,3720,O
:,3720,O
Retrospective,3720,O
case,3720,O
series,3720,O
.,3720,O
METHODS,3721,O
:,3721,O
Patients,3721,O
that,3721,O
received,3721,O
Botox,3721,B-Chemical
injections,3721,O
for,3721,O
spasmodic,3721,B-Disease
dysphonia,3721,I-Disease
between,3721,O
January,3721,O
2000,3721,O
and,3721,O
October,3721,O
2009,3721,O
were,3721,O
evaluated,3721,O
.,3721,O
Patients,3722,O
with,3722,O
ADSD,3722,B-Disease
were,3722,O
identified,3722,O
.,3722,O
The,3723,O
number,3723,O
of,3723,O
treatments,3723,O
received,3723,O
and,3723,O
adverse,3723,O
effects,3723,O
were,3723,O
noted,3723,O
.,3723,O
For,3724,O
patients,3724,O
with,3724,O
bilateral,3724,O
abductor,3724,O
paralysis,3724,B-Disease
",",3724,O
age,3724,O
",",3724,O
sex,3724,O
",",3724,O
paralytic,3724,O
Botox,3724,B-Chemical
dose,3724,O
",",3724,O
prior,3724,O
Botox,3724,B-Chemical
dose,3724,O
",",3724,O
and,3724,O
course,3724,O
following,3724,O
paralysis,3724,B-Disease
were,3724,O
noted,3724,O
.,3724,O
RESULTS,3725,O
:,3725,O
From,3725,O
a,3725,O
database,3725,O
of,3725,O
452,3725,O
patients,3725,O
receiving,3725,O
Botox,3725,B-Chemical
",",3725,O
352,3725,O
patients,3725,O
had,3725,O
been,3725,O
diagnosed,3725,O
with,3725,O
ADSD,3725,B-Disease
.,3725,O
Of,3726,O
these,3726,O
352,3726,O
patients,3726,O
",",3726,O
eight,3726,O
patients,3726,O
suffered,3726,O
bilateral,3726,O
abductor,3726,O
paralysis,3726,B-Disease
",",3726,O
and,3726,O
two,3726,O
suffered,3726,O
this,3726,O
complication,3726,O
twice,3726,O
.,3726,O
All,3727,O
affected,3727,O
patients,3727,O
were,3727,O
females,3727,O
over,3727,O
the,3727,O
age,3727,O
of,3727,O
50,3727,O
years,3727,O
.,3727,O
Most,3728,O
patients,3728,O
had,3728,O
received,3728,O
treatments,3728,O
prior,3728,O
to,3728,O
abductor,3728,O
paralysis,3728,B-Disease
and,3728,O
continued,3728,O
receiving,3728,O
after,3728,O
paralysis,3728,B-Disease
.,3728,O
Seven,3729,O
patients,3729,O
recovered,3729,O
after,3729,O
a,3729,O
brief,3729,O
period,3729,O
of,3729,O
activity,3729,O
restrictions,3729,O
",",3729,O
and,3729,O
one,3729,O
underwent,3729,O
a,3729,O
tracheotomy,3729,O
.,3729,O
The,3730,O
incidence,3730,O
of,3730,O
abductor,3730,O
paralysis,3730,B-Disease
after,3730,O
Botox,3730,B-Chemical
injection,3730,O
for,3730,O
ADSD,3730,B-Disease
was,3730,O
0.34,3730,O
%,3730,O
.,3730,O
CONCLUSIONS,3731,O
:,3731,O
Bilateral,3731,O
abductor,3731,O
paralysis,3731,B-Disease
is,3731,O
a,3731,O
rare,3731,O
complication,3731,O
of,3731,O
Botox,3731,B-Chemical
injections,3731,O
for,3731,O
ADSD,3731,B-Disease
",",3731,O
causing,3731,O
difficulty,3731,O
with,3731,O
breathing,3731,O
upon,3731,O
exertion,3731,O
.,3731,O
The,3732,O
likely,3732,O
mechanism,3732,O
of,3732,O
paralysis,3732,B-Disease
is,3732,O
diffusion,3732,O
of,3732,O
Botox,3732,B-Chemical
around,3732,O
the,3732,O
muscular,3732,O
process,3732,O
of,3732,O
the,3732,O
arytenoid,3732,O
to,3732,O
the,3732,O
posterior,3732,O
cricoarytenoid,3732,O
muscles,3732,O
.,3732,O
The,3733,O
paralysis,3733,B-Disease
is,3733,O
temporary,3733,O
",",3733,O
and,3733,O
watchful,3733,O
waiting,3733,O
with,3733,O
restriction,3733,O
of,3733,O
activity,3733,O
is,3733,O
the,3733,O
recommended,3733,O
management,3733,O
.,3733,O
Mitochondrial,3734,B-Disease
impairment,3734,I-Disease
contributes,3734,O
to,3734,O
cocaine-induced,3734,B-Chemical
cardiac,3734,B-Disease
dysfunction,3734,I-Disease
:,3734,O
Prevention,3734,O
by,3734,O
the,3734,O
targeted,3734,O
antioxidant,3734,O
MitoQ,3734,B-Chemical
.,3734,O
The,3735,O
goal,3735,O
of,3735,O
this,3735,O
study,3735,O
was,3735,O
to,3735,O
assess,3735,O
mitochondrial,3735,O
function,3735,O
and,3735,O
ROS,3735,O
production,3735,O
in,3735,O
an,3735,O
experimental,3735,O
model,3735,O
of,3735,O
cocaine-induced,3735,B-Chemical
cardiac,3735,B-Disease
dysfunction,3735,I-Disease
.,3735,O
We,3736,O
hypothesized,3736,O
that,3736,O
cocaine,3736,B-Disease
abuse,3736,I-Disease
may,3736,O
lead,3736,O
to,3736,O
altered,3736,O
mitochondrial,3736,O
function,3736,O
that,3736,O
in,3736,O
turn,3736,O
may,3736,O
cause,3736,O
left,3736,B-Disease
ventricular,3736,I-Disease
dysfunction,3736,I-Disease
.,3736,O
Seven,3737,O
days,3737,O
of,3737,O
cocaine,3737,B-Chemical
administration,3737,O
to,3737,O
rats,3737,O
led,3737,O
to,3737,O
an,3737,O
increased,3737,O
oxygen,3737,B-Chemical
consumption,3737,O
detected,3737,O
in,3737,O
cardiac,3737,O
fibers,3737,O
",",3737,O
specifically,3737,O
through,3737,O
complex,3737,O
I,3737,O
and,3737,O
complex,3737,O
III,3737,O
.,3737,O
ROS,3738,O
levels,3738,O
were,3738,O
increased,3738,O
",",3738,O
specifically,3738,O
in,3738,O
interfibrillar,3738,O
mitochondria,3738,O
.,3738,O
In,3739,O
parallel,3739,O
there,3739,O
was,3739,O
a,3739,O
decrease,3739,O
in,3739,O
ATP,3739,B-Chemical
synthesis,3739,O
",",3739,O
whereas,3739,O
no,3739,O
difference,3739,O
was,3739,O
observed,3739,O
in,3739,O
subsarcolemmal,3739,O
mitochondria,3739,O
.,3739,O
This,3740,O
uncoupling,3740,O
effect,3740,O
on,3740,O
oxidative,3740,O
phosphorylation,3740,O
was,3740,O
not,3740,O
detectable,3740,O
after,3740,O
short-term,3740,O
exposure,3740,O
to,3740,O
cocaine,3740,B-Chemical
",",3740,O
suggesting,3740,O
that,3740,O
these,3740,O
mitochondrial,3740,B-Disease
abnormalities,3740,I-Disease
were,3740,O
a,3740,O
late,3740,O
rather,3740,O
than,3740,O
a,3740,O
primary,3740,O
event,3740,O
in,3740,O
the,3740,O
pathological,3740,O
response,3740,O
to,3740,O
cocaine,3740,B-Chemical
.,3740,O
MitoQ,3741,B-Chemical
",",3741,O
a,3741,O
mitochondrial-targeted,3741,O
antioxidant,3741,O
",",3741,O
was,3741,O
shown,3741,O
to,3741,O
completely,3741,O
prevent,3741,O
these,3741,O
mitochondrial,3741,B-Disease
abnormalities,3741,I-Disease
as,3741,O
well,3741,O
as,3741,O
cardiac,3741,B-Disease
dysfunction,3741,I-Disease
characterized,3741,O
here,3741,O
by,3741,O
a,3741,O
diastolic,3741,B-Disease
dysfunction,3741,I-Disease
studied,3741,O
with,3741,O
a,3741,O
conductance,3741,O
catheter,3741,O
to,3741,O
obtain,3741,O
pressure-volume,3741,O
data,3741,O
.,3741,O
Taken,3742,O
together,3742,O
",",3742,O
these,3742,O
results,3742,O
extend,3742,O
previous,3742,O
studies,3742,O
and,3742,O
demonstrate,3742,O
that,3742,O
cocaine-induced,3742,B-Chemical
cardiac,3742,B-Disease
dysfunction,3742,I-Disease
may,3742,O
be,3742,O
due,3742,O
to,3742,O
a,3742,O
mitochondrial,3742,B-Disease
defect,3742,I-Disease
.,3742,O
Trimethoprim-induced,3743,B-Chemical
immune,3743,O
hemolytic,3743,B-Disease
anemia,3743,I-Disease
in,3743,O
a,3743,O
pediatric,3743,O
oncology,3743,O
patient,3743,O
presenting,3743,O
as,3743,O
an,3743,O
acute,3743,O
hemolytic,3743,O
transfusion,3743,O
reaction,3743,O
.,3743,O
A,3744,O
10-year-old,3744,O
male,3744,O
with,3744,O
acute,3744,B-Disease
leukemia,3744,I-Disease
presented,3744,O
with,3744,O
post-chemotherapy,3744,O
anemia,3744,B-Disease
.,3744,O
During,3745,O
red,3745,O
cell,3745,O
transfusion,3745,O
",",3745,O
he,3745,O
developed,3745,O
hemoglobinuria,3745,B-Disease
.,3745,O
Transfusion,3746,O
reaction,3746,O
workup,3746,O
was,3746,O
negative,3746,O
.,3746,O
Drug-induced,3747,O
immune,3747,O
hemolytic,3747,B-Disease
anemia,3747,I-Disease
was,3747,O
suspected,3747,O
because,3747,O
of,3747,O
positive,3747,O
direct,3747,O
antiglobulin,3747,O
test,3747,O
",",3747,O
negative,3747,O
eluate,3747,O
",",3747,O
and,3747,O
microspherocytes,3747,O
on,3747,O
smear,3747,O
pre-,3747,O
and,3747,O
post-transfusion,3747,O
.,3747,O
Drug,3748,O
studies,3748,O
using,3748,O
the,3748,O
indirect,3748,O
antiglobulin,3748,O
test,3748,O
were,3748,O
strongly,3748,O
positive,3748,O
with,3748,O
trimethoprim,3748,B-Chemical
and,3748,O
trimethoprim-sulfamethoxazole,3748,B-Chemical
but,3748,O
negative,3748,O
with,3748,O
sulfamethoxazole,3748,B-Chemical
.,3748,O
The,3749,O
patient,3749,O
recovered,3749,O
after,3749,O
discontinuing,3749,O
the,3749,O
drug,3749,O
",",3749,O
with,3749,O
no,3749,O
recurrence,3749,O
in,3749,O
2,3749,O
years,3749,O
.,3749,O
Other,3750,O
causes,3750,O
of,3750,O
anemia,3750,B-Disease
should,3750,O
be,3750,O
considered,3750,O
in,3750,O
patients,3750,O
with,3750,O
worse-than-expected,3750,O
anemia,3750,B-Disease
after,3750,O
chemotherapy,3750,O
.,3750,O
Furthermore,3751,O
",",3751,O
hemolysis,3751,B-Disease
during,3751,O
transfusion,3751,O
is,3751,O
not,3751,O
always,3751,O
a,3751,O
transfusion,3751,O
reaction,3751,O
.,3751,O
Verapamil,3752,B-Chemical
stimulation,3752,O
test,3752,O
in,3752,O
hyperprolactinemia,3752,B-Disease
:,3752,O
loss,3752,O
of,3752,O
prolactin,3752,O
response,3752,O
in,3752,O
anatomic,3752,O
or,3752,O
functional,3752,O
stalk,3752,O
effect,3752,O
.,3752,O
AIM,3753,O
:,3753,O
Verapamil,3753,B-Chemical
stimulation,3753,O
test,3753,O
was,3753,O
previously,3753,O
investigated,3753,O
as,3753,O
a,3753,O
tool,3753,O
for,3753,O
differential,3753,O
diagnosis,3753,O
of,3753,O
hyperprolactinemia,3753,B-Disease
",",3753,O
but,3753,O
with,3753,O
conflicting,3753,O
results,3753,O
.,3753,O
Macroprolactinemia,3754,B-Disease
was,3754,O
never,3754,O
considered,3754,O
in,3754,O
those,3754,O
previous,3754,O
studies,3754,O
.,3754,O
Here,3755,O
",",3755,O
we,3755,O
aimed,3755,O
to,3755,O
re-investigate,3755,O
the,3755,O
diagnostic,3755,O
value,3755,O
of,3755,O
verapamil,3755,B-Chemical
in,3755,O
a,3755,O
population,3755,O
who,3755,O
were,3755,O
all,3755,O
screened,3755,O
for,3755,O
macroprolactinemia,3755,B-Disease
.,3755,O
Prolactin,3756,O
responses,3756,O
to,3756,O
verapamil,3756,B-Chemical
in,3756,O
65,3756,O
female,3756,O
patients,3756,O
(,3756,O
age,3756,O
:,3756,O
29.9,3756,O
+/-,3756,O
8.1,3756,O
years,3756,O
),3756,O
with,3756,O
hyperprolactinemia,3756,B-Disease
were,3756,O
tested,3756,O
in,3756,O
a,3756,O
descriptive,3756,O
",",3756,O
matched,3756,O
case-control,3756,O
study,3756,O
.,3756,O
METHODS,3757,O
:,3757,O
Verapamil,3757,B-Chemical
80,3757,O
mg,3757,O
",",3757,O
p.o,3757,O
.,3757,O
was,3758,O
administered,3758,O
",",3758,O
and,3758,O
then,3758,O
PRL,3758,O
levels,3758,O
were,3758,O
measured,3758,O
at,3758,O
8th,3758,O
and,3758,O
16th,3758,O
hours,3758,O
",",3758,O
by,3758,O
immunometric,3758,O
chemiluminescence,3758,O
.,3758,O
Verapamil,3759,B-Chemical
responsiveness,3759,O
was,3759,O
determined,3759,O
by,3759,O
peak,3759,O
percent,3759,O
change,3759,O
in,3759,O
basal,3759,O
prolactin,3759,O
levels,3759,O
(,3759,O
PRL,3759,O
),3759,O
.,3759,O
RESULTS,3760,O
:,3760,O
Verapamil,3760,B-Chemical
significantly,3760,O
increased,3760,O
PRL,3760,O
levels,3760,O
in,3760,O
healthy,3760,O
controls,3760,O
(,3760,O
N.,3760,O
8,3760,O
",",3760,O
PRL,3760,O
:,3760,O
183,3760,O
%,3760,O
),3760,O
",",3760,O
macroprolactinoma,3760,B-Disease
(,3760,O
N.,3760,O
8,3760,O
",",3760,O
PRL,3760,O
:,3760,O
7,3760,O
%,3760,O
),3760,O
",",3760,O
microprolactinoma,3760,B-Disease
(,3760,O
N.,3760,O
19,3760,O
",",3760,O
PRL,3760,O
:,3760,O
21,3760,O
%,3760,O
),3760,O
",",3760,O
macroprolactinemia,3760,B-Disease
(,3760,O
N.,3760,O
23,3760,O
",",3760,O
PRL,3760,O
:,3760,O
126,3760,O
%,3760,O
),3760,O
",",3760,O
but,3760,O
not,3760,O
in,3760,O
pseudoprolactinoma,3760,B-Disease
(,3760,O
N.,3760,O
8,3760,O
",",3760,O
PRL,3760,O
:,3760,O
0.8,3760,O
%,3760,O
),3760,O
",",3760,O
and,3760,O
risperidone-induced,3760,B-Chemical
hyperprolactinemia,3760,B-Disease
(,3760,O
N.,3760,O
7,3760,O
",",3760,O
PRL,3760,O
:,3760,O
3,3760,O
%,3760,O
),3760,O
.,3760,O
ROC,3761,O
curve,3761,O
analysis,3761,O
revealed,3761,O
that,3761,O
unresponsiveness,3761,O
to,3761,O
verapamil,3761,B-Chemical
defined,3761,O
as,3761,O
PRL,3761,O
<,3761,O
7,3761,O
%,3761,O
",",3761,O
discriminated,3761,O
anatomical,3761,O
or,3761,O
functional,3761,O
stalk,3761,O
effect,3761,O
(,3761,O
sensitivity,3761,O
:,3761,O
74,3761,O
%,3761,O
",",3761,O
specificity,3761,O
:,3761,O
73,3761,O
%,3761,O
",",3761,O
AUC,3761,O
:,3761,O
0.855+/-0.04,3761,O
",",3761,O
P,3761,O
<,3761,O
0.001,3761,O
",",3761,O
CI,3761,O
:,3761,O
0.768-0.942,3761,O
),3761,O
associated,3761,O
with,3761,O
pseudoprolactinoma,3761,B-Disease
or,3761,O
risperidone-induced,3761,B-Chemical
hyperprolactinemia,3761,B-Disease
",",3761,O
respectively,3761,O
.,3761,O
CONCLUSION,3762,O
:,3762,O
Verapamil,3762,B-Chemical
responsiveness,3762,O
is,3762,O
not,3762,O
a,3762,O
reliable,3762,O
finding,3762,O
for,3762,O
the,3762,O
differential,3762,O
diagnosis,3762,O
of,3762,O
hyperprolactinemia,3762,B-Disease
.,3762,O
However,3763,O
",",3763,O
verapamil,3763,B-Chemical
unresponsiveness,3763,O
discriminates,3763,O
stalk,3763,O
effect,3763,O
(,3763,O
i.e.,3763,O
",",3763,O
anatomically,3763,O
or,3763,O
functionally,3763,O
inhibited,3763,O
dopaminergic,3763,O
tonus,3763,O
),3763,O
from,3763,O
other,3763,O
causes,3763,O
of,3763,O
hyperprolactinemia,3763,B-Disease
with,3763,O
varying,3763,O
degrees,3763,O
of,3763,O
responsiveness,3763,O
.,3763,O
Blockade,3764,O
of,3764,O
endothelial-mesenchymal,3764,O
transition,3764,O
by,3764,O
a,3764,O
Smad3,3764,O
inhibitor,3764,O
delays,3764,O
the,3764,O
early,3764,O
development,3764,O
of,3764,O
streptozotocin-induced,3764,B-Chemical
diabetic,3764,B-Disease
nephropathy,3764,I-Disease
.,3764,O
OBJECTIVE,3765,O
:,3765,O
A,3765,O
multicenter,3765,O
",",3765,O
controlled,3765,O
trial,3765,O
showed,3765,O
that,3765,O
early,3765,O
blockade,3765,O
of,3765,O
the,3765,O
renin-angiotensin,3765,O
system,3765,O
in,3765,O
patients,3765,O
with,3765,O
type,3765,B-Disease
1,3765,I-Disease
diabetes,3765,I-Disease
and,3765,O
normoalbuminuria,3765,O
did,3765,O
not,3765,O
retard,3765,O
the,3765,O
progression,3765,O
of,3765,O
nephropathy,3765,B-Disease
",",3765,O
suggesting,3765,O
that,3765,O
other,3765,O
mechanism,3765,O
(,3765,O
s,3765,O
),3765,O
are,3765,O
involved,3765,O
in,3765,O
the,3765,O
pathogenesis,3765,O
of,3765,O
early,3765,O
diabetic,3765,B-Disease
nephropathy,3765,I-Disease
(,3765,O
diabetic,3765,B-Disease
nephropathy,3765,I-Disease
),3765,O
.,3765,O
We,3766,O
have,3766,O
previously,3766,O
demonstrated,3766,O
that,3766,O
endothelial-mesenchymal-transition,3766,O
(,3766,O
EndoMT,3766,O
),3766,O
contributes,3766,O
to,3766,O
the,3766,O
early,3766,O
development,3766,O
of,3766,O
renal,3766,O
interstitial,3766,O
fibrosis,3766,B-Disease
independently,3766,O
of,3766,O
microalbuminuria,3766,O
in,3766,O
mice,3766,O
with,3766,O
streptozotocin,3766,B-Chemical
(,3766,O
STZ,3766,B-Chemical
),3766,O
-induced,3766,O
diabetes,3766,B-Disease
.,3766,O
In,3767,O
the,3767,O
present,3767,O
study,3767,O
",",3767,O
we,3767,O
hypothesized,3767,O
that,3767,O
blocking,3767,O
EndoMT,3767,O
reduces,3767,O
the,3767,O
early,3767,O
development,3767,O
of,3767,O
diabetic,3767,B-Disease
nephropathy,3767,I-Disease
.,3767,O
RESEARCH,3768,O
DESIGN,3768,O
AND,3768,O
METHODS,3768,O
:,3768,O
EndoMT,3768,O
was,3768,O
induced,3768,O
in,3768,O
a,3768,O
mouse,3768,O
pancreatic,3768,O
microvascular,3768,O
endothelial,3768,O
cell,3768,O
line,3768,O
(,3768,O
MMEC,3768,O
),3768,O
in,3768,O
the,3768,O
presence,3768,O
of,3768,O
advanced,3768,O
glycation,3768,O
end,3768,O
products,3768,O
(,3768,O
AGEs,3768,O
),3768,O
and,3768,O
in,3768,O
the,3768,O
endothelial,3768,O
lineage-traceble,3768,O
mouse,3768,O
line,3768,O
Tie2-Cre,3768,O
;,3768,O
Loxp-EGFP,3768,O
by,3768,O
administration,3768,O
of,3768,O
AGEs,3768,O
",",3768,O
with,3768,O
nonglycated,3768,O
mouse,3768,O
albumin,3768,O
serving,3768,O
as,3768,O
a,3768,O
control,3768,O
.,3768,O
Phosphorylated,3769,O
Smad3,3769,O
was,3769,O
detected,3769,O
by,3769,O
immunoprecipitation/Western,3769,O
blotting,3769,O
and,3769,O
confocal,3769,O
microscopy,3769,O
.,3769,O
Blocking,3770,O
studies,3770,O
using,3770,O
receptor,3770,O
for,3770,O
AGE,3770,O
siRNA,3770,O
and,3770,O
a,3770,O
specific,3770,O
inhibitor,3770,O
of,3770,O
Smad3,3770,O
(,3770,O
SIS3,3770,O
),3770,O
were,3770,O
performed,3770,O
in,3770,O
MMECs,3770,O
and,3770,O
in,3770,O
STZ-induced,3770,B-Chemical
diabetic,3770,B-Disease
nephropathy,3770,I-Disease
in,3770,O
Tie2-Cre,3770,O
;,3770,O
Loxp-EGFP,3770,O
mice,3770,O
.,3770,O
RESULTS,3771,O
:,3771,O
Confocal,3771,O
microscopy,3771,O
and,3771,O
real-time,3771,O
PCR,3771,O
demonstrated,3771,O
that,3771,O
AGEs,3771,O
induced,3771,O
EndoMT,3771,O
in,3771,O
MMECs,3771,O
and,3771,O
in,3771,O
Tie2-Cre,3771,O
;,3771,O
Loxp-EGFP,3771,O
mice,3771,O
.,3771,O
Immunoprecipitation/Western,3772,O
blotting,3772,O
showed,3772,O
that,3772,O
Smad3,3772,O
was,3772,O
activated,3772,O
by,3772,O
AGEs,3772,O
but,3772,O
was,3772,O
inhibited,3772,O
by,3772,O
SIS3,3772,O
in,3772,O
MMECs,3772,O
and,3772,O
in,3772,O
STZ-induced,3772,B-Chemical
diabetic,3772,B-Disease
nephropathy,3772,I-Disease
.,3772,O
Confocal,3773,O
microscopy,3773,O
and,3773,O
real-time,3773,O
PCR,3773,O
further,3773,O
demonstrated,3773,O
that,3773,O
SIS3,3773,O
abrogated,3773,O
EndoMT,3773,O
",",3773,O
reduced,3773,O
renal,3773,O
fibrosis,3773,B-Disease
",",3773,O
and,3773,O
retarded,3773,O
progression,3773,O
of,3773,O
nephropathy,3773,B-Disease
.,3773,O
CONCLUSIONS,3774,O
:,3774,O
EndoMT,3774,O
is,3774,O
a,3774,O
novel,3774,O
pathway,3774,O
leading,3774,O
to,3774,O
early,3774,O
development,3774,O
of,3774,O
diabetic,3774,B-Disease
nephropathy,3774,I-Disease
.,3774,O
Blockade,3775,O
of,3775,O
EndoMT,3775,O
by,3775,O
SIS3,3775,O
may,3775,O
provide,3775,O
a,3775,O
new,3775,O
strategy,3775,O
to,3775,O
retard,3775,O
the,3775,O
progression,3775,O
of,3775,O
diabetic,3775,B-Disease
nephropathy,3775,I-Disease
and,3775,O
other,3775,O
diabetes,3775,B-Disease
complications,3775,I-Disease
.,3775,O
Cytostatic,3776,O
and,3776,O
anti-angiogenic,3776,O
effects,3776,O
of,3776,O
temsirolimus,3776,B-Chemical
in,3776,O
refractory,3776,O
mantle,3776,B-Disease
cell,3776,I-Disease
lymphoma,3776,I-Disease
.,3776,O
Mantle,3777,B-Disease
cell,3777,I-Disease
lymphoma,3777,I-Disease
(,3777,O
MCL,3777,B-Disease
),3777,O
is,3777,O
a,3777,O
rare,3777,O
and,3777,O
aggressive,3777,O
type,3777,O
of,3777,O
B-cell,3777,B-Disease
non-Hodgkin,3777,I-Disease
's,3777,I-Disease
lymphoma,3777,I-Disease
.,3777,O
Patients,3778,O
become,3778,O
progressively,3778,O
refractory,3778,O
to,3778,O
conventional,3778,O
chemotherapy,3778,O
",",3778,O
and,3778,O
their,3778,O
prognosis,3778,O
is,3778,O
poor,3778,O
.,3778,O
However,3779,O
",",3779,O
a,3779,O
38,3779,O
%,3779,O
remission,3779,O
rate,3779,O
has,3779,O
been,3779,O
recently,3779,O
reported,3779,O
in,3779,O
refractory,3779,O
MCL,3779,B-Disease
treated,3779,O
with,3779,O
temsirolimus,3779,B-Chemical
",",3779,O
a,3779,O
mTOR,3779,O
inhibitor.Here,3779,O
we,3779,O
had,3779,O
the,3779,O
opportunity,3779,O
to,3779,O
study,3779,O
a,3779,O
case,3779,O
of,3779,O
refractory,3779,O
MCL,3779,B-Disease
who,3779,O
had,3779,O
tumor,3779,B-Disease
regression,3779,O
two,3779,O
months,3779,O
after,3779,O
temsirolimus,3779,B-Chemical
treatment,3779,O
",",3779,O
and,3779,O
a,3779,O
progression-free,3779,O
survival,3779,O
of,3779,O
10,3779,O
months,3779,O
.,3779,O
In,3780,O
this,3780,O
case,3780,O
",",3780,O
lymph,3780,O
node,3780,O
biopsies,3780,O
were,3780,O
performed,3780,O
before,3780,O
and,3780,O
six,3780,O
months,3780,O
after,3780,O
temsirolimus,3780,B-Chemical
therapy,3780,O
.,3780,O
Comparison,3781,O
of,3781,O
the,3781,O
two,3781,O
biopsies,3781,O
showed,3781,O
that,3781,O
temsirolimus,3781,B-Chemical
inhibited,3781,O
tumor,3781,B-Disease
cell,3781,O
proliferation,3781,O
through,3781,O
cell,3781,O
cycle,3781,O
arrest,3781,O
",",3781,O
but,3781,O
did,3781,O
not,3781,O
induce,3781,O
any,3781,O
change,3781,O
in,3781,O
the,3781,O
number,3781,O
of,3781,O
apoptotic,3781,O
tumor,3781,B-Disease
cells,3781,O
.,3781,O
Apart,3782,O
from,3782,O
this,3782,O
cytostatic,3782,O
effect,3782,O
",",3782,O
temsirolimus,3782,B-Chemical
had,3782,O
an,3782,O
antiangiogenic,3782,O
effect,3782,O
with,3782,O
decrease,3782,O
of,3782,O
tumor,3782,B-Disease
microvessel,3782,O
density,3782,O
and,3782,O
of,3782,O
VEGF,3782,O
expression,3782,O
.,3782,O
Moreover,3783,O
",",3783,O
numerous,3783,O
patchy,3783,O
",",3783,O
well-limited,3783,O
fibrotic,3783,O
areas,3783,O
",",3783,O
compatible,3783,O
with,3783,O
post-necrotic,3783,O
tissue,3783,O
repair,3783,O
",",3783,O
were,3783,O
found,3783,O
after,3783,O
6-month,3783,O
temsirolimus,3783,B-Chemical
therapy,3783,O
.,3783,O
Thus,3784,O
",",3784,O
temsirolimus,3784,B-Chemical
reduced,3784,O
tumor,3784,B-Disease
burden,3784,O
through,3784,O
associated,3784,O
cytostatic,3784,O
and,3784,O
anti-angiogenic,3784,O
effects.This,3784,O
dual,3784,O
effect,3784,O
of,3784,O
temsirolimus,3784,B-Chemical
on,3784,O
tumor,3784,B-Disease
tissue,3784,O
could,3784,O
contribute,3784,O
to,3784,O
its,3784,O
recently,3784,O
reported,3784,O
efficiency,3784,O
in,3784,O
refractory,3784,O
MCL,3784,B-Disease
resistant,3784,O
to,3784,O
conventional,3784,O
chemotherapy,3784,O
.,3784,O
Syncope,3785,B-Disease
caused,3785,O
by,3785,O
hyperkalemia,3785,B-Disease
during,3785,O
use,3785,O
of,3785,O
a,3785,O
combined,3785,O
therapy,3785,O
with,3785,O
the,3785,O
angiotensin-converting,3785,B-Chemical
enzyme,3785,O
inhibitor,3785,O
and,3785,O
spironolactone,3785,B-Chemical
.,3785,O
A,3786,O
76,3786,O
year-old,3786,O
woman,3786,O
with,3786,O
a,3786,O
history,3786,O
of,3786,O
coronary,3786,O
artery,3786,O
bypass,3786,O
grafting,3786,O
and,3786,O
prior,3786,O
myocardial,3786,B-Disease
infarction,3786,I-Disease
was,3786,O
transferred,3786,O
to,3786,O
the,3786,O
emergency,3786,O
room,3786,O
with,3786,O
loss,3786,B-Disease
of,3786,I-Disease
consciousness,3786,I-Disease
due,3786,O
to,3786,O
marked,3786,O
bradycardia,3786,B-Disease
caused,3786,O
by,3786,O
hyperkalemia,3786,B-Disease
.,3786,O
The,3787,O
concentration,3787,O
of,3787,O
serum,3787,O
potassium,3787,B-Chemical
was,3787,O
high,3787,O
",",3787,O
and,3787,O
normal,3787,O
sinus,3787,O
rhythm,3787,O
was,3787,O
restored,3787,O
after,3787,O
correction,3787,O
of,3787,O
the,3787,O
serum,3787,O
potassium,3787,B-Chemical
level,3787,O
.,3787,O
The,3788,O
cause,3788,O
of,3788,O
hyperkalemia,3788,B-Disease
was,3788,O
considered,3788,O
to,3788,O
be,3788,O
several,3788,O
doses,3788,O
of,3788,O
spiranolactone,3788,B-Chemical
",",3788,O
an,3788,O
aldosterone,3788,B-Chemical
antagonist,3788,O
",",3788,O
in,3788,O
addition,3788,O
to,3788,O
the,3788,O
long-term,3788,O
intake,3788,O
of,3788,O
ramipril,3788,B-Chemical
",",3788,O
an,3788,O
ACE,3788,O
inhibitor,3788,O
.,3788,O
This,3789,O
case,3789,O
is,3789,O
a,3789,O
good,3789,O
example,3789,O
of,3789,O
electrolyte,3789,O
imbalance,3789,O
causing,3789,O
acute,3789,O
life-threatening,3789,O
cardiac,3789,O
events,3789,O
.,3789,O
Clinicians,3790,O
should,3790,O
be,3790,O
alert,3790,O
to,3790,O
the,3790,O
possibility,3790,O
of,3790,O
hyperkalemia,3790,B-Disease
",",3790,O
especially,3790,O
in,3790,O
elderly,3790,O
patients,3790,O
using,3790,O
ACE/ARB,3790,O
in,3790,O
combination,3790,O
with,3790,O
potassium,3790,B-Chemical
sparing,3790,O
agents,3790,O
and,3790,O
who,3790,O
have,3790,O
mild,3790,O
renal,3790,B-Disease
disturbance,3790,I-Disease
.,3790,O
Diffuse,3791,O
skeletal,3791,O
pain,3791,B-Disease
after,3791,O
administration,3791,O
of,3791,O
alendronate,3791,B-Chemical
.,3791,O
BACKGROUND,3792,O
:,3792,O
Osteoporosis,3792,B-Disease
is,3792,O
caused,3792,O
by,3792,O
bone,3792,O
resorption,3792,O
in,3792,O
excess,3792,O
of,3792,O
bone,3792,O
formation,3792,O
",",3792,O
and,3792,O
bisphosphonates,3792,B-Chemical
",",3792,O
are,3792,O
used,3792,O
to,3792,O
inhibit,3792,O
bone,3792,O
resorption,3792,O
.,3792,O
Alendronate,3793,B-Chemical
",",3793,O
a,3793,O
biphosphonate,3793,B-Chemical
",",3793,O
is,3793,O
effective,3793,O
for,3793,O
both,3793,O
the,3793,O
treatment,3793,O
and,3793,O
prevention,3793,O
of,3793,O
osteoporosis,3793,B-Disease
in,3793,O
postmenopausal,3793,O
women,3793,O
.,3793,O
Side,3794,O
effects,3794,O
are,3794,O
relatively,3794,O
few,3794,O
and,3794,O
prominently,3794,O
gastrointestinal,3794,O
.,3794,O
Musculoskeletal,3795,B-Disease
pain,3795,I-Disease
may,3795,O
be,3795,O
an,3795,O
important,3795,O
side,3795,O
effect,3795,O
in,3795,O
these,3795,O
patients,3795,O
.,3795,O
We,3796,O
presented,3796,O
a,3796,O
patient,3796,O
admitted,3796,O
to,3796,O
our,3796,O
out-patient,3796,O
clinic,3796,O
with,3796,O
diffuse,3796,O
skeletal,3796,O
pain,3796,B-Disease
after,3796,O
three,3796,O
consecutive,3796,O
administration,3796,O
of,3796,O
alendronate,3796,B-Chemical
.,3796,O
CONCLUSION,3797,O
:,3797,O
We,3797,O
conclude,3797,O
that,3797,O
patients,3797,O
with,3797,O
osteoporosis,3797,B-Disease
can,3797,O
report,3797,O
pain,3797,B-Disease
",",3797,O
and,3797,O
bisphosphonate-related,3797,B-Chemical
pain,3797,B-Disease
should,3797,O
also,3797,O
be,3797,O
considered,3797,O
before,3797,O
ascribing,3797,O
this,3797,O
complaint,3797,O
to,3797,O
osteoporosis,3797,B-Disease
.,3797,O
Cerebrospinal,3798,O
fluid,3798,O
penetration,3798,O
of,3798,O
high-dose,3798,O
daptomycin,3798,B-Chemical
in,3798,O
suspected,3798,O
Staphylococcus,3798,O
aureus,3798,O
meningitis,3798,B-Disease
.,3798,O
OBJECTIVE,3799,O
:,3799,O
To,3799,O
report,3799,O
a,3799,O
case,3799,O
of,3799,O
methicillin-sensitive,3799,B-Chemical
Staphylococcus,3799,O
aureus,3799,O
(,3799,O
MSSA,3799,O
),3799,O
bacteremia,3799,B-Disease
with,3799,O
suspected,3799,O
MSSA,3799,O
meningitis,3799,B-Disease
treated,3799,O
with,3799,O
high-dose,3799,O
daptomycin,3799,B-Chemical
assessed,3799,O
with,3799,O
concurrent,3799,O
serum,3799,O
and,3799,O
cerebrospinal,3799,O
fluid,3799,O
(,3799,O
CSF,3799,O
),3799,O
concentrations,3799,O
.,3799,O
CASE,3800,O
SUMMARY,3800,O
:,3800,O
A,3800,O
54-year-old,3800,O
male,3800,O
presented,3800,O
to,3800,O
the,3800,O
emergency,3800,O
department,3800,O
with,3800,O
generalized,3800,O
weakness,3800,B-Disease
and,3800,O
presumed,3800,O
health-care-associated,3800,O
pneumonia,3800,B-Disease
shown,3800,O
on,3800,O
chest,3800,O
radiograph,3800,O
.,3800,O
Treatment,3801,O
was,3801,O
empirically,3801,O
initiated,3801,O
with,3801,O
vancomycin,3801,B-Chemical
",",3801,O
levofloxacin,3801,B-Chemical
",",3801,O
and,3801,O
piperacillin/tazobactam,3801,B-Chemical
.,3801,O
Blood,3802,O
cultures,3802,O
revealed,3802,O
S.,3802,O
aureus,3802,O
susceptible,3802,O
to,3802,O
oxacillin,3802,B-Chemical
.,3802,O
Empiric,3803,O
antibiotic,3803,O
treatment,3803,O
was,3803,O
narrowed,3803,O
to,3803,O
nafcillin,3803,B-Chemical
on,3803,O
day,3803,O
4,3803,O
.,3803,O
On,3804,O
day,3804,O
8,3804,O
",",3804,O
the,3804,O
patient,3804,O
developed,3804,O
acute,3804,B-Disease
renal,3804,I-Disease
failure,3804,I-Disease
(,3804,O
serum,3804,O
creatinine,3804,B-Chemical
1.9,3804,O
mg/dL,3804,O
",",3804,O
increased,3804,O
from,3804,O
1.2,3804,O
mg/dL,3804,O
the,3804,O
previous,3804,O
day,3804,O
and,3804,O
0.8,3804,O
mg/dL,3804,O
on,3804,O
admission,3804,O
),3804,O
.,3804,O
The,3805,O
patient,3805,O
's,3805,O
Glasgow,3805,O
Coma,3805,O
Score,3805,O
was,3805,O
3,3805,O
",",3805,O
with,3805,O
normal,3805,O
findings,3805,O
shown,3805,O
on,3805,O
computed,3805,O
tomography,3805,O
scan,3805,O
of,3805,O
the,3805,O
head,3805,O
72,3805,O
hours,3805,O
following,3805,O
an,3805,O
episode,3805,O
of,3805,O
cardiac,3805,B-Disease
arrest,3805,I-Disease
on,3805,O
day,3805,O
10,3805,O
.,3805,O
The,3806,O
patient,3806,O
experienced,3806,O
relapsing,3806,O
MSSA,3806,O
bacteremia,3806,B-Disease
on,3806,O
day,3806,O
9,3806,O
",",3806,O
increasing,3806,O
the,3806,O
suspicion,3806,O
for,3806,O
a,3806,O
central,3806,O
nervous,3806,O
system,3806,O
(,3806,O
CNS,3806,O
),3806,O
infection,3806,B-Disease
.,3806,O
Nafcillin,3807,B-Chemical
was,3807,O
discontinued,3807,O
and,3807,O
daptomycin,3807,B-Chemical
9,3807,O
mg/kg,3807,O
daily,3807,O
was,3807,O
initiated,3807,O
for,3807,O
suspected,3807,O
meningitis,3807,B-Disease
and,3807,O
was,3807,O
continued,3807,O
until,3807,O
the,3807,O
patient,3807,O
's,3807,O
death,3807,O
on,3807,O
day,3807,O
16,3807,O
.,3807,O
Daptomycin,3808,B-Chemical
serum,3808,O
and,3808,O
CSF,3808,O
trough,3808,O
concentrations,3808,O
were,3808,O
11.21,3808,O
ug/mL,3808,O
and,3808,O
0.52,3808,O
ug/mL,3808,O
",",3808,O
respectively,3808,O
",",3808,O
prior,3808,O
to,3808,O
the,3808,O
third,3808,O
dose,3808,O
.,3808,O
Lumbar,3809,O
puncture,3809,O
results,3809,O
were,3809,O
inconclusive,3809,O
and,3809,O
no,3809,O
further,3809,O
blood,3809,O
cultures,3809,O
were,3809,O
positive,3809,O
for,3809,O
MSSA,3809,O
.,3809,O
Creatine,3810,B-Chemical
kinase,3810,O
levels,3810,O
were,3810,O
normal,3810,O
prior,3810,O
to,3810,O
daptomycin,3810,B-Chemical
therapy,3810,O
and,3810,O
were,3810,O
not,3810,O
reassessed,3810,O
.,3810,O
DISCUSSION,3811,O
:,3811,O
Daptomycin,3811,B-Chemical
was,3811,O
initiated,3811,O
in,3811,O
our,3811,O
patient,3811,O
secondary,3811,O
to,3811,O
possible,3811,O
nafcillin-induced,3811,B-Chemical
acute,3811,O
interstitial,3811,B-Disease
nephritis,3811,I-Disease
and,3811,O
relapsing,3811,O
bacteremia,3811,B-Disease
.,3811,O
At,3812,O
a,3812,O
dose,3812,O
of,3812,O
9,3812,O
mg/kg,3812,O
",",3812,O
resultant,3812,O
penetration,3812,O
of,3812,O
5,3812,O
%,3812,O
was,3812,O
higher,3812,O
than,3812,O
in,3812,O
previous,3812,O
reports,3812,O
",",3812,O
more,3812,O
consistent,3812,O
with,3812,O
inflamed,3812,O
meninges,3812,O
.,3812,O
CONCLUSIONS,3813,O
:,3813,O
High-dose,3813,O
daptomycin,3813,B-Chemical
may,3813,O
be,3813,O
an,3813,O
alternative,3813,O
option,3813,O
for,3813,O
MSSA,3813,O
bacteremia,3813,B-Disease
with,3813,O
or,3813,O
without,3813,O
a,3813,O
CNS,3813,O
source,3813,O
in,3813,O
patients,3813,O
who,3813,O
have,3813,O
failed,3813,O
or,3813,O
can,3813,O
not,3813,O
tolerate,3813,O
standard,3813,O
therapy,3813,O
.,3813,O
Further,3814,O
clinical,3814,O
evaluation,3814,O
in,3814,O
patients,3814,O
with,3814,O
confirmed,3814,O
meningitis,3814,B-Disease
is,3814,O
warranted,3814,O
.,3814,O
The,3815,O
role,3815,O
of,3815,O
nitric,3815,B-Chemical
oxide,3815,I-Chemical
in,3815,O
convulsions,3815,B-Disease
induced,3815,O
by,3815,O
lindane,3815,B-Chemical
in,3815,O
rats,3815,O
.,3815,O
Lindane,3816,B-Chemical
is,3816,O
an,3816,O
organochloride,3816,O
pesticide,3816,O
and,3816,O
scabicide,3816,O
.,3816,O
It,3817,O
evokes,3817,O
convulsions,3817,B-Disease
mainly,3817,O
trough,3817,O
the,3817,O
blockage,3817,O
of,3817,O
GABA,3817,B-Chemical
(,3817,O
A,3817,O
),3817,O
receptors,3817,O
.,3817,O
Nitric,3818,B-Chemical
oxide,3818,I-Chemical
(,3818,O
NO,3818,B-Chemical
),3818,O
",",3818,O
gaseous,3818,O
neurotransmitter,3818,O
",",3818,O
has,3818,O
contradictor,3818,O
role,3818,O
in,3818,O
epileptogenesis,3818,O
due,3818,O
to,3818,O
opposite,3818,O
effects,3818,O
of,3818,O
L-arginine,3818,B-Chemical
",",3818,O
precursor,3818,O
of,3818,O
NO,3818,B-Chemical
syntheses,3818,O
(,3818,O
NOS,3818,O
),3818,O
",",3818,O
and,3818,O
L-NAME,3818,B-Chemical
(,3818,O
NOS,3818,O
inhibitor,3818,O
),3818,O
observed,3818,O
in,3818,O
different,3818,O
epilepsy,3818,B-Disease
models,3818,O
.,3818,O
The,3819,O
aim,3819,O
of,3819,O
the,3819,O
current,3819,O
study,3819,O
was,3819,O
to,3819,O
determine,3819,O
the,3819,O
effects,3819,O
of,3819,O
NO,3819,B-Chemical
on,3819,O
the,3819,O
behavioral,3819,O
and,3819,O
EEG,3819,O
characteristics,3819,O
of,3819,O
lindane-induced,3819,B-Chemical
epilepsy,3819,B-Disease
in,3819,O
male,3819,O
Wistar,3819,O
albino,3819,O
rats,3819,O
.,3819,O
The,3820,O
administration,3820,O
of,3820,O
L-arginine,3820,B-Chemical
(,3820,O
600,3820,O
",",3820,O
800,3820,O
and,3820,O
1000,3820,O
mg/kg,3820,O
",",3820,O
i.p,3820,O
.,3820,O
),3820,O
in,3821,O
dose-dependent,3821,O
manner,3821,O
significantly,3821,O
increased,3821,O
convulsion,3821,B-Disease
incidence,3821,O
and,3821,O
severity,3821,O
and,3821,O
shortened,3821,O
latency,3821,O
time,3821,O
to,3821,O
first,3821,O
convulsion,3821,B-Disease
elicited,3821,O
by,3821,O
lower,3821,O
lindane,3821,B-Chemical
dose,3821,O
(,3821,O
4,3821,O
mg/kg,3821,O
",",3821,O
i.p,3821,O
.,3821,O
),3821,O
.,3821,O
On,3822,O
the,3822,O
contrary,3822,O
",",3822,O
pretreatment,3822,O
with,3822,O
L-NAME,3822,B-Chemical
(,3822,O
500,3822,O
",",3822,O
700,3822,O
and,3822,O
900,3822,O
mg/kg,3822,O
",",3822,O
i.p,3822,O
.,3822,O
),3822,O
decreased,3823,O
convulsion,3823,B-Disease
incidence,3823,O
and,3823,O
severity,3823,O
and,3823,O
prolonged,3823,O
latency,3823,O
time,3823,O
to,3823,O
convulsion,3823,B-Disease
following,3823,O
injection,3823,O
with,3823,O
a,3823,O
convulsive,3823,B-Disease
dose,3823,O
of,3823,O
lindane,3823,B-Chemical
(,3823,O
8,3823,O
mg/kg,3823,O
",",3823,O
i.p,3823,O
.,3823,O
),3823,O
.,3823,O
EEG,3824,O
analyses,3824,O
showed,3824,O
increase,3824,O
of,3824,O
number,3824,O
and,3824,O
duration,3824,O
of,3824,O
ictal,3824,O
periods,3824,O
in,3824,O
EEG,3824,O
of,3824,O
rats,3824,O
receiving,3824,O
l-arginine,3824,B-Chemical
prior,3824,O
to,3824,O
lindane,3824,B-Chemical
and,3824,O
decrease,3824,O
of,3824,O
this,3824,O
number,3824,O
in,3824,O
rats,3824,O
pretreated,3824,O
with,3824,O
L-NAME,3824,B-Chemical
.,3824,O
These,3825,O
results,3825,O
support,3825,O
the,3825,O
conclusion,3825,O
that,3825,O
NO,3825,B-Chemical
plays,3825,O
a,3825,O
role,3825,O
of,3825,O
endogenous,3825,O
convulsant,3825,O
in,3825,O
rat,3825,O
model,3825,O
of,3825,O
lindane,3825,B-Chemical
seizures,3825,B-Disease
.,3825,O
Late-onset,3826,O
scleroderma,3826,B-Disease
renal,3826,I-Disease
crisis,3826,I-Disease
induced,3826,O
by,3826,O
tacrolimus,3826,B-Chemical
and,3826,O
prednisolone,3826,B-Chemical
:,3826,O
a,3826,O
case,3826,O
report,3826,O
.,3826,O
Scleroderma,3827,B-Disease
renal,3827,I-Disease
crisis,3827,I-Disease
(,3827,O
SRC,3827,B-Disease
),3827,O
is,3827,O
a,3827,O
rare,3827,O
complication,3827,O
of,3827,O
systemic,3827,B-Disease
sclerosis,3827,I-Disease
(,3827,O
SSc,3827,B-Disease
),3827,O
but,3827,O
can,3827,O
be,3827,O
severe,3827,O
enough,3827,O
to,3827,O
require,3827,O
temporary,3827,O
or,3827,O
permanent,3827,O
renal,3827,O
replacement,3827,O
therapy,3827,O
.,3827,O
Moderate,3828,O
to,3828,O
high,3828,O
dose,3828,O
corticosteroid,3828,B-Chemical
use,3828,O
is,3828,O
recognized,3828,O
as,3828,O
a,3828,O
major,3828,O
risk,3828,O
factor,3828,O
for,3828,O
SRC,3828,B-Disease
.,3828,O
Furthermore,3829,O
",",3829,O
there,3829,O
have,3829,O
been,3829,O
reports,3829,O
of,3829,O
thrombotic,3829,B-Disease
microangiopathy,3829,I-Disease
precipitated,3829,O
by,3829,O
cyclosporine,3829,B-Chemical
in,3829,O
patients,3829,O
with,3829,O
SSc,3829,B-Disease
.,3829,O
In,3830,O
this,3830,O
article,3830,O
",",3830,O
we,3830,O
report,3830,O
a,3830,O
patient,3830,O
with,3830,O
SRC,3830,B-Disease
induced,3830,O
by,3830,O
tacrolimus,3830,B-Chemical
and,3830,O
corticosteroids,3830,B-Chemical
.,3830,O
The,3831,O
aim,3831,O
of,3831,O
this,3831,O
work,3831,O
is,3831,O
to,3831,O
call,3831,O
attention,3831,O
to,3831,O
the,3831,O
risk,3831,O
of,3831,O
tacrolimus,3831,B-Chemical
use,3831,O
in,3831,O
patients,3831,O
with,3831,O
SSc,3831,B-Disease
.,3831,O
The,3832,O
risk,3832,O
and,3832,O
associated,3832,O
factors,3832,O
of,3832,O
methamphetamine,3832,B-Chemical
psychosis,3832,B-Disease
in,3832,O
methamphetamine-dependent,3832,B-Chemical
patients,3832,O
in,3832,O
Malaysia,3832,O
.,3832,O
OBJECTIVE,3833,O
:,3833,O
The,3833,O
objective,3833,O
of,3833,O
this,3833,O
study,3833,O
was,3833,O
to,3833,O
determine,3833,O
the,3833,O
risk,3833,O
of,3833,O
lifetime,3833,O
and,3833,O
current,3833,O
methamphetamine-induced,3833,B-Chemical
psychosis,3833,B-Disease
in,3833,O
patients,3833,O
with,3833,O
methamphetamine,3833,B-Chemical
dependence,3833,O
.,3833,O
The,3834,O
association,3834,O
between,3834,O
psychiatric,3834,O
co-morbidity,3834,O
and,3834,O
methamphetamine-induced,3834,B-Chemical
psychosis,3834,B-Disease
was,3834,O
also,3834,O
studied,3834,O
.,3834,O
METHODS,3835,O
:,3835,O
This,3835,O
was,3835,O
a,3835,O
cross-sectional,3835,O
study,3835,O
conducted,3835,O
concurrently,3835,O
at,3835,O
a,3835,O
teaching,3835,O
hospital,3835,O
and,3835,O
a,3835,O
drug,3835,O
rehabilitation,3835,O
center,3835,O
in,3835,O
Malaysia,3835,O
.,3835,O
Patients,3836,O
with,3836,O
the,3836,O
diagnosis,3836,O
of,3836,O
methamphetamine,3836,B-Chemical
based,3836,O
on,3836,O
DSM-IV,3836,O
were,3836,O
interviewed,3836,O
using,3836,O
the,3836,O
Mini,3836,O
International,3836,O
Neuropsychiatric,3836,O
Interview,3836,O
(,3836,O
M.I.N.I,3836,O
.,3836,O
),3836,O
for,3837,O
methamphetamine-induced,3837,B-Chemical
psychosis,3837,B-Disease
and,3837,O
other,3837,O
Axis,3837,O
I,3837,O
psychiatric,3837,B-Disease
disorders,3837,I-Disease
.,3837,O
The,3838,O
information,3838,O
on,3838,O
sociodemographic,3838,O
background,3838,O
and,3838,O
drug,3838,O
use,3838,O
history,3838,O
was,3838,O
obtained,3838,O
from,3838,O
interview,3838,O
or,3838,O
medical,3838,O
records,3838,O
.,3838,O
RESULTS,3839,O
:,3839,O
Of,3839,O
292,3839,O
subjects,3839,O
",",3839,O
47.9,3839,O
%,3839,O
of,3839,O
the,3839,O
subjects,3839,O
had,3839,O
a,3839,O
past,3839,O
history,3839,O
of,3839,O
psychotic,3839,B-Disease
symptoms,3839,I-Disease
and,3839,O
13.0,3839,O
%,3839,O
of,3839,O
the,3839,O
patients,3839,O
were,3839,O
having,3839,O
current,3839,O
psychotic,3839,B-Disease
symptoms,3839,I-Disease
.,3839,O
Co-morbid,3840,O
major,3840,O
depressive,3840,B-Disease
disorder,3840,I-Disease
(,3840,O
OR=7.18,3840,O
",",3840,O
95,3840,O
CI=2.612-19.708,3840,O
),3840,O
",",3840,O
bipolar,3840,B-Disease
disorder,3840,I-Disease
(,3840,O
OR=13.807,3840,O
",",3840,O
95,3840,O
CI=5.194-36.706,3840,O
),3840,O
",",3840,O
antisocial,3840,B-Disease
personality,3840,I-Disease
disorder,3840,I-Disease
(,3840,O
OR=12.619,3840,O
",",3840,O
95,3840,O
CI=6.702-23.759,3840,O
),3840,O
and,3840,O
heavy,3840,O
methamphetamine,3840,B-Chemical
uses,3840,O
were,3840,O
significantly,3840,O
associated,3840,O
with,3840,O
lifetime,3840,O
methamphetamine-induced,3840,B-Chemical
psychosis,3840,B-Disease
after,3840,O
adjusted,3840,O
for,3840,O
other,3840,O
factors,3840,O
.,3840,O
Major,3841,B-Disease
depressive,3841,I-Disease
disorder,3841,I-Disease
(,3841,O
OR=2.870,3841,O
",",3841,O
CI=1.154-7.142,3841,O
),3841,O
and,3841,O
antisocial,3841,B-Disease
personality,3841,I-Disease
disorder,3841,I-Disease
(,3841,O
OR=3.299,3841,O
",",3841,O
95,3841,O
CI=1.375-7.914,3841,O
),3841,O
were,3841,O
the,3841,O
only,3841,O
factors,3841,O
associated,3841,O
with,3841,O
current,3841,O
psychosis,3841,B-Disease
.,3841,O
CONCLUSION,3842,O
:,3842,O
There,3842,O
was,3842,O
a,3842,O
high,3842,O
risk,3842,O
of,3842,O
psychosis,3842,B-Disease
in,3842,O
patients,3842,O
with,3842,O
methamphetamine,3842,B-Chemical
dependence,3842,O
.,3842,O
It,3843,O
was,3843,O
associated,3843,O
with,3843,O
co-morbid,3843,O
affective,3843,B-Disease
disorder,3843,I-Disease
",",3843,O
antisocial,3843,B-Disease
personality,3843,I-Disease
",",3843,O
and,3843,O
heavy,3843,O
methamphetamine,3843,B-Chemical
use,3843,O
.,3843,O
It,3844,O
is,3844,O
recommended,3844,O
that,3844,O
all,3844,O
cases,3844,O
of,3844,O
methamphetamine,3844,B-Chemical
dependence,3844,O
should,3844,O
be,3844,O
screened,3844,O
for,3844,O
psychotic,3844,B-Disease
symptoms,3844,I-Disease
.,3844,O
Cerebellar,3845,O
sensory,3845,O
processing,3845,O
alterations,3845,O
impact,3845,O
motor,3845,O
cortical,3845,O
plasticity,3845,O
in,3845,O
Parkinson,3845,B-Disease
's,3845,I-Disease
disease,3845,I-Disease
:,3845,O
clues,3845,O
from,3845,O
dyskinetic,3845,B-Disease
patients,3845,O
.,3845,O
The,3846,O
plasticity,3846,O
of,3846,O
primary,3846,O
motor,3846,O
cortex,3846,O
(,3846,O
M1,3846,O
),3846,O
in,3846,O
patients,3846,O
with,3846,O
Parkinson,3846,B-Disease
's,3846,I-Disease
disease,3846,I-Disease
(,3846,O
PD,3846,B-Disease
),3846,O
and,3846,O
levodopa-induced,3846,B-Chemical
dyskinesias,3846,B-Disease
(,3846,O
LIDs,3846,B-Disease
),3846,O
is,3846,O
severely,3846,O
impaired,3846,O
.,3846,O
We,3847,O
recently,3847,O
reported,3847,O
in,3847,O
young,3847,O
healthy,3847,O
subjects,3847,O
that,3847,O
inhibitory,3847,O
cerebellar,3847,O
stimulation,3847,O
enhanced,3847,O
the,3847,O
sensorimotor,3847,O
plasticity,3847,O
of,3847,O
M1,3847,O
that,3847,O
was,3847,O
induced,3847,O
by,3847,O
paired,3847,O
associative,3847,O
stimulation,3847,O
(,3847,O
PAS,3847,O
),3847,O
.,3847,O
This,3848,O
study,3848,O
demonstrates,3848,O
that,3848,O
the,3848,O
deficient,3848,O
sensorimotor,3848,O
M1,3848,O
plasticity,3848,O
in,3848,O
16,3848,O
patients,3848,O
with,3848,O
LIDs,3848,B-Disease
could,3848,O
be,3848,O
reinstated,3848,O
by,3848,O
a,3848,O
single,3848,O
session,3848,O
of,3848,O
real,3848,O
inhibitory,3848,O
cerebellar,3848,O
stimulation,3848,O
but,3848,O
not,3848,O
sham,3848,O
stimulation,3848,O
.,3848,O
This,3849,O
was,3849,O
evident,3849,O
only,3849,O
when,3849,O
a,3849,O
sensory,3849,O
component,3849,O
was,3849,O
involved,3849,O
in,3849,O
the,3849,O
induction,3849,O
of,3849,O
plasticity,3849,O
",",3849,O
indicating,3849,O
that,3849,O
cerebellar,3849,O
sensory,3849,O
processing,3849,O
function,3849,O
is,3849,O
involved,3849,O
in,3849,O
the,3849,O
resurgence,3849,O
of,3849,O
M1,3849,O
plasticity,3849,O
.,3849,O
The,3850,O
benefit,3850,O
of,3850,O
inhibitory,3850,O
cerebellar,3850,O
stimulation,3850,O
on,3850,O
LIDs,3850,B-Disease
is,3850,O
known,3850,O
.,3850,O
To,3851,O
explore,3851,O
whether,3851,O
this,3851,O
benefit,3851,O
is,3851,O
linked,3851,O
to,3851,O
the,3851,O
restoration,3851,O
of,3851,O
sensorimotor,3851,O
plasticity,3851,O
of,3851,O
M1,3851,O
",",3851,O
we,3851,O
conducted,3851,O
an,3851,O
additional,3851,O
study,3851,O
looking,3851,O
at,3851,O
changes,3851,O
in,3851,O
LIDs,3851,B-Disease
and,3851,O
PAS-induced,3851,O
plasticity,3851,O
after,3851,O
10,3851,O
sessions,3851,O
of,3851,O
either,3851,O
bilateral,3851,O
",",3851,O
real,3851,O
inhibitory,3851,O
cerebellar,3851,O
stimulation,3851,O
or,3851,O
sham,3851,O
stimulation,3851,O
.,3851,O
Only,3852,O
real,3852,O
and,3852,O
not,3852,O
sham,3852,O
stimulation,3852,O
had,3852,O
an,3852,O
antidyskinetic,3852,O
effect,3852,O
and,3852,O
it,3852,O
was,3852,O
paralleled,3852,O
by,3852,O
a,3852,O
resurgence,3852,O
in,3852,O
the,3852,O
sensorimotor,3852,O
plasticity,3852,O
of,3852,O
M1,3852,O
.,3852,O
These,3853,O
results,3853,O
suggest,3853,O
that,3853,O
alterations,3853,O
in,3853,O
cerebellar,3853,O
sensory,3853,O
processing,3853,O
function,3853,O
",",3853,O
occurring,3853,O
secondary,3853,O
to,3853,O
abnormal,3853,O
basal,3853,O
ganglia,3853,O
signals,3853,O
reaching,3853,O
it,3853,O
",",3853,O
may,3853,O
be,3853,O
an,3853,O
important,3853,O
element,3853,O
contributing,3853,O
to,3853,O
the,3853,O
maladaptive,3853,O
sensorimotor,3853,O
plasticity,3853,O
of,3853,O
M1,3853,O
and,3853,O
the,3853,O
emergence,3853,O
of,3853,O
abnormal,3853,B-Disease
involuntary,3853,I-Disease
movements,3853,I-Disease
.,3853,O
The,3854,O
function,3854,O
of,3854,O
P2X3,3854,O
receptor,3854,O
and,3854,O
NK1,3854,O
receptor,3854,O
antagonists,3854,O
on,3854,O
cyclophosphamide-induced,3854,B-Chemical
cystitis,3854,B-Disease
in,3854,O
rats,3854,O
.,3854,O
PURPOSE,3855,O
:,3855,O
The,3855,O
purpose,3855,O
of,3855,O
the,3855,O
study,3855,O
is,3855,O
to,3855,O
explore,3855,O
the,3855,O
function,3855,O
of,3855,O
P2X3,3855,O
and,3855,O
NK1,3855,O
receptors,3855,O
antagonists,3855,O
on,3855,O
cyclophosphamide,3855,B-Chemical
(,3855,O
CYP,3855,B-Chemical
),3855,O
-induced,3855,O
cystitis,3855,B-Disease
in,3855,O
rats,3855,O
.,3855,O
METHODS,3856,O
:,3856,O
Sixty,3856,O
female,3856,O
Sprague-Dawley,3856,O
(,3856,O
SD,3856,O
),3856,O
rats,3856,O
were,3856,O
randomly,3856,O
divided,3856,O
into,3856,O
three,3856,O
groups,3856,O
.,3856,O
The,3857,O
rats,3857,O
in,3857,O
the,3857,O
control,3857,O
group,3857,O
were,3857,O
intraperitoneally,3857,O
(,3857,O
i.p,3857,O
.,3857,O
),3857,O
injected,3858,O
with,3858,O
0.9,3858,O
%,3858,O
saline,3858,O
(,3858,O
4,3858,O
ml/kg,3858,O
),3858,O
;,3858,O
the,3858,O
rats,3858,O
in,3858,O
the,3858,O
model,3858,O
group,3858,O
were,3858,O
i.p,3858,O
.,3858,O
injected,3859,O
with,3859,O
CYP,3859,B-Chemical
(,3859,O
150,3859,O
mg/kg,3859,O
),3859,O
;,3859,O
and,3859,O
the,3859,O
rats,3859,O
in,3859,O
the,3859,O
intervention,3859,O
group,3859,O
were,3859,O
i.p,3859,O
.,3859,O
injected,3860,O
with,3860,O
CYP,3860,B-Chemical
with,3860,O
subsequently,3860,O
perfusion,3860,O
of,3860,O
bladder,3860,O
with,3860,O
P2X3,3860,O
and,3860,O
NK1,3860,O
receptors,3860,O
',3860,O
antagonists,3860,O
",",3860,O
Suramin,3860,B-Chemical
and,3860,O
GR,3860,B-Chemical
82334,3860,I-Chemical
.,3860,O
Spontaneous,3861,O
pain,3861,B-Disease
behaviors,3861,O
following,3861,O
the,3861,O
administration,3861,O
of,3861,O
CYP,3861,B-Chemical
were,3861,O
observed,3861,O
.,3861,O
Urodynamic,3862,O
parameters,3862,O
",",3862,O
bladder,3862,O
pressure-volume,3862,O
curve,3862,O
",",3862,O
maximum,3862,O
voiding,3862,O
pressure,3862,O
(,3862,O
MVP,3862,O
),3862,O
",",3862,O
and,3862,O
maximum,3862,O
cystometric,3862,O
capacity,3862,O
(,3862,O
MCC,3862,O
),3862,O
",",3862,O
were,3862,O
recorded,3862,O
.,3862,O
Pathological,3863,O
changes,3863,O
in,3863,O
bladder,3863,O
tissue,3863,O
were,3863,O
observed,3863,O
.,3863,O
Immunofluorescence,3864,O
was,3864,O
used,3864,O
to,3864,O
detect,3864,O
the,3864,O
expression,3864,O
of,3864,O
P2X3,3864,O
and,3864,O
NK1,3864,O
receptors,3864,O
in,3864,O
bladder,3864,O
.,3864,O
RESULTS,3865,O
:,3865,O
Cyclophosphamide,3865,B-Chemical
treatment,3865,O
increased,3865,O
the,3865,O
spontaneous,3865,O
pain,3865,B-Disease
behaviors,3865,O
scores,3865,O
.,3865,O
The,3866,O
incidence,3866,O
of,3866,O
bladder,3866,O
instability,3866,O
during,3866,O
urine,3866,O
storage,3866,O
period,3866,O
of,3866,O
model,3866,O
group,3866,O
was,3866,O
significantly,3866,O
higher,3866,O
than,3866,O
intervention,3866,O
group,3866,O
(,3866,O
X,3866,O
(,3866,O
2,3866,O
),3866,O
=,3866,O
7.619,3866,O
",",3866,O
P,3866,O
=,3866,O
0.007,3866,O
),3866,O
and,3866,O
control,3866,O
group,3866,O
(,3866,O
X,3866,O
(,3866,O
2,3866,O
),3866,O
=,3866,O
13.755,3866,O
",",3866,O
P,3866,O
=,3866,O
0.000,3866,O
),3866,O
.,3866,O
MCC,3867,O
in,3867,O
the,3867,O
model,3867,O
group,3867,O
was,3867,O
lower,3867,O
than,3867,O
the,3867,O
control,3867,O
and,3867,O
intervention,3867,O
groups,3867,O
(,3867,O
P,3867,O
<,3867,O
0.01,3867,O
),3867,O
.,3867,O
Histological,3868,O
changes,3868,O
evident,3868,O
in,3868,O
model,3868,O
and,3868,O
intervention,3868,O
groups,3868,O
rats,3868,O
',3868,O
bladder,3868,O
included,3868,O
edema,3868,B-Disease
",",3868,O
vasodilation,3868,O
",",3868,O
and,3868,O
infiltration,3868,O
of,3868,O
inflammatory,3868,O
cells,3868,O
.,3868,O
In,3869,O
model,3869,O
group,3869,O
",",3869,O
the,3869,O
expression,3869,O
of,3869,O
P2X3,3869,O
receptor,3869,O
increased,3869,O
in,3869,O
urothelium,3869,O
and,3869,O
suburothelium,3869,O
",",3869,O
and,3869,O
NK1,3869,O
receptor,3869,O
increased,3869,O
in,3869,O
suburothelium,3869,O
",",3869,O
while,3869,O
the,3869,O
expression,3869,O
of,3869,O
them,3869,O
in,3869,O
intervention,3869,O
group,3869,O
was,3869,O
lower,3869,O
.,3869,O
CONCLUSIONS,3870,O
:,3870,O
In,3870,O
CYP-induced,3870,B-Chemical
cystitis,3870,B-Disease
",",3870,O
the,3870,O
expression,3870,O
of,3870,O
P2X3,3870,O
and,3870,O
NK1,3870,O
receptors,3870,O
increased,3870,O
in,3870,O
urothelium,3870,O
and/or,3870,O
suburothelium,3870,O
.,3870,O
Perfusion,3871,O
of,3871,O
bladder,3871,O
with,3871,O
P2X3,3871,O
and,3871,O
NK1,3871,O
receptors,3871,O
antagonists,3871,O
ameliorated,3871,O
the,3871,O
bladder,3871,O
function,3871,O
.,3871,O
Acute,3872,O
hepatitis,3872,B-Disease
associated,3872,O
with,3872,O
clopidogrel,3872,B-Chemical
:,3872,O
a,3872,O
case,3872,O
report,3872,O
and,3872,O
review,3872,O
of,3872,O
the,3872,O
literature,3872,O
.,3872,O
Drug-induced,3873,O
hepatotoxicity,3873,B-Disease
is,3873,O
a,3873,O
common,3873,O
cause,3873,O
of,3873,O
acute,3873,O
hepatitis,3873,B-Disease
",",3873,O
and,3873,O
the,3873,O
recognition,3873,O
of,3873,O
the,3873,O
responsible,3873,O
drug,3873,O
may,3873,O
be,3873,O
difficult,3873,O
.,3873,O
We,3874,O
describe,3874,O
a,3874,O
case,3874,O
of,3874,O
clopidogrel-related,3874,B-Chemical
acute,3874,O
hepatitis,3874,B-Disease
.,3874,O
The,3875,O
diagnosis,3875,O
is,3875,O
strongly,3875,O
suggested,3875,O
by,3875,O
an,3875,O
accurate,3875,O
medical,3875,O
history,3875,O
and,3875,O
liver,3875,O
biopsy,3875,O
.,3875,O
Reports,3876,O
about,3876,O
cases,3876,O
of,3876,O
hepatotoxicity,3876,B-Disease
due,3876,O
to,3876,O
clopidogrel,3876,B-Chemical
are,3876,O
increasing,3876,O
in,3876,O
the,3876,O
last,3876,O
few,3876,O
years,3876,O
",",3876,O
after,3876,O
the,3876,O
increased,3876,O
use,3876,O
of,3876,O
this,3876,O
drug,3876,O
.,3876,O
In,3877,O
conclusion,3877,O
",",3877,O
we,3877,O
believe,3877,O
that,3877,O
physicians,3877,O
should,3877,O
carefully,3877,O
consider,3877,O
the,3877,O
risk,3877,O
of,3877,O
drug-induced,3877,O
hepatic,3877,B-Disease
injury,3877,I-Disease
when,3877,O
clopidogrel,3877,B-Chemical
is,3877,O
prescribed,3877,O
.,3877,O
Bortezomib,3878,B-Chemical
and,3878,O
dexamethasone,3878,B-Chemical
as,3878,O
salvage,3878,O
therapy,3878,O
in,3878,O
patients,3878,O
with,3878,O
relapsed/refractory,3878,O
multiple,3878,B-Disease
myeloma,3878,I-Disease
:,3878,O
analysis,3878,O
of,3878,O
long-term,3878,O
clinical,3878,O
outcomes,3878,O
.,3878,O
Bortezomib,3879,B-Chemical
(,3879,O
bort,3879,B-Chemical
),3879,O
-dexamethasone,3879,O
(,3879,O
dex,3879,B-Chemical
),3879,O
is,3879,O
an,3879,O
effective,3879,O
therapy,3879,O
for,3879,O
relapsed/refractory,3879,O
(,3879,O
R/R,3879,O
),3879,O
multiple,3879,B-Disease
myeloma,3879,I-Disease
(,3879,O
MM,3879,B-Disease
),3879,O
.,3879,O
This,3880,O
retrospective,3880,O
study,3880,O
investigated,3880,O
the,3880,O
combination,3880,O
of,3880,O
bort,3880,B-Chemical
(,3880,O
1.3,3880,O
mg/m,3880,O
(,3880,O
2,3880,O
),3880,O
on,3880,O
days,3880,O
1,3880,O
",",3880,O
4,3880,O
",",3880,O
8,3880,O
",",3880,O
and,3880,O
11,3880,O
every,3880,O
3,3880,O
weeks,3880,O
),3880,O
and,3880,O
dex,3880,B-Chemical
(,3880,O
20,3880,O
mg,3880,O
on,3880,O
the,3880,O
day,3880,O
of,3880,O
and,3880,O
the,3880,O
day,3880,O
after,3880,O
bort,3880,B-Chemical
),3880,O
as,3880,O
salvage,3880,O
treatment,3880,O
in,3880,O
85,3880,O
patients,3880,O
with,3880,O
R/R,3880,O
MM,3880,B-Disease
after,3880,O
prior,3880,O
autologous,3880,O
stem,3880,O
cell,3880,O
transplantation,3880,O
or,3880,O
conventional,3880,O
chemotherapy,3880,O
.,3880,O
The,3881,O
median,3881,O
number,3881,O
of,3881,O
prior,3881,O
lines,3881,O
of,3881,O
therapy,3881,O
was,3881,O
2,3881,O
.,3881,O
Eighty-seven,3882,O
percent,3882,O
of,3882,O
the,3882,O
patients,3882,O
had,3882,O
received,3882,O
immunomodulatory,3882,O
drugs,3882,O
included,3882,O
in,3882,O
some,3882,O
line,3882,O
of,3882,O
therapy,3882,O
before,3882,O
bort-dex,3882,B-Chemical
.,3882,O
The,3883,O
median,3883,O
number,3883,O
of,3883,O
bort-dex,3883,B-Chemical
cycles,3883,O
was,3883,O
6,3883,O
",",3883,O
up,3883,O
to,3883,O
a,3883,O
maximum,3883,O
of,3883,O
12,3883,O
cycles,3883,O
.,3883,O
On,3884,O
an,3884,O
intention-to-treat,3884,O
basis,3884,O
",",3884,O
55,3884,O
%,3884,O
of,3884,O
the,3884,O
patients,3884,O
achieved,3884,O
at,3884,O
least,3884,O
partial,3884,O
response,3884,O
",",3884,O
including,3884,O
19,3884,O
%,3884,O
CR,3884,O
and,3884,O
35,3884,O
%,3884,O
achieved,3884,O
at,3884,O
least,3884,O
very,3884,O
good,3884,O
partial,3884,O
response,3884,O
.,3884,O
Median,3885,O
durations,3885,O
of,3885,O
response,3885,O
",",3885,O
time,3885,O
to,3885,O
next,3885,O
therapy,3885,O
and,3885,O
treatment-free,3885,O
interval,3885,O
were,3885,O
8,3885,O
",",3885,O
11.2,3885,O
",",3885,O
and,3885,O
5.1,3885,O
months,3885,O
",",3885,O
respectively,3885,O
.,3885,O
The,3886,O
most,3886,O
relevant,3886,O
adverse,3886,O
event,3886,O
was,3886,O
peripheral,3886,B-Disease
neuropathy,3886,I-Disease
",",3886,O
which,3886,O
occurred,3886,O
in,3886,O
78,3886,O
%,3886,O
of,3886,O
the,3886,O
patients,3886,O
(,3886,O
grade,3886,O
II,3886,O
",",3886,O
38,3886,O
%,3886,O
;,3886,O
grade,3886,O
III,3886,O
",",3886,O
21,3886,O
%,3886,O
),3886,O
and,3886,O
led,3886,O
to,3886,O
treatment,3886,O
discontinuation,3886,O
in,3886,O
6,3886,O
%,3886,O
.,3886,O
With,3887,O
a,3887,O
median,3887,O
follow,3887,O
up,3887,O
of,3887,O
22,3887,O
months,3887,O
",",3887,O
median,3887,O
time,3887,O
to,3887,O
progression,3887,O
",",3887,O
progression-free,3887,O
survival,3887,O
(,3887,O
PFS,3887,O
),3887,O
and,3887,O
overall,3887,O
survival,3887,O
(,3887,O
OS,3887,O
),3887,O
were,3887,O
8.9,3887,O
",",3887,O
8.7,3887,O
",",3887,O
and,3887,O
22,3887,O
months,3887,O
",",3887,O
respectively,3887,O
.,3887,O
Prolonged,3888,O
PFS,3888,O
and,3888,O
OS,3888,O
were,3888,O
observed,3888,O
in,3888,O
patients,3888,O
achieving,3888,O
CR,3888,O
and,3888,O
receiving,3888,O
bort-dex,3888,B-Chemical
a,3888,O
single,3888,O
line,3888,O
of,3888,O
prior,3888,O
therapy,3888,O
.,3888,O
Bort-dex,3889,B-Chemical
was,3889,O
an,3889,O
effective,3889,O
salvage,3889,O
treatment,3889,O
for,3889,O
MM,3889,B-Disease
patients,3889,O
",",3889,O
particularly,3889,O
for,3889,O
those,3889,O
in,3889,O
first,3889,O
relapse,3889,O
.,3889,O
Pubertal,3890,O
exposure,3890,O
to,3890,O
Bisphenol,3890,B-Chemical
A,3890,I-Chemical
increases,3890,O
anxiety-like,3890,B-Disease
behavior,3890,O
and,3890,O
decreases,3890,O
acetylcholinesterase,3890,O
activity,3890,O
of,3890,O
hippocampus,3890,O
in,3890,O
adult,3890,O
male,3890,O
mice,3890,O
.,3890,O
The,3891,O
negative,3891,O
effects,3891,O
of,3891,O
Bisphenol,3891,B-Chemical
A,3891,I-Chemical
(,3891,O
BPA,3891,B-Chemical
),3891,O
on,3891,O
neurodevelopment,3891,O
and,3891,O
behaviors,3891,O
have,3891,O
been,3891,O
well,3891,O
established,3891,O
.,3891,O
Acetylcholinesterase,3892,O
(,3892,O
AChE,3892,O
),3892,O
is,3892,O
a,3892,O
regulatory,3892,O
enzyme,3892,O
which,3892,O
is,3892,O
involved,3892,O
in,3892,O
anxiety-like,3892,B-Disease
behavior,3892,O
.,3892,O
This,3893,O
study,3893,O
investigated,3893,O
behavioral,3893,O
phenotypes,3893,O
and,3893,O
AChE,3893,O
activity,3893,O
in,3893,O
male,3893,O
mice,3893,O
following,3893,O
BPA,3893,B-Chemical
exposure,3893,O
during,3893,O
puberty,3893,O
.,3893,O
On,3894,O
postnatal,3894,O
day,3894,O
(,3894,O
PND,3894,O
),3894,O
35,3894,O
",",3894,O
male,3894,O
mice,3894,O
were,3894,O
exposed,3894,O
to,3894,O
50mg,3894,O
BPA/kg,3894,B-Chemical
diet,3894,O
per,3894,O
day,3894,O
for,3894,O
a,3894,O
period,3894,O
of,3894,O
35,3894,O
days,3894,O
.,3894,O
On,3895,O
PND71,3895,O
",",3895,O
a,3895,O
behavioral,3895,O
assay,3895,O
was,3895,O
performed,3895,O
using,3895,O
the,3895,O
elevated,3895,O
plus,3895,O
maze,3895,O
(,3895,O
EPM,3895,O
),3895,O
and,3895,O
the,3895,O
light/dark,3895,O
test,3895,O
.,3895,O
In,3896,O
addition,3896,O
",",3896,O
AChE,3896,O
activity,3896,O
was,3896,O
measured,3896,O
in,3896,O
the,3896,O
prefrontal,3896,O
cortex,3896,O
",",3896,O
hypothalamus,3896,O
",",3896,O
cerebellum,3896,O
and,3896,O
hippocampus,3896,O
.,3896,O
Results,3897,O
from,3897,O
our,3897,O
behavioral,3897,O
phenotyping,3897,O
indicated,3897,O
that,3897,O
anxiety-like,3897,B-Disease
behavior,3897,O
was,3897,O
increased,3897,O
in,3897,O
mice,3897,O
exposed,3897,O
to,3897,O
BPA,3897,B-Chemical
.,3897,O
AChE,3898,O
activity,3898,O
was,3898,O
significantly,3898,O
decreased,3898,O
in,3898,O
the,3898,O
hippocampus,3898,O
of,3898,O
mice,3898,O
with,3898,O
BPA,3898,B-Chemical
compared,3898,O
to,3898,O
control,3898,O
mice,3898,O
",",3898,O
whereas,3898,O
no,3898,O
difference,3898,O
was,3898,O
found,3898,O
in,3898,O
the,3898,O
prefrontal,3898,O
cortex,3898,O
",",3898,O
hypothalamus,3898,O
and,3898,O
cerebellum,3898,O
.,3898,O
Our,3899,O
findings,3899,O
showed,3899,O
that,3899,O
pubertal,3899,O
BPA,3899,B-Chemical
exposure,3899,O
increased,3899,O
anxiety-like,3899,B-Disease
behavior,3899,O
",",3899,O
which,3899,O
may,3899,O
be,3899,O
associated,3899,O
with,3899,O
decreased,3899,O
AChE,3899,O
activity,3899,O
of,3899,O
the,3899,O
hippocampus,3899,O
in,3899,O
adult,3899,O
male,3899,O
mice,3899,O
.,3899,O
Further,3900,O
studies,3900,O
are,3900,O
necessary,3900,O
to,3900,O
investigate,3900,O
the,3900,O
cholinergic,3900,O
signaling,3900,O
of,3900,O
the,3900,O
hippocampus,3900,O
in,3900,O
PBE,3900,O
induced,3900,O
anxiety-like,3900,B-Disease
behaviors,3900,O
.,3900,O
Biochemical,3901,O
effects,3901,O
of,3901,O
Solidago,3901,O
virgaurea,3901,O
extract,3901,O
on,3901,O
experimental,3901,O
cardiotoxicity,3901,B-Disease
.,3901,O
Cardiovascular,3902,B-Disease
diseases,3902,I-Disease
(,3902,O
CVDs,3902,B-Disease
),3902,O
are,3902,O
the,3902,O
major,3902,O
health,3902,O
problem,3902,O
of,3902,O
advanced,3902,O
as,3902,O
well,3902,O
as,3902,O
developing,3902,O
countries,3902,O
of,3902,O
the,3902,O
world,3902,O
.,3902,O
The,3903,O
aim,3903,O
of,3903,O
the,3903,O
present,3903,O
study,3903,O
was,3903,O
to,3903,O
investigate,3903,O
the,3903,O
protective,3903,O
effect,3903,O
of,3903,O
the,3903,O
Solidago,3903,O
virgaurea,3903,O
extract,3903,O
on,3903,O
isoproterenol-induced,3903,B-Chemical
cardiotoxicity,3903,B-Disease
in,3903,O
rats,3903,O
.,3903,O
The,3904,O
subcutaneous,3904,O
injection,3904,O
of,3904,O
isoproterenol,3904,B-Chemical
(,3904,O
30,3904,O
mg/kg,3904,O
),3904,O
into,3904,O
rats,3904,O
twice,3904,O
at,3904,O
an,3904,O
interval,3904,O
of,3904,O
24,3904,O
h,3904,O
",",3904,O
for,3904,O
two,3904,O
consecutive,3904,O
days,3904,O
",",3904,O
led,3904,O
to,3904,O
a,3904,O
significant,3904,O
increase,3904,O
in,3904,O
serum,3904,O
lactate,3904,B-Chemical
dehydrogenase,3904,O
",",3904,O
creatine,3904,B-Chemical
phosphokinase,3904,O
",",3904,O
alanine,3904,B-Chemical
transaminase,3904,O
",",3904,O
aspartate,3904,B-Chemical
transaminase,3904,O
",",3904,O
and,3904,O
angiotensin-converting,3904,B-Chemical
enzyme,3904,O
activities,3904,O
",",3904,O
total,3904,O
cholesterol,3904,B-Chemical
",",3904,O
triglycerides,3904,B-Chemical
",",3904,O
free,3904,O
serum,3904,O
fatty,3904,B-Chemical
acid,3904,I-Chemical
",",3904,O
cardiac,3904,O
tissue,3904,O
malondialdehyde,3904,B-Chemical
(,3904,O
MDA,3904,B-Chemical
),3904,O
",",3904,O
and,3904,O
nitric,3904,B-Chemical
oxide,3904,I-Chemical
levels,3904,O
and,3904,O
a,3904,O
significant,3904,O
decrease,3904,O
in,3904,O
levels,3904,O
of,3904,O
glutathione,3904,B-Chemical
and,3904,O
superoxide,3904,B-Chemical
dismutase,3904,O
in,3904,O
cardiac,3904,O
tissue,3904,O
as,3904,O
compared,3904,O
to,3904,O
the,3904,O
normal,3904,O
control,3904,O
group,3904,O
(,3904,O
P,3904,O
<,3904,O
0.05,3904,O
),3904,O
.,3904,O
Pretreatment,3905,O
with,3905,O
S.,3905,O
virgaurea,3905,O
extract,3905,O
for,3905,O
5,3905,O
weeks,3905,O
at,3905,O
a,3905,O
dose,3905,O
of,3905,O
250,3905,O
mg/kg,3905,O
followed,3905,O
by,3905,O
isoproterenol,3905,B-Chemical
injection,3905,O
significantly,3905,O
prevented,3905,O
the,3905,O
observed,3905,O
alterations,3905,O
.,3905,O
Captopril,3906,B-Chemical
(,3906,O
50,3906,O
mg/kg/day,3906,O
",",3906,O
given,3906,O
orally,3906,O
),3906,O
",",3906,O
an,3906,O
inhibitor,3906,O
of,3906,O
angiotensin-converting,3906,B-Chemical
enzyme,3906,O
used,3906,O
as,3906,O
a,3906,O
standard,3906,O
cardioprotective,3906,O
drug,3906,O
",",3906,O
was,3906,O
used,3906,O
as,3906,O
a,3906,O
positive,3906,O
control,3906,O
in,3906,O
this,3906,O
study,3906,O
.,3906,O
The,3907,O
data,3907,O
of,3907,O
the,3907,O
present,3907,O
study,3907,O
suggest,3907,O
that,3907,O
S.,3907,O
virgaurea,3907,O
extract,3907,O
exerts,3907,O
its,3907,O
protective,3907,O
effect,3907,O
by,3907,O
decreasing,3907,O
MDA,3907,B-Chemical
level,3907,O
and,3907,O
increasing,3907,O
the,3907,O
antioxidant,3907,O
status,3907,O
in,3907,O
isoproterenol-treated,3907,B-Chemical
rats,3907,O
.,3907,O
The,3908,O
study,3908,O
emphasizes,3908,O
the,3908,O
beneficial,3908,O
action,3908,O
of,3908,O
S.,3908,O
virgaurea,3908,O
extract,3908,O
as,3908,O
a,3908,O
cardioprotective,3908,O
agent,3908,O
.,3908,O
Real-world,3909,O
data,3909,O
on,3909,O
the,3909,O
efficacy,3909,O
and,3909,O
safety,3909,O
of,3909,O
lenalidomide,3909,O
and,3909,O
dexamethasone,3909,O
in,3909,O
patients,3909,O
with,3909,O
relapsed/refractory,3909,O
multiple,3909,O
myeloma,3909,I-Disease
who,3909,O
were,3909,O
treated,3909,O
according,3909,O
to,3909,O
the,3909,O
standard,3909,O
clinical,3909,O
practice,3909,O
:,3909,O
a,3909,O
study,3909,O
of,3909,O
the,3909,O
Greek,3909,O
Myeloma,3909,O
Study,3909,O
Group,3909,O
.,3909,O
Lenalidomide,3910,O
and,3910,O
dexamethasone,3910,O
(,3910,I-Chemical
RD,3910,O
),3910,B-Chemical
is,3910,O
a,3910,O
standard,3910,O
of,3910,O
care,3910,O
for,3910,O
relapsed/refractory,3910,O
multiple,3910,O
myeloma,3910,I-Disease
(,3910,I-Disease
RRMM,3910,O
),3910,I-Disease
",",3910,I-Disease
but,3910,O
there,3910,O
is,3910,O
limited,3910,O
published,3910,O
data,3910,O
on,3910,O
its,3910,O
efficacy,3910,O
and,3910,O
safety,3910,O
in,3910,O
the,3910,O
``,3910,O
real,3910,O
world,3910,O
'',3910,O
(,3910,I-Chemical
RW,3910,O
),3910,O
",",3910,O
according,3910,O
to,3910,O
the,3910,O
International,3910,O
Society,3910,O
of,3910,O
Pharmacoeconomics,3910,O
and,3910,O
Outcomes,3910,O
Research,3910,O
definition,3910,O
.,3910,O
We,3911,O
studied,3911,O
212,3911,O
RRMM,3911,O
patients,3911,O
who,3911,O
received,3911,O
RD,3911,O
in,3911,O
RW,3911,O
.,3911,O
Objective,3912,O
response,3912,O
(,3912,O
>,3912,O
PR,3912,O
(,3912,O
partial,3912,O
response,3912,O
),3912,O
),3912,O
rate,3912,O
was,3912,O
77.4,3912,O
%,3912,O
(,3912,O
complete,3912,O
response,3912,O
(,3912,O
CR,3912,O
),3912,O
",",3912,O
20.2,3912,O
%,3912,O
),3912,O
.,3912,O
Median,3913,O
time,3913,O
to,3913,O
first,3913,O
and,3913,O
best,3913,O
response,3913,O
was,3913,O
2,3913,O
and,3913,O
5,3913,O
months,3913,O
",",3913,O
respectively,3913,O
.,3913,O
Median,3914,O
time,3914,O
to,3914,O
CR,3914,O
when,3914,O
RD,3914,O
was,3914,O
given,3914,O
as,3914,O
2nd,3914,O
or,3914,O
>,3914,O
2,3914,O
(,3914,O
nd,3914,O
),3914,O
-line,3914,O
treatment,3914,O
at,3914,O
4,3914,O
and,3914,O
11,3914,O
months,3914,O
",",3914,O
respectively,3914,O
.,3914,O
Quality,3915,O
of,3915,O
response,3915,O
was,3915,O
independent,3915,O
of,3915,O
previous,3915,O
lines,3915,O
of,3915,O
therapies,3915,O
or,3915,O
previous,3915,O
exposure,3915,O
to,3915,O
thalidomide,3915,O
or,3915,O
bortezomib,3915,O
.,3915,O
Median,3916,O
duration,3916,O
of,3916,O
response,3916,O
was,3916,O
34.4,3916,O
months,3916,O
",",3916,O
and,3916,O
it,3916,O
was,3916,O
higher,3916,O
in,3916,O
patients,3916,O
who,3916,O
received,3916,O
RD,3916,O
until,3916,O
progression,3916,O
(,3916,O
not,3916,O
reached,3916,O
versus,3916,O
19,3916,O
months,3916,O
",",3916,O
p,3916,O
<,3916,O
0.001,3916,O
),3916,O
.,3916,O
Improvement,3917,O
of,3917,O
humoral,3917,O
immunity,3917,O
occurred,3917,O
in,3917,O
60,3917,O
%,3917,O
of,3917,O
responders,3917,O
(,3917,O
p,3917,O
<,3917,O
0.001,3917,O
),3917,O
and,3917,O
in,3917,O
the,3917,O
majority,3917,O
of,3917,O
patients,3917,O
who,3917,O
achieved,3917,O
stable,3917,O
disease,3917,O
.,3917,O
Adverse,3918,O
events,3918,O
were,3918,O
reported,3918,O
in,3918,O
68.9,3918,O
%,3918,O
of,3918,O
patients,3918,O
(,3918,O
myelosuppression,3918,O
in,3918,O
49.4,3918,O
%,3918,O
),3918,O
and,3918,O
12.7,3918,O
%,3918,O
of,3918,O
patients,3918,O
needed,3918,O
hospitalization,3918,O
.,3918,O
Peripheral,3919,O
neuropathy,3919,I-Disease
was,3919,O
observed,3919,O
only,3919,O
in,3919,O
2.5,3919,O
%,3919,O
of,3919,O
patients,3919,O
and,3919,O
deep,3919,O
vein,3919,I-Disease
thrombosis,3919,I-Disease
in,3919,O
5.7,3919,O
%,3919,O
.,3919,O
Dose,3920,O
reductions,3920,O
were,3920,O
needed,3920,O
in,3920,O
31,3920,O
%,3920,O
of,3920,O
patients,3920,O
and,3920,O
permanent,3920,O
discontinuation,3920,O
in,3920,O
38.9,3920,O
%,3920,O
.,3920,O
Median,3921,O
time,3921,O
to,3921,O
treatment,3921,O
discontinuation,3921,O
was,3921,O
16.8,3921,O
months,3921,O
.,3921,O
Performance,3922,O
status,3922,O
(,3922,O
PS,3922,O
),3922,O
and,3922,O
initial,3922,O
lenalidomide,3922,O
dose,3922,O
predicted,3922,O
for,3922,O
treatment,3922,O
discontinuation,3922,O
.,3922,O
Extra-medullary,3923,O
relapses,3923,O
occurred,3923,O
in,3923,O
3.8,3923,O
%,3923,O
of,3923,O
patients,3923,O
.,3923,O
Our,3924,O
study,3924,O
confirms,3924,O
that,3924,O
RD,3924,O
is,3924,O
effective,3924,O
and,3924,O
safe,3924,O
in,3924,O
RRMM,3924,O
in,3924,O
the,3924,O
RW,3924,O
;,3924,O
it,3924,O
produces,3924,O
durable,3924,O
responses,3924,O
especially,3924,O
in,3924,O
patients,3924,O
who,3924,O
continue,3924,O
on,3924,O
treatment,3924,O
till,3924,O
progression,3924,O
and,3924,O
improves,3924,O
humoral,3924,O
immunity,3924,O
even,3924,O
in,3924,O
patients,3924,O
with,3924,O
stable,3924,O
disease,3924,O
.,3924,O
The,3925,O
cytogenetic,3925,O
action,3925,O
of,3925,O
ifosfamide,3925,B-Chemical
",",3925,O
mesna,3925,B-Chemical
",",3925,O
and,3925,O
their,3925,O
combination,3925,O
on,3925,O
peripheral,3925,O
rabbit,3925,O
lymphocytes,3925,O
:,3925,O
an,3925,O
in,3925,O
vivo/in,3925,O
vitro,3925,O
cytogenetic,3925,O
study,3925,O
.,3925,O
Ifosfamide,3926,B-Chemical
(,3926,O
IFO,3926,B-Chemical
),3926,O
is,3926,O
an,3926,O
alkylating,3926,O
nitrogen,3926,B-Chemical
mustard,3926,O
",",3926,O
administrated,3926,O
as,3926,O
an,3926,O
antineoplasmic,3926,O
agent,3926,O
.,3926,O
It,3927,O
is,3927,O
characterized,3927,O
by,3927,O
its,3927,O
intense,3927,O
urotoxic,3927,O
action,3927,O
",",3927,O
leading,3927,O
to,3927,O
hemorrhagic,3927,O
cystitis,3927,O
.,3927,O
This,3928,O
side,3928,O
effect,3928,O
of,3928,O
IFO,3928,B-Chemical
raises,3928,O
the,3928,O
requirement,3928,O
for,3928,O
the,3928,O
co-administration,3928,O
with,3928,O
sodium,3928,B-Chemical
2-sulfanylethanesulfonate,3928,I-Chemical
(,3928,O
Mesna,3928,B-Chemical
),3928,O
aiming,3928,O
to,3928,O
avoid,3928,O
or,3928,O
minimize,3928,O
this,3928,O
effect,3928,O
.,3928,O
IFO,3929,B-Chemical
and,3929,O
Mesna,3929,B-Chemical
were,3929,O
administrated,3929,O
separately,3929,O
on,3929,O
rabbit,3929,O
's,3929,O
lymphocytes,3929,O
in,3929,O
vivo,3929,O
",",3929,O
which,3929,O
were,3929,O
later,3929,O
developed,3929,O
in,3929,O
vitro,3929,O
.,3929,O
Cytogenetic,3930,O
markers,3930,O
for,3930,O
sister,3930,O
chromatid,3930,O
exchanges,3930,O
(,3930,O
SCEs,3930,O
),3930,O
",",3930,O
proliferation,3930,O
rate,3930,O
index,3930,O
(,3930,O
PRI,3930,O
),3930,O
and,3930,O
Mitotic,3930,O
Index,3930,O
were,3930,O
recorded,3930,O
.,3930,O
Mesna,3931,B-Chemical
's,3931,O
action,3931,O
",",3931,O
in,3931,O
conjunction,3931,O
with,3931,O
IFO,3931,B-Chemical
reduces,3931,O
the,3931,O
frequency,3931,O
of,3931,O
SCEs,3931,O
",",3931,O
in,3931,O
comparison,3931,O
with,3931,O
the,3931,O
SCEs,3931,O
recordings,3931,O
obtained,3931,O
when,3931,O
IFO,3931,B-Chemical
is,3931,O
administered,3931,O
alone,3931,O
.,3931,O
In,3932,O
addition,3932,O
to,3932,O
this,3932,O
",",3932,O
when,3932,O
high,3932,O
concentrations,3932,O
of,3932,O
Mesna,3932,B-Chemical
were,3932,O
administered,3932,O
alone,3932,O
significant,3932,O
reductions,3932,O
of,3932,O
the,3932,O
PRI,3932,O
were,3932,O
noted,3932,O
",",3932,O
than,3932,O
with,3932,O
IFO,3932,B-Chemical
acting,3932,O
at,3932,O
the,3932,O
same,3932,O
concentration,3932,O
on,3932,O
the,3932,O
lymphocytes,3932,O
.,3932,O
Mesna,3933,B-Chemical
significantly,3933,O
reduces,3933,O
IFO,3933,B-Chemical
's,3933,O
genotoxicity,3933,B-Disease
",",3933,O
while,3933,O
when,3933,O
administered,3933,O
in,3933,O
high,3933,O
concentrations,3933,O
it,3933,O
acts,3933,O
in,3933,O
an,3933,O
inhibitory,3933,O
fashion,3933,O
on,3933,O
the,3933,O
cytostatic,3933,O
action,3933,O
of,3933,O
the,3933,O
drug,3933,O
.,3933,O
Risk,3934,O
factors,3934,O
and,3934,O
predictors,3934,O
of,3934,O
levodopa-induced,3934,B-Chemical
dyskinesia,3934,B-Disease
among,3934,O
multiethnic,3934,O
Malaysians,3934,O
with,3934,O
Parkinson,3934,B-Disease
's,3934,I-Disease
disease,3934,I-Disease
.,3934,O
Chronic,3935,O
pulsatile,3935,O
levodopa,3935,B-Chemical
therapy,3935,O
for,3935,O
Parkinson,3935,B-Disease
's,3935,I-Disease
disease,3935,I-Disease
(,3935,O
PD,3935,B-Disease
),3935,O
leads,3935,O
to,3935,O
the,3935,O
development,3935,O
of,3935,O
motor,3935,O
fluctuations,3935,O
and,3935,O
dyskinesia,3935,B-Disease
.,3935,O
We,3936,O
studied,3936,O
the,3936,O
prevalence,3936,O
and,3936,O
predictors,3936,O
of,3936,O
levodopa-induced,3936,B-Chemical
dyskinesia,3936,B-Disease
among,3936,O
multiethnic,3936,O
Malaysian,3936,O
patients,3936,O
with,3936,O
PD,3936,B-Disease
.,3936,O
METHODS,3937,O
:,3937,O
This,3937,O
is,3937,O
a,3937,O
cross-sectional,3937,O
study,3937,O
involving,3937,O
95,3937,O
patients,3937,O
with,3937,O
PD,3937,B-Disease
on,3937,O
uninterrupted,3937,O
levodopa,3937,B-Chemical
therapy,3937,O
for,3937,O
at,3937,O
least,3937,O
6,3937,O
months,3937,O
.,3937,O
The,3938,O
instrument,3938,O
used,3938,O
was,3938,O
the,3938,O
UPDRS,3938,O
questionnaires,3938,O
.,3938,O
The,3939,O
predictors,3939,O
of,3939,O
dyskinesia,3939,B-Disease
were,3939,O
determined,3939,O
using,3939,O
multivariate,3939,O
logistic,3939,O
regression,3939,O
analysis,3939,O
.,3939,O
RESULTS,3940,O
:,3940,O
The,3940,O
mean,3940,O
age,3940,O
was,3940,O
65.6,3940,O
+,3940,O
8.5,3940,O
years,3940,O
.,3940,O
The,3941,O
mean,3941,O
onset,3941,O
age,3941,O
was,3941,O
58.5,3941,O
+,3941,O
9.8,3941,O
years,3941,O
.,3941,O
The,3942,O
median,3942,O
disease,3942,O
duration,3942,O
was,3942,O
6,3942,O
(,3942,O
7,3942,O
),3942,O
years,3942,O
.,3942,O
Dyskinesia,3943,B-Disease
was,3943,O
present,3943,O
in,3943,O
44,3943,O
%,3943,O
(,3943,O
n,3943,O
=,3943,O
42,3943,O
),3943,O
with,3943,O
median,3943,O
levodopa,3943,B-Chemical
therapy,3943,O
of,3943,O
3,3943,O
years,3943,O
.,3943,O
There,3944,O
were,3944,O
64.3,3944,O
%,3944,O
Chinese,3944,O
",",3944,O
31,3944,O
%,3944,O
Malays,3944,O
",",3944,O
and,3944,O
3.7,3944,O
%,3944,O
Indians,3944,O
and,3944,O
other,3944,O
ethnic,3944,O
groups,3944,O
.,3944,O
Eighty-one,3945,O
percent,3945,O
of,3945,O
patients,3945,O
with,3945,O
dyskinesia,3945,B-Disease
had,3945,O
clinical,3945,O
fluctuations,3945,O
.,3945,O
Patients,3946,O
with,3946,O
dyskinesia,3946,B-Disease
had,3946,O
lower,3946,O
onset,3946,O
age,3946,O
(,3946,O
p,3946,O
<,3946,O
0.001,3946,O
),3946,O
",",3946,O
longer,3946,O
duration,3946,O
of,3946,O
levodopa,3946,B-Chemical
therapy,3946,O
(,3946,O
p,3946,O
<,3946,O
0.001,3946,O
),3946,O
",",3946,O
longer,3946,O
disease,3946,O
duration,3946,O
(,3946,O
p,3946,O
<,3946,O
0.001,3946,O
),3946,O
",",3946,O
higher,3946,O
total,3946,O
daily,3946,O
levodopa,3946,B-Chemical
dose,3946,O
(,3946,O
p,3946,O
<,3946,O
0.001,3946,O
),3946,O
",",3946,O
and,3946,O
higher,3946,O
total,3946,O
UPDRS,3946,O
scores,3946,O
(,3946,O
p,3946,O
=,3946,O
0.005,3946,O
),3946,O
than,3946,O
patients,3946,O
without,3946,O
dyskinesia,3946,B-Disease
.,3946,O
The,3947,O
three,3947,O
significant,3947,O
predictors,3947,O
of,3947,O
dyskinesia,3947,B-Disease
were,3947,O
duration,3947,O
of,3947,O
levodopa,3947,B-Chemical
therapy,3947,O
",",3947,O
onset,3947,O
age,3947,O
",",3947,O
and,3947,O
total,3947,O
daily,3947,O
levodopa,3947,B-Chemical
dose,3947,O
.,3947,O
CONCLUSIONS,3948,O
:,3948,O
The,3948,O
prevalence,3948,O
of,3948,O
levodopa-induced,3948,B-Chemical
dyskinesia,3948,B-Disease
in,3948,O
our,3948,O
patients,3948,O
was,3948,O
44,3948,O
%,3948,O
.,3948,O
The,3949,O
most,3949,O
significant,3949,O
predictors,3949,O
were,3949,O
duration,3949,O
of,3949,O
levodopa,3949,B-Chemical
therapy,3949,O
",",3949,O
total,3949,O
daily,3949,O
levodopa,3949,B-Chemical
dose,3949,O
",",3949,O
and,3949,O
onset,3949,O
age,3949,O
.,3949,O
An,3950,O
unexpected,3950,O
diagnosis,3950,O
in,3950,O
a,3950,O
renal-transplant,3950,O
patient,3950,O
with,3950,O
proteinuria,3950,B-Disease
treated,3950,O
with,3950,O
everolimus,3950,B-Chemical
:,3950,O
AL,3950,B-Disease
amyloidosis,3950,B-Disease
.,3950,O
Proteinuria,3951,B-Disease
is,3951,O
an,3951,O
expected,3951,O
complication,3951,O
in,3951,O
transplant,3951,O
patients,3951,O
treated,3951,O
with,3951,O
mammalian,3951,O
target,3951,O
of,3951,O
rapamycin,3951,B-Chemical
inhibitors,3951,O
(,3951,O
mTOR-i,3951,O
),3951,O
.,3951,O
However,3952,O
",",3952,O
clinical,3952,O
suspicion,3952,O
should,3952,O
always,3952,O
be,3952,O
supported,3952,O
by,3952,O
histological,3952,O
evidence,3952,O
in,3952,O
order,3952,O
to,3952,O
investigate,3952,O
potential,3952,O
alternate,3952,O
diagnoses,3952,O
such,3952,O
as,3952,O
acute,3952,O
or,3952,O
chronic,3952,O
rejection,3952,O
",",3952,O
interstitial,3952,O
fibrosis,3952,B-Disease
and,3952,O
tubular,3952,O
atrophy,3952,B-Disease
",",3952,O
or,3952,O
recurrent,3952,O
or,3952,O
de,3952,O
novo,3952,O
glomerulopathy,3952,B-Disease
.,3952,O
In,3953,O
this,3953,O
case,3953,O
we,3953,O
report,3953,O
the,3953,O
unexpected,3953,O
diagnosis,3953,O
of,3953,O
amyloidosis,3953,B-Disease
in,3953,O
a,3953,O
renal-transplant,3953,O
patient,3953,O
with,3953,O
pre-transplant,3953,O
monoclonal,3953,O
gammapathy,3953,O
of,3953,O
undetermined,3953,O
significance,3953,O
who,3953,O
developed,3953,O
proteinuria,3953,B-Disease
after,3953,O
conversion,3953,O
from,3953,O
tacrolimus,3953,B-Chemical
to,3953,O
everolimus,3953,B-Chemical
.,3953,O
Long-term,3954,O
oral,3954,O
galactose,3954,B-Chemical
treatment,3954,O
prevents,3954,O
cognitive,3954,B-Disease
deficits,3954,I-Disease
in,3954,O
male,3954,O
Wistar,3954,O
rats,3954,O
treated,3954,O
intracerebroventricularly,3954,O
with,3954,O
streptozotocin,3954,B-Chemical
.,3954,O
Basic,3955,O
and,3955,O
clinical,3955,O
research,3955,O
has,3955,O
demonstrated,3955,O
that,3955,O
dementia,3955,B-Disease
of,3955,O
sporadic,3955,O
Alzheimer,3955,B-Disease
's,3955,I-Disease
disease,3955,I-Disease
(,3955,O
sAD,3955,O
),3955,O
type,3955,O
is,3955,O
associated,3955,O
with,3955,O
dysfunction,3955,O
of,3955,O
the,3955,O
insulin-receptor,3955,O
(,3955,O
IR,3955,O
),3955,O
system,3955,O
followed,3955,O
by,3955,O
decreased,3955,O
glucose,3955,B-Chemical
transport,3955,O
via,3955,O
glucose,3955,B-Chemical
transporter,3955,O
GLUT4,3955,O
and,3955,O
decreased,3955,O
glucose,3955,B-Chemical
metabolism,3955,O
in,3955,O
brain,3955,O
cells,3955,O
.,3955,O
An,3956,O
alternative,3956,O
source,3956,O
of,3956,O
energy,3956,O
is,3956,O
d-galactose,3956,B-Chemical
(,3956,O
the,3956,O
C-4-epimer,3956,O
of,3956,O
d-glucose,3956,B-Chemical
),3956,O
which,3956,O
is,3956,O
transported,3956,O
into,3956,O
the,3956,O
brain,3956,O
by,3956,O
insulin-independent,3956,O
GLUT3,3956,O
transporter,3956,O
where,3956,O
it,3956,O
might,3956,O
be,3956,O
metabolized,3956,O
to,3956,O
glucose,3956,B-Chemical
via,3956,O
the,3956,O
Leloir,3956,O
pathway,3956,O
.,3956,O
Exclusively,3957,O
parenteral,3957,O
daily,3957,O
injections,3957,O
of,3957,O
galactose,3957,B-Chemical
induce,3957,O
memory,3957,B-Disease
deterioration,3957,I-Disease
in,3957,O
rodents,3957,O
and,3957,O
are,3957,O
used,3957,O
to,3957,O
generate,3957,O
animal,3957,O
aging,3957,O
model,3957,O
",",3957,O
but,3957,O
the,3957,O
effects,3957,O
of,3957,O
oral,3957,O
galactose,3957,B-Chemical
treatment,3957,O
on,3957,O
cognitive,3957,O
functions,3957,O
have,3957,O
never,3957,O
been,3957,O
tested,3957,O
.,3957,O
We,3958,O
have,3958,O
investigated,3958,O
the,3958,O
effects,3958,O
of,3958,O
continuous,3958,O
daily,3958,O
oral,3958,O
galactose,3958,B-Chemical
(,3958,O
200,3958,O
mg/kg/day,3958,O
),3958,O
treatment,3958,O
on,3958,O
cognitive,3958,B-Disease
deficits,3958,I-Disease
in,3958,O
streptozotocin-induced,3958,B-Chemical
(,3958,O
STZ-icv,3958,B-Chemical
),3958,O
rat,3958,O
model,3958,O
of,3958,O
sAD,3958,O
",",3958,O
tested,3958,O
by,3958,O
Morris,3958,O
Water,3958,O
Maze,3958,O
and,3958,O
Passive,3958,O
Avoidance,3958,O
test,3958,O
",",3958,O
respectively,3958,O
.,3958,O
One,3959,O
month,3959,O
of,3959,O
oral,3959,O
galactose,3959,B-Chemical
treatment,3959,O
initiated,3959,O
immediately,3959,O
after,3959,O
the,3959,O
STZ-icv,3959,B-Chemical
administration,3959,O
",",3959,O
successfully,3959,O
prevented,3959,O
development,3959,O
of,3959,O
the,3959,O
STZ-icv-induced,3959,B-Chemical
cognitive,3959,B-Disease
deficits,3959,I-Disease
.,3959,O
Beneficial,3960,O
effect,3960,O
of,3960,O
oral,3960,O
galactose,3960,B-Chemical
was,3960,O
independent,3960,O
of,3960,O
the,3960,O
rat,3960,O
age,3960,O
and,3960,O
of,3960,O
the,3960,O
galactose,3960,B-Chemical
dose,3960,O
ranging,3960,O
from,3960,O
100,3960,O
to,3960,O
300,3960,O
mg/kg/day,3960,O
.,3960,O
Additionally,3961,O
",",3961,O
oral,3961,O
galactose,3961,B-Chemical
administration,3961,O
led,3961,O
to,3961,O
the,3961,O
appearance,3961,O
of,3961,O
galactose,3961,B-Chemical
in,3961,O
the,3961,O
blood,3961,O
.,3961,O
The,3962,O
increase,3962,O
of,3962,O
galactose,3962,B-Chemical
concentration,3962,O
in,3962,O
the,3962,O
cerebrospinal,3962,O
fluid,3962,O
was,3962,O
several,3962,O
times,3962,O
lower,3962,O
after,3962,O
oral,3962,O
than,3962,O
after,3962,O
parenteral,3962,O
administration,3962,O
of,3962,O
the,3962,O
same,3962,O
galactose,3962,B-Chemical
dose,3962,O
.,3962,O
Oral,3963,O
galactose,3963,B-Chemical
exposure,3963,O
might,3963,O
have,3963,O
beneficial,3963,O
effects,3963,O
on,3963,O
learning,3963,O
and,3963,O
memory,3963,O
ability,3963,O
and,3963,O
could,3963,O
be,3963,O
worth,3963,O
investigating,3963,O
for,3963,O
improvement,3963,O
of,3963,O
cognitive,3963,B-Disease
deficits,3963,I-Disease
associated,3963,O
with,3963,O
glucose,3963,B-Disease
hypometabolism,3963,I-Disease
in,3963,O
AD,3963,B-Disease
.,3963,O
An,3964,O
investigation,3964,O
of,3964,O
the,3964,O
pattern,3964,O
of,3964,O
kidney,3964,B-Disease
injury,3964,I-Disease
in,3964,O
HIV-positive,3964,O
persons,3964,O
exposed,3964,O
to,3964,O
tenofovir,3964,B-Chemical
disoproxil,3964,I-Chemical
fumarate,3964,I-Chemical
:,3964,O
an,3964,O
examination,3964,O
of,3964,O
a,3964,O
large,3964,O
population,3964,O
database,3964,O
(,3964,O
MHRA,3964,O
database,3964,O
),3964,O
.,3964,O
The,3965,O
potential,3965,O
for,3965,O
tenofovir,3965,B-Chemical
to,3965,O
cause,3965,O
a,3965,O
range,3965,O
of,3965,O
kidney,3965,O
syndromes,3965,O
has,3965,O
been,3965,O
established,3965,O
from,3965,O
mechanistic,3965,O
and,3965,O
randomised,3965,O
clinical,3965,O
trials,3965,O
.,3965,O
However,3966,O
",",3966,O
the,3966,O
exact,3966,O
pattern,3966,O
of,3966,O
kidney,3966,O
involvement,3966,O
is,3966,O
still,3966,O
uncertain,3966,O
.,3966,O
We,3967,O
undertook,3967,O
a,3967,O
descriptive,3967,O
analysis,3967,O
of,3967,O
Yellow,3967,O
Card,3967,O
records,3967,O
of,3967,O
407,3967,O
HIV-positive,3967,O
persons,3967,O
taking,3967,O
tenofovir,3967,B-Chemical
disoproxil,3967,I-Chemical
fumarate,3967,I-Chemical
(,3967,O
TDF,3967,B-Chemical
),3967,O
as,3967,O
part,3967,O
of,3967,O
their,3967,O
antiretroviral,3967,O
therapy,3967,O
regimen,3967,O
and,3967,O
submitted,3967,O
to,3967,O
the,3967,O
Medicines,3967,O
and,3967,O
Healthcare,3967,O
Products,3967,O
Regulatory,3967,O
Agency,3967,O
(,3967,O
MHRA,3967,O
),3967,O
with,3967,O
suspected,3967,O
kidney,3967,O
adverse,3967,O
effects,3967,O
.,3967,O
Reports,3968,O
that,3968,O
satisfy,3968,O
defined,3968,O
criteria,3968,O
were,3968,O
classified,3968,O
as,3968,O
acute,3968,B-Disease
kidney,3968,I-Disease
injury,3968,I-Disease
",",3968,O
kidney,3968,B-Disease
tubular,3968,I-Disease
dysfunction,3968,I-Disease
and,3968,O
Fanconi,3968,B-Disease
syndrome,3968,I-Disease
.,3968,O
Of,3969,O
the,3969,O
407,3969,O
Yellow,3969,O
Card,3969,O
records,3969,O
analysed,3969,O
",",3969,O
106,3969,O
satisfied,3969,O
criteria,3969,O
for,3969,O
TDF-related,3969,B-Chemical
kidney,3969,B-Disease
disease,3969,I-Disease
",",3969,O
of,3969,O
which,3969,O
53,3969,O
(,3969,O
50,3969,O
%,3969,O
),3969,O
had,3969,O
features,3969,O
of,3969,O
kidney,3969,B-Disease
tubular,3969,I-Disease
dysfunction,3969,I-Disease
",",3969,O
35,3969,O
(,3969,O
33,3969,O
%,3969,O
),3969,O
were,3969,O
found,3969,O
to,3969,O
have,3969,O
features,3969,O
of,3969,O
glomerular,3969,B-Disease
dysfunction,3969,I-Disease
and,3969,O
18,3969,O
(,3969,O
17,3969,O
%,3969,O
),3969,O
had,3969,O
Fanconi,3969,B-Disease
syndrome,3969,I-Disease
.,3969,O
The,3970,O
median,3970,O
TDF,3970,B-Chemical
exposure,3970,O
was,3970,O
316,3970,O
days,3970,O
(,3970,O
interquartile,3970,O
range,3970,O
120-740,3970,O
),3970,O
.,3970,O
The,3971,O
incidence,3971,O
of,3971,O
hospitalisation,3971,O
for,3971,O
TDF,3971,B-Chemical
kidney,3971,O
adverse,3971,O
effects,3971,O
was,3971,O
high,3971,O
",",3971,O
particularly,3971,O
amongst,3971,O
patients,3971,O
with,3971,O
features,3971,O
of,3971,O
Fanconi,3971,B-Disease
syndrome,3971,I-Disease
.,3971,O
The,3972,O
pattern,3972,O
of,3972,O
kidney,3972,O
syndromes,3972,O
in,3972,O
this,3972,O
population,3972,O
series,3972,O
mirrors,3972,O
that,3972,O
reported,3972,O
in,3972,O
randomised,3972,O
clinical,3972,O
trials,3972,O
.,3972,O
Cessation,3973,O
of,3973,O
TDF,3973,B-Chemical
was,3973,O
associated,3973,O
with,3973,O
complete,3973,O
restoration,3973,O
of,3973,O
kidney,3973,O
function,3973,O
in,3973,O
up,3973,O
half,3973,O
of,3973,O
the,3973,O
patients,3973,O
in,3973,O
this,3973,O
report,3973,O
.,3973,O
Incidence,3974,O
of,3974,O
postoperative,3974,B-Disease
delirium,3974,I-Disease
is,3974,O
high,3974,O
even,3974,O
in,3974,O
a,3974,O
population,3974,O
without,3974,O
known,3974,O
risk,3974,O
factors,3974,O
.,3974,O
PURPOSE,3975,O
:,3975,O
Postoperative,3975,B-Disease
delirium,3975,I-Disease
is,3975,O
a,3975,O
recognized,3975,O
complication,3975,O
in,3975,O
populations,3975,O
at,3975,O
risk,3975,O
.,3975,O
The,3976,O
aim,3976,O
of,3976,O
this,3976,O
study,3976,O
is,3976,O
to,3976,O
assess,3976,O
the,3976,O
prevalence,3976,O
of,3976,O
early,3976,O
postoperative,3976,B-Disease
delirium,3976,I-Disease
in,3976,O
a,3976,O
population,3976,O
without,3976,O
known,3976,O
risk,3976,O
factors,3976,O
admitted,3976,O
to,3976,O
the,3976,O
ICU,3976,O
for,3976,O
postoperative,3976,O
monitoring,3976,O
after,3976,O
elective,3976,O
major,3976,O
surgery,3976,O
.,3976,O
The,3977,O
secondary,3977,O
outcome,3977,O
investigated,3977,O
is,3977,O
to,3977,O
identify,3977,O
eventual,3977,O
independent,3977,O
risk,3977,O
factors,3977,O
among,3977,O
demographic,3977,O
data,3977,O
and,3977,O
anesthetic,3977,O
drugs,3977,O
used,3977,O
.,3977,O
METHODS,3978,O
:,3978,O
An,3978,O
observational,3978,O
",",3978,O
prospective,3978,O
study,3978,O
was,3978,O
conducted,3978,O
on,3978,O
a,3978,O
consecutive,3978,O
cohort,3978,O
of,3978,O
patients,3978,O
admitted,3978,O
to,3978,O
our,3978,O
ICU,3978,O
within,3978,O
and,3978,O
for,3978,O
at,3978,O
least,3978,O
24,3978,O
h,3978,O
after,3978,O
major,3978,O
surgical,3978,O
procedures,3978,O
.,3978,O
Exclusion,3979,O
criteria,3979,O
were,3979,O
any,3979,O
preexisting,3979,O
predisposing,3979,O
factor,3979,O
for,3979,O
delirium,3979,B-Disease
or,3979,O
other,3979,O
potentially,3979,O
confounding,3979,O
neurological,3979,B-Disease
dysfunctions,3979,I-Disease
.,3979,O
Patients,3980,O
were,3980,O
assessed,3980,O
daily,3980,O
using,3980,O
the,3980,O
confusion,3980,B-Disease
assessment,3980,O
method,3980,O
for,3980,O
the,3980,O
ICU,3980,O
scale,3980,O
for,3980,O
3,3980,O
days,3980,O
after,3980,O
the,3980,O
surgical,3980,O
procedure,3980,O
.,3980,O
Early,3981,O
postoperative,3981,B-Disease
delirium,3981,I-Disease
incidence,3981,O
risk,3981,O
factors,3981,O
were,3981,O
then,3981,O
assessed,3981,O
through,3981,O
three,3981,O
different,3981,O
multiple,3981,O
regression,3981,O
models,3981,O
.,3981,O
RESULTS,3982,O
:,3982,O
According,3982,O
to,3982,O
the,3982,O
confusion,3982,O
assessment,3982,O
method,3982,O
for,3982,O
the,3982,O
ICU,3982,O
scale,3982,O
",",3982,O
28,3982,O
%,3982,O
of,3982,O
patients,3982,O
were,3982,O
diagnosed,3982,O
with,3982,O
early,3982,O
postoperative,3982,B-Disease
delirium,3982,I-Disease
.,3982,O
The,3983,O
use,3983,O
of,3983,O
thiopentone,3983,B-Chemical
was,3983,O
significantly,3983,O
associated,3983,O
with,3983,O
an,3983,O
eight-fold-higher,3983,O
risk,3983,O
for,3983,O
delirium,3983,B-Disease
compared,3983,O
to,3983,O
propofol,3983,B-Chemical
(,3983,O
57.1,3983,O
%,3983,O
vs.,3983,O
7.1,3983,O
%,3983,O
",",3983,O
RR,3983,O
=,3983,O
8.0,3983,O
",",3983,O
X2,3983,O
=,3983,O
4.256,3983,O
;,3983,O
df,3983,O
=,3983,O
1,3983,O
;,3983,O
0.05,3983,O
<,3983,O
p,3983,O
<,3983,O
0.02,3983,O
),3983,O
.,3983,O
CONCLUSION,3984,O
:,3984,O
In,3984,O
this,3984,O
study,3984,O
early,3984,O
postoperative,3984,B-Disease
delirium,3984,I-Disease
was,3984,O
found,3984,O
to,3984,O
be,3984,O
a,3984,O
very,3984,O
common,3984,O
complication,3984,O
after,3984,O
major,3984,O
surgery,3984,O
",",3984,O
even,3984,O
in,3984,O
a,3984,O
population,3984,O
without,3984,O
known,3984,O
risk,3984,O
factors,3984,O
.,3984,O
Thiopentone,3985,B-Chemical
was,3985,O
independently,3985,O
associated,3985,O
with,3985,O
an,3985,O
increase,3985,O
in,3985,O
its,3985,O
relative,3985,O
risk,3985,O
.,3985,O
A,3986,O
single,3986,O
neurotoxic,3986,B-Disease
dose,3986,O
of,3986,O
methamphetamine,3986,B-Chemical
induces,3986,O
a,3986,O
long-lasting,3986,O
depressive-like,3986,B-Disease
behaviour,3986,O
in,3986,O
mice,3986,O
.,3986,O
Methamphetamine,3987,B-Chemical
(,3987,O
METH,3987,B-Chemical
),3987,O
triggers,3987,O
a,3987,O
disruption,3987,O
of,3987,O
the,3987,O
monoaminergic,3987,O
system,3987,O
and,3987,O
METH,3987,B-Chemical
abuse,3987,O
leads,3987,O
to,3987,O
negative,3987,O
emotional,3987,O
states,3987,O
including,3987,O
depressive,3987,B-Disease
symptoms,3987,I-Disease
during,3987,O
drug,3987,O
withdrawal,3987,O
.,3987,O
However,3988,O
",",3988,O
it,3988,O
is,3988,O
currently,3988,O
unknown,3988,O
if,3988,O
the,3988,O
acute,3988,O
toxic,3988,O
dosage,3988,O
of,3988,O
METH,3988,B-Chemical
also,3988,O
causes,3988,O
a,3988,O
long-lasting,3988,O
depressive,3988,B-Disease
phenotype,3988,O
and,3988,O
persistent,3988,O
monoaminergic,3988,O
deficits,3988,O
.,3988,O
Thus,3989,O
",",3989,O
we,3989,O
now,3989,O
assessed,3989,O
the,3989,O
depressive-like,3989,B-Disease
behaviour,3989,O
in,3989,O
mice,3989,O
at,3989,O
early,3989,O
and,3989,O
long-term,3989,O
periods,3989,O
following,3989,O
a,3989,O
single,3989,O
high,3989,O
METH,3989,B-Chemical
dose,3989,O
(,3989,O
30,3989,O
mg/kg,3989,O
",",3989,O
i.p,3989,O
.,3989,O
),3989,O
.,3989,O
METH,3990,B-Chemical
did,3990,O
not,3990,O
alter,3990,O
the,3990,O
motor,3990,O
function,3990,O
and,3990,O
procedural,3990,O
memory,3990,O
of,3990,O
mice,3990,O
as,3990,O
assessed,3990,O
by,3990,O
swimming,3990,O
speed,3990,O
and,3990,O
escape,3990,O
latency,3990,O
to,3990,O
find,3990,O
the,3990,O
platform,3990,O
in,3990,O
a,3990,O
cued,3990,O
version,3990,O
of,3990,O
the,3990,O
water,3990,O
maze,3990,O
task,3990,O
.,3990,O
However,3991,O
",",3991,O
METH,3991,B-Chemical
significantly,3991,O
increased,3991,O
the,3991,O
immobility,3991,O
time,3991,O
in,3991,O
the,3991,O
tail,3991,O
suspension,3991,O
test,3991,O
at,3991,O
3,3991,O
and,3991,O
49,3991,O
days,3991,O
post-administration,3991,O
.,3991,O
This,3992,O
depressive-like,3992,B-Disease
profile,3992,O
induced,3992,O
by,3992,O
METH,3992,B-Chemical
was,3992,O
accompanied,3992,O
by,3992,O
a,3992,O
marked,3992,O
depletion,3992,O
of,3992,O
frontostriatal,3992,O
dopaminergic,3992,O
and,3992,O
serotonergic,3992,O
neurotransmission,3992,O
",",3992,O
indicated,3992,O
by,3992,O
a,3992,O
reduction,3992,O
in,3992,O
the,3992,O
levels,3992,O
of,3992,O
dopamine,3992,B-Chemical
",",3992,O
DOPAC,3992,B-Chemical
and,3992,O
HVA,3992,B-Chemical
",",3992,O
tyrosine,3992,B-Chemical
hydroxylase,3992,O
and,3992,O
serotonin,3992,B-Chemical
",",3992,O
observed,3992,O
at,3992,O
both,3992,O
3,3992,O
and,3992,O
49,3992,O
days,3992,O
post-administration,3992,O
.,3992,O
In,3993,O
parallel,3993,O
",",3993,O
another,3993,O
neurochemical,3993,O
feature,3993,O
of,3993,O
depression,3993,B-Disease
--,3993,O
astroglial,3993,O
dysfunction,3993,O
--,3993,O
was,3993,O
unaffected,3993,O
in,3993,O
the,3993,O
cortex,3993,O
and,3993,O
the,3993,O
striatal,3993,O
levels,3993,O
of,3993,O
the,3993,O
astrocytic,3993,O
protein,3993,O
marker,3993,O
",",3993,O
glial,3993,O
fibrillary,3993,O
acidic,3993,O
protein,3993,O
",",3993,O
were,3993,O
only,3993,O
transiently,3993,O
increased,3993,O
at,3993,O
3,3993,O
days,3993,O
.,3993,O
These,3994,O
findings,3994,O
demonstrate,3994,O
for,3994,O
the,3994,O
first,3994,O
time,3994,O
that,3994,O
a,3994,O
single,3994,O
high,3994,O
dose,3994,O
of,3994,O
METH,3994,B-Chemical
induces,3994,O
long-lasting,3994,O
depressive-like,3994,B-Disease
behaviour,3994,O
in,3994,O
mice,3994,O
associated,3994,O
with,3994,O
a,3994,O
persistent,3994,O
disruption,3994,O
of,3994,O
frontostriatal,3994,O
dopaminergic,3994,O
and,3994,O
serotonergic,3994,O
homoeostasis,3994,O
.,3994,O
Linezolid-induced,3995,B-Chemical
optic,3995,B-Disease
neuropathy,3995,I-Disease
.,3995,O
Many,3996,O
systemic,3996,O
antimicrobials,3996,O
have,3996,O
been,3996,O
implicated,3996,O
to,3996,O
cause,3996,O
ocular,3996,O
adverse,3996,O
effects,3996,O
.,3996,O
This,3997,O
is,3997,O
especially,3997,O
relevant,3997,O
in,3997,O
multidrug,3997,O
therapy,3997,O
where,3997,O
more,3997,O
than,3997,O
one,3997,O
drug,3997,O
can,3997,O
cause,3997,O
a,3997,O
similar,3997,O
ocular,3997,O
adverse,3997,O
effect,3997,O
.,3997,O
We,3998,O
describe,3998,O
a,3998,O
case,3998,O
of,3998,O
progressive,3998,O
loss,3998,B-Disease
of,3998,I-Disease
vision,3998,I-Disease
associated,3998,O
with,3998,O
linezolid,3998,B-Chemical
therapy,3998,O
.,3998,O
A,3999,O
45-year-old,3999,O
male,3999,O
patient,3999,O
who,3999,O
was,3999,O
on,3999,O
treatment,3999,O
with,3999,O
multiple,3999,O
second-line,3999,O
anti-tuberculous,3999,O
drugs,3999,O
including,3999,O
linezolid,3999,B-Chemical
and,3999,O
ethambutol,3999,B-Chemical
for,3999,O
extensively,3999,B-Disease
drug-resistant,3999,I-Disease
tuberculosis,3999,I-Disease
(,3999,O
XDR-TB,3999,B-Disease
),3999,O
presented,3999,O
to,3999,O
us,3999,O
with,3999,O
painless,3999,O
progressive,3999,O
loss,3999,B-Disease
of,3999,I-Disease
vision,3999,I-Disease
in,3999,O
both,3999,O
eyes,3999,O
.,3999,O
Color,4000,O
vision,4000,O
was,4000,O
defective,4000,O
and,4000,O
fundus,4000,O
examination,4000,O
revealed,4000,O
optic,4000,B-Disease
disc,4000,I-Disease
edema,4000,I-Disease
in,4000,O
both,4000,O
eyes,4000,O
.,4000,O
Ethambutol-induced,4001,B-Chemical
toxic,4001,B-Disease
optic,4001,I-Disease
neuropathy,4001,I-Disease
was,4001,O
suspected,4001,O
and,4001,O
tablet,4001,O
ethambutol,4001,B-Chemical
was,4001,O
withdrawn,4001,O
.,4001,O
Deterioration,4002,B-Disease
of,4002,I-Disease
vision,4002,I-Disease
occurred,4002,O
despite,4002,O
withdrawal,4002,O
of,4002,O
ethambutol,4002,B-Chemical
.,4002,O
Discontinuation,4003,O
of,4003,O
linezolid,4003,B-Chemical
resulted,4003,O
in,4003,O
marked,4003,O
improvement,4003,O
of,4003,O
vision,4003,O
.,4003,O
Our,4004,O
report,4004,O
emphasizes,4004,O
the,4004,O
need,4004,O
for,4004,O
monitoring,4004,O
of,4004,O
visual,4004,O
function,4004,O
in,4004,O
patients,4004,O
on,4004,O
long-term,4004,O
linezolid,4004,B-Chemical
treatment,4004,O
.,4004,O
Resuscitation,4005,O
with,4005,O
lipid,4005,O
",",4005,O
epinephrine,4005,B-Chemical
",",4005,O
or,4005,O
both,4005,O
in,4005,O
levobupivacaine-induced,4005,B-Chemical
cardiac,4005,B-Disease
toxicity,4005,I-Disease
in,4005,O
newborn,4005,O
piglets,4005,O
.,4005,O
BACKGROUND,4006,O
:,4006,O
The,4006,O
optimal,4006,O
dosing,4006,O
regimens,4006,O
of,4006,O
lipid,4006,O
emulsion,4006,O
",",4006,O
epinephrine,4006,B-Chemical
",",4006,O
or,4006,O
both,4006,O
are,4006,O
not,4006,O
yet,4006,O
determined,4006,O
in,4006,O
neonates,4006,O
in,4006,O
cases,4006,O
of,4006,O
local,4006,O
anaesthetic,4006,O
systemic,4006,O
toxicity,4006,B-Disease
(,4006,O
LAST,4006,O
),4006,O
.,4006,O
METHODS,4007,O
:,4007,O
Newborn,4007,O
piglets,4007,O
received,4007,O
levobupivacaine,4007,B-Chemical
until,4007,O
cardiovascular,4007,B-Disease
collapse,4007,I-Disease
occurred,4007,O
.,4007,O
Standard,4008,O
cardiopulmonary,4008,O
resuscitation,4008,O
was,4008,O
started,4008,O
and,4008,O
electrocardiogram,4008,O
(,4008,O
ECG,4008,O
),4008,O
was,4008,O
monitored,4008,O
for,4008,O
ventricular,4008,B-Disease
tachycardia,4008,I-Disease
",",4008,O
fibrillation,4008,B-Disease
",",4008,O
or,4008,O
QRS,4008,O
prolongation,4008,O
.,4008,O
Piglets,4009,O
were,4009,O
then,4009,O
randomly,4009,O
allocated,4009,O
to,4009,O
four,4009,O
groups,4009,O
:,4009,O
control,4009,O
(,4009,O
saline,4009,O
),4009,O
",",4009,O
Intralipid,4009,O
(,4009,O
),4009,O
alone,4009,O
",",4009,O
epinephrine,4009,B-Chemical
alone,4009,O
",",4009,O
or,4009,O
a,4009,O
combination,4009,O
of,4009,O
Intralipd,4009,O
plus,4009,O
epinephrine,4009,B-Chemical
.,4009,O
Resuscitation,4010,O
continued,4010,O
for,4010,O
30,4010,O
min,4010,O
or,4010,O
until,4010,O
there,4010,O
was,4010,O
a,4010,O
return,4010,O
of,4010,O
spontaneous,4010,O
circulation,4010,O
(,4010,O
ROSC,4010,O
),4010,O
accompanied,4010,O
by,4010,O
a,4010,O
mean,4010,O
arterial,4010,O
pressure,4010,O
at,4010,O
or,4010,O
superior,4010,O
to,4010,O
the,4010,O
baseline,4010,O
pressure,4010,O
and,4010,O
normal,4010,O
sinus,4010,O
rhythm,4010,O
for,4010,O
a,4010,O
period,4010,O
of,4010,O
30,4010,O
min,4010,O
.,4010,O
RESULTS,4011,O
:,4011,O
ROSC,4011,O
was,4011,O
achieved,4011,O
in,4011,O
only,4011,O
one,4011,O
of,4011,O
the,4011,O
control,4011,O
piglets,4011,O
compared,4011,O
with,4011,O
most,4011,O
of,4011,O
the,4011,O
treated,4011,O
piglets,4011,O
.,4011,O
Mortality,4012,O
was,4012,O
not,4012,O
significantly,4012,O
different,4012,O
between,4012,O
the,4012,O
three,4012,O
treatment,4012,O
groups,4012,O
",",4012,O
but,4012,O
was,4012,O
significantly,4012,O
lower,4012,O
in,4012,O
all,4012,O
the,4012,O
treatment,4012,O
groups,4012,O
compared,4012,O
with,4012,O
control,4012,O
.,4012,O
The,4013,O
number,4013,O
of,4013,O
ECG,4013,O
abnormalities,4013,O
was,4013,O
zero,4013,O
in,4013,O
the,4013,O
Intralipid,4013,O
only,4013,O
group,4013,O
",",4013,O
but,4013,O
14,4013,O
and,4013,O
17,4013,O
",",4013,O
respectively,4013,O
",",4013,O
in,4013,O
the,4013,O
epinephrine,4013,B-Chemical
and,4013,O
epinephrine,4013,B-Chemical
plus,4013,O
lipid,4013,O
groups,4013,O
(,4013,O
P,4013,O
<,4013,O
0.05,4013,O
),4013,O
.,4013,O
CONCLUSIONS,4014,O
:,4014,O
Lipid,4014,O
emulsion,4014,O
with,4014,O
or,4014,O
without,4014,O
epinephrine,4014,B-Chemical
",",4014,O
or,4014,O
epinephrine,4014,B-Chemical
alone,4014,O
were,4014,O
equally,4014,O
effective,4014,O
in,4014,O
achieving,4014,O
a,4014,O
return,4014,O
to,4014,O
spontaneous,4014,O
circulation,4014,O
in,4014,O
this,4014,O
model,4014,O
of,4014,O
LAST,4014,O
.,4014,O
Epinephrine,4015,B-Chemical
alone,4015,O
or,4015,O
in,4015,O
combination,4015,O
with,4015,O
lipid,4015,O
was,4015,O
associated,4015,O
with,4015,O
an,4015,O
increased,4015,O
number,4015,O
of,4015,O
ECG,4015,O
abnormalities,4015,O
compared,4015,O
with,4015,O
lipid,4015,O
emulsion,4015,O
alone,4015,O
.,4015,O
Incidence,4016,O
of,4016,O
heparin-induced,4016,B-Chemical
thrombocytopenia,4016,B-Disease
type,4016,I-Disease
II,4016,I-Disease
and,4016,O
postoperative,4016,O
recovery,4016,O
of,4016,O
platelet,4016,O
count,4016,O
in,4016,O
liver,4016,O
graft,4016,O
recipients,4016,O
:,4016,O
a,4016,O
retrospective,4016,O
cohort,4016,O
analysis,4016,O
.,4016,O
BACKGROUND,4017,O
:,4017,O
Thrombocytopenia,4017,B-Disease
in,4017,O
patients,4017,O
with,4017,O
end-stage,4017,B-Disease
liver,4017,I-Disease
disease,4017,I-Disease
is,4017,O
a,4017,O
common,4017,O
disorder,4017,O
caused,4017,O
mainly,4017,O
by,4017,O
portal,4017,B-Disease
hypertension,4017,I-Disease
",",4017,O
low,4017,O
levels,4017,O
of,4017,O
thrombopoetin,4017,O
",",4017,O
and,4017,O
endotoxemia,4017,B-Disease
.,4017,O
The,4018,O
impact,4018,O
of,4018,O
immune-mediated,4018,O
heparin-induced,4018,B-Chemical
thrombocytopenia,4018,B-Disease
type,4018,I-Disease
II,4018,I-Disease
(,4018,O
HIT,4018,B-Disease
type,4018,I-Disease
II,4018,I-Disease
),4018,O
as,4018,O
a,4018,O
cause,4018,O
of,4018,O
thrombocytopenia,4018,B-Disease
after,4018,O
liver,4018,O
transplantation,4018,O
is,4018,O
not,4018,O
yet,4018,O
understood,4018,O
",",4018,O
with,4018,O
few,4018,O
literature,4018,O
citations,4018,O
reporting,4018,O
contradictory,4018,O
results,4018,O
.,4018,O
The,4019,O
aim,4019,O
of,4019,O
our,4019,O
study,4019,O
was,4019,O
to,4019,O
demonstrate,4019,O
the,4019,O
perioperative,4019,O
course,4019,O
of,4019,O
thrombocytopenia,4019,B-Disease
after,4019,O
liver,4019,O
transplantation,4019,O
and,4019,O
determine,4019,O
the,4019,O
occurrence,4019,O
of,4019,O
clinical,4019,O
HIT,4019,B-Disease
type,4019,I-Disease
II,4019,I-Disease
.,4019,O
METHOD,4020,O
:,4020,O
We,4020,O
retrospectively,4020,O
evaluated,4020,O
the,4020,O
medical,4020,O
records,4020,O
of,4020,O
205,4020,O
consecutive,4020,O
adult,4020,O
patients,4020,O
who,4020,O
underwent,4020,O
full-size,4020,O
liver,4020,O
transplantation,4020,O
between,4020,O
January,4020,O
2006,4020,O
and,4020,O
December,4020,O
2010,4020,O
due,4020,O
to,4020,O
end-stage,4020,O
or,4020,O
malignant,4020,O
liver,4020,O
disease,4020,O
.,4020,O
Preoperative,4021,O
platelet,4021,O
count,4021,O
",",4021,O
postoperative,4021,O
course,4021,O
of,4021,O
platelets,4021,O
",",4021,O
and,4021,O
clinical,4021,O
signs,4021,O
of,4021,O
HIT,4021,B-Disease
type,4021,I-Disease
II,4021,I-Disease
were,4021,O
analyzed,4021,O
.,4021,O
RESULTS,4022,O
:,4022,O
A,4022,O
total,4022,O
of,4022,O
155,4022,O
(,4022,O
75.6,4022,O
%,4022,O
),4022,O
of,4022,O
205,4022,O
patients,4022,O
had,4022,O
thrombocytopenia,4022,B-Disease
before,4022,O
transplantation,4022,O
",",4022,O
significantly,4022,O
influenced,4022,O
by,4022,O
Model,4022,O
of,4022,O
End-Stage,4022,B-Disease
Liver,4022,I-Disease
Disease,4022,I-Disease
score,4022,O
and,4022,O
liver,4022,B-Disease
cirrhosis,4022,I-Disease
.,4022,O
The,4023,O
platelet,4023,O
count,4023,O
exceeded,4023,O
"100,000/uL",4023,O
in,4023,O
most,4023,O
of,4023,O
the,4023,O
patients,4023,O
(,4023,O
n,4023,O
=,4023,O
193,4023,O
),4023,O
at,4023,O
a,4023,O
medium,4023,O
of,4023,O
7,4023,O
d.,4023,O
Regarding,4023,O
HIT,4023,B-Disease
II,4023,I-Disease
",",4023,O
there,4023,O
were,4023,O
four,4023,O
(,4023,O
1.95,4023,O
%,4023,O
),4023,O
patients,4023,O
with,4023,O
a,4023,O
background,4023,O
of,4023,O
HIT,4023,B-Disease
type,4023,I-Disease
II,4023,I-Disease
.,4023,O
CONCLUSIONS,4024,O
:,4024,O
The,4024,O
incidence,4024,O
of,4024,O
HIT,4024,B-Disease
in,4024,O
patients,4024,O
with,4024,O
end-stage,4024,B-Disease
hepatic,4024,I-Disease
failure,4024,I-Disease
is,4024,O
",",4024,O
with,4024,O
about,4024,O
1.95,4024,O
%,4024,O
",",4024,O
rare,4024,O
.,4024,O
For,4025,O
further,4025,O
reduction,4025,O
of,4025,O
HIT,4025,B-Disease
type,4025,I-Disease
II,4025,I-Disease
",",4025,O
the,4025,O
use,4025,O
of,4025,O
intravenous,4025,O
heparin,4025,B-Chemical
should,4025,O
be,4025,O
avoided,4025,O
and,4025,O
the,4025,O
prophylactic,4025,O
anticoagulation,4025,O
should,4025,O
be,4025,O
performed,4025,O
with,4025,O
low-molecular-weight,4025,O
heparin,4025,B-Chemical
after,4025,O
normalization,4025,O
of,4025,O
platelet,4025,O
count,4025,O
.,4025,O
Takotsubo,4026,B-Disease
syndrome,4026,I-Disease
(,4026,O
or,4026,O
apical,4026,B-Disease
ballooning,4026,I-Disease
syndrome,4026,I-Disease
),4026,O
secondary,4026,O
to,4026,O
Zolmitriptan,4026,B-Chemical
.,4026,O
Takotsubo,4027,B-Disease
syndrome,4027,I-Disease
(,4027,O
TS,4027,B-Disease
),4027,O
",",4027,O
also,4027,O
known,4027,O
as,4027,O
broken,4027,B-Disease
heart,4027,I-Disease
syndrome,4027,I-Disease
",",4027,O
is,4027,O
characterized,4027,O
by,4027,O
left,4027,O
ventricle,4027,O
apical,4027,O
ballooning,4027,O
with,4027,O
elevated,4027,O
cardiac,4027,O
biomarkers,4027,O
and,4027,O
electrocardiographic,4027,O
changes,4027,O
suggestive,4027,O
of,4027,O
an,4027,O
acute,4027,B-Disease
coronary,4027,I-Disease
syndrome,4027,I-Disease
(,4027,O
ie,4027,O
",",4027,O
ST-segment,4027,O
elevation,4027,O
",",4027,O
T,4027,O
wave,4027,O
inversions,4027,O
",",4027,O
and,4027,O
pathologic,4027,O
Q,4027,O
waves,4027,O
),4027,O
.,4027,O
We,4028,O
report,4028,O
a,4028,O
case,4028,O
of,4028,O
54-year-old,4028,O
woman,4028,O
with,4028,O
medical,4028,O
history,4028,O
of,4028,O
mitral,4028,B-Disease
valve,4028,I-Disease
prolapse,4028,I-Disease
and,4028,O
migraines,4028,B-Disease
",",4028,O
who,4028,O
was,4028,O
admitted,4028,O
to,4028,O
the,4028,O
hospital,4028,O
for,4028,O
substernal,4028,O
chest,4028,B-Disease
pain,4028,I-Disease
and,4028,O
electrocardiogram,4028,O
demonstrated,4028,O
1/2,4028,O
mm,4028,O
ST-segment,4028,O
elevation,4028,O
in,4028,O
leads,4028,O
II,4028,O
",",4028,O
III,4028,O
",",4028,O
aVF,4028,O
",",4028,O
V5,4028,O
",",4028,O
and,4028,O
V6,4028,O
and,4028,O
positive,4028,O
troponin,4028,O
I.,4028,O
Emergent,4028,O
coronary,4028,O
angiogram,4028,O
revealed,4028,O
normal,4028,O
coronary,4028,O
arteries,4028,O
with,4028,O
moderately,4028,O
reduced,4028,O
left,4028,O
ventricular,4028,O
ejection,4028,O
fraction,4028,O
with,4028,O
wall,4028,O
motion,4028,O
abnormalities,4028,O
consistent,4028,O
with,4028,O
TS,4028,B-Disease
.,4028,O
Detailed,4029,O
history,4029,O
obtained,4029,O
retrospectively,4029,O
revealed,4029,O
that,4029,O
the,4029,O
patient,4029,O
took,4029,O
zolmitriptan,4029,B-Chemical
sparingly,4029,O
only,4029,O
when,4029,O
she,4029,O
had,4029,O
migraines,4029,B-Disease
.,4029,O
But,4030,O
before,4030,O
this,4030,O
event,4030,O
",",4030,O
she,4030,O
was,4030,O
taking,4030,O
zolmitriptan,4030,B-Chemical
2-3,4030,O
times,4030,O
daily,4030,O
for,4030,O
several,4030,O
days,4030,O
because,4030,O
of,4030,O
a,4030,O
persistent,4030,O
migraine,4030,B-Disease
headache,4030,I-Disease
.,4030,O
She,4031,O
otherwise,4031,O
reported,4031,O
that,4031,O
she,4031,O
is,4031,O
quite,4031,O
active,4031,O
",",4031,O
rides,4031,O
horses,4031,O
",",4031,O
and,4031,O
does,4031,O
show,4031,O
jumping,4031,O
without,4031,O
any,4031,O
limitations,4031,O
in,4031,O
her,4031,O
physical,4031,O
activity,4031,O
.,4031,O
There,4032,O
was,4032,O
no,4032,O
evidence,4032,O
of,4032,O
any,4032,O
recent,4032,O
stress,4032,O
or,4032,O
status,4032,B-Disease
migrainosus,4032,I-Disease
.,4032,O
Extensive,4033,O
literature,4033,O
search,4033,O
revealed,4033,O
multiple,4033,O
cases,4033,O
of,4033,O
coronary,4033,B-Disease
artery,4033,I-Disease
vasospasm,4033,I-Disease
secondary,4033,O
to,4033,O
zolmitriptan,4033,B-Chemical
",",4033,O
but,4033,O
none,4033,O
of,4033,O
the,4033,O
cases,4033,O
were,4033,O
associated,4033,O
with,4033,O
TS,4033,B-Disease
.,4033,O
Depression,4034,B-Disease
",",4034,O
impulsiveness,4034,B-Disease
",",4034,O
sleep,4034,O
",",4034,O
and,4034,O
memory,4034,O
in,4034,O
past,4034,O
and,4034,O
present,4034,O
polydrug,4034,O
users,4034,O
of,4034,O
"3,4-methylenedioxymethamphetamine",4034,B-Chemical
(,4034,O
MDMA,4034,B-Chemical
",",4034,O
ecstasy,4034,B-Chemical
),4034,O
.,4034,O
RATIONALE,4035,O
:,4035,O
Ecstasy,4035,B-Chemical
(,4035,O
"3,4-methylenedioxymethamphetamine",4035,B-Chemical
",",4035,O
MDMA,4035,B-Chemical
),4035,O
is,4035,O
a,4035,O
worldwide,4035,O
recreational,4035,O
drug,4035,O
of,4035,O
abuse,4035,O
.,4035,O
Unfortunately,4036,O
",",4036,O
the,4036,O
results,4036,O
from,4036,O
human,4036,O
research,4036,O
investigating,4036,O
its,4036,O
psychological,4036,O
effects,4036,O
have,4036,O
been,4036,O
inconsistent,4036,O
.,4036,O
OBJECTIVES,4037,O
:,4037,O
The,4037,O
present,4037,O
study,4037,O
aimed,4037,O
to,4037,O
be,4037,O
the,4037,O
largest,4037,O
to,4037,O
date,4037,O
in,4037,O
sample,4037,O
size,4037,O
and,4037,O
5HT-related,4037,O
behaviors,4037,O
;,4037,O
the,4037,O
first,4037,O
to,4037,O
compare,4037,O
present,4037,O
ecstasy,4037,B-Chemical
users,4037,O
with,4037,O
past,4037,O
users,4037,O
after,4037,O
an,4037,O
abstinence,4037,O
of,4037,O
4,4037,O
or,4037,O
more,4037,O
years,4037,O
",",4037,O
and,4037,O
the,4037,O
first,4037,O
to,4037,O
include,4037,O
robust,4037,O
controls,4037,O
for,4037,O
other,4037,O
recreational,4037,O
substances,4037,O
.,4037,O
METHODS,4038,O
:,4038,O
A,4038,O
sample,4038,O
of,4038,O
997,4038,O
participants,4038,O
(,4038,O
52,4038,O
%,4038,O
male,4038,O
),4038,O
was,4038,O
recruited,4038,O
to,4038,O
four,4038,O
control,4038,O
groups,4038,O
(,4038,O
non-drug,4038,O
(,4038,O
ND,4038,O
),4038,O
",",4038,O
alcohol/nicotine,4038,B-Chemical
(,4038,O
AN,4038,B-Chemical
),4038,O
",",4038,O
cannabis/alcohol/nicotine,4038,B-Chemical
(,4038,O
CAN,4038,B-Chemical
),4038,O
",",4038,O
non-ecstasy,4038,O
polydrug,4038,O
(,4038,O
PD,4038,O
),4038,O
),4038,O
",",4038,O
and,4038,O
two,4038,O
ecstasy,4038,B-Chemical
polydrug,4038,O
groups,4038,O
(,4038,O
present,4038,O
(,4038,O
MDMA,4038,B-Chemical
),4038,O
and,4038,O
past,4038,O
users,4038,O
(,4038,O
EX-MDMA,4038,O
),4038,O
.,4038,O
Participants,4039,O
completed,4039,O
a,4039,O
drug,4039,O
history,4039,O
questionnaire,4039,O
",",4039,O
Beck,4039,O
Depression,4039,B-Disease
Inventory,4039,O
",",4039,O
Barratt,4039,O
Impulsiveness,4039,B-Disease
Scale,4039,O
",",4039,O
Pittsburgh,4039,O
Sleep,4039,O
Quality,4039,O
Index,4039,O
",",4039,O
and,4039,O
Wechsler,4039,O
Memory,4039,O
Scale-Revised,4039,O
which,4039,O
",",4039,O
in,4039,O
total,4039,O
",",4039,O
provided,4039,O
13,4039,O
psychometric,4039,O
measures,4039,O
.,4039,O
RESULTS,4040,O
:,4040,O
While,4040,O
the,4040,O
CAN,4040,B-Chemical
and,4040,O
PD,4040,O
groups,4040,O
tended,4040,O
to,4040,O
record,4040,O
greater,4040,O
deficits,4040,O
than,4040,O
the,4040,O
non-drug,4040,O
controls,4040,O
",",4040,O
the,4040,O
MDMA,4040,B-Chemical
and,4040,O
EX-MDMA,4040,O
groups,4040,O
recorded,4040,O
greater,4040,O
deficits,4040,O
than,4040,O
all,4040,O
the,4040,O
control,4040,O
groups,4040,O
on,4040,O
ten,4040,O
of,4040,O
the,4040,O
13,4040,O
psychometric,4040,O
measures,4040,O
.,4040,O
Strikingly,4041,O
",",4041,O
despite,4041,O
prolonged,4041,O
abstinence,4041,O
(,4041,O
mean,4041,O
",",4041,O
4.98,4041,O
;,4041,O
range,4041,O
",",4041,O
4-9,4041,O
years,4041,O
),4041,O
",",4041,O
past,4041,O
ecstasy,4041,B-Chemical
users,4041,O
showed,4041,O
few,4041,O
signs,4041,O
of,4041,O
recovery,4041,O
.,4041,O
Compared,4042,O
with,4042,O
present,4042,O
ecstasy,4042,B-Chemical
users,4042,O
",",4042,O
the,4042,O
past,4042,O
users,4042,O
showed,4042,O
no,4042,O
change,4042,O
for,4042,O
ten,4042,O
measures,4042,O
",",4042,O
increased,4042,O
impairment,4042,O
for,4042,O
two,4042,O
measures,4042,O
",",4042,O
and,4042,O
improvement,4042,O
on,4042,O
just,4042,O
one,4042,O
measure,4042,O
.,4042,O
CONCLUSIONS,4043,O
:,4043,O
Given,4043,O
this,4043,O
record,4043,O
of,4043,O
impaired,4043,B-Disease
memory,4043,I-Disease
and,4043,O
clinically,4043,O
significant,4043,O
levels,4043,O
of,4043,O
depression,4043,B-Disease
",",4043,O
impulsiveness,4043,B-Disease
",",4043,O
and,4043,O
sleep,4043,B-Disease
disturbance,4043,I-Disease
",",4043,O
the,4043,O
prognosis,4043,O
for,4043,O
the,4043,O
current,4043,O
generation,4043,O
of,4043,O
ecstasy,4043,B-Chemical
users,4043,O
is,4043,O
a,4043,O
major,4043,O
cause,4043,O
for,4043,O
concern,4043,O
.,4043,O
Association,4044,O
of,4044,O
common,4044,O
genetic,4044,O
variants,4044,O
of,4044,O
HOMER1,4044,O
gene,4044,O
with,4044,O
levodopa,4044,B-Chemical
adverse,4044,O
effects,4044,O
in,4044,O
Parkinson,4044,B-Disease
's,4044,I-Disease
disease,4044,I-Disease
patients,4044,O
.,4044,O
Levodopa,4045,B-Chemical
is,4045,O
the,4045,O
most,4045,O
effective,4045,O
symptomatic,4045,O
therapy,4045,O
for,4045,O
Parkinson,4045,B-Disease
's,4045,I-Disease
disease,4045,I-Disease
",",4045,O
but,4045,O
its,4045,O
chronic,4045,O
use,4045,O
could,4045,O
lead,4045,O
to,4045,O
chronic,4045,O
adverse,4045,O
outcomes,4045,O
",",4045,O
such,4045,O
as,4045,O
motor,4045,O
fluctuations,4045,O
",",4045,O
dyskinesia,4045,B-Disease
and,4045,O
visual,4045,B-Disease
hallucinations,4045,I-Disease
.,4045,O
HOMER1,4046,O
is,4046,O
a,4046,O
protein,4046,O
with,4046,O
pivotal,4046,O
function,4046,O
in,4046,O
glutamate,4046,B-Chemical
transmission,4046,O
",",4046,O
which,4046,O
has,4046,O
been,4046,O
related,4046,O
to,4046,O
the,4046,O
pathogenesis,4046,O
of,4046,O
these,4046,O
complications,4046,O
.,4046,O
This,4047,O
study,4047,O
investigates,4047,O
whether,4047,O
polymorphisms,4047,O
in,4047,O
the,4047,O
HOMER1,4047,O
gene,4047,O
promoter,4047,O
region,4047,O
are,4047,O
associated,4047,O
with,4047,O
the,4047,O
occurrence,4047,O
of,4047,O
the,4047,O
chronic,4047,O
complications,4047,O
of,4047,O
levodopa,4047,B-Chemical
therapy,4047,O
.,4047,O
A,4048,O
total,4048,O
of,4048,O
205,4048,O
patients,4048,O
with,4048,O
idiopathic,4048,B-Disease
Parkinson,4048,I-Disease
's,4048,I-Disease
disease,4048,I-Disease
were,4048,O
investigated,4048,O
.,4048,O
Patients,4049,O
were,4049,O
genotyped,4049,O
for,4049,O
rs4704559,4049,O
",",4049,O
rs10942891,4049,O
and,4049,O
rs4704560,4049,O
by,4049,O
allelic,4049,O
discrimination,4049,O
with,4049,O
Taqman,4049,O
assays,4049,O
.,4049,O
The,4050,O
rs4704559,4050,O
G,4050,O
allele,4050,O
was,4050,O
associated,4050,O
with,4050,O
a,4050,O
lower,4050,O
prevalence,4050,O
of,4050,O
dyskinesia,4050,B-Disease
(,4050,O
prevalence,4050,O
ratio,4050,O
(,4050,O
PR,4050,O
),4050,O
=0.615,4050,O
",",4050,O
95,4050,O
%,4050,O
confidence,4050,O
interval,4050,O
(,4050,O
CI,4050,O
),4050,O
0.426-0.887,4050,O
",",4050,O
P=0.009,4050,O
),4050,O
and,4050,O
visual,4050,B-Disease
hallucinations,4050,I-Disease
(,4050,O
PR=0.515,4050,O
",",4050,O
95,4050,O
%,4050,O
CI,4050,O
0.295-0.899,4050,O
",",4050,O
P=0.020,4050,O
),4050,O
.,4050,O
Our,4051,O
data,4051,O
suggest,4051,O
that,4051,O
HOMER1,4051,O
rs4704559,4051,O
G,4051,O
allele,4051,O
has,4051,O
a,4051,O
protective,4051,O
role,4051,O
for,4051,O
the,4051,O
development,4051,O
of,4051,O
levodopa,4051,B-Chemical
adverse,4051,O
effects,4051,O
.,4051,O
Crocin,4052,B-Chemical
improves,4052,O
lipid,4052,O
dysregulation,4052,O
in,4052,O
subacute,4052,O
diazinon,4052,B-Chemical
exposure,4052,O
through,4052,O
ERK1/2,4052,O
pathway,4052,O
in,4052,O
rat,4052,O
liver,4052,O
.,4052,O
INTRODUCTION,4053,O
:,4053,O
Diazinon,4053,B-Chemical
Yis,4053,O
one,4053,O
of,4053,O
the,4053,O
most,4053,O
broadly,4053,O
used,4053,O
organophosphorus,4053,B-Chemical
insecticides,4053,O
in,4053,O
agriculture,4053,O
.,4053,O
It,4054,O
has,4054,O
been,4054,O
shown,4054,O
that,4054,O
exposure,4054,O
to,4054,O
diazinon,4054,B-Chemical
may,4054,O
interfere,4054,O
with,4054,O
lipid,4054,O
metabolism,4054,O
.,4054,O
Moreover,4055,O
",",4055,O
the,4055,O
hypolipidemic,4055,O
effect,4055,O
of,4055,O
crocin,4055,B-Chemical
has,4055,O
been,4055,O
established,4055,O
.,4055,O
Earlier,4056,O
studies,4056,O
revealed,4056,O
the,4056,O
major,4056,O
role,4056,O
of,4056,O
Extracellular,4056,O
signal-regulated,4056,O
kinase,4056,O
(,4056,O
ERK,4056,O
),4056,O
pathways,4056,O
in,4056,O
low-density,4056,O
lipoprotein,4056,O
receptor,4056,O
(,4056,O
LDLr,4056,O
),4056,O
expression,4056,O
.,4056,O
The,4057,O
aim,4057,O
of,4057,O
this,4057,O
study,4057,O
was,4057,O
to,4057,O
evaluate,4057,O
changes,4057,O
in,4057,O
the,4057,O
regulation,4057,O
of,4057,O
lipid,4057,O
metabolism,4057,O
",",4057,O
ERK,4057,O
and,4057,O
LDLr,4057,O
expression,4057,O
in,4057,O
the,4057,O
liver,4057,O
of,4057,O
rats,4057,O
exposed,4057,O
to,4057,O
subacute,4057,O
diazinon,4057,B-Chemical
.,4057,O
Furthermore,4058,O
ameliorating,4058,O
effect,4058,O
of,4058,O
crocin,4058,B-Chemical
on,4058,O
diazinon,4058,B-Chemical
induced,4058,O
disturbed,4058,O
cholesterol,4058,B-Chemical
homeostasis,4058,O
was,4058,O
studied,4058,O
.,4058,O
METHODS,4059,O
:,4059,O
24,4059,O
Rats,4059,O
were,4059,O
divided,4059,O
into,4059,O
4,4059,O
groups,4059,O
and,4059,O
received,4059,O
following,4059,O
treatments,4059,O
for,4059,O
4,4059,O
weeks,4059,O
;,4059,O
Corn,4059,O
oil,4059,O
(,4059,O
control,4059,O
),4059,O
",",4059,O
diazinon,4059,B-Chemical
(,4059,O
15mg/kg,4059,O
per,4059,O
day,4059,O
",",4059,O
orally,4059,O
),4059,O
and,4059,O
crocin,4059,B-Chemical
(,4059,O
12.5,4059,O
and,4059,O
25mg/kg,4059,O
per,4059,O
day,4059,O
",",4059,O
intraperitoneally,4059,O
),4059,O
in,4059,O
combination,4059,O
with,4059,O
diazinon,4059,B-Chemical
(,4059,O
15,4059,O
mg/kg,4059,O
),4059,O
.,4059,O
The,4060,O
levels,4060,O
of,4060,O
cholesterol,4060,B-Chemical
",",4060,O
triglyceride,4060,B-Chemical
and,4060,O
LDL,4060,O
in,4060,O
blood,4060,O
of,4060,O
rats,4060,O
were,4060,O
analyzed,4060,O
.,4060,O
Moreover,4061,O
mRNA,4061,O
levels,4061,O
of,4061,O
LDLr,4061,O
and,4061,O
ERK1/2,4061,O
as,4061,O
well,4061,O
as,4061,O
protein,4061,O
levels,4061,O
of,4061,O
total,4061,O
and,4061,O
activated,4061,O
forms,4061,O
of,4061,O
ERK1/2,4061,O
in,4061,O
rat,4061,O
liver,4061,O
were,4061,O
evaluated,4061,O
by,4061,O
Western,4061,O
blotting,4061,O
and,4061,O
quantitative,4061,O
real,4061,O
time,4061,O
polymerase,4061,O
chain,4061,O
reaction,4061,O
analysis,4061,O
.,4061,O
RESULTS,4062,O
:,4062,O
Our,4062,O
data,4062,O
showed,4062,O
that,4062,O
subacute,4062,O
exposure,4062,O
to,4062,O
diazinon,4062,B-Chemical
significantly,4062,O
increased,4062,O
concentrations,4062,O
of,4062,O
cholesterol,4062,B-Chemical
",",4062,O
triglyceride,4062,B-Chemical
and,4062,O
LDL,4062,O
.,4062,O
Moreover,4063,O
diazinon,4063,B-Chemical
decreased,4063,O
ERK1/2,4063,O
protein,4063,O
phosphorylation,4063,O
and,4063,O
LDLr,4063,O
transcript,4063,O
.,4063,O
Crocin,4064,B-Chemical
reduced,4064,O
inhibition,4064,O
of,4064,O
ERK,4064,O
activation,4064,O
and,4064,O
diazinon-induced,4064,B-Chemical
hyperlipemia,4064,B-Disease
and,4064,O
increased,4064,O
levels,4064,O
of,4064,O
LDLr,4064,O
transcript,4064,O
.,4064,O
CONCLUSIONS,4065,O
:,4065,O
Crocin,4065,B-Chemical
may,4065,O
be,4065,O
considered,4065,O
as,4065,O
a,4065,O
novel,4065,O
protective,4065,O
agent,4065,O
in,4065,O
diazinon-induced,4065,B-Chemical
hyperlipemia,4065,B-Disease
through,4065,O
modulating,4065,O
of,4065,O
ERK,4065,O
pathway,4065,O
and,4065,O
increase,4065,O
of,4065,O
LDLr,4065,O
expression,4065,O
.,4065,O
GEM-P,4066,B-Chemical
chemotherapy,4066,O
is,4066,O
active,4066,O
in,4066,O
the,4066,O
treatment,4066,O
of,4066,O
relapsed,4066,O
Hodgkin,4066,B-Disease
lymphoma,4066,I-Disease
.,4066,O
Hodgkin,4067,B-Disease
lymphoma,4067,I-Disease
(,4067,O
HL,4067,B-Disease
),4067,O
is,4067,O
a,4067,O
relatively,4067,O
chemosensitive,4067,O
malignancy,4067,B-Disease
.,4067,O
However,4068,O
",",4068,O
for,4068,O
those,4068,O
who,4068,O
relapse,4068,O
",",4068,O
high-dose,4068,O
chemotherapy,4068,O
with,4068,O
autologous,4068,O
stem,4068,O
cell,4068,O
transplant,4068,O
is,4068,O
the,4068,O
treatment,4068,O
of,4068,O
choice,4068,O
which,4068,O
relies,4068,O
on,4068,O
adequate,4068,O
disease,4068,O
control,4068,O
with,4068,O
salvage,4068,O
chemotherapy,4068,O
.,4068,O
Regimens,4069,O
commonly,4069,O
used,4069,O
often,4069,O
require,4069,O
inpatient,4069,O
administration,4069,O
and,4069,O
can,4069,O
be,4069,O
difficult,4069,O
to,4069,O
deliver,4069,O
due,4069,O
to,4069,O
toxicity,4069,B-Disease
.,4069,O
Gemcitabine,4070,B-Chemical
and,4070,O
cisplatin,4070,B-Chemical
have,4070,O
activity,4070,O
in,4070,O
HL,4070,B-Disease
",",4070,O
non-overlapping,4070,O
toxicity,4070,B-Disease
with,4070,O
first-line,4070,O
chemotherapeutics,4070,O
",",4070,O
and,4070,O
may,4070,O
be,4070,O
delivered,4070,O
in,4070,O
an,4070,O
outpatient,4070,O
setting,4070,O
.,4070,O
In,4071,O
this,4071,O
retrospective,4071,O
single-centre,4071,O
analysis,4071,O
",",4071,O
patients,4071,O
with,4071,O
relapsed,4071,O
or,4071,O
refractory,4071,O
HL,4071,B-Disease
treated,4071,O
with,4071,O
gemcitabine,4071,B-Chemical
"1,000",4071,O
mg/m,4071,O
(,4071,O
2,4071,O
),4071,O
day,4071,O
(,4071,O
D,4071,O
),4071,O
1,4071,O
",",4071,O
D8,4071,O
and,4071,O
D15,4071,O
;,4071,O
methylprednisolone,4071,B-Chemical
"1,000",4071,O
mg,4071,O
D1-5,4071,O
;,4071,O
and,4071,O
cisplatin,4071,B-Chemical
100,4071,O
mg/m,4071,O
(,4071,O
2,4071,O
),4071,O
D15,4071,O
",",4071,O
every,4071,O
28,4071,O
days,4071,O
(,4071,O
GEM-P,4071,B-Chemical
),4071,O
were,4071,O
included,4071,O
.,4071,O
Demographic,4072,O
",",4072,O
survival,4072,O
",",4072,O
response,4072,O
and,4072,O
toxicity,4072,B-Disease
data,4072,O
were,4072,O
recorded,4072,O
.,4072,O
Forty-one,4073,O
eligible,4073,O
patients,4073,O
were,4073,O
identified,4073,O
:,4073,O
median,4073,O
age,4073,O
27,4073,O
.,4073,O
One,4074,O
hundred,4074,O
and,4074,O
twenty-two,4074,O
cycles,4074,O
of,4074,O
GEM-P,4074,B-Chemical
were,4074,O
administered,4074,O
in,4074,O
total,4074,O
(,4074,O
median,4074,O
3,4074,O
cycles,4074,O
;,4074,O
range,4074,O
1-6,4074,O
),4074,O
.,4074,O
Twenty,4075,O
of,4075,O
41,4075,O
(,4075,O
48,4075,O
%,4075,O
),4075,O
patients,4075,O
received,4075,O
GEM-P,4075,B-Chemical
as,4075,O
second-line,4075,O
treatment,4075,O
and,4075,O
11/41,4075,O
(,4075,O
27,4075,O
%,4075,O
),4075,O
as,4075,O
third-line,4075,O
therapy,4075,O
.,4075,O
Overall,4076,O
response,4076,O
rate,4076,O
(,4076,O
ORR,4076,O
),4076,O
to,4076,O
GEM-P,4076,B-Chemical
in,4076,O
the,4076,O
entire,4076,O
cohort,4076,O
was,4076,O
80,4076,O
%,4076,O
(,4076,O
complete,4076,O
response,4076,O
(,4076,O
CR,4076,O
),4076,O
37,4076,O
%,4076,O
",",4076,O
partial,4076,O
response,4076,O
44,4076,O
%,4076,O
),4076,O
with,4076,O
14/15,4076,O
CR,4076,O
confirmed,4076,O
as,4076,O
a,4076,O
metabolic,4076,O
CR,4076,O
on,4076,O
PET,4076,O
and,4076,O
ORR,4076,O
of,4076,O
85,4076,O
%,4076,O
in,4076,O
the,4076,O
20,4076,O
second-line,4076,O
patients,4076,O
.,4076,O
The,4077,O
most,4077,O
common,4077,O
grade,4077,O
3/4,4077,O
toxicities,4077,B-Disease
were,4077,O
haematological,4077,O
:,4077,O
neutropenia,4077,B-Disease
54,4077,O
%,4077,O
and,4077,O
thrombocytopenia,4077,B-Disease
51,4077,O
%,4077,O
.,4077,O
Median,4078,O
follow-up,4078,O
from,4078,O
the,4078,O
start,4078,O
of,4078,O
GEM-P,4078,B-Chemical
was,4078,O
4.5,4078,O
years,4078,O
.,4078,O
Following,4079,O
GEM-P,4079,B-Chemical
",",4079,O
5-year,4079,O
progression-free,4079,O
survival,4079,O
was,4079,O
46,4079,O
%,4079,O
(,4079,O
95,4079,O
%,4079,O
confidence,4079,O
interval,4079,O
(,4079,O
CI,4079,O
),4079,O
",",4079,O
30-62,4079,O
%,4079,O
),4079,O
and,4079,O
5-year,4079,O
overall,4079,O
survival,4079,O
was,4079,O
59,4079,O
%,4079,O
(,4079,O
95,4079,O
%,4079,O
CI,4079,O
",",4079,O
43-74,4079,O
%,4079,O
),4079,O
.,4079,O
Fourteen,4080,O
of,4080,O
41,4080,O
patients,4080,O
proceeded,4080,O
directly,4080,O
to,4080,O
autologous,4080,O
transplant,4080,O
.,4080,O
GEM-P,4081,B-Chemical
is,4081,O
a,4081,O
salvage,4081,O
chemotherapy,4081,O
with,4081,O
relatively,4081,O
high,4081,O
response,4081,O
rates,4081,O
",",4081,O
leading,4081,O
to,4081,O
successful,4081,O
transplantation,4081,O
in,4081,O
appropriate,4081,O
patients,4081,O
",",4081,O
in,4081,O
the,4081,O
treatment,4081,O
of,4081,O
relapsed,4081,O
or,4081,O
refractory,4081,O
HL,4081,B-Disease
.,4081,O
Basal,4082,O
functioning,4082,O
of,4082,O
the,4082,O
hypothalamic-pituitary-adrenal,4082,O
(,4082,O
HPA,4082,O
),4082,O
axis,4082,O
and,4082,O
psychological,4082,O
distress,4082,O
in,4082,O
recreational,4082,O
ecstasy,4082,B-Chemical
polydrug,4082,O
users,4082,O
.,4082,O
RATIONALE,4083,O
:,4083,O
Ecstasy,4083,B-Chemical
(,4083,O
MDMA,4083,B-Chemical
),4083,O
is,4083,O
a,4083,O
psychostimulant,4083,O
drug,4083,O
which,4083,O
is,4083,O
increasingly,4083,O
associated,4083,O
with,4083,O
psychobiological,4083,B-Disease
dysfunction,4083,I-Disease
.,4083,O
While,4084,O
some,4084,O
recent,4084,O
studies,4084,O
suggest,4084,O
acute,4084,O
changes,4084,O
in,4084,O
neuroendocrine,4084,O
function,4084,O
",",4084,O
less,4084,O
is,4084,O
known,4084,O
about,4084,O
long-term,4084,O
changes,4084,O
in,4084,O
HPA,4084,O
functionality,4084,O
in,4084,O
recreational,4084,O
users,4084,O
.,4084,O
OBJECTIVES,4085,O
:,4085,O
The,4085,O
current,4085,O
study,4085,O
is,4085,O
the,4085,O
first,4085,O
to,4085,O
explore,4085,O
the,4085,O
effects,4085,O
of,4085,O
ecstasy-polydrug,4085,B-Chemical
use,4085,O
on,4085,O
psychological,4085,O
distress,4085,O
and,4085,O
basal,4085,O
functioning,4085,O
of,4085,O
the,4085,O
HPA,4085,O
axis,4085,O
through,4085,O
assessing,4085,O
the,4085,O
secretion,4085,O
of,4085,O
cortisol,4085,B-Chemical
across,4085,O
the,4085,O
diurnal,4085,O
period,4085,O
.,4085,O
METHOD,4086,O
:,4086,O
Seventy-six,4086,O
participants,4086,O
(,4086,O
21,4086,O
nonusers,4086,O
",",4086,O
29,4086,O
light,4086,O
ecstasy-polydrug,4086,B-Chemical
users,4086,O
",",4086,O
26,4086,O
heavy,4086,O
ecstasy-polydrug,4086,B-Chemical
users,4086,O
),4086,O
completed,4086,O
a,4086,O
substance,4086,O
use,4086,O
inventory,4086,O
and,4086,O
measures,4086,O
of,4086,O
psychological,4086,O
distress,4086,O
at,4086,O
baseline,4086,O
",",4086,O
then,4086,O
two,4086,O
consecutive,4086,O
days,4086,O
of,4086,O
cortisol,4086,B-Chemical
sampling,4086,O
(,4086,O
on,4086,O
awakening,4086,O
",",4086,O
30,4086,O
min,4086,O
post,4086,O
awakening,4086,O
",",4086,O
between,4086,O
1400,4086,O
and,4086,O
1600,4086,O
hours,4086,O
and,4086,O
pre,4086,O
bedtime,4086,O
),4086,O
.,4086,O
On,4087,O
day,4087,O
2,4087,O
",",4087,O
participants,4087,O
also,4087,O
attended,4087,O
the,4087,O
laboratory,4087,O
to,4087,O
complete,4087,O
a,4087,O
20-min,4087,O
multitasking,4087,O
stressor,4087,O
.,4087,O
RESULTS,4088,O
:,4088,O
Both,4088,O
user,4088,O
groups,4088,O
exhibited,4088,O
significantly,4088,O
greater,4088,O
levels,4088,O
of,4088,O
anxiety,4088,B-Disease
and,4088,O
depression,4088,B-Disease
than,4088,O
nonusers,4088,O
.,4088,O
On,4089,O
day,4089,O
1,4089,O
",",4089,O
all,4089,O
participants,4089,O
exhibited,4089,O
a,4089,O
typical,4089,O
cortisol,4089,B-Chemical
profile,4089,O
",",4089,O
though,4089,O
light,4089,O
users,4089,O
had,4089,O
significantly,4089,O
elevated,4089,O
levels,4089,O
pre-bed,4089,O
.,4089,O
On,4090,O
day,4090,O
2,4090,O
",",4090,O
heavy,4090,O
users,4090,O
demonstrated,4090,O
elevated,4090,O
levels,4090,O
upon,4090,O
awakening,4090,O
and,4090,O
all,4090,O
ecstasy-polydrug,4090,B-Chemical
users,4090,O
demonstrated,4090,O
elevated,4090,O
pre-bed,4090,O
levels,4090,O
compared,4090,O
to,4090,O
non-users,4090,O
.,4090,O
Significant,4091,O
between,4091,O
group,4091,O
differences,4091,O
were,4091,O
also,4091,O
observed,4091,O
in,4091,O
afternoon,4091,O
cortisol,4091,B-Chemical
levels,4091,O
and,4091,O
in,4091,O
overall,4091,O
cortisol,4091,B-Chemical
secretion,4091,O
across,4091,O
the,4091,O
day,4091,O
.,4091,O
CONCLUSIONS,4092,O
:,4092,O
The,4092,O
increases,4092,O
in,4092,O
anxiety,4092,B-Disease
and,4092,O
depression,4092,B-Disease
are,4092,O
in,4092,O
line,4092,O
with,4092,O
previous,4092,O
observations,4092,O
in,4092,O
recreational,4092,O
ecstasy-polydrug,4092,B-Chemical
users,4092,O
.,4092,O
Dysregulated,4093,O
diurnal,4093,O
cortisol,4093,B-Chemical
may,4093,O
be,4093,O
indicative,4093,O
of,4093,O
inappropriate,4093,O
anticipation,4093,O
of,4093,O
forthcoming,4093,O
demands,4093,O
and,4093,O
hypersecretion,4093,O
may,4093,O
lead,4093,O
to,4093,O
the,4093,O
increased,4093,O
psychological,4093,O
and,4093,O
physical,4093,O
morbidity,4093,O
associated,4093,O
with,4093,O
heavy,4093,O
recreational,4093,O
use,4093,O
of,4093,O
ecstasy,4093,B-Chemical
.,4093,O
Ifosfamide,4094,B-Chemical
related,4094,O
encephalopathy,4094,B-Disease
:,4094,O
the,4094,O
need,4094,O
for,4094,O
a,4094,O
timely,4094,O
EEG,4094,O
evaluation,4094,O
.,4094,O
BACKGROUND,4095,O
:,4095,O
Ifosfamide,4095,B-Chemical
is,4095,O
an,4095,O
alkylating,4095,O
agent,4095,O
useful,4095,O
in,4095,O
the,4095,O
treatment,4095,O
of,4095,O
a,4095,O
wide,4095,O
range,4095,O
of,4095,O
cancers,4095,B-Disease
including,4095,O
sarcomas,4095,B-Disease
",",4095,O
lymphoma,4095,B-Disease
",",4095,O
gynecologic,4095,B-Disease
and,4095,I-Disease
testicular,4095,I-Disease
cancers,4095,I-Disease
.,4095,O
Encephalopathy,4096,B-Disease
has,4096,O
been,4096,O
reported,4096,O
in,4096,O
10-40,4096,O
%,4096,O
of,4096,O
patients,4096,O
receiving,4096,O
high-dose,4096,O
IV,4096,O
ifosfamide,4096,B-Chemical
.,4096,O
OBJECTIVE,4097,O
:,4097,O
To,4097,O
highlight,4097,O
the,4097,O
role,4097,O
of,4097,O
electroencephalogram,4097,O
(,4097,O
EEG,4097,O
),4097,O
in,4097,O
the,4097,O
early,4097,O
detection,4097,O
and,4097,O
management,4097,O
of,4097,O
ifosfamide,4097,B-Chemical
related,4097,O
encephalopathy,4097,B-Disease
.,4097,O
METHODS,4098,O
:,4098,O
Retrospective,4098,O
chart,4098,O
review,4098,O
including,4098,O
clinical,4098,O
data,4098,O
and,4098,O
EEG,4098,O
recordings,4098,O
was,4098,O
done,4098,O
on,4098,O
five,4098,O
patients,4098,O
",",4098,O
admitted,4098,O
to,4098,O
MD,4098,O
Anderson,4098,O
Cancer,4098,B-Disease
Center,4098,O
between,4098,O
years,4098,O
2009,4098,O
and,4098,O
2012,4098,O
",",4098,O
who,4098,O
developed,4098,O
ifosfamide,4098,B-Chemical
related,4098,O
acute,4098,O
encephalopathy,4098,B-Disease
.,4098,O
RESULTS,4099,O
:,4099,O
All,4099,O
five,4099,O
patients,4099,O
experienced,4099,O
symptoms,4099,O
of,4099,O
encephalopathy,4099,B-Disease
soon,4099,O
after,4099,O
(,4099,O
within,4099,O
12,4099,O
h-2,4099,O
days,4099,O
),4099,O
receiving,4099,O
ifosfamide,4099,B-Chemical
.,4099,O
Two,4100,O
patients,4100,O
developed,4100,O
generalized,4100,O
convulsions,4100,B-Disease
while,4100,O
one,4100,O
patient,4100,O
developed,4100,O
continuous,4100,O
non-convulsive,4100,B-Disease
status,4100,I-Disease
epilepticus,4100,I-Disease
(,4100,O
NCSE,4100,B-Disease
),4100,O
that,4100,O
required,4100,O
ICU,4100,O
admission,4100,O
and,4100,O
intubation,4100,O
.,4100,O
Initial,4101,O
EEG,4101,O
showed,4101,O
epileptiform,4101,O
discharges,4101,O
in,4101,O
three,4101,O
patients,4101,O
;,4101,O
run,4101,O
of,4101,O
triphasic,4101,O
waves,4101,O
in,4101,O
one,4101,O
patient,4101,O
and,4101,O
moderate,4101,O
degree,4101,O
diffuse,4101,O
generalized,4101,O
slowing,4101,O
.,4101,O
Mixed,4102,O
pattern,4102,O
with,4102,O
the,4102,O
presence,4102,O
of,4102,O
both,4102,O
sharps,4102,O
and,4102,O
triphasic,4102,O
waves,4102,O
were,4102,O
also,4102,O
noted,4102,O
.,4102,O
Repeat,4103,O
EEGs,4103,O
within,4103,O
24_h,4103,O
of,4103,O
symptom,4103,O
onset,4103,O
showed,4103,O
marked,4103,O
improvement,4103,O
that,4103,O
was,4103,O
correlated,4103,O
with,4103,O
clinical,4103,O
improvement,4103,O
.,4103,O
CONCLUSIONS,4104,O
:,4104,O
Severity,4104,O
of,4104,O
ifosfamide,4104,B-Chemical
related,4104,O
encephalopathy,4104,B-Disease
correlates,4104,O
with,4104,O
EEG,4104,O
changes,4104,O
.,4104,O
We,4105,O
suggest,4105,O
a,4105,O
timely,4105,O
EEG,4105,O
evaluation,4105,O
for,4105,O
patients,4105,O
receiving,4105,O
ifosfamide,4105,B-Chemical
who,4105,O
develop,4105,O
features,4105,O
of,4105,O
encephalopathy,4105,B-Disease
.,4105,O
Incidence,4106,O
of,4106,O
contrast-induced,4106,B-Chemical
nephropathy,4106,B-Disease
in,4106,O
hospitalised,4106,O
patients,4106,O
with,4106,O
cancer,4106,B-Disease
.,4106,O
OBJECTIVES,4107,O
:,4107,O
To,4107,O
determine,4107,O
the,4107,O
frequency,4107,O
of,4107,O
and,4107,O
possible,4107,O
factors,4107,O
related,4107,O
to,4107,O
contrast-induced,4107,B-Chemical
nephropathy,4107,B-Disease
(,4107,O
CIN,4107,O
),4107,O
in,4107,O
hospitalised,4107,O
patients,4107,O
with,4107,O
cancer,4107,B-Disease
.,4107,O
METHODS,4108,O
:,4108,O
Ninety,4108,O
adult,4108,O
patients,4108,O
were,4108,O
enrolled,4108,O
.,4108,O
Patients,4109,O
with,4109,O
risk,4109,O
factors,4109,O
for,4109,O
acute,4109,B-Disease
renal,4109,I-Disease
failure,4109,I-Disease
were,4109,O
excluded,4109,O
.,4109,O
Blood,4110,O
samples,4110,O
were,4110,O
examined,4110,O
the,4110,O
day,4110,O
before,4110,O
contrast-enhanced,4110,B-Chemical
computed,4110,O
tomography,4110,O
(,4110,O
CT,4110,O
),4110,O
and,4110,O
serially,4110,O
for,4110,O
3,4110,O
days,4110,O
thereafter,4110,O
.,4110,O
CIN,4111,O
was,4111,O
defined,4111,O
as,4111,O
an,4111,O
increase,4111,O
in,4111,O
serum,4111,O
creatinine,4111,B-Chemical
(,4111,O
Cr,4111,B-Chemical
),4111,O
of,4111,O
0.5,4111,O
mg/dl,4111,O
or,4111,O
more,4111,O
",",4111,O
or,4111,O
elevation,4111,O
of,4111,O
Cr,4111,B-Chemical
to,4111,O
25,4111,O
%,4111,O
over,4111,O
baseline,4111,O
.,4111,O
Relationships,4112,O
between,4112,O
CIN,4112,O
and,4112,O
possible,4112,O
risk,4112,O
factors,4112,O
were,4112,O
investigated,4112,O
.,4112,O
RESULTS,4113,O
:,4113,O
CIN,4113,O
was,4113,O
detected,4113,O
in,4113,O
18/90,4113,O
(,4113,O
20,4113,O
%,4113,O
),4113,O
patients,4113,O
.,4113,O
CIN,4114,O
developed,4114,O
in,4114,O
25.5,4114,O
%,4114,O
patients,4114,O
who,4114,O
underwent,4114,O
chemotherapy,4114,O
and,4114,O
in,4114,O
11,4114,O
%,4114,O
patients,4114,O
who,4114,O
did,4114,O
not,4114,O
(,4114,O
P,4114,O
=,4114,O
0.1,4114,O
),4114,O
.,4114,O
CIN,4115,O
more,4115,O
frequently,4115,O
developed,4115,O
in,4115,O
patients,4115,O
who,4115,O
had,4115,O
undergone,4115,O
CT,4115,O
within,4115,O
45,4115,O
days,4115,O
after,4115,O
the,4115,O
last,4115,O
chemotherapy,4115,O
(,4115,O
P,4115,O
=,4115,O
0.005,4115,O
),4115,O
;,4115,O
it,4115,O
was,4115,O
also,4115,O
an,4115,O
independent,4115,O
risk,4115,O
factor,4115,O
(,4115,O
P,4115,O
=,4115,O
0.017,4115,O
),4115,O
.,4115,O
CIN,4116,O
was,4116,O
significantly,4116,O
more,4116,O
after,4116,O
treatment,4116,O
with,4116,O
bevacizumab/irinotecan,4116,B-Chemical
(,4116,O
P,4116,O
=,4116,O
0.021,4116,O
),4116,O
and,4116,O
in,4116,O
patients,4116,O
with,4116,O
hypertension,4116,B-Disease
(,4116,O
P,4116,O
=,4116,O
0.044,4116,O
),4116,O
.,4116,O
CONCLUSIONS,4117,O
:,4117,O
The,4117,O
incidence,4117,O
of,4117,O
CIN,4117,O
after,4117,O
CT,4117,O
in,4117,O
hospitalised,4117,O
oncological,4117,O
patients,4117,O
was,4117,O
20,4117,O
%,4117,O
.,4117,O
CIN,4118,O
developed,4118,O
4.5-times,4118,O
more,4118,O
frequently,4118,O
in,4118,O
patients,4118,O
with,4118,O
cancer,4118,B-Disease
who,4118,O
had,4118,O
undergone,4118,O
recent,4118,O
chemotherapy,4118,O
.,4118,O
Hypertension,4119,B-Disease
and,4119,O
the,4119,O
combination,4119,O
of,4119,O
bevacizumab/irinotecan,4119,B-Chemical
may,4119,O
be,4119,O
additional,4119,O
risk,4119,O
factors,4119,O
for,4119,O
CIN,4119,O
development,4119,O
.,4119,O
KEY,4120,O
POINTS,4120,O
:,4120,O
.,4120,O
Contrast-induced,4121,B-Chemical
nephropathy,4121,B-Disease
(,4121,O
CIN,4121,O
),4121,O
is,4121,O
a,4121,O
concern,4121,O
for,4121,O
oncological,4121,O
patients,4121,O
undergoing,4121,O
CT.,4121,O
.,4121,O
CIN,4122,O
occurs,4122,O
more,4122,O
often,4122,O
when,4122,O
CT,4122,O
is,4122,O
performed,4122,O
<,4122,O
45,4122,O
days,4122,O
after,4122,O
chemotherapy,4122,O
.,4122,O
.,4123,O
Hypertension,4124,B-Disease
and,4124,O
treatment,4124,O
with,4124,O
bevacizumab,4124,B-Chemical
appear,4124,O
to,4124,O
be,4124,O
additional,4124,O
risk,4124,O
factors,4124,O
.,4124,O
Syndrome,4125,B-Disease
of,4125,I-Disease
inappropriate,4125,I-Disease
antidiuretic,4125,I-Disease
hormone,4125,I-Disease
secretion,4125,O
associated,4125,O
with,4125,O
desvenlafaxine,4125,B-Chemical
.,4125,O
OBJECTIVE,4126,O
:,4126,O
To,4126,O
report,4126,O
a,4126,O
case,4126,O
of,4126,O
syndrome,4126,B-Disease
of,4126,I-Disease
inappropriate,4126,I-Disease
anti-diuretic,4126,I-Disease
hormone,4126,I-Disease
(,4126,O
SIADH,4126,B-Disease
),4126,O
secretion,4126,O
associated,4126,O
with,4126,O
desvenlafaxine,4126,B-Chemical
.,4126,O
CASE,4127,O
SUMMARY,4127,O
:,4127,O
A,4127,O
57-year,4127,O
old,4127,O
female,4127,O
with,4127,O
hyponatraemia,4127,B-Disease
.,4127,O
Her,4128,O
medications,4128,O
included,4128,O
desvenlafaxine,4128,B-Chemical
",",4128,O
and,4128,O
symptoms,4128,O
included,4128,O
nausea,4128,B-Disease
",",4128,O
anxiety,4128,B-Disease
and,4128,O
confusion,4128,B-Disease
.,4128,O
The,4129,O
serum,4129,O
sodium,4129,B-Chemical
at,4129,O
this,4129,O
time,4129,O
was,4129,O
120,4129,O
mmol/L,4129,O
",",4129,O
serum,4129,O
osmolality,4129,O
was,4129,O
263,4129,O
mosmol/kg,4129,O
",",4129,O
urine,4129,O
osmolality,4129,O
410,4129,O
mosmol/kg,4129,O
and,4129,O
urine,4129,O
sodium,4129,B-Chemical
63,4129,O
mmol/L,4129,O
",",4129,O
consistent,4129,O
with,4129,O
a,4129,O
diagnosis,4129,O
of,4129,O
SIADH,4129,B-Disease
.,4129,O
Desvenlafaxine,4130,B-Chemical
was,4130,O
ceased,4130,O
and,4130,O
fluid,4130,O
restriction,4130,O
implemented,4130,O
.,4130,O
After,4131,O
4,4131,O
days,4131,O
the,4131,O
sodium,4131,B-Chemical
increased,4131,O
to,4131,O
128,4131,O
mmol/L,4131,O
and,4131,O
fluid,4131,O
restriction,4131,O
was,4131,O
relaxed,4131,O
.,4131,O
During,4132,O
her,4132,O
further,4132,O
3,4132,O
weeks,4132,O
inpatient,4132,O
admission,4132,O
the,4132,O
serum,4132,O
sodium,4132,B-Chemical
ranged,4132,O
from,4132,O
134,4132,O
to,4132,O
137,4132,O
mmol/L,4132,O
during,4132,O
treatment,4132,O
with,4132,O
mirtazapine,4132,B-Chemical
.,4132,O
DISCUSSION,4133,O
:,4133,O
SIADH,4133,B-Disease
has,4133,O
been,4133,O
widely,4133,O
reported,4133,O
with,4133,O
a,4133,O
range,4133,O
of,4133,O
antidepressants,4133,O
.,4133,O
This,4134,O
case,4134,O
report,4134,O
suggests,4134,O
that,4134,O
desvenlafaxine,4134,B-Chemical
might,4134,O
cause,4134,O
clinically,4134,O
significant,4134,O
hyponatremia,4134,B-Disease
.,4134,O
CONCLUSIONS,4135,O
:,4135,O
Clinicians,4135,O
should,4135,O
be,4135,O
aware,4135,O
of,4135,O
the,4135,O
potential,4135,O
for,4135,O
antidepressants,4135,O
to,4135,O
cause,4135,O
hyponatremia,4135,B-Disease
",",4135,O
and,4135,O
take,4135,O
appropriate,4135,O
corrective,4135,O
action,4135,O
where,4135,O
necessary,4135,O
.,4135,O
Oxidative,4136,O
stress,4136,O
on,4136,O
cardiotoxicity,4136,B-Disease
after,4136,O
treatment,4136,O
with,4136,O
single,4136,O
and,4136,O
multiple,4136,O
doses,4136,O
of,4136,O
doxorubicin,4136,B-Chemical
.,4136,O
The,4137,O
mechanism,4137,O
of,4137,O
doxorubicin,4137,B-Chemical
(,4137,O
DOX,4137,B-Chemical
),4137,O
-induced,4137,O
cardiotoxicity,4137,B-Disease
remains,4137,O
controversial,4137,O
.,4137,O
Wistar,4138,O
rats,4138,O
(,4138,O
n,4138,O
=,4138,O
66,4138,O
),4138,O
received,4138,O
DOX,4138,B-Chemical
injections,4138,O
intraperitoneally,4138,O
and,4138,O
were,4138,O
randomly,4138,O
assigned,4138,O
to,4138,O
2,4138,O
experimental,4138,O
protocols,4138,O
:,4138,O
(,4138,O
1,4138,O
),4138,O
rats,4138,O
were,4138,O
killed,4138,O
before,4138,O
(,4138,O
-24,4138,O
h,4138,O
",",4138,O
n,4138,O
=,4138,O
8,4138,O
),4138,O
and,4138,O
24,4138,O
h,4138,O
after,4138,O
(,4138,O
+24,4138,O
h,4138,O
",",4138,O
n,4138,O
=,4138,O
8,4138,O
),4138,O
a,4138,O
single,4138,O
dose,4138,O
of,4138,O
DOX,4138,B-Chemical
(,4138,O
4,4138,O
mg/kg,4138,O
body,4138,O
weight,4138,O
),4138,O
to,4138,O
determine,4138,O
the,4138,O
DOX,4138,B-Chemical
acute,4138,O
effect,4138,O
and,4138,O
(,4138,O
2,4138,O
),4138,O
rats,4138,O
(,4138,O
n,4138,O
=,4138,O
58,4138,O
),4138,O
received,4138,O
4,4138,O
injections,4138,O
of,4138,O
DOX,4138,B-Chemical
(,4138,O
4,4138,O
mg/kg,4138,O
body,4138,O
weight/week,4138,O
),4138,O
and,4138,O
were,4138,O
killed,4138,O
before,4138,O
the,4138,O
first,4138,O
injection,4138,O
(,4138,O
M0,4138,O
),4138,O
and,4138,O
1,4138,O
week,4138,O
after,4138,O
each,4138,O
injection,4138,O
(,4138,O
M1,4138,O
",",4138,O
M2,4138,O
",",4138,O
M3,4138,O
",",4138,O
and,4138,O
M4,4138,O
),4138,O
to,4138,O
determine,4138,O
the,4138,O
chronological,4138,O
effects,4138,O
.,4138,O
Animals,4139,O
used,4139,O
at,4139,O
M0,4139,O
(,4139,O
n,4139,O
=,4139,O
8,4139,O
),4139,O
were,4139,O
also,4139,O
used,4139,O
at,4139,O
moment,4139,O
-24,4139,O
h,4139,O
of,4139,O
acute,4139,O
study,4139,O
.,4139,O
Cardiac,4140,O
total,4140,O
antioxidant,4140,O
performance,4140,O
(,4140,O
TAP,4140,O
),4140,O
",",4140,O
DNA,4140,O
damage,4140,O
",",4140,O
and,4140,O
morphology,4140,O
analyses,4140,O
were,4140,O
carried,4140,O
out,4140,O
at,4140,O
each,4140,O
time,4140,O
point,4140,O
.,4140,O
Single,4141,O
dose,4141,O
of,4141,O
DOX,4141,B-Chemical
was,4141,O
associated,4141,O
with,4141,O
increased,4141,O
cardiac,4141,B-Disease
disarrangement,4141,I-Disease
",",4141,O
necrosis,4141,B-Disease
",",4141,O
and,4141,O
DNA,4141,O
damage,4141,O
(,4141,O
strand,4141,O
breaks,4141,O
(,4141,O
SBs,4141,O
),4141,O
and,4141,O
oxidized,4141,O
pyrimidines,4141,O
),4141,O
and,4141,O
decreased,4141,O
TAP,4141,O
.,4141,O
The,4142,O
chronological,4142,O
study,4142,O
showed,4142,O
an,4142,O
effect,4142,O
of,4142,O
a,4142,O
cumulative,4142,O
dose,4142,O
on,4142,O
body,4142,O
weight,4142,O
(,4142,O
R,4142,O
=,4142,O
-0.99,4142,O
",",4142,O
p,4142,O
=,4142,O
0.011,4142,O
),4142,O
",",4142,O
necrosis,4142,B-Disease
(,4142,O
R,4142,O
=,4142,O
1.00,4142,O
",",4142,O
p,4142,O
=,4142,O
0.004,4142,O
),4142,O
",",4142,O
TAP,4142,O
(,4142,O
R,4142,O
=,4142,O
0.95,4142,O
",",4142,O
p,4142,O
=,4142,O
0.049,4142,O
),4142,O
",",4142,O
and,4142,O
DNA,4142,O
SBs,4142,O
(,4142,O
R,4142,O
=,4142,O
-0.95,4142,O
",",4142,O
p,4142,O
=,4142,O
0.049,4142,O
),4142,O
.,4142,O
DNA,4143,O
SBs,4143,O
damage,4143,O
was,4143,O
negatively,4143,O
associated,4143,O
with,4143,O
TAP,4143,O
(,4143,O
R,4143,O
=,4143,O
-0.98,4143,O
",",4143,O
p,4143,O
=,4143,O
0.018,4143,O
),4143,O
",",4143,O
and,4143,O
necrosis,4143,B-Disease
(,4143,O
R,4143,O
=,4143,O
-0.97,4143,O
",",4143,O
p,4143,O
=,4143,O
0.027,4143,O
),4143,O
.,4143,O
Our,4144,O
results,4144,O
suggest,4144,O
that,4144,O
oxidative,4144,O
damage,4144,O
is,4144,O
associated,4144,O
with,4144,O
acute,4144,O
cardiotoxicity,4144,B-Disease
induced,4144,O
by,4144,O
a,4144,O
single,4144,O
dose,4144,O
of,4144,O
DOX,4144,B-Chemical
only,4144,O
.,4144,O
Increased,4145,O
resistance,4145,O
to,4145,O
the,4145,O
oxidative,4145,O
stress,4145,O
is,4145,O
plausible,4145,O
for,4145,O
the,4145,O
multiple,4145,O
dose,4145,O
of,4145,O
DOX,4145,B-Chemical
.,4145,O
Thus,4146,O
",",4146,O
different,4146,O
mechanisms,4146,O
may,4146,O
be,4146,O
involved,4146,O
in,4146,O
acute,4146,O
toxicity,4146,B-Disease
versus,4146,O
chronic,4146,O
toxicity,4146,B-Disease
.,4146,O
Tacrolimus-related,4147,B-Chemical
seizure,4147,B-Disease
after,4147,O
pediatric,4147,O
liver,4147,O
transplantation,4147,O
--,4147,O
a,4147,O
single-center,4147,O
experience,4147,O
.,4147,O
To,4148,O
identify,4148,O
the,4148,O
risk,4148,O
factors,4148,O
for,4148,O
new-onset,4148,O
seizures,4148,B-Disease
after,4148,O
pediatric,4148,O
LT,4148,O
and,4148,O
to,4148,O
assess,4148,O
their,4148,O
clinical,4148,O
implications,4148,O
and,4148,O
long-term,4148,O
prognosis,4148,O
.,4148,O
The,4149,O
clinical,4149,O
and,4149,O
laboratory,4149,O
data,4149,O
of,4149,O
27,4149,O
consecutive,4149,O
children,4149,O
who,4149,O
underwent,4149,O
LT,4149,O
from,4149,O
January,4149,O
2007,4149,O
to,4149,O
December,4149,O
2010,4149,O
in,4149,O
our,4149,O
center,4149,O
were,4149,O
analyzed,4149,O
retrospectively,4149,O
.,4149,O
Patients,4150,O
were,4150,O
divided,4150,O
into,4150,O
seizures,4150,B-Disease
group,4150,O
and,4150,O
a,4150,O
non-seizures,4150,O
group,4150,O
.,4150,O
Pre-operative,4151,O
",",4151,O
intra-operative,4151,O
",",4151,O
and,4151,O
post-operative,4151,O
data,4151,O
were,4151,O
collected,4151,O
.,4151,O
Seizures,4152,B-Disease
occurred,4152,O
in,4152,O
four,4152,O
children,4152,O
",",4152,O
an,4152,O
incidence,4152,O
of,4152,O
14.8,4152,O
%,4152,O
.,4152,O
All,4153,O
exhibited,4153,O
generalized,4153,O
tonic-clonic,4153,B-Disease
seizures,4153,I-Disease
within,4153,O
the,4153,O
first,4153,O
two,4153,O
wk,4153,O
after,4153,O
LT.,4153,O
Univariate,4153,O
analysis,4153,O
showed,4153,O
that,4153,O
the,4153,O
risk,4153,O
factors,4153,O
associated,4153,O
with,4153,O
seizures,4153,B-Disease
after,4153,O
pediatric,4153,O
LT,4153,O
included,4153,O
gender,4153,O
",",4153,O
pediatric,4153,O
end-stage,4153,B-Disease
liver,4153,I-Disease
disease,4153,I-Disease
score,4153,O
before,4153,O
surgery,4153,O
",",4153,O
Child-Pugh,4153,O
score,4153,O
before,4153,O
surgery,4153,O
",",4153,O
serum,4153,O
total,4153,O
bilirubin,4153,B-Chemical
after,4153,O
surgery,4153,O
",",4153,O
and,4153,O
trough,4153,O
TAC,4153,B-Chemical
level,4153,O
.,4153,O
Multivariate,4154,O
analysis,4154,O
showed,4154,O
that,4154,O
trough,4154,O
TAC,4154,B-Chemical
level,4154,O
was,4154,O
the,4154,O
only,4154,O
independent,4154,O
risk,4154,O
factor,4154,O
associated,4154,O
with,4154,O
the,4154,O
seizures,4154,B-Disease
.,4154,O
All,4155,O
children,4155,O
who,4155,O
experienced,4155,O
seizures,4155,B-Disease
survived,4155,O
with,4155,O
good,4155,O
graft,4155,O
function,4155,O
and,4155,O
remained,4155,O
seizure-free,4155,B-Disease
without,4155,O
anti-epileptic,4155,O
drugs,4155,O
over,4155,O
a,4155,O
mean,4155,O
follow-up,4155,O
period,4155,O
of,4155,O
33.7,4155,O
+,4155,O
14.6,4155,O
months,4155,O
.,4155,O
High,4156,O
trough,4156,O
TAC,4156,B-Chemical
level,4156,O
was,4156,O
the,4156,O
predominant,4156,O
factor,4156,O
that,4156,O
contributed,4156,O
to,4156,O
seizures,4156,B-Disease
in,4156,O
the,4156,O
early,4156,O
post-operative,4156,O
period,4156,O
after,4156,O
pediatric,4156,O
LT.,4156,O
High,4156,O
PELD,4156,O
and,4156,O
Child-Pugh,4156,O
scores,4156,O
before,4156,O
LT,4156,O
and,4156,O
high,4156,O
post-operative,4156,O
serum,4156,O
Tbil,4156,O
may,4156,O
be,4156,O
contributory,4156,O
risk,4156,O
factors,4156,O
for,4156,O
TAC-related,4156,B-Chemical
seizures,4156,B-Disease
.,4156,O
The,4157,O
flavonoid,4157,B-Chemical
apigenin,4157,B-Chemical
delays,4157,O
forgetting,4157,O
of,4157,O
passive,4157,O
avoidance,4157,O
conditioning,4157,O
in,4157,O
rats,4157,O
.,4157,O
The,4158,O
present,4158,O
experiments,4158,O
were,4158,O
performed,4158,O
to,4158,O
study,4158,O
the,4158,O
effect,4158,O
of,4158,O
the,4158,O
flavonoid,4158,B-Chemical
apigenin,4158,B-Chemical
(,4158,O
20,4158,O
mg/kg,4158,O
intraperitoneally,4158,O
(,4158,O
i.p,4158,O
.,4158,O
),4159,O
",",4159,O
1,4159,O
h,4159,O
before,4159,O
acquisition,4159,O
),4159,O
",",4159,O
on,4159,O
24,4159,O
h,4159,O
retention,4159,O
performance,4159,O
and,4159,O
forgetting,4159,O
of,4159,O
a,4159,O
step-through,4159,O
passive,4159,O
avoidance,4159,O
task,4159,O
",",4159,O
in,4159,O
young,4159,O
male,4159,O
Wistar,4159,O
rats,4159,O
.,4159,O
There,4160,O
were,4160,O
no,4160,O
differences,4160,O
between,4160,O
saline-,4160,O
and,4160,O
apigenin-treated,4160,O
groups,4160,O
in,4160,O
the,4160,O
24,4160,O
h,4160,O
retention,4160,O
trial,4160,O
.,4160,O
Furthermore,4161,O
",",4161,O
apigenin,4161,O
did,4161,O
not,4161,O
prevent,4161,O
the,4161,O
amnesia,4161,O
induced,4161,O
by,4161,O
scopolamine,4161,O
(,4161,O
1mg/kg,4161,O
",",4161,O
i.p.,4161,O
",",4161,O
30,4161,O
min,4161,O
before,4161,O
the,4161,O
acquisition,4161,O
),4161,O
.,4161,O
The,4162,O
saline-,4162,O
and,4162,O
apigenin-treated,4162,O
rats,4162,O
that,4162,O
did,4162,O
not,4162,O
step,4162,O
through,4162,O
into,4162,O
the,4162,O
dark,4162,O
compartment,4162,O
during,4162,O
the,4162,O
cut-off,4162,O
time,4162,O
(,4162,O
540,4162,O
s,4162,O
),4162,O
were,4162,O
retested,4162,O
weekly,4162,O
for,4162,O
up,4162,O
to,4162,O
eight,4162,O
weeks,4162,O
.,4162,O
In,4163,O
the,4163,O
saline,4163,O
treated,4163,O
group,4163,O
",",4163,O
the,4163,O
first,4163,O
significant,4163,O
decline,4163,O
in,4163,O
passive,4163,O
avoidance,4163,O
response,4163,O
was,4163,O
observed,4163,O
at,4163,O
four,4163,O
weeks,4163,O
",",4163,O
and,4163,O
complete,4163,O
memory,4163,I-Disease
loss,4163,O
was,4163,O
found,4163,O
five,4163,O
weeks,4163,O
after,4163,O
the,4163,O
acquisition,4163,O
of,4163,O
the,4163,O
passive,4163,O
avoidance,4163,O
task,4163,O
.,4163,O
At,4164,O
the,4164,O
end,4164,O
of,4164,O
the,4164,O
experimental,4164,O
period,4164,O
",",4164,O
60,4164,O
%,4164,O
of,4164,O
the,4164,O
animals,4164,O
treated,4164,O
with,4164,O
apigenin,4164,O
still,4164,O
did,4164,O
not,4164,O
step,4164,O
through,4164,O
.,4164,O
These,4165,O
data,4165,O
suggest,4165,O
that,4165,O
1,4165,O
),4165,O
apigenin,4165,O
delays,4165,O
the,4165,O
long-term,4165,O
forgetting,4165,O
but,4165,O
did,4165,O
not,4165,O
modulate,4165,O
the,4165,O
24,4165,O
h,4165,O
retention,4165,O
of,4165,O
fear,4165,O
memory,4165,O
and,4165,O
2,4165,O
),4165,O
the,4165,O
obtained,4165,O
beneficial,4165,O
effect,4165,O
of,4165,O
apigenin,4165,O
on,4165,O
the,4165,O
passive,4165,O
avoidance,4165,O
conditioning,4165,O
is,4165,O
mediated,4165,O
by,4165,O
mechanisms,4165,O
that,4165,O
do,4165,O
not,4165,O
implicate,4165,O
its,4165,O
action,4165,O
on,4165,O
the,4165,O
muscarinic,4165,O
cholinergic,4165,O
system,4165,O
.,4165,O
Cholecystokinin-octapeptide,4166,B-Chemical
restored,4166,O
morphine-induced,4166,B-Chemical
hippocampal,4166,O
long-term,4166,O
potentiation,4166,O
impairment,4166,O
in,4166,O
rats,4166,O
.,4166,O
Cholecystokinin-octapeptide,4167,B-Chemical
(,4167,O
CCK-8,4167,B-Chemical
),4167,O
",",4167,O
which,4167,O
is,4167,O
a,4167,O
typical,4167,O
brain-gut,4167,O
peptide,4167,O
",",4167,O
exerts,4167,O
a,4167,O
wide,4167,O
range,4167,O
of,4167,O
biological,4167,O
activities,4167,O
on,4167,O
the,4167,O
central,4167,O
nervous,4167,O
system,4167,O
.,4167,O
We,4168,O
have,4168,O
previously,4168,O
reported,4168,O
that,4168,O
CCK-8,4168,B-Chemical
significantly,4168,O
alleviated,4168,O
morphine-induced,4168,B-Chemical
amnesia,4168,B-Disease
and,4168,O
reversed,4168,O
spine,4168,O
density,4168,O
decreases,4168,O
in,4168,O
the,4168,O
CA1,4168,O
region,4168,O
of,4168,O
the,4168,O
hippocampus,4168,O
in,4168,O
morphine-treated,4168,B-Chemical
animals,4168,O
.,4168,O
Here,4169,O
",",4169,O
we,4169,O
investigated,4169,O
the,4169,O
effects,4169,O
of,4169,O
CCK-8,4169,B-Chemical
on,4169,O
long-term,4169,O
potentiation,4169,O
(,4169,O
LTP,4169,O
),4169,O
in,4169,O
the,4169,O
lateral,4169,O
perforant,4169,O
path,4169,O
(,4169,O
LPP,4169,O
),4169,O
-granule,4169,O
cell,4169,O
synapse,4169,O
of,4169,O
rat,4169,O
dentate,4169,O
gyrus,4169,O
(,4169,O
DG,4169,O
),4169,O
in,4169,O
acute,4169,O
saline,4169,O
or,4169,O
morphine-treated,4169,B-Chemical
rats,4169,O
.,4169,O
Population,4170,O
spikes,4170,O
(,4170,O
PS,4170,O
),4170,O
",",4170,O
which,4170,O
were,4170,O
evoked,4170,O
by,4170,O
stimulation,4170,O
of,4170,O
the,4170,O
LPP,4170,O
",",4170,O
were,4170,O
recorded,4170,O
in,4170,O
the,4170,O
DG,4170,O
region,4170,O
.,4170,O
Acute,4171,O
morphine,4171,B-Chemical
(,4171,O
30mg/kg,4171,O
",",4171,O
s.c.,4171,O
),4171,O
treatment,4171,O
significantly,4171,O
attenuated,4171,O
hippocampal,4171,O
LTP,4171,O
and,4171,O
CCK-8,4171,B-Chemical
(,4171,O
1ug,4171,O
",",4171,O
i.c.v,4171,O
.,4171,O
),4171,O
restored,4172,O
the,4172,O
amplitude,4172,O
of,4172,O
PS,4172,O
that,4172,O
was,4172,O
attenuated,4172,O
by,4172,O
morphine,4172,B-Chemical
injection,4172,O
.,4172,O
Furthermore,4173,O
",",4173,O
microinjection,4173,O
of,4173,O
CCK-8,4173,B-Chemical
(,4173,O
0.1,4173,O
and,4173,O
1ug,4173,O
",",4173,O
i.c.v,4173,O
.,4173,O
),4173,O
also,4174,O
significantly,4174,O
augmented,4174,O
hippocampal,4174,O
LTP,4174,O
in,4174,O
saline-treated,4174,O
(,4174,O
1ml/kg,4174,O
",",4174,O
s.c.,4174,O
),4174,O
rats,4174,O
.,4174,O
Pre-treatment,4175,O
of,4175,O
the,4175,O
CCK2,4175,O
receptor,4175,O
antagonist,4175,O
"L-365,260",4175,O
(,4175,O
10ug,4175,O
",",4175,O
i.c.v,4175,O
),4175,O
reversed,4175,O
the,4175,O
effects,4175,O
of,4175,O
CCK-8,4175,B-Chemical
",",4175,O
but,4175,O
the,4175,O
CCK1,4175,O
receptor,4175,O
antagonist,4175,O
"L-364,718",4175,O
(,4175,O
10ug,4175,O
",",4175,O
i.c.v,4175,O
),4175,O
did,4175,O
not,4175,O
.,4175,O
The,4176,O
present,4176,O
results,4176,O
demonstrate,4176,O
that,4176,O
CCK-8,4176,B-Chemical
attenuates,4176,O
the,4176,O
effect,4176,O
of,4176,O
morphine,4176,B-Chemical
on,4176,O
hippocampal,4176,O
LTP,4176,O
through,4176,O
CCK2,4176,O
receptors,4176,O
and,4176,O
suggest,4176,O
an,4176,O
ameliorative,4176,O
function,4176,O
of,4176,O
CCK-8,4176,B-Chemical
on,4176,O
morphine-induced,4176,B-Chemical
memory,4176,B-Disease
impairment,4176,I-Disease
.,4176,O
Glial,4177,O
activation,4177,O
and,4177,O
post-synaptic,4177,O
neurotoxicity,4177,B-Disease
:,4177,O
the,4177,O
key,4177,O
events,4177,O
in,4177,O
Streptozotocin,4177,B-Chemical
(,4177,O
ICV,4177,O
),4177,O
induced,4177,O
memory,4177,B-Disease
impairment,4177,I-Disease
in,4177,O
rats,4177,O
.,4177,O
In,4178,O
the,4178,O
present,4178,O
study,4178,O
the,4178,O
role,4178,O
of,4178,O
glial,4178,O
activation,4178,O
and,4178,O
post,4178,O
synaptic,4178,O
toxicity,4178,B-Disease
in,4178,O
ICV,4178,O
Streptozotocin,4178,B-Chemical
(,4178,O
STZ,4178,B-Chemical
),4178,O
induced,4178,O
memory,4178,B-Disease
impaired,4178,I-Disease
rats,4178,O
was,4178,O
explored,4178,O
.,4178,O
In,4179,O
experiment,4179,O
set,4179,O
up,4179,O
1,4179,O
:,4179,O
Memory,4179,B-Disease
deficit,4179,I-Disease
was,4179,O
found,4179,O
in,4179,O
Morris,4179,O
water,4179,O
maze,4179,O
test,4179,O
on,4179,O
14-16,4179,O
days,4179,O
after,4179,O
STZ,4179,B-Chemical
(,4179,O
ICV,4179,O
;,4179,O
3mg/Kg,4179,O
),4179,O
administration,4179,O
.,4179,O
STZ,4180,B-Chemical
causes,4180,O
increased,4180,O
expression,4180,O
of,4180,O
GFAP,4180,O
",",4180,O
CD11b,4180,O
and,4180,O
TNF-a,4180,O
indicating,4180,O
glial,4180,O
activation,4180,O
and,4180,O
neuroinflammation,4180,B-Disease
.,4180,O
STZ,4181,B-Chemical
also,4181,O
significantly,4181,O
increased,4181,O
the,4181,O
level,4181,O
of,4181,O
ROS,4181,O
",",4181,O
nitrite,4181,B-Chemical
",",4181,O
Ca,4181,B-Chemical
(,4181,O
2+,4181,O
),4181,O
and,4181,O
reduced,4181,O
the,4181,O
mitochondrial,4181,O
activity,4181,O
in,4181,O
synaptosomal,4181,O
preparation,4181,O
illustrating,4181,O
free,4181,O
radical,4181,O
generation,4181,O
and,4181,O
excitotoxicity,4181,B-Disease
.,4181,O
Increased,4182,O
expression,4182,O
and,4182,O
activity,4182,O
of,4182,O
Caspase-3,4182,O
was,4182,O
also,4182,O
observed,4182,O
in,4182,O
STZ,4182,B-Chemical
treated,4182,O
rat,4182,O
which,4182,O
specify,4182,O
apoptotic,4182,O
cell,4182,O
death,4182,O
in,4182,O
hippocampus,4182,O
and,4182,O
cortex,4182,O
.,4182,O
STZ,4183,B-Chemical
treatment,4183,O
showed,4183,O
decrease,4183,O
expression,4183,O
of,4183,O
post,4183,O
synaptic,4183,O
markers,4183,O
CaMKIIa,4183,O
and,4183,O
PSD-95,4183,O
",",4183,O
while,4183,O
",",4183,O
expression,4183,O
of,4183,O
pre,4183,O
synaptic,4183,O
markers,4183,O
(,4183,O
synaptophysin,4183,O
and,4183,O
SNAP-25,4183,O
),4183,O
remains,4183,O
unaltered,4183,O
indicating,4183,O
selective,4183,O
post,4183,O
synaptic,4183,O
neurotoxicity,4183,B-Disease
.,4183,O
Oral,4184,O
treatment,4184,O
with,4184,O
Memantine,4184,B-Chemical
(,4184,O
10mg/kg,4184,O
),4184,O
and,4184,O
Ibuprofen,4184,B-Chemical
(,4184,O
50,4184,O
mg/kg,4184,O
),4184,O
daily,4184,O
for,4184,O
13,4184,O
days,4184,O
attenuated,4184,O
STZ,4184,B-Chemical
induced,4184,O
glial,4184,O
activation,4184,O
",",4184,O
apoptotic,4184,O
cell,4184,O
death,4184,O
and,4184,O
post,4184,O
synaptic,4184,O
neurotoxicity,4184,B-Disease
in,4184,O
rat,4184,O
brain,4184,O
.,4184,O
Further,4185,O
",",4185,O
in,4185,O
experiment,4185,O
set,4185,O
up,4185,O
2,4185,O
:,4185,O
where,4185,O
memory,4185,O
function,4185,O
was,4185,O
not,4185,O
affected,4185,O
i.e,4185,O
.,4185,O
7-9,4186,O
days,4186,O
after,4186,O
STZ,4186,B-Chemical
treatment,4186,O
.,4186,O
The,4187,O
level,4187,O
of,4187,O
GFAP,4187,O
",",4187,O
CD11b,4187,O
",",4187,O
TNF-a,4187,O
",",4187,O
ROS,4187,O
and,4187,O
nitrite,4187,B-Chemical
levels,4187,O
were,4187,O
increased,4187,O
.,4187,O
On,4188,O
the,4188,O
other,4188,O
hand,4188,O
",",4188,O
apoptotic,4188,O
marker,4188,O
",",4188,O
synaptic,4188,O
markers,4188,O
",",4188,O
mitochondrial,4188,O
activity,4188,O
and,4188,O
Ca,4188,B-Chemical
(,4188,O
2+,4188,O
),4188,O
levels,4188,O
remained,4188,O
unaffected,4188,O
.,4188,O
Collective,4189,O
data,4189,O
indicates,4189,O
that,4189,O
neuroinflammatory,4189,B-Disease
process,4189,O
and,4189,O
oxidative,4189,O
stress,4189,O
occurs,4189,O
earlier,4189,O
to,4189,O
apoptosis,4189,O
and,4189,O
does,4189,O
not,4189,O
affect,4189,O
memory,4189,O
function,4189,O
.,4189,O
Present,4190,O
study,4190,O
clearly,4190,O
suggests,4190,O
that,4190,O
glial,4190,O
activation,4190,O
and,4190,O
post,4190,O
synaptic,4190,O
neurotoxicity,4190,B-Disease
are,4190,O
the,4190,O
key,4190,O
factors,4190,O
in,4190,O
STZ,4190,B-Chemical
induced,4190,O
memory,4190,B-Disease
impairment,4190,I-Disease
and,4190,O
neuronal,4190,O
cell,4190,O
death,4190,O
.,4190,O
Comparison,4191,O
of,4191,O
effects,4191,O
of,4191,O
isotonic,4191,O
sodium,4191,B-Chemical
chloride,4191,I-Chemical
with,4191,O
diltiazem,4191,B-Chemical
in,4191,O
prevention,4191,O
of,4191,O
contrast-induced,4191,B-Chemical
nephropathy,4191,B-Disease
.,4191,O
INTRODUCTION,4192,O
AND,4192,O
OBJECTIVE,4192,O
:,4192,O
Contrast-induced,4192,B-Chemical
nephropathy,4192,B-Disease
(,4192,O
CIN,4192,O
),4192,O
significantly,4192,O
increases,4192,O
the,4192,O
morbidity,4192,O
and,4192,O
mortality,4192,O
of,4192,O
patients,4192,O
.,4192,O
The,4193,O
aim,4193,O
of,4193,O
this,4193,O
study,4193,O
is,4193,O
to,4193,O
investigate,4193,O
and,4193,O
compare,4193,O
the,4193,O
protective,4193,O
effects,4193,O
of,4193,O
isotonic,4193,O
sodium,4193,B-Chemical
chloride,4193,I-Chemical
with,4193,O
sodium,4193,B-Chemical
bicarbonate,4193,I-Chemical
infusion,4193,O
and,4193,O
isotonic,4193,O
sodium,4193,B-Chemical
chloride,4193,I-Chemical
infusion,4193,O
with,4193,O
diltiazem,4193,B-Chemical
",",4193,O
a,4193,O
calcium,4193,B-Chemical
channel,4193,O
blocker,4193,O
",",4193,O
in,4193,O
preventing,4193,O
CIN,4193,O
.,4193,O
MATERIALS,4194,O
AND,4194,O
METHODS,4194,O
:,4194,O
Our,4194,O
study,4194,O
included,4194,O
patients,4194,O
who,4194,O
were,4194,O
administered,4194,O
30-60,4194,O
mL,4194,O
of,4194,O
iodinated,4194,O
contrast,4194,B-Chemical
agent,4194,O
for,4194,O
percutaneous,4194,O
coronary,4194,O
angiography,4194,O
(,4194,O
PCAG,4194,O
),4194,O
",",4194,O
all,4194,O
with,4194,O
creatinine,4194,B-Chemical
values,4194,O
between,4194,O
1.1,4194,O
and,4194,O
3.1,4194,O
mg/dL,4194,O
.,4194,O
Patients,4195,O
were,4195,O
divided,4195,O
into,4195,O
three,4195,O
groups,4195,O
and,4195,O
each,4195,O
group,4195,O
had,4195,O
20,4195,O
patients,4195,O
.,4195,O
The,4196,O
first,4196,O
group,4196,O
of,4196,O
patients,4196,O
was,4196,O
administered,4196,O
isotonic,4196,O
sodium,4196,B-Chemical
chloride,4196,I-Chemical
;,4196,O
the,4196,O
second,4196,O
group,4196,O
was,4196,O
administered,4196,O
a,4196,O
solution,4196,O
that,4196,O
of,4196,O
5,4196,O
%,4196,O
dextrose,4196,B-Chemical
and,4196,O
sodium,4196,B-Chemical
bicarbonate,4196,I-Chemical
",",4196,O
while,4196,O
the,4196,O
third,4196,O
group,4196,O
was,4196,O
administered,4196,O
isotonic,4196,O
sodium,4196,B-Chemical
chloride,4196,I-Chemical
before,4196,O
and,4196,O
after,4196,O
the,4196,O
contrast,4196,B-Chemical
injection,4196,O
.,4196,O
The,4197,O
third,4197,O
group,4197,O
received,4197,O
an,4197,O
additional,4197,O
injection,4197,O
of,4197,O
diltiazem,4197,B-Chemical
the,4197,O
day,4197,O
before,4197,O
and,4197,O
first,4197,O
2,4197,O
days,4197,O
after,4197,O
the,4197,O
contrast,4197,B-Chemical
injection,4197,O
.,4197,O
All,4198,O
of,4198,O
the,4198,O
patients,4198,O
',4198,O
plasma,4198,O
blood,4198,B-Chemical
urea,4198,I-Chemical
nitrogen,4198,I-Chemical
(,4198,O
BUN,4198,B-Chemical
),4198,O
and,4198,O
creatinine,4198,B-Chemical
levels,4198,O
were,4198,O
measured,4198,O
on,4198,O
the,4198,O
second,4198,O
and,4198,O
seventh,4198,O
day,4198,O
after,4198,O
the,4198,O
administration,4198,O
of,4198,O
intravenous,4198,O
contrast,4198,B-Chemical
material,4198,O
.,4198,O
RESULTS,4199,O
:,4199,O
The,4199,O
basal,4199,O
creatinine,4199,B-Chemical
levels,4199,O
were,4199,O
similar,4199,O
for,4199,O
all,4199,O
three,4199,O
groups,4199,O
(,4199,O
p,4199,O
>,4199,O
0.05,4199,O
),4199,O
.,4199,O
Among,4200,O
a,4200,O
total,4200,O
of,4200,O
60,4200,O
patients,4200,O
included,4200,O
in,4200,O
the,4200,O
study,4200,O
",",4200,O
16,4200,O
patients,4200,O
developed,4200,O
acute,4200,B-Disease
renal,4200,I-Disease
failure,4200,I-Disease
(,4200,O
ARF,4200,B-Disease
),4200,O
on,4200,O
the,4200,O
second,4200,O
day,4200,O
after,4200,O
contrast,4200,B-Chemical
material,4200,O
was,4200,O
injected,4200,O
(,4200,O
26.6,4200,O
%,4200,O
),4200,O
.,4200,O
The,4201,O
number,4201,O
of,4201,O
patients,4201,O
who,4201,O
developed,4201,O
ARF,4201,B-Disease
on,4201,O
the,4201,O
second,4201,O
day,4201,O
after,4201,O
the,4201,O
injection,4201,O
in,4201,O
the,4201,O
first,4201,O
group,4201,O
was,4201,O
five,4201,O
(,4201,O
25,4201,O
%,4201,O
),4201,O
",",4201,O
in,4201,O
the,4201,O
second,4201,O
group,4201,O
was,4201,O
six,4201,O
(,4201,O
30,4201,O
%,4201,O
),4201,O
and,4201,O
the,4201,O
third,4201,O
group,4201,O
was,4201,O
five,4201,O
(,4201,O
25,4201,O
%,4201,O
),4201,O
(,4201,O
p,4201,O
>,4201,O
0.05,4201,O
),4201,O
.,4201,O
CONCLUSION,4202,O
:,4202,O
There,4202,O
was,4202,O
no,4202,O
significant,4202,O
difference,4202,O
between,4202,O
isotonic,4202,O
sodium,4202,B-Chemical
chloride,4202,I-Chemical
",",4202,O
sodium,4202,B-Chemical
bicarbonate,4202,I-Chemical
and,4202,O
isotonic,4202,O
sodium,4202,B-Chemical
chloride,4202,I-Chemical
with,4202,O
diltiazem,4202,B-Chemical
application,4202,O
in,4202,O
prevention,4202,O
of,4202,O
CIN,4202,O
.,4202,O
Neurocognitive,4203,O
and,4203,O
neuroradiologic,4203,O
central,4203,O
nervous,4203,O
system,4203,O
late,4203,O
effects,4203,O
in,4203,O
children,4203,O
treated,4203,O
on,4203,O
Pediatric,4203,O
Oncology,4203,O
Group,4203,O
(,4203,O
POG,4203,O
),4203,O
P9605,4203,O
(,4203,O
standard,4203,O
risk,4203,O
),4203,O
and,4203,O
P9201,4203,O
(,4203,O
lesser,4203,O
risk,4203,O
),4203,O
acute,4203,B-Disease
lymphoblastic,4203,I-Disease
leukemia,4203,I-Disease
protocols,4203,O
(,4203,O
ACCL0131,4203,O
),4203,O
:,4203,O
a,4203,O
methotrexate,4203,B-Chemical
consequence,4203,O
?,4203,O
A,4204,O
report,4204,O
from,4204,O
the,4204,O
Children,4204,O
's,4204,O
Oncology,4204,O
Group,4204,O
.,4204,O
Concerns,4205,O
about,4205,O
long-term,4205,O
methotrexate,4205,B-Chemical
(,4205,O
MTX,4205,B-Chemical
),4205,O
neurotoxicity,4205,B-Disease
in,4205,O
the,4205,O
1990s,4205,O
led,4205,O
to,4205,O
modifications,4205,O
in,4205,O
intrathecal,4205,O
(,4205,O
IT,4205,O
),4205,O
therapy,4205,O
",",4205,O
leucovorin,4205,O
rescue,4205,O
",",4205,O
and,4205,O
frequency,4205,O
of,4205,O
systemic,4205,O
MTX,4205,B-Chemical
administration,4205,O
in,4205,O
children,4205,O
with,4205,O
acute,4205,B-Disease
lymphoblastic,4205,I-Disease
leukemia,4205,I-Disease
.,4205,O
In,4206,O
this,4206,O
study,4206,O
",",4206,O
neurocognitive,4206,O
outcomes,4206,O
and,4206,O
neuroradiologic,4206,O
evidence,4206,O
of,4206,O
leukoencephalopathy,4206,B-Disease
were,4206,O
compared,4206,O
in,4206,O
children,4206,O
treated,4206,O
with,4206,O
intense,4206,O
central,4206,O
nervous,4206,O
system,4206,O
(,4206,O
CNS,4206,O
),4206,O
-directed,4206,O
therapy,4206,O
(,4206,O
P9605,4206,O
),4206,O
versus,4206,O
those,4206,O
receiving,4206,O
fewer,4206,O
CNS-directed,4206,O
treatment,4206,O
days,4206,O
during,4206,O
intensive,4206,O
consolidation,4206,O
(,4206,O
P9201,4206,O
),4206,O
.,4206,O
A,4207,O
total,4207,O
of,4207,O
66,4207,O
children,4207,O
from,4207,O
16,4207,O
Pediatric,4207,O
Oncology,4207,O
Group,4207,O
institutions,4207,O
with,4207,O
``,4207,O
standard-risk,4207,O
'',4207,O
acute,4207,B-Disease
lymphoblastic,4207,I-Disease
leukemia,4207,I-Disease
",",4207,O
1.00,4207,O
to,4207,O
9.99,4207,O
years,4207,O
at,4207,O
diagnosis,4207,O
",",4207,O
without,4207,O
evidence,4207,O
of,4207,O
CNS,4207,O
leukemia,4207,B-Disease
at,4207,O
diagnosis,4207,O
were,4207,O
enrolled,4207,O
on,4207,O
ACCL0131,4207,O
:,4207,O
28,4207,O
from,4207,O
P9201,4207,O
and,4207,O
38,4207,O
from,4207,O
P9605,4207,O
.,4207,O
Magnetic,4208,O
resonance,4208,O
imaging,4208,O
scans,4208,O
and,4208,O
standard,4208,O
neuropsychological,4208,O
tests,4208,O
were,4208,O
performed,4208,O
>,4208,O
2.6,4208,O
years,4208,O
after,4208,O
the,4208,O
end,4208,O
of,4208,O
treatment,4208,O
.,4208,O
Significantly,4209,O
more,4209,O
P9605,4209,O
patients,4209,O
developed,4209,O
leukoencephalopathy,4209,B-Disease
compared,4209,O
with,4209,O
P9201,4209,O
patients,4209,O
(,4209,O
68,4209,O
%,4209,O
",",4209,O
95,4209,O
%,4209,O
confidence,4209,O
interval,4209,O
49,4209,O
%,4209,O
-83,4209,O
%,4209,O
vs.,4209,O
22,4209,O
%,4209,O
",",4209,O
95,4209,O
%,4209,O
confidence,4209,O
interval,4209,O
5,4209,O
%,4209,O
-44,4209,O
%,4209,O
;,4209,O
P=0.001,4209,O
),4209,O
identified,4209,O
as,4209,O
late,4209,O
as,4209,O
7.7,4209,O
years,4209,O
after,4209,O
the,4209,O
end,4209,O
of,4209,O
treatment,4209,O
.,4209,O
Overall,4210,O
",",4210,O
40,4210,O
%,4210,O
of,4210,O
patients,4210,O
scored,4210,O
<,4210,O
85,4210,O
on,4210,O
either,4210,O
Verbal,4210,O
or,4210,O
Performance,4210,O
IQ,4210,O
.,4210,O
Children,4211,O
on,4211,O
both,4211,O
studies,4211,O
had,4211,O
significant,4211,O
attention,4211,B-Disease
problems,4211,I-Disease
",",4211,O
but,4211,O
P9605,4211,O
children,4211,O
scored,4211,O
below,4211,O
average,4211,O
on,4211,O
more,4211,O
neurocognitive,4211,O
measures,4211,O
than,4211,O
those,4211,O
treated,4211,O
on,4211,O
P9201,4211,O
(,4211,O
82,4211,O
%,4211,O
",",4211,O
14/17,4211,O
measures,4211,O
vs.,4211,O
24,4211,O
%,4211,O
",",4211,O
4/17,4211,O
measures,4211,O
),4211,O
.,4211,O
This,4212,O
supports,4212,O
ongoing,4212,O
concerns,4212,O
about,4212,O
intensive,4212,O
MTX,4212,B-Chemical
exposure,4212,O
as,4212,O
a,4212,O
major,4212,O
contributor,4212,O
to,4212,O
CNS,4212,O
late,4212,O
effects,4212,O
.,4212,O
Tranexamic,4213,B-Chemical
acid,4213,I-Chemical
overdosage-induced,4213,O
generalized,4213,O
seizure,4213,B-Disease
in,4213,O
renal,4213,B-Disease
failure,4213,I-Disease
.,4213,O
We,4214,O
report,4214,O
a,4214,O
45-year-old,4214,O
lady,4214,O
with,4214,O
chronic,4214,B-Disease
kidney,4214,I-Disease
disease,4214,I-Disease
stage,4214,O
4,4214,O
due,4214,O
to,4214,O
chronic,4214,O
tubulointerstial,4214,B-Disease
disease,4214,I-Disease
.,4214,O
She,4215,O
was,4215,O
admitted,4215,O
to,4215,O
our,4215,O
center,4215,O
for,4215,O
severe,4215,O
anemia,4215,B-Disease
due,4215,O
to,4215,O
menorrhagia,4215,B-Disease
and,4215,O
deterioration,4215,B-Disease
of,4215,I-Disease
renal,4215,I-Disease
function,4215,I-Disease
.,4215,O
She,4216,O
was,4216,O
infused,4216,O
three,4216,O
units,4216,O
of,4216,O
packed,4216,O
cells,4216,O
during,4216,O
a,4216,O
session,4216,O
of,4216,O
hemodialysis,4216,O
.,4216,O
Tranexamic,4217,B-Chemical
acid,4217,I-Chemical
(,4217,O
TNA,4217,B-Chemical
),4217,O
1,4217,O
g,4217,O
8-hourly,4217,O
was,4217,O
administered,4217,O
to,4217,O
her,4217,O
to,4217,O
control,4217,O
bleeding,4217,B-Disease
per,4217,O
vaginum,4217,O
.,4217,O
Two,4218,O
hours,4218,O
after,4218,O
the,4218,O
sixth,4218,O
dose,4218,O
of,4218,O
TNA,4218,B-Chemical
",",4218,O
she,4218,O
had,4218,O
an,4218,O
episode,4218,O
of,4218,O
generalized,4218,O
tonic,4218,B-Disease
clonic,4218,I-Disease
convulsions,4218,I-Disease
.,4218,O
TNA,4219,B-Chemical
was,4219,O
discontinued,4219,O
.,4219,O
Investigations,4220,O
of,4220,O
the,4220,O
patient,4220,O
revealed,4220,O
no,4220,O
biochemical,4220,O
or,4220,O
structural,4220,O
central,4220,O
nervous,4220,B-Disease
system,4220,I-Disease
abnormalities,4220,I-Disease
that,4220,O
could,4220,O
have,4220,O
provoked,4220,O
the,4220,O
convulsions,4220,B-Disease
.,4220,O
She,4221,O
did,4221,O
not,4221,O
require,4221,O
any,4221,O
further,4221,O
dialytic,4221,O
support,4221,O
.,4221,O
She,4222,O
had,4222,O
no,4222,O
further,4222,O
episodes,4222,O
of,4222,O
convulsion,4222,B-Disease
till,4222,O
dis-charge,4222,O
and,4222,O
during,4222,O
the,4222,O
two,4222,O
months,4222,O
of,4222,O
follow-up,4222,O
.,4222,O
Thus,4223,O
",",4223,O
the,4223,O
precipitating,4223,O
cause,4223,O
of,4223,O
convulsions,4223,B-Disease
was,4223,O
believed,4223,O
to,4223,O
be,4223,O
an,4223,O
overdose,4223,B-Disease
of,4223,O
TNA,4223,B-Chemical
.,4223,O
Pre-treatment,4224,O
of,4224,O
bupivacaine-induced,4224,B-Chemical
cardiovascular,4224,B-Disease
depression,4224,I-Disease
using,4224,O
different,4224,O
lipid,4224,O
formulations,4224,O
of,4224,O
propofol,4224,B-Chemical
.,4224,O
BACKGROUND,4225,O
:,4225,O
Pre-treatment,4225,O
with,4225,O
lipid,4225,O
emulsions,4225,O
has,4225,O
been,4225,O
shown,4225,O
to,4225,O
increase,4225,O
lethal,4225,O
doses,4225,O
of,4225,O
bupivacaine,4225,B-Chemical
",",4225,O
and,4225,O
the,4225,O
lipid,4225,O
content,4225,O
of,4225,O
propofol,4225,B-Chemical
may,4225,O
alleviate,4225,O
bupivacaine-induced,4225,B-Chemical
cardiotoxicity,4225,B-Disease
.,4225,O
The,4226,O
aim,4226,O
of,4226,O
this,4226,O
study,4226,O
is,4226,O
to,4226,O
investigate,4226,O
the,4226,O
effects,4226,O
of,4226,O
propofol,4226,B-Chemical
in,4226,O
intralipid,4226,O
or,4226,O
medialipid,4226,O
emulsions,4226,O
on,4226,O
bupivacaine-induced,4226,B-Chemical
cardiotoxicity,4226,B-Disease
.,4226,O
METHODS,4227,O
:,4227,O
Rats,4227,O
were,4227,O
anaesthetised,4227,O
with,4227,O
ketamine,4227,B-Chemical
and,4227,O
were,4227,O
given,4227,O
0.5,4227,O
mg/kg/min,4227,O
propofol,4227,B-Chemical
in,4227,O
intralipid,4227,O
(,4227,O
Group,4227,O
P,4227,O
),4227,O
",",4227,O
propofol,4227,B-Chemical
in,4227,O
medialipid,4227,O
(,4227,O
Group,4227,O
L,4227,O
),4227,O
",",4227,O
or,4227,O
saline,4227,O
(,4227,O
Group,4227,O
C,4227,O
),4227,O
over,4227,O
20,4227,O
min,4227,O
.,4227,O
Thereafter,4228,O
",",4228,O
2,4228,O
mg/kg/min,4228,O
bupivacaine,4228,B-Chemical
0.5,4228,O
%,4228,O
was,4228,O
infused,4228,O
.,4228,O
We,4229,O
recorded,4229,O
time,4229,O
to,4229,O
first,4229,O
dysrhythmia,4229,B-Disease
occurrence,4229,O
",",4229,O
respective,4229,O
times,4229,O
to,4229,O
25,4229,O
%,4229,O
and,4229,O
50,4229,O
%,4229,O
reduction,4229,O
of,4229,O
the,4229,O
heart,4229,O
rate,4229,O
(,4229,O
HR,4229,O
),4229,O
and,4229,O
mean,4229,O
arterial,4229,O
pressure,4229,O
",",4229,O
and,4229,O
time,4229,O
to,4229,O
asystole,4229,B-Disease
and,4229,O
total,4229,O
amount,4229,O
of,4229,O
bupivacaine,4229,B-Chemical
consumption,4229,O
.,4229,O
Blood,4230,O
and,4230,O
tissue,4230,O
samples,4230,O
were,4230,O
collected,4230,O
following,4230,O
asystole,4230,B-Disease
.,4230,O
RESULTS,4231,O
:,4231,O
The,4231,O
time,4231,O
to,4231,O
first,4231,O
dysrhythmia,4231,B-Disease
occurrence,4231,O
",",4231,O
time,4231,O
to,4231,O
25,4231,O
%,4231,O
and,4231,O
50,4231,O
%,4231,O
reductions,4231,O
in,4231,O
HR,4231,O
",",4231,O
and,4231,O
time,4231,O
to,4231,O
asystole,4231,B-Disease
were,4231,O
longer,4231,O
in,4231,O
Group,4231,O
P,4231,O
than,4231,O
the,4231,O
other,4231,O
groups,4231,O
.,4231,O
The,4232,O
cumulative,4232,O
bupivacaine,4232,B-Chemical
dose,4232,O
given,4232,O
at,4232,O
those,4232,O
time,4232,O
points,4232,O
was,4232,O
higher,4232,O
in,4232,O
Group,4232,O
P.,4232,O
Plasma,4232,O
bupivacaine,4232,B-Chemical
levels,4232,O
were,4232,O
significantly,4232,O
lower,4232,O
in,4232,O
Group,4232,O
P,4232,O
than,4232,O
in,4232,O
Group,4232,O
C.,4232,O
Bupivacaine,4232,B-Chemical
levels,4232,O
in,4232,O
the,4232,O
brain,4232,O
and,4232,O
heart,4232,O
were,4232,O
significantly,4232,O
lower,4232,O
in,4232,O
Group,4232,O
P,4232,O
and,4232,O
Group,4232,O
L,4232,O
than,4232,O
in,4232,O
Group,4232,O
C.,4232,O
CONCLUSION,4232,O
:,4232,O
We,4232,O
conclude,4232,O
that,4232,O
pre-treatment,4232,O
with,4232,O
propofol,4232,B-Chemical
in,4232,O
intralipid,4232,O
",",4232,O
compared,4232,O
with,4232,O
propofol,4232,B-Chemical
in,4232,O
medialipid,4232,O
or,4232,O
saline,4232,O
",",4232,O
delayed,4232,O
the,4232,O
onset,4232,O
of,4232,O
bupivacaine-induced,4232,B-Chemical
cardiotoxic,4232,B-Disease
effects,4232,O
as,4232,O
well,4232,O
as,4232,O
reduced,4232,O
plasma,4232,O
bupivacaine,4232,B-Chemical
levels,4232,O
.,4232,O
Further,4233,O
studies,4233,O
are,4233,O
needed,4233,O
to,4233,O
explore,4233,O
tissue,4233,O
bupivacaine,4233,B-Chemical
levels,4233,O
of,4233,O
propofol,4233,B-Chemical
in,4233,O
medialipid,4233,O
and,4233,O
adapt,4233,O
these,4233,O
results,4233,O
to,4233,O
clinical,4233,O
practice,4233,O
.,4233,O
Drug-Induced,4234,B-Disease
Acute,4234,I-Disease
Liver,4234,I-Disease
Injury,4234,I-Disease
Within,4234,O
12,4234,O
Hours,4234,O
After,4234,O
Fluvastatin,4234,B-Chemical
Therapy,4234,O
.,4234,O
Although,4235,O
statins,4235,B-Chemical
are,4235,O
generally,4235,O
well-tolerated,4235,O
drugs,4235,O
",",4235,O
recent,4235,O
cases,4235,O
of,4235,O
drug-induced,4235,B-Disease
liver,4235,I-Disease
injury,4235,I-Disease
associated,4235,O
with,4235,O
their,4235,O
use,4235,O
have,4235,O
been,4235,O
reported,4235,O
.,4235,O
A,4236,O
52-year-old,4236,O
Chinese,4236,O
man,4236,O
reported,4236,O
with,4236,O
liver,4236,B-Disease
damage,4236,I-Disease
",",4236,O
which,4236,O
appeared,4236,O
12,4236,O
hours,4236,O
after,4236,O
beginning,4236,O
treatment,4236,O
with,4236,O
fluvastatin,4236,B-Chemical
.,4236,O
Patient,4237,O
presented,4237,O
with,4237,O
complaints,4237,O
of,4237,O
increasing,4237,O
nausea,4237,B-Disease
",",4237,O
anorexia,4237,B-Disease
",",4237,O
and,4237,O
upper,4237,O
abdominal,4237,B-Disease
pain,4237,I-Disease
.,4237,O
His,4238,O
laboratory,4238,O
values,4238,O
showed,4238,O
elevated,4238,O
creatine,4238,B-Chemical
kinase,4238,O
and,4238,O
transaminases,4238,O
.,4238,O
Testing,4239,O
for,4239,O
autoantibodies,4239,O
was,4239,O
also,4239,O
negative,4239,O
.,4239,O
The,4240,O
liver,4240,O
biochemistries,4240,O
eventually,4240,O
normalized,4240,O
within,4240,O
3,4240,O
weeks,4240,O
of,4240,O
stopping,4240,O
the,4240,O
fluvastatin,4240,B-Chemical
.,4240,O
Therefore,4241,O
",",4241,O
when,4241,O
prescribing,4241,O
statins,4241,O
",",4241,O
the,4241,O
possibility,4241,O
of,4241,O
hepatic,4241,B-Disease
damage,4241,I-Disease
should,4241,O
be,4241,O
taken,4241,O
into,4241,O
account,4241,O
.,4241,O
Fluconazole,4242,B-Chemical
associated,4242,O
agranulocytosis,4242,B-Disease
and,4242,O
thrombocytopenia,4242,B-Disease
.,4242,O
CASE,4243,O
:,4243,O
We,4243,O
describe,4243,O
a,4243,O
second,4243,O
case,4243,O
of,4243,O
fluconazole,4243,B-Chemical
associated,4243,O
agranulocytosis,4243,B-Disease
with,4243,O
thrombocytopenia,4243,B-Disease
and,4243,O
recovery,4243,O
upon,4243,O
discontinuation,4243,O
of,4243,O
therapy,4243,O
.,4243,O
The,4244,O
patient,4244,O
began,4244,O
to,4244,O
have,4244,O
changes,4244,O
in,4244,O
white,4244,O
blood,4244,O
cells,4244,O
and,4244,O
platelets,4244,O
within,4244,O
48,4244,O
h,4244,O
of,4244,O
administration,4244,O
of,4244,O
fluconazole,4244,B-Chemical
and,4244,O
began,4244,O
to,4244,O
recover,4244,O
with,4244,O
48,4244,O
h,4244,O
of,4244,O
discontinuation,4244,O
.,4244,O
This,4245,O
case,4245,O
highlights,4245,O
that,4245,O
drug-induced,4245,O
blood,4245,B-Disease
dyscrasias,4245,I-Disease
can,4245,O
occur,4245,O
unexpectedly,4245,O
as,4245,O
a,4245,O
result,4245,O
of,4245,O
treatment,4245,O
with,4245,O
a,4245,O
commonly,4245,O
used,4245,O
drug,4245,O
thought,4245,O
to,4245,O
be,4245,O
``,4245,O
safe,4245,O
'',4245,O
.,4245,O
CONCLUSION,4246,O
:,4246,O
According,4246,O
to,4246,O
Naranjo,4246,O
's,4246,O
algorithm,4246,O
the,4246,O
likelihood,4246,O
that,4246,O
our,4246,O
patient,4246,O
's,4246,O
agranulocytosis,4246,B-Disease
and,4246,O
thrombocytopenia,4246,B-Disease
occurred,4246,O
as,4246,O
a,4246,O
result,4246,O
of,4246,O
therapy,4246,O
with,4246,O
fluconazole,4246,B-Chemical
is,4246,O
probable,4246,O
",",4246,O
with,4246,O
a,4246,O
total,4246,O
of,4246,O
six,4246,O
points,4246,O
.,4246,O
We,4247,O
feel,4247,O
that,4247,O
the,4247,O
weight,4247,O
of,4247,O
the,4247,O
overall,4247,O
evidence,4247,O
of,4247,O
this,4247,O
evidence,4247,O
is,4247,O
strong,4247,O
.,4247,O
In,4248,O
particular,4248,O
the,4248,O
temporal,4248,O
relationship,4248,O
of,4248,O
bone,4248,B-Disease
marrow,4248,I-Disease
suppression,4248,I-Disease
to,4248,O
the,4248,O
initiation,4248,O
of,4248,O
fluconazole,4248,B-Chemical
and,4248,O
the,4248,O
abatement,4248,O
of,4248,O
symptoms,4248,O
that,4248,O
rapidly,4248,O
reversed,4248,O
immediately,4248,O
following,4248,O
discontinuation,4248,O
.,4248,O
Two-dimensional,4249,O
speckle,4249,O
tracking,4249,O
echocardiography,4249,O
combined,4249,O
with,4249,O
high-sensitive,4249,O
cardiac,4249,O
troponin,4249,O
T,4249,O
in,4249,O
early,4249,O
detection,4249,O
and,4249,O
prediction,4249,O
of,4249,O
cardiotoxicity,4249,B-Disease
during,4249,O
epirubicine-based,4249,B-Chemical
chemotherapy,4249,O
.,4249,O
AIMS,4250,O
:,4250,O
To,4250,O
investigate,4250,O
whether,4250,O
alterations,4250,O
of,4250,O
myocardial,4250,B-Disease
strain,4250,I-Disease
and,4250,O
high-sensitive,4250,O
cardiac,4250,O
troponin,4250,O
T,4250,O
(,4250,O
cTnT,4250,O
),4250,O
could,4250,O
predict,4250,O
future,4250,O
cardiac,4250,B-Disease
dysfunction,4250,I-Disease
in,4250,O
patients,4250,O
after,4250,O
epirubicin,4250,B-Chemical
exposure,4250,O
.,4250,O
METHODS,4251,O
:,4251,O
Seventy-five,4251,O
patients,4251,O
with,4251,O
non-Hodgkin,4251,B-Disease
lymphoma,4251,I-Disease
treated,4251,O
with,4251,O
epirubicin,4251,B-Chemical
were,4251,O
studied,4251,O
.,4251,O
Blood,4252,O
collection,4252,O
and,4252,O
echocardiography,4252,O
were,4252,O
performed,4252,O
at,4252,O
baseline,4252,O
",",4252,O
1,4252,O
day,4252,O
after,4252,O
the,4252,O
third,4252,O
cycle,4252,O
",",4252,O
and,4252,O
1,4252,O
day,4252,O
after,4252,O
completion,4252,O
of,4252,O
chemotherapy,4252,O
.,4252,O
Patients,4253,O
were,4253,O
studied,4253,O
using,4253,O
echocardiography,4253,O
during,4253,O
follow-up,4253,O
.,4253,O
Global,4254,O
longitudinal,4254,O
(,4254,O
GLS,4254,O
),4254,O
",",4254,O
circumferential,4254,O
(,4254,O
GCS,4254,O
),4254,O
",",4254,O
and,4254,O
radial,4254,O
strain,4254,O
(,4254,O
GRS,4254,O
),4254,O
were,4254,O
calculated,4254,O
using,4254,O
speckle,4254,O
tracking,4254,O
echocardiography,4254,O
.,4254,O
Left,4255,O
ventricular,4255,O
ejection,4255,O
fraction,4255,O
was,4255,O
analysed,4255,O
by,4255,O
real-time,4255,O
3D,4255,O
echocardiography,4255,O
.,4255,O
Cardiotoxicity,4256,B-Disease
was,4256,O
defined,4256,O
as,4256,O
a,4256,O
reduction,4256,O
of,4256,O
the,4256,O
LVEF,4256,O
of,4256,O
>,4256,O
5,4256,O
%,4256,O
to,4256,O
<,4256,O
55,4256,O
%,4256,O
with,4256,O
symptoms,4256,O
of,4256,O
heart,4256,B-Disease
failure,4256,I-Disease
or,4256,O
an,4256,O
asymptomatic,4256,O
reduction,4256,O
of,4256,O
the,4256,O
LVEF,4256,O
of,4256,O
>,4256,O
10,4256,O
%,4256,O
to,4256,O
<,4256,O
55,4256,O
%,4256,O
.,4256,O
RESULTS,4257,O
:,4257,O
Fourteen,4257,O
patients,4257,O
(,4257,O
18.67,4257,O
%,4257,O
),4257,O
developed,4257,O
cardiotoxicity,4257,B-Disease
after,4257,O
treatment,4257,O
.,4257,O
GLS,4258,O
(,4258,O
-18.48,4258,O
+,4258,O
1.72,4258,O
%,4258,O
vs.,4258,O
-15.96,4258,O
+,4258,O
1.6,4258,O
%,4258,O
),4258,O
",",4258,O
GCS,4258,O
(,4258,O
-20.93,4258,O
+,4258,O
2.86,4258,O
%,4258,O
vs.,4258,O
-19.20,4258,O
+,4258,O
3.21,4258,O
%,4258,O
),4258,O
",",4258,O
and,4258,O
GRS,4258,O
(,4258,O
39.23,4258,O
+,4258,O
6.44,4258,O
%,4258,O
vs.,4258,O
34.98,4258,O
+,4258,O
6.2,4258,O
%,4258,O
),4258,O
were,4258,O
markedly,4258,O
reduced,4258,O
and,4258,O
cTnT,4258,O
was,4258,O
elevated,4258,O
from,4258,O
0.0010,4258,O
+,4258,O
0.0020,4258,O
to,4258,O
0.0073,4258,O
+,4258,O
0.0038,4258,O
ng/mL,4258,O
(,4258,O
P,4258,O
all,4258,O
<,4258,O
0.01,4258,O
),4258,O
at,4258,O
the,4258,O
completion,4258,O
of,4258,O
chemotherapy,4258,O
compared,4258,O
with,4258,O
baseline,4258,O
values,4258,O
.,4258,O
A,4259,O
>,4259,O
15.9,4259,O
%,4259,O
decrease,4259,O
in,4259,O
GLS,4259,O
[,4259,O
sensitivity,4259,O
",",4259,O
86,4259,O
%,4259,O
;,4259,O
specificity,4259,O
",",4259,O
75,4259,O
%,4259,O
;,4259,O
area,4259,O
under,4259,O
the,4259,O
curve,4259,O
(,4259,O
AUC,4259,O
),4259,O
=,4259,O
0.815,4259,O
;,4259,O
P,4259,O
=,4259,O
0.001,4259,O
],4259,O
and,4259,O
a,4259,O
>,4259,O
0.004,4259,O
ng/mL,4259,O
elevation,4259,O
in,4259,O
cTnT,4259,O
(,4259,O
sensitivity,4259,O
",",4259,O
79,4259,O
%,4259,O
;,4259,O
specificity,4259,O
",",4259,O
64,4259,O
%,4259,O
;,4259,O
AUC,4259,O
=,4259,O
0.757,4259,O
;,4259,O
P,4259,O
=,4259,O
0.005,4259,O
),4259,O
from,4259,O
baseline,4259,O
to,4259,O
the,4259,O
third,4259,O
cycle,4259,O
of,4259,O
chemotherapy,4259,O
predicted,4259,O
later,4259,O
cardiotoxicity,4259,B-Disease
.,4259,O
The,4260,O
decrease,4260,O
in,4260,O
GLS,4260,O
remained,4260,O
the,4260,O
only,4260,O
independent,4260,O
predictor,4260,O
of,4260,O
cardiotoxicity,4260,B-Disease
(,4260,O
P,4260,O
=,4260,O
0.000,4260,O
),4260,O
.,4260,O
CONCLUSIONS,4261,O
:,4261,O
GLS,4261,O
combined,4261,O
with,4261,O
cTnT,4261,O
may,4261,O
provide,4261,O
a,4261,O
reliable,4261,O
and,4261,O
non-invasive,4261,O
method,4261,O
to,4261,O
predict,4261,O
cardiac,4261,B-Disease
dysfunction,4261,I-Disease
in,4261,O
patients,4261,O
receiving,4261,O
anthracycline-based,4261,B-Chemical
chemotherapy,4261,O
.,4261,O
Prevention,4262,O
of,4262,O
etomidate-induced,4262,B-Chemical
myoclonus,4262,B-Disease
:,4262,O
which,4262,O
is,4262,O
superior,4262,O
:,4262,O
Fentanyl,4262,B-Chemical
",",4262,O
midazolam,4262,B-Chemical
",",4262,O
or,4262,O
a,4262,O
combination,4262,O
?,4262,O
A,4263,O
Retrospective,4263,O
comparative,4263,O
study,4263,O
.,4263,O
BACKGROUND,4264,O
:,4264,O
In,4264,O
this,4264,O
retrospective,4264,O
comparative,4264,O
study,4264,O
",",4264,O
we,4264,O
aimed,4264,O
to,4264,O
compare,4264,O
the,4264,O
effectiveness,4264,O
of,4264,O
fentanyl,4264,B-Chemical
",",4264,O
midazolam,4264,B-Chemical
",",4264,O
and,4264,O
a,4264,O
combination,4264,O
of,4264,O
fentanyl,4264,B-Chemical
and,4264,O
midazolam,4264,B-Chemical
to,4264,O
prevent,4264,O
etomidate-induced,4264,B-Chemical
myoclonus,4264,B-Disease
.,4264,O
MATERIAL,4265,O
AND,4265,O
METHODS,4265,O
:,4265,O
This,4265,O
study,4265,O
was,4265,O
performed,4265,O
based,4265,O
on,4265,O
anesthesia,4265,O
records,4265,O
.,4265,O
Depending,4266,O
on,4266,O
the,4266,O
drugs,4266,O
that,4266,O
would,4266,O
be,4266,O
given,4266,O
before,4266,O
the,4266,O
induction,4266,O
of,4266,O
anesthesia,4266,O
with,4266,O
etomidate,4266,B-Chemical
",",4266,O
the,4266,O
patients,4266,O
were,4266,O
separated,4266,O
into,4266,O
4,4266,O
groups,4266,O
:,4266,O
no,4266,O
pretreatment,4266,O
(,4266,O
Group,4266,O
NP,4266,O
),4266,O
",",4266,O
fentanyl,4266,B-Chemical
1,4266,O
ug.kg-1,4266,O
(,4266,O
Group,4266,O
F,4266,O
),4266,O
",",4266,O
midazolam,4266,B-Chemical
0.03,4266,O
mg.kg-1,4266,O
(,4266,O
Group,4266,O
M,4266,O
),4266,O
",",4266,O
and,4266,O
midazolam,4266,B-Chemical
0.015,4266,O
mg.kg-1,4266,O
+,4266,O
fentanyl,4266,B-Chemical
0.5,4266,O
ug.kg-1,4266,O
(,4266,O
Group,4266,O
FM,4266,O
),4266,O
.,4266,O
Patients,4267,O
who,4267,O
received,4267,O
the,4267,O
same,4267,O
anesthetic,4267,O
procedure,4267,O
were,4267,O
selected,4267,O
:,4267,O
2,4267,O
minutes,4267,O
after,4267,O
intravenous,4267,O
injections,4267,O
of,4267,O
the,4267,O
pretreatment,4267,O
drugs,4267,O
",",4267,O
anesthesia,4267,O
is,4267,O
induced,4267,O
with,4267,O
0.3,4267,O
mg.kg-1,4267,O
etomidate,4267,B-Chemical
injected,4267,O
intravenously,4267,O
over,4267,O
a,4267,O
period,4267,O
of,4267,O
20-30,4267,O
seconds,4267,O
.,4267,O
Myoclonic,4268,B-Disease
movements,4268,I-Disease
are,4268,O
evaluated,4268,O
",",4268,O
which,4268,O
were,4268,O
observed,4268,O
and,4268,O
graded,4268,O
according,4268,O
to,4268,O
clinical,4268,O
severity,4268,O
during,4268,O
the,4268,O
2,4268,O
minutes,4268,O
after,4268,O
etomidate,4268,B-Chemical
injection,4268,O
.,4268,O
The,4269,O
severity,4269,O
of,4269,O
pain,4269,B-Disease
due,4269,O
to,4269,O
etomidate,4269,B-Chemical
injection,4269,O
",",4269,O
mean,4269,O
arterial,4269,O
pressure,4269,O
",",4269,O
heart,4269,O
rate,4269,O
",",4269,O
and,4269,O
adverse,4269,O
effects,4269,O
were,4269,O
also,4269,O
evaluated,4269,O
.,4269,O
RESULTS,4270,O
:,4270,O
Study,4270,O
results,4270,O
showed,4270,O
that,4270,O
myoclonus,4270,B-Disease
incidence,4270,O
was,4270,O
85,4270,O
%,4270,O
",",4270,O
40,4270,O
%,4270,O
",",4270,O
70,4270,O
%,4270,O
",",4270,O
and,4270,O
25,4270,O
%,4270,O
in,4270,O
Group,4270,O
NP,4270,O
",",4270,O
Group,4270,O
F,4270,O
",",4270,O
Group,4270,O
M,4270,O
",",4270,O
and,4270,O
Group,4270,O
FM,4270,O
",",4270,O
respectively,4270,O
",",4270,O
and,4270,O
were,4270,O
significantly,4270,O
lower,4270,O
in,4270,O
Group,4270,O
F,4270,O
and,4270,O
Group,4270,O
FM,4270,O
.,4270,O
CONCLUSIONS,4271,O
:,4271,O
We,4271,O
conclude,4271,O
that,4271,O
pretreatment,4271,O
with,4271,O
fentanyl,4271,B-Chemical
or,4271,O
combination,4271,O
of,4271,O
fentanyl,4271,B-Chemical
and,4271,O
midazolam,4271,B-Chemical
was,4271,O
effective,4271,O
in,4271,O
preventing,4271,O
etomidate-induced,4271,B-Chemical
myoclonus,4271,B-Disease
.,4271,O
Cholestatic,4272,B-Disease
presentation,4272,O
of,4272,O
yellow,4272,O
phosphorus,4272,B-Chemical
poisoning,4272,B-Disease
.,4272,O
Yellow,4273,O
phosphorus,4273,B-Chemical
",",4273,O
a,4273,O
component,4273,O
of,4273,O
certain,4273,O
pesticide,4273,O
pastes,4273,O
and,4273,O
fireworks,4273,O
",",4273,O
is,4273,O
well,4273,O
known,4273,O
to,4273,O
cause,4273,O
hepatotoxicity,4273,B-Disease
.,4273,O
Poisoning,4274,B-Disease
with,4274,O
yellow,4274,O
phosphorus,4274,B-Chemical
classically,4274,O
manifests,4274,O
with,4274,O
acute,4274,B-Disease
hepatitis,4274,I-Disease
leading,4274,O
to,4274,O
acute,4274,B-Disease
liver,4274,I-Disease
failure,4274,I-Disease
which,4274,O
may,4274,O
need,4274,O
liver,4274,O
transplantation,4274,O
.,4274,O
We,4275,O
present,4275,O
a,4275,O
case,4275,O
of,4275,O
yellow,4275,O
phosphorus,4275,B-Chemical
poisoning,4275,B-Disease
in,4275,O
which,4275,O
a,4275,O
patient,4275,O
presented,4275,O
with,4275,O
florid,4275,O
clinical,4275,O
features,4275,O
of,4275,O
cholestasis,4275,B-Disease
highlighting,4275,O
the,4275,O
fact,4275,O
that,4275,O
cholestasis,4275,B-Disease
can,4275,O
rarely,4275,O
be,4275,O
a,4275,O
presenting,4275,O
feature,4275,O
of,4275,O
yellow,4275,O
phosphorus,4275,B-Chemical
hepatotoxicity,4275,B-Disease
.,4275,O
Vasovagal,4276,B-Disease
syncope,4276,I-Disease
and,4276,O
severe,4276,O
bradycardia,4276,B-Disease
following,4276,O
intranasal,4276,O
dexmedetomidine,4276,B-Chemical
for,4276,O
pediatric,4276,O
procedural,4276,O
sedation,4276,O
.,4276,O
We,4277,O
report,4277,O
syncope,4277,B-Disease
and,4277,O
bradycardia,4277,B-Disease
in,4277,O
an,4277,O
11-year-old,4277,O
girl,4277,O
following,4277,O
administration,4277,O
of,4277,O
intranasal,4277,O
dexmedetomidine,4277,B-Chemical
for,4277,O
sedation,4277,O
for,4277,O
a,4277,O
voiding,4277,O
cystourethrogram,4277,O
.,4277,O
Following,4278,O
successful,4278,O
completion,4278,O
of,4278,O
VCUG,4278,O
and,4278,O
a,4278,O
60-min,4278,O
recovery,4278,O
period,4278,O
",",4278,O
the,4278,O
patient,4278,O
's,4278,O
level,4278,O
of,4278,O
consciousness,4278,O
and,4278,O
vital,4278,O
signs,4278,O
returned,4278,O
to,4278,O
presedation,4278,O
levels,4278,O
.,4278,O
Upon,4279,O
leaving,4279,O
the,4279,O
sedation,4279,O
area,4279,O
",",4279,O
the,4279,O
patient,4279,O
collapsed,4279,O
",",4279,O
with,4279,O
no,4279,O
apparent,4279,O
inciting,4279,O
event,4279,O
.,4279,O
The,4280,O
patient,4280,O
quickly,4280,O
regained,4280,O
consciousness,4280,O
and,4280,O
no,4280,O
injury,4280,O
occurred,4280,O
.,4280,O
The,4281,O
primary,4281,O
abnormality,4281,O
found,4281,O
was,4281,O
persistent,4281,O
bradycardia,4281,B-Disease
",",4281,O
and,4281,O
she,4281,O
was,4281,O
admitted,4281,O
to,4281,O
the,4281,O
hospital,4281,O
for,4281,O
telemetric,4281,O
observation,4281,O
.,4281,O
The,4282,O
bradycardia,4282,B-Disease
lasted,4282,O
~2,4282,O
h,4282,O
",",4282,O
and,4282,O
further,4282,O
cardiac,4282,O
workup,4282,O
revealed,4282,O
no,4282,O
underlying,4282,O
abnormality,4282,O
.,4282,O
Unanticipated,4283,O
and,4283,O
previously,4283,O
unreported,4283,O
outcomes,4283,O
may,4283,O
be,4283,O
witnessed,4283,O
as,4283,O
we,4283,O
expand,4283,O
the,4283,O
use,4283,O
of,4283,O
certain,4283,O
sedatives,4283,O
to,4283,O
alternative,4283,O
routes,4283,O
of,4283,O
administration,4283,O
.,4283,O
Paradoxical,4284,O
severe,4284,O
agitation,4284,B-Disease
induced,4284,O
by,4284,O
add-on,4284,O
high-doses,4284,O
quetiapine,4284,B-Chemical
in,4284,O
schizo-affective,4284,B-Disease
disorder,4284,I-Disease
.,4284,O
We,4285,O
report,4285,O
the,4285,O
case,4285,O
of,4285,O
a,4285,O
35-year-old,4285,O
patient,4285,O
suffering,4285,O
from,4285,O
schizo-affective,4285,B-Disease
disorder,4285,I-Disease
since,4285,O
the,4285,O
age,4285,O
of,4285,O
19,4285,O
years,4285,O
",",4285,O
treated,4285,O
by,4285,O
a,4285,O
combination,4285,O
of,4285,O
first-generation,4285,O
antipsychotics,4285,O
",",4285,O
zuclopenthixol,4285,B-Chemical
(,4285,O
100,4285,O
mg/day,4285,O
),4285,O
and,4285,O
lithium,4285,B-Chemical
(,4285,O
1200,4285,O
mg/day,4285,O
),4285,O
(,4285,O
serum,4285,O
lithium=0.85,4285,B-Chemical
mEq/l,4285,O
),4285,O
.,4285,O
This,4286,O
patient,4286,O
had,4286,O
no,4286,O
associated,4286,O
personality,4286,B-Disease
disorder,4286,I-Disease
(,4286,O
particularly,4286,O
no,4286,O
antisocial,4286,B-Disease
disorder,4286,I-Disease
),4286,O
and,4286,O
no,4286,O
substance,4286,B-Disease
abuse,4286,I-Disease
disorder,4286,I-Disease
.,4286,O
Within,4287,O
the,4287,O
48,4287,O
h,4287,O
following,4287,O
the,4287,O
gradual,4287,O
introduction,4287,O
of,4287,O
quetiapine,4287,B-Chemical
(,4287,O
up,4287,O
to,4287,O
600,4287,O
mg/day,4287,O
),4287,O
",",4287,O
the,4287,O
patient,4287,O
presented,4287,O
severe,4287,O
agitation,4287,B-Disease
without,4287,O
an,4287,O
environmental,4287,O
explanation,4287,O
",",4287,O
contrasting,4287,O
with,4287,O
the,4287,O
absence,4287,O
of,4287,O
a,4287,O
history,4287,O
of,4287,O
aggressiveness,4287,B-Disease
or,4287,O
personality,4287,B-Disease
disorder,4287,I-Disease
.,4287,O
The,4288,O
diagnoses,4288,O
of,4288,O
manic,4288,B-Disease
shift,4288,O
and,4288,O
akathisia,4288,B-Disease
were,4288,O
dismissed,4288,O
.,4288,O
The,4289,O
withdrawal,4289,O
and,4289,O
the,4289,O
gradual,4289,O
reintroduction,4289,O
of,4289,O
quetiapine,4289,B-Chemical
2,4289,O
weeks,4289,O
later,4289,O
",",4289,O
which,4289,O
led,4289,O
to,4289,O
another,4289,O
severe,4289,O
agitation,4289,B-Disease
",",4289,O
enabled,4289,O
us,4289,O
to,4289,O
attribute,4289,O
the,4289,O
agitation,4289,B-Disease
specifically,4289,O
to,4289,O
quetiapine,4289,B-Chemical
.,4289,O
Antioxidant,4290,O
effects,4290,O
of,4290,O
bovine,4290,O
lactoferrin,4290,O
on,4290,O
dexamethasone-induced,4290,B-Chemical
hypertension,4290,B-Disease
in,4290,O
rat,4290,O
.,4290,O
Dexamethasone-,4291,B-Chemical
(,4291,O
Dex-,4291,B-Chemical
),4291,O
induced,4291,O
hypertension,4291,B-Disease
is,4291,O
associated,4291,O
with,4291,O
enhanced,4291,O
oxidative,4291,O
stress,4291,O
.,4291,O
Lactoferrin,4292,O
(,4292,O
LF,4292,O
),4292,O
is,4292,O
an,4292,O
iron-binding,4292,B-Chemical
glycoprotein,4292,O
with,4292,O
antihypertensive,4292,O
properties,4292,O
.,4292,O
In,4293,O
this,4293,O
study,4293,O
",",4293,O
we,4293,O
investigated,4293,O
the,4293,O
effect,4293,O
of,4293,O
chronic,4293,O
administration,4293,O
of,4293,O
LF,4293,O
on,4293,O
oxidative,4293,O
stress,4293,O
and,4293,O
hypertension,4293,B-Disease
upon,4293,O
Dex,4293,B-Chemical
administration,4293,O
.,4293,O
Male,4294,O
Wistar,4294,O
rats,4294,O
were,4294,O
treated,4294,O
by,4294,O
Dex,4294,B-Chemical
(,4294,O
30,4294,O
u,4294,O
g/kg/day,4294,O
subcutaneously,4294,O
),4294,O
or,4294,O
saline,4294,O
for,4294,O
14,4294,O
days,4294,O
.,4294,O
Oral,4295,O
bovine,4295,O
LF,4295,O
(,4295,O
30,4295,O
",",4295,O
100,4295,O
",",4295,O
300,4295,O
mg/kg,4295,O
),4295,O
was,4295,O
given,4295,O
from,4295,O
day,4295,O
8,4295,O
to,4295,O
14,4295,O
in,4295,O
a,4295,O
reversal,4295,O
study,4295,O
.,4295,O
In,4296,O
a,4296,O
prevention,4296,O
study,4296,O
",",4296,O
rats,4296,O
received,4296,O
4,4296,O
days,4296,O
of,4296,O
LF,4296,O
treatment,4296,O
followed,4296,O
by,4296,O
Dex,4296,B-Chemical
and,4296,O
continued,4296,O
during,4296,O
the,4296,O
test,4296,O
period,4296,O
.,4296,O
Systolic,4297,O
blood,4297,O
pressure,4297,O
(,4297,O
SBP,4297,O
),4297,O
was,4297,O
measured,4297,O
using,4297,O
tail-cuff,4297,O
method,4297,O
.,4297,O
Thymus,4298,O
weight,4298,O
was,4298,O
used,4298,O
as,4298,O
a,4298,O
marker,4298,O
of,4298,O
glucocorticoid,4298,O
activity,4298,O
.,4298,O
Plasma,4299,O
hydrogen,4299,B-Chemical
peroxide,4299,I-Chemical
(,4299,O
H2O2,4299,B-Chemical
),4299,O
concentration,4299,O
and,4299,O
ferric,4299,O
reducing,4299,O
antioxidant,4299,O
power,4299,O
(,4299,O
FRAP,4299,O
),4299,O
value,4299,O
were,4299,O
determined,4299,O
.,4299,O
Dexamethasone,4300,B-Chemical
significantly,4300,O
increased,4300,O
SBP,4300,O
and,4300,O
plasma,4300,O
H2O2,4300,B-Chemical
level,4300,O
and,4300,O
decreased,4300,O
thymus,4300,O
and,4300,O
body,4300,O
weights,4300,O
.,4300,O
LF,4301,O
lowered,4301,O
(,4301,O
P,4301,O
<,4301,O
0.01,4301,O
),4301,O
and,4301,O
dose,4301,O
dependently,4301,O
prevented,4301,O
(,4301,O
P,4301,O
<,4301,O
0.001,4301,O
),4301,O
Dex-induced,4301,B-Chemical
hypertension,4301,B-Disease
.,4301,O
LF,4302,O
prevented,4302,O
body,4302,O
weight,4302,B-Disease
loss,4302,I-Disease
and,4302,O
significantly,4302,O
reduced,4302,O
the,4302,O
elevated,4302,O
plasma,4302,O
H2O2,4302,B-Chemical
and,4302,O
increased,4302,O
FRAP,4302,O
values,4302,O
.,4302,O
Chronic,4303,O
administration,4303,O
of,4303,O
LF,4303,O
strongly,4303,O
reduced,4303,O
the,4303,O
blood,4303,O
pressure,4303,O
and,4303,O
production,4303,O
of,4303,O
ROS,4303,O
and,4303,O
improved,4303,O
antioxidant,4303,O
capacity,4303,O
in,4303,O
Dex-induced,4303,B-Chemical
hypertension,4303,B-Disease
",",4303,O
suggesting,4303,O
the,4303,O
role,4303,O
of,4303,O
inhibition,4303,O
of,4303,O
oxidative,4303,O
stress,4303,O
as,4303,O
another,4303,O
mechanism,4303,O
of,4303,O
antihypertensive,4303,O
action,4303,O
of,4303,O
LF,4303,O
.,4303,O
The,4304,O
association,4304,O
between,4304,O
tranexamic,4304,B-Chemical
acid,4304,I-Chemical
and,4304,O
convulsive,4304,B-Disease
seizures,4304,B-Disease
after,4304,O
cardiac,4304,O
surgery,4304,O
:,4304,O
a,4304,O
multivariate,4304,O
analysis,4304,O
in,4304,O
11,4304,O
529,4304,O
patients,4304,O
.,4304,O
Because,4305,O
of,4305,O
a,4305,O
lack,4305,O
of,4305,O
contemporary,4305,O
data,4305,O
regarding,4305,O
seizures,4305,B-Disease
after,4305,O
cardiac,4305,O
surgery,4305,O
",",4305,O
we,4305,O
undertook,4305,O
a,4305,O
retrospective,4305,O
analysis,4305,O
of,4305,O
prospectively,4305,O
collected,4305,O
data,4305,O
from,4305,O
11,4305,O
529,4305,O
patients,4305,O
in,4305,O
whom,4305,O
cardiopulmonary,4305,O
bypass,4305,O
was,4305,O
used,4305,O
from,4305,O
January,4305,O
2004,4305,O
to,4305,O
December,4305,O
2010,4305,O
.,4305,O
A,4306,O
convulsive,4306,B-Disease
seizure,4306,B-Disease
was,4306,O
defined,4306,O
as,4306,O
a,4306,O
transient,4306,O
episode,4306,O
of,4306,O
disturbed,4306,O
brain,4306,O
function,4306,O
characterised,4306,O
by,4306,O
abnormal,4306,B-Disease
involuntary,4306,I-Disease
motor,4306,I-Disease
movements,4306,I-Disease
.,4306,O
Multivariate,4307,O
regression,4307,O
analysis,4307,O
was,4307,O
performed,4307,O
to,4307,O
identify,4307,O
independent,4307,O
predictors,4307,O
of,4307,O
postoperative,4307,O
seizures,4307,B-Disease
.,4307,O
A,4308,O
total,4308,O
of,4308,O
100,4308,O
(,4308,O
0.9,4308,O
%,4308,O
),4308,O
patients,4308,O
developed,4308,O
postoperative,4308,O
convulsive,4308,B-Disease
seizures,4308,B-Disease
.,4308,O
Generalised,4309,B-Disease
and,4309,I-Disease
focal,4309,I-Disease
seizures,4309,I-Disease
were,4309,O
identified,4309,O
in,4309,O
68,4309,O
and,4309,O
32,4309,O
patients,4309,O
",",4309,O
respectively,4309,O
.,4309,O
The,4310,O
median,4310,O
(,4310,O
IQR,4310,O
[,4310,O
range,4310,O
],4310,O
),4310,O
time,4310,O
after,4310,O
surgery,4310,O
when,4310,O
the,4310,O
seizure,4310,B-Disease
occurred,4310,O
was,4310,O
7,4310,O
(,4310,O
6-12,4310,O
[,4310,O
1-216,4310,O
],4310,O
),4310,O
h,4310,O
and,4310,O
8,4310,O
(,4310,O
6-11,4310,O
[,4310,O
4-18,4310,O
],4310,O
),4310,O
h,4310,O
",",4310,O
respectively,4310,O
.,4310,O
Epileptiform,4311,O
findings,4311,O
on,4311,O
electroencephalography,4311,O
were,4311,O
seen,4311,O
in,4311,O
19,4311,O
patients,4311,O
.,4311,O
Independent,4312,O
predictors,4312,O
of,4312,O
postoperative,4312,O
seizures,4312,B-Disease
included,4312,O
age,4312,O
",",4312,O
female,4312,O
sex,4312,O
",",4312,O
redo,4312,O
cardiac,4312,O
surgery,4312,O
",",4312,O
calcification,4312,O
of,4312,O
ascending,4312,O
aorta,4312,O
",",4312,O
congestive,4312,B-Disease
heart,4312,I-Disease
failure,4312,I-Disease
",",4312,O
deep,4312,O
hypothermic,4312,B-Disease
circulatory,4312,O
arrest,4312,O
",",4312,O
duration,4312,O
of,4312,O
aortic,4312,O
cross-clamp,4312,O
and,4312,O
tranexamic,4312,B-Chemical
acid,4312,I-Chemical
.,4312,O
When,4313,O
tested,4313,O
in,4313,O
a,4313,O
multivariate,4313,O
regression,4313,O
analysis,4313,O
",",4313,O
tranexamic,4313,B-Chemical
acid,4313,I-Chemical
was,4313,O
a,4313,O
strong,4313,O
independent,4313,O
predictor,4313,O
of,4313,O
seizures,4313,B-Disease
(,4313,O
OR,4313,O
14.3,4313,O
",",4313,O
95,4313,O
%,4313,O
CI,4313,O
5.5-36.7,4313,O
;,4313,O
p,4313,O
<,4313,O
0.001,4313,O
),4313,O
.,4313,O
Patients,4314,O
with,4314,O
convulsive,4314,B-Disease
seizures,4314,B-Disease
had,4314,O
2.5,4314,O
times,4314,O
higher,4314,O
in-hospital,4314,O
mortality,4314,O
rates,4314,O
and,4314,O
twice,4314,O
the,4314,O
length,4314,O
of,4314,O
hospital,4314,O
stay,4314,O
compared,4314,O
with,4314,O
patients,4314,O
without,4314,O
convulsive,4314,B-Disease
seizures,4314,B-Disease
.,4314,O
Mean,4315,O
(,4315,O
IQR,4315,O
[,4315,O
range,4315,O
],4315,O
),4315,O
length,4315,O
of,4315,O
stay,4315,O
in,4315,O
the,4315,O
intensive,4315,O
care,4315,O
unit,4315,O
was,4315,O
115,4315,O
(,4315,O
49-228,4315,O
[,4315,O
32-481,4315,O
],4315,O
),4315,O
h,4315,O
in,4315,O
patients,4315,O
with,4315,O
convulsive,4315,B-Disease
seizures,4315,B-Disease
compared,4315,O
with,4315,O
26,4315,O
(,4315,O
22-69,4315,O
[,4315,O
14-1080,4315,O
],4315,O
),4315,O
h,4315,O
in,4315,O
patients,4315,O
without,4315,O
seizures,4315,B-Disease
(,4315,O
p,4315,O
<,4315,O
0.001,4315,O
),4315,O
.,4315,O
Convulsive,4316,B-Disease
seizures,4316,B-Disease
are,4316,O
a,4316,O
serious,4316,O
postoperative,4316,B-Disease
complication,4316,I-Disease
after,4316,O
cardiac,4316,O
surgery,4316,O
.,4316,O
As,4317,O
tranexamic,4317,B-Chemical
acid,4317,I-Chemical
is,4317,O
the,4317,O
only,4317,O
modifiable,4317,O
factor,4317,O
",",4317,O
its,4317,O
administration,4317,O
",",4317,O
particularly,4317,O
in,4317,O
doses,4317,O
exceeding,4317,O
80,4317,O
mg.kg,4317,O
(,4317,O
-1,4317,O
),4317,O
",",4317,O
should,4317,O
be,4317,O
weighed,4317,O
against,4317,O
the,4317,O
risk,4317,O
of,4317,O
postoperative,4317,O
seizures,4317,B-Disease
.,4317,O
Dysfunctional,4318,B-Disease
overnight,4318,I-Disease
memory,4318,I-Disease
consolidation,4318,O
in,4318,O
ecstasy,4318,B-Chemical
users,4318,O
.,4318,O
Sleep,4319,O
plays,4319,O
an,4319,O
important,4319,O
role,4319,O
in,4319,O
the,4319,O
consolidation,4319,O
and,4319,O
integration,4319,O
of,4319,O
memory,4319,O
in,4319,O
a,4319,O
process,4319,O
called,4319,O
overnight,4319,O
memory,4319,O
consolidation,4319,O
.,4319,O
Previous,4320,O
studies,4320,O
indicate,4320,O
that,4320,O
ecstasy,4320,B-Chemical
users,4320,O
have,4320,O
marked,4320,O
and,4320,O
persistent,4320,O
neurocognitive,4320,O
and,4320,O
sleep-related,4320,B-Disease
impairments,4320,I-Disease
.,4320,O
We,4321,O
extend,4321,O
past,4321,O
research,4321,O
by,4321,O
examining,4321,O
overnight,4321,O
memory,4321,O
consolidation,4321,O
among,4321,O
regular,4321,O
ecstasy,4321,B-Chemical
users,4321,O
(,4321,O
n=12,4321,O
),4321,O
and,4321,O
drug,4321,O
naive,4321,O
healthy,4321,O
controls,4321,O
(,4321,O
n=26,4321,O
),4321,O
.,4321,O
Memory,4322,O
recall,4322,O
of,4322,O
word,4322,O
pairs,4322,O
was,4322,O
evaluated,4322,O
before,4322,O
and,4322,O
after,4322,O
a,4322,O
period,4322,O
of,4322,O
sleep,4322,O
",",4322,O
with,4322,O
and,4322,O
without,4322,O
interference,4322,O
prior,4322,O
to,4322,O
testing,4322,O
.,4322,O
In,4323,O
addition,4323,O
",",4323,O
we,4323,O
assessed,4323,O
neurocognitive,4323,O
performances,4323,O
across,4323,O
tasks,4323,O
of,4323,O
learning,4323,O
",",4323,O
memory,4323,O
and,4323,O
executive,4323,O
functioning,4323,O
.,4323,O
Ecstasy,4324,B-Chemical
users,4324,O
demonstrated,4324,O
impaired,4324,B-Disease
overnight,4324,I-Disease
memory,4324,I-Disease
consolidation,4324,O
",",4324,O
a,4324,O
finding,4324,O
that,4324,O
was,4324,O
more,4324,O
pronounced,4324,O
following,4324,O
associative,4324,O
interference,4324,O
.,4324,O
Additionally,4325,O
",",4325,O
ecstasy,4325,B-Chemical
users,4325,O
demonstrated,4325,O
impairments,4325,O
on,4325,O
tasks,4325,O
recruiting,4325,O
frontostriatal,4325,O
and,4325,O
hippocampal,4325,O
neural,4325,O
circuitry,4325,O
",",4325,O
in,4325,O
the,4325,O
domains,4325,O
of,4325,O
proactive,4325,O
interference,4325,O
memory,4325,O
",",4325,O
long-term,4325,O
memory,4325,O
",",4325,O
encoding,4325,O
",",4325,O
working,4325,O
memory,4325,O
and,4325,O
complex,4325,O
planning,4325,O
.,4325,O
We,4326,O
suggest,4326,O
that,4326,O
ecstasy-associated,4326,B-Chemical
dysfunction,4326,O
in,4326,O
fronto-temporal,4326,O
circuitry,4326,O
may,4326,O
underlie,4326,O
overnight,4326,O
consolidation,4326,O
memory,4326,B-Disease
impairments,4326,I-Disease
in,4326,O
regular,4326,O
ecstasy,4326,B-Chemical
users,4326,O
.,4326,O
Normoammonemic,4327,O
encephalopathy,4327,B-Disease
:,4327,O
solely,4327,O
valproate,4327,B-Chemical
induced,4327,O
or,4327,O
multiple,4327,O
mechanisms,4327,O
?,4327,O
A,4328,O
77-year-old,4328,O
woman,4328,O
presented,4328,O
with,4328,O
subacute,4328,O
onset,4328,O
progressive,4328,O
confusion,4328,B-Disease
",",4328,O
aggression,4328,B-Disease
",",4328,O
auditory,4328,B-Disease
hallucinations,4328,I-Disease
and,4328,O
delusions,4328,B-Disease
.,4328,O
In,4329,O
the,4329,O
preceding,4329,O
months,4329,O
",",4329,O
the,4329,O
patient,4329,O
had,4329,O
a,4329,O
number,4329,O
of,4329,O
admissions,4329,O
with,4329,O
transient,4329,O
unilateral,4329,O
hemiparesis,4329,B-Disease
with,4329,O
facial,4329,O
droop,4329,O
",",4329,O
and,4329,O
had,4329,O
been,4329,O
started,4329,O
on,4329,O
valproate,4329,B-Chemical
for,4329,O
presumed,4329,O
hemiplegic,4329,B-Disease
migraine,4329,I-Disease
.,4329,O
Valproate,4330,B-Chemical
was,4330,O
withdrawn,4330,O
soon,4330,O
after,4330,O
admission,4330,O
and,4330,O
her,4330,O
cognitive,4330,O
abilities,4330,O
have,4330,O
gradually,4330,O
improved,4330,O
over,4330,O
3,4330,O
months,4330,O
of,4330,O
follow-up,4330,O
.,4330,O
Valproate,4331,B-Chemical
levels,4331,O
taken,4331,O
prior,4331,O
to,4331,O
withdrawal,4331,O
were,4331,O
subtherapeutic,4331,O
and,4331,O
the,4331,O
patient,4331,O
was,4331,O
normoammonaemic,4331,O
.,4331,O
EEG,4332,O
undertaken,4332,O
during,4332,O
inpatient,4332,O
stay,4332,O
showed,4332,O
changes,4332,O
consistent,4332,O
with,4332,O
encephalopathy,4332,B-Disease
",",4332,O
and,4332,O
low,4332,O
titre,4332,O
N-methyl-D-aspartate,4332,B-Chemical
(,4332,O
NMDA,4332,B-Chemical
),4332,O
receptor,4332,O
antibodies,4332,O
were,4332,O
present,4332,O
in,4332,O
this,4332,O
patient,4332,O
.,4332,O
The,4333,O
possible,4333,O
aetiologies,4333,O
of,4333,O
valproate-induced,4333,B-Chemical
encephalopathy,4333,B-Disease
and,4333,O
NMDA,4333,B-Chemical
receptor-associated,4333,O
encephalitis,4333,B-Disease
present,4333,O
a,4333,O
diagnostic,4333,O
dilemma,4333,O
.,4333,O
We,4334,O
present,4334,O
a,4334,O
putative,4334,O
combinatorial,4334,O
hypothesis,4334,O
to,4334,O
explain,4334,O
this,4334,O
patient,4334,O
's,4334,O
symptoms,4334,O
.,4334,O
Cerebellar,4335,O
and,4335,O
oculomotor,4335,O
dysfunction,4335,O
induced,4335,O
by,4335,O
rapid,4335,O
infusion,4335,O
of,4335,O
pethidine,4335,B-Chemical
.,4335,O
Pethidine,4336,B-Chemical
is,4336,O
an,4336,O
opioid,4336,O
that,4336,O
gains,4336,O
its,4336,O
popularity,4336,O
for,4336,O
the,4336,O
effective,4336,O
pain,4336,B-Disease
control,4336,O
through,4336,O
acting,4336,O
on,4336,O
the,4336,O
opioid-receptors,4336,O
.,4336,O
However,4337,O
",",4337,O
rapid,4337,O
pain,4337,B-Disease
relief,4337,O
sometimes,4337,O
brings,4337,O
about,4337,O
unfavourable,4337,O
side,4337,O
effects,4337,O
that,4337,O
largely,4337,O
limit,4337,O
its,4337,O
clinical,4337,O
utility,4337,O
.,4337,O
Common,4338,O
side,4338,O
effects,4338,O
include,4338,O
nausea,4338,B-Disease
",",4338,O
vomiting,4338,B-Disease
and,4338,O
hypotension,4338,B-Disease
.,4338,O
In,4339,O
patients,4339,O
with,4339,O
impaired,4339,O
renal,4339,O
and,4339,O
liver,4339,O
function,4339,O
",",4339,O
and,4339,O
those,4339,O
who,4339,O
need,4339,O
long-term,4339,O
pain,4339,B-Disease
control,4339,O
",",4339,O
pethidine,4339,B-Chemical
may,4339,O
cause,4339,O
excitatory,4339,O
central,4339,O
nervous,4339,O
system,4339,O
(,4339,O
CNS,4339,O
),4339,O
effects,4339,O
through,4339,O
its,4339,O
neurotoxic,4339,B-Disease
metabolite,4339,O
",",4339,O
norpethidine,4339,B-Chemical
",",4339,O
resulting,4339,O
in,4339,O
irritability,4339,B-Disease
and,4339,O
seizure,4339,B-Disease
attack,4339,O
.,4339,O
On,4340,O
the,4340,O
contrary,4340,O
",",4340,O
though,4340,O
not,4340,O
clinically,4340,O
apparent,4340,O
",",4340,O
pethidine,4340,B-Chemical
potentially,4340,O
causes,4340,O
inhibitory,4340,O
impacts,4340,O
on,4340,O
the,4340,O
CNS,4340,O
and,4340,O
impairs,4340,O
normal,4340,O
cerebellar,4340,O
and,4340,O
oculomotor,4340,O
function,4340,O
in,4340,O
the,4340,O
short,4340,O
term,4340,O
.,4340,O
In,4341,O
this,4341,O
case,4341,O
report,4341,O
",",4341,O
we,4341,O
highlight,4341,O
opioid,4341,O
's,4341,O
inhibitory,4341,O
side,4341,O
effects,4341,O
on,4341,O
the,4341,O
cerebellar,4341,O
structure,4341,O
that,4341,O
causes,4341,O
dysmetria,4341,B-Disease
",",4341,O
dysarthria,4341,B-Disease
",",4341,O
reduced,4341,O
smooth,4341,O
pursuit,4341,O
gain,4341,O
and,4341,O
decreased,4341,O
saccadic,4341,O
velocity,4341,O
.,4341,O
Baboon,4342,B-Disease
syndrome,4342,I-Disease
induced,4342,O
by,4342,O
ketoconazole,4342,B-Chemical
.,4342,O
A,4343,O
27-year-old,4343,O
male,4343,O
patient,4343,O
presented,4343,O
with,4343,O
a,4343,O
maculopapular,4343,B-Disease
eruption,4343,I-Disease
on,4343,O
the,4343,O
flexural,4343,O
areas,4343,O
and,4343,O
buttocks,4343,O
after,4343,O
using,4343,O
oral,4343,O
ketoconazole,4343,B-Chemical
.,4343,O
The,4344,O
patient,4344,O
was,4344,O
diagnosed,4344,O
with,4344,O
drug-induced,4344,O
baboon,4344,B-Disease
syndrome,4344,I-Disease
based,4344,O
on,4344,O
his,4344,O
history,4344,O
",",4344,O
which,4344,O
included,4344,O
prior,4344,O
sensitivity,4344,O
to,4344,O
topical,4344,O
ketoconazole,4344,B-Chemical
",",4344,O
a,4344,O
physical,4344,O
examination,4344,O
",",4344,O
and,4344,O
histopathological,4344,O
findings,4344,O
.,4344,O
Baboon,4345,B-Disease
syndrome,4345,I-Disease
is,4345,O
a,4345,O
drug-,4345,O
or,4345,O
contact,4345,O
allergen-related,4345,O
maculopapular,4345,B-Disease
eruption,4345,I-Disease
that,4345,O
typically,4345,O
involves,4345,O
the,4345,O
flexural,4345,O
and,4345,O
gluteal,4345,O
areas,4345,O
.,4345,O
To,4346,O
the,4346,O
best,4346,O
of,4346,O
our,4346,O
knowledge,4346,O
",",4346,O
this,4346,O
is,4346,O
the,4346,O
first,4346,O
reported,4346,O
case,4346,O
of,4346,O
ketoconazole-induced,4346,B-Chemical
baboon,4346,B-Disease
syndrome,4346,I-Disease
in,4346,O
the,4346,O
English,4346,O
literature,4346,O
.,4346,O
A,4347,O
Case,4347,O
of,4347,O
Sudden,4347,B-Disease
Cardiac,4347,I-Disease
Death,4347,I-Disease
due,4347,O
to,4347,O
Pilsicainide-Induced,4347,B-Chemical
Torsades,4347,B-Disease
de,4347,I-Disease
Pointes,4347,I-Disease
.,4347,O
An,4348,O
84-year-old,4348,O
male,4348,O
received,4348,O
oral,4348,O
pilsicainide,4348,B-Chemical
",",4348,O
a,4348,O
pure,4348,O
sodium,4348,B-Chemical
channel,4348,O
blocker,4348,O
with,4348,O
slow,4348,O
recovery,4348,O
kinetics,4348,O
",",4348,O
to,4348,O
convert,4348,O
his,4348,O
paroxysmal,4348,O
atrial,4348,B-Disease
fibrillation,4348,I-Disease
to,4348,O
a,4348,O
sinus,4348,O
rhythm,4348,O
;,4348,O
the,4348,O
patient,4348,O
developed,4348,O
sudden,4348,B-Disease
cardiac,4348,I-Disease
death,4348,I-Disease
two,4348,O
days,4348,O
later,4348,O
.,4348,O
The,4349,O
Holter,4349,O
electrocardiogram,4349,O
",",4349,O
which,4349,O
was,4349,O
worn,4349,O
by,4349,O
chance,4349,O
",",4349,O
revealed,4349,O
torsade,4349,B-Disease
de,4349,I-Disease
pointes,4349,I-Disease
with,4349,O
gradually,4349,O
prolonged,4349,O
QT,4349,O
intervals,4349,O
.,4349,O
This,4350,O
drug,4350,O
is,4350,O
rapidly,4350,O
absorbed,4350,O
from,4350,O
the,4350,O
gastrointestinal,4350,O
tract,4350,O
",",4350,O
and,4350,O
most,4350,O
of,4350,O
it,4350,O
is,4350,O
excreted,4350,O
from,4350,O
the,4350,O
kidney,4350,O
.,4350,O
Although,4351,O
the,4351,O
patient,4351,O
's,4351,O
renal,4351,O
function,4351,O
was,4351,O
not,4351,O
highly,4351,O
impaired,4351,O
and,4351,O
the,4351,O
dose,4351,O
of,4351,O
pilsicainide,4351,B-Chemical
was,4351,O
low,4351,O
",",4351,O
the,4351,O
plasma,4351,O
concentration,4351,O
of,4351,O
pilsicainide,4351,B-Chemical
may,4351,O
have,4351,O
been,4351,O
high,4351,O
",",4351,O
which,4351,O
can,4351,O
produce,4351,O
torsades,4351,B-Disease
de,4351,I-Disease
pointes,4351,I-Disease
in,4351,O
the,4351,O
octogenarian,4351,O
.,4351,O
Although,4352,O
the,4352,O
oral,4352,O
administration,4352,O
of,4352,O
class,4352,O
IC,4352,O
drugs,4352,O
",",4352,O
including,4352,O
pilsicainide,4352,B-Chemical
",",4352,O
is,4352,O
effective,4352,O
to,4352,O
terminate,4352,O
atrial,4352,B-Disease
fibrillation,4352,I-Disease
",",4352,O
careful,4352,O
consideration,4352,O
must,4352,O
be,4352,O
taken,4352,O
before,4352,O
giving,4352,O
these,4352,O
drugs,4352,O
to,4352,O
octogenarians,4352,O
.,4352,O
All-trans,4353,B-Chemical
retinoic,4353,I-Chemical
acid-induced,4353,O
inflammatory,4353,O
myositis,4353,B-Disease
in,4353,O
a,4353,O
patient,4353,O
with,4353,O
acute,4353,B-Disease
promyelocytic,4353,I-Disease
leukemia,4353,I-Disease
.,4353,O
All-trans,4354,B-Chemical
retinoic,4354,I-Chemical
acid,4354,I-Chemical
(,4354,O
ATRA,4354,B-Chemical
),4354,O
",",4354,O
a,4354,O
component,4354,O
of,4354,O
standard,4354,O
therapy,4354,O
for,4354,O
acute,4354,B-Disease
promyelocytic,4354,I-Disease
leukemia,4354,I-Disease
(,4354,O
APL,4354,B-Disease
),4354,O
",",4354,O
is,4354,O
associated,4354,O
with,4354,O
potentially,4354,O
serious,4354,O
but,4354,O
treatable,4354,O
adverse,4354,O
effects,4354,O
involving,4354,O
numerous,4354,O
organ,4354,O
systems,4354,O
",",4354,O
including,4354,O
rare,4354,O
skeletal,4354,O
muscle,4354,O
involvement,4354,O
.,4354,O
Only,4355,O
a,4355,O
handful,4355,O
of,4355,O
cases,4355,O
of,4355,O
ATRA-induced,4355,B-Chemical
myositis,4355,B-Disease
in,4355,O
children,4355,O
have,4355,O
been,4355,O
reported,4355,O
",",4355,O
and,4355,O
none,4355,O
in,4355,O
the,4355,O
radiology,4355,O
literature,4355,O
.,4355,O
We,4356,O
present,4356,O
such,4356,O
a,4356,O
case,4356,O
in,4356,O
a,4356,O
15-year-old,4356,O
boy,4356,O
with,4356,O
APL,4356,B-Disease
",",4356,O
where,4356,O
recognition,4356,O
of,4356,O
imaging,4356,O
findings,4356,O
played,4356,O
a,4356,O
crucial,4356,O
role,4356,O
in,4356,O
making,4356,O
the,4356,O
diagnosis,4356,O
and,4356,O
facilitated,4356,O
prompt,4356,O
",",4356,O
effective,4356,O
treatment,4356,O
.,4356,O
Tolerability,4357,O
of,4357,O
lomustine,4357,B-Chemical
in,4357,O
combination,4357,O
with,4357,O
cyclophosphamide,4357,B-Chemical
in,4357,O
dogs,4357,O
with,4357,O
lymphoma,4357,B-Disease
.,4357,O
This,4358,O
retrospective,4358,O
study,4358,O
describes,4358,O
toxicity,4358,B-Disease
associated,4358,O
with,4358,O
a,4358,O
protocol,4358,O
of,4358,O
lomustine,4358,B-Chemical
(,4358,O
CCNU,4358,B-Chemical
),4358,O
and,4358,O
cyclophosphamide,4358,B-Chemical
(,4358,O
CTX,4358,B-Chemical
),4358,O
in,4358,O
dogs,4358,O
with,4358,O
lymphoma,4358,B-Disease
.,4358,O
CCNU,4359,B-Chemical
was,4359,O
administered,4359,O
per,4359,O
os,4359,O
(,4359,O
PO,4359,O
),4359,O
at,4359,O
a,4359,O
targeted,4359,O
dosage,4359,O
of,4359,O
60,4359,O
mg/m,4359,O
(,4359,O
2,4359,O
),4359,O
body,4359,O
surface,4359,O
area,4359,O
on,4359,O
day,4359,O
0,4359,O
",",4359,O
CTX,4359,B-Chemical
was,4359,O
administered,4359,O
PO,4359,O
at,4359,O
a,4359,O
targeted,4359,O
dosage,4359,O
of,4359,O
250,4359,O
mg/m,4359,O
(,4359,O
2,4359,O
),4359,O
divided,4359,O
over,4359,O
days,4359,O
0,4359,O
through,4359,O
4,4359,O
",",4359,O
and,4359,O
all,4359,O
dogs,4359,O
received,4359,O
prophylactic,4359,O
antibiotics,4359,O
.,4359,O
Ninety,4360,O
treatments,4360,O
were,4360,O
given,4360,O
to,4360,O
the,4360,O
57,4360,O
dogs,4360,O
included,4360,O
in,4360,O
the,4360,O
study,4360,O
.,4360,O
Neutropenia,4361,B-Disease
was,4361,O
the,4361,O
principal,4361,O
toxic,4361,O
effect,4361,O
",",4361,O
and,4361,O
the,4361,O
overall,4361,O
frequency,4361,O
of,4361,O
grade,4361,O
4,4361,O
neutropenia,4361,B-Disease
after,4361,O
the,4361,O
first,4361,O
treatment,4361,O
of,4361,O
CCNU/CTX,4361,B-Chemical
was,4361,O
30,4361,O
%,4361,O
(,4361,O
95,4361,O
%,4361,O
confidence,4361,O
interval,4361,O
",",4361,O
19-43,4361,O
%,4361,O
),4361,O
.,4361,O
The,4362,O
mean,4362,O
body,4362,O
weight,4362,O
of,4362,O
dogs,4362,O
with,4362,O
grade,4362,O
4,4362,O
neutropenia,4362,B-Disease
(,4362,O
19.7,4362,O
kg,4362,O
+,4362,O
13.4,4362,O
kg,4362,O
),4362,O
was,4362,O
significantly,4362,O
less,4362,O
than,4362,O
the,4362,O
mean,4362,O
body,4362,O
weight,4362,O
of,4362,O
dogs,4362,O
that,4362,O
did,4362,O
not,4362,O
develop,4362,O
grade,4362,O
4,4362,O
neutropenia,4362,B-Disease
(,4362,O
31.7,4362,O
kg,4362,O
+,4362,O
12.4,4362,O
kg,4362,O
;,4362,O
P,4362,O
=,4362,O
.005,4362,O
),4362,O
.,4362,O
One,4363,O
dog,4363,O
(,4363,O
3,4363,O
%,4363,O
),4363,O
developed,4363,O
hematologic,4363,O
changes,4363,O
suggestive,4363,O
of,4363,O
hepatotoxicity,4363,B-Disease
.,4363,O
No,4364,O
dogs,4364,O
had,4364,O
evidence,4364,O
of,4364,O
either,4364,O
renal,4364,B-Disease
toxicity,4364,I-Disease
or,4364,O
hemorrhagic,4364,O
cystitis,4364,O
.,4364,O
Adverse,4365,O
gastrointestinal,4365,O
effects,4365,O
were,4365,O
uncommon,4365,O
.,4365,O
On,4366,O
the,4366,O
basis,4366,O
of,4366,O
the,4366,O
findings,4366,O
reported,4366,O
herein,4366,O
",",4366,O
a,4366,O
dose,4366,O
of,4366,O
60,4366,O
mg/m,4366,O
(,4366,O
2,4366,O
),4366,O
of,4366,O
CCNU,4366,B-Chemical
combined,4366,O
with,4366,O
250,4366,O
mg/m,4366,O
(,4366,O
2,4366,O
),4366,O
of,4366,O
CTX,4366,B-Chemical
(,4366,O
divided,4366,O
over,4366,O
5,4366,O
days,4366,O
),4366,O
q,4366,O
4,4366,O
wk,4366,O
is,4366,O
tolerable,4366,O
in,4366,O
tumor-bearing,4366,B-Disease
dogs,4366,O
.,4366,O
Nelarabine,4367,B-Chemical
neurotoxicity,4367,B-Disease
with,4367,O
concurrent,4367,O
intrathecal,4367,O
chemotherapy,4367,O
:,4367,O
Case,4367,O
report,4367,O
and,4367,O
review,4367,O
of,4367,O
literature,4367,O
.,4367,O
Severe,4368,O
nelarabine,4368,B-Chemical
neurotoxicity,4368,B-Disease
in,4368,O
a,4368,O
patient,4368,O
who,4368,O
received,4368,O
concurrent,4368,O
intrathecal,4368,O
(,4368,O
IT,4368,O
),4368,O
chemotherapy,4368,O
is,4368,O
reported,4368,O
.,4368,O
A,4369,O
37-year-old,4369,O
Caucasian,4369,O
woman,4369,O
with,4369,O
a,4369,O
history,4369,O
of,4369,O
T-cell,4369,B-Disease
lymphoblastic,4369,I-Disease
lymphoma,4369,I-Disease
was,4369,O
admitted,4369,O
for,4369,O
relapsed,4369,O
disease,4369,O
.,4369,O
She,4370,O
was,4370,O
originally,4370,O
treated,4370,O
with,4370,O
induction,4370,O
chemotherapy,4370,O
followed,4370,O
by,4370,O
an,4370,O
autologous,4370,O
transplant,4370,O
.,4370,O
She,4371,O
developed,4371,O
relapsed,4371,O
disease,4371,O
10,4371,O
months,4371,O
later,4371,O
with,4371,O
leukemic,4371,B-Disease
involvement,4371,O
.,4371,O
She,4372,O
was,4372,O
re-induced,4372,O
with,4372,O
nelarabine,4372,B-Chemical
1500,4372,O
mg/m,4372,O
(,4372,O
2,4372,O
),4372,O
on,4372,O
days,4372,O
1,4372,O
",",4372,O
3,4372,O
",",4372,O
and,4372,O
5,4372,O
with,4372,O
1,4372,O
dose,4372,O
of,4372,O
IT,4372,O
cytarabine,4372,B-Chemical
100,4372,O
mg,4372,O
on,4372,O
day,4372,O
2,4372,O
as,4372,O
central,4372,O
nervous,4372,O
system,4372,O
(,4372,O
CNS,4372,O
),4372,O
prophylaxis,4372,O
.,4372,O
At,4373,O
the,4373,O
time,4373,O
of,4373,O
treatment,4373,O
",",4373,O
she,4373,O
was,4373,O
on,4373,O
continuous,4373,O
renal,4373,O
replacement,4373,O
therapy,4373,O
due,4373,O
to,4373,O
sequelae,4373,O
of,4373,O
tumor,4373,B-Disease
lysis,4373,I-Disease
syndrome,4373,I-Disease
(,4373,O
TLS,4373,B-Disease
),4373,O
.,4373,O
She,4374,O
tolerated,4374,O
therapy,4374,O
well,4374,O
",",4374,O
entered,4374,O
a,4374,O
complete,4374,O
remission,4374,O
",",4374,O
and,4374,O
recovered,4374,O
her,4374,O
renal,4374,O
function,4374,O
.,4374,O
She,4375,O
received,4375,O
a,4375,O
second,4375,O
cycle,4375,O
of,4375,O
nelarabine,4375,B-Chemical
without,4375,O
additional,4375,O
IT,4375,O
prophylaxis,4375,O
one,4375,O
month,4375,O
later,4375,O
.,4375,O
A,4376,O
week,4376,O
after,4376,O
this,4376,O
second,4376,O
cycle,4376,O
",",4376,O
she,4376,O
noted,4376,O
numbness,4376,O
in,4376,O
her,4376,O
lower,4376,O
extremities,4376,O
.,4376,O
Predominantly,4377,O
sensory,4377,O
",",4377,O
though,4377,O
also,4377,O
motor,4377,O
and,4377,O
autonomic,4377,O
",",4377,O
peripheral,4377,B-Disease
neuropathy,4377,I-Disease
started,4377,O
in,4377,O
her,4377,O
feet,4377,O
",",4377,O
ascended,4377,O
proximally,4377,O
to,4377,O
the,4377,O
mid-thoracic,4377,O
region,4377,O
",",4377,O
and,4377,O
eventually,4377,O
included,4377,O
her,4377,O
distal,4377,O
upper,4377,O
extremities,4377,O
.,4377,O
A,4378,O
magnetic,4378,O
resonance,4378,O
imaging,4378,O
(,4378,O
MRI,4378,O
),4378,O
of,4378,O
her,4378,O
spine,4378,O
demonstrated,4378,O
changes,4378,O
from,4378,O
C2,4378,O
to,4378,O
C6,4378,O
consistent,4378,O
with,4378,O
subacute,4378,O
combined,4378,O
degeneration,4378,O
.,4378,O
Nelarabine,4379,B-Chemical
was,4379,O
felt,4379,O
to,4379,O
be,4379,O
the,4379,O
cause,4379,O
of,4379,O
her,4379,O
symptoms,4379,O
.,4379,O
Her,4380,O
neuropathy,4380,B-Disease
stabilized,4380,O
and,4380,O
showed,4380,O
slight,4380,O
improvement,4380,O
and,4380,O
ultimately,4380,O
received,4380,O
an,4380,O
unrelated,4380,O
",",4380,O
reduced-intensity,4380,O
allogeneic,4380,O
transplant,4380,O
while,4380,O
in,4380,O
complete,4380,O
remission,4380,O
",",4380,O
but,4380,O
relapsed,4380,O
disease,4380,O
10,4380,O
weeks,4380,O
later,4380,O
.,4380,O
She,4381,O
is,4381,O
currently,4381,O
being,4381,O
treated,4381,O
with,4381,O
best,4381,O
supportive,4381,O
care,4381,O
.,4381,O
To,4382,O
our,4382,O
knowledge,4382,O
",",4382,O
this,4382,O
is,4382,O
the,4382,O
first,4382,O
published,4382,O
case,4382,O
report,4382,O
of,4382,O
severe,4382,O
neurotoxicity,4382,B-Disease
caused,4382,O
by,4382,O
nelarabine,4382,B-Chemical
in,4382,O
a,4382,O
patient,4382,O
who,4382,O
received,4382,O
concurrent,4382,O
IT,4382,O
chemotherapy,4382,O
.,4382,O
Valproate-induced,4383,B-Chemical
hyperammonemic,4383,B-Disease
encephalopathy,4383,B-Disease
in,4383,O
a,4383,O
renal,4383,O
transplanted,4383,O
patient,4383,O
.,4383,O
Neurological,4384,B-Disease
complications,4384,I-Disease
after,4384,O
renal,4384,O
transplantation,4384,O
constitute,4384,O
an,4384,O
important,4384,O
cause,4384,O
of,4384,O
morbidity,4384,O
and,4384,O
mortality,4384,O
.,4384,O
Their,4385,O
differential,4385,O
diagnosis,4385,O
is,4385,O
difficult,4385,O
and,4385,O
essential,4385,O
for,4385,O
subsequent,4385,O
patient,4385,O
's,4385,O
management,4385,O
.,4385,O
Valproate-induced,4386,B-Chemical
hyperammonemic,4386,B-Disease
encephalopathy,4386,B-Disease
is,4386,O
an,4386,O
uncommon,4386,O
but,4386,O
serious,4386,O
effect,4386,O
of,4386,O
valproate,4386,B-Chemical
treatment,4386,O
.,4386,O
Here,4387,O
",",4387,O
we,4387,O
describe,4387,O
the,4387,O
case,4387,O
of,4387,O
a,4387,O
15-year-old,4387,O
girl,4387,O
who,4387,O
was,4387,O
on,4387,O
a,4387,O
long-term,4387,O
therapy,4387,O
with,4387,O
valproate,4387,B-Chemical
due,4387,O
to,4387,O
epilepsy,4387,B-Disease
and,4387,O
revealed,4387,O
impaired,4387,B-Disease
consciousness,4387,I-Disease
with,4387,O
hyperammonemia,4387,B-Disease
12,4387,O
days,4387,O
after,4387,O
renal,4387,O
transplantation,4387,O
.,4387,O
After,4388,O
withdraw,4388,O
of,4388,O
valproate,4388,B-Chemical
",",4388,O
patients,4388,O
',4388,O
symptoms,4388,O
resolved,4388,O
within,4388,O
24,4388,O
h.,4388,O
Clinicians,4388,O
should,4388,O
increase,4388,O
their,4388,O
awareness,4388,O
for,4388,O
potential,4388,O
complication,4388,O
of,4388,O
valproate,4388,B-Chemical
",",4388,O
especially,4388,O
in,4388,O
transplanted,4388,O
patients,4388,O
.,4388,O
Necrotising,4389,B-Disease
fasciitis,4389,I-Disease
after,4389,O
bortezomib,4389,B-Chemical
and,4389,O
dexamethasone-containing,4389,B-Chemical
regimen,4389,O
in,4389,O
an,4389,O
elderly,4389,O
patient,4389,O
of,4389,O
Waldenstrom,4389,B-Disease
macroglobulinaemia,4389,I-Disease
.,4389,O
Bortezomib,4390,B-Chemical
and,4390,O
high-dose,4390,O
dexamethasone-containing,4390,B-Chemical
regimens,4390,O
are,4390,O
considered,4390,O
to,4390,O
be,4390,O
generally,4390,O
tolerable,4390,O
with,4390,O
few,4390,O
severe,4390,O
bacterial,4390,B-Disease
infections,4390,I-Disease
in,4390,O
patients,4390,O
with,4390,O
B-cell,4390,O
malignancies,4390,B-Disease
.,4390,O
However,4391,O
",",4391,O
information,4391,O
is,4391,O
limited,4391,O
concerning,4391,O
the,4391,O
safety,4391,O
of,4391,O
the,4391,O
regimen,4391,O
in,4391,O
elderly,4391,O
patients,4391,O
.,4391,O
We,4392,O
report,4392,O
a,4392,O
case,4392,O
of,4392,O
a,4392,O
76-year-old,4392,O
man,4392,O
with,4392,O
Waldenstrom,4392,B-Disease
macroglobulinaemia,4392,I-Disease
who,4392,O
suffered,4392,O
necrotising,4392,B-Disease
fasciitis,4392,I-Disease
without,4392,O
neutropenia,4392,B-Disease
after,4392,O
the,4392,O
combination,4392,O
treatment,4392,O
with,4392,O
bortezomib,4392,B-Chemical
",",4392,O
high-dose,4392,O
dexamethasone,4392,B-Chemical
and,4392,O
rituximab,4392,O
.,4392,O
Despite,4393,O
immediate,4393,O
intravenous,4393,O
antimicrobial,4393,O
therapy,4393,O
",",4393,O
he,4393,O
succumbed,4393,O
23,4393,O
h,4393,O
after,4393,O
the,4393,O
onset,4393,O
.,4393,O
Physicians,4394,O
should,4394,O
recognise,4394,O
the,4394,O
possibility,4394,O
of,4394,O
fatal,4394,O
bacterial,4394,B-Disease
infections,4394,I-Disease
related,4394,O
to,4394,O
bortezomib,4394,B-Chemical
plus,4394,O
high-dose,4394,O
dexamethasone,4394,B-Chemical
in,4394,O
elderly,4394,O
patients,4394,O
",",4394,O
and,4394,O
we,4394,O
believe,4394,O
this,4394,O
case,4394,O
warrants,4394,O
further,4394,O
investigation,4394,O
.,4394,O
An,4395,O
integrated,4395,O
characterization,4395,O
of,4395,O
serological,4395,O
",",4395,O
pathological,4395,O
",",4395,O
and,4395,O
functional,4395,O
events,4395,O
in,4395,O
doxorubicin-induced,4395,B-Chemical
cardiotoxicity,4395,B-Disease
.,4395,O
Many,4396,O
efficacious,4396,O
cancer,4396,B-Disease
treatments,4396,O
cause,4396,O
significant,4396,O
cardiac,4396,O
morbidity,4396,O
",",4396,O
yet,4396,O
biomarkers,4396,O
or,4396,O
functional,4396,O
indices,4396,O
of,4396,O
early,4396,O
damage,4396,O
",",4396,O
which,4396,O
would,4396,O
allow,4396,O
monitoring,4396,O
and,4396,O
intervention,4396,O
",",4396,O
are,4396,O
lacking,4396,O
.,4396,O
In,4397,O
this,4397,O
study,4397,O
",",4397,O
we,4397,O
have,4397,O
utilized,4397,O
a,4397,O
rat,4397,O
model,4397,O
of,4397,O
progressive,4397,O
doxorubicin,4397,B-Chemical
(,4397,O
DOX,4397,B-Chemical
),4397,O
-induced,4397,O
cardiomyopathy,4397,B-Disease
",",4397,O
applying,4397,O
multiple,4397,O
approaches,4397,O
",",4397,O
including,4397,O
cardiac,4397,O
magnetic,4397,O
resonance,4397,O
imaging,4397,O
(,4397,O
MRI,4397,O
),4397,O
",",4397,O
to,4397,O
provide,4397,O
the,4397,O
most,4397,O
comprehensive,4397,O
characterization,4397,O
to,4397,O
date,4397,O
of,4397,O
the,4397,O
timecourse,4397,O
of,4397,O
serological,4397,O
",",4397,O
pathological,4397,O
",",4397,O
and,4397,O
functional,4397,O
events,4397,O
underlying,4397,O
this,4397,O
toxicity,4397,B-Disease
.,4397,O
Hannover,4398,O
Wistar,4398,O
rats,4398,O
were,4398,O
dosed,4398,O
with,4398,O
1.25,4398,O
mg/kg,4398,O
DOX,4398,B-Chemical
weekly,4398,O
for,4398,O
8,4398,O
weeks,4398,O
followed,4398,O
by,4398,O
a,4398,O
4,4398,O
week,4398,O
off-dosing,4398,O
``,4398,O
recovery,4398,O
'',4398,O
period,4398,O
.,4398,O
Electron,4399,O
microscopy,4399,O
of,4399,O
the,4399,O
myocardium,4399,O
revealed,4399,O
subcellular,4399,B-Disease
degeneration,4399,I-Disease
and,4399,O
marked,4399,O
mitochondrial,4399,O
changes,4399,O
after,4399,O
a,4399,O
single,4399,O
dose,4399,O
.,4399,O
Histopathological,4400,O
analysis,4400,O
revealed,4400,O
progressive,4400,O
cardiomyocyte,4400,B-Disease
degeneration,4400,I-Disease
",",4400,O
hypertrophy/cytomegaly,4400,B-Disease
",",4400,O
and,4400,O
extensive,4400,O
vacuolation,4400,O
after,4400,O
two,4400,O
doses,4400,O
.,4400,O
Extensive,4401,O
replacement,4401,O
fibrosis,4401,B-Disease
(,4401,O
quantified,4401,O
by,4401,O
Sirius,4401,O
red,4401,O
staining,4401,O
),4401,O
developed,4401,O
during,4401,O
the,4401,O
off-dosing,4401,O
period,4401,O
.,4401,O
Functional,4402,O
indices,4402,O
assessed,4402,O
by,4402,O
cardiac,4402,O
MRI,4402,O
(,4402,O
including,4402,O
left,4402,O
ventricular,4402,O
ejection,4402,O
fraction,4402,O
(,4402,O
LVEF,4402,O
),4402,O
",",4402,O
cardiac,4402,O
output,4402,O
",",4402,O
and,4402,O
E/A,4402,O
ratio,4402,O
),4402,O
declined,4402,O
progressively,4402,O
",",4402,O
reaching,4402,O
statistical,4402,O
significance,4402,O
after,4402,O
two,4402,O
doses,4402,O
and,4402,O
culminating,4402,O
in,4402,O
``,4402,O
clinical,4402,O
'',4402,O
LV,4402,O
dysfunction,4402,I-Disease
by,4402,O
12,4402,O
weeks,4402,O
.,4402,O
Significant,4403,O
increases,4403,O
in,4403,O
peak,4403,O
myocardial,4403,O
contrast,4403,O
enhancement,4403,O
and,4403,O
serological,4403,O
cardiac,4403,O
troponin,4403,O
I,4403,O
(,4403,O
cTnI,4403,O
),4403,O
emerged,4403,O
after,4403,O
eight,4403,O
doses,4403,O
",",4403,O
importantly,4403,O
preceding,4403,O
the,4403,O
LVEF,4403,O
decline,4403,O
to,4403,O
<,4403,O
50,4403,O
%,4403,O
.,4403,O
Troponin,4404,O
I,4404,O
levels,4404,O
positively,4404,O
correlated,4404,O
with,4404,O
delayed,4404,O
and,4404,O
peak,4404,O
gadolinium,4404,B-Chemical
contrast,4404,O
enhancement,4404,O
",",4404,O
histopathological,4404,O
grading,4404,O
",",4404,O
and,4404,O
diastolic,4404,B-Disease
dysfunction,4404,I-Disease
.,4404,O
In,4405,O
summary,4405,O
",",4405,O
subcellular,4405,O
cardiomyocyte,4405,B-Disease
degeneration,4405,I-Disease
was,4405,O
the,4405,O
earliest,4405,O
marker,4405,O
",",4405,O
followed,4405,O
by,4405,O
progressive,4405,O
functional,4405,O
decline,4405,O
and,4405,O
histopathological,4405,O
manifestations,4405,O
.,4405,O
Myocardial,4406,O
contrast,4406,O
enhancement,4406,O
and,4406,O
elevations,4406,O
in,4406,O
cTnI,4406,O
occurred,4406,O
later,4406,O
.,4406,O
However,4407,O
",",4407,O
all,4407,O
indices,4407,O
predated,4407,O
``,4407,O
clinical,4407,O
'',4407,O
LV,4407,B-Disease
dysfunction,4407,I-Disease
and,4407,O
thus,4407,O
warrant,4407,O
further,4407,O
evaluation,4407,O
as,4407,O
predictive,4407,O
biomarkers,4407,O
.,4407,O
Intradermal,4408,O
glutamate,4408,B-Chemical
and,4408,O
capsaicin,4408,B-Chemical
injections,4408,O
:,4408,O
intra-,4408,O
and,4408,O
interindividual,4408,O
variability,4408,O
of,4408,O
provoked,4408,O
hyperalgesia,4408,B-Disease
and,4408,O
allodynia,4408,B-Disease
.,4408,O
Intradermal,4409,O
injections,4409,O
of,4409,O
glutamate,4409,B-Chemical
and,4409,O
capsaicin,4409,B-Chemical
are,4409,O
attractive,4409,O
to,4409,O
use,4409,O
in,4409,O
human,4409,O
experimental,4409,O
pain,4409,B-Disease
models,4409,O
because,4409,O
hyperalgesia,4409,B-Disease
and,4409,O
allodynia,4409,B-Disease
mimic,4409,O
isolated,4409,O
aspects,4409,O
of,4409,O
clinical,4409,O
pain,4409,B-Disease
disorders,4409,I-Disease
.,4409,O
The,4410,O
aim,4410,O
of,4410,O
the,4410,O
present,4410,O
study,4410,O
was,4410,O
to,4410,O
investigate,4410,O
the,4410,O
reproducibility,4410,O
of,4410,O
these,4410,O
models,4410,O
.,4410,O
Twenty,4411,O
healthy,4411,O
male,4411,O
volunteers,4411,O
(,4411,O
mean,4411,O
age,4411,O
24,4411,O
years,4411,O
;,4411,O
range,4411,O
18-38,4411,O
years,4411,O
),4411,O
received,4411,O
intradermal,4411,O
injections,4411,O
of,4411,O
glutamate,4411,B-Chemical
and,4411,O
capsaicin,4411,B-Chemical
in,4411,O
the,4411,O
volar,4411,O
forearm,4411,O
.,4411,O
Magnitudes,4412,O
of,4412,O
secondary,4412,O
pinprick,4412,O
hyperalgesia,4412,B-Disease
and,4412,O
brush-evoked,4412,O
allodynia,4412,B-Disease
were,4412,O
investigated,4412,O
using,4412,O
von,4412,O
Frey,4412,O
filaments,4412,O
(,4412,O
gauges,4412,O
10,4412,O
",",4412,O
15,4412,O
",",4412,O
60,4412,O
and,4412,O
100,4412,O
g,4412,O
),4412,O
and,4412,O
brush,4412,O
strokes,4412,O
.,4412,O
Areas,4413,O
of,4413,O
secondary,4413,B-Disease
hyperalgesia,4413,I-Disease
and,4413,O
allodynia,4413,B-Disease
were,4413,O
quantified,4413,O
immediately,4413,O
after,4413,O
injection,4413,O
and,4413,O
after,4413,O
15,4413,O
",",4413,O
30,4413,O
and,4413,O
60,4413,O
min,4413,O
.,4413,O
Two,4414,O
identical,4414,O
experiments,4414,O
separated,4414,O
by,4414,O
at,4414,O
least,4414,O
7,4414,O
days,4414,O
were,4414,O
performed,4414,O
.,4414,O
Reproducibility,4415,O
across,4415,O
and,4415,O
within,4415,O
volunteers,4415,O
(,4415,O
inter-,4415,O
and,4415,O
intra-individual,4415,O
variation,4415,O
",",4415,O
respectively,4415,O
),4415,O
was,4415,O
assessed,4415,O
using,4415,O
intraclass,4415,O
correlation,4415,O
coefficient,4415,O
(,4415,O
ICC,4415,O
),4415,O
and,4415,O
coefficient,4415,O
of,4415,O
variation,4415,O
(,4415,O
CV,4415,O
),4415,O
.,4415,O
Secondary,4416,O
pinprick,4416,O
hyperalgesia,4416,B-Disease
was,4416,O
observed,4416,O
as,4416,O
a,4416,O
marked,4416,O
increase,4416,O
in,4416,O
the,4416,O
visual,4416,O
analogue,4416,O
scale,4416,O
(,4416,O
VAS,4416,O
),4416,O
response,4416,O
to,4416,O
von,4416,O
Frey,4416,O
gauges,4416,O
60,4416,O
and,4416,O
100,4416,O
g,4416,O
(,4416,O
P,4416,O
<,4416,O
0.001,4416,O
),4416,O
after,4416,O
glutamate,4416,B-Chemical
injection,4416,O
.,4416,O
For,4417,O
capsaicin,4417,B-Chemical
",",4417,O
secondary,4417,O
pinprick,4417,O
hyperalgesia,4417,B-Disease
was,4417,O
detected,4417,O
with,4417,O
all,4417,O
von,4417,O
Frey,4417,O
gauges,4417,O
(,4417,O
P,4417,O
<,4417,O
0.001,4417,O
),4417,O
.,4417,O
Glutamate,4418,B-Chemical
evoked,4418,O
reproducible,4418,O
VAS,4418,O
response,4418,O
to,4418,O
all,4418,O
von,4418,O
Frey,4418,O
gauges,4418,O
(,4418,O
ICC,4418,O
>,4418,O
0.60,4418,O
),4418,O
and,4418,O
brush,4418,O
strokes,4418,O
(,4418,O
ICC,4418,O
>,4418,O
0.83,4418,O
),4418,O
.,4418,O
Capsaicin,4419,B-Chemical
injection,4419,O
was,4419,O
reproducible,4419,O
for,4419,O
secondary,4419,B-Disease
hyperalgesia,4419,I-Disease
(,4419,O
ICC,4419,O
>,4419,O
0.70,4419,O
),4419,O
and,4419,O
allodynia,4419,B-Disease
(,4419,O
ICC,4419,O
>,4419,O
0.71,4419,O
),4419,O
.,4419,O
Intra-individual,4420,O
variability,4420,O
was,4420,O
generally,4420,O
lower,4420,O
for,4420,O
the,4420,O
VAS,4420,O
response,4420,O
to,4420,O
von,4420,O
Frey,4420,O
and,4420,O
brush,4420,O
compared,4420,O
with,4420,O
areas,4420,O
of,4420,O
secondary,4420,B-Disease
hyperalgesia,4420,I-Disease
and,4420,O
allodynia,4420,B-Disease
.,4420,O
In,4421,O
conclusion,4421,O
",",4421,O
glutamate,4421,B-Chemical
and,4421,O
capsaicin,4421,B-Chemical
yield,4421,O
reproducible,4421,O
hyperalgesic,4421,B-Disease
and,4421,O
allodynic,4421,B-Disease
responses,4421,O
",",4421,O
and,4421,O
the,4421,O
present,4421,O
model,4421,O
is,4421,O
well,4421,O
suited,4421,O
for,4421,O
basic,4421,O
research,4421,O
",",4421,O
as,4421,O
well,4421,O
as,4421,O
for,4421,O
assessing,4421,O
the,4421,O
modulation,4421,O
of,4421,O
central,4421,O
phenomena,4421,O
.,4421,O
Ocular-specific,4422,O
ER,4422,O
stress,4422,O
reduction,4422,O
rescues,4422,O
glaucoma,4422,B-Disease
in,4422,O
murine,4422,O
glucocorticoid-induced,4422,O
glaucoma,4422,B-Disease
.,4422,O
Administration,4423,O
of,4423,O
glucocorticoids,4423,O
induces,4423,O
ocular,4423,B-Disease
hypertension,4423,I-Disease
in,4423,O
some,4423,O
patients,4423,O
.,4423,O
If,4424,O
untreated,4424,O
",",4424,O
these,4424,O
patients,4424,O
can,4424,O
develop,4424,O
a,4424,O
secondary,4424,O
glaucoma,4424,B-Disease
that,4424,O
resembles,4424,O
primary,4424,B-Disease
open-angle,4424,I-Disease
glaucoma,4424,I-Disease
(,4424,O
POAG,4424,B-Disease
),4424,O
.,4424,O
The,4425,O
underlying,4425,O
pathology,4425,O
of,4425,O
glucocorticoid-induced,4425,O
glaucoma,4425,B-Disease
is,4425,O
not,4425,O
fully,4425,O
understood,4425,O
",",4425,O
due,4425,O
in,4425,O
part,4425,O
to,4425,O
lack,4425,O
of,4425,O
an,4425,O
appropriate,4425,O
animal,4425,O
model,4425,O
.,4425,O
Here,4426,O
",",4426,O
we,4426,O
developed,4426,O
a,4426,O
murine,4426,O
model,4426,O
of,4426,O
glucocorticoid-induced,4426,O
glaucoma,4426,B-Disease
that,4426,O
exhibits,4426,O
glaucoma,4426,B-Disease
features,4426,O
that,4426,O
are,4426,O
observed,4426,O
in,4426,O
patients,4426,O
.,4426,O
Treatment,4427,O
of,4427,O
WT,4427,O
mice,4427,O
with,4427,O
topical,4427,O
ocular,4427,O
0.1,4427,O
%,4427,O
dexamethasone,4427,B-Chemical
led,4427,O
to,4427,O
elevation,4427,O
of,4427,O
intraocular,4427,O
pressure,4427,O
(,4427,O
IOP,4427,O
),4427,O
",",4427,O
functional,4427,O
and,4427,O
structural,4427,O
loss,4427,O
of,4427,O
retinal,4427,B-Disease
ganglion,4427,I-Disease
cells,4427,O
",",4427,O
and,4427,O
axonal,4427,B-Disease
degeneration,4427,I-Disease
",",4427,O
resembling,4427,O
glucocorticoid-induced,4427,O
glaucoma,4427,B-Disease
in,4427,O
human,4427,O
patients,4427,O
.,4427,O
Furthermore,4428,O
",",4428,O
dexamethasone-induced,4428,B-Chemical
ocular,4428,B-Disease
hypertension,4428,I-Disease
was,4428,O
associated,4428,O
with,4428,O
chronic,4428,O
ER,4428,O
stress,4428,O
of,4428,O
the,4428,O
trabecular,4428,O
meshwork,4428,O
(,4428,O
TM,4428,O
),4428,O
.,4428,O
Similar,4429,O
to,4429,O
patients,4429,O
",",4429,O
withdrawal,4429,O
of,4429,O
dexamethasone,4429,B-Chemical
treatment,4429,O
reduced,4429,O
elevated,4429,O
IOP,4429,O
and,4429,O
ER,4429,O
stress,4429,O
in,4429,O
this,4429,O
animal,4429,O
model,4429,O
.,4429,O
Dexamethasone,4430,B-Chemical
induced,4430,O
the,4430,O
transcriptional,4430,O
factor,4430,O
CHOP,4430,O
",",4430,O
a,4430,O
marker,4430,O
for,4430,O
chronic,4430,O
ER,4430,O
stress,4430,O
",",4430,O
in,4430,O
the,4430,O
anterior,4430,O
segment,4430,O
tissues,4430,O
",",4430,O
and,4430,O
Chop,4430,O
deletion,4430,O
reduced,4430,O
ER,4430,O
stress,4430,O
in,4430,O
these,4430,O
tissues,4430,O
and,4430,O
prevented,4430,O
dexamethasone-induced,4430,B-Chemical
ocular,4430,B-Disease
hypertension,4430,I-Disease
.,4430,O
Furthermore,4431,O
",",4431,O
reduction,4431,O
of,4431,O
ER,4431,O
stress,4431,O
in,4431,O
the,4431,O
TM,4431,O
with,4431,O
sodium,4431,B-Chemical
4-phenylbutyrate,4431,I-Chemical
prevented,4431,O
dexamethasone-induced,4431,B-Chemical
ocular,4431,B-Disease
hypertension,4431,I-Disease
in,4431,O
WT,4431,O
mice,4431,O
.,4431,O
Our,4432,O
data,4432,O
indicate,4432,O
that,4432,O
ER,4432,O
stress,4432,O
contributes,4432,O
to,4432,O
glucocorticoid-induced,4432,O
ocular,4432,B-Disease
hypertension,4432,I-Disease
and,4432,O
suggest,4432,O
that,4432,O
reducing,4432,O
ER,4432,O
stress,4432,O
has,4432,O
potential,4432,O
as,4432,O
a,4432,O
therapeutic,4432,O
strategy,4432,O
for,4432,O
treating,4432,O
glucocorticoid-induced,4432,O
glaucoma,4432,B-Disease
.,4432,O
Effects,4433,O
of,4433,O
ginsenosides,4433,B-Chemical
on,4433,O
opioid-induced,4433,O
hyperalgesia,4433,B-Disease
in,4433,O
mice,4433,O
.,4433,O
Opioid-induced,4434,O
hyperalgesia,4434,B-Disease
(,4434,O
OIH,4434,B-Disease
),4434,O
is,4434,O
characterized,4434,O
by,4434,O
nociceptive,4434,O
sensitization,4434,O
caused,4434,O
by,4434,O
the,4434,O
cessation,4434,O
of,4434,O
chronic,4434,O
opioid,4434,O
use,4434,O
.,4434,O
OIH,4435,B-Disease
can,4435,O
limit,4435,O
the,4435,O
clinical,4435,O
use,4435,O
of,4435,O
opioid,4435,O
analgesics,4435,O
and,4435,O
complicate,4435,O
withdrawal,4435,O
from,4435,O
opioid,4435,B-Disease
addiction,4435,I-Disease
.,4435,O
In,4436,O
this,4436,O
study,4436,O
",",4436,O
we,4436,O
investigated,4436,O
the,4436,O
effects,4436,O
of,4436,O
Re,4436,O
",",4436,O
Rg1,4436,O
",",4436,O
and,4436,O
Rb1,4436,O
ginsenosides,4436,O
",",4436,O
the,4436,O
bioactive,4436,O
components,4436,O
of,4436,O
ginseng,4436,O
",",4436,O
on,4436,O
OIH,4436,B-Disease
.,4436,O
OIH,4437,B-Disease
was,4437,O
achieved,4437,O
in,4437,O
mice,4437,O
after,4437,O
subcutaneous,4437,O
administration,4437,O
of,4437,O
morphine,4437,B-Chemical
for,4437,O
7,4437,O
consecutive,4437,O
days,4437,O
three,4437,O
times,4437,O
per,4437,O
day,4437,O
.,4437,O
During,4438,O
withdrawal,4438,O
(,4438,O
days,4438,O
8,4438,O
and,4438,O
9,4438,O
),4438,O
",",4438,O
these,4438,O
mice,4438,O
were,4438,O
administered,4438,O
Re,4438,B-Chemical
",",4438,O
Rg1,4438,B-Chemical
",",4438,O
or,4438,O
Rb1,4438,B-Chemical
intragastrically,4438,O
two,4438,O
times,4438,O
per,4438,O
day,4438,O
.,4438,O
On,4439,O
the,4439,O
test,4439,O
day,4439,O
(,4439,O
day,4439,O
10,4439,O
),4439,O
",",4439,O
mice,4439,O
were,4439,O
subjected,4439,O
to,4439,O
the,4439,O
thermal,4439,O
sensitivity,4439,O
test,4439,O
and,4439,O
the,4439,O
acetic,4439,B-Chemical
acid-induced,4439,O
writhing,4439,O
test,4439,O
.,4439,O
Re,4440,B-Chemical
(,4440,O
300,4440,O
mg/kg,4440,O
),4440,O
inhibited,4440,O
OIH,4440,B-Disease
in,4440,O
both,4440,O
the,4440,O
thermal,4440,O
sensitivity,4440,O
test,4440,O
and,4440,O
the,4440,O
acetic,4440,B-Chemical
acid-induced,4440,O
writhing,4440,O
test,4440,O
.,4440,O
However,4441,O
",",4441,O
the,4441,O
Rg1,4441,O
and,4441,O
Rb1,4441,O
ginsenosides,4441,O
failed,4441,O
to,4441,O
prevent,4441,O
OIH,4441,B-Disease
in,4441,O
either,4441,O
test,4441,O
.,4441,O
Furthermore,4442,O
",",4442,O
Rg1,4442,B-Chemical
showed,4442,O
a,4442,O
tendency,4442,O
to,4442,O
aggravate,4442,O
OIH,4442,B-Disease
in,4442,O
the,4442,O
acetic,4442,B-Chemical
acid-induced,4442,O
writhing,4442,O
test,4442,O
.,4442,O
Our,4443,O
data,4443,O
suggested,4443,O
that,4443,O
the,4443,O
ginsenoside,4443,B-Chemical
Re,4443,I-Chemical
",",4443,O
but,4443,O
not,4443,O
Rg1,4443,B-Chemical
or,4443,O
Rb1,4443,B-Chemical
",",4443,O
may,4443,O
contribute,4443,O
toward,4443,O
reversal,4443,O
of,4443,O
OIH,4443,B-Disease
.,4443,O
A,4444,O
comparison,4444,O
of,4444,O
severe,4444,O
hemodynamic,4444,O
disturbances,4444,O
between,4444,O
dexmedetomidine,4444,B-Chemical
and,4444,O
propofol,4444,B-Chemical
for,4444,O
sedation,4444,O
in,4444,O
neurocritical,4444,O
care,4444,O
patients,4444,O
.,4444,O
OBJECTIVE,4445,O
:,4445,O
Dexmedetomidine,4445,B-Chemical
and,4445,O
propofol,4445,B-Chemical
are,4445,O
commonly,4445,O
used,4445,O
sedatives,4445,O
in,4445,O
neurocritical,4445,O
care,4445,O
as,4445,O
they,4445,O
allow,4445,O
for,4445,O
frequent,4445,O
neurologic,4445,O
examinations,4445,O
.,4445,O
However,4446,O
",",4446,O
both,4446,O
agents,4446,O
are,4446,O
associated,4446,O
with,4446,O
significant,4446,O
hemodynamic,4446,O
side,4446,O
effects,4446,O
.,4446,O
The,4447,O
primary,4447,O
objective,4447,O
of,4447,O
this,4447,O
study,4447,O
is,4447,O
to,4447,O
compare,4447,O
the,4447,O
prevalence,4447,O
of,4447,O
severe,4447,O
hemodynamic,4447,O
effects,4447,O
in,4447,O
neurocritical,4447,O
care,4447,O
patients,4447,O
receiving,4447,O
dexmedetomidine,4447,B-Chemical
and,4447,O
propofol,4447,B-Chemical
.,4447,O
DESIGN,4448,O
:,4448,O
Multicenter,4448,O
",",4448,O
retrospective,4448,O
",",4448,O
propensity-matched,4448,O
cohort,4448,O
study,4448,O
.,4448,O
SETTING,4449,O
:,4449,O
Neurocritical,4449,O
care,4449,O
units,4449,O
at,4449,O
two,4449,O
academic,4449,O
medical,4449,O
centers,4449,O
with,4449,O
dedicated,4449,O
neurocritical,4449,O
care,4449,O
teams,4449,O
and,4449,O
board-certified,4449,O
neurointensivists,4449,O
.,4449,O
PATIENTS,4450,O
:,4450,O
Neurocritical,4450,O
care,4450,O
patients,4450,O
admitted,4450,O
between,4450,O
July,4450,O
2009,4450,O
and,4450,O
September,4450,O
2012,4450,O
were,4450,O
evaluated,4450,O
and,4450,O
then,4450,O
matched,4450,O
1:1,4450,O
based,4450,O
on,4450,O
propensity,4450,O
scoring,4450,O
of,4450,O
baseline,4450,O
characteristics,4450,O
.,4450,O
INTERVENTIONS,4451,O
:,4451,O
Continuous,4451,O
sedation,4451,O
with,4451,O
dexmedetomidine,4451,B-Chemical
or,4451,O
propofol,4451,B-Chemical
.,4451,O
MEASUREMENTS,4452,O
AND,4452,O
MAIN,4452,O
RESULTS,4452,O
:,4452,O
A,4452,O
total,4452,O
of,4452,O
342,4452,O
patients,4452,O
(,4452,O
105,4452,O
dexmedetomidine,4452,B-Chemical
and,4452,O
237,4452,O
propofol,4452,B-Chemical
),4452,O
were,4452,O
included,4452,O
in,4452,O
the,4452,O
analysis,4452,O
",",4452,O
with,4452,O
190,4452,O
matched,4452,O
(,4452,O
95,4452,O
in,4452,O
each,4452,O
group,4452,O
),4452,O
by,4452,O
propensity,4452,O
score,4452,O
.,4452,O
The,4453,O
primary,4453,O
outcome,4453,O
of,4453,O
this,4453,O
study,4453,O
was,4453,O
a,4453,O
composite,4453,O
of,4453,O
severe,4453,O
hypotension,4453,B-Disease
(,4453,O
mean,4453,O
arterial,4453,O
pressure,4453,O
<,4453,O
60,4453,O
mm,4453,O
Hg,4453,O
),4453,O
and,4453,O
bradycardia,4453,B-Disease
(,4453,O
heart,4453,O
rate,4453,O
<,4453,O
50,4453,O
beats/min,4453,O
),4453,O
during,4453,O
sedative,4453,O
infusion,4453,O
.,4453,O
No,4454,O
difference,4454,O
in,4454,O
the,4454,O
primary,4454,O
composite,4454,O
outcome,4454,O
in,4454,O
both,4454,O
the,4454,O
unmatched,4454,O
(,4454,O
30,4454,O
%,4454,O
vs,4454,O
30,4454,O
%,4454,O
",",4454,O
p,4454,O
=,4454,O
0.94,4454,O
),4454,O
or,4454,O
matched,4454,O
cohorts,4454,O
(,4454,O
28,4454,O
%,4454,O
vs,4454,O
34,4454,O
%,4454,O
",",4454,O
p,4454,O
=,4454,O
0.35,4454,O
),4454,O
could,4454,O
be,4454,O
found,4454,O
.,4454,O
When,4455,O
analyzed,4455,O
separately,4455,O
",",4455,O
no,4455,O
differences,4455,O
could,4455,O
be,4455,O
found,4455,O
in,4455,O
the,4455,O
prevalence,4455,O
of,4455,O
severe,4455,O
hypotension,4455,B-Disease
or,4455,O
bradycardia,4455,B-Disease
in,4455,O
either,4455,O
the,4455,O
unmatched,4455,O
or,4455,O
matched,4455,O
cohorts,4455,O
.,4455,O
CONCLUSIONS,4456,O
:,4456,O
Severe,4456,O
hypotension,4456,B-Disease
and,4456,O
bradycardia,4456,B-Disease
occur,4456,O
at,4456,O
similar,4456,O
prevalence,4456,O
in,4456,O
neurocritical,4456,O
care,4456,O
patients,4456,O
who,4456,O
receive,4456,O
dexmedetomidine,4456,B-Chemical
or,4456,O
propofol,4456,B-Chemical
.,4456,O
Providers,4457,O
should,4457,O
similarly,4457,O
consider,4457,O
the,4457,O
likelihood,4457,O
of,4457,O
hypotension,4457,B-Disease
or,4457,O
bradycardia,4457,B-Disease
before,4457,O
starting,4457,O
either,4457,O
sedative,4457,O
.,4457,O
Hydroxytyrosol,4458,B-Chemical
ameliorates,4458,O
oxidative,4458,O
stress,4458,O
and,4458,O
mitochondrial,4458,B-Disease
dysfunction,4458,I-Disease
in,4458,O
doxorubicin-induced,4458,B-Chemical
cardiotoxicity,4458,B-Disease
in,4458,O
rats,4458,O
with,4458,O
breast,4458,B-Disease
cancer,4458,I-Disease
.,4458,O
Oxidative,4459,O
stress,4459,O
is,4459,O
involved,4459,O
in,4459,O
several,4459,O
processes,4459,O
including,4459,O
cancer,4459,B-Disease
",",4459,O
aging,4459,O
and,4459,O
cardiovascular,4459,B-Disease
disease,4459,I-Disease
",",4459,O
and,4459,O
has,4459,O
been,4459,O
shown,4459,O
to,4459,O
potentiate,4459,O
the,4459,O
therapeutic,4459,O
effect,4459,O
of,4459,O
drugs,4459,O
such,4459,O
as,4459,O
doxorubicin,4459,B-Chemical
.,4459,O
Doxorubicin,4460,B-Chemical
causes,4460,O
significant,4460,O
cardiotoxicity,4460,B-Disease
characterized,4460,O
by,4460,O
marked,4460,O
increases,4460,O
in,4460,O
oxidative,4460,O
stress,4460,O
and,4460,O
mitochondrial,4460,B-Disease
dysfunction,4460,I-Disease
.,4460,O
Herein,4461,O
",",4461,O
we,4461,O
investigate,4461,O
whether,4461,O
doxorubicin-associated,4461,B-Chemical
chronic,4461,O
cardiac,4461,B-Disease
toxicity,4461,I-Disease
can,4461,O
be,4461,O
ameliorated,4461,O
with,4461,O
the,4461,O
antioxidant,4461,O
hydroxytyrosol,4461,B-Chemical
in,4461,O
rats,4461,O
with,4461,O
breast,4461,B-Disease
cancer,4461,I-Disease
.,4461,O
Thirty-six,4462,O
rats,4462,O
bearing,4462,O
breast,4462,B-Disease
tumors,4462,I-Disease
induced,4462,O
chemically,4462,O
were,4462,O
divided,4462,O
into,4462,O
4,4462,O
groups,4462,O
:,4462,O
control,4462,O
",",4462,O
hydroxytyrosol,4462,B-Chemical
(,4462,O
0.5mg/kg,4462,O
",",4462,O
5days/week,4462,O
),4462,O
",",4462,O
doxorubicin,4462,B-Chemical
(,4462,O
1mg/kg/week,4462,O
),4462,O
",",4462,O
and,4462,O
doxorubicin,4462,B-Chemical
plus,4462,O
hydroxytyrosol,4462,B-Chemical
.,4462,O
Cardiac,4463,B-Disease
disturbances,4463,I-Disease
at,4463,O
the,4463,O
cellular,4463,O
and,4463,O
mitochondrial,4463,O
level,4463,O
",",4463,O
mitochondrial,4463,O
electron,4463,O
transport,4463,O
chain,4463,O
complexes,4463,O
I-IV,4463,O
and,4463,O
apoptosis-inducing,4463,O
factor,4463,O
",",4463,O
and,4463,O
oxidative,4463,O
stress,4463,O
markers,4463,O
have,4463,O
been,4463,O
analyzed,4463,O
.,4463,O
Hydroxytyrosol,4464,B-Chemical
improved,4464,O
the,4464,O
cardiac,4464,B-Disease
disturbances,4464,I-Disease
enhanced,4464,O
by,4464,O
doxorubicin,4464,B-Chemical
by,4464,O
significantly,4464,O
reducing,4464,O
the,4464,O
percentage,4464,O
of,4464,O
altered,4464,O
mitochondria,4464,O
and,4464,O
oxidative,4464,O
damage,4464,O
.,4464,O
These,4465,O
results,4465,O
suggest,4465,O
that,4465,O
hydroxytyrosol,4465,B-Chemical
improve,4465,O
the,4465,O
mitochondrial,4465,O
electron,4465,O
transport,4465,O
chain,4465,O
.,4465,O
This,4466,O
study,4466,O
demonstrates,4466,O
that,4466,O
hydroxytyrosol,4466,B-Chemical
protect,4466,O
rat,4466,O
heart,4466,B-Disease
damage,4466,I-Disease
provoked,4466,O
by,4466,O
doxorubicin,4466,B-Chemical
decreasing,4466,O
oxidative,4466,O
damage,4466,O
and,4466,O
mitochondrial,4466,O
alterations,4466,O
.,4466,O
Amiodarone-induced,4467,B-Chemical
myxoedema,4467,O
coma,4467,O
.,4467,O
A,4468,O
62-year-old,4468,O
man,4468,O
was,4468,O
found,4468,O
to,4468,O
have,4468,O
bradycardia,4468,B-Disease
",",4468,O
hypothermia,4468,B-Disease
and,4468,O
respiratory,4468,B-Disease
failure,4468,I-Disease
3,4468,O
weeks,4468,O
after,4468,O
initiation,4468,O
of,4468,O
amiodarone,4468,B-Chemical
therapy,4468,O
for,4468,O
atrial,4468,B-Disease
fibrillation,4468,I-Disease
.,4468,O
Thyroid-stimulating,4469,O
hormone,4469,O
was,4469,O
found,4469,O
to,4469,O
be,4469,O
168,4469,O
uIU/mL,4469,O
(,4469,O
nl,4469,O
.,4469,O
0.3-5,4470,O
uIU/mL,4470,O
),4470,O
and,4470,O
free,4470,O
thyroxine,4470,B-Chemical
(,4470,O
FT4,4470,O
),4470,O
was,4470,O
<,4470,O
0.2,4470,O
ng/dL,4470,O
(,4470,O
nl,4470,O
.,4470,O
0.8-1.8,4471,O
ng/dL,4471,O
),4471,O
.,4471,O
He,4472,O
received,4472,O
intravenous,4472,O
fluids,4472,O
",",4472,O
vasopressor,4472,O
therapy,4472,O
and,4472,O
stress,4472,O
dose,4472,O
steroids,4472,B-Chemical
;,4472,O
he,4472,O
was,4472,O
intubated,4472,O
and,4472,O
admitted,4472,O
to,4472,O
the,4472,O
intensive,4472,O
care,4472,O
unit,4472,O
.,4472,O
He,4473,O
received,4473,O
500,4473,O
ug,4473,O
of,4473,O
intravenous,4473,O
levothyroxine,4473,B-Chemical
in,4473,O
the,4473,O
first,4473,O
18,4473,O
h,4473,O
of,4473,O
therapy,4473,O
",",4473,O
and,4473,O
150,4473,O
ug,4473,O
intravenous,4473,O
daily,4473,O
thereafter,4473,O
.,4473,O
Haemodynamic,4474,O
improvement,4474,O
",",4474,O
along,4474,O
with,4474,O
complete,4474,O
recovery,4474,O
of,4474,O
mental,4474,O
status,4474,O
",",4474,O
occurred,4474,O
after,4474,O
48,4474,O
h.,4474,O
Twelve,4474,O
hours,4474,O
after,4474,O
the,4474,O
initiation,4474,O
of,4474,O
therapy,4474,O
",",4474,O
FT4,4474,O
was,4474,O
0.96,4474,O
ng/dL,4474,O
.,4474,O
The,4475,O
patient,4475,O
was,4475,O
maintained,4475,O
on,4475,O
levothyroxine,4475,B-Chemical
175,4475,O
(,4475,O
g,4475,O
POorally,4475,O
daily,4475,O
.,4475,O
A,4476,O
thyroid,4476,O
ultrasound,4476,O
showed,4476,O
diffuse,4476,O
heterogeneity,4476,O
.,4476,O
The,4477,O
24,4477,O
hour,4477,O
excretion,4477,O
of,4477,O
iodine,4477,B-Chemical
was,4477,O
3657,4477,O
(,4477,O
mcg,4477,O
(,4477,O
25-756,4477,O
(,4477,O
mcg,4477,O
),4477,O
.,4477,O
The,4478,O
only,4478,O
two,4478,O
cases,4478,O
of,4478,O
amiodarone-induced,4478,B-Chemical
myxoedema,4478,O
coma,4478,O
in,4478,O
the,4478,O
literature,4478,O
report,4478,O
patient,4478,O
death,4478,O
despite,4478,O
supportive,4478,O
therapy,4478,O
and,4478,O
thyroid,4478,O
hormone,4478,O
replacement,4478,O
.,4478,O
This,4479,O
case,4479,O
represents,4479,O
the,4479,O
most,4479,O
thoroughly,4479,O
investigated,4479,O
case,4479,O
of,4479,O
amiodarone-induced,4479,B-Chemical
myxoedema,4479,O
coma,4479,O
with,4479,O
a,4479,O
history,4479,O
significant,4479,O
for,4479,O
subclinical,4479,O
thyroid,4479,B-Disease
disease,4479,I-Disease
.,4479,O
Use,4480,O
of,4480,O
argatroban,4480,B-Chemical
and,4480,O
catheter-directed,4480,O
thrombolysis,4480,B-Disease
with,4480,O
alteplase,4480,O
in,4480,O
an,4480,O
oncology,4480,O
patient,4480,O
with,4480,O
heparin-induced,4480,B-Chemical
thrombocytopenia,4480,B-Disease
with,4480,O
thrombosis,4480,B-Disease
.,4480,O
PURPOSE,4481,O
:,4481,O
The,4481,O
case,4481,O
of,4481,O
an,4481,O
oncology,4481,O
patient,4481,O
who,4481,O
developed,4481,O
heparin-induced,4481,B-Chemical
thrombocytopenia,4481,B-Disease
with,4481,O
thrombosis,4481,B-Disease
(,4481,O
HITT,4481,B-Disease
),4481,O
and,4481,O
was,4481,O
treated,4481,O
with,4481,O
argatroban,4481,B-Chemical
plus,4481,O
catheter-directed,4481,O
thrombolysis,4481,B-Disease
(,4481,O
CDT,4481,O
),4481,O
with,4481,O
alteplase,4481,O
is,4481,O
presented,4481,O
.,4481,O
SUMMARY,4482,O
:,4482,O
A,4482,O
63-year-old,4482,O
Caucasian,4482,O
man,4482,O
with,4482,O
renal,4482,O
amyloidosis,4482,B-Disease
undergoing,4482,O
peripheral,4482,O
blood,4482,O
stem,4482,O
cell,4482,O
collection,4482,O
for,4482,O
an,4482,O
autologous,4482,O
stem,4482,O
cell,4482,O
transplant,4482,O
developed,4482,O
extensive,4482,O
bilateral,4482,O
upper-extremity,4482,B-Disease
deep,4482,I-Disease
venous,4482,I-Disease
thrombosis,4482,I-Disease
(,4482,O
DVT,4482,B-Disease
),4482,O
and,4482,O
pulmonary,4482,B-Disease
embolism,4482,I-Disease
secondary,4482,O
to,4482,O
heparin-induced,4482,B-Chemical
thrombocytopenia,4482,B-Disease
.,4482,O
A,4483,O
continuous,4483,O
i.v,4483,O
.,4483,O
infusion,4484,O
of,4484,O
argatroban,4484,B-Chemical
was,4484,O
initiated,4484,O
",",4484,O
and,4484,O
the,4484,O
patient,4484,O
was,4484,O
managed,4484,O
on,4484,O
the,4484,O
general,4484,O
medical,4484,O
floor,4484,O
.,4484,O
After,4485,O
one,4485,O
week,4485,O
of,4485,O
therapy,4485,O
",",4485,O
he,4485,O
was,4485,O
transferred,4485,O
to,4485,O
the,4485,O
intensive,4485,O
care,4485,O
unit,4485,O
with,4485,O
cardiopulmonary,4485,O
compromise,4485,O
related,4485,O
to,4485,O
superior,4485,B-Disease
vena,4485,I-Disease
cava,4485,I-Disease
(,4485,I-Disease
SVC,4485,I-Disease
),4485,I-Disease
syndrome,4485,I-Disease
.,4485,O
A,4486,O
percutaneous,4486,O
mechanical,4486,O
thrombectomy,4486,O
and,4486,O
CDT,4486,O
with,4486,O
alteplase,4486,O
were,4486,O
attempted,4486,O
",",4486,O
but,4486,O
the,4486,O
procedure,4486,O
was,4486,O
aborted,4486,O
due,4486,O
to,4486,O
epistaxis,4486,B-Disease
.,4486,O
The,4487,O
epistaxis,4487,B-Disease
resolved,4487,O
the,4487,O
next,4487,O
day,4487,O
",",4487,O
and,4487,O
the,4487,O
patient,4487,O
was,4487,O
restarted,4487,O
on,4487,O
argatroban,4487,B-Chemical
.,4487,O
A,4488,O
second,4488,O
percutaneous,4488,O
mechanical,4488,O
thrombectomy,4488,O
was,4488,O
performed,4488,O
six,4488,O
days,4488,O
later,4488,O
and,4488,O
resulted,4488,O
in,4488,O
partial,4488,O
revascularization,4488,O
of,4488,O
the,4488,O
SVC,4488,O
and,4488,O
central,4488,O
veins,4488,O
.,4488,O
Postthrombectomy,4489,O
continuous,4489,O
CDT,4489,O
with,4489,O
alteplase,4489,O
was,4489,O
commenced,4489,O
while,4489,O
argatroban,4489,B-Chemical
was,4489,O
withheld,4489,O
",",4489,O
and,4489,O
complete,4489,O
patency,4489,O
of,4489,O
the,4489,O
SVC,4489,O
and,4489,O
central,4489,O
veins,4489,O
was,4489,O
achieved,4489,O
after,4489,O
three,4489,O
days,4489,O
of,4489,O
therapy,4489,O
.,4489,O
Alteplase,4490,O
was,4490,O
discontinued,4490,O
",",4490,O
and,4490,O
the,4490,O
patient,4490,O
was,4490,O
reinitiated,4490,O
on,4490,O
argatroban,4490,B-Chemical
;,4490,O
ultimately,4490,O
",",4490,O
he,4490,O
was,4490,O
transitioned,4490,O
to,4490,O
warfarin,4490,B-Chemical
for,4490,O
long-term,4490,O
anticoagulation,4490,O
.,4490,O
Although,4491,O
the,4491,O
patient,4491,O
recovered,4491,O
",",4491,O
he,4491,O
experienced,4491,O
permanent,4491,O
vision,4491,O
and,4491,O
hearing,4491,O
loss,4491,O
",",4491,O
as,4491,O
well,4491,O
as,4491,O
end-stage,4491,B-Disease
renal,4491,I-Disease
disease,4491,I-Disease
.,4491,O
CONCLUSION,4492,O
:,4492,O
A,4492,O
63-year-old,4492,O
man,4492,O
with,4492,O
renal,4492,O
amyloidosis,4492,B-Disease
and,4492,O
SVC,4492,B-Disease
syndrome,4492,I-Disease
secondary,4492,O
to,4492,O
HITT,4492,B-Disease
was,4492,O
successfully,4492,O
treated,4492,O
with,4492,O
argatroban,4492,B-Chemical
and,4492,O
CDT,4492,O
with,4492,O
alteplase,4492,O
.,4492,O
Effects,4493,O
of,4493,O
dehydroepiandrosterone,4493,B-Chemical
in,4493,O
amphetamine-induced,4493,B-Chemical
schizophrenia,4493,B-Disease
models,4493,O
in,4493,O
mice,4493,O
.,4493,O
OBJECTIVE,4494,O
:,4494,O
To,4494,O
examine,4494,O
the,4494,O
effects,4494,O
of,4494,O
dehydroepiandrosterone,4494,B-Chemical
(,4494,O
DHEA,4494,B-Chemical
),4494,O
on,4494,O
animal,4494,O
models,4494,O
of,4494,O
schizophrenia,4494,B-Disease
.,4494,O
METHODS,4495,O
:,4495,O
Seventy,4495,O
Swiss,4495,O
albino,4495,O
female,4495,O
mice,4495,O
(,4495,O
25-35,4495,O
g,4495,O
),4495,O
were,4495,O
divided,4495,O
into,4495,O
4,4495,O
groups,4495,O
:,4495,O
amphetamine-free,4495,B-Chemical
(,4495,O
control,4495,O
),4495,O
",",4495,O
amphetamine,4495,B-Chemical
",",4495,O
50,4495,O
",",4495,O
and,4495,O
100,4495,O
mg/kg,4495,O
DHEA,4495,B-Chemical
.,4495,O
The,4496,O
DHEA,4496,B-Chemical
was,4496,O
administered,4496,O
intraperitoneally,4496,O
(,4496,O
ip,4496,O
),4496,O
for,4496,O
5,4496,O
days,4496,O
.,4496,O
Amphetamine,4497,B-Chemical
(,4497,O
3,4497,O
mg/kg,4497,O
ip,4497,O
),4497,O
induced,4497,O
hyper,4497,B-Disease
locomotion,4497,O
",",4497,O
apomorphine,4497,B-Chemical
(,4497,O
1.5,4497,O
mg/kg,4497,O
subcutaneously,4497,O
[,4497,O
sc,4497,O
],4497,O
),4497,O
induced,4497,O
climbing,4497,O
",",4497,O
and,4497,O
haloperidol,4497,B-Chemical
(,4497,O
1.5,4497,O
mg/kg,4497,O
sc,4497,O
),4497,O
induced,4497,O
catalepsy,4497,B-Disease
tests,4497,O
were,4497,O
used,4497,O
as,4497,O
animal,4497,O
models,4497,O
of,4497,O
schizophrenia,4497,B-Disease
.,4497,O
The,4498,O
study,4498,O
was,4498,O
conducted,4498,O
at,4498,O
the,4498,O
Animal,4498,O
Experiment,4498,O
Laboratories,4498,O
",",4498,O
Department,4498,O
of,4498,O
Pharmacology,4498,O
",",4498,O
Medical,4498,O
School,4498,O
",",4498,O
Eskisehir,4498,O
Osmangazi,4498,O
University,4498,O
",",4498,O
Eskisehir,4498,O
",",4498,O
Turkey,4498,O
between,4498,O
March,4498,O
and,4498,O
May,4498,O
2012,4498,O
.,4498,O
Statistical,4499,O
analysis,4499,O
was,4499,O
carried,4499,O
out,4499,O
using,4499,O
Kruskal-Wallis,4499,O
test,4499,O
for,4499,O
hyper,4499,B-Disease
locomotion,4499,O
",",4499,O
and,4499,O
one-way,4499,O
ANOVA,4499,O
for,4499,O
climbing,4499,O
and,4499,O
catalepsy,4499,B-Disease
tests,4499,O
.,4499,O
RESULTS,4500,O
:,4500,O
In,4500,O
the,4500,O
amphetamine-induced,4500,B-Chemical
locomotion,4500,O
test,4500,O
",",4500,O
there,4500,O
were,4500,O
significant,4500,O
increases,4500,O
in,4500,O
all,4500,O
movements,4500,O
compared,4500,O
with,4500,O
the,4500,O
amphetamine-free,4500,B-Chemical
group,4500,O
.,4500,O
Both,4501,O
DHEA,4501,B-Chemical
50,4501,O
mg/kg,4501,O
(,4501,O
p,4501,O
<,4501,O
0.05,4501,O
),4501,O
",",4501,O
and,4501,O
100,4501,O
mg/kg,4501,O
(,4501,O
p,4501,O
<,4501,O
0.01,4501,O
),4501,O
significantly,4501,O
decreased,4501,O
all,4501,O
movements,4501,O
compared,4501,O
with,4501,O
the,4501,O
amphetamine-induced,4501,B-Chemical
locomotion,4501,O
group,4501,O
.,4501,O
There,4502,O
was,4502,O
a,4502,O
significant,4502,O
difference,4502,O
between,4502,O
groups,4502,O
in,4502,O
the,4502,O
haloperidol-induced,4502,B-Chemical
catalepsy,4502,B-Disease
test,4502,O
(,4502,O
p,4502,O
<,4502,O
0.05,4502,O
),4502,O
.,4502,O
There,4503,O
was,4503,O
no,4503,O
significant,4503,O
difference,4503,O
between,4503,O
groups,4503,O
in,4503,O
terms,4503,O
of,4503,O
total,4503,O
climbing,4503,O
time,4503,O
in,4503,O
the,4503,O
apomorphine-induced,4503,B-Chemical
climbing,4503,O
test,4503,O
(,4503,O
p,4503,O
>,4503,O
0.05,4503,O
),4503,O
.,4503,O
CONCLUSION,4504,O
:,4504,O
We,4504,O
observed,4504,O
that,4504,O
DHEA,4504,B-Chemical
reduced,4504,O
locomotor,4504,O
activity,4504,O
and,4504,O
increased,4504,O
catalepsy,4504,B-Disease
at,4504,O
both,4504,O
doses,4504,O
",",4504,O
while,4504,O
it,4504,O
had,4504,O
no,4504,O
effect,4504,O
on,4504,O
climbing,4504,O
behavior,4504,O
.,4504,O
We,4505,O
suggest,4505,O
that,4505,O
DHEA,4505,B-Chemical
displays,4505,O
typical,4505,O
neuroleptic-like,4505,O
effects,4505,O
",",4505,O
and,4505,O
may,4505,O
be,4505,O
used,4505,O
in,4505,O
the,4505,O
treatment,4505,O
of,4505,O
schizophrenia,4505,B-Disease
.,4505,O
Availability,4506,O
of,4506,O
human,4506,O
induced,4506,O
pluripotent,4506,O
stem,4506,O
cell-derived,4506,O
cardiomyocytes,4506,O
in,4506,O
assessment,4506,O
of,4506,O
drug,4506,O
potential,4506,O
for,4506,O
QT,4506,B-Disease
prolongation,4506,I-Disease
.,4506,O
Field,4507,O
potential,4507,O
duration,4507,O
(,4507,O
FPD,4507,O
),4507,O
in,4507,O
human-induced,4507,O
pluripotent,4507,O
stem,4507,O
cell-derived,4507,O
cardiomyocytes,4507,O
(,4507,O
hiPS-CMs,4507,O
),4507,O
",",4507,O
which,4507,O
can,4507,O
express,4507,O
QT,4507,O
interval,4507,O
in,4507,O
an,4507,O
electrocardiogram,4507,O
",",4507,O
is,4507,O
reported,4507,O
to,4507,O
be,4507,O
a,4507,O
useful,4507,O
tool,4507,O
to,4507,O
predict,4507,O
K,4507,B-Chemical
(,4507,O
+,4507,O
),4507,O
channel,4507,O
and,4507,O
Ca,4507,B-Chemical
(,4507,O
2+,4507,O
),4507,O
channel,4507,O
blocker,4507,O
effects,4507,O
on,4507,O
QT,4507,O
interval,4507,O
.,4507,O
However,4508,O
",",4508,O
there,4508,O
is,4508,O
no,4508,O
report,4508,O
showing,4508,O
that,4508,O
this,4508,O
technique,4508,O
can,4508,O
be,4508,O
used,4508,O
to,4508,O
predict,4508,O
multichannel,4508,O
blocker,4508,O
potential,4508,O
for,4508,O
QT,4508,B-Disease
prolongation,4508,I-Disease
.,4508,O
The,4509,O
aim,4509,O
of,4509,O
this,4509,O
study,4509,O
is,4509,O
to,4509,O
show,4509,O
that,4509,O
FPD,4509,O
from,4509,O
MEA,4509,O
(,4509,O
Multielectrode,4509,O
array,4509,O
),4509,O
of,4509,O
hiPS-CMs,4509,O
can,4509,O
detect,4509,O
QT,4509,B-Disease
prolongation,4509,I-Disease
induced,4509,O
by,4509,O
multichannel,4509,O
blockers,4509,O
.,4509,O
hiPS-CMs,4510,O
were,4510,O
seeded,4510,O
onto,4510,O
MEA,4510,O
and,4510,O
FPD,4510,O
was,4510,O
measured,4510,O
for,4510,O
2min,4510,O
every,4510,O
10min,4510,O
for,4510,O
30min,4510,O
after,4510,O
drug,4510,O
exposure,4510,O
for,4510,O
the,4510,O
vehicle,4510,O
and,4510,O
each,4510,O
drug,4510,O
concentration,4510,O
.,4510,O
IKr,4511,O
and,4511,O
IKs,4511,O
blockers,4511,O
concentration-dependently,4511,O
prolonged,4511,O
corrected,4511,O
FPD,4511,O
(,4511,O
FPDc,4511,O
),4511,O
",",4511,O
whereas,4511,O
Ca,4511,B-Chemical
(,4511,O
2+,4511,O
),4511,O
channel,4511,O
blockers,4511,O
concentration-dependently,4511,O
shortened,4511,O
FPDc,4511,O
.,4511,O
Also,4512,O
",",4512,O
the,4512,O
multichannel,4512,O
blockers,4512,O
Amiodarone,4512,B-Chemical
",",4512,O
Paroxetine,4512,B-Chemical
",",4512,O
Terfenadine,4512,B-Chemical
and,4512,O
Citalopram,4512,B-Chemical
prolonged,4512,O
FPDc,4512,O
in,4512,O
a,4512,O
concentration,4512,O
dependent,4512,O
manner,4512,O
.,4512,O
Finally,4513,O
",",4513,O
the,4513,O
IKr,4513,O
blockers,4513,O
",",4513,O
Terfenadine,4513,B-Chemical
and,4513,O
Citalopram,4513,B-Chemical
",",4513,O
which,4513,O
are,4513,O
reported,4513,O
to,4513,O
cause,4513,O
Torsade,4513,B-Disease
de,4513,I-Disease
Pointes,4513,I-Disease
(,4513,O
TdP,4513,B-Disease
),4513,O
in,4513,O
clinical,4513,O
practice,4513,O
",",4513,O
produced,4513,O
early,4513,O
afterdepolarization,4513,O
(,4513,O
EAD,4513,O
),4513,O
.,4513,O
hiPS-CMs,4514,O
using,4514,O
MEA,4514,O
system,4514,O
and,4514,O
FPDc,4514,O
can,4514,O
predict,4514,O
the,4514,O
effects,4514,O
of,4514,O
drug,4514,O
candidates,4514,O
on,4514,O
QT,4514,O
interval,4514,O
.,4514,O
This,4515,O
study,4515,O
also,4515,O
shows,4515,O
that,4515,O
this,4515,O
assay,4515,O
can,4515,O
help,4515,O
detect,4515,O
EAD,4515,O
for,4515,O
drugs,4515,O
with,4515,O
TdP,4515,B-Disease
potential,4515,O
.,4515,O
Dermal,4516,O
developmental,4516,O
toxicity,4516,B-Disease
of,4516,O
N-phenylimide,4516,O
herbicides,4516,O
in,4516,O
rats,4516,O
.,4516,O
BACKGROUND,4517,O
:,4517,O
S-53482,4517,B-Chemical
and,4517,O
S-23121,4517,B-Chemical
are,4517,O
N-phenylimide,4517,O
herbicides,4517,O
and,4517,O
produced,4517,O
embryolethality,4517,B-Disease
",",4517,O
teratogenicity,4517,B-Disease
(,4517,O
mainly,4517,O
ventricular,4517,B-Disease
septal,4517,I-Disease
defects,4517,I-Disease
and,4517,O
wavy,4517,O
ribs,4517,O
),4517,O
",",4517,O
and,4517,O
growth,4517,B-Disease
retardation,4517,I-Disease
in,4517,O
rats,4517,O
in,4517,O
conventional,4517,O
oral,4517,O
developmental,4517,O
toxicity,4517,B-Disease
studies,4517,O
.,4517,O
Our,4518,O
objective,4518,O
in,4518,O
this,4518,O
study,4518,O
was,4518,O
to,4518,O
investigate,4518,O
whether,4518,O
the,4518,O
compounds,4518,O
induce,4518,O
developmental,4518,O
toxicity,4518,B-Disease
via,4518,O
the,4518,O
dermal,4518,O
route,4518,O
",",4518,O
which,4518,O
is,4518,O
more,4518,O
relevant,4518,O
to,4518,O
occupational,4518,O
exposure,4518,O
",",4518,O
hence,4518,O
better,4518,O
addressing,4518,O
human,4518,O
health,4518,O
risks,4518,O
.,4518,O
METHODS,4519,O
:,4519,O
S-53482,4519,B-Chemical
was,4519,O
administered,4519,O
dermally,4519,O
to,4519,O
rats,4519,O
at,4519,O
30,4519,O
",",4519,O
100,4519,O
",",4519,O
and,4519,O
300,4519,O
mg/kg,4519,O
during,4519,O
organogenesis,4519,O
",",4519,O
and,4519,O
S-23121,4519,B-Chemical
was,4519,O
administered,4519,O
at,4519,O
200,4519,O
",",4519,O
400,4519,O
",",4519,O
and,4519,O
800,4519,O
mg/kg,4519,O
(,4519,O
the,4519,O
maximum,4519,O
applicable,4519,O
dose,4519,O
level,4519,O
),4519,O
.,4519,O
Fetuses,4520,O
were,4520,O
obtained,4520,O
by,4520,O
a,4520,O
Cesarean,4520,O
section,4520,O
and,4520,O
examined,4520,O
for,4520,O
external,4520,O
",",4520,O
visceral,4520,O
",",4520,O
and,4520,O
skeletal,4520,O
alterations,4520,O
.,4520,O
RESULTS,4521,O
:,4521,O
Dermal,4521,O
exposure,4521,O
of,4521,O
rats,4521,O
to,4521,O
S-53482,4521,B-Chemical
at,4521,O
300,4521,O
mg/kg,4521,O
produced,4521,O
patterns,4521,O
of,4521,O
developmental,4521,O
toxicity,4521,B-Disease
similar,4521,O
to,4521,O
those,4521,O
resulting,4521,O
from,4521,O
oral,4521,O
exposure,4521,O
.,4521,O
Toxicity,4522,B-Disease
included,4522,O
embryolethality,4522,B-Disease
",",4522,O
teratogenicity,4522,B-Disease
",",4522,O
and,4522,O
growth,4522,B-Disease
retardation,4522,I-Disease
.,4522,O
Dermal,4523,O
administration,4523,O
of,4523,O
S-23121,4523,B-Chemical
at,4523,O
800,4523,O
mg/kg,4523,O
resulted,4523,O
in,4523,O
an,4523,O
increased,4523,O
incidence,4523,O
of,4523,O
embryonic,4523,B-Disease
death,4523,I-Disease
and,4523,O
ventricular,4523,B-Disease
septal,4523,I-Disease
defect,4523,I-Disease
",",4523,O
but,4523,O
retarded,4523,O
fetal,4523,O
growth,4523,O
was,4523,O
not,4523,O
observed,4523,O
as,4523,O
it,4523,O
was,4523,O
following,4523,O
oral,4523,O
exposure,4523,O
to,4523,O
S-23121,4523,B-Chemical
.,4523,O
CONCLUSIONS,4524,O
:,4524,O
Based,4524,O
on,4524,O
the,4524,O
results,4524,O
",",4524,O
S-53482,4524,B-Chemical
and,4524,O
S-23121,4524,B-Chemical
were,4524,O
teratogenic,4524,B-Disease
when,4524,O
administered,4524,O
dermally,4524,O
to,4524,O
pregnant,4524,O
rats,4524,O
as,4524,O
were,4524,O
the,4524,O
compounds,4524,O
administered,4524,O
orally,4524,O
.,4524,O
Thus,4525,O
",",4525,O
investigation,4525,O
of,4525,O
the,4525,O
mechanism,4525,O
and,4525,O
its,4525,O
human,4525,O
relevancy,4525,O
become,4525,O
more,4525,O
important,4525,O
.,4525,O
Rates,4526,O
of,4526,O
Renal,4526,B-Disease
Toxicity,4526,I-Disease
in,4526,O
Cancer,4526,B-Disease
Patients,4526,O
Receiving,4526,O
Cisplatin,4526,B-Chemical
With,4526,O
and,4526,O
Without,4526,O
Mannitol,4526,B-Chemical
.,4526,O
BACKGROUND,4527,O
:,4527,O
Cisplatin,4527,B-Chemical
is,4527,O
a,4527,O
widely,4527,O
used,4527,O
antineoplastic,4527,O
.,4527,O
One,4528,O
of,4528,O
the,4528,O
major,4528,O
complications,4528,O
of,4528,O
cisplatin,4528,B-Chemical
use,4528,O
is,4528,O
dose-limiting,4528,O
nephrotoxicity,4528,B-Disease
.,4528,O
There,4529,O
are,4529,O
many,4529,O
strategies,4529,O
to,4529,O
prevent,4529,O
this,4529,O
toxicity,4529,B-Disease
",",4529,O
including,4529,O
the,4529,O
use,4529,O
of,4529,O
mannitol,4529,B-Chemical
as,4529,O
a,4529,O
nephroprotectant,4529,O
in,4529,O
combination,4529,O
with,4529,O
hydration,4529,O
.,4529,O
OBJECTIVE,4530,O
:,4530,O
We,4530,O
aimed,4530,O
to,4530,O
evaluate,4530,O
the,4530,O
rates,4530,O
of,4530,O
cisplatin-induced,4530,B-Chemical
nephrotoxicity,4530,B-Disease
in,4530,O
cancer,4530,B-Disease
patients,4530,O
receiving,4530,O
single-agent,4530,O
cisplatin,4530,B-Chemical
with,4530,O
and,4530,O
without,4530,O
mannitol,4530,B-Chemical
.,4530,O
METHODS,4531,O
:,4531,O
This,4531,O
single-center,4531,O
retrospective,4531,O
analysis,4531,O
was,4531,O
a,4531,O
quasi,4531,O
experiment,4531,O
created,4531,O
by,4531,O
the,4531,O
national,4531,O
mannitol,4531,B-Chemical
shortage,4531,O
.,4531,O
Data,4532,O
were,4532,O
collected,4532,O
on,4532,O
adult,4532,O
cancer,4532,B-Disease
patients,4532,O
receiving,4532,O
single-agent,4532,O
cisplatin,4532,B-Chemical
as,4532,O
an,4532,O
outpatient,4532,O
from,4532,O
January,4532,O
2011,4532,O
to,4532,O
September,4532,O
2012,4532,O
.,4532,O
The,4533,O
primary,4533,O
outcome,4533,O
was,4533,O
acute,4533,B-Disease
kidney,4533,I-Disease
injury,4533,I-Disease
(,4533,O
AKI,4533,B-Disease
),4533,O
.,4533,O
RESULTS,4534,O
:,4534,O
We,4534,O
evaluated,4534,O
143,4534,O
patients,4534,O
who,4534,O
received,4534,O
single-agent,4534,O
cisplatin,4534,B-Chemical
;,4534,O
97.2,4534,O
%,4534,O
of,4534,O
patients,4534,O
had,4534,O
head,4534,B-Disease
and,4534,I-Disease
neck,4534,I-Disease
cancer,4534,I-Disease
as,4534,O
their,4534,O
primary,4534,O
malignancy,4534,B-Disease
.,4534,O
Patients,4535,O
who,4535,O
did,4535,O
not,4535,O
receive,4535,O
mannitol,4535,B-Chemical
were,4535,O
more,4535,O
likely,4535,O
to,4535,O
develop,4535,O
nephrotoxicity,4535,B-Disease
:,4535,O
odds,4535,O
ratio,4535,O
[,4535,O
OR,4535,O
],4535,O
=,4535,O
2.646,4535,O
(,4535,O
95,4535,O
%,4535,O
CI,4535,O
=,4535,O
1.008,4535,O
",",4535,O
6.944,4535,O
;,4535,O
P,4535,O
=,4535,O
0.048,4535,O
),4535,O
.,4535,O
Patients,4536,O
who,4536,O
received,4536,O
the,4536,O
100,4536,O
mg/m,4536,O
(,4536,O
2,4536,O
),4536,O
dosing,4536,O
and,4536,O
patients,4536,O
who,4536,O
had,4536,O
a,4536,O
history,4536,O
of,4536,O
hypertension,4536,B-Disease
also,4536,O
had,4536,O
a,4536,O
higher,4536,O
likelihood,4536,O
of,4536,O
developing,4536,O
nephrotoxicity,4536,B-Disease
:,4536,O
OR,4536,O
=,4536,O
11.494,4536,O
(,4536,O
95,4536,O
%,4536,O
CI,4536,O
=,4536,O
4.149,4536,O
",",4536,O
32.258,4536,O
;,4536,O
P,4536,O
<,4536,O
0.0001,4536,O
),4536,O
and,4536,O
OR,4536,O
=,4536,O
3.219,4536,O
(,4536,O
95,4536,O
%,4536,O
CI,4536,O
=,4536,O
1.228,4536,O
",",4536,O
8.439,4536,O
;,4536,O
P,4536,O
=,4536,O
0.017,4536,O
),4536,O
",",4536,O
respectively,4536,O
.,4536,O
CONCLUSIONS,4537,O
:,4537,O
When,4537,O
limited,4537,O
quantities,4537,O
of,4537,O
mannitol,4537,B-Chemical
are,4537,O
available,4537,O
",",4537,O
it,4537,O
should,4537,O
preferentially,4537,O
be,4537,O
given,4537,O
to,4537,O
patients,4537,O
at,4537,O
particularly,4537,O
high,4537,O
risk,4537,O
of,4537,O
nephrotoxicity,4537,B-Disease
.,4537,O
Our,4538,O
analysis,4538,O
suggests,4538,O
that,4538,O
those,4538,O
patients,4538,O
receiving,4538,O
the,4538,O
dosing,4538,O
schedule,4538,O
of,4538,O
100,4538,O
mg/m,4538,O
(,4538,O
2,4538,O
),4538,O
cisplatin,4538,B-Chemical
every,4538,O
3,4538,O
weeks,4538,O
and,4538,O
those,4538,O
with,4538,O
hypertension,4538,B-Disease
are,4538,O
at,4538,O
the,4538,O
greatest,4538,O
risk,4538,O
of,4538,O
nephrotoxicity,4538,B-Disease
and,4538,O
would,4538,O
benefit,4538,O
from,4538,O
the,4538,O
addition,4538,O
of,4538,O
mannitol,4538,B-Chemical
.,4538,O
Metformin,4539,B-Chemical
protects,4539,O
against,4539,O
seizures,4539,B-Disease
",",4539,O
learning,4539,O
and,4539,O
memory,4539,O
impairments,4539,O
and,4539,O
oxidative,4539,O
damage,4539,O
induced,4539,O
by,4539,O
pentylenetetrazole-induced,4539,B-Chemical
kindling,4539,O
in,4539,O
mice,4539,O
.,4539,O
Cognitive,4540,B-Disease
impairment,4540,I-Disease
",",4540,O
the,4540,O
most,4540,O
common,4540,O
and,4540,O
severe,4540,O
comorbidity,4540,O
of,4540,O
epilepsy,4540,B-Disease
",",4540,O
greatly,4540,O
diminishes,4540,O
the,4540,O
quality,4540,O
of,4540,O
life,4540,O
.,4540,O
However,4541,O
",",4541,O
current,4541,O
therapeutic,4541,O
interventions,4541,O
for,4541,O
epilepsy,4541,B-Disease
can,4541,O
also,4541,O
cause,4541,O
untoward,4541,O
cognitive,4541,O
effects,4541,O
.,4541,O
Thus,4542,O
",",4542,O
there,4542,O
is,4542,O
an,4542,O
urgent,4542,O
need,4542,O
for,4542,O
new,4542,O
kinds,4542,O
of,4542,O
agents,4542,O
targeting,4542,O
both,4542,O
seizures,4542,B-Disease
and,4542,O
cognition,4542,B-Disease
deficits,4542,I-Disease
.,4542,O
Oxidative,4543,O
stress,4543,O
is,4543,O
considered,4543,O
to,4543,O
play,4543,O
an,4543,O
important,4543,O
role,4543,O
in,4543,O
epileptogenesis,4543,O
and,4543,O
cognitive,4543,B-Disease
deficits,4543,I-Disease
",",4543,O
and,4543,O
antioxidants,4543,O
have,4543,O
a,4543,O
putative,4543,O
antiepileptic,4543,O
potential,4543,O
.,4543,O
Metformin,4544,B-Chemical
",",4544,O
the,4544,O
most,4544,O
commonly,4544,O
prescribed,4544,O
antidiabetic,4544,O
oral,4544,O
drug,4544,O
",",4544,O
has,4544,O
antioxidant,4544,O
properties,4544,O
.,4544,O
This,4545,O
study,4545,O
was,4545,O
designed,4545,O
to,4545,O
evaluate,4545,O
the,4545,O
ameliorative,4545,O
effects,4545,O
of,4545,O
metformin,4545,B-Chemical
on,4545,O
seizures,4545,B-Disease
",",4545,O
cognitive,4545,B-Disease
impairment,4545,I-Disease
and,4545,O
brain,4545,O
oxidative,4545,O
stress,4545,O
markers,4545,O
observed,4545,O
in,4545,O
pentylenetetrazole-induced,4545,B-Chemical
kindling,4545,O
animals,4545,O
.,4545,O
Male,4546,O
C57BL/6,4546,O
mice,4546,O
were,4546,O
administered,4546,O
with,4546,O
subconvulsive,4546,O
dose,4546,O
of,4546,O
pentylenetetrazole,4546,B-Chemical
(,4546,O
37,4546,O
mg/kg,4546,O
",",4546,O
i.p,4546,O
.,4546,O
),4546,O
every,4547,O
other,4547,O
day,4547,O
for,4547,O
14,4547,O
injections,4547,O
.,4547,O
Metformin,4548,B-Chemical
was,4548,O
injected,4548,O
intraperitoneally,4548,O
in,4548,O
dose,4548,O
of,4548,O
200mg/kg,4548,O
along,4548,O
with,4548,O
alternate-day,4548,O
PTZ,4548,B-Chemical
.,4548,O
We,4549,O
found,4549,O
that,4549,O
metformin,4549,B-Chemical
suppressed,4549,O
the,4549,O
progression,4549,O
of,4549,O
kindling,4549,O
",",4549,O
ameliorated,4549,O
the,4549,O
cognitive,4549,B-Disease
impairment,4549,I-Disease
and,4549,O
decreased,4549,O
brain,4549,O
oxidative,4549,O
stress,4549,O
.,4549,O
Thus,4550,O
the,4550,O
present,4550,O
study,4550,O
concluded,4550,O
that,4550,O
metformin,4550,B-Chemical
may,4550,O
be,4550,O
a,4550,O
potential,4550,O
agent,4550,O
for,4550,O
the,4550,O
treatment,4550,O
of,4550,O
epilepsy,4550,B-Disease
as,4550,O
well,4550,O
as,4550,O
a,4550,O
protective,4550,O
medicine,4550,O
against,4550,O
cognitive,4550,B-Disease
impairment,4550,I-Disease
induced,4550,O
by,4550,O
seizures,4550,B-Disease
.,4550,O
P53,4551,O
inhibition,4551,O
exacerbates,4551,O
late-stage,4551,O
anthracycline,4551,B-Chemical
cardiotoxicity,4551,B-Disease
.,4551,O
AIMS,4552,O
:,4552,O
Doxorubicin,4552,B-Chemical
(,4552,O
DOX,4552,B-Chemical
),4552,O
is,4552,O
an,4552,O
effective,4552,O
anti-cancer,4552,O
therapeutic,4552,O
",",4552,O
but,4552,O
is,4552,O
associated,4552,O
with,4552,O
both,4552,O
acute,4552,O
and,4552,O
late-stage,4552,O
cardiotoxicity,4552,B-Disease
.,4552,O
Children,4553,O
are,4553,O
particularly,4553,O
sensitive,4553,O
to,4553,O
DOX-induced,4553,B-Chemical
heart,4553,B-Disease
failure,4553,I-Disease
.,4553,O
Here,4554,O
",",4554,O
the,4554,O
impact,4554,O
of,4554,O
p53,4554,O
inhibition,4554,O
on,4554,O
acute,4554,O
vs.,4554,O
late-stage,4554,O
DOX,4554,B-Chemical
cardiotoxicity,4554,B-Disease
was,4554,O
examined,4554,O
in,4554,O
a,4554,O
juvenile,4554,O
model,4554,O
.,4554,O
METHODS,4555,O
AND,4555,O
RESULTS,4555,O
:,4555,O
Two-week-old,4555,O
MHC-CB7,4555,O
mice,4555,O
(,4555,O
which,4555,O
express,4555,O
dominant-interfering,4555,O
p53,4555,O
in,4555,O
cardiomyocytes,4555,O
),4555,O
and,4555,O
their,4555,O
non-transgenic,4555,O
(,4555,O
NON-TXG,4555,O
),4555,O
littermates,4555,O
received,4555,O
weekly,4555,O
DOX,4555,B-Chemical
injections,4555,O
for,4555,O
5,4555,O
weeks,4555,O
(,4555,O
25,4555,O
mg/kg,4555,O
cumulative,4555,O
dose,4555,O
),4555,O
.,4555,O
One,4556,O
week,4556,O
after,4556,O
the,4556,O
last,4556,O
DOX,4556,B-Chemical
treatment,4556,O
(,4556,O
acute,4556,O
stage,4556,O
),4556,O
",",4556,O
MHC-CB7,4556,O
mice,4556,O
exhibited,4556,O
improved,4556,O
cardiac,4556,O
function,4556,O
and,4556,O
lower,4556,O
levels,4556,O
of,4556,O
cardiomyocyte,4556,O
apoptosis,4556,O
when,4556,O
compared,4556,O
with,4556,O
the,4556,O
NON-TXG,4556,O
mice,4556,O
.,4556,O
Surprisingly,4557,O
",",4557,O
by,4557,O
13,4557,O
weeks,4557,O
following,4557,O
the,4557,O
last,4557,O
DOX,4557,B-Chemical
treatment,4557,O
(,4557,O
late,4557,O
stage,4557,O
),4557,O
",",4557,O
MHC-CB7,4557,O
exhibited,4557,O
a,4557,O
progressive,4557,O
decrease,4557,O
in,4557,O
cardiac,4557,O
function,4557,O
and,4557,O
higher,4557,O
rates,4557,O
of,4557,O
cardiomyocyte,4557,O
apoptosis,4557,O
when,4557,O
compared,4557,O
with,4557,O
NON-TXG,4557,O
mice,4557,O
.,4557,O
p53,4558,O
inhibition,4558,O
blocked,4558,O
transient,4558,O
DOX-induced,4558,B-Chemical
STAT3,4558,O
activation,4558,O
in,4558,O
MHC-CB7,4558,O
mice,4558,O
",",4558,O
which,4558,O
was,4558,O
associated,4558,O
with,4558,O
enhanced,4558,O
induction,4558,O
of,4558,O
the,4558,O
DNA,4558,O
repair,4558,O
proteins,4558,O
Ku70,4558,O
and,4558,O
Ku80,4558,O
.,4558,O
Mice,4559,O
with,4559,O
cardiomyocyte-restricted,4559,O
deletion,4559,O
of,4559,O
STAT3,4559,O
exhibited,4559,O
worse,4559,O
cardiac,4559,O
function,4559,O
",",4559,O
higher,4559,O
levels,4559,O
of,4559,O
cardiomyocyte,4559,O
apoptosis,4559,O
",",4559,O
and,4559,O
a,4559,O
greater,4559,O
induction,4559,O
of,4559,O
Ku70,4559,O
and,4559,O
Ku80,4559,O
in,4559,O
response,4559,O
to,4559,O
DOX,4559,B-Chemical
treatment,4559,O
during,4559,O
the,4559,O
acute,4559,O
stage,4559,O
when,4559,O
compared,4559,O
with,4559,O
control,4559,O
animals,4559,O
.,4559,O
CONCLUSION,4560,O
:,4560,O
These,4560,O
data,4560,O
support,4560,O
a,4560,O
model,4560,O
wherein,4560,O
a,4560,O
p53-dependent,4560,O
cardioprotective,4560,O
pathway,4560,O
",",4560,O
mediated,4560,O
via,4560,O
STAT3,4560,O
activation,4560,O
",",4560,O
mitigates,4560,O
DOX-induced,4560,B-Chemical
myocardial,4560,O
stress,4560,O
during,4560,O
drug,4560,O
delivery,4560,O
.,4560,O
Furthermore,4561,O
",",4561,O
these,4561,O
data,4561,O
suggest,4561,O
an,4561,O
explanation,4561,O
as,4561,O
to,4561,O
how,4561,O
p53,4561,O
inhibition,4561,O
can,4561,O
result,4561,O
in,4561,O
cardioprotection,4561,O
during,4561,O
drug,4561,O
treatment,4561,O
and,4561,O
",",4561,O
paradoxically,4561,O
",",4561,O
enhanced,4561,O
cardiotoxicity,4561,B-Disease
long,4561,O
after,4561,O
the,4561,O
cessation,4561,O
of,4561,O
drug,4561,O
treatment,4561,O
.,4561,O
Metronidazole-induced,4562,B-Chemical
encephalopathy,4562,B-Disease
:,4562,O
an,4562,O
uncommon,4562,O
scenario,4562,O
.,4562,O
Metronidazole,4563,B-Chemical
can,4563,O
produce,4563,O
neurological,4563,O
complications,4563,O
although,4563,O
it,4563,O
is,4563,O
not,4563,O
a,4563,O
common,4563,O
scenario,4563,O
.,4563,O
We,4564,O
present,4564,O
a,4564,O
case,4564,O
where,4564,O
a,4564,O
patient,4564,O
developed,4564,O
features,4564,O
of,4564,O
encephalopathy,4564,B-Disease
following,4564,O
prolonged,4564,O
metronidazole,4564,B-Chemical
intake,4564,O
.,4564,O
Magnetic,4565,O
resonance,4565,O
imaging,4565,O
(,4565,O
MRI,4565,O
),4565,O
brain,4565,O
showed,4565,O
abnormal,4565,O
signal,4565,O
intensity,4565,O
involving,4565,O
both,4565,O
dentate,4565,O
nuclei,4565,O
of,4565,O
cerebellum,4565,O
and,4565,O
splenium,4565,O
of,4565,O
corpus,4565,O
callosum,4565,O
.,4565,O
The,4566,O
diagnosis,4566,O
of,4566,O
metronidazole,4566,B-Chemical
toxicity,4566,B-Disease
was,4566,O
made,4566,O
by,4566,O
the,4566,O
MRI,4566,O
findings,4566,O
and,4566,O
supported,4566,O
clinically,4566,O
.,4566,O
Aconitine-induced,4567,B-Chemical
Ca2+,4567,B-Chemical
overload,4567,O
causes,4567,O
arrhythmia,4567,B-Disease
and,4567,O
triggers,4567,O
apoptosis,4567,O
through,4567,O
p38,4567,O
MAPK,4567,O
signaling,4567,O
pathway,4567,O
in,4567,O
rats,4567,O
.,4567,O
Aconitine,4568,B-Chemical
is,4568,O
a,4568,O
major,4568,O
bioactive,4568,O
diterpenoid,4568,O
alkaloid,4568,O
with,4568,O
high,4568,O
content,4568,O
derived,4568,O
from,4568,O
herbal,4568,O
aconitum,4568,O
plants,4568,O
.,4568,O
Emerging,4569,O
evidence,4569,O
indicates,4569,O
that,4569,O
voltage-dependent,4569,O
Na,4569,B-Chemical
(,4569,O
+,4569,O
),4569,O
channels,4569,O
have,4569,O
pivotal,4569,O
roles,4569,O
in,4569,O
the,4569,O
cardiotoxicity,4569,B-Disease
of,4569,O
aconitine,4569,B-Chemical
.,4569,O
However,4570,O
",",4570,O
no,4570,O
reports,4570,O
are,4570,O
available,4570,O
on,4570,O
the,4570,O
role,4570,O
of,4570,O
Ca,4570,B-Chemical
(,4570,O
2+,4570,O
),4570,O
in,4570,O
aconitine,4570,B-Chemical
poisoning,4570,B-Disease
.,4570,O
In,4571,O
this,4571,O
study,4571,O
",",4571,O
we,4571,O
explored,4571,O
the,4571,O
importance,4571,O
of,4571,O
pathological,4571,O
Ca,4571,B-Chemical
(,4571,O
2+,4571,O
),4571,O
signaling,4571,O
in,4571,O
aconitine,4571,B-Chemical
poisoning,4571,B-Disease
in,4571,O
vitro,4571,O
and,4571,O
in,4571,O
vivo,4571,O
.,4571,O
We,4572,O
found,4572,O
that,4572,O
Ca,4572,B-Chemical
(,4572,O
2+,4572,O
),4572,O
overload,4572,O
lead,4572,O
to,4572,O
accelerated,4572,O
beating,4572,O
rhythm,4572,O
in,4572,O
adult,4572,O
rat,4572,O
ventricular,4572,O
myocytes,4572,O
and,4572,O
caused,4572,O
arrhythmia,4572,B-Disease
in,4572,O
conscious,4572,O
freely,4572,O
moving,4572,O
rats,4572,O
.,4572,O
To,4573,O
investigate,4573,O
effects,4573,O
of,4573,O
aconitine,4573,B-Chemical
on,4573,O
myocardial,4573,B-Disease
injury,4573,I-Disease
",",4573,O
we,4573,O
performed,4573,O
cytotoxicity,4573,B-Disease
assay,4573,O
in,4573,O
neonatal,4573,O
rat,4573,O
ventricular,4573,O
myocytes,4573,O
(,4573,O
NRVMs,4573,O
),4573,O
",",4573,O
as,4573,O
well,4573,O
as,4573,O
measured,4573,O
lactate,4573,B-Chemical
dehydrogenase,4573,O
level,4573,O
in,4573,O
the,4573,O
culture,4573,O
medium,4573,O
of,4573,O
NRVMs,4573,O
and,4573,O
activities,4573,O
of,4573,O
serum,4573,O
cardiac,4573,O
enzymes,4573,O
in,4573,O
rats,4573,O
.,4573,O
The,4574,O
results,4574,O
showed,4574,O
that,4574,O
aconitine,4574,B-Chemical
resulted,4574,O
in,4574,O
myocardial,4574,B-Disease
injury,4574,I-Disease
and,4574,O
reduced,4574,O
NRVMs,4574,O
viability,4574,O
dose-dependently,4574,O
.,4574,O
To,4575,O
confirm,4575,O
the,4575,O
pro-apoptotic,4575,O
effects,4575,O
",",4575,O
we,4575,O
performed,4575,O
flow,4575,O
cytometric,4575,O
detection,4575,O
",",4575,O
cardiac,4575,O
histology,4575,O
",",4575,O
transmission,4575,O
electron,4575,O
microscopy,4575,O
and,4575,O
terminal,4575,O
deoxynucleotidyl,4575,O
transferase-mediated,4575,O
dUTP-biotin,4575,B-Chemical
nick,4575,O
end,4575,O
labeling,4575,O
assay,4575,O
.,4575,O
The,4576,O
results,4576,O
showed,4576,O
that,4576,O
aconitine,4576,B-Chemical
stimulated,4576,O
apoptosis,4576,O
time-dependently,4576,O
.,4576,O
The,4577,O
expression,4577,O
analysis,4577,O
of,4577,O
Ca,4577,B-Chemical
(,4577,O
2+,4577,O
),4577,O
handling,4577,O
proteins,4577,O
demonstrated,4577,O
that,4577,O
aconitine,4577,B-Chemical
promoted,4577,O
Ca,4577,B-Chemical
(,4577,O
2+,4577,O
),4577,O
overload,4577,O
through,4577,O
the,4577,O
expression,4577,O
regulation,4577,O
of,4577,O
Ca,4577,B-Chemical
(,4577,O
2+,4577,O
),4577,O
handling,4577,O
proteins,4577,O
.,4577,O
The,4578,O
expression,4578,O
analysis,4578,O
of,4578,O
apoptosis-related,4578,O
proteins,4578,O
revealed,4578,O
that,4578,O
pro-apoptotic,4578,O
protein,4578,O
expression,4578,O
was,4578,O
upregulated,4578,O
",",4578,O
and,4578,O
anti-apoptotic,4578,O
protein,4578,O
BCL-2,4578,O
expression,4578,O
was,4578,O
downregulated,4578,O
.,4578,O
Furthermore,4579,O
",",4579,O
increased,4579,O
phosphorylation,4579,O
of,4579,O
MAPK,4579,O
family,4579,O
members,4579,O
",",4579,O
especially,4579,O
the,4579,O
P-P38/P38,4579,O
ratio,4579,O
was,4579,O
found,4579,O
in,4579,O
cardiac,4579,O
tissues,4579,O
.,4579,O
Hence,4580,O
",",4580,O
our,4580,O
results,4580,O
suggest,4580,O
that,4580,O
aconitine,4580,B-Chemical
significantly,4580,O
aggravates,4580,O
Ca,4580,B-Chemical
(,4580,O
2+,4580,O
),4580,O
overload,4580,O
and,4580,O
causes,4580,O
arrhythmia,4580,B-Disease
and,4580,O
finally,4580,O
promotes,4580,O
apoptotic,4580,O
development,4580,O
via,4580,O
phosphorylation,4580,O
of,4580,O
P38,4580,O
mitogen-activated,4580,O
protein,4580,O
kinase,4580,O
.,4580,O
Chronic,4581,O
treatment,4581,O
with,4581,O
metformin,4581,B-Chemical
suppresses,4581,O
toll-like,4581,O
receptor,4581,O
4,4581,O
signaling,4581,O
and,4581,O
attenuates,4581,O
left,4581,B-Disease
ventricular,4581,I-Disease
dysfunction,4581,I-Disease
following,4581,O
myocardial,4581,B-Disease
infarction,4581,I-Disease
.,4581,O
Acute,4582,O
treatment,4582,O
with,4582,O
metformin,4582,B-Chemical
has,4582,O
a,4582,O
protective,4582,O
effect,4582,O
in,4582,O
myocardial,4582,B-Disease
infarction,4582,I-Disease
by,4582,O
suppression,4582,O
of,4582,O
inflammatory,4582,O
responses,4582,O
due,4582,O
to,4582,O
activation,4582,O
of,4582,O
AMP-activated,4582,B-Chemical
protein,4582,O
kinase,4582,O
(,4582,O
AMPK,4582,O
),4582,O
.,4582,O
In,4583,O
the,4583,O
present,4583,O
study,4583,O
",",4583,O
the,4583,O
effect,4583,O
of,4583,O
chronic,4583,O
pre-treatment,4583,O
with,4583,O
metformin,4583,B-Chemical
on,4583,O
cardiac,4583,B-Disease
dysfunction,4583,I-Disease
and,4583,O
toll-like,4583,O
receptor,4583,O
4,4583,O
(,4583,O
TLR4,4583,O
),4583,O
activities,4583,O
following,4583,O
myocardial,4583,B-Disease
infarction,4583,I-Disease
and,4583,O
their,4583,O
relation,4583,O
with,4583,O
AMPK,4583,O
were,4583,O
assessed,4583,O
.,4583,O
Male,4584,O
Wistar,4584,O
rats,4584,O
were,4584,O
randomly,4584,O
assigned,4584,O
to,4584,O
one,4584,O
of,4584,O
5,4584,O
groups,4584,O
(,4584,O
n=6,4584,O
),4584,O
:,4584,O
normal,4584,O
control,4584,O
and,4584,O
groups,4584,O
were,4584,O
injected,4584,O
isoproterenol,4584,B-Chemical
after,4584,O
chronic,4584,O
pre-treatment,4584,O
with,4584,O
0,4584,O
",",4584,O
25,4584,O
",",4584,O
50,4584,O
",",4584,O
or,4584,O
100mg/kg,4584,O
of,4584,O
metformin,4584,B-Chemical
twice,4584,O
daily,4584,O
for,4584,O
14,4584,O
days,4584,O
.,4584,O
Isoproterenol,4585,B-Chemical
(,4585,O
100mg/kg,4585,O
),4585,O
was,4585,O
injected,4585,O
subcutaneously,4585,O
on,4585,O
the,4585,O
13th,4585,O
and,4585,O
14th,4585,O
days,4585,O
to,4585,O
induce,4585,O
acute,4585,B-Disease
myocardial,4585,I-Disease
infarction,4585,I-Disease
.,4585,O
Isoproterenol,4586,B-Chemical
alone,4586,O
decreased,4586,O
left,4586,O
ventricular,4586,O
systolic,4586,O
pressure,4586,O
and,4586,O
myocardial,4586,O
contractility,4586,O
indexed,4586,O
as,4586,O
LVdp/dtmax,4586,O
and,4586,O
LVdp/dtmin,4586,O
.,4586,O
The,4587,O
left,4587,B-Disease
ventricular,4587,I-Disease
dysfunction,4587,I-Disease
was,4587,O
significantly,4587,O
lower,4587,O
in,4587,O
the,4587,O
groups,4587,O
treated,4587,O
with,4587,O
25,4587,O
and,4587,O
50mg/kg,4587,O
of,4587,O
metformin,4587,B-Chemical
.,4587,O
Metfromin,4588,O
markedly,4588,O
lowered,4588,O
isoproterenol-induced,4588,B-Chemical
elevation,4588,O
in,4588,O
the,4588,O
levels,4588,O
of,4588,O
TLR4,4588,O
mRNA,4588,O
",",4588,O
myeloid,4588,O
differentiation,4588,O
protein,4588,O
88,4588,O
(,4588,O
MyD88,4588,O
),4588,O
",",4588,O
tumor,4588,B-Disease
necrosis,4588,B-Disease
factor-alpha,4588,O
(,4588,O
TNF-a,4588,O
),4588,O
",",4588,O
and,4588,O
interleukin,4588,O
6,4588,O
(,4588,O
IL-6,4588,O
),4588,O
in,4588,O
the,4588,O
heart,4588,O
tissues,4588,O
.,4588,O
Similar,4589,O
changes,4589,O
were,4589,O
also,4589,O
seen,4589,O
in,4589,O
the,4589,O
serum,4589,O
levels,4589,O
of,4589,O
TNF-a,4589,O
and,4589,O
IL-6,4589,O
.,4589,O
However,4590,O
",",4590,O
the,4590,O
lower,4590,O
doses,4590,O
of,4590,O
25,4590,O
and,4590,O
50mg/kg,4590,O
were,4590,O
more,4590,O
effective,4590,O
than,4590,O
100mg/kg,4590,O
.,4590,O
Phosphorylated,4591,O
AMPKa,4591,O
(,4591,O
p-AMPK,4591,O
),4591,O
in,4591,O
the,4591,O
myocardium,4591,O
was,4591,O
significantly,4591,O
elevated,4591,O
by,4591,O
25mg/kg,4591,O
of,4591,O
metformin,4591,B-Chemical
",",4591,O
slightly,4591,O
by,4591,O
50mg/kg,4591,O
",",4591,O
but,4591,O
not,4591,O
by,4591,O
100mg/kg,4591,O
.,4591,O
Chronic,4592,O
pre-treatment,4592,O
with,4592,O
metformin,4592,B-Chemical
reduces,4592,O
post-myocardial,4592,O
infarction,4592,I-Disease
cardiac,4592,O
dysfunction,4592,O
and,4592,O
suppresses,4592,O
inflammatory,4592,O
responses,4592,O
",",4592,O
possibly,4592,O
through,4592,O
inhibition,4592,O
of,4592,O
TLR4,4592,O
activities,4592,O
.,4592,O
This,4593,O
mechanism,4593,O
can,4593,O
be,4593,O
considered,4593,O
as,4593,O
a,4593,O
target,4593,O
to,4593,O
protect,4593,O
infarcted,4593,O
myocardium,4593,O
.,4593,O
Neuroleptic,4594,B-Disease
malignant,4594,I-Disease
syndrome,4594,I-Disease
induced,4594,O
by,4594,O
combination,4594,O
therapy,4594,O
with,4594,O
tetrabenazine,4594,B-Chemical
and,4594,O
tiapride,4594,B-Chemical
in,4594,O
a,4594,O
Japanese,4594,O
patient,4594,O
with,4594,O
Huntington,4594,B-Disease
's,4594,I-Disease
disease,4594,I-Disease
at,4594,O
the,4594,O
terminal,4594,O
stage,4594,O
of,4594,O
recurrent,4594,O
breast,4594,B-Disease
cancer,4594,I-Disease
.,4594,O
We,4595,O
herein,4595,O
describe,4595,O
the,4595,O
case,4595,O
of,4595,O
an,4595,O
81-year-old,4595,O
Japanese,4595,O
woman,4595,O
with,4595,O
neuroleptic,4595,B-Disease
malignant,4595,I-Disease
syndrome,4595,I-Disease
that,4595,O
occurred,4595,O
36,4595,O
days,4595,O
after,4595,O
the,4595,O
initiation,4595,O
of,4595,O
combination,4595,O
therapy,4595,O
with,4595,O
tiapride,4595,B-Chemical
(,4595,O
75,4595,O
mg/day,4595,O
),4595,O
and,4595,O
tetrabenazine,4595,B-Chemical
(,4595,O
12.5,4595,O
mg/day,4595,O
),4595,O
for,4595,O
Huntington,4595,B-Disease
's,4595,I-Disease
disease,4595,I-Disease
.,4595,O
The,4596,O
patient,4596,O
had,4596,O
been,4596,O
treated,4596,O
with,4596,O
tiapride,4596,B-Chemical
or,4596,O
tetrabenazine,4596,B-Chemical
alone,4596,O
without,4596,O
any,4596,O
adverse,4596,O
effects,4596,O
before,4596,O
the,4596,O
administration,4596,O
of,4596,O
the,4596,O
combination,4596,O
therapy,4596,O
.,4596,O
She,4597,O
also,4597,O
had,4597,O
advanced,4597,O
breast,4597,B-Disease
cancer,4597,I-Disease
when,4597,O
the,4597,O
combination,4597,O
therapy,4597,O
was,4597,O
initiated,4597,O
.,4597,O
To,4598,O
the,4598,O
best,4598,O
of,4598,O
our,4598,O
knowledge,4598,O
",",4598,O
the,4598,O
occurrence,4598,O
of,4598,O
neuroleptic,4598,B-Disease
malignant,4598,I-Disease
syndrome,4598,I-Disease
due,4598,O
to,4598,O
combination,4598,O
therapy,4598,O
with,4598,O
tetrabenazine,4598,B-Chemical
and,4598,O
tiapride,4598,B-Chemical
has,4598,O
not,4598,O
been,4598,O
previously,4598,O
reported,4598,O
.,4598,O
Tetrabenazine,4599,B-Chemical
should,4599,O
be,4599,O
administered,4599,O
very,4599,O
carefully,4599,O
in,4599,O
combination,4599,O
with,4599,O
other,4599,O
neuroleptic,4599,B-Chemical
drugs,4599,I-Chemical
",",4599,O
particularly,4599,O
in,4599,O
patients,4599,O
with,4599,O
a,4599,O
worsening,4599,O
general,4599,O
condition,4599,O
.,4599,O
A,4600,O
metoprolol-terbinafine,4600,B-Chemical
combination,4600,O
induced,4600,O
bradycardia,4600,B-Disease
.,4600,O
To,4601,O
report,4601,O
a,4601,O
sinus,4601,B-Disease
bradycardia,4601,I-Disease
induced,4601,O
by,4601,O
metoprolol,4601,B-Chemical
and,4601,O
terbinafine,4601,B-Chemical
drug-drug,4601,O
interaction,4601,O
and,4601,O
its,4601,O
management,4601,O
.,4601,O
A,4602,O
63,4602,O
year-old,4602,O
Caucasian,4602,O
man,4602,O
on,4602,O
metoprolol,4602,B-Chemical
200,4602,O
mg/day,4602,O
for,4602,O
stable,4602,O
coronary,4602,B-Disease
artery,4602,I-Disease
disease,4602,I-Disease
was,4602,O
prescribed,4602,O
a,4602,O
90-day,4602,O
course,4602,O
of,4602,O
oral,4602,O
terbinafine,4602,B-Chemical
250,4602,O
mg/day,4602,O
for,4602,O
onychomycosis,4602,B-Disease
.,4602,O
On,4603,O
the,4603,O
49th,4603,O
day,4603,O
of,4603,O
terbinafine,4603,B-Chemical
therapy,4603,O
",",4603,O
he,4603,O
was,4603,O
brought,4603,O
to,4603,O
the,4603,O
emergency,4603,O
room,4603,O
for,4603,O
a,4603,O
decrease,4603,O
of,4603,O
his,4603,O
global,4603,O
health,4603,O
status,4603,O
",",4603,O
confusion,4603,B-Disease
and,4603,O
falls,4603,O
.,4603,O
The,4604,O
electrocardiogram,4604,O
revealed,4604,O
a,4604,O
37,4604,O
beats/min,4604,O
sinus,4604,B-Disease
bradycardia,4604,I-Disease
.,4604,O
A,4605,O
score,4605,O
of,4605,O
7,4605,O
on,4605,O
the,4605,O
Naranjo,4605,O
adverse,4605,B-Disease
drug,4605,I-Disease
reaction,4605,I-Disease
probability,4605,O
scale,4605,O
indicates,4605,O
a,4605,O
probable,4605,O
relationship,4605,O
between,4605,O
the,4605,O
patient,4605,O
's,4605,O
sinus,4605,B-Disease
bradycardia,4605,I-Disease
and,4605,O
the,4605,O
drug,4605,O
interaction,4605,O
between,4605,O
metoprolol,4605,B-Chemical
and,4605,O
terbinafine,4605,B-Chemical
.,4605,O
The,4606,O
heart,4606,O
rate,4606,O
ameliorated,4606,O
first,4606,O
with,4606,O
a,4606,O
decrease,4606,O
in,4606,O
the,4606,O
dose,4606,O
of,4606,O
metoprolol,4606,B-Chemical
.,4606,O
It,4607,O
was,4607,O
subsequently,4607,O
changed,4607,O
to,4607,O
bisoprolol,4607,B-Chemical
and,4607,O
the,4607,O
heart,4607,O
rate,4607,O
remained,4607,O
normal,4607,O
.,4607,O
By,4608,O
inhibiting,4608,O
the,4608,O
cytochrome,4608,O
P450,4608,O
2D6,4608,O
",",4608,O
terbinafine,4608,B-Chemical
had,4608,O
decreased,4608,O
metoprolol,4608,B-Chemical
's,4608,O
clearance,4608,O
",",4608,O
leading,4608,O
in,4608,O
metoprolol,4608,B-Chemical
accumulation,4608,O
which,4608,O
has,4608,O
resulted,4608,O
in,4608,O
clinically,4608,O
significant,4608,O
sinus,4608,B-Disease
bradycardia,4608,I-Disease
.,4608,O
Optochiasmatic,4609,O
and,4609,O
peripheral,4609,B-Disease
neuropathy,4609,I-Disease
due,4609,O
to,4609,O
ethambutol,4609,B-Chemical
overtreatment,4609,O
.,4609,O
Ethambutol,4610,B-Chemical
is,4610,O
known,4610,O
to,4610,O
cause,4610,O
optic,4610,B-Disease
neuropathy,4610,I-Disease
and,4610,O
",",4610,O
more,4610,O
rarely,4610,O
",",4610,O
axonal,4610,O
polyneuropathy,4610,B-Disease
.,4610,O
We,4611,O
characterize,4611,O
the,4611,O
clinical,4611,O
",",4611,O
neurophysiological,4611,O
",",4611,O
and,4611,O
neuroimaging,4611,O
findings,4611,O
in,4611,O
a,4611,O
72-year-old,4611,O
man,4611,O
who,4611,O
developed,4611,O
visual,4611,B-Disease
loss,4611,I-Disease
and,4611,O
paresthesias,4611,B-Disease
after,4611,O
11,4611,O
weeks,4611,O
of,4611,O
exposure,4611,O
to,4611,O
a,4611,O
supratherapeutic,4611,O
dose,4611,O
of,4611,O
ethambutol,4611,B-Chemical
.,4611,O
This,4612,O
case,4612,O
demonstrates,4612,O
the,4612,O
selective,4612,O
vulnerability,4612,O
of,4612,O
the,4612,O
anterior,4612,O
visual,4612,O
pathways,4612,O
and,4612,O
peripheral,4612,O
nerves,4612,O
to,4612,O
ethambutol,4612,B-Chemical
toxicity,4612,B-Disease
.,4612,O
Testosterone,4613,B-Chemical
ameliorates,4613,O
streptozotocin-induced,4613,B-Chemical
memory,4613,B-Disease
impairment,4613,I-Disease
in,4613,O
male,4613,O
rats,4613,O
.,4613,O
AIM,4614,O
:,4614,O
To,4614,O
study,4614,O
the,4614,O
effects,4614,O
of,4614,O
testosterone,4614,B-Chemical
on,4614,O
streptozotocin,4614,B-Chemical
(,4614,O
STZ,4614,B-Chemical
),4614,O
-induced,4614,O
memory,4614,B-Disease
impairment,4614,I-Disease
in,4614,O
male,4614,O
rats,4614,O
.,4614,O
METHODS,4615,O
:,4615,O
Adult,4615,O
male,4615,O
Wistar,4615,O
rats,4615,O
were,4615,O
intracerebroventricularly,4615,O
(,4615,O
icv,4615,O
),4615,O
infused,4615,O
with,4615,O
STZ,4615,B-Chemical
(,4615,O
750,4615,O
ug,4615,O
),4615,O
on,4615,O
d,4615,O
1,4615,O
and,4615,O
d,4615,O
3,4615,O
",",4615,O
and,4615,O
a,4615,O
passive,4615,O
avoidance,4615,O
task,4615,O
was,4615,O
assessed,4615,O
2,4615,O
weeks,4615,O
after,4615,O
the,4615,O
first,4615,O
injection,4615,O
of,4615,O
STZ,4615,B-Chemical
.,4615,O
Castration,4616,O
surgery,4616,O
was,4616,O
performed,4616,O
in,4616,O
another,4616,O
group,4616,O
of,4616,O
rats,4616,O
",",4616,O
and,4616,O
the,4616,O
passive,4616,O
avoidance,4616,O
task,4616,O
was,4616,O
assessed,4616,O
4,4616,O
weeks,4616,O
after,4616,O
the,4616,O
operation,4616,O
.,4616,O
Testosterone,4617,B-Chemical
(,4617,O
1,4617,O
mg.kg,4617,O
(,4617,O
-1,4617,O
),4617,O
.d,4617,O
(,4617,O
-1,4617,O
),4617,O
",",4617,O
sc,4617,O
),4617,O
",",4617,O
the,4617,O
androgen,4617,B-Chemical
receptor,4617,O
antagonist,4617,O
flutamide,4617,B-Chemical
(,4617,O
10,4617,O
mg.kg,4617,O
(,4617,O
-1,4617,O
),4617,O
.d,4617,O
(,4617,O
-1,4617,O
),4617,O
",",4617,O
ip,4617,O
),4617,O
",",4617,O
the,4617,O
estrogen,4617,B-Chemical
receptor,4617,O
antagonist,4617,O
tamoxifen,4617,B-Chemical
(,4617,O
1,4617,O
mg.kg,4617,O
(,4617,O
-1,4617,O
),4617,O
.d,4617,O
(,4617,O
-1,4617,O
),4617,O
",",4617,O
ip,4617,O
),4617,O
or,4617,O
the,4617,O
aromatase,4617,O
inhibitor,4617,O
letrozole,4617,B-Chemical
(,4617,O
4,4617,O
mg.kg,4617,O
(,4617,O
-1,4617,O
),4617,O
.d,4617,O
(,4617,O
-1,4617,O
),4617,O
",",4617,O
ip,4617,O
),4617,O
were,4617,O
administered,4617,O
for,4617,O
6,4617,O
d,4617,O
after,4617,O
the,4617,O
first,4617,O
injection,4617,O
of,4617,O
STZ,4617,B-Chemical
.,4617,O
RESULTS,4618,O
:,4618,O
STZ,4618,B-Chemical
administration,4618,O
and,4618,O
castration,4618,O
markedly,4618,O
decreased,4618,O
both,4618,O
STL1,4618,O
(,4618,O
the,4618,O
short,4618,O
memory,4618,O
),4618,O
and,4618,O
STL2,4618,O
(,4618,O
the,4618,O
long,4618,O
memory,4618,O
),4618,O
in,4618,O
passive,4618,O
avoidance,4618,O
tests,4618,O
.,4618,O
Testosterone,4619,B-Chemical
replacement,4619,O
almost,4619,O
restored,4619,O
the,4619,O
STL1,4619,O
and,4619,O
STL2,4619,O
in,4619,O
castrated,4619,O
rats,4619,O
",",4619,O
and,4619,O
significantly,4619,O
prolonged,4619,O
the,4619,O
STL1,4619,O
and,4619,O
STL2,4619,O
in,4619,O
STZ-treated,4619,B-Chemical
rats,4619,O
.,4619,O
Administration,4620,O
of,4620,O
flutamide,4620,B-Chemical
",",4620,O
letrozole,4620,B-Chemical
or,4620,O
tamoxifen,4620,B-Chemical
significantly,4620,O
impaired,4620,B-Disease
the,4620,I-Disease
memory,4620,I-Disease
in,4620,O
intact,4620,O
rats,4620,O
",",4620,O
and,4620,O
significantly,4620,O
attenuated,4620,O
the,4620,O
testosterone,4620,B-Chemical
replacement,4620,O
in,4620,O
improving,4620,O
STZ-,4620,B-Chemical
and,4620,O
castration-induced,4620,O
memory,4620,B-Disease
impairment,4620,I-Disease
.,4620,O
CONCLUSION,4621,O
:,4621,O
Testosterone,4621,B-Chemical
administration,4621,O
ameliorates,4621,O
STZ-,4621,B-Chemical
and,4621,O
castration-induced,4621,O
memory,4621,B-Disease
impairment,4621,I-Disease
in,4621,O
male,4621,O
Wistar,4621,O
rats,4621,O
.,4621,O
Behavioral,4622,O
and,4622,O
neurochemical,4622,O
studies,4622,O
in,4622,O
mice,4622,O
pretreated,4622,O
with,4622,O
garcinielliptone,4622,B-Chemical
FC,4622,I-Chemical
in,4622,O
pilocarpine-induced,4622,B-Chemical
seizures,4622,B-Disease
.,4622,O
Garcinielliptone,4623,B-Chemical
FC,4623,I-Chemical
(,4623,O
GFC,4623,B-Chemical
),4623,O
isolated,4623,O
from,4623,O
hexanic,4623,O
fraction,4623,O
seed,4623,O
extract,4623,O
of,4623,O
species,4623,O
Platonia,4623,O
insignis,4623,O
Mart,4623,O
.,4623,O
It,4624,O
is,4624,O
widely,4624,O
used,4624,O
in,4624,O
folk,4624,O
medicine,4624,O
to,4624,O
treat,4624,O
skin,4624,B-Disease
diseases,4624,I-Disease
in,4624,O
both,4624,O
humans,4624,O
and,4624,O
animals,4624,O
as,4624,O
well,4624,O
as,4624,O
the,4624,O
seed,4624,O
decoction,4624,O
has,4624,O
been,4624,O
used,4624,O
to,4624,O
treat,4624,O
diarrheas,4624,B-Disease
and,4624,O
inflammatory,4624,B-Disease
diseases,4624,I-Disease
.,4624,O
However,4625,O
",",4625,O
there,4625,O
is,4625,O
no,4625,O
research,4625,O
on,4625,O
GFC,4625,B-Chemical
effects,4625,O
in,4625,O
the,4625,O
central,4625,O
nervous,4625,O
system,4625,O
of,4625,O
rodents,4625,O
.,4625,O
The,4626,O
present,4626,O
study,4626,O
aimed,4626,O
to,4626,O
evaluate,4626,O
the,4626,O
GFC,4626,B-Chemical
effects,4626,O
at,4626,O
doses,4626,O
of,4626,O
25,4626,O
",",4626,O
50,4626,O
or,4626,O
75,4626,O
mg/kg,4626,O
on,4626,O
seizure,4626,B-Disease
parameters,4626,O
to,4626,O
determine,4626,O
their,4626,O
anticonvulsant,4626,O
activity,4626,O
and,4626,O
its,4626,O
effects,4626,O
on,4626,O
amino,4626,B-Chemical
acid,4626,I-Chemical
(,4626,O
r-aminobutyric,4626,B-Chemical
acid,4626,I-Chemical
(,4626,O
GABA,4626,B-Chemical
),4626,O
",",4626,O
glutamine,4626,B-Chemical
",",4626,O
aspartate,4626,B-Chemical
and,4626,O
glutathione,4626,B-Chemical
),4626,O
levels,4626,O
as,4626,O
well,4626,O
as,4626,O
on,4626,O
acetylcholinesterase,4626,O
(,4626,O
AChE,4626,O
),4626,O
activity,4626,O
in,4626,O
mice,4626,O
hippocampus,4626,O
after,4626,O
seizures,4626,B-Disease
.,4626,O
GFC,4627,B-Chemical
produced,4627,O
an,4627,O
increased,4627,O
latency,4627,O
to,4627,O
first,4627,O
seizure,4627,B-Disease
",",4627,O
at,4627,O
doses,4627,O
25mg/kg,4627,O
(,4627,O
20.12,4627,O
+,4627,O
2.20,4627,O
min,4627,O
),4627,O
",",4627,O
50mg/kg,4627,O
(,4627,O
20.95,4627,O
+,4627,O
2.21,4627,O
min,4627,O
),4627,O
or,4627,O
75,4627,O
mg/kg,4627,O
(,4627,O
23.43,4627,O
+,4627,O
1.99,4627,O
min,4627,O
),4627,O
when,4627,O
compared,4627,O
with,4627,O
seized,4627,O
mice,4627,O
.,4627,O
In,4628,O
addition,4628,O
",",4628,O
GABA,4628,B-Chemical
content,4628,O
of,4628,O
mice,4628,O
hippocampus,4628,O
treated,4628,O
with,4628,O
GFC75,4628,O
plus,4628,O
P400,4628,O
showed,4628,O
an,4628,O
increase,4628,O
of,4628,O
46.90,4628,O
%,4628,O
when,4628,O
compared,4628,O
with,4628,O
seized,4628,O
mice,4628,O
.,4628,O
In,4629,O
aspartate,4629,B-Chemical
",",4629,O
glutamine,4629,B-Chemical
and,4629,O
glutamate,4629,B-Chemical
levels,4629,O
detected,4629,O
a,4629,O
decrease,4629,O
of,4629,O
5.21,4629,O
%,4629,O
",",4629,O
13.55,4629,O
%,4629,O
and,4629,O
21.80,4629,O
%,4629,O
",",4629,O
respectively,4629,O
in,4629,O
mice,4629,O
hippocampus,4629,O
treated,4629,O
with,4629,O
GFC75,4629,O
plus,4629,O
P400,4629,O
when,4629,O
compared,4629,O
with,4629,O
seized,4629,O
mice,4629,O
.,4629,O
Hippocampus,4630,O
mice,4630,O
treated,4630,O
with,4630,O
GFC75,4630,O
plus,4630,O
P400,4630,O
showed,4630,O
an,4630,O
increase,4630,O
in,4630,O
AChE,4630,O
activity,4630,O
(,4630,O
63.30,4630,O
%,4630,O
),4630,O
when,4630,O
compared,4630,O
with,4630,O
seized,4630,O
mice,4630,O
.,4630,O
The,4631,O
results,4631,O
indicate,4631,O
that,4631,O
GFC,4631,B-Chemical
can,4631,O
exert,4631,O
anticonvulsant,4631,O
activity,4631,O
and,4631,O
reduce,4631,O
the,4631,O
frequency,4631,O
of,4631,O
installation,4631,O
of,4631,O
pilocarpine-induced,4631,B-Chemical
status,4631,B-Disease
epilepticus,4631,I-Disease
",",4631,O
as,4631,O
demonstrated,4631,O
by,4631,O
increase,4631,O
in,4631,O
latency,4631,O
to,4631,O
first,4631,O
seizure,4631,B-Disease
and,4631,O
decrease,4631,O
in,4631,O
mortality,4631,O
rate,4631,O
of,4631,O
animals,4631,O
.,4631,O
In,4632,O
conclusion,4632,O
",",4632,O
our,4632,O
data,4632,O
suggest,4632,O
that,4632,O
GFC,4632,B-Chemical
may,4632,O
influence,4632,O
in,4632,O
epileptogenesis,4632,O
and,4632,O
promote,4632,O
anticonvulsant,4632,O
actions,4632,O
in,4632,O
pilocarpine,4632,B-Chemical
model,4632,O
by,4632,O
modulating,4632,O
the,4632,O
GABA,4632,B-Chemical
and,4632,O
glutamate,4632,B-Chemical
contents,4632,O
and,4632,O
of,4632,O
AChE,4632,O
activity,4632,O
in,4632,O
seized,4632,O
mice,4632,O
hippocampus,4632,O
.,4632,O
This,4633,O
compound,4633,O
may,4633,O
be,4633,O
useful,4633,O
to,4633,O
produce,4633,O
neuronal,4633,O
protection,4633,O
and,4633,O
it,4633,O
can,4633,O
be,4633,O
considered,4633,O
as,4633,O
an,4633,O
anticonvulsant,4633,O
agent,4633,O
.,4633,O
Standard,4634,O
operating,4634,O
procedures,4634,O
for,4634,O
antibiotic,4634,O
therapy,4634,O
and,4634,O
the,4634,O
occurrence,4634,O
of,4634,O
acute,4634,B-Disease
kidney,4634,I-Disease
injury,4634,I-Disease
:,4634,O
a,4634,O
prospective,4634,O
",",4634,O
clinical,4634,O
",",4634,O
non-interventional,4634,O
",",4634,O
observational,4634,O
study,4634,O
.,4634,O
INTRODUCTION,4635,O
:,4635,O
Acute,4635,B-Disease
kidney,4635,I-Disease
injury,4635,I-Disease
(,4635,O
AKI,4635,B-Disease
),4635,O
occurs,4635,O
in,4635,O
7,4635,O
%,4635,O
of,4635,O
hospitalized,4635,O
and,4635,O
66,4635,O
%,4635,O
of,4635,O
Intensive,4635,O
Care,4635,O
Unit,4635,O
(,4635,O
ICU,4635,O
),4635,O
patients,4635,O
.,4635,O
It,4636,O
increases,4636,O
mortality,4636,O
",",4636,O
hospital,4636,O
length,4636,O
of,4636,O
stay,4636,O
",",4636,O
and,4636,O
costs,4636,O
.,4636,O
The,4637,O
aim,4637,O
of,4637,O
this,4637,O
study,4637,O
was,4637,O
to,4637,O
investigate,4637,O
",",4637,O
whether,4637,O
there,4637,O
is,4637,O
an,4637,O
association,4637,O
between,4637,O
adherence,4637,O
to,4637,O
guidelines,4637,O
(,4637,O
standard,4637,O
operating,4637,O
procedures,4637,O
(,4637,O
SOP,4637,O
),4637,O
),4637,O
for,4637,O
potentially,4637,O
nephrotoxic,4637,B-Disease
antibiotics,4637,O
and,4637,O
the,4637,O
occurrence,4637,O
of,4637,O
AKI,4637,B-Disease
.,4637,O
METHODS,4638,O
:,4638,O
This,4638,O
study,4638,O
was,4638,O
carried,4638,O
out,4638,O
as,4638,O
a,4638,O
prospective,4638,O
",",4638,O
clinical,4638,O
",",4638,O
non-interventional,4638,O
",",4638,O
observational,4638,O
study,4638,O
.,4638,O
Data,4639,O
collection,4639,O
was,4639,O
performed,4639,O
over,4639,O
a,4639,O
total,4639,O
of,4639,O
170,4639,O
days,4639,O
in,4639,O
three,4639,O
ICUs,4639,O
at,4639,O
Charite,4639,O
-,4639,O
Universitaetsmedizin,4639,O
Berlin,4639,O
.,4639,O
A,4640,O
total,4640,O
of,4640,O
675,4640,O
patients,4640,O
were,4640,O
included,4640,O
;,4640,O
163,4640,O
of,4640,O
these,4640,O
had,4640,O
therapy,4640,O
with,4640,O
vancomycin,4640,B-Chemical
",",4640,O
gentamicin,4640,B-Chemical
",",4640,O
or,4640,O
tobramycin,4640,B-Chemical
;,4640,O
were,4640,O
>,4640,O
18,4640,O
years,4640,O
;,4640,O
and,4640,O
treated,4640,O
in,4640,O
the,4640,O
ICU,4640,O
for,4640,O
>,4640,O
24,4640,O
hours,4640,O
.,4640,O
Patients,4641,O
with,4641,O
an,4641,O
adherence,4641,O
to,4641,O
SOP,4641,O
>,4641,O
70,4641,O
%,4641,O
were,4641,O
classified,4641,O
into,4641,O
the,4641,O
high,4641,O
adherence,4641,O
group,4641,O
(,4641,O
HAG,4641,O
),4641,O
and,4641,O
patients,4641,O
with,4641,O
an,4641,O
adherence,4641,O
of,4641,O
<,4641,O
70,4641,O
%,4641,O
into,4641,O
the,4641,O
low,4641,O
adherence,4641,O
group,4641,O
(,4641,O
LAG,4641,O
),4641,O
.,4641,O
AKI,4642,B-Disease
was,4642,O
defined,4642,O
according,4642,O
to,4642,O
RIFLE,4642,O
criteria,4642,O
.,4642,O
Adherence,4643,O
to,4643,O
SOPs,4643,O
was,4643,O
evaluated,4643,O
by,4643,O
retrospective,4643,O
expert,4643,O
audit,4643,O
.,4643,O
Development,4644,O
of,4644,O
AKI,4644,B-Disease
was,4644,O
compared,4644,O
between,4644,O
groups,4644,O
with,4644,O
exact,4644,O
Chi2-test,4644,O
and,4644,O
multivariate,4644,O
logistic,4644,O
regression,4644,O
analysis,4644,O
(,4644,O
two-sided,4644,O
P,4644,O
<,4644,O
0.05,4644,O
),4644,O
.,4644,O
RESULTS,4645,O
:,4645,O
LAG,4645,O
consisted,4645,O
of,4645,O
75,4645,O
patients,4645,O
(,4645,O
46,4645,O
%,4645,O
),4645,O
versus,4645,O
88,4645,O
HAG,4645,O
patients,4645,O
(,4645,O
54,4645,O
%,4645,O
),4645,O
.,4645,O
AKI,4646,B-Disease
occurred,4646,O
significantly,4646,O
more,4646,O
often,4646,O
in,4646,O
LAG,4646,O
with,4646,O
36,4646,O
%,4646,O
versus,4646,O
21,4646,O
%,4646,O
in,4646,O
HAG,4646,O
(,4646,O
P,4646,O
=,4646,O
0.035,4646,O
),4646,O
.,4646,O
Basic,4647,O
characteristics,4647,O
were,4647,O
comparable,4647,O
",",4647,O
except,4647,O
an,4647,O
increased,4647,O
rate,4647,O
of,4647,O
soft,4647,O
tissue,4647,O
infections,4647,B-Disease
in,4647,O
LAG,4647,O
.,4647,O
Multivariate,4648,O
analysis,4648,O
revealed,4648,O
an,4648,O
odds,4648,O
ratio,4648,O
of,4648,O
2.5-fold,4648,O
for,4648,O
LAG,4648,O
to,4648,O
develop,4648,O
AKI,4648,B-Disease
compared,4648,O
with,4648,O
HAG,4648,O
(,4648,O
95,4648,O
%,4648,O
confidence,4648,O
interval,4648,O
1.195,4648,O
to,4648,O
5.124,4648,O
",",4648,O
P,4648,O
=,4648,O
0.039,4648,O
),4648,O
.,4648,O
CONCLUSION,4649,O
:,4649,O
Low,4649,O
adherence,4649,O
to,4649,O
SOPs,4649,O
for,4649,O
potentially,4649,O
nephrotoxic,4649,B-Disease
antibiotics,4649,O
was,4649,O
associated,4649,O
with,4649,O
a,4649,O
higher,4649,O
occurrence,4649,O
of,4649,O
AKI,4649,B-Disease
.,4649,O
TRIAL,4650,O
REGISTRATION,4650,O
:,4650,O
Current,4650,O
Controlled,4650,O
Trials,4650,O
ISRCTN54598675,4650,O
.,4650,O
Registered,4651,O
17,4651,O
August,4651,O
2007,4651,O
.,4651,O
Rhabdomyolysis,4652,B-Disease
in,4652,O
a,4652,O
hepatitis,4652,B-Disease
C,4652,I-Disease
virus,4652,I-Disease
infected,4652,I-Disease
patient,4652,O
treated,4652,O
with,4652,O
telaprevir,4652,B-Chemical
and,4652,O
simvastatin,4652,B-Chemical
.,4652,O
A,4653,O
46-year,4653,O
old,4653,O
man,4653,O
with,4653,O
a,4653,O
chronic,4653,O
hepatitis,4653,B-Disease
C,4653,I-Disease
virus,4653,I-Disease
infection,4653,I-Disease
received,4653,O
triple,4653,O
therapy,4653,O
with,4653,O
ribavirin,4653,B-Chemical
",",4653,O
pegylated,4653,B-Chemical
interferon,4653,I-Chemical
and,4653,O
telaprevir,4653,B-Chemical
.,4653,O
The,4654,O
patient,4654,O
also,4654,O
received,4654,O
simvastatin,4654,B-Chemical
.,4654,O
One,4655,O
month,4655,O
after,4655,O
starting,4655,O
the,4655,O
antiviral,4655,O
therapy,4655,O
",",4655,O
the,4655,O
patient,4655,O
was,4655,O
admitted,4655,O
to,4655,O
the,4655,O
hospital,4655,O
because,4655,O
he,4655,O
developed,4655,O
rhabdomyolysis,4655,B-Disease
.,4655,O
At,4656,O
admission,4656,O
simvastatin,4656,B-Chemical
and,4656,O
all,4656,O
antiviral,4656,O
drugs,4656,O
were,4656,O
discontinued,4656,O
because,4656,O
toxicity,4656,B-Disease
due,4656,O
to,4656,O
a,4656,O
drug-drug,4656,O
interaction,4656,O
was,4656,O
suspected,4656,O
.,4656,O
The,4657,O
creatine,4657,B-Chemical
kinase,4657,O
peaked,4657,O
at,4657,O
"62,246",4657,O
IU/L,4657,O
and,4657,O
the,4657,O
patient,4657,O
was,4657,O
treated,4657,O
with,4657,O
intravenous,4657,O
normal,4657,O
saline,4657,O
.,4657,O
The,4658,O
patient,4658,O
's,4658,O
renal,4658,O
function,4658,O
remained,4658,O
unaffected,4658,O
.,4658,O
Fourteen,4659,O
days,4659,O
after,4659,O
hospitalization,4659,O
",",4659,O
creatine,4659,B-Chemical
kinase,4659,O
level,4659,O
had,4659,O
returned,4659,O
to,4659,O
230,4659,O
IU/L,4659,O
and,4659,O
the,4659,O
patient,4659,O
was,4659,O
discharged,4659,O
.,4659,O
Telaprevir,4660,B-Chemical
was,4660,O
considered,4660,O
the,4660,O
probable,4660,O
causative,4660,O
agent,4660,O
of,4660,O
an,4660,O
interaction,4660,O
with,4660,O
simvastatin,4660,B-Chemical
according,4660,O
to,4660,O
the,4660,O
Drug,4660,O
Interaction,4660,O
Probability,4660,O
Scale,4660,O
.,4660,O
The,4661,O
interaction,4661,O
is,4661,O
due,4661,O
to,4661,O
inhibition,4661,O
of,4661,O
CYP3A4-mediated,4661,O
simvastatin,4661,B-Chemical
clearance,4661,O
.,4661,O
Simvastatin,4662,B-Chemical
plasma,4662,O
concentration,4662,O
increased,4662,O
30,4662,O
times,4662,O
in,4662,O
this,4662,O
patient,4662,O
and,4662,O
statin,4662,B-Chemical
induced,4662,O
muscle,4662,B-Disease
toxicity,4662,I-Disease
is,4662,O
related,4662,O
to,4662,O
the,4662,O
concentration,4662,O
of,4662,O
the,4662,O
statin,4662,B-Chemical
in,4662,O
blood,4662,O
.,4662,O
In,4663,O
conclusion,4663,O
",",4663,O
with,4663,O
this,4663,O
case,4663,O
we,4663,O
illustrate,4663,O
that,4663,O
telaprevir,4663,B-Chemical
as,4663,O
well,4663,O
as,4663,O
statins,4663,B-Chemical
are,4663,O
susceptible,4663,O
to,4663,O
clinical,4663,O
relevant,4663,O
drug-drug,4663,O
interactions,4663,O
.,4663,O
Combination,4664,O
of,4664,O
bortezomib,4664,B-Chemical
",",4664,O
thalidomide,4664,B-Chemical
",",4664,O
and,4664,O
dexamethasone,4664,B-Chemical
(,4664,O
VTD,4664,O
),4664,O
as,4664,O
a,4664,O
consolidation,4664,O
therapy,4664,O
after,4664,O
autologous,4664,O
stem,4664,O
cell,4664,O
transplantation,4664,O
for,4664,O
symptomatic,4664,O
multiple,4664,B-Disease
myeloma,4664,I-Disease
in,4664,O
Japanese,4664,O
patients,4664,O
.,4664,O
Consolidation,4665,O
therapy,4665,O
for,4665,O
patients,4665,O
with,4665,O
multiple,4665,B-Disease
myeloma,4665,I-Disease
(,4665,O
MM,4665,B-Disease
),4665,O
has,4665,O
been,4665,O
widely,4665,O
adopted,4665,O
to,4665,O
improve,4665,O
treatment,4665,O
response,4665,O
following,4665,O
autologous,4665,O
stem,4665,O
cell,4665,O
transplantation,4665,O
.,4665,O
In,4666,O
this,4666,O
study,4666,O
",",4666,O
we,4666,O
retrospectively,4666,O
analyzed,4666,O
the,4666,O
safety,4666,O
and,4666,O
efficacy,4666,O
of,4666,O
combination,4666,O
regimen,4666,O
of,4666,O
bortezomib,4666,B-Chemical
",",4666,O
thalidomide,4666,B-Chemical
",",4666,O
and,4666,O
dexamethasone,4666,B-Chemical
(,4666,O
VTD,4666,O
),4666,O
as,4666,O
consolidation,4666,O
therapy,4666,O
in,4666,O
24,4666,O
Japanese,4666,O
patients,4666,O
with,4666,O
newly,4666,O
diagnosed,4666,O
MM,4666,B-Disease
.,4666,O
VTD,4667,O
consisted,4667,O
of,4667,O
bortezomib,4667,B-Chemical
at,4667,O
a,4667,O
dose,4667,O
of,4667,O
1.3,4667,O
mg/m,4667,O
(,4667,O
2,4667,O
),4667,O
and,4667,O
dexamethasone,4667,B-Chemical
at,4667,O
a,4667,O
dose,4667,O
of,4667,O
40,4667,O
mg/day,4667,O
on,4667,O
days,4667,O
1,4667,O
",",4667,O
8,4667,O
",",4667,O
15,4667,O
",",4667,O
and,4667,O
22,4667,O
of,4667,O
a,4667,O
35-day,4667,O
cycle,4667,O
",",4667,O
with,4667,O
daily,4667,O
oral,4667,O
thalidomide,4667,B-Chemical
at,4667,O
a,4667,O
dose,4667,O
of,4667,O
100,4667,O
mg/day,4667,O
.,4667,O
Grade,4668,O
3-4,4668,O
neutropenia,4668,B-Disease
and,4668,O
thrombocytopenia,4668,B-Disease
were,4668,O
documented,4668,O
in,4668,O
four,4668,O
and,4668,O
three,4668,O
patients,4668,O
(,4668,O
17,4668,O
and,4668,O
13,4668,O
%,4668,O
),4668,O
",",4668,O
respectively,4668,O
",",4668,O
but,4668,O
drug,4668,O
dose,4668,O
reduction,4668,O
due,4668,O
to,4668,O
cytopenia,4668,B-Disease
was,4668,O
not,4668,O
required,4668,O
in,4668,O
any,4668,O
case,4668,O
.,4668,O
Peripheral,4669,B-Disease
neuropathy,4669,I-Disease
was,4669,O
common,4669,O
(,4669,O
63,4669,O
%,4669,O
),4669,O
",",4669,O
but,4669,O
severe,4669,O
grade,4669,O
3-4,4669,O
peripheral,4669,B-Disease
neuropathy,4669,I-Disease
was,4669,O
not,4669,O
observed,4669,O
.,4669,O
Very,4670,O
good,4670,O
partial,4670,O
response,4670,O
or,4670,O
better,4670,O
response,4670,O
(,4670,O
>,4670,O
VGPR,4670,O
),4670,O
rates,4670,O
before,4670,O
and,4670,O
after,4670,O
consolidation,4670,O
therapy,4670,O
were,4670,O
54,4670,O
and,4670,O
79,4670,O
%,4670,O
",",4670,O
respectively,4670,O
.,4670,O
Patients,4671,O
had,4671,O
a,4671,O
significant,4671,O
probability,4671,O
of,4671,O
improving,4671,O
from,4671,O
<,4671,O
VGPR,4671,O
before,4671,O
consolidation,4671,O
therapy,4671,O
to,4671,O
>,4671,O
VGPR,4671,O
after,4671,O
consolidation,4671,O
therapy,4671,O
(,4671,O
p,4671,O
=,4671,O
0.041,4671,O
),4671,O
.,4671,O
The,4672,O
VTD,4672,O
regimen,4672,O
may,4672,O
be,4672,O
safe,4672,O
and,4672,O
effective,4672,O
as,4672,O
a,4672,O
consolidation,4672,O
therapy,4672,O
in,4672,O
the,4672,O
treatment,4672,O
of,4672,O
MM,4672,O
in,4672,O
Japanese,4672,O
population,4672,O
.,4672,O
Conversion,4673,O
to,4673,O
sirolimus,4673,B-Chemical
ameliorates,4673,O
cyclosporine-induced,4673,B-Chemical
nephropathy,4673,B-Disease
in,4673,O
the,4673,O
rat,4673,O
:,4673,O
focus,4673,O
on,4673,O
serum,4673,O
",",4673,O
urine,4673,O
",",4673,O
gene,4673,O
",",4673,O
and,4673,O
protein,4673,O
renal,4673,O
expression,4673,O
biomarkers,4673,O
.,4673,O
Protocols,4674,O
of,4674,O
conversion,4674,O
from,4674,O
cyclosporin,4674,B-Chemical
A,4674,I-Chemical
(,4674,O
CsA,4674,B-Chemical
),4674,O
to,4674,O
sirolimus,4674,B-Chemical
(,4674,O
SRL,4674,B-Chemical
),4674,O
have,4674,O
been,4674,O
widely,4674,O
used,4674,O
in,4674,O
immunotherapy,4674,O
after,4674,O
transplantation,4674,O
to,4674,O
prevent,4674,O
CsA-induced,4674,B-Chemical
nephropathy,4674,B-Disease
",",4674,O
but,4674,O
the,4674,O
molecular,4674,O
mechanisms,4674,O
underlying,4674,O
these,4674,O
protocols,4674,O
remain,4674,O
nuclear,4674,O
.,4674,O
This,4675,O
study,4675,O
aimed,4675,O
to,4675,O
identify,4675,O
the,4675,O
molecular,4675,O
pathways,4675,O
and,4675,O
putative,4675,O
biomarkers,4675,O
of,4675,O
CsA-to-SRL,4675,B-Chemical
conversion,4675,O
in,4675,O
a,4675,O
rat,4675,O
model,4675,O
.,4675,O
Four,4676,O
animal,4676,O
groups,4676,O
(,4676,O
n,4676,O
=,4676,O
6,4676,O
),4676,O
were,4676,O
tested,4676,O
during,4676,O
9,4676,O
weeks,4676,O
:,4676,O
control,4676,O
",",4676,O
CsA,4676,B-Chemical
",",4676,O
SRL,4676,B-Chemical
",",4676,O
and,4676,O
conversion,4676,O
(,4676,O
CsA,4676,B-Chemical
for,4676,O
3,4676,O
weeks,4676,O
followed,4676,O
by,4676,O
SRL,4676,B-Chemical
for,4676,O
6,4676,O
weeks,4676,O
),4676,O
.,4676,O
Classical,4677,O
and,4677,O
emergent,4677,O
serum,4677,O
",",4677,O
urinary,4677,O
",",4677,O
and,4677,O
kidney,4677,O
tissue,4677,O
(,4677,O
gene,4677,O
and,4677,O
protein,4677,O
expression,4677,O
),4677,O
markers,4677,O
were,4677,O
assessed,4677,O
.,4677,O
Renal,4678,B-Disease
lesions,4678,I-Disease
were,4678,O
analyzed,4678,O
in,4678,O
hematoxylin,4678,B-Chemical
and,4678,O
eosin,4678,B-Chemical
",",4678,O
periodic,4678,O
acid-Schiff,4678,O
",",4678,O
and,4678,O
Masson,4678,O
's,4678,O
trichrome,4678,O
stains,4678,O
.,4678,O
SRL-treated,4679,B-Chemical
rats,4679,O
presented,4679,O
proteinuria,4679,B-Disease
and,4679,O
NGAL,4679,O
(,4679,O
serum,4679,O
and,4679,O
urinary,4679,O
),4679,O
as,4679,O
the,4679,O
best,4679,O
markers,4679,O
of,4679,O
renal,4679,B-Disease
impairment,4679,I-Disease
.,4679,O
Short,4680,O
CsA,4680,B-Chemical
treatment,4680,O
presented,4680,O
slight,4680,O
or,4680,O
even,4680,O
absent,4680,O
kidney,4680,B-Disease
lesions,4680,I-Disease
and,4680,O
TGF-b,4680,O
",",4680,O
NF-,4680,O
kb,4680,O
",",4680,O
mTOR,4680,O
",",4680,O
PCNA,4680,O
",",4680,O
TP53,4680,O
",",4680,O
KIM-1,4680,O
",",4680,O
and,4680,O
CTGF,4680,O
as,4680,O
relevant,4680,O
gene,4680,O
and,4680,O
protein,4680,O
changes,4680,O
.,4680,O
Prolonged,4681,O
CsA,4681,B-Chemical
exposure,4681,O
aggravated,4681,O
renal,4681,B-Disease
damage,4681,I-Disease
",",4681,O
without,4681,O
clear,4681,O
changes,4681,O
on,4681,O
the,4681,O
traditional,4681,O
markers,4681,O
",",4681,O
but,4681,O
with,4681,O
changes,4681,O
in,4681,O
serums,4681,O
TGF-,4681,O
b,4681,O
and,4681,O
IL-7,4681,O
",",4681,O
TBARs,4681,O
clearance,4681,O
",",4681,O
and,4681,O
kidney,4681,O
TGF-b,4681,O
and,4681,O
mTOR,4681,O
.,4681,O
Conversion,4682,O
to,4682,O
SRL,4682,B-Chemical
prevented,4682,O
CsA-induced,4682,B-Chemical
renal,4682,B-Disease
damage,4682,I-Disease
evolution,4682,O
(,4682,O
absent/mild,4682,O
grade,4682,O
lesions,4682,O
),4682,O
",",4682,O
while,4682,O
NGAL,4682,O
(,4682,O
serum,4682,O
versus,4682,O
urine,4682,O
),4682,O
seems,4682,O
to,4682,O
be,4682,O
a,4682,O
feasible,4682,O
biomarker,4682,O
of,4682,O
CsA,4682,B-Chemical
replacement,4682,O
to,4682,O
SRL,4682,B-Chemical
.,4682,O
Kinin,4683,O
B2,4683,O
receptor,4683,O
deletion,4683,O
and,4683,O
blockage,4683,O
ameliorates,4683,O
cisplatin-induced,4683,B-Chemical
acute,4683,B-Disease
renal,4683,I-Disease
injury,4683,I-Disease
.,4683,O
Cisplatin,4684,B-Chemical
treatment,4684,O
has,4684,O
been,4684,O
adopted,4684,O
in,4684,O
some,4684,O
chemotherapies,4684,O
;,4684,O
however,4684,O
",",4684,O
this,4684,O
drug,4684,O
can,4684,O
induce,4684,O
acute,4684,B-Disease
kidney,4684,I-Disease
injury,4684,I-Disease
due,4684,O
its,4684,O
ability,4684,O
to,4684,O
negatively,4684,O
affect,4684,O
renal,4684,O
function,4684,O
",",4684,O
augment,4684,O
serum,4684,O
levels,4684,O
of,4684,O
creatinine,4684,B-Chemical
and,4684,O
urea,4684,B-Chemical
",",4684,O
increase,4684,O
the,4684,O
acute,4684,B-Disease
tubular,4684,I-Disease
necrosis,4684,I-Disease
score,4684,O
and,4684,O
up-regulate,4684,O
cytokines,4684,O
(,4684,O
e.g.,4684,O
",",4684,O
IL-1b,4684,O
and,4684,O
TNF-a,4684,O
),4684,O
.,4684,O
The,4685,O
kinin,4685,O
B2,4685,O
receptor,4685,O
has,4685,O
been,4685,O
associated,4685,O
with,4685,O
the,4685,O
inflammation,4685,B-Disease
process,4685,O
",",4685,O
as,4685,O
well,4685,O
as,4685,O
the,4685,O
regulation,4685,O
of,4685,O
cytokine,4685,O
expression,4685,O
",",4685,O
and,4685,O
its,4685,O
deletion,4685,O
resulted,4685,O
in,4685,O
an,4685,O
improvement,4685,O
in,4685,O
the,4685,O
diabetic,4685,B-Disease
nephropathy,4685,I-Disease
status,4685,O
.,4685,O
To,4686,O
examine,4686,O
the,4686,O
role,4686,O
of,4686,O
the,4686,O
kinin,4686,O
B2,4686,O
receptor,4686,O
in,4686,O
cisplatin-induced,4686,B-Chemical
acute,4686,B-Disease
kidney,4686,I-Disease
injury,4686,I-Disease
",",4686,O
kinin,4686,O
B2,4686,O
receptor,4686,O
knockout,4686,O
mice,4686,O
were,4686,O
challenged,4686,O
with,4686,O
cisplatin,4686,B-Chemical
.,4686,O
Additionally,4687,O
",",4687,O
WT,4687,O
mice,4687,O
were,4687,O
treated,4687,O
with,4687,O
a,4687,O
B2,4687,O
receptor,4687,O
antagonist,4687,O
after,4687,O
cisplatin,4687,B-Chemical
administration,4687,O
.,4687,O
B2,4688,O
receptor-deficient,4688,O
mice,4688,O
were,4688,O
less,4688,O
sensitive,4688,O
to,4688,O
this,4688,O
drug,4688,O
than,4688,O
the,4688,O
WT,4688,O
mice,4688,O
",",4688,O
as,4688,O
shown,4688,O
by,4688,O
reduced,4688,O
weight,4688,B-Disease
loss,4688,I-Disease
",",4688,O
better,4688,O
preservation,4688,O
of,4688,O
kidney,4688,O
function,4688,O
",",4688,O
down,4688,O
regulation,4688,O
of,4688,O
inflammatory,4688,O
cytokines,4688,O
and,4688,O
less,4688,O
acute,4688,B-Disease
tubular,4688,I-Disease
necrosis,4688,I-Disease
.,4688,O
Moreover,4689,O
",",4689,O
treatment,4689,O
with,4689,O
the,4689,O
kinin,4689,O
B2,4689,O
receptor,4689,O
antagonist,4689,O
effectively,4689,O
reduced,4689,O
the,4689,O
levels,4689,O
of,4689,O
serum,4689,O
creatinine,4689,B-Chemical
and,4689,O
blood,4689,O
urea,4689,B-Chemical
after,4689,O
cisplatin,4689,B-Chemical
administration,4689,O
.,4689,O
Thus,4690,O
",",4690,O
our,4690,O
data,4690,O
suggest,4690,O
that,4690,O
the,4690,O
kinin,4690,O
B2,4690,O
receptor,4690,O
is,4690,O
involved,4690,O
in,4690,O
cisplatin-induced,4690,B-Chemical
acute,4690,B-Disease
kidney,4690,I-Disease
injury,4690,I-Disease
by,4690,O
mediating,4690,O
the,4690,O
necrotic,4690,B-Disease
process,4690,O
and,4690,O
the,4690,O
expression,4690,O
of,4690,O
inflammatory,4690,O
cytokines,4690,O
",",4690,O
thus,4690,O
resulting,4690,O
in,4690,O
declined,4690,O
renal,4690,O
function,4690,O
.,4690,O
These,4691,O
results,4691,O
highlight,4691,O
the,4691,O
kinin,4691,O
B2,4691,O
receptor,4691,O
antagonist,4691,O
treatment,4691,O
in,4691,O
amelioration,4691,O
of,4691,O
nephrotoxicity,4691,B-Disease
induced,4691,O
by,4691,O
cisplatin,4691,B-Chemical
therapy,4691,O
.,4691,O
Safety,4692,O
and,4692,O
efficacy,4692,O
of,4692,O
fluocinolone,4692,B-Chemical
acetonide,4692,I-Chemical
intravitreal,4692,O
implant,4692,O
(,4692,O
0.59,4692,O
mg,4692,O
),4692,O
in,4692,O
birdshot,4692,B-Disease
retinochoroidopathy,4692,I-Disease
.,4692,O
PURPOSE,4693,O
:,4693,O
To,4693,O
report,4693,O
the,4693,O
treatment,4693,O
outcomes,4693,O
of,4693,O
the,4693,O
fluocinolone,4693,B-Chemical
acetonide,4693,I-Chemical
intravitreal,4693,O
implant,4693,O
(,4693,O
0.59,4693,O
mg,4693,O
),4693,O
in,4693,O
patients,4693,O
with,4693,O
birdshot,4693,B-Disease
retinochoroidopathy,4693,I-Disease
whose,4693,O
disease,4693,O
is,4693,O
refractory,4693,O
or,4693,O
intolerant,4693,O
to,4693,O
conventional,4693,O
immunomodulatory,4693,O
therapy,4693,O
.,4693,O
METHODS,4694,O
:,4694,O
A,4694,O
retrospective,4694,O
case,4694,O
series,4694,O
involving,4694,O
11,4694,O
birdshot,4694,B-Disease
retinochoroidopathy,4694,I-Disease
patients,4694,O
(,4694,O
11,4694,O
eyes,4694,O
),4694,O
.,4694,O
Eleven,4695,O
patients,4695,O
(,4695,O
11,4695,O
eyes,4695,O
),4695,O
underwent,4695,O
surgery,4695,O
for,4695,O
fluocinolone,4695,B-Chemical
acetonide,4695,I-Chemical
implant,4695,O
(,4695,O
0.59,4695,O
mg,4695,O
),4695,O
.,4695,O
Treatment,4696,O
outcomes,4696,O
of,4696,O
interest,4696,O
were,4696,O
noted,4696,O
at,4696,O
baseline,4696,O
",",4696,O
before,4696,O
fluocinolone,4696,B-Chemical
acetonide,4696,I-Chemical
implant,4696,O
",",4696,O
and,4696,O
then,4696,O
at,4696,O
6,4696,O
months,4696,O
",",4696,O
1,4696,O
year,4696,O
",",4696,O
2,4696,O
years,4696,O
",",4696,O
3,4696,O
years,4696,O
",",4696,O
and,4696,O
beyond,4696,O
3,4696,O
years,4696,O
.,4696,O
Disease,4697,O
activity,4697,O
markers,4697,O
",",4697,O
including,4697,O
signs,4697,O
of,4697,O
ocular,4697,O
inflammation,4697,B-Disease
",",4697,O
evidence,4697,O
of,4697,O
retinal,4697,B-Disease
vasculitis,4697,I-Disease
",",4697,O
Swedish,4697,O
interactive,4697,O
threshold,4697,O
algorithm-short,4697,O
wavelength,4697,O
automated,4697,O
perimetry,4697,O
Humphrey,4697,O
visual,4697,O
field,4697,O
analysis,4697,O
",",4697,O
electroretinographic,4697,O
parameters,4697,O
",",4697,O
and,4697,O
optical,4697,O
coherence,4697,O
tomography,4697,O
were,4697,O
recorded,4697,O
.,4697,O
Data,4698,O
on,4698,O
occurrence,4698,O
of,4698,O
cataract,4698,B-Disease
and,4698,O
raised,4698,B-Disease
intraocular,4698,I-Disease
pressure,4698,I-Disease
were,4698,O
collected,4698,O
in,4698,O
all,4698,O
eyes,4698,O
.,4698,O
RESULTS,4699,O
:,4699,O
Intraocular,4699,O
inflammation,4699,B-Disease
was,4699,O
present,4699,O
in,4699,O
54.5,4699,O
",",4699,O
9.9,4699,O
",",4699,O
11.1,4699,O
",",4699,O
and,4699,O
0,4699,O
%,4699,O
of,4699,O
patients,4699,O
at,4699,O
baseline,4699,O
",",4699,O
6,4699,O
months,4699,O
",",4699,O
1,4699,O
year,4699,O
",",4699,O
2,4699,O
years,4699,O
",",4699,O
3,4699,O
years,4699,O
",",4699,O
and,4699,O
beyond,4699,O
3,4699,O
years,4699,O
after,4699,O
receiving,4699,O
the,4699,O
implant,4699,O
",",4699,O
respectively,4699,O
.,4699,O
Active,4700,O
vasculitis,4700,B-Disease
was,4700,O
noted,4700,O
in,4700,O
36.3,4700,O
%,4700,O
patients,4700,O
at,4700,O
baseline,4700,O
and,4700,O
0,4700,O
%,4700,O
at,4700,O
3,4700,O
years,4700,O
of,4700,O
follow-up,4700,O
.,4700,O
More,4701,O
than,4701,O
20,4701,O
%,4701,O
(,4701,O
47.61-67.2,4701,O
%,4701,O
),4701,O
reduction,4701,O
in,4701,O
central,4701,O
retinal,4701,O
thickness,4701,O
was,4701,O
noted,4701,O
in,4701,O
all,4701,O
patients,4701,O
with,4701,O
cystoid,4701,B-Disease
macular,4701,I-Disease
edema,4701,I-Disease
at,4701,O
6,4701,O
months,4701,O
",",4701,O
1,4701,O
year,4701,O
",",4701,O
2,4701,O
years,4701,O
",",4701,O
and,4701,O
3,4701,O
years,4701,O
postimplant,4701,O
.,4701,O
At,4702,O
baseline,4702,O
",",4702,O
54.5,4702,O
%,4702,O
patients,4702,O
were,4702,O
on,4702,O
immunomodulatory,4702,O
agents,4702,O
.,4702,O
This,4703,O
percentage,4703,O
decreased,4703,O
to,4703,O
45.45,4703,O
",",4703,O
44.4,4703,O
",",4703,O
and,4703,O
14.28,4703,O
%,4703,O
at,4703,O
1,4703,O
year,4703,O
",",4703,O
2,4703,O
years,4703,O
",",4703,O
and,4703,O
3,4703,O
years,4703,O
postimplant,4703,O
",",4703,O
respectively,4703,O
.,4703,O
Adverse,4704,O
events,4704,O
included,4704,O
increased,4704,B-Disease
intraocular,4704,I-Disease
pressure,4704,I-Disease
(,4704,O
54.5,4704,O
%,4704,O
),4704,O
and,4704,O
cataract,4704,B-Disease
formation,4704,O
(,4704,O
100,4704,O
%,4704,O
),4704,O
.,4704,O
CONCLUSION,4705,O
:,4705,O
The,4705,O
data,4705,O
suggest,4705,O
that,4705,O
fluocinolone,4705,B-Chemical
acetonide,4705,I-Chemical
implant,4705,O
(,4705,O
0.59,4705,O
mg,4705,O
),4705,O
helps,4705,O
to,4705,O
control,4705,O
inflammation,4705,B-Disease
in,4705,O
otherwise,4705,O
treatment-refractory,4705,O
cases,4705,O
of,4705,O
birdshot,4705,B-Disease
retinochoroidopathy,4705,I-Disease
.,4705,O
It,4706,O
is,4706,O
associated,4706,O
with,4706,O
significant,4706,O
side,4706,O
effects,4706,O
of,4706,O
cataract,4706,B-Disease
and,4706,O
ocular,4706,B-Disease
hypertension,4706,I-Disease
requiring,4706,O
treatment,4706,O
.,4706,O
Optimal,4707,O
precurarizing,4707,O
dose,4707,O
of,4707,O
rocuronium,4707,B-Chemical
to,4707,O
decrease,4707,O
fasciculation,4707,B-Disease
and,4707,O
myalgia,4707,B-Disease
following,4707,O
succinylcholine,4707,B-Chemical
administration,4707,O
.,4707,O
BACKGROUND,4708,O
:,4708,O
Succinylcholine,4708,B-Chemical
commonly,4708,O
produces,4708,O
frequent,4708,O
adverse,4708,O
effects,4708,O
",",4708,O
including,4708,O
muscle,4708,B-Disease
fasciculation,4708,I-Disease
and,4708,O
myalgia,4708,B-Disease
.,4708,O
The,4709,O
current,4709,O
study,4709,O
identified,4709,O
the,4709,O
optimal,4709,O
dose,4709,O
of,4709,O
rocuronium,4709,B-Chemical
to,4709,O
prevent,4709,O
succinylcholine-induced,4709,B-Chemical
fasciculation,4709,B-Disease
and,4709,O
myalgia,4709,B-Disease
and,4709,O
evaluated,4709,O
the,4709,O
influence,4709,O
of,4709,O
rocuronium,4709,B-Chemical
on,4709,O
the,4709,O
speed,4709,O
of,4709,O
onset,4709,O
produced,4709,O
by,4709,O
succinylcholine,4709,B-Chemical
.,4709,O
METHODS,4710,O
:,4710,O
This,4710,O
randomized,4710,O
",",4710,O
double-blinded,4710,O
study,4710,O
was,4710,O
conducted,4710,O
in,4710,O
100,4710,O
patients,4710,O
randomly,4710,O
allocated,4710,O
into,4710,O
five,4710,O
groups,4710,O
of,4710,O
20,4710,O
patients,4710,O
each,4710,O
.,4710,O
Patients,4711,O
were,4711,O
randomized,4711,O
to,4711,O
receive,4711,O
0.02,4711,O
",",4711,O
0.03,4711,O
",",4711,O
0.04,4711,O
",",4711,O
0.05,4711,O
and,4711,O
0.06,4711,O
mg/kg,4711,O
rocuronium,4711,B-Chemical
as,4711,O
a,4711,O
precurarizing,4711,O
dose,4711,O
.,4711,O
Neuromuscular,4712,O
monitoring,4712,O
after,4712,O
each,4712,O
precurarizing,4712,O
dose,4712,O
was,4712,O
recorded,4712,O
from,4712,O
the,4712,O
adductor,4712,O
pollicis,4712,O
muscle,4712,O
using,4712,O
acceleromyography,4712,O
with,4712,O
train-of-four,4712,O
stimulation,4712,O
of,4712,O
the,4712,O
ulnar,4712,O
nerve,4712,O
.,4712,O
All,4713,O
patients,4713,O
received,4713,O
succinylcholine,4713,B-Chemical
1.5,4713,O
mg/kg,4713,O
at,4713,O
2,4713,O
minutes,4713,O
after,4713,O
the,4713,O
precurarization,4713,O
",",4713,O
and,4713,O
were,4713,O
assessed,4713,O
the,4713,O
incidence,4713,O
and,4713,O
severity,4713,O
of,4713,O
fasciculations,4713,B-Disease
",",4713,O
while,4713,O
myalgia,4713,B-Disease
was,4713,O
assessed,4713,O
at,4713,O
24,4713,O
hours,4713,O
after,4713,O
surgery,4713,O
.,4713,O
RESULTS,4714,O
:,4714,O
The,4714,O
incidence,4714,O
and,4714,O
severity,4714,O
of,4714,O
visible,4714,O
muscle,4714,B-Disease
fasciculation,4714,I-Disease
was,4714,O
significantly,4714,O
less,4714,O
with,4714,O
increasing,4714,O
the,4714,O
amount,4714,O
of,4714,O
precurarizing,4714,O
dose,4714,O
of,4714,O
rocuronium,4714,B-Chemical
(,4714,O
P,4714,O
<,4714,O
0.001,4714,O
),4714,O
.,4714,O
Those,4715,O
of,4715,O
myalgia,4715,B-Disease
tend,4715,O
to,4715,O
decrease,4715,O
according,4715,O
to,4715,O
increasing,4715,O
the,4715,O
amount,4715,O
of,4715,O
precurarizing,4715,O
dose,4715,O
of,4715,O
rocuronium,4715,B-Chemical
",",4715,O
but,4715,O
there,4715,O
was,4715,O
no,4715,O
significance,4715,O
(,4715,O
P,4715,O
=,4715,O
0.072,4715,O
),4715,O
.,4715,O
The,4716,O
onset,4716,O
time,4716,O
of,4716,O
succinylcholine,4716,B-Chemical
was,4716,O
significantly,4716,O
longer,4716,O
with,4716,O
increasing,4716,O
the,4716,O
amount,4716,O
of,4716,O
precurarizing,4716,O
dose,4716,O
of,4716,O
rocuronium,4716,B-Chemical
(,4716,O
P,4716,O
<,4716,O
0.001,4716,O
),4716,O
.,4716,O
CONCLUSIONS,4717,O
:,4717,O
Precurarization,4717,O
with,4717,O
0.04,4717,O
mg/kg,4717,O
rocuronium,4717,B-Chemical
was,4717,O
the,4717,O
optimal,4717,O
dose,4717,O
considering,4717,O
the,4717,O
reduction,4717,O
in,4717,O
the,4717,O
incidence,4717,O
and,4717,O
severity,4717,O
of,4717,O
fasciculation,4717,B-Disease
and,4717,O
myalgia,4717,B-Disease
with,4717,O
acceptable,4717,O
onset,4717,O
time,4717,O
",",4717,O
and,4717,O
the,4717,O
safe,4717,O
and,4717,O
effective,4717,O
precurarization,4717,O
.,4717,O
Absence,4718,O
of,4718,O
PKC-alpha,4718,O
attenuates,4718,O
lithium-induced,4718,B-Chemical
nephrogenic,4718,B-Disease
diabetes,4718,I-Disease
insipidus,4718,I-Disease
.,4718,O
Lithium,4719,B-Chemical
",",4719,O
an,4719,O
effective,4719,O
antipsychotic,4719,O
",",4719,O
induces,4719,O
nephrogenic,4719,B-Disease
diabetes,4719,I-Disease
insipidus,4719,I-Disease
(,4719,O
NDI,4719,B-Disease
),4719,O
in,4719,O
40,4719,O
%,4719,O
of,4719,O
patients,4719,O
.,4719,O
The,4720,O
decreased,4720,O
capacity,4720,O
to,4720,O
concentrate,4720,O
urine,4720,O
is,4720,O
likely,4720,O
due,4720,O
to,4720,O
lithium,4720,B-Chemical
acutely,4720,O
disrupting,4720,O
the,4720,O
cAMP,4720,B-Chemical
pathway,4720,O
and,4720,O
chronically,4720,O
reducing,4720,O
urea,4720,B-Chemical
transporter,4720,O
(,4720,O
UT-A1,4720,O
),4720,O
and,4720,O
water,4720,O
channel,4720,O
(,4720,O
AQP2,4720,O
),4720,O
expression,4720,O
in,4720,O
the,4720,O
inner,4720,O
medulla,4720,O
.,4720,O
Targeting,4721,O
an,4721,O
alternative,4721,O
signaling,4721,O
pathway,4721,O
",",4721,O
such,4721,O
as,4721,O
PKC-mediated,4721,O
signaling,4721,O
",",4721,O
may,4721,O
be,4721,O
an,4721,O
effective,4721,O
method,4721,O
of,4721,O
treating,4721,O
lithium-induced,4721,B-Chemical
polyuria,4721,B-Disease
.,4721,O
PKC-alpha,4722,O
null,4722,O
mice,4722,O
(,4722,O
PKCa,4722,O
KO,4722,O
),4722,O
and,4722,O
strain-matched,4722,O
wild,4722,O
type,4722,O
(,4722,O
WT,4722,O
),4722,O
controls,4722,O
were,4722,O
treated,4722,O
with,4722,O
lithium,4722,B-Chemical
for,4722,O
0,4722,O
",",4722,O
3,4722,O
or,4722,O
5,4722,O
days,4722,O
.,4722,O
WT,4723,O
mice,4723,O
had,4723,O
increased,4723,O
urine,4723,O
output,4723,O
and,4723,O
lowered,4723,O
urine,4723,O
osmolality,4723,O
after,4723,O
3,4723,O
and,4723,O
5,4723,O
days,4723,O
of,4723,O
treatment,4723,O
whereas,4723,O
PKCa,4723,O
KO,4723,O
mice,4723,O
had,4723,O
no,4723,O
change,4723,O
in,4723,O
urine,4723,O
output,4723,O
or,4723,O
concentration,4723,O
.,4723,O
Western,4724,O
blot,4724,O
analysis,4724,O
revealed,4724,O
that,4724,O
AQP2,4724,O
expression,4724,O
in,4724,O
medullary,4724,O
tissues,4724,O
was,4724,O
lowered,4724,O
after,4724,O
3,4724,O
and,4724,O
5,4724,O
days,4724,O
in,4724,O
WT,4724,O
mice,4724,O
;,4724,O
however,4724,O
",",4724,O
AQP2,4724,O
was,4724,O
unchanged,4724,O
in,4724,O
PKCa,4724,O
KO,4724,O
.,4724,O
Similar,4725,O
results,4725,O
were,4725,O
observed,4725,O
with,4725,O
UT-A1,4725,O
expression,4725,O
.,4725,O
Animals,4726,O
were,4726,O
also,4726,O
treated,4726,O
with,4726,O
lithium,4726,B-Chemical
for,4726,O
6,4726,O
weeks,4726,O
.,4726,O
Lithium-treated,4727,B-Chemical
WT,4727,O
mice,4727,O
had,4727,O
19-fold,4727,O
increased,4727,O
urine,4727,O
output,4727,O
whereas,4727,O
treated,4727,O
PKCa,4727,O
KO,4727,O
animals,4727,O
had,4727,O
a,4727,O
4-fold,4727,O
increase,4727,O
in,4727,O
output,4727,O
.,4727,O
AQP2,4728,O
and,4728,O
UT-A1,4728,O
expression,4728,O
was,4728,O
lowered,4728,O
in,4728,O
6,4728,O
week,4728,O
lithium-treated,4728,B-Chemical
WT,4728,O
animals,4728,O
whereas,4728,O
in,4728,O
treated,4728,O
PKCa,4728,O
KO,4728,O
mice,4728,O
",",4728,O
AQP2,4728,O
was,4728,O
only,4728,O
reduced,4728,O
by,4728,O
2-fold,4728,O
and,4728,O
UT-A1,4728,O
expression,4728,O
was,4728,O
unaffected,4728,O
.,4728,O
Urinary,4729,O
sodium,4729,B-Chemical
",",4729,O
potassium,4729,B-Chemical
and,4729,O
calcium,4729,B-Chemical
were,4729,O
elevated,4729,O
in,4729,O
lithium-fed,4729,B-Chemical
WT,4729,O
but,4729,O
not,4729,O
in,4729,O
lithium-fed,4729,B-Chemical
PKCa,4729,O
KO,4729,O
mice,4729,O
.,4729,O
Our,4730,O
data,4730,O
show,4730,O
that,4730,O
ablation,4730,O
of,4730,O
PKCa,4730,O
preserves,4730,O
AQP2,4730,O
and,4730,O
UT-A1,4730,O
protein,4730,O
expression,4730,O
and,4730,O
localization,4730,O
in,4730,O
lithium-induced,4730,B-Chemical
NDI,4730,B-Disease
",",4730,O
and,4730,O
prevents,4730,O
the,4730,O
development,4730,O
of,4730,O
the,4730,O
severe,4730,O
polyuria,4730,B-Disease
associated,4730,O
with,4730,O
lithium,4730,B-Chemical
therapy,4730,O
.,4730,O
Is,4731,O
Dysguesia,4731,B-Disease
Going,4731,O
to,4731,O
be,4731,O
a,4731,O
Rare,4731,O
or,4731,O
a,4731,O
Common,4731,O
Side-effect,4731,O
of,4731,O
Amlodipine,4731,B-Chemical
?,4731,O
A,4732,O
very,4732,O
rare,4732,O
side-effect,4732,O
of,4732,O
amlodipine,4732,B-Chemical
is,4732,O
dysguesia,4732,B-Disease
.,4732,O
A,4733,O
review,4733,O
of,4733,O
the,4733,O
literature,4733,O
produced,4733,O
only,4733,O
one,4733,O
case,4733,O
.,4733,O
We,4734,O
report,4734,O
a,4734,O
case,4734,O
about,4734,O
a,4734,O
female,4734,O
with,4734,O
essential,4734,O
hypertension,4734,B-Disease
on,4734,O
drug,4734,O
treatment,4734,O
with,4734,O
amlodipine,4734,B-Chemical
developed,4734,O
loss,4734,B-Disease
of,4734,I-Disease
taste,4734,I-Disease
sensation,4734,I-Disease
.,4734,O
Condition,4735,O
moderately,4735,O
improved,4735,O
on,4735,O
stoppage,4735,O
of,4735,O
the,4735,O
drug,4735,O
for,4735,O
25,4735,O
days,4735,O
.,4735,O
We,4736,O
conclude,4736,O
that,4736,O
amlodipine,4736,B-Chemical
can,4736,O
cause,4736,O
dysguesia,4736,B-Disease
.,4736,O
Here,4737,O
",",4737,O
we,4737,O
describe,4737,O
the,4737,O
clinical,4737,O
presentation,4737,O
and,4737,O
review,4737,O
the,4737,O
relevant,4737,O
literature,4737,O
on,4737,O
amlodipine,4737,B-Chemical
and,4737,O
dysguesia,4737,B-Disease
.,4737,O
Rhabdomyolysis,4738,B-Disease
in,4738,O
association,4738,O
with,4738,O
simvastatin,4738,B-Chemical
and,4738,O
dosage,4738,O
increment,4738,O
in,4738,O
clarithromycin,4738,B-Chemical
.,4738,O
Clarithromycin,4739,B-Chemical
is,4739,O
the,4739,O
most,4739,O
documented,4739,O
cytochrome,4739,O
P450,4739,O
3A4,4739,O
(,4739,O
CYP3A4,4739,O
),4739,O
inhibitor,4739,O
to,4739,O
cause,4739,O
an,4739,O
adverse,4739,O
interaction,4739,O
with,4739,O
simvastatin,4739,B-Chemical
.,4739,O
This,4740,O
particular,4740,O
case,4740,O
is,4740,O
of,4740,O
interest,4740,O
as,4740,O
rhabdomyolysis,4740,B-Disease
only,4740,O
occurred,4740,O
after,4740,O
an,4740,O
increase,4740,O
in,4740,O
the,4740,O
dose,4740,O
of,4740,O
clarithromycin,4740,B-Chemical
.,4740,O
The,4741,O
patient,4741,O
developed,4741,O
raised,4741,O
cardiac,4741,O
biomarkers,4741,O
without,4741,O
any,4741,O
obvious,4741,O
cardiac,4741,O
issues,4741,O
",",4741,O
a,4741,O
phenomenon,4741,O
that,4741,O
has,4741,O
been,4741,O
linked,4741,O
to,4741,O
rhabdomyolysis,4741,B-Disease
previously,4741,O
.,4741,O
To,4742,O
date,4742,O
",",4742,O
there,4742,O
has,4742,O
been,4742,O
no,4742,O
reported,4742,O
effect,4742,O
of,4742,O
rhabdomyolysis,4742,B-Disease
on,4742,O
the,4742,O
structure,4742,O
and,4742,O
function,4742,O
of,4742,O
cardiac,4742,O
muscle,4742,O
.,4742,O
Clinicians,4743,O
need,4743,O
to,4743,O
be,4743,O
aware,4743,O
of,4743,O
prescribing,4743,O
concomitant,4743,O
medications,4743,O
that,4743,O
increase,4743,O
the,4743,O
risk,4743,O
of,4743,O
myopathy,4743,B-Disease
or,4743,O
inhibit,4743,O
the,4743,O
CYP3A4,4743,O
enzyme,4743,O
.,4743,O
Our,4744,O
case,4744,O
suggests,4744,O
that,4744,O
troponin,4744,O
elevation,4744,O
could,4744,O
be,4744,O
associated,4744,O
with,4744,O
statin,4744,B-Chemical
induced,4744,O
rhabdomyolysis,4744,B-Disease
",",4744,O
which,4744,O
may,4744,O
warrant,4744,O
further,4744,O
studies,4744,O
.,4744,O
Characterization,4745,O
of,4745,O
a,4745,O
novel,4745,O
BCHE,4745,O
``,4745,O
silent,4745,O
'',4745,O
allele,4745,O
:,4745,O
point,4745,O
mutation,4745,O
(,4745,O
p.Val204Asp,4745,O
),4745,O
causes,4745,O
loss,4745,O
of,4745,O
activity,4745,O
and,4745,O
prolonged,4745,O
apnea,4745,B-Disease
with,4745,O
suxamethonium,4745,B-Chemical
.,4745,O
Butyrylcholinesterase,4746,B-Disease
deficiency,4746,I-Disease
is,4746,O
characterized,4746,O
by,4746,O
prolonged,4746,O
apnea,4746,B-Disease
after,4746,O
the,4746,O
use,4746,O
of,4746,O
muscle,4746,O
relaxants,4746,O
(,4746,O
suxamethonium,4746,B-Chemical
or,4746,O
mivacurium,4746,B-Chemical
),4746,O
in,4746,O
patients,4746,O
who,4746,O
have,4746,O
mutations,4746,O
in,4746,O
the,4746,O
BCHE,4746,O
gene,4746,O
.,4746,O
Here,4747,O
",",4747,O
we,4747,O
report,4747,O
a,4747,O
case,4747,O
of,4747,O
prolonged,4747,O
neuromuscular,4747,O
block,4747,O
after,4747,O
administration,4747,O
of,4747,O
suxamethonium,4747,B-Chemical
leading,4747,O
to,4747,O
the,4747,O
discovery,4747,O
of,4747,O
a,4747,O
novel,4747,O
BCHE,4747,O
variant,4747,O
(,4747,O
c.695T,4747,O
>,4747,O
A,4747,O
",",4747,O
p.Val204Asp,4747,O
),4747,O
.,4747,O
Inhibition,4748,O
studies,4748,O
",",4748,O
kinetic,4748,O
analysis,4748,O
and,4748,O
molecular,4748,O
dynamics,4748,O
were,4748,O
undertaken,4748,O
to,4748,O
understand,4748,O
how,4748,O
this,4748,O
mutation,4748,O
disrupts,4748,O
the,4748,O
catalytic,4748,O
triad,4748,O
and,4748,O
determines,4748,O
a,4748,O
``,4748,O
silent,4748,O
'',4748,O
phenotype,4748,O
.,4748,O
Low,4749,O
activity,4749,O
of,4749,O
patient,4749,O
plasma,4749,O
butyrylcholinesterase,4749,O
with,4749,O
butyrylthiocholine,4749,B-Chemical
(,4749,O
BTC,4749,B-Chemical
),4749,O
and,4749,O
benzoylcholine,4749,B-Chemical
",",4749,O
and,4749,O
values,4749,O
of,4749,O
dibucaine,4749,B-Chemical
and,4749,O
fluoride,4749,B-Chemical
numbers,4749,O
fit,4749,O
with,4749,O
heterozygous,4749,O
atypical,4749,O
silent,4749,O
genotype,4749,O
.,4749,O
Electrophoretic,4750,O
analysis,4750,O
of,4750,O
plasma,4750,O
BChE,4750,O
of,4750,O
the,4750,O
proband,4750,O
and,4750,O
his,4750,O
mother,4750,O
showed,4750,O
that,4750,O
patient,4750,O
has,4750,O
a,4750,O
reduced,4750,O
amount,4750,O
of,4750,O
tetrameric,4750,O
enzyme,4750,O
in,4750,O
plasma,4750,O
and,4750,O
that,4750,O
minor,4750,O
fast-moving,4750,O
BChE,4750,O
components,4750,O
:,4750,O
monomer,4750,O
",",4750,O
dimer,4750,O
",",4750,O
and,4750,O
monomer-albumin,4750,O
conjugate,4750,O
are,4750,O
missing,4750,O
.,4750,O
Kinetic,4751,O
analysis,4751,O
showed,4751,O
that,4751,O
the,4751,O
p.Val204Asp/p.Asp70Gly-p.Ala539Thr,4751,O
BChE,4751,O
displays,4751,O
a,4751,O
pure,4751,O
Michaelian,4751,O
behavior,4751,O
with,4751,O
BTC,4751,B-Chemical
as,4751,O
the,4751,O
substrate,4751,O
.,4751,O
Both,4752,O
catalytic,4752,O
parameters,4752,O
Km,4752,O
=,4752,O
265,4752,O
uM,4752,O
for,4752,O
BTC,4752,B-Chemical
",",4752,O
two,4752,O
times,4752,O
higher,4752,O
than,4752,O
that,4752,O
of,4752,O
the,4752,O
atypical,4752,O
enzyme,4752,O
",",4752,O
and,4752,O
a,4752,O
low,4752,O
Vmax,4752,O
are,4752,O
consistent,4752,O
with,4752,O
the,4752,O
absence,4752,O
of,4752,O
activity,4752,O
against,4752,O
suxamethonium,4752,B-Chemical
.,4752,O
Molecular,4753,O
dynamic,4753,O
(,4753,O
MD,4753,O
),4753,O
simulations,4753,O
showed,4753,O
that,4753,O
the,4753,O
overall,4753,O
effect,4753,O
of,4753,O
the,4753,O
mutation,4753,O
p.Val204Asp,4753,O
is,4753,O
disruption,4753,O
of,4753,O
hydrogen,4753,B-Chemical
bonding,4753,O
between,4753,O
Gln223,4753,O
and,4753,O
Glu441,4753,O
",",4753,O
leading,4753,O
Ser198,4753,O
and,4753,O
His438,4753,O
to,4753,O
move,4753,O
away,4753,O
from,4753,O
each,4753,O
other,4753,O
with,4753,O
subsequent,4753,O
disruption,4753,O
of,4753,O
the,4753,O
catalytic,4753,O
triad,4753,O
functionality,4753,O
regardless,4753,O
of,4753,O
the,4753,O
type,4753,O
of,4753,O
substrate,4753,O
.,4753,O
MD,4754,O
also,4754,O
showed,4754,O
that,4754,O
the,4754,O
enzyme,4754,O
volume,4754,O
is,4754,O
increased,4754,O
",",4754,O
suggesting,4754,O
a,4754,O
pre-denaturation,4754,O
state,4754,O
.,4754,O
This,4755,O
fits,4755,O
with,4755,O
the,4755,O
reduced,4755,O
concentration,4755,O
of,4755,O
p.Ala204Asp/p.Asp70Gly-p.Ala539Thr,4755,O
tetrameric,4755,O
enzyme,4755,O
in,4755,O
the,4755,O
plasma,4755,O
and,4755,O
non-detectable,4755,O
fast,4755,O
moving-bands,4755,O
on,4755,O
electrophoresis,4755,O
gels,4755,O
.,4755,O
Delayed,4756,O
anemia,4756,B-Disease
after,4756,O
treatment,4756,O
with,4756,O
injectable,4756,O
artesunate,4756,B-Chemical
in,4756,O
the,4756,O
Democratic,4756,O
Republic,4756,O
of,4756,O
the,4756,O
Congo,4756,O
:,4756,O
a,4756,O
manageable,4756,O
issue,4756,O
.,4756,O
Cases,4757,O
of,4757,O
delayed,4757,O
hemolytic,4757,B-Disease
anemia,4757,I-Disease
have,4757,O
been,4757,O
described,4757,O
after,4757,O
treatment,4757,O
with,4757,O
injectable,4757,O
artesunate,4757,B-Chemical
",",4757,O
the,4757,O
current,4757,O
World,4757,O
Health,4757,O
Organization,4757,O
(,4757,O
WHO,4757,O
),4757,O
-recommended,4757,O
first-line,4757,O
drug,4757,O
for,4757,O
the,4757,O
treatment,4757,O
of,4757,O
severe,4757,O
malaria,4757,B-Disease
.,4757,O
A,4758,O
total,4758,O
of,4758,O
350,4758,O
patients,4758,O
(,4758,O
215,4758,O
[,4758,O
61.4,4758,O
%,4758,O
],4758,O
<,4758,O
5,4758,O
years,4758,O
of,4758,O
age,4758,O
and,4758,O
135,4758,O
[,4758,O
38.6,4758,O
%,4758,O
],4758,O
>,4758,O
5,4758,O
years,4758,O
of,4758,O
age,4758,O
),4758,O
were,4758,O
followed-up,4758,O
after,4758,O
treatment,4758,O
with,4758,O
injectable,4758,O
artesunate,4758,B-Chemical
for,4758,O
severe,4758,O
malaria,4758,B-Disease
in,4758,O
hospitals,4758,O
and,4758,O
health,4758,O
centers,4758,O
of,4758,O
the,4758,O
Democratic,4758,O
Republic,4758,O
of,4758,O
the,4758,O
Congo,4758,O
.,4758,O
Complete,4759,O
series,4759,O
of,4759,O
hemoglobin,4759,O
(,4759,O
Hb,4759,O
),4759,O
measurements,4759,O
were,4759,O
available,4759,O
for,4759,O
201,4759,O
patients,4759,O
.,4759,O
A,4760,O
decrease,4760,O
in,4760,O
Hb,4760,O
levels,4760,O
between,4760,O
2,4760,O
and,4760,O
5,4760,O
g/dL,4760,O
was,4760,O
detected,4760,O
in,4760,O
23,4760,O
(,4760,O
11.4,4760,O
%,4760,O
),4760,O
patients,4760,O
during,4760,O
the,4760,O
follow-up,4760,O
period,4760,O
.,4760,O
For,4761,O
five,4761,O
patients,4761,O
",",4761,O
Hb,4761,O
levels,4761,O
decreased,4761,O
below,4761,O
5,4761,O
g/dL,4761,O
during,4761,O
at,4761,O
least,4761,O
one,4761,O
follow-up,4761,O
visit,4761,O
.,4761,O
All,4762,O
cases,4762,O
of,4762,O
delayed,4762,O
anemia,4762,B-Disease
were,4762,O
clinically,4762,O
manageable,4762,O
and,4762,O
resolved,4762,O
within,4762,O
one,4762,O
month,4762,O
.,4762,O
Regulation,4763,O
of,4763,O
signal,4763,O
transducer,4763,O
and,4763,O
activator,4763,O
of,4763,O
transcription,4763,O
3,4763,O
and,4763,O
apoptotic,4763,O
pathways,4763,O
by,4763,O
betaine,4763,B-Chemical
attenuates,4763,O
isoproterenol-induced,4763,B-Chemical
acute,4763,O
myocardial,4763,B-Disease
injury,4763,I-Disease
in,4763,O
rats,4763,O
.,4763,O
The,4764,O
present,4764,O
study,4764,O
was,4764,O
designed,4764,O
to,4764,O
investigate,4764,O
the,4764,O
cardioprotective,4764,O
effects,4764,O
of,4764,O
betaine,4764,B-Chemical
on,4764,O
acute,4764,O
myocardial,4764,B-Disease
ischemia,4764,I-Disease
induced,4764,O
experimentally,4764,O
in,4764,O
rats,4764,O
focusing,4764,O
on,4764,O
regulation,4764,O
of,4764,O
signal,4764,O
transducer,4764,O
and,4764,O
activator,4764,O
of,4764,O
transcription,4764,O
3,4764,O
(,4764,O
STAT3,4764,O
),4764,O
and,4764,O
apoptotic,4764,O
pathways,4764,O
as,4764,O
the,4764,O
potential,4764,O
mechanism,4764,O
underlying,4764,O
the,4764,O
drug,4764,O
effect,4764,O
.,4764,O
Male,4765,O
Sprague,4765,O
Dawley,4765,O
rats,4765,O
were,4765,O
treated,4765,O
with,4765,O
betaine,4765,B-Chemical
(,4765,O
100,4765,O
",",4765,O
200,4765,O
",",4765,O
and,4765,O
400,4765,O
mg/kg,4765,O
),4765,O
orally,4765,O
for,4765,O
40,4765,O
days,4765,O
.,4765,O
Acute,4766,O
myocardial,4766,B-Disease
ischemic,4766,I-Disease
injury,4766,I-Disease
was,4766,O
induced,4766,O
in,4766,O
rats,4766,O
by,4766,O
subcutaneous,4766,O
injection,4766,O
of,4766,O
isoproterenol,4766,B-Chemical
(,4766,O
85,4766,O
mg/kg,4766,O
),4766,O
",",4766,O
for,4766,O
two,4766,O
consecutive,4766,O
days,4766,O
.,4766,O
Serum,4767,O
cardiac,4767,O
marker,4767,O
enzyme,4767,O
",",4767,O
histopathological,4767,O
variables,4767,O
and,4767,O
expression,4767,O
of,4767,O
protein,4767,O
levels,4767,O
were,4767,O
analyzed,4767,O
.,4767,O
Oral,4768,O
administration,4768,O
of,4768,O
betaine,4768,B-Chemical
(,4768,O
200,4768,O
and,4768,O
400,4768,O
mg/kg,4768,O
),4768,O
significantly,4768,O
reduced,4768,O
the,4768,O
level,4768,O
of,4768,O
cardiac,4768,O
marker,4768,O
enzyme,4768,O
in,4768,O
the,4768,O
serum,4768,O
and,4768,O
prevented,4768,O
left,4768,O
ventricular,4768,B-Disease
remodeling,4768,I-Disease
.,4768,O
Western,4769,O
blot,4769,O
analysis,4769,O
showed,4769,O
that,4769,O
isoproterenol-induced,4769,B-Chemical
phosphorylation,4769,O
of,4769,O
STAT3,4769,O
was,4769,O
maintained,4769,O
or,4769,O
further,4769,O
enhanced,4769,O
by,4769,O
betaine,4769,B-Chemical
treatment,4769,O
in,4769,O
myocardium,4769,O
.,4769,O
Furthermore,4770,O
",",4770,O
betaine,4770,B-Chemical
(,4770,O
200,4770,O
and,4770,O
400,4770,O
mg/kg,4770,O
),4770,O
treatment,4770,O
increased,4770,O
the,4770,O
ventricular,4770,O
expression,4770,O
of,4770,O
Bcl-2,4770,O
and,4770,O
reduced,4770,O
the,4770,O
level,4770,O
of,4770,O
Bax,4770,O
",",4770,O
therefore,4770,O
causing,4770,O
a,4770,O
significant,4770,O
increase,4770,O
in,4770,O
the,4770,O
ratio,4770,O
of,4770,O
Bcl-2/Bax,4770,O
.,4770,O
The,4771,O
protective,4771,O
role,4771,O
of,4771,O
betaine,4771,B-Chemical
on,4771,O
myocardial,4771,B-Disease
damage,4771,I-Disease
was,4771,O
further,4771,O
confirmed,4771,O
by,4771,O
histopathological,4771,O
examination,4771,O
.,4771,O
In,4772,O
summary,4772,O
",",4772,O
our,4772,O
results,4772,O
showed,4772,O
that,4772,O
betaine,4772,B-Chemical
pretreatment,4772,O
attenuated,4772,O
isoproterenol-induced,4772,B-Chemical
acute,4772,O
myocardial,4772,B-Disease
ischemia,4772,I-Disease
via,4772,O
the,4772,O
regulation,4772,O
of,4772,O
STAT3,4772,O
and,4772,O
apoptotic,4772,O
pathways,4772,O
.,4772,O
Quetiapine-induced,4773,B-Chemical
neutropenia,4773,B-Disease
in,4773,O
a,4773,O
bipolar,4773,B-Disease
patient,4773,O
with,4773,O
hepatocellular,4773,B-Disease
carcinoma,4773,I-Disease
.,4773,O
OBJECTIVE,4774,O
:,4774,O
Quetiapine,4774,B-Chemical
is,4774,O
a,4774,O
dibenzothiazepine,4774,O
derivative,4774,O
",",4774,O
similar,4774,O
to,4774,O
clozapine,4774,B-Chemical
",",4774,O
which,4774,O
has,4774,O
the,4774,O
highest,4774,O
risk,4774,O
of,4774,O
causing,4774,O
blood,4774,B-Disease
dyscrasias,4774,I-Disease
",",4774,O
especially,4774,O
neutropenia,4774,B-Disease
.,4774,O
There,4775,O
are,4775,O
some,4775,O
case,4775,O
reports,4775,O
about,4775,O
this,4775,O
side,4775,O
effect,4775,O
of,4775,O
quetiapine,4775,B-Chemical
",",4775,O
but,4775,O
possible,4775,O
risk,4775,O
factors,4775,O
are,4775,O
seldom,4775,O
discussed,4775,O
and,4775,O
identified,4775,O
.,4775,O
A,4776,O
case,4776,O
of,4776,O
a,4776,O
patient,4776,O
with,4776,O
hepatocellular,4776,B-Disease
carcinoma,4776,I-Disease
that,4776,O
developed,4776,O
neutropenia,4776,B-Disease
after,4776,O
treatment,4776,O
with,4776,O
quetiapine,4776,B-Chemical
is,4776,O
described,4776,O
here,4776,O
.,4776,O
CASE,4777,O
REPORT,4777,O
:,4777,O
A,4777,O
62-year-old,4777,O
Taiwanese,4777,O
widow,4777,O
with,4777,O
bipolar,4777,B-Disease
disorder,4777,I-Disease
was,4777,O
diagnosed,4777,O
with,4777,O
hepatocellular,4777,B-Disease
carcinoma,4777,I-Disease
at,4777,O
age,4777,O
60,4777,O
.,4777,O
She,4778,O
developed,4778,O
leucopenia,4778,B-Disease
after,4778,O
being,4778,O
treated,4778,O
with,4778,O
quetiapine,4778,B-Chemical
.,4778,O
After,4779,O
quetiapine,4779,B-Chemical
was,4779,O
discontinued,4779,O
",",4779,O
her,4779,O
white,4779,O
blood,4779,O
cell,4779,O
count,4779,O
returned,4779,O
to,4779,O
normal,4779,O
.,4779,O
CONCLUSIONS,4780,O
:,4780,O
Although,4780,O
neutropenia,4780,B-Disease
is,4780,O
not,4780,O
a,4780,O
common,4780,O
side,4780,O
effect,4780,O
of,4780,O
quetiapine,4780,B-Chemical
",",4780,O
physicians,4780,O
should,4780,O
be,4780,O
cautious,4780,O
about,4780,O
its,4780,O
presentation,4780,O
and,4780,O
associated,4780,O
risk,4780,O
factors,4780,O
.,4780,O
Hepatic,4781,B-Disease
dysfunction,4781,I-Disease
may,4781,O
be,4781,O
one,4781,O
of,4781,O
the,4781,O
possible,4781,O
risk,4781,O
factors,4781,O
",",4781,O
and,4781,O
concomitant,4781,O
fever,4781,B-Disease
may,4781,O
be,4781,O
a,4781,O
diagnostic,4781,O
marker,4781,O
for,4781,O
adverse,4781,O
reaction,4781,O
to,4781,O
quetiapine,4781,B-Chemical
.,4781,O
Lateral,4782,O
antebrachial,4782,O
cutaneous,4782,O
neuropathy,4782,B-Disease
after,4782,O
steroid,4782,B-Chemical
injection,4782,O
at,4782,O
lateral,4782,O
epicondyle,4782,O
.,4782,O
BACKGROUND,4783,O
AND,4783,O
OBJECTIVES,4783,O
:,4783,O
This,4783,O
report,4783,O
aimed,4783,O
to,4783,O
present,4783,O
a,4783,O
case,4783,O
of,4783,O
lateral,4783,O
antebrachial,4783,O
cutaneous,4783,O
neuropathy,4783,B-Disease
(,4783,O
LACNP,4783,O
),4783,O
that,4783,O
occurred,4783,O
after,4783,O
a,4783,O
steroid,4783,B-Chemical
injection,4783,O
in,4783,O
the,4783,O
lateral,4783,O
epicondyle,4783,O
to,4783,O
treat,4783,O
lateral,4783,B-Disease
epicondylitis,4783,I-Disease
in,4783,O
a,4783,O
40-year-old,4783,O
woman,4783,O
.,4783,O
MATERIAL,4784,O
AND,4784,O
METHOD,4784,O
:,4784,O
A,4784,O
40-year-old,4784,O
woman,4784,O
presented,4784,O
with,4784,O
decreased,4784,O
sensation,4784,O
and,4784,O
paresthesia,4784,B-Disease
over,4784,O
her,4784,O
right,4784,O
lateral,4784,O
forearm,4784,O
;,4784,O
the,4784,O
paresthesia,4784,B-Disease
had,4784,O
occurred,4784,O
after,4784,O
a,4784,O
steroid,4784,B-Chemical
injection,4784,O
in,4784,O
the,4784,O
right,4784,O
lateral,4784,O
epicondyle,4784,O
3,4784,O
months,4784,O
before,4784,O
.,4784,O
Her,4785,O
sensation,4785,O
of,4785,O
light,4785,O
touch,4785,O
and,4785,O
pain,4785,B-Disease
was,4785,O
diminished,4785,O
over,4785,O
the,4785,O
lateral,4785,O
side,4785,O
of,4785,O
the,4785,O
right,4785,O
forearm,4785,O
and,4785,O
wrist,4785,O
area,4785,O
.,4785,O
RESULTS,4786,O
:,4786,O
The,4786,O
sensory,4786,O
action,4786,O
potential,4786,O
amplitude,4786,O
of,4786,O
the,4786,O
right,4786,O
lateral,4786,O
antebrachial,4786,O
cutaneous,4786,O
nerve,4786,O
(,4786,O
LACN,4786,O
),4786,O
(,4786,O
6.2,4786,O
uV,4786,O
),4786,O
was,4786,O
lower,4786,O
than,4786,O
that,4786,O
of,4786,O
the,4786,O
left,4786,O
(,4786,O
13.1,4786,O
uV,4786,O
),4786,O
.,4786,O
The,4787,O
difference,4787,O
of,4787,O
amplitude,4787,O
between,4787,O
both,4787,O
sides,4787,O
was,4787,O
significant,4787,O
because,4787,O
there,4787,O
was,4787,O
more,4787,O
than,4787,O
a,4787,O
50,4787,O
%,4787,O
reduction,4787,O
.,4787,O
She,4788,O
was,4788,O
diagnosed,4788,O
with,4788,O
right,4788,O
LACNP,4788,O
(,4788,O
mainly,4788,O
axonal,4788,O
involvement,4788,O
),4788,O
on,4788,O
the,4788,O
basis,4788,O
of,4788,O
the,4788,O
clinical,4788,O
manifestation,4788,O
and,4788,O
the,4788,O
electrodiagnostic,4788,O
findings,4788,O
.,4788,O
Her,4789,O
symptoms,4789,O
improved,4789,O
through,4789,O
physical,4789,O
therapy,4789,O
but,4789,O
persisted,4789,O
to,4789,O
some,4789,O
degree,4789,O
.,4789,O
CONCLUSION,4790,O
:,4790,O
This,4790,O
report,4790,O
describes,4790,O
the,4790,O
case,4790,O
of,4790,O
a,4790,O
woman,4790,O
with,4790,O
LACNP,4790,O
that,4790,O
developed,4790,O
after,4790,O
a,4790,O
steroid,4790,B-Chemical
injection,4790,O
for,4790,O
the,4790,O
treatment,4790,O
of,4790,O
lateral,4790,B-Disease
epicondylitis,4790,I-Disease
.,4790,O
An,4791,O
electrodiagnostic,4791,O
study,4791,O
",",4791,O
including,4791,O
a,4791,O
nerve,4791,O
conduction,4791,O
study,4791,O
of,4791,O
the,4791,O
LACN,4791,O
",",4791,O
was,4791,O
helpful,4791,O
to,4791,O
diagnose,4791,O
right,4791,O
LACNP,4791,O
and,4791,O
to,4791,O
find,4791,O
the,4791,O
passage,4791,O
of,4791,O
the,4791,O
LACN,4791,O
on,4791,O
the,4791,O
lateral,4791,O
epicondyle,4791,O
.,4791,O
Curcumin,4792,B-Chemical
prevents,4792,O
maleate-induced,4792,B-Chemical
nephrotoxicity,4792,B-Disease
:,4792,O
relation,4792,O
to,4792,O
hemodynamic,4792,O
alterations,4792,O
",",4792,O
oxidative,4792,O
stress,4792,O
",",4792,O
mitochondrial,4792,O
oxygen,4792,B-Chemical
consumption,4792,O
and,4792,O
activity,4792,O
of,4792,O
respiratory,4792,O
complex,4792,O
I,4792,O
.,4792,O
The,4793,O
potential,4793,O
protective,4793,O
effect,4793,O
of,4793,O
the,4793,O
dietary,4793,O
antioxidant,4793,O
curcumin,4793,B-Chemical
(,4793,O
120,4793,O
mg/Kg/day,4793,O
for,4793,O
6,4793,O
days,4793,O
),4793,O
against,4793,O
the,4793,O
renal,4793,B-Disease
injury,4793,I-Disease
induced,4793,O
by,4793,O
maleate,4793,B-Chemical
was,4793,O
evaluated,4793,O
.,4793,O
Tubular,4794,O
proteinuria,4794,B-Disease
and,4794,O
oxidative,4794,O
stress,4794,O
were,4794,O
induced,4794,O
by,4794,O
a,4794,O
single,4794,O
injection,4794,O
of,4794,O
maleate,4794,B-Chemical
(,4794,O
400,4794,O
mg/kg,4794,O
),4794,O
in,4794,O
rats,4794,O
.,4794,O
Maleate-induced,4795,B-Chemical
renal,4795,B-Disease
injury,4795,I-Disease
included,4795,O
increase,4795,O
in,4795,O
renal,4795,O
vascular,4795,O
resistance,4795,O
and,4795,O
in,4795,O
the,4795,O
urinary,4795,O
excretion,4795,O
of,4795,O
total,4795,O
protein,4795,O
",",4795,O
glucose,4795,B-Chemical
",",4795,O
sodium,4795,B-Chemical
",",4795,O
neutrophil,4795,O
gelatinase-associated,4795,O
lipocalin,4795,O
(,4795,O
NGAL,4795,O
),4795,O
and,4795,O
N-acetyl,4795,O
b-D-glucosaminidase,4795,O
(,4795,O
NAG,4795,O
),4795,O
",",4795,O
upregulation,4795,O
of,4795,O
kidney,4795,B-Disease
injury,4795,I-Disease
molecule,4795,O
(,4795,O
KIM,4795,O
),4795,O
-1,4795,O
",",4795,O
decrease,4795,O
in,4795,O
renal,4795,O
blood,4795,O
flow,4795,O
and,4795,O
claudin-2,4795,O
expression,4795,O
besides,4795,O
of,4795,O
necrosis,4795,B-Disease
and,4795,O
apoptosis,4795,O
of,4795,O
tubular,4795,O
cells,4795,O
on,4795,O
24,4795,O
h.,4795,O
Oxidative,4795,O
stress,4795,O
was,4795,O
determined,4795,O
by,4795,O
measuring,4795,O
the,4795,O
oxidation,4795,O
of,4795,O
lipids,4795,O
and,4795,O
proteins,4795,O
and,4795,O
diminution,4795,O
in,4795,O
renal,4795,O
Nrf2,4795,O
levels,4795,O
.,4795,O
Studies,4796,O
were,4796,O
also,4796,O
conducted,4796,O
in,4796,O
renal,4796,O
epithelial,4796,O
LLC-PK1,4796,O
cells,4796,O
and,4796,O
in,4796,O
mitochondria,4796,O
isolated,4796,O
from,4796,O
kidneys,4796,O
of,4796,O
all,4796,O
the,4796,O
experimental,4796,O
groups,4796,O
.,4796,O
Maleate,4797,B-Chemical
induced,4797,O
cell,4797,O
damage,4797,O
and,4797,O
reactive,4797,O
oxygen,4797,B-Chemical
species,4797,O
(,4797,O
ROS,4797,O
),4797,O
production,4797,O
in,4797,O
LLC-PK1,4797,O
cells,4797,O
in,4797,O
culture,4797,O
.,4797,O
In,4798,O
addition,4798,O
",",4798,O
maleate,4798,B-Chemical
treatment,4798,O
reduced,4798,O
oxygen,4798,B-Chemical
consumption,4798,O
in,4798,O
ADP-stimulated,4798,B-Chemical
mitochondria,4798,O
and,4798,O
diminished,4798,O
respiratory,4798,O
control,4798,O
index,4798,O
when,4798,O
using,4798,O
malate/glutamate,4798,B-Chemical
as,4798,O
substrate,4798,O
.,4798,O
The,4799,O
activities,4799,O
of,4799,O
both,4799,O
complex,4799,O
I,4799,O
and,4799,O
aconitase,4799,O
were,4799,O
also,4799,O
diminished,4799,O
.,4799,O
All,4800,O
the,4800,O
above-described,4800,O
alterations,4800,O
were,4800,O
prevented,4800,O
by,4800,O
curcumin,4800,B-Chemical
.,4800,O
It,4801,O
is,4801,O
concluded,4801,O
that,4801,O
curcumin,4801,B-Chemical
is,4801,O
able,4801,O
to,4801,O
attenuate,4801,O
in,4801,O
vivo,4801,O
maleate-induced,4801,B-Chemical
nephropathy,4801,B-Disease
and,4801,O
in,4801,O
vitro,4801,O
cell,4801,O
damage,4801,O
.,4801,O
The,4802,O
in,4802,O
vivo,4802,O
protection,4802,O
was,4802,O
associated,4802,O
to,4802,O
the,4802,O
prevention,4802,O
of,4802,O
oxidative,4802,O
stress,4802,O
and,4802,O
preservation,4802,O
of,4802,O
mitochondrial,4802,O
oxygen,4802,B-Chemical
consumption,4802,O
and,4802,O
activity,4802,O
of,4802,O
respiratory,4802,O
complex,4802,O
I,4802,O
",",4802,O
and,4802,O
the,4802,O
in,4802,O
vitro,4802,O
protection,4802,O
was,4802,O
associated,4802,O
to,4802,O
the,4802,O
prevention,4802,O
of,4802,O
ROS,4802,O
production,4802,O
.,4802,O
Incidence,4803,O
of,4803,O
solid,4803,O
tumours,4803,B-Disease
among,4803,O
pesticide,4803,O
applicators,4803,O
exposed,4803,O
to,4803,O
the,4803,O
organophosphate,4803,B-Chemical
insecticide,4803,O
diazinon,4803,B-Chemical
in,4803,O
the,4803,O
Agricultural,4803,O
Health,4803,O
Study,4803,O
:,4803,O
an,4803,O
updated,4803,O
analysis,4803,O
.,4803,O
OBJECTIVE,4804,O
:,4804,O
Diazinon,4804,B-Chemical
",",4804,O
a,4804,O
common,4804,O
organophosphate,4804,B-Chemical
insecticide,4804,O
with,4804,O
genotoxic,4804,O
properties,4804,O
",",4804,O
was,4804,O
previously,4804,O
associated,4804,O
with,4804,O
lung,4804,B-Disease
cancer,4804,I-Disease
in,4804,O
the,4804,O
Agricultural,4804,O
Health,4804,O
Study,4804,O
(,4804,O
AHS,4804,O
),4804,O
cohort,4804,O
",",4804,O
but,4804,O
few,4804,O
other,4804,O
epidemiological,4804,O
studies,4804,O
have,4804,O
examined,4804,O
diazinon-associated,4804,B-Chemical
cancer,4804,B-Disease
risk,4804,O
.,4804,O
We,4805,O
used,4805,O
updated,4805,O
diazinon,4805,B-Chemical
exposure,4805,O
and,4805,O
cancer,4805,B-Disease
incidence,4805,O
information,4805,O
to,4805,O
evaluate,4805,O
solid,4805,O
tumour,4805,B-Disease
risk,4805,O
in,4805,O
the,4805,O
AHS,4805,O
.,4805,O
METHODS,4806,O
:,4806,O
Male,4806,O
pesticide,4806,O
applicators,4806,O
in,4806,O
Iowa,4806,O
and,4806,O
North,4806,O
Carolina,4806,O
reported,4806,O
lifetime,4806,O
diazinon,4806,B-Chemical
use,4806,O
at,4806,O
enrolment,4806,O
(,4806,O
1993-1997,4806,O
),4806,O
and,4806,O
follow-up,4806,O
(,4806,O
1998-2005,4806,O
),4806,O
;,4806,O
cancer,4806,B-Disease
incidence,4806,O
was,4806,O
assessed,4806,O
through,4806,O
2010,4806,O
(,4806,O
North,4806,O
Carolina,4806,O
),4806,O
/2011,4806,O
(,4806,O
Iowa,4806,O
),4806,O
.,4806,O
Among,4807,O
applicators,4807,O
with,4807,O
usage,4807,O
information,4807,O
sufficient,4807,O
to,4807,O
evaluate,4807,O
exposure-response,4807,O
patterns,4807,O
",",4807,O
we,4807,O
used,4807,O
Poisson,4807,O
regression,4807,O
to,4807,O
estimate,4807,O
adjusted,4807,O
rate,4807,O
ratios,4807,O
(,4807,O
RRs,4807,O
),4807,O
and,4807,O
95,4807,O
%,4807,O
CI,4807,O
for,4807,O
cancer,4807,B-Disease
sites,4807,O
with,4807,O
>,4807,O
10,4807,O
exposed,4807,O
cases,4807,O
for,4807,O
both,4807,O
lifetime,4807,O
(,4807,O
LT,4807,O
),4807,O
exposure,4807,O
days,4807,O
and,4807,O
intensity-weighted,4807,O
(,4807,O
IW,4807,O
),4807,O
lifetime,4807,O
exposure,4807,O
days,4807,O
(,4807,O
accounting,4807,O
for,4807,O
factors,4807,O
impacting,4807,O
exposure,4807,O
),4807,O
.,4807,O
RESULTS,4808,O
:,4808,O
We,4808,O
observed,4808,O
elevated,4808,O
lung,4808,B-Disease
cancer,4808,I-Disease
risks,4808,O
(,4808,O
N=283,4808,O
),4808,O
among,4808,O
applicators,4808,O
with,4808,O
the,4808,O
greatest,4808,O
number,4808,O
of,4808,O
LT,4808,O
(,4808,O
RR=1.60,4808,O
;,4808,O
95,4808,O
%,4808,O
CI,4808,O
1.11,4808,O
to,4808,O
2.31,4808,O
;,4808,O
Ptrend=0.02,4808,O
),4808,O
and,4808,O
IW,4808,O
days,4808,O
of,4808,O
diazinon,4808,B-Chemical
use,4808,O
(,4808,O
RR=1.41,4808,O
;,4808,O
95,4808,O
%,4808,O
CI,4808,O
0.98,4808,O
to,4808,O
2.04,4808,O
;,4808,O
Ptrend=0.08,4808,O
),4808,O
.,4808,O
Kidney,4809,B-Disease
cancer,4809,I-Disease
(,4809,O
N=94,4809,O
),4809,O
risks,4809,O
were,4809,O
non-significantly,4809,O
elevated,4809,O
(,4809,O
RRLT,4809,O
days=1.77,4809,O
;,4809,O
95,4809,O
%,4809,O
CI,4809,O
0.90,4809,O
to,4809,O
3.51,4809,O
;,4809,O
Ptrend=0.09,4809,O
;,4809,O
RRIW,4809,O
days,4809,O
1.37,4809,O
;,4809,O
95,4809,O
%,4809,O
CI,4809,O
0.64,4809,O
to,4809,O
2.92,4809,O
;,4809,O
Ptrend=0.50,4809,O
),4809,O
",",4809,O
as,4809,O
were,4809,O
risks,4809,O
for,4809,O
aggressive,4809,O
prostate,4809,B-Disease
cancer,4809,I-Disease
(,4809,O
N=656,4809,O
),4809,O
.,4809,O
CONCLUSIONS,4810,O
:,4810,O
Our,4810,O
updated,4810,O
evaluation,4810,O
of,4810,O
diazinon,4810,B-Chemical
provides,4810,O
additional,4810,O
evidence,4810,O
of,4810,O
an,4810,O
association,4810,O
with,4810,O
lung,4810,B-Disease
cancer,4810,I-Disease
risk,4810,O
.,4810,O
Newly,4811,O
identified,4811,O
links,4811,O
to,4811,O
kidney,4811,B-Disease
cancer,4811,I-Disease
and,4811,O
associations,4811,O
with,4811,O
aggressive,4811,O
prostate,4811,B-Disease
cancer,4811,I-Disease
require,4811,O
further,4811,O
evaluation,4811,O
.,4811,O
Associations,4812,O
of,4812,O
Ozone,4812,B-Chemical
and,4812,O
PM2.5,4812,O
Concentrations,4812,O
With,4812,O
Parkinson,4812,B-Disease
's,4812,I-Disease
Disease,4812,I-Disease
Among,4812,O
Participants,4812,O
in,4812,O
the,4812,O
Agricultural,4812,O
Health,4812,O
Study,4812,O
.,4812,O
OBJECTIVE,4813,O
:,4813,O
This,4813,O
study,4813,O
describes,4813,O
associations,4813,O
of,4813,O
ozone,4813,B-Chemical
and,4813,O
fine,4813,O
particulate,4813,B-Chemical
matter,4813,I-Chemical
with,4813,O
Parkinson,4813,B-Disease
's,4813,I-Disease
disease,4813,I-Disease
observed,4813,O
among,4813,O
farmers,4813,O
in,4813,O
North,4813,O
Carolina,4813,O
and,4813,O
Iowa,4813,O
.,4813,O
METHODS,4814,O
:,4814,O
We,4814,O
used,4814,O
logistic,4814,O
regression,4814,O
to,4814,O
determine,4814,O
the,4814,O
associations,4814,O
of,4814,O
these,4814,O
pollutants,4814,O
with,4814,O
self-reported,4814,O
",",4814,O
doctor-diagnosed,4814,O
Parkinson,4814,B-Disease
's,4814,I-Disease
disease,4814,I-Disease
.,4814,O
Daily,4815,O
predicted,4815,O
pollutant,4815,O
concentrations,4815,O
were,4815,O
used,4815,O
to,4815,O
derive,4815,O
surrogates,4815,O
of,4815,O
long-term,4815,O
exposure,4815,O
and,4815,O
link,4815,O
them,4815,O
to,4815,O
study,4815,O
participants,4815,O
',4815,O
geocoded,4815,O
addresses,4815,O
.,4815,O
RESULTS,4816,O
:,4816,O
We,4816,O
observed,4816,O
positive,4816,O
associations,4816,O
of,4816,O
Parkinson,4816,B-Disease
's,4816,I-Disease
disease,4816,I-Disease
with,4816,O
ozone,4816,B-Chemical
(,4816,O
odds,4816,O
ratio,4816,O
=,4816,O
1.39,4816,O
;,4816,O
95,4816,O
%,4816,O
CI,4816,O
:,4816,O
0.98,4816,O
to,4816,O
1.98,4816,O
),4816,O
and,4816,O
fine,4816,O
particulate,4816,B-Chemical
matter,4816,I-Chemical
(,4816,O
odds,4816,O
ratio,4816,O
=,4816,O
1.34,4816,O
;,4816,O
95,4816,O
%,4816,O
CI,4816,O
:,4816,O
0.93,4816,O
to,4816,O
1.93,4816,O
),4816,O
in,4816,O
North,4816,O
Carolina,4816,O
but,4816,O
not,4816,O
in,4816,O
Iowa,4816,O
.,4816,O
CONCLUSIONS,4817,O
:,4817,O
The,4817,O
plausibility,4817,O
of,4817,O
an,4817,O
effect,4817,O
of,4817,O
ambient,4817,O
concentrations,4817,O
of,4817,O
these,4817,O
pollutants,4817,O
on,4817,O
Parkinson,4817,B-Disease
's,4817,I-Disease
disease,4817,I-Disease
risk,4817,O
is,4817,O
supported,4817,O
by,4817,O
experimental,4817,O
data,4817,O
demonstrating,4817,O
damage,4817,O
to,4817,O
dopaminergic,4817,O
neurons,4817,O
at,4817,O
relevant,4817,O
concentrations,4817,O
.,4817,O
Additional,4818,O
studies,4818,O
are,4818,O
needed,4818,O
to,4818,O
address,4818,O
uncertainties,4818,O
related,4818,O
to,4818,O
confounding,4818,O
and,4818,O
to,4818,O
examine,4818,O
temporal,4818,O
aspects,4818,O
of,4818,O
the,4818,O
associations,4818,O
we,4818,O
observed,4818,O
.,4818,O
Low,4819,O
functional,4819,O
programming,4819,O
of,4819,O
renal,4819,O
AT2R,4819,O
mediates,4819,O
the,4819,O
developmental,4819,O
origin,4819,O
of,4819,O
glomerulosclerosis,4819,B-Disease
in,4819,O
adult,4819,O
offspring,4819,O
induced,4819,O
by,4819,O
prenatal,4819,O
caffeine,4819,B-Chemical
exposure,4819,O
.,4819,O
UNASSIGNED,4820,O
:,4820,O
Our,4820,O
previous,4820,O
study,4820,O
has,4820,O
indicated,4820,O
that,4820,O
prenatal,4820,O
caffeine,4820,B-Chemical
exposure,4820,O
(,4820,O
PCE,4820,O
),4820,O
could,4820,O
induce,4820,O
intrauterine,4820,B-Disease
growth,4820,I-Disease
retardation,4820,I-Disease
(,4820,O
IUGR,4820,B-Disease
),4820,O
of,4820,O
offspring,4820,O
.,4820,O
Recent,4821,O
research,4821,O
suggested,4821,O
that,4821,O
IUGR,4821,B-Disease
is,4821,O
a,4821,O
risk,4821,O
factor,4821,O
for,4821,O
glomerulosclerosis,4821,B-Disease
.,4821,O
However,4822,O
",",4822,O
whether,4822,O
PCE,4822,O
could,4822,O
induce,4822,O
glomerulosclerosis,4822,B-Disease
and,4822,O
its,4822,O
underlying,4822,O
mechanisms,4822,O
remain,4822,O
unknown,4822,O
.,4822,O
This,4823,O
study,4823,O
aimed,4823,O
to,4823,O
demonstrate,4823,O
the,4823,O
induction,4823,O
to,4823,O
glomerulosclerosis,4823,B-Disease
in,4823,O
adult,4823,O
offspring,4823,O
by,4823,O
PCE,4823,O
and,4823,O
its,4823,O
intrauterine,4823,O
programming,4823,O
mechanisms,4823,O
.,4823,O
A,4824,O
rat,4824,O
model,4824,O
of,4824,O
IUGR,4824,B-Disease
was,4824,O
established,4824,O
by,4824,O
PCE,4824,O
",",4824,O
male,4824,O
fetuses,4824,O
and,4824,O
adult,4824,O
offspring,4824,O
at,4824,O
the,4824,O
age,4824,O
of,4824,O
postnatal,4824,O
week,4824,O
24,4824,O
were,4824,O
euthanized,4824,O
.,4824,O
The,4825,O
results,4825,O
revealed,4825,O
that,4825,O
the,4825,O
adult,4825,O
offspring,4825,O
kidneys,4825,O
in,4825,O
the,4825,O
PCE,4825,O
group,4825,O
exhibited,4825,O
glomerulosclerosis,4825,B-Disease
as,4825,O
well,4825,O
as,4825,O
interstitial,4825,B-Disease
fibrosis,4825,I-Disease
",",4825,O
accompanied,4825,O
by,4825,O
elevated,4825,O
levels,4825,O
of,4825,O
serum,4825,O
creatinine,4825,B-Chemical
and,4825,O
urine,4825,O
protein,4825,O
.,4825,O
Renal,4826,O
angiotensin,4826,B-Chemical
II,4826,I-Chemical
receptor,4826,O
type,4826,O
2,4826,O
(,4826,O
AT2R,4826,O
),4826,O
gene,4826,O
expression,4826,O
in,4826,O
adult,4826,O
offspring,4826,O
was,4826,O
reduced,4826,O
by,4826,O
PCE,4826,O
",",4826,O
whereas,4826,O
the,4826,O
renal,4826,O
angiotensin,4826,B-Chemical
II,4826,I-Chemical
receptor,4826,O
type,4826,O
1a,4826,O
(,4826,O
AT1aR,4826,O
),4826,O
/AT2R,4826,O
expression,4826,O
ratio,4826,O
was,4826,O
increased,4826,O
.,4826,O
The,4827,O
fetal,4827,O
kidneys,4827,O
in,4827,O
the,4827,O
PCE,4827,O
group,4827,O
displayed,4827,O
an,4827,O
enlarged,4827,O
Bowman,4827,O
's,4827,O
space,4827,O
and,4827,O
a,4827,O
shrunken,4827,O
glomerular,4827,O
tuft,4827,O
",",4827,O
accompanied,4827,O
by,4827,O
a,4827,O
reduced,4827,O
cortex,4827,O
width,4827,O
and,4827,O
an,4827,O
increase,4827,O
in,4827,O
the,4827,O
nephrogenic,4827,O
zone/cortical,4827,O
zone,4827,O
ratio,4827,O
.,4827,O
Observation,4828,O
by,4828,O
electronic,4828,O
microscope,4828,O
revealed,4828,O
structural,4828,O
damage,4828,O
of,4828,O
podocytes,4828,O
;,4828,O
the,4828,O
reduced,4828,O
expression,4828,O
level,4828,O
of,4828,O
podocyte,4828,O
marker,4828,O
genes,4828,O
",",4828,O
nephrin,4828,O
and,4828,O
podocin,4828,O
",",4828,O
was,4828,O
also,4828,O
detected,4828,O
by,4828,O
q-PCR,4828,O
.,4828,O
Moreover,4829,O
",",4829,O
AT2R,4829,O
gene,4829,O
and,4829,O
protein,4829,O
expressions,4829,O
in,4829,O
fetal,4829,O
kidneys,4829,O
were,4829,O
inhibited,4829,O
by,4829,O
PCE,4829,O
",",4829,O
associated,4829,O
with,4829,O
the,4829,O
repression,4829,O
of,4829,O
the,4829,O
gene,4829,O
expression,4829,O
of,4829,O
glial-cell-line-derived,4829,O
neurotrophic,4829,O
factor,4829,O
(,4829,O
GDNF,4829,O
),4829,O
/tyrosine,4829,O
kinase,4829,O
receptor,4829,O
(,4829,O
c-Ret,4829,O
),4829,O
signaling,4829,O
pathway,4829,O
.,4829,O
These,4830,O
results,4830,O
demonstrated,4830,O
that,4830,O
PCE,4830,O
could,4830,O
induce,4830,O
dysplasia,4830,B-Disease
of,4830,I-Disease
fetal,4830,I-Disease
kidneys,4830,I-Disease
as,4830,O
well,4830,O
as,4830,O
glomerulosclerosis,4830,B-Disease
of,4830,O
adult,4830,O
offspring,4830,O
",",4830,O
and,4830,O
the,4830,O
low,4830,O
functional,4830,O
programming,4830,O
of,4830,O
renal,4830,O
AT2R,4830,O
might,4830,O
mediate,4830,O
the,4830,O
developmental,4830,O
origin,4830,O
of,4830,O
adult,4830,O
glomerulosclerosis,4830,B-Disease
.,4830,O
"1,3-Butadiene",4831,B-Chemical
",",4831,O
CML,4831,B-Disease
and,4831,O
the,4831,O
t,4831,O
(,4831,O
9:22,4831,O
),4831,O
translocation,4831,O
:,4831,O
A,4831,O
reality,4831,O
check,4831,O
.,4831,O
UNASSIGNED,4832,O
:,4832,O
Epidemiological,4832,O
studies,4832,O
of,4832,O
"1,3-butadiene",4832,B-Chemical
have,4832,O
suggest,4832,O
that,4832,O
exposures,4832,O
to,4832,O
humans,4832,O
are,4832,O
associated,4832,O
with,4832,O
chronic,4832,B-Disease
myeloid,4832,I-Disease
leukemia,4832,I-Disease
(,4832,O
CML,4832,B-Disease
),4832,O
.,4832,O
CML,4833,B-Disease
has,4833,O
a,4833,O
well-documented,4833,O
association,4833,O
with,4833,O
ionizing,4833,O
radiation,4833,O
",",4833,O
but,4833,O
reports,4833,O
of,4833,O
associations,4833,O
with,4833,O
chemical,4833,O
exposures,4833,O
have,4833,O
been,4833,O
questioned,4833,O
.,4833,O
Ionizing,4834,O
radiation,4834,O
is,4834,O
capable,4834,O
of,4834,O
inducing,4834,O
the,4834,O
requisite,4834,O
CML-associated,4834,B-Disease
t,4834,O
(,4834,O
9:22,4834,O
),4834,O
translocation,4834,O
(,4834,O
Philadelphia,4834,B-Disease
chromosome,4834,I-Disease
),4834,O
in,4834,O
appropriate,4834,O
cells,4834,O
in,4834,O
vitro,4834,O
but,4834,O
",",4834,O
thus,4834,O
far,4834,O
",",4834,O
chemicals,4834,O
have,4834,O
not,4834,O
shown,4834,O
this,4834,O
capacity,4834,O
.,4834,O
We,4835,O
have,4835,O
proposed,4835,O
that,4835,O
"1,3-butadiene",4835,B-Chemical
metabolites,4835,O
be,4835,O
so,4835,O
tested,4835,O
as,4835,O
a,4835,O
reality,4835,O
check,4835,O
on,4835,O
the,4835,O
epidemiological,4835,O
reports,4835,O
.,4835,O
In,4836,O
order,4836,O
to,4836,O
conduct,4836,O
reliable,4836,O
testing,4836,O
in,4836,O
this,4836,O
regard,4836,O
",",4836,O
it,4836,O
is,4836,O
essential,4836,O
that,4836,O
a,4836,O
positive,4836,O
control,4836,O
for,4836,O
induction,4836,O
be,4836,O
available,4836,O
.,4836,O
We,4837,O
have,4837,O
used,4837,O
ionizing,4837,O
radiation,4837,O
to,4837,O
develop,4837,O
such,4837,O
a,4837,O
control,4837,O
.,4837,O
Results,4838,O
described,4838,O
here,4838,O
demonstrate,4838,O
that,4838,O
this,4838,O
agent,4838,O
does,4838,O
in,4838,O
fact,4838,O
induce,4838,O
pathogenic,4838,O
t,4838,O
(,4838,O
9:22,4838,O
),4838,O
translocations,4838,O
in,4838,O
a,4838,O
human,4838,O
myeloid,4838,O
cell,4838,O
line,4838,O
in,4838,O
vitro,4838,O
",",4838,O
but,4838,O
does,4838,O
so,4838,O
at,4838,O
low,4838,O
frequencies,4838,O
.,4838,O
Conditions,4839,O
that,4839,O
will,4839,O
be,4839,O
required,4839,O
for,4839,O
studies,4839,O
of,4839,O
"1,3-butadiene",4839,B-Chemical
are,4839,O
discussed,4839,O
.,4839,O
Cancer,4840,B-Disease
incidence,4840,O
and,4840,O
metolachlor,4840,B-Chemical
use,4840,O
in,4840,O
the,4840,O
Agricultural,4840,O
Health,4840,O
Study,4840,O
:,4840,O
An,4840,O
update,4840,O
.,4840,O
UNASSIGNED,4841,O
:,4841,O
Metolachlor,4841,B-Chemical
",",4841,O
a,4841,O
widely,4841,O
used,4841,O
herbicide,4841,O
",",4841,O
is,4841,O
classified,4841,O
as,4841,O
a,4841,O
Group,4841,O
C,4841,O
carcinogen,4841,O
by,4841,O
the,4841,O
U.S.,4841,O
Environmental,4841,O
Protection,4841,O
Agency,4841,O
based,4841,O
on,4841,O
increased,4841,O
liver,4841,B-Disease
neoplasms,4841,I-Disease
in,4841,O
female,4841,O
rats,4841,O
.,4841,O
Epidemiologic,4842,O
studies,4842,O
of,4842,O
the,4842,O
health,4842,O
effects,4842,O
of,4842,O
metolachlor,4842,B-Chemical
have,4842,O
been,4842,O
limited,4842,O
.,4842,O
The,4843,O
Agricultural,4843,O
Health,4843,O
Study,4843,O
(,4843,O
AHS,4843,O
),4843,O
is,4843,O
a,4843,O
prospective,4843,O
cohort,4843,O
study,4843,O
including,4843,O
licensed,4843,O
private,4843,O
and,4843,O
commercial,4843,O
pesticide,4843,O
applicators,4843,O
in,4843,O
Iowa,4843,O
and,4843,O
North,4843,O
Carolina,4843,O
enrolled,4843,O
1993-1997,4843,O
.,4843,O
We,4844,O
evaluated,4844,O
cancer,4844,B-Disease
incidence,4844,O
through,4844,O
2010/2011,4844,O
(,4844,O
NC/IA,4844,O
),4844,O
for,4844,O
"49,616",4844,O
applicators,4844,O
",",4844,O
53,4844,O
%,4844,O
of,4844,O
whom,4844,O
reported,4844,O
ever,4844,O
using,4844,O
metolachlor,4844,B-Chemical
.,4844,O
We,4845,O
used,4845,O
Poisson,4845,O
regression,4845,O
to,4845,O
evaluate,4845,O
relations,4845,O
between,4845,O
two,4845,O
metrics,4845,O
of,4845,O
metolachlor,4845,B-Chemical
use,4845,O
(,4845,O
lifetime,4845,O
days,4845,O
",",4845,O
intensity-weighted,4845,O
lifetime,4845,O
days,4845,O
),4845,O
and,4845,O
cancer,4845,B-Disease
incidence,4845,O
.,4845,O
We,4846,O
saw,4846,O
no,4846,O
association,4846,O
between,4846,O
metolachlor,4846,B-Chemical
use,4846,O
and,4846,O
incidence,4846,O
of,4846,O
all,4846,O
cancers,4846,B-Disease
combined,4846,O
(,4846,O
n,4846,O
=,4846,O
"5,701",4846,O
with,4846,O
a,4846,O
5-year,4846,O
lag,4846,O
),4846,O
or,4846,O
most,4846,O
site-specific,4846,O
cancers,4846,B-Disease
.,4846,O
For,4847,O
liver,4847,B-Disease
cancer,4847,I-Disease
",",4847,O
in,4847,O
analyses,4847,O
restricted,4847,O
to,4847,O
exposed,4847,O
workers,4847,O
",",4847,O
elevations,4847,O
observed,4847,O
at,4847,O
higher,4847,O
categories,4847,O
of,4847,O
use,4847,O
were,4847,O
not,4847,O
statistically,4847,O
significant,4847,O
.,4847,O
However,4848,O
",",4848,O
trends,4848,O
for,4848,O
both,4848,O
lifetime,4848,O
and,4848,O
intensity-weighted,4848,O
lifetime,4848,O
days,4848,O
of,4848,O
metolachor,4848,B-Chemical
use,4848,O
were,4848,O
positive,4848,O
and,4848,O
statistically,4848,O
significant,4848,O
with,4848,O
an,4848,O
unexposed,4848,O
reference,4848,O
group,4848,O
.,4848,O
A,4849,O
similar,4849,O
pattern,4849,O
was,4849,O
observed,4849,O
for,4849,O
follicular,4849,B-Disease
cell,4849,I-Disease
lymphoma,4849,I-Disease
",",4849,O
but,4849,O
no,4849,O
other,4849,O
lymphoma,4849,B-Disease
subtypes,4849,O
.,4849,O
An,4850,O
earlier,4850,O
suggestion,4850,O
of,4850,O
increased,4850,O
lung,4850,B-Disease
cancer,4850,I-Disease
risk,4850,O
at,4850,O
high,4850,O
levels,4850,O
of,4850,O
metolachlor,4850,B-Chemical
use,4850,O
in,4850,O
this,4850,O
cohort,4850,O
was,4850,O
not,4850,O
confirmed,4850,O
in,4850,O
this,4850,O
update,4850,O
.,4850,O
This,4851,O
suggestion,4851,O
of,4851,O
an,4851,O
association,4851,O
between,4851,O
metolachlor,4851,B-Chemical
and,4851,O
liver,4851,B-Disease
cancer,4851,I-Disease
among,4851,O
pesticide,4851,O
applicators,4851,O
is,4851,O
a,4851,O
novel,4851,O
finding,4851,O
and,4851,O
echoes,4851,O
observation,4851,O
of,4851,O
increased,4851,O
liver,4851,B-Disease
neoplasms,4851,I-Disease
in,4851,O
some,4851,O
animal,4851,O
studies,4851,O
.,4851,O
However,4852,O
",",4852,O
our,4852,O
findings,4852,O
for,4852,O
both,4852,O
liver,4852,B-Disease
cancer,4852,I-Disease
and,4852,O
follicular,4852,O
cell,4852,O
lymphoma,4852,B-Disease
warrant,4852,O
follow-up,4852,O
to,4852,O
better,4852,O
differentiate,4852,O
effects,4852,O
of,4852,O
metolachlor,4852,B-Chemical
use,4852,O
from,4852,O
other,4852,O
factors,4852,O
.,4852,O
Mechanisms,4853,O
Underlying,4853,O
Latent,4853,O
Disease,4853,O
Risk,4853,O
Associated,4853,O
with,4853,O
Early-Life,4853,O
Arsenic,4853,B-Chemical
Exposure,4853,O
:,4853,O
Current,4853,O
Research,4853,O
Trends,4853,O
and,4853,O
Scientific,4853,O
Gaps,4853,O
.,4853,O
BACKGROUND,4854,O
:,4854,O
Millions,4854,O
of,4854,O
individuals,4854,O
worldwide,4854,O
",",4854,O
particularly,4854,O
those,4854,O
living,4854,O
in,4854,O
rural,4854,O
and,4854,O
developing,4854,O
areas,4854,O
",",4854,O
are,4854,O
exposed,4854,O
to,4854,O
harmful,4854,O
levels,4854,O
of,4854,O
inorganic,4854,B-Chemical
arsenic,4854,I-Chemical
(,4854,O
iAs,4854,B-Chemical
),4854,O
in,4854,O
their,4854,O
drinking,4854,O
water,4854,O
.,4854,O
Inorganic,4855,B-Chemical
As,4855,I-Chemical
exposure,4855,O
during,4855,O
key,4855,O
developmental,4855,O
periods,4855,O
is,4855,O
associated,4855,O
with,4855,O
a,4855,O
variety,4855,O
of,4855,O
adverse,4855,O
health,4855,O
effects,4855,O
including,4855,O
those,4855,O
that,4855,O
are,4855,O
evident,4855,O
in,4855,O
adulthood,4855,O
.,4855,O
There,4856,O
is,4856,O
considerable,4856,O
interest,4856,O
in,4856,O
identifying,4856,O
the,4856,O
molecular,4856,O
mechanisms,4856,O
that,4856,O
relate,4856,O
early-life,4856,O
iAs,4856,B-Chemical
exposure,4856,O
to,4856,O
the,4856,O
development,4856,O
of,4856,O
these,4856,O
latent,4856,O
diseases,4856,O
",",4856,O
particularly,4856,O
in,4856,O
relationship,4856,O
to,4856,O
cancer,4856,B-Disease
.,4856,O
OBJECTIVES,4857,O
:,4857,O
This,4857,O
work,4857,O
summarizes,4857,O
research,4857,O
on,4857,O
the,4857,O
molecular,4857,O
mechanisms,4857,O
that,4857,O
underlie,4857,O
the,4857,O
increased,4857,O
risk,4857,O
of,4857,O
cancer,4857,B-Disease
development,4857,O
in,4857,O
adulthood,4857,O
that,4857,O
is,4857,O
associated,4857,O
with,4857,O
early-life,4857,O
iAs,4857,B-Chemical
exposure,4857,O
.,4857,O
DISCUSSION,4858,O
:,4858,O
Epigenetic,4858,O
reprogramming,4858,O
that,4858,O
imparts,4858,O
functional,4858,O
changes,4858,O
in,4858,O
gene,4858,O
expression,4858,O
",",4858,O
the,4858,O
development,4858,O
of,4858,O
cancer,4858,B-Disease
stem,4858,O
cells,4858,O
",",4858,O
and,4858,O
immunomodulation,4858,O
are,4858,O
plausible,4858,O
underlying,4858,O
mechanisms,4858,O
by,4858,O
which,4858,O
early-life,4858,O
iAs,4858,B-Chemical
exposure,4858,O
elicits,4858,O
latent,4858,O
carcinogenic,4858,O
effects,4858,O
.,4858,O
CONCLUSIONS,4859,O
:,4859,O
Evidence,4859,O
is,4859,O
mounting,4859,O
that,4859,O
relates,4859,O
early-life,4859,O
iAs,4859,B-Chemical
exposure,4859,O
and,4859,O
cancer,4859,B-Disease
development,4859,O
later,4859,O
in,4859,O
life,4859,O
.,4859,O
Future,4860,O
research,4860,O
should,4860,O
include,4860,O
animal,4860,O
studies,4860,O
that,4860,O
address,4860,O
mechanistic,4860,O
hypotheses,4860,O
and,4860,O
studies,4860,O
of,4860,O
human,4860,O
populations,4860,O
that,4860,O
integrate,4860,O
early-life,4860,O
exposure,4860,O
",",4860,O
molecular,4860,O
alterations,4860,O
",",4860,O
and,4860,O
latent,4860,O
disease,4860,O
outcomes,4860,O
.,4860,O
